<SEC-DOCUMENT>0001178913-24-001124.txt : 20240328
<SEC-HEADER>0001178913-24-001124.hdr.sgml : 20240328
<ACCEPTANCE-DATETIME>20240328060318
ACCESSION NUMBER:		0001178913-24-001124
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240328
DATE AS OF CHANGE:		20240328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		24793250

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>zk2431185.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cmmb="http://www.anchiano.com/20231231" xmlns:ecd="http://xbrl.sec.gov/ecd/2023"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>Chemomab Therapeutics Ltd. - 1534248 - 2024</title></head><body><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:footnote id="FN20240325165534634" xml:lang="en-US">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</ix:footnote>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20230101to20231231" id="FFact_0000000000489">0001534248</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20230101to20231231" id="FFact_0000000000490">FY</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20230101to20231231" id="FFact_0000000000491">false</ix:nonNumeric><ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="C_20200501to20200510" id="Fxbrl_20230131233234992">2023-05-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="C_20211001to20211024" id="Fxbrl_20230131233722905">2024-10-31</ix:nonNumeric><ix:footnote id="FN20240325103209570" xml:lang="en-US">Less than 1 thousand</ix:footnote>
<ix:footnote id="FN20230201025135527" xml:lang="en-US">The weighted average share price is based on the Company&#8217;s ordinary share valuation as at the grant date. </ix:footnote>
<ix:footnote id="FN20230201025203207" xml:lang="en-US">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</ix:footnote>
<ix:footnote id="FN20230201025249960" xml:lang="en-US">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</ix:footnote>
<ix:footnote id="FN20230201025314607" xml:lang="en-US">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</ix:footnote>
</ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cmmb-20231231.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20230101to20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210316"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cmmb:CapitalAdditionsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200510"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-05-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200501to20200510"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211001to20211024"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-10-24</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211024"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-10-24</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231212"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-12</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtCurrencyAxis_currencyUSD"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtCurrencyAxis_currencyUSD"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtCurrencyAxis_currencyILS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtCurrencyAxis_currencyILS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtCurrencyAxis_currencyXXX"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtCurrencyAxis_currencyXXX"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsSeventeenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-19</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220401to20220425_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-22</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-15</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231101to20231117"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-17</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231031"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231001to20231031_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RothCapitalPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:MarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RothCapitalPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:MarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_Per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="FFact_0000000000106" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230214141238310" toRefs="FN20240325165534634"/><ix:relationship fromRefs="FFact_0000000000107" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230131213329528" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20240325100018415" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_s_20240325100018414" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20240325103200378" toRefs="FN20240325103209570"/><ix:relationship fromRefs="FFact_0000000000373" toRefs="FN20230201025135527"/><ix:relationship fromRefs="FFact_0000000000377" toRefs="FN20230201025203207"/><ix:relationship fromRefs="FFact_0000000000378" toRefs="FN20230201025203207"/><ix:relationship fromRefs="FFact_0000000000379" toRefs="FN20230201025249960"/><ix:relationship fromRefs="FFact_0000000000380" toRefs="FN20230201025249960"/><ix:relationship fromRefs="FFact_0000000000381" toRefs="FN20230201025314607"/><ix:relationship fromRefs="FFact_0000000000382" toRefs="FN20230201025314607"/><ix:relationship fromRefs="Fxbrl_20230207232638785_Fact_0000000000130" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230207232638785_Fact_0000000000129" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230207232638785_Fact_0000000000128" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230207232832534" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230208004108785" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230208004148281" toRefs="FN20240325165534634"/><ix:relationship fromRefs="Fxbrl_20230208004208753" toRefs="FN20240325165534634"/></ix:resources></ix:header></div><div><div style="">
  <div>
    <div>
      <div>
        <div>
          <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>UNITED STATES</span></span></span></span></span></div>
              </div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>SECURITIES AND EXCHANGE COMMISSION</span></span></span></span></span></div>
              </div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Washington, D.C. 20549</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>FORM <ix:nonNumeric id="Fxbrl_20230213103251859" name="dei:DocumentType" contextRef="C_20230101to20231231">20-F</ix:nonNumeric></span></span></span></span></span></div>
              </div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(Mark One)</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><ix:nonNumeric id="Fxbrl_20240325124822695" name="dei:DocumentRegistrationStatement" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span>&#8195;REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>OR</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><ix:nonNumeric id="Fxbrl_20240325124850731" name="dei:DocumentAnnualReport" contextRef="C_20230101to20231231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span>&#8195;ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934&#8201;&#8201;</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>For the fiscal year ended <ix:nonNumeric id="Fxbrl_20240325125020590" name="dei:DocumentPeriodEndDate" contextRef="C_20230101to20231231" format="ixt:date-monthname-day-year-en"><ix:nonNumeric id="Fxbrl_20240325125039815" name="dei:CurrentFiscalYearEndDate" contextRef="C_20230101to20231231" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20240325125103526" name="dei:DocumentFiscalYearFocus" contextRef="C_20230101to20231231">2023</ix:nonNumeric></ix:nonNumeric></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>OR</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><ix:nonNumeric id="Fxbrl_20240325125127518" name="dei:DocumentTransitionReport" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span>&#8195;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>For the transition period from &#8195;&#8195;&#8195;&#8195; to</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>OR</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><ix:nonNumeric id="Fxbrl_20240325125149159" name="dei:DocumentShellCompanyReport" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span>&#8195;SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Date of event requiring this shell company report</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Commission File Number <ix:nonNumeric id="Fxbrl_20240325125212477" name="dei:EntityFileNumber" contextRef="C_20230101to20231231">001-40490</ix:nonNumeric></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25"><img alt="image0.jpg" src="cmmb_img01.jpg" style="width:212px;height:112px"/></div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:16pt;font-weight:bold"><span style="font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonNumeric id="Fxbrl_20230213104107012" name="dei:EntityRegistrantName" contextRef="C_20230101to20231231">Chemomab Therapeutics Ltd.</ix:nonNumeric></span></span></span></span></span></div>
              </div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(Exact name of Registrant as specified in its charter)</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Not Applicable</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(Translation of Registrant&#8217;s name into English)</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>State of <ix:nonNumeric id="Fxbrl_20240325171717506" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20230101to20231231" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(Jurisdiction of incorporation or organization)</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20240325130645061" name="dei:EntityAddressAddressLine1" contextRef="C_20230101to20231231">Kiryat
              Atidim, Building 7</ix:nonNumeric><ix:nonNumeric id="Fxbrl_20240325130702398" name="dei:EntityAddressCityOrTown" contextRef="C_20230101to20231231">,
              Tel Aviv</ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20240327173314698" name="dei:EntityAddressPostalZipCode" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"><ix:nonNumeric id="Fxbrl_20240325125444047" name="dei:EntityAddressPostalZipCode" contextRef="C_20230101to20231231">6158002</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20240325125500854" name="dei:EntityAddressCountry" contextRef="C_20230101to20231231" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>+972 77-331-0156</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(Address of principal executive offices)</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20240325125533965" name="dei:ContactPersonnelName" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Sigal Fattal</ix:nonNumeric></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chief Financial Officer</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20240325130613231" name="dei:EntityAddressAddressLine1" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Kiryat Atidim Building 7</ix:nonNumeric></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20240325130913214" name="dei:EntityAddressCityOrTown" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Tel Aviv</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20240325130944047" name="dei:EntityAddressCountry" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Telephone: (<ix:nonNumeric id="Fxbrl_20240325130506462" name="dei:CityAreaCode" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">855</ix:nonNumeric>) <ix:nonNumeric id="Fxbrl_20240325130536510" name="dei:LocalPhoneNumber" contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">492-5563</ix:nonNumeric></span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></span></span></span></div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Securities registered or to be registered, pursuant to Section 12(b) of the Act</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:55.72%;vertical-align:bottom;border-bottom:#000000 2px solid">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Title of each class</span></span></span></span></div>
                    </td>
                    <td style="width:0.69%;vertical-align:bottom">
                      <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:12pt">&#160;</div>
                    </td>
                    <td style="width:14.7%;vertical-align:bottom;border-bottom:#000000 2px solid">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Trading Symbol(s)</span></span></span></span></div>
                    </td>
                    <td style="width:0.69%;vertical-align:bottom">
                      <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:12pt">&#160;</div>
                    </td>
                    <td style="width:28.19%;vertical-align:bottom;border-bottom:#000000 2px solid">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Name of each exchange on which registered</span></span></span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:55.72%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20230213103433506" name="dei:Security12bTitle" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td style="width:0.69%;vertical-align:top">
                      <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:12pt">&#160;</div>
                    </td>
                    <td style="width:14.7%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20230213103437662" name="dei:TradingSymbol" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">CMMB</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td style="width:0.69%;vertical-align:top">
                      <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:12pt">&#160;</div>
                    </td>
                    <td style="width:28.19%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20230213103445669" name="dei:SecurityExchangeName" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</span></span></span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:55.72%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20230213103508728" name="dei:Security12bTitle" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">Ordinary shares, no par-value</ix:nonNumeric>*</span></span></span></span></div>
                    </td>
                    <td style="width:0.69%;vertical-align:top">&#160;</td>
                    <td style="width:14.7%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20230213103458685" name="dei:TradingSymbol" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">NA</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td style="width:0.69%;vertical-align:top">&#160;</td>
                    <td style="width:28.19%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20230213103452851" name="dei:SecurityExchangeName" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>*Not for trading; only in connection with the registration of American Depository Shares.</span></span></span></span></div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif;font-weight:bold">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Securities registered or to be registered pursuant to Section 12(g) of the Act: <span style="font-weight:bold">None</span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: <span style="font-weight:bold">None</span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital stock or common stock as of the close of the period covered by the annual report. As of December 31, 2023, the registrant had outstanding <ix:nonFraction id="Fxbrl_20240325131407326" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">284,094,700</ix:nonFraction> ordinary shares, no par value.</span></span></span></span></div>
              <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
                <div style="page-break-after:always">
                  <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
                </div>
              </div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Yes <span>&#9744;</span> <ix:nonNumeric id="Fxbrl_20240325131448134" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_20230101to20231231">No</ix:nonNumeric> <span style="font-weight:bold">&#9746;</span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Yes <span>&#9744;</span><span style="font-weight:bold">&#160;</span> <ix:nonNumeric id="Fxbrl_20240325131518183" name="dei:EntityVoluntaryFilers" contextRef="C_20230101to20231231">No</ix:nonNumeric> <span style="font-weight:bold">&#9746;</span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Note-Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20240325131547950" name="dei:EntityCurrentReportingStatus" contextRef="C_20230101to20231231">Yes</ix:nonNumeric> <span style="font-weight:bold">&#9746;</span> No <span>&#9744;</span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><ix:nonNumeric id="Fxbrl_20240325131614371" name="dei:EntityInteractiveDataCurrent" contextRef="C_20230101to20231231">Yes</ix:nonNumeric> <span style="font-weight:bold">&#9746;</span><span style="font-weight:bold">&#160;</span>No <span>&#9744;</span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:25.65%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>&#9744;</span> Large accelerated filer</span></span></span></span></div>
                    </td>
                    <td style="width:19.51%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>&#9744;</span> Accelerated filer</span></span></span></span></div>
                    </td>
                    <td style="width:24.41%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-size:12pt;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>&#9746;</span><span> <ix:nonNumeric id="Fxbrl_20240325131641177" name="dei:EntityFilerCategory" contextRef="C_20230101to20231231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></span></span></span></span></span></div>
                    </td>
                    <td style="width:30.43%;vertical-align:top">
                      <div style="line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><ix:nonNumeric id="Fxbrl_20240325172008738" name="dei:EntityEmergingGrowthCompany" contextRef="C_20230101to20231231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span> Emerging growth company</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8201;provided pursuant to Section 13(a) of the Exchange Act. <span><ix:nonNumeric id="Fxbrl_20240325172437467" name="dei:EntityExTransitionPeriod" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.<span><ix:nonNumeric id="Fxbrl_20240327182011473" name="dei:IcfrAuditorAttestationFlag" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></span></span></div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;<span><ix:nonNumeric id="Fxbrl_20240325173248259" name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></span></span></div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span>&#9744;</span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:11.83%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>&#9746;</span> <ix:nonNumeric id="Fxbrl_20240325172525187" name="dei:DocumentAccountingStandard" contextRef="C_20230101to20231231">U.S. GAAP</ix:nonNumeric></span></span></span></span></div>
                    </td>
                    <td style="width:80.38%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>&#9744;</span> International Financial Reporting Standards as issued by the International Accounting Standards Board</span></span></span></span></div>
                    </td>
                    <td style="width:7.79%;vertical-align:top">
                      <div style="text-align:center;line-height:1.25;color:#000000;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>&#9744;</span><span style="font-weight:bold"> Other</span></span></span></span></span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.</span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Item 17 <span>&#9744;</span> Item 18 <span>&#9744;</span></span></span></span></span></div>
              <div style="line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Yes <span>&#9744;</span> No <span style="font-weight:bold"><ix:nonNumeric id="Fxbrl_20240325132317597" name="dei:EntityShellCompany" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Yes <span>&#9744;</span> No <span style="font-weight:bold"><ix:nonNumeric id="Fxbrl_20240327183652256" name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="C_20230101to20231231" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b) </span></span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Yes <span>&#9744;</span> No <span style="font-weight:bold">&#9746;</span></span></span></span></span></div>
            </div>
            <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
              <div style="page-break-after:always">
                <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
              </div>
            </div>
            <div style="line-height:1.25">&#160;</div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <!-- Field: Include-Text; File: PF\body.htm; Date: 2024%2D03%2D28T11:43:18; Size: 0x00158396; Options: XMLPreprocess -->
<div><br/>

<table cellspacing="0" cellpadding="0" border="0" id="zd6e8c163259a45e5b48fbad91a7efb60" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td colspan="2" style="vertical-align: top; font-weight: bold">
        <div style="line-height: 1.25; font-family: Times New Roman,serif"><a href="#FORWARD-LOOKING">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
        STATEMENTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">2<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top; font-weight: bold">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#INFORMATION">PRESENTATION OF FINANCIAL
        AND OTHER INFORMATION</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">5<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#PARTI">PART I</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">6<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item1">ITEM 1. IDENTITY OF DIRECTORS,
        SENIOR MANAGEMENT AND ADVISERS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">6<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item2">ITEM 2. OFFER STATISTICS AND EXPECTED
        TIMETABLE</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">6<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item3">ITEM 3. KEY INFORMATION</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">6<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">[Reserved.]</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">6<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Capitalization and Indebtedness</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">6<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Reasons for the Offer and Use of Proceeds</div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">6<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Risk Factors</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">6<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item4">ITEM 4. INFORMATION ON THE COMPANY</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">38<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">History and Development of the Company</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">38<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Business Overview</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">39<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Organizational Structure</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Property, Plants and Equipment</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item4A">ITEM 4A. UNRESOLVED STAFF COMMENTS</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">91<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item5">ITEM 5. OPERATING AND FINANCIAL
        REVIEW AND PROSPECTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">91<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Operating Results</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">92<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Liquidity and Capital Resources</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">98<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Research and Development, Patents and Licenses,
        Etc.</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">100<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Trend Information</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">100<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">E.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Critical Accounting Estimates</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">100<br/> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item6">ITEM 6. DIRECTORS, SENIOR MANAGEMENT
        AND EMPLOYEES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">102<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Directors and Senior Management</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">102<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Compensation</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">104<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Board Practices</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">110<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Employees</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">120<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">E.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Share Ownership</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">120<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">F.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Disclosure of a Registrant&#8217;s Action to Recover
        Erroneously Awarded Compensation</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">120<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top; font-weight: bold">
        <div style="line-height: 1.25; font-family: Times New Roman,serif"><a href="#Item7">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">121<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top; font-weight: bold">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Major Shareholders</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">121<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Related Party Transactions</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">123<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Interests of Experts and Counsel</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">124<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item8">ITEM 8. FINANCIAL INFORMATION</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">124<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Consolidated Statements and Other Financial Information</div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">124<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Significant Changes</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">124<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item9">ITEM 9. THE OFFER AND LISTING</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Offer and Listing Details</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Plan of Distribution</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Markets</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Selling Shareholders</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">E.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Dilution</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">F.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Expenses of the Issue</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item10">ITEM 10. ADDITIONAL INFORMATION</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" colspan="2" style="vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Share Capital</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Memorandum and Articles of Association</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">Material Contracts</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">125<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">D.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">Exchange Controls</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">126<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">E.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">Taxation</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">126<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">F.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">Dividends and Paying Agents</div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">137<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">G.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">Statement by Experts</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">138<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">H.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">Documents on Display</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">138<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">I.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">Subsidiary Information</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">138<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 6%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 89%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 6%; vertical-align: top">
        <div style="margin-left: 18pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">J.</div> </td>
    <td style="width: 89%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">Annual Report to Security Holders</div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">138<br/> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" border="0" id="z047ed5df93fd4e61b2cf9bcbd2213d89" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item11">ITEM 11. QUANTITATIVE AND QUALITATIVE
        DISCLOSURES ABOUT MARKET RISK</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">138<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item12">ITEM 12. DESCRIPTION OF SECURITIES
        OTHER THAN EQUITY SECURITIES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">139<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#PARTII">PART II</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">147<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item13">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES
        AND DELINQUENCIES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">147<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item14">ITEM 14. MATERIAL MODIFICATIONS
        TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">147<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item15">ITEM 15. CONTROLS AND PROCEDURES</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">147<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16">ITEM 16. [RESERVED]</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">148<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16A">ITEM 16A. AUDIT COMMITTEE FINANCIAL
        EXPERT</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">148<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16B">ITEM 16B. CODE OF ETHICS</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">148<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16C">ITEM 16C. PRINCIPAL ACCOUNTANT
        FEES AND SERVICES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">149<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16D">ITEM 16D. EXEMPTIONS FROM THE
        LISTING STANDARDS FOR AUDIT COMMITTEES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">150<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16E">ITEM 16E. PURCHASES OF EQUITY
        SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">150<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16F">ITEM 16F. CHANGE IN REGISTRANT&#8217;S
        CERTIFYING ACCOUNTANT</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">150<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16G">ITEM 16G. CORPORATE GOVERNANCE</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">150<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16H">ITEM 16H. MINE SAFETY DISCLOSURE</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">151<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16I">ITEM 16I. DISCLOSURE REGARDING
        FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></div> </td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right">151<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16J">ITEM 16J. INSIDER TRADING POLICY</a></div>
        </td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right">151<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item16K">ITEM 16K. CYBERSECURITY</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">151<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#PARTIII">PART III</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">152<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item17">ITEM 17. FINANCIAL STATEMENTS</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">152<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item18">ITEM 18. FINANCIAL STATEMENTS</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">153<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#Item19">ITEM 19. EXHIBITS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">153<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><a href="#SIGNATURES">SIGNATURES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">155<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 95%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: bottom; text-align: right"><br/> </td> </tr>
  <tr>
    <td style="width: 95%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">INDEX</div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">F-1<br/> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">INTRODUCTION</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;&#160;&#160;&#160;
In this Annual Report on Form 20-F (the &#8220;Annual Report&#8221;), unless context otherwise requires:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z734a2bafb07b4e2ab4a50b20b4b4da55" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div>&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif">references to &#8220;Chemomab
        Therapeutics Ltd.&#8221;, &#8220;Chemomab,&#8221; the &#8220;Company,&#8221; &#8220;us,&#8221; &#8220;we&#8221; and &#8220;our&#8221;
        refer to Chemomab Therapeutics Ltd., an Israeli company and its consolidated subsidiaries; however, with respect to the presentation of
        financial results for historical periods that preceded the Merger (as defined below), these terms refer to the financial results of the
        Company&#8217;s wholly owned subsidiary, Chemomab Ltd., which was the accounting acquirer in the Merger;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8c6230e8b945466db41396703c1c7c18" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif">references to &#8220;ordinary
        shares,&#8221; &#8220;our shares&#8221; and similar expressions refer to the Company&#8217;s ordinary shares, no nominal (par) value;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4d7754ecbfdc4ac8afe1680a79d7d4cc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">references to &#8220;ADS&#8221;
        refer to the American Depositary Shares listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;CMMB,&#8221;
        each representing twenty (20) ordinary shares;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbd700405a4fa4734ad9065a9f87c58f6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">references to &#8220;dollars,&#8221;
        &#8220;U.S. dollars&#8221; and &#8220;$&#8221; are to United States Dollars;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2ba07382c688436d913b213203b18789" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">references to &#8220;NIS&#8221;
        are to New Israeli Shekels;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z970519f5cab3418ba0ba9fa0cbca4a04" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">references to the &#8220;Companies
        Law&#8221; are to Israel&#8217;s Companies Law, 5759-1999, as amended;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf4645925184e4bcd85580c96776eaf77" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">references to the &#8220;SEC&#8221;
        are to the U.S. Securities and Exchange Commission; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb944f0b5eb6648e39c2e7afe77faf352" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">references to the &#8220;Merger&#8221;
        refer to the merger involving Anchiano Therapeutics Ltd., or Anchiano, and Chemomab Ltd., whereby a wholly owned subsidiary of Anchiano
        merged with and into Chemomab Ltd., with Chemomab Ltd. surviving as a wholly owned subsidiary of Anchiano. Upon consummation of the Merger
        on March 16, 2021, Anchiano changed its name to &#8220;Chemomab Therapeutics Ltd.&#8221; and the business conducted by Chemomab Ltd. became
        primarily the business conducted by the Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;This Annual Report
contains estimates, projections and other information concerning our industry and our business, as well as data regarding market research,
estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or
similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and
circumstances that are assumed in this information. The industry in which we operate is subject to a high degree of uncertainty and risk
due to a variety of factors, including those discussed under the headings &#8220;Special Note Regarding Forward-Looking Statements&#8221;
and Item 3.D. &#8220;Risk Factors&#8221; in this Annual Report.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%2%%%-->

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">CAUTIONARY STATEMENT REGARDING
FORWARD-LOOKING<span id="FORWARD-LOOKING"><!--Anchor--></span> STATEMENTS AND A SUMMARY OF RISK FACTORS</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;This Annual Report
contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. We intend such forward-looking
statements to be covered by the safe harbor provisions for forward-looking statements as contained in Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements
contained in this Annual Report other than statements of historical fact, including, without limitation, statements regarding our future
operating results and financial position, including our revenue and operating expenses profitability; our business strategies and plans;
our expectations regarding the development of our industry and the competitive environment in which we operate; our expectations regarding
partnerships and collaborations; our objectives for future operations; our ability to raise additional capital to fund our operations;
and the sufficiency of our cash, cash equivalents and short-term investments, are forward-looking statements. The words &#8220;may,&#8221;
&#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;
&#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate,&#8221; &#8220;possible,&#8221; &#8220;forecasts,&#8221;
&#8220;aims&#8221; or the negative of these terms and similar expressions are intended to identify forward-looking statements, though
not all forward-looking statements use these words or expressions. These forward-looking statements are contained principally in the sections
titled Item 3.D. &#8220;Key Information-Risk Factors,&#8221; Item 4. &#8220;Information on the Company,&#8221; and Item 5. &#8220;Operating
and Financial Review and Prospects.&#8221; These statements are neither promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to,
the following:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc1e6a812bf7f4f37982a328554198336" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we have incurred significant
        losses since inception and anticipate that we will continue to incur increasing levels of operating losses over the next several years
        and for the foreseeable future. We are unable to predict the extent of any future losses or when we will become profitable, if at all.
        Even if we become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis;&#160;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we have a limited operating history
        and funding, which may make it difficult to evaluate our prospects and likelihood of success;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">our business is highly dependent
        on the success of our lead product candidate, CM-101, and any other product candidates that we advance into clinical studies. All of our
        programs will require significant additional clinical development;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">our central objective is to design
        and develop targeted treatments for inflammation and fibrosis with an initial focus on the antagonism of CCL24 signaling, which is known
        to regulate fibrotic and inflammatory processes. While several studies are currently underway, our approach in the area of fibrotic diseases
        is novel and unproven and may not result in marketable products;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">the successful completion of
        clinical studies is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable foreign
        regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates.
        We may experience negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional
        clinical studies or trials or abandon some or all of our product development programs, which could have a material adverse effect on our
        business;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we may encounter difficulties
        enrolling patients in our clinical studies, including any public health emergencies and related clinical development activities could
        be delayed or otherwise adversely affected;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">our ongoing and future clinical
        studies may reveal significant adverse events or immunogenicity-related responses and may result in a safety profile that could delay
        or prevent regulatory approval or market acceptance of our product candidate;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">the regulatory approval processes
        of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable
        to obtain regulatory approval for CM-101 or any other product candidates, our business will be substantially harmed;&#160;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">if we do not achieve our projected
        development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates may
        be delayed and our business will be harmed;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we face substantial competition,
        which may result in others discovering, developing or commercializing products before or more successfully than us;&#160;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we have been granted Orphan Drug
        Designation for CM-101 in connection with three indications and may seek Orphan Drug Designation for other indications or product candidates,
        and we may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity,
        and may not receive Orphan Drug Designation for other indications or for our other product candidates;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we expect to experience significant
        growth in the number of our employees over time and the scope of our operations, particularly in the areas of product candidate development,
        regulatory affairs and sales and marketing. We will therefore need to expand our organization, and we may experience difficulties in managing
        this growth, which could disrupt our operations;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">if we are unable to protect our
        patents or other proprietary rights, or if we infringe the patents or other proprietary rights of others, our competitiveness and business
        prospects may be materially damaged. In addition, changes in patent laws or patent jurisprudence could diminish the value of patents in
        general, thereby impairing our ability to protect our product candidates;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">risks related to our operations
        in Israel could materially adversely impact our business, financial condition and results of operations;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">our principal executive offices
        are located in Israel and US and certain of our product candidates may be manufactured at third-party facilities located in Europe. In
        addition, our business strategy includes potentially expanding internationally if any of our product candidates receives regulatory approval.
        A variety of risks associated with operating internationally could materially adversely affect our business;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">holders of ADSs are not treated
        as holders of our Ordinary Shares;&#160;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">holders of ADSs may not have
        the same voting rights as the holders of our Ordinary Shares and may not receive voting materials in time to be able to exercise their
        right to vote;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">holders of ADSs may be subject
        to limitations on the transfer of their ADSs and the withdrawal of the underlying Ordinary Shares;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we are entitled to amend the
        deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without
        the prior consent of the ADS holders;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">ADSs holders may not be entitled
        to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s)
        in any such action;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226; <br/> </div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">obtaining and maintaining our
        patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental
        patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements;&#160;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">the regulatory approval processes
        of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable
        to obtain regulatory approval for CM-101 or any other product candidates, our business will be substantially harmed;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">obtaining and maintaining regulatory
        approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our
        product candidates in other jurisdictions;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">even if we obtain regulatory
        approval for CM-101 or any product candidate, we will still face extensive and ongoing regulatory requirements and obligations and any
        product candidates, if approved, may face future development and regulatory difficulties;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">disruptions at the FDA and other
        government agencies caused by funding shortages or global health concerns could hinder our ability to hire, retain or deploy key leadership
        and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner
        or at all, which could negatively impact our business;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">if we do not achieve our projected
        development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates may
        be delayed and our business will be harmed;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we face substantial competition,
        which may result in others discovering, developing or commercializing products before or more successfully than us;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">even if CM-101 or any other product
        candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors
        or others in the medical community necessary for commercial success;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we rely completely on third-party
        suppliers to manufacture our clinical drug supplies for our product candidates, and we intend to rely on third parties to produce preclinical,
        clinical, and commercial supplies of any future product candidates;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">if we are unable to establish
        sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing
        CM-101, if approved;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">a variety of risks associated
        with operating internationally could materially adversely affect our business;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">conditions in Israel, including
        the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel&#8217;s war against them, may affect our operations;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">because a certain portion of
        our expenses are incurred in currencies other than the U.S. Dollar, our results of operations may be harmed by currency fluctuations and
        inflation;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we received Israeli government
        grants for certain of their research and development activities as detailed below. The terms of those grants require us to satisfy specified
        conditions in order to transfer outside of Israel the manufacture of products based on know-how funded by the Israel Innovation Authority
        or to transfer outside of Israel the know-how itself. If we fail to comply with the requirements of Israeli law in this regard, we may
        be required to pay penalties, and it may impair our ability to sell our technology outside of Israel;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we will need to raise additional
        capital to fund our operations, which may be unavailable to us on acceptable terms or at all, or may cause dilution or place significant
        restrictions on our ability to operate our business;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">the trading price of the ADSs
        has been highly volatile, and is expected to continue to be volatile;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">we have not paid dividends in
        the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of the
        ADSs; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">if we fail to continue to meet
        all applicable Nasdaq requirements, Nasdaq may delist the ADSs, which could have an adverse impact on the liquidity and market price of
        the ADSs.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif"> <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;You should not rely
on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Annual Report
primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial
condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties
and other factors described in the section titled &#8220;Risk factors&#8221; and elsewhere in this Annual Report. Moreover, we operate
in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for
us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report.
The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events
or circumstances could differ materially from those described in the forward-looking statements.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;The forward-looking
statements made in this Annual Report relate only to events as of the date on which the statements are made. We undertake no obligation
to update any forward-looking statements made in this Annual Report to reflect events or circumstances after the date of this Annual Report
or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint
ventures or investments.<br/> &#160;</div>

<div style="text-align: center; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">PRESENTATION
OF FINANCIAL <span id="INFORMATION"><!--Anchor--></span>INFORMATION</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Our consolidated financial
statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. We present
our consolidated financial statements in U.S. dollars.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Our fiscal year ends
on December 31 of each year.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Certain monetary amounts,
percentages and other figures included elsewhere in this Annual Report have been subject to rounding adjustments. Accordingly, figures
shown as totals in certain tables or charts may not be the arithmetic aggregation of the figures that precede them, and figures expressed
as percentages in the text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation of the percentages
that precede them.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">PART I<span id="PARTI"><!--Anchor--></span></div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">Item 1<span id="Item1"><!--Anchor--></span>. Identity
of Directors, Senior Management and Advisers</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top"><br/> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif">
        <div style="line-height: 1.25">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br/> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">Item 2<span id="Item2"><!--Anchor--></span>. Offer
Statistics and Expected Timetable</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top"><br/> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif">
        <div style="line-height: 1.25">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold">Item 3<span id="Item3"><!--Anchor--></span>.
Key Information</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="za581b3d5b30e4317bba1527ba5ffa488" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: middle">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-weight: bold">A.</span>&#160;</div>
        </td>
    <td style="width: 97%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-weight: bold">[Reserved.]</span>&#160;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8da62bad31ee48d397e572584237fec1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-weight: bold">Capitalization and
        Indebtedness</span>&#160;</div>
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"> <br/> </div>
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif">
        <div style="line-height: 1.25">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z33ab4c53390941518e1a996be60e462b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-weight: bold">Reasons for the Offer
        and Use of Proceeds</span>&#160;</div>
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"> <br/> </div>
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif">
        <div style="line-height: 1.25">Not applicable.</div> </div> </td> </tr>
  </table>

<div style="text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="zdd018ad2cb2e49dcb08810d129e0a31c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-weight: bold">D.</span>&#160;</div>
        </td>
    <td style="width: 97%; vertical-align: top">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-weight: bold">Risk Factors</span>&#160;</div>
        </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman, serif">&#160;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; text-indent: 36pt"><span style="font-family: Times New Roman,serif; font-style: italic">You
should carefully consider the risks and uncertainties described below and the other information contained in this Annual Report before
making an investment decision. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also
impair our business operations. Our business, financial condition, results of operations, or strategic objectives could be materially
and adversely affected by any of these risks and uncertainties. The trading price and value of our ordinary shares could decline due to
any of these risks and uncertainties, and you may lose all or part of your investment. This Annual Report also contains forward- looking
statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking
statements as a result of certain factors, including the risks and uncertainties faced by us described below and elsewhere in this Annual
Report.</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">Risks Relating to Our Business
and Industry</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold">Our limited
operating history and funding may make it difficult to evaluate our prospects and likelihood of success.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We are a clinical-stage biopharmaceutical
company with a limited operating history. We were&#160; incorporated in 2011, have no products approved for commercial sale and have not
generated any revenue. Our operations to date have been limited to organizing and staffing the company, business planning, raising capital,
establishing our intellectual property portfolio and conducting research and development of our product candidates, technology related
to CCL24 and novel therapies for the treatment of inflammation and fibrosis. Our approach to the discovery and development of product
candidates is unproven, and we do not know whether we will be able to develop any products of commercial value. In addition, our lead
product candidate, CM-101, is in relatively early clinical development for the treatment of primary sclerosing cholangitis (PSC) (as defined
below) and systemic sclerosis (SSc) (as defined below). The clinical programs will require substantial additional development and clinical
research, both in time and resources, before we are in a position to apply for or receive regulatory approvals and begin generating revenue
in connection with the sale of such product candidates. We have not yet demonstrated the ability to successfully complete a large-scale,
pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, or arrange for a third party to do so on our
behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about
our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully
developing and commercializing pharmaceutical products. &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Our business is
highly dependent on the success of our lead product candidate, CM-101, and any other product candidates that we advance into clinical
studies. All of our programs will require significant additional clinical development.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We currently have no products
that are approved for commercial sale and may never be able to develop marketable products. We are relatively early in our development
efforts and have only one product candidate, CM-101, in clinical development. Because CM-101 is our lead product candidate, if CM-101
encounters safety or efficacy problems, development delays, regulatory issues or other problems, our development plans and business would
be significantly harmed. We have completed a Phase 1a single ascending dose (SAD) safety study with healthy volunteers, a Phase 1b multiple
ascending dose (MAD) study of CM-101 in non-alcoholic fatty liver disease, or NAFLD, a Phase 2a safety, Pk and liver fibrosis biomarker
study in non-alcoholic steatohepatitis, or NASH patients, an open-label exploratory study in severe lung injury in hospitalized COVID-19
patients and completed recruitment of patients in a Phase 2 PSC trial.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We expect that a substantial
portion of our efforts and expenditures over the next few years will be devoted to CM-101, which will require additional clinical development,
management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, building
of a commercial organization, substantial investment and significant marketing efforts before we can generate any revenues from any commercial
sales. We cannot be certain that we will be able to successfully complete any of these activities. In addition, if one or more of our
product candidates are approved, we may need to ensure access to sufficient commercial manufacturing capacity and conduct significant
marketing efforts in connection with any commercial launch. These efforts will require substantial investment, and we may not have the
financial resources to continue the development of our product candidates. &#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">We
will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic
transactions or partnerships, to complete development of CM-101 or any other product candidates. If we are unable to raise such financing
or complete such a transaction, we may not be able to fund the clinical trials of our product candidates and potentially commercialize
those product candidates.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">As a result of the expected
development timeline to potentially obtain FDA approval for CM-101, the substantial additional costs associated with the development of
our product candidates, including the costs associated with clinical trials related thereto, and the substantial cost of commercializing
CM-101, we will need to raise substantial additional funding through public or private equity or debt transactions or a strategic combination
or partnership. If we are delayed in obtaining funding or are unable to complete a strategic transaction, we may have to delay or discontinue
development activities on CM-101 and our other product candidates. Even if we are able to fund continued development of CM-101 or any
of our other product candidates is approved, we expect that we will need to raise substantial additional funding through public or private
equity or debt securities or complete a strategic transaction or partnership to successfully commercialize CM-101 or any other product
candidate.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We believe our cash and cash
equivalents and bank deposits as of December 31, 2023 will be sufficient to fund our operations through March 31, 2025. Sales of our ADSs
dilute the ownership interest of our shareholders and may cause the price per ADS to decrease. Changing circumstances may cause us to
consume capital significantly faster or slower than we currently anticipate. We have based these estimates on assumptions that may prove
to be wrong, and we could exhaust our available financial resources sooner than currently anticipated.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our liquidity, and ability to raise additional
capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</div>

<div style="line-height: 1.25">

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">the costs and timing for potential additional clinical trials in order to gain possible regulatory approval
        for CM-101and our other product candidates;</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">the market price of our ADSs and the availability and cost of additional equity capital from existing and
        potential new investors;</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">our ability to retain the listing of our ADSs on the Nasdaq Capital Market;</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">general economic and industry conditions affecting the availability and cost of capital, including as a
        result of deteriorating market conditions due to investor concerns regarding inflation and continued hostilities between Israel and Hamas,
        and Russia and Ukraine;</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">our ability to control costs associated with our operations;</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the costs of filing, prosecuting, defending and
        enforcing any patent claims and other intellectual property rights; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the terms and conditions of our existing collaborative
        and licensing agreements.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The sale of additional equity
or convertible debt securities would likely result in substantial dilution to our shareholders. If we raise additional funds through the
incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of our capital stock and
could contain covenants that would restrict our operations. We also cannot predict what consideration might be available, if any, to us
or our shareholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available
to us, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the
normal course of business which may, among other alternatives, cause us to further delay, substantially reduce or discontinue operational
activities to conserve our cash resources. &#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Our
approach in the area of fibrotic diseases is novel and unproven and may not result in marketable products. </span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our central objective is to
design and develop targeted treatments for inflammation and fibrosis with an initial focus on the neutralization of CCL24 signaling, which
is shown to regulate fibrotic and inflammatory processes. While several studies are currently underway, this mechanism has not yet been
proven to successfully treat inflammation and fibrosis in patients. Targeting CCL24 to treat inflammation and fibrosis is a novel approach
in a rapidly developing field, and there can be no assurance that we can avoid unforeseen problems or delays in the development of our
product candidates, that such problems or delays will not result in unanticipated costs, or that any such development problems can or
will be solved. We have only completed clinical studies of our lead product candidate, CM-101, in relatively early trials in healthy volunteers,
NAFLD, NASH and COVID-19 lung injury patients. Therefore, we may ultimately discover that our approach does not possess properties required
for therapeutic effectiveness. As a result, we may elect to abandon the program or never succeed in developing a marketable product, which
would have a significant effect on the success and profitability of our business. &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold">Clinical
development involves a lengthy, complex and expensive process, with an uncertain outcome.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">&#160;</span>&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Before obtaining the
requisite regulatory approvals from the FDA or other comparable foreign regulatory authorities for the sale of any of our product candidates,
we must support our application with clinical studies that prove that such product candidate is safe and effective in humans. Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. In particular, the general approach
for FDA approval of a new drug requires positive data from two well-controlled Phase 3 clinical studies of the relevant drug in the relevant
patient population. Failure can occur at any time during the clinical study process. We may experience delays in initiating and completing
any clinical studies that we are conducting or intend to conduct, including as a result of public health emergencies, and we do not know
whether our ongoing or planned clinical studies will begin or progress on schedule, need to be redesigned, enroll patients on time or
be completed on schedule, or at all.</div>

<div style="text-indent: 24.5pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Phase 3 clinical studies
typically involve hundreds of patients, have significant costs and take years to complete. A product candidate can fail at any stage of
testing, even after observing promising signals of activity in earlier preclinical studies or clinical trials. The results of preclinical
studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical studies. In addition,
initial or interim success in clinical studies may not be indicative of results obtained when such studies are completed. There is typically
an extremely high rate of attrition from the failure of product candidates proceeding through clinical studies. Product candidates in
later stages of clinical studies may fail to show the desired safety and efficacy profile despite having progressed through preclinical
studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced
clinical studies due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier studies. Most product
candidates that commence clinical studies are never approved as products and there can be no assurance that any of our future clinical
studies will ultimately be successful or support further clinical development of CM-101. Product candidates that appear promising in the
early phases of development may fail to reach the market for several reasons, including:</div>

<div style="text-indent: 24.5pt; line-height: 1.25">

<div style="line-height: 1.25">

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of
        our clinical studies;</div> </div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">obtaining regulatory authorizations to commence a trial or consensus with regulatory authorities on trial&#8217;s
        design;</div> </div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">reaching an agreement on acceptable terms with prospective clinical research organizations, or CROs, and
        clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial
        sites;</div> </div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">obtaining IRB approval at each site, or Independent Ethics Committee, or IEC, approval at sites outside
        the United States;</div> </div> </div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues
        or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;</div> </div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">clinical studies may show the product candidates to be less effective than expected (e.g., a clinical study
        could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities;</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">failure to establish clinical endpoints that applicable regulatory authorities would consider clinically
        meaningful;</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the occurrence of serious adverse events in trials
        of the same class of agents conducted by other companies;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">adding a sufficient number of clinical study
        sites;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">manufacturing sufficient quantities of product
        candidate with sufficient quality for use in clinical studies;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">having patients complete a trial or return for
        post-treatment follow-up;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">recruiting suitable patients to participate in
        a trial in a timely manner and in sufficient numbers;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">a facility manufacturing our product candidates
        or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down
        due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations
        of product candidates in the manufacturing process;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">third-party clinical investigators losing the
        licenses or permits necessary to perform our clinical studies, not performing our clinical studies on our anticipated schedule or consistent
        with the clinical study protocol, GCP, or other regulatory requirements;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">third-party contractors not performing data collection
        or analysis in a timely or accurate manner;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">manufacturing costs, formulation issues, pricing
        or reimbursement issues, or other factors that make a product candidate uneconomical; or</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the proprietary rights of others and their competing
        products and technologies that may prevent our product candidates from being commercialized.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;In addition, differences
in trial design between early-stage clinical studies and later-stage clinical studies make it difficult to extrapolate the results of
earlier clinical studies to later clinical studies. Moreover, clinical data are often susceptible to varying interpretations and analyses,
and many companies that have believed their product candidates performed satisfactorily in clinical studies have nonetheless failed to
obtain marketing approval of their products.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;In addition, the standards
used by the FDA and comparable foreign regulatory authorities when regulating us require judgment and can change, which makes it difficult
to predict with certainty how they will be applied. For more information, see &#8220;<span style="font-style: italic">Risk Factors &#8211;
Risks Related to Our Regulatory Approvals</span>.&#8221;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Successful completion
of clinical studies is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable
foreign regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product
candidates. We may experience negative or inconclusive results, which may result in us deciding, or us being required by regulators, to
conduct additional clinical studies or trials or abandon some or all of our product development programs, which could have a material
adverse effect on our business. &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold">We may
incur additional costs or experience delays in completing the development and commercialization of CM-101 or any other product candidates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We may experience delays in
initiating or completing clinical studies. We also may experience numerous unforeseen events during, or as a result of, any future clinical
studies that could delay or prevent our ability to receive marketing approval or commercialize CM-101 or any other product candidates,
including:</div>

<div style="line-height: 1.25">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">regulators, IRBs, or IECs may not authorize us or our investigators to commence a clinical study or conduct
        a clinical study at a prospective trial site;</div> </div> </div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">the FDA or other comparable regulatory authorities may disagree with our clinical study design, including
        with respect to dosing levels administered in our planned clinical studies, which may delay or prevent us from initiating our clinical
        studies with our originally intended trial design;</div> </div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">
        <div style="line-height: 1.25">
        <div style="text-align: left; line-height: 1.25">we may experience delays in reaching, or fail to reach, agreement on acceptable terms
        with prospective trial sites and prospective CROs, which can be subject to extensive negotiation and may vary significantly among different
        CROs and trial sites;</div> </div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the number of subjects required for clinical
        studies of any product candidates may be larger than we anticipate or subjects may drop out of these clinical studies or fail to return
        for post-treatment follow-up at a higher rate than we anticipate;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">our third-party contractors may fail to comply
        with regulatory requirements or meet our contractual obligations to us in a timely manner, or at all, or may deviate from the clinical
        study protocol or drop out of the trial, which may require that we add new clinical study sites or investigators;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">due to the impact of emerging public health threats,
        we may experience, delays and interruptions to clinical studies, we may experience delays or interruptions to our manufacturing supply
        chain, or we could suffer delays in reaching, or we may fail to reach, agreement on acceptable terms with third-party service providers
        on whom we rely;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">additional delays and interruptions to our clinical
        studies could extend the duration of the trials and increase the overall costs to finish the trials as our fixed costs are not substantially
        reduced during delays;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">we may elect to, or regulators, IRBs, Data Safety Monitoring Boards
        or ethics committees may require that us or its investigators, suspend or terminate clinical research or trials for various reasons, including
        noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">we may not have the financial resources available to begin and complete
        the planned trials, or the cost of clinical studies of any product candidates may be greater than we anticipate; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the supply or quality of our product candidates
        or other materials necessary to conduct clinical studies of our product candidates may be insufficient or inadequate to initiate or complete
        a given clinical study.</div> </td> </tr>
  </table>

<div><br/> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt">Our product development costs
will increase if we experience additional delays in clinical testing or in obtaining marketing approvals. We do not know whether any of
our clinical studies will begin as planned, will need to be restructured or will be completed on schedule, or at all. If we do not achieve
our product development goals in the time frames we announce and expects, the approval and commercialization of our product candidates
may be delayed or prevented entirely. Significant clinical study delays also could shorten any periods during which we may have the exclusive
right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing
our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our
clinical development programs may harm our business, financial condition and results of operations significantly.<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold">Our ongoing
and future clinical studies may reveal significant adverse events or immunogenicity related responses and may result in a safety profile
that could delay or prevent regulatory approval or market acceptance of our product candidate.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We completed our Phase 1a
and Phase 1b and Phase 2a clinical studies of our product candidate, CM-101, in healthy volunteers, NAFLD, NASH and COVID-19 lung injury
patients, and, with the exception of a number of reported minor adverse events (including mild headaches, changes in blood pressure and
mild-moderate increases in liver enzymes,) and one serious adverse event (a transient ischemic attack or seizure judged to be unrelated
to administration of CM-101), CM-101 was observed to be generally well-tolerated across all doses in about 70 trial participants. Some
potential therapeutics developed in the biopharmaceutical industry that initially showed therapeutic promise in early-stage trials have
later been found to cause side effects that prevented their further development and ultimately commercialization. Even if side effects
do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance
of the approved product due to its tolerability versus other therapies.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Protein biopharmaceuticals, including monoclonal
antibodies, or mAbs, may be immunogenic and promote immune responses against themselves. In particular, anti-drug antibodies, or ADAs,
may be produced by patients following infusion mAbs and may disturb the pharmacokinetics of mAbs, neutralize their therapeutic activities
or induce allergic or autoimmune symptoms. Clinical immunogenicity can range from mild, transient antibody responses with no apparent
clinical manifestations to loss of therapeutic efficacy and even life-threatening reactions. Several approved therapeutic antibodies have
been found to induce neutralizing antibodies, as illustrated by the approved anti-TNFa antibodies infliximab and adalimumab as well as
the approved anti-IL-17 mAb ixekizumab. Our product candidate, CM-101, is a humanized antibody that, similar to other humanized approved
mAbs, was shown to include several non-germline sequences that may serve as a source for immunogenicity in therapeutic antibodies. Clinical
studies to date have not identified any anti-drug antibodies, or ADAs. Additional larger clinical studies will be needed to address the
risk of immunogenicity and, if discovered, our business will be materially and adversely affected.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Additionally, if unacceptable
side effects, including materialized risks of immunogenicity, do arise in the development of our product candidates, we, the FDA or the
IRBs at the institutions in which our studies are conducted, or the Data Safety Monitoring Board, if constituted for our clinical studies,
could recommend a suspension or termination of our clinical studies, or the FDA or comparable foreign regulatory authorities could order
us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related
side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability
claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have
to train medical personnel using our product candidates to understand the side effect profiles for our clinical studies and upon any commercialization
of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates
could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Additionally, if one or more
of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products,
a number of potentially significant negative consequences could result, including:</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">regulatory authorities may withdraw approvals of such product;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">regulatory authorities may require additional
        warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><br/> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">additional restrictions may be imposed on the
        marketing of the particular product or the manufacturing processes for the product or any component thereof;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">we may be required to implement a Risk Evaluation
        and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">we could be sued and held liable for harm caused
        to patients;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the product may become less competitive; and</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">our reputation may suffer.</div> </td> </tr>
  </table>

<div><br/> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Any of these events could
prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business,
results of operations and prospects.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Interim,
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available or as additional analyses are conducted and are subject to audit and verification procedures that could result in material changes
in the final data.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">From time to time, we may
publicly disclose preliminary, interim or topline data from our clinical trials. The preliminary data is based on a preliminary analysis
of then available data, and the results and related findings and conclusions are subject to change following a more comprehensive review
of the data related to the particular study or trial. For example, we may report tumor responses in certain patients that are unconfirmed
at the time and which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions,
estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully
and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or
different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline
data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary
data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition,
we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient
data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further,
additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common
stock.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In addition, the information
we choose to publicly disclose regarding a particular clinical trial is typically selected from a more extensive amount of available information.
You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure,
and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views,
activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ
from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability
to obtain approval for any product candidates that we may develop in the future may be harmed, which could harm our business, financial
condition, results of operations and prospects.<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay. </span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">As product candidates progress
through preclinical studies and clinical trials to regulatory approval and commercialization, it is common that various aspects of the
development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing
batch size, minimize costs and achieve consistent quality and results. Any material manufacturing changes made to any product candidate
that we may develop could perform differently and affect the results of planned clinical trials or other clinical trials conducted with
the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition
of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to
commercialize any product candidates that we may develop in the future, if approved, and generate revenue.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">If
we encounter difficulties enrolling patients in our clinical studies, including due to COVID-19 or other public health emergencies, our
clinical development activities could be delayed or otherwise adversely affected.</span><br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We may experience difficulties
in patient enrollment in our clinical studies for a variety of reasons. The timely completion of clinical studies in accordance with our
protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion.
The enrollment of patients depends on many factors, including:</div>

<div style="text-align: justify; line-height: 1.25">

<div style="text-align: left; line-height: 1.25">

<div style="line-height: 1.25">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">the patient eligibility and exclusion criteria defined in the protocol;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the need to receive study drug via an IV infusion;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the size of the patient population required for
        analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the willingness or availability of patients to
        participate in our trials (including due to fears of contracting COVID-19);</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the proximity of patients to trial sites;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the design of the trial;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">our ability to recruit clinical study investigators
        with the appropriate competencies and experience;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">clinicians&#8217; and patients&#8217; perceptions
        as to the potential advantages and risks of the product candidate being studied with respect to other available therapies, including any
        new products that may be approved for the indications we are investigating;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the availability of competing commercially available
        therapies and other competing product candidates&#8217; clinical studies;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">our ability to obtain and maintain patient informed
        consents; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the risk that patients enrolled in clinical studies
        will drop out of the trials before completion.</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Further, timely enrollment
in clinical studies is reliant on clinical study sites which may be adversely affected by global health matters, including, among other
things, pandemics or armed conflicts. For example, our clinical study sites were previously affected by the COVID-19 pandemic.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Some factors from a resurgent
emerging public health emergencies that we believe could potentially adversely affect enrollment in our trials include:</div>

<div style="text-align: justify; line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: left; line-height: 1.25">

<div style="line-height: 1.25">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the diversion of healthcare resources away from
        the conduct of clinical study matters to focus on pandemic concerns, including the attention of infectious disease physicians serving
        as our clinical study investigators, hospitals serving as our clinical study sites and hospital staff supporting the conduct of our clinical
        studies;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the inability of patients to come to hospitals
        to participate in our trials, which may force us to conduct our trials in patients&#8217; homes, rendering the trials more difficult and
        costly to conduct;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">limitations on travel that interrupt key trial
        activities, such as clinical study site initiations and monitoring; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">employee furlough days that delay necessary interactions
        with local regulators, ethics committees and other important agencies and contractors.</div> </td> </tr>
  </table>

<div><br/> </div> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 34pt; line-height: 1.25; font-family: Times New Roman,serif">These and other factors arising
from a resurgent COVID-19 pandemic or other emerging public health emergencies could adversely impact our clinical studies.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">The
market opportunities for CM-101, if approved, may be smaller than we anticipate. </span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We expect to initially seek
approval of CM-101 for the treatment of PSC and SSc. Our projections of the number of PSC and SSc patients is based on our beliefs and
estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations and publicly
available databases, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of patients, and
the number of patients may turn out to be lower than we expected. The potential addressable patient population for our current programs
or future product candidates may be limited. The ultimate market opportunity for our product candidates will depend on, among other things,
the final labeling for such product candidates as agreed with the FDA or comparable foreign regulatory authorities, acceptance by the
medical community and patient access, potential competition and drug pricing and reimbursement. Even if we obtain significant market share
for any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining
marketing approval for additional indications.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Due
to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product
candidates; these decisions may prove to be wrong and may adversely affect our business.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We have limited financial
and human resources and intend to initially focus on research programs and product candidates for a limited set of indications. As a result,
we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater
commercial potential or a greater likelihood of success.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">There can be no assurance that we will ever
be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates
through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts
and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">If product liability
lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization
of our product candidates.</span><br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We face an inherent risk of
product liability as a result of testing CM-101, and will face an even greater risk if we commercialize any products. For example, we
may be sued if any of our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical
studies, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects
in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could
also be asserted under state consumer protection acts. If we cannot successfully defend itself against product liability claims, we may
incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require
significant financial and management resources. Our inability to obtain sufficient product liability insurance at an acceptable cost to
protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We will need
to obtain additional insurance for clinical studies as we continue clinical development of CM-101 and as additional product candidates
enter clinical studies. However, we may be unable to obtain, or may obtain on unfavorable terms, clinical study insurance in amounts adequate
to cover any liabilities from any of our clinical studies. Our insurance policies may also have various exclusions, and we may be subject
to a product liability claim for which we have no coverage. We may have to pay any amount awarded by a court or negotiated in a settlement
that exceeds our coverage limitations or that are not covered by insurance, and we may not have, or be able to obtain, sufficient capital
to pay such amounts. Even if our agreements with any future corporate collaborators entitles us to indemnification against losses, such
indemnification may not be available or adequate should any claim arise.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">We
have been granted Orphan Drug Designation for CM-101 in connection with three indications and may seek Orphan Drug Designation for other
indications or product candidates, and we may be unable to maintain the benefits associated with Orphan Drug Designation, including the
potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for our other product candidates.</span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Regulatory authorities in
some jurisdictions, including the United States and Europe, may designate drugs intended for relatively small patient populations as orphan
drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition,
which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater
than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from
sales in the United States. In the United States, Orphan Drug Designation has entitled a party to financial incentives such as opportunities
for grant funding toward clinical study costs, tax advantages and user-fee waivers. In addition, if a product that has Orphan Drug Designation
subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug
exclusivity, which means that the FDA may not approve any other applications, including a full NDA to market the same product for the
same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan
drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. However, Orphan Drug Designation neither shortens
the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.
In 2022, the Eleventh Circuit&#8217;s decision in Catalyst Pharmaceuticals, Inc. v. FDA challenges FDA&#8217;s long-standing interpretation
and provides that the orphan drug exclusivity should be applied to block FDA approval of the same drug for the &#8220;same disease or
condition&#8221; instead of the approved indication during the exclusivity period. If the Catalyst decision is applied beyond the facts
of that case, FDA may revoke approvals or the grant of subsequent orphan exclusivity periods for the same drugs approved for different
indications within the same orphan-designated disease or condition. Catalyst has created some uncertainty with respect to the scope of
the orphan drug exclusivity and may increase legal challenges in the field. FDA may work with the Congress to amend the orphan drug provisions
in the law to provide more clarity to stakeholders. The extent of the impact of the Catalyst decision on the industry and on FDA&#8217;s
regulation and policies with respect to orphan exclusivity as well as the impact of any future legislation on orphan drug approval and
exclusivity is unclear.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In Catalyst Pharms., Inc.
v. Becerra, 14 F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that the orphan drug exclusivity
only applies to the approved use or indication within an eligible disease. This decision created uncertainty in the application of the
orphan drug exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies
with the court&#8217;s order in Catalyst, FDA intends to continue to apply its longstanding interpretation of the regulations to matters
outside of the scope of the Catalyst order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the
uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications
within the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation,
agency decisions, and administrative actions will impact the scope of the orphan drug exclusivity.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The FDA and EMA granted Orphan
Drug Designation to CM-101 in its primary indications of PSC, SSc and idiopathic pulmonary fibrosis, or IPF. We may seek Orphan Drug Designations
for CM-101 in other indications or for other product candidates. There can be no assurance that we will be able to obtain such designations.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Even if we obtain Orphan Drug
Designation for any product candidate in specific indications, we may not be the first to obtain marketing approval of such product candidate
for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive
marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication
or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable
to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Further, even if we obtain
orphan drug exclusivity in the United States for a product, that exclusivity may not effectively protect the product from competition
because different drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved,
the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later
drug is safer, more effective or makes a major contribution to patient care.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">We
will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;As of December 31, 2023, we had
20 employees / full time consultants. In the future, we expect to experience significant growth in the number of our employees and the
scope of our operations, particularly in the areas of product candidate development, regulatory affairs and sales and marketing. We may
have difficulty identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities
on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors.
Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial
amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may
result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced
productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources
from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our
expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement
our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively
will depend, in part, on our ability to effectively manage any future growth.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25"><span style="font-family: Times New Roman,serif">&#160;Many of
the biopharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources,
different risk profiles and a longer history in the industry than we do. If we are unable to continue to attract and retain high-quality
personnel and consultants, the rate and success at which we can discover and develop product candidates and operate our business will
be limited.<br/> </span><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="font-weight: bold; font-style: italic">We have
incurred significant operating losses since our inception and anticipate we will incur continued losses for the foreseeable future.</span>&#160;</div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We have has funded our operations
to date through proceeds from sales of our equity and grants from the Israel Innovation Authority, or the IIA, which as of December 31,
2023, resulted in gross proceeds of approximately $98.5 million. As of December 31, 2023, our cash, cash equivalents and deposits were
approximately $19.9 million. We have incurred net losses in each year since our inception, and we have an accumulated deficit of $88.7
million as of December 31, 2023. We expect our existing cash, cash equivalents and bank deposits will allow us to fund our operating expenses
and capital expenditure requirements through March 31, 2025.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Substantially all of
our operating losses have resulted from general and administrative costs associated with our operations, and costs associated with our
research and development programs, including for our preclinical and clinical product candidates. We expect to incur increasing levels
of operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses,
have had and will continue to have an adverse effect on our shareholders&#8217; deficit and working capital. In any particular quarter
or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause the price of
our ADSs to decline.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;We expect our research
and development expenses to significantly increase in connection with our clinical studies of our product candidates. In addition, if
we obtain marketing approval for our product candidates, we will incur significant sales and marketing, legal, and outsourced-manufacturing
expenses. As a public company, we expect to continue to incur significant and increasing operating losses for the foreseeable future.
Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are also unable to predict the
extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain
or increase our profitability on a quarterly or annual basis.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><span style="font-weight: bold; font-style: italic">We
may be subject to cyber-attacks or other disruptions to or breaches of our information technology, systems or networks that could irreparably
damage our reputation and our business, expose us to liability and materially and adversely affect our results of operations.</span>&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;In conducting our business,
we routinely collect, store and otherwise process proprietary, confidential or sensitive data, including personal information and proprietary
technology and information about our business and patients, suppliers and business partners, including proprietary technology. The secure
maintenance, transmission and other processing of this data and information is critical to our operations and business strategy. Our employees
occasionally work remotely, based on a hybrid work model, which creates a heightened risk of cyber-attacks or other disruptions to or
breaches of our information technology, systems or networks.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;We may be subject to
cyber-attacks or other disruptions to or breaches of our information technology, systems or networks caused by computer viruses, software
bugs, server malfunctions, software or hardware failure, illegal hacking, criminal fraud or impersonation, ransomware attacks, denial-of-service
attacks, malware, social engineering or phishing attacks, acts of vandalism or terrorism, unauthorized access, theft or employee malfeasance
or error.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Cyber-attacks are increasing
in number and sophistication, are well-financed, in some cases supported by state actors, and are designed to not only attack, but also
to evade detection. Since the techniques used to obtain unauthorized access to information technology, systems, and networks, or to otherwise
sabotage them, change frequently, have become increasingly complex and sophisticated, including through the use of artificial intelligence,
and are often not recognized until launched against a target, we and third parties associated with us may be unable to anticipate these
techniques or to implement adequate preventative measures. Cyber-attacks can originate from a wide variety of sources, including organized
crime, hackers, activists, terrorists, nation-states, nation-state supported actors and others, any of which may see their effectiveness
enhanced by the use of artificial intelligence.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;In addition, certain
global geopolitical events can increase our cybersecurity risk. For example, due to the ongoing Russia-Ukraine conflict, there have been
publicized threats to increase cyber-attack activity against the critical infrastructure of any nation or organization that retaliates
against Russia for its invasion of Ukraine. There have also been similar publicized threats in connection with the geopolitical tension
with the Iranian regime and more specifically in connection with the terror attacks by Hamas on Israel, since October 7,&#160;2023. These
threats include threats to harm Western countries&#8217; infrastructure and assets. The costs to us to reduce the risk of or alleviate
cybersecurity breaches and vulnerabilities could be significant.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Any type of security
breach, attack or misuse of data, whether actual or perceived, and whether experienced by us or an associated third party, could harm
our reputation or deter existing or prospective patients from enrolling or continuing in clinical trials, increase our operating expenses
in order to contain and remediate the&#160;incident, expose us to unbudgeted or uninsured liability, disrupt our operations, divert management
focus away from other priorities, increase our risk of regulatory scrutiny, result in litigation from patients, employees or other third
parties, lead to the imposition of penalties, reporting obligations and fines under state, federal and foreign laws or by payment networks
or adversely affect our continued payment network registration and financial institution sponsorship. Moreover, any such compromise of
our information security could result in the loss, misappropriation, corruption or unauthorized publication of our confidential business
or proprietary information or personal or sensitive information, or that of other parties with which we do business, an interruption or
other failure of our information technology, systems, networks or operations, the unauthorized transfer of cash or other of our assets,
the unauthorized release of patient or employee data or a violation of laws, regulations, industry standards or other legal or contractual
obligations related to privacy, data protection and information security. Computer programmers and hackers also may be able to develop
and deploy viruses, worms and other malicious software programs that attack our products, or that otherwise exploit any security vulnerabilities,
and any such attack, if successful, could expose us to liability to patient claims. In addition, our ability to monitor our third-party
service providers&#8217; data security is limited. Some of our third-party service providers may store or have access to our data and
may not have effective controls, processes, or practices to protect our information from loss, unauthorized disclosure, unauthorized use
or misappropriation or other cyber-attacks or other disruptions to or breaches of information security. A vulnerability in our third-party
service providers&#8217; software or information technology, systems or networks, a failure of our third-party service providers&#8217;
safeguards, policies or procedures, or a cyber-attack or other disruption to or breach of information security affecting any of these
third parties could irreparably damage our reputation and business. The costs related to significant cyber-attacks or other disruptions
to or breaches of our information technology, systems or networks could be material and cause us to incur significant expenses. If the
information technology, systems or networks of third parties associated with us become subject to cyber-attacks or other disruptions or
security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate
the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. Any of the
foregoing could irreparably damage our reputation and business, which could have a material adverse effect on our results of operations.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;We cannot ensure that
any limitation of liability provisions in our agreements with patients, service providers, business partners and other third parties with
which we do business would be enforceable or adequate or would otherwise protect us from any liabilities or damages with respect to any
particular claim in connection with a cyber-attack or other disruption to or breach of information security. Additionally, we cannot be
certain that our insurance coverage will be adequate for cybersecurity liabilities actually incurred, that insurance will continue to
be available to us on economically reasonable terms, or at all, or that our insurer will not deny coverage as to any future claim.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">Risks Related to Our Intellectual Property Rights</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">If
we are unable to protect our patents or other proprietary rights, or if we infringe the patents or other proprietary rights of others,
our competitiveness and business prospects may be materially damaged.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Patent and other proprietary
rights are essential to our business. Our success depends to a significant degree on our ability to obtain and enforce patents and licenses
to patent rights, both in the United States and in other countries. We cannot guarantee that pending patent applications will result in
issued patents, that patents issued or licensed will not be challenged or circumvented by competitors, that the patents and other intellectual
property rights of us and our business partners will not be found to be invalid or that the intellectual property rights of others will
not prevent us from selling our products or from executing on our strategies.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;The patent position
of a biopharmaceutical company is often uncertain and involves complex legal and factual questions. Significant litigation concerning
patents and products is pervasive in our industry. Patent claims include challenges to the coverage and validity of our patents on products
or processes as well as allegations that our products infringe patents held by competitors or other third parties. A loss in any of these
types of cases could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of
sales, or otherwise materially affect future results of operations. We also rely on trademarks, copyrights, trade secrets and know-how
to develop, maintain and strengthen our competitive positions. Third parties may know, discover or independently develop equivalent proprietary
information or techniques, or they may gain access to our trade secrets or disclose such trade secrets to the public.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Although our employees,
consultants, parties to collaboration agreements and other business partners are generally subject to confidentiality or similar agreements
to protect our confidential and proprietary information, these agreements may be breached, and we may not have adequate remedies for any
breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our
employees, consultants, parties to collaboration agreements and other business partners use intellectual property owned by others in their
work for the company, disputes may arise as to the rights in related or resulting know-how and inventions.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Furthermore, our intellectual
property, other proprietary technology and other sensitive company data is potentially vulnerable to loss, damage or misappropriation
from system malfunction, computer viruses, unauthorized access to data or misappropriation or misuse thereof by those with permitted access
and other events. While we have invested to protect our intellectual property and other data, and continue to work diligently in this
area, there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber incidents or other events. Such
events could have a material adverse effect on our reputation, business, financial condition or results of operations. Misappropriation
or other loss of our intellectual property from any of the foregoing could have a material adverse effect on our competitive position
and may cause us to incur substantial litigation costs.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman, serif"><br/> <span style="font-weight: bold; font-style: italic">We
may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent,
which might adversely affect our ability to develop, manufacture and market our product candidates.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">From time to time we may identify
patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are
irrelevant to our business based on various factors, including our interpretation of the scope of the patent claims and our interpretation
of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while
we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately
predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may
be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims.
If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from
commercializing our product candidates or be required to obtain a license under such patent, which may not be available on reasonable
terms or at all. We might, if possible, also be forced to redesign our product candidates so that it no longer infringes, misappropriates
or otherwise violates the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. Any of
the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Changes
in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product
candidates.</span><br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As is the case with other biopharmaceutical
and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing
patents in the biopharmaceutical and pharmaceutical industries involves both technological and legal complexity. Therefore, obtaining
and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the Leahy-Smith
America Invents Act, or the AIA, which was passed in September 2011, resulted in significant changes to the United States patent system.</div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">An important change introduced
by the AIA is that, as of March 16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221;
system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming
the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor
to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the
invention earlier. A third party that files a patent application in the USPTO after that date but before we could therefore be awarded
a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be
cognizant of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances
could prevent us from promptly filing patent applications on our inventions.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Among some of the other changes
introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third
parties to challenge any issued patent with the USPTO. This applies to all of our United States patents, even those issued before March
16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts
necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO
to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court
action.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Accordingly, a third party
may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the
third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our
business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our
licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We may become involved in
opposition, interference, derivation, inter partes review, post-grant review, reexamination or other proceedings challenging our or our
licensors&#8217; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding
could reduce the scope of, or invalidate, our owned or in-licensed patent rights, in whole or in part, allow third parties to commercialize
our technology or products and compete directly with us, without payment to it, or result in our inability to manufacture or commercialize
products without infringing third-party patent rights.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Additionally, the United States
Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain
patents in the future, this combination of events has created uncertainty with respect to the validity, enforceability and value of patents,
once obtained. Depending on decisions by Congress, the federal courts and the USPTO, as well as similar bodies in other jurisdictions,
the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to
enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent
laws have also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that
are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future
that may be important for our business, and these laws and regulations patents could continue to change in unpredictable ways that could
have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><br/>
&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">The USPTO and European and other patent agencies
require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process.
In addition, periodic maintenance, renewal and annuity fees on any issued patent are due to be paid to the USPTO and European and other
patent agencies over the lifetime of a patent. While an inadvertent failure to make payment of such fees or to comply with such provisions
can in many cases be cured by additional payment of a late fee or by other means in accordance with the applicable rules, there are situations
in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss
of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application
include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and
submit formal documents within prescribed time limits. If we or our licensors fails to maintain the patents and patent applications covering
our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors
might be able to enter the market, which would hurt our&#160; competitive position and could impair our ability to successfully commercialize
our product candidates in any indication for which they are approved, which could have a material adverse effect on our business, financial
condition, results of operations, and prospects.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold"><br/> Risks Related to Our Regulatory Approvals
&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold">The regulatory
approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are
ultimately unable to obtain regulatory approval for CM-101 or any other product candidates, our business will be substantially harmed.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The time required to obtain
approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical
studies and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies,
regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s
clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application.
Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that
our data is insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical
testing and receives approval of any regulatory filing for our product candidates, the FDA and other comparable foreign regulatory authorities
may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have
not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for CM-101
or any other product candidate. We are not permitted to market any of our product candidates in the United States until we receive regulatory
approval of an NDA from the FDA.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Prior to obtaining approval
to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled
clinical studies, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidate is safe and effective
for its intended use. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the
preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA
and other regulatory authorities.</div>

<div style="line-height: 1.25">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the FDA or any foreign regulatory bodies can
        delay, limit or deny approval of our product candidates or require us to conduct additional preclinical or clinical testing or abandon
        a program for many reasons, including:</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the FDA or comparable foreign regulatory authorities
        may disagree with the design or implementation of our clinical studies;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">we may be unable to demonstrate to the satisfaction
        of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">serious and unexpected drug-related side effects
        experienced by participants in our clinical studies or by individuals using drugs similar to our product candidates, or other products
        containing the active ingredient in our product candidates;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">negative or ambiguous results from our clinical
        studies or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities
        for approval;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the population studied in the clinical study
        may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">we may be unable to demonstrate that a product
        candidate&#8217;s clinical and other benefits outweigh its safety risks;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the FDA or comparable foreign regulatory authorities
        may disagree with our interpretation of data from preclinical studies or clinical trials;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the data collected from clinical studies of our
        product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory
        approval in the United States or elsewhere, and we may be required to conduct additional clinical studies;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the FDA&#8217;s or the applicable foreign regulatory
        agency&#8217;s disagreement regarding the formulation, labeling and/or the specifications of our product candidates;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the FDA or comparable foreign regulatory authorities
        may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which our contracts
        for clinical and commercial supplies; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the approval policies or regulations of the FDA
        or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</div>
        </td> </tr>
  </table>

<div><br/> </div> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;Moreover, preclinical and clinical
data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed
satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority
approval. We cannot guarantee that the FDA or foreign regulatory authorities will interpret trial results as we do, and more trials could
be required before we are able to submit applications seeking approval of our product candidates. To the extent that the results of the
trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to
expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product
candidates. Furthermore, the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign regulatory authorities
delaying, limiting or denying approval of our product candidates.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Of the large number
of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This
lengthy approval process, as well as the unpredictability of future clinical trial results, may result in us failing to obtain regulatory
approval to market CM-101 or any other product candidate, which would significantly harm our business, results of operations and prospects.</div>

<div style="text-indent: 24.5pt; line-height: 1.25">&#160;<br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;In addition, the FDA
or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than
we originally requested, and the FDA or applicable foreign regulatory agency may approve a product candidate with a REMS or a label that
does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Regulatory
authorities may also grant approval contingent on the performance of costly post-marketing clinical trials. Any of the foregoing scenarios
could materially harm the commercial prospects for our product candidates.&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;In order to market
any product outside of the United States, we must establish and comply with the numerous and varying safety, efficacy, and other regulatory
requirements of other countries. Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not
guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining
regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Our product candidates
may not receive marketing approval even if they achieve their primary endpoints in future Phase 3 clinical studies or registrational trials.
The FDA or comparable foreign regulatory authorities may disagree with our trial designs and our interpretation of data from preclinical
studies or clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate
even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 or registrational clinical study. In addition,
any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than our request or may
grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or comparable foreign regulatory authorities
may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product
candidates, if approved.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Furthermore, even if
the FDA or other comparable foreign regulatory authority grants marketing approval of a product candidate, comparable regulatory authorities
in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United
States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted
by regulatory authorities in other jurisdictions. The marketing approval processes in other countries may implicate all of the risks detailed
above regarding FDA approval in the United States, as well as other risks. In many jurisdictions outside the United States, a product
candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we
intend to charge for our products is also subject to approval.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Obtaining foreign regulatory
approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could
delay or prevent the introduction of our products in certain countries. Failure to obtain marketing approval in other countries or any
delay or other setback in obtaining such approval would impair our ability to market our product candidates in such foreign markets. Any
such impairment would reduce the size of our potential market, which could have a material adverse impact on our business, results of
operations, and prospects.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Even
if we obtain regulatory approval for CM-101 or any product candidate, we will still face extensive and ongoing regulatory requirements
and obligations and any product candidate, if approved, may face future development and regulatory difficulties.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Any product candidate for
which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution,
adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other
things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements
include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements,
continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance
of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for
any clinical studies that we conduct post-approval.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Even if marketing approval
of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may
be marketed or to the conditions of approval, including a requirement to implement a REMS. If any of our product candidates receives marketing
approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product
candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety
or efficacy of a product. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs
may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well
as state consumer protection laws.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In addition, later discovery
of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply
with regulatory requirements, may yield various results, including:</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">restrictions on manufacturing such products;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">restrictions on the labeling or marketing of products;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">restrictions on product manufacturing, distribution or use;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">requirements to conduct post-marketing studies or clinical trials;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">warning letters or untitled letters;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">withdrawal of the products from the market;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">refusal to approve pending applications or supplements to approved
        applications that we submit;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">recall of products;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">fines, restitution or disgorgement of profits or revenues;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">suspension or withdrawal of marketing approvals;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">refusal to permit the import or export of our products;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">product seizure; or</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">injunctions or the imposition of civil or criminal penalties.</div>
        </td> </tr>
  </table>

<div><br/> </div> </div> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Further, the FDA&#8217;s
policies may change, and additional government regulations may be enacted that could impose extensive and ongoing regulatory requirements
and obligations on any product candidate for which we obtain marketing approval. If we are&#160; slow or unable to adapt to changes in
existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may
lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or
sustain profitability.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder our ability to hire, retain
or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized
in a timely manner or at all, which could negatively impact our business.</span>&#160;</div>

<div style="line-height: 1.25">&#160;<br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;The ability of the
FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability
to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times
at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research
and development activities is subject to the political process, which is inherently fluid and unpredictable.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Disruptions at the FDA and
other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would
harm our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the United States government
has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical
activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process
our regulatory submissions, which could harm our business.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">During the COVID-19 pandemic,
the FDA imposed preventive measures, including postponements of non-United States manufacturing and product inspections. If global health
concerns re-occur, similar restrictions could be implemented that might prevent the FDA or other regulatory authorities from conducting
their regular inspections, reviews, or other regulatory activities. This could significantly impact the ability of the FDA or other regulatory
authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.<br/>
&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">Risks Related to Commercialization
of Our Product Candidates</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">If
we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization
of our product candidates may be delayed and our business will be harmed.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 34pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;For planning purposes,
we sometimes estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives.
These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the
regulatory submissions or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these
milestones, such as the completion of an ongoing clinical study, the initiation of other clinical studies, receipt of regulatory approval
or the commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones
are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates,
including:</div>

<div style="text-indent: 25pt; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">our available capital resources or capital constraints
        we experience;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the rate of progress, costs and results of our
        clinical studies and research and development activities, including the extent of scheduling conflicts with participating clinicians and
        collaborators;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">our ability to identify and enroll patients who
        meet clinical study eligibility criteria;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">our receipt of authorizations by the FDA and
        comparable foreign regulatory authorities, and the timing thereof;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">other actions, decisions or rules issued by regulators;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">our ability to access sufficient, reliable and
        affordable supplies of materials used in the manufacture of our product candidates;</div> </td> </tr>
  </table>

<div style="font-family: Times New Roman,Times,serif"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">our ability to manufacture and supply clinical
        study materials to our clinical sites on a timely basis;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the efforts of our collaborators with respect
        to the commercialization of our products, if any; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">the securing of, costs related to, and timing
        issues associated with, commercial product manufacturing as well as sales and marketing activities.</div> </td> </tr>
  </table>

<div><br/> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 34pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;If we fail to achieve
announced milestones in the timeframes we expect, the commercialization of any of our product candidates may be delayed, and our business,
results of operations, financial condition and prospects may be adversely affected.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-weight: bold; font-style: italic">We
face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than it.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The development and commercialization
of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or
commercialize in the future from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies
worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations
that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and
commercialization.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">There are a number of large
biopharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of inflammation
and fibrosis. Companies that we are&#160; aware of that are targeting the treatment of inflammation and fibrosis include large companies
with significant financial resources such as Biogen, Inc., AbbVie Inc., Bristol Myers Squibb Co., and Novartis AG. However, we do not
know of any other companies currently in clinical development with an anti CCL24 mAb. For additional information regarding our competition,
see &#8220;Business Overview - Competition.&#8221;</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Many of our current or potential
competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and
development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals, and marketing approved products
than we do.&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold"><span style="font-family: Times New Roman,serif">Even
if CM-101 or any other product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians,
patients, third-party payors or others in the medical community necessary for commercial success.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">If CM-101 or any other product
candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients,
third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant
product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number
of factors, including but not limited to:</div>

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25">

<div style="text-align: left; text-indent: 25pt; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the efficacy and potential advantages compared
        to alternative treatments;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">effectiveness of sales and marketing efforts;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the cost of treatment with respect to alternative
        treatments, including any similar generic treatments;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">our ability to offer our products for sale at
        competitive prices;</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the convenience and ease of administration compared
        to alternative treatments;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the willingness of the target patient population
        to try new therapies and of physicians to prescribe these therapies;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the strength of marketing and distribution support;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the timing of market introduction of competitive
        products;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the availability of third-party coverage and adequate
        reimbursement;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">product labeling or product insert requirements
        of the FDA, EMA or other regulatory authorities, including any limitations on warnings contained in a product&#8217;s approved labeling;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the prevalence and severity of any side effects;
        and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">any restrictions on the use of our product together
        with other medications.</div> </td> </tr>
  </table>

<div><br/> </div> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Because we expect sales of
our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product
candidates to find market acceptance would harm its business and could require us to seek additional financing.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">We rely
completely on third-party suppliers to manufacture our clinical drug supplies for our product candidates, and we intend to rely on third
parties to produce preclinical, clinical, and commercial supplies of any future product candidates.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;We do not currently
have, nor do we plan to acquire, the infrastructure or capability to internally manufacture our clinical drug supply of our product candidates,
or any future product candidates, for use in the conduct of our preclinical studies and clinical trials.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;We lack the internal
resources and the capabilities to manufacture any product candidates on a clinical or commercial scale. The facilities used by our contract
manufacturers to manufacture the active pharmaceutical ingredient and final drug product must complete a pre-approval inspection by the
FDA and other comparable foreign regulatory agencies to assess compliance with applicable requirements, including cGMPs, after we submit
our NDA or relevant foreign regulatory market application to the applicable regulatory agency.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160; &#160; We are responsible for setting the product specifications and approving master batch records, but do not oversee the
manufacturing process itself, and are completely dependent on our contract manufacturers to comply with cGMPs for manufacture of both
active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms
to our specifications and the strict regulatory requirements of the FDA or applicable foreign regulatory agencies, they will not be able
to pass a pre-approval inspection or secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have
no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance, and qualified
personnel. Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or products
for such companies, which exposes our manufacturers to regulatory risks for the production of such materials and products. As a result,
failure to satisfy the regulatory requirements for the production of those materials and products may affect the regulatory clearance
of our contract manufacturers&#8217; facilities generally. If the FDA or an applicable foreign regulatory agency determines now or in
the future that these facilities for the manufacture of our product candidates are noncompliant, we may need to find alternative manufacturing
facilities, which would adversely impact our ability to develop, obtain regulatory approval for or market our product candidates. Our
reliance on contract manufacturers also exposes us to the possibility that they, or third parties with access to their facilities, will
have access to and may compromise our trade secrets or other proprietary information.&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold; font-style: italic">If
we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we
may not be successful in commercializing CM-101, if approved. </span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We do not have any infrastructure
for the sales, marketing or distribution of CM-101, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness
of doing so. In order to market and successfully commercialize CM-101 or any other product candidate we develop, if approved, we must
build our sales, distribution, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform
these services. We expect to build a focused sales, distribution and marketing infrastructure to market CM-101, if approved. There are
significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability
to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales
and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development
of our internal sales, marketing and distribution capabilities could delay any product launch, which would adversely impact the commercialization
of that product. Additionally, if the commercial launch of CM-101 for which we recruit a sales force and establishes marketing capabilities
is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This
may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Factors that may inhibit our
efforts to commercialize our product candidates on our own include:</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25">

<div style="text-align: left; text-indent: 25pt; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">our inability to recruit, train and retain adequate numbers of effective
        sales and marketing personnel;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">the inability of sales personnel to obtain access to physicians or
        attain adequate numbers of physicians to prescribe our products; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman, serif">unforeseen costs and expenses associated with creating an independent
        sales and marketing organization.</div> </td> </tr>
  </table> <br/> </div> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We do not anticipate having
the resources in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets
overseas. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for
such capabilities, the collaborator&#8217;s strategic interest in a product and such collaborator&#8217;s ability to successfully market
and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of CM-101, if approved, for certain
markets overseas; however, we cannot guarantee that we will be able to establish or maintain such collaborative arrangements, or if able
to do so, that we will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any
revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">If we are unable to build our
own sales force or negotiate a collaborative relationship for the commercialization of CM-101, we may be forced to delay the potential
commercialization of CM-101 or reduce the scope of our sales or marketing activities for CM-101. If we need to increase our expenditures
to fund commercialization activities for CM-101, we will need to obtain additional capital, which may not be available to us on acceptable
terms, or at all. We may also have to enter into collaborative arrangements for CM-101 at an earlier stage than otherwise would be ideal
and we may be required to relinquish rights to CM-101 or otherwise agree to terms unfavorable to us. Any of these occurrences may have
an adverse effect on our business, operating results and prospects.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">If we are unable to establish
adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful
in commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have
extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing
and sales functions, we may be unable to compete successfully against these more established companies.<span style="font-family: Times New Roman, serif"><br/>
</span>&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold; font-style: italic">A
variety of risks associated with operating internationally could materially adversely affect our business.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our research and development
facilities and certain of our executives are located in Israel and certain of our product candidates may be manufactured at third-party
facilities located in Europe. In addition, our business strategy includes potentially expanding internationally if any of our product
candidates receives regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</div>

<div style="text-align: justify; line-height: 1.25">

<div style="text-align: left; line-height: 1.25">

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25">

<div style="text-align: left; text-indent: 25pt; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">multiple, conflicting and changing laws and regulations,
        such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental
        approvals, permits and licenses;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">failure by us to obtain and maintain regulatory
        approvals for the use of our products in various countries;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">additional potentially relevant third-party patent
        rights;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">complexities and difficulties in obtaining protection
        and enforcing our intellectual property;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">difficulties in staffing and managing foreign
        operations;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">complexities associated with managing multiple
        payor reimbursement regimes, government payors or patient self-pay systems;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">limits in our ability to penetrate international
        markets;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">financial risks, such as longer payment cycles,
        difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and
        exposure to foreign currency exchange rate fluctuations;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">natural disasters, political and economic instability,
        including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">certain expenses including, among others, expenses
        for travel, translation and insurance; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">regulatory and compliance risks that relate to
        maintaining accurate information and control over sales and activities that may fall within the purview of the United States Foreign Corrupt
        Practices Act, its books and records provisions, or its anti-bribery provisions.</div> </td> </tr>
  </table>

<div><br/> </div> </div> </div> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Any of these factors could
significantly harm our international expansion and operations and, consequently, our results of operations.&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Risks Related to Our Incorporation
and Location in Israel</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold; font-style: italic">Conditions
in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and elsewhere in the region, and
Israel&#8217;s war against them, may affect our operations.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our headquarters, ten of our employees, including
our Chief Executive Officer and Chief Financial Officer, and two members of our board of directors (not including our Chief Executive
Officer) are located in Israel and therefore our business and operations are at risk of being directly affected by economic, political,
geopolitical and military conditions in Israel.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Since the establishment of
the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations
active in the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various
parts of Israel, which have negatively affected business conditions in Israel.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In October 2023, Hamas terrorists
infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas
also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza
Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians
and soldiers in the southern part of the country. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and
a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. In addition,
since the commencement of these events, there have been continued hostilities along Israel&#8217;s northern border with Lebanon (with
the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen, as described below). It is possible that hostilities
with Hezbollah in Lebanon will escalate, and that other terrorist organizations, including Palestinian military organizations in the West
Bank as well as other hostile countries, such as Iran, will join the hostilities.&#160; Such clashes may escalate in the future into a
greater regional conflict.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The intensity and duration
of Israel&#8217;s current war against Hamas is difficult to predict, as are the war&#8217;s economic implications, that may involve a
downgrade in Israel's credit rating by rating agencies (such as the recent downgrade by Moody&#8217;s of its credit rating of Israel from
A1 to A2, as well as the downgrade of its outlook rating from &#8220;stable&#8221; to &#8220;negative&#8221;), for our business and operations
and for Israel's economy in general.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In connection with the war,
several hundred thousand Israeli military reservists were called up to service. With the exception of one employee, all of our Israeli
personnel (including employees, consultants and directors) are exempt from military reserve duty, including our Chief Executive Officer
and Chief Financial Officer. The single employee who was called up has since returned to work.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">CM-101 clinical trial supplies
for our Phase 2 PSC trial are manufactured by our supplier in Denmark and are not required to be manufactured in Israel under the regulations
of the Israel Innovation Authority of the Israeli Ministry of Economy and Industry.&#160; CM-101 clinical trial supplies for our Phase
2 PSC trial are packaged and stored in Germany for ongoing importation to an Israeli depot and final distribution to our clinical sites
in Israel. The current inventory at the Israeli depot and sites is sufficient to support the ongoing patient enrollment and activity.
Resupply to the depot and sites is triggered based on product usage. That process is ongoing during the study and has been proceeding
without any complications at this time.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">As of the date of this annual
report, we have not experienced any impact to patient treatment visits in accordance with our protocol and active patients continue to
receive treatments as scheduled.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">Depending on the intensity and duration of the current war with Hamas, or any future
hostilities that may emerge, PSC patients at Israeli hospitals may elect to either withdraw from the clinical trial or relocate to a different
hospital outside of Israel. Also, the hospital staff at Israeli hospitals available to help with the conduct of the CM-101 trial may become
limited due to the general call-up of reservists to military service in the war with Hamas, or otherwise related to the ongoing hostilities.
We do not anticipate these factors will have any material adverse effect on our ability to complete the PSC clinical trial on time due
to the comparatively low ratio of patients currently being treated at Israeli hospitals relative to the total number of patients enrolled
in the clinical trial globally. Additionally, treatment of patients in the core placebo-controlled component of the trial will soon be
concluded, with treatment only continuing for the open label extension portion of the trial. Even if there were disruptions to Israeli
clinical operations going forward, we believe that the combination of the relatively advanced stage of the trial (patient enrollment has
been completed) and the relatively low number of trial participants remaining in Israel make it unlikely that the trial results or timelines
would be substantially compromised. In addition, we are establishing contingency strategies to mitigate any future risks if there are
breakdowns in communications or normal site operations.&#160; Moreover, the planning, management and execution of the CM-101 clinical
trial is led primarily from the US, where our Chief Medical Officer, our Vice President of Global Clinical Operations and most of their
team members are located.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our commercial insurance does
not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers
the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure that such government coverage
will be maintained or that it will sufficiently cover our potential damages.</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">It is currently not possible
to predict the duration or severity of the ongoing conflict or its effects on our business, operations and financial conditions. The conflict
is rapidly evolving and could disrupt our operations in Israel and hamper our ability to raise additional funds or sell our securities,
among other outcomes.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In addition, some countries
around the world restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions on doing
business with Israel and Israeli companies if hostilities in Israel or political instability in the region continue or increase. These
restrictions may limit materially our ability to obtain raw materials from these countries or sell our products and provide our services
to companies and customers in these countries. In addition, there have been increased efforts by countries, activists and organizations
to cause companies and consumers to boycott Israeli goods and services. In addition, in January 2024 the International Court of Justice,
or ICJ, issued an&#160;interim ruling&#160;in a case&#160;filed by South Africa against Israel in December 2023, making allegations of
genocide amid and in connection with the war in Gaza, and ordered Israel, among other things, to&#160; take measures to prevent genocidal
acts,&#160; prevent and punish incitement to genocide, and take steps to provide basic services and humanitarian aid to civilians in Gaza.
There are concerns that companies and businesses will terminate, and may have already terminated, certain commercial relationships with
Israeli companies following the ICJ decision. The foregoing efforts by countries, activists and organizations, particularly if they become
more widespread, as well as the ICJ rulings and future rulings and orders of other tribunals against Israel (if handed), may materially
and adversely impact our ability to sell and provide our products and services outside of Israel.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Furthermore, following Hamas&#8217;
attack on Israel and Israel&#8217;s security cabinet declaration of war against Hamas, the Houthi movement, which controls parts of Yemen,
launched a number of attacks on marine vessels traversing the Red Sea, which marine vessels were thought to either be in route towards
Israel or to be partly owned by Israeli businessmen. The Red Sea is a vital maritime route for international trade traveling to or from
Israel. As a result of such disruptions, we may experience in the future delays in supplier deliveries, extended lead times, and increased
cost of freight, increased insurance costs, purchased materials and manufacturing labor costs.&#160; The risk of ongoing supply disruptions
may further result in delayed deliveries of our products and may also have adverse impact on economic conditions in Israel.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">Finally,
political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior</span>
to October 2023, the Israeli government pursued extensive changes to Israel&#8217;s judicial system, which sparked extensive political
debate and unrest. In response to such initiative, many individuals, organizations and institutions, both within and outside of Israel,
voiced concerns that the proposed changes may negatively impact the business environment in Israel including due to reluctance of foreign
investors to invest or transact business in Israel, as well as to increased currency fluctuations, downgrades in credit rating, increased
interest rates, increased volatility in security markets and other changes in macroeconomic conditions. To date, these initiatives have
been substantially put on hold. If such changes to Israel&#8217;s judicial system are again pursued by the government and approved by
the parliament, this may have an adverse effect on our business, our results of operations and our ability to raise additional funds,
if deemed necessary by our management and board of directors.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold; font-style: italic">Because
a certain portion of our expenses are incurred in currencies other than the U.S. Dollar, our results of operations may be harmed by currency
fluctuations and inflation.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our reporting and functional
currency is the United States Dollar, but some portion of our clinical studies and operations expenses are in NIS. As a result, we are
exposed to some currency fluctuation risks. Fluctuation in the exchange rates of foreign currency has an influence on the cost of goods
sold and our financing revenues and expenses. We may, in the future, decide to enter into currency hedging transactions to decrease the
risk of financial exposure from fluctuations in the exchange rate of the currencies mentioned above with respect to the U.S. Dollar. These
measures, however, may not adequately protect us from adverse effects.<span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold; font-style: italic">We
received Israeli government grants for certain of our research and development activities as detailed below. The terms of those grants
require us to satisfy specified conditions in order to transfer outside of Israel the manufacture of products based on know-how funded
by the Israel Innovation Authority or to transfer outside of Israel the know-how itself. If we fail to comply with the requirements of
Israeli law in this regard, we may be required to pay penalties, and it may impair our ability to sell our technology outside of Israel.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Some of our research and development
efforts were financed through grants that were received from the Israel Innovation Authority of the Israeli Ministry of Economy and Industry,
or the IIA (formerly known as the Office of the Chief Scientist). When know-how is developed using IIA grants, the Encouragement of Research,
Development and Technological Innovation in Industry Law 5744-1984, or the Innovation Law, and the regulations thereunder, restrict our
ability to transfer outside of Israel either the manufacture of products based on IIA-funded know-how or the know-how itself. Such restrictions
continue to apply even after financial obligations to the IIA are paid in full. The consideration available to our shareholders in a future
transaction involving the transfer outside of Israel of know-how developed with IIA funding (such as a merger or similar transaction)
may be reduced by any amounts that we are required to pay to the IIA.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Risks Related to our ADSs</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">We will
need to raise additional capital to fund our operations, which may be unavailable to us on acceptable terms or at all, or may cause dilution
or place significant restrictions on our ability to operate our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;&#160;&#160;
If our available cash resources are insufficient to satisfy our liquidity requirements, we will be required to raise additional capital
through issuances of equity or convertible debt securities, or seek debt financing or other form of third-party funding.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;&#160;&#160;
If we are unable to obtain adequate financing or financing on terms satisfactory to us when needed, our ability to continue to pursue
our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited,
and could have a material adverse effect on our business, financial condition, results of operations and prospects.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;&#160;&#160;
The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to
our shareholders would result. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and
privileges senior to those of holders of our ADSs. The terms of debt securities issued or borrowings pursuant to a credit agreement could
impose significant restrictions on our operations. If we raise funds through collaborations or licensing arrangements, we might be required
to relinquish significant rights to our product candidates or grant licenses on terms that are not favorable to us.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">The trading
price of the ADSs has been highly volatile, and is expected to continue to be volatile.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The trading price of the ADSs
has been highly volatile, particularly over the last year. For example, on January 3, 2023, the closing price of the ADSs was $2.94 and
on December 12, 2023, the closing price of the ADSs was $0.45. This volatility may affect the price at which you are able to sell ADSs.
Our ADS price is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and
economic factors that are beyond our control. In addition, while the stock market in general has experienced high volatility, biotechnology
companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to operating
performance. Broad market and industry factors may negatively affect the market price of the ADSs, regardless of our actual operating
performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">We have
not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited
to the value of the ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We have never paid dividends
and do not anticipate paying dividends in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements,
financial condition, prospects and other factors our board of directors may deem relevant. If we do not pay dividends, the ADSs may be
less valuable because a return on your investment will only occur if our ADS price appreciates and you sell your ADS thereafter. In addition,
the Companies Law imposes restrictions on our ability to declare and pay dividends.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">If we continue
to fail to meet all applicable Nasdaq requirements, Nasdaq may delist the ADSs, which could have an adverse impact on the liquidity and
market price of the ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our ADSs are listed on Nasdaq.
To continue to be listed on Nasdaq, we are required to satisfy a number of conditions, including our bid price not falling below $1.00
per ADS for 30 consecutive days.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On November 3, 2023, we received a letter
from Nasdaq&#8217;s Listing Qualifications Department that for the last 30 consecutive business days, the closing bid price for our ADSs
was below $1.00, which is the minimum closing bid price required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5450(a)(1).
We were provided a compliance period until May 6, 2024, to regain compliance with the minimum closing bid price requirement. The company
has not yet regained compliance with the minimum closing bid price requirement. Nasdaq frequently grants out of-compliance companies another
180-day extension to regain compliance, and the company plans to apply for this additional extension if compliance has not been reestablished
before May 6, 2024.</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">If we are delisted from Nasdaq,
trading in our securities may be conducted, if available, on the OTC Markets or, if available, via another market. In the event of such
delisting, our shareholders would likely find it significantly more difficult to dispose of, or to obtain accurate quotations as to the
value of our securities, and our ability to raise future capital through the sale of our securities could be severely limited. In addition,
if our securities were delisted from Nasdaq, our ADSs could be considered a &#8220;penny stock&#8221; under the U.S. federal securities
laws. Additional regulatory requirements apply to trading by broker-dealers of penny stocks that could result in the loss of an effective
trading market for our securities.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">As a foreign
private issuer whose ADSs are listed on the Nasdaq, we intend to follow certain home country corporate governance practices instead of
certain Nasdaq requirements.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">As
a foreign private issuer whose ADSs are listed on the Nasdaq, we are permitted to follow certain home country corporate governance practices
instead of certain requirements of the rules of the Nasdaq. </span>&#160;<span style="font-family: Times New Roman,serif">For more information
regarding our corporate governance practices and foreign private issuer status, see Item 16G. &#8220;Corporate Governance.&#8221;</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Accordingly, our shareholders
and, indirectly, our ADS holders may not be afforded the same protection as provided under the Nasdaq corporate governance rules. Following
our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the Nasdaq
may provide less protection than is accorded to investors of domestic issuers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">As a foreign
private issuer, we are not subject to U.S. proxy rules and are exempt from certain reports under the Exchange Act.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">As of June 30, 2023, we became a foreign private issuer and are not now subject to the
requirements that are imposed upon U.S. domestic issuers by the SEC. As a foreign private issuer, we are exempt from the rules and regulations
under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors, and principal shareholders
are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Furthermore, although
under regulations promulgated under the Companies Law, as an Israeli public company listed on the Nasdaq, we are required to disclose
the compensation of our five most highly compensated officers on an individual basis, this disclosure is not as extensive as that required
of U.S. domestic reporting companies. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports
and financial statements with the SEC, as frequently or as promptly as U.S. domestic reporting companies whose securities are registered
under the Exchange Act. These exemptions and leniencies reduce the frequency and scope of information and protections available to you
in comparison to those applicable to a U.S. domestic reporting companies.</div> </div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">If we cease
to qualify as a foreign private issuer, we would be required to comply fully with the reporting requirements of the Exchange Act applicable
to U.S. domestic issuers, and we would incur significant legal, accounting and other expenses that we do not incur as a foreign private
issuer.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We would lose our foreign private
issuer status if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are U.S. citizens
or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. We cannot assure you
that at June 30, 2024, the next determination date of our foreign private issuer status, we will qualify as a foreign private issuer.
If we cease to qualify as a foreign private issuer at this determination date, we will be required to begin reporting as a domestic issuer
on January 1, 2025. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly
higher. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic
issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer.&#160; In addition,
we would lose our ability to rely upon exemptions from certain Nasdaq corporate governance requirements that are available to foreign
private issuers.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Holders
of ADSs are not treated as holders of our ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Holders of ADSs are not treated
as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement
and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore
do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">You may
not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise
your right to vote.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Except as described in the
deposit agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by the
ADSs. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify
you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the matters to
be voted on and explain how ADS holders may instruct the depositary how to vote. We cannot guarantee that ADS holders will receive the
voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs. For instructions
to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to
the laws of Israel and the provisions of our articles of association or similar documents, to vote or to have its agents vote the ordinary
shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions,
you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do
so.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Otherwise, ADS holders will
not be able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, ADS holders
may not know about the meeting far enough in advance to withdraw those ordinary shares. In any event, the depositary will not exercise
any discretion in voting deposited securities and it will only vote or attempt to vote as instructed. In addition, the depositary and
its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This
means that you may not be able to exercise your right to vote and there may be nothing you can do if your ordinary shares are not voted
as you requested.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Holders
of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">ADSs are transferable on the
books of the depositary. However, the depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the
depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so. These limitations on transfer
may have a material adverse effect on the value of the ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">We are
entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the
deposit agreement, without the prior consent of the ADS holders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We are entitled to amend the
deposit agreement and to change the rights of the ADS holders under the terms of such agreement without the prior consent of the ADS holders.
We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us or to the depositary.
Amendments may reflect, among other things, operational changes in the ADS program, legal developments affecting ADSs or changes in the
terms of our business relationship with the depositary. If an amendment adds or increases fees or charges, except for taxes and other
governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices
a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS
holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold the ADSs, to agree to
the amendment and to be bound by the ADSs and the deposit agreement as amended. If we make an amendment to the deposit agreement that
is disadvantageous to ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their
ADSs and become direct holders of the underlying ordinary shares, but they will have no right to any compensation whatsoever.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">ADS holders
may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes
to the plaintiff(s) in any such action.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The deposit agreement governing
the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs
irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to the
ADSs or the deposit agreement.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">If this jury trial waiver provision
is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary
opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances
of that case in accordance with the applicable state and federal law. We believe that a contractual pre-dispute jury trial waiver provision
is generally enforceable, including under the laws of the State of New York, which governs the deposit agreement. In determining whether
to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently
and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">If any holders or beneficial
owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs,
including claims under federal securities laws, such holder or beneficial owner may not be entitled to a jury trial with respect to such
claims, which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is brought against
us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would
be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including
results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims,
the judge or justice hearing such claims, and the venue of the hearing.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">No condition, stipulation or
provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of
compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold; font-style: italic">We
presently anticipate that we will not be classified as a passive foreign investment company, but no assurances can be provided in this
regard.</span>&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">We would be classified as a passive foreign investment company, or PFIC, for any taxable
year if, after the application of certain look-through rules, either: (i) 75% or more of our gross income for such year is &#8220;passive
income&#8221; (as defined in the relevant provisions of the Internal Revenue Code of 1986, as amended, or the Code), or (ii) 50% or more
of the value of our assets (generally determined on the basis of a quarterly average) during such year is attributable to assets that
produce or are held for the production of passive income. Passive income generally includes, among other things, rents, dividends, interest,
royalties, gains from the disposition of passive assets, and gains from commodities and securities transactions. For the purposes of this
test, we will be treated as owning a proportionate share of the assets and earning a proportionate share of the income of any other corporation
of which we own, directly or indirectly, at least 25% (by value) of the stock. Although the conclusion cannot be free from doubt, we do
not believe that we would be treated as a PFIC for our 2023 taxable year, but no assurances can be made in this regard.&#160;If we were
treated as a PFIC, a U.S. holder of the ordinary shares may be subject to adverse U.S. federal income tax consequences, such as taxation
at the highest marginal ordinary income tax rates on capital gains and on certain actual or deemed distributions, interest charges on
certain taxes treated as deferred, and additional reporting requirements. U.S. Holders should consult their own tax advisors and should
read the discussion below under &#8220;Item 10. Additional Information - E. Taxation - Material U.S. Federal Income Tax Considerations
for U.S. Holders.&#8221;</div> </div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item4"><!--Anchor--></span>Item 4. Information
on the Company</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z5bc2264115464436bb46d3257322d159" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">History and Development of
        the Company</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160; <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;We were incorporated on November
30, 2011, under the laws of the State of Israel. In March 2021, in connection with the Merger, we changed our name from Anchiano Therapeutics
Ltd. to Chemomab Therapeutics Ltd. Our principal executive offices are located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002,
and our phone number is +972-77-331-0156. Our website is: www.chemomab.com.&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We use our website as a means
of disclosing material non-public information. Such disclosures will be included on our website in the &#8220;Investor Relations&#8221;
sections. Accordingly, investors should monitor such sections of our website, in addition to following our press releases, SEC filings
and public conference calls and webcasts. Information contained on, or that can be accessed through, our website does not constitute a
part of this Annual Report and is not incorporated by reference herein. We have included our website address in this Annual Report solely
for informational purposes. Our SEC filings are available to you on the SEC&#8217;s website at http://www.sec.gov. This site contains
reports and other information regarding issuers that file electronically with the SEC. The information on that website is not part of
this Annual Report and is not incorporated by reference herein.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our agent for service of process
in the United States is Chemomab Therapeutics, Inc. which maintains its principal offices at One Kendall Square, Building 1400E, Suite
14-105, Cambridge, MA 02139. Its telephone number is (857) 259-4622.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">For a description of our principal
capital expenditures and divestitures, see Item 5. &#8220;Operating and Financial Review and Prospects-Liquidity and Capital Resources&#8221;
and Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z34da4f9ce3134193bb54f8ddc3e93d87" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Business Overview</div> </td>
        </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Overview</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We are a clinical-stage biotechnology
company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs.
Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, we have developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening
fibrotic and inflammatory diseases.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We have pioneered the therapeutic
targeting of CCL24, a chemokine also known as eotaxin-2, which promotes various types of cellular processes that regulate inflammatory
and fibrotic activities through the CCR3 receptor. CCL24 is expressed in various types of cells, including immune cells, endothelial cells
and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity
that modulates the complex interplay of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and fibrotic
diseases. This innovative approach is being developed for difficult-to-treat rare diseases, also known as orphan indications or diseases,
such as primary sclerosing cholangitis and systemic sclerosis for which patients have no established disease-modifying or standard-of-care
treatment options. We estimate that there are approximately 77 thousand patients suffering from PSC in the United States., European Union
and Japan, representing a more than $1 billion market opportunity, and approximately 170,000 patients suffering from SSc in those same
markets, representing a more than $1.5 billion market opportunity.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">CM-101, our lead clinical product
candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory
and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and fibrosis through a
novel and differentiated mechanism of action. We are currently conducting a Phase 2 clinical study in PSC, a rare obstructive and cholestatic
liver disease, in the United States., Europe and Israel. Patient recruitment for the trial has been completed. The randomized, placebo-controlled
study design includes two doses of CM-101 (10 or 20mg/kg) vs placebo, administered once every three weeks for 15 weeks, as well as an
open label extension in which all patients are eligible to receive CM-101 for an additional 33 weeks. A topline readout of initial trial
results is expected midyear 2024.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The CM-101 SSc clinical program is Phase
2-ready and we have an open IND in the United States for a Phase 2 clinical trial. However, Chemomab has suspended initiation of this
study while we focus our resources on completing the Phase 2 PSC trial.&#160; We believe that CM-101 could have disease-modifying potential
in this poorly treated condition. While our primary focus is on these two rare indications, early in the year we reported results from
a completed Phase 2a clinical study in patients with liver fibrosis due to NASH.&#160; This trial provided safety and pharmacokinetic
(&#8220;PK&#8221;) data and information useful for assessing our current subcutaneous formulation of CM-101. Additionally, the trial measured
a number of biomarkers that may be relevant to the activity of CM-101 in other fibro-inflammatory conditions. The initial trial results
showed that the trial met its primary endpoint of safety and tolerability, and that CM-101 demonstrated statistically significant data
consistent and positive activity across secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments.
A secondary analysis, that further confirmed and extended these initial results was reported at the 2023 EASL Congress in June 2023.</div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Fibrosis is the abnormal and
excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, which provides structural
and biochemical support to surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and
thickening of connective tissues, affecting tissue properties and potentially leading to organ dysfunction and failure. Fibrosis can occur
in many different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive
fibrotic conditions. Fibrosis and inflammation are intrinsically linked. While a healthy inflammatory response is necessary for efficient
tissue repair; after disease or injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis that in turn can
further stimulate inflammatory processes in a fibro-inflammatory vicious cycle.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">2023 Developments</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Completed
Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moved Up Expected Topline Readout to Midyear 2024</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">On
January 3, 2024, Chemomab announced the</span>&#160;<span style="font-family: Times New Roman,serif">early completion of patient enrollment
in the Phase 2 SPRING trial assessing CM-101 as a treatment for PSC. Early completion of patient enrollment enabled the company to accelerate
the timeline for its expected readout of topline data from the trial. We now expect to report topline data by midyear 2024, rather than
in the second half of 2024 as previously projected. Chemomab management noted that acceleration of these timelines was enabled by the
enthusiastic response of both clinicians and patients to our PSC clinical trial.</span></div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold"><span style="font-family: Times New Roman,serif">Presented
Data </span>at the ACR Convergence 2023 Conference that Further Supports the Key Role of CCL24 in the Pathogenesis of Systemic Sclerosis</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On November 16, 2023, Chemomab
reported that SSc patient data presented at the ACR Convergence 2023 conference showed that high serum levels of our CCL24 target are
associated with more severe manifestations of the disease and that CCL24 activates endothelial cells in specific ways that result in SSc-associated
fibrosis.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Received
FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On November 15, 2023, Chemomab
announced that the U.S. Food and Drug Administration (FDA) had granted CM-101 Fast Track designation for the treatment of PSC in adult
patients. Programs with Fast Track designation can benefit from early and more frequent interactions with the FDA during the clinical
development process. Therapeutic candidates with Fast Track designation may also be eligible for priority review and accelerated approval
if supported by clinical data, CM-101 has also received Orphan Drug designation from the FDA and the European Medicines Agency.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Reported
New Data Supporting CM-101&#8217;s Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and Highlighting CCL24&#8217;s
Unique Association with Key PSC Pathways</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On November 13, 2023, Chemomab reported on several
data presentations at AASLD's The Liver Meeting<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>
2023.&#160; One presentation included additional proteomic analyses of data from the company&#8217;s Phase 2a liver fibrosis clinical
trial in NASH patients that showed consistent and significant improvements in liver-related pathology pathways after treatment with CM-101.
In a second oral presentation, Chemomab researchers discussed proteomic analyses of PSC patients that provided further evidence that CCL24
is a key driver of the inflammatory and fibrotic processes underlying PSC and other disorders.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Disclosed Receipt of Nasdaq
Notice Regarding Minimum Bid Price Requirement</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On November 6, 2023, Chemomab announced that the
company had received notice from the Nasdaq&#160;that the company was not currently in compliance with the&#160;minimum bid price requirement
for continued listing on the Nasdaq Capital Market. The notice indicated that the company had 180 days to regain compliance. The Notice
had no immediate effect on the listing of the Company's ADSs, which continue to trade on the Nasdaq Capital Market. The company may, if
appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement.&#160;</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Published
Peer-Reviewed Research Article Demonstrating the Key Role of CCL24 in PSC</div>

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On June 28, 2023, the company
reported publication of a peer-reviewed research article in the June issue of the respected journal&#160;<span style="font-family: Times New Roman, serif; font-style: italic">JCI
Insight</span>. It was produced through collaborations with prominent academic groups and supports the key role of CCL24 in driving the
self-perpetuating fibrosis and inflammation that result in the severe liver damage characterizing PSC. The publication also includes preclinical
studies showing that CM-101, Chemomab's CCL24-neutralizing antibody, is effective in interrupting these fibro-inflammatory processes and
could potentially improve patient outcomes.&#160;</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">New Executive
Appointments</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On June 5, 2023, we announced
that Adi Mor, PhD, co-founder and former Chief Executive Officer (CEO), and then Director and Chief Scientific Officer, had been reappointed
to the additional role of CEO, replacing&#160;Dale Pfost, PhD.&#160;Sigal Fattal, former Chief Financial Officer (CFO) and then Vice President,
Finance, was reappointed to the role of CFO, replacing&#160;Donald Marvin. Nissim Darvish, MD, PhD, was appointed Chairman of the Board,
replacing Dr. Pfost. All the appointments were effective&#160;June 1, 2023.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Presented
Patient Data at 2023 EULAR Congress Highlighting How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis
(SSc)</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On June 3, 2023, in a poster at the 2023 European
Congress of Rheumatology, hosted by the European Alliance of Association for Rheumatology (EULAR), researchers presented patient data
that further elucidated the key role of CCL24 in the pathology and prognosis of SSc and related fibrotic diseases, and supported the rationale
for the potential therapeutic utility of Chemomab's CCL24-neutralizing antibody CM-101 for the treatment of SSc and other fibro-inflammatory
diseases.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Announced FDA Clearance of Investigational
New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with SSc</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On February 21, 2023, Chemomab announced that the
FDA had cleared the company's Investigational New Drug (IND) application to evaluate CM-101 in a Phase 2 clinical trial in adults with
SSc. The CM-101 SSc trial has not yet been initiated.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Reported
Primary and Secondary Analyses of CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On January 3, 2023, Chemomab
reported topline results from its&#160;Phase 2a trial assessing CM-101 in nonalcoholic steatohepatitis (NASH) patients with liver fibrosis.
The trial met its primary endpoint of safety and tolerability, and CM-101 demonstrated promising activity in secondary endpoints that
included a range of liver fibrosis biomarkers and physiologic assessments measured at baseline and at week 20. Key findings included:</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman, serif"><br/>

<div style="line-height: 1.25">

<div style="text-align: left; line-height: 1.25">

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25">

<div style="text-align: left; text-indent: 25pt; line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="font-family: Times New Roman,serif">CM-101 continued to appear well tolerated when administered subcutaneously</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="font-family: Times New Roman,serif">CM-101 administered subcutaneously demonstrated favorable pharmacokinetics and target
        engagement profiles <br/> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="font-family: Times New Roman,serif">CM-101-treated patients showed greater improvements than the placebo group in a number
        of liver fibrosis-related biomarkers</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="font-family: Times New Roman,serif">A majority of CM-101-treated patients showed improvements in more than one liver fibrosis-related
        biomarker&#8212;almost 60% of CM-101-treated patients responded in at least three biomarkers&#160;at week 20, compared to no patients
        in the placebo group.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top"><br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#8226;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">
        <div style="font-family: Times New Roman,serif">A higher proportion of patients in the CM-101-treated group showed improvement in a physiologic
        measure of liver stiffness&#160;as compared to placebo.</div> </td> </tr>
  </table>

<div><br/> </div> </div> </div> </div> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On June 21, 2023, the company
reported additional results from secondary analyses of this trial. The results were included in a late-breaking poster presentation at
the 2023 EASL Congress.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup>Overall, the data showed
improvements across an additional set of inflammatory and fibrotic biomarkers that are consistent with the clinical results released in
January. Additionally, in NASH patients at greater risk of disease progression, CM-101 treatment resulted in a greater biomarker response
than in NASH patients with lower risk disease or in placebo-treated patients. <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Pipeline</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25"><img src="image00019.jpg" alt=""/></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our lead product candidate,
CM-101, is a first-in-class humanized monoclonal antibody targeting CCL24 that is being assessed in two orphan indications: PSC and SSc.
CCL24 has been extensively studied in airway inflammation and, more recently, we have demonstrated in preclinical studies and early clinical
studies that it plays an important role in additional indications, including inflammation and fibrosis of the liver, skin and lung. While
CCL24 is found in low levels in blood and tissue samples from healthy volunteers, elevated levels of both CCL24 and its receptor CCR3
have been found in patients with PSC, SSc and NASH. CCL24 levels have also been correlated to different stages of disease. Based on extensive
preclinical, nonclinical and early clinical studies, we expect that neutralizing CCL24 will result in anti-fibrotic and anti-inflammatory
effects in patients. CM-101 has been granted orphan drug designation by both the FDA and the EMA in its primary indications of PSC and
SSc. In addition, CM-101 was recently granted a Fast Track designation in PSC from the FDA. These designations provide multiple benefits
for these indications, including the potential for accelerated clinical and regulatory pathways as well as exclusive marketing and development
rights for a period of time.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">PSC is a rare, chronic cholestatic
liver disease characterized by progressive inflammation, fibrosis, and destruction of the intrahepatic and extrahepatic bile ducts. The
cause of the disease is not known, although a high proportion of PSC patients also have inflammatory bowel disease. Fibrosis and inflammatory
responses induce a progressive spread of the fibrotic condition. Cholestasis is a symptom of liver injury and is characterized as the
interruption of bile flow from hepatocytes to the intestine, which leads to bile acid accumulation in the liver, resulting in oxidative
stress, inflammation, apoptosis and fibrosis. PSC affects approximately 30,000-45,000 patients in the United States. It leads to end-stage
liver disease and cancer, which causes about half of PSC deaths. About half of patients require liver transplantation, but PSC then re-occurs
in about 20% of transplant recipients, Median transplant-free survival is estimated at 10-20 years.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">No treatment aside from a liver
transplant has been associated with change of the disease course or significant long-term improvement in the clinical outcome. PSC is
a clear serious unmet medical need with no FDA approved therapeutics and for which the current standard of care is inadequate.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">SSc is a rare connective tissue
disease characterized by excessive fibrosis and extracellular matrix accumulation in the skin, lung and other visceral organs. The disease
initiates with an early inflammatory phase involving the immune cell network, as well as endothelial cells. As the disease progresses,
the inflammation increases and fibroblasts and myofibroblasts generate tissue fibrosis, while endothelial cells promote vascular injury,
which can lead to skin fibrosis, interstitial lung disease, myocardial insufficiency, vascular obliteration, distal ulcerations and gangrene.
SSC affects approximately 75,000-100,000 patients in the United States. SSc has the highest mortality rate among the systemic rheumatic
diseases and has high unmet need, as current treatments manage only disease manifestations and there is no disease modifying drug available.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We are primarily focused on
the orphan indications PSC and SSc but believe that CM-101 may have additional applications in other fibrotic-inflammatory disease areas
such as idiopathic pulmonary fibrosis, or IPF and nonalcoholic steatohepatitis, or NASH. CM-101 has shown promising anti-fibrotic and
anti-inflammatory effects in preclinical studies of liver fibrosis and PSC, with significant reductions in fibrotic genes, liver enzymes,
bile acid and cholangiocyte proliferation, all reflecting a potential improvement in disease status. In preclinical studies of SSc, CM-101
reduced inflammatory and fibrotic injury resulting in reductions in dermal thickness, collagen concentration in the skin and the lung,
and immune cell infiltration in the lung.<span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We have completed two Phase
1a single ascending dose studies with intravenous, or IV, and subcutaneous, or SC, administrations of CM-101 in 40 healthy volunteers.
The drug was shown to be well-tolerated, with a PK profile supporting dosing once every 2-4 weeks. We also completed a Phase 1b multiple
administration ascending dose study in 16 non-alcoholic fatty liver disease (NAFLD) patients, expanding the safety, tolerability, and
pharmacodynamics database with patients with early liver disease. Early evidence of anti-fibrotic activity was also seen in this study.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In the first half of 2023 we
reported topline and secondary results from our Phase 2a randomized, double-blind, placebo-controlled study in patients with liver fibrosis
associated with NASH. The trial met its primary endpoint of safety and tolerability, and CM-101 demonstrated promising activity in secondary
endpoints that included pharmacokinetic and target engagement profiles of the SC formulation, as well as a range of liver fibrosis biomarkers
and physiologic assessments measured at baseline and at week 20.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The trial enrolled 23 NASH
patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo. Patients received eight doses of 5
mg/kg of study drug administered by SC injection once every two weeks, for a treatment period of 16 weeks. Key findings of the CM-101
Phase 2a trial included the following.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8bda24a647c0471593dedb7868b84de7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 appeared to be well tolerated when administered
        subcutaneously. Most reported adverse events observed were mild, with one unrelated serious adverse event reported. No significant injection
        site reactions were reported and no anti-drug antibodies, or ADAs, were detected.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z455508e6d1284082ac5a49c1c675e076" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 administered subcutaneously demonstrated
        favorable pharmacokinetics and target engagement profiles as expected, which were similar to what we have previously reported.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z4e49a81a1865481dab8458ebadd3fc77" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101-treated patients showed greater improvements
        than the placebo group in a number of liver fibrosis-related biomarkers, including ProC-3, ProC-4, ProC-18, TIMP-1 and ELF.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zbb8e68ba899f4fccbb0d84bc6ff6ded3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">A majority of CM-101-treated patients showed improvements
        in more than one liver fibrosis-related biomarker&#8212;almost 60% of CM-101 patients responded in at least three biomarkers at week 20,
        compared to no patients in the placebo group.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zc16b4bf0a4734b9bb762b4a8d5ae083d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">A higher proportion of patients in the CM-101-treated
        group showed improvement in a physiologic measure of liver stiffness as compared to placebo (reduction of at least one grade of fibrosis
        score as assessed by the non-invasive elastography method known as FibroScan&#174;).</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zd225f1a4675c41719ed697f6ef56b355" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101-treated patients with higher CCL24 levels
        at baseline showed greater reductions in fibrosis-related biomarkers than patients with lower levels. Multiple fibrosis-related biomarkers
        showed more pronounced reductions in CM-101-treated patients who had higher CCL24 levels at baseline than in patients with lower CCL24
        baseline levels, adding to the growing body of evidence validating the role of CCL24 in the pathophysiology of fibrotic liver disease.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">After completion of the study, the unblinded data showed that patients in the CM-101-treated group had
        higher baseline levels of fibrosis compared to placebo patients. The impact of this difference on the results, if any, is unknown.</div>
        </div> </td> </tr>
  </table> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In a secondary analysis reported
in June of 2023, CM-101-treated patients showed improvements in an additional set of biomarkers associated with active fibrosis and inflammation
including AST/ALT ratio, Neutrophil-to-Lymphocyte Ratio (NLR), FIB-4, and PRO-C3. Some of these biomarker scores were further improved
in CM-101-treated patients with higher FibroScan-AST (FAST) scores, which categorize study patients based on the risk of disease progression.
It is noteworthy that as an overall indicator of fibrogenesis and fibrotic disease, PRO-C3 may potentially be viewed as a &#8220;bridge&#8221;
to PSC and other anti-fibrotic indications.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Liver fibrosis experts working
with Chemomab noted that it is encouraging that consistent positive improvements were seen across a range of fibro-inflammatory biomarkers
in both CM-101 Phase 2a study analyses, and that greater improvement in biomarkers in the higher FAST score-enriched subgroup provides
further evidence of CM-101's potential to have a positive impact on fibrotic diseases such as NASH and PSC, whose pathophysiology may
be associated with the dual fibro-inflammatory mechanism that CM-101 is intended to address</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Data from this trial provided
important insights in support of the CM-101 development program, including the favorable safety and tolerability of CM-101 in patients
with serious liver disease, confirmation of early signs of biomarker activity that are relevant for a number of fibro-inflammatory disorders,
and additional tolerability and pharmacokinetic data needed to assess next steps in the development of our current subcutaneous formulation.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Earlier, we also reported positive
clinical data from an investigator-initiated clinical study assessing CM-101 activity and safety in hospitalized patients with severe
lung injury derived from COVID-19. The objective of the study was to evaluate the drug&#8217;s safety and activity in hospitalized COVID-19
patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also relevant in systemic sclerosis.
The open label, single arm trial enrolled 16 hospitalized adult COVID-19 patients with severe respiratory involvement. All patients were
receiving standard of care therapy. All were treated with a single 10mg/kg intravenous dose of CM-101 on the first day of the study and
followed for 30 days. Administration of CM-101 to this acutely ill patient population appeared to be well tolerated. CM-101 exposures
and target engagement profiles were similar to what our researchers have seen in previous clinical studies of CM-101. Importantly, rapid
reductions in serum biomarkers of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment with CM-101. Overall,
this study confirmed and extended the safety and tolerability profile of CM-101 and demonstrated clinically relevant changes in biomarkers
associated with lung inflammation and fibrogenesis, further supporting CM-101&#8217;s anti-inflammatory and anti-fibrotic effects.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We are currently conducting
a randomized, double-blind, placebo-controlled study of CM-101 in PSC patients and recently announced completion of patient enrollment
in the trial. A topline data readout is expected in midyear 2024. In addition, a Phase 2a clinical trial in SSc has an open IND in the
U.S. Chemomab currently plans to initiate patient enrollment in this trial after assessing the PSC Phase 2 topline clinical data readout
and when financial resources permit.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The Phase 2 SPRING study recently
completed enrollment of the targeted 68 patients with PSC who are treated with CM-101 or placebo for 15 weeks. The trial design includes
2 dose cohorts of CM-101 (10or 20mg/kg) vs placebo as well as an open-label extension of 33 weeks to evaluate the safety, tolerability
and durability of effect over longer treatment durations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We may also explore CM-101 in other indications,
where the dual activity of CM-101 acting on both inflammation and fibrosis could provide new avenues for treating inflammatory and fibrotic
conditions.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Chemomab was founded in 2011,
based on a novel discovery originating from the Sourasky Medical Center in Tel-Aviv, Israel, where Professor Jacob George first identified
CCL24 as a key regulator of unstable plaque formation in atherosclerotic patients. In our early years, we focused on research directed
at clarifying the role and effectiveness of CCL24 blockade. In 2015, we selected our proprietary lead product candidate, CM-101, and started
product development directed towards human testing.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt">We have assembled an executive team with highly
relevant experience in inflammation and fibrosis, and biologics drug discovery and clinical development. Adi Mor, Ph.D., our Chief Executive
Officer, Chief Scientific Officer and Co-founder, has 15 years of experience in immunology and has led the CM-101 program from discovery
stage into Phase 2 clinical studies. Matthew Frankel, M.D., our Chief Medical Officer, brings deep experience in clinical development.
Dr. Frankel, who is based in the U.S., has more than 25 years of experience in the discovery and clinical development of novel therapeutics
and has held senior executive roles at both global pharmaceutical and biotechnology companies. Jack Lawler, our Vice President of Global
Development Operations, is highly experienced in managing clinical trials across a wide range ofindications and geographies.<br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Company strategy</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We aim to become a world-leading
company for the treatment of diseases involving inflammation and fibrosis, developing novel therapies across a wide range of indications.
To achieve this, we are focused on the following key strategies:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z1950746e941944d6aa5a16560ba05209" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Advance
        our lead product, CM-101, for the treatment of PSC and potentially SSc, through clinical development to approval</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The clinical development plan
of lead product candidate CM-101 was optimized to maximize the clinical information obtained, generating additional important data to
support future advancement to registration trials, and decreasing the overall risk of the CM-101 clinical development program in the lead
indication of PSC and potentially SSc, as well as potentially in additional indications where the scientific rationale is strong.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We expect that the current
PSC trial design will provide important data on the clinical dose response relationship to inform the broader development program and
to identify the optimal dose to advance in later PSC trials, as well as in clinical trials in other indications.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z9acbeea13fd94b81b29d1c61fbf8c1d1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Selectively
        evaluate partnership opportunities</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We continuously explore partnership
opportunities to advance CM-101 development in PSC and SSc, and possibly NASH, identifying companies with drugs (either approved or in
development) that could possibly be combined with CM-101, extending the development of CM-101 to new indications beyond PSC and SSc, and
seeking additional significant commercial or drug development capabilities that may accelerate CM-101&#8217;s time to market.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zbb3b3a1325b14c5694620b62b5bd521e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Explore
        opportunities for CM-101 in additional inflammatory/fibrotic indications</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We continue to evaluate the
potential benefit of CM-101 outside of our current lead indications of PSC and SSc, in order to maximize the product&#8217;s potential.
CM-101 has shown anti-fibrotic activity in animal models and human tissue studies of IPF and NASH. We will continue to assess ways to
leverage the dual anti-inflammatory and anti-fibrotic activity of CM-101 in new disease areas and to form additional collaborations with
global medical researchers and drug developers.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z259135cd43bd47ea81810df67c3304c4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Strengthen
        our intellectual property portfolio</div> </td> </tr>
  </table>

<div style="line-height: 1.25; text-indent: 9pt"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt">We believe that we have developed a strong intellectual
property portfolio and will continue to seek, maintain, and defend our patent rights, whether developed internally or licensed to protect
and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business
proprietary position in the field of inflammation and fibrosis.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Fibrosis
and inflammation</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Tissue damage activates a repair
process that includes acute inflammation followed by either successful complete repair or tissue replacement by fibrosis. However, persistent
and repeated damage can result in continuous activation of the repair process leading to chronic inflammation, progressive tissue fibrosis
and sclerosis.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Fibrosis is an accumulation
of non-functional tissue and can occur in many different tissues, including lung, liver, kidney, muscle, skin and the gastrointestinal
tract, resulting in a number of chronic fibrotic conditions. Liver fibrosis is the process of excessive accumulation of extracellular
matrix proteins, predominantly collagen, which occurs as the result of liver injury. In cases of acute temporary damage, these changes
are transient and liver fibrosis may resolve. In chronic cases, however, the liver damage persists and chronic inflammation and accumulation
of the extracellular matrix eventually lead to cirrhosis. The various fibrotic manifestations in conditions like SSc are still not well
understood. Disease progression is characterized by an early inflammatory onset followed by tissue fibrosis, vascular injury and organ
damage. Fibrosis, and specifically lung fibrosis, is the main cause of disease progression and mortality in SSc, although manifestation
of the disease in other organs can cause patients considerable distress and adversely impact their health and their quality of life.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Fibrosis and inflammation are
intrinsically linked; a healthy inflammatory response is necessary for efficient wound healing; however, a prolonged response can contribute
to the pathogenesis of fibrosis. The inflammatory response during chronic liver injury is a dynamic process with intrahepatic accumulation
of diverse immune cells. Recruitment and infiltration of these cells to the liver and their localization is mainly determined by chemokines
and cytokines that are produced by hepatocytes, immune cells, biliary epithelial cells, and endothelial cells. Notably, activated liver
fibroblasts, the hepatic stellate cells, or HSCs, secrete various chemokines, thereby contributing to the ongoing immune response during
fibrotic liver diseases. Similarly, for SSc, the early inflammatory phase leading to fibrosis in multiple organs of the body includes
activation of the immune cell network of lymphocytes, eosinophils, and monocytes, as well as endothelial and endothelial progenitor cells.
In the advanced SSc phase, fibroblasts and myofibroblasts take the lead to generate tissue fibrosis.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Chemokine
involvement in inflammation and fibrosis</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Chemokines are a group of small
signaling proteins thought to be involved in the etiology, or causation, of multiple inflammatory diseases. They are not only implicated
in immune cell recruitment during inflammation, but also contribute to immune surveillance, direct cells to target organs in homeostasis,
and exert pleiotropic, or diverse, effects on non-immune cells, for instance, directly influencing the functionality of fibrogenic cells.
Chemokines and their corresponding chemokine receptors are key players in orchestrating the sequential influx of immune cells into damaged
or diseased organs, driving inflammatory responses to specific triggers.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In the liver, chemokines have
a key role in the development of inflammation and wound healing responses, which can lead to either resolution of liver injury or promote,
if ongoing, maladaptive responses with chronic inflammation, fibrosis, and development of clinically manifest liver disease. Although
the pathophysiology underlying PSC has not yet been fully clarified, animal models of PSC have contributed to dissecting the molecular
basis of this disease and highlighting the role of cytokines and chemokines as important pathogenetic mediators of liver inflammation
and fibrosis. Recently published studies demonstrated that in most of the processes suggested for the onset and development of PSC, chemokines
and chemokine receptors play a key role. Hematopoietic stem cells&#160;(HSCs) may be the main producers of cytokines and play an initial
role in the progression of liver fibrosis by attracting different types of immune cells, resulting in further production of cytokines
and liver injury in a vicious disease cycle. Extensive proliferation, trans-differentiation and activation of HSCs result in ongoing chronic
tissue remodeling and severe fibrosis. In addition, chemokines are also involved in promoting polarization of the recruited immune cells.
Therefore, chemokines may participate in PSC by promoting migration of inflammatory and fibrotic cells, by activating inflammatory and
fibrotic cells locally, or by inducing cytokines that promote collagen</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">and matrix deposition.<span style="font-family: Times New Roman, serif"><br/>
</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Likewise, in SSc pathogenesis,
chemokines foster migration and activation of inflammatory and fibrotic cells, inducing the secretion of cytokines that promote collagen
and matrix deposition in affected organs. Indeed, patients with SSc exhibit increased systemic levels of proinflammatory chemokines and
some of these have also been shown to correlate with limited or diffuse cutaneous disease phenotype and/or to organ-specific pathology
such as lung disease or skin vascular inflammation.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">The role
of CCL24</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">CCL24 is a chemokine that promotes
various types of cellular processes that regulate inflammatory and fibrotic activities through the CCR3 receptor. This chemokine is known
to be expressed by activated T-cells, monocytes, epithelial cells and endothelial cells, as well as by activated fibroblasts. CCL24 induces
chemotaxis and activation of CCR3-expressing cells, including immune cells and fibroblasts.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We have been the driving force
in establishing the role of CCL24 in the pathogenesis of PSC and SSc, however, others have highlighted its contribution to other indications.
For example, published work has shown that both CCL24 and CCR3 are involved in lung and skin inflammation and fibrosis. CCR3 is robustly
expressed on eosinophils and recent data has suggested that eosinophilic inflammation may be involved in the pathogenesis and progression
of SSc. For example, in SSc patients, eosinophil counts, but not total leukocytes, were significantly higher than in patients with other
connective autoimmune diseases. Eosinophil counts correlated positively with both interstitial lung disease severity and the modified
Rodnan skin thickness score, or mRSS.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Notably, CCR3 was shown to
be expressed on oral and dermal fibroblasts where it modulates wound healing and tissue remodeling processes. A recent academic study
also demonstrated overexpression of CCR3 on monocyte populations isolated from SSc patients. CCL24 was shown to be involved in proinflammatory
reactions, specifically contributing to the type 2 immune reaction involving Th2 lymphocytes and M2 macrophages that were shown to be
present in skin lesions of SSc patients. Accordingly, CCL24 was found to play a dominant role in inducing profibrotic effects and to be
overexpressed in fibrotic lungs and bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis, a disease sharing similar
lung dysfunction features with SSc. Furthermore, CCL24 was shown to promote collagen production in human lung fibroblasts and to be constitutively
expressed by dermal fibroblasts.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Prior studies support the role
of CCL24/CCR3 signaling in the pathogenesis of SSc and these findings have been further explored by Chemomab in SSc and for the first
time, in PSC.</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25"><img src="image3.jpg" alt="" style="width: 652px; height: 407px"/></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">CCL24 is a critical mediator
promoting inflammation and fibrosis</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Challenges
to drug development in fibrosis and inflammation</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Successful treatment of fibrotic
disorders has in large part remained elusive, primarily due to incomplete understanding of the complexity and multi-mechanism contributions
to disease progression. This has complicated preclinical investigations for new products and new targets, with animal models having limited
resemblance to human disease. Additionally, preclinical animal data is often of short treatment duration and does not capture the effects
of treating chronic fibrotic indications. This is particularly applicable to complex, orphan indications like SSc, where there is still
no approved standard of care or proven target mechanism. Most drug approvals in this space have been focused on fibrosis of the lungs
i.e., idiopathic pulmonary fibrosis, or IPF, interstitial lung disease, or ILD, and pulmonary arterial hypertension, or PAH.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman Greek,serif">Most approved anti-fibrotic
products target extracellular components, given their biological accessibility, and inhibition of receptors and ligands preventing downstream
signaling is considered to be a potentially effective option for alleviating fibrosis. PDGF and TGF-&#946; are commonly studied targets
in fibrosis and there are two approved products that target these pathways, pirfenidone and nintedanib. Both pirfenidone and nintedanib
are approved for the treatment of IPF, with nintedanib also recently approved for treatment of systemic sclerosis associated interstitial
lung disease and chronic fibrosing interstitial lung diseases. Due to the strong associations between inflammation and fibrosis, companies
have devoted efforts to anti-inflammatory drugs with the hope that reduction in inflammation will attenuate fibrosis. For example, companies
have targeted TNF-&#945;, a commonly explored anti-inflammatory mechanism in fibrotic indications. Despite the success of targeting cytokines,
inflammatory factors and immune cells in pure inflammatory autoimmune diseases, such as blocking TNF-&#945;, these results have generally
not been reproduced in studies targeting inflammatory fibrotic indications. Nonetheless, tocilizumab, a monoclonal antibody targeting
IL-6R, was recently approved for the treatment of ILD associated with systemic sclerosis. Treatments that inhibit certain pure anti-fibrotic
pathways, such as nintedanib and pirfenidone, have resulted in limited clinical benefit. <span style="font-family: Times New Roman, serif">We
believe that these results highlight the importance of a dual mechanism that, with adequate selectivity, is designed to target inflammatory
processes and also directly prevent fibrosis resulting in blockage of multiple disease-contributing mechanisms.</span></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Notwithstanding challenges in the field
of fibrosis and inflammation, there is significant and growing industry interest given the associated unmet medical need and the continuing
opportunity to identify better therapeutic targets. For example, in 2024 Gilead acquired Cymabay for its PPAR agonist in Primary biliary
cirrhosis.&#160; In 2019 Novartis completed two transactions related to the treatment of NASH, a liver metabolic fibrotic disease. It
acquired IFM Tre for NLRP3 antagonists for a $310 million upfront payment and total potential consideration of $1.5 billion and licensed
an integrin inhibitor from Pliant Therapeutics for an $80 million upfront payment. Additionally, Gilead Sciences licensed two preclinical
programs, one in NASH for a $15 million upfront payment (total potential consideration of $785 million) and the other for TGF-&#946; inhibitors
in fibrosis for an $80 million upfront payment and total potential consideration of $1.4 billion. In 2020, Roche acquired Promedior for
a $390 million upfront payment and total potential consideration of $1 billion in milestones for its Phase 2 product in pulmonary fibrosis,
and Bayer partnered with Recursion Pharmaceuticals to develop and commercialize preclinical-stage small molecule treatments for fibrotic
conditions for a $30 million upfront payment and total potential consideration of $1 billion. Boehringer Ingelheim also acquired Enleofen
Bio in a deal potentially worth $1 billion for its NASH and ILD anti-IL11 platform. More recently, Mediar, a high-profile start-up targeting
novel mechanisms for fibrotic diseases, reported a $105 million Series A financing.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Targeting
chemokines as a treatment for fibrotic indications</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We believe that our approach,
selectively targeting fibrotic conditions by attenuating both inflammation and fibrosis, may be an optimal approach for both effectiveness
and reduction of toxicity. As central regulators of initiation and progression of fibrotic disorders, chemokines are an ideal target to
impact both inflammation and fibrosis. Some chemokines are also disease-specific, allowing for potential selectivity.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Chemokine receptors, or CCRs,
have been more extensively studied as drug targets in fibrotic conditions compared to chemokine ligands, however, the therapeutic effects
of CCR inhibitors have generally fallen short in the clinic. Pharmaceutical companies have previously explored the CCL24 ligand receptor,
CCR3, and its other ligands CCL7 and CCL11, with small or large molecule inhibitors. These programs were directed at inhibiting eosinophilic
trafficking in respiratory and allergic inflammation, however, despite promising preclinical data, most programs were discontinued largely
due to poor safety profiles and limited efficacy of the antagonist used. To our knowledge, only Alkahest has an active program that explores
CCR3 inhibition, which is under license from Boehringer Ingelheim and is being developed as a treatment for wet AMD. In contrast, we believe
CCL24 presents a more promising opportunity. Unlike other CCR3 ligands, CCL24 binds only to the CCR3 receptor and is also organ/disease-specific,
which together could provide enhanced selectivity and tolerability. For example, in PSC, CCL24 is elevated in the liver and cholangiocytes
(bile duct epithelia) and immune cells that play a key role in the progression of the disease.&#160; Likewise, elevation of CCL24 has
been shown in fibrotic lungs and bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis, a disease sharing similar
lung dysfunction features with SSc and which recently was correlated, by us, with disease severity and lung involvement in a cohort of
SSc patients from the United Kingdom. Furthermore, CCL24 is constitutively expressed by skin and dermal fibroblasts. The</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">use of an antibody in targeting this chemokine is a novel approach
to targeting fibrosis.<span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Our expertise and approach
to drug discovery</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We are a clinical stage biotechnology
company focused on the discovery and development of novel drugs to address fibrotic indications with unmet medical needs. CCL24 is a key
target promoting fibrosis as it regulates the two main processes that drive fibrosis: fibroblast activation and immune cell migration
and activation. Using our expertise in monoclonal antibody, or mAb, development and deep knowledge of chemokine biology, we are developing
CM-101, a proprietary, first-in-class, fully humanized mAb that through research and studies to date, has been shown to neutralize CCL24
and by so doing inhibits its disease-related functions in both inflammation and fibrosis. This represents an innovative approach to anti-fibrotic
drug discovery and is a key differentiator for us. The ability of CM-101 to directly attenuate fibroblast activation and concurrently
attenuate recruitment of immune cells is novel and could address a wide range of hard-to-treat fibrotic diseases.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our ongoing collaborations
are complementary to both preclinical and clinical aspects of research and development. We have created an extensive panel of in vitro,
ex vivo and in vivo assays which we have used to further the understanding of fibrotic processes together with the role of CCL24 in various
diseases and the effects of its neutralization by CM-101. These assays have allowed us to sequentially explore target validation and proof
of mechanism in disease relevant human and animal samples that we believe helps de-risk the translation of CM-101 into the clinic.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Target
expression and engagement</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We regularly collaborate with
leading academic centers around the world to investigate the role of CCL24 and CM-101 in various indications. For example, we work with
The Royal Free Hospital, or RFH, in London, and Birmingham University in Birmingham, United Kingdom to access liver biopsy and serum samples
from patients with PSC. Using immunohistochemistry and florescence microscopy to stain CCL24 and CCR3, it explores the expression patterns
of these targets in disease relevant human samples and compares them to healthy volunteers. Similarly, we have tested biopsies of SSc
patients through a collaboration with the University of Florence in Italy and serum samples of SSc patients through a collaboration with
Leeds University in the UK.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Proof of
mechanism</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We explore fibroblast activation
and immune cell recruitment in response to CM-101 treatment through inhouse ex vivo and in vitro assays. We have executed multiple validated
genetic and treatment-based disease models in fibrotic and inflammatory indications in which we have investigated CM-101&#8217;s effects.
Additionally, as part of a collaboration with Nordic Biosciences, Copenhagen, Denmark, we have gained access to proprietary tools and
expertise to explore the effects of CM-101 on key fibrogenesis and fibrolysis biomarkers. Nordic Biosciences is a world-leading extracellular
matrix specialist and continues to contribute additional analyses to our clinical samples.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25"><br/> &#160;<span style="font-family: sans-serif; font-size: 12pt"><br/>
</span><img src="image00020.jpg" alt=""/><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"><br/> <span style="font-family: Times New Roman, serif"><br/>
</span></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">We have
created a broad array of biological assays to explore CCL24 and CM-101</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We may explore next-generation
biologic products, and, based on our wide database of patient samples and extensive knowledge and experience in fibrosis, may identify
targets that could complement CCL24 inhibition. Next-generation assets could therefore be dual targeting and would be screened through
the panel of assays available to us that evaluate target expression in fibrotic tissues as well as the anti-fibrotic activity of potential
candidates. Similar to CM-101, this process would establish proof-of-biological-mechanism in both animal models and human tissue prior
to commencing product development and initiating</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">clinical studies.<span style="font-family: Times New Roman, serif"><br/>
</span>&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Our pipeline</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">CM-101
in PSC and SSc</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our lead product, CM-101, is
a first-in-class humanized monoclonal antibody targeting CCL24 that is being developed initially for the treatment of PSC and SSc, with
potential future opportunities in other fibrotic-inflammatory indications. We have completed two Phase 1a studies of CM-101 in healthy
volunteers as well as a Phase 1b safety, tolerability and proof-of-mechanism study in NAFLD patients and a Phase 2a liver fibrosis biomarker
study in NASH patients with liver fibrosis, which was reported in 2023. Topline results showed favorable safety and tolerability profiles
for CM-101 in patients with serious liver disease, confirmed early signs of biomarker activity that are also relevant for a number of
fibro-inflammatory disorders, and reinforced tolerability and pharmacokinetic data relevant to the development of our current subcutaneous
formulation.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">A Phase 2 study in PSC is now
ongoing in Europe, the U.S. and Israel.&#160; We recently announced the completion of patient enrollment in this trial and acceleration
of the expected readout of the topline results to midyear 2024. A global Phase 2 study in SSc that will assess the clinical and biological
effects of CM-101 in this patient population has an open U.S. IND and is Phase 2-ready. Chemomab currently plans to initiate patient enrollment
in the SSc trial following the successful completion of the PSC Phase 2 study and as resources permit.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Primary
Sclerosing Cholangitis</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">PSC is a progressive, rare,
and chronic cholestatic liver disorder that is characterized by thickening, inflammation, and fibrosis of the intra- and extra-hepatic
bile ducts. This generally leads to cholestasis, liver damage, cirrhosis, and eventually liver failure. The exact cause of PSC remains
mostly unknown; however, immune system dysregulation, genes, viruses, and bacteria may be involved. PSC is commonly associated with inflammatory
bowel disease, or IBD. Approximately three in every four individuals with PSC also have ulcerative colitis. Most individuals affected
with PSC are adults with an average age of 40 years at diagnosis; however, it may also occur in children. Disease progression, symptoms,
and severity may vary greatly between individuals. Patients in the initial stages of PSC are generally asymptomatic or have only mild
symptoms.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Abdominal discomfort, fatigue,
and pruritus, or itching, are common initial symptoms of PSC that can be severe and debilitating. The initial step in diagnosing PSC is
to evaluate liver enzyme levels through blood tests. Physicians will then confirm a diagnosis with cholangiography ultrasound and, in
rare cases, a liver biopsy. As the disease progresses, bile flow from the liver is obstructed and is subsequently absorbed into the bloodstream
leading to the yellowing of the mucous membranes, whites of the eyes, and skin. Furthermore, individuals may also experience abdominal
pain, malaise, light-colored stools, nausea, dark urine, weight loss, and/or hepatomegaly or splenomegaly. PSC patients have a 40-fold
increased risk of liver cancer and a 400-fold increased risk of cholangiocarcinoma, and the disease may lead to other conditions including
osteoporosis, bacterial cholangitis, portal hypertension, bleeding, as well as vitamin deficiencies.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">There are currently no specific
medical therapies that can alter or cure the course of the disease; instead, available treatments are directed towards slowing the progression
of PSC and treating symptoms. In certain individuals, endoscopic surgery may be performed to enlarge the narrowed bile ducts and to remove
blockages. Complications due to vitamin deficiencies can be prevented with the help of vitamin supplements, while infections and inflammation
can be controlled by using antibiotics. Cholestyramine and UCDA can be effective in managing itching and can be used with or without antihistamines.
Patients with advanced symptoms such as end-stage liver disease, recurrent bacterial cholangitis and intractable pruritus, will often
undergo liver transplantation, however, in 20-25% of cases, PSC will recur even after liver transplantation. The median survival is 10-12
years without intervention.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Systemic
Sclerosis</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">SSc is an autoimmune inflammatory
condition that results in widespread fibrosis and vascular abnormalities affecting the skin, lungs, gastrointestinal tract, heart and
kidneys. Other key features of SSc include thickening and hardening of the skin, autoantibody production and abnormal nail fold capillaries.
The underlying mechanisms that cause SSc are complex and for the most part unknown but most likely involve a combination of factors including
the immune system, genetics, and environmental triggers. Various pathways are involved in the pathogenesis of SSc including cytokines
that injure blood vessels, growth factors that stimulate collagen, integrin signaling, morphogen pathways, and co-stimulatory pathways.
SSc is generally diagnosed between the age of 30 and 50 years and is more prevalent in women.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Given that SSc can affect many
different parts of the body there are a multitude of different symptoms of the disease. The most widely observed symptoms include fatigue,
arthralgia, and myalgia. However, the earliest sign is often the Raynaud phenomenon in which the body&#8217;s normal response to cold
or emotional stress is exaggerated, resulting in abnormal spasms in arterioles. Cutaneous features include sclerosis of the skin, particularly
the face and hands. Gastrointestinal symptoms of the upper tract include acid reflux and of the lower tract include bloating, nausea and
incontinence. Cardiopulmonary presentations include interstitial lung disease, pulmonary arterial hypertension and cardiac scleroderma.
Renal and ocular symptoms can also present and 20% of SSc patients have an overlapping diagnosis with other connective tissue diseases
and can develop arthritis, lupus or myositis. SSc is subdivided into two main types related to the distribution of skin involvement: diffuse
cutaneous (two-thirds of cases) and limited cutaneous. Diffuse SSc, or dcSSc, is rapidly progressive with more significant organ involvement.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">There is no cure for SSc. Established
treatments can help with symptoms and may modify the disease outcome only if given early in the disease course. Prescribed medications,
used off-label, primarily focus on suppressing inflammation with NSAIDs and dilating abnormal or constricted blood vessels with losartan,
sildenafil, iloprost and SSRIs, or selective serotonin reuptake inhibitors, as well as treatments to manage individual organ involvement.
The only three drugs that are approved for the treatment of SSc symptoms are bosentan by Actelion Pharmaceuticals, approved in Europe
for the prevention of digital ulcer development, nintedanib by Boehringer Ingelheim, and tocilizumab by Roche, approved in the United
States, Europe and Japan for the treatment of SSc associated interstitial lung disease. The clinical course of SSc is determined by the
extent of vascular and fibrosis complications and has the highest mortality rate among the systemic rheumatic diseases. Forty percent
of patients die within 10 years of disease onset, with pulmonary involvement being the leading cause of death.<span style="font-family: Times New Roman, serif"><br/>
</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Our
CM-101may have disease-modifying potential</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The dual anti-fibrotic and
anti-inflammatory activity of CM-101 enables the targeting of a wide range of pathogenic mechanisms and may afford patients a new treatment
that may have a more impactful effect on disease progression.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25"><img src="image00021.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Targeting
CCL24 offers a dual activity approach</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In order to understand CCL24&#8217;s
role in disease pathophysiology, we have collected data on CCL24 levels from patients with multiple fibrotic-inflammatory indications,
including those with PSC, SSc and NASH. PSC patients&#8217; liver biopsies and SSc skin samples were stained for CCL24 and its receptor,
CCR3. Blood samples taken from PSC and SSc patients were used to further evaluate the role of the CCL24-CCR3 axis exploring levels of
circulating CCL24 and CCR3. To explore the influence of CCL24 on disease status, CCL24 serum levels were correlated with fibrotic biomarkers
and disease severity markers.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">CCL24 levels
in liver biopsies from PSC patients</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">PSC pathology generally initiates
with bile duct damage leading to cholestasis, bile duct inflammation and fibrosis and finally to substantial liver damage. We assessed
the accumulation and cellular localization of CCL24 in livers of PSC patients focusing on CCL24 levels in the periductal damaged zone
that is most relevant to disease pathology. CCL24 was mainly found in inflammatory cells in the liver of PSC patients. Due to the robust
liver inflammatory insult in PSC, reflected by massive accumulation of resident and recruited immune cells in the periductal space, CCL24
positive staining was extensive. Specific and robust CCL24 staining was also shown in cholangiocytes, the epithelial cells of the bile
ducts. Activated myofibroblasts that surround the bile ducts, whether they originate from hepatic stellate cells or portal fibroblasts,
are the main drivers of the excess extracellular matrix accumulation in this area, comprising the unique &#8220;onion ring&#8221; shape
seen in PSC liver sections. The collective expression pattern shows high CCL24 levels in areas that are most affected in PSC and highlights
its central role in PSC related liver pathology.</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"><br/> <br/> &#160;<img src="image00022.jpg" alt=""/></div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Elevated
CCL24 staining in liver biopsies from PSC patients</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">CCR24 levels
association with PSC related pathways</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">To further elucidate the involvement
of CCL24 in PSC and its association with disease-related pathways, sera from healthy controls (n=30) and from patients with PSC (n=45)
were analyzed using the Olink proximity extension assay (PEA) of 3072 proteins. Serum proteomics data were analyzed according to three
comparisons: (1) healthy controls vs. patients with PSC, (2) fibrosis severity in patients, defined by ELF score (9.8 cutoff), and (3)
serum levels of CCL24 in patients.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Differentially expressed proteins
(DEPs) from each of the three comparisons were interpreted using Ingenuity Pathway Analysis (IPA), to identify dysregulated canonical
biological pathways, upstream regulators, and toxicity-functions. The enriched canonical pathways, upstream regulators and toxicity-functions
overlapped between the three comparisons (disease, fibrosis and CCL24), suggesting that there are biological mechanisms related to PSC
and its progression also related to CCL24 expression levels. Overlapping canonical pathways included HSC activation pathway, immune cell
trafficking pathways (granulocyte and agranulocyte adhesion and diapedesis) and inflammation pathways (Th1 and Th2 activation, Th1 activation
and pathogen induced cytokine storm).&#160; In patients with PSC, those that had high levels of CCL24 also showed significantly higher
average expression of these pathways.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; text-align: center"><img src="image00023.jpg" alt=""/></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">PSC-related mechanisms are
upregulated in patients with high CCL24 levels. (A) Analysis over-view: sera from patients with PSC and HC were analyzed by the Olink
Explore 3072 proteomic platform, and differentially expressed proteins (DEPs) were compared by disease, fibrosis or CCL24. (B) Score plots
of principal component analysis of proteome profiles in HC and Patients with PSC with low or high ELF scores. (C) Correlation of CCL24
to representative proteins associated with inflammation/chemotaxis (CCL7 or CXCL10), in HC (n = 30) or patients with PSC with ALP &gt;
1.5 ULN (n = 34). (D-I) Ingenuity Pathway Analysis of canonical pathways, upstream regulators and liver-related toxicity functions. Venn
diagrams show top 30 significant canonical pathways (D), top 20 significant upstream regulators (F), and significant liver-related toxicities
(H). The average ex-pression of protein lists of specific canonical pathways (E), upstream regulators (G) and liver-related toxicities
(I) is presented for HC and patients with low and high CCL24 serum levels. Boxes rep-resent interquartile ranges with medians (n = 20-30).
*, p &lt; 0.05; **, p &lt; 0.01; ****, P &lt; 0.0001.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">CCL24 levels
correlate with ELF score</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">CCR3 levels
in circulating PBMCs in PSC patients</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Chronic liver inflammation
is driven in most hepatic injuries by several different immune cell populations originating from either resident hepatic immune cells
or recruited cells from the circulation to the damaged site. In collaboration with the Kaplan Medical Center, Israel, we explored systemic
changes of CCR3, given that this could impact cell recruitment to the PSC damaged liver. Peripheral blood mononuclear cells (PBMCs) from
ten PSC patients and healthy controls were stained for expression of CCR3 and demonstrated that levels were significantly higher in PSC
patient samples compared to healthy donors.<span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">CCL24 and
CCR3 levels in skin biopsies from SSc patients</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We analyzed skin samples from
diffuse SSc patients and healthy volunteers and the SSc samples showed elevations in CCL24 and CCR3. Specifically, higher accumulation
of CCL24 on immune cells skin infiltration was shown in the SSc samples and CCR3 was evident in skin fibroblasts, immune cells and endothelial
cells. These elevations led to a CCL24-mediated robust activation of CCR3 expressing cells, which enhances the recruitment of immune cells
and fibroblasts to the diseased organ.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; text-indent: 0.4pt; line-height: 1.25; font-family: Times New Roman,serif"><img src="image00024.jpg" alt=""/><br/>
&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">SSc patients
showed elevated levels of CCL24 in skin tissue</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25"><img src="image00025.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">SSc patients
showed elevated levels of CCR3 in skin tissue</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; text-indent: 27pt">&#160;&#160; <span style="font-style: italic">CCL24
levels in serum samples from SSc patients and correlation with fibrotic biomarkers</span><br/> &#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our researchers analyzed SSc
serum samples that showed that CCL24 levels were significantly increased in SSc patients compared with healthy individuals. Notably, in
diffuse SSc patients, CCL24 levels were fourfold higher than in healthy control patients.&#160; Additionally, the levels of CCL24 were
correlated with a biomarker of SSc severity, anti-topoisomerase, an autoantibody seen in diffuse SSc patients.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif"><span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25"><img src="image00026.jpg" alt=""/></div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; text-indent: 36pt">CCL24 levels in serum samples
from SSc patients and association with disease manifestations and mortality</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The relationship between
serum CCL24 levels and disease characteristics in a comprehensive real-life cohort of patients with SSc (n=213)&#160;was further studied.
The study highlights the association between higher CCL24 levels with critical clinical variables linked to the most severe forms of SSc.
Specifically, these variables include male gender, anti-Scl70 positivity, severity of skin fibrosis, presence of ILD, presence of digital
ulcers and lung microvascular impairment as measured by DLco. In a longitudinal setting, high serum CCL24 was predictive of lung deterioration.
Accordingly, a higher baseline CCL24 level was associated with SSc-related mortality.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; line-height: 1.25"><img src="image00027.jpg" alt=""/></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt">Comparison of baseline serum
CCL24 levels based on the occurrence of rapid ILD progression (A) and the relationship between baseline serum CCL24 levels and the relative
change in FVC over the following 12 months (B).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif"><img src="image00028.jpg" alt=""/><br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt">Cumulative incidence curves
comparing SSc-related and other-cause mortality in SSc patients with High and Low baseline CCL24 Status</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Preclinical
Efficacy of CM-101 in models of PSC</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Preclinical experiments in
models of PSC</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z4ef8e87948f14b17b75746c139671c52" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Human hepatic stellate cells demonstrated reduced
        transition to myofibroblasts following incubation of CM-101 with CCL24.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z4458183641e641068c2d02fd43130227" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Human hepatic stellate cells showed reduced motility
        towards CCL24 following treatment with CM-101.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zd7f510f405ac4cad96f4a91e48636af8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 demonstrated in vivo activity on liver
        fibrosis and cholangiocyte proliferation induced by bile duct ligation in the Sprague Dawley rat model.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z67d786385f794855a2218fadba94ac7b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 (D8-a murine surrogate of CM-101) inhibits
        the progression of liver fibrosis and bile duct damage in a chronic cholangitis cholestasis model using the hepatobiliary toxin ANIT.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z663e8f77d8844e1e97c0f994cb65c733" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 (D8) reduces bile duct epithelial cell
        (cholangiocyte) proliferation, collagen deposition, macrophage infiltration, liver enzymes, bile acid and circulating inflammatory monocytes
        in an experimental cholangitis model in MDR2 knockout mice.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z4cc2ba90c44a4e72b34f07c2692ec8e4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 reduces liver enzymes, fibrosis, collagen,
        and fibrotic gene expression in a TAA-induced liver fibrosis model in rats.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z1f59500ada01473daa36439f8627bce8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 (D8) prevented fibrosis and inflammation
        in a TAA-induced liver fibrosis model in mice.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Results from the multi-drug
resistant 2, or MDR2, knock out mouse model that reflects sclerosing cholangitis and the thioacetamide (TAA) rat model reflecting liver
fibrosis are described below.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; text-indent: 27pt">&#160;&#160;
CM-101 demonstrates anti-cholestatic, anti-inflammatory, and anti-fibrotic activity in MDR2 knock out mouse model in vivo</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Mice with targeted disruption
of the MDR2 transporter gene develop chronic and progressive hepatic sclerosing cholangitis that closely resembles PSC and therefore this
model has been extensively used to study the pathogenesis and progression of PSC. Using MDR2 knockout mice (six weeks of age), we tested
the ability of CM-101 (D8) to attenuate PSC related symptoms. Mice (n=15/group) received either vehicle control, or CM-101 10 mg/kg SC
twice weekly during weeks 6-12 following established disease and were sacrificed at the end of week 12. In this study mice were tested
for changes in alkaline phosphatase, or ALP, bile acid levels, collagen deposition (histology, Sirius red), macrophage presence in the
liver and cholangiocyte proliferation. We observed a significant decrease in all three core pathologies that play a role in PSC: inflammation,
fibrosis and cholangiocyte proliferation after CM-101 (D8) treatment compared to non-active treatment. Reduction in the serum markers
that represent the cholestatic state, ALP and bile acid, was also observed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif"><br/> <span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div style="text-align: center; line-height: 1.25"><img src="image13.jpg" alt="" style="width: 578px; height: 261px"/></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt"><span style="font-weight: bold">CM-101
reduces liver fibrosis, inflammation and bile duct epithelial proliferation in MDR2 knockout model</span><br/> &#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; text-indent: 36pt">CM-101
demonstrates in vivo activity in a thioacetamide induced liver fibrosis model in rats using a therapeutic model</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">To assess the potential efficacy
of CM-101 on liver fibrosis, we used the TAA-induced liver fibrosis model. Liver fibrosis was induced by intraperitoneal administration
of TAA at a dose of 250 mg/kg twice weekly for eight weeks. Rats (n=10/group) received either vehicle control or CM-101 2.5 mg/kg IV twice
weekly during weeks four to eight following established fibrosis and were sacrificed at week eight. After eight weeks of TAA treatment,
all vehicle-treated animals had developed liver fibrosis, as confirmed by Sirius-red-stained liver histology.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif"><br/> <span style="font-family: Times New Roman, serif"><br/> </span></div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25"><img src="image00029.jpg" alt=""/></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">CM-101 reduces
fibrosis in rat livers</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Plasma ALP, ALT, and AST levels
decreased in the CM-101 study arm. Liver collagen content and fibrotic areas were significantly reduced in the CM-101 treated group compared
to non-active treatment. CM-101 was also shown to reduce fibrotic markers in the TAA treated rats.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">&#160;Efficacy of CM-101 in
models of SSc</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span style="font-family: Times New Roman, serif"><br/>
</span>Preclinical experiments in models of SSc</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zfd120cdef6204446a659a3433285ec8f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 reduces SSc serum-induced dermal fibroblast
        activation and transition to myofibroblasts and interferes with endothelial cell activation.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z654daf564b8c48e9b20aef6b86fd38ed" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 treatment attenuated skin fibrotic remodeling
        in the bleomycin (BLM)-induced dermal fibrosis mouse model.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z81b82424ac584571958dbd036c79ffe1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">CM-101 attenuated lung fibrosis and inflammation
        in the bleomycin (BLM)-induced pulmonary fibrosis mouse model.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt">Results from the bleomycin
(BLM)-induced dermal and lung fibrosis mouse models are discussed below in more detail.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; text-indent: 36pt">CM-101
treatment attenuates skin fibrotic remodeling in the bleomycin (BLM)-induced dermal fibrosis mouse model</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; text-indent: 36pt">The activity of CM-101 (D8) in SSc was tested in
the dermal bleomycin model. Treatment started after the onset of fibrotic signs, eight days following the first BLM injection. Histological
assessment of skin lesions stained with H&amp;E and Masson&#8217;s trichrome revealed significant elevation of dermal thickness and collagen
deposition following 21 days of BLM administration. This elevation was significantly reduced when mice were treated with 2.5 mg/kg CM-101
with significant reductions in both skin thickness and collagen deposition compared with the mouse group treated with BLM alone.<br/>
<br/> &#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25"><img src="image00030.jpg" alt=""/></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">CM-101 treatment
attenuates skin fibrotic remodeling in the bleomycin-induced dermal fibrosis mouse model</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Another feature that characterizes
the BLM model and is representative of human SSc is the development of bronchoalveolar inflammation. To evaluate the effect of CM-101
on lung inflammation, we collected bronchoalveolar lavage, or, BAL, fluid, and assessed the number of white blood cells, or WBC, and mononuclear
cells. Treatment with BLM for 21 days significantly increased WBC and mononuclear cells in BAL fluid and the number of WBC and mononuclear
cells was decreased significantly following CM-101 treatment compared with the group that was administered only BLM. This data supports
the anti-inflammatory effect of CM-101 in SSc.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; text-indent: 36pt">CM-101
inhibits lung fibrosis in the BLM-induced pulmonary fibrosis mouse model</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We also tested CM-101 in the
experimental lung SSc model where mice were given a single intratracheal administration of BLM followed by either CM-101, non-active treatments
(PBS or control immunoglobulin G (IgG)) or the approved anti-fibrosis drugs, pirfenidone and nintedanib. CM-101 had a significant anti-fibrotic
and anti-inflammatory effect in the experimental BLM-induced lung fibrosis model as compared with non-active treatment-treated animals.
BLM animals treated with non-active treatments showed massive immune cell infiltration, extensive fibrosis and severe tissue injury. CM-101-treated
mice exhibited significantly reduced levels of lung fibrosis similar to levels in healthy animals and showed superior effects compared
to the approved fibrosis drugs pirfenidone and nintedanib.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div class="BRPFPageFooter">

<div style="line-height: 1.25"><br/> </div> </div>

<div class="BRPFPageHeader">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><img src="image00031.jpg" alt=""/><br/>
&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold; text-indent: 36pt">CM-101 attenuates
lung fibrosis and collagen deposition in the bleomycin (BLM)-induced pulmonary fibrosis mouse model</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold; text-indent: 36pt">Preclinical
safety and toxicology of CM-101</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Preclinical safety evaluation
of CM-101 included tissue cross reactivity, assessment of the effect of CM-101 on pro-inflammatory cytokine secretion ex-vivo, and in
vivo GLP toxicology studies in mice and non-human primates. No safety concerns were observed in these preclinical assessments.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Immunogenicity may be triggered
following administration of humanized monoclonal antibodies, an effect that is frequently seen with approved mAbs. To date, no meaningful
ADA effects were identified in three completed clinical studies, which supports a preliminary conclusion that CM-101 may have low immunogenic
potential.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">As summarized below, there were no safety concerns
related to CM-101 in any of the other preclinical safety experiments.<span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold; text-indent: 36pt">Summary of key preclinical safety
experiments</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">

<table cellspacing="0" cellpadding="0" id="z8c5da606a3194f5fbe2eafaa44db0070" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: #000000 2px solid; width: 50%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Preclinical findings</div> </td>
    <td style="width: 2%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 48%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Observation</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-style: italic">Ex vivo</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><br/> &#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Antibody dependent cell-cytotoxic (ADCC) and complement dependent cell-cytotoxic (CDC)
        activity was tested in PBMCs from healthy volunteers.</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">CM-101 did not have Fc-related effector functions such as ADCC and CDC.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Cytokine release was assessed in human whole blood from healthy volunteers.</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="line-height: 1.25">CM-101 did not induce pro-inflammatory cytokine secretion.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Tissue cross reactivity was evaluated from healthy human tissues.</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">CM-101 does not bind non-specifically to healthy tissues, and therefore is expected
        to only bind to its target, circulating CCL24.</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-style: italic">In vivo</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div>
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">GLP repeated dose 4-week toxicity study of CM-101 (IV) in mice.</div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="line-height: 1.25">1. No obvious treatment related adverse reactions.<br/> &#160;</div>
        <div style="line-height: 1.25">2. No gross or microscopic pathological findings.<br/> &#160;</div>
        <div style="line-height: 1.25">3. No cases of treatment related mortality were observed.<br/> &#160;</div>
        <div style="line-height: 1.25">4. No significant elevation was seen in IL1&#946;, IL2, IL4, IL5, IL10, GM-CSF, IFN and TNF&#945;.</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">

<table cellspacing="0" cellpadding="0" id="zeeba2982c03f42e1af71f02dd1f7952a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 50%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">GLP repeated dose (up to 50 mg/kg) 6-month toxicity study of CM-101 (SC) in Cynomolgus
        Monkey.</div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8203;</div>
        <div style="text-align: justify; line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 48%; vertical-align: top">
        <div style="line-height: 1.25">1. No obvious treatment related adverse reactions.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div>
        <div style="line-height: 1.25">2. No clinical signs or injection site reactions.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">3. No cases of treatment related mortality were observed.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">4. Blood and urine tests were found to be within normal ranges for monkeys.<br/> &#160;</div>
        <div style="line-height: 1.25">5. No treatment-related organ weight changes and no treatment-related necropsy findings.<br/> &#160;</div>
        <div style="line-height: 1.25">6. No treatment-related histopathology findings.<br/> &#160;</div>
        <div style="line-height: 1.25">7. Three samples from treated animals were confirmed ADA positive but there was no obvious correlation
        between positive ADA results and CM-101 serum concentrations or systemic exposure.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Preclinical
proof of mechanism studies for CM-101</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We conducted a series of in
vitro and in vivo studies to demonstrate the proposed mechanism of action and provide proof-of-concept for administering CM-101 in the
clinic for target indications.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;<span style="font-family: Times New Roman, serif; font-style: italic">Affinity,
selectivity, and binding kinetics</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We evaluated the kinetic binding
parameters of CM-101 to human CCL24, as well as the specificity of CM-101 binding to other chemokines using commercial binding assays.
CM-101 demonstrated a strong and stable, high affinity binding to CCL24.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">CM-101 reduced CCL24 dependent
CCR3 activation</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In an <span style="font-family: Times New Roman, serif; font-style: italic">in
vitro</span> assay, CM-101 was shown to robustly attenuate the ability of CCL24 to induce activation of the CCR3 receptor following pre-incubation
of CCL24 with CM-101.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"><br/> <span style="font-family: Times New Roman, serif"><br/>
</span>&#160;</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25"><img src="image00032.jpg" alt=""/></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Clinical
Development of CM-101</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Completed clinical studies</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The CM-101 Phase 1 program
included two Phase 1a single administration, or SAD, studies, using IV and SC administration with doses ranging from 0.75-10 mg/kg, in
healthy volunteers and a Phase 1b multiple administration (MAD) study (5 administrations) in NAFLD patients with normal liver function,
testing 2.5 mg/kg IV and 5 mg/kg SC. In the Phase 1 studies 42 subjects have received at least one CM-101 dose, the majority by IV infusion
(12/42 subjects received SC).</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Safety</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The first Phase 1a study, which
was a single-center, randomized double-blind, placebo-controlled, single-dose, dose-escalation study, included four escalating dose groups
of eight subjects each. In each dose group subjects were randomized in a 3:1 ratio to receive a single IV infusion of either CM-101 (n=6)
or placebo (n=2). A total of 24 subjects were enrolled into the study and randomized to the treatment groups (0.75 mg/ kg, 2.5 mg/kg,
5.0 mg/kg, 10 mg/kg) and eight subjects received a placebo. All 32 subjects completed the study as planned. Single, IV doses of CM-101
were well tolerated up to the highest dose level (10 mg/ kg) in healthy subjects. No severe or serious adverse events, or AEs, occurred
during the study and all CM-101 related AEs were mild, with one moderate AE reported in the placebo group (myalgia).</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The second Phase 1a study was
also a single-center, randomized double-blind, placebo-controlled, single-dose study, but evaluated only one dose group. Subjects were
randomized in a 3:1 ratio to receive a single SC injection of either CM-101 5 mg/kg (n=6) or matching placebo (n=2). A total of eight
subjects were enrolled into the study and randomized; all eight subjects completed the study as planned. Single SC administration of 5
mg/kg of CM-101 was well tolerated with no severe or serious AEs occurring during the study. A total of 6 AEs were reported in two subjects
treated with CM-101; only one AE was classified as related to CM-101 (change in diastolic blood pressure) and that AE was classified as
mild in intensity.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In both Phase 1a studies, all
AEs reported were resolved; no subjects discontinued the study prematurely due to AEs, and no concomitant medications were required for
treatment of any drug-related AEs. No clinically significant changes in laboratory tests (hematology, chemistry or urinalysis), vital
signs, ECG, physical examination or infusion site examination were observed. In the first Phase 1a study with CM-101 delivered by IV administration,
the effect on cytokine secretion was tested pre-treatment and o<span style="font-family: Times New Roman Greek, serif">ne hour, eight
hours and 24 hours post drug administration. Serum levels of a panel of cytokines including IL-6, IFN&#947;, GM-CSF, TNF-&#945;, IL-2,
IL-4, IL-8 and IL-10 showed no significant change at all tested CM-101 doses and timepoints. These findings suggest that single CM-101
administration does not cause immune activation nor cytokine secretion. Additionally, none of the subjects in either of the Phase 1a studies
tested positive for anti-drug antibodies (ADA).</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The multiple administration
randomized, placebo-controlled, Phase 1b study in NAFLD patients with normal liver function tests evaluated two dose levels. The first
dose level of 2.5 mg/kg CM-101 was administered as an IV infusion and the second dose level of 5 mg/kg was administered as an SC injection.
Both dose levels involved five drug administrations over 12 weeks (Q3W), providing 15 weeks of treatment coverage. At both dose levels,
subjects were randomized in a 3:1 ratio to receive either CM-101 (n=6 per cohort) (2.5 mg/kg IV or 5 mg/kg SC) or matching placebo (n=2
per cohort). Five repeated IV and SC CM-101 administrations were well tolerated and there were no deaths, or severe or serious drug related
AEs reported throughout the study. Only mild to moderate AEs were reported in the CM-101 treatment groups of which only two AEs were classified
as possibly related to CM-101. No injection site reactions or clinically significant trends in laboratory tests (hematology, chemistry,
or urinalysis), vital signs, ECG or physical examination were observed. One patient experienced a non-drug-related SAE. This patient was
a 61-year-old female that was subsequently diagnosed with a non-treatment related meningioma. The tumor was treated surgically, and the
patient was discontinued from the study.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Pharmacokinetics with single-dose
administration</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">PK analysis was conducted for
the Phase 1 studies and the quantification of CM-101 in plasma samples was performed using a validated ELISA-based assay by Eurofins (UK).
Following IV infusion in healthy volunteers, CM-101 exhibited a biphasic serum concentration vs. time curve (rapid distribution phase
and slow elimination phase) which is typical for monoclonal antibodies. Target-mediated drug disposition (TMDD), or presence of ADAs,
was not evident in the analyzed concentration vs. time curves of CM-101, which exhibited linear terminal slope without apparent TMDD kinetics
or other concentration-dependent changes of the elimination kinetics. Comparison of the PK data of 5 mg/kg CM-101 using IV administration
against SC administration indicates consistent distribution and elimination behavior of CM-101.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">At either IV or SC administration,
the values of the PK parameters obtained in the non-compartmental and compartmental analysis of CM-101 concentration vs. time data appear
to be typical for monoclonal antibodies that undergo FcRn-mediated recycling. The terminal half-life of CM-101 was long for both SC and
IV formulations, which supports administration of CM-101 at a frequency of once every 2-4 weeks.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Pharmacokinetics with multiple-dose
administration</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">PK analysis of the data from
the Phase 1b study was conducted to evaluate CM-101 following multiple IV infusion of 2.5 mg/kg or 5 mg/kg SC injections of CM-101 in
NAFLD patients. Following repeated IV infusions (2.5 mg/kg Q3W) and SC injection (5 mg/kg Q3W), CM-101 exhibited a long terminal half-life,
similar to the terminal half-life seen in the single dose studies. CM-101 accumulated over time, resulting in significant systemic exposure
over time and potentially reaching a steady state.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Overall, CM-101 reached steady
state conditions more slowly following SC injection, as compared to IV infusion. The inter-patient variability in CM-101 serum concentrations
was higher for SC dosing injection, as compared to IV. The trough CM-101 serum concentrations after repeated 5 mg/kg SC injections were
proportionally higher than those after 2.5 mg/kg IV infusions, considering the difference in administration modes. Comparison of the PK
data of CM-101 in the Phase 1b to the Phase 1a studies indicates a consistency in PK behavior of CM-101.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Pharmacodynamics and target
engagement of CM-101</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Serum was taken from patients
in all three Phase 1 studies at different times and the levels of both CCL24 and CM-101 were measured. Total CCL24 levels represent CM-101&#8217;s
engagement to its target. Total CCL24 levels were increased following administration of the drug, which indicates that CM-101 is effective
in target engagement, as the higher levels of CCL24 correlated significantly with greater doses of CM-101, and such levels decreased gradually
from the peak of CM-101 administration. These findings demonstrate that CM-101 effectively binds to CCL24 in the circulation, which reflects
a strong drug-target interaction.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In the Phase 1b study, CM-101
treatment of 2.5mg/kg IV attained the highest levels of total CCL24 by the third administration, maintaining these levels until the end
of treatment. CM-101 5mg/kg administered by SC injection reached the highest levels of CCL24 by the fourth treatment and maintained these
levels until the end of treatment. The matching placebo did not have any effect on CCL24 levels.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">As exemplified in the in-vitro
studies, binding of CCL24 by CM-101 attenuates the binding of CCL24 to its cognate CCR3 receptor, thereby reducing its downstream activation.
Altogether, CCL24 levels following treatment with CM-101 provide strong evidence for target engagement and pharmacodynamic response of
CM-101 in healthy volunteers and patients.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Phase 1b exploratory endpoints</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Fibrotic biomarkers were analyzed
as part of the Phase 1b study in NAFLD patients with normal liver function. Circulating fibrotic biomarkers were tested in serum pre-
and post-treatment. The analysis included data from patients that presented with more active disease, reflected by baseline elastography
(FibroScan) score &gt;4 kPa. Tissue inhibitor of metalloproteinases-1 (TIMP-1) and tissue inhibitor of metalloproteinases-2 (TIMP-2),
considered well established fibrotic biomarkers, were evaluated, and showed that CM-101 treatment led to reductions of both markers by
week 15. The growth factor PDGF-AA, known as a pro-fibrotic secreted factor, was also reduced in CM-101 treated patients. Conversely,
in the placebo group TIMP-1, TIMP-2 and PDGF-AA all increased.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Evaluation of the fibrogenesis
and fibrolysis/inflammatory biomarkers, Pro-C3, Pro-C4 and C3M measured in serum, conducted by Nordic Bioscience, Copenhagen, Denmark,
were also used as sensitive indicators of the liver&#8217;s fibrotic state. In accordance with reduced liver stiffness, Pro-C3, Pro-C4
and C3M were all reduced in the CM-101 treated groups. No reductions were identified in the placebo control group.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Changes in liver stiffness,
a measurement of liver fibrosis, were also evaluated using FibroScan measurements taken at screening and end of treatment (EoT) following
15 weeks of treatment coverage. 80% of CM-101 treated patients had significant decreases in FibroScan measurements, unlike placebo patients
where there was no significant change from baseline.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Results of investigator-initiated clinical study
of CM-101 in patients with COVID-19-derived lung damage</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On November 9, 2022, encouraging
clinical data from an investigator-initiated clinical study assessing CM-101 activity and safety in hospitalized patients with severe
lung injury derived from COVID-19 infection was presented at the 2022 Union Conference, an international conference on lung health. A
key rationale for the study is that some of the mechanisms underlying lung inflammation resulting from COVID-19 infection are similar
to those seen in systemic sclerosis and other chronic diseases involving lung inflammation and fibrosis.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The objective was to evaluate
the safety and activity of CM-101 in hospitalized COVID-19 patients with severe pneumonia, including its impact on biomarkers related
to lung inflammation that are also relevant in SSc.<span style="font-family: Times New Roman, serif; font-weight: bold">&#160;</span>The
open label, single arm trial enrolled 16 hospitalized adult COVID-19 patients with severe respiratory involvement. All patients were receiving
standard of care therapy. All were treated with a single 10mg/kg intravenous dose of CM-101 on the first day of the study and followed
for 30 days.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Administration of CM-101 to
this acutely ill patient population appeared well tolerated. CM-101 exposures and target engagement profiles were similar to what our
researchers have seen in previous clinical studies of CM-101.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Importantly, rapid reductions
in serum biomarkers of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment with CM-101.<span style="font-family: Times New Roman, serif; font-weight: bold">&#160;</span>Overall,
this study confirmed and extended the safety and tolerability profile of CM-101 and demonstrated clinically relevant changes in biomarkers
associated with lung inflammation and fibrogenesis, further supporting CM-101&#8217;s anti-inflammatory and anti-fibrotic effects.<span style="font-family: Times New Roman, serif; font-weight: bold">&#160;</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Moreover, we believe that these
results add to the data suggesting that CM-101 has the potential to attenuate lung inflammation and fibrosis, further strengthening the
rationale for treating SSc patients with this drug. These new clinical data also contribute to a growing body of evidence demonstrating
CM-101&#8217;s anti-fibrotic and anti-inflammatory effects in varied organs including the lung, liver and skin.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Primary endpoints for the study
were safety and tolerability. Secondary endpoints included the evaluation of the pharmacokinetic and target engagement profile of the
SC formulation as well as changes in relevant biomarkers that may provide further mechanistic understanding of CM-101 effects on liver
fibrosis. This trial was primarily designed to assess a subcutaneous formulation of CM-101 and to evaluate the drug&#8217;s impact on
liver fibrosis biomarkers relevant to both NASH and fibro-inflammatory conditions that represent the focus for Chemomab, such as PSC and
SSc.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The randomized, placebo-controlled
trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo. Patients received
eight doses of 5 mg/kg of study drug administered by subcutaneous injection once every two weeks, for a treatment period of 16 weeks.
Key findings of the CM-101 Phase 2a trial included the following.</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">CM-101 appeared to be well tolerated when administered subcutaneously. Most reported adverse events observed
        were mild, with one unrelated serious adverse event reported. No significant injection site reactions were reported and no anti-drug antibodies
        were detected.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">CM-101 administered subcutaneously demonstrated favorable pharmacokinetics and target engagement profiles
        as expected and were similar to what we have previously reported.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">CM-101-treated patients showed greater improvements than the placebo group in a number of liver fibrosis-related
        biomarkers, including ProC-3, ProC-4, ProC-18, TIMP-1 and ELF.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">A majority of CM-101-treated patients showed improvements in more than one liver fibrosis-related biomarker&#8212;almost
        60% of CM-101 patients responded in at least three biomarkers at week 20, compared to no patients in the placebo group.</div> </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">A higher proportion of patients in the CM-101-treated group showed improvement in a physiologic measure
        of liver stiffness as compared to placebo (reduction of at least one grade of fibrosis score as assessed by the non-invasive elastography
        method known as FibroScan&#174;).</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">CM-101-treated patients with higher CCL24 levels at baseline showed greater reductions in fibrosis-related
        biomarkers than patients with lower levels. Multiple fibrosis-related biomarkers showed more pronounced reductions in CM-101-treated patients
        who had higher CCL24 levels at baseline than in patients with lower CCL24 levels at baseline, adding to the growing body of evidence validating
        the role of CCL24 in the pathophysiology of fibrotic liver disease.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">After completion of the study, the unblinded data showed that patients in the CM-101-treated group had
        higher baseline levels of fibrosis compared to placebo patients. The impact of this difference on the results, if any, is unknown.</div>
        </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Secondary analysis results
of Phase 2a study in patients with liver fibrosis derived from NASH</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In June 2023, at the 2023 EASL
Congress,<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup>Chemomab researchers reported topline results
from secondary analyses of the Phase 2a liver fibrosis trial assessing CM-101, in patients with NASH. The results were included in a late-breaking
poster presentation.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Overall, the data showed improvements
across an additional set of inflammatory and fibrotic biomarkers that are consistent with the positive clinical results Chemomab released
in January of 2023. Additionally, in NASH patients at greater risk of disease progression, CM-101 treatment resulted in a greater biomarker
response than in NASH patients with lower risk disease or in placebo-treated patients.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The new analyses&#160;assessed
additional biomarkers and also used the FibroScan-AST (FAST) score to categorize study patients based on progressive disease risk, thereby
enabling the evaluation of CM-101 activity in the main target population of patients with more active disease.&#160;FAST is a validated
score composed of non-invasive FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>&#160;and
AST measurements that is used to identify patients with a high risk of NASH progression.&#160;The results showed that:</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="font-family: Times New Roman, serif">FAST scores were improved in a higher proportion of CM-101-treated patients than in placebo
        patients.</div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="font-family: Times New Roman, serif">CM-101-treated patients with higher FAST scores demonstrated greater improvements in
        key&#160;fibro-inflammatory biomarkers, such as Pro-C3, than patients with lower FAST scores or placebo patients.</div> </div> </div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="font-family: Times New Roman, serif">CM-101-treated patients with higher FAST scores showed improvements in several&#160;fibro-inflammatory
        biomarkers generally comparable&#160;to those achieved in several recent successful NASH clinical trials.</div> </div> </div> </div> </td>
        </tr>
  </table> <br/> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Additionally, in these secondary
analyses, CM-101-treated patients showed improvements in an additional set of biomarkers associated with active fibrosis and inflammation:</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="font-family: Times New Roman, serif">
        <div>FIB-4, an index for determining NASH status that includes age, platelet count,&#160;AST and ALT levels, was improved in CM-101-treated
        patients vs. placebo patients.</div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="font-family: Times New Roman, serif">
        <div>AST/ALT ratio, a liver enzyme ratio, was improved in CM-101-treated patients vs. placebo patients.</div> </div> </div> </div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="font-family: Times New Roman, serif">
        <div>Neutrophil-to-Lymphocyte Ratio (NLR), an indicator of inflammation, was improved in CM-101-treated patients vs. placebo patients,
        and NLR was further improved in groups with higher FAST scores.</div> </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="font-family: Times New Roman, serif">
        <div>&#160;PRO-C3, which captures active fibrogenesis and correlates with fibrotic disease severity, was improved in CM-101-treated patients
        vs. placebo patients and was further improved in groups with higher FAST scores. As an overall indicator of fibrogenesis and fibrotic
        disease, PRO-C3 is also considered a potential "bridge" to PSC and other anti-fibrotic indications.</div> </div> </div> </div> </div>
        </td> </tr>
  </table> <br/> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
</div> </div> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We believe the that the data
analyses from this trial provide important insights in support of the CM-101 development program, including the favorable safety and tolerability
of CM-101 in patients with serious liver disease, confirmation of early signs of biomarker activity that are relevant for a number of
fibro-inflammatory disorders, and support of the tolerability and pharmacokinetic data needed to assess next steps in the development
of our current subcutaneous formulation.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Other clinical
development activities for CM-101</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In 2022, we reported positive
clinical data from an investigator-initiated clinical study assessing CM-101 activity and safety in hospitalized patients with severe
lung injury derived from COVID-19. The objective of the study was to evaluate the drug&#8217;s safety and activity in hospitalized COVID-19
patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also relevant in systemic sclerosis.
The open label, single arm trial enrolled 16 hospitalized adult COVID-19 patients with severe respiratory involvement. All patients were
receiving standard of care therapy. All were treated with a single 10mg/kg intravenous dose of CM-101 on the first day of the study and
followed for 30 days. Administration of CM-101 to this acutely ill patient population appeared to be well tolerated. CM-101 exposures
and target engagement profiles were similar to what our researchers have seen in previous clinical studies of CM-101. Importantly, rapid
reductions in serum biomarkers of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment with CM-101. Overall,
this study confirmed and extended the safety and tolerability profile of CM-101 and demonstrated clinically relevant changes in biomarkers
associated with lung inflammation and fibrogenesis, further supporting CM-101&#8217;s anti-inflammatory and anti-fibrotic effects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Together, these promising results
provide initial support for CM-101&#8217;s anti-fibrotic and anti-inflammatory mechanisms in humans and support further testing of CM-101
in PSC and SSc patients.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Current and planned clinical
studies for PSC and SSc</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We have completed patient enrollment
and are currently treating enrolled patients in a CM-101 Phase 2 PSC study at multiple sites in Israel, the U.S, and Europe. We also gave
a Phase 2-ready SSc clinical trial with an open U.S. IND that is ready for initiation of patient enrollment following the successful completion
of the PSC study and available resources.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The ongoing Phase 2 trial in
PSC is a randomized, double-blind, placebo-controlled, study designed to evaluate the safety and efficacy of CM-101 in adult subjects
with PSC. Participants must have a serum alkaline phosphatase, or ALP, level of at least 1.5 times the upper limit of normal (x 1.5 ULN).
Subjects with concomitant inflammatory bowel disease (IBD) are eligible for recruitment if their disease is stable and there is an absence
of high-grade dysplasia in colonic biopsies within 18 months of randomization. Subjects are randomized to receive 10 mg/kg or 20mg/kg
of CM-101 IV, or placebo, in a 2:1 ratio. Patients receive a dose of investigational product once every three weeks for a total of five
administrations resulting in a total coverage of 15 weeks during the double-blind portion of the study. The study design also includes
a 33-week long open-label extension period during which all participants receive either 10 mg/kg or 20 mg/kg of CM-101 via IV administration
every three weeks.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The primary endpoint for the
study is safety and tolerability. Secondary endpoints include evaluations of changes from baseline in serum ALP levels and the fibrotic
marker enhanced liver function, or ELF, score at week 15. ALP is a liver enzyme that is elevated in cholestasis and the ELF score is a
biochemical test panel made up of serum markers that are indicators of the extracellular matrix. Additional secondary endpoints include
evaluations of changes from baseline in other liver enzymes and additional fibrotic markers, including AST, ALT, Pro-C3 and Pro-C5, as
well as PK, PD and ADA parameters.<span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The planned Phase 2 study in
SSc would enable an expedited path to proof-of-concept data and further elucidation of different CM-101 mechanisms of action in treating
SSc skin, lung and vascular damage. The U.S. FDA cleared our IND application to commence the Phase 2 SSc trial, which could be initiated
following successful completion of the Phase 2 PSC clinical study and available resources.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;<span style="font-family: Times New Roman, serif; font-weight: bold">Competition</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The development and commercialization
of new drug products is highly competitive across major pharmaceutical companies, specialty pharmaceutical companies and biotechnology
companies worldwide. We face competition with respect to our current product and expect to face competition with respect to any product
candidates that we may develop or commercialize in the future. Specifically, there are a number of companies developing treatments for
fibrotic/inflammatory diseases, including multiple major pharmaceutical and biotechnology companies with substantially greater resources
than us. We are a small biotech company with limited resources compared to the major pharmaceutical companies, however, we believe that
the unique CM-101 platform together with our knowledge and experience in inflammatory-fibrotic research provides us with competitive advantages.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Therapeutic options for PSC
and SSc are limited and despite significant biopharmaceutical industry investment, the FDA has not approved any disease modifying therapies
for the treatment of PSC or SSc. Liver transplant is currently the only treatment shown to improve clinical outcomes for PSC patients
while SSc patients are being treated with drugs that were approved for different manifestations of the disease like interstitial lung
disease (nintedanib, Boehringer Ingelheim and tocilizumab, Hoffmann-La Roche).</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We are assessing CM-101, a
first-in-class monoclonal antibody that interferes directly with both inflammation and fibrosis, into clinical development for the treatment
of PSC and SSc. There are a number of large biopharmaceutical and biotechnology companies that are currently pursuing the development
of products for the treatment of fibrotic indications like PSC and SSc, such as, Mitsubishi Tanabe Pharma, Horizon Therapeutics, Pliant
Therapeutics,&#160;and others. However, we know of no other companies currently in clinical development with a monoclonal antibody that
targets CCL24.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Although the approach is novel
with respect to targeting both inflammation and fibrosis, we will need to compete with products further advanced in the pipeline towards
market approval. Investigational products, include:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc23085161f4f4332b131f6da99319992" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">PSC</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">There are currently no FDA-approved
therapies for the treatment of PSC. Companies currently developing product candidates in Phase 3 clinical studies include Dr. Falk Pharma,
targeting cholestasis and liver metabolism (Dr. Falk; norUrso), rather than anti-fibrotic and anti-inflammatory manifestations of PSC.
Other companies with clinical candidates in earlier stages of development include Mirum Pharmaceuticals and Pliant Inc. As shown in the
table below, most competitors are targeting the metabolic or symptomatic aspects of PSC. Only the Chemomab and Pliant compounds have disease
modifying potential, and we believe that our unique dual anti-fibrotic and anti-inflammatory activity gives CM-101 at potential advantage.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Unlike Most PSC Competitors,
CM-101&#8217;s Unique Dual Activity Has Disease-Modifying Potential</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<div style="text-align: center; line-height: 1.25"><img src="image00033.jpg" alt=""/></div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z2e816e1c08be4b21850b282d5d91dcaf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">SSc</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">There are currently two FDA
approved products for the treatment of clinical manifestations of SSc--nintedanib, marketed by Boehringer Ingelheim GmbH and tocilizumab,
marketed by Hoffmann-La Roche for the treatment of interstitial lung disease. Companies currently developing product candidates in SSc
in early clinical stage include Horizon, Mitsubishi Tanabe, GS Johnson &amp; Johnson, Vicore, Sanofi, Merck and others.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The availability of reimbursement
from government and other third-party payors will affect the pricing and competitiveness of CM-101 and any future products. More advanced
competitors also may obtain regulatory approval for their products more rapidly than us, which could result in competitors establishing
a strong market position.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Intellectual Property</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Overview</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We strive to protect and enhance
the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including
seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade
secrets relating to our proprietary technology platform and know-how, continuing technological innovation and in-licensing opportunities
to develop, strengthen, and maintain our proprietary position in the field of inflammation and fibrosis that may present areas of opportunity
for the development of our business. We may also rely on regulatory protection afforded through data exclusivity, market exclusivity,
and patent term extensions, where available.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our commercial success may
depend in part on our ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions
and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without
infringing the valid enforceable patents and proprietary rights of third parties. Our ability to prevent third parties from making, using,
selling, offering to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable licenses,
patents, or trade secrets that cover these activities. In certain cases, enforcement of these rights may depend on third party licensors.
With respect to both licensed and company-owned intellectual property rights, we cannot be sure that patents will be granted with respect
to any of our pending patent applications or with respect to any patent applications that may be filed by us in the future, nor can we
be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting
our commercial products and methods of manufacturing the same.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">As of the date of this Annual
Report on Form 20-F, we owned or licensed seven pending or issued US patents and patent applications as well as patents and patent applications
in other jurisdictions. The first patent family has been issued in each of the United States, Europe (validated in France, Germany and
the United Kingdom) and Israel to the Tel Aviv Souraski Medical Center, whose rights have been licensed to Chemomab on an exclusive basis.
A composition of matter patent was issued in United States and certain corresponding foreign jurisdictions. To date, three additional
patent families were filed concerning the use of anti CCL24 antibodies in specific indications, dosing regimens, and routes of administration.
We will seek United States and foreign patent protection for a variety of additional technologies, including: research compounds and methods,
candidate compounds and antibodies for modulating the activity of CCL24, methods for treating diseases of interest, and methods for treating
our products. We will seek additional protection, in part, through confidentiality and proprietary information agreements.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Company
Owned Intellectual Property</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We own multiple families of
patent applications that pertain to anti-CCL24 monoclonal antibody compositions capable of blocking CCL24 activity and methods for treating
or preventing diseases associated with inflammation and fibrosis. Certain applications in these families relate to our CM-101 antibody,
backup variants, various unit dosages, dosing regimens, and other routes of administration. Patents that are or will be issued from these
submissions will expire between the years 2035 to 2041, subject to possible patent term adjustments and/or extensions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In addition to the above, we
have established expertise and development capabilities focused in the areas of preclinical research and development, manufacturing and
manufacturing process development, quality control, quality assurance, regulatory affairs, and clinical study design and implementation.
We believe that our focus and expertise will help us develop products based on our proprietary intellectual property.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Licensed
IP</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">As mentioned above, we have
obtained an exclusive license from the Tel Aviv Souraski Medical Center for one patent, which is expected to expire in 2029. This patent
was issued in each of the United States, Europe and Israel, and pertains to anti CCL24 inhibitors (specifically, anti CCL24 antibodies)
and methods of using such inhibitors for treating inflammatory, autoimmune and cardiovascular diseases.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Trade Secret
Protection</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We may rely, in some circumstances, on trade
secrets to protect our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality
agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality
of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information
technology systems.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Material
Agreements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Tel-Aviv Souraski Medical
Center (TASMC) License Agreement</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In December 2011, we entered
into a license agreement, or the TASMC Agreement, with the Medical Research, Infrastructure, Health Services Fund of the Tel Aviv Souraski
Medical Center., or TASMC, for the research, development and commercialization of the CCL24 platform and CCR3 blockade platform (CM-101),
which license includes patent rights covering the foregoing platforms and related know how and products. Under the terms of the TASMC
Agreement, we are responsible for the research, development, manufacturing and commercialization of CM-101. This license was granted on
an exclusive basis and we were also granted rights to sublicense the instant license to third parties pursuant to certain terms described
therein.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In accordance with the TASMC
Agreement, we paid TASMC a non-refundable and non-creditable payment in four milestone installments, related to TASMC&#8217;s past patent
maintenance and prosecution costs.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Certain additional terms of the TASMC Agreement
include:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z21aa40d9c4d04950a8df038d7dde4aa7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">We will be required to pay TASMC non-refundable
        and non-creditable milestone payments of up to (i) $300,000 upon the submission of an NDA, BLA or equivalent for each of the licensed
        products to the FDA and to equivalent European and Asian foreign regulatory agencies, and (ii) $600,000 upon the grant by the FDA or equivalent
        European and/or Asian regulatory agencies of their marketing approval for each licensed product;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zc946e8ee26c049bc98c565faa691fb5b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">In the event of an &#8220;exit,&#8221; as such
        term is defined therein, we must pay TASMC an exit fee of 1% of the transaction consideration (which shall be capped at $3 million);</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zcf012ba06ad04411bf9d62f41b737fa5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">In the event we sublicense a licensed product,
        we must pay TASMC a sublicense fee of 10% of all attributed income, in addition to a low-single digit percentage tiered royalty payment
        of our earned royalties.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Unless terminated earlier,
the TASMC Agreement will expire upon the later of the expiration of the last-to-expire valid patent claim and any extension granted prior
thereto. The termination of the TASMC Agreement will not preclude TASMC from receiving sublicense payments or royalties. In addition to
the foregoing, the TASMC Agreement includes customary termination provisions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">CMC Collaboration Agreement</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In June 2015, we entered into
a collaboration agreement, or the CMC Agreement, with CMC ICOS Biologics, Inc. (acquired by AGC Biologics in 2018), or CMC, which, under
the terms thereof, granted the us certain licenses to use proprietary rights, materials and know-how of CMC for purposes of research and
development of CM-101 as well as commercialization thereof. Pursuant to the terms of the CMC Agreement, we received (i) a worldwide, non-exclusive,
non-transferable, non-sublicensable license for research purposes, or the Research License, and (ii) an option, or the Option License,
to a worldwide, non-exclusive, non-transferable, sublicensable license for commercialization purposes, subject to a fee schedule in addition
to that described below.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In accordance with the terms
of the CMC Agreement, we agreed to pay in exchange for the foregoing license payments to CMC upon the achievement of certain pre-determined
clinical and regulatory events, an amount stipulated in the CMC Agreement, aggregating a six-digit number. Additionally, for any product
that is commercialized pursuant to the CMC Agreement, we are required to pay CMC a royalty payment based on annual aggregate worldwide
net sales thresholds for such products. In the event CMC exclusively manufactures our products, CMC agrees to waive the foregoing royalty.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Unless terminated earlier pursuant
to the customary termination provisions set forth in the CMC Agreement, the Research License will expire upon the conclusion of the term
as defined therein, and the Option License will expire upon the later of (a) the tenth anniversary following our obtainment of regulatory
approval, or (b) the last to expire of the patent rights and country-by-country basis.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Manufacturing</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our product candidate, CM-101,
is a monoclonal antibody amenable to standard formulation technologies. We have developed the biological process and manufactured kilogram
quantities through processes similar to the manufacturing processes that will be required to provide drug product for the Phase 2 clinical
studies. The manufacturing process of the drug substance used for such product candidates is robust, well established and requires the
use of readily available starting materials. The biological route is amenable to large-scale production and does not require unconventional
equipment or handling during the manufacturing process. We have obtained an adequate supply chain of the drug substance for CM-101 from
our contract manufacturing organization, or CMO, to satisfy both our clinical and preclinical requirements for this year. We rely on a
sole supplier for the manufacture of CM-101. Our manufacturer has the capabilities to support late stage clinical studies as well as product
launch and marketing.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We do not own or operate facilities for
clinical drug manufacturing, storage, distribution or quality testing. Currently, all of our clinical manufacturing is outsourced to third-party
manufacturers. As our development programs expand and we build new process efficiencies, we expect to continually evaluate this strategy
with the objective of satisfying demand for our clinical studies and, if approved, the manufacture, sale and distribution of commercial
products.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Commercialization</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We intend to develop and, if
approved by the FDA, to commercialize our product candidates alone or in collaboration with others. We may work in combination with one
or more large pharmaceutical partners for certain indications, where specialist capabilities are needed. We intend to enter into distribution
or licensing arrangements for global or regional commercialization rights. We will, however, continuously review our partnering strategy
in the light of new clinical data and market understanding.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Regulatory Matters</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The Food and Drug Administration, or FDA,
and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements
upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those that we are developing.
These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture,
quality control, safety, effectiveness, labelling, storage, record keeping, approval, advertising and promotion, distribution, post-approval
monitoring and reporting, sampling and export and import of our product candidates.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">United
States government regulation of drug products</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Drugs in the United States
are subject to rigorous regulation under the Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The FDA also regulates
biological products under the FDCA and the Public Health Service Act, or PHSA. If we advance clinical development of a biologic candidate
in the future, these development activities will be subject to additional regulatory requirements specific to biologics. The process of
obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations
requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements
at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative
or judicial sanctions, such as the FDA&#8217;s refusal to approve a pending New Drug Application, or NDA, withdrawal of an approval, imposition
of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The process required by the
FDA before a drug or biologic may be marketed in the United States generally involves the following:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><span style="font-family: Times New Roman, serif"><br/>
</span></div>

<table cellspacing="0" cellpadding="0" id="ze86987b52e7841c08f710418e08bf0bd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">completion of preclinical laboratory tests, animal
        studies and formulation studies in compliance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">submission to the FDA of an Investigational New
        Drug application, or IND, which must become effective before human clinical studies may begin;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">approval by an Institutional Review Board, or
        IRB, at each clinical site before each study may be initiated;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">performance of adequate and well-controlled human
        clinical studies in accordance with Good Clinical Practice, or GCP requirements to establish the safety and efficacy of the proposed drug
        product for each indication;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">completion of all manufacturing requirements to
        ensure robust manufacturing process, and product quality and safety as per Good Manufacturing Practice, or cGMP guidelines;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">completion of non-clinical reproductive studies,
        as applicable, prior to late stage clinical studies and NDA or Biologics License Application, or BLA, submission;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">development of an appropriate pediatric plan for
        clinical testing or exclusion, pre- or post-approval, as applicable;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">submission to the FDA of an NDA or BLA;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">satisfactory completion of an FDA advisory committee
        review, if applicable;&#160;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">satisfactory completion of an FDA inspection of
        the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that
        the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">satisfactory completion of FDA audits of clinical
        study sites to assure compliance with GCPs and the integrity of the clinical data;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">payment of user fees and securing FDA approval
        of the NDA;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">FDA review and approval of an NDA or BLA; and</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">compliance with any post-approval requirements,
        including the potential requirement to implement a Risk Evaluation and Mitigation Strategies, or REMS, and the potential requirement to
        conduct post-approval studies.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Preclinical
studies</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Preclinical studies include
laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy.
An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available
clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND
is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns
or questions related to one or more proposed clinical studies and places the clinical study on a clinical hold. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. As a result, submission of an IND may not
result in the FDA allowing clinical studies to initiate.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Clinical
studies</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Clinical studies involve the
administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP
requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation
in any clinical study. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical study and any
subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating
in the clinical study must review and approve the plan for any clinical study before it initiates at that institution. Information about
certain clinical studies must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination
on their www.clinicaltrials.gov website.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Human clinical studies are
typically conducted in three sequential phases, which may overlap or be combined. A fourth, or post-approval, phase may include additional
clinical studies. These phases generally include the following:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc179d183ac7f407b9ebfc5119bdb1e81" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold">Phase
        1:</span> The drug or biologic is initially introduced into healthy human subjects or patients with the target disease or condition and
        tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of
        its effectiveness. For some products for severe or life-threatening diseases, especially if the product may be too toxic to administer
        to healthy humans, the initial clinical trials may be conducted in individuals having a specific disease for which use the tested product
        is indicated.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold">Phase
        2:</span> The drug or biologic is administered is administered to a limited patient population to identify possible adverse effects and
        safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and
        optimal dosage.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold">Phase
        3:</span> The drug or biologic is administered to an expanded patient population, generally at geographically dispersed clinical study
        sites, in well-controlled clinical studies to generate enough data to statistically evaluate the efficacy and safety of the product for
        approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold">Phase
        4:</span> Phase 4 clinical trials are studies required of, or agreed to by, a sponsor that are conducted after the FDA has approved a
        product for marketing. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic
        indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves
        a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from
        these clinical trials to meet all or part of any Phase 4 clinical trial requirement. Failure to promptly conduct Phase 4 clinical trials
        where necessary could result in withdrawal of approval for products approved under accelerated approval regulations.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Progress reports detailing
the results of the clinical studies must be submitted at least annually to the FDA and more frequently if serious adverse events occur.
Phase 1, Phase 2 and Phase 3 studies may not be completed successfully within any specified period, or at all. Furthermore, the FDA or
the sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are
being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution
if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected
serious harm to patients.<span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Marketing
approval</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Assuming successful completion
of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to
the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an
NDA or BLA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA or BLA is subject
to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the
FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA, for a new molecular entity to review and act on
the submission. This review typically takes twelve months from the date the NDA or BLA is submitted to FDA because the FDA has approximately
two months to make a &#8220;filing&#8221; decision.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In addition, under the Pediatric
Research Equity Act of 2003, or PREA, as amended and reauthorized, certain NDAs/BLAs or supplements thereof must contain data that are
adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and
to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its
own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of
the product for use in adults, or full or partial waivers from the pediatric data requirements. An Agreed Initial Pediatric Study Plan
requesting a waiver from the requirement to conduct clinical studies may be submitted to the FDA.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The FDA also may require submission
of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication
plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk
minimization tools.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The FDA conducts a preliminary
review of all NDAs/BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA/BLA for filing. In this event,
the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the
FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews
an NDA/BLA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured,
processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The FDA may refer an application
for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific
experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Before approving an NDA, the
FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless
it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical
study sites to assure compliance with GCP requirements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">After evaluating the NDA/BLA
and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing
facilities and clinical study sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response
letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA/BLA and may
require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those
conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Even if the FDA approves a
product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included
in the product labeling, require that post-approval studies, including Phase 4 clinical studies, be conducted to further assess a drug&#8217;s
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential
market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing
studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing
changes, and additional labeling claims, are subject to further testing requirements</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">and FDA review and approval.<span style="font-family: Times New Roman, serif"><br/>
</span>&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">FDA Expedited
Development and Review Programs</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The FDA has various programs,
including fast track designation, priority review, accelerated<span style="font-family: Times New Roman, serif; font-style: italic">&#160;</span>approval,
and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs
that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet
medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The FDA has a fast track designation
program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically,
new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and
demonstrate the potential to address unmet medical needs for the disease or condition. With regard to a fast track product, the FDA may
consider for review sections of the NDA/BLA on a rolling basis before the complete application is submitted, if the sponsor provides a
schedule for the submission of the sections of the NDA/BLA, the FDA agrees to accept sections of the NDA/BLA and determines that the schedule
is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA/BLA. In November 2023, the
Company announced that the FDA had awarded Fast Track status to CM-101 for the treatment of PSC in adult patients.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Any product submitted to the
FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to
expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has
the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the
treatment, diagnosis, or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to
the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In addition, a product may
be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible
for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict
clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity,
or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require
a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible
morbidity or mortality, or other clinical endpoint and to submit promotional materials for preapproval and pre-use review, which could
adversely impact the timing of the commercial launch of the product. In addition, the drug may be subject to accelerated withdrawal procedures.
On December 29, 2022, the Consolidated Appropriations Act, 2023, including the Food and Drug Omnibus Reform Act (FDORA), was signed into
law. FDORA made several changes to the FDA&#8217;s authorities and its regulatory framework, including, among other changes, reforms to
the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth
procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The Food and Drug Administration
Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to
receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221;
if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or
condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation
includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation
is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria
are met. If a product is designated as breakthrough therapy, the FDA will</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">work to expedite the development and review of such drug.<span style="font-family: Times New Roman, serif"><br/>
</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In addition, the FDA may review
new drug applications under the Oncology Center of Excellence Real-Time Oncology Review (&#8220;RTOR&#8221;), which, according to the
FDA, aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as early as
possible, while maintaining and improving review quality. Drugs considered for review under RTOR must be likely to demonstrate substantial
improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same or other
indications, and must have straight-forward study designs and endpoints that can be easily interpreted. RTOR allows the FDA to review
much of the data in an NDA/BLA earlier, before the applicant formally submits the complete application. This analysis of the pre-submission
package gives the FDA and applicants an early opportunity to address data quality and potential review issues and allows the FDA to provide
early feedback regarding the most effective way to analyze data to properly address key regulatory questions.<span style="font-family: Times New Roman, serif"><br/>
</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Fast track designation, priority review,
accelerated approval, and breakthrough therapy designation do not change the standards for approval but may expedite the development or
approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets
the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Orphan
drug designation and exclusivity</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Under the Orphan Drug Act,
the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally
meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation
that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be
recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted,
the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage
in or shorten the duration of the regulatory review and approval process. As of the current date, we have obtained orphan drug designation
for three indications, PSC, SSc and IPF.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">If a product with orphan status receives the first
FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease
or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity
means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain
limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication
broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not
bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the
same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a
major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA
may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients.
Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain
approval for the same product but for a different indication for which the orphan product has exclusivity.<span style="font-family: Times New Roman, serif"><br/>
</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In <span style="font-family: Times New Roman, serif; font-style: italic">Catalyst
Pharms., Inc. v. Becerra</span>, 14 F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that the
orphan drug exclusivity only applies to the approved use or indication within an eligible disease. This decision created uncertainty in
the application of the orphan drug exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that
while the agency complies with the court&#8217;s order in <span style="font-family: Times New Roman, serif; font-style: italic">Catalyst</span>,
FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the <span style="font-family: Times New Roman, serif; font-style: italic">Catalyst</span>
order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug
is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease
or condition that have not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions
will impact the scope of the orphan drug exclusivity.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">United
States marketing exclusivity</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Market exclusivity provisions
under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent
marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is
a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule
or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated
New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does
not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four
years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity
for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were
conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications,
dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical
investigations and does not prohibit the FDA from approving ANDAs for the original non-modified version of the drug. Five-year and three-year
exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to
conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical studies necessary to
demonstrate safety and effectiveness.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Abbreviated Licensure Pathway
of Biological Products as Biosimilars or Interchangeable Biosimilars</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The Patient Protection and Affordable Care Act (Affordable
Care Act or ACA), signed into law in 2010, includes the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created
an abbreviated approval pathway for biological products shown to be highly similar to an FDA-licensed reference biological product. The
BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase patient access to affordable treatments.
An application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following, unless
the FDA determines otherwise:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd68f9c6ac65947a3a6c16cdeae769aa4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Analytical studies demonstrating that the proposed
        biosimilar product is highly similar to the approved product notwithstanding minor differences in clinically inactive components;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5b571e1b49414c998ff1e0e9a375892a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Animal studies (including the assessment of toxicity); and</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z50d754ea0a6b4c33a147a43bbad380df" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">A clinical trial or trials (including the assessment
        of immunogenicity and pharmacokinetic or pharmacodynamic) sufficient to demonstrate safety, purity and potency in one or more conditions
        for which the reference product is licensed and intended to be used.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In addition, an application must include information
demonstrating that:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z227349169d4a40ebaf5b2accbf4d3bd3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The proposed biosimilar product and reference
        product utilize the same mechanism of action for the condition(s) of use prescribed, recommended or suggested in the proposed labeling,
        but only to the extent the mechanism(s) of action are known for the reference product;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf691f47c7bd24827b38be0b90c4558a8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The condition or conditions of use prescribed,
        recommended or suggested in the labeling for the proposed biosimilar product have been previously approved for the reference product;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc85f998ab696432b879800bb50fef0e8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">The route of administration, the dosage form and the strength of the
        proposed biosimilar product are the same as those for the reference product; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2a26dbdf59e542feb53ee996b1d657cd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">The facility in which the biological product is manufactured, processed,
        packed or held meets standards designed to assure that the biological product continues to be safe, pure and potent.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Biosimilarity means that the
biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and
that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity
and potency of the product. In addition, the law provides for a designation of &#8220;interchangeability&#8221; between the reference
and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare
provider who prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient
to show that:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb86eeb4291be4eecb4e317602cc46903" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">The proposed product is biosimilar to the reference product;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z752c8b8cf23c471f9c8249c58d4a7a17" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The proposed product is expected to produce the
        same clinical result as the reference product in any given patient; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160; &#160;</div>

<table cellspacing="0" cellpadding="0" id="z14159ae0bce2470a9f617c0bd9a634af" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">For a product that is administered more than once
        to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar
        and the reference product is no greater than the risk of using the reference product without such alternation or switch.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">FDA approval is required before
a biosimilar may be marketed in the United States. However, complexities associated with the large and intricate structures of biological
products and the process by which such products are manufactured pose significant hurdles to the FDA&#8217;s implementation of the law
that are still being worked out by the FDA. For example, the FDA has discretion over the kind and amount of scientific evidence&#8212;laboratory,
preclinical and/or clinical&#8212;required to demonstrate biosimilarity to a licensed biological product.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The FDA intends to consider
the totality of the evidence provided by a sponsor to support a demonstration of biosimilarity and recommends that sponsors use a stepwise
approach in the development of their biosimilar products. Biosimilar product applications thus may not be required to duplicate the entirety
of preclinical and clinical testing used to establish the underlying safety and effectiveness of the reference product. However, the FDA
may refuse to approve a biosimilar application if there is insufficient information to show that the active ingredients are the same or
to demonstrate that any impurities or differences in active ingredients do not affect the safety, purity or potency of the biosimilar
product. In addition, as with BLAs, biosimilar product applications will not be approved unless the product is manufactured in facilities
designed to assure and preserve the biological product&#8217;s safety, purity and potency.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The submission of a biosimilar
application does not guarantee that the FDA will accept the application for filing and review, as the FDA may refuse to accept applications
that it finds are insufficiently complete. The FDA will treat a biosimilar application or supplement as incomplete if, among other reasons,
any applicable user fees assessed under the Biosimilar User Fee Act of 2012 have not been paid. In addition, the FDA may accept an application
for filing but deny approval on the basis that the sponsor has not demonstrated biosimilarity, in which case the sponsor may choose to
conduct further analytical, preclinical or clinical studies and submit a BLA for licensure as a new biological product.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The timing of final FDA approval
of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product
is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are
biosimilar to the branded product. The FDA cannot approve a biosimilar application for twelve years from the date of first licensure of
the reference product.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Additionally, a biosimilar
product sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference product
may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease or
condition (an orphan drug) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference
product may be approved until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year
orphan drug exclusivity period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the
life of a patent, and thus block biosimilarity applications from being approved on or after the patent expiration date. In addition, the
FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests,
and the manufacturer undertakes, studies on the effect of its product in children, a so-called pediatric extension.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Pediatric exclusivity is another
type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory
exclusivity periods. This six-month exclusivity may be granted based on the voluntary completion of a pediatric study in accordance with
an FDA-issued &#8220;Written Request&#8221; for such a study.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Post-approval
requirements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Drugs and biologics manufactured
or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things,
requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting
of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other
labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products
and the establishments where such products are manufactured, as well as new application fees for supplemental applications with clinical
data.<span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The FDA may impose a number
of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including
Phase 4 clinical studies, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In addition, drug and biologic
manufacturers and other entities involved in the manufacture and distribution of approved drugs and biologics are required to register
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies
for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose
reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly,
manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Once an approval of a drug
or biologic is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies
to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include,
among other things:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zf73a0141d79d495ea5ee3617252f9a7a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Restrictions on the marketing or manufacturing
        of the product, complete withdrawal of the product from the market or product recalls;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd7a34537e27b4e14b22698a43e64b825" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Fines, warning letters or holds on post-approval
        clinical studies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbf00c03f10094140a1ac11e50129c140" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Refusal of the FDA to approve pending NDAs or
        BLAs or supplements to approved NDAs or BLAs, or suspension or revocation of product approvals;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcddb6f00e6374121839560dbdd9b16d6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Product seizure or detention, or refusal to permit
        the import or export of products; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbaf9885272b94e8ea66e89b6b4d9d6ce" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Injunctions or the imposition of civil or criminal
        penalties.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted by a manufacturer
and any third parties acting on behalf of a manufacturer only for the approved indications and in a manner consistent with the approved
label for the product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses,
and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Other healthcare
laws</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Healthcare providers, physicians,
and third party payors play a primary role in the recommendation and prescription of drug products for which we obtain marketing approval.
Arrangements with third party payors, healthcare providers and physicians, in connection with the clinical research, sales, marketing
and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly applicable fraud
and abuse and other healthcare laws and regulations. In the United States, these laws include, without limitation, state and federal anti-kickback,
physician self-referral prohibitions, false claims, physician transparency, and patient data privacy and security laws and regulations,
including but not limited to those described below:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif"><span style="font-family: Times New Roman, serif"><br/> </span></div>

<table cellspacing="0" cellpadding="0" id="zc3e217c43dcf4ab2895af19d14123113" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The federal Anti-Kickback Statute, or AKS, which
        makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully
        solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly,
        in cash or in kind, that is intended to induce or reward, referrals including the purchase recommendation, order or prescription of a
        particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. A person
        or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
        In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
        Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z13d37f7b697440b38756cbcfe75d5310" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The federal civil and criminal false claims laws,
        including the FCA, which can be enforced through &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty
        laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing
        to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent;
        knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay or transmit money or property
        to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Similar to the
        AKS and Stark Law, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order
        to have committed a violation;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z88275c7f415d4a58bdb71a69168e0024" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The federal Health Insurance Portability and Accountability
        Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting
        to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations,
        or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of
        the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material
        fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services
        relating to healthcare matters;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z2a1cd6eb309742a6972fd0998c888593" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">HIPAA, as amended by the Health Information Technology
        for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain
        covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform
        services for them that involve the creation, use, receipt, maintenance or disclosure of individually identifiable health information,
        relating to the privacy, security and transmission of individually identifiable health information;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z502094abfaae4571bc4936c8d5bc0d08" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The federal Physician Payments Sunshine Act, created
        under Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively,
        the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologics and medical supplies for which payment
        is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare
        and Medicaid Services, or CMS, under the Open Payments Program, information related to payments or other transfers of value made to physicians
        (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such
        as physician assistants and nurse practitioners, among others),&#160; and teaching hospitals, as well as ownership and investment interests
        held by physicians and their immediate family members; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z5f87614490634884b2648475264b2c43" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Analogous state and foreign laws and regulations,
        such as state and foreign anti-kickback, physician self-referral prohibitions, false claims, consumer protection and unfair competition
        laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements
        as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers;
        state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and
        the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare
        providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing
        and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided
        to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and
        state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each
        other in significant ways and may not have the same effect, thus complicating compliance efforts.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Because of the breadth of these
laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of a pharmaceutical
manufacturer&#8217;s business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business
arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities
will conclude that a pharmaceutical manufacturer&#8217;s business practices do not comply with current or future statutes, regulations
or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against
a pharmaceutical manufacturer, and it is not successful in defending itself or asserting its rights, those actions could have a significant
impact on its business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, imprisonment,
monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reporting obligations
and oversight if we become subject to integrity and oversight agreements to resolve allegations of non-compliance, contractual damages,
reputational harm, diminished profits and future earnings, and curtailment of operations, any of which could adversely affect a pharmaceutical
manufacturer&#8217;s ability to operate its business and the results of operations. In addition, commercialization of any drug product
outside the United States will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign
laws.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">Prescription
drug advertising is subject to federal, state and foreign regulations. In the United States, the FDA regulates prescription drug promotion,
including direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their
first use. Any distribution of prescription drug products and pharmaceutical samples must comply with the United States Prescription Drug
Marketing Act, or PDMA, a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug
Supply Chain Security Act, or DSCSA, has imposed new &#8220;track and trace&#8221; requirements on the distribution of prescription drug
products by manufacturers, distributors, and other entities in the drug supply chain. The DSCSA requires product identifiers (i.e., serialization)
on prescription drug products in order to eventually establish an electronic interoperable prescription product system to identify and
trace certain prescription drugs distributed in the United States and preempts existing state drug pedigree laws and regulations on this
topic. The DSCSA also establishes new requirements for the licensing of wholesale distributors and third-party logistic providers. The
FDA is in the process of finalizing regulations addressing national standards for the licensure of wholesale distributors and third-party
logistics providers.</span>&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In the United States, numerous
federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal
and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information.
For example, in June&#160;2018, the State of California enacted the California Consumer Privacy Act of 2018, or the CCPA, which came into
effect on January&#160;1, 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which
may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their
personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information
is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected
to increase data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and
clinical study regulations, as currently written, the CCPA may impact certain of our business activities. The CCPA could mark the beginning
of a trend toward more stringent state privacy legislation in the United States, which could increase our potential liability and adversely
affect our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In the event we decide to conduct clinical
studies or continue to enroll subjects in our ongoing or future clinical studies, we may be subject to additional privacy restrictions.
The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic
Area, or EEA, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective
on May&#160;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including
requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates,
providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality
of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR
also imposes strict rules&#160;on the transfer of personal data to countries outside the EEA, including the United States, and permits
data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20&#160;million
or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations
to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations
of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may increase our responsibility and
liability with respect to personal data that we process where such processing is subject to the GDPR, and we may be required to put in
place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the
GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices,
and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection
with our European activities. Further, the United Kingdom&#8217;s decision to leave the EU, often referred to as Brexit, has created uncertainty
with regard to data protection regulation in the United Kingdom and transfers of personal data to the UK and from the UK to both the EEA
and countries outside the UK/EEA. For the time being, transfers of personal data from the EU to the UK are covered by an adequacy decision
of the EU Commission, and the UK has recently implemented its own regime for safeguarding transfers from the UK to countries outside the
UK/EEA which sit alongside the new EU safeguards which were brought in during 2021.&#160; However, both the adequacy decision and the
UK regime remain vulnerable to withdrawal or legal challenge.&#160; Further both the new UK and EU personal data transfer regimes remain
relatively untested and therefore impose risk that a transfer of personal data and/or its subsequent processing would be held unlawful
and give rise to liabilities from administrative fines and/or damages claims from data subjects.&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Current
and future healthcare reform legislation</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In both the United States and
certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system. In particular,
in 2010 the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid
Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed
care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives
to programs that increase the federal government&#8217;s comparative effectiveness research.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August&#160;2011,
the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on
Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021,
was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This
includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and, due to subsequent
legislative amendments, will remain in effect through 2031, with the exception of a temporary suspension implemented under various COVID-19
relief legislation from May 1, 2020, through March 31, 2022. Under current legislation, the actual reduction in Medicare payments can
vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. The American Taxpayer Relief Act of 2012 further reduced
Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five&#160;years. The Bipartisan Budget Act of 2018, also amended
the ACA, effective January&#160;1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate
in Medicare Part&#160;D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;.</span></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Additionally, there has been
heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription
drugs and biologics. In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions
that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government
to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers
that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs,
with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket
prescription drug costs for beneficiaries, among other changes. The impact of these legislative, executive, and administrative actions
and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a
whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability, or commercialize any of the product candidates for which we receive approval. At the state level, legislatures
have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or
patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures
and, in some cases, designed to encourage importation from other countries and bulk purchasing.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Legislative and regulatory
proposals, and enactment of laws, at the foreign, federal and state levels, directed at containing or lowering the cost of healthcare,
will continue into the future.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Rest of
World Regulation</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">For
other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements
governing product development, the conduct of clinical studies, manufacturing, distribution, marketing approval, product licensing, pricing
and reimbursement vary from country to country. Additionally, clinical studies must be conducted in accordance with GCP requirements and
the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span>&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">If we fail to comply with applicable
foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product
recalls, seizure of products, operating restrictions and criminal prosecution.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Additionally, to the extent
that any of our product candidates, once approved, are sold in a foreign country, we may be subject to applicable post-marketing requirements,
including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments
or other transfers of value to healthcare professionals.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Coverage
and reimbursement</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Successful commercialization
of new drug products depends in part on the extent to which reimbursement for those drug products will be available from government health
administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private
health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels.
The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a
drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products
are paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government
health administration authorities, private health coverage insurers and other third-party payors.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">A primary trend in the United States healthcare
industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting
coverage and the amount of reimbursement for particular drug products. In many countries, the prices of drug products are subject to varying
price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially
lower than in the United States. Other countries allow companies to fix their own prices for drug products but monitor and control company
profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United
States.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In the United States, the principal
decisions about reimbursement for new drug products are typically made by CMS, an agency within the U.S. Department of Health and Human
Services. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors
tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party
payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">The
Medicare Prescription Drug,&#160;Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part&#160;D program
to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part&#160;D, Medicare beneficiaries may enroll in prescription
drug plans offered by private entities that provide coverage of outpatient prescription drugs. While all Medicare drug plans must give
at least a standard level of coverage set by Medicare, Part&#160;D prescription drug plan sponsors are not required to pay for all covered
Part&#160;D drugs, and each Part&#160;D prescription drug plan can develop its own drug formulary that identifies which drugs it will
cover and at what tier or level. However, Part&#160;D prescription drug formularies must include drugs within each therapeutic category
and class of covered Part&#160;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&#160;D
prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs
of prescription drugs may increase demand for drugs for which we obtain marketing approval. Any negotiated prices for any of our products
covered by a Part&#160;D prescription drug plan will likely be lower than the prices it might otherwise obtain. Moreover, while the MMA
applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations
in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from
non-governmental payors.</span>&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">89</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">For a drug product to receive
federal reimbursement under the Medicaid or Medicare Part&#160;B programs or to be sold directly to United States government agencies,
the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount
on a given product is calculated based on the average manufacturer price, or AMP, and Medicaid rebate amounts reported by the manufacturer.
As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of the
law these newly eligible entities (with the exception of children&#8217;s hospitals) will not be eligible to receive discounted 340B pricing
on orphan drugs. As 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula
and AMP definition described above could cause the required 340B discount to increase. If third-party payors do not consider our drugs
to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit under their plans
or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">These laws, and state and federal
healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding
and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency
with which any such product candidate is prescribed or used.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Outside of the United States,
the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the European
Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only
after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness
of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement
or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes
and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical
devices will likely continue as countries attempt to manage healthcare expenditures.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Employees and Human Capital
Resources</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">As of December 31, 2023, we
had 20 full-time employees/consultants, including 7 with Ph.D. or M.D. degrees and including 13 who are engaged in research and development
activities. We are dependent on our management and scientific personnel, and it is crucial that we continue to attract and retain valuable
employees. To facilitate attraction and retention, we strive to make ourselves an inclusive and safe workplace, with opportunities for
our employees to grow and develop in their careers, supported by strong compensation and benefits programs. None of our employees are
represented by labor unions or covered by collective bargaining agreements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">90</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Corporate Information and History</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We were incorporated on November
30, 2011, under the laws of the State of Israel. In March 2021, in connection with the Merger, we changed our name from Anchiano Therapeutics
Ltd. to Chemomab Therapeutics Ltd. Our principal executive offices are located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002,
and our phone number is +972-77-331-0156. Our website is:&#160;<span style="font-family: Times New Roman, serif; font-style: italic">www.chemomab.com.</span>&#160;The
information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Available Information</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our investor relations website
is<span style="font-family: Times New Roman, serif; font-style: italic"> https://investors.chemomab.com/</span>. We promptly make available
on our investor relations website, free of charge, the reports that we file or furnish with the SEC, corporate governance information
(including our Code of Business Conduct and Ethics) and all press releases. The SEC maintains a website at www.sec.gov that contains reports,
proxy and information statements and other information regarding Chemomab and other issuers that file electronically with the SEC.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 4A<span id="Item4A"><!--Anchor--></span>.
Unresolved Staff Comments</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;None.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item5"><!--Anchor--></span>Item 5. Operating
and Financial Review and Prospects</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">&#160;You
should read the following discussion together with the consolidated financial statements and related notes included elsewhere in this
Annual Report. The statements contained in this discussion regarding industry outlook, our expectations regarding our future performance,
planned investments in our expansion into additional geographies, research and development, sales and marketing and general and administrative
functions as well as other non-historical statements contained in this discussion are forward-looking statements. These forward-looking
statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described in Item
3.D. entitled &#8220;Risk factors&#8221; and &#8220;Special note regarding forward-looking statements&#8221; included elsewhere in this
Annual Report. Our actual results may differ materially from those contained in or implied by any forward-looking statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Overview</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman,serif">We are a clinical-stage
biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with
high unmet needs. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, we developed
CM-101, a monoclonal antibody designed to bind and block CCL24 activity. We believe CM-101 has demonstrated the potential to treat multiple
severe and life-threatening fibrotic and inflammatory diseases.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">91</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman,serif">We have pioneered the therapeutic
targeting of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and fibrotic activities through
the CCR3 receptor. The chemokine is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells.
We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity that modulates the
complex interplay of both of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and clinical fibrotic
diseases. This innovative approach is being developed for difficult to treat rare diseases, also known as orphan indications or diseases,
such as PSC and SSc, for which patients have no established disease-modifying treatment options. We estimate that there are approximately
77 thousand patients suffering from PSC in the U.S., EU and Japan, representing over a $1 billion market opportunity, and approximately
170 thousand patients suffering from SSc in those same markets, representing over a $1.5 billion market opportunity.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman,serif">CM-101, our lead clinical
product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of the soluble chemokine CCL24,
also known as eotaxin-2, as a regulator of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with
the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of action. Based on these findings, we
are actively advancing CM-101 in Phase 2 clinical studies directed toward two distinct clinical indications that include patients with
liver or skin, and/or lung fibrosis. We are currently conducting a Phase 2 clinical study in PSC, a rare obstructive and cholestatic liver
disease. The study completed recruitment of patients in the U.S., Europe and Israel and topline results are expected around mid 2024.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">A. Components
of Operating Results</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Revenues</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">To date, we have not generated
any revenue from product sales and do not expect to generate any revenue from product sales in the near future. If development efforts
for our product candidates are successful and result in our receipt of necessary regulatory approvals, or if our development efforts otherwise
lead to any commercialized products or additional license agreements with third parties, then we may generate revenue in the future from
product sales.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Research
and Development Expenses, net</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Research and development expenses
consist primarily of costs incurred in connection with the development of our product candidates. These expenses include:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb47bb3c1574e4c28bbcf1b4410153566" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">expenses incurred under agreements with clinical
        research organizations and contract manufacturing organizations, as well as investigative sites and consultants that conduct our clinical
        trials, preclinical studies and other scientific development services;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf649591c792a4b43bf3aba3705b638da" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">manufacturing scale-up expenses and the cost of
        acquiring and manufacturing preclinical and clinical trial materials;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z59a4ce7877cb415c8b4d967078b356bb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">employee-related expenses, including salaries,
        related benefits, travel and share-based compensation expenses for employees engaged in research and development functions, as well as
        external costs, such as fees paid to outside consultants engaged in such activities;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z85a5daf8521443b297c3e4d4a661a5e4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">license maintenance fees and milestone fees incurred
        in connection with various license agreements;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9f0c397118b9490188386eab807e9801" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">costs related to compliance with regulatory requirements;
        and</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6896296686b24255a80cb5122d5534db" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">depreciation and other expenses.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We recognize external development
costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We do not allocate employee
costs or facility expenses, including depreciation or other indirect costs, to specific programs because these resources are deployed
across multiple programs and, as such, the related costs are not separately classified. We use internal resources primarily to oversee
our research, as well as for managing our preclinical development, process development, manufacturing and clinical development activities.
Our employees work across multiple programs; therefore, we do not track the related expenses by program.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">92</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">Research
and development activities are fundamental to our business. Product candidates in later stages of clinical development generally have
higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage
clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years
as we continue to advance the development of our product candidates. We also expect to incur additional expenses related to milestone
and royalty payments payable to third parties with whom we have entered into license agreements.</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">General and Administrative
Expenses</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">General and administrative
expenses consist primarily of salaries and related benefits, share-based compensation expenses for personnel in executive and administrative
functions, insurance and professional fees for legal, consulting, accounting and audit services.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We anticipate that our general
and administrative expenses will increase in the future due to increased headcount and professional fees to support our continued research
activities and development of our product candidates. We also anticipate that we will continue to incur accounting, audit, legal, regulatory,
compliance, director and officer insurance costs, as well as investor and public relations expenses associated with being a public company.
Additionally, once we believe that regulatory approval of a product candidate appears likely, we will begin to incur a material increase
in payroll and related expenses as a result of preparation for commercial operations, particularly in respect of sales and marketing.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Financing
Expenses, Net</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">&#160;</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Financing expenses, net consist
primarily of income or expenses related to revaluation of foreign currencies and interest income on our bank deposits.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">93</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Results of Operations</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">&#160;</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The following table summarizes
our results of operations for the years ended December 31, 2023 2022 and 2021:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z71f88b8e454f42199a5883d2358b8f85" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="10" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Year ended December 31,</div>
        </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">2023</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-weight: bold; text-align: center">
        2022</td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-weight: bold; text-align: center">
        2021</td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="10" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">(in
        thousands</span>)</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Operating Expenses:</div> </td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="10" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><br/> </div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Research and development</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">18,381</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">16,977</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">6,334</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">General and administrative</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">7,078</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">11,556</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">6,033</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Total operating expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">25,459</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">28,533</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">12,367</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif"></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Financing (income) expense, net</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(1,238</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(353</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">111</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Loss before taxes</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">24,221</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">28,180</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">12,478</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Taxes on income (benefit)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(534</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif"></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Net loss</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">24,221</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">7,646</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">2,478</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our results of operations have
varied in the past and can be expected to vary in the future due to numerous factors. We believe that period-to-period comparisons of
our operating results are not necessarily meaningful and should not be relied upon as indications of future performance.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Year ended December
31, 2023, Compared to the Year Ended December 31, 2022</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Research and development expenses</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Research and development expenses increased
by approximately $1.4 million, or 8.3%, to approximately $18.4 million for the year ended December 31, 2023, compared to approximately
$17 million for the year ended December 31, 2022. The increase resulted primarily from a continued investment in the clinical programs
of the Company.&#160;</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">General and administrative
expenses</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">General and administrative expenses decreased by approximately $4.5 million, or 38.8%,
to approximately $7.1 million for the year ended December 31, 2023, compared to approximately $11.6 million for the year ended December
31, 2022. The decrease was primarily due to a decrease in headcount,&#160;professional fees,&#160;insurance expenses and share-based compensation.</div>
</div>

<div style="text-align: center; line-height: 1.25"><br/> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">94</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Financing (income) expense, net</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Financing income, net, increased by approximately $885 thousand,
or 250%, to net income of $1,238 thousand for the year ended December 31, 2023, compared to a net income of $353 thousand for the year
ended December 31, 2022. Financing income, net for the year ended December 31, 2023, was primarily related interest income on deposits
offset by foreign currency exchange rate differences.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Taxes on Income</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The tax benefit in 2022 is related to a tax return of Chemomab
Therapeutics Inc., a wholly owned subsidiary of ours, derived by carryback of net operating losses.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Year ended December 31, 2022, Compared to the
Year Ended December 31, 2021</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Research and development expenses</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Research and development expenses increased by approximately $10.7
million, or 168%, to approximately $17.0 million for the year ended December 31, 2022, compared to approximately $6.3 million for the
year ended December 31, 2021. The increase resulted primarily from an increase in headcount and payments to consultants and subcontractors
for clinical and pre-clinical activities.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">General and administrative expenses</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">General and administrative expenses increased by approximately $5.6 million, or 92%,
to approximately $11.6 million for the year ended December 31, 2022, compared to approximately $6.0 million for the year ended December
31, 2021. This increase was primarily due to an increase in headcount and professional fees and insurance expenses and share-based compensation.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Financing (income) expense, net</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Financing expenses, net, increased by approximately $464 thousand,
or 418%, to net income of $353 thousand for the year ended December 31, 2022, compared to a net loss of $111 thousand for the year ended
December 31, 2021. Financing expense, net for the year ended December 31, 2022, was primarily related to foreign currency exchange rate
differences, offset by interest income on deposits. Financing income, net for 2021 was primarily related to interest income on deposits,
offset by foreign currency exchange rate differences.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Taxes on Income</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25"><br/>

<div style="text-align: left; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Tax benefit, net, for the year ended December
31, 2022, was $534 thousand. The tax benefit is related to a tax return of Chemomab Therapeutics Inc., a wholly owned subsidiary of the
Company, derived by carryback of net operating losses. Chemomab Therapeutics Inc. received $351 thousand in December 2022 on account of
previous years and expects to receive the remainder $183 thousand in 2023.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">95</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Cash Flows</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The following table summarizes
our cash flows for the years ended December 31, 2023, 2022 and 2021:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z9b0f5012d7824bc890011599f8a9586b" style="font: 10pt Times New Roman,Times,serif; text-align: left; color: rgb(0, 0, 0); width: 100%">
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="14" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Year ended December 31,</div>
        </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Increase/(decrease)</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-weight: bold; text-align: center">
        2023</td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">2022</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">&#160;</td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; text-align: center; font-weight: bold">
        %</td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; font-weight: bold; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="14" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">(in thousands)</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Net cash used in operating activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(23,611</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(20,370</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(12,374</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(3,241</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">16</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 40%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Net cash provided by (used in) investing activities</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">15,879</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">19,533</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(45,186</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(3,654</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(19)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Net cash provided by (used in) financing activities</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">3,504</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(808</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">61,074</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">4,312</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">534</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 40%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Net increase (decrease) in
        cash, cash equivalents and restricted cash</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(4,228</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(1,645</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">3,514</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">(2,584</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">)<br/> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">157</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Year ended December
31, 2023, Compared to the Year Ended December 31, 2022</div> </div>

<div><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Operating activities</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash used in operating activities for the year ended December
31, 2023, was approximately $23.6 million and included net loss of $24.2 million, partially offset by net cash used by changes in operating
assets and liabilities of approximately $0.9 million and non-cash charges of $1.6 million, which mainly included share-based compensation
expenses.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash used in operating activities for the year ended December
31, 2022, was approximately $20.4 million and included net loss of $27.6 million, partially offset by net cash provided by changes in
operating assets and liabilities of $4 million and non-cash charges of $3.3 million, which mainly included share-based compensation expenses.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Investing activities</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash provided by investing activities for the year ended December
31, 2023, was approximately $15.9 million, which was primarily related to funds received from bank deposits.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash provided in investing activities for the year ended December
31, 2022, was $19.5 million, which was primarily related to funds received from bank deposits.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">96</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Financing activities</div>

<div style="text-align: justify; line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash provided by financing activities for the year ended December
31, 2023, was approximately $3.5 million, consisting of $2.9 million of proceeds from the sale of ADSs, $0.6 million of proceeds from
the sale of treasury shares.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash used by financing activities for the year ended December
31, 2022, was $0.8 million, consisting of $0.3 million of proceeds from the sale of ADSs, $0.14 million proceeds from the exercise of
stock options offset by repurchases of shares in the amount of $1.2 million.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Year ended December 31, 2022, Compared to the
Year Ended December 31, 2021</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Operating activities</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash used in operating activities for the year ended December
31, 2022, was approximately $20.4 million and included net loss of $27.6 million, partially offset by net cash used by changes in operating
assets and liabilities of approximately $4.0 million and non-cash charges of $3.3 million, which mainly included share-based compensation
expenses.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><br/> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Net cash used in operating activities for the year ended December 31, 2021, was approximately $12.4 million and included net loss of $12.5
million, partially offset by net cash provided by changes in operating assets and liabilities of $1.9 million and non-cash charges of
$2.0 million, which mainly included share-based compensation expenses.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Investing activities</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash provided by investing activities for the year ended December
31, 2022, was approximately $19.5 million, which was primarily related to investment in short-term deposits offset by purchasing of fixed
assets.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash used in investing activities for the year ended December
31, 2021, was $45.2 million, which was primarily related to purchase of fixed assets and investment in bank deposits.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25">&#160;<span style="font-style: italic">Financing activities</span></div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash used in financing activities for the year ended December
31, 2022, was approximately $0.8 million, consisting of $0.3 million of proceeds from the sale of ADSs, $0.1 million of proceeds from
the exercise of stock options offset by the repurchase of shares in the amount of $1.2 million.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Net cash provided by financing activities for the year ended December
31, 2021, was $61.1 million, consisting of $58.7 million of proceeds from the sale of ADSs, primarily from the Private Placement (as defined
and described below) and issuances under the Sales Agreement with Cantor, and $2.4 million of cash acquired in the Merger.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Funding
Requirements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">&#160;</span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We expect our expenses to increase
substantially as we advance the clinical trials of our product candidate. In addition, we expect to continue to incur additional costs
associated with operating as a public company.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We believe that our existing
cash, cash equivalents and bank deposits will enable us to fund our operating expenses and capital expenditure requirements through March
31, 2025. We have based these estimates on assumptions that may prove to be wrong, and we could expend our capital resources sooner than
we expect. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses
related to product manufacturing, sales, marketing and distribution.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">97</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Until such time, if ever, that
we generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through the sales of our securities
and through other outside funding sources. Debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends. If we raise additional funds through government and other third-party funding, collaboration agreements, strategic
alliances, licensing arrangements or marketing and distribution arrangements, then we may have to relinquish valuable rights to our technologies,
future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are
unable to raise additional funds through equity or debt financings when needed, then we may be required to delay, limit, reduce or terminate
our product development or future commercialization efforts or grant rights to develop and market products or product candidates that
we would otherwise prefer to develop and market.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">B. Liquidity
and Capital Resources</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In connection with the Merger,
on March 15, 2021, we entered into Securities Purchase Agreements with certain investors, pursuant to which we agreed to sell approximately
$45.5 million of the ADSs in a private placement transaction (the Private Placement). The Private Placement closed on March 22, 2021,
at which time we sold 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The
warrants expire five years from the date of issuance, and, if exercised in full, will provide proceeds of approximately $4.5 million.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On April 30, 2021, we entered into the Sales
Agreement with Cantor Fitzgerald &amp; Co. (Cantor). Pursuant to the Sales Agreement, we may offer and sell, from time to time, ADSs having
an aggregate offering price of up to $75 million through Cantor (the ATM Facility). Sales of ADSs, if any, under the Sales Agreement will
be issued and sold pursuant to our Registration Statement on Form S-3 which was declared effective on May 17, 2021, and will be made in
sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act. &#160;Pursuant
to the Sales Agreement, Cantor has agreed to act as sales agent on a best efforts basis and use commercially reasonable efforts to sell
on our behalf all of the ADSs we requested to be sold in accordance with the Sales Agreement, consistent with Cantor&#8217;s normal trading
and sales practices, on mutually agreed terms.</div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On April 25, 2022, we filed
a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000 of ADSs in connection with the reactivation of the
ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities
we are able to offer and sell under such registration statement during any twelve month period to one-third of our unaffiliated public
float.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">During the year ended December
31, 2022,&#160;we&#160;sold 130,505 ADSs at an average price of USD 2.11 per ADS, through the ATM facility, resulting in gross proceeds
of $275,000.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">During the year ended December
31, 2023, we sold 2,572,900 ADSs at an average price of USD 1.22 per ADS, through the ATM facility, resulting in gross proceeds of $3.145
million.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">During the year ended December
31, 2023, we sold 582,023 ADSs which were held in treasury for consideration of approximately $580 thousand.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">98</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As shown in the accompanying consolidated
financial statements, we have incurred losses and cash flow deficits from operations since inception, resulting in an accumulated deficit
as of December 31, 2023, of $88.7 million. We have financed operations to date primarily through public and private placements of equity
securities. We anticipate that we will continue to incur net losses for the foreseeable future. We believe that our existing cash, cash
equivalents and bank deposits will be sufficient to fund our projected cash needs through March 31, 2025. To meet future capital needs
we would need to raise additional capital through equity or debt financing or other strategic transactions. However, any such financing
may not be available to us on favorable terms or at all. Our failure to obtain sufficient funds on commercially acceptable terms when
needed would have a material adverse effect on our business, results of operations and financial condition.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Current
Outlook</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We estimate that our current
liquidity resources will allow us to execute our business plans through March 31, 2025.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Developing drugs, conducting
preclinical and clinical trials, obtaining commercial manufacturing capabilities and commercializing products is expensive, and we will
need to raise substantial additional funds to achieve our strategic objectives. We will require significant additional financing in the
future to fund our operations, including if and when we progress into clinical trials of our product candidates, obtain regulatory approval
for one or more of our product candidates, obtain commercial manufacturing capabilities and commercialize one or more of our product candidates.
Our future capital requirements will depend on many factors, including, but not limited to:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf900193304d449d4a879474024ae2614" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the progress and costs of our preclinical and
        clinical trials and other research and development activities;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z39361e4616a848aea1cc9f3af370bde7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the scope, prioritization and number of our preclinical
        and clinical trials and other research and development programs;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2d6d8ba6415547c9be3407ed4e96ac21" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the amount of revenues and contributions we receive
        under future licensing, collaboration, development and commercialization arrangements with respect to our product candidates;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8289157f8c5e47f3a843561cb6795efb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the costs of development and expansion of our
        operational infrastructure;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3655d8bdd03242afb2ec8c642917e52f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the costs and timing of obtaining regulatory approval
        for one or more of our product candidates;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc8d62213451140fd81b90cf7d0ab32fa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">our ability, or that of our collaborators, to
        achieve development milestones, marketing approval and other events or developments under potential future licensing agreements;</div>
        </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd5e45317b1744aecbc77f498b865f465" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the costs of filing, prosecuting, enforcing and
        defending patent claims and other intellectual property rights;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z34ae48184c9d447cb3a3198d74e31679" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the costs and timing of securing manufacturing
        arrangements for clinical or commercial production;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7cc4526f4b034068928e5216cc061b25" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the costs of contracting with third parties to
        provide sales and marketing capabilities for us or establishing such capabilities ourselves;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7dba3ae165ba4d93bb2a2be0d4214558" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226; <br/> </div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the costs of acquiring or undertaking development
        and commercialization efforts for any future products, product candidates or technology;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">99</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="zae2f652f7ded429293cf671817ece50d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the magnitude of our general and administrative
        expenses; and</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z31855d7935ca49f7af0d46587e3bcada" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">any additional costs that we may incur under future
        in- and out-licensing arrangements relating to one or more of our product candidates.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Until we can generate significant
recurring revenues, we expect to satisfy our future cash needs through capital raising or by out-licensing and/or co-developing applications
of one or more of our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if
at all. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or
commercialization efforts with respect to, one or more of our product candidates and make the necessary change to our operations to reduce
the level of our expenditures in line with available resources.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We are a development-stage
company and it is not possible for us to predict with any degree of accuracy the outcome of our research and development efforts. As such,
it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events
that are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause financial information
to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain trends,
uncertainties, demands, commitments and events are described in this item.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">C. Research
and Development, Patents and Licenses</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">For information concerning
our research and development policies and a description of the amount spent during each of the last three fiscal years on company-sponsored
research and development activities, see &#8220;Item 5. Operating and Financial Review and Prospects&#8212;Results of Operations.&#8221;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">D. Trend
Information</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Other than as disclosed elsewhere
in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2023
to December 31, 2023 that are reasonably likely to have a material adverse effect on our revenue, profitability, liquidity or capital
resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial
condition.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">E. Critical
Accounting Estimates</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our financial statements are
prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of our financial statements
and related disclosures in accordance with GAAP requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base
our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates
under different assumptions or conditions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif">While
our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements, we believe that the
following accounting estimates are those that include a higher degree of judgment or complexity and are reasonably likely to have a material
impact on our financial condition or results of operations and are therefore considered critical accounting estimates.</span>&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">100</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Share-Based Compensation</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We apply Accounting Standard
Codification (ASC) 718-10, &#8220;Share-Based Payment,&#8221; which requires the measurement and recognition of compensation expenses
for all share-based payment awards made to employees and directors, including employee options under our option plans based on estimated
fair values.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">ASC 718-10 requires that we
estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The fair value of the award
is recognized as an expense over the requisite service periods in our statements of comprehensive loss. We recognize share-based award
forfeitures as they occur, rather than estimate by applying a forfeiture rate.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In June 2018, the Financial
Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07, &#8220;Compensation-Stock Compensation (Topic 718):
Improvements to Nonemployee Share-Based Payment Accounting&#8221;, which simplifies the accounting for nonemployee share-based payment
transactions by aligning the measurement and classification guidance, with certain exceptions, to that for share-based payment awards
to employees. The amendments expand the scope of the accounting standard for share-based payment awards to include share-based payment
awards granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes
the guidance related to equity-based payments to non-employees. We adopted these amendments on January 1, 2019.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We recognize compensation expenses
for the fair value of non-employee awards over the requisite service period of each award.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We estimate the fair value
of options granted as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions,
of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the
options are exercised or expire). We determine the fair value per share of the underlying stock by taking into consideration our most
recent sales of stock, as well as additional factors that we deem relevant. Our board determined the fair value of ordinary shares based
on valuations performed using the Option Pricing Method subject to relevant facts and circumstances. We have historically been a private
company and lack company-specific historical and implied volatility information of our stock. Expected volatility is estimated based on
volatility of similar companies in the biotechnology sector. Historically, we have not paid dividends and have no foreseeable plans to
issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected
option term is calculated for options granted to employees and directors using the &#8220;simplified&#8221; method. Grants to non-employees
are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted
and our results of operations.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">101</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item6"><!--Anchor--></span>Item
6. Directors, Senior Management and Employees</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z93f2b1993163475d8ec920dbc44ccb55" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Directors and Senior Management</div>
        </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;The following table sets forth the
name and position of each of our executive officers and directors as of March 28, 2024:</div> </div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z3e8c11a7c7c64a25b499b9f2c7deb481" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: #000000 2px solid; width: 30.02%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Name</div> </td>
    <td style="width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 4.33%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Age</div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 64.35%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Position</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Executive Officers:</div>
        </td>
    <td style="width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: top; background-color: rgb(204, 238, 255)"><br/> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Adi Mor</div> </td>
    <td style="width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">42 <br/> </div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Director, Chief Executive Officer and Chief Scientific
        Officer</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Sigal Fattal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td style="width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">53 <br/> </div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Chief Financial Officer</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Matthew Frankel</div> </td>
    <td style="width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">55 <br/> </div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Chief Medical Officer</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Non-Employee Directors:</div>
        </td>
    <td style="width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Nissim Darvish&#8224;(2)(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td style="width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">58</div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Chairman of the Board</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Alan Moses&#8224;(1)</div> </td>
    <td style="width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">75 <br/> </div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Director</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Claude Nicaise&#8224;(1)</div> </td>
    <td style="width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">70 <br/> </div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Director</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Neil Cohen&#8224;(2)(3)</div> </td>
    <td style="width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">59 <br/> </div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Director</div> </td> </tr>
  <tr>
    <td style="width: 30.02%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Jill Quigley&#8224;(1)</div> </td>
    <td style="width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 4.33%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">48 <br/> </div> </td>
    <td style="white-space: nowrap; width: 0.65%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 64.35%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Director</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><span style="font-family: Times New Roman, serif"><br/>
</span>&#160;&#8224; Independent Director</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z3b1dab8bdafb48c3ba475c07ebd4c7af" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(1)</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Member of Audit Committee</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 97%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(2)</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Member of Compensation Committee</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 97%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(3)</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Member of Corporate Governance and Nominating
        Committee</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Executive Officers</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Dr.
Adi Mor </span>is the co-founder of Chemomab Ltd., the wholly-owned subsidiary of the Company, and served as Chemomab Ltd.&#8217;s Chief
Executive Officer, Chief Scientific Officer and a member of Chemomab Ltd.&#8217;s board of directors from its formation in 2011 until
the Chemomab Ltd.&#8211;- Anchiano Therapeutics Ltd. merger that was consummated on March 16, 2021 (the &#8220;Merger&#8221;). Dr. Mor
previously served as Chief Executive Officer of the Company through October 25, 2021. Dr. Mor has in-depth knowledge in immunology focusing
on rare diseases and broad experience in designing, developing and patenting a novel class of monoclonal antibodies to treat inflammatory
and fibrotic diseases. Dr. Mor received her Ph.D. in immunology from Tel Aviv University in the Department of Neurobiochemistry in Israel
and is the lead author of numerous scientific journal publications regarding immunology and inflammatory disorders.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Sigal Fattal</span> previously
served as Chemomab Ltd.&#8217;s interim Chief Financial Officer from October 2020 until the Merger and continued in that capacity for
the Company following the Merger until November 8, 2021, following which she became the Company&#8217;s VP of Finance. Prior to joining
Chemomab Ltd., from March 2017 to December 2019, Ms. Fattal served as Chief Financial Officer at BiomX (NYSE American: PHGE), a clinical
stage microbiome product discovery company. Prior to joining BiomX, Ms. Fattal served as Chief Financial Officer at Evogene (Nasdaq and
TASE: EVGN), a computational biology company, from 2013 to 2016. Prior to that time, Ms. Fattal served in multiple financial and operational
executive roles in various companies. Ms. Fattal also currently serves as co-founder of Simbiz, which was founded in September 2020 and
which offers one-stop-shop corporate services to startup companies. Ms. Fattal is a certified CPA (Isr.), and holds a BA in Accounting
and Economics, and an MBA, both from Tel Aviv University.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">102</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Dr.
Matthew B. Frankel</span> has 20 years of experience in the pharmaceutical industry, encompassing clinical development and medical affairs.
From 2018 until November 2022, Dr. Frankel served as Vice President, Clinical Development and Medical Affairs, Specialty Pharma at Boehringer-Ingelheim
Pharmaceuticals, Inc. Prior to that, he served as the Vice President &amp; Head, Immunology and Dermatology Medical Unit at Novartis Pharmaceuticals
Corporation from 2016 to 2018. From 2012 to 2016, Dr. Frankel served as the Executive Medical Director of Sandoz and from 2010 through
2012 held the role of Global Medical Director, Clinical Development at Reata Pharmaceuticals (RETA). From 2003 through 2010, he held various
senior roles across different companies in the research field. Dr. Frankel received his undergraduate degree from Vassar College, his
MD from the University of California, Los Angeles School of Medicine, and his MBA from the J. L. Kellogg Graduate School of Management.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Directors</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 30.7pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">

<div style="text-align: justify; text-indent: 30.7pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 30.7pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-style: italic">Nissim
Darvish</span>, M.D., Ph.D. has served on our Board since March 16, 2021 and as chairman of the Board since June 2023. Dr. Darvish is
a General Partner at Eliraz Ventures, a venture capital fund. Dr. Darvish currently serves as a director of several private companies.
Prior to his current position, Dr. Darvish served as a Venture Partner at OrbiMed Israel and as a member of the boards of directors of
9 Meters Biopharma Inc. and Medigus Ltd. Previously, Dr. Darvish was employed at Pitango Venture Capital, where he was a General Partner
managing life sciences investments. He was also the founder and CEO of Impulse Dynamics, where he oversaw a $250 million realization event.
Dr. Darvish obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his post-doctoral
research at NIH. He has published over 100 patents and authored over 20 publications.</div> </div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 30.7pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Alan
Moses, MD, FACP</span>&#160;has served on our Board since March 16, 2021. Dr. Moses is board certified by the ABIM with subspecialty certification
in Endocrinology and Metabolism and is a Fellow of the American College of Physicians. Dr. Moses currently serves on the board of directors
of BioFabUSA, a position he has held since 2018. Prior to that time, from 2008 to 2018, Dr. Moses served as the Global Chief Medical Officer
of Novo Nordisk A/S (CPH: NOVO-B), a company he joined in 2004. Dr. Moses served as a Professor of Medicine at Harvard Medical School
from 2002 to 2006, and in collaboration with MIT, he co-founded and co-directed the Clinical Investigator Training Program, which focused
on training physician-scientists in translational research. Dr. Moses previously served as the Senior Vice President and Chief Medical
Officer of the Joslin Diabetes Center from 1998 to 2004. Dr. Moses holds a BS from Duke University, North Carolina and an MD from Washington
University School of Medicine, Missouri.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Claude
Nicaise, MD</span>&#160;has served on our Board since March 16, 2021. Dr. Nicaise is a physician with extensive U.S. and international
experience in clinical drug development, strategic management, worldwide regulatory strategy, pharmaceuticals, biotechnology, including
clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the owner and founder of Clinical Regulatory Services,
which provides consulting services to the life science and biotechnology industry in support of all aspects of clinical and regulatory
development. Since 2015, Dr. Nicaise has served on the board of directors and as the Chairman of the Compensation Committee of Sarepta
Therapeutics, Inc. (NASDAQ: SRPT). Dr Nicaise has also served on the board of directors of Mynoryx Therapeutics since 2017. Prior to that
time, from 2008 to 2014, Dr. Nicaise served as the Senior Vice President of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984
and 2008, he held numerous senior management roles at Bristol Myers Squibb (NYSE: BMY). Dr. Nicaise holds an MD and a degree in Internal
Medicine, Clinical Oncology, from Brussels University, Belgium.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">103</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Neil
Cohen</span>&#160;has served as a member of our Board since April 2020 and served as our interim Chief Executive Officer from October
2020 until the consummation of the Merger. Mr. Cohen has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since
January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen
has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired
or completed successful initial public offerings, including Compugen (Nasdaq: CGEN), Shopping.com (Nasdaq: SHOP, acquired by EBAY), Broadlight
(acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner at SKY, an Israeli middle-market private equity
firm, Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business
Editor of The Jerusalem Post and began his career in the private equity group at N M Rothschild &amp; Sons Limited in London. Mr. Cohen
received a B.A. and M.A. in Oriental Studies, with first class honors, from Oxford University.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-style: italic">Jill M. Quigley</span>
has served as a member of our Board since June 2022. Since September 2023 Ms. Quigley serves as CEO of a stealth biotech company. Since
December 2020, Ms. Quigley has served as a member of the board of directors of Terns Pharmaceuticals, Inc. (Nasdaq: TERN), including her
role as chairperson of its audit committee. From November 2018 until December 2021, Ms. Quigley served as Chief Operating Officer of Passage
BIO, Inc. (Nasdaq: PASG). Previously, she served as the Interim Chief Executive Officer and General Counsel of Nutrinia, Inc., from January
2016 to November 2018. From July 2012 to January 2016, Ms. Quigley served in various roles at Shire plc, most recently as Senior Legal
Counsel. Ms. Quigley received her undergraduate degree in Communications, Legal Institutions, Economics &amp; Governance (CLEG) from American
University and J.D. from Rutgers School of Law.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="zc407a382b73b4f149cc418844cd5f5ab" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Compensation</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">
<br/> </span></div>

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">&#160;&#160;
Directors.</span> Under the Companies Law, the compensation of our directors requires the approval of our compensation committee, the
subsequent approval of the board of directors and, unless exempted under regulations promulgated under the Companies Law, the approval
of the shareholders at a general meeting. If the compensation of our directors is inconsistent with our stated compensation policy, then,
those provisions that must be included in the compensation policy according to the Companies Law must have been considered by the compensation
committee and board of directors, and shareholder approval by a simple majority will also be required, provided that:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z99bcc47ceb544b3aa90d8a5630936be5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">at least a majority of the shares held by all
        shareholders who are not controlling shareholders and do not have a personal interest in such matter, present and voting at such meeting,
        are voted in favor of the compensation package, excluding abstentions; or</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the total number of shares of non-controlling
        shareholders and shareholders who do not have a personal interest in such matter voting against the compensation package does not exceed
        two percent (2%) of the aggregate voting rights in the Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">&#160;&#160;&#160;
Executive Officers other than the Chief Executive Officer</span>. The Companies Law requires the approval of the compensation of a public
company&#8217;s executive officers (other than the chief executive officer) in the following order: (1) the compensation committee, (2)
the company&#8217;s board of directors, and (3) if such compensation arrangement is inconsistent with the company&#8217;s stated compensation
policy, the company&#8217;s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation).
However, if the shareholders of the company do not approve a compensation arrangement with such executive officer that is inconsistent
with the company&#8217;s stated compensation policy, the compensation committee and board of directors may override the shareholders&#8217;
decision if each of the compensation committee and the board of directors provide detailed reasons for their decision.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">104</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">An amendment to an existing
arrangement with an office holder (who is not a director) requires only the approval of the compensation committee, if the compensation
committee determines that the amendment is not material in comparison to the existing arrangement. However, under the Companies Law, an
amendment to an existing arrangement with an office holder (who is not a director) who is subordinate to the chief executive officer will
not require the approval of the compensation committee, if (1) the amendment is approved by the chief executive officer, (2) the company&#8217;s
compensation policy provides that a non-material amendment to the terms of service of an office holder (other than the chief executive
officer) may be approved by the chief executive officer and (3) the engagement terms are consistent with the company&#8217;s compensation
policy.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"><span style="font-style: italic">Chief
Executive Officer</span>. Under the Companies Law, the compensation of a public company&#8217;s chief executive officer is required to
be approved by: (1) the company&#8217;s compensation committee; (2) the company&#8217;s board of directors, and (3) the company&#8217;s
shareholders (by a special majority vote as discussed above with respect to the approval of director compensation). However, if the shareholders
of the company do not approve the compensation arrangement with the chief executive officer, the compensation committee and board of directors
may override the shareholders&#8217; decision if each of the compensation committee and the board of directors provide detailed reasons
for their decision. The approval of each of the compensation committee and the board of directors should be in accordance with the company&#8217;s
stated compensation policy; however, in special circumstances, they may approve compensation terms of a chief executive officer that are
inconsistent with such policy provided that they have considered those provisions that must be included in the compensation policy according
to the Companies Law and that shareholder approval is obtained (by a special majority vote as discussed above with respect to the approval
of director compensation). In addition, the compensation committee may waive the shareholder approval requirement with regards to the
approval of the engagement terms of a candidate for the chief executive officer position, if they determine that the compensation arrangement
is consistent with the company&#8217;s compensation policy and that the chief executive officer candidate did not have a prior business
relationship with the company or a controlling shareholder of the company and that subjecting the approval of the engagement to a shareholder
vote would impede the company&#8217;s ability to employ the chief executive officer candidate.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Compensation of Directors and
Executive Officers</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;The aggregate compensation
paid by us and our subsidiaries to our directors and executive officers, including share-based compensation expenses recorded in our financial
statements, for the year ended December 31, 2023, was approximately $4.4 million (including $1.3 million in share-based compensation).
This amount includes deferred or contingent compensation accrued for such year (and excludes deferred or contingent amounts accrued for
during the year ended December 31, 2022 and paid during the year ended December 31, 2023). This amount includes approximately $0.2 million
set aside or accrued to provide pension, severance, retirement or similar benefits or expenses, but does not include business travel,
relocation, professional and business association dues and expenses reimbursed to our directors and executive officers.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;During the year ended
December 31, 2023, our directors and officers were granted options to purchase an aggregate of 12,656,020 ordinary shares (equal to 632,801
ADSs), at a weighted average exercise price of $1.4 per share.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">105</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;

<div style="line-height: 1.25">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;The following is a summary of the
salary expenses, bonus and social benefit costs of our five most highly compensated executive officers in 2023, or the &#8220;Covered
Executives&#8221;. All amounts reported reflect the cost to us as recognized in our financial statements for the year ended December 31,
2023.</div> </div>

<div style="line-height: 1.25"> <br/> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" id="zdcd17cf196ec4c06acbd40f157be9385" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5.16%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94.84%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Adi Mor, <span style="font-style: italic">Chief Executive Officer, Chief Scientific
        Officer and Director</span>. Compensation expenses recorded in 2023 were $0.33 million in salary expenses.</div> </td> </tr>
  <tr>
    <td style="width: 5.16%; vertical-align: top">&#160;</td>
    <td style="width: 94.84%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 5.16%; vertical-align: top">&#8226;</td>
    <td style="width: 94.84%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Dale Pfost, <span style="font-style: italic">former Chief Executive Officer and Chairman
        of the Board</span> (1). Compensation expenses recorded in 2023 were $0.7 million in salary expenses and $16 thousand in social benefits.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 5.16%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94.84%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">Donald Marvin, <span style="font-style: italic">former Chief Financial Officer, Chief
        Operating Officer and Executive Vice President (2)</span>. Compensation expenses recorded in 2023 were $0.6 million in salary expenses
        and $32 thousand&#160; in social benefits.</div> </td> </tr>
  <tr>
    <td style="width: 5.16%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 94.84%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5.16%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="width: 94.84%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Sigal Fattal, <span style="font-style: italic">Chief Financial
        Officer</span>. Compensation expenses recorded in 2023 were $0.3 million in salary expenses and $22 thousand in social benefits.</div>
        </div> </td> </tr>
  <tr>
    <td style="width: 5.16%; vertical-align: top">&#160;</td>
    <td style="width: 94.84%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 5.16%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div>
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 94.84%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">Matthew Frankel, <span style="font-style: italic">Chief Medical Officer</span>. Compensation expenses recorded
        in 2023 were $0.8 million in salary expenses and $50 thousand in social benefits.</div> </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">(1) Dale Pfost resigned from his positions as Chief Executive Officer and Chairman of the Board on June
        1, 2023. The salary amount includes severance.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div>
        <div style="line-height: 1.25">(2) Donald Marvin resigned from his positions as Chief Financial Officer, Chief Operating Officer and Executive
        Vice President on June 1, 2023. The salary amount includes severance.</div> </td> </tr>
  </table> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160; <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 33.5pt; line-height: 1.25">&#160;The salary expenses summarized above include the gross salary paid to the Covered
Executives, severance and bonus.&#160;The benefit costs include the social benefits paid by us on behalf of the Covered Executives, contributions
made by us to an insurance policy, pension fund or 401(K) fund.</div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;We recorded equity-based compensation
expenses in our financial statements for the year ended December 31, 2023, of $1.3 million.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; text-indent: 9pt">&#160; <br/> </div>

<div style="text-align: justify; text-indent: 33.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;All equity-based compensation
grants to our Covered Executives were made in accordance with the parameters of our compensation policy and were approved by our compensation
committee and board of directors. Assumptions and key variables used in the calculation of such amounts are described in Note 8 to our
audited consolidated financial statements included in Item 18 of this Annual Report.<br/> &#160; <br/> </div>

<div style="text-align: justify; text-indent: 27pt; line-height: 1.25">&#160;&#160;&#160; Additionally, we annually pay to each of our
non-employee directors a cash retainer of $40,000 (or $65,000 for the Chairperson) with an additional annual payment for service on board
committees as follows: $15,500 for the chairperson of the audit committee and $7,625 for the other committee members. $11,000 for the
chairperson of the compensation committee and $5,500 for the other committee members. $9,000 for the chairperson of the corporate governance
and nominating committee or any other board committee and $4,500 for the other committee members.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;In addition, upon election, non-employee directors (other
than the Chairperson), will be granted equity awards equal to 0.1% of our share capital on a fully diluted basis, under our incentive
plan, which will vest on a monthly basis over a period of three years. In addition, each non-employee director will be granted equity
awards under our incentive plan (provided the director is still in office) equal to 0.06% of our share capital on a fully diluted basis,
which will vest on the first anniversary of the date on which such options were granted, subject to such director&#8217;s continued service
through such date.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The non-employee Chairperson, on election, will be granted an equity award equal to
0.2% of our share capital on a fully diluted basis, under our incentive plan, which will vest on a monthly basis over a period of three
years. In addition, the non-employee Chairperson will be granted equity awards under our incentive plan (provided the Chairperson is still
in office) equal to 0.1% of our share capital on a fully diluted basis, which will vest on the first anniversary of the date on which
such options were granted, subject to such Chairperson continued service through such date.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">106</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Equity Incentive Plans</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We maintain (i) the 2011 Share Option Plan
(the &#8220;2011 Plan&#8221;), (ii) the 2017 Plan and (iii) the 2015 Plan, which was assumed by our company from the Subsidiary upon the
effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of our company
(formerly known as Anchiano Therapeutics Ltd.) as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal
adjustment to exercise price. As of December 31, 2023, a total of 1,422,153 ADSs were reserved for issuance under the 2015 Plan, of which
172,276 ADSs had been issued pursuant to previous exercises options, and 341,322 ADSs&#160;were issuable under outstanding options. Of
such outstanding options, options to purchase 319,708 ADSs had vested and were exercisable as of that date, with a weighted average exercise
price of $5.98 per ADS.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As of December 31, 2023, a total of 1,153,069
of ADSs were reserved for issuance under the 2017 Plan, of which&#160;1,152,333 ADSs&#160;were issuable under outstanding options. Of
such outstanding options, options to purchase 184,474 ADSs had vested and were exercisable as of that date, with a weighted average exercise
price of $3.91 per ADS. No ADSs had been issued pursuant to previous exercises options.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">2011 Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">On December 19, 2011, our board
of directors adopted the 2011 Plan to allocate options to purchase our ordinary shares to our directors, officers, employees and consultants,
and those of our affiliated companies (as such term is defined under the 2011 Plan), or the Grantees. The 2011 Plan is administered by
our board of directors or a committee that was designated by our board of directors for such purpose (the &#8220;Administrator&#8221;).</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Under the 2011 Plan, we may
grant options to purchase ordinary shares (&#8220;Options&#8221;), under four tracks: (i) Approved 102 capital gains Options through a
trustee, which was approved by the Israeli Tax Authority in accordance with Section 102(a) of the Israeli Income Tax Ordinance (&#8220;ITO&#8221;),
and granted under the tax track set forth in Section 102(b)(2) of the ITO, or the Approved 102 Capital Gains Options. The holding period
under this tax track is 24 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment
of Section 102 of the ITO, or any applicable tax ruling or guidelines; (ii) Approved 102 Earned Income Options through a trustee, granted
under the tax track set forth is Section 102(b)(1) of the ITO, or the Approved 102 Earned Income Options. The holding period under this
tax track is 12 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment of Section
102 of the ITO; (iii) Unapproved 102 Options (the Options will not be allocated through a trustee and will not be subject to a holding
period), or the Unapproved 102 Options; and (iv) 3(i) Options (the Options will not be subject to a holding period). These Options shall
be subject to taxation pursuant to Section 3(i) of the ITO, or Section 3(i).</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Options pursuant to the first
three tax tracks (under Section 102 of the ITO) can be granted to our employees and directors and the grant of Options under Section 3(i)
can be granted to our consultants and controlling shareholders (a controlling shareholder is defined under the Section 102 of the ITO
is a person who holds, directly or indirectly, alone or together with a &#8220;relative,&#8221; (i) the right to at least 10% of the company&#8217;s
issued capital or 10% of the voting power; (ii) the right to hold at least 10% of the company&#8217;s issued capital or 10% of the voting
power, or the right to purchase such rights; (iii) the right to receive at least 10% of the company&#8217;s profits; or (iv) the right
to appoint a company&#8217;s director). Grantees who are not Israeli residents may be granted options that are subject to the applicable
tax laws in their respective jurisdictions.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">107</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We determine, in our sole discretion,
under which of the first three tax tracks above the Options are granted and we notify the Grantee in a grant letter, as to the elected
tax track. As mentioned above, consultants and controlling shareholders can only be granted Section 3(i) Options.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The number of ordinary shares
authorized to be issued under the 2011 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares
issued as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares
or other capital change), or issuance of rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions of
ordinary shares and the number of ordinary shares shall be rounded up to the closest number of ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Unless otherwise determined
by the Administrator, the exercise price of an Option granted under the 2011 Plan will be the average of the market price of our ordinary
shares during the 22 business days prior to the date on which our board of directors authorized the grant of Options; provided, however,
that such exercise price cannot be lower than the market price at the close of the trading day at which it was granted by our board of
directors. The exercise price will be specified in the grant letter every Grantee received from us in which the Grantee notifies of the
decision to grant him/her Options under the 2011 Plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Unless otherwise determined
by the Administrator, the Options granted under the 2011 Plan will become vested and may be exercised in 16 equal portions of 6.25% of
the total number of Options, at the end of each quarter following the day the Options were granted. Unless otherwise determined by our
board of directors, the Options may be exercised for ten years following the date of grant, unless terminated earlier, and as long as
the Grantee is employed by us (or by an affiliated company), or provides service to us (or an affiliated company).</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The Administrator may, in its
absolute discretion, accelerate the time at which Options granted under the 2011 Plan or any portion of which will vest.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Unless otherwise determined
by the Administrator, in the event that the Grantee&#8217;s employment was terminated, not for Cause (as defined in the 2011 Plan), the
Grantee may exercise that portion of the Options that had vested as of the date of such termination until the end of the specified term
in the grant letter or the 2011 Plan. The portion of the Options that had not vested at such date, will be forfeited and can be re-granted
according to the terms of the 2011 Plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">2015 Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In November 2015, the Subsidiary&#8217;s
board of directors adopted, and its shareholders subsequently approved, the 2015 Plan. The 2015 Plan provides for the grant of options,
restricted shares, restricted share units and other share-based awards to the Subsidiary&#8217;s (following the Merger, the Company&#8217;s)
and its subsidiaries&#8217; and affiliates&#8217; directors, employees, officers, consultants, advisors, and any other person whose services
are considered valuable to us or our affiliates. Any such grants are intended to incentivize the foregoing persons to continue as service
providers, to increase their efforts on our behalf or on behalf of our subsidiaries or affiliates, and to promote the success of our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The 2015 Plan is administered
by our board of directors or by a committee designated by the board of directors, which determines, subject to Israeli law, the grantees
of awards and the terms of the grant, including, exercise prices, vesting schedules, acceleration of vesting and the other matters necessary
in the administration of the 2015 Plan. The 2015 Plan enables us to issue awards under various tax regimes, including, without limitation,
pursuant to Section 102 of the Israeli Income Tax Ordinance, or the Ordinance, and under Section 3(i) of the Ordinance and Section 422
of the United States Internal Revenue Code of 1986, as amended, or the Code.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">108</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The 2015 Plan provides that
options granted to our employees, directors and officers who are not controlling shareholders and who are considered Israeli residents
are intended to qualify for special tax treatment under the &#8220;capital gain track&#8221; provisions of Section 102(b) of the Ordinance.
Our Israeli non-employee service providers and controlling shareholders may only be granted options under Section 3(i) of the Ordinance,
which does not provide for similar tax benefits.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Options granted under the 2015
Plan to U.S. residents may qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code, or may be non-qualified.
The exercise price for &#8220;incentive stock options&#8221; must not be less than the fair market value on the date on which an option
is granted, or 110% of the fair market value if the option holder holds more than 10% of our share capital.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Options and other awards granted
under the 2015 Plan generally vest over four years commencing on the date of grant, such that 25% vests on the first anniversary of the
date of grant and an additional 6.25% vests at the end of each subsequent calendar quarter over the course of the next three years, provided
that the participant remains continuously employed or engaged by us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Options, other than certain
incentive share options, that are not exercised within ten years from the grant date expire, unless otherwise determined by our board
of directors or our designated committee, as applicable. Share options that qualify as &#8220;incentive stock options&#8221; and are granted
to a person holding more than 10% of our voting power will expire within five years from the date of the grant. In the event of the death
of a grantee while employed by or performing service for us or our subsidiary or within three months after the date of the employee&#8217;s
termination, or the termination of a grantee&#8217;s employment or services for reasons of disability, the grantee, or in the case of
death, his or her legal successor, may exercise options or other awards that have vested prior to termination within a period of one year
from the date of disability or death. If we terminate a grantee&#8217;s employment or service for cause, all of the grantee&#8217;s vested
and unvested options or other awards will expire on the date of termination. If a grantee&#8217;s employment or service is terminated
for any other reason, the grantee may generally exercise his or her vested options or other award within three months of the date of termination.
Any expired or unvested options return to the pool and become available for reissuance. From time to time, we may consider issuing options
with slightly different terms or accelerating, extending or otherwise modifying options in accordance with applicable law and regulation
and the terms of the 2015 Plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">In the event of a merger or
consolidation, or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on us, then
without the consent of the option holder, our board of directors or our designated committee, as applicable, may, but is not required,
to (i) cause any outstanding award to be assumed or an equivalent award to be substituted by such successor corporation, or (ii) in case
the successor corporation does not assume or substitute the award (a) provide the grantee with the option to exercise the award as to
all or part of the shares or (b) cancel the options and pay in cash an amount determined by the board of directors or the committee as
fair in the circumstances. Notwithstanding the foregoing, our board of directors or our designated committee may upon such event amend,
modify or terminate the terms of any award, including conferring the right to purchase any other security or asset that the board of directors
or the committee shall deem, in good faith, appropriate.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The 2015 plan was assumed by
our company from the Subsidiary upon the effectiveness of the Merger.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">2017 Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On February 22, 2017, our board of directors
adopted the 2017 Plan to allocate a variety of share-based awards to our directors, officers, employees, consultants, advisors and service
providers, and those of our affiliates (companies that control us, are controlled by us or are under common control with us) (the &#8220;Participants&#8221;).
The 2017 Plan is currently administered by our board of directors and may be administered by a committee designated by our board of directors
for such purpose.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">109</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Under the 2017 Plan, we may
grant options to purchase ordinary shares or ADSs, restricted shares or ADSs, restricted share units and other awards based on our ordinary
shares, all of which are referred to as Awards. We may grant Awards under the same four tracks as described above with respect to the
2011 Plan, subject to the same conditions as apply for the 2011 Plan. In addition, we may grant incentive stock options and nonqualified
stock options to Participants who are residents of the United States, and we may grant awards to Participants who are residents of other
countries that comply with the laws of those jurisdictions.<span style="font-family: Times New Roman, serif"><br/> </span>&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The number of ordinary shares
authorized to be issued under the 2017 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares
issued as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares
or other capital change), issuance of rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions of ordinary
shares and the number of ordinary shares shall be rounded down to the closest number of ordinary shares.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z77b896dab7f8414ca5ac7314a2aa2c37" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Board Practices</div> </td>
        </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Corporate Governance Practices</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">As an Israeli company, we
are subject to various corporate governance requirements under the Companies Law. However, pursuant to regulations promulgated under the
Companies Law, companies with securities traded on certain U.S. stock exchanges, including Nasdaq, may, subject to certain conditions,
&#8220;opt out&#8221; from the Companies Law requirements to appoint external directors and related Companies Law rules concerning the
composition of the audit committee and compensation committee of the board of directors (other than the gender diversification rule under
the Companies Law, which requires the appointment of a director from the other gender if at the time a director is appointed all members
of the board of directors are of the same gender). In accordance with these regulations, we elected to &#8220;opt out&#8221; from those
requirements of the Companies Law. Under these regulations, the exemptions from such Companies Law requirements will continue to be available
to us so long as: (i) we do not have a &#8220;controlling shareholder&#8221; (as such term is defined under the Companies Law), (ii) our
ADSs are traded on a U.S. stock exchange, Nasdaq, and (iii) we comply with the director independence requirements and the audit committee
and compensation committee composition requirements under U.S. laws (including applicable rules of Nasdaq) applicable to U.S. domestic
issuers.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We are a &#8220;foreign private
issuer&#8221; (as such term is defined in Rule 3b-4 under the Exchange Act). As a foreign private issuer, we are permitted to comply with
Israeli corporate governance practices instead of the corporate governance rules of Nasdaq, provided that we disclose which requirements
we are not following and the equivalent Israeli requirement. As a foreign private issuer, we are exempt under the Exchange Act from, among
other things, the rules prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders
are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we
are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as
U.S. companies whose securities are registered under the Exchange Act. For more information regarding our corporate governance practices
and foreign private issuer status, see Item 16G. &#8220;Corporate Governance.&#8221;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">110</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Board of Directors</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 34.5pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;Under the Israeli Companies Law, 5759-1999
(the &#8220;Companies Law&#8221;), our board of directors is responsible for setting our general policies and supervising the performance
of management. Our board of directors may exercise all powers and may take all actions that are not specifically granted by the Companies
Law or our articles of association to our shareholders or to management. Our executive officers are responsible for our day-to-day management
and have individual responsibilities established by our board of directors.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;Under the Companies
Law, the chief executive officer of a public company, or a relative of the chief executive officer, may not serve as the chairperson of
the board of directors of such public company, and the chairperson of the board of directors of a public company, or a relative of the
chairperson, may not be vested with authorities of the chief executive officer of such public company without obtaining shareholder approval
pursuant to special majority requirements set forth in the Companies Law.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 34.5pt; line-height: 1.25">&#160;Our board of directors is currently composed of six (6) members. Our board of
directors consists of three classes of directors (as illustrated below), each serving staggered three-year terms. Upon expiration of the
term of a class of directors, directors in that class will be elected for a three-year term at the Annual General Meeting of shareholders
in the year in which that term expires. Each director&#8217;s term continues until the election and qualification of his or her successor,
or his or her earlier death, resignation or removal. Any increase or decrease in the number of directors will be distributed among the
three classes so that, as nearly as possible, each class will consist of&#160;one-third&#160;of the directors. The division of our board
of directors into three classes with staggered three-year terms may delay or prevent a change of management or a change of control of
our company.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zcbe99347e7c840dfaf64d190b721d4ea" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Class I consists of Nissim Darvish and Jill Quigley, each with a term
        expiring at the 2025 annual meeting of shareholders.</div> </td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Class II consists of Neil Cohen and Claude Nicaise, each with a term
        expiring at the 2026 annual meeting of shareholders.</div> </td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Class III consists of Adi Mor and Alan Moses,
        each with a term expiring at the 2024 annual meeting of shareholders.&#160;</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our directors are appointed
by a simple majority vote of holders of our ordinary shares, participating and voting at an annual general meeting of our shareholders,
provided that (i) in the event of a contested election, the method of calculation of the votes and the manner in which the resolutions
will be presented to our shareholders at the general meeting will be determined by our board of directors in its discretion, and (ii)
in the event that our board of directors does not or is unable to make a determination on such matter, then the directors will be elected
by a plurality of the voting power represented at the general meeting in person or by proxy and voting on the election of directors.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Each director will hold office
until the annual general meeting of our shareholders for the year in which such director&#8217;s term expires, unless the tenure of such
director expires earlier pursuant to the Companies Law or unless such director is removed from office as described below.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under our Articles of Association,
the approval of the holders of at least 65% of the total voting power of our shareholders is generally required to remove any of our directors
from office or any amendment to this provision shall require the approval of at least 65% of the total voting power of our shareholders
to remove any of our directors from office. In addition, vacancies on our board of directors may only be filled by a vote of a simple
majority of the directors then in office. A director so appointed will hold office until the next annual general meeting of our shareholders
for the election of the class of directors in respect of which the vacancy was created, or in the case of a vacancy due to the number
of directors being less than the minimum number of directors stated in our Articles of Association, the new director filling the vacancy
will serve until the next annual general meeting of our shareholders for the election of the class of directors to which such director
was assigned by our board of directors.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">111</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Chairperson
of the Board</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our Articles of Association
provide that the Chairperson of our board of directors is appointed by the members of our board of directors from among them. Under the
Companies Law, the chief executive officer of a public company, or a relative of the chief executive officer, may not serve as the chairperson
of the board of directors of such public company, and the chairperson of the board of directors of a public company, or a relative of
the chairperson, may not be vested with authorities of the chief executive officer of such public company without shareholder approval
consisting of a majority vote of the shares present and voting at a shareholders meeting, and in addition, either:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9565bae7eada48a0914070c58b6536d2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">at least a majority of the shares of non-controlling
        shareholders and shareholders that do not have a personal interest in the approval voted at the meeting are voted in favor (disregarding
        abstentions); or</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the total number of shares of non-controlling
        shareholders and shareholders who do not have a personal interest in such appointment that re voted against such appointment does not
        exceed two percent (2%) of the aggregate voting rights in the company.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The shareholders&#8217; approval
can be effective for a period of up to five years following an initial public offering, and subsequently, for additional periods of up
to three years.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In addition, a person who
is subordinated, directly or indirectly, to the chief executive officer may not serve as the chairperson of the board of directors; the
chairperson of the board of directors may not be vested with authorities that are granted to persons who are subordinated to the chief
executive officer; and the chairperson of the board of directors may not serve in any other position in the company or in a controlled
subsidiary, but may serve as a director or chairperson of a controlled subsidiary.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">External
Directors</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under the Companies Law, companies
incorporated under the laws of the State of Israel that are &#8220;public companies,&#8221; including companies with shares listed on
Nasdaq, are required to appoint at least two external directors. Pursuant to regulations promulgated under the Companies Law, companies
with <span style="font-family: Times New Roman,serif">shares</span> traded on certain U.S. stock exchanges, including Nasdaq, which do
not have a &#8220;controlling shareholder,&#8221; may, subject to certain conditions, &#8220;opt out&#8221; from the Companies Law requirements
to appoint external directors and related Companies Law rules concerning the composition of the audit committee and compensation committee
of the board of directors. In accordance with these regulations, we have elected to &#8220;opt out&#8221; from the Companies Law requirement
to appoint external directors and related Companies Law rules concerning the composition of the audit committee and compensation committee
of our board of directors.<br/> &#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Committees of our Board of
Directors</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Audit Committee</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under the Companies Law, the Exchange Act and Nasdaq
rules, we are required to establish an audit committee, and we have a separately-designated standing audit committee established in accordance
with section 3(a)(58)(A) of the Exchange Act.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The responsibilities of an audit committee under
the Companies Law include identifying and addressing flaws in the business management of the company, reviewing and approving related
party transactions, establishing whistleblower procedures, overseeing the company&#8217;s internal audit system and the performance of
its internal auditor, and assessing the scope of the work and recommending the fees of the company&#8217;s independent accounting firm.
In addition, the audit committee is required to determine whether certain related party actions and transactions are &#8220;material&#8221;
or &#8220;extraordinary&#8221; for the purpose of the requisite approval procedures under the Companies Law and to establish procedures
for considering proposed transactions with a controlling shareholder.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">112</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In accordance with U.S. law and Nasdaq requirements,
our audit committee is also responsible for the appointment, compensation and oversight of the work of our independent auditors and for
assisting our board of directors in monitoring our financial statements, the effectiveness of our internal controls and our compliance
with legal and regulatory requirements.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under the Companies Law and related regulations,
the audit committee must consist of at least three directors who meet certain independence criteria. Under the Nasdaq rules, we are required
to maintain an audit committee consisting of at least three independent directors, all of whom are financially literate and one of whom
has accounting or related financial management expertise. Each of the members of the audit committee is required to be &#8220;independent&#8221;
as such term is defined in Rule 10A-3(b)(1) under the Exchange Act.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The members of the audit committee are Jill Quigley,
Alan Moses and Claude Nicaise. Jill Quigley is the chairperson of the audit committee and is a financial expert under the rules of the
SEC. Our board of directors has concluded that each member of the audit committee is independent under the rules and regulations of Nasdaq
and the SEC.&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Compensation
Committee</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25">Under both the Companies Law and Nasdaq rules, we are required to establish a compensation
committee.&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The responsibilities of a compensation committee
under the Companies Law include recommending to the board of directors, for ultimate shareholder approval by a special majority, a policy
governing the compensation of directors and officers based on specified criteria, reviewing modifications to and implementing such compensation
policy from time to time, and approving the actual compensation terms of directors and officers prior to approval by the board of directors.</div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In accordance with U.S. law and Nasdaq requirements,
our compensation committee is also responsible for the appointment, compensation and oversight of the work of any compensation consultant,
independent legal counsel and other advisors retained by the compensation committee.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The Companies Law and related regulations require
the appointment of a compensation committee that complies with the requirements of Nasdaq. Under Nasdaq rules, we are required to maintain
a compensation committee consisting of at least two independent directors; each of the members of the compensation committee is required
to be independent under Nasdaq rules relating to compensation committee members, which are different from the general test for independence
of board and committee members. The members of the compensation committee are Nissim Darvish and Neil Cohen. Nissim Darvish is the chairperson
of the compensation committee. Our board of directors has determined that each member of the compensation committee is independent within
the meaning of the independent director guidelines of Nasdaq and under Rule 10C-1 under the Exchange Act.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">113</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Compensation Policy under
the Companies Law</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In general, under the Companies
Law, a public company must have a compensation policy approved by the board of directors after receiving and considering the recommendations
of the compensation committee. In addition, our compensation policy must be approved at least once every three years, first, by our board
of directors, upon the recommendation of our compensation committee, and second, by a simple majority of the ordinary shares present,
in person or by proxy, and voting (excluding abstentions) at a general meeting of shareholders, provided that either:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zceca1260fbef46d19254d017ccb1cd98" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">such majority includes at least a majority of
        the shares held by shareholders who are not controlling shareholders and shareholders who do not have a personal interest in such compensation
        policy; or</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the total number of shares of non-controlling
        shareholders and shareholders who do not have a personal interest in the compensation policy and who vote against the policy does not
        exceed two percent (2%) of the aggregate voting rights in the Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under special circumstances,
the board of directors may approve the compensation policy despite the objection of the shareholders on the condition that the compensation
committee and then the board of directors decide, on the basis of detailed grounds and after discussing again the compensation policy,
that approval of the compensation policy, despite the objection of shareholders, is for the benefit of the company.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If a company that initially
offers its securities to the public, like us, adopts a compensation policy in advance of its initial public offering, and describes it
in its prospectus for such offering, then such compensation policy shall be deemed a validly adopted policy in accordance with the Companies
Law requirements described above. Furthermore, if the compensation policy is established in accordance with the aforementioned relief,
then it will remain in effect for a term of five years from the date such company becomes a public company.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The compensation policy must
be based on certain considerations, include certain provisions and reference certain matters as set forth in the Companies Law. The compensation
policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation,
insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy
must be determined and later reevaluated according to certain factors, including: the advancement of the company&#8217;s objectives, business
plan and long-term strategy; the creation of appropriate incentives for office holders, while considering, among other things, the company&#8217;s
risk management policy; the size and the nature of the company&#8217;s operations; and with respect to variable compensation, the contribution
of the office holder towards the achievement of the company&#8217;s long-term goals and the maximization of its profits, all with a long-term
objective and according to the position of the office holder. The compensation policy must furthermore consider the following additional
factors:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z92d8a3f747e24e5fa7b109aacf586f60" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the education, skills, experience, expertise and
        accomplishments of the relevant office holder;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the office holder&#8217;s position and responsibilities;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">prior compensation agreements with the office
        holder;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the ratio between the cost of the terms of employment
        of an office holder and the cost of the employment of other employees of the company, including employees employed through contractors
        who provide services to the company, in particular the ratio between such cost to the average and median salary of such employees of the
        company, as well as the impact of disparities between them on the work relationships in the company;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">if the terms of employment include variable components
        - the possibility of reducing variable components at the discretion of the board of directors and the possibility of setting a limit on
        the value of non-cash variable equity-based components; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">if the terms of employment include severance compensation
        - the term of employment or office of the office holder, the terms of the office holder&#8217;s compensation during such period, the company&#8217;s
        performance during such period, the office holder&#8217;s individual contribution to the achievement of the company goals and the maximization
        of its profits and the circumstances under which he or she is leaving the company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">114</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The compensation policy must
also include, among other things:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze6243481a0234655982879a82ea023ef" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">with regards to variable components:</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">with the exception of office holders who report
        to the chief executive officer, a means of determining the variable components on the basis of long-term performance and measurable criteria;
        provided that the company may determine that an immaterial part of the variable components of the compensation package of an office holder
        shall be awarded based on non-measurable criteria, or if such amount is not higher than three months&#8217; salary per annum, taking into
        account such office holder&#8217;s contribution to the company;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the ratio between variable and fixed components,
        as well as the limit of the values of variable components at the time of their payment, or in the case of equity-based compensation, at
        the time of grant;</div> </td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a condition under which the office holder will
        return to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part of the office holder&#8217;s
        terms of employment, if such amounts were paid based on information later to be discovered to be wrong, and such information was restated
        in the company&#8217;s financial statements;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the minimum holding or vesting period of variable
        equity-based components to be set in the terms of office or employment, as applicable, while taking into consideration long-term incentives;
        and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a limit to retirement grants.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our compensation policy is
designed to promote retention and motivation of directors and executive officers, incentivize superior individual excellence, align the
interests of our directors and executive officers with our long-term performance and provide a risk management tool. To that end, a portion
of our executive officer compensation package is targeted to reflect our short and long-term goals, as well as the executive officer&#8217;s
individual performance. On the other hand, our compensation policy includes measures designed to reduce the executive officer&#8217;s
incentives to take excessive risks that may harm us in the long-term, such as limits on the value of cash bonuses and equity-based compensation,
limitations on the ratio between the variable and the total compensation of an executive officer and minimum vesting periods and performance
based vesting for equity-based compensation.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our compensation policy also
addresses our executive officers&#8217; individual characteristics (such as their respective position, education, scope of responsibilities
and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers and considers the
internal ratios between compensation of our executive officers and directors and other employees. Pursuant to our compensation policy,
the compensation that may be granted to an executive officer may include: base salary, annual bonuses and other cash bonuses (such as
a signing bonus and special bonuses with respect to any special achievements, such as outstanding personal achievement, outstanding personal
effort or outstanding company performance), equity-based compensation, benefits and retirement and termination of service arrangements.
All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base salary.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">An annual cash bonus may be
awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may
be granted to our executive officers other than our Chief Executive Officer will be based on performance objectives and a discretionary
evaluation of the executive officer&#8217;s overall performance by our Chief Executive Officer and subject to minimum thresholds. The
annual cash bonus that may be granted to executive officers other than our Chief Executive Officer may alternatively be based entirely
on a discretionary evaluation. Furthermore, our Chief Executive Officer will be entitled to approve performance objectives for executive
officers who report to her.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The measurable performance
objectives of our Chief Executive Officer will be determined annually by our compensation committee and board of directors. A non-material
portion of the Chief Executive Officer&#8217;s annual cash bonus, as provided in our compensation policy, may be based on a discretionary
evaluation of the Chief Executive Officer&#8217;s overall performance by the compensation committee and the board of directors.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">115</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The equity-based compensation
under our compensation policy for our executive officers (including members of our board of directors) is designed in a manner consistent
with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the
alignment between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to strengthen
the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation
in the form of share options or other equity-based awards, such as restricted shares and restricted share units, in accordance with our
equity incentive plan then in place. The equity-based compensation shall be granted from time to time and be individually determined and
awarded according to the performance, educational background, prior business experience, qualifications, role and the personal responsibilities
of the executive officer.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In addition, our compensation
policy contains compensation recovery provisions which allow us under certain conditions to recover bonuses paid in excess, enable our
Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer who reports directly to her
(provided that the changes of the terms of employment are in accordance with our compensation policy) and allow us to exculpate, indemnify
and insure our executive officers and directors to the maximum extent permitted by Israeli law subject to certain limitations set forth
therein.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our compensation policy also
provides for compensation to the members of our board of directors either (i) in accordance with the amounts provided in the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief
for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to time, or (ii)
in accordance with the amounts determined in our compensation policy.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our compensation policy was
approved by our board of directors and shareholders and became effective on July 19, 2021.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Corporate Governance and Nominating
Committee</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We have established a Corporate Governance and
Nominating Committee, responsible for making recommendations to the board of directors regarding candidates for directorships and the
size and composition of the board. In addition, the committee is responsible for overseeing our corporate governance guidelines and reporting
and making recommendations to the board concerning corporate governance matters. Under the Companies Law, nominations for director may
also, under certain circumstances, be made by shareholders in accordance with the conditions prescribed by applicable law and our articles
of association. The members of the Corporate Governance and Nominating Committee are Neil Cohen and Nissim Darvish. Neil Cohen is the
chairperson of the Corporate Governance and Nominating Committee. Our board of directors has determined that each member of the Corporate
Governance and Nominating Committee is independent within the meaning of the independent director guidelines of Nasdaq.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Internal Auditor</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under the Companies Law, the board of directors
is required to appoint an internal auditor recommended by the audit committee. The role of the internal auditor is to examine, among other
things, whether the company&#8217;s actions comply with applicable law and proper business procedures. The internal auditor may not be
an interested party, a director or an officer of the company, or a relative of any of the foregoing, nor may the internal auditor be our
independent accountant or a representative thereof. Yisrael Gewirtz of Grant Thornton Israel currently serves as our internal auditor.</div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Approval of Related Party Transactions
under Israeli Law</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">116</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Fiduciary
duties of directors and Executive Officers</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">An office holder&#8217;s fiduciary
duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with
which a reasonable office holder in the same position would have acted under the same circumstances. The duty of care includes, among
other things, a duty to use reasonable means, in light of the circumstances, to obtain:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze8f1a63d4bba46e8bea0c373967c00c8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">information on the business advisability of a
        given action brought for his, her or its approval or performed by virtue of his, her or its position; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">all other important information pertaining to
        such action.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The duty of loyalty requires
that an office holder act in good faith and in the best interests of the company, and includes, among other things, the duty to:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7b45fc4753e143c99ed0ec287e3376f6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">refrain from any act involving a conflict of interest
        between the performance of his, her or its duties in the company and his, her or its other duties or personal affairs;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">refrain from any activity that is competitive
        with the business of the company;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">refrain from exploiting any business opportunity
        of the company for the purpose of gaining a personal advantage for himself, herself or itself or others; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">disclose to the company any information or documents
        relating to the company&#8217;s affairs which the office holder received as a result of his, her or its position as an office holder.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under the Companies Law, a
company may approve an act specified above which would otherwise constitute a breach of the office holder&#8217;s duty of loyalty, provided
that the office holder acted in good faith, neither the act nor its approval harms the company, and the office holder discloses his, her
or its personal interest a sufficient time before the approval of such act. Any such approval is subject to the terms of the Companies
Law setting forth, among other things, the appropriate bodies of the company required to provide such approval and the methods of obtaining
such approval.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Disclosure
of Personal Interests of an Office Holder and Approval of Certain Transactions</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The Companies Law requires
that an office holder promptly disclose to the board of directors any personal interest that such office holder may have and all related
material information known to such office holder concerning any existing or proposed transaction with the company. A personal interest
includes an interest of any person in an act or transaction of a company, including a personal interest of one&#8217;s relative or of
a corporate body in which such person or a relative of such person is a 5% or greater shareholder, director or general manager or in which
such person has the right to appoint at least one director or the general manager, but excluding a personal interest stemming solely from
one&#8217;s ownership of shares in the company. A personal interest includes the personal interest of a person for whom the office holder
holds a voting proxy or the personal interest of the office holder with respect to the officer holder&#8217;s vote on behalf of a person
for whom he or she holds a proxy even if such shareholder has no personal interest in the matter.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If it is determined that an
office holder has a personal interest in a non-extraordinary transaction, meaning any transaction that is in the ordinary course of business,
on market terms or that is not likely to have a material impact on the company&#8217;s profitability, assets or liabilities, approval
by the board of directors is required for the transaction unless the company&#8217;s articles of association provide for a different method
of approval. Any such transaction that is adverse to the company&#8217;s interests may not be approved by the board of directors.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">117</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Approval first by the company&#8217;s
audit committee and subsequently by the board of directors is required for an extraordinary transaction (meaning any transaction that
is not in the ordinary course of business, not on market terms or that is likely to have a material impact on the company&#8217;s profitability,
assets or liabilities) in which an office holder has a personal interest.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">A director and any other office
holder who has a personal interest in a transaction which is considered at a meeting of the board of directors or the audit committee
may generally (unless it is with respect to a transaction which is not an extraordinary transaction) not be present at such a meeting
or vote on that matter unless a majority of the directors or members of the audit committee, as applicable, have a personal interest in
the matter. If a majority of the members of the audit committee or the board of directors have a personal interest in the matter, then
all of the directors may participate in deliberations of the audit committee or board of directors, as applicable, with respect to such
transaction and vote on the approval thereof and, in such case, shareholder approval is also required.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Certain disclosure and approval
requirements apply under Israeli law to certain transactions with controlling shareholders, certain transactions in which a controlling
shareholder has a personal interest and certain arrangements regarding the terms of service or employment of a controlling shareholder.
For these purposes, a controlling shareholder is any shareholder that has the ability to direct the company&#8217;s actions, including
any shareholder holding 25% or more of the voting rights if no other shareholder owns more than 50% of the voting rights in the company.
Two or more shareholders with a personal interest in the approval of the same transaction are deemed to be one shareholder.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">For a description of the approvals
required under Israeli law for compensation arrangements of officers and directors, see &#8220;-Compensation of Directors and Executive
Officers.&#8221;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Shareholder
Duties</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Pursuant to the Companies
Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain
from abusing his or her power with respect to the company, including, among other things, in voting at a general meeting and at shareholder
class meetings with respect to the following matters:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbafbd8ac950641758fd1057ea4619e25" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">an amendment to the company&#8217;s articles of
        association;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">an increase of the company&#8217;s authorized
        share capital;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a merger; or</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">interested party transactions that require shareholder
        approval.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In addition, a shareholder
has a general duty to refrain from discriminating against other shareholders.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Certain shareholders also
have a duty of fairness toward the company. These shareholders include any controlling shareholder, any shareholder who knows that it
has the power to determine the outcome of a shareholder vote and any shareholder who has the power to appoint or to prevent the appointment
of an office holder of the company or exercise any other rights available to it under the company&#8217;s articles of association with
respect to the company. The Companies Law does not define the substance of this duty of fairness, except to state that the remedies generally
available upon a breach of contract will also apply in the event of a breach of the duty of fairness.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">118</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Exculpation,
Insurance and Indemnification of Office Holders</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under the Companies Law, a
company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office
holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty
of care but only if a provision authorizing such exculpation is included in its articles of association. Our Articles of Association include
such a provision. An Israeli company may not exculpate a director from liability arising out of a prohibited dividend or distribution
to shareholders.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">An Israeli company may indemnify
an office holder in respect of the following liabilities and expenses incurred for acts performed as an office holder, either in advance
of an event or following an event, provided a provision authorizing such indemnification is contained in its articles of association:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z58f5a50c98484241b45341ccbc75bc5b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a financial liability imposed on him or her in
        favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an
        undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited
        to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking
        to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances,
        and such undertaking shall detail the above mentioned events and amount or criteria;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">reasonable litigation expenses, including legal
        fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized
        to conduct such investigation or proceeding, <span style="font-family: Times New Roman, serif; font-style: italic">provided</span> that
        (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability,
        such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation
        or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal
        intent; and (2) in connection with a monetary sanction;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">reasonable litigation expenses, including legal
        fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf or
        by a third-party or in connection with criminal proceedings in which the office holder was acquitted or as a result of a conviction for
        an offense that does not require proof of criminal intent; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">expenses, including reasonable litigation expenses
        and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain
        compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions
        of the Israeli Securities Law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">An Israeli company may insure
an office holder against the following liabilities incurred for acts performed as an office holder if and to the extent provided in the
company&#8217;s articles of association:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zdcc46beb4f36457195140cc2b1a1d3c6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a breach of the duty of loyalty to the company,
        to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a breach of the duty of care to the company or
        to a third-party, including a breach arising out of the negligent conduct of the office holder;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a financial liability imposed on the office holder
        in favor of a third-party;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a financial liability imposed on the office holder
        in favor of a third-party harmed by a breach in an administrative proceeding; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">expenses, including reasonable litigation expenses
        and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain
        provisions of the Israeli Securities Law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">119</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">An Israeli company may not
indemnify or insure an office holder against any of the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z25df611e9cf34eebaa227bfef86b1a1c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a breach of the duty of loyalty, except to the
        extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a breach of the duty of care committed intentionally
        or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">an act or omission committed with intent to derive
        illegal personal benefit; or</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a fine, monetary sanction or forfeit levied against
        the office holder.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under the Companies Law, exculpation,
indemnification and insurance of office holders must be approved by the compensation committee and the board of directors (and, with respect
to directors and the chief executive officer, by the shareholders). However, under regulations promulgated under the Companies Law, the
insurance of office holders does not require shareholder approval and may be approved by only the compensation committee if the engagement
terms are determined in accordance with the company&#8217;s compensation policy, which was approved by the shareholders by the same special
majority required to approve a compensation policy, provided that the insurance policy is on market terms and the insurance policy is
not likely to materially impact the company&#8217;s profitability, assets or obligations.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our Articles of Association
allow us to exculpate, indemnify and insure our office holders for any liability imposed on them as a consequence of an act (including
any omission) which was performed by virtue of being an office holder. Our office holders are currently covered by a directors and officers&#8217;
liability insurance policy.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We have entered into indemnification
agreements with each of our directors and executive officers exculpating them in advance, to the fullest extent permitted by law, from
liability to us for damages caused to us as a result of a breach of duty of care, and undertaking to indemnify them to the fullest extent
permitted by law. This indemnification is limited to events determined as foreseeable by the board of directors based on our activities,
and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In the opinion of the SEC,
indemnification of directors and office holders for liabilities arising under the Securities Act, however, is against public policy and
therefore unenforceable.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z091b44da67924d1aaa2ecefb88375649" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">&#160;<span style="font-family: Times New Roman,serif; font-weight: bold">D.</span></div>
        </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Employees</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">As of December 31, 2023, we
had 20 full-time employees/consultants, including 7 with Ph.D. or M.D. degrees and including 13 who are engaged in research and development
activities. We are dependent on our management and scientific personnel, and it is crucial that we continue to attract and retain valuable
employees. To facilitate attraction and retention, we strive to make ourselves an inclusive and safe workplace, with opportunities for
our employees to grow and develop in their careers, supported by strong compensation and benefits programs. None of our employees are
represented by labor unions or covered by collective bargaining agreements. &#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z83d43a4f930341f69b96ee7642eaf947" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">E.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Share Ownership</div> </td>
        </tr>
  </table>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman, serif"> <br/> </span></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"><span style="font-family: Times New Roman, serif">For
information regarding the share ownership of directors and officers, see Item 7.A. &#8220;Major Shareholders and Related Party Transactions-Major
Shareholders.&#8221; For information as to our equity incentive plans, see Item 6.B. &#8220;Director, Senior Management and Employees-Compensation-
Equity incentive plans.&#8221;</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8131116402a840f2bc18e564d4481d3b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">F.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Disclosure of a Registrant&#8217;s
        Action to Recover Erroneously Awarded Compensation</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">120</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item7"><!--Anchor--></span>Item
7. Major Shareholders and Related Party Transactions</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6882a8590ed849919032cfd36eb8af60" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Major Shareholders</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The beneficial ownership of
ordinary shares is determined in accordance with the SEC rules and generally includes any ordinary shares over which a person exercises
sole or shared voting or investment power. For purposes of the table below, we deem shares subject to options or warrants that are currently
exercisable or exercisable within 60 days of December 31, 2023, to be outstanding and to be beneficially owned by the person holding the
options or warrants for the purposes of computing the percentage ownership of that person but we do not treat them as outstanding for
the purpose of computing the percentage ownership of any other person. The percentage of shares beneficially owned is based on 284,094,700
ordinary shares outstanding as of December 31, 2023.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">All of our shareholders, including
the shareholders listed below, have the same voting rights attached to their ordinary shares.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">A description of any material
relationship that our principal shareholders have had with us or any of our affiliates within the past three years is included under &#8220;Certain
relationships and related party transactions.&#8221;</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zd28fa011738d47c2abb8e9ae21aee895" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">NAME OF BENEFICIAL OWNER</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Total</div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Beneficial</div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Ownership (ADSs)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Percentage of</div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">ADSs Beneficially</div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Owned</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">5% and Greater Shareholders</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">OrbiMed Israel (1)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">2,270,091</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25">15.9 <br/> </div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Rivendell Investments 2017-9(2)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">1,131,563</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">8.0</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Kobi George(3)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">733,645</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">5.1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Apeiron Group(4)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">770,388</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">5.4</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Directors and Executive Officers</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Adi Mor (5)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">733,645</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">5.1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Sigal Fattal (6)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">53,114</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Matthew Frankel (7)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">39,062</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Neil Cohen (8)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">170,279</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">1.2</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Nissim Darvish (9)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">34,267</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Alan Moses (10)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">18,373</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Claude Nicaise (11)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">18,373</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Jill Quigley (12)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">7,577</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">All current executive officers and directors as
        a group (8 persons)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">1,074,690</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">7.39</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">%<br/>
        </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">* Less than one percent (1%)</div> </div>

<table cellspacing="0" cellpadding="0" id="z6ca516ca8f9a43e0a0460ffdee34ef1a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(1)</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to a Schedule 13D/A filed with
        the SEC by OrbiMed Israel BioFund GP Limited Partnership (&#8220;OrbiMed BioFund&#8221;) and OrbiMed Israel GP Ltd. (&#8220;OrbiMed GP&#8221;,
        and together with OrbiMed BioFund, &#8220;OrbiMed Israel&#8221;) on March 11, 2024, such amount consists of (i) 2,241,274 ADSs and (ii)
        28,817 ADSs issuable upon the exercise of warrants to purchase ADSs. OrbiMed GP, a company that acts as general partner of certain limited
        partnerships, is the general partner of OrbiMed BioFund, which is the general partner of OrbiMed Israel Partners Limited Partnership,
        which is the entity that holds the foregoing securities. The address of OrbiMed Israel is 5 Hahoshlim St., Herzliya Pituach, Israel. Telephone:
        +972 73 2822600.</div> </div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">&#160;</td>
    <td style="width: 95.9%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(2)</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Represents 1,108,509 ADSs, representing 22,170,180
        ordinary shares, held by Rivendell Investments 2017-9 LLC, or Rivendell, as reported by Rivendell on Schedule 13G filed with the SEC on
        March 26, 2021, and 23,054 ADSs, representing 461,080 ordinary shares, issuable upon the exercise of warrants. Rivendell is the shareholder
        of record. Peter Thiel is the beneficial owner of Rivendell and has sole voting and investment power over the securities held by Rivendell.
        The address of Rivendell is 1209 Orange Street, Wilmington, Delaware 19801.</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">121</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(3)</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Consists of (i) 251,147 ADSs owned directly by
        Dr. George, (ii) 317,075 ADSs owned by Dr. Adi Mor (Dr. George&#8217;s spouse), (iii) 33,725 options to purchase 33,725 ADSs issued directly
        to Dr. George, issuable upon the exercise of options, and (iv) 131,698 options to purchase 131,698 ADSs, issued to Dr. Mor, (Dr. George&#8217;s
        spouse), as reported by Dr. Adi Mor on Schedule 13D/A filed with the SEC on November 17, 2022.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(4)</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The Apeiron Group consists of (i) Apeiron SICAV
        Ltd. - Presight Capital Fund One, of which owns 438,993 ADSs, (ii) Apeiron Presight Capital Fund II, LP, of which owns 288,170 ADSs and
        28,817 ADSs issuable upon the exercise of warrants and (iii) Apeiron Investment Group Ltd., of which owns 14,408 ADSs issuable upon the
        exercise of warrants. Each of Fabian Hansen and Christian Angermayer may be deemed to share voting and investment power with respect to
        the ADSs held by the Apeiron Group.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(5)</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Consists of (i) 317,075 ADSs owned directly by
        Dr. Mor, (ii) 251,147 ADSs owned by Dr. George, (Dr. Mor&#8217;s spouse), (iii) 131,698 ADSs issued to Dr. Mor, issuable upon the exercise
        of options within 60 days of the date hereof, and (iv) 33,725 options to purchase 33,725 ADSs issued to Dr. George, (Dr. Mor&#8217;s spouse)
        issuable upon the exercise thereof within 60 days of the date hereof, as reported by Dr. Adi Mor on Schedule 13D/A filed with the SEC
        on November 17, 2022.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(6)</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Includes 15,002 ADSs, and 38,112ADSs issuable
        upon the exercise of options within 60 days of the date hereof.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(7)</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Represents 39,062 ADSs issuable upon the exercise
        of options within 60 days of the date hereof.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(8)</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Includes 151,218 ADSs, and 19,061 ADSs issuable
        upon the exercise of options within 60 days of the date hereof.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(9)</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Includes 1,200 ADSs, and 33,067 ADSs issuable upon the exercise of
        options within 60 days of the date hereof.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(10)</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Represents 18,373 ADSs issuable upon the exercise
        of options within 60 days of the date hereof.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(11)</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Represents 18,373 ADSs issuable upon the exercise
        of options within 60 days of the date hereof.</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 4.1%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">(12)</div> </td>
    <td style="width: 95.9%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Represents 7,577 ADSs issuable upon the exercise
        of options within 60 days of the date hereof.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Significant Changes in Ownership</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">To our knowledge, other than
as disclosed in the table above, our other filings with the SEC and this Annual Report, there has been no significant change in the percentage
ownership held by any major shareholder during the past three years.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Voting Rights</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Neither our major shareholders
nor our directors and executive officers will have different or special voting rights with respect to their ordinary shares.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Registered Holders</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As of the date of this Annual Report, there
are seven shareholders of record of our ordinary shares, of whom five are in the United States. The number of record holders is not representative
of the number of beneficial holders of our ordinary shares, as most of the shares we have issued, including those represented by ADSs
are currently recorded in the name of our ADS registrar, The Bank of New York Mellon.&#160;</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Change in Control Arrangements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We are not aware of any arrangement
that may at a subsequent date, result in a change of control of the Company.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">122</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="zcf5683a2e52847fdadb2dc67c785462a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Related Party Transactions</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Other Transactions</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Agreements with Directors and
Officers</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Employment
and Consulting Agreements.</span> We have entered into written employment agreements with each of our executive officers. See Item 6.
&#8220;Management-Employment and Consulting Agreements with Executive Officers.&#8221;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Awards.</span>
Since our inception, we have granted options to purchase our ordinary shares to our executive officers and certain of our directors. Such
option agreements may contain acceleration provisions upon certain merger, acquisition or change of control transactions and other circumstances.
We describe our option plans under &#8220;Equity Incentive Plans.&#8221;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Exculpation,
Indemnification and Insurance.</span> Our Articles of Association permit us to exculpate, indemnify and insure certain of our office holders
to the fullest extent permitted by the Companies Law. We have entered into agreements with certain office holders, exculpating them from
a breach of their duty of care to us to the fullest extent permitted by law and undertaking to indemnify them to the fullest extent permitted
by law, subject to certain exceptions, including with respect to liabilities resulting from the IPO to the extent that such liabilities
are not covered by insurance. See Item 6. &#8220;Directors, Senior Management and Employees-Exculpation, Insurance and Indemnification
of Directors and Officers.&#8221;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif"><span style="font-style: italic">The
Repurchase Agreement.</span> As previously reported in&#160;our Registration Statement on Form S-4 (File No. 333-252070), filed with SEC
on January 13, 2021 and declared effective by the SEC on February 10, 2021, Chemomab Ltd. filed an application with the Israel Tax Authority
for a tax ruling (the &#8220;Tax Ruling&#8221;) in connection with the Merger, pursuant to which certain of Chemomab Ltd.&#8217;s shareholders
were entitled to defer an immediate Israeli tax liability resulting from the exchange of shares that otherwise would have been deemed
a sale. The deferral of the aforementioned tax liability is set to lapse on March 16, 2023, which is the two-year anniversary of the closing
date of the Merger. Dr. Adi Mor, co-founder of Chemomab Ltd. and both our Chief Scientific Officer and a Class III director, and Professor
Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), will be required to pay a substantial
tax liability to the Israeli Tax Authority upon the expiration date of the deferral period. In order to pay this tax liability, the Co-Founders
had to sell part of their holdings in the Company.&#160;In light of the foregoing, we elected to enter into a share purchase agreement
(the &#8220;Repurchase Arrangement&#8221;) with the Co-Founders whereby we agreed, subject to the requisite court approval required under
Section 303(a) of the Companies Law, which we received on November 14, 2022, to repurchase up to 582,023 of our ADSs owned by the Co-Founders,
for consideration not to exceed an aggregate amount of $2,500,000, depending on the market price of the ADSs at the time of any repurchase.
Accordingly, on November 16, 2022, we repurchased the entire amount of 582,023 ADSs from the Co-Founders at a price of $2.0848 and for
total consideration of approximately $1,218,000.</div> </div> </div> </div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Related Party Transaction Policy</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our board of directors has
adopted a written related party transaction policy that sets forth the policies and procedures for the review and approval or ratification
of related person transactions. This policy covers interested party transactions under the Companies Law, interested party transactions
as defined in Part I, Item 7.B of Form 20-F and transactions between the Company and an interested party, which are material to the Company
or the interested party, and any such transactions between the Company and an interested party that are unusual in their nature or conditions,
involving goods, services, or tangible or intangible assets.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">123</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z90cd52c01bce45c793917f23a06e4450" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Interests of Experts and Counsel</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold"><span id="Item8"><!--Anchor--></span>Item
8. Financial Information</span>&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9c9141e69b1244c8855c78792872b594" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Consolidated Statements and
        Other Financial Information</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Consolidated
Financial Statements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">See Item 18. &#8220;Financial
Statements.&#8221;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Legal and
Arbitration Proceedings</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">From time to time, we may
be involved in various claims and legal proceedings arising from the normal course of our business activities and operations. Other than
as noted below, we are not presently a party to any litigation the outcome of which, we believe, if determined adversely to us, would
individually or taken together have a material adverse effect on our business, operating results, cash flows or financial condition. Defending
such proceedings is costly and can impose a significant burden on management and employees. The outcomes of any such claims or proceedings,
regardless of the merits, is inherently uncertain and can have an adverse impact on us because of defense and settlement costs, diversion
of management resources and other factors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Dividend
Policy</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We do not anticipate paying
any dividends in the foreseeable future. We currently intend to retain future earnings, if any, to finance operations and expand our business.
Our board of directors has sole discretion whether to pay dividends. If our board of directors decides to pay dividends, the form, frequency
and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual
restrictions, restrictions under our Credit Facility and other factors that our directors may deem relevant. The Companies Law imposes
restrictions on our ability to declare and pay dividends.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Payment of dividends may be
subject to Israeli withholding taxes. See Item 10.E. &#8220;Taxation-Israeli Tax Considerations&#8221; for additional information.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z18b0e35e793a4ac4b9bbc730323cc0de" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Significant Changes</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">None.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">124</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item9"><!--Anchor--></span>Item
9. The Offer and Listing</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zca8c15132c5d40ba84af2b0b31c5695f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Offer and Listing Details</div>
        </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our ADSs are listed on Nasdaq
under the symbol &#8220;CMMB&#8221;.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9708c38f4fa043bd82e69b64ee6205ed" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Plan of Distribution</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5a279d37db8c47cc8f3144cc610c18ce" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Markets</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">Our ADSs are listed on Nasdaq
under the symbol &#8220;CMMB&#8221;.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8882eafd474845ebb23278952095e433" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">D.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Selling Shareholders</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zecbd9b96772841be87d8e2f782b660ff" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">E.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Dilution</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z343a126ee7a84b9eaebe1dcf6fe2e9b4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">F.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Expenses of the Issue</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item10"><!--Anchor--></span>Item
10. Additional Information</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbfb6c1d2353b45e18413fe7d539078e7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">A.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Share Capital</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z95f06b60a0ce491ebbf43e4849cd3b2e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">B.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Memorandum and Articles of
        Association</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">A copy of our Articles of
Association is attached as Exhibit 1.1 to this Annual Report. Other than as set forth below, the information called for by this Item is
set forth in Exhibit 2.1 to this Annual Report and is incorporated by reference into this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8fdbe5db62f246b3badd94d66dd34c56" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">C.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Material Contracts</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Except as disclosed below
or otherwise disclosed in this Annual Report (including the Exhibits), we are not currently, nor have we been for the two years immediately
preceding the date of this Annual Report, party to any material contract, other than contracts entered into in the ordinary course of
business.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z02e73a1a88ff4faaa7094f050b32621c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">Form of Deposit Agreement between Chemomab Therapeutics
        Ltd. (f/k/a Anchiano Therapeutics Ltd.), the Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued
        by the Company, dated February 14, 2019 (incorporated by reference to Exhibit 4.1 to the Registrants registration statement on Form S-1
        filed with the SEC on January 13, 2023). <span style="font-family: Times New Roman,serif">&#160;</span></div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">125</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Form of Indemnification Agreement (incorporated
        by reference to Exhibit 10.7 of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities
        and Exchange Commission on February 10, 2021). See Item 6, "Directors, Senior Management and Employees" for more information about this
        document.</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;Compensation Policy for Officers and Directors
        (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021,
        filed with the SEC on March 30, 2022). See Item 6, "Directors, Senior Management and Employees" for more information about this document.</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">2011 Incentive Plan for Employees, Officers and
        Consultants (previously filed as Exhibit 10.6 of our Registration Statement on Form F-1 (File No. 333-229155) as filed with the SEC on
        January 7, 2019 and incorporated by reference herein). See Item 6, "Directors, Senior Management and Employees" for more information about
        this document.</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">2017 Equity-Based Incentive Plan (previously filed
        as Exhibit 10.8 of our Registration Statement on Form F-1 (File No. 333-229155) as filed with the SEC on January 7, 2019 and incorporated
        by reference herein). See Item 6, "Directors, Senior Management and Employees" for more information about this document.</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Chemomab Ltd. 2015 Share Incentive Plan (incorporated
        by reference to Exhibit 10.4 to the Registrant&#8217;s registration statement on Form S-4 (SEC file number 333- 252070), filed with the
        SEC on January 13, 2021) See Item 6, "Directors, Senior Management and Employees" for more information about this document.</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">Tel-Aviv Souraski Medical Center (TASMC) License
        Agreement between Chemomab Ltd. and the Medical Research, Infrastructure, Health Services Fund of the Tel Aviv Souraski Medical Center.,
        dated December 1, 2011, as amended on May 9, 2013 (incorporated by reference to Exhibit 10.8 of the Company&#8217;s Amendment No. 1 to
        its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021).</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"> <br/> </div> </td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">CMC Collaboration Agreement between Chemomab
        Ltd. and CMC ICOS Biologics, Inc., dated June 7, 2015 (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Amendment No.
        1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021).</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4fa4e30e221848caab2ae5bf7abdac75" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">D.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Exchange Controls</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">There are currently no Israeli
currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the ordinary shares or interest
or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, have been, or will be, in
a state of war with Israel.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8d08e5c9364947599143fe43cf3e6a04" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">E.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Taxation</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">126</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Israeli Tax Considerations</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">General corporate tax structure
in Israel</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Israeli companies are generally
subject to corporate tax. The standard corporate tax rate in 2023 was 23%. However, the effective tax rate payable by a company that derives
income from a &#8220;Preferred Enterprise&#8221;, a &#8220;Special Preferred Enterprise&#8221;, a &#8220;Preferred Technological Enterprise&#8221;,
or a "Special Preferred Technology Enterprise" (as discussed below) may be considerably less. Capital gains derived by an Israeli company
are generally subject to the prevailing corporate tax rate.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Law for the Encouragement
of Capital Investments, 5719-1959</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The Law for the Encouragement
of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in
production facilities (or other eligible assets).</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The Investment Law was significantly amended
effective as of April 1, 2005 (the &#8220;2005 Amendment&#8221;), as of January 1, 2011 (the &#8220;2011 Amendment&#8221;) and as of January
1, 2017 (the &#8220;2017 Amendment&#8221;). Pursuant to the 2005 Amendment, tax benefits granted in accordance with the provisions of
the Investment Law prior to its revision by the 2005 Amendment remain in force but any benefits granted subsequently are subject to the
provisions of the amended Investment Law. Similarly, the 2011 Amendment introduced new benefits to replace those granted in accordance
with the provisions of the Investment Law in effect prior to the 2011 Amendment. However, companies entitled to benefits under the Investment
Law as in effect prior to January 1, 2011, were entitled to choose to continue to enjoy such benefits, provided that certain conditions
are met, or elect instead, irrevocably, to forego such benefits and have the benefits of the 2011 Amendment apply. The 2017 Amendment
introduced new benefits for Preferred Technological Enterprises, alongside the existing tax benefits.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Tax benefits under the 2011
Amendment</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The 2011 Amendment introduced
new benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221; (as such terms are
defined in the Investment Law) as of January 1, 2011. The definition of a Preferred Company includes a company incorporated in Israel
that is not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled and
managed from Israel.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Pursuant to the 2011 Amendment,
a Preferred Company was entitled to a reduced corporate tax rate of 15% with respect to its income derived from its Preferred Enterprise
in 2011 and 2012, unless the Preferred Enterprise is located in a certain development zone, in which case the rate was 10%. Under the
2011 Amendment, together with amendments to the Investment Law from 2014 and 2017, such corporate tax rate was reduced from 15% and 10%,
respectively, to 12.5% and 7%, respectively, in 2013, 16% and 9% respectively, in 2014, 2015 and 2016, and 16% and 7.5%, respectively,
in 2017 and thereafter. Income derived by a Preferred Company from a &#8220;Special Preferred Enterprise&#8221; (as such term is defined
in the Investment Law) would be entitled, during a benefits period of 10 years, to further reduced tax rates of 8%, or 5% if the Special
Preferred Enterprise is located in a certain development zone. Since January 1, 2017, the definition for &#8220;Special Preferred Enterprise&#8221;
includes less stringent conditions.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Dividends distributed from
preferred income which is attributed to a &#8220;Preferred Enterprise&#8221; or to a "Special Preferred Enterprise" should generally be
subject to withholding tax at source at the following rates: (i) Israeli resident corporations-0%, (although, if such dividends are subsequently
distributed to individuals or a non-Israeli company the below rates detailed in sub sections (ii) and (iii) shall apply), (ii) Israeli
resident individuals-20% and (iii) non-Israeli residents (individuals and corporations)- subject to the receipt in advance of a valid
certificate from the Israel Tax Authority (&#8220;ITA&#8221;) allowing for a reduced tax rate, 20% or such lower rate as may be provided
under the provisions of any applicable double tax treaty.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">127</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The 2011 Amendment also provided
transitional provisions to address companies already enjoying existing tax benefits under the Investment Law. These transitional provisions
provide, among other things, that unless an irrevocable request is made to apply the provisions of the Investment Law as amended in 2011
with respect to income to be derived as of January 1, 2011, a &#8220;Benefited Enterprise&#8221; (as such term is defined under the Investment
Law) can elect to continue to benefit from the benefits provided to it before the 2011 Amendment came into effect, provided that certain
conditions are met.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We currently do not intend
to implement the 2011 Amendment.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Tax benefits under the 2017
Amendment</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The 2017 Amendment was enacted
as part of the Economic Efficiency Law that was published on December 29, 2016, and is effective as of January 1, 2017. The 2017 Amendment
provided new tax benefits for two types of &#8220;Preferred Technological Enterprises,&#8221; as described below, and is in addition to
the other existing tax beneficial programs under the Investment Law.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The 2017 Amendment provides
that a technology company satisfying certain conditions should qualify as a Preferred Technological Enterprise (&#8220;PTE&#8221;) and
thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technological Income,&#8221; as defined
in the Investment Law. The tax rate is further reduced to 7.5% for a PTE located in development zone &#8220;A&#8221;. In addition, a PTE
will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of certain &#8220;Benefited Intangible Assets&#8221;
(as defined in the Investment Law) to a related foreign company if the Benefited Intangible Assets were acquired from a foreign company
on or after January 1, 2017 for at least NIS 200 million, and the sale received prior approval from the National Authority for Technological
Innovation (previously known as the Israeli Office of the Chief Scientist), to which we refer as IIA.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The 2017 Amendment further
provides that a technology company satisfying certain conditions (group turnover of at least NIS 10 billion) should qualify as a &#8220;Special
Preferred Technological Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate of 6% on &#8220;Preferred Technological
Income&#8221; regardless of the company&#8217;s geographic location within Israel. In addition, a Special Preferred Technological Enterprise
should enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain &#8220;Benefited Intangible Assets&#8221;
to a related foreign company if the Benefited Intangible Assets were either developed by the Special Preferred Technological Enterprise
or acquired from a foreign company on or after January 1, 2017, and the sale received prior approval from IIA. A Special Preferred Technological
Enterprise that acquires Benefited Intangible Assets from a foreign company for more than NIS 500 million should be eligible for these
benefits for at least ten years, subject to certain approvals as specified in the Investment Law.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Dividends distributed to Israeli
shareholders by a PTE or a Special Preferred Technology Enterprise, paid out of Preferred Technological Income, should generally subject
to withholding tax at source at the rate of 20% (in the case of non-Israeli shareholders subject to the receipt in advance of a valid
certificate from the ITA allowing for a reduced tax rate, 20%, or such a lower rate as may be provided in an applicable tax treaty). However,
if such dividends are paid to an Israeli company, no tax is generally required to be withheld (although, if such dividends are subsequently
distributed to individuals or a non-Israeli company, the aforesaid should apply). If such dividends are distributed to a foreign company
that holds solely or together with other foreign companies 90% or more in the Israeli company and other conditions are met, the withholding
tax rate should be 4% (or such lower rate as may be provided in an applicable tax treaty, in either case, subject to the receipt in advance
of a valid certificate from the ITA allowing for such reduced tax rate).</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">128</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Currently we have not exhausted
the benefits we believe we may qualify for as a PTE and continue to examine the degree to which we may qualify as a PTE, the amount of
Preferred Technological Income that we may have and other benefits that we may receive from the 2017 Amendment in the future.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Tax benefits and grants for
research and development</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Israeli tax law allows, under
certain conditions, a tax deduction for expenditures, including capital expenditures, in scientific research in the fields of industry,
agriculture, transportation or energy, for the year in which they are incurred. Expenditures are deemed related to scientific research
and development projects, if:</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zdb4aba1dd9304f3e97bfeef52b86f0e1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The expenditures are approved by the relevant
        Israeli government ministry, determined by the field of research;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The research and development must be for the promotion
        of the company; and</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">The research and development is carried out by
        or on behalf of the company seeking such tax deduction.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The amount of such deductible expenses is reduced
by the sum of any funds received through government grants for the finance of such scientific research and development projects. No deduction
under these research and development deduction rules is allowed if such deduction is related to an expense invested in an asset depreciable
under the general depreciation rules of the Ordinance. Expenditures that are unqualified under the conditions above are deductible in
equal amounts over three years.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">From time to time we may apply
to the Israel Innovation Authority for approval to allow a tax deduction for all or most of research and development expenses during the
year incurred. There can be no assurance that such application will be accepted.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Taxation
of our shareholders</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Capital
gains taxes applicable to non-Israeli resident shareholders</span>. Capital gain tax is imposed on the disposition of capital assets by
an Israeli resident for tax purposes, and on the disposition of such assets by a non-Israeli resident for tax purposes if those assets
are (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly or indirectly,
rights to assets the majority of which are located in Israel, unless a specific exemption is available or unless a tax treaty between
Israel and the shareholder&#8217;s country of residence provides otherwise. The Ordinance distinguishes between &#8220;Real Capital Gain&#8221;
and the &#8220;Inflationary Surplus.&#8221; Real Capital Gain is the excess of the total capital gain over Inflationary Surplus.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Inflationary Surplus is a portion of the
total capital gain which is equivalent to the increase in the relevant asset&#8217;s cost base that is attributable to the increase in
the Israeli consumer price index or, in certain circumstances, a foreign currency exchange rate, between the date of purchase and the
date of disposition. Inflationary Surplus attributed to the period after December 31, 1993, is not currently subject to tax in Israel.</div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Real Capital Gain accrued
by individuals from the sale of our shares should generally be taxed at the rate of 25%. However, if the individual shareholder is a &#8220;substantial
shareholder&#8221; (as defined below) at the time of sale or at any time during the preceding 12-month period, such capital gain should
be taxed at the rate of 30%. Furthermore, where an individual claimed real interest expenses and linkage differentials on securities,
the capital gain on the sale of the securities should be taxed at a rate of 30%. Real Capital Gain derived by corporations should generally
be subject to the corporate tax rate (23% in 2023).</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">129</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Individual and corporate shareholders
dealing in securities in Israel are taxed at the tax rates applicable to business income (a corporate tax rate for a corporation and a
marginal tax rate of up to 47% for an individual in 2023, excluding surtax as discussed below) unless contrary provisions in a relevant
tax treaty applies.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">A non-Israeli resident who
derives capital gains from the sale of shares in an Israeli resident company that were purchased upon or after the company was listed
for trading on a stock exchange outside of Israel, should be exempt from Israeli capital gains tax so long as the capital gain derived
from the sale of shares was not attributed to a permanent establishment that the non-Israeli resident maintains in Israel. However, non-Israeli
entities (including corporations) should not be entitled to the foregoing exemption if Israeli residents: (i) have a controlling interest
of more than 25% in such non-Israeli entity or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits
of such non-Israeli corporation, whether directly or indirectly. In addition, such exemption is not applicable to a person whose gains
from selling or otherwise disposing of the shares are deemed to be business income.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Additionally, a sale of securities
by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty, subject to the
eligibility of such person to the treaty benefits. For example, under Convention Between the Government of the United States of America
and the Government of the State of Israel with respect to Taxes on Income, as amended (the &#8220;U.S. Israel Tax Treaty&#8221;), the
sale, exchange or other disposition of shares by a shareholder who is a United States resident (for purposes of the U.S. Israel Tax Treaty)
holding the shares as a capital asset and is entitled to claim the benefits afforded to such a resident by the U.S. Israel Tax Treaty
(a &#8220;Treaty U.S. Resident&#8221;) is generally exempt from Israeli capital gains tax unless: (i) the capital gain arising from such
sale, exchange or disposition is attributed to real estate located in Israel; (ii) the capital gain arising from such sale, exchange or
disposition is attributed to royalties; (iii) the capital gain arising from the such sale, exchange or disposition is attributed to a
permanent establishment in Israel, under certain terms; (iv) such Treaty U.S. Resident holds, directly or indirectly, shares representing
10% or more of the voting capital during any part of the 12 month period preceding the disposition, subject to certain conditions; or
(v) such Treaty U.S. Resident, being an individual, was present in Israel for 183 days or more during the relevant taxable year. In such
case, the sale, exchange or disposition of our shares would be subject to Israeli tax, to the extent applicable; however, under the U.S.
Israel Tax Treaty, a Treaty U.S. resident would be permitted to claim a credit for such taxes against the U.S. federal income tax imposed
with respect to such sale, exchange or disposition, subject to the limitations under U.S. law applicable to foreign tax credits. The U.S.
Israel Tax Treaty does not relate to tax credits against U.S. state or local taxes.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Shareholders may be required
to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale, by presenting
a valid withholding exemption certificate issued by the ITA prior to the applicable payment. In addition, in transactions involving a
sale of all of the shares of an Israeli resident company, in the form of a merger or otherwise, the ITA may require from shareholders
who are not liable for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the ITA
to confirm their status as a non-Israeli resident for tax purposes, and, in the absence of such declarations or exemptions, may require
the purchaser of the shares to withhold taxes.</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">130</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Taxation
of non-Israeli shareholders on receipt of dividends</span>. Non-Israeli residents (either individuals or corporations) are generally subject
to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, which tax will be withheld at source,
unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt in advance
of a valid certificate from the ITA allowing for a reduced tax rate). With respect to a person who is a &#8220;substantial shareholder&#8221;
at the time of receiving the dividend or on any time during the preceding twelve months, the applicable tax rate is 30%. A &#8220;substantial
shareholder&#8221; is generally a person who alone or together with such person&#8217;s relative or another person who collaborates with
such person on a permanent basis, holds, directly or indirectly, 10% or more of any of the &#8220;means of control&#8221; of the corporation.
&#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an executive officer, receive
assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. Such
dividends are generally subject to Israeli withholding tax at a rate of 25% so long as the shares are registered with a nominee company
(whether the recipient is a substantial shareholder or not), or 20% if the dividend is distributed from income attributed to a Preferred
Enterprise or PTE, subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate, 20% or such
lower rate as may be provided in an applicable tax treaty. For example, under the U.S. Israel Tax Treaty, and subject to the eligibility
to the benefits under this treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary
shares who is a Treaty U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by a
Preferred Enterprise, that are paid to a United States corporation holding 10% or more of the outstanding voting capital throughout the
tax year in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25% of the
gross income for such preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed
from income attributed to a Preferred Enterprise are not entitled to such reduction under the tax treaty but are subject to a withholding
tax rate of 15% for a shareholder that is a U.S. corporation, provided that the conditions related to 10% or more holding and to our gross
income for the previous year (as set forth in the previous sentence) are met. If the dividend is attributable partly to income derived
from a Preferred Enterprise, and partly to other sources of income, the withholding rate will be a blended rate reflecting the relative
portions of the two types of income. We cannot assure you that we will designate the profits that we may distribute in a way that will
reduce shareholders&#8217; tax liability. The aforementioned rates under the U.S. Israel Tax Treaty would not apply if the dividend income
is derived through a permanent establishment of the Treaty U.S. Resident in Israel. U.S. residents who are subject to Israeli withholding
tax on a dividend may be entitled to a credit or deduction for United States federal income tax purposes in the amount of the taxes withheld,
subject to detailed rules contained in U.S. tax legislation.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">A non-Israeli resident who
receives dividends from which full tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect
to such income, provided that (i) such income was not generated from business conducted in Israel by the taxpayer, (ii) the taxpayer has
no other taxable sources of income in Israel with respect to which a tax return is required to be filed, and (iii) the taxpayer is not
obligated to pay surtax (as further explained below).</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Surtax.</span>
Subject to the provisions of an applicable tax treaty, individuals who are subject to tax in Israel (whether any such individual is an
Israeli resident or non-Israeli resident) are also subject to an additional tax at a rate of 3% on annual taxable income (including, but
not limited to, dividends, interest and capital gain) exceeding NIS 698,280 for 2023, which amount is linked to the annual change in the
Israeli consumer price index.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Estate
and Gift Tax.</span> Israeli law presently does not impose estate or gift taxes.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Material U.S. Federal Income
Tax Considerations for U.S. Holders</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The following is a description
of certain material United States federal income tax considerations of the ownership and disposition of our ordinary shares. This description
addresses only the United States federal income tax consequences to U.S. Holders (as defined below) that hold our ordinary shares as capital
assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and that have the
U.S. dollar as their functional currency. This discussion is based upon the Code, applicable U.S. Treasury regulations, administrative
pronouncements and judicial decisions, in each case as in effect on the date hereof, all of which are subject to change (possibly with
retroactive effect). No ruling will be requested from the Internal Revenue Service (the &#8220;IRS&#8221;) regarding the tax consequences
of the ownership or disposition of the ordinary shares, and there can be no assurance that the IRS will agree with the discussion set
out below. This summary does not address any U.S. tax consequences other than U.S. federal income tax consequences (e.g., the estate and
gift tax or the Medicare tax on net investment income) and does not address any state, local or non-U.S. tax consequences.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">131</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">This description does not
address tax considerations applicable to holders that may be subject to special tax rules, including, without limitation:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z797ca6d64c3e413095f5a0da360e438a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">banks, financial institutions or insurance companies;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">real estate investment trusts or regulated investment
        companies;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">dealers or brokers;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">traders that elect to mark to market;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">tax-exempt entities or organizations;</div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8220;individual retirement accounts&#8221; and
        other tax-deferred accounts;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">certain former citizens or long-term residents
        of the United States;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">persons that are resident or ordinarily resident
        in or have a permanent establishment in a jurisdiction outside the United States;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">persons that acquired our ordinary shares pursuant
        to the exercise of any employee share option or otherwise as compensation for the performance of services;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">persons holding our ordinary shares as part of
        a &#8220;hedging,&#8221; &#8220;integrated&#8221; or &#8220;conversion&#8221; transaction or as a position in a &#8220;straddle&#8221;
        for United States federal income tax purposes;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">persons subject to special tax accounting as a
        result of any item of gross income with respect to the ordinary shares being taken into account in an applicable financial statement;</div>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">partnerships or other pass-through entities and
        persons holding the ordinary shares through partnerships or other pass-through entities; or</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">holders that own directly, indirectly or through
        attribution 10% or more of the total voting power or value of all of our outstanding shares.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">132</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">For purposes of this description,
a &#8220;U.S. Holder&#8221; is a beneficial owner of our ordinary shares that, for United States federal income tax purposes, is:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfc1e3b68fb1b4253a58cee8f9d91018c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">an individual who is a citizen or resident of
        the United States;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a corporation (or other entity treated as a corporation
        for United States federal income tax purposes) created or organized in or under the laws of the United States or any state thereof, including
        the District of Columbia;</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">an estate the income of which is subject to United
        States federal income taxation regardless of its source; or</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 3.28%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 96.72%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 3.28%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="width: 96.72%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">a trust if such trust has validly elected to be
        treated as a United States person for United States federal income tax purposes or if (1) a court within the United States is able to
        exercise primary supervision over its administration and (2) one or more United States persons have the authority to control all of the
        substantial decisions of such trust.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If an entity or arrangement
treated as a partnership for United States federal income tax purposes holds our ordinary shares, the tax treatment of a partner in such
partnership will generally depend on the status of the partner and the activities of the partnership. Such a partner or partnership should
consult its tax advisor as to the particular United States federal income tax consequences of owning and disposing of our ordinary shares
in its particular circumstance.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">You should
consult your tax advisor with respect to the United States federal, state, local and non-U.S. consequences of owning and disposing of
our ordinary shares.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Distributions</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Subject to the discussion
under &#8220;-Passive Foreign Investment Company Considerations&#8221; below, the gross amount of any distribution made to you with respect
to our ordinary shares, before reduction for any Israeli taxes withheld therefrom, generally will be includible in your income as dividend
income on the date on which the dividends are actually or constructively received, to the extent such distribution is paid out of our
current or accumulated earnings and profits as determined under United States federal income tax principles. To the extent that the amount
of any distribution by us exceeds our current and accumulated earnings and profits as determined under United States federal income tax
principles, it will be treated first as a tax-free return of your adjusted tax basis in our ordinary shares and thereafter as capital
gain. However, we do not expect to maintain calculations of our earnings and profits under United States federal income tax principles
and, therefore, you should expect that the entire amount of any distribution generally will be taxable as dividend income to you. Non-corporate
U.S. Holders may qualify for the lower rates of taxation with respect to dividends on ordinary shares applicable to long-term capital
gains (i.e., gains from the sale of capital assets held for more than one year), provided<span style="font-style: italic">&#160;</span>that
we are not a PFIC (as discussed below under &#8220;-Passive Foreign Investment Company Considerations&#8221;) with respect to you in our
taxable year in which the dividend was paid or in the prior taxable year and certain other conditions are met, including certain holding
period requirements and the absence of certain risk reduction transactions. However, such dividends will not be eligible for the dividends
received deduction generally allowed to corporate U.S. Holders. You should consult your tax advisor regarding the availability of the
lower rate for dividends paid with respect to our shares.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The amount of any distribution
paid in foreign currency will be equal to the U.S. dollar value of such currency, translated at the spot rate of exchange on the date
such distribution is received, regardless of whether the payment is in fact converted into U.S. dollars at that time.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">133</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Dividends paid to you with
respect to our ordinary shares generally will be treated as foreign source income, which may be relevant in calculating your foreign tax
credit limitation. Subject to certain conditions and limitations, Israeli tax withheld on dividends may be credited against your United
States federal income tax liability or, at your election, be deducted from your U.S. federal taxable income. Dividends that we distribute
generally should constitute &#8220;passive category income&#8221; for purposes of the foreign tax credit. However, if we are a &#8220;United
States-owned foreign corporation,&#8221; solely for foreign tax credit purposes, a portion of the dividends allocable to our U.S. source
earnings and profits may be recharacterized as U.S. source. A &#8220;United States-owned foreign corporation&#8221; is any foreign corporation
in which United States persons own, directly or indirectly, 50% or more (by vote or by value) of the stock. In general, United States-owned
foreign corporations with less than 10% of earnings and profits attributable to sources within the United States are excepted from these
rules. In the event we are treated as a &#8220;United States-owned foreign corporation,&#8221; if 10% or more of our earnings and profits
are attributable to sources within the United States, a portion of the dividends paid on our ordinary shares allocable to our U.S. source
earnings and profits will be treated as U.S. source, and, as such, a U.S. Holder may not offset any foreign tax withheld as a credit against
U.S. federal income tax imposed on that portion of dividends. A foreign tax credit for foreign taxes imposed on distributions may be denied
if you do not satisfy certain minimum holding period requirements. The rules relating to the determination of the foreign tax credit are
complex, and you should consult your tax advisor regarding the availability of a U.S. foreign tax credit in your particular circumstances
and the possibility of claiming a deduction (in lieu of the U.S. foreign tax credit) for any foreign taxes paid or withheld.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Sale, Exchange
or Other Disposition of Ordinary Shares</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Subject to the discussion
under &#8220;-Passive Foreign Investment Company Considerations&#8221; below, you generally will recognize gain or loss on the sale, exchange
or other disposition of our ordinary shares equal to the difference between the amount realized on such sale, exchange or other disposition
and your adjusted tax basis in our ordinary shares, and such gain or loss will be capital gain or loss. If you are a non-corporate U.S.
Holder, capital gain from the sale, exchange or other disposition of ordinary shares is generally eligible for a preferential rate of
taxation applicable to capital gains, if your holding period for such ordinary shares exceeds one year (i.e., such gain is long-term capital
gain). The deductibility of capital losses for United States federal income tax purposes is subject to limitations under the Code. Any
such gain or loss that a U.S. Holder recognizes generally will be treated as U.S. source income or loss for foreign tax credit limitation
purposes.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If the consideration received
upon the sale or other disposition of our ordinary shares is paid in foreign currency, the amount realized will be the U.S. dollar value
of the payment received, translated at the spot rate of exchange on the date of the sale or other disposition. If the ordinary shares
are treated as traded on an established securities market and you are either a cash basis taxpayer or an accrual basis taxpayer who has
made a special election (which must be applied consistently from year to year and cannot be changed without the consent of the IRS), the
U.S. dollar value of the amount realized in foreign currency will be determined by translating the amount received at the spot rate of
exchange on the settlement date of the sale. If our ordinary shares are not treated as traded on an established securities market, or
you are an accrual basis taxpayer that does not elect to determine the amount realized using the spot rate of exchange on the settlement
date, you will recognize foreign currency gain or loss to the extent of any difference between the U.S. dollar amount realized on the
date of sale or disposition (as determined above) and the U.S. dollar value of the currency received translated at the spot rate of exchange
on the settlement date, and such gain or loss generally will constitute U.S. source ordinary income or loss.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The adjusted tax basis in
an ordinary share generally will be equal to the cost of such ordinary share. If you used foreign currency to purchase the ordinary shares,
the cost of the ordinary shares will be the U.S. dollar value of the foreign currency purchase price on the date of purchase, translated
at the spot rate of exchange on that date. If our ordinary shares are treated as traded on an established securities market and you are
either a cash basis taxpayer or an accrual basis taxpayer who has made the special election described above, the U.S. dollar value of
the cost of such ordinary shares will be determined by translating the amount paid at the spot rate of exchange on the settlement date
of the purchase.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">134</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Passive
Foreign Investment Company Considerations</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">If a non-U.S. company is classified
as a PFIC in any taxable year, a U.S. Holder of such PFIC&#8217;s shares will be subject to special rules generally intended to reduce
or eliminate any benefits from the deferral of U.S. federal income tax that such U.S. Holder could derive from investing in a non-U.S.
company that does not distribute all of its earnings on a current basis.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In general, a non-U.S. corporation
will be classified as a PFIC for any taxable year if at least (i) 75% of its gross income is classified as &#8220;passive income&#8221;
or (ii) 50% of its gross assets (determined on the basis of a quarterly average) produce or are held for the production of passive income
(the &#8220;asset test&#8221;). Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities
and securities transactions and the excess of gains over losses from the disposition of assets which produce passive income. For these
purposes, cash and other assets readily convertible into cash are considered passive assets, and the company&#8217;s goodwill and other
unbooked intangibles are generally taken into account. In making this determination, the non-U.S. corporation is treated as earning its
proportionate share of any income and owning its proportionate share of any assets of any corporation in which it directly or indirectly
holds 25% or more (by value) of the stock.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Although the conclusion cannot
be free from doubt, we do not believe that we would be treated as a PFIC for the taxable year ended December 31, 2023, but no assurances
can be made in this regard. However, our status as a PFIC requires a factual determination that depends on, among other things, our income,
assets and operations in each year. Fluctuations in the market price of our ordinary shares may cause our classification as a PFIC for
the current or future taxable years to change because the value of our assets for purposes of the asset test, including the value of our
goodwill and unbooked intangibles, may be determined by reference to the market price of our shares from time to time (which may be volatile).
Among other matters, if our market capitalization subsequently declines, it may make our classification as a PFIC more likely for the
current or future taxable years. The composition of our income and assets may also be affected by how, and how quickly, we use our liquid
assets. Therefore, there can be no assurance that we will not be treated as a PFIC for our current taxable year or any future taxable
year.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Under the PFIC rules, if we
were considered a PFIC at any time that you hold our ordinary shares, we would continue to be treated as a PFIC with respect to your investment
in all succeeding years during which you own our ordinary shares (regardless of whether we continue to meet the tests described above)
unless (i) we have ceased to be a PFIC and (ii) you have made a &#8220;deemed sale&#8221; election under the PFIC rules. If such election
is made, you will be deemed to have sold your ordinary shares at their fair market value on the last day of the last taxable year in which
we were a PFIC, and any gain from the deemed sale would be subject to the rules described in the following paragraph. After the deemed
sale election, so long as we do not become a PFIC in a subsequent taxable year, the ordinary shares with respect to which such election
was made will not be treated as shares in a PFIC. You should consult your tax advisor as to the possibility and consequences of making
a deemed sale election if we are (or were to become) and then cease to be a PFIC, and such election becomes available.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If we are considered a PFIC
at any time that you hold ordinary shares, unless you make one of the elections described below, any gain recognized by you on a sale
or other disposition of the ordinary shares, as well as the amount of any &#8220;excess distribution&#8221; (defined below) received by
you, would be allocated ratably over your holding period for the ordinary shares. The amounts allocated to the taxable year of the sale
or other disposition (or the taxable year of receipt, in the case of an excess distribution) and to any year before we became a PFIC would
be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for
individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed. For purposes of these rules,
an excess distribution is the amount by which any distribution received by you on your ordinary shares in a taxable year exceeds 125%
of the average of the annual distributions on the ordinary shares during the preceding three taxable years or your holding period, whichever
is shorter. Distributions below the 125% threshold are treated as dividends taxable in the year of receipt and are not subject to the
highest tax rates or the interest charge described above.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">135</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If we are treated as a PFIC
with respect to you for any taxable year, you will be deemed to own shares in any entities in which we directly or indirectly own equity
that are also PFICs, and you may be subject to the tax consequences described above with respect to the shares of such lower-tier PFIC
you would be deemed to own.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Mark-to-market elections</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If we are a PFIC for any taxable
year during which you hold ordinary shares, then in lieu of being subject to the tax and interest charge rules discussed above, you may
make an election to include gain on the ordinary shares as ordinary income under a mark-to-market method, provided that such ordinary
shares are &#8220;marketable.&#8221; The ordinary shares will be marketable if they are &#8220;regularly traded&#8221; on a qualified
exchange or other market, as defined in applicable U.S. Treasury regulations, such as the Nasdaq Global Select Market. For these purposes,
the ordinary shares will be considered regularly traded during any calendar year during which they are traded, other than in <span style="font-style: italic">de
minimis </span>quantities, on at least 15 days during each calendar quarter. Any trades that have as their principal purpose meeting this
requirement will be disregarded. However, because a mark-to-market election cannot be made for any lower-tier PFICs that we may own, you
will generally continue to be subject to the PFIC rules discussed above with respect to your indirect interest in any investments we hold
that are treated as an equity interest in a PFIC for United States federal income tax purposes. As a result, it is possible that any mark-to-market
election will be of limited benefit. If you make an effective mark-to-market election, in each year that we are a PFIC, you will include
in ordinary income the excess of the fair market value of your ordinary shares at the end of the year over your adjusted tax basis in
the ordinary shares. You will be entitled to deduct as an ordinary loss in each such year the excess of your adjusted tax basis in the
ordinary shares over their fair market value at the end of the year, but only to the extent of the net amount previously included in income
as a result of the mark-to-market election. If you make an effective mark-to-market election, in each year that we are a PFIC, any gain
that you recognize upon the sale or other disposition of your ordinary shares will be treated as ordinary income and any loss will be
treated as ordinary loss, but only to the extent of the net amount of previously included income as a result of the mark-to-market election.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Your adjusted tax basis in
the ordinary shares will be increased by the amount of any income inclusion and decreased by the amount of any deductions under the mark-to-market
rules discussed above. If you make an effective mark-to-market election, it will be effective for the taxable year for which the election
is made and all subsequent taxable years unless the ordinary shares are no longer regularly traded on a qualified exchange or the IRS
consents to the revocation of the election. You should consult your tax advisor about the availability of the mark-to-market election,
and whether making the election would be advisable in your particular circumstances.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Qualified electing fund elections</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In certain circumstances,
a U.S. equity holder in a PFIC may avoid the adverse tax and interest-charge regime described above by making a &#8220;qualified electing
fund&#8221; or QEF election to include in income its share of the corporation&#8217;s income on a current basis. However, you may make
a qualified electing fund election with respect to the ordinary shares only if we agree to furnish you annually with a PFIC annual information
statement as specified in the applicable U.S. Treasury regulations. There is no assurance that we will be able to timely provide the information
necessary for you to make a qualified electing fund election if we are classified as a PFIC.&#160; U.S. Holders should consult with their
U.S. tax advisors concerning the availability of a QEF election, if we are classified as a PFIC for any taxable year.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">136</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Tax reporting</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If you own ordinary shares
during any year in which we are a PFIC and you recognize gain on a disposition of such ordinary shares or receive distributions with respect
to such ordinary shares, you generally will be required to file an IRS Form 8621 with respect to us, generally with your federal income
tax return for that year. If we are a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing
requirements.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">You should
consult your tax advisor regarding whether we are a PFIC as well as the potential U.S. federal income tax consequences of holding and
disposing of our ordinary shares if we are or become classified as a PFIC, including the possibility of making a mark-to-market or QEF
election in your particular circumstances.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Backup
Withholding Tax and Information Reporting Requirements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Dividend payments on and proceeds
paid from the sale or other taxable disposition of the ordinary shares may be subject to information reporting to the IRS. In addition,
a U.S. Holder may be subject to backup withholding on cash payments received in connection with dividend payments and proceeds from the
sale or other taxable disposition of ordinary shares made within the United States or through certain U.S. related financial intermediaries.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Backup withholding will not
apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number, provides other required certification and otherwise
complies with the applicable requirements of the backup withholding rules or who is otherwise exempt from backup withholding (and, when
required, demonstrates such exemption). Backup withholding is not an additional tax. Rather, any amount withheld under the backup withholding
rules will be creditable or refundable against the U.S. Holder&#8217;s U.S. federal income tax liability, provided the required information
is timely furnished to the IRS.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Foreign
Asset Reporting</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Certain U.S. Holders are required
to report their holdings of certain foreign financial assets, including equity of foreign entities, if the aggregate value of all of these
assets exceeds certain threshold amounts by filing an IRS Form 8938 with their federal income tax return. Our ordinary shares are expected
to constitute foreign financial assets subject to these requirements unless the ordinary shares are held in an account at certain financial
institutions. U.S. Holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect
to their ownership and disposition of our ordinary shares and the significant penalties for non-compliance.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">The above
description is not intended to constitute a complete analysis of all tax consequences relating to the ownership and disposition of our
ordinary shares. You should consult your tax advisor concerning the tax consequences of your particular situation.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb32c039bf7824a65a148c94a8f0d9b03" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">F.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Dividends and Paying Agents</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">137</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z7be44cb76acb4040b59d6d1f78e67b86" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">G.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Statement by Experts</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbc8530df2fae4793a6db464b013bb1d4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">H.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Documents on Display</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We are subject to the informational
requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports
on Form 20-F and reports on Form 6-K. The SEC maintains an internet website that contains reports and other information about issuers,
like us, that file electronically with the SEC. The address of that website is www.sec.gov.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We maintain a corporate website
at <span style="font-style: italic">http://www.chemomab.com</span>. Information contained on, or that can be accessed through our website
does not constitute a part of this Annual Report on Form 20-F. We also make available on our website&#8217;s investor relations page at
<span style="font-style: italic">http://investors.chemomab.com</span>, free of charge, our Annual Report and the text of our reports on
Form 6-K and 8-K, including any amendments to these reports, as well as certain other SEC filings, as soon as reasonably practicable after
they are electronically filed with or furnished to the SEC. The information contained on our website is not incorporated by reference
in this Annual Report.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As a foreign private issuer, we are exempt
under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our officers,
directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16
of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the
SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we will file with
the SEC, within four months after the end of each subsequent fiscal year, or such applicable time as required by the SEC, an annual report
on Form 20-F containing financial statements audited by an independent registered public accounting firm. We also intend to furnish certain
other material information to the SEC under cover of Form 6-K.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We will send our transfer
agent a copy of all notices of shareholders&#8217; meetings and other reports, communications and information that are made generally
available to shareholders. The transfer agent has agreed to mail to all shareholders a notice containing the information (or a summary
of the information) contained in any notice of a meeting of our shareholders received by the transfer agent and will make available to
all shareholders such notices and all such other reports and communications received by the transfer agent.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z954a9a14d78f46dd9a2358a3bfa57eef" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">I.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Subsidiary Information</div>
        </td> </tr>
  </table>

<div><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Not applicable.</div> <br/>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">J.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-weight: bold">Annual Report to Security Holders</div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Not applicable.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item11"><!--Anchor--></span>Item
11. Quantitative and Qualitative Disclosures about Market Risk</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We are exposed to market risk
from changes in exchange rates, interest rates and inflation. All of these market risks arise in the ordinary course of business, as we
do not engage in speculative trading activities. The following analysis provides additional information regarding these risks.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Interest
rate risk</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our investments are subject
to market risk due to changes in interest rates, which may affect our interest income and fair market value of our investments. To minimize
this risk, we maintain our portfolio in a variety of high-grade securities, including U.S. treasury bonds and government agencies. The
primary objectives of our investment activities are to support liquidity, preserve principal and to maximize income without significantly
increasing risk.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">138</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">As of December 31, 2023, we
had $19.86 million of cash and cash equivalent, bank deposits and marketable securities. Interest-earning instruments carry a degree of
interest rate risk. However, our historical interest income has not fluctuated significantly. A hypothetical 10% change in interest rates
would not have had a material impact on our financial results for the years ended December 30, 2022 and 2023. We do not enter into investments
for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Foreign
Currency Exchange Risk</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our functional currency is the U.S. Dollar.
We are exposed to foreign exchange rate risk. We are located in Israel, where part of our general and administrative expenses costs is
incurred in New Israeli Shekels. During each of the years ended December 31, 2023, and 2022, we recognized foreign currency transaction
loss of $14 thousand and $607 thousand, respectively. These foreign currency transaction gains and losses were recorded in financial expenses.
We believe that a 10% change in the exchange rate between the U.S. Dollar and New Israeli Shekel would not have a material impact on our
financial position or results of operations.</div> </div>

<div style="text-align: justify; line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">As we continue to grow our
business, our results of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates,
which could adversely impact our results of operations. To date, we have not entered into any foreign currency hedging contracts to mitigate
our exposure to foreign currency exchange risk.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item12"><!--Anchor--></span>Item
12. Description of Securities Other than Equity Securities</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z12c1d15e0ba6407c9e3c8e440f35290d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">A.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Debt Securities</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z7709dbfaf81d4a91a8edb8bda88a905f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">B.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Warrants and Rights</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zad16eb73d55440bc9dc6f74f5bf11fae" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">C.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Other Securities</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z336951cbc5d34a7ba4e30f54415d9302" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">D.</div> </td>
    <td style="width: 97%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">American Depositary Shares</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The Bank of New York Mellon,
as depositary, registers and delivers our ADSs. Each ADS will represent ordinary shares (or a right to receive twenty (20) ordinary shares).
Each ADS will also represent any other securities, cash or other property which may be held by the depositary. The depositary&#8217;s
office at which our ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New&#160;York&#160;10286.</div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">You may hold ADSs either (A)&#160;directly
(i)&#160;by having an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name or (ii)&#160;by having
uncertificated ADSs registered in your name or (B)&#160;indirectly by holding a security entitlement in ADSs through your broker or other
financial institution that is a direct or indirect participant in DTC. If you hold ADSs directly, you are a registered ADS holder, also
referred to as an ADS holder. This description assumes you are an ADS holder. If you hold our ADSs indirectly, you must rely on the procedures
of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your
broker or financial institution to find out what those procedures are.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">139</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Registered holders of uncertificated
ADSs will receive statements from the depositary confirming their holdings.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">As an ADS holder, we will
not treat you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder rights. The depositary
will be the holder of the ordinary shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit
agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights
as well as the rights and obligations of the depositary. New York law governs the deposit agreement and our ADSs.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The following is a summary
of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the
form of ADR. For directions on how to obtain copies of those documents see &#8220;<span style="font-style: italic">Where You Can Find
More Information</span>.&#8221;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Dividends and Other Distributions</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">How will you receive dividends
and other distributions on the shares?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The depositary has agreed
to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on ordinary shares or other
deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number
of ordinary shares your ADSs represent.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold">Cash.</span>&#160;&#160;&#160;The
depositary will convert any cash dividend or other cash distribution we pay on the ordinary shares into U.S. dollars, if it can do so
on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is
needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders
to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of our ADS holders who have not been
paid. It will not invest the foreign currency and it will not be liable for any interest.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Before making a distribution,
any withholding taxes or other governmental charges that must be paid will be deducted. See &#8220;Taxation and Government Programs.&#8221;
It will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates
fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.</div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold">Shares.</span>&#160;&#160;&#160;The
depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution. The depositary
will only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fraction of an ADS (or ADSs representing
those ordinary shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional
ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed ordinary shares (or
ADSs representing those ordinary shares) sufficient to pay its fees and expenses in connection with that distribution.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold">Rights
to purchase additional shares.</span>&#160;&#160;&#160;If we offer holders of our securities any rights to subscribe for additional ordinary
shares or any other rights, the depositary may (i)&#160;exercise those rights on behalf of ADS holders, (ii)&#160;distribute those rights
to ADS holders or (iii)&#160;sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment
of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse.&#160;<span style="font-style: italic">In
that case, you will receive no value for them.</span>&#160;The depositary will exercise or distribute rights only if we ask it to and
provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase
the securities to which the rights relate and distribute those securities or, in the case of ordinary shares, new ADSs representing the
new ordinary shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities
laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or
certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">140</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-weight: bold">Other
Distributions.</span>&#160;&#160;&#160;The depositary will send to ADS holders anything else we distribute on deposited securities by
any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary will have a choice. It
may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold
what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to
distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that
distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection
with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS
holders, and the securities distributed may be subject to restrictions on transfer.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The depositary is not responsible
if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register
ADSs, ordinary shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit
the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make
on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Deposit, Withdrawal and Cancellation</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">How are ADSs issued?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The depositary will deliver
ADSs if you or your broker deposits ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment
of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register
the appropriate number of ADSs in the names you request and will deliver our ADSs to or upon the order of the person or persons that made
the deposit.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">How can ADS holders withdraw
the deposited securities?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">You may surrender your ADSs
for the purpose of withdrawal at the depositary&#8217;s office. Upon payment of its fees and expenses and of any taxes or charges, such
as stamp taxes or stock transfer taxes or fees, the depositary will deliver the ordinary shares and any other deposited securities underlying
our ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense,
the depositary will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender
of ADSs to the extent it would require delivery of a fraction of a deposited share or other securities. The depositary may charge you
a fee and its expenses for instructing the custodian regarding delivery of deposited securities.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">How do ADS holders interchange
between certificated ADSs and uncertificated ADSs?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">You may surrender your ADR
to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to
the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt
by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs
for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">141</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Voting Rights</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">How do you vote?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">ADS holders may instruct the
depositary how to vote the number of deposited ordinary shares their ADSs represent. If we request the depositary to solicit your voting
instructions (and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting
materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary
how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as
far as practical, subject to the laws of Israel and the provisions of our articles of association or similar documents, to vote or to
have its agents vote the ordinary shares or other deposited securities as instructed by ADS holders. If we do not request the depositary
to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you
instruct, but it is not required to do so.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,serif; font-style: italic">Except
by instructing the depositary as described above, you won&#8217;t be able to exercise voting rights unless you surrender your ADSs and
withdraw the ordinary shares. However, you may not know about the meeting enough in advance to withdraw the ordinary shares.</span>&#160;In
any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as
instructed.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We cannot assure you that
you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary
and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions.
This means that you may not be able to exercise your right to vote and there may be nothing you can do if your ordinary shares are not
voted as you requested.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In order to give you a reasonable
opportunity to instruct the Depositary as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary
to act, we agree to give the Depositary notice of any such meeting and details concerning the matters to be voted upon at least 45&#160;days
in advance of the meeting date.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Fees and Expenses</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" border="0" id="ze8d1b6cc7e124e2eba3af735dc197154" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 49%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Persons depositing or withdrawing ordinary shares
        or<span style="font-family: Times New Roman, serif"><br/> </span>ADS holders must pay</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">&#8203;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 50%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">For</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Issuance of ADSs, including issuances resulting from a distribution
        of ordinary shares or rights or other property Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement
        terminates</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$.05 (or less) per ADS</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Any cash distribution to ADS holders</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">A fee equivalent to the fee that would be payable if securities distributed
        to you had been ordinary shares and the ordinary shares had been deposited for issuance of ADSs</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Distribution of securities distributed to holders of deposited securities
        (including rights) that are distributed by the depositary to ADS holders</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">$.05 (or less) per ADS per calendar year</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Depositary services</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">142</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z20d051be2d52421eabdf8d59c0553f3c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 49%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Persons depositing or withdrawing ordinary shares
        or<span style="font-family: Times New Roman, serif"><br/> </span>ADS holders must pay</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">&#8203;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 50%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">For</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Registration or transfer fees</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Transfer and registration of ordinary shares on our share register
        to or from the name of the depositary or its agent when you deposit or withdraw ordinary shares</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Expenses of the depositary</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8203;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Cable, telex and facsimile transmissions (when expressly provided in
        the deposit agreement)</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Converting foreign currency to U.S. dollars</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Taxes and other governmental charges the depositary or the
        custodian have to pay on any ADSs or ordinary shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</div>
        </div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8203;</div> </td>
    <td style="white-space: nowrap; width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">As necessary</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="white-space: nowrap; width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">Any charges incurred by the depositary or its agents for servicing
        the deposited securities</div> </td>
    <td style="width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8203;</div> </td>
    <td style="white-space: nowrap; width: 50%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">As necessary</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The depositary collects its
fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal
or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from
the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for
depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts
of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling
a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally
refuse to provide fee-attracting services until its fees for those services are paid.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">From time to time, the depositary
may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of our ADS program,
waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing
its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency or other service providers that are
owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The depositary may convert
foreign currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as an agent,
fiduciary or broker on behalf of any other person and earns revenue, including, without limitation, fees and spreads that it will retain
for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion
made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for
its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit
agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined
will be most favorable to ADS holders, subject to its obligations under the deposit agreement. The methodology used to determine exchange
rates used in currency conversions is available upon request.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Payment of Taxes</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">You will be responsible for
any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary
may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such
taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes
owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the
number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid
the taxes.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">143</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Tender and Exchange Offers;
Redemption, Replacement or Cancellation of Deposited Securities</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The depositary will not tender
deposited securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject
to any conditions or procedures the depositary may establish.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If deposited securities are
redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call
for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of
those ADSs.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If there is any change in
the deposited securities such as a subdivision, combination or other reclassification, or any merger, consolidation, recapitalization
or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu
of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement.
However, if the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could
not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the
net proceeds upon surrender of our ADSs.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If there is a replacement
of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs
representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited
securities.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">If there are no deposited
securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become
apparently worthless, the depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders.</div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Amendment and Termination</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">How may the deposit agreement
be amended?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We may agree with the depositary
to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except
for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar
items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30&#160;days after the
depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold
your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">How may the deposit agreement
be terminated?</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The depositary will initiate
termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if:</div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z1c791ecc87da4484be7b8ed313886363" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">90&#160;days have passed since the depositary
        told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z11b0920b3cf747d8831c65b213e6d3bc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">we delist our ADSs from an exchange on which they
        were listed and do not list our ADSs on another exchange within a reasonable time;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z9e0bdd06d34840b3a2ea2ccf90f363bb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">we appear to be insolvent or enter insolvency
        proceedings;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="zfc345db1979d4e27adcde6aa3623c3ec" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">all or substantially all the value of the deposited
        securities has been distributed either in cash or in the form of securities;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z8ad1ae3140f0450db7a92c4947fcf209" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">there are no deposited securities underlying our
        ADSs or the underlying deposited securities have become apparently worthless; or</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="ze810bbb7cabd4107a9a7d354f20a4113" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">there has been a replacement of deposited securities.</div>
        </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">144</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If the deposit agreement is terminated,
the depositary will notify ADS holders at least 90&#160;days before the termination date. At any time after the termination date, the
depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other
cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro&#160;rata benefit of the
ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.</div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">After the termination date
and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that
the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders
of that kind if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing
sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities,
but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other
distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties
under the deposit agreement except as described in this paragraph.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Limitations on Obligations
and Liability</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic">Limits on our obligations
and the obligations of the depositary; Limits on liability to holders of ADSs</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The deposit agreement expressly
limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and
the depositary:</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="zc3f12f7fd2e642fabf966d18cc8dfd99" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">are only obligated to take the actions specifically
        set forth in the deposit agreement without negligence or bad faith and the depositary will not be a fiduciary or have any fiduciary duty
        to holders of ADSs;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z64367e0b7e3a4b1cb174cf28590e61f1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">are not liable if we are or it is prevented or
        delayed by law or circumstances beyond our or its control from performing our or its obligations under the deposit agreement;</div> </td>
        </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="zb4591cb0886b403b921c6574454e3dc2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">are not liable if we exercise or it exercises
        discretion permitted under the deposit agreement;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="za53b3cdc74024e39b6530843d7b9c059" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">are not liable for the inability of any holder
        of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the
        deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;</div> </td>
        </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="zbe1192fcec524a77a870c4a3176918de" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">have no obligation to become involved in a lawsuit
        or other proceeding related to our ADSs or the deposit agreement on your behalf or on behalf of any other person;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z1235b1f773f046ba866dc4aaeb12d60b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">are not liable for the acts or omissions of any
        securities depository, clearing agency or settlement system;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z91f007f74c3c49589110c8163bb316d6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">may rely upon any documents we believe or it believes
        in good faith to be genuine and to have been signed or presented by the proper person; and</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z39e1e64683644c029178d6581153e7ce" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">the depositary has no duty to make any determinations
        or provide any information as to our status, or any liability for any tax consequences that may be incurred by ADS holders as a result
        of owning or holding ADSs or liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit reduced
        rate of withholdings or refund of amounts withheld in respect of tax or any other tax benefit.</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In the deposit agreement,
we and the depositary agree to indemnify each other under certain circumstances.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">145</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Requirements for Depositary
Actions</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Before the depositary will
deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:</div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z5c290331af634f75867e69557200aa8a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">payment of stock transfer or other taxes or other
        governmental charges and transfer or registration fees charged by third parties for the transfer of any ordinary shares or other deposited
        securities;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z6a8c62263c624a80b8ac93b5cfec4538" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">satisfactory proof of the identity and genuineness
        of any signature or other information it deems necessary; and</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z1d3372ae72c74463a921f5874fd2b888" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">compliance with regulations it may establish,
        from time to time, consistent with the deposit agreement, including presentation of transfer documents.</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The depositary may refuse
to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time
if the depositary or we think it advisable to do so.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Your Right to Receive the Ordinary
Shares Underlying your ADSs</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">ADS holders have the right
to cancel their ADSs and withdraw the underlying ordinary shares at any time except:</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="zc128bf2fe9974d3dad4a78c34d484922" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">when temporary delays arise because: (i)&#160;the
        depositary has closed its transfer books or we have closed our transfer books; (ii)&#160;the transfer of ordinary shares is blocked to
        permit voting at a shareholders&#8217; meeting; or (iii)&#160;we are paying a dividend on our shares;</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="ze0d33e6c28724855968cf44bde45e7af" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">when you owe money to pay fees, taxes and similar
        charges; or</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z7e2f564d844b441ba23ba44f74c29cc6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">when it is necessary to prohibit withdrawals in
        order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited
        securities.</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">This right of withdrawal may not be limited by
any other provision of the deposit agreement.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Direct Registration System</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In the deposit agreement,
all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile,
will apply to our ADSs. DRS is a system administered by DTC that facilitates interchange between registered holding of uncertificated
ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant,
claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs
to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior
authorization from the ADS holder to register that transfer.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">In connection with and in
accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary
will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of
transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding
any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance
on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement
will not constitute negligence or bad faith on the part of the depositary.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">146</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Shareholder Communications;
Inspection of Register of Holders of ADSs</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The depositary will make available
for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally
available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications
available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those
holders about a matter unrelated to our business or our ADSs.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Jury Trial Waiver</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The deposit agreement provides
that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary
arising out of or relating to our shares, our ADSs or the deposit agreement, including any claim under the U.S. federal securities laws.
If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable
in the facts and circumstances of that case in accordance with applicable case law.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="PARTII"><!--Anchor--></span>PART
II</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item13"><!--Anchor--></span>Item
13. Defaults, Dividend Arrearages and Delinquencies</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">None.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 14<span id="Item14"><!--Anchor--></span>.
Material Modifications to the Rights of Security Holders and Use of Proceeds</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">None.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 15<span id="Item15"><!--Anchor--></span>.
Controls and Procedures</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Disclosure
Controls and Procedures</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">We have evaluated, with the
participation of our chief executive officer and chief financial officer, the effectiveness of our disclosure controls and procedures
(as that term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2023. There are inherent limitations
to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention
or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable
assurance of achieving their control objectives. Based upon our evaluation, our chief executive officer and chief financial officer concluded
that our disclosure controls and procedures were effective as of December 31, 2023 to provide reasonable assurance that information required
to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within
the time periods specified in the applicable rules and forms, and that it is accumulated and communicated to our management, including
our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Management&#8217;s
Annual Report on Internal Control over Financial Reporting</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our management is responsible
for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is
defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;promulgated under the Exchange Act as a process designed by, or under the supervision
of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP and includes those policies and procedures that:</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">

<div>

<table cellspacing="0" cellpadding="0" id="za44d9c72ae0142ebba3f746255c73c04" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: right; vertical-align: top; width: 36pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">pertain to the maintenance of records that in
        reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</div> </td> </tr>
  </table> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">147</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<table cellspacing="0" cellpadding="0" id="zbeec196c3ded4aeeb0f2278099854178" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top; width: 36pt">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">provide reasonable assurance that transactions are recorded as necessary
        to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance
        with authorizations of our management; and</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div>

<table cellspacing="0" cellpadding="0" id="ze853a52a4eb74c2da2d9cfd568fff688" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top; width: 36pt">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#8226;</div> </td>
    <td style="text-align: left; vertical-align: top; width: auto">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">provide reasonable assurance regarding prevention or timely detection
        of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</div> </td>
        </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future
periods are subject to the risks that controls may become inadequate because of changes in conditions or that the degree of compliance
with the policies or procedures may deteriorate.</div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">Our management, including our
Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting at December&#160;31,
2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO) in Internal Control&#8212;Integrated Framework (2013). Based on that assessment under those criteria, management determined that,
as of December&#160;31, 2023, our internal control over financial reporting was effective.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Attestation
Report of the Registered Public Accounting Firm</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">This Annual Report on Form
20-F does not include an attestation report of our independent registered public accounting firm due to our status as an emerging growth
company, as defined in Rule 12b-2 of the Exchange Act.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-style: italic; font-weight: bold">Changes
in Internal Control over Financial Reporting</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">There were no changes in our
internal controls over financing reporting during the last fiscal year.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="Item16"><!--Anchor--></span>Item
16. [Reserved]</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16A<span id="Item16A"><!--Anchor--></span>.
Audit Committee Financial Expert</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25">The members of the audit committee are Jill Quigley, Alan Moses and Claude Nicaise.
Claude Nicaise is the chairperson of the audit committee and is a financial expert under the rules of the SEC. Our board of directors
has concluded that the composition of the audit committee meets the requirements for independence under the rules and regulations of Nasdaq
and the SEC.<br/> &#160; <br/> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16B<span id="Item16B"><!--Anchor--></span>.
Code of Ethics</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25">We have adopted a Code of Business Conduct and Ethics that includes provisions ranging
from restrictions on gifts to conflicts of interest. All of our employees and directors are bound by this Code of Business Conduct and
Ethics. Violations of our Code of Business Conduct and Ethics may be reported to the audit committee. The Code of Business Conduct and
Ethics includes provisions applicable to all of our employees, including senior financial officers and members of our board of directors
and is posted on our website. We intend to post amendments to or waivers from any such Code of Business Conduct and Ethics.</div> </div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We granted no waivers under
our Code of Ethics and Conduct in 2023.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">148</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16C<span id="Item16C"><!--Anchor--></span>.
Principal Accountant Fees and Services</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Somekh Chaikin, a member firm of KPMG International,
located in Tel Aviv, Israel, PCAOB ID 1057, has served as our independent registered public accounting firm for the years 2023, 2022 and
2021. The following table sets forth fees billed to us by our independent registered public accounting firm during the fiscal years ended
December 31, 2023, 2022 and 2021 for (i) services rendered for the audit of our annual financial statements and the review of our quarterly
financial statements; (ii) services by our independent registered public accounting firm that are reasonably related to the performance
of the audit or review of our financial statements and that are not reported as audit fees; (iii) services rendered during the period
in connection with tax compliance, tax advice and tax planning; and (iv) all other fees for services rendered.&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160; <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">

<table cellspacing="0" cellpadding="0" class="cfttable" id="z6cd77716f0404544b1c434d77c89cc81" style="font: 10pt Times New Roman,Times,serif; text-align: left; color: rgb(0, 0, 0); width: 100%">
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="10" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold; text-align: center">Year ended December 31,</div>
        </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> 2023</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> 2022</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"> 2021</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="10" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif">(in thousands)</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Audit Fees</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">233</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">223</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">173</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Tax Fees</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">4</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">30</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">29</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Total</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">237</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">253</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">202</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><span style="font-family: Times New Roman, serif"><br/>
</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Audit Fees</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Audit fees for the years ended
December 31, 2023, 2022 and 2021 consisted of fees for professional services provided in connection with the audit of our annual consolidated
financial statements and audit services that are normally provided by an independent registered public accounting firm in connection with
statutory and regulatory filings or engagements for those years. &#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Tax Fees</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Tax fees for the years ended December 31,
2023, and 2022 refer to professional services rendered by our auditors, which include ongoing tax advisory, tax compliance and tax consulting
associated with transfer pricing.</div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">Pre-Approval Policies and Procedures</div> </div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our audit committee has the
sole authority to approve the scope of the audit and any audit-related services, as well as all audit fees and terms. The audit committee
must pre-approve any audit and non-audit services provided by our independent registered public accounting firm. The audit committee will
not approve the engagement of the independent registered public accounting firm to perform any services that the independent registered
public accounting firm would be prohibited from providing under applicable laws, rules and regulations, including those of self-regulating
organizations. The audit committee will approve permitted non-audit services by our independent registered public accounting firm only
if it determines that using a different firm to perform such services will be less efficient or cost-effective. The audit committee reviews
and pre-approves the statutory audit fees that can be provided by the independent registered public accounting firm on an annual basis.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">149</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16D<span id="Item16D"><!--Anchor--></span>.
Exemptions from the Listing Standards for Audit Committees</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16E<span id="Item16E"><!--Anchor--></span>.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">None.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16F<span id="Item16F"><!--Anchor--></span>.
Change in Registrant&#8217;s Certifying Accountant</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">None.</div>

<div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16G<span id="Item16G"><!--Anchor--></span>.
Corporate Governance</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We are a &#8220;foreign private
issuer&#8221; (as such term is defined in Rule 3b-4 under the Exchange Act) and our ordinary shares are listed on the Nasdaq Capital Market.
Under the Listing Rules of the Nasdaq Stock Market, listed companies that are foreign private issuers are permitted to follow home country
practice in lieu of the corporate governance provisions specified by the Listing Rules of the Nasdaq Stock Market with limited exceptions.
We rely on this &#8220;home country practice exemption&#8221; with respect to the quorum requirement for shareholder meetings. Whereas
under the Listing Rules of the Nasdaq Stock Market, a quorum requires the presence, in person or by proxy, of holders of at least 331/3%
of the total issued outstanding voting power of our shares at each general meeting of shareholders, pursuant to our Articles of Association,
and as permitted under the Companies Law, the quorum required for a general meeting of shareholders consists of at least two shareholders
present in person or by proxy in accordance with the Companies Law, who hold or represent at least 331/3% of the total outstanding voting
power of our shares, except if (i) any such general meeting of shareholders was initiated by and convened pursuant to a resolution adopted
by the board of directors and (ii) at the time of such general meeting, we qualify to use the forms and rules of a &#8220;foreign private
issuer,&#8221; the requisite quorum will consist of two or more shareholders present in person or by proxy who hold or represent at least
25% of the total outstanding voting power of our shares (and if the meeting is adjourned for a lack of quorum, the quorum for such adjourned
meeting will be, subject to certain exceptions, any number of shareholders).</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We otherwise comply with and
intend to continue to comply with the rules generally applicable to U.S. domestic companies listed on the Nasdaq Capital Market. We may
in the future, however, decide to use other foreign private issuer exemptions with respect to some or all of the Listing Rules of the
Nasdaq Stock Market. Following our home country governance practices may provide less protection than is accorded to investors under the
Listing Rules of the Nasdaq Stock Market applicable to domestic issuers.</div>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">150</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Board Diversity
Matrix</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The table below provides certain
information regarding the diversity of our board of directors as of the date of this Annual Report.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">

<table cellspacing="0" cellpadding="2" border="0" id="z1c712f0dc78e47d3aa03bd6b8487ec37" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td colspan="5" style="border-top: rgb(0, 0, 0) 1px solid; width: 100%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Board Diversity Matrix</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">As of the date of this
        Annual Report</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Country of Principal Executive Offices:</div>
        </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 45.7%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Israel</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Foreign Private Issuer</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 45.7%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Yes</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Disclosure Prohibited under Home Country
        Law</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 45.7%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">No</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Total Number of Directors</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 45.7%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">6</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 9.11%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Female</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 7.56%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Male</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 19.74%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Non-</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Binary/Transgender</div>
        </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 9.28%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Did Not<br/> Disclose<br/>
        Gender</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Part I: Gender Identity</div>
        </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 45.7%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Directors</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 9.11%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 7.56%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">4</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 19.74%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">0</div> </td>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 9.28%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">0</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Part II: Demographic
        Background</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 45.7%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Underrepresented Individual in Home Country
        Jurisdiction</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 45.7%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">0</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">LGBTQ+</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 1px solid; width: 45.7%; vertical-align: top; border-right: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">0</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 1px solid; width: 54.3%; vertical-align: top; border-bottom: rgb(0, 0, 0) 1px solid; border-left: rgb(0, 0, 0) 1px solid">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">Did Not Disclose Demographic Background</div>
        </td>
    <td colspan="4" style="border: rgb(0, 0, 0) 1px solid; width: 45.7%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">0</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16H<span id="Item16H"><!--Anchor--></span>.
Mine Safety Disclosure</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16I<span id="Item16I"><!--Anchor--></span>.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16J<span id="Item16J"><!--Anchor--></span>.
Insider Trading Policies</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Not applicable.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 16K<span id="Item16K"><!--Anchor--></span>.&#160;
Cybersecurity Risk Management Policies and Procedures</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Risk management and strategy</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We maintain a cyber risk management program designed to identify,
assess, manage, mitigate, and respond to material risks from cybersecurity threats&#160;to our critical computer networks, third party
hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information
that is proprietary, strategic, or competitive in nature, and our clinical trial and related data (&#8220;Information Systems and Data&#8221;).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The underlying processes and controls of our cyber risk management
program incorporate various practices and standards for cybersecurity and information technology. We conduct an annual assessment performed
by a third-party service provider of our cyber risk management program. The annual risk assessment identifies, quantifies, and categorizes
material cyber risks to our Company. In addition,&#160;we, in conjunction with the third-party cyber risk assessment vendor, develop a
risk mitigation plan designed to address such risks, and where necessary, remediate potential vulnerabilities identified through the annual
assessment process.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">In addition, we maintain various policies to help identify, address,
and mitigate risks from cybersecurity threats, including, for example in areas such as information security, access on/offboarding, and
access and account management. We monitor threat intelligence as well as other information obtained from governmental, public, or private
sources, including external consultants engaged by us. We also partner with IT and cybersecurity providers, such as cybersecurity consultants.
We leverage these third-party providers and solutions to support our cybersecurity risk management strategy and processes, which include,
for example, maintenance of an IT assets inventory, periodic vulnerability scanning, identity access management controls, endpoint protection,
endpoint detection and response, remote monitoring management on certain devices, encryption of certain data, critical data backups, infrastructure
maintenance, incident detection and response, cybersecurity strategy, and cyber risk advisory, assessment and remediation.&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">151</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">Our assessment and management of material risks
from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes. For example, (1) cybersecurity risk
is addressed as a component of the Company&#8217;s enterprise risk management program and identified in the Company&#8217;s risk register;
(2) the security department/security management works with management to prioritize our risk management processes and mitigate cybersecurity
threats that are more likely to lead to a material impact to our business; or (3) our senior management evaluates material risks from
cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates
our overall enterprise risk.</div> </div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We have implemented third-party risk management processes to manage
material risks from cybersecurity threats associated with reliance on vendors, critical service providers, and other third parties we
engage, such as software-as-a-service providers, data hosting companies, and contract research organizations. These processes include,
for example, conducting risk assessment for certain vendors, reviewing vendor security assessments and questionnaires, and conducting
annual reviews of vendor audits and reports.&#160;Depending on the nature of the services provided, the sensitivity of the Information
Systems and Data at issue, and the identity of the provider, our third-party risk management process may involve different levels of assessment
designed to help identify cybersecurity risks associated with a provider.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">For a description of the risks from cybersecurity threats that
may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 3. Section D Risk Factors in this Annual
Report on Form 20-F, including &#8220;Cyber-attacks, security breaches or other disruptions to our information technology systems, or
those of third parties upon which we rely, or our data could irreparably damage our reputation and our business, expose us to liability
and materially and adversely affect our results of operations.&#8221;</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Governance</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The audit committee of the board of directors oversees
our cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity stakeholders,
including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber
risk services brief the audit committee of the board of directors on cyber vulnerabilities identified through the risk management process,
the effectiveness of our cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis.
In addition, cybersecurity risks are reviewed by our board of directors at least annually, as part of our corporate risk oversight processes.&#160;</div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Our Chief Information Security Officer (&#8220;CISO&#8221;) is
responsible for oversight and administration of our cyber risk management program, and for informing senior management and other relevant
stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents. Our CISO is a Certified Information
Systems Security Professional and has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and
processes directly or via selection of strategic third-party partners.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">&#160;We have developed an incident response plan&#160;that
is designed to escalate certain cybersecurity incidents to members of management, including the CISO, depending on the circumstances.
Such members of management work with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity
incidents of which they are notified. In addition, the Company&#8217;s incident response plan includes reporting to the audit committee
of the board of directors for certain cybersecurity incidents.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">PART III<span id="PARTIII"><!--Anchor--></span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 17<span id="Item17"><!--Anchor--></span>.
Financial Statements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">We have elected to provide
financial statements pursuant to Item 18.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">152</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 18<span id="Item18"><!--Anchor--></span>.
Financial Statements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The audited consolidated financial
statements as required under Item 18 are attached hereto starting on page F-1 of this Annual Report. The audit report of Somekh Chaikin,
a member firm of KPMG International, an independent registered public accounting firm, is included herein preceding the audited consolidated
financial statements.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Item 19<span id="Item19"><!--Anchor--></span>.
Exhibits</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z663f3eb9f16f4458b362a5a1ba735acd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 10%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Exhibit&#160;No.</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold">Description</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">1.1</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">Amended
        and Restated Articles of Association (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s current report on Form 8-K filed
        with the SEC on March 17, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_2-1.htm">2.1</a></div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_2-1.htm">Description of Securities</a></div>
        </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">2.2</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">Form
        of Deposit Agreement between Chemomab Therapeutics Ltd. (f/k/a Anchiano Therapeutics Ltd.), the Bank of New York Mellon as Depositary,
        and owners and holders from time to time of ADSs issued by the Company, dated February 14, 2019 (incorporated by reference to Exhibit
        4.1 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#tANF">4.1</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#tANF">Form
        of Indemnification Agreement (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Amendment No. 1 to its Registration Statement
        on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">4.2+</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">Compensation
        Policy for Officers and Directors (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Annual Report on Form 10-K for the
        fiscal year ended December 31, 2021, filed with the SEC on March 30, 2022)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">4.3</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">2011
        Incentive Plan for Employees, Officers and Consultants (previously filed as Exhibit&#160;10.6 of our Registration Statement on Form&#160;F-1
        (File No.&#160;333-229155) as filed with the SEC on January&#160;7, 2019 and incorporated by reference herein).</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">+4.4+</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">2017
        Equity-Based Incentive Plan (previously filed as Exhibit&#160;10.8 of our Registration Statement on Form&#160;F-1 (File No.&#160;333-229155)
        as filed with the SEC on January&#160;7, 2019 and incorporated by reference herein).</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">4.5+</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">Chemomab
        Ltd. 2015 Share Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s registration statement on Form S-4
        (SEC file number 333- 252070), filed with the SEC on January 13, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">4.6+</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">Tel-Aviv
        Souraski Medical Center (TASMC) License Agreement between Chemomab Ltd. and the Medical Research, Infrastructure, Health Services Fund
        of the Tel Aviv Souraski Medical Center., dated December 1, 2011, as amended on May 9, 2013 (incorporated by reference to Exhibit 10.8
        of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on
        February 10, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">4.7+</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">CMC
        Collaboration Agreement between Chemomab Ltd. and CMC ICOS Biologics, Inc., dated June 7, 2015 (incorporated by reference to Exhibit 10.9
        of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on
        February 10, 2021)</a></div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">153</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm">4.8</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm"><span style="font-family: Times New Roman, serif"><span style="text-decoration: underline">Controlled
        Equity Offering</span></span><sup style="vertical-align: text-top; line-height: 1; font-size: smaller"><span style="text-decoration: underline">SM</span></sup><span style="font-family: Times New Roman, serif"><span style="text-decoration: underline">&#160;Sales
        Agreement, dated April 30, 2021, by and between the Company and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2
        of the Company&#8217;s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on April 30, 2021)</span></span></a></div>
        </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">4.9+</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">Employment
        Agreement, dated September 1, 2021, by and between Chemomab Therapeutics, Inc. and Dale Pfost (incorporated by reference to Exhibit 10.9
        to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">&#160;</td>
    <td style="width: 90%; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">4.10+</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">Employment
        Agreement, dated November 8, 2021, by and between Chemomab Therapeutics, Inc. and Donald Marvin (incorporated by reference to Exhibit
        10.10 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">4.11+</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">Consulting
        Agreement, dated April 18, 2022, by and between Chemomab Ltd. and Dr. Adi Mor (incorporated by reference to Exhibit 10.11 to the Registrants
        registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">&#160;</td>
    <td style="width: 90%; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323003334/exhibit_1-2.htm">4.12</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323003334/exhibit_1-2.htm">Sales
        Agreement, dated October 16, 2023, by and between the Registrant and&#160;Roth Capital Partners, LLC (incorporated by reference to Exhibit
        1.2 of the Company&#8217;s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on October 16, 2023)</a></div>
        </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1534248/000117891322001304/zk2227534.htm">8.1</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1534248/000117891322001304/zk2227534.htm">List
        of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s annual report on Form 10-K for the year-ended December
        31, 2021, filed with the SEC on March 30, 2022)</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_12-1.htm">12.1</a></div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_12-1.htm">Certification of the
        Chief Executive Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</a></div>
        </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_12-2.htm">12.2</a></div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_12-2.htm">Certification of the
        Chief Financial Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</a></div>
        </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_13-1.htm">13.1&#8224;</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_13-1.htm">Certification of the
        Chief Executive Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_13-2.htm">13.2&#8224;</a></div>
        </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_13-2.htm">Certification of the
        Chief Financial Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_15-1.htm">15.1</a></div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_15-1.htm">Consent of Independent
        Registered Public Accounting Firm</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_97-1.htm">97.1</a></div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"><a href="exhibit_97-1.htm">Chemomab Therapeutics
        Compensation Recovery Policy</a></div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">&#160;</td>
    <td style="width: 90%; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">101.INS</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Inline XBRL Instance Document</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">&#160;</td>
    <td style="width: 90%; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">101.SCH</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Inline XBRL Taxonomy Extension Schema Document</div>
        </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">101.CAL</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Inline XBRL Taxonomy Extension Calculation Linkbase
        Document</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">101.DEF</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Inline XBRL Taxonomy Extension Definition Linkbase
        Document</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">101.LAB</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Inline XBRL Taxonomy Extension Label Linkbase
        Document</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">101.PRE</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Inline XBRL Taxonomy Extension Presentation Linkbase
        Document</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 10%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">104</div> </td>
    <td style="width: 90%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">Cover Page Interactive Data File (formatted as
        Inline XBRL and contained in Exhibit 101)</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">+ Indicates management contract or compensatory
plan.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">&#8224; The certifications furnished in Exhibits
13.1 and 13,2 hereto are deemed to accompany this Annual Report on Form&#160;20-F&#160;and will not be deemed &#8220;filed&#8221; for
purposes of Section&#160;18 or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically
incorporates it by reference.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif">++ Portions of this Exhibit (indicated with [***])
have been omitted as the Registrant has determined that (i)&#160;the omitted information is not material and (ii)&#160;the omitted information
would likely cause competitive harm to the Registrant if publicly disclosed.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,serif"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">154</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,serif; font-weight: bold"><span id="SIGNATURES"><!--Anchor--></span>SIGNATURES</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">The registrant hereby certifies
that it meets all of the requirements for filing on Form 20&#8209;F and that it has duly caused and authorized the undersigned to sign
this annual report on its behalf.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; border-collapse: separate">
  <tr>
    <td style="vertical-align: top; width: 50%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold"><br/> </div> </td>
    <td colspan="2" style="vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-weight: bold">CHEMOMAB THERAPEUTICS LTD.</div>
        </td>
    <td style="vertical-align: top; width: 11%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 35%">&#160;</td>
    <td style="vertical-align: top; width: 11%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: top; text-align: left; width: 50%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">Date: March 28, 2024</div> </td>
    <td style="vertical-align: top; width: 4%; padding-bottom: 2px">
        <div style="text-align: left; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt">By: </div> </td>
    <td style="vertical-align: top; white-space: nowrap; text-align: left; border-bottom: #000000 2px solid; width: 35%">/s/ <span style="font-family: Times New Roman, serif">Adi
        Mor</span></td>
    <td style="vertical-align: top; width: 11%; padding-bottom: 2px">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="vertical-align: top; width: 4%">Name:</td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: left; width: 35%"><span style="font-family: Times New Roman, serif">Adi
        Mor</span></td>
    <td style="vertical-align: top; width: 11%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="vertical-align: top; width: 4%">Title:</td>
    <td style="vertical-align: top; width: 35%"><span style="font-family: Times New Roman, serif">Chief Executive Officer</span></td>
    <td style="vertical-align: top; width: 11%">&#160;</td> </tr>
  </table> </div>

<div style="line-height: 1.25"> <br/> </div> </div>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">155</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <br/> </div>
<!-- Field: /Include-Text -->
<div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

          <tr>
            <td style="width:100%;vertical-align:top">
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd.</span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">and its subsidiaries</span></span></div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Financial</span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statements</span></span></div>
              <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
      <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Financial Statements as of December 31, 2023</span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center"/>
        </div>
      </div>
      <div style="line-height:1.25">&#160;</div>
      <a id="a_001"></a><div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contents</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%">

            <tr>
              <td style="width:90%">&#160;</td>
              <td style="width:10%;font-weight:bold;text-align:right;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></td>
            </tr>
            <tr>
              <td style="width:90%">&#160;</td>
              <td style="width:10%;text-align:right;vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="width:90%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Firm_integixAnchor">Report of Independent Registered Public Accounting Firm</a></span></span>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong style="color:#000000;font-family:Times New Roman, Times, serif;font-style:normal;font-variant-ligatures:normal;white-space:normal;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-size:13.3333px;text-align:left"><span style="color:#212529">(PCAOB ID <ix:nonNumeric id="Fxbrl_20240325200052033" name="dei:AuditorFirmId" contextRef="C_20230101to20231231">1057</ix:nonNumeric>)</span></strong></span></span></p>
              </td>
              <td style="width:10%;text-align:right;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-2</span></span></td>
            </tr>
            <tr>
              <td style="width:90%">&#160;</td>
              <td style="width:10%;text-align:right;vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="width:90%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Sheets_integixAnchor">Consolidated Balance Sheets</a></span></span></td>
              <td style="width:10%;text-align:right;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-3</span></span></td>
            </tr>
            <tr>
              <td style="width:90%">&#160;</td>
              <td style="width:10%;text-align:right;vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="width:90%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Operations_integixAnchor">Consolidated Statements of Operations</a></span></span></td>
              <td style="width:10%;text-align:right;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-4</span></span></td>
            </tr>
            <tr>
              <td style="width:90%">&#160;</td>
              <td style="width:10%;text-align:right;vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width:90%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Equity_integixAnchor">Consolidated Statements of Changes in Equity</a></span></span></td>
              <td rowspan="1" style="width:10%;text-align:right;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-5</span></span></td>
            </tr>
            <tr>
              <td rowspan="1" style="width:90%">&#160;</td>
              <td rowspan="1" style="width:10%;text-align:right;vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width:90%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#flows_integixAnchor">Consolidated Statements of Cash Flows</a></span></span></td>
              <td rowspan="1" style="width:10%;text-align:right;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-6</span></span></td>
            </tr>
            <tr>
              <td rowspan="1" style="width:90%">&#160;</td>
              <td rowspan="1" style="width:10%">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width:90%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Notes_integixAnchor">Notes to the Consolidated Financial Statements</a></span></span></td>
              <td rowspan="1" style="width:10%;text-align:right;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-7 - F-26</span></span></td>
            </tr>

        </table>
      </div>
      <div style="line-height:1.25">&#160;</div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
      <div>
        <div style="line-height:1.25"><img alt="image00001.jpg" src="cmmb_img02.jpg" style="width:108px;height:53px"/></div>
      </div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Somekh Chaikin</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">KPMG Millennium Tower</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17 Ha&#8217;arba&#8217;a Street, PO Box 609</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel Aviv 61006, Israel</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">+972 3 684 8000</span></span></div>
        <div style="line-height:1.25">&#160;</div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Report of Independent Registered Public Accounting <span id="Firm_integixAnchor"></span>Firm</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To the Shareholders and Board of Directors,</span></span></div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd.:</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion on the Consolidated Financial Statements</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited the accompanying consolidated balance sheets of Chemomab Therapeutics Ltd. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2023, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis for Opinion</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></div>
      <div style="line-height:1.25;text-align:justify">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></span></div>
      <div style="line-height:1.25;text-align:justify">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-right:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325173623987" name="dei:AuditorName" contextRef="C_20230101to20231231">Somekh Chaikin</ix:nonNumeric></span></span></div>
      <div style="text-align:justify;margin-right:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Member Firm of KPMG International</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;margin-right:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have served as the Company&#8217;s auditor since 2015.</span></span></div>
      <div style="text-align:justify;margin-right:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325173629952" name="dei:AuditorLocation" contextRef="C_20230101to20231231">Tel Aviv, Israel</ix:nonNumeric></span></span></div>
      <div style="text-align:justify;margin-right:42.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 27, 2024</span></span></div>
      <div style="text-align:justify;margin-right:42.5pt;line-height:1.25">&#160;</div>
      <div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#169;</sup> 2023 KPMG Somekh Chaikin, an Israeli partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.</span></span>
          <p style="margin:0pt">&#160;</p>
        </div>
        <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
          <div style="text-align:center;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 2</span></span></span></div>
        </div>
      </div>
    </div>
  </div>
  <div>
    <div>
      <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
        <div>
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;page-break-after:always;background-color:#000000;margin-top:5pt;margin-bottom:10pt"/>
        </div>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold">
          <p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Balance <span id="Sheets_integixAnchor"></span>Sheets as of</span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
        </div>
      </div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands (except share and per share amounts)</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></td>
            <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
            <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
              </div>
            </td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current assets</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,292</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000039" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,519</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposit</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000040" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,492</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000041" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,374</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213102216110_Fact_0000000000040" name="us-gaap:RestrictedCashCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213102216110_Fact_0000000000041" name="us-gaap:RestrictedCashCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other receivables and prepaid expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,037</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000043" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,766</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total current assets</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000044" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,897</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000045" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,736</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current assets</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term prepaid expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000048" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">559</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131220311598" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">733</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207200450049_Fact_0000000000050" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207200450049_Fact_0000000000051" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000052" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">303</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000053" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right-of-use assets</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000054" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000055" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total non-current assets</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000056" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,254</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000057" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,327</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total assets</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000058" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,151</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000059" name="us-gaap:Assets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,063</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current liabilities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000060" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">516</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000061" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,688</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000062" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,423</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000063" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,378</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee and related expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000064" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">823</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000065" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,560</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000066" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000067" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total current liabilities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000068" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,838</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000069" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,749</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current liabilities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current<span style="font-weight:bold">&#160;</span>operating lease liabilities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000070" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000071" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total non-current liabilities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000072" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000073" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitments and contingent liabilities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"><ix:nonFraction id="Fxbrl_20240325094639969" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231" unitRef="usd" xsi:nil="true"/></td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"><ix:nonFraction id="Fxbrl_20240325094654148" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231" unitRef="usd" xsi:nil="true"/></td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total liabilities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000074" name="us-gaap:Liabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,154</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000075" name="us-gaap:Liabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,840</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shareholders' equity</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary Shares <ix:nonFraction id="Fxbrl_20240325124641641" name="us-gaap:CommonStockNoParValue" contextRef="C_20211231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20230201163052384" name="us-gaap:CommonStockNoParValue" contextRef="C_20221231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20230131220607422" name="us-gaap:CommonStockNoParValue" contextRef="C_20231231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> par value - Authorized: <ix:nonFraction id="Fxbrl_20240325124631855" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230131221123913" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230131221114549" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">650,000,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares as of December 31, 2023, 2022 and 2021;</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issued and outstanding: <ix:nonFraction id="Fxbrl_20240325094937707" name="us-gaap:SharesOutstanding" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230213101830930" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">284,094,700</ix:nonFraction></ix:nonFraction>, <ix:nonFraction id="Fxbrl_20240325094948068" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240325094832822" name="us-gaap:SharesOutstanding" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">232,636,700</ix:nonFraction></ix:nonFraction> Ordinary shares at December 31, 2023 and 2022, respectively and <ix:nonFraction id="Fxbrl_s_20230131221353660" name="us-gaap:SharesOutstanding" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230131221353661" name="us-gaap:CommonStockSharesIssued" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></ix:nonFraction> Ordinary shares at December 31, 2021</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131221528825" name="us-gaap:CommonStockValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131221535249" name="us-gaap:CommonStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Treasury share at cost (<ix:nonFraction id="Fxbrl_20230207202558860" name="us-gaap:TreasuryStockCommonShares" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,640,460</ix:nonFraction> shares as of December 31, 2022)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207202444619" name="us-gaap:TreasuryStockValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207202534021" name="us-gaap:TreasuryStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in capital</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000086" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,675</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000087" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,260</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated deficit</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000088" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">88,678</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000089" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63,819</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total shareholders&#8217; equity</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000090" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,997</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000091" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,223</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total liabilities and shareholders&#8217; equity</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,151</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000093" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,063</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%">

            <tr>
              <td style="width:25%;border-top:2px solid rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief Executive Officer and Director</span></span></td>
              <td colspan="1" style="width:25%">&#160;</td>
              <td style="width:25%;border-top:2px solid rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chief Financial Officer</span></span></td>
              <td colspan="1" style="width:25%">&#160;</td>
            </tr>

        </table>
      </div>&#160;<div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date of approval of the financial statements: March 27, 2024</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span>
        <p style="margin:0pt">&#160;</p>
        <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 3</span></span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:5pt;margin-bottom:10pt"/>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Statements of <span id="Operations_integixAnchor"></span>Operations for the year ended</span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
        </div>
      </div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands (except share and per share amounts)</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></div>
              </div>
            </td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
              </div>
            </td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
              </div>
            </td>
            <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
              </div>
            </td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:top;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:top;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000094" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,381</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000095" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,977</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325095930537" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,334</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000096" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,078</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000097" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,556</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325095935768" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,033</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000098" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,459</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000099" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,533</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325095940813" name="us-gaap:OperatingExpenses" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,367</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financing expense (income), net</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230131223230473" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,238</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230131223237304" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325095946273" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">111</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="vertical-align:top;padding-left:23%;width:52%;vertical-align:bottom">
              <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">`</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207212310873_Fact_0000000000102" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207212310873_Fact_0000000000103" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,180</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325095953001" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefit</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131223639023" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000101" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100001097" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for the year</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000102" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000103" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100006496" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;padding-bottom:4px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per Ordinary Share</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;padding-bottom:4px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:#000000 double 4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;border-bottom:#000000 double 4px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131213305203" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000104" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.103</ix:nonFraction></ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:#000000 double 4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;border-bottom:#000000 double 4px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131213312166" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000105" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.121</ix:nonFraction></ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:#000000 double 4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;border-bottom:#000000 double 4px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_s_20240325100011534" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240325100011535" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.060</ix:nonFraction></ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;padding-bottom:4px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of Ordinary* Shares outstanding, basic, and diluted</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;padding-bottom:4px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:#000000 double 4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;border-bottom:#000000 double 4px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214141238310" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000106" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">234,998,859</ix:nonFraction></ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:#000000 double 4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;border-bottom:#000000 double 4px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131213329528" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000107" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">227,589,288</ix:nonFraction></ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:#000000 double 4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%;border-bottom:#000000 double 4px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_s_20240325100018414" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240325100018415" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">207,468,650</ix:nonFraction></ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</span></span></div>
      </div>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span>
        <p style="margin:0pt">&#160;</p>
        <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 4</span></span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:5pt;margin-bottom:10pt"/>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold">
          <p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Statements of Changes in <span id="Equity_integixAnchor"></span>Equity</span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
        </div>
      </div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands (except share amounts)</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary</span></span></div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shares</span></span></div>
              </div>
            </td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25">
                <div style="line-height:1.25">&#160;</div>
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Treasury</span></span></div>
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">share</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional</span></span></div>
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">paid in</span></span></div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">capital</span></span></div>
              </div>
            </td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated</span></span></div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deficit</span></span></div>
              </div>
            </td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Total</span></span></span></div>
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Shareholders&#8217; </span></span></span></div>
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">equity</span></span></span></div>
              </div>
            </td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;text-align:center"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD</span></span></strong></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;width:16%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2021*</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207232832534" name="us-gaap:SharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">9,274,838</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004148281" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004108785" name="us-gaap:SharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230208004208753" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000128" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,497</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000129" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">23,695</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000130" name="us-gaap:StockholdersEquity" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,802</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004236209" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004232608" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207232932528" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004229458" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207232938175" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effect of reverse capitalization transaction</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207232946871" name="cmmb:EffectOfReverseCapitalizationTransactionShares" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">152,299,702</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004310594" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004631164" name="cmmb:EffectOfReverseCapitalizationTransactionShares" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004302609" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207232952864" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004258843" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207232958504" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares and warrants, net of issuance costs</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233006128" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">66,381,520</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004339738" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004626295" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004335122" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233012248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,637</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004332317" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233018475" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,637</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233039147" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">134,240</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004521301" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004621028" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004724885" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233033563" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004807831" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233028090" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for the year</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004352160" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004349447" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004345432" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233044479" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233049858" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2021</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207234506438" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004359870" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004449318" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004357072" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233106443" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207234203847" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233116634" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="vertical-align:bottom;width:16%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2022</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207234515566" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004830175" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004835440" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230208004846448" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233129314" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233133644" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233141194" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004855201" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004852649" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233154315" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004943313" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233147476" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net of issuance costs</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233201211" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,576,400</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004904248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004910523" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004901083" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233210018" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004950211" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233216009" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233237975" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,970,000</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004927217" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004915442" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004923369" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233227671" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004959684" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233221400" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Treasury share at cost</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004938057" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233301376" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233406606" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004934609" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208004932393" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233411324" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for the year</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208005011611" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208005008418" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208005005802" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233416622" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233422744" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2022</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233430996" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">232,636,700</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230208005022333" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233657770" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233728393" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233439472" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,260</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230207233445148" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63,819</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233450251" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,223</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td rowspan="1" style="vertical-align:bottom;width:16%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2023</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230207234515566" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">232,636,700</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230208004830175" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230208004835440" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230208004846448" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230207233129314" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,260</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230207233133644" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63,819</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100756924_xbrl_20230207233141194" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,223</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230208004855201" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230208004852649" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230207233154315" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230208004943313" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100645650_xbrl_20230207233147476" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net of issuance costs</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230207233201211" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">51,458,000</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230208004904248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230208004910523" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230208004901083" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230207233210018" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,924</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230208004950211" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100655099_xbrl_20230207233216009" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,924</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of treasury share at cost</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230208004938057" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230207233301376" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,640,460</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230207233406606" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230208004934609" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230208004932393" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">638</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100724019_xbrl_20230207233411324" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">580</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for the year</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230208005011611" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230208005008418" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230208005005802" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230207233416622" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325100739987_xbrl_20230207233422744" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:16%;padding-bottom:4px;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2023</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233430996" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">284,094,700</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230208005022333" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233657770" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233728393" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233439472" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,675</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233445148" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">88,678</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325100745487_xbrl_20230207233450251" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,997</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*&#8201;Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</span></span>
          <p style="margin:0pt">&#160;</p>
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 5</span></span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:5pt;margin-bottom:10pt"/>
        </div>
      </div>
    </div>
  </div>
</div><div style="">
  <div>
    <div>
      <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold">
          <p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statements of Cash <span id="flows_integixAnchor"></span>flows for the year ended</span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center;margin-top:5pt;margin-bottom:5pt"/>
        </div>
      </div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands</span></span></div>
      <div style="line-height:1.25">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;text-align:center">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;text-align:center">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;text-align:center">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
              </div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
              </div>
            </td>
            <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows from operating activities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for the year</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000149" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000150" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104742349" name="us-gaap:ProfitLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments for operating activities:</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000151" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000152" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104746496" name="us-gaap:Depreciation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000153" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000154" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104750812" name="us-gaap:ShareBasedCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in other receivables and prepaid expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000155" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">903</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000156" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104755091" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,058</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in trade payables</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000157" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,172</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000158" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104759425" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,175</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in accrued expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000159" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201002431792" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,823</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104804410" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,279</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in employees and related expenses</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000161" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">737</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000162" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">907</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104808746" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in operating leases</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000163" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230201002424683" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104815058" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash used in operating activities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000165" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">23,611</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000166" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,370</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104819434" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,374</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows from investing activities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in deposits</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000167" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,882</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000168" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,601</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104823921" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,951</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term lease deposit</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000169" name="cmmb:LongTermLeaseDeposit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131235620864" name="cmmb:LongTermLeaseDeposit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104828616" name="cmmb:LongTermLeaseDeposit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of asset held for sale</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000171" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131235631064" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104835346" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000173" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000174" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104839642" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) investing activities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000175" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,879</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000176" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,533</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325104844087" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">45,186</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows from financing activities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash acquired in Merger</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000177" name="cmmb:CashAcquiredInMerger" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131235649216" name="cmmb:CashAcquiredInMerger" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104926796" name="cmmb:CashAcquiredInMerger" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,427</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000179" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131235658097" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104931102" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of treasury share</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201000241409" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000182" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104937430" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of treasury share</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104521419" name="us-gaap:ProceedsFromSaleOfTreasuryStock" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">580</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104453631_xbrl_20230201000241409" name="us-gaap:ProceedsFromSaleOfTreasuryStock" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104453631_Fact_0000000000182" name="us-gaap:ProceedsFromSaleOfTreasuryStock" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares net of issuance costs</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000183" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,924</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000184" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104942102" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,637</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) financing activities</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201002754453" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,504</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000186" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">808</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325104946388" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,074</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in cash, cash equivalents and restricted cash</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230201002721687" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,228</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000188" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,645</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105003435" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,514</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at beginning of the year</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,596</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000190" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,241</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105007045" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,727</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at end of the year</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000191" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,368</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000192" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,596</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105011131" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,241</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Supplementary cash flows information:</span></span></span></div>
      <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;<div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">A.</span>&#160; &#160; &#160; &#160; &#160;&#160;<span style="font-weight:bold">Cash paid and received during the year for:</span></span></span><br/>&#160;</div>
      </div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income taxes received</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><strong><ix:nonFraction id="Fxbrl_20230214142748754" name="cmmb:IncomeTaxesReceived" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">187</ix:nonFraction></strong></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230214143241770" name="cmmb:IncomeTaxesReceived" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105045604" name="cmmb:IncomeTaxesReceived" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
              <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest received</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233819452" name="cmmb:InterestReceived" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,463</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207233829491" name="cmmb:InterestReceived" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">972</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105050333" name="cmmb:InterestReceived" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span>&#160; &#160; &#160; &#160; &#160;&#160;<span style="font-weight:bold">Significant non- cash transaction:</span></span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">&#160;</span></span></span></div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right-of-use asset recognized with corresponding lease liability</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><strong><ix:nonFraction id="FFact_0000000000193" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction></strong></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000194" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105059739" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
              <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities assumed; net of non-cash assets received in Merger</span></span></div>
            </td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000195" name="us-gaap:LiabilitiesAssumed1" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20230131235456185" name="us-gaap:LiabilitiesAssumed1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
              <div style="line-height:1.25">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105106698" name="us-gaap:LiabilitiesAssumed1" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></span></div>
              </div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25">&#160;</div>
      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements</span></span>
        <p style="margin:0pt">&#160;</p>
        <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 6</span></span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:5pt;margin-bottom:10pt"/>
      </div>
      <div>
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="Notes_integixAnchor"></span>Notes to the Financial Statements as at December 31, 2023</span></span></div>
        </div>
      </div>
    </div>
  </div>
  <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:5pt;text-align:center"/>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000208" name="us-gaap:NatureOfOperations" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 1 - General</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.</span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics Inc.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company currently has no products approved for sale. The Company&#8217;s operations are funded primarily by its Shareholders. The Company has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it obtains marketing approval for its products. Continuation of the Company&#8217;s development programs depend on its future ability to raise sources of financing. The Company believes that its cash and cash equivalents and bank deposits as of December 31, 2023 will be sufficient to fund its operations through March 31, 2025.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 14, 2020, the Company (formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and Plan of Merger (the "Merger" and &#8220;Merger Agreement&#8221;) with Chemomab Ltd., an Israeli limited company, and CMB Acquisition Ltd., an Israeli limited company and a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;). On March 16, 2021, (the &#8220;Effective Time&#8221;), the Company consummated the Merger pursuant to the Merger Agreement Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. surviving the Merger as the Company's wholly owned subsidiary. In connection with the Merger, on March 16, 2021, the Company changed its name from &#8220;Anchiano Therapeutics Ltd.&#8221; To &#8220;Chemomab Therapeutics Ltd." and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.</span></span></div>
                <div>&#160;</div>
              </td>
            </tr>

        </table>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd. option was assumed by the Company, based on the same exchange ratio.</span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For accounting purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab Share Incentive Plan (the &#8220;2015 Plan&#8221;), with such options representing the right to purchase a number of ADSs equal to approximately <ix:nonFraction id="Fxbrl_20230131220949272" name="cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger" contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12.86</ix:nonFraction> multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 7</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 1 - General (cont&#8217;d)</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3. (cont'd)</span></span></div>
          <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in $ thousands):</span></span></div>
        <ix:nonNumeric id="Fxbrl_20240325095248894" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000202" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,427</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Asset held for sale</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000203" name="cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid and other assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000204" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000205" name="cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,187</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net acquired assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000206" name="cmmb:EstimatedFairValueOfNetAssetsAcquired" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <div style="line-height:1.25">
    <p style="margin:0pt">&#160;</p>
  </div>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000234" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 2 - Summary of Significant Accounting Policies</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div>
          <ix:nonNumeric id="Fxbrl_20240325101130571" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">A.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Basis of Preparation</span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</span></span></div>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101147320" name="us-gaap:UseOfEstimates" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Use of estimates</span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></span></div>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101207112" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Foreign currency</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101223928" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Cash and cash equivalents</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.</span></span></div>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 8</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></span></div>
          <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20240325101245836" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">E.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Restricted cash</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325102921313" name="cmmb:ShortTermBankDepositsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Short-term bank deposits</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101332820" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">G.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Property and equipment</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Annual rates at depreciation are as follows:</span></span><br/>&#160;</div>
            <ix:nonNumeric id="Fxbrl_20240325101112603" name="cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock" contextRef="C_20230101to20231231" escape="true">
              <div>
                <div style="margin-left:36pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" rowspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000214" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000215" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furniture and equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000216" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">7</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" rowspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvement - <ix:nonNumeric id="FFact_0000000000217" name="cmmb:AnnualRatesOfDepreciation" contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">over the shorter of the lease term or the estimated useful life of the improvement</ix:nonNumeric></span></span></div>
                        </td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>
            </ix:nonNumeric>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101350742" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">H.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Impairment of long-lived assets</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101409349" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">I.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Research and Development</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages. </span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 9</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
            </div>
          </div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></span></div>
          <div style="line-height:1.25;font-weight:bold">&#160;</div>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20240325101429788" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">J.</span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income taxes</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101455682" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">K.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Fair value of financial instruments</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#8217;s own credit risk.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <div>
                  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 10</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
                </div>
              </div>
              <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">K.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Fair value of financial instruments (cont'd)</span></span></span></div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
            </ix:exclude></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#8217;s non<span style="font-weight:bold">- </span>financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div>
          <div style="line-height:1.25">&#160;</div>
        </div>
        <ix:nonNumeric id="Fxbrl_20240325101553859" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">L.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Share-based compensation</span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</span></span></div>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101618954" name="cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">M.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Government-sponsored research and development</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101636106" name="cmmb:SeverancePayPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">N.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Severance pay</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of <ix:nonFraction id="Fxbrl_20230215220314714" name="cmmb:PercentageOfMonthlyDepositsRate" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.33</ix:nonFraction>% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $<ix:nonFraction id="Fxbrl_20230215220321806" name="us-gaap:SeveranceCosts1" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction>, $<ix:nonFraction id="Fxbrl_20230215220329094" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction> thousand, and $<ix:nonFraction id="Fxbrl_20240325101644612" name="us-gaap:SeveranceCosts1" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction> thousand for the year ended December 31, 2023, 2022 and 2021, respectively.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 11</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20240325101706426" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">O.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Concentrations of credit risk:</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101730315" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">P.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Leases</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2023 5% in 2022 and 5.2% in 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325101745826" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Q.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Principles of consolidation</span></span></span></div>
            <div style="line-height:1.25;text-align:justify">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 12</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></span></div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div>
        </ix:exclude></div>
        <ix:nonNumeric id="Fxbrl_20240325101803004" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">R.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Earnings per ordinary share</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.</span></span></div>
          </div>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000244" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 3 - Cash and Cash Equivalents</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325103135178" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000235" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtCurrencyAxis_currencyUSD" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,718</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000236" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtCurrencyAxis_currencyUSD" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,663</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In NIS</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000237" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtCurrencyAxis_currencyILS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,574</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000238" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtCurrencyAxis_currencyILS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,756</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In other currencies</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*<ix:nonFraction id="Fxbrl_20240325103200378" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtCurrencyAxis_currencyXXX" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000240" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtCurrencyAxis_currencyXXX" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000241" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,292</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000242" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,519</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:nonNumeric>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*Less than 1 thousand</span></span></div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000252" name="cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock" contextRef="C_20230101to20231231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 4 - Other Receivables and Prepaid Expenses</span></span></strong></p>
    <p style="margin:0pt">&#160;</p>
    <ix:nonNumeric id="Fxbrl_20240325103414977" name="cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" contextRef="C_20230101to20231231" escape="true">
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government institutions</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000245" name="cmmb:ReceivablesFromGovernmentInstitutions" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">289</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000246" name="cmmb:ReceivablesFromGovernmentInstitutions" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">459</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000247" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000248" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,307</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000249" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,037</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000250" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,766</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000270" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 5 - Property and Equipment, Net</span></span></strong></p>
    <div>
      <div>
        <ix:nonNumeric id="Fxbrl_20240325104029249" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000253" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000254" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furniture and equipment</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000255" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000256" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000257" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">400</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000258" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">399</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Website development</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000259" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000260" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000261" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000262" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201032006902" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000264" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">532</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less - accumulated depreciation</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000265" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">226</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000266" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201033845372" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">303</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000268" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 13</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000294" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 6 - Leases</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter &#8211; &#8220;The Agreement&#8221; .(According to the Agreement, Chemomab Leased a space in Atidim Park, Tel-Aviv for a period of <ix:nonNumeric id="Fxbrl_20230131233210356" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_20200510" format="ixt-sec:durwordsen">three years</ix:nonNumeric>, through <span style="-sec-ix-hidden:Fxbrl_20230131233234992">May 2023</span>. Chemomab was granted an option to extend the lease term by additional <ix:nonNumeric id="Fxbrl_20230131233301410" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20200501to20200510">three years</ix:nonNumeric>.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab returned the previous office and lab space to the property owner and leased a larger space in Atidim Park Tel-Aviv, for a term of <ix:nonNumeric id="Fxbrl_20230131233734834" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_20211024" format="ixt-sec:duryear">3</ix:nonNumeric> years, through <span style="-sec-ix-hidden:Fxbrl_20230131233722905">October 2024</span>. In addition, Chemomab was granted an option to extend the lease term by additional <ix:nonNumeric id="Fxbrl_20230201000916081" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20211001to20211024">three years</ix:nonNumeric>. The annual lease and management fees are approximately $<ix:nonFraction id="Fxbrl_20230131234005244" name="cmmb:AnnualRentAndManagementFees" contextRef="C_20211001to20211024" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction> thousand. Pursuant to the Amendment, the bank guarantee issued in 2020 was canceled and a substitute bank guarantee of approximately $<ix:nonFraction id="Fxbrl_20240325135011021" name="cmmb:BankGuaranteesToPropertyOwner" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction> thousand was issued to the property owner during 2023.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above operating leases are included in &#8220;Operating lease right-of-use assets&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2023, 2022 and 2021 represent the Company&#8217;s right to use the underlying asset for the lease term. The Company&#8217;s obligations to pay lease payments are included in the current liabilities as &#8220;Operating lease liabilities&#8221; and in the non-current liabilities as &#8220;Non-current operating lease liabilities&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2023, 2022 and 2021. Based on the present value of the lease payments for the remaining lease term of the Company&#8217;s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $<ix:nonFraction id="Fxbrl_20230131234456429" name="cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" contextRef="C_20231212" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction> thousand on December 12, 2023.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the years ended December 31, 2023, 2022 and 2021, the Company recognized an increase in right of use assets of $<ix:nonFraction id="Fxbrl_20230131234508150" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction>, $<ix:nonFraction id="Fxbrl_20230131234513790" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction> thousand and $<ix:nonFraction id="Fxbrl_20240325105850271" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction> thousand, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023 the Company concluded it reasonably certain in the lease agreement for additional <ix:nonNumeric id="Fxbrl_20240325112042565" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20230101to20231231">three years</ix:nonNumeric> and accordingly performed a reassessment of the right of use asset which resulted in a new right of use asset in the amount of $<ix:nonFraction id="Fxbrl_20240325112804525" name="cmmb:ReassessmentOfRightOfUseAsset" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction> thousand as of December 31, 2023.</span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, 2022, and 2021 operating right-of-use asset was $<ix:nonFraction id="Fxbrl_20230214143811730" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction> thousand, $<ix:nonFraction id="Fxbrl_20230214143818906" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction> thousand and $<ix:nonFraction id="Fxbrl_20240325105759783" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction> thousand, respectively. The operating lease liabilities were $<ix:nonFraction id="Fxbrl_20230214143827206" name="us-gaap:OperatingLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction> thousand, $<ix:nonFraction id="Fxbrl_20230214143833566" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">214</ix:nonFraction> thousand and $<ix:nonFraction id="Fxbrl_20240325105743080" name="us-gaap:OperatingLeaseLiability" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">343</ix:nonFraction> thousand, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As most of the Chemomab&#8217;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#8217;s incremental borrowing rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was <ix:nonFraction id="Fxbrl_20230131234937485" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">9</ix:nonFraction>% in 2023 <ix:nonFraction id="Fxbrl_20230131234957047" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% in 2022 and <ix:nonFraction id="Fxbrl_20240325105827270" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20210101to20211231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.2</ix:nonFraction>% in 2021.</span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of lease liabilities under noncancellable leases as of December 31, 2023, are as follows: (in thousands):</span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="margin-left:36pt">
          <ix:nonNumeric id="Fxbrl_20240325105733072" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325112906183" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325112921124" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325112940611" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325113005077" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total future minimum lease payments</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000290" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">464</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:88%;padding-bottom:4px;vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less imputed interest:</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000291" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of operating lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000292" name="us-gaap:OperatingLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">392</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 14</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000311" name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 7 - Commitments and Contingent Liabilities</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exclusive License Agreement (hereinafter- &#8220;the License Agreement&#8221;)</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (&#8220;Fund"), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee;</span></span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(i)</span></span><span style="padding-left:24pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to certain additional terms set forth therein.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to pay the Fund the following non-refundable, non-creditable amounts:</span></span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)</span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230215222406006" name="us-gaap:LongTermPurchaseCommitmentDescription" contextRef="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember">$100 thousand upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;</ix:nonNumeric></span></span></span></div>
              </td>
            </tr>

        </table>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:35.45pt">&#160;</td>
              <td style="width:35.45pt;vertical-align:top"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(b)</span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230215222519809" name="us-gaap:LongTermPurchaseCommitmentDescription" contextRef="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember">$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.</ix:nonNumeric></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-indent:36pt;line-height:1.25;text-align:justify"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023 no payments were made to the Fund.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition to the payments described above, <ix:nonNumeric id="Fxbrl_20230215222713212" name="us-gaap:OtherCommitmentsDescription" contextRef="C_20230101to20231231">upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.</ix:nonNumeric></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (&#8220;IIA&#8221;) for the support of certain research and development activities conducted in Israel.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In return for the IIA&#8217;s participation, Chemomab is committed to pay royalties at rate of <ix:nonFraction id="Fxbrl_20230201002925810" name="cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct" contextRef="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% of sales of the developed product (linked to U.S. dollar), up to <ix:nonFraction id="Fxbrl_20230201002935951" name="cmmb:MaximumPercentageOfPaymentsOfRoyalties" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology or development out of Israel.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab did not receive any grants from the IIA in the years ended December 31, 2023, 2022 and-2021.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 15</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
            </div>
          </div>
          <div style="line-height:1.25;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 7 - Commitments and Contingent Liabilities (cont&#8217;d)</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exclusive License Agreement (hereinafter- &#8220;the License Agreement&#8221;) (cont&#8217;d)</span></span></span></div>
                  <div style="font-weight:bold">&#160;</div>
                </td>
              </tr>

          </table>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since Chemomab &#8217;s incorporation through December 31, 2023 Chemomab received $<ix:nonFraction id="Fxbrl_20230201002951961" name="cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,227</ix:nonFraction> thousand from the IIA, which were recognized as a reduction of research and development expenses.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, Chemomab has no commitment for royalties payable.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">B.</span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2015, Chemomab entered into a license agreement with subcontractor (&#8220;the Subcontractor&#8221;), under which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediates and active pharmaceutical ingredients. According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with Chemomab's specifications and timeline. From time to time, Chemomab and the Subcontractor have been signing additional agreements for additional manufacturing and final process lock of the product for clinical use Under the agreement, Chemomab is also obligated to pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2023, 2022 and 2021, Chemomab recorded expenses related to the above agreements in the amounts of $<ix:nonFraction id="Fxbrl_20230213125722009" name="us-gaap:RoyaltyExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,832</ix:nonFraction>, $<ix:nonFraction id="Fxbrl_20230213125731080" name="us-gaap:RoyaltyExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,222</ix:nonFraction> thousand and $<ix:nonFraction id="Fxbrl_20240325141025378" name="us-gaap:RoyaltyExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,590</ix:nonFraction> thousand, respectively. The expenses were recorded under research and development expenses.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">C.</span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the bank imposed restriction on a bank deposit in the amount of $<ix:nonFraction id="Fxbrl_20230213125744104" name="us-gaap:RestrictedInvestments" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction> thousand for the purpose of secure lease payments under an office lease agreement.</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">D.</span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2022, the Israeli tax authority ("ITA&#8221;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 2022. The ITA raised several claims, mainly in respect with the recoverability of VAT related to the Merger Agreement expenses and the classification of the Company as a holding company. In July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued an assessment. In November 2022, the Company filed an appeal to the ITA&#8217;s assessment. The Company has recorded a provision in 2022 that is inherently subjective due to the inherent uncertainty of these matters and the judicial process, therefore, the outcome may differ from the estimated liability recorded by the Company during 2022.</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023 the ITA rejected the company&#8217;s appeal on the assessment. The Company is expected to submit an appeal in April 2024 to the Israeli district court. Based on the consultancy of its tax advisors, The Company estimates that the amount of provision recorded in 2022 remains adequate.</span></span></span></div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <div style="line-height:1.25">
    <p style="margin:0pt">&#160;</p>
    <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 16</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
  </div>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000385" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20230101to20231231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Note 8 - Share Capital</span></span></strong></span></span></p>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:34.9pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right attached to shares</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:34.9pt;margin-left:36pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">1.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Voting</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Dividends</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since its inception, the Company has not declared any dividends.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Financing rounds</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately $<ix:nonFraction id="Fxbrl_20230213133908909" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.5</ix:nonFraction> million of its American Depositary Shares )ADSs( in a private placement transaction, (or "The Private Placement"). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers <ix:nonFraction id="Fxbrl_20230213133843633" name="cmmb:NumberOfWarrantsPurchaseUpAdss" contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,619,270</ix:nonFraction> ADSs together with warrants to purchase up to <ix:nonFraction id="Fxbrl_20230213133849363" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">261,929</ix:nonFraction> ADSs at an exercise price of $<ix:nonFraction id="Fxbrl_20230213133830904" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">17.35</ix:nonFraction> per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately $<ix:nonFraction id="Fxbrl_20230213133820824" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction> million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $<ix:nonFraction id="Fxbrl_20230213133808746" name="cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">75</ix:nonFraction> million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued <ix:nonFraction id="Fxbrl_20230213133801744" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">699,806</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20230213133754484" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">22.75</ix:nonFraction> per ADS under the ATM Agreement, resulting in gross proceeds of $<ix:nonFraction id="Fxbrl_20230213133747440" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,917</ix:nonFraction> thousand.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $<ix:nonFraction id="Fxbrl_20230213133711976" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20220401to20220425_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">18,125,000</ix:nonFraction> of its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float. During the year ended December 31, 2022, the Company issued <ix:nonFraction id="Fxbrl_20230213133726969" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">130,505</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20230213133719951" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">2.11</ix:nonFraction> per ADS under the ATM Agreement, resulting in gross proceeds of $<ix:nonFraction id="Fxbrl_20230213133734136" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction> thousand. During the year ended December 31, 2023, the Company issued <ix:nonFraction id="Fxbrl_20240325123733602" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">772,900</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20240325123743170" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.83</ix:nonFraction> per ADS under the ATM Agreement, resulting in net proceeds of $<ix:nonFraction id="Fxbrl_20240325164632464" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,371</ix:nonFraction> thousand.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div style="width:100%">
              <div>
                <div>
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 17</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note 8 - Share Capital (cont&#8217;d)</span></span></span></div>
          <div style="line-height:1.25">&#160;</div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 19, 2022, the Company entered&#160; into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with Dr. Adi Mor, co-founder of Chemomab Ltd., then Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), whereby the Company agreed, subject to the requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which the Company received on November 14, 2022, to repurchase up to <ix:nonFraction id="Fxbrl_20230213133614438" name="cmmb:RepurchaseOfAmericanDepositaryReceiptsShares" contextRef="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">582,023</ix:nonFraction> of the Company's ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $<ix:nonFraction id="Fxbrl_20230213133621142" name="cmmb:RepurchaseOfAmericanDepositaryReceipts" contextRef="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,500,000</ix:nonFraction>, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the company repurchased the entire amount of <ix:nonFraction id="Fxbrl_20230213133633159" name="cmmb:RepurchaseOfAmericanDepositaryReceiptsShares" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">582,023</ix:nonFraction> ADSs (the "Treasury Shares") from the Co-Founders at an average price of $<ix:nonFraction id="Fxbrl_20230213133700406" name="cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="USD_Per_Share" scale="0" decimals="4" format="ixt:num-dot-decimal">2.0848</ix:nonFraction> and for total consideration of approximately $<ix:nonFraction id="Fxbrl_20230213133643190" name="cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction> thousand.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 17, 2023, the company sold the Treasury Shares for an aggregate consideration of approximately $<ix:nonFraction id="Fxbrl_20240325170937255" name="us-gaap:ProceedsFromSaleOfTreasuryStock" contextRef="C_20231101to20231117" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">580</ix:nonFraction> thousand.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $<ix:nonFraction id="Fxbrl_20240325171010296" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20231001to20231031" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,863,664</ix:nonFraction> of its ADSs in connection with the reactivation of the ATM Facility and pursuant to Rule 415(a)(6) under the Securities Act of 1933 Form F-3, which, subject to certain exceptions, limits the number of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, the Company entered into an At the Market Offering Agreement (the "Roth ATM Agreement") with Roth Capital Partners, LLC, (&#8220;Roth&#8221;). According to the Roth ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $<ix:nonFraction id="Fxbrl_20240325171044931" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20231001to20231031_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,863,664</ix:nonFraction> through Roth or the Roth ATM Agreement. From October 30, 2023 through December 31, 2023, the Company issued <ix:nonFraction id="Fxbrl_20240325171233284" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,800,000</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20240325171244020" name="cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.96</ix:nonFraction> per ADS under the Roth ATM Agreement, resulting in net proceeds of $<ix:nonFraction id="Fxbrl_20240325171253164" name="cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,553</ix:nonFraction> thousand.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Share-based compensation</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Share-based compensation plan:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company maintains (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;),&#8201;which was assumed by the Company from Chemomab upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 18</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
            </div>
          </div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 8 - Share Capital (cont&#8217;d)</span></span></div>
          <div style="line-height:1.25;font-weight:bold">&#160;</div>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, a total of <ix:nonFraction id="Fxbrl_20230207224906305" name="cmmb:NumberOfStockReservedForIssuance" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">28,443,060</ix:nonFraction> of our Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223247056" name="cmmb:NumberOfStockAdssResveredForIssuance" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,422,153</ix:nonFraction> ADSs) were reserved for issuance under the 2015 Plan, of which <ix:nonFraction id="Fxbrl_20230207225529762" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">3,445,520</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223254041" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">172,276</ix:nonFraction> ADSs) had been issued pursuant to previous option exercise, and <ix:nonFraction id="Fxbrl_20230207225556251" name="cmmb:NumberOfOptionsIssuableOutstanding" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">6,826,440</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223300376" name="cmmb:NumberOfAdssOptionsIssuableOutstanding" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">341,322</ix:nonFraction> ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase <ix:nonFraction id="Fxbrl_20230207225618055" name="cmmb:NumberOfOptionsVestedAndExercisable" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">6,394,160</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223309640" name="cmmb:NumberOfAdssVestedAndExercisable" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">319,708</ix:nonFraction> ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $<ix:nonFraction id="Fxbrl_20230207224602275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.30</ix:nonFraction> per Ordinary Share (or $<ix:nonFraction id="Fxbrl_20230207223316544" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">5.98</ix:nonFraction> per ADS). During the year ended December 31, 2023, options to purchase <ix:nonFraction id="Fxbrl_20230207224845387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">16,634,300</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223324626" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">831,715</ix:nonFraction> ADSs) were canceled.</span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, a total of <ix:nonFraction id="Fxbrl_20230207225827725" name="cmmb:NumberOfStockReservedForIssuance" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">23,061,380</ix:nonFraction> of our Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225729518" name="cmmb:NumberOfStockAdssResveredForIssuance" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,153,069</ix:nonFraction> of our ADSs) were reserved for issuance under the 2017 Plan, of which <ix:nonFraction id="Fxbrl_20230207225858382" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">23,046,660</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225738550" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,152,333</ix:nonFraction> ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase <ix:nonFraction id="Fxbrl_20230207225916606" name="cmmb:NumberOfOptionsVestedAndExercisable" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">3,689,480</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225743877" name="cmmb:NumberOfAdssVestedAndExercisable" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">184,474</ix:nonFraction> ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $<ix:nonFraction id="Fxbrl_20230207225929980" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.20</ix:nonFraction> per Ordinary Share (or $<ix:nonFraction id="Fxbrl_20230207225750293" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">3.91</ix:nonFraction> per ADS). During the year ended December 31, 2023, options to purchase 3,739,320 Ordinary Shares (equal to 186,966 ADSs) were canceled.</span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The expenses that were recognized in the consolidated statements of operations for services received from employees and service providers are as follows:</span></span></div>
              </td>
            </tr>

        </table>
        <ix:nonNumeric id="Fxbrl_20240325123602369" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div>&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000338" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000339" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325160020593_Fact_0000000000339" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000340" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000341" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325160020594_Fact_0000000000341" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total share-based compensation expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000342" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000343" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325160020595_Fact_0000000000343" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <div>&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The number and weighted average exercise price of options are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240325123629767" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="line-height:1.25;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average</span></span></div>
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at January 1</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000345" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.38</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000346" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000347" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20210101to20211231" format="ixt-sec:duryear">8.12</ix:nonNumeric></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000348" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20201231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20201231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">10,455,580</ix:nonFraction></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000350" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20200101to20201231" format="ixt-sec:duryear">7.8</ix:nonNumeric></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquired in Merger</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214225414206" name="cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000351" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201024457584" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">609,535</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000352" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000353" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,970,000</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201024523067" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.08</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230201024530820" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">134,220</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000356" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.32</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000357" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,240,120</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000358" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">1.25</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000359" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,712,275</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000360" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000361" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,398,400</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000362" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.8</ix:nonNumeric></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000363" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.62</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">17,784,640</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000365" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20210101to20211231" format="ixt-sec:duryear">9.79</ix:nonNumeric></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at December 31</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.33</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000368" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.42</ix:nonNumeric></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.38</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000370" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000371" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20210101to20211231" format="ixt-sec:duryear">8.12</ix:nonNumeric></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <div>
                  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 19</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
                </div>
              </div>
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 8 - Share Capital (cont&#8217;d)</span></span></div>
              <div style="line-height:1.25;font-weight:bold">&#160;</div>
            </ix:exclude></div>
            <div style="line-height:1.25;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average</span></span></div>
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at January 1</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853866_Fact_0000000000345" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.33</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853866_Fact_0000000000346" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325121853866_Fact_0000000000347" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.42</ix:nonNumeric></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853866_Fact_0000000000348" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.38</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853866_Fact_0000000000349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325121853866_Fact_0000000000350" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20210101to20211231" format="ixt-sec:duryear">8.12</ix:nonNumeric></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325122846802" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325122903364" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,970,000</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325122952018" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.39</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325123000932" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">20,373,620</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325123010115" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.32</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20240325123027691" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,240,120</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853884_Fact_0000000000360" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853884_Fact_0000000000361" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">15,055,180</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325121853884_Fact_0000000000362" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20230101to20231231" format="ixt-sec:duryear">5.86</ix:nonNumeric></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853884_Fact_0000000000363" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853884_Fact_0000000000364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,398,400</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325121853884_Fact_0000000000365" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.8</ix:nonNumeric></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at December 31</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853889_Fact_0000000000366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853889_Fact_0000000000367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">29,873,100</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325121853889_Fact_0000000000368" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20230101to20231231" format="ixt-sec:duryear">5.99</ix:nonNumeric></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853889_Fact_0000000000369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.33</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325121853889_Fact_0000000000370" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240325121853889_Fact_0000000000371" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.42</ix:nonNumeric></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair value measurement:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows:</span></span></div>
        <ix:nonNumeric id="Fxbrl_20240325123652785" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20230101to20231231" escape="true">
          <div>
            <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
            <div style="line-height:1.25;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:27pt;padding-bottom:2px;width:84%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023 grants</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average share price (in U.S. dollar)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(a)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000373" name="us-gaap:SharePrice" contextRef="C_20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price (in U.S. dollar)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20231231_srtRangeAxis_srtMinimumMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.06</ix:nonFraction>-<ix:nonFraction id="FFact_0000000000376" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20231231_srtRangeAxis_srtMaximumMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.09</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life of options (in years)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(b)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000377" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">4.53</ix:nonNumeric>-<ix:nonNumeric id="FFact_0000000000378" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">9.46</ix:nonNumeric></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(c)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000379" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">97.79</ix:nonFraction>%-<ix:nonFraction id="FFact_0000000000380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">112.94</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(d)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000381" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.71</ix:nonFraction>%-<ix:nonFraction id="FFact_0000000000382" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.43</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20230101to20231231" unitRef="Pure" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </ix:nonNumeric>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:72pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The weighted average share price is based on the Company&#8217;s Ordinary Share valuation as at the grant date.</span></span></div>
              </td>
            </tr>

        </table>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:72pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(b)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div><ix:exclude>
          <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
            <div>
              <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 20</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
            </div>
          </div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 8 - Share Capital (cont&#8217;d)</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:36pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">B.</span></span></td>
                  <td style="width:auto;vertical-align:top">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation (cont&#8217;d)</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4) (cont'd)</span></span></div>
            <div style="text-align:justify;margin-left:54pt;line-height:1.25">&#160;</div>
          </div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:72pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(c)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</span></span></div>
              </td>
            </tr>

        </table>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:72pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(d)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</span></span></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000399" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 9 - Research and Development</span></span></strong></p>
    <div>
      <div>
        <div style="line-height:1.25">
          <ix:nonNumeric id="Fxbrl_20240325111225857" name="cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consultants and subcontractors</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325111304537" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,014</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000386" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,052</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000387" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,894</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325111310016" name="us-gaap:OfficersCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,362</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000388" name="us-gaap:OfficersCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,867</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000389" name="us-gaap:OfficersCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,789</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease and maintenance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325111315367" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000390" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000391" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325111320717" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000392" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000393" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325111247489" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000394" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325111250767" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">400</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325111258130" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,381</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000396" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,977</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000397" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,334</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 21</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000417" name="cmmb:GeneralAndAdministrativeDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 10 - General and Administrative</span></span></strong></p>
    <div>
      <div>
        <div style="line-height:1.25">
          <ix:nonNumeric id="Fxbrl_20240325110555714" name="cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110603691" name="us-gaap:SalariesAndWages" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,545</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000400" name="us-gaap:SalariesAndWages" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,435</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000401" name="us-gaap:SalariesAndWages" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">943</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional services</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110618011" name="us-gaap:ProfessionalFees" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,139</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000402" name="us-gaap:ProfessionalFees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,596</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000403" name="us-gaap:ProfessionalFees" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,695</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110622931" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000404" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000405" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fees to Directors</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110632753" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000406" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201004651041" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Insurance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110648131" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">648</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000408" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000409" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rent and maintenance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110658345" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000410" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000411" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110704195" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">323</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000412" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,423</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000413" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110711541" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,078</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000414" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,556</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000415" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,033</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000458" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Note 11 - Income Taxes</span></span></strong></span></span></p>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax rates</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ordinary taxable income in Israel is subject to a corporate tax rate of <ix:nonFraction id="FFact_0000000000418" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryIL" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction>%.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company&#8217;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.</span></span></span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab Inc. is subject to a federal flat tax rate of <ix:nonFraction id="FFact_0000000000419" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction>% and state tax as applicable.</span></span></span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>B.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax assessments</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2023, the Company&#8217;s tax reports through December 31, 2018 are considered closed to audit inspections by the Israeli Tax Authority (&#8220;ITA&#8221;) due to statute of limitation rules effective in Israel.</span></span></span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company has not yet been assessed by the ITA since inception.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

              <tr style="vertical-align:top">
                <td style="width:36pt">&#160;</td>
                <td style="text-align:right;vertical-align:top;width:36pt">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">C.</span></span></span></span></span></div>
                </td>
                <td style="text-align:left;vertical-align:top;width:auto">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Losses for tax purposes carried forward to future years</span></span></span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2023, the Company and its subsidiaries had approximately $<ix:nonFraction id="Fxbrl_20230213140532094" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20231231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">165</ix:nonFraction> million (approximately $<ix:nonFraction id="Fxbrl_20230213140537759" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20221231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">159</ix:nonFraction> million and $<ix:nonFraction id="Fxbrl_20240325142108415" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20211231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">143</ix:nonFraction> million as of December 31, 2022 and 2021 respectively) of net operating loss carryforwards which are available to reduce future taxable income with no limitation on the period of use.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></span></span></div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        <div><ix:exclude>
          <div style="line-height:1.25">
            <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 22</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          </div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 11 - Income Taxes (cont&#8217;d)</span></span></span></span></div>
          <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px">

                <tr style="vertical-align:top">
                  <td style="width:36pt">&#160;</td>
                  <td style="text-align:right;vertical-align:top;width:36pt">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span></span></span></div>
                  </td>
                  <td style="text-align:left;vertical-align:top;width:auto">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Losses for tax purposes carried forward to future years (cont'd)</span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="width:36pt">&#160;</td>
                  <td style="text-align:right;vertical-align:top;width:36pt">&#160;</td>
                  <td style="text-align:left;vertical-align:top;width:auto">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. Chemomab Therapeutics Inc received $<ix:nonFraction id="Fxbrl_20230213140710654" name="cmmb:ReceivedAmountOfChemomabTherapeuticsInc" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction> thousand in December 2022 on account of 2016 and 2017 and received the remainder $<ix:nonFraction id="Fxbrl_20230213140716671" name="cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction> thousand in 2023. Accordingly, a tax benefit in the total amount of $<ix:nonFraction id="Fxbrl_20230213140722797" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction> thousand was recorded in the Company&#8217;s statement of operations during 2022.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px">

              <tr style="vertical-align:top">
                <td style="width:36pt">&#160;</td>
                <td style="text-align:right;vertical-align:top;width:36pt">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span style="font-weight:bold">D.</span></span></span></strong></span></span></div>
                </td>
                <td style="text-align:left;vertical-align:top;width:auto">
                  <p style="font-size:10pt;font-family:Times New Roman,Times,serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Deferred taxes</span></span></strong></span></span></p>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In respect of:</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:72pt">
          <ix:nonNumeric id="Fxbrl_20240325113702579" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2021</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net operating loss carry-forward</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113127688" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,258</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000422" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,550</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000423" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,396</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113134551" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000424" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,774</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000425" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research and development costs</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113142383" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,041</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000426" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,858</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000427" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,449</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113151187" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000428" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000429" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross deferred tax assets</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113158306" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,471</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000430" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000431" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="width:64%;padding-bottom:2px;vertical-align:baseline">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less - Valuation allowance</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325113204191" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,471</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000432" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000433" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net deferred tax assets</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113212847" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230201010225989_Fact_0000000000426" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230201010225989_Fact_0000000000427" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized.</span></span></span></span></div>
          <div>&#160;</div>
        </div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company has established a valuation allowance to offset deferred tax assets on December 31, 2023, 2022 and 2021 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2023 was an increase of approximately $<ix:nonFraction id="Fxbrl_20230201010356964" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20230101to20231231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction> million.</span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        </div>
        <div><ix:exclude>
          <div style="line-height:1.25">
            <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 23</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
          </div>
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note 11 - Income Taxes (cont&#8217;d)</span></span></span></span></div>
          <div style="line-height:1.25;font-weight:bold">&#160;</div>
        </ix:exclude></div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px">

              <tr style="vertical-align:top">
                <td style="width:36pt">&#160;</td>
                <td style="text-align:right;vertical-align:top;width:36pt">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="font-weight:bold">E.</span></strong></span></span></div>
                </td>
                <td style="text-align:left;vertical-align:top;width:auto">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Roll forward of valuation allowance</span></span></span></p>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:72pt">
          <ix:nonNumeric id="Fxbrl_20240325113717888" name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at January 1, 2021</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000438" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,200</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Currency translation Income</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000439" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,425</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax assets acquired through merger</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230201010515039" name="cmmb:TaxAssetsAcquiredThroughMergerValuationAllowance" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,535</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income tax expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000440" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,870</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at December 31, 2021</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000441" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Currency translation Income</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230201010936607" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,316</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income tax expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000444" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,481</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at December 31, 2022</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325112211572_Fact_0000000000441" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Currency translation Income</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325112219753_xbrl_20230201010936607" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,295</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income tax expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325112200162_Fact_0000000000444" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,571</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at December 31, 2023</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000445" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,471</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px">

            <tr style="vertical-align:top">
              <td style="width:36pt">&#160;</td>
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="font-weight:bold">F.</span></strong></span></span></div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Reconciliation of theoretical income tax expense to actual income tax expense</span></span></span></p>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A reconciliation of the Company&#8217;s theoretical income tax expense to actual income tax expense is as follows:</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:72pt">
          <ix:nonNumeric id="Fxbrl_20240325113734351" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">202</span>1</span></span></span></span></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Loss before income taxes</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325113300491" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000447" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,180</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000448" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Statutory tax rate</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113309002" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20230101to20231231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000449" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000450" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20210101to20211231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Theoretical tax benefit</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325113316316" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,571</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000451" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,481</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000452" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,870</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Change in temporary differences for which deferred taxes were not recognized</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325113329731" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,177</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230213113429979_Fact_0000000000453" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,696</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230213113429979_Fact_0000000000454" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,332</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax rate differential</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113338019" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230213113425908_Fact_0000000000453" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230213113425908_Fact_0000000000454" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">101</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Non-deductible expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113354492" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">346</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230213113423827_Fact_0000000000453" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">744</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230213113423827_Fact_0000000000454" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325113401417" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,392</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230213113421604_Fact_0000000000453" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,879</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325114521690" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,064</ix:nonFraction></span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Actual income tax expense (Benefit)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325115329121" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20240325115408857" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20240325115419350" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;</span></span></span></span>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px">

              <tr style="vertical-align:top">
                <td style="width:36pt">&#160;</td>
                <td style="text-align:right;vertical-align:top;width:36pt">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="font-weight:bold">G</span></strong></span></span></div>
                </td>
                <td style="text-align:left;vertical-align:top;width:auto">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Accounting for uncertainty in income taxes</span></span></span></p>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align:justify;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the year ended December 31, 2023, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company&#8217;s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</span></span></span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 24</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000477" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 12 - Related Parties Balances and Transactions</span></span></strong></p>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balances with Related Parties:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following Related Party payables are included in the consolidated Balance Sheets:</span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:36pt">
          <ix:nonNumeric id="Fxbrl_20240325105624656" name="cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000459" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000460" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">891</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued expenses</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000461" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000462" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000463" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">564</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000464" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">949</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 19, 2022, the Company entered into a share purchase agreement with the Company's Co- Founders, see Note 8B(4).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">B.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions with Related Parties:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:36pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following transactions with related parties are included in the consolidated Statements of Operations:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:36pt">
          <ix:nonNumeric id="Fxbrl_20240325105648481" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105700969" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,795</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000466" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,409</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000467" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,255</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105708763" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,304</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000468" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,466</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000469" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional Services</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105715263" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000470" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000471" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105723270" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000472" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000473" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325105729174" name="us-gaap:CostOfRevenue" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,393</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000474" name="us-gaap:CostOfRevenue" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,142</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000475" name="us-gaap:CostOfRevenue" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,310</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 25</span></span></span></span></p></div><hr style="page-break-after:always;height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;margin-top:5pt;margin-bottom:3pt;text-align:center"/><div><div><div style="text-align:right"><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></span></span></div><div><p style="margin:0pt">&#160;</p><span style="width:100%;vertical-align:top"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2023</span></span></span></span></span></span></span></div><div><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left;margin-top:5pt;margin-bottom:10pt"/></div></div></div>
</div><div style="">
  <ix:nonNumeric id="FFact_0000000000488" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20230101to20231231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;font-size:10pt">Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders</span></p>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:36pt">
          <ix:nonNumeric id="Fxbrl_20240325110054121" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands, except share and per share data</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(255, 255, 255)">
                  <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110200438" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,221</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000478" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000479" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(255, 255, 255)">
                  <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_s_20240325110207874" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240325110207874" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">234,998,859</ix:nonFraction></ix:nonFraction></span></span></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong><ix:nonFraction id="Fxbrl_s_20230215224008037" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230215224008037" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">227,589,288</ix:nonFraction></ix:nonFraction></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong><ix:nonFraction id="Fxbrl_20230131213429326" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000481" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">207,468,650</ix:nonFraction></ix:nonFraction></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(255, 255, 255)">
                  <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Net&#160;loss&#160;per&#160;share&#160;attributable&#160;to&#160;ordinary&#160;shareholders,&#160;basic&#160;and&#160;diluted</span></span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_s_20240325110215226" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240325110215226" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20230101to20231231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.103</ix:nonFraction></ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230131213444247" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000482" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.121</ix:nonFraction></ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230131213458553" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000483" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.060</ix:nonFraction></ix:nonFraction></span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:0.55pt;margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:36pt">
          <ix:nonNumeric id="Fxbrl_20240325110121565" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_20230101to20231231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of shares</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding options to purchase ordinary shares</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240325110228946" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">29,873,100</ix:nonFraction></span></span></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000485" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000486" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:10pt 0pt 0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 26</span></span></p>
  <hr style="border:none;border-bottom:4px solid #000000;border-top:1px solid #000000;height:10px;width:100%;color:#000000;text-align:center;text-align:center"/>
</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exhibit_2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 2.1</u></div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">As of the date of this Annual Report on Form 20-F, Chemomab Therapeutics Ltd., an Israeli company (&#8220;we,&#8221; &#8220;our&#8221; and the
      &#8220;Company&#8221;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share. The following description of
      such securities is intended as a summary of the terms of such securities as currently in effect and is qualified in its entirety by the provisions of our amended and restated articles of association, a copy of which is filed as an exhibit to this
      Annual Report on Form 20-F and is incorporated by reference herein. We encourage you to read our amended and restated articles of association and the applicable provisions of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), for additional
      information.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">DESCRIPTION OF ORDINARY SHARES</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Registration Number and Purposes of the Company</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We are registered with the Israeli Registrar of Companies. Our registration number is 51-4672625. Our affairs are governed by our amended and
      restated articles of association, applicable Israeli law and the Companies Law. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful act or activity.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Voting Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">All ordinary shares will have identical voting and other rights in all respects.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Transfer of Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Our fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association,
      unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of the Nasdaq Capital Market. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and
      restated articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are, have been, or will be, in a state of war with Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Election of Directors</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; text-indent: 36pt;">Under our amended and restated articles of association, our board of directors must consist of not less than three (3) but no more than 11
      (eleven) directors. Pursuant to our amended and restated articles of association, each of our directors will be appointed by a simple majority vote of holders of our ordinary shares, participating and voting at an annual general meeting of our
      shareholders, provided that (i) in the event of a contested election, the method of calculation of the votes and the manner in which the resolutions will be presented to our shareholders at the general meeting shall be determined by our board of
      directors in its discretion, and (ii) in the event that our board of directors does not or is unable to make a determination on such matter, then the directors will be elected by a majority of the voting power represented at the general meeting in
      person or by proxy and voting on the election of directors, provided that if the number of such nominees exceeds the number of directors to be elected, then as among such elected nominees the election shall be by a plurality of the votes cast. In
      addition, our directors are divided into three classes, one class being elected each year at the annual general meeting of our shareholders, and shall serve on our board of directors until the third annual general meeting following such election or
      re-election or until they are removed by a vote of 65% of the total voting power of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance with the Companies Law and our amended and restated
      articles of association. In addition, our amended and restated articles of association provide that vacancies on our board of directors may be filled by a vote of a simple majority of directors then in office. Any director so appointed will hold
      office until the next annual general meeting of our shareholders for the election of the class of directors in respect of which the vacancy was created, or in the case of a vacancy due to the number of directors being less than the maximum number of
      directors stated in our amended and restated articles of association, until the next annual general meeting of our shareholders for the election of the class of directors to which such director was assigned by our board of directors.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Dividend and Liquidation Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies
      Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our amended and restated articles of association do
      not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two
      years, according to our then last reviewed or audited financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the end of the period to which the financial statements relate is not
      more than six months prior to the date of the distribution. If we do not meet such criteria, then we may distribute dividends only with court approval; as a company listed on an exchange outside of Israel, however, court approval is not required if
      the proposed distribution is in the form of an equity repurchase, provided that we notify our creditors of the proposed equity repurchase and allow such creditors an opportunity to initiate a court proceeding to review the repurchase. If within 30
      days such creditors do not file an objection, then we may proceed with the repurchase without obtaining court approval. In each case, we are only permitted to distribute a dividend if our board of directors and, if applicable, the court determines
      that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary
      shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be
      authorized in the future.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Exchange Controls</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the
      ordinary shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, have been, or will be, in a state of war with Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Shareholder Meetings</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year and no later than 15 months
      after the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to in our amended and restated articles of association as special general meetings. Our board of directors may call
      special general meetings of our shareholders whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene a special general
      meeting of our shareholders upon the written request of (i) any two or more of our directors, (ii) one-quarter or more of the serving members of our board of directors or (iii) as a company listed on an exchange in the U.S., one or more shareholders
      holding, in the aggregate, either (a) 10% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 10% or more of our outstanding voting power.</div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Under Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting of the shareholders may request that
      the board of directors include a matter in the agenda of a general meeting of the shareholders to be convened in the future, provided that it is appropriate to discuss such a matter at the general meeting. Notwithstanding the foregoing, as a company
      listed on an exchange outside of Israel, a matter relating to the appointment or removal of a director may only be requested by one or more shareholders holding at least 5% of the voting rights at the general meeting of the shareholders. Our amended
      and restated articles of association contain procedural guidelines and disclosure items with respect to the submission of shareholder proposals for general meetings.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at
      general meetings of shareholders are the shareholders of record on a date to be decided by the board of directors, which, as a company listed on an exchange outside Israel, may be between four and 60 days prior to the date of the meeting.
      Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a general meeting of shareholders:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 36pt;">
      <table cellspacing="0" cellpadding="0" border="0" align="left" style="width: 89%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z008dcb41aaf44d82a8990f06f85b4fbc">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">amendments to our articles of association;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">appointment, terms of service or and termination of service of our auditors;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">appointment of directors, including external directors (if applicable);</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">approval of certain related party transactions;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">increases or reductions of our authorized share capital;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">a merger; and</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">the exercise of our board of directors&#8217; powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of
                its powers is required for our proper management.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days
      prior to the meeting and if the agenda of the meeting includes, among other things, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be
      provided at least 35 days prior to the meeting. Under the Companies Law and our amended and restated articles of association, shareholders are not permitted to take action by way of written consent in lieu of a meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Quorum</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Pursuant to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all
      matters submitted to a vote before the shareholders at a general meeting of shareholders. The quorum required for our general meetings of shareholders consists of at least two shareholders present in person or by proxy who hold or represent between
      them at least 33&#8531;% of the total outstanding voting rights, provided, however, that with respect to any general meeting that was convened pursuant to a resolution adopted by the board of directors and which at the time of such general meeting we
      qualify as a &#8220;foreign private issuer,&#8221; the requisite quorum shall consist of two or more shareholders present in person or by proxy who hold or represent between them at least 25% of the total outstanding voting rights. The requisite quorum shall be
      present within half an hour of the time fixed for the commencement of the general meeting. A general meeting adjourned for lack of a quorum shall be adjourned either to the same day in the next week, at the same time and place, to such day and at
      such time and place as indicated in the notice to such meeting, or to such day and at such time and place as the chairperson of the meeting shall determine. At the reconvened meeting, any number of shareholders present in person or by proxy shall
      constitute a quorum, unless a meeting was called pursuant to a request by our shareholders, in which case the quorum required is one or more shareholders, present in person or by proxy and holding the number of shares required to call the meeting as
      described above.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Vote Requirements</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Our amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise
      required by the Companies Law or by our amended and restated articles of association. Under the Companies Law, certain actions require the approval of a special majority, including: (i) an extraordinary transaction with a controlling shareholder or
      in which the controlling shareholder has a personal interest, (ii) the terms of employment or other engagement of a controlling shareholder of the company or a controlling shareholder&#8217;s relative (even if such terms are not extraordinary) and (iii)
      certain compensation-related matters described above under &#8220;Management-Compensation Committee-Compensation Policy under the Companies Law.&#8221; Under our amended and restated articles of association, the alteration of the rights, privileges, preferences
      or obligations of any class of our shares (to the extent there are classes other than ordinary shares) requires the approval of a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the
      governing documents relevant to such class), in addition to a majority of all classes of shares voting together as a single class at a shareholder meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Under our amended and restated articles of association, the approval of the holders of at least 65% of the total voting power of our shareholders
      is generally required to remove any of our directors from office, to amend the provision requiring the approval of at least 65% of the total voting power of our shareholders to remove any of our directors from office, or certain other provisions
      regarding our staggered board, shareholder proposals, the size of our board and plurality voting in contested elections. Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a
      scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, which requires the approval of holders holding at least 75% of the voting rights represented at the meeting and voting on the resolution.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Access to Corporate Records</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Under the Companies Law, all shareholders generally have the right to review minutes of our general meetings, our shareholder register (including
      with respect to material shareholders), our articles of association, our financial statements, other documents as provided in the Companies Law and any document we are required by law to file publicly with the Israeli Registrar of Companies or the
      Israeli Securities Authority. Any shareholder who specifies the purpose of its request may request to review any document in our possession that relates to any action or transaction with a related party which requires shareholder approval under the
      Companies Law. We may deny a request to review a document if we determine that the request was not made in good faith, that the document contains a trade secret or a patent or that the document&#8217;s disclosure may otherwise impair our interests.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Acquisitions under Israeli Law</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic; font-weight: bold;">Full Tender Offer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">A person wishing to acquire shares of a public Israeli company who would, as a result, hold over 90% of the target company&#8217;s voting rights or the
      target company&#8217;s issued and outstanding share capital (or of a class thereof), is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company
      (or the applicable class). If (a) the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company (or the applicable class) and the shareholders who accept the offer constitute a majority of
      the offerees that do not have a personal interest in the acceptance of the tender offer or (b) the shareholders who did not accept the tender offer hold less than 2% of the issued and outstanding share capital of the company (or of the applicable
      class), all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. A shareholder who had its shares so transferred may petition an Israeli court within six months from the date of acceptance of
      the full tender offer, regardless of whether such shareholder agreed to the offer, to determine whether the tender offer was for less than fair value and whether the fair value should be paid as determined by the court. However, an offeror may
      provide in the offer that a shareholder who accepted the offer will not be entitled to petition the court for appraisal rights as described in the preceding sentence, as long as the offeror and the company disclosed the information required by law in
      connection with the full tender offer. If the full tender offer was not accepted in accordance with any of the above alternatives, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s
      voting rights or the company&#8217;s issued and outstanding share capital (or of the applicable class) from shareholders who accepted the tender offer. Shares purchased in contradiction to the full tender offer rules under the Companies Law will have no
      rights and will become dormant shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic; font-weight: bold;">Special Tender Offer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if, as a
      result of the acquisition, the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the
      Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if, as a result of the acquisition, the purchaser would become a holder of more than 45% of the voting rights in the
      company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company. These requirements do not apply if (i) the acquisition occurs in the context of a private placement by the company that received
      shareholder approval as a private placement whose purpose is to give the purchaser 25% or more of the voting rights in the company, if there is no person who holds 25% or more of the voting rights in the company or as a private placement whose
      purpose is to give the purchaser 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company, (ii) the acquisition was from a shareholder holding 25% or more of the voting rights in the company and
      resulted in the purchaser becoming a holder of 25% or more of the voting rights in the company, or (iii) the acquisition was from a shareholder holding more than 45% of the voting rights in the company and resulted in the purchaser becoming a holder
      of more than 45% of the voting rights in the company. A special tender offer must be extended to all shareholders of a company. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s
      outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser, its controlling shareholders, holders of 25% or more of
      the voting rights in the company and any person having a personal interest in the acceptance of the tender offer, or anyone on their behalf, including any such person&#8217;s relatives and entities under their control).</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In the event that a special tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the
      offer, or may abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. The board of directors shall also disclose any personal interest that any of the directors has with respect to the
      special tender offer or in connection therewith. An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or foreseeable special tender offer
      or to impair the chances of its acceptance, is liable to the potential purchaser and shareholders for damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit of the company.
      However, office holders of the target company may negotiate with the potential purchaser in order to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">If a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the offer within four
      days of the last day set for the acceptance of the offer and they will be considered to have accepted the offer from the first day it was made.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the
      purchaser or such controlling person or entity at the time of the offer may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the
      date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. Shares purchased in contradiction to the special tender offer rules under the Companies Law will have no
      rights and will become dormant shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic; font-weight: bold;">Merger</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain conditions described under the
      Companies Law are met, a simple majority of the outstanding shares of each party to the merger that are represented and voting on the merger. The board of directors of a merging company is required pursuant to the Companies Law to discuss and
      determine whether in its opinion there exists a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial
      status of the merging companies. If the board of directors determines that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of the merging companies, the boards of directors must
      jointly prepare a merger proposal for submission to the Israeli Registrar of Companies.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">For purposes of the shareholder vote of a merging company whose shares are held by the other merging company, or by a person or entity holding 25%
      or more of the voting rights at the general meeting of shareholders of the other merging company, or by a person or entity holding the right to appoint 25% or more of the directors of the other merging company, unless a court rules otherwise, the
      merger will not be deemed approved if a majority of the shares voted on the matter at the general meeting of shareholders (excluding abstentions) that are held by shareholders other than the other party to the merger, or by any person or entity who
      holds 25% or more of the voting rights of the other party or the right to appoint 25% or more of the directors of the other party, or any one on their behalf including their relatives or corporations controlled by any of them, vote against the
      merger. In addition, if the non-surviving entity of the merger has more than one class of shares, the merger must be approved by each class of shareholders. If the transaction would have been approved but for the separate approval of each class or
      the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable,
      taking into account the valuation of the merging companies and the consideration offered to the shareholders. If a merger is with a company&#8217;s controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the
      merger is instead subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Under the Companies Law, each merging company must deliver to its secured creditors the merger proposal and inform its unsecured creditors of the
      merger proposal and its content. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving
      company will be unable to satisfy the obligations of the merging company, and may further give instructions to secure the rights of creditors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger is filed
      with the Israeli Registrar of Companies and 30 days from the date that shareholder approval of both merging companies is obtained.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Anti-Takeover Measures</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares
      providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. As of this Current Report on Form 8-K, no preferred shares will be authorized under our amended and restated articles of
      association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or
      otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and restated articles of
      association, which requires the prior approval of the holders of a majority of the voting power attached to our issued and outstanding shares at a general meeting of our shareholders. The convening of the meeting, the shareholders entitled to
      participate and the vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law and our amended articles of association, as described above in &#8220;-Shareholder Meetings.&#8221; In addition, as disclosed
      under &#8220;-Election of Directors,&#8221; we have a classified board structure, which effectively limits the ability of any investor or potential investor or group of investors or potential investors to gain control of our board of directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Borrowing Powers</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Pursuant to the Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take all
      actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Changes in Capital</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Our amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to Israeli law
      and must be approved by a resolution duly passed by our shareholders at a general meeting of shareholders. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of
      sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Exclusive Forum</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Our amended and restated articles of association provide that unless we consent in writing to the selection of an alternative forum, the United
      States District Court for the Southern District of New York shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act and/or the Exchange Act. Our amended and restated articles of
      association also provide that unless we consent in writing to the selection of an alternative forum, the competent courts in Tel Aviv, Israel shall be the exclusive forum for any derivative action or proceeding brought on behalf of the Company, any
      action asserting a breach of a fiduciary duty owed by any of our directors, officers or other employees to the Company or our shareholders or any action asserting a claim arising pursuant to any provision of the Companies Law or the Israeli
      Securities Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Transfer Agent and Registrar</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The transfer agent and registrar for our ordinary shares and ADSs is Computershare. Its address is 1290 Avenue of the
      Americas, 9th Floor, New York, NY 10104, and its telephone number is (212) 805-7100.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Listing</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Our ordinary shares represented by American Depositary Shares are listed on the Nasdaq Capital Market under the symbol &#8220;CMMB.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">American Depositary Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The Bank of New York Mellon, as depositary, registers and delivers our ADSs. Each ADS will represent ordinary shares (or a right to receive twenty
      (20) ordinary shares). Each ADS will also represent any other securities, cash or other property which may be held by the depositary. The depositary&#8217;s office at which our ADSs will be administered and its principal executive office are located at 240
      Greenwich Street, New York, New York 10286.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">You may hold ADSs either (A) directly (i) by having an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name
      or (ii) by having uncertificated ADSs registered in your name or (B) indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in DTC. If you hold ADSs directly,
      you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold our ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of
      ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder
      rights. The depositary will be the holder of the ordinary shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or
      beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and our ADSs.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit
      agreement and the form of ADR. For directions on how to obtain copies of those documents see &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Dividends and Other Distributions</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">How will you receive dividends and other distributions on the shares?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on ordinary
      shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><font style="font-weight: bold;">Cash.</font> The depositary will convert any cash dividend or other cash distribution we pay on the ordinary
      shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the
      depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of our ADS holders who have not been paid. It will not invest the foreign
      currency and it will not be liable for any interest.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Before making a distribution, any withholding taxes or other governmental charges that must be paid will be deducted. See &#8220;Taxation and Government
      Programs.&#8221; It will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all
      of the value of the distribution.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><font style="font-weight: bold;">Shares.</font> The depositary may distribute additional ADSs representing any ordinary shares we distribute as a
      dividend or free distribution. The depositary will only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fraction of an ADS (or ADSs representing those ordinary shares) and distribute the net proceeds in the
      same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed ordinary shares (or ADSs representing those ordinary
      shares) sufficient to pay its fees and expenses in connection with that distribution.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><font style="font-weight: bold;">Rights to purchase additional shares.</font> If we offer holders of our securities any rights to subscribe for
      additional ordinary shares or any other rights, the depositary may (i) exercise those rights on behalf of ADS holders, (ii) distribute those rights to ADS holders or (iii) sell those rights and distribute the net proceeds to ADS holders, in each case
      after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. <font style="font-style: italic;">In that case, you will receive no value for them.</font> The
      depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and
      distribute those securities or, in the case of ordinary shares, new ADSs representing the new ordinary shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the
      ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><font style="font-weight: bold;">Other Distributions.</font> The depositary will send to ADS holders anything else we distribute on deposited
      securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary will have a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does
      with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives
      satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws
      may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no
      obligation to register ADSs, ordinary shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that
      you may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Deposit, Withdrawal and Cancellation</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">How are ADSs issued?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The depositary will deliver ADSs if you or your broker deposits ordinary shares or evidence of rights to receive ordinary shares with the
      custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver our ADSs to or
      upon the order of the person or persons that made the deposit.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">How can ADS holders withdraw the deposited securities?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">You may surrender your ADSs for the purpose of withdrawal at the depositary&#8217;s office. Upon payment of its fees and expenses and of any taxes or
      charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the ordinary shares and any other deposited securities underlying our ADSs to the ADS holder or a person the ADS holder designates at the office of the
      custodian. Or, at your request, risk and expense, the depositary will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a
      fraction of a deposited share or other securities. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">How do ADS holders interchange between certificated ADSs and uncertificated ADSs?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR
      and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs
      requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Voting Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">How do you vote?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">ADS holders may instruct the depositary how to vote the number of deposited ordinary shares their ADSs represent. If we request the depositary to
      solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain
      how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Israel and the provisions of
      our articles of association or similar documents, to vote or to have its agents vote the ordinary shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can
      still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">Except by instructing the depositary as described above, you won&#8217;t be able to exercise voting rights unless you surrender your
      ADSs and withdraw the ordinary shares. However, you may not know about the meeting enough in advance to withdraw the ordinary shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as
      instructed.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In
      addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote and there may be
      nothing you can do if your ordinary shares are not voted as you requested.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In order to give you a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to Deposited Securities, if
      we request the Depositary to act, we agree to give the Depositary notice of any such meeting and details concerning the matters to be voted upon at least 45 days in advance of the meeting date.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Fees and Expenses</div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0b2d48022b164912aaa570266aa3a2a4">

        <tr>
          <td style="width: 44.04%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Persons depositing or withdrawing ordinary shares or<br>
              ADS holders must pay</div>
          </td>
          <td style="width: 0.68%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">&#8203;</div>
          </td>
          <td style="width: 53.94%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">For</div>
          </td>
          <td style="width: 0.66%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">&#8203;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 53.94%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Issuance of ADSs, including issuances resulting from a distribution of ordinary shares or rights or other property Cancellation of ADSs for the purpose of
              withdrawal, including if the deposit agreement terminates</div>
          </td>
          <td style="width: 0.66%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 53.94%; vertical-align: top;">&#160;</td>
          <td style="width: 0.66%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">$.05 (or less) per ADS</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 53.94%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Any cash distribution to ADS holders</div>
          </td>
          <td style="width: 0.66%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 53.94%; vertical-align: top;">&#160;</td>
          <td style="width: 0.66%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the ordinary shares had been deposited for
              issuance of ADSs</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 53.94%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders</div>
          </td>
          <td style="width: 0.66%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 53.94%; vertical-align: top;">&#160;</td>
          <td style="width: 0.66%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">$.05 (or less) per ADS per calendar year</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 53.94%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Depositary services</div>
          </td>
          <td style="width: 0.66%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 44.04%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 53.94%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 0.66%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Persons depositing or withdrawing ordinary shares or<br>
              ADS holders must pay</div>
          </td>
          <td style="width: 0.68%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">&#8203;</div>
          </td>
          <td style="width: 53.94%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">For</div>
          </td>
          <td style="width: 0.66%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">&#8203;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Registration or transfer fees</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 53.94%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw ordinary
              shares</div>
          </td>
          <td style="width: 0.66%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 53.94%; vertical-align: top;">&#160;</td>
          <td style="width: 0.66%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Expenses of the depositary</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 53.94%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)</div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Converting foreign currency to U.S. dollars</div>
          </td>
          <td style="width: 0.66%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 53.94%; vertical-align: top;">&#160;</td>
          <td style="width: 0.66%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Taxes and other governmental charges the depositary or the custodian have to pay on any ADSs or ordinary shares underlying ADSs,
                such as stock transfer taxes, stamp duty or withholding taxes</div>
            </div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td nowrap="nowrap" style="width: 53.94%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">As necessary</div>
          </td>
          <td style="width: 0.66%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td style="width: 0.68%; vertical-align: top;">&#160;</td>
          <td nowrap="nowrap" style="width: 53.94%; vertical-align: top;">&#160;</td>
          <td style="width: 0.66%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.04%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Any charges incurred by the depositary or its agents for servicing the deposited securities</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td style="width: 0.68%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
          <td nowrap="nowrap" style="width: 53.94%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">As necessary</div>
          </td>
          <td style="width: 0.66%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8203;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for
      the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the
      fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect
      any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting
      services until its fees for those services are paid.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and
      maintenance of our ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers,
      dealers, foreign currency or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The depositary may convert foreign currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and
      not as an agent, fiduciary or broker on behalf of any other person and earns revenue, including, without limitation, fees and spreads that it will retain for its own account. The revenue is based on, among other things, the difference between the
      exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the
      exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be most favorable to ADS holders,
      subject to its obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Payment of Taxes</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your
      ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited
      securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any
      proceeds, or send to ADS holders any property, remaining after it has paid the taxes.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder
      surrendering ADSs and subject to any conditions or procedures the depositary may establish.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the
      depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">If there is any change in the deposited securities such as a subdivision, combination or other reclassification, or any merger, consolidation,
      recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as
      deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the
      depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of our ADSs.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may
      distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities
      underlying ADSs have become apparently worthless, the depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Amendment and Termination</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">How may the deposit agreement be amended?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or
      increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become
      effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the
      ADRs and the deposit agreement as amended.</div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">How may the deposit agreement be terminated?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the
      deposit agreement if:</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
      <div style="margin-left: 18pt;">
        <table cellspacing="0" cellpadding="0" border="0" align="left" style="width: 89%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

            <tr>
              <td style="width: 3%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
              </td>
              <td style="width: 97%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
                  <div style="line-height: 1.25; color: #000000;">90 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;</div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 3%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
              </td>
              <td style="width: 97%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">we delist our ADSs from an exchange on which they were listed and do not list our ADSs on another exchange within a reasonable time;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 3%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
              </td>
              <td style="width: 97%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">we appear to be insolvent or enter insolvency proceedings;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 3%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
              </td>
              <td style="width: 97%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 3%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
              </td>
              <td style="width: 97%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">there are no deposited securities underlying our ADSs or the underlying deposited securities have become apparently worthless; or</div>
              </td>
            </tr>
            <tr>
              <td style="width: 3%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
              </td>
              <td style="width: 97%; vertical-align: top;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">there has been a replacement of deposited securities.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">If the deposit agreement will terminate, the depositary will notify ADS holders at least 90 days before the termination date. At any time after
      the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability
      for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited
      securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind if it would interfere with the selling process. The depositary may
      refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the
      depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the
      deposit agreement except as described in this paragraph.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Limitations on Obligations and Liability</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">Limits on our obligations and the obligations of the depositary; Limits on liability to holders of ADSs</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of
      the depositary. We and the depositary:</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
        <div style="margin-left: 18pt;">
          <table cellspacing="0" cellpadding="0" border="0" align="left" style="width: 89%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                </td>
                <td style="width: 97%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith and the depositary will not be a
                    fiduciary or have any fiduciary duty to holders of ADSs;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                </td>
                <td style="width: 97%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">are not liable if we are or it is prevented or delayed by law or circumstances beyond our or its control from performing our or its obligations under
                    the deposit agreement;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                </td>
                <td style="width: 97%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">are not liable if we exercise or it exercises discretion permitted under the deposit agreement;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                </td>
                <td style="width: 97%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders
                    of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                </td>
                <td style="width: 97%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">have no obligation to become involved in a lawsuit or other proceeding related to our ADSs or the deposit agreement on your behalf or on behalf of any
                    other person;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                </td>
                <td style="width: 97%; vertical-align: top;">
                  <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">are not liable for the acts or omissions of any securities depository, clearing agency or settlement system;</div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height: 1.25; clear: both;">
          <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
              <div style="margin-left: 18pt;">
                <table cellspacing="0" cellpadding="0" border="0" align="left" style="width: 89%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

                    <tr>
                      <td style="width: 3%; vertical-align: top;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                      </td>
                      <td style="width: 97%; vertical-align: top;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person; and</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 3%; vertical-align: top;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                      </td>
                      <td style="width: 97%; vertical-align: top;">
                        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">the depositary has no duty to make any determinations or provide any information as to our status, or any liability for any tax consequences that
                          may be incurred by ADS holders as a result of owning or holding ADSs or liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit reduced rate of withholdings or refund of amounts withheld
                          in respect of tax or any other tax benefit.</div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Requirements for Depositary Actions</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may
      require:</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25; color: rgb(0, 0, 0);">
        <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
          <div style="margin-left: 18pt;">
            <table cellspacing="0" cellpadding="0" border="0" align="left" style="width: 89%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

                <tr>
                  <td style="width: 3%; vertical-align: top;">
                    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                  </td>
                  <td style="width: 97%; vertical-align: top;">
                    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of
                      any ordinary shares or other deposited securities;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 3%; vertical-align: top;">
                    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                  </td>
                  <td style="width: 97%; vertical-align: top;">
                    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 3%; vertical-align: top;">
                    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                  </td>
                  <td style="width: 97%; vertical-align: top;">
                    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25; clear: both;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
                <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed
      or at any time if the depositary or we think it advisable to do so.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Your Right to Receive the Ordinary Shares Underlying your ADSs</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time except:</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
      <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25; color: rgb(0, 0, 0);">
          <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
            <div style="margin-left: 18pt;">
              <table cellspacing="0" cellpadding="0" border="0" align="left" style="width: 89%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

                  <tr>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                    </td>
                    <td style="width: 97%; vertical-align: top;">
                      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
                        <div style="line-height: 1.25; color: #000000;">when temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii) the transfer of ordinary shares is blocked to permit
                          voting at a shareholders&#8217; meeting; or (iii) we are paying a dividend on our shares;</div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                    </td>
                    <td style="width: 97%; vertical-align: top;">
                      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
                        <div style="line-height: 1.25; color: #000000;">when you owe money to pay fees, taxes and similar charges; or</div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 3%; vertical-align: top;">
                      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#8226;</div>
                    </td>
                    <td style="width: 97%; vertical-align: top;">
                      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
                        <div style="line-height: 1.25; color: #000000;">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited
                          securities.</div>
                      </div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height: 1.25; clear: both;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">
                  <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">This right of withdrawal may not be limited by any other provision of the deposit agreement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Direct Registration System</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification
      System, or Profile, will apply to our ADSs. DRS is a system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is
      a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account
      of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand
      that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on
      behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance on and compliance with instructions received by the depositary through the
      DRS/Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Shareholder Communications; Inspection of Register of Holders of ADSs</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited
      securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the
      register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or our ADSs.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Jury Trial Waiver</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have
      against us or the depositary arising out of or relating to our shares, our ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court
      would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>exhibit_12-1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 12.1</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">OF THE SARBANES OXLEY ACT OF 2002</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">I, Adi Mor, certify that:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">1. I have reviewed this Annual Report on Form 20-F of Chemomab Therapeutics Ltd.;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
      the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
      in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
      supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
      designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our
      conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the
      registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting;
      and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
      reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
      which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the
      registrant&#8217;s internal control over financial reporting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zb71e8adc8cb345e9ae4ed07a5f59b193" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Date: March 28, 2024</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
            </div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><u>/s/ Adi Mor</u></div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Adi Mor</div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Chief Executive Officer</div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">(Principal Executive Officer)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><img width="624" height="15" src="image00034.jpg"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>exhibit_12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 12.2</u></div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">OF THE SARBANES OXLEY ACT OF 2002</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
    </div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">I, Sigal Fattal, certify that:</div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">1. I have reviewed this Annual Report on Form 20-F of Chemomab Therapeutics Ltd.;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
      necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
      all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
      procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
      designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
      prepared;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">b. Designed such internal control over financial reporting, or caused such internal control over financial
      reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
      principles;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this
      report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that
      occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over
      financial reporting; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
      financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over
      financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">b. Any fraud, whether or not material, that involves management or other employees who have a significant
      role in the registrant&#8217;s internal control over financial reporting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zbd76fdf287f545f588ddd6f5c9859494" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Date: March 28, 2024</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
            </div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><u>/s/ Sigal Fattal</u></div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Sigal Fattal</div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Chief Financial Officer</div>
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">(Principal Financial Officer)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><img width="624" height="15" src="image00034.jpg"></div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>exhibit_13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 13.1</u></div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</div>
    <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</div>
    <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 906</div>
    <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">I, Adi Mor, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
      that the Annual Report on Form 20-F of Chemomab Therapeutics Ltd. for the fiscal year ended December 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in
      such Annual Report on Form 20-F fairly presents, in all material respects, the financial condition and results of operations of Chemomab Therapeutics Ltd.</div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="ze9712866ab8f4b818d8663b414bab396" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: middle;">&#160;</td>
          <td style="width: 50.16%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Date: March 28, 2024</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><u>/s/ Adi Mor</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Adi Mor</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Chief Executive Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">(Principal Executive Officer)</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="line-height: 1.25;">
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <img width="624" height="15" src="image00034.jpg"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>exhibit_13-2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 13.2</u></div>
    <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 906</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">I, Sigal Fattal, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
      2002, that the Annual Report on Form 20-F of Chemomab Therapeutics Ltd. for the fiscal year ended December 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information
      contained in such Annual Report on Form 20-F fairly presents, in all material respects, the financial condition and results of operations of Chemomab Therapeutics Ltd.</div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zfef55df5b5444e8b9936872363c13c57" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: middle;">&#160;</td>
          <td style="width: 50.16%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Date: March 28, 2024</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><u>/s/ Sigal Fattal</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Sigal Fattal</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Chief Financial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">&#160;</td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">(Principal Financial Officer)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><img width="624" height="15" src="image00034.jpg"></div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>exhibit_15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    <div>
      <div style="line-height: 1.25;">
        <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 15.1</u></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">The Board of Directors<br>
          Chemomab Therapeutics Ltd.:</div>
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">We consent to the incorporation by reference in the registration statement on Form F-3 (No. 333-275002) and registration statements on Form S-8 (No. 333-266868 and No. 333-259489) of our report
          dated March 27, 2024, with respect to the consolidated financial statements of Chemomab Therapeutics Ltd.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z74542f1829ff40d88d0635d5b2559c7c">

          <tr>
            <td style="width: 100%; vertical-align: middle;">
              <div style="line-height: 1.25; font-style: italic;">/s/ Somekh Chaikin</div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 100%; vertical-align: middle;">
              <div style="line-height: 1.25;">Member Firm of KPMG International</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Tel Aviv, Israel</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; line-height: 1.25;">March 28, 2024</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div> <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>exhibit_97-1.htm
<DESCRIPTION>EXHIBIT 97.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> </u>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 97.1</u><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.<br>
      <font style="color: rgb(0, 0, 0);">POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Chemomab Therapeutics Ltd. (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the &#8220;<font style="font-weight: bold; font-style: italic;">Policy</font>&#8221;),
        effective as of October 2, 2023 (the &#8220;<font style="font-weight: bold; font-style: italic;">Effective Date</font>&#8221;).&#160; Capitalized terms used in this Policy but not otherwise defined herein are
        defined in Section 11.</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z134a8e50a99c48699f345715a14ff25d">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Persons Subject to Policy</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This Policy shall apply to and be binding and enforceable on current and former Officers. In addition, the Committee and the Board may
      apply this Policy to persons who are not Officers, and such application shall apply in the manner determined by the Committee and the Board in their sole discretion.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z27bcd7cf4a2a4308850354c0cfb69c84">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Compensation Subject to Policy</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This Policy shall apply to Incentive-Based Compensation received on or after the Effective Date. For purposes of this Policy, the date
      on which Incentive-Based Compensation is &#8220;received&#8221; shall be determined under the Applicable Rules, which generally provide that Incentive-Based Compensation is &#8220;received&#8221; in the Company&#8217;s fiscal period during which the relevant Financial Reporting
      Measure is attained or satisfied, without regard to whether the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8cc53b18d19043bba919c149f25f5d9b">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Recovery of Compensation</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">In the event that the
        Company is required to prepare a Restatement, the Company shall recover, reasonably promptly and in accordance with Section 4 below, the portion of any Incentive-Based Compensation that is Erroneously Awarded Compensation, unless the Committee and
        the Board have determined that recovery from the relevant current or former Officer would be Impracticable. Recovery shall be required in accordance with the preceding sentence regardless of whether the applicable Officer engaged in misconduct or
        otherwise caused or contributed to the requirement for the Restatement and regardless of whether or when restated financial statements are filed by the Company.&#160; For clarity, the recovery of Erroneously Awarded Compensation under this Policy will
        not give rise to any Officer&#8217;s right to voluntarily terminate employment for &#8220;good reason&#8221; or due to a &#8220;constructive termination&#8221; (or any similar term of like effect) under any plan, program or policy of or agreement with the Company or any of its
        affiliates</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1b6055b2fd8f44eb97c340140894aa5c">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Manner of Recovery; Limitation on Duplicative Recovery</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">The Committee and the Board
        shall, in its sole discretion, determine the manner of recovery of any Erroneously Awarded Compensation, which may include, without limitation, reduction or cancellation by the Company or an affiliate of the Company of Incentive-Based Compensation
        or Erroneously Awarded Compensation, reimbursement or repayment by any person subject to this Policy, and, to the extent permitted by law, an offset of the Erroneously Awarded Compensation against other compensation payable by the Company or an
        affiliate of the Company to such person. Notwithstanding the foregoing, unless otherwise prohibited by the Applicable Rules, to the extent this Policy provides for recovery of Erroneously Awarded Compensation already recovered by the Company
        pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 or Other Recovery Arrangements, the amount of Erroneously Awarded Compensation already recovered by the Company from the recipient of such Erroneously Awarded Compensation may be credited to
        the amount of Erroneously Awarded Compensation required to be recovered pursuant to this Policy from such person</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za326efa3ef1d4d809a3e91d709ec2d76">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">5.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Administration</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This Policy shall be administered, interpreted and construed by the Committee, which is authorized to make all determinations necessary,
      appropriate or advisable for such purpose. The Board may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable law, and in such event references herein to the &#8220;Committee&#8221; shall be deemed to be
      references to the Board.&#160; Subject to any permitted review by the applicable national securities exchange or association pursuant to the Applicable Rules, all determinations and decisions made by the Committee pursuant to the provisions of this Policy
      shall be final, conclusive and binding on all persons, including the Company and its affiliates, shareholders and employees. The Committee may delegate administrative duties with respect to this Policy to one or more directors or employees of the
      Company, as permitted under applicable law, including any Applicable Rules.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6401ab0317804041a7d3fb5b063562aa">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">6.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Interpretation</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This Policy shall be interpreted and applied in a manner that is consistent with the requirements of the Applicable Rules, and to the
      extent this Policy is inconsistent with such Applicable Rules, it shall be deemed amended to the minimum extent necessary to ensure compliance therewith.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0ac7161560bf4b958cf749496498fd03">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">7.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>No Indemnification; No Liability</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Company shall not indemnify or insure any person against the loss of any Erroneously Awarded Compensation pursuant to this Policy,
      nor shall the Company directly or indirectly pay or reimburse any person for any premiums for third-party insurance policies that such person may elect to purchase to fund such person&#8217;s potential obligations under this Policy.&#160; None of the Company,
      an affiliate of the Company or any member of the Committee or the Board shall have any liability to any person as a result of actions taken under this Policy.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z952fec9294ee4cc2aa496f333a9b180a">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">8.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Application; Enforceability</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">Except as otherwise
        determined by the Committee or the Board, the adoption of this Policy does not limit, and is intended to apply in addition to, any Other Recovery Arrangements. </font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Without
        limiting the foregoing, in the event of a conflict between this Policy and the Compensation Policy, the latter shall prevail, except with respect to the recovery of any portion of Incentive-Based Compensation that is Erroneously Awarded
        Compensation that would not be recoverable under the Compensation Policy, in which case this Policy shall prevail.&#160; <font style="color: rgb(0, 0, 0);">Subject to Section 4, the remedy specified in this Policy shall not be exclusive and shall be in
          addition to every other right or remedy at law or in equity that may be available to the Company or an affiliate of the Company</font> or is otherwise required by applicable law and regulations.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z87e09cbfddae42c2b3ed1601e1ce88b5">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">9.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Severability</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The provisions in this Policy are intended to be applied to the fullest extent of the law; provided, however, to the extent that any
      provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the
      extent necessary to conform to any limitations required under applicable law.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8b0c2a5f9834412ca4cfb3f638a4c96d">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">10.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Amendment and Termination</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">The Board or the Committee may amend, modify or terminate this Policy in whole or in part at any time and from time
      to time in its sole discretion. This Policy will terminate automatically when the Company does not have a class of securities listed on a national securities exchange or association in the U.S.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeaa2a12eeacf4391b6ee465bc2c74472">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">11.</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;"><u>Definitions</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">Applicable Rules</font>&#8221; means Section 10D of the Exchange
      Act, Rule 10D-1 promulgated thereunder, the listing rules of the national securities exchange or association on which the Company&#8217;s securities are listed, and any applicable rules, standards or other guidance adopted by the Securities and Exchange
      Commission or any national securities exchange or association on which the Company&#8217;s securities are listed.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">Board</font>&#8221; means the Board of Directors of the Company.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">&#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Compensation Policy</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">&#8221; means </font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">the Company&#8217;s compensation policy for officers and directors, as adopted in accordance with the Israeli Companies Law 5759-1999 and as in effect from
        time to time.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">Committee</font>&#8221; means the Compensation Committee of the
      Board or, in the absence of such a committee, a majority of the independent directors serving on the Board.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">Erroneously Awarded Compensation</font>&#8221; means the amount of
      Incentive-Based Compensation received by a current or former Officer that exceeds the amount of Incentive-Based Compensation that would have been received by such current or former Officer based on a restated Financial Reporting Measure, as
      determined on a pre-tax basis in accordance with the Applicable Rules.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">Exchange Act</font>&#8221; means the Securities Exchange Act of
      1934, as amended.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">Financial Reporting Measure</font>&#8221; means any measure
      determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including GAAP, IFRS and non-GAAP/IFRS financial measures, as
      well as stock price and total shareholder return.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">GAAP</font>&#8221; means United States generally accepted
      accounting principles.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">IFRS</font>&#8221; means international financial reporting
      standards as adopted by the International Accounting Standards Board.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">Impracticable</font>&#8221; means (a) the direct expense paid to
      third parties to assist in enforcing recovery would exceed the Erroneously Awarded Compensation; provided that the Company has (i) made reasonable attempt(s) to recover the Erroneously Awarded Compensation, (ii) documented such reasonable attempt(s)
      and (iii) provided such documentation to the relevant listing exchange or association, (b) the recovery would violate the Company&#8217;s home country laws adopted prior to November 28, 2022 pursuant to an opinion of home country counsel; provided that the
      Company has (i) obtained an opinion of home country counsel, acceptable to the relevant listing exchange or association, that recovery would result in such a violation and (ii) provided such opinion to the relevant listing exchange or association, or
      (c) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations
      thereunder.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">&#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Incentive-Based Compensation</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">&#8221; means, with respect to a Restatement, any compensation that is granted, earned, or vested based wholly or in part upon the attainment of one or more Financial Reporting Measures and received by a person: (a) after such person began
        service as an Officer; (b) who served as an Officer at any time during the performance period for that compensation; (c) while the Company </font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">has a class of securities
        listed on a national securities exchange or association; and (d) <font style="color: rgb(0, 0, 0);">during the applicable Three-Year Period.</font></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">&#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Officer</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">&#8221; means </font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">each person who the Company determines serves as a Company officer, as defined in Section 16 of the Securities Exchange Act of 1934, as amended<font style="color: rgb(0, 0, 0);">.</font></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">&#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; font-style: italic;">Other Recovery Arrangements</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">&#8221;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; font-style: italic;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">means any clawback, recoupment, forfeiture or similar
        policies or provisions of the Company or its affiliates, including any such policies or provisions of such effect contained in any employment agreement, bonus plan, incentive plan, equity-based plan or award agreement thereunder or similar plan,
        program or agreement of the Company or an affiliate or required under applicable law (including, without limitation, the Compensation Policy).</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-weight: bold; font-style: italic;">Restatement</font>&#8221; means an accounting restatement to
      correct the Company&#8217;s material noncompliance with any financial reporting requirement under securities laws, including restatements that correct an error in previously issued financial statements (a) that is material to the previously issued
      financial statements or (b) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period<font style="font-style: italic;">.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">&#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Three-Year Period</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0);">&#8221;
        means, with respect to a Restatement, the three completed fiscal years immediately preceding the date that the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not
        required, concludes, or reasonably should have concluded, that the Company is required to prepare such Restatement, or, if earlier, the date on which a court, regulator or other legally authorized body directs the Company to prepare such
        Restatement.</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;<font style="color: rgb(0, 0, 0);">The &#8220;Three-Year Period&#8221; also includes any transition period (that results from a change in the Company&#8217;s fiscal year)
          within or immediately following the three completed fiscal years identified in the preceding sentence.</font>&#160;<font style="color: rgb(0, 0, 0);">However, a transition period between the last day of the Company&#8217;s previous fiscal year end and the
          first day of its new fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year</font>.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">ACKNOWLEDGMENT AND CONSENT TO</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br>
      </font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The undersigned has received a copy of the Policy for Recovery of Erroneously Awarded Compensation (the &#8220;Policy&#8221;) adopted by Chemomab Therapeutics Ltd.
      (the &#8220;Company&#8221;), and has read and understands the Policy. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Policy.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">As a condition of receiving Incentive-Based Compensation from the Company, the undersigned agrees that any Incentive-Based Compensation received on or
      after the Effective Date is subject to recovery pursuant to the terms of the Policy. To the extent the Company&#8217;s recovery right conflicts with any other contractual rights the undersigned may have with the Company, the undersigned understands that
      the terms of the Policy shall supersede any such contractual rights. The terms of the Policy shall apply in addition to any right of recoupment against the undersigned under the Compensation Policy or applicable law and regulations.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb67df9ab65564bd9ad0156a5d9372475">

        <tr>
          <td style="width: 27.86%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">___________________</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Date</div>
          </td>
          <td style="width: 72.14%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">________________________________________</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Signature</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 27.86%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 72.14%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">________________________________________</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Name</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 27.86%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 72.14%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">________________________________________</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Title</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">5</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cmmb_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cmmb_img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0O!W<# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHII8#=_L_P"?Y\4G)*R;M=V7F ZFLZKC)QG_
M #WK/BU%))FAP<J2#^!QZ>ON:CU&"60I(CD!!D@$\@9Z<'_)[=YC4A-M1E=Q
MW#7L:V<]**S;&[$P\L]5X/7KV[?Y_G<9L].@_P YJ:M54DF]6VDEWU5_N3&D
MV[(FSCKQ15.?D%E;.W)P/Y=/\XZ46ET+A3CJI*_B.#V]O\]JC)MZQ:5DT^]T
MOQ(4I.4DXM);2Z/1?U_3+E%%%64%%12-M^;/09QS_GGI3D?>N:SC.\I0:Y6O
MAN_B75_U_P $7,K\MUS6O;K8?12;AG&>:6M!A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M];?H?L.#5:-*$*J5XQM+3>5E;E\K?\ =1117 =@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'*3C%/:-[+M>U]>NR"BBBD2%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_D,SXLI8;EC3<8R;2YY:Q>UWOMO;0_ISMO\ @L[\+KAPGV1E.?[D7Y<R=?\
M.*[7PW_P5K^&GB+6[/2(D"-=/&@8B%1F0@#D2>_Y=Z_E&N?#MFK;X(T&XY&T
M $?IQU[?H<58T>UO-%U2WO8)-DT11D=6(*XY'3GC\OUK]7S'Z'>0T:+EAZ6(
ME**D[NH[.VMK=/+YZGFRXNJSK4X0G!PFKJ2MNN7?7NU_6_\ >S\-_C1X4^(.
MGP7=IJEDDDZ*RPF:/>=P! "@^IQ_G->QY5U# @J1D,.F/4'TK^&GX8?M8?%'
MX8^.-$U6?Q#>_P#".6,]NUS:K=3;'CCE4LNS(4Y4<YK^KS]DK]K+PM^T-X0L
M[VQNX(;FWMDBD221%D>54!) !)))/YCVQ7\:^*7A%FW V+J55AZD\JE-I5.5
MOV&J48S?63=W?H?699G-'&TW'F4J\-'%/XMM5]_KY'VQN(&.OH?_ -=.5L\'
MKVJ&-2PR#D'D'G&/;Z_K^%3JNWZU^&QA6C7LG^[CI=WLX^[=?XM/E]Y[D9*4
M$VK2>OI_6O\ 5AU%%%=@!112')'!Q2;:3:3?DMW]X <D<'%1R!L##?I[?U_3
MM4M8OB+4TT71=2U>3_5:=:37<G^[$NX]>.F?SIPC>:EJI2Y59MM+;2VNOFB*
MGP2T;T^SOTV>Y7UCQ%HN@PB76M6L],BRH,EY,(4R< 8+<9)( ^M?D+_P4!_X
M+ ?!C]AS[&-9U"PUG[5OQ]CE@N -NWU<==WXFOYU_P#@N5_P65UW5%UOX,_!
M'7KOP[XOT+4H()[FTNFM9"-/OX?M #P/O)9(V!XYW8K^/SXR?'CXT_M!M"?B
MKXFO?$(MB=OVR[FN< @;N)2?0$U]YDW V:YI[\J,J-)J+AS+2JI6U5K[)]?T
M/GL5GN"P+M.:JUK6Y+N\4FK+7J^K[H_O<A_X.I?V=Y!DZ<W/K%;CW_YZG(Q_
M.I'_ .#J/]GF(973F/KB*V_^.?T_^M_G5_\ "+6,T>(+=5*##?)CGZC\O?KF
MK6G>&-/DBG$T"LR#NBG_ .OCCM_6OOZ7A0_8-UH575:5M79/3=7?_#GF0XGI
MRGS1I*/+O%VYDGR]5WW^]=4?ZS?_  3\_P""O_P;_;C:Z31-0L=(:V,8VW<D
M$!;?NQ@!VS]W\.]?L!8ZII^K(+C3;Z"\@.")('$B$>H8=NO(^M?XMG[.G[0?
MQ>_9ZUM;_P"&OB2\T&SBF22Z2UNY[;S$0YQ^Y.#QG@^OI7]]7_!%7_@J]:_&
M/P)H7A/QOK9O?$K-)ITCW=P))9)XKB2WS\[[R25'N>G/2OA,^X(QF42JSIM3
MC&W+!)W<;)R;>WNVU_$]JAG%#%1IO51D_>DG:TK^['3^;IOIJ?U?CIZ^]%9^
MEW:WUC:WB$%+J%)D]U<9!'L1W'I5\@Y!!X[C_/\ D5^?3;AHHN33MIZZOY?T
MSVX/FBGM=)V?32XM%%%,H**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ7#QMN)+Y.TYS@=OX?Y_7VI+87$@=I23UV'@_P!.G_UN:=!-*FZ-S^\W-LZ
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MU?SKXX<3SAPWF<*$81JTL)6<;[:0[+I_5C['(8<U?#0_>Z)1;6S3:NW\MO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2'.#@9-+12>J:NU?JMU]X"#.!D8-+110DTDFVVDE=[OS
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M;S53R;A-L>,;B,<Y[$Y&?S_.H&TV4RED0^1_ST ZA>^>GM5I)Y[\;&3:AYW
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MKC2;N&&.YB$N9&C*KL!SSZ=S7H]1&%#D,-RMD%3T(/8^M5%VL]?=::72Z?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC/\ D5A4=2%2*C"R^7OWMIY6W^1G[6G:_->[:V?1)]NW0LH4).WD_A^/3O\
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MC*,E>+NKVOJ%%%%,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV78QVD;>,'CM[U_2I\ /^"HWPY^,OB6P\*0;+.XE6&(RS^4B[A&N<D,>_?\
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MW<_+.W]W-?O1H/C+P[XB)_L35(+\C&?*D1\9]=K'CBO\67X?_M!_%[X RO\
M\*EUZ\T(7!&_[+/+!G&<9\O(R,\=./I7]$O_  2U_P""[_BG]FU;Y_V@]>O/
M$/GB,PBXG-SMV[MV//9#SE?6OY_S?@O,\K;<:<J]*4GK"+T6A]U@LXPF84X5
M8S5*J_L2>JM;Y>9_I)S7ACF6,*><?J!_GH<_I5F:;RX3)@GC./IU_P _RZU^
M77_!/;_@IA\)_P!O'P8OB[PY?V.GNT]W EI/)#%.S6EQ+;X$:.V=WE97K7ZD
MCRYHP5(>-@"I'*D=B/45\A7A[)JG*FX5(Z5$^^GDOG_P3WD[I.]T]G\OZ95L
M[O[2"2I&"1Z_Y_7\.]:XN )A'M/)Z]^3VX/XXS6BL*HI$8"Y]!C_ #SSS^E1
M&!<[W4%L\' SG\\?_JZ5-)QB[RUZ))V=]+/SU_(B;=^5Q?*UK+HM4?@)_P '
M#T._]B;Q.IS@V$O/UF'].WI^=?Y8>B6\%Q)?6GD@-]NO/GP,_P#'S(3V_P >
M_K@?ZH7_  <-N6_8I\3$9'^@2?\ HX?TK_+/\-S1?:+Y G[S[=>?-CTN)?<?
M_7SR*_8_"S T\95J\\4Y1O)75[6:T7S];GQ_%.)=##TN1MTTUHF]4TM7??[N
MI5U_[+8)86OV9#)]NM/WF!Q_I,1/;/X?S-?ZF7_!N[A_V)/#&./] C//_78C
M_P"O7^6MXF\N6:PC*Y?[?9?-@?\ /S&<Y_(?6O\ 4K_X-XXS%^Q+X8'_ $XQ
M>W_+;^@_7\JS\3LMCA:D*M.FJ2E-*5HK63M=W2[=V7PQ5C/"59.,[MN7*Y7N
MK+;MUL?OXG7;[]?QQFK51QC R1R?\D_7-25^,N$5.4HJS>C\_P"K'UE%.--7
M=[ZKR5E9:>04444S4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;8I8]J=2$ @@]#UIK=7VOKZ 5+>[69BHSQZC_P"L/\/>KE11PI&25 !/H/\
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M_P"?VF$R;!PBZTJ:EHE.$M>5Z-[JUUMI;UU/\YF[_P"#77]IN=%7^U&."?\
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MN;=O9=NK^5QI-[$M%(#D9I:UC)22E%W3U3$%%%%, HHHH **** "BD)QUH)
MQGO4N<%>\DK6OY7V^\->PM%%%4 4444 %%%% !1110 4444 %%)D9QWI:2DI
M7LT[.SMT?8 HHHI@%%%% !1110 ASQ@XYY]_\_YZ4M%%2HI.4E>\FF[MM:)+
M1=-@"BBBJ;LKO1 %%(#D9%+234DFG=/9@(3@9- .1D4M%+WN:]URVVMK?O<
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M?X<WU479]5Z'^1=JK"'QIXT?C U[4"1W_P!9GUY_'G%8FN3K/I-RRJ0 K@C
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M@^>+3:E96M;ST_R=C[?TG_@HY^T9#J,-Q?ZO??V<KQ[\W+X"*PS_ !],=O\
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M6(8]>O\ ^NK!&>"*6N=TW*JYS?-%I)1>MFK:_@_P!PA**BXIJ+TNMK6M;[A
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ME3Q2?^@,U3JP;I_G\J>N]M!W2:3:N]EW'4444#"BBB@!,#&,<4S8<_[.<_\
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M4@X(:[MP0?0@R9!HU[ 7J;L7T_G_ (U1_M;2O^@GI_\ X&6W_P <I?[6TO\
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MX&6__P <I/[6TK_H)Z?_ .!EM_\ '*+/L_N&:%%9_P#:VE?]!/3_ /P,MO\
MXY4\=Y:3?ZFZMI?^N<\3_P#H+&EKV_K^F@+-%%% !1110 444QY(XQND=(U'
M)9V"@?BQ H "Q)POX_Y_P_"GUG_VII:D@ZC8*>X-Y;@_D9*7^UM+'74K ?\
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M/4/"VL6$D,J@J?M42]0&'WI 0,'\*^@TN=%EE2Z;4-/WXX/VRVS\V#@?O.G
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M5Y)UA7YE?\%;/^3,?B?_ -@#6/\ TB-?IK7YE?\ !6S_ ),Q^)__ & -8_\
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M/09XY.??\^M7%.Y0?45\/*+C9]'>W_!['=&I&4I15_=ZVT>B>C^9'),L9 )
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MO_!/H^>G6C%1J:2M)<K6O6W5?\&Q>$2;=C*K ]0P# _@1C]*^<_C)^S)\/\
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M<!R@9LYY[_\ ZZ]<>"&24.>#GVXQ^!(_ CW]:^!]G[.<H5HS3CNDG=/S6_\
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M/_UZ\"5*M"HY0E=/I+:^G]?\&R/0C*,HIV\[K?S3\T2YSTHJ.-UD4,G*]/\
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MJDN96:Z=VOSZO?I_ARUM'\3?"LSJ K:_98('K+^G3\._-?[!O_!,9U?]AOX
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M\_3\ZR9[<#5$6WB$D)="QQD<GIQC@= ,?SK0LT:)G-RS+O.?FSC/;&1UY_\
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M"-F 5$Y8[5/ ]_?'^E-_P;?_   ^(7P0^ DEGXZT:ZTF>\1IH$N8)82Z/;1
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MBU6Q^(AA,S4$YVC2K<UXN_+HY.R7;?7U/"S+(J$*<\3AV[Q5E3L[QVN[;_\
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M]CZ]?:OAS]LS]AWX7_M3?"[5_ >J:%I5D+JSN%%Q!;0QR[PK2+\Q!YW8^O\
M+]*X9\2\TR"FL+.U>G*LG.I.3;2NDTMU:UWZGG8C)L*Y*2M3<(JG&UN5:K9^
M?]:7M_CV0#0[\M?/<H+E25:$.HPRDJ?E/.01^'?UKZ]_9 _;5^(7['/C+7/$
M?@S4+VZ@\16EK87%EYLCV\4<!G^98T8!21/R?]FOH?\ X*9_\$N?B-^R)\6=
M<GT'0M1_X5Y;7DTJZF;>7[.(V);_ %JJL6 Q( _/FORI@: H&MF65@YC<<'8
MR\$8^O;GIVK]HRBOD7']*TN251-3G"?+SJ<6F]'O%/3SZZGQF95,3DV)4XRJ
M25FXV7[N4&K<KDE:^M_ZL?8_[3?QE7X[:O>?$.^D1M>UJ>2ZNH0<LDEPQED!
M4DL,,3C)/6ODMKEK:T0R(JEQAN,8!&,<'C_#\#4]S#%;VR3PSM),V"T.<JO&
M<8_EGI53<FHQ".0[67&0.,?E^7/ZFOU7"8.66T80A>%.E"-.G&&L9**6CEVL
MCXNO7IRKJ;BY.=1RDM=&VF[I>?WKR-+P+I"W/C[P?=6CL\S:]8DJK9ZR9Z8S
M^7KTK_8 _P""8$;Q?L+_ +/Z2 AQX3?=GU.H79K_ "#OAU/_ &5\0?"(MSYK
M_P!O60*DYP/,'MD>F>N:_P!?;_@F-,UQ^PY\ 97&UG\*.2/^XA=CIVK^??'2
MK"HLMY8I/VK;:6_[N5U]_P#P3]'X0J>T=>2ORJFE%/HN:&G_  3[UHHHK^=3
M[@#SQZU^9'_!6E=G[&/Q0YZZ!K/ZV+?XU^F]?F7_ ,%:P#^QE\3P>AT#6,]O
M^7%J]#*KO,<$N^*H_P#I:,JJ7))M:J,M?)VO^2/\BC6;6.7QMXSE=RBC7[_<
M0<8_>>OTQ_G&<?69+0Z3<P02B5]K@98$]/SZ_J?ROZ^\A\;>-(%SY3Z_?@OV
M^_SZCU_ >G%.;0M.739GBGWW)#$1EE)+%> ![]/?]*_O3 T/^,?I1;<X_5TG
M9)\KY(I1NMK[=&?C&.E;,ZC<Y<T*\73@EH_A?O-;?UL?W^_\&SOC+1/AM^RY
MKOB7Q5=QZ?I%DMS-<7$TBQ(D<=G&[,SOA<!>?U.:_*S_ (+7?\%DO$'Q5\;^
M,O@A\-=:-QX!_M/4=/M=5T^X=E:VCN)5C83QN8N0!TX]*_%?X#?\%+_BC\#?
M@EXA^!VCK-::7KL%U:O<1>;&ZK<VZVY(97 R% Z@\9]*_/F6YO-4N9IM2N[B
M]>:629[NX??*6E9G)+G/)SW)_/BOP3#^'_UC/<9F>9-0PWUA5*-*Z:FKW]]-
MNVMEW5^Y]AB,^]EAZ-.DD\7.GRR;LE"/NI\CZO:WJM];I+H"7]W+K.IWTM]-
M-+)</-<R>8Q+L6^\W/!/6LW4/&L4&-#3RQ$Q$2$=V8@+WXR2.,9)P*[+P5X%
M\<_%/Q+9^"/ &FW.KZC=7$,*P6\4DSD.XW86/G[K$U_9/_P3_P#^#;SPI\9/
MA%HGC+XP6MSHWB>6.WNI;:X1(&#>8KC,<\9;[N#U_P :]W,^,<@X;YL'R/VL
M*=J=.,/<6W*^9:]5Z>8LLP6+Q[E5K3YJ3T:=]W9O?\?F?R=_#;]AO]ISXOZ/
M#XD\ >!M5UC1+A0\=S;:?=3QLK' P\2E<9/8_P")[ZX_X)<_MLS8'_"M/$2A
M#D :3?XX_P" ?U_J:_U8_P!D+]A3X5_LM?#:Q^'NF^'M)U*"RC6(3W-K%-(P
M5LY+  'UZ5]92?#+X<1XW>#O#XSZV$7^%?G&-\5\UK35.A1BJ47^[M)IVTM=
M=_\ /0]V&1831Q3CRZ--?:LKNW?\OS_Q[)?^":?[< A2V7X6^(,1X 8Z/?Y^
M48!X7'X?SJW;?\$V/VVHX6^T?##7Q'$A+$Z1?X  Y.=OI[>G'6O]@A?A;\-W
M&Y?!GA_GN+"+^@J&[^$GPXN;::W/@W0%$T;1D_8(NC BO+H>)F=49Q<VY14[
MM2ETZ+K=15[=_74TK9!@*L+.C%R6JZ*]TV_P/\77Q_\  ;XI?!N>:Y^)F@7N
MA0V[X+75M-;#>6VQJ?-'.7P,9ZFO,3>1^(0#$X"P=-F?F&.,GD'@$C']:_U2
MOV[/^",?P=_:K\.:XMU96>F7!ADNX!:1P0L9K=A<1KC8<[F11^E?Q,_M\_\
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M:0;;>WC(^]&G][^?)K]XM_( '?\ SBOY(/\ @U@11^SUJ 7CYY/I_P >L?\
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M6-I-KDK"K$ 9[C&?8US>FWN_6M(T"5#_ ,3*^AL0Q_A\T[<\Y_K_ (_WS_\
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MUXPA^YC16J4D]9:;)IV_X<@U*YE+"RV98L(X0,Y=CPH'!SGKCFOV\_X(^_\
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MM=V6EE;KVZ[7\R#3;B\U2=[**!I+J5MEO&BEGD<Y "J%RQSC@ Y)'>OZDO\
M@@[_ ,$SKOX\>)X_%WQ-T#4;*WTRYMKNR:]TV5(95WF3(><1JP^53D9X]Z_G
MK_9V\!ZYXP^.?PZM=$T6;5M/_MJT%\((WD0QFX@!WX5@05W=<?SK_7(_8<^$
M7@SX>_ ?P#-HOANTT34KC1+,WC0P)'*\GV:$DOM123DG/Y5^!>)O$N*P^<5,
M#@L14ITZ,FFE=*TMTO*VOS/NL@RG"RP[KSHQM-1Y4[Z.*2UN]+Z??N?4/P_\
M$Z'X \*:!X8T.QMK*VT72;#3$%O$L6Y;.W2#<P7^)MF3ZDUV#PJ[;B?PQ_\
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MQ'Y S#@0#^+M7^Q_=P_:+6YM_P#GO;S0_P#?V-D_]FK_ #S_ /@Y#_X)O/\
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M@\TQ<:&/JT93J8>I*T:;C&[7M':+>E^_0^/S+AIX:G*T+T*<M)+5M:/9:O\
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MU!K^)?\ X.E/V7KGQ,/!WB3P!X39I1X:675[RQMR2TRW]_EY6BCY/EA!\QX
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ME?YC/_!SAX%T/P7^V!X)B\+:7#I=O<6/B-YTMD5%=Q/IF&;8J@GYCU'<BO\
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MP8_V!_VAAUV^$$_].-G_ )_K7^/G?6+77CSQG.7P%\07Y*YQDB3/3./08/\
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MB[F<X48T;-QQ$Y1Y9-7CMKKK^"VZF?"&%A*C[><>1PFVN7KJENK+7Y['Z;&
M-G<<CGK_ /JXZ^_XU3BL LV]SN )(!'?M[=<>N:T5;<,XQ3J_G)59I2C?22L
M_P -5YZ'Z'&,$O=2M+7J[^>H 8& , 4445F6%(1D$4M% &3J&DV.JVSV6HPI
M<6TH(DBD 965A@@\$<CCGZU_F??\'-GAO0?"W[2-C#H=C!IZR/&S"%53<?M<
MO)PHY./TS7^F3-(XE" '!/7\?\_7W-?YIW_!T-")?VF]*#-M7=!^'^E2_P#Z
MS7Z#X=U)TN(\))RE:5K).RYFXV;2W?K;Y=/!S!TZF&Q$(QE%4M')KK96L^J]
M.^OG_-9H]ZT\*63G[Z@!NO## Y_ XY]J^V?^";%E_9G[;GPN3S-_F:]HQSUQ
MF_3K[<_IFOAN"V:W,$D.64*N7&>!WZ9Z?YP:^[/^":$*7?[:OPNE:4%DU[1^
M/^W]#_\ 6_0\&OZDXQK0J9!B(-WFL-.^EE?D6O\ D?!Y9*%/-J',K0>CLM>:
MZLW:[\]?0_V(=)_Y!6F?]@^S_P#2:.M"J&E<:7IH]+"S_P#2>.K]?PV]WZL_
M65LO0*^"/^"AW[6$/[(?P#\6?$Z:-9$TS0]3NB&;8,16TW&2#Z>E?>]?SS_\
M'(4DL?[ ?Q,,4AC;_A$M<PRG!'^B7/T_F,<UZ&44(8K,L'AZD>>%7$4X2CM=
M2DDU]QG6DXTIR3Y6HW3[?U_2/\WO]IKXA0?&KXW^*OBI!(%_M_4+R\$8;)'V
MJ<S<GC..W'Z<5X6]F;M)MTWE?(2">_YD?ACO6;X8TV9[**:YN&(*#&[//&>N
M?3MS_2KDUO)?:[HNBPR;!J6HV]F64\_O6VY_#FOZT^IPR++Z:I4E3C3I*:;E
MK\*W[6[^FY^(XBM/,<W4*LW.<:G+"7+I*S6FNFBZ_P"9_15_P;3_  X\-^,_
MVF+^U\5:/;ZS;6\LKQ?:8TD4,MW&%9=Z,"<<#&#BO]-70]!TKPYI\.EZ-:16
M5C JI%;PJJHBJ,* % ' XZ5_)O\ \$#?^"8D/P5\)^'?C\UXLLGB'3[2[9/+
M .;J..X^]N)[?W1C&:_K/@NVEF*;2!SSVX_0_AC%?S/Q;F%7-LUQ&(]M*M"F
MN75OECRM+E2>CMY'[%EE.5/"4XSI*G-))VL[I):Z=]_^&-"BBBODCT0HHHH
M**** "BBB@ HHHH *_([_@K[^PRO[</P%B\)FZ^S?\(O!K.H[MF_/VB*VXQE
M>?W'KR#]*_7&O/\ XHH3\/O&1SP=!OO_ $6W^/\ GMT82O4P^(I5J<N6I3FI
M0?G?]3'$0]K2E3M=35I.]K+>_P"!_C+_ +1'P$D_9Z^,OB;X;)?&Z&B7UW:<
M#:!]GG,7W03Z'C/_ -;R*&SABE>9RN[D[2??MG\/?\:^W_\ @I.S6_[:_P 4
M6>7S =>U@!3QC-^<8SGW^O&:^$-20I(9ED&)6(V>F>1G'7'TZ'MFO[B\.LRQ
M.*R6FZJ7M'1BY6UYHVC;;J[;=+OJ?B><4$LUJP=1\KM'VG+:^J]VVFJ[[OOT
M.B\'3MJ'Q#\(VP;Y4U^RP,\ "7'3MUQ[<=J_U^?^"8$7D_L+_L_Q_P!WPFX_
M\J%W7^0%X#A:Q\=>#KKKYFNV#<'(&90:_P!?[_@F!+YW["_[/\G][PFY_P#*
MA=U^(>-C;Q6%O?\ B/OI[CNNW8^ZX/IJFJT8_![-:KJ[P?KU^1]\T445^"'W
M 5^9?_!6HD?L9?$_!P?[ U@_E8M_3-?II7YF?\%:<']C+XGYX_XI_6?_ $@:
MN_*_^1C@O^PFC_Z6C.M_"J7_ )6?Y$NJ7 N/B'XPL)6VK+X@OE+D\ &3 ],?
MYYZU)JMJNB,L-J_G>:I.Y<'!/&203T'6J?B+3_-\=^,YHI<,-?OSD=L2$^N<
MCCG^HK0A@$%H]S=R^88E)^?V&<?-G\.OXD\?W;E.(GA,JH24K*-&+E):_9C_
M $OGH?A.<2I+,I0>MZZ3I;7ES1M+LK=5:_?<[;]G;X32?M!?&CPS\*99&A/B
M&_M+/S2I.W[5.(,XX/ZC..QK_6U_X)H?L<G]B[]G3PA\)_M/VG^R=!TJT$A7
M9GR;6$=,G'3_ #UK_,$_X):>!?&GBG]L;X:Z[H_AZ[N])M=>TDS7L43M&@2^
M1F)94V_=]_T%?[ VE KIFG*1@K868(]"+>,']:_EOQ5SBKCLVIT5-NE#GER]
MI+E5_P#(_7<BH1C@H-Q2E*,;ZZM-7N[._7J7%7;[G_/^<U#=0&>,J&*^X_S^
M?MVJS28^;=D_3_/^<U^2S<M&ES7:OK:R[_(]Q)15DM$5[6 P1A2Q;W/^?R]N
MU6:**H84444 1RR"-&8]@2/RX_,\53M+QKAF!1@ >"><_P">Y_2B_M6N4 #,
MNU@V!WQR1[ CZ\T^V4!-F""."3_/\?K4<_[SDDK)VY9=^_W$N232^U*]EZ6Z
M_/Y==RMJEA::I:RV-Y$D]K<*4EB<91U(P00001R>W?TK^$K_ (.=?V6GBGTO
MQ%\,? 9'EM<W&H7.FVG7_5MND:* >YY..O/)K^\%HR"<GJ3V_P#KU\5_MR?#
M/P/XP^ /Q"U#Q/H%GJES9Z'>R027$,3M&PMICN!>-B.G;T%>WE.-^HXW#UUS
M2C"<4XQDXWNTOPW/,KTIUHU:?*H2JKW=G:V_DF]OQ\C_ !MVU+4I'.F2VTMG
M=6'RSQ$$-N7Y&5@0"#D?YQ52_M)OLKW?G-!.BL5<'# @9R#E2.??G'N*]V^.
M$FF6OQZ^)MG9VT=O#9ZQ>""! %50+R50H '& <<#![\<UXUK=O-J5I,(P8OE
M8!03@\9/;.?QK^O,MK?VGP[2:A)W@N7>[;Y7O\TO^!J?G=>,<%BY0DO8J-17
M;?-9Z=%OW27W,_T3?^#7759I/V?KX7]^UPP,@4NQ. +:+U)]^,\']"OYN_\
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M0H4ZGM(TH*TTV^5NU[]7V]-NY^.\2X&M#$5:^*MR5&NENR5M-.FRVZV/K/\
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M ./O#CL.A]NAK]A?^"^(=OVZ?$H0E3_:$OS?2'_.#[U^.J),[B/?^\*X#?\
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MZ<;.O\?C4IO+\;>-#GA=>U#(]_,]!U_''XDU_L#_ /!5(X_8*_:'S_T**?\
MIQLZ_P ?'4;1[CQWXSD5AY:Z_?Y4D]!)R/\ ]0[GVK]<\**<YYA6::4(RO+O
M\,-G;K>WJ?)\64W4P4=TDTV^C2>WJ_\ @==4=7NIEE5B$!Y!)[$'UY'/7O\
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MZ5_D3:4'_P"$[\&RN24;7[' /;,GX\<^]?Z[G_!)(@_L8?"\CI_PC^CX_P#
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M *?\ _UO_P#@E);.?V,/A>BM@C0='Y[_ /'BOX=N?Y5^F]K$J*.A<#DX_/G
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MEY?UHU\]3S"HXQY<12A'2T)1O*/PJS\_3[[M,_V_!\OWF^G4U7NX(KBVEAN
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MVDWU]#$UR9)+>!I$0?NCEB.@Q_6OXI-*OD@@BMG@:.>,!75T 96'4$<$&O\
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MB^ T,J?M ?#@E\JVM6>SD\#[5#QCM_7O7CGA1)5T^%G;*E!CGV]/T_D:]C^
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M?\%%/ GQ7^%/A#X'Z<H_MC0-+L;6=@(Q\UM"ENW(;/WCG[N><&OZ8J_S2/\
M@U]UZ:+]I/4+>^N@D:F0+YCD _Z5$!U/'\_Y'_2TCECE0/$ZNC<AE.00:_E/
MCC*Z.4Y]B</04E!MS;D[WE)N[OYG[!E-6M7P-&K6E&<I1BTXJRMRKIT_RL/H
MHHKX\](**** "BBB@ HHHH *3!W9SQZ?Y_G^%+28.[.>/3_/\_PK.I]C23]^
M/PMJVN[U6@"UP?Q1)_X5YXQQU_L&_P ?]^CBN\KYB_:K^*NE_"KX6^(M1U:5
M(XM0TC4H(R^>2D2YQP>@<?B![5UX>E.O6ITJ<7*<IQ48K=NZT7F9U9J$')IV
MV;[)]7_7_!_R;/\ @IK)./VU/B@)9"4_M[6,#)_Z"#X_P_H*^#K^WN!B4/E"
M?E&3U[=!_7^M?5__  43\3CQ9^UI\0M?L7WVU[K>IR1%#QB2]9AC..WMS]:^
M8M/MY7A$ERQ9&4;0WZ?3@$^@&<=J_MOP_P (O['H0JIQJ1HP]R]G&T8ZO]/+
MJ]S\8SVJUF%:M[2#AHDXJUFK+MY_\#6[Z'X:I<3>.?!XG<O$-<L=JD\C]X/7
M/./\^G^OS_P3&54_8<^ *J, >%'P/^XC>5_D!^!&>R^(OA%F),1UZR"J"3UE
M],XYX_6O]?K_ ()AR"7]AKX 2#HWA1\?^#&\K\A\<%9Y>NU>2UU?\.2/KN"Y
M.:KS;4N:DFFE;[4'JMKZGWO112 $9R<\_P"?_P!5?SRY-2BN5OFOJME:V_WG
MWHM?F5_P5K!/[&/Q/Q_T -8_](6K]-:_,O\ X*UMM_8Q^)Y_Z@&L'\K%_P"F
M:]'*_P#D8X+_ +":7_I:(JW]G*V]C_(MU=&/C'QJF[#'7M0P<X_CX_P]3WK)
MU,Q6^C74<X$CLK[3PV/E///I[_7K3-<>XNOB'XP@A<KO\07X&#_TU]_Q_*K^
ML:%<6^ERR7#"3]VS>N?E&<\X].XX[CI7]OTH3_L.A%JSGAXI?.,5;?\ X=^;
ML?AV:QY,SG*5KO%TW;2Z:<5\M%=KNNQ_H5_\&LDT:_L^ZDA=58R2;5)P<?98
MN/S./>OZXT!"C/\ G_/6O\X+_@W]_P""D7ASX-Z]HGP2NBZ7FN:C!:HH1\%I
MVBMQR%([<9_E7^CQ:R^?;6TPZ300RCZ21J_]:_D#C3 3P&<UU.:FZ\I3LMXV
M:T;[^]\MNY^P975E6P].4J<J?)!05]5)6B[JWH3T445\@>H%%%% !1110 A(
M'4XI:H7L<T@7RG*X9<X] 1D=>?\ /;-7(PRHH;DXY_SWH ?7S1^UY*;;]GKX
MD3)PR:#>$$>UM.>IZ5]+U\R?MB$#]G7XE$]/[!O?_26XK;#M^WI:\O[V&O32
M2W)FDXNZZ/\ (_QXOVF_$MYJG[1'Q*CN)6:&#7;S*L21@74XZ<\\_P#ZJ\U@
MEBEA)AP,#D<?Y/?Z?R[7]H.U^V_M$_%-8AM*ZW>YZ<XO)N>HY]OIV'/F26\^
MFMYTC?N5.YA[ ]<<]?\ &O[QX%YWP[A'SJ=Z6LUHMH_=R[,_$>)H48XNM3CS
M)QVBF^9R=FHZ;W>G3I<Z&V><*=LOE_5F7/Y=3_*BNM\-_"[Q/\1;<WF@0W!A
M3AC%\HR #ZCCTXHK2OCJE.K.*7.D_BNG?X7W_J[Z'R4,!.45*IC*.'D]71J1
M;G#;1V6^_P"'S_VQRK$\_P!*EHHK_/ZE15-R:;DY6NWY6_R/Z>;;MY%:2UCD
MD$A W#'KU'T_H1_6IU!  (QCT]*=16KO*49.4O=BXJ-_=L_(05"T$+G+1H3[
MHIZ?45-157:VN)I/=)]=5VU_-$#P18^6&+/_ %S7^@HBAC3GRT4^R*/QX _S
MS4](<X..M#FU%[M=EJVNR_R)Y%S*7962Z+;5+OI_D+12#.!GK2U,7S).S5U>
MSW7J6%%%%, HHHH **** "BBD!!S@].M)R2=FTGJ]7;1;@+13=R^O\_\*4'/
M2IC.$G:,DWV3 :^?P[__ %_\_P!*:F<GT[_TJ6D&!P./:L94&ZZJ\[2W:OK=
M=%Y/K_5ZYO=M;YA\V[_9_P _K^F/>ESCK14;!B?:KFW2C)Q4IN3ND];-V5O0
M2U=MO,#&K'/]/\_D>GM7SS^T1\!_#'QS\'SZ#XCM(;A;6WNGM/,C5B)9E4$C
M*GKL7WZBOHE00 *IW@F*J(@#DG<",\<=>_Y?C7?E^*Q.'KX;$4:KH8BG*,X5
M(NSIR6MT^G;YF,Z%.:::T;][^\O/[NA_$7^U?^R3XV^!7C/5]2N--GA\)FZG
M%CLC^3R_,)CVA 3]P>F..F0*^-K65KUL+%+'&#D%XW0<=_G"]/3U'XU_>/\
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MQ-K KCYAU[4WXAZ-_P ([\4/%GA&6WEMQI.H3V]FLL3Q@&*=T&#(HSA5/'.
M![UQ-ZMY;7$<$P)1B,<9&T\=NN?7Z_2OZ;S#"X?B?*/:756+I)2E3M*+:BO@
M=GJM/^&1^2?5:F29A*I0GRSB_@;:33U^[Y7_ $_T$_\ @B%_P6*MOB/X9TKX
M<_&;7VE\52F'3].ANKEY9""B10A<L?XSCCZ8ZU_7KI%_#J-A::A <P7L"3Q'
MU20 @_E_GM7^-W^PO\5!\%/VB?!/CK6KR2T\.:5JFGW5XPE=(A'#=))(2J,,
MX4'''IQZ?ZK?["_[9?PM_:D^&&@W_@35[.[.G:7;6TX$Z[_-CA4MP[9[C-?R
M_P 4\/K(\5&E!5/955*24T^96MOZ?UN?HV4YE/'488BK*DZD59\E[6TNG_>T
MT[Z=S[_HS441)7)Z=CQCOR"./Z5GWEV1^[A(WYQ_G_$?@37R*A)MJ*YK;V_K
M[SZ2+YHJ5FKI.SWU-7/?MZT9K)S=FVX(,O7MC_'./QS[5<M/.\O]]][O_GZ=
M<\_ABI&6L\X[T4U@>HZ_SH8D#MG_ #TS_G%9*<TY*4).ST<5=-/;YJ^H_P!7
M8=10/\XHK5.Z3LU?H]_GYB"BBC- !12 @]#4,[%1N)"J.I8@ =>I/'^?K1&T
M[6:L^O\ 77R)G+EBY6;M;1;ZM(GHJC#<QS(?(GBF()!\J2.3!!P02A(!'<>O
MO5F(N1\_K_G_ .OFAZ24;/57NMOO(A54W%*,M5=Z:1\GU3]42T444&I^ 7_!
MPX0/V*O$_7_CQD_]'$?UK_+,T)YDGOF;B 7UYZ?\_,G8<^YSQTK_ %,/^#A[
M_DRKQ/\ ]>$N,?\ 7;_#-?Y9?AZ.>6>_5O\ 4F_O/R^TR_7CTXK]_P#!JNX5
M:U-Q4H-MNZU6RNO,^%XR471IJ>L>9<R[JRT]2?Q$+F0V+)S!]NL_3)_TF/KG
MGDG\?QK_ %*_^#=[C]BGPQ_UX1?^C1_+I7^6SXA^T1_8(T_U7VZSZ8)XN(\9
MSSV_P]:_U)O^#=[/_#%/AC(P?L,?_H[_ !KV/&N$8X##/W6W4BXO[5M-//S_
M *MKP<J:PT_9?#S/3MHM]-_30_H"HHHK^:#[4**** "BBB@ KYF_;!4M^SO\
M2@.O]@7N/_ 6X']<U],$XZ_A[U\R_M?LP_9V^)1[_P!@WN/_  %N#_GO6N%J
M+Z[AH*[E[:G>VMO?CH_5$SOR2MO9VOM^/XG^-K\7K41_'3XT$C]__P +.\:E
M3]=?OBO?'M].?:N U>66/3)TGXEV,$X]LCI^G/IZDUZ)\7)1+\<_C06XG'Q-
M\;!/_!_? ?CBO/M9@F?3)WF&9-C%3SZ8!ZGCTXZC-?WEE>&I+(,/5J^UO]5I
M^[/9-TXM<M];==_SN?BV-M_:DO:Z-U_>MM*7,FK7^SWZVU/[X/\ @V(@+_".
M9Y1\PF8@G_KA$??@\_IGW_LZMABWA'_3-?Y5_&5_P;#3JOP@G2;.\ROCV!@B
M]N<?_6'M_9I:$FWB)_N+COQBOY.\2)<V;IZN/O*+?;38_3<CC.,*CDU)2::Y
M?A2M'2W?_@D[#(Y_/TKYF_:>^"?AKX[?#G6/!_B2VCNK.6PN]T<B*X.V)Y =
MI#=P.QQSWKZ6DW[3LZ_Y_P GO67?6GF:??AAEWLKM%&!U:"1?YG^O%? X3$O
M#8FE5BI<U.2G#^7FBU:_](]'%TYUE[&$;*:M4FU]C2ZB_P";U[]3_(-_X*P_
M!K1/@3^UIK_@SPK;I:V46HS[8HU$8PRM(?E55'7_ #WKX+%]<"#[."?/*8''
M<CUQC\.G\Z_H&_X+Z?LE_%"#]J#Q+\58=/G'AT7DLWG^6-FSR]I^8]N:_G;6
MY;+*#_IL9,?3^)?EXQ]#Z>G:O[,X(XEK8K(\-*M#]XH05FEK:*]Y7=S\VS[#
MX?"XFG&$K.$5=Q?O.S7Q?W?2WD?T=?\ !M1XST?P?^TM?S:S<16[32RH&E=4
MRS7<?'+#_/3V_P!,O1=9L]<L(M0LI%DMYE5D=6#*0PR,$$@U_BQ?LZ?'?Q[^
MSU\3?#6M>#[N:SN;_6;2.X:)MF5EF!;).!C('KZ'-?ZS?_!-GXIZI\4?V6OA
M]XDU>^BN=7O]'TR:Y_?QO+ODLT9]RAB<[CSZGIGO^$>*>!I_VQ]:C3J1J5K<
M\VOW/+I:S_FVO?S9]MD6*C5PM.U2+@](W?O.22OY:6_3H?HP<X^7_/\ 2D5L
M_7N*CB\SRES][O\ YZ9]?QI_"*6/8$D_3G_/K7XXU-5WRWY5I)OX6E;X?/\
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MW7K:WKV[V8XB4./LX/EY^;ZYYS[<?E[U]G_\$TL_\-N?"W_L/:/GK_T$%_\
MKU\8GSMX^SY\K(W=/7G],X[U]G?\$TO^3W/A;_V']'_]."U^L^(S_P"$ZK_%
M_@2V^+X>O]=3X?AV_P#:M/\ 5>]]A:^??YG^P)\*_P#DG/@S_L 6'_HNN_K@
M/A7_ ,DY\&?]@"P_]%UW]?QW/XY?XI?FS]>6R]%^1DZNI;3=3!7<OV"\ZC/_
M "[R?AT_6O\ )\_X+WOJ$'[=?B4P02JG]HR_.L3A,^21][;MYZ]?;/<?ZR=S
M&)K>>$])898S]'1E/\Z_B5_X.$OV ?"MAX9\3_'Z#2E.L!9+D7(C);=G9UY[
M=AT-?9\#8Z. SFEB)58THPL[-V4TI1O'S;/(S>A[7!U:/LY576O!=>1RMKY+
MOT/X55DNI LEX28L#=DYR.^>#SSS7T;^S9^T5XU_9U^(_AC5_ 5W-937^LVD
M,S0R-$2DDH+9(*^@]N,U\W:-'>7,$\U_D6L4\\9!'.R.5T[\Y ''^13]1D-E
M=Z9J-J,&QNHKF(@'@QG(//?^76OZIS#$+-\E4J#=ZM-N*6RDXQV^\_,<+3GE
M>.HQJ6E%5.5PC\-HVZ=^_P O,_V'_P#@FW\3=6^*G[+O@'Q7K]XMSJVH:/ID
M]R6F223?+9J[9PS'J>]??E?Q!?\ !NS^WYXU^)&H:7\(-;U@?V1HUK#;0P3S
MQ1JJVYBA4 ,03A3@<]^.U?VYI,&^975T/1E8,IS[J2/<$<8K^/,]RZME^9XF
MC6<>=U)3LNTG?]?R/UC"8RG7P\*BC*,6^2[6B:MJ^R=]"R-V3GIV_P _SS^%
M-:14QN/6G @C(JM/$SL",_A[?U]*\!ITXOEO)\RWU?16TL==24E#F@N9WC9)
M7NG9=._?YEK.>E%-4%5 ]!4<DRQD D#/K_GMWK2*<K63;?1(N*E*R2=VEHE?
M4FHI%.X CO2,V/KV%*4E%-RTM^?9>;[ .HI!G'/6D?=M.WKBE&7-%2LU=7LU
MK]P-V3=F[=%O\O,CG1)$VN.,_P"?\>>*_!K_ (+Z^+Y_"'[&_B:YTB]CAO%L
MI0$CN464$S8^Z'#?@!W''K^ZFH70M=-OYYY4B,5I<R([NJ*'2&1@-S$#/R\9
MZ]J_S8/^"^W[>OQIU?X\^)?@+%J\DO@HW4EOY$<L4D139O[,>Y''K7T'#6#K
M9GFV7X6E&H_:XFGS<J?N)M+F=KVMWM:QQ8JO&G0G4J)*GR2O&7Q-Z:-;>GD^
MA_-5>ZQJOBB;4-:OY'ENFO;PEW.]B/M#@<DGMT[]OKGBXBL8_MI.+LY4?4_(
M.?7D=!]!20^?8JUNV<2.TC< 9+DN?U)/Z=JS-<97BLTAC>262\ME98T9VPT\
M88!5!SP?3)XSWQ_>=/ X'A+AB>,4Y>UAA/?O:RDH*\WM;7KI^A^1.E]:Q]J:
MFHUJ]E%;<K:T?7EZ=[G]3/\ P:]?#GQ6_P"U-XU\=W=K<#2KVR\/00S,A",8
M9M1=P&QC@3 GD]1ZU_I(&( EE')_S]#^-?S4?\&Y_P"S?X*T3]CGP[\4X-.C
M@\3:GK,UO<RO$4E:.VL+"2,'<H. T[X]\].M?TN+G SUK^$N+\RCG><XO&W;
M52HTI)V>EM8OM^C1^LY;1GA\/3H581O24>5I>[RV5EY/OWU["UYG\6&E/P[\
M9!>G]@7^?QB/3\OTXYKTRO-OBTCCX<^,BF?^0!?^G_/(_P!/Q_6O!PVE6FM'
M[T$G+_$M^_<ZJZDX73=EK)+=K2WW/4_QX?\ @H49A^WG^T48/^AR3S>V3_9M
MC_+V[G'3I\EZS/(UG((#R$._YO;IS@__ *^.M?6W_!0OS3^WA^T8(/O'QBN_
MZC3;+UX_+BOC[4TDMK.<L.60D_D2>O/^&>17]U<%TZ=7AK"QJRC%?5(6MO+W
M(_!MMI?[^A^39E2HSSF<JS;:J1Y(_P#+Q?#K)?UW5C^U;_@TP8&Z\3<@G?:Y
MZ?WINV21^/I7]Z%?P4?\&EAS>>)CZR6_TZRU_>O7\B>(-*-'BC,*<6G%35K:
MK5'ZGEZ4<+22O915K_X8A1117Q1VA1110 4444 ?S_\ _!P^P7]BGQ03VL)/
M_1]?Y9WAD7#W-Z>?)^WW><8Q_P ?$GN/?CKW]2?]3#_@X@V_\,4^*-W3[!+Z
M_P#/:O\ +1\-RR0RWS,<0"_N^QY'VF3\>>OZU^\^#M.-3$3@XIN3LG+X5=QU
M?Z]D?#\91YL/&WQ*2>OVMO=CW;_S-W3EE'CWP:9,B(^(+#'3IYG48_KVSBO]
M=S_@DEC_ (8P^%^.G_"/Z/C_ , A7^0_8&X?QWX,;'[O_A(+ KT_YZ#T]L=?
MQS7^N]_P2/X_8O\ AA_V -'_ /2%:U\:*'LZF%FK*//R\J[KEN[=/Z^?3P@F
ML$[VOV5[+;?^]W/TXHHHK\!/KPHHHH **** &EP#@]?\_P">*_S0_P#@Z)60
M_M-Z9Y6=^^$C_P "Y?Z#BO\ 2\* G)Z_Y_SQ7^:-_P '1+-_PTUI>S._=#CW
M/VN0=/\ /ZFOL>"(TY9[AN>7*E9W>BNI*VO;U/,S/F^J5KI;>[;M[N_SO\C^
M:6VW""+S_P#7[%V9*^AV]_7_ #C-?:G_  3+S_PVQ\+_ #\[O[>TC;]/MZ8_
M^OCM[U\7VD,KVT;S#,H1=F>/7&,<?3\?>OM#_@F9G_AMCX7B?[XU_2 N,?\
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M4D]>5<O-?M_25]3^5%?^"=7[2EQ:FX.D7_FE04_T5C[C_ED?\]>.:]L^ /\
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M+X*:?\<_V?\ XB>"+FSCN9M;TA;:#<FZ3<+F%_DQ@[L*1QD]N]?Y87_!1?\
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M.TOWO.;U'_+"(C\_SZ>G/]G=L,6\(_Z9K_*OXQ_^#8B8'X0SB3Y6\YL ]?\
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MS=/-\%*-KJM"U_\ $AXK_=ZO^']4?YVV@&0Z;!]ISY6U O [+QC]/P]Z]E^
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M,^MOV7/VFOB;^R1X[TKQ9\.;V:R$E_"UX\3 ?Z.T@=\ECP.!^=?Z2W_!*?\
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M_>T4:::U2L_>WLM-#X[/<=*O_LM"2E35/FE)7<G)]K/7I;M^4\5Y;.FZZP'
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M^<BM<-K6I]^>%K[?$M_ZVN9UY-0[)NS:WZ;7_$_QX_\ @H69E_;S_:(,.?\
MD<D,OU_LVQ_F,^W0]*^2M>AEGLGV<D(=WY>G'3VY]*^M/^"B#S0_MX_M$-&N
M[?XQC+>W_$MLAQ]!_G/-?)6J3SK92;%SN4[N.@QUR??_ !]:_MSA:=LAP<(V
MBZ>#I<MK+65&+=N^[Z'XUG51PSN*A=J=17E+XM&O+?7KZ']IO_!I?&([GQ*/
MX@]KG@>LN>PZ=OK[U_>A7\&7_!ID2;OQ*3UW6O\ .7-?WFU_)W'M_P#67'W_
M )E^7YW/UW+&W@J+>KY5K\D%%%%?&G>%%%% !1110!_/]_P<0;?^&*?%&[I]
M@E]?^>U?Y9.@F19+XR_\>XO[SKTQ]IDSG/(_SS7^IM_P<0+N_8I\4#I_H$G_
M */K_+,\/B6:6^MW7]R;^\&_IUN9#]/_ -9K][\&ES8N4;M7DOEJM5YH^'XR
M:6'@[M-23UV6BU7G^OJ=+I!8^./!A.?)_M^PV]_^6@XR/U[YQGM7^NU_P23_
M .3,?AACI_8&C_\ I"O^17^1#HYF_P"$\\&PE2(EU^QVMSCB0_GV'7O7^N]_
MP23&/V,?A@!_T+^C?^D*_P#ZJZ_&Z7-/![+EJ-:;/I?S;[^IKP<[X6>R=MEM
M:ZU]7U_0_36BBBOYY/LPHHHH **** &%U!P3S7^:%_P=%EA^TUIA3.[?#CK_
M ,_<OX?Y^M?Z7AC!;=7^:%_P=&L5_:9TPK]X/$0/7_2Y?6OJ^#[+.L,]]8MI
M_P"):'EYFZGU2O?E6CY/33?^E]Q_-A9-.UFA?.\(-HPOIQCJ/\^F*^S/^"9*
M2M^VS\,&N/O?\)!H^.,#_C_3V_SVYZ?&6F2R-;1M(,$(.,8Z ?G_ )[\U]J_
M\$TY2W[;'PO..1K^D8Z]1?KV(K^H<YJ+_5G&1LHN=%M)::<BWV\_1?.WY=DU
M7ESE*?QMR?-'U6UK7=O0_P!BW2N-+TT>EA9_^D\=7ZS-&).DZ:3_ ,^%G_Z3
M1^G^>:TZ_C1Z-]=7_6A^QQ=XQ>NJ3U33U76^H4C#<,&EI#G!P*ERY4Y:Z:Z;
MZ=BK7T:T9^>O_!0#]D7X>_M2_"G7=+\<6,5[!IFEW-S$LB,^'BA<*0%_WCUZ
M'CTK_)[_ &X/AKX7^#'[1WC/P'X9MS;:?I.K:A;0QA6"JD%TT:@;L=AQR?ID
MFO\ 9RUW18M<T;4])GXCU&TFM7Y_AE7:><U_"3_P7*_X(J7EG/KWQK^$VDW6
MM:]JD]UJ%]%:K/<E%F+SR$HC-C#8[8_6OO>#>+,1DF+HTJ?*L/5E'VCGO%.U
MVM5KW/#S++7BZ4G*3C-7Y(Q?NM)*UUY>74_BZ$44EJIM.9V4;@#W(SZD=>.?
MPZU]:?L3?M4?%#]C[XS>$/''@F]FL8/^$BT\:U(A5?\ B5W%TD6HAF( "FUD
ME#>V0..OR!JFD^(/ .O7/ACQ+:R6.LV,K0W5K-&4DC>,E'!1QD$-CT Z<8-;
M7VF^N[6188\EHW^95SMX^\#ZCDY[5_46+RS"<7<.5J=/E<:V&;YU934W'[&^
MM['YW2J5,MS/FG:'(X_%HI6:NNB>UC_6Q_X)U_\ !0?X8_M@^ -$30=9M+SQ
M%9V-M_:NVZC9Q.T:;@P$AYWJ^>G?%?J6CQN.)(WQ_=96P.G:O\@_]@3_ (*6
M_%7]A6]N_P#A%#<WD5W(GF"1!.$"$XP&23 ^8].F.V,U_9__ ,$L?^"YWACX
M_7HTCXR^(+'1=1N7ABM8+B:WM7DDD)4@*PC).XC@<\_3'\R9YP#G>3TJ^*J4
ME+#4I6C[S=1IM)>[;_+_ "_0,/C\%5E35'E52LK\MDHW27Q==.C?S\OZNT<,
M,#MV_P \_P">]/KE_"WB;1O%>EVNL:+=)=V5Y$LL$L;JZNC#((*G!X(QCUKI
MR0.M?G\X2IS<)1DFK:-6>I[=*?-34FX/NXN\5\Q:I2>=Y@VXVYY_K_\ 8Y_E
M4AE<N O3.#T/I[?_ *C5@XQD@#'<]OQJ(S2;TVT]Y:>J_3_@&M.K&\FE>VCN
MM.CNF9\Z2R';_ <9SG/X_P!/\*DBA,!*QC //?T]/K_7VJV"K<C!QW]*BED,
M>7/"HI8GI@ 9)Y]L_E6BFY)15N75V^RWW\W?\/2Y-:491@_A49+6'6[6]NFF
MIB317DUUM<'R>_!]>><=,^^,=>:\=^/'QU\'?L^>";_Q;XLO;:TL+6UFD+23
M)&,JC =6'?\ SQSYM\7OVZ?V?_@Q/?Z=XV\8Z9I6H6L,^Z*XOK6%A(D;,H*N
MP(YP*_A-_P""RO\ P6RUWXE>+=?^$/PZU%-1\'3/+;QWMFT4JE,%LB6)#WXR
M&XYZ]_HL@X>QV<X_#T(X6M[&4H.I45-V]FVDY*5K>C[/<X<17ITJ-2JJK;B^
M9KFV:L^6QR/_  64_P""K'B7]H'6/$/P^\$>())_!TTLUNB6MR-NT$C&8WW?
M>K^8>ULKN"%IM19W2>>5P\KLS,SL6/S$%OXNY]_4BU-XGUOQ#JLUUJ#32":2
M25GDR?OL7Z^Q)_.O3_AQ\*_B!\=-;N?"W@'1KG5KG2HX;JZCM;>2=HXYRX5F
M$664?NCU].W-?U;PY@\MX8I4UR4</[&,8JI)1BY25ES3>FKUO=GY-F^(QV95
M94>;GIRG*=XRYG&"5U9+5.^GIN<!'IT)C$RK\I *G![\]>_MZ_3-4I[B('9=
M$>6AS'TZCIW/^>,\&OH#XB?"C7OAA:'2O$EC)8:K:CRYX)D>-T=0592KC(*M
MG.?TQ7SDIM;N<K>2B- <@EMH..G.!U'Z_K^MT,UIUL'3<YIQJI.,X-.RTM=J
M]E;Y?>?,932F\56C7G-.$FH=6K-+5]W?IWVV.L\$ZUJ>I>._!UC<9_L^+7K'
MRN.RR8'(YY![D\C%?Z_O_!+Y%C_86_9^1/NKX38#_P &%W7^0;X)BMO^$Z\'
M1V3+)C7;#D'.1Y@ZD<\_CST]1_KZ?\$P%9?V%_V?U888>$WS^.H79_K7\P^.
M^,HUX9;1HRYE3Q,I-O>_LI)_*[^\_9>&I*2J<J:BJ:5GU:<=?7>[[L^^J0;N
M<^O'^?\ )I:*_FUQO*,KM<M]%L[]SZL*_,K_ (*V%A^QA\4-O7_A']8Q_P"
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MBO(.H**** "L_5O^05J?_8/O?_2:2M"J&J_\@O4O^O"\_P#2>2FMUZK\P/\
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M67E?<^1XJA.K@4G!.>SC]C5K7FTU[+;I=ZE^ZDECQ'M_=M]YAVSP>?:OK_\
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MY5^3MEHL5^[O=,88@"4;.W([<D'ZX!S[U^LG_!6^2.?]J#X@QN!'MUK4]I(
MR1=OQ_+TY'>OR3:]NR@@V%8EP%< C<.!UZ'\/UYK]_X3S"CC,GP<?:-*.%I0
MG%.[;4(JVO6^MOOZGRU7+I4L3B:B7LI^VDTUIU5K='O\CK/AM;&R^)?A2.,E
MX1KUD%=N1CS1CT'3^M?[ W_!,AMW[#OP"..OA1_TU&\%?X_OPZED3Q[X0,ZX
MC.N6(#'.?]:.Y(_3CU[FO]?_ /X)B,&_8:^ !4Y!\*/S_P!Q&\K\,\9*3I5<
M'=:.K*S\N65E]UKGVG"4ZDG7C-[0T6_VHJ_S_ ^]J***_"C[8*_,C_@K:/\
MC#'XGL.H\/ZQ_P"D+?X_I7Z;U^97_!6P,?V,?B?M&3_8&L<#K_QXL1_*NS+I
M*..PDG>RKTV[*[^);&=5)TYIJZMUV[G^0_K%_<6OCGQFXC)"Z_?GID8$I)/
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MJQT*M.G*+YJ+;2EVE>UK?UW.AHIJMN4'U%.KC.A.^JV84444 %%%% !1110
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M/TT['T%+!TZ3HVI)^SYN65U[MVM%WT]1(HH[:)(HE5(XU5(T4;55$&%11V
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MY,8MWE;!/'(SWXK^6S7_ -FK]HFR\RUD^'OB1;2R/F23-H>J +'"<N[-]FP
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MJP8<$%;<@@_7'3O7]LGP'_X-:[;X:?$G0_&&L:P-2L]-N[:>2VEMOD=8I0[
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MD4!;B(DEF@ Z#OZ<U_K+_L.V&H:;^S]X-M=3MY;:[CTRP66*5&C=6%JH(*N
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MZ+?\#TKX;6SQ?#WPC;2J5EBT*Q21""&5A$,J0<$'Z_I7;PQ")0H[=/\ /O\
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M?!-A8^%_(\P'[';1KG=MQ]SR^Z_RK]CX4\4IX27L<UE*I"VM:3OK9):;[_\
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M":W[,WQXTW]L?X::UK?@7Q!96%MK>DO-/-HNHQ1*J7RDDO);JHP.I)P/6O\
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MY):)6ZKJ=D<134*=.,$HR]_;=1LW&^]K:=+V+5G=@C[-*I=>>3@^I[\>_P!
M/>JEQ:Q-<X50%ZC  YQD=>.#R/?CL:@@8CG:1U^<\=,^W]:DDDDS\JEN/O>V
M,GMC_P#7Z\5X>:9#',*=2C*:4)1DN5[:I:_=TWT^1Z&'JTJ475]HU&7NM._N
M-VZ]EU?8]G^!7[3'C/\ 9Z\<66O6]W>7.DP3Q#[&)7$6TE5/ RIQG/2OZS_V
M7_VT_ _QA^'&F^)-=UJRTK49Y1;&UFGC63]W!"<X8H069B!QVZX-?QC"^CG_
M -%GL]_HQ /S=NHZ_A_]<B\9?$#PY?60T#7+ZPT^VN$F^SPRRHAP1NX5PO0
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MGO4U%<[H?O55A)P=US)=?Z0^^B_X(U45/NC'X?X4ZBBNAW=]=>^]O/Y"$!R
M:6BBE&Z23=VEJ[;ON 5"_4Y_R,5-16=:FZB24N5IW\NF_P!PT^Z36UF9%K9-
M'</+O8@YXZ 9.>/Z8SQ^=7YY3&!@$_3_ #T[?6K%-90W6G0IJE%1?O+F<GTO
M?^OT&FN9.4;I6NM5=)6W&Q.74$@CZ]?Q]_6I*0# P*6M!/=V5E?1;V\KA111
M0(8Z%B"#C'X4\< #THHIMMV\A**3<K:O?Y"$9!%-12HY.?U_SUI]%%W:W0.5
M<RE;5)I>CM?\@II ) (/0\_Y_P \^].HJ)*3MRRY6FG>U[I/5?,8=.!1115
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<;JUF[M.]UV6B\SR89-).49SC)<\>2-O?6NFOW+[]Q8[JV#_ &AT_<(<L"%
M..H(P.H]_P#Z_L_[+6CZ]KW[1/@R_P!#M[H:9#J=AYYB5Q'\MTI8G:,=.QZC
M\J\<\-Z3=>/M9MO"_A^WDEO;^1(HXTB?!:0A -RJW<X_^N:_IP_X)W_L:P?#
MCPQ;Z_XYT&!-4 6ZMYI4=I -BLK#*QC(;N ><\\8K^//'[QHP%')<3@%45?$
MXJA4PU*C3JQYFJL>3FY4]>5M7:72Q]_P[DM:52'/9QIN+Y^71)<ONW\^JO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK_D594;5"CL *T7-UM;]?O9<N3DARM\VO,G\MA:***9F%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH S[JT,SJP8C!SZ_T_SZ^EV--B!>N/\
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M>HG?5;,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBFE@/K2<E%7D[)=0'45B:QXATC0;5[W5KR*SMHU+/)*RJH4=3DD<<?UZ5Q
M$7QH^&TS%(_%&GLP[":(_H')IQ]Y)Q3:>VC_ *OY!<]2HKRV7XS_  V@_P!;
MXGT]/K-$/YR4Q/C9\,Y/N>*M./\ V\0__'*;36Z:^7E?]0/5:*\WM?BW\/KV
M:.WM?$=A++(ZHB+-$2S,< #$G<UZ'#-'<1)-"P>-QN5AR"#[BD!+11G'6F*Z
MMT.<?3^E #Z*YG7/&'AWPXT::SJ=O9-*VR,32(NYL$X&YEYP#5[2=>TG7(O.
MTN\BNX_[T;!AV]"?6C7L!L4444 %%<?KGCWPIX<F6#6=8M;&5\A5FD12<$ X
MW,/45MZ1K>EZ[;"\TJ[BO+=NDD3!E/XJ2/UH#RZ[FK1110 44UW6-6=R%502
MQ/0 5Y_J'Q4\!Z5/);7_ (AL;>>(E7C>:,,I'4$%QTZ4TF]DWZ(+GH5%>32?
M''X81??\5Z<.<<W$/]914R?&GX:R;=GBC3VWG"XGBY)Z<^9CFAIK=-?+RO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>HY]^GY06?[!GQ5T0R7K>,=3D^4MMW3#]?.XQ[_AZU^^\VQXR'7<".AY]O\
M/^15"[LK1[.8F%>(F[#L,UVX2LJ;YE%2C/E2NEU:V]%\M!-0<W9M5.57?3EO
MI\]S^4;]HWX:?$WX;26J'Q9J2_:+I(/]=,N-Y/I,?3_.*^AOA;^Q9\4_%O@?
M2?%D?C34G&HV\$P4-.?]='O'/G'C!KUC_@H=9P27>E)" I&JQ<#UR_I_^KL>
M*_47]D.P@?X(>%$F028T^RZ\]+=0#S_GGM7J8^G1HQHRE:?,HS<+6LFEZ_UH
M$&]>W]?I^1^</@#]BKXF>'=?T?5[OQ5J,\5MJ%K/)&QDPR),K%3F4\$#G(_G
M7[4^%+&;3- TZRG<R2P0(CNW4D* <\GGBM8:?:* !"GRX(X'&.G;_P"M5L *
M, 8'H*\-M-NRLNB-!LBET*YQD52M+1H'9B[-D]\_U_4?K6A12 _#;_@J)XV\
M2>'O$W@>PT;4;BRCO==$4IA=E&W[%=M@[67NH.#QD9ZU]D?L(76J7?@=)=2O
MI+V5XPV^0DGF-?5F/^37P?\ \%7YQ'XM\ +MR6\0 !L9Q_H-X?Z5]N_\$_V8
M^ X]S;LQ#W_Y9+^M=,X3E1I2Y+0C%KF[W:#_ (>WX'Z*4445S ?SM?\ !4/Q
M?XLT/QOHL>B:O=62-+<!EAD=0<2P#D!AV)]>.*_2?_@GEJ^JZO\ !33;K5[J
M6[N3"I:25BQ.7_VB>?\ $>M?F3_P5%59/B#H2L/E\VZ_]'V_^-?IK_P3VB"_
M!7347 'DKR/]_P!<=L\<=OQKKY*?U53M:7/O9[6C^O\ F<E.4Y5JLG%RY?=3
MO:VD7R]MNMOGH?=@O6-QY01L9QNYQ_A[8]>_>M.H5B1/F/7U_P C/O\ _6%2
M@YZ5RORU\SJ3;2NK.VJ[&'XGD>+P]K$B$ATL)V4CJ"%X(]Z_DE_:+\?>.K_X
MXZ[HEMXCOK*V?5+F&-%ED"@&X*@?ZQ1TZCT^E?UL^*/^1>UC/3[!/_Z#7\@'
M[3$&_P#:#O?+81,=>D!8<9S<G(X([C/^%=^ A"51N4>:RNOP,,3=4W-:2C\+
M\W;IUV_IGV?\/OV&?BG\2_#MAKL'C?4XX[J*.8$-,P.] PP?M '.?S_*O5K;
M_@GY\4].FLT;QGJ;B":-FYG^8+U_Y;'\:_5/]D6SA3X+^%RRJ[G3[,EB,Y)@
M'-?3C6=NQRT2DYST'6IQ->$Y3C[-)+2*71JRW\UY:= H*KRJ52IS\T4TK;:(
M\0^!'P\U3P!X,T?2=4O9;RYMH"LDLI.YCN/7)8]".#U]L5[Q34V@;4QA>,#M
M_GK^-.K@44FY6U>_R.@*SM5F:"PN)5ZHA(_(UHUG:L,V%P",@HW_ *":8'\Z
M/[9L_C#Q[^T):^&]*U^ZTJ.YN[*W$44D@'(BCZ*\?4@'I7I;_P#!/_XHMX>@
MUJ/QKJ3-):I.$#2\DID?\MCUX'Z8YXX;]HF(_P##97A\1OL0ZGI.Y!Q_%#GC
MW_F?0U_0'X9@A?PKHR2('1M.@W*1P<Q\\?YYK5I14'%W<E[R\_Z_JQB^6:JP
MG-M*733DT757N^VMV?RH>)-$^-?[/WQ)T_6[J_UF^TG3;F.68DW'E%8IMS9)
M9A]T=>F.YK]Y?V5?VL?#GQ=T"RM]1U*WM-3@BCM_L\DJ^8T@51C!().3QQGM
MZ5M_MA>!O"LOP=\4:DVCVQO([&\9)S&F]6$!((.TD'/<&OYL/V4[CQ&OQ]M(
M;+69[:P37XU:T1W",HN%&W (&.W2NRG3G6H3<8^_3LEY+37S\_4X7-TI48N;
MJ4Y-..EM>:/SW_7R/[)P<@$=" 1]#2U!:Y^S6V>OD0Y^OEK4]><>H%%%% &7
MK=T;+2-1NQUM[264?\!7-?S._M<_M(>.?&?CW5?"/A26]631KV8O]F:0_+!(
MR'.S'MGGFOW,_:E^,R?";P9?7#)N-W:21#D _.A/\17/3''UK\//V2[2R^)O
MQK\=>)-5L$NH+V/4IHQ*H<#S+@.,$AAGG'&?KZ]>&I\RG.2O&*3:MOTT\]3E
MKRA*I3IRFXM.]EUVM>VI]0?\$\OVE_$?B_74^'^O+/\ :]-1896N&?=NB98R
M6##/?_\ 5D5^XA!C;(R<GI]>_P#3'ZU_,K\/OB%#\$OVG_$,\&GFWMI]6NH8
MPN$4!KL;>X'08X'?TYK^C?X=>+%\:^%[#70N!=Q12XX/WT#=1D<?7_ZY7IRI
M-.WN25[>OFO6W]7%2I1E#W9WE&3Y9]8M6T\_GZG=@Y -+117(=85\]?M575U
M9? /XB75E,T%U#I"M%*I(9&^TPC(((P<$U]"U\[_ +5T?G? 'XC1YQNT=1G_
M +>83_2JB[2B[7M).WHQ2=DWV3?W(_D[^&NH?$OQ]\39_#4?BK45CN]7:$$3
M2D*'FV@?ZS''^?2OU%O/^">WQ4O[2SU&+QKJ0$]O'-A6FQEANY_?=NH_2OS@
M_9BOH]-_:#L[1E#F37DY/7FYQCD_A^HK^P'PU!!-X=T9FC4[K" ]/5?_ *]>
ME6JJ$(-KFYUS*-K<C277KM^C1R4E.M&3J)QBY)P5U=6MO9_GT^X_EN\5^&_C
M)^S#\0-.U.ZU+5M3TNQFBFG=S/Y>V.7<V26<#"KSWQ[U^[O[)O[36G?&CPO;
M/<S1PW=M$D#HS@L71!G.=ISD\\>H[5I_M?\ P]\,ZQ\)?$MU-IELUZMC=F.X
M:-2ZL(200Q4D8//6OP$_9,^+6J?#WXQ0^#K>>4VUWK2QE4;Y LDX3'4=CCIW
MIQA'%8>4G'EE#3F77;I_GYB3JPKPIRJ<R:;U6OV>UOG_ %?^L#(QGMZTN:K1
M9DMH&R1NAB8\X^\BG\__ *]3(-HZY_'/^?\ ]5>7TO?7L==Y<]N7W;-\U^NF
MEBI>HIMKDCAQ!,1CK_JF[]L=1S^AK^6+]NWQ7XXB^-U]I6EZ_>V=N]UY2I'+
M(J_. ,8#KW/]>O7^I^[0_9[EL_\ +";C_MFQZ>O;K7\I'[>]RUM\=[I@G(U!
M.>F<LO\ 3OBNO"0E4<XP=VX7:LO+37\_)^9R8G2$IR?LY:Q6MU*+MVVZ*_ZG
MT1\+?V&OBI\0?#EEKW_";:G&MS#'-]Z8YWJ&Q_K?0^F._7IT>I?L&?%BVU+3
MXU\8:HZ6EW$[$-,=RH>A'G=^/Z#FOU^_902&7X/>&IM@W/86A.1ZP@U]%/I=
MC(V]X$+9SD@?X54\3[LZ3@HZ6NDKIZ=?EY=CIIKW*;OM!>CNKGEWP,\*ZAX-
M^'VC:'J5S)=75I:V\<DLF=[,D04DY)//O7L-,2-8U"(H51T IQ&?4<]J\^3:
MBVE=K9;7^9H)]T$\G_/^<FO,?BY>36_P\\2S0,T<L=A,4=>"#Y4GO7IY&1BO
M*OC)&5^&_B@CD_V=/Q_VRD]AV-72A"*C&UO>6FKT;5_+N9R]ISPY?AUY]NZ^
M=^Q_)%)\3O'[_M$"R_X2.^^RC7]GD^=(!M^T]/OXY''/;%?US_!Z>:Y^'?AJ
M:=VDEDL(6=VR228TY_K7\>MI8_:?VCF=CMV^("1T_P"?KMGU_P ^_P#8/\'0
M(_AUX93/2PA _P"_4==V+I1A&ER1L[7>FKV_5_@PA%7E/[4M&];/;I_P#T^O
M#?VAGNT^&>NM92O#.+2X*2(2"I$1QT[U[E7BGQ^<)\.-;)&?]$N>/^V)KBCS
M.2Y=[Z>I;;2;2NUTVN?S<?#GQOXUL_VBM*TZZU^\DMI=:A4PM-)M93=8(V[\
M'CC\3VK^I7PP[2>'M'=R69K" LQZD[>I]S7\J7A2W^T_M-:-,"$"ZU;X'3.+
MO/..!_GMQ7]57A08\-Z*/33[<?DE=6*CRJDVO?<???=Z=.AA0A).<W]M_#OR
M['05#<*7@G4<%H9%!]"48#]33I'V+G&:(W\Q<XQ_]>N'F7-R];7L;<\>;DO[
MUKVUV/PO_:!_8]^)WQ,^-%SK.E>)]2L-.EG++%$91& 4XSMF4<$<<?\ U^&\
M7?L&?%71M)EN(_&.IN8())20TQP%5<D_ON/Z>]?OX=-L#/YY@C\[/W]HSGZX
MZ_\ ZJP?&EG:OX:UIGA5MNGW!&0#C"=L_6NRG7]Z/-!2<=(_=:_GIT?ZF')*
M$YUIU&URM)):I75E]_\ 6A_+#\*O@I\3/%OQ&U3P:/&>I&2TEFA(\R8D;)?+
MZ>=D'/YU]C0?\$\?BO#//>'QIJAW!FV[INO!_P">Q/\ GMTJ[^RI;[_VM?&"
M2?-%_:-^ AY 'VT;<>G'%?OA]BML;?*7'3&/PKIEB/9M1J4XMWNFNSY=-%V_
M(VI3DX2?PJ:M9KHK:J_I_6Q^2W[(O[._COX6>.[J[\0:Y>WUKO<*D[2E1^\!
M&-SD=/I@8]*_7'[P!!..O^??WK%ET2T#B2WB6*3.2R\'/X UKP(8XD0DDJ,9
M/^?S]Z\^NX56[1Y8NS:N]U9_FB]?4EKS#XQW4UE\.?$US;LR31:?.R,I(((A
MD(Q^5>GUY?\ &-5E^'/B9,\-I\P/7_GE)2@O>C9:*4?S _D?TSXE?$35_P!H
M>2S_ .$@U!;2+7MGE>;*4*_:<8QO QC@CIZ5_7[\.GE?P%X.>9B\S>&]':1V
MY+.;&$LQ]R>:_CMBG30_VBB(XPYF\09)''_+T?7V-?V(?#=_,^'_ (+DQC?X
M9T5L?[UA :[,9&WLWRI<T=U]K2.Z_K]#GI-.I55M5RW>NMTFO^#UV.UI"0!D
MTM0SQF6-D!()';_/4=JX3H(K@">%E5L9SR.>W7CN.WI7YD_M#_MNP_!#5M4\
M.(HN;BU>YM@-^&S&70<;2<C\\# K[@^*WBY_AOX&U;Q(<R&RMYY@,\GRX]^,
MMM]/U-?R^1:WKG[7W[0URLEO-%IU_J\[AG!9-C2N_P#!O7TQVZUUT81]E*<U
MS*_+;:S;7O?*RT\V<F*YX\DZ;:J7Y5O9IM.S7]?Y:W]M_&/]KOXQ_P#$KN-6
MTC1KVX(66(S&$*5XP1L7&?7KG\*^[[?_ ()I?$YK&//CS4MS1*YR9>K*&(.+
MCU/YX[5^F7[/G[.?A/X4>&;"V73;5M22")C<B,"3<0"3N\L-G_ZWK7U,(QM"
MJ1@ #'H!Q]?TK/GY7%K2S5M-+=_Z_(SA0FI<T[RDX\V]K2TTL?S%?';]D+XU
M?#;0;RXTOQ-J]_+9QO,JQF?+>4-X&/-/WL?7TK[?_P""?G[4WQ%\83VWPV\5
M^'M0MAI<2P-?W0EQ(82L1;YT&,\GJ>M?KWJ?A;0]9B>'5+&&[C<,&610P(.<
MYR/?\L5AZ#\,?!'AB[:^T30;*PNG)+2P0QHQR03RJ ]1GK4U)\_WW;MN;4*+
MA*<Y-WG9\N_+W^9WK' )QG K.AO&DG:,QL ">><'GMZ^HQCC\JT&.%8^QK+@
MNE>X9-A&#U^A_P XSC\^*R.DTI9$BBDEE(6.-&=V/ "*"6)/; !K\C/V\/VJ
MK?P#%_PC?AJ\%S>:CYEO_HTGSHYPG1"3G+?H.*_4?X@S2V_@;Q=/ 2LT'A[5
MY8B.H=+&9E(]P<$>]?R'>+-:USQI\?HK7Q#-<36L.N%$2X9F4K]IP  ^1C'^
M1TKKPE_:*U_-6TZ:_P!>5^AE4J<LH0M\=U?56M:VOS_K8^HO@O\ LL_&#X^7
M=UKUWXHU;3(+UO/A5FFQB0LV%S*GJ,=?R.:Y?]H']G?XT_LT:QI7B"R\0ZOK
M%I92^?.J-/MV1LK8;#N!P#G/-?T3?!CPOI&E?#SP[-I=K%;R?8(2QB"J7;RD
MZ[0#^O'>MCQWX"T'XF^'M2T75=.AN)9[=X8Y9D#%2R$9&58_ESZ=.,:KE.I*
M3TUL_P"D$7R<L)3YI.]M.W3[K'QU_P $^?VJ+[X]Z)=:#J-N\-UX=TQ7E9V+
M,S1R00'.5'/SD^_X5^EU?"_[*'[*MM^S[K_BG5+5U,6N121+&JL F^XCFQRB
MC^#''7BONBLWOIK_ ,,7%R:O*/*^U[_H@HHHI%!1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K%N[>X>4E"<;B?O'IG@>U;5%:4ZCIRYDD]+:H'J4X-T,/[
MS)/U)X_'GC-/11)AA[XS]<?T_P ]K! 88(R*:JE3P>/3%<N)BZTE=7BY:J.E
MMM=]5_P=KW)M+FO=<J6S6O-=:]OO\Q=OR[3S5>]7-I<*.,Q,/IQ5JJUX";6<
M+P3&V#S_ $K>FE!PBOABXI>B:*\[:[7/P6_X*&V5QI]_I=S)('1]6B(7KU9^
M.?7_ #BOU._8^E$OP2\*N!C.GV9QZ9MU-?EA_P %%(+JVO=*DNI/-@;5H2J9
M)P"6(X_3CCMTK]3?V/'1_@AX5,8VC^S[/ QT_<#''3_]5>WFLZ<J5#E3<E"*
M<NFBCHM/^&[]\X7N_P"M?ZN?4IY!'J*AB1T)+'K_ )_R>].57#9)XY_SZG\:
MEKPI15T[WMJK7MKW[V&ESN,I1E%Q;LF^]M=-]M J-I IQ_G^1IYR0<<&HEC.
M<L<_Y[8Z>]7&VK?3IW_K_AQ3<]%!:MZR>T4FKW7FK_IY?A1_P54LXY_$7@>9
MB 8]=5@3QC_0[SW]*^L/V!]=T6P\#+'>:M9P.(_NRS*I_P!6HX!_I^ KX[_X
M*T_:9-8\&6UJYCEFUP*C E<'['<GJ".<#_#'6OG;X(? #]HCQ;X?^T^"_$UY
M9VK)D)%=W48 *@_\LP<?4\\?EZ-+]YA'"<E!*2M)[;+39_=Y]SE;J_6'*_,H
M.,'%)W?-RMO\?+S/Z5F\6^&F4XUS3O\ P(2FQ^*_#?.==TX_]O"#^OUK\'8_
MV3?VP1%(#XRU')Z?\3"]/;UQ_P#JIUK^R;^V"BD/XRU'J?\ F(7IZCCG'8\_
MC6*H4[<OUB%FU?1Z;:/;4UE.5W/V<FXV22;]Y/ENU]_;[S@O^"H5]9ZEXWT5
M].O(+C$T_P \4@8#][!Z$CUQGK^E?I]_P3J61?@EI8D.3Y"\YS_'Z_Y^OI^"
M7[3/PU^)G@74+&U^(&JSZA?R7.8I)9I9F559-_,N#SD'CKWK][O^"=H9?@EI
M>]LGR5YSG^/^==.(I<N"A:<9VGRQY4]8Z._G^NICAI5/:U%)<JFW-0:]Y:)7
MOVV_/N??%XCO%A&VGUQ]/Y]/3O26<<B)AWW<>GU_E3KI))8B(GVGU_SZ].>.
M_I2VD<D<8$C;CZ_Y].G''XUY$H\W+>_NNZZ:Z;Z>1WF9XG_Y%[6/^O"X_P#0
M#7\?'[3UM<WW[05XMLQB\O7G9FR1PMR<G_.<<]*_L%\4G;X=UD^EA/\ ^@U_
M(5^T6S:C\>=>L[;,-PVJW*12$[?G-SA<'D]?;/KBO:R=0]K.4Y)<JNDU>[TT
M_P"&U,:JD^6UN6_O)J]^UC^E/]DO7]%L/@OX7M;O6;%+B.PLPRO.H8$6ZYX)
M^H]NU?3A\6^&@H4Z[IH9N!_I*=3T'7\*_GD^%G[-'[46L^'+#4M \6WT&DSQ
M1R6\45Y=JBHZ;D "# PI' XY'>NXO_V3OVPI;[3Y8O&FI"**ZBDF'VZ^&Z-2
M-PQCG(XP?K7#B8Q]I)J<?>FW9+:]O(I)17,DV^5>ZGZ;)Z(_?+3CYI:YCG2>
M"4[HGC.Y2N,<'OR,9Z_K6M7EOP9T/7_#GPT\*Z+XFN7NM<L+$Q:C<.S.\LWG
M2-N+-\Q.TJ,&O4JX[OFDK.T6K2Z2TZ>GW&BV3VOT[!69JY(T^X_W#_(UIUF:
MPVW3KEB,XC;C\#515VEW:7WL'LS^=_\ :(L9W_;&T&^>98+:+4]++%V*J-C0
MY)R/0?GQWK]\/"_B?PXGAG18WUJP#KIUN"#<+G(3!'K_ )[5_/#^VE9ZWXA_
M:(M]/\-W+6>I27EE' ZN8V$A6-004.<[N>!U_&NE\7_!3]JOPGX';Q2GBG4W
MM;:Q,Z11WEX3L$>\ *!CH./J/P]"6$UC>K"*TMVN[;?UIZ'%&,J-.H[.JY.[
M2WZ?I^*Z6/T^_;)^*7ARW^%?B/18=0M;B:XL;I5$<JL?GA*]O?I_];G\6?V*
M/V</%7B_XE+XZL)2--MM8%PP#,,JDJR'A00?EQ@#C-?-&B>,?B]\4?%2^!_$
M6KWOVBZNA9;;N>?YB[[.0Q)QD]AS^E?TB?L1? ?4?A%X,CCU9UEEO8Q-G+'_
M %B =6P3T]_YUZDXX?!X524_WDE:<?YG:.JZ6WO;SZG%&$J\Z?+)<D?ANOAM
M;1][O_)L^\+88MX5[I%&I^JHHJ>D QP!2U\T_+8]E7LKZNRN^[ZL*"<<GH*3
M<,XSS4-T2MM<,."()2#Z$1L0:->PS\?_ /@J3J\5WX1TO3=,U*W-S-=0Q21)
M*"XW(X(('(Y'(Y!_G>_8&_9W?0O"-EXLN8U9M4L(R[XY;ST60Y)&?U%?CM^U
M+X[\?^(OCGJ&E:GK4\NCV.M2,EO)<2-&J1W#* %)VC@D<' K]L?V=/VI/"'@
MKX6>']%O;NW\^UL[:-\O'G*0A3U8>E>XL/BHX1*C3YE.W,[:V=K+IY'!.6'E
M6]I*ZM9*?1M65K;W7>WE9GQU_P %$?AG9_#'5=-\8V5L(I[[5HGDD10"?,9I
M"21TY')/KWK]7?V,O%%CK_P5\*NE[!-=MI]F7A60-(#]G!;*]>/\?>OS<_;L
M^+7A/XU>#8[/3KBVEN+8"2/8R%E=$8 \,2,9'8?7O7F7_!*SQAXW;XIMX5U?
M5IIM"M(-0C@M'GD:-5AM9A$%0Y4;2./_ -=:8C!XF>!C4J1Y94E[T7H^5)?C
MN9T:E&G7:ISYHU791_E>FK;]?TU=S^BFBC-%?/GIA7SU^U4&;X!_$0*<$Z0,
M'T_TF&OH6OG3]J]O^,?_ (CE&PPT=<'T/VF'FKI_Q(?XX_FA2ORNRN[.R\[:
M'\H'[/Y^Q_M(Z?+<2*D0\01$R,0% ^U@G+8XP.O3'TK^P/PMXH\.CPYHN=;T
M\ :?;;@9TX^7OW'IQ7\8WA2'4KSQQJ$.C2,FLMJLHM9HR0ZN9/DPRY(^;G S
M[<5]M1:+^U)%9PV=OXAUA1+$/((NKS"H1\H&WH/;I@8^GM5\-*LXR5J<8JT;
M_;ORW:6^]K7_ %/+I3G&7LZD9.4Y*6CLDE;SVM:Z^_R_:#]LOXY>&=(^&VOZ
M-!J%K<W$UE<J/)E5SEHF7L1_+^5?D#^Q;^S=K?Q0^(B_$:V_X]+'5Q<$DL?E
MCE60XP,=.>OK6UX=_8Y_:-^*>G22>(M=O;F*4'*7%S=O\I&"#O7'<C_.:_8#
M]BG]GW6/@3X5FTK5SNGD)).6)RR 9RP'<5E*=+"X:<*<KUFTI)[6T3=K_P!7
MOHS94ZE3$7JPDE'6G)::76C:=NGXZ:GW$D;+!#&.#''&A^JJ%[_2E*L%Y;_/
MTZ=*GJK=)(\>(VVG_/\ G!XKRH:M1;23DG=]/Z_KL=DJ<9-MWNX\N[M;T[^8
MDV1:7))S^XF/3_IFU?RN_MRO:ZC\?KC3RF)&U&,;B!@'*X[]/U'K7]3A21+&
MY#MN/V>;_P!%M_G XK^5;]NHB+X^7DD*[9_MHVO@@A^ ,8]..?7T/%=^!DZ>
M(FU*+23UV6C6NW_#NYSXJ$/86DVG&-H7ZO3?[K[^6Q_0K^S+KWA[3/A/X=M)
M]8L(I([*U4H\ZA@1".W;M_\ 6KWU?%OAH/SKNG<G 'VE.3Z#G)R>:_GE\$?L
MV_M3>*O"VFZIX:\67]MIL\43PQ)?7<:JC)E0-HQ]W&/2NY'[)W[80GTQCXSU
M+9#<0O./M]]AD7[PY7!ST]^M8U:<.>ZJQ:J2L[?9U6NJ^?R^:="3J**E"453
M4>5WTEHO/5>31_0'!<0748EMY4FB8 J\9W*0>A!'7-2G)Z''->1_!+0/$7AK
MP#I&E>*+E[O5[>V@2YGD9W9G6,!B2_/WLUZ[7'4@GS0NVMKK1_>=1$ZN3D']
M!_6O-OC"0GPZ\2%N0MA,3]!%)7IU>8?&0A?AQXF+?=&GSY_[]25<':5-?RRC
M;[T1RJ+G)7O):W=[671=#^/&_P!<BA_:.CC@0H?^$@PV!@G_ $H#/^<BOZ^_
MA LUQ\.O"<JM@&P@)'//[E..G_U^@K^09K>TU#]H[=&@W1^(.>.XNO\ (Q7]
MA7P;"Q?#CPPF1QI\ '_?J/\ I_+VKULPG+FI3Y4[QVMI\,5M;IY&&%JJI!WD
MG--W2TMM;^O^&/3\'9CO@>W^?2O$OCV?+^&^N,_*BTN,CCG,1[=/_P!5>WYQ
MUKQ+X_R(OPVUTL-P%I<<<\_NCVKRZ3ESPLM.>-]/-?(UJQ33E=W47:S].G4_
MF5\,7;R_M/Z((5*I_;=ON'(S_I?/';MZ?A7]6WA/_D6M$_[!UO\ ^@"OY:_!
M-K:W7[2.CS(JHRZU!@$8.?M0/K^M?U+^%QM\.Z,/2P@_] KT,SY>:E:+3Y=>
MS=E=Z?KJC+"34Z2][FDM'O=;;FZ0",$9%   P!BEHKRCJ\[:[7,AH9UN?,WC
M9G[O^?SQT_"J7BLA_#&M'_J'7/\ Z!S^==&1G@BN5\:2B+PQK0'4Z?<CCGG9
MWS_GZ5<5S-12?,WI_7_#>I-I.6K3A;X;:WNOO5KGX;_LJ-_QESXQ /']HWW
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M>#/^Q9T7_P!((*ZL>K3A.-U!I<L7LFDKOYG/3IOFJ2;NJEO71=SL$5ESDY_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7UK]?(+F*9BJ$$C@X&/\^W\JD%O"JE4BCC!&#LC5/_00*9#:QPL610">>/\
M]7;MW]ZJ<N=MV4;JUHZ+Y%)6279)?<6!NYSZ\?Y_R:\0_:/\-:IXP^"_CKPY
MHR&34M3TL06J* 2T@N(GP ?937N%(RA@590P/4, 0?J#Q407(DKMVMJW=Z U
M=-=U;3S/Y<O@'^PK\9_#'QEM_%.LZ9.EG%K*7&]E3&Q9P^1COC]?T_II\)VU
MS9Z'IMK<@B2"SAC8''WE&#T_K[XK>%K;*<K;P ^HAC!_,+FIP,=!CZ"NFIB)
MU(*$DFU]KKT_R(ITXTUIN]WU?KYA4%QYGE-Y>-W;/KCCV^OZ<U/17.:%.R\[
MRAYP&[ SC_ZW']?PQ5RBB@"&Y4O;SH.KPRJ/JR,!^IK^=/\ ;,_8_P#C!X^^
M*U]XE\+6,TMLTYDC= I' R,9QW'YY-?T477F^7^ZZ_Y_IZ<U#;VZ.F;B"%G]
M6B1C^94G\^:WA[D)33BV_=L]]UJE;\2*D(U(N,EH_P /->?8_G&T3X;?ME^%
MM'MM+TJ/4(XX42,!1'PJKCC_ #].!6@?"7[;B2VTT:ZCN,B&7B+@'KG&.WX#
M^7]&/V2T/6UM_P#OQ%_\31]DM/\ GUM_^_$?_P 33GB)2CRJ*AW<='+1?%WU
M7ET'"$8148K;R^1\+_LS:;\7+2SM#X\$XG\I/-\UA][ W# Z<_X<5]NW;3K&
MK1$?*5+9] 1G'Y=O?VJIJL5PBH+*-5^89V(%['I@#]/Q[4NV\:TC4@>8=@?.
M.AQG]/ZYYKFOK:S];:&SA:"G=._3JMO\S0M;M)E W L!S_G_ #_A=QGJ,_A7
M/-:W4#(UN "?O=/;]/?^=;T>[8N[KC_/^1QZ4E*\I*S7+;6VCNKZ&9\T_M!?
ML]>%OC)H=VNL6JSW:0R?9R02P=E/3'3G'_UL5^&^L?L9_&WX<>.HM7^'-I>Q
MP0WS,GEMQY1W] Y( SC^?M7],/7@C(J VULQRUO Q]3#&3^JUT4ZKIQG'E4E
M-6=]OZ_435VGKH?SM>(]._;KGEMK"V&H_8@BQ/\ ZG&!N!]^F,Y_#'./)-._
M8P^/?Q,^)>BZG\1K2\ETLW-NUWYA!39YH+Y"L.,9)X_.OZ:Y[/-PI2UMM@/)
M\B+CUQE?3IG^5:B6MNH4BV@5@!RL* C'OMS_ /7JH8B4$N6*5E:_5W6[\]-&
M0Z:=15+NZ5K=/N/#?@;\$/#'P>\-66F:):0PN;:/SOD7=YA0*W)&>W^37O59
M<WVL3J(P!%GG'3_..F?Y5IKG SUQSUK"4G)MMW;-!:***0!7->+K:XO?#^IV
MEL"9;BSGB4#J2R@#T_2NEH(SU&?J*J$N62E:]GLP/QJ_9Q_9M\?>#OVD?$WC
M;5[26/2KZ]O)89"JA2LET)!SZX]??US7[*U&L,*G<L4:L>K+&H)_$#-243G*
M;O)M_P"0!2#/.?7C_/\ GO[4M%9N-W%W:Y6W9;.ZMKW 0D#KQ7 ?%'2;O7/
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MGJ,_A1110 4444 &/;]**** #'M^E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cmmb_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cmmb_img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  U &P# 2(  A$! Q$!_\0
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@"BBBO..H**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>cmmb-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cmmb="http://www.anchiano.com/20231231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" targetNamespace="http://www.anchiano.com/20231231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>0004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity" id="StatementsOfChangesInEquity">
        <link:definition>0005 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0006 - Statement - Statements of Cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/General" id="General">
        <link:definition>0007 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
        <link:definition>0009 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses" id="OtherReceivablesAndPrepaidExpenses">
        <link:definition>0010 - Disclosure - Other Receivables and Prepaid Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>0011 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/Leases" id="Leases">
        <link:definition>0012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
        <link:definition>0013 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapital" id="ShareCapital">
        <link:definition>0014 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopment" id="ResearchAndDevelopment">
        <link:definition>0015 - Disclosure - Research and Development</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrative" id="GeneralAndAdministrative">
        <link:definition>0016 - Disclosure - General and Administrative</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions" id="RelatedPartiesBalancesAndTransactions">
        <link:definition>0018 - Disclosure - Related Parties Balances and Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders" id="NetLossPerShareAttributableToOrdinaryShareholders">
        <link:definition>0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralTables" id="GeneralTables">
        <link:definition>0022 - Disclosure - General (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>0023 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
        <link:definition>0024 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables" id="OtherReceivablesAndPrepaidExpensesTables">
        <link:definition>0025 - Disclosure - Other Receivables and Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>0026 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesTables" id="LeasesTables">
        <link:definition>0027 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalTables" id="ShareCapitalTables">
        <link:definition>0028 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentTables" id="ResearchAndDevelopmentTables">
        <link:definition>0029 - Disclosure - Research and Development (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeTables" id="GeneralAndAdministrativeTables">
        <link:definition>0030 - Disclosure - General and Administrative (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>0031 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables" id="RelatedPartiesBalancesAndTransactionsTables">
        <link:definition>0032 - Disclosure - Related Parties Balances and Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables" id="NetLossPerShareAttributableToOrdinaryShareholdersTables">
        <link:definition>0033 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralDetails" id="GeneralDetails">
        <link:definition>0034 - Disclosure - General (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails" id="GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails">
        <link:definition>0035 - Disclosure - General (Schedule of net assets acquired based on their estimated fair value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" id="SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0036 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
        <link:definition>0037 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails" id="CashAndCashEquivalentsDetails">
        <link:definition>0038 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails" id="OtherReceivablesAndPrepaidExpensesDetails">
        <link:definition>0039 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetDetails">
        <link:definition>0040 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails" id="LeasesNarrativeDetails">
        <link:definition>0041 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" id="LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
        <link:definition>0042 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails" id="CommitmentsAndContingentLiabilitiesDetails">
        <link:definition>0043 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails" id="ShareCapitalNarrativeDetails">
        <link:definition>0044 - Disclosure - Share Capital (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails" id="ShareCapitalShare-basedCompensationExpensesDetails">
        <link:definition>0045 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails" id="ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails">
        <link:definition>0046 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" id="ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
        <link:definition>0047 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" id="ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
        <link:definition>0048 - Disclosure - Research and Development (Schedule of Research and Development) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" id="GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
        <link:definition>0049 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>0050 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" id="IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
        <link:definition>0051 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails" id="IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails">
        <link:definition>0052 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails" id="IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails">
        <link:definition>0053 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" id="RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
        <link:definition>0054 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" id="RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
        <link:definition>0055 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails" id="NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails">
        <link:definition>0056 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" id="NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
        <link:definition>0057 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AdditionalWorkOrderAmount" id="cmmb_AdditionalWorkOrderAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateAmountCommitmentToPay" id="cmmb_AggregateAmountCommitmentToPay" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateAmountOfCommitmentPaid" id="cmmb_AggregateAmountOfCommitmentPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateOfferingPriceOfAtMarketOfferingAgreement" id="cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmericanDepositarySharesMember" id="cmmb_AmericanDepositarySharesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualRatesOfDepreciation" id="cmmb_AnnualRatesOfDepreciation" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualRentAndManagementFees" id="cmmb_AnnualRentAndManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AtmAgreementMember" id="cmmb_AtmAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BankGuaranteesToPropertyOwner" id="cmmb_BankGuaranteesToPropertyOwner" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CantorMember" id="cmmb_CantorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CapitalAdditionsOneMember" id="cmmb_CapitalAdditionsOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashAcquiredInMerger" id="cmmb_CashAcquiredInMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashPaidAndReceivedDuringYearForAbstract" id="cmmb_CashPaidAndReceivedDuringYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" id="cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConsultantsAndSubcontractorsExpense" id="cmmb_ConsultantsAndSubcontractorsExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CumulativeAmountsOfGrantsReceivedAndRecognized" id="cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrencyTransactionLossValuationAllowance" id="cmmb_CurrencyTransactionLossValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" id="cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EarningsPerShareCalculationNumeratorAbstract" id="cmmb_EarningsPerShareCalculationNumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectOfReverseCapitalizationTransaction" id="cmmb_EffectOfReverseCapitalizationTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EffectOfReverseCapitalizationTransactionShares" id="cmmb_EffectOfReverseCapitalizationTransactionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EstimatedFairValueOfNetAssetsAcquired" id="cmmb_EstimatedFairValueOfNetAssetsAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ExpectsToReceiveAmountOfChemomabTherapeuticsInc" id="cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FinanceIncomeExpensesNet" id="cmmb_FinanceIncomeExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FormerChemomabSecurityHoldersMember" id="cmmb_FormerChemomabSecurityHoldersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GeneralAndAdministrativeDisclosureTextBlock" id="cmmb_GeneralAndAdministrativeDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" id="cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncomeTaxDisclosureLineItems" id="cmmb_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncomeTaxDisclosureTable" id="cmmb_IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="IncomeTaxesReceived" id="cmmb_IncomeTaxesReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncomeTaxExpenseValuationAllowance" id="cmmb_IncomeTaxExpenseValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncrementalBorrowingRateOfLeases" id="cmmb_IncrementalBorrowingRateOfLeases" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InterestReceived" id="cmmb_InterestReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InvestorsMember" id="cmmb_InvestorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LaboratoryEquipmentMember" id="cmmb_LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LienOnBankDeposit" id="cmmb_LienOnBankDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LongTermLeaseDeposit" id="cmmb_LongTermLeaseDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" id="cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MarketOfferingAgreementMember" id="cmmb_MarketOfferingAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumPercentageOfPaymentsOfRoyalties" id="cmmb_MaximumPercentageOfPaymentsOfRoyalties" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" id="cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsDisclosureAbstract" id="cmmb_NatureOfOperationsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdsIssuedAndOutstandingAfterMerger" id="cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdssOptionsIssuableOutstanding" id="cmmb_NumberOfAdssOptionsIssuableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdssVestedAndExercisable" id="cmmb_NumberOfAdssVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOptionsIssuableOutstanding" id="cmmb_NumberOfOptionsIssuableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOptionsVestedAndExercisable" id="cmmb_NumberOfOptionsVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOrdinarySharesConsistedInDs" id="cmmb_NumberOfOrdinarySharesConsistedInDs" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockAdssResveredForIssuance" id="cmmb_NumberOfStockAdssResveredForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockReservedForIssuance" id="cmmb_NumberOfStockReservedForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfVestedAndExercisable" id="cmmb_NumberOfVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsPurchaseUpAdss" id="cmmb_NumberOfWarrantsPurchaseUpAdss" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" id="cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="OrdinarySharesNoParValuePerShareMember" id="cmmb_OrdinarySharesNoParValuePerShareMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" id="cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" id="cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PaymentsForInvestmentInDeposits" id="cmmb_PaymentsForInvestmentInDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PercentageOfMonthlyDepositsRate" id="cmmb_PercentageOfMonthlyDepositsRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltyPaymentsOnSaleOfProduct" id="cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromSaleOfAdss" id="cmmb_ProceedsFromSaleOfAdss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReassessmentOfRightOfUseAsset" id="cmmb_ReassessmentOfRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReceivablesFromGovernmentInstitutions" id="cmmb_ReceivablesFromGovernmentInstitutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReceivedAmountOfChemomabTherapeuticsInc" id="cmmb_ReceivedAmountOfChemomabTherapeuticsInc" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RecoverabilityOfVatAmount" id="cmmb_RecoverabilityOfVatAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RentAndMaintenanceGeneralAndAdministrativeExpense" id="cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RentAndMaintenanceResearchAndDevelopmentExpense" id="cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RepurchaseArrangementMember" id="cmmb_RepurchaseArrangementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RepurchaseOfAmericanDepositaryReceipts" id="cmmb_RepurchaseOfAmericanDepositaryReceipts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RepurchaseOfAmericanDepositaryReceiptsShares" id="cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RothCapitalPartnersLlcMember" id="cmmb_RothCapitalPartnersLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockLineItems" id="cmmb_SaleOfStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStocksPricePerShare" id="cmmb_SaleOfStocksPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockTable" id="cmmb_SaleOfStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="SaleOfStockValueOfSharesIssuedInTransaction" id="cmmb_SaleOfStockValueOfSharesIssuedInTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ScheduleOfAnnualRateOfDeprecationTableTextBlock" id="cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfGeneralAndAdministrativeTableTextBlock" id="cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" id="cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRelatedPartyPayablesTableTextBlock" id="cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfResearchAndDevelopmentTableTextBlock" id="cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" id="cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayPolicyTextBlock" id="cmmb_SeverancePayPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" id="cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationGeneralAndAdministrativeExpense" id="cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationResearchAndDevelopmentExpense" id="cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareholdingPercentageImmediatelyFollowingMerger" id="cmmb_ShareholdingPercentageImmediatelyFollowingMerger" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermBankDepositsPolicyTextBlock" id="cmmb_ShortTermBankDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodNewIssues" id="cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodValueNewIssues" id="cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" id="cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" id="cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesStockOptionsExercised1" id="cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxAssetsAcquiredThroughMergerValuationAllowance" id="cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" id="cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TwoThousandsFifteenPlanMember" id="cmmb_TwoThousandsFifteenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandsSeventeenPlanMember" id="cmmb_TwoThousandsSeventeenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" id="cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>cmmb-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#StatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#StatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails" roleURI="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#OtherReceivablesAndPrepaidExpensesDetails" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_Liabilities_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_StockholdersEquity_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_CommonStockValue_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_TreasuryStockValue_22" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_AdditionalPaidInCapital_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_OperatingExpenses_3" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_19"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_cmmb_PaymentsForInvestmentInDeposits_10" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_cmmb_LongTermLeaseDeposit_11" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_12" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_cmmb_CashAcquiredInMerger_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_17" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_18" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_19" order="40" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_cmmb_ReceivablesFromGovernmentInstitutions_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_5"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_ConsultantsAndSubcontractorsExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_us-gaap_OfficersCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_5" order="40" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_SalariesAndWages_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_ProfessionalFees_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_GeneralInsuranceExpense_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7" order="60" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_0" xlink:to="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_0" xlink:to="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_0" xlink:to="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_0" xlink:to="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4" order="30" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>cmmb-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#StatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#GeneralDetails" roleURI="http://www.anchiano.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#LeasesNarrativeDetails" roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ShareCapitalShare-basedCompensationExpensesDetails" roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#IncomeTaxesDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_56"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_58"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6" xlink:to="loc_dei_AddressTypeDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_6" xlink:to="loc_dei_BusinessContactMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6" xlink:to="loc_dei_AddressTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AmendmentFlag_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentType_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentRegistrationStatement_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_18" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_19" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_20" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentShellCompanyReport_21" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFileNumber_22" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityRegistrantName_23" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_24" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_25" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_26" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_27" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_28" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCountry_29" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_30" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CityAreaCode_31" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_ContactPersonnelName_32" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_33" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_34" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_Security12bTitle_35" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_TradingSymbol_36" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_SecurityExchangeName_37" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_38" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_39" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_40" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_41" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFilerCategory_42" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntitySmallBusiness_43" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_44" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentAccountingStandard_45" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_46" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_47" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityShellCompany_48" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityPublicFloat_49" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_50" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorName_51" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorLocation_52" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorFirmId_53" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_WrittenCommunications_54" order="440" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_SolicitingMaterial_55" order="450" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_PreCommencementTenderOffer_56" order="460" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_57" order="470" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_58" order="480" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_TreasuryStockCommonMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_21" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_23" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_cmmb_FormerChemomabSecurityHoldersMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_14" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cmmb_AnnualRatesOfDepreciation_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" order="20" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_cmmb_LaboratoryEquipmentMember_4" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS" xlink:label="loc_currency_ILS_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_XXX" xlink:label="loc_currency_XXX_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_USD_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_XXX_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS" xlink:label="loc_currency_ILS_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LeaseExpirationDate1_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_AnnualRentAndManagementFees_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_BankGuaranteesToPropertyOwner_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_ReassessmentOfRightOfUseAsset_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_15" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_16" order="110" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS" xlink:label="loc_currency_ILS_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_CapitalAdditionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_cmmb_CapitalAdditionsOneMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_LeaseAgreementsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_CurrencyAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_7" xlink:to="loc_currency_AllCurrenciesDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7" xlink:to="loc_currency_EUR_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7" xlink:to="loc_currency_ILS_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_7" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_12" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_12" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_StatementScenarioAxis_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_15" xlink:to="loc_srt_ScenarioUnspecifiedDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_15" xlink:to="loc_srt_ScenarioForecastMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_15" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentDescription_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsDescription_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_24" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_26" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_27" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RoyaltyExpense_28" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AggregateAmountCommitmentToPay_29" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AggregateAmountOfCommitmentPaid_30" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AdditionalWorkOrderAmount_31" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_LienOnBankDeposit_32" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RestrictedInvestments_33" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_RecoverabilityOfVatAmount_34" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_37"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_43"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_44"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_45"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_46"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_47"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_49"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_SaleOfStockTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_CantorMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_RothCapitalPartnersLlcMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_cmmb_InvestorsMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_cmmb_AtmAgreementMember_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_cmmb_RepurchaseArrangementMember_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_cmmb_MarketOfferingAgreementMember_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14" xlink:to="loc_us-gaap_ClassOfStockDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_PlanNameAxis_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_18" xlink:to="loc_us-gaap_PlanNameDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_18" xlink:to="loc_cmmb_TwoThousandsFifteenPlanMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_18" xlink:to="loc_cmmb_TwoThousandsSeventeenPlanMember_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_18" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_24" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_25" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_27" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_28" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ProceedsFromSaleOfAdss_29" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_30" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_31" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_SaleOfStocksPricePerShare_32" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfStockReservedForIssuance_33" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfStockAdssResveredForIssuance_34" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_35" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfOptionsIssuableOutstanding_36" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfVestedAndExercisable_37" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfAdssVestedAndExercisable_38" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfOptionsVestedAndExercisable_39" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_40" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_41" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_43" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_44" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_45" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_46" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_47" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_48" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_49" order="260" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharePrice_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" order="80" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" xlink:to="loc_srt_RangeAxis_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" xlink:to="loc_us-gaap_AwardTypeAxis_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL" xlink:label="loc_country_IL_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_IncomeTaxDisclosureTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_srt_ScenarioForecastMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementGeographicalAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_IL_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_US_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_10" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10" xlink:to="loc_us-gaap_DomesticCountryMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_10" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_us-gaap_RelatedPartyMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_2" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>cmmb-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_19"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_20"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_37"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_43"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_44"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_45"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_46"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_47"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_48"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_49"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_50"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_51"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_52"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_53"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_54"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_55"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_56"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_57"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_58"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_59"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_60"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_61"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_62"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_63"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_64"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_65"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_66"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_67"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_68"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_69"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_70"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_71"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_72"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_73"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_74"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_75"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_76"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_77"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_78"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_79"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_80"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_81"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_82"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_83"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_84"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_85"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_86"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_87"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_88"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_89"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_90"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_91"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_92"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_93"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_94"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_95"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_96"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_97"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_98"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_99"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_100"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_101"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_102"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_103"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_104"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_105"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_106"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_107"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_108"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_109"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_110"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_111"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_112"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_113"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_114"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_115"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_116"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_117"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_118"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_119"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_120"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_121"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_122"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_123"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_124"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_125"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_126"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_127"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_128"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_129"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_130"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_131"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_132"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_133"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_134"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_135"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_136"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_137"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_138"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_139"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_140"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_141"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_142"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_143"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_144"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_145"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_146"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_147"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_148"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_149"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_150"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_151"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_152"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_153"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_154"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_155"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_156"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_157"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_158"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_159"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_160"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_161"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_162"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_163"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_164"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_165"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_166"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_167"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_168"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_169"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_170"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_171"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_172"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_173"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_174"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_175"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_176"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_177"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_178"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_179"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_180"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_181"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_182"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_183"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_184"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_185"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_186"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_187"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_188"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_189"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_190"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_191"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_192"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_193"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_194"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_195"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_196"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_197"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_198"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_199"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_200"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_201"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_202"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_203"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_204"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_205"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_206"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_207"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_208"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_209"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_210"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_211"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_212"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_213"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_214"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_215"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_216"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_217"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_218"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_219"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_220"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_221"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_222"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_223"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_224"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_225"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_226"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_227"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_228"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_229"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_230"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_231"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_232"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_233"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_234"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_235"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_236"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_237"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_238"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_239"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_240"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_241"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_242"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_243"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_244"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_245"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_246"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_247"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_248"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_249"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_250"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_251"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_252"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_253"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_254"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_255"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_256"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_257"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_258"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_259"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_260"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_261"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_262"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_263"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_264"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_265"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_266"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_267"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_268"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_269"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_270"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_271"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_272"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_273"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_274"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_275"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_276"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_277"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_278"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_279"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_280"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_281"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_282"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_283"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_284"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_285"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_286"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_287"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_288"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_289"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_290"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL" xlink:label="loc_country_IL_292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR_294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS" xlink:label="loc_currency_ILS_295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS" xlink:label="loc_currency_ILS_296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD_297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_XXX" xlink:label="loc_currency_XXX_298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_728"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_729"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_730"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_731"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_732"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_733"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_734"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_735"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_736"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_737"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_738"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_739"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_740"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_741"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_742"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_743"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_744"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_745"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_746"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_747"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_748"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_749"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_750"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_751"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_752"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_753"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_754"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_755"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_756"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_757"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_758"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_759"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_760"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_761"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_762"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_763"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_764"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_765"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_766"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_767"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_768"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_769"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_770"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_771"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_772"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_773"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_774"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_775"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_0" xml:lang="en-US">Additional work order amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_1" xml:lang="en-US">Additional Work Order Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_2" xml:lang="en-US">Additional work order</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateAmountCommitmentToPay_0" xml:lang="en-US">Aggregate amount commitment to pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateAmountCommitmentToPay_1" xml:lang="en-US">Aggregate amount commitment to pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateAmountOfCommitmentPaid_0" xml:lang="en-US">Aggregate amount of commitment paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateAmountOfCommitmentPaid_1" xml:lang="en-US">Aggregate amount of commitment paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_0" xml:lang="en-US">It represents as a aggregate offering price of at the market offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_1" xml:lang="en-US">Aggregate Offering Price Of At Market Offering Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_2" xml:lang="en-US">Aggregate offering price of at the market offering agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AmericanDepositarySharesMember_0" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AmericanDepositarySharesMember_1" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_0" xml:lang="en-US">Annual rates of depreciation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_1" xml:lang="en-US">Annual Rates Of Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_2" xml:lang="en-US">Annual rates of depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AnnualRentAndManagementFees_0" xml:lang="en-US">Annual rent and management fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AnnualRentAndManagementFees_1" xml:lang="en-US">Annual rent and management fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AtmAgreementMember_0" xml:lang="en-US">ATM agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AtmAgreementMember_1" xml:lang="en-US">ATM agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BankGuaranteesToPropertyOwner_0" xml:lang="en-US">Bank guarantees to property owner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BankGuaranteesToPropertyOwner_1" xml:lang="en-US">Bank guarantees to property owner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0" xml:lang="en-US">The amount of of asset held for sale recogized prior to the completion of merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Asset Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2" xml:lang="en-US">Asset held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0" xml:lang="en-US">Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CantorMember_0" xml:lang="en-US">Represents about Cantor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CantorMember_1" xml:lang="en-US">Cantor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CapitalAdditionsOneMember_0" xml:lang="en-US">FDA or equivalent agency marketing approval [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CapitalAdditionsOneMember_1" xml:lang="en-US">Capital Additions One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_CapitalAdditionsOneMember_2" xml:lang="en-US">FDA or equivalent agency marketing approval [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CashAcquiredInMerger_0" xml:lang="en-US">Cash acquired in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CashAcquiredInMerger_1" xml:lang="en-US">Cash acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_0" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_1" xml:lang="en-US">Cash Paid And Received During Year For [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_2" xml:lang="en-US">A. Cash paid and received during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_0" xml:lang="en-US">It represents as a change in temporary differences for which deferred taxes were not recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_1" xml:lang="en-US">Change In Temporary Differences For Deferred Taxes Not Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_2" xml:lang="en-US">Change in temporary differences for which deferred taxes were not recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_0" xml:lang="en-US">Consultants and subcontractors expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_1" xml:lang="en-US">Consultants And Subcontractors Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_2" xml:lang="en-US">Consultants and subcontractors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_0" xml:lang="en-US">The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_1" xml:lang="en-US">Cumulative Amounts Of Grants Received And Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_2" xml:lang="en-US">Cumulative amounts of grants received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to currency transaction loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_1" xml:lang="en-US">Currency Transaction Loss Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_2" xml:lang="en-US">Currency transaction income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_0" xml:lang="en-US">Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_1" xml:lang="en-US">Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_2" xml:lang="en-US">Denominator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_0" xml:lang="en-US">Earnings Per Share Calculation Numerator Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" xml:lang="en-US">Earnings Per Share Calculation Numerator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_2" xml:lang="en-US">Numerator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_0" xml:lang="en-US">The amount of effect due reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_1" xml:lang="en-US">Effect of reverse capitalization transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0" xml:lang="en-US">The number of shares isued due to effect of reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1" xml:lang="en-US">Effect Of Reverse Capitalization Transaction Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2" xml:lang="en-US">Effect of reverse capitalization transaction (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xml:lang="en-US">The amount of estimated fair value of the net assets acquired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1" xml:lang="en-US">Estimated Fair Value Of Net Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2" xml:lang="en-US">Net acquired assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_0" xml:lang="en-US">The amount expects to receive of Chemomab Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_1" xml:lang="en-US">Expects To Receive Amount Of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_2" xml:lang="en-US">Expects to receive amount of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_0" xml:lang="en-US">The net amount of finance income earned and finance expenses incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_1" xml:lang="en-US">Financing expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_2" xml:lang="en-US">Finance Income (Expenses), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_0" xml:lang="en-US">This represents former Chemomab security holders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_1" xml:lang="en-US">Former Chemomab Security Holders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_0" xml:lang="en-US">The entire disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1" xml:lang="en-US">General And Administrative Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_2" xml:lang="en-US">General and Administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_1" xml:lang="en-US">Government Sponsored Research And Development [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_2" xml:lang="en-US">Government-sponsored research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxDisclosureLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxDisclosureLineItems_1" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxDisclosureTable_0" xml:lang="en-US">Disclosure of information pertaining to income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxDisclosureTable_1" xml:lang="en-US">Income Tax Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxesReceived_0" xml:lang="en-US">It represents income taxes received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxesReceived_1" xml:lang="en-US">Income Taxes Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncomeTaxesReceived_2" xml:lang="en-US">Income taxes received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to income tax expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_1" xml:lang="en-US">Income Tax Expense Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_2" xml:lang="en-US">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_0" xml:lang="en-US">It represents incremental borrowing rate of leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_1" xml:lang="en-US">Incremental Borrowing Rate Of Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_2" xml:lang="en-US">incremental borrowing rate of leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_InterestReceived_0" xml:lang="en-US">The amount of interest received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_InterestReceived_1" xml:lang="en-US">Interest Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_InterestReceived_2" xml:lang="en-US">Interest received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_InvestorsMember_0" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_InvestorsMember_1" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LaboratoryEquipmentMember_0" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LaboratoryEquipmentMember_1" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_LaboratoryEquipmentMember_2" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LienOnBankDeposit_0" xml:lang="en-US">Lien on bank deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LienOnBankDeposit_1" xml:lang="en-US">Lien on bank deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LongTermLeaseDeposit_0" xml:lang="en-US">Long-term lease deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LongTermLeaseDeposit_1" xml:lang="en-US">Long Term Lease Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_LongTermLeaseDeposit_2" xml:lang="en-US">Long-term lease deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_0" xml:lang="en-US">Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_1" xml:lang="en-US">Losses And Benefits For Tax Purposes For The Year For Which Deferred Taxes Were Not Recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_2" xml:lang="en-US">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MarketOfferingAgreementMember_0" xml:lang="en-US">Market Offering Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MarketOfferingAgreementMember_1" xml:lang="en-US">This member stands for market offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_MarketOfferingAgreementMember_2" xml:lang="en-US">Market offering agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_0" xml:lang="en-US">The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_1" xml:lang="en-US">Maximum Percentage Of Payments Of Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_2" xml:lang="en-US">Maximum percentage of payments of royalties (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_0" xml:lang="en-US">This represents Merger Agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company inclued proposed merger of CMB Acquisition Ltd, wholly owned subsidiary of our company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" xml:lang="en-US">Merger Agreement With Cmb Acquisition Ltd Subsidiary Of Ours And Chemomb [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_2" xml:lang="en-US">Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_0" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_1" xml:lang="en-US">Nature Of Operations Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_2" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0" xml:lang="en-US">Number of ADS issued and outstanding after the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1" xml:lang="en-US">Number of ADS issued and outstanding after the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_0" xml:lang="en-US">Number of ADSs options issuable outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_1" xml:lang="en-US">Number of ADSs options issuable outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdssVestedAndExercisable_0" xml:lang="en-US">Number of ADSs vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdssVestedAndExercisable_1" xml:lang="en-US">Number of ADSs vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_0" xml:lang="en-US">It represents number of options issuable outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_1" xml:lang="en-US">Number Of Options Issuable Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_2" xml:lang="en-US">Number of options issuable outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_0" xml:lang="en-US">It represents number of options vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_1" xml:lang="en-US">Number Of Options Vested And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_2" xml:lang="en-US">Number of options vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_0" xml:lang="en-US">Represent the number of ordinary shares consisted in one American depository share (ADS).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_1" xml:lang="en-US">Number Of Ordinary Shares Consisted In Ds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_2" xml:lang="en-US">Number of ordinary shares represented by each ADS (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_0" xml:lang="en-US">Number of stock option ADSs resvered for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_1" xml:lang="en-US">Number Of Stock Adss Resvered For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_2" xml:lang="en-US">Number of stock option ADSs reversed for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_0" xml:lang="en-US">It represents number of stock resvered for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_1" xml:lang="en-US">Number Of Stock Reserved For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_2" xml:lang="en-US">Number of stock reserved for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_0" xml:lang="en-US">It represents number of vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_1" xml:lang="en-US">Number Of Vested And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_2" xml:lang="en-US">Number of vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_0" xml:lang="en-US">Number of warrants purchase ADS's.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_1" xml:lang="en-US">Number Of Warrants Purchase Up Adss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_2" xml:lang="en-US">Number of warrants purchase ADS's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_0" xml:lang="en-US">Operating right-of-use assets and operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_1" xml:lang="en-US">Operating Right Of Use Assets And Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_2" xml:lang="en-US">Operating right-of-use assets and operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0" xml:lang="en-US">Other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2" xml:lang="en-US">Other Receivables and Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_0" xml:lang="en-US">Payment on commencement of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_1" xml:lang="en-US">Payment On Long Term Purchase Commitment Commencement Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_2" xml:lang="en-US">Payment on commencement of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_0" xml:lang="en-US">The amount of payments for investm,ents in deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_1" xml:lang="en-US">Investment in deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_2" xml:lang="en-US">Payments for Investment in Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PercentageOfMonthlyDepositsRate_0" xml:lang="en-US">Percentage of monthly deposits rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PercentageOfMonthlyDepositsRate_1" xml:lang="en-US">Percentage of monthly deposits rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_0" xml:lang="en-US">The percentage of royalty payments on sale of product developed with funding received from the IIA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_1" xml:lang="en-US">Percentage Of Royalty Payments On Sale Of Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_2" xml:lang="en-US">Royalty payments on sale of product (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ProceedsFromSaleOfAdss_0" xml:lang="en-US">Proceeds from sale of ADS's.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ProceedsFromSaleOfAdss_1" xml:lang="en-US">Proceeds from sale of ADS's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReassessmentOfRightOfUseAsset_0" xml:lang="en-US">Reassessment Of Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReassessmentOfRightOfUseAsset_1" xml:lang="en-US">Represent the amount of reassessment of the right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ReassessmentOfRightOfUseAsset_2" xml:lang="en-US">Reassessment of the right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_0" xml:lang="en-US">Government institutions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_1" xml:lang="en-US">Receivables From Government Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_2" xml:lang="en-US">Government institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_0" xml:lang="en-US">The received amount of Chemomab Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_1" xml:lang="en-US">Received Amount Of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_2" xml:lang="en-US">Received amount of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_0" xml:lang="en-US">It represents recoverability of VAT amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_1" xml:lang="en-US">Recoverability Of Vat Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_2" xml:lang="en-US">Recoverability of VAT amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to professional services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Professional Services From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Professional services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to research and develeopment expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Research And Development Expense From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_2" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to salaries and related expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Salaries And Related Expenses From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to share based payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Share Based Payments From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" xml:lang="en-US">Share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative related rent and maintenance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_1" xml:lang="en-US">Rent And Maintenance General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_2" xml:lang="en-US">Rent and maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development related rent and maintenance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_1" xml:lang="en-US">Rent And Maintenance Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_2" xml:lang="en-US">Lease and maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseArrangementMember_0" xml:lang="en-US">This member stands for Repurchase Arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseArrangementMember_1" xml:lang="en-US">Repurchase Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseArrangementMember_2" xml:lang="en-US">Repurchase arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">Represents the amount of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_0" xml:lang="en-US">It represents repurchase of American Depositary Receipts shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_1" xml:lang="en-US">Repurchase Of American Depositary Receipts Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_2" xml:lang="en-US">Number of shares repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RothCapitalPartnersLlcMember_0" xml:lang="en-US">Roth Capital Partners Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RothCapitalPartnersLlcMember_1" xml:lang="en-US">This member stands for Roth Capital Partners, LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_RothCapitalPartnersLlcMember_2" xml:lang="en-US">Roth Capital Partners, LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockLineItems_1" xml:lang="en-US">Sale Of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_0" xml:lang="en-US">Per share amount received by the company for each share of common stock issued or sold in the stock transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_1" xml:lang="en-US">Sale Of Stocks Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_2" xml:lang="en-US">Share price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockTable_0" xml:lang="en-US">Different names of stock transactions and the different attributes of each transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockTable_1" xml:lang="en-US">Sale Of Stock [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_0" xml:lang="en-US">Represents the amount of sale of stock value of shares issued in transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_1" xml:lang="en-US">Sale Of Stock Value Of Shares Issued In Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_2" xml:lang="en-US">Issuance and sale of of ADS upto</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_0" xml:lang="en-US">Tabular disclosure of the annual rate of deprecation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1" xml:lang="en-US">Schedule Of Annual Rate Of Deprecation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_2" xml:lang="en-US">Schedule of annual rate of deprecation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_0" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1" xml:lang="en-US">Schedule Of General And Administrative [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_2" xml:lang="en-US">Schedule of general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_0" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_2" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of related party payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1" xml:lang="en-US">Schedule Of Related Party Payables [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_2" xml:lang="en-US">Schedule of related party payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_0" xml:lang="en-US">Tabular disclosure of research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1" xml:lang="en-US">Schedule Of Research And Development [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_2" xml:lang="en-US">Schedule of research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_0" xml:lang="en-US">This represents security holders of Anchiano as of immediately prior to the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_1" xml:lang="en-US">Security holders of Anchiano as of immediately prior to the merger [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for severance pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_1" xml:lang="en-US">Severance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_2" xml:lang="en-US">Severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_0" xml:lang="en-US">It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Ads Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_2" xml:lang="en-US">Options to purchase ordinary shares cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0" xml:lang="en-US">It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Ads Outstanding Period Increase Decrease Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2" xml:lang="en-US">Weighted average exercise price of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_0" xml:lang="en-US">Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_2" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_0" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award, Options, Acquired In Merger, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average price of shares acquired in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2" xml:lang="en-US">Acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative related share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_1" xml:lang="en-US">Share Based Compensation General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development related share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_1" xml:lang="en-US">Share Based Compensation Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0" xml:lang="en-US">shareholding percentage immediately following the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1" xml:lang="en-US">Shareholding percentage immediately following the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_0" xml:lang="en-US">Short Term Bank Deposits [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_1" xml:lang="en-US">Disclosure of accounting policy for Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_2" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_0" xml:lang="en-US">it represents number of shares and warrants issued during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_1" xml:lang="en-US">Stock And Warrants Issued During Period New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Stock And Warrants Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_0" xml:lang="en-US">Number of new stocks of American Depository Shares ("ADS") issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_1" xml:lang="en-US">Stock Issued During Period American Depository Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_2" xml:lang="en-US">Number of ADSs issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_0" xml:lang="en-US">Number of options acquired, including both vested and non-vested options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_1" xml:lang="en-US">Stock Issued During Period Shares Stock Options Acquired In Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_2" xml:lang="en-US">Acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_1" xml:lang="en-US">Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_2" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_1" xml:lang="en-US">Tax Assets Acquired Through Merger Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_2" xml:lang="en-US">Tax assets acquired through merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">It represents Total consideration of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Total Consideration Of Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Total consideration of repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_0" xml:lang="en-US">2015 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_1" xml:lang="en-US">Two Thousands Fifteen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_2" xml:lang="en-US">2015 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_0" xml:lang="en-US">2017 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_1" xml:lang="en-US">Two Thousands Seventeen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_2" xml:lang="en-US">2017 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">It represents weighted average price of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Weighted Average Price Of Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Weighted average price of repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">U.S. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_EUR_0" xml:lang="en-US">Euro [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_ILS_0" xml:lang="en-US">ILS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_ILS_1" xml:lang="en-US">NIS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_USD_0" xml:lang="en-US">USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_XXX_0" xml:lang="en-US">Other currencies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain_0" xml:lang="en-US">Address Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm Id</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember_0" xml:lang="en-US">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName_0" xml:lang="en-US">Contact Personnel Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard_0" xml:lang="en-US">Document Accounting Standard</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag_0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems_0" xml:lang="en-US">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable_0" xml:lang="en-US">Document Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement_0" xml:lang="en-US">Document Registration Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport_0" xml:lang="en-US">Document Shell Company Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_0" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInformationFormerLegalOrRegisteredName_0" xml:lang="en-US">Entity Information, Former Legal or Registered Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_0" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_PreCommencementTenderOffer_0" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Name of Exchange on which Security is Registered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SolicitingMaterial_0" xml:lang="en-US">Soliciting Material</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_WrittenCommunications_0" xml:lang="en-US">Written Communications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis_0" xml:lang="en-US">Currency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember_0" xml:lang="en-US">Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain_0" xml:lang="en-US">Scenario [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_0" xml:lang="en-US">Recognized liability for royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xml:lang="en-US">Less - accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional paid in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0" xml:lang="en-US">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments for operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Outstanding options to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_0" xml:lang="en-US">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0" xml:lang="en-US">Prepaid and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalAdditionsMember_0" xml:lang="en-US">New Drug Application and Biological License Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_0" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and contingent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue_0" xml:lang="en-US">Common Stock, No Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 228,090,300 shares at December 31, 2021 and 9,274,838 shares at December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2023, 2022 and 2021;Issued and outstanding: 284,094,700, 232,636,700 Ordinary shares at December 31, 2023 and 2022, respectively and 228,090,300 Ordinary shares at December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0" xml:lang="en-US">Deferred taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Principles of consolidation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue_0" xml:lang="en-US">Related Party Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CostOfRevenue_1" xml:lang="en-US">Total related party expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0" xml:lang="en-US">Incremental borrowing rate based on credit rating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Gross deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0" xml:lang="en-US">Research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Net operating loss carry-forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0" xml:lang="en-US">Share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Less - Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Balance at December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Balance at January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsCurrent_0" xml:lang="en-US">Short-term bank deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Federal [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic and diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">Net Loss Per Share Attributable to Ordinary Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0" xml:lang="en-US">Statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Corporate tax rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0" xml:lang="en-US">Employee and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair value of financial instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Functional currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US">Foreign currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_0" xml:lang="en-US">Furniture and Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_1" xml:lang="en-US">Furniture and equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xml:lang="en-US">General and Administrative Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and administrative [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralInsuranceExpense_0" xml:lang="en-US">Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0" xml:lang="en-US">Impairment of long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_0" xml:lang="en-US">Income taxes paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_1" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_2" xml:lang="en-US">Income taxes paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Actual income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0" xml:lang="en-US">Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1" xml:lang="en-US">Tax rate differential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Theoretical tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1" xml:lang="en-US">Non-deductible expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Change in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0" xml:lang="en-US">Change in accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0" xml:lang="en-US">Change in employees and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0" xml:lang="en-US">Change in leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1" xml:lang="en-US">Change in operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Change in other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAgreementsMember_0" xml:lang="en-US">2020 Lien [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1_0" xml:lang="en-US">Lease expiry date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_1" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_0" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_0" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_0" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of maturity of lease liabilities under our non-cancelable operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total future minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1" xml:lang="en-US">2027</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Less imputed interest:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1" xml:lang="en-US">Lease term, option to extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0" xml:lang="en-US">Lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1_0" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1_1" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount_0" xml:lang="en-US">Payment for licensed agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_0" xml:lang="en-US">Category of Item Purchased [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentDescription_0" xml:lang="en-US">Description of application payment for licensed product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations_0" xml:lang="en-US">General</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0" xml:lang="en-US">Significant non- cash transaction:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1" xml:lang="en-US">B. Significant non- cash transaction:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoninterestExpenseDirectorsFees_0" xml:lang="en-US">Fees to Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Financing expense (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">Financing expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3" xml:lang="en-US">Nonoperating Income (Expense), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation_0" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_0" xml:lang="en-US">Decrease in the carrying amount of the right-of-use asset due to impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_1" xml:lang="en-US">Increase in the carrying amount of the right-of-use asset due to impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Present value of operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_3" xml:lang="en-US">Present value of operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Non-current operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Non-current&#160;operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsDescription_0" xml:lang="en-US">Decsription of occurrence for payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_0" xml:lang="en-US">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable_0" xml:lang="en-US">Other Commitments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_0" xml:lang="en-US">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_1" xml:lang="en-US">Other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0" xml:lang="en-US">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_1" xml:lang="en-US">Related Party Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense_0" xml:lang="en-US">Other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Purchase of treasury share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0" xml:lang="en-US">Preferred shares par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xml:lang="en-US">Prepaid Expense and Other Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US">Other accounts receivable and prepaid expenses, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">The Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0" xml:lang="en-US">Proceeds from preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1" xml:lang="en-US">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_0" xml:lang="en-US">Proceeds from Other Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_1" xml:lang="en-US">Issuance of shares net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_0" xml:lang="en-US">Sale of asset held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_0" xml:lang="en-US">Proceeds from Sale of Treasury Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_1" xml:lang="en-US">Treasury stock at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_2" xml:lang="en-US">Sale of treasury share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees_0" xml:lang="en-US">Professional services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss_0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss_1" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss_2" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0" xml:lang="en-US">Property and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0" xml:lang="en-US">Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_0" xml:lang="en-US">Annual rates of depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0" xml:lang="en-US">Schedule of Property And Equpment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US">Schedule of property and equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyMember_0" xml:lang="en-US">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Parties Balances and Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_0" xml:lang="en-US">Research and Development [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0" xml:lang="en-US">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent_0" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedInvestments_0" xml:lang="en-US">Bank restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_0" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense_0" xml:lang="en-US">Royality expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalariesAndWages_0" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalariesAndWages_1" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Weighted Average Number of Shares Excluded From Computation of Diluted Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of weighted average number of shares excluded from computation of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0" xml:lang="en-US">Schedule of components of cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0" xml:lang="en-US">Summary of the effect of share-based compensation on the statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" xml:lang="en-US">Schedule of the effect of share-based compensation on the statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Significant Components of the Company's Deferred Tax Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of significant components of the company's deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US">Schedule of computation of basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of reconciliation of theoretical income tax expense to actual income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0" xml:lang="en-US">Schedule of net assets acquired based on their estimated fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Transaction With Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of transaction with related parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Summary of assumptions used to calculate the fair value of the options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of assumptions used to calculate the fair value of the options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0" xml:lang="en-US">Summary of number and weighted average exercise prices of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1" xml:lang="en-US">Schedule of number and weighted average exercise prices of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0" xml:lang="en-US">Exercise price (in U.S. dollar)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life of options (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0" xml:lang="en-US">Expected volatility, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0" xml:lang="en-US">Expected volatility, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0" xml:lang="en-US">Risk-free interest rate, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0" xml:lang="en-US">Risk-free interest rate, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Options to purchase ADS cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice_0" xml:lang="en-US">Weighted average share price (in U.S. dollar)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding_0" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding_1" xml:lang="en-US">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding_2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_0" xml:lang="en-US">Website Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_1" xml:lang="en-US">Website development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1" xml:lang="en-US">Shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0" xml:lang="en-US">Reverse stock split conversion ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Exercise of Options, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Exercise of options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_1" xml:lang="en-US">Sale of treasury share at cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Exercise of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_0" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1" xml:lang="en-US">Sale of treasury share at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Events After Balance Sheet Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0" xml:lang="en-US">Schedule of Roll Forward of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1" xml:lang="en-US">Schedule of roll forward of valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_1" xml:lang="en-US">Supplementary cash flows information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_0" xml:lang="en-US">Capital losses carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonMember_0" xml:lang="en-US">Treasury Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonMember_1" xml:lang="en-US">Treasury share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonShares_0" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue_0" xml:lang="en-US">Treasury share at cost (11,640,460 shares as of December 31, 2022)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue_1" xml:lang="en-US">Treasury Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockValue_2" xml:lang="en-US">Treasury stock (11,640,460 shares as of December 31, 2022)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xml:lang="en-US">Net change in the total valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_1" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_2" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_3" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountCommitmentToPay_4" xlink:to="lab_cmmb_AggregateAmountCommitmentToPay_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountCommitmentToPay_5" xlink:to="lab_cmmb_AggregateAmountCommitmentToPay_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountOfCommitmentPaid_6" xlink:to="lab_cmmb_AggregateAmountOfCommitmentPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountOfCommitmentPaid_7" xlink:to="lab_cmmb_AggregateAmountOfCommitmentPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_8" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_9" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_10" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_11" xlink:to="lab_cmmb_AmericanDepositarySharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_12" xlink:to="lab_cmmb_AmericanDepositarySharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_13" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_14" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_15" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRentAndManagementFees_16" xlink:to="lab_cmmb_AnnualRentAndManagementFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRentAndManagementFees_17" xlink:to="lab_cmmb_AnnualRentAndManagementFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtmAgreementMember_18" xlink:to="lab_cmmb_AtmAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtmAgreementMember_19" xlink:to="lab_cmmb_AtmAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BankGuaranteesToPropertyOwner_20" xlink:to="lab_cmmb_BankGuaranteesToPropertyOwner_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BankGuaranteesToPropertyOwner_21" xlink:to="lab_cmmb_BankGuaranteesToPropertyOwner_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_22" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_23" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_24" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_25" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_26" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_27" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CantorMember_28" xlink:to="lab_cmmb_CantorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CantorMember_29" xlink:to="lab_cmmb_CantorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_30" xlink:to="lab_cmmb_CapitalAdditionsOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_31" xlink:to="lab_cmmb_CapitalAdditionsOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_32" xlink:to="lab_cmmb_CapitalAdditionsOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInMerger_33" xlink:to="lab_cmmb_CashAcquiredInMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInMerger_34" xlink:to="lab_cmmb_CashAcquiredInMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_35" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_36" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_37" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_38" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_39" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_40" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_41" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_42" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_43" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_44" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_45" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_46" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_47" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_48" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_49" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_50" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_51" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_52" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_53" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_54" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_55" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_56" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_57" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_58" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_59" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_60" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_61" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_62" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_63" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_64" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_65" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_66" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_67" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_68" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_69" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_70" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_71" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_72" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_73" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_74" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_75" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_76" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_77" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_78" xlink:to="lab_cmmb_IncomeTaxDisclosureLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_79" xlink:to="lab_cmmb_IncomeTaxDisclosureLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_80" xlink:to="lab_cmmb_IncomeTaxDisclosureTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_81" xlink:to="lab_cmmb_IncomeTaxDisclosureTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_82" xlink:to="lab_cmmb_IncomeTaxesReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_83" xlink:to="lab_cmmb_IncomeTaxesReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_84" xlink:to="lab_cmmb_IncomeTaxesReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_85" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_86" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_87" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_88" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_89" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_90" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_91" xlink:to="lab_cmmb_InterestReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_92" xlink:to="lab_cmmb_InterestReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_93" xlink:to="lab_cmmb_InterestReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InvestorsMember_94" xlink:to="lab_cmmb_InvestorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InvestorsMember_95" xlink:to="lab_cmmb_InvestorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_96" xlink:to="lab_cmmb_LaboratoryEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_97" xlink:to="lab_cmmb_LaboratoryEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_98" xlink:to="lab_cmmb_LaboratoryEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LienOnBankDeposit_99" xlink:to="lab_cmmb_LienOnBankDeposit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LienOnBankDeposit_100" xlink:to="lab_cmmb_LienOnBankDeposit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_101" xlink:to="lab_cmmb_LongTermLeaseDeposit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_102" xlink:to="lab_cmmb_LongTermLeaseDeposit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_103" xlink:to="lab_cmmb_LongTermLeaseDeposit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_104" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_105" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_106" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MarketOfferingAgreementMember_107" xlink:to="lab_cmmb_MarketOfferingAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MarketOfferingAgreementMember_108" xlink:to="lab_cmmb_MarketOfferingAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MarketOfferingAgreementMember_109" xlink:to="lab_cmmb_MarketOfferingAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_110" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_111" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_112" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_113" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_114" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_115" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_116" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_117" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_118" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_119" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_120" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_121" xlink:to="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_122" xlink:to="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssVestedAndExercisable_123" xlink:to="lab_cmmb_NumberOfAdssVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssVestedAndExercisable_124" xlink:to="lab_cmmb_NumberOfAdssVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_125" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_126" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_127" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_128" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_129" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_130" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_131" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_132" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_133" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_134" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_135" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_136" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_137" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_138" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_139" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_140" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_141" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_142" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_143" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_144" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_145" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_146" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_147" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_148" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_149" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_150" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_151" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_152" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_153" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_154" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_155" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_156" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_157" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_158" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_159" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfMonthlyDepositsRate_160" xlink:to="lab_cmmb_PercentageOfMonthlyDepositsRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfMonthlyDepositsRate_161" xlink:to="lab_cmmb_PercentageOfMonthlyDepositsRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_162" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_163" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_164" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfAdss_165" xlink:to="lab_cmmb_ProceedsFromSaleOfAdss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfAdss_166" xlink:to="lab_cmmb_ProceedsFromSaleOfAdss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReassessmentOfRightOfUseAsset_167" xlink:to="lab_cmmb_ReassessmentOfRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReassessmentOfRightOfUseAsset_168" xlink:to="lab_cmmb_ReassessmentOfRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReassessmentOfRightOfUseAsset_169" xlink:to="lab_cmmb_ReassessmentOfRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_170" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_171" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_172" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_173" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_174" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_175" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_176" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_177" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_178" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_179" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_180" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_181" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_182" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_183" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_184" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_185" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_186" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_187" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_188" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_189" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_190" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_191" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_192" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_193" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_194" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_195" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_196" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_197" xlink:to="lab_cmmb_RepurchaseArrangementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_198" xlink:to="lab_cmmb_RepurchaseArrangementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_199" xlink:to="lab_cmmb_RepurchaseArrangementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_200" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_201" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_202" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_203" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_204" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_205" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RothCapitalPartnersLlcMember_206" xlink:to="lab_cmmb_RothCapitalPartnersLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RothCapitalPartnersLlcMember_207" xlink:to="lab_cmmb_RothCapitalPartnersLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RothCapitalPartnersLlcMember_208" xlink:to="lab_cmmb_RothCapitalPartnersLlcMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockLineItems_209" xlink:to="lab_cmmb_SaleOfStockLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockLineItems_210" xlink:to="lab_cmmb_SaleOfStockLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_211" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_212" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_213" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockTable_214" xlink:to="lab_cmmb_SaleOfStockTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockTable_215" xlink:to="lab_cmmb_SaleOfStockTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_216" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_217" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_218" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_219" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_220" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_221" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_222" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_223" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_224" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_225" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_226" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_227" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_228" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_229" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_230" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_231" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_232" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_233" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_234" xlink:to="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_235" xlink:to="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_236" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_237" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_238" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_239" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_240" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_241" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_242" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_243" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_244" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_245" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_246" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_247" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_248" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_249" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_250" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_251" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_252" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_253" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_254" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_255" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_256" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_257" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_258" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_259" xlink:to="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_260" xlink:to="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_261" xlink:to="lab_cmmb_ShortTermBankDepositsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_262" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_263" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_264" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_265" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_266" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_267" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_268" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_269" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_270" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_271" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_272" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_273" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_274" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_275" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_276" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_277" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_278" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_279" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_280" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_281" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_282" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_283" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_284" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_285" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_286" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_287" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_288" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_289" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_290" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_291" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_292" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_293" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_294" xlink:to="lab_currency_EUR_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_295" xlink:to="lab_currency_ILS_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_296" xlink:to="lab_currency_ILS_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD_297" xlink:to="lab_currency_USD_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_XXX_298" xlink:to="lab_currency_XXX_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain_299" xlink:to="lab_dei_AddressTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_300" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_301" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_302" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_303" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember_304" xlink:to="lab_dei_BusinessContactMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_305" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName_306" xlink:to="lab_dei_ContactPersonnelName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_307" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard_308" xlink:to="lab_dei_DocumentAccountingStandard_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_309" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag_310" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_311" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_312" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_313" xlink:to="lab_dei_DocumentInformationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable_314" xlink:to="lab_dei_DocumentInformationTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_315" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement_316" xlink:to="lab_dei_DocumentRegistrationStatement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport_317" xlink:to="lab_dei_DocumentShellCompanyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_318" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_319" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_320" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_321" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_322" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_323" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_324" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_325" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_326" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_327" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_328" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_329" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_330" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_331" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_332" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_333" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationFormerLegalOrRegisteredName_334" xlink:to="lab_dei_EntityInformationFormerLegalOrRegisteredName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_335" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_336" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_337" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_338" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_339" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_340" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_341" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_342" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_343" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_344" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_345" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_346" xlink:to="lab_dei_PreCommencementTenderOffer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_347" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_348" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_349" xlink:to="lab_dei_SolicitingMaterial_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_350" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_351" xlink:to="lab_dei_WrittenCommunications_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_352" xlink:to="lab_srt_CurrencyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_353" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_354" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_355" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember_356" xlink:to="lab_srt_ScenarioForecastMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain_357" xlink:to="lab_srt_ScenarioUnspecifiedDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_358" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_359" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_360" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_361" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent_362" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_363" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_364" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_365" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_366" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_367" xlink:to="lab_us-gaap_AdditionalPaidInCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_368" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_369" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_370" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_371" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_372" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_373" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_374" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_375" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_376" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_377" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_378" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_379" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_380" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_381" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_382" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_383" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_384" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_385" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_386" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_387" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_388" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_389" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_390" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_391" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalAdditionsMember_392" xlink:to="lab_us-gaap_CapitalAdditionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_393" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_394" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_395" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_396" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_397" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_398" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_399" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_400" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_401" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_402" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_403" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_404" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_405" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_406" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_407" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_408" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock_409" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_410" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_411" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_412" xlink:to="lab_us-gaap_CommonStockNoParValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_413" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_414" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_415" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_416" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_417" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_418" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_419" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_420" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_421" xlink:to="lab_us-gaap_CostOfRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_422" xlink:to="lab_us-gaap_CostOfRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_423" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_424" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_425" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_426" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_427" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_428" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_429" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_430" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_431" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_432" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_433" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_434" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_435" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent_436" xlink:to="lab_us-gaap_DepositsAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_437" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_438" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_439" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_440" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_441" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_442" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_443" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_444" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_445" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_446" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_447" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_448" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_449" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_450" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_451" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_452" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_453" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_454" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_455" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_456" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_457" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_458" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_459" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_460" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_461" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralInsuranceExpense_462" xlink:to="lab_us-gaap_GeneralInsuranceExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_463" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_464" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_465" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_466" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_467" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_468" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_469" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_470" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_471" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_472" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_473" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_474" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_475" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_476" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_477" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_478" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_479" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_480" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_481" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_482" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_483" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_484" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_485" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_486" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_487" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_488" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_489" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_490" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_491" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_492" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_493" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_494" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_495" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_496" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_497" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_498" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_499" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember_500" xlink:to="lab_us-gaap_LeaseAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1_501" xlink:to="lab_us-gaap_LeaseExpirationDate1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_502" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_503" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_504" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_505" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_506" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_507" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_508" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_509" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_510" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_511" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_512" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_513" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_514" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_515" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_516" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_517" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_518" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_519" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_520" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_521" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_522" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_523" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_524" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_525" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_526" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_527" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_528" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_529" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_530" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_531" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_532" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1_533" xlink:to="lab_us-gaap_LiabilitiesAssumed1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1_534" xlink:to="lab_us-gaap_LiabilitiesAssumed1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_535" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_536" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_537" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_538" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_539" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_540" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_541" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount_542" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_543" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentDescription_544" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_545" xlink:to="lab_us-gaap_NatureOfOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_546" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_547" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_548" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_549" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_550" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_551" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_552" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_553" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_554" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_555" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_556" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_557" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_558" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_559" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoninterestExpenseDirectorsFees_560" xlink:to="lab_us-gaap_NoninterestExpenseDirectorsFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_561" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_562" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_563" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_564" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation_565" xlink:to="lab_us-gaap_OfficersCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_566" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_567" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_568" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_569" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_570" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_571" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_572" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_573" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_574" xlink:to="lab_us-gaap_OperatingLeaseLiability_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_575" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_576" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_577" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_578" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_579" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_580" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDescription_581" xlink:to="lab_us-gaap_OtherCommitmentsDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_582" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_583" xlink:to="lab_us-gaap_OtherCommitmentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_584" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_585" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_586" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_587" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense_588" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_589" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_590" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_591" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_592" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_593" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_594" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_595" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_596" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_597" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_598" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_599" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_600" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_601" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_602" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_603" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_604" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_605" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_606" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_607" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_608" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_609" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_610" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_611" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_612" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_613" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_614" xlink:to="lab_us-gaap_ProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_615" xlink:to="lab_us-gaap_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_616" xlink:to="lab_us-gaap_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_617" xlink:to="lab_us-gaap_ProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_618" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_619" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_620" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_621" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_622" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_624" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_625" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_626" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_627" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_628" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_629" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_630" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember_631" xlink:to="lab_us-gaap_RelatedPartyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_632" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_633" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_634" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_635" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_636" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_637" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_638" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_639" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_640" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_641" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_642" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_643" xlink:to="lab_us-gaap_RestrictedCashCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_644" xlink:to="lab_us-gaap_RestrictedCashCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_645" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments_646" xlink:to="lab_us-gaap_RestrictedInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_647" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_648" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_649" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_650" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_651" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_652" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_653" xlink:to="lab_us-gaap_RoyaltyExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_654" xlink:to="lab_us-gaap_SalariesAndWages_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_655" xlink:to="lab_us-gaap_SalariesAndWages_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_656" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_657" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_658" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_659" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_660" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_661" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_662" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_663" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_664" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_665" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_666" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_667" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_668" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_669" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_670" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_671" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_672" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_673" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_674" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_675" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_676" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_677" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_678" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_679" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_680" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_681" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_682" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_683" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_684" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_685" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_686" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_687" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_688" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_689" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_690" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_691" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_692" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_693" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_694" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_695" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_696" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_697" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_698" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_699" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_700" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_701" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_702" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_703" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_704" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_705" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_706" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_707" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_708" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_709" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_710" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_711" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_712" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_713" xlink:to="lab_us-gaap_SharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_714" xlink:to="lab_us-gaap_SharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_715" xlink:to="lab_us-gaap_SharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_716" xlink:to="lab_us-gaap_SharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_717" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_718" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_719" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_720" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_721" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_722" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_723" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_724" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_725" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_726" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_727" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_728" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_729" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_730" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_731" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_732" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_733" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_734" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_735" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_736" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_737" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_738" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_739" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_740" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_741" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_742" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_743" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_744" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_745" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_746" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_747" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_748" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_749" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_750" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_751" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_752" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_753" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_754" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_755" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_756" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_757" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_758" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_759" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_760" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember_761" xlink:to="lab_us-gaap_TreasuryStockCommonMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember_762" xlink:to="lab_us-gaap_TreasuryStockCommonMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares_763" xlink:to="lab_us-gaap_TreasuryStockCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_764" xlink:to="lab_us-gaap_TreasuryStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_765" xlink:to="lab_us-gaap_TreasuryStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_766" xlink:to="lab_us-gaap_TreasuryStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_767" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_768" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_769" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_770" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_771" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_772" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_773" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_774" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_775" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>cmmb-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#BalanceSheetsParenthetical" roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#StatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#StatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#StatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#General" roleURI="http://www.anchiano.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#CashAndCashEquivalents" roleURI="http://www.anchiano.com/role/CashAndCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#OtherReceivablesAndPrepaidExpenses" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#PropertyAndEquipmentNet" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#Leases" roleURI="http://www.anchiano.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#CommitmentsAndContingentLiabilities" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ShareCapital" roleURI="http://www.anchiano.com/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ResearchAndDevelopment" roleURI="http://www.anchiano.com/role/ResearchAndDevelopment"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#GeneralAndAdministrative" roleURI="http://www.anchiano.com/role/GeneralAndAdministrative"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#IncomeTaxes" roleURI="http://www.anchiano.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#RelatedPartiesBalancesAndTransactions" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#NetLossPerShareAttributableToOrdinaryShareholders" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#GeneralTables" roleURI="http://www.anchiano.com/role/GeneralTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#CashAndCashEquivalentsTables" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#OtherReceivablesAndPrepaidExpensesTables" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#LeasesTables" roleURI="http://www.anchiano.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ShareCapitalTables" roleURI="http://www.anchiano.com/role/ShareCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ResearchAndDevelopmentTables" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#GeneralAndAdministrativeTables" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#IncomeTaxesTables" roleURI="http://www.anchiano.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#RelatedPartiesBalancesAndTransactionsTables" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersTables" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#GeneralDetails" roleURI="http://www.anchiano.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails" roleURI="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#OtherReceivablesAndPrepaidExpensesDetails" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#LeasesNarrativeDetails" roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ShareCapitalShare-basedCompensationExpensesDetails" roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#IncomeTaxesDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20231231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_55"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_5" xlink:to="loc_dei_AddressTypeDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_5" xlink:to="loc_dei_BusinessContactMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_DocumentInformationLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityCentralIndexKey_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_AmendmentFlag_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentType_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentRegistrationStatement_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_CurrentFiscalYearEndDate_13" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentFiscalYearFocus_14" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentPeriodEndDate_15" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentAnnualReport_16" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentTransitionReport_17" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentShellCompanyReport_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityFileNumber_19" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityRegistrantName_20" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityTaxIdentificationNumber_22" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressAddressLine1_23" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressAddressLine2_24" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressCityOrTown_25" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressCountry_26" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityAddressPostalZipCode_27" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_CityAreaCode_28" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_ContactPersonnelName_29" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_LocalPhoneNumber_30" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_31" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_Security12bTitle_32" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_TradingSymbol_33" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_SecurityExchangeName_34" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_35" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityVoluntaryFilers_36" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityCurrentReportingStatus_37" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityInteractiveDataCurrent_38" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityFilerCategory_39" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntitySmallBusiness_40" order="320" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityEmergingGrowthCompany_41" order="330" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentAccountingStandard_42" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityExTransitionPeriod_43" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_IcfrAuditorAttestationFlag_44" order="360" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityShellCompany_45" order="370" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityPublicFloat_46" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_47" order="390" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_AuditorName_48" order="400" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_AuditorLocation_49" order="410" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_AuditorFirmId_50" order="420" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_WrittenCommunications_51" order="430" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_SolicitingMaterial_52" order="440" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_PreCommencementTenderOffer_53" order="450" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_54" order="460" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_55" order="470" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_AssetsNoncurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrent_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_Liabilities_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_CommonStockValue_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_TreasuryStockValue_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_AdditionalPaidInCapital_28" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_StockholdersEquity_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockNoParValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_SharesOutstanding_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_TreasuryStockCommonMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_12" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_13" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_23" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_34"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_cmmb_PaymentsForInvestmentInDeposits_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_cmmb_LongTermLeaseDeposit_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_cmmb_CashAcquiredInMerger_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_19" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_28" xlink:to="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_28" xlink:to="loc_cmmb_IncomeTaxesReceived_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_28" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_28" xlink:to="loc_cmmb_InterestReceived_30" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_33" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_33" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_33" xlink:to="loc_us-gaap_LiabilitiesAssumed1_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/General">
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalents">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_ShortTermBankDepositsPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_SeverancePayPolicyTextBlock_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_17" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_18" order="170" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralTables">
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_cmmb_FormerChemomabSecurityHoldersMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_11" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_PercentageOfMonthlyDepositsRate_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SeveranceCosts1_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_IncrementalBorrowingRateOfLeases_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" xlink:to="loc_cmmb_AnnualRatesOfDepreciation_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD" xlink:label="loc_currency_USD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS" xlink:label="loc_currency_ILS_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_XXX" xlink:label="loc_currency_XXX_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_USD_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_XXX_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_ReceivablesFromGovernmentInstitutions_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS" xlink:label="loc_currency_ILS_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReassessmentOfRightOfUseAsset" xlink:label="loc_cmmb_ReassessmentOfRightOfUseAsset_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LeaseExpirationDate1_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_AnnualRentAndManagementFees_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_BankGuaranteesToPropertyOwner_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_ReassessmentOfRightOfUseAsset_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseLiability_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_14" order="100" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR" xlink:label="loc_currency_EUR_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS" xlink:label="loc_currency_ILS_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_CapitalAdditionsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_cmmb_CapitalAdditionsOneMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_LeaseAgreementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_CurrencyAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_6" xlink:to="loc_currency_AllCurrenciesDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6" xlink:to="loc_currency_EUR_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6" xlink:to="loc_currency_ILS_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_10" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_StatementScenarioAxis_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_12" xlink:to="loc_srt_ScenarioUnspecifiedDomain_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_12" xlink:to="loc_srt_ScenarioForecastMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_15" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentDescription_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_OtherCommitmentsDescription_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_19" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_20" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_21" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_RoyaltyExpense_23" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AggregateAmountCommitmentToPay_24" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AggregateAmountOfCommitmentPaid_25" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AdditionalWorkOrderAmount_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_LienOnBankDeposit_27" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_RestrictedInvestments_28" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_RecoverabilityOfVatAmount_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RothCapitalPartnersLlcMember" xlink:label="loc_cmmb_RothCapitalPartnersLlcMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_MarketOfferingAgreementMember" xlink:label="loc_cmmb_MarketOfferingAgreementMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_44"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_cmmb_SaleOfStockTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_CantorMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_RothCapitalPartnersLlcMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_InvestorsMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_us-gaap_PrivatePlacementMember_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_AtmAgreementMember_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_RepurchaseArrangementMember_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_MarketOfferingAgreementMember_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12" xlink:to="loc_us-gaap_ClassOfStockDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_PlanNameAxis_15" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_15" xlink:to="loc_us-gaap_PlanNameDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_15" xlink:to="loc_cmmb_TwoThousandsFifteenPlanMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_15" xlink:to="loc_cmmb_TwoThousandsSeventeenPlanMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_cmmb_SaleOfStockLineItems_19" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_19" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_us-gaap_PreferredStockSharesIssued_20" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_21" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_22" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_ProceedsFromSaleOfAdss_24" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_SaleOfStocksPricePerShare_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_NumberOfStockReservedForIssuance_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_NumberOfStockAdssResveredForIssuance_29" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_30" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_NumberOfOptionsIssuableOutstanding_31" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_NumberOfVestedAndExercisable_32" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_NumberOfAdssVestedAndExercisable_33" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_NumberOfOptionsVestedAndExercisable_34" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_35" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_36" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_38" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_39" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_40" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_41" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_42" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_43" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_19" xlink:to="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_44" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharePrice_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_11" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_12" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14" order="70" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ConsultantsAndSubcontractorsExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_OfficersCompensation_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_SalariesAndWages_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_ProfessionalFees_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_GeneralInsuranceExpense_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL" xlink:label="loc_country_IL_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_IncomeTaxDisclosureTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_srt_ScenarioForecastMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementGeographicalAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4" xlink:to="loc_srt_SegmentGeographicalDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_IL_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_US_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8" xlink:to="loc_us-gaap_DomesticCountryMember_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_cmmb_IncomeTaxDisclosureLineItems_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_CurrencyTransactionLossValuationAllowance_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_IncomeTaxExpenseValuationAllowance_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_us-gaap_RelatedPartyMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20231231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4" order="0" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image00034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00034.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0X!W\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image3.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )\ _L# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZOV?1117JGXF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME1HYK2P>,P\*T8N2J5Z]&AE\X86HY4J;M"=2D^:<7B'.-&'^EA17YW_L$_\
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M5]HJLL;A'2GBJ>,G)1CRRJ3Q56'LGS.BJ2I2G.4')E%%%>F?C 4444 %%%%
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M45Z!^3!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)2Q4I>R3:PR2J587_4RBBBOJ3^$PHHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH?LZ?L8?#?PK\1M-O;74M!\;^+]:^(7QG\4>$M3LDFCM]4\#ZS\;?&7Q%OO
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MZO9Z-X3U-],9;C6/(DF%CKD6KV?E:7;3C][:W&KO)$6M$6OUD_X*Y?M#^/\
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MVTC%1A!>[",5H%%?P$?\'BW_  4A^-7PM^,/[,?['/[/'Q_^)GPF.D> ]?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/"7C3P_?FVTWP[XRCN8M)\6W%II^J:9>:9X@O9O#FF@'^O+17^;5_P $S/\
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M[3NMGVE_S-_X)M_\$<?^'>W_  3E^.W[ '_#1G_"W?\ A=>H?&B^_P"%M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF2TM=<\4^!/AUIMAX1CO(;[1)M6TRQU'Q/P_PX_8Y_X+-_\ !';XT?M<Z/\
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MP+\0()$\1:%:R7C1/%%JUH@M-6M]Z2H&CO80LCA#,[B*?SH&8_O(G&17P_\
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MMH=0T35[1EN=,U:R\W[3I]] ?,M;J.*902F#_+LO[&?P+^!/_!3K]DSX0?\
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MVXEN)''I5,[R"GAN'*69<22SZGE4:F*C*CEF88W%X+,JF$P]+"X:&!S:CDF
MCD.62P\9O#T,SKU<PQJ^L5\-["O.C1YH8',)5<RGALL67RQ;A2:J8K#4:-?#
M1K5)U:DJ^#GCL0\PQ2J.*J5,+"&&H?NZ=5U(*<_,?^#9S_E#U^SK_P!C7\=/
M_5T>-Z_>^ORS_P""3W_!++X8_P#!*[X#ZQ\+O"?BG_A9GQ%\<:X=<^*WQ?\
M[$\0^#/^%@3:7J&O-X+C_P"%?ZE\0OB'H?A3_A$_#VN/X?W^'-0M$UW[/_:V
MK0R7TH\G]3*^#XNQF!S'BC/\PRRO4Q6!QV:XW%X:O4H2PTJD,37G6;5&<I5(
MP4IRC2=7V=6I24*E6AAZDY4*?OY-1Q&&RK+L/BJ<:6(P^#H4:M.-155&5*FH
M6<XI1<FHIS4>:$9-QA4J12J2****^=/2"BBB@ HHHH **** "BBB@ HK^?K]
M@#]DSQI^U7^R/\)OCW\0_P!O7_@HMHWC#QY_PGG]KZ;X,_:DU;3O#5M_PB_Q
M,\9^#-/_ +-L]<\-^(M4A\[2_#ME/>?:M8O/,OY;J6'[/;O%:P?8_P#P['_Z
MR$?\%/O_ !+'_P# &OTS.>"^%<ASC-<CS#CZG''Y-F6.RK&QI<,9K5I1Q>78
MJK@\2J=15DJE-5J,U":24XVDEJ>#A<US'&8;#8NCD[='%4*.(I.6/P\9.E7I
MPJP<H\MT^6:NNC5C]/J*\(_9Z^!7_#/G@O4_!G_"X_CO\;_[3\47OB?_ (2O
M]H7XA?\ "RO&FG_;=)T72O\ A'M,UW^R-%^R>%[3^Q?[2LM)^RR>1JVK:U>?
M:'^W^7%[O7Y]CJ.%P^,KT<%C/[0PE.IRT,;]7J87ZQ"R?M/J]5RJ4KMM<DVW
MI?J>U1E4G2A*K2]C4DKSI<\:G(_Y>>-HR]4K!1117(:'\Y_QI_X+B_M&>"OV
MEOVU/@;\$O\ @F7KG[1?@S]A)K#5/C;\4O#_ .U1X3\%ZAIG@J\\,2>*G\50
M_#CQ#\)+G4K^2+3]/U[R]"\.Z_XCO9?['9I);8WD"5^MOP0_;K_9O^-7[(OP
MV_;9D^(/A_X3? GXC>&+?Q$OB7XT>(O#/P[L_"5P=0O-#U30/%NLZWK,7AO3
MM6T;Q#INI:'<O%K5SI]Y=63SZ7>WME-;W$O\='QW_8M^,O[8/[<'_!PDOP$^
M,OQK\"_$CX7CX/>(K#X0_#WXB:YX0^&G[2.AW/A?4+OQ;\+?B_X;\/+;:CXX
M&J^%] U;2_ %BVL:;8V7B77)$U%;FRU*<V_4_MP_$?X>?'C]AC_@C9^TC^RY
M\+OAYX6_8"_9Q\<^(]%_: ^$7Q-^'?Q,^.GP(_9\^)V@Z=X4TC3X?VDOA[X$
M>;XE?$#P;I.JGQI%?^)[Z^O-7\;P>,+?5]:75=0^(;6>L_N.,X)X=Q]/A_!Y
M?26 Q5?^R8YGB\-+'5YPEC.$:.=PP^*I8['8BE/'9UC7.EDSR_#X;#Q<,1AJ
MM.M7A2A/X2AGF94)9A6Q$OK%*'UMX6C56'IQDJ.<RP#J494,/3DJ&!H\L\:L
M15JU6I4ZL)0A*<E_;%X+^-WP8^)/P]G^+?P[^+OPP\>_"FVM=4OKGXF^"_'W
MA3Q3\/;>RT.%[C6KN?QIH>K7WAN*UT>WCDGU2XDU)8M/A1Y;MX45F'A_A;_@
MH5^P+XZ\4Z'X&\$_MP_L@>,?&OB?6+/P]X:\'^%OVEO@OXA\4^(=?U&Y2ST_
M0]#\/Z3XUN]6U;6+Z[D2UL]-L+2XO;JY=(((7E8*?XUO#/@WX;?$[_@GI_P7
M ^-G@3]H_P"$&L?!GXI>%O@%XSU[P%^Q%^S;^T#\$_@_X ^*7@/Q6]S'9>$O
MA]^TNWPZTZYT?X@II=LGQ/B\)>*M4GL;6[DU1;2^FM]"\)W7O'_!+3XW?L?_
M +3?_!27]ESXN>,_CG_P3X^'OQ>^&7P#U3X1?"G]GS]D7X ?M+?#RQ^*OC34
MM+N+B;7/'/C3X]? _P"%7@VT\2^%H+G47\&>$O#6I^+-5EU>WC?0_$FHK$PN
M/(K>'6$P^#S[&RKYUB(91]8C.G1RK$TJN$K4\FP&9T:&80J86=2'M,1C9X2I
M7=/#T:-+"O'3:H5XJEV0XEK5*V7T?9X*E+&^S:E/%TIQJPEC<1A9U,/*-:,7
MRTZ$:T(<U2=2554%^\IMR_K\M?VHOV9[[X=>,?C!9?M$_ N\^$GP[UJ^\-_$
M#XI6OQ;\ 7'PZ\#>(M,N;"RU+0/&/C>'Q _AGPSK6GWFJ:9:7VE:UJ=E?6ES
MJ-A!<01RW=NDGP9\5OV_O'_AG_@J!^PQ^QW\/K7X4>*_@'^U7\!_BE\7M9^(
M$<&M:[XLG/A/P]XEU[PE>_#[Q7HGC.W\&2>%]<M]*TVZDN;KPQXB_M*PNGGT
MS4[9)[>:/^3A_P!I;P;\'_\ @EI_P5P_X)P>+?"OQ4A_;,U3]JCXV?$J7X/6
M_P +/'UT^B_!ZU\8_"[Q+XB^+WB+QC9>'KOP3X?\">'?#OA/6-2FU+6O$%A)
MJJ2Z')HD%_I^OZ;J,OZSZ9/<VO\ P5._X($7-G9OJ-W;?\$MO%4]KI\4D4,E
M]<P_ '7)(+..:=D@B>YE584DF=(D9PTC*@)&O^HF%RIYC6Q7ML32>$XLAERQ
M5.-.G7P^ X7I9GE^;T)1:YXRQ5>:HU8WH2>&O"4G&:4K/ZN,6%A2Y*4_;9/+
M$^RDY2IU<1FSPN)P=1->ZU2@N>#M47M=4KQ;_I M/VN_V3]0^*A^!=A^T]^S
MQ>_&U=0?26^#MI\:OAM<_%1=5BC\V33#\/8?$K^+1J$<7[Q[(Z1]I2/YVC"\
MUX3XT_X*;_L;?#K]LG3_ -AKQW\7O"G@WXRW_P -K7XA'4?%GB[P%X7\!VFH
M:MXKT?PGX8^%$VO>(O%^EZC<_&?QA)K,6O\ ACX>:7H6HZCJ'ABVGU:2:V\[
M3;>__@F^-WQ.MOVB/ =]\?M=3PQX _;&\/\ [?.C:]\;/V:?@G_P3S\&_"G5
M?V7M/?XQ:E9IXY^-/[8L'PMF^+LVL:]XTU#2-%L](\2_&:U.I^,M5M=)N-#O
M]7\+W4UG^\O[1D7[%W[,?_!QJGQ _; ^#_P^T/X6_'K]E'P;'\&O$/B3]G6?
MXC>'/&/[6EU\8?!\.G^+]%A\.^ /%C#XKV9TV:SO/B*UI%K?A\WFF#6-?TVV
MU?3Y;G2OX<9?E]7V6)K9ICL3/),\Q$,#@L/_ +2\SRA99)K#.K1IO&8:I2S"
M5>D\/2JTJM.@ZU'%8C#R4WG3XFQ&(CSTH82A3CCL!3E7K5/W2PN-^M)>UY9R
M]A5C/#JG-5)PG"=3DG2I5$XG]/7CW]J;]F/X5^.="^%_Q/\ VC/@1\./B7XH
M^R'PS\._'OQ>^'W@_P <^(OM\PM['^PO"7B'Q#IVOZO]MN"(+3^S]/N/M,Q$
M4.]R%K:^+_[0/P&_9[T?2_$/Q\^-OPB^!^@:YJ+:1HNN?%_XD^#?AIH^L:LD
M#73Z7I>I>--:T6RU#45MD>X:RM)IKE8%:4Q"-2P_@)_:NTM?A;^US_P53^$W
M[<&M?L?_  H\6_M6?%SQ#=_##XN_M>_LB_M6?'OXKZI\'-8FU.R^&?BC]DWX
MH_ G1=9T/P9:>$-*_P"$<L"DNARS0>)- T;1[Q-5C\,W&C:9]E?M :1\)/V<
M/VQ/^"1GQ9_X*E:=?_'S]ASPU_P3>\,_"K1_BSXT^%'Q!^(OP:;XYV^C>)KJ
MTUKQ_P#"7Q!X8USQ7=>(-=\(W/A.YO="\4^"M1\476K7&@:W?:5(?!%_/X>Q
M?AM@XK+)1S',,5]<R_$8V-+!Y?*I/-I4<HIYDJ&059\F&Q=5UYSP<J,:M>NO
M9JM[/GD\-3T_UGKOZTGAL-1]CB*=!SK8E1C@U/&/"N>80C>K1BJ:593<:=/W
MN3FY4JLOZ*O^"=_[>7Q,_;!_:%_X*._"_P 8Z5\,;?P/^R3^T%HOPO\ A%KW
MP]L=?AU#Q7X-U>V\674.M>+]4U3QAXFTC7=2N(=$T^:SU'PQI_AO2I8;B:1=
M/E26!HLS]M7_ (*IR_L\_M!>$/V-/V9?V8?B%^W!^V/XJ\)-\1+_ .#?@+Q3
MHWPZ\-?#[X>K(8XO$WQ-^*GB'2=>T3P<-2(!TJWO-(FMG$^F+J^HZ++XB\*Q
MZ]^=G_!NW:?#6S^/'_!8-?@U\-O$?PB^$MU^U-X U7X:_#OQ7X1UGP!J_AWP
M/K>D_$36/#*KX(\06.F:SX2T?5-(OK36O#7A[4-.L)])\-ZCI-E]CMDA2%.:
M_:&^,FE_\$K/^"Y'Q@_;8_:E\)?$2W_9"_;"_9G\%_#70?C_ .&_".K^//#'
MPN^(/@BW\"6=SX2\2VWAVWOM:T2WU5O 7GQV-GI]]J.IWGB?2]0TRPO]/MO$
MMUX?PJ\.Y7+C'.LNI9;+%_4.'L'CLJR)SJX6>:YE_9.45982I#"5UB959_6<
M9CJN%P.*CB*U2A.C0K6E=Z1S+%+)<#B9XI4?K&95J&+QZC"K'"87ZYC(*M&5
M:FZ2C'V5'#PJXBDZ<(U%.I#2Q^Z'[*W[5'Q0^*?P7\<?%']KK]F;7/V!];^'
M/BG5]"\5>&_BS\4/!/BKPLNBZ3H^C:O)X[T;XGZ9'X?T#4?!3C5WTYM?NK#3
M-/&I:7J=O!<W2VDLJ=C?_M9_!WQS^S]\;/C3^S1\8_@K\>8/A7\/O'GB)-4^
M&_Q"\+?%'PC:^)O#'A#5O$6F:/XBOO 'B.[2%;B;3XC=Z>-5T[4);,R_9Y[=
MBLZ?SR?\%C/VD+7_ (*;_P#!+*'XO?L.Z=\1?B7\!_AK^US\.KGXY'6?A5\1
M](TWQU\*?!.A2^(M?\2)X%:QT3Q_XW^%/A7Q)K_A+4?%-SI,6CRPR>']7O8+
MFW'AN;4K/Y._8!U#X:?&?X^_MK?M"_ ;XW_L77&A1_\ !-7XS_#;XH? []AW
M]DS]K/\ 9E^%#0Z1IEO<^"?&NN:=\;O#-CX'N?'5G),NB(=)UR35IM MY?LV
MDPQ1ZK>W<4.":&)RO&9YB:=;*J^'S"M2K9+1PF.Q&%RR6&JX",<!F%:O/$XO
M"5<='$U7AWCJ\73Y*<)2K.I-T*GGE2EBZ& IRABZ=2A3E#'3K4*57%*K&NWB
M,/"FJ5&M"@Z<%45"F^;FDTJ:C'VGZ.^ _P#@LE^T[XH_9Z_X(S?%G4/ OP'A
M\1_\%$OVE=7^#?QKLK/PQ\08]$\+^&-/^(E[X1AOOA;;3?%"XOM$UYM-MDGE
MNO%FI>-]/:^+R+I:0$6R_NQJ_P"UC^RQX?\ BO:? ;7OVEOV?]$^.6H7NGZ=
M8?!C5_C)\.M-^*][J&KPI<:586GPZO/$</B^YO=3MY(Y]/M8='>>]AD26V25
M&5C_ !?_  ?_ .3*_P#@UP_[/N\3?^KNU6M'4O$'[-_P+_X+ FW_ &39/A!^
MWEXV_:!_X* 0:E\=?V9?C=^QGXGOOVGOV4_B#;_$L:SXX^+WP7_:?O? .F6]
MIX*\!ZPC^(-+OCXRG\):9HGDZC>:;XF@'BOQK9^WF?!&58_$8REA*-?!2P:X
MOKTXX+"SE1J_V?Q-F.%P\,9C)1J8? T,-@:')2J8N5"A55.-%XJE4</:<&%S
MW%X>E1G6G"NJSR:G-UZL54A]9RK"5:LJ%%.-3$5*N(J.4XT54J1YW/V4XJ7+
M_=?1117XB?=!17+^-_#'_";>"_%_@S_A(?%'A'_A+O"^O^&/^$K\$:M_8'C3
MPQ_;^DW>E?\ "0^$-=^SW?\ 8OBC1?M?]I:!JWV6Y_L[5K:TO/L\WD^6WYT_
M\.Q_^LA'_!3[_P 2Q_\ P!KZ')LNR''4JT\WXD_L.K"I&-&E_8^-S+V\'&\J
MGM,+.$:7++W>22;>ZT.+%5\92E!8; _6XM-RE]9I4.1WLH\M1-RNM;K3IN?I
M]17Y@_\ #L?_ *R$?\%/O_$L?_P!KQS]HK]@K6OA'^S[\=?BOX;_ &__ /@I
M5>^(OAC\'/B=\0] LM<_:JN[G1;O6O!?@G6_$FEVNKV]AX.TV^N-+N+[38(M
M0ALM1T^[EM'ECM[VUF9)X_HL%PKP?C\9A,#A^/XNOC<30PE!3X7S:,76Q%6%
M&FI2]M[L7.<;RZ*[.*KF&9T:52K/)GR4H2J3MF&&;Y81YI67+J[)V76WF?M#
M17SI^Q]KFM>)OV2?V6_$GB35]4\0>(O$'[.GP2US7]?UR_N]6UK6]:U;X:>&
M;_5-7U?5+^6XOM2U34KZXGO=0U"]GFN[R[FEN+B62:1W;Z+KXG,L'/+<PQ^7
M3G&I/ 8W%8*=2":C4EA:\Z$IQ3U49.#DD]4FKZGJT*JKT*-=)Q5:E3JJ+U<5
M4@II-K2Z3LPHHHKB-0HHHH **** "BBB@ HHI"0 22  "23P !R22>  .IH
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M$WP_TB72YQ<VAL_"GP5^'MI/&'266!9H-4DU&WGB@\N.*6)D>,7 F9O[:_\
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MPGX\\%?$"Z^'RZ;;W7AFSMM<TZ\\-ZSJD,[WL(U"QD:);?\ E[^(WP9UQO\
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M*=.MA:]./-&:@W*,)\D;N$?ZF_A[^W/\$-$_9D_9?^-7[5GQU_9Z_9[\1_M
M?!?X<?$-;3XA?$[PC\)_#NJ>(?%'@?P]XF\26'@B#XC^+HKZ^TW2KS6O+BM1
MJNLWUC9R6BW][<2O]HE^T=%UK1_$FD:7XA\/:MIFO:!KFGV>KZ+KFBWUKJFD
M:QI6HV\=WI^IZ7J5C+/9:AI]]:RQ7-G>VDTUM=6\L<T$KQNK'^$3_@H//^RQ
M\.?A_P#\$Z_VB+_XT?"N']L/X=_\$ROV<]%\+?LC?M3_ +)&O_M/_L]_M._#
MFZ\--=Z3X:\/W=OX"\3Z-X#^(][XGU+5]$?4!K6CZLL%UI$L>J^"-(N-<\1:
MI_9=^Q+K6K^(OV/?V8-;UWX-6O[/&KZC\"/A;<7WP,L-+N-"T_X42GP=I"CP
M-IV@WJIJ&@:;X?C5+'3]!U5$U?1;.*#3-71-2M;I1\/Q1PQA\IRW YOAI8OE
MS#'YA0G2Q&&EA*-&5"M5<*>#C6C&>,H0H^R_VW#3Q&&E*7LJDL/7C[%^[E6:
M5<7B:^#JJC?#X?#5%*G55:<U4IPYIUW!N-&I*HY_N*L:55)<T54IOG/J"BBB
MOA3WPHKS#XS?#'_A<GPV\2?#?_A87Q0^%7_"1_V/_P 5[\&?%G_"#?$G0?[(
MU[2]>_XIOQ3_ &?JG]E_VI_9?]C:Q_H,_P!MT'4=4T[]U]K\Z/X0_P"'8_\
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M 4444 %?,'[;O_)E_P"UW_V;!\??_54^+*^GZ^8/VW?^3+_VN_\ LV#X^_\
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MTNVE]QG.K3IZU)QAO:[LWRJ[26[:6ME=ZJRU/5*:S*BEG9451EF8A5 ]23@
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M_P"#D/4])N_^"RG[8.D:)!LTWP?J7PP\)PWC7BWT^K2Z=\'O 5S>:E<S1I'
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ME\+K+0=2N(7CT.UD\ Z=HMW:3*D$4EXL2^;826UZ\T9LY+BWE$KN)U_R>_\
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M,U;K.3T7O:IW:3=OKRTO;._@6YL;JVO+9V=4N+6>*XA=HV9)%66%G1F1U9'
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M'_)S/$3_ ++KB[_U?Y@?=</_ /(AR3_L49;_ .H=$****^%/7"BBB@ HHHH
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MB:)/X6\1231,;/3AITEK'YFJR62:)>?9-5M[<6GF*5F743<6LZQQRF6PL?\
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M+8-Q=F'PE:Z7J^D7$][XCO+;45TVWMUU&/[+%I5KINEOJ&P&+_2]9LX);"V
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M59_[L8_]4+XBK]/J_,']E;_E)-_P59_[L8_]4+XBKZKA'_D0>*'_ &0N7_\
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MMN?>O[#/BVXUOX7:SX9NI&=O!/BBZL+ --+.\>BZM!#JNGQ,\OS#R9YM0A1
M2D<<:(C87:OVK7YY?\$^["X30/BGJ[1A;2_\2Z%80N"27N=,T>6XN@V1@%(M
M6LUP.1_%@\#]#:_F'Q/P]##<>\2TL,HQIRQM.O)0^%5\5A,/BL4O58FM6YO[
MU]%L?G'$,(4\YQ\::2BZRFTNDZE.%2I_Y4E*_GT6P4445\&>,%%%% !1110
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MY-R=ETNV]/([(PA!6A",%>]HQ25W:[TZNRN^M@HHHJ2@HHHH **** "BBB@
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M $S ****\([ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]!0A"E"%*E"-.G3C&%.G"*A"$()1A"$(I1C&,4HQC%)1222204445)04444
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M6::3%KMO<P6N@:_KWA7Q58:EH\AO-)UKP5XM\2:#J4UMJ6DVFJR:WI.JZ99
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M&#POX?U*>V\66>E^O>-?VK?#GA/Q#XRTG2/A=\:/B5H'PP:6+XL?$#X;^%M
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M!EN190:KX@DT^S29+);9]5NX+);J5S%$Z:.A_M4^&&_X6-%\3?AW\4_@/?\
MPR\!7OQ4UO3OBEI?@^]EU+X;:;]O34_%_AR_^%'C?XH:'JUOIMQIUQ::AH0U
M:#Q=9SRZ>;CP['!JNES7@!]045\RZ3^T/XGU70/&FOS?LQ?M!>'(/#/A&_\
M&&@Q^*#\#[+_ (6%:6:K(FG^&I],^-FL0:+JUU;217L6G?$63P-<K:-+YL:7
M=I>6EOYE\)_VQM7\3?L\?!WXM?$'X'_$O0?&WQ>TSP-:>"/ 'A__ (5EJM[\
M6/%/BKX?R^/IY_AD++XMZUIFA>$_[)TS7]3M+OXR>)?ASJ5AI>EL->MK&]D@
MAN #[GHK@/AOXVU7Q[X>?6M:^&OC_P"%.HPZC<Z?/X3^)">#?^$AB^SI!*E\
MEQX!\9>/?"U[IUW'<(UM=:;XEO?G2>WN$M[JWG@C[^@ HHHH **** "BBB@
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M?_54^+*]WA?_ )*;AW_L>Y1_ZL,.<F/_ -QQO_8)B?\ TS,/V(O^3+_V1/\
MLV#X!?\ JJ?"=?3]?,'[$7_)E_[(G_9L'P"_]53X3KZ?HXH_Y*;B+_L>YO\
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M?^+)X9_^:P_UDH_]"GB/_P ,6/\ _E7]?<?N[7X1? +_ )3[?MN_]FP>$_\
MU&_V1*/^%^_\%]O^C(_V8/\ PK/#?_T7=?)GA#X:?\%J/!?[7GQ3_;2TO]D#
MX.7'Q2^+G@/3_AYXDT'4/'_P[E\ 66BZ;9?#FP@NM#TNW_:3M?$5MJCP_#'0
M&EFO_%6I6C27>KE+*-;BR33_ +S@C@19#A./:.8<=>%T9\0\!YCP_EWLO$3A
MJJI9CB<ZR#'4HUFL8O94G0R[$N55W2DH1M>:/'S;-WC*F3RHY1Q U@LXH8VO
MS9)CXVH4\+C*4G']T^:7/7@E%;J[Z']2%%?A%_POW_@OM_T9'^S!_P"%9X;_
M /HNZ/\ A?O_  7V_P"C(_V8/_"L\-__ $7=?!_\0DS#_HN/"C_Q9/#/_P U
MGL?ZR4?^A3Q'_P"&+'__ "K^ON/W=HK\(O\ A?O_  7V_P"C(_V8/_"L\-__
M $7='_"_?^"^W_1D?[,'_A6>&_\ Z+NC_B$F8?\ 1<>%'_BR>&?_ )K#_62C
M_P!"GB/_ ,,6/_\ E7]?<?N[17X1?\+]_P""^W_1D?[,'_A6>&__ *+NC_A?
MO_!?;_HR/]F#_P *SPW_ /1=T?\ $),P_P"BX\*/_%D\,_\ S6'^LE'_ *%/
M$?\ X8L?_P#*OZ^X_=VBOPB_X7[_ ,%]O^C(_P!F#_PK/#?_ -%W1_POW_@O
MM_T9'^S!_P"%9X;_ /HNZ/\ B$F8?]%QX4?^+)X9_P#FL/\ 62C_ -"GB/\
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M;_HR/]F#_P *SPW_ /1=T?\ $),P_P"BX\*/_%D\,_\ S6'^LE'_ *%/$?\
MX8L?_P#*OZ^X_=VBOPB_X7[_ ,%]O^C(_P!F#_PK/#?_ -%W1_POW_@OM_T9
M'^S!_P"%9X;_ /HNZ/\ B$F8?]%QX4?^+)X9_P#FL/\ 62C_ -"GB/\ \,6/
M_P#E7]?<?N[17X1?\+]_X+[?]&1_LP?^%9X;_P#HNZ/^%^_\%]O^C(_V8/\
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M._\ P^K]/J*/[?X)_P"B _\ -JS;_P"4A]3S7_H<_P#F.PWE_>]?O\C\P?\
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M\/./^L>__!3[_P 1._\ P^K]/J*^>_M_@G_H@/\ S:LV_P#E)V_4\U_Z'/\
MYCL-Y?WO7[_(_,'_ (><?]8]_P#@I]_XB=_^'U'_  \X_P"L>_\ P4^_\1._
M_#ZOT^HH_M_@G_H@/_-JS;_Y2'U/-?\ H<_^8[#>7][U^_R/S!_X><?]8]_^
M"GW_ (B=_P#A]1_P\X_ZQ[_\%/O_ !$[_P##ZOT^HH_M_@G_ *(#_P VK-O_
M )2'U/-?^AS_ .8[#>7][U^_R/S!_P"'G'_6/?\ X*??^(G?_A]1_P /./\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_S'8;R_O>OW^1^8/_#SC_K'O_P4^_\ $3O_ ,/J/^'G'_6/?_@I]_XB=_\
MA]7Z?44?V_P3_P!$!_YM6;?_ "D/J>:_]#G_ ,QV&\O[WK]_D?F#_P /./\
MK'O_ ,%/O_$3O_P^H_X><?\ 6/?_ (*??^(G?_A]7Z?44?V_P3_T0'_FU9M_
M\I#ZGFO_ $.?_,=AO+^]Z_?Y'Y@_\/./^L>__!3[_P 1._\ P^H_X><?]8]_
M^"GW_B)W_P"'U?I]11_;_!/_ $0'_FU9M_\ *0^IYK_T.?\ S'8;R_O>OW^1
M^8/_  \X_P"L>_\ P4^_\1.__#ZN#\)_\%B_ACX^UKQCX;\"_L>_\% O&GB+
MX=ZH-#^(&@>$_P!GWP_XCUKP-K37>J6"Z1XQTO1_B=>7WAG5&OM$UJR&GZU!
M979N](U2W$7G:?=I%^O5?A%_P2;_ .3T/^"PO_9S]K_ZM;]IZOL<AH<!9OPQ
MQUGU3@FK1K<)9?D>-P^'AQ/F<J>+EFW$67Y+4A6E*CS0C1I8R5>#AK*I",9>
MZV>7C)YQALPRC!QS6,HYE6Q=*I-X##J5-8;!5<4G!*5FYRI<KOM&3:U2/I__
M (><?]8]_P#@I]_XB=_^'U'_  \X_P"L>_\ P4^_\1.__#ZOT^HKX[^W^"?^
MB _\VK-O_E)ZGU/-?^AS_P"8[#>7][U^_P C\P?^'G'_ %CW_P""GW_B)W_X
M?4?\/./^L>__  4^_P#$3O\ \/J_3ZBC^W^"?^B _P#-JS;_ .4A]3S7_H<_
M^8[#>7][U^_R/S!_X><?]8]_^"GW_B)W_P"'U'_#SC_K'O\ \%/O_$3O_P /
MJ_3ZBC^W^"?^B _\VK-O_E(?4\U_Z'/_ )CL-Y?WO7[_ "/S!_X><?\ 6/?_
M (*??^(G?_A]1_P\X_ZQ[_\ !3[_ ,1._P#P^K]/J*/[?X)_Z(#_ ,VK-O\
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MUR2A)QA+$XFSMS8>@N5]VG7J4+I=U=/>-UJ?Z'=%?YU/_#]K_@JM_P!'3?\
MF$/V<?\ YT-'_#]K_@JM_P!'3?\ F$/V<?\ YT->K_Q++QY_T-N$?_"_.?\
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MCIO_ #"'[./_ ,Z&C_B67CS_ *&W"/\ X7YS_P#. /\ 7S*/^@;,O_!.%_\
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M1]7TO0L:IXS\2W7V/PU9:-8'^TO)-J;>SL(K7W?_ (>(?MB?]%@_\Q_\+O\
MYB:^V\1/ /C'BWBO%Y[EN9<-4,)B,MX;P<*>.QF:4\2JN3\,Y1DV)E*%#)L3
M25.IBLOK5*#59REAY4I5(TJDITH>3DGTB^"<MRVE@Z^5\53JPKXZJY4L#E$J
M?+B<?B<532<\\IRNJ=:*G>*2FI*+E%*3_I\HK^8/_AXA^V)_T6#_ ,Q_\+O_
M )B:/^'B'[8G_18/_,?_  N_^8FOB?\ B5[C_P#Z&_!__APSK_Z'SUO^)FN
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M5[O"_P#R4W#O_8]RC_U88<Y,?_N.-_[!,3_Z9F?,'_!&?_E&S^SA_P!U@_\
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M'\8_$7Q5X.U+5;B6YDBA^SZ-9Z_-JUQ&SYF@LI(4#/(H/R/^P[^R[IG[&O\
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MZV%K4L10G*G6HS4Z<XNSC*+_ !3VDGI*+<6FFT?ZR/PT^(GA+XN_#SP1\4O
M>J1:WX+^(7A;0_&/A?58>%O=$\0Z=;ZGI\KQY+07 M[E$NK:3$UK<I+;3*DT
M3J.WK\/_ /@WK^)M]\0O^";WA#1-0U&;4I_A)\3OB3\,HI+B:2XN+6Q6]T[X
M@:;ISRRN\GE6&G^/[:VL(-PCM-,2RL[=([:WAC7]P*_RZXHR9\.\1YYD3E*H
MLIS7&X&G5FK2JT</B)PH5I*R2=:BJ=316][30_?\!BOKN"PF+LE]8P]&LXK5
M1E4A&4HW_NR;C\@HHHKP3K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#V(N#?_6\R,^<S7_D><+?]A>:?^J?%'[NT445^4'T84444 %%%% !1110
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M0RG[>7_16OV1O_"\^,G_ ,X2C_B&4_;R_P"BM?LC?^%Y\9/_ )PE?W.T4?\
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M  HO'/\ \[BC_ATY^T7_ -#I\%?_  HO'/\ \[BOZ$J*/^)CO$S_ *"LG_\
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M?!7_ ,*+QS_\[BC_ (=.?M%_]#I\%?\ PHO'/_SN*_H2HH_XF.\3/^@K)_\
MPTTO_E@?\2[^&W_0-F__ (=:O_R!_/;_ ,.G/VB_^AT^"O\ X47CG_YW%'_#
MIS]HO_H=/@K_ .%%XY_^=Q7]"5%'_$QWB9_T%9/_ .&FE_\ + _XEW\-O^@;
M-_\ PZU?_D#^>W_ATY^T7_T.GP5_\*+QS_\ .XJ6'_@DW^T*TT2W'C?X-16Y
MEC$\L.N^-[B:.$N!+)% _P /[9)I43<T<3W%NLC@(TT08NO]!M%#^D;XF6?^
MUY0O-931NO-7FU=>::[H:^CQX;)IO"YLTFG9YM6L_)V@G9[.S3[-,_(SX1_\
M$H?!>A7]GJ_QA\<W?C@6["5_"GAJSF\.Z%/(%QY&H:S)=3:YJ%IN)?;81^'I
MRR(&G:+S(I/U9\.^'-!\(Z'IGAKPQI&GZ#H&C6D=CI>D:7:Q6=A8VL0^6*"W
MA544$EGD<@R2RN\LK/*[NVU17YIQ5QSQ7QI7IUN),XQ.8*BV\/AK4L/@L,VF
MG*A@L-"CAH5'%\LJWLG7G%)5*DK'Z3PQP5POP=0J4.',GPV7>V26(Q"=2OC,
M0HV:C7QN)G6Q52FFN:-)U?8PDY2A3BY.Y1117R1]2%%%% !1110 5^$7_!)O
M_D]#_@L+_P!G/VO_ *M;]IZOW=K\(O\ @DW_ ,GH?\%A?^SG[7_U:W[3U?J_
M!/\ R;KQG_[$7!O_ *WF1GSF:_\ (\X6_P"PO-/_ %3XH_=VBBBOR@^C"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /6FXM/G<@_C<1_]E%B?_5?EH4445^4'T04444 %%%% !1110 4444 %%%%
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M?^K##G)C_P#<<;_V"8G_ -,S/F#_ ((S_P#*-G]G#_NL'_J^OBC7Z?5^8/\
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MM;)MVU/@[_@DW_R>A_P6%_[.?M?_ %:W[3U?N[7\NG_!.G]N']E7X-?M1?\
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M_CU5O$/_ "Z?]O'_ +1KFZ .M_MZS_YYW/\ WQ%_\>H_MZS_ .>=S_WQ%_\
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M>=S_ -\1?_'JY*B@#K?[>L_^>=S_ -\1?_'J/[>L_P#GG<_]\1?_ !ZN2HH
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M_'_D*?\ ^-4?VOI__/Q_Y"G_ /C5<310!VW]KZ?_ ,_'_D*?_P"-4?VOI_\
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MW@76TM[G6_">IV^K:K\6H $N8(_ 3B%Y=#T6\M9(FU'7O$NFV>HZ;)*=,M]
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M_M?3_P#GX_\ (4__ ,:H_M?3_P#GX_\ (4__ ,:KB:* .V_M?3_^?C_R%/\
M_&J/[7T__GX_\A3_ /QJN)HH [;^U]/_ .?C_P A3_\ QJC^U]/_ .?C_P A
M3_\ QJN)HH [;^U]/_Y^/_(4_P#\:H_M?3_^?C_R%/\ _&JXFB@#MO[7T_\
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M_P 2+A#_ .A<.3BW_H)X=_\ "',__GAZ_P!/3YI_X? ?\$ZO^CA__,2_'/\
M^=G1_P /@/\ @G5_T</_ .8E^.?_ ,[.OI;_ (8O_8[_ .C3OV:?_#$_"[_Y
MEJ/^&+_V._\ HT[]FG_PQ/PN_P#F6H^L>!O_ $*/%?\ \2+A#_Z%PY.+?^@G
MAW_PAS/_ .>'K_3T^:?^'P'_  3J_P"CA_\ S$OQS_\ G9T?\/@/^"=7_1P_
M_F)?CG_\[.OI;_AB_P#8[_Z-._9I_P##$_"[_P"9:C_AB_\ 8[_Z-._9I_\
M#$_"[_YEJ/K'@;_T*/%?_P 2+A#_ .A<.3BW_H)X=_\ "',__GAZ_P!/3YI_
MX? ?\$ZO^CA__,2_'/\ ^=G1_P /@/\ @G5_T</_ .8E^.?_ ,[.OI;_ (8O
M_8[_ .C3OV:?_#$_"[_YEJ/^&+_V._\ HT[]FG_PQ/PN_P#F6H^L>!O_ $*/
M%?\ \2+A#_Z%PY.+?^@GAW_PAS/_ .>'K_3T^:?^'P'_  3J_P"CA_\ S$OQ
MS_\ G9T?\/@/^"=7_1P__F)?CG_\[.OI;_AB_P#8[_Z-._9I_P##$_"[_P"9
M:C_AB_\ 8[_Z-._9I_\ #$_"[_YEJ/K'@;_T*/%?_P 2+A#_ .A<.3BW_H)X
M=_\ "',__GAZ_P!/3\I?V_\ _@I9^Q-\;?V/_C;\+?AA\:?^$F\=^+]#T.S\
M.Z%_PKCXM:+_ &A<V?C'PYJMS'_:?B#P'I.C6GEV%A=S[[[4+:-_*\J-FFDC
MC?C?^"-7_!0]_&&GZ1^R#\9]::3Q3HE@\'P2\5:E.SR>(= TVV>:3X=:E<S$
ML=8\/6,$L_A2XD<IJ&@6\FAGR+O1M,36/J?_ (*4_LN_LS>!/V'OC_XL\$?L
MZ_ KP;XJT;P]X>GT?Q-X5^$?@#P]X@TJ:?QSX6M)IM-UG2/#]GJ-C+-:7%Q:
MRR6MS$\EO/-"Y,<KJWEG_!(+_@G?_P *+\+67[2GQBT,1_&3QQH^[P-X?U.W
M'VKX9>"M6M^;JX@E7=8^-?%ME+G4%(%[H/AZ9-#D:SOM3\2:>O[!1Q7@^OH_
M<4PHX/B*DJW%V)CPW0SW'Y3C<^?%4,FRAQQ. K9=EV HTLII82=%9I&K0FWA
MY5Z?M7B,1@(1^9E3XF?&>7N53!2Y<MIO'3P='$TL&LN>*Q%X5H5Z]:4L3*HI
M_5^6:]]0ERJ$*S/W.HHHK^2#]("BN.\<>/O"_P .]&;7/%6HK8VA<PVT*(T]
M[J%UL9UM+"U3]Y/,RJ23\D,*_O+F:&(-(/AWQ7^V=XDN9Y(?!GAG2M*L@65+
MO7FGU349%R"DRV]I/8V5G(1P\,C:F@R=LQ."/L.&^!.)N*XRK93E[EA(3=.>
M/Q-2&&P:FOBA&K4?-7G&ZYX8>%:5.ZYU&ZOZF R;,,R3EAJ%Z2?*ZU22ITDU
MNE*6LVNJ@I-75TC]$Z*_*0?M5_&<2!_[=TPKOW>4= TGRR,Y\LD6PEV$?+D2
M"3'1]WS5ZOX%_;)U.*XM[/X@Z#:75D[B.36O#Z26UY;JQ'[ZXTRXFFM[P+D^
M9]EGL66,9C@FD&V3ZK'^"W&V"P\\13I9=F+@G*5# 8R4L0XI7?)#%8?"QJ22
M6D*<Y5)/W80E)I'HUN$\WI0<XQH5[*[A1JMSMY*I"FI/RBVWLDV?H)16-X?\
M0Z+XJTBSUWP]J-MJNE7\?F6UY;,61L'#QR(P66">)P8Y[:=(YX)5:.:-'4J-
MFORFK2JT*M2C7I5*-:E.5.K2JPE3JTJD&XSIU*<TI0G"2<91DE*+3329\Y*,
MH2E"<91E%N,HR3C*,D[-23LTT]&FKI[A11169(4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ;>@_\?DG_ %[/_P"C8:ZVN2T'_C\D
M_P"O9_\ T;#76T %%%% !1110!Q.K_\ (1N/^V7_ *(BK-K2U?\ Y"-Q_P!L
MO_1$59M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>5?&[XS^ ?V?/A=XO^+WQ,U8:1X0\&Z8]_?2
M(JR7VH74CI;:9H>CVKO$+W6M;U&:VTS2K3S(TEO+F+SYK>W6:XB]5KBOB-\.
M_!OQ:\"^*?AM\0M"L_$O@SQEI%UH?B#1;Y6,-W8W2CYHY$*S6E[:3I#>Z;J%
MK)#>Z;J-M:ZA8SP7EM!,G;ELLOCF. EFT,54RI8S#/,J>!G3IXV> 5:#Q<<)
M.M&5*.)E0]HJ$JL7353EY_=N95_;NA66&=..(=*I[!U5)TE6Y7[-U%%J3@IV
MYU%WY;VU/Y$_@?\ \%$+;X@?\%+O!?[5O[2WBE_ WPWT"Q^(.B:'I\-CXB\3
M:7\//"FI> O%VC>&?#]AIOAO2-4UB_N+K5=6MGUG5+71]VH:Q?WFJ7,5C8!(
M++]]?^'P'_!.K_HX?_S$OQS_ /G9U^-'P._X)]+^SA_P51^%_P %_BOX1T/X
MI_!7QGI_Q6U[X>ZAXX\,Z1XE\,>-O#>G?#?Q;?6=MK6E:K876B3>*_!^HII\
M>MV;V:M::E%INO6-O!8:IH\S_P!%O_#%_P"QW_T:=^S3_P"&)^%W_P RU?UA
MXUXOP4J9OP?4^H\6XG+9< Y-_8,N#\UR' 953R6.99W##T*F'S7)LQQBS"CB
M(XJ.-=2O&:J6IUZ4<53Q$I_G/"M+BN.&S->URZG76<XKZXLSP^,K8B6*>'P;
MG.,\/BJ%)T)4W3=+E@U;6$G3E!1^:?\ A\!_P3J_Z.'_ /,2_'/_ .=G1_P^
M _X)U?\ 1P__ )B7XY__ #LZ^EO^&+_V._\ HT[]FG_PQ/PN_P#F6H_X8O\
MV._^C3OV:?\ PQ/PN_\ F6K\9^L>!O\ T*/%?_Q(N$/_ *%SZGDXM_Z">'?_
M  AS/_YX>O\ 3T^:?^'P'_!.K_HX?_S$OQS_ /G9T?\ #X#_ ()U?]'#_P#F
M)?CG_P#.SKZ6_P"&+_V._P#HT[]FG_PQ/PN_^9:C_AB_]CO_ *-._9I_\,3\
M+O\ YEJ/K'@;_P!"CQ7_ /$BX0_^A<.3BW_H)X=_\(<S_P#GAZ_T]/FG_A\!
M_P $ZO\ HX?_ ,Q+\<__ )V='_#X#_@G5_T</_YB7XY__.SKZ6_X8O\ V._^
MC3OV:?\ PQ/PN_\ F6H_X8O_ &._^C3OV:?_  Q/PN_^9:CZQX&_]"CQ7_\
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M^QW_ -&G?LT_^&)^%W_S+5Z7\._@O\'?A#_;'_"IOA/\-/A?_P )#_9_]O\
M_"N_ GA;P5_;G]D_;O[*_MC_ (1K2M,_M/\ LS^T]2_L_P"V^?\ 8O[0OOLW
ME_:Y_,Z\1Q7X<97PCQCD'"64<;4\?Q9A,FP=3$\1YMD6-PF&I93G^7YUS0I9
M9E&75O:55@YT;RJ5(ISB^56;,H9=GF(S++,;F6)RJ5'+:F*JQIX'#8RE4J2Q
M.#K86SE7Q->-HNJI:*+]UZZV7I=%%%?CI].%%%% '6Z#_P ><G_7R_\ Z*AK
M;K$T'_CSD_Z^7_\ 14-;= !1110 4444 %%%% !1110 4444 %%%% !1110
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M#A*U#"\4X6$*>*]M3P.9\B2^LQG3?U7$SM92JT73>'G)WG4ISHIOEH(\_BS
MTY0IYC3BHU.:-+$6T]HFOW51VT<HV]FWO*+A?2![Y1117\]GPP4444 %%%%
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MTF>[6MGM'UVZ@Q_('^6=2T^*_@B[E6$ZI):R-T%S9W2IU ^:>&.:W0<]7E4
M9).%./G:[TA%Z+CZ<<?_ %O_ -?'%<K?68C##'KZ?Y_3K4?VOC(ZN-&2ZKDD
MNW::^6_FC#^P<OFO=EB(ONJD'\[.G*_R_P""?>$5]9SVBW\-W;26+Q^<MXDT
M;6S1#.9!.&\K8,'+;L#!R00:Y:Z^(7@NT9UD\06,I0D-]B\[4 &!(*[K"*Y3
M<"""-V1CG%?&5SXKOH_#,?@^*ZN$2[UD:E*!(2&AA@6'[.<YQ"93!=!$*XN8
M%G^]N)V=!T))EC+@,7(Y8D]2 26/X$UTSSB;C#V5*%W%.7.Y22EUBE%Q=E;1
MMWUVTUYJ?#U*+J?6*]1Q4Y*FJ:C%RIJS4Y2DII-W=XJ-E:_,[V7T^?BOX-.?
M)N[V?'/RZ;=PY^GVN.VK.E^,?AF(_P#'AKT@R1NCM=/(X[_/JB'!ZCCZX-?%
MMQ\8].LM0O;&V\(7LZ6%W<V337&H6]I(\EI-);R-]G%M,8@71BBO(SXQN )P
M.O\ "/C[0/&MW<Z7#I]YI.JP6SWGV2[,%Q%<6T;HDKV]U!P6B:2/S(I8HFVN
M&3> V,I9ECM?X*MJU&";2TW7M)-;[M?D>E+A:G1HJO5P^+]E9/VDJM-JSM9V
MIQ5M[[675I:OZEA^,W@V3/GG5+%0 2US9QO@'/\ !97-W(Q&.0J,?0&O0=(U
MW2->MS<Z/J%M?PJ0)#"_[R)F&56:%PLT#,!N59HT++R 1S7Q3K%DB*Q ]?<G
M^8'U]ZK?#CQ)<^'?'FB*L[)9ZGJ$&DWD//E2QZC*EI'N'11%<2PW); ^:W0L
M<5>'S6NZL(5HTY0G)1<HIQE&[23WDFDWJK7LM'?1^=B<BPWL*E3#3K1J4X.:
MA.49PERJ[C\,9)RL[2YFKVNK'V]J6OZ)H[*FJ:MI]A(Z[TBN;J&*9U_O1P,_
MFN.#RB,*P7^(O@I-X.OVI*?>$<5W*>F<*([=RY(Z!-Q/09-?%OQ!N[N;XA>*
M8;J:1_)UF]2%&;*I )W%N O&W$!B4'KM"@G&#5[1[-9<9&>F,@GGG/7//I3J
MYO6C4G&-&FHQE**YG.4GRNVMG"U[7V=N[W:HY!AW1IU*E>LY3ITYM04(Q3G%
M2Y5S1FW:]KZ7WMT/L2/XB^#9<;-:0YY&;+4DXX_OV:^H_,>M2GQ]X04$MK<
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M>(=8U2X9W>^U:^NB9#DJ+BYDG"#).$3S-B*.%4 +@"O3K#2+>*(NR@*JEF)
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M7J!^?;'Y5]<^+O!>D>,+18;]##=P*PM-0A \^#=R48' F@9L,\+D#<-\;1R
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MK[#%:$=V!C)'3CG'_P!;G_#@5R?EZBA(:QO%([-;S9&/8QC%/5KT=;.[R/\
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M[PQKM6&&-%"UX/XG\)WGA.ZDLI/%.CWMU&IW6=M]O^TH-BN$FS:&TAE;<C+
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MF(&3C//->4W^F>&YY7GCT'5;$R2L_DZ9KBV\:AF#8#:CI6LN,?=PH5<<*JC
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M[6:7+)-/IN[_ *=]+GHTLWP=*K&K0QU.G46TK2C:]KI\\+-/K=6NO*YX?8?
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M_P BS_\ QVM*B@#-_LC3_P#GW_\ (L__ ,=H_LC3_P#GW_\ (L__ ,=K2HH
MS?[(T_\ Y]__ "+/_P#':/[(T_\ Y]__ "+/_P#':TJ* ,W^R-/_ .??_P B
MS_\ QVC^R-/_ .??_P BS_\ QVM*B@#-_LC3_P#GW_\ (L__ ,=H_LC3_P#G
MW_\ (L__ ,=K2HH S?[(T_\ Y]__ "+/_P#':/[(T_\ Y]__ "+/_P#':TJ*
M ,W^R-/_ .??_P BS_\ QVC^R-/_ .??_P BS_\ QVM*B@#-_LC3_P#GW_\
M(L__ ,=H_LC3_P#GW_\ (L__ ,=K2HH S?[(T_\ Y]__ "+/_P#':/[(T_\
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MTN?^^XO_ (S1_8-G_P ]+G_ON+_XS6W10!B?V#9_\]+G_ON+_P",T?V#9_\
M/2Y_[[B_^,UMT4 8G]@V?_/2Y_[[B_\ C-']@V?_ #TN?^^XO_C-;=% &)_8
M-G_STN?^^XO_ (S1_8-G_P ]+G_ON+_XS6W10!B?V#9_\]+G_ON+_P",T?V#
M9_\ /2Y_[[B_^,UMT4 8G]@V?_/2Y_[[B_\ C-']@V?_ #TN?^^XO_C-;=%
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MK_P(^%/[*W_!U[^S1X._9Z\">%/@_P"!O&/@:/Q3=^!?AWH=IX5\&V-YXD^
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M])^&5_K/A6/[3XCT40CQMI_AM[J&_CNK59K6.>:+^33_ ()_?L,?L[?MT?\
M!>7_ (*G^%_VG/"-S\1_A]\+/BY^T1\1],^'=QK>M:/X7U_Q@?V@[KPKI&H^
M*(M!U#2[[5K;0=.\0:U+8Z:U['93W5X1J$5W9>?97/LW_!T%\// /P:\8?\
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MNI?"KP1XUT7PGKEE.?+U#1/$FHZ7JVG[7:]LX$1V7^9/_@WQN_$?[/\ J_\
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M^-/[+GQ%_P"%8?$N;XZ?#[P;+XE_X1'P)XUW>&]<T?QE=:IIW]C?$3PQXMT
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M\4>$?BIHNKV<L<JO&1/8WLZ LIV,5<?,H-? /[-7[77CO_@F-^PO_P %M?\
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M?_@HS_PT/_PG/_#2^E?$O3/^%.?\*D_X1G_A"O\ A8GC_P $^.?/_P"%A?\
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M?[%_X5+X/L/"G_"B_P#A5/\ :/\ PD'V+P?X\\*?;_\ A9W_  LFP_LKS?\
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MI_PEG]E^7_PA/B'[%_9_V[?=_:OL=M0_X*%?\$?_ /AO']LC]CG]K7_AH?\
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M[6O_  2-_P"&I/\ @I7^R1_P4/\ ^&@O^$%_X99TWP!I_P#PJ#_A5'_"3?\
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MKKQ!;27=U:/I&H:AH-S]J_M:_P#!(W_AJ3_@I7^R1_P4/_X:"_X07_AEG3?
M&G_\*@_X51_PDW_"=?\ "#?$#QCXZ\[_ (6!_P +)\/?\(Q_:G_"6?V7Y?\
MPA/B'[%_9_V[?=_:OL=M^S%%:U^-^*,3C(8^MFCEB:>78G*:3C@\OIT*67XN
M$J>)P]'"4\+#"4O;1F^>K3H1KMVE[7FC%J*>1952H2P\,):E+$TL9.];$2J3
MQ%&2E2J3K2K2K3Y'%<L)5'32NN6S:?@G[3_[-7PF_:_^ WQ)_9Q^.&AS:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0U!WT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** &-Q@CKG'U_S_6GT8YSCFBLX0<9SEHE)W27H
MO>?GI8 JO% (W=@.6.3SWX'^/Y_E8I@D4[N?N]?\_P"/^.-4W9I7L[)VZZZ?
MB'/RIKFY5/1J]KVU_"UQ6&>G4<BE&<#(P::DBOG';\:?4<EIN2NKKWHVT;TM
M)^:2MZ,49*23B^:/1K8****H8A 8>HI:8H89!Z?YZ?Y_K2-(JG:3R!G_ #]?
M\*QA*/*ZLX^SD[*;EIMHM>W;_@ VEI=6OIYM_KY$=S;K<Q>6W3(/Y5*HV(%4
M9VJ /PIL<J29VD'''!SZ_P"%2YJXRC5@W3G=.Z4HZV?EY@G>S6J$QR#CG%1/
M"'D23^[_ )/YCCC].M0F]A$<DFX81L$]N_\ @?0^WK(]S&D'GDC8!G/;_/%6
MHNDVK.,G\3V;;25WZJPTVMFUHU\GNBQ4)CW*ZD<' ],__K!J*UO(KK/ED'']
M,?XT^.YCD:10PS&3D=QC'7WY'\^E*5%N<9V:E2UVZ2V_'4%)QZVMK?M;6_E:
MQ$0]N(HXU)7)W>W!Y/KTS^&*NU$LJ/GI\OX^G(_2GJP8 CH:MRYE>VS:<EU?
MGYH3JQJ<K3BVTW=/6>N[7EL.IK*''\J=0!C@5C4@JL73G%2ISBU)/KM;2UG_
M ,,--IW6C(XQM!7N#^/^>:DIFY?,VY&[;T[^O\N:?2HP5*FJ4;<M/W8V[;J_
M9Z["YN9MW3UL[='V^0449YQWHK1-.]FG9V=NC[, JN 1(,=VP?PX'Y]ZL56B
MGBF=U4@LI[9]OUY'\ZY\3AI8CV<HZ.C4C/FZQ5U>WJDT]BHNU^NFQ9J)@2W3
MKCGMTJ6F/(J8SW_"M:M'VRC'722>BO?R^9/.H)R;25M6]D*N1D=NQ_S_ )_2
MG4S=N3*=2./\_P"3^-,1V/R_Q#KGK_GU_+BJ4'2IOXI*+TBE[R3M9):;?+J1
M[2/-%=)*\9?9?E?N][#^C\]QQ^E/H(SU%%13@X<_\LI<ZO\ $G+=->70N_Z?
MAH%%-9@H)/05$EPCMM'7_P"OBM&TK7=KNR\WI_FB7.":BY)-[)BPQ"+?C^)B
M?SZ_G_G%!!R>#U/:I%=6SM.<'!J-YT21(R0&?H/T'^>??'6LZM'ZS;WGI>5U
M9W5K?@BU-M\UU*^E][[+?Y6%7((QSGK[<G_/^14M0S31P*7<@#J33XY%E174
MY5AD&BE3E3BTWHWHNB25M-%ON_47,FW9W:W[I[Z_IY#ZK7%NL_E[OX&R/\_U
M_0U*LH9V0=5_S_G^M5 TZ7$K2?ZE5)'ZX_#I[^M=--24FXM1E&-TGN[K1+O>
MXVFM&K;/5=]4RVXQ@CZ?X?RIX& !5&WOX+J0QHP+#G'Y_AVZ?Y-XL <$\UQ*
M,*56I4DXQ3:@NZE]I??_ %8+MI+5V_K\/U%J&6$2)LQQG/\ G]/R_.:BNA)<
MT9I>]'X9=5>VWW($VFFG9IW7JB&2$21>6>F,?I_CS_G%19DCDCB5<QA>3Z<C
MC]>OOGM5E22.?6HA/&9-@P6'&:4:\.2,I-*,W:*D[>]*R5O-VL/VG+[L[--R
M48R?VVK77FB1R< >M,&X9X//M_\ 6IDUS'#)&CD!FS@<_P"><?Y[RK*K D'I
MUKGE0=2K*3J-/112UM%I+7;=W7S7D3[6,;0;BF[NS>]M;_+08(^2V.??^G_U
MZ>R^8N#P321ER23]T]/\_P"??M3W)"L1U ITL%2H\T(I.,_C5M)RNFI/K>-K
M?>3[15(.33Y;/1JUUUZ]>FHD:"-0HZ4^HXF+(">IJ2NFW+IVLA4W%P@XJT7%
M-+LK;?(****"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0G )/0#)_"F1RK*"5(.#@X
M.?4?T-/8!E*GH00?QJ&"W2W#!% W$DX]R3_6@">BC'.<<T@8-G'8XI+F]ZZ5
MD]+7V\^SN%]EU>R[V[ <X.!DTBC'7J>3074,%)Y;H*4G )/05/(I5%-N[BK*
M/2,GNUYM-+^M%S+75:?%KML]?S()8!(Z,1RIR.>_(_P_+\[%(#D CH:6M&WH
MG?39=BN9M15[I?#V2>NGJ%%(6"XSW.*JW=P+=5).-S >G<#^M"3=NE]K[$.2
M2;U?+NHZO7R_'T+=(PW CU&*1&#J&'((!_2H_/3SO)R-V,X_#/\ G^>>*:C*
M[LG>*N[=$NHT[I-;/5,2"$0A@!C))ZYZDD_T_*IB,C!H+!1DTM3+WT^;WE+1
MWZZ?Y%.3E)MN\MWW\O\ @%*269;F.-5S&0,G\N/_ *_;O5PC(P::K*^2N"5.
M#3CG!QUI3<7324$XJ-FHZN:_S^8D[ZIW[-?HT,/[O+?PXYSV_'_/\J>K!E##
MH>13702(48 @C!JNTT5KY4)*KNX Y]S_ $_^M6=.'(K1NH-)J+WAHM/U?F5I
MR]>?F^7+;OWO^!*D(21Y/[W^1^0XY_7K4N.<]S2;AZ_SI<@#/:JYH5))7C*<
M&K*]VG%<JT\EH)M[R;V2N^R2_)6_,6HF4*,_D,__ %O\^M/1U<94U#<?=7_>
M'\Q3]E3K-*23LVKVOROJOP,IU'"G*I%WT36MD[M+=>HNP_>Q[?A_G_.*GIH8
M<+WP#^E-,BJP0GD_Y_J*QI4*>&4FG92LVWI=[<WJ]#1SYDFVM[?-V]WU\MR2
MBF&10P0GYC_];_$?F/6E+@,%[G_/^?\ ]>.A:[:V[:_UNB>:.OO+1\KUZOIZ
M^0ZD QGWI<]/?I2$A02> .M3:,G=V;@WK_*VM?30J]O)=1&&1[CI0N0H_P ]
MZ4$, 1R#TI:E4X^T]JMY1Y7;9W<6G]R2"]UY;KYC')",5&2!P/4^GX]*9 [O
M&"XPW_UO\G\<=JFI.!Z ?E6M_=M97O>^M_0JZY;<JO>_-UM;89( RCZ]O\^U
M,P>F*FP,8QQ2%E#<]0/TZ_\ UZX*F$=6JZCY8N48*=KNZCO?TZ?GH"GRK6V^
MEW;T_70KJY281<8(]S[_ -<U:JONB)\W(^4[>^?3^G3_ &<58!SR.AKHHPC3
MC[.%N2/P172#2M^-W\S*$FW-N2E>7-&SO:#227WIE6VM4MO-VY_>R%SGU/\
MG_\ 55JFJZMG:<X.#3JUBDDE%+EZ6V+3OJG?LUY>93BM1#*\B@Y=N>_I_A_G
MI5RH//3?L[YQFDEN(XG1&(!;H#GW_P #_.LZ%*,745+7FES.*^R[:_?N_P#)
M#=7VK<N;F:M%O?9:+[B?')/KC]*6BBM$DM$K:MZ=WJQ!1113 **** "BBB@
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M7S/_ ,%B/$WB/0?#_A70M'U74+*/5O$-GI3O:W4T+F.ZUC3+0_/&P;[LA'#
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M\<5^G?[(?[%9_9\\9>)M2BU;7=1MM4O)I(H]1U?4;^*!76U $*75Q-'&!Y'
M0*!EL8R:V>!RZG3Q"JU92K48+E:FOWDM$KQ>JMIIW^12QE6I.,72<(.ZFMW9
MJRUTLM=_E;O]D^.?VE/A]\.]?/AO7M>TJPORP3R;JZABE9OF.U0[ DC:3QZ>
MU9%G^U=\.+[6=,T2T\0Z3<7>J7<=G!#%=PM(7E)"@(I8]C_+U%?SS?M=^!O%
M/QN_;V\1>$9]8UNPT?0=4MULTL-0O;*.02)=D[OLTL6_J.I.,#L!G]+?A;_P
M3;TGP_XR\-^.+C7O$4MSHU[::C'#-KNJ20N\2[@&ADNC&P)8Y!7!X&#BO?JY
M)P]A<IPV+Q$JOUFOAHUO9J7NU)U*2E=::)3>OIVNSDCBJZFZ<5S0A4<6TFN2
M"?+R\VO,VO>NK)OIN?IU\1?C#X5^&UA%>>(-7L+&-R.;JXCB ^9%_B8'JX[Y
M[]:\G_X; ^%;V5K=1^*M#D%Q,L2A;^W)W%D7[JN6&-WIZ],"OQP_X+1>(/$.
MA:'X2LM(U74+%M9\266DR?9+J>!O+N=;TNU/^K92IVS,,C'MZUG^#/\ @G+=
M3_"31_%D/B'Q5/J,NCPZNL;:_J\BF>2RANTQ&;LKM+L. ,'ICC%/!<+Y73P-
M'%YE*2^L*DX24U%7J1<FK26O36^_J.6.K\THTH-P@XQM)OF:BFNNMK[]KI.]
MW;^B+P1XYT+QSIJZIHU_:7L+ #?;S1RCD9ZH?PZ?UKN*_FZ_8O\ VD?'/P;^
M.US\!_&][=1:(8FELVU$EY'?SY8(E$UP&E;(9,#?W'>OZ-;"\%]IME?1$,MW
M;07"L,8*RH'!!Z8(-?(9[E5/+\1&6';>$Q-Y4'*W-;2Z=NSZ]3T\)B%6H\TO
MCC?VB2>ZUNE;7\RW-/%;QM+/(D4:@DN[!5  R>3]*^?D_:+\!R?$&#X?)KFF
M/K,_$=JMU"9V_>11Y"!\GF4#CC)QFO7O&%A_:>@WEL9)(MT,K;XW:-P1!+C!
M4@]??KBOXT/$GQ%^(?@O_@HS'K2ZOK'_  C^C:I):%'NKA[0A=1TM_G5RT1.
MV-QE@>,]C3R;)O[3IXJ46E.E'F4=D];-MV?3T;[JQS8_&_5>7WE#12U5^:[L
MU9M:I:]?1[']J0F1E5P1M89W9X ^O3_ZU>$_$?XZ^!_A?+$NNZUIM@]R0$6Y
MN(8F8MOP%#,"1F,YQGITK1^&OC0>*?AY9Z]<R@B2PDF:7(&""^"<#CIGZ^^:
M_D7_ ."A_P =?B%\4/BSJ^BZ1J^IPZ=X-U&.,_8+B:W'EI#(Y\PP&/<,W/\
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M!-*R*I^95P&)]9!^?Y[?@KQAI7C;0[?7-+N8+FVGSLDB977Y1D\CTZU^./\
MP4-^*/B&;]E_P5XC@NKBWO\ 4+^".:2W8PN1)-H9/W<8YF8<^N>.:^NO^"=U
MQ>ZA^S;X3U*[N9[F[N3+YC3R/(V&CC/5F8_Q$COW'O\ &SRVG'"5JE3^+#%.
MFG:\925VV]-W;?==5K<])9I'VJI\C=Z4*R:^)JHE:*A>[:]==>Q]9?$#XJ^&
M_A\EF^MZC:67VR[BM(A<3)'OEF941%W8RQ9P !Z]NI[C1=9@UG3K?4("'AN8
MHIHF7[KI*H967CD$$$$9SFOP>_X*W^)_$^BZS\,+#1[Z_M(9/'/AN6?[+-+%
MN1M1TW>C["-RD%L@\8/(-?L-\$M:%Q\)?!]U)(7FA\&Z3/*S'+-)'ID<C,Y/
M5B0<D_C7J8_)*.&R?+L=2]I4GBXJ523TC&[22VV?>_F3A\QE5JU*+BDXS<>9
M_9^&R<;]+WW*/Q>_:#\&?"%U3Q)JMEIY89'VJ5(^J*^?F([.#FO3_#_B33O$
M?A[2?%6F7$5W8ZG9Q7D$MNPE1TD!*D;,YSM./6OY:_\ @IKXL^('QM^*Z>&/
M#EYJ2:9$T\4KZ;-- 5>&*TMP"ULR]"'ZD<@]#7Z_?\$O_B7J_B_X'#PSXDN)
M9[[P5/%X=B%P2TICM6F&9&8;W;)4%G)8]S2QG#%3#9=#%U*,G["=&=:*U5JK
M7*HN*TMO=KKL"QRKU)4EJ[N5*6R7*E:Z=^OWKS/TON+VQMK;^T-0G@MH$4L9
MKEUB1!SRSN5 Z'KZY[U\T^)?VL?A;X<O;JQG\5:")K9MK(-0MMQ.T'[H<D_A
MFOB3_@K#^U%XA^"GPP@\->"+MHO$GB:+9910!&N'*_:%;RQ@R#  SM(KX@_9
M[_X)^:O\?_">D_$3QYK_ (KM=3UFW:^>(:]J]K&7601 >2ETB= <KM'(/&>:
M*.1*.!P^98J2IT\34<:=.]I>SA))R=[=GI;I?J9U,5)3=.G:7(DW/?623:3W
M^)^OKT_=7P)^TOX!\=7<-EHVNZ9>S2N5$=O<Q2NI &0P1B5Z@\CN./7N/B7\
M8?"GPR@MYO$6J6.GI= F,WDZ0AP/[I<KGD'I7YB?L[?L,/\  _Q_)J=EJVOW
ML$E[)(5O=6U&\B571!@+<7$BC_5@\#J3QS7S5_P69UGQ3<^)?@_X1T/4-0LH
M-9O;BVN_L-Q/;LRJMV1EH65@?D&,MUSZUU3R/!O'4:=&;JT)8?V\W&2<M:D(
M*]E[K7,G;U-%C*BP[<GRSC-15XZ322;2[62>J>_J?J]9_MG_  KO+F""W\3:
M,PFD"92\A91GCDAB .G)_/I7U;X6\2Z;XLTB#6-)NH+VSG *3VTBRQ-E$?AT
M)4\.#U[U_/G\$O\ @FI::O\ #SPSXFN/$7B=]0U*>!+K=X@U8LB26UO*S!3=
M_+\SM@@>HZ5^YGP+^%\'PA^'^F>#+:ZNKR.Q"$3WEU+>3,1;PP_--,[R'_59
MY;J2>]>-FN$PN&2^KMMJI.G+F:;O3:C)OJM=%\SNP\YSBI.'+&2YOBOR[<J2
M\U]UCV.BBBO$.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "HRX$BKGD@\?Y_#_)J2J#
MQQ_;$?<=X'W=_'(7^'\./TJ90E4LHW7+*,W;JHM-KT8%HRJ)!'W/_P!;_$?Y
M!KP/XI?M ^"OA7JEOI.OZOI]C=740FCBN)XTD*MM((5B3C##M@9[5[M.2C-)
MV2-FS]%S_3_/-?R+_P#!3;QY\1O'OQMN+_P_?:G'8>&)7TF06,T\4*F#R3\X
M@*H3\A.2">N3UKZ[A+A_^W<;6HSYI4J5'VDE'1WEI#76]I7=MVCRL;C9X:/,
MTOXS2;T]Q1BY>M[O4_J[TKQMHFM^&8?$]M?6K6#P^<+A94,:KEAEFSP#MXS[
M\5X'J'[6?PRTW4KK3+GQ1HL4UM)L:-[ZW5B< \!G]_2OE;]@WQ!!\7O@#=^#
M[S5;B>_M-/C@O6^TNL\+M(V,NC^8A(D7'3K7PU^UG^P/-X6\&_$[XIZ5X@\2
MQZIX?TZ;5=/CCUW53&\L*H%'D"ZV/]XY!4@]<5V4.'\+0SO$Y5B[OV=:E&,^
M90;]K[/E2NG>W-9^AY\\RFZ=.O'2,X2O_BA)^[))[\JT>[T/V!'[8OPK:]M;
M"'Q3HDLUPVP)'>V[LIP3R%8D=.^*]"U7X_\ @G3-/CU*XUK38[<KO61[J)58
M9'W26P?P/UK^8_\ X)]?LD:_\;(W\7^+/$'B9KF)&O CZWJD:*Q%L %C%RJX
M_>L=N".M?MUXO_8ATSQ7X(T_0VUC6H_LT3)OBUB_CD;)')=+A7;& >OOUKU,
MZX=R/)\2L)5G4=;FBI>\GRJ<>9<RLK::MG32Q.*K4E5YTJ4DG"48>\Y))\K5
M]%?K=[>9[LO[87PHE4X\6:$67EA]OMLJ!U)&_@=N?K77>"_VAO 7Q U/^RM*
MU[2KN6/#?N;F&0<AF&"&QT0X/2OY0/CW^SIXA^&'Q_T#X=:-XF\3M8:_XB@T
M:X5M<U.4K!/=W$+%6>Y9D.V,?,"#G-?N9^S-^PVGPLU%]8;6=>G*623JUUK&
MHW 9TMI3C]]<.#R_3!'..:57A[(Z>!C7E6E3<DG&7,I2M>*YXPLN:[>L5*RO
M>^A@L;BI5HQE%/FDH22BU?2]I2^RM[RMY=S[H\??M-?#[X>^(6\/:OK^EVER
MGE QSW,*,/,(4$Y8#D_UQ530?VHOAKKWBN#0;3Q)HTMS/9QSQE+V AA( %13
MN W'/"Y))XK^;C]I/PYXP^-/[=GB7X<_VOK4.E6<NF1JMG?W=OA#-<Y;=!(C
M9VV^,Y_&OTO^&G_!."T\,^+?#'B%-?\ $<AAL-,O9'DU[59 9$\J9HVW79!0
MMQM/!'&",UK4X<R'"X.,Z^(J_6*F%J23;C&,I4E#VEK^;5HWU[Z!3S'$3C5E
M%:1J."IJ/-:/,E&:DFKJVMK*]['ZQ?$'XO>%? /AP^(=;U.QLK3S+=4>YG1
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M+V'SYT3?&Z[@R[CEA@]LCTXXK@IOVQ_A?%+H\;>)=&_XG0W0#[9#D@,5_O\
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M8JR7O65[IWVTV/7P.(G7IR]I9RB[72M?KMKW'T445XAW!1110 4444 %%%%
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M[+1IM:;M:G5A,;.<^6JG%2<[)QL[IM]]4DGKUT/U[JK-(<A5!SGW_P _3O\
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MPV6SG@^QK\:/V\_V7M:_9YUGP#I.@>(/$?V3Q#>W,1+ZSJ4P<*;AL R7#_\
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M:I34K1[--O2UW"*6(FOXG*UK+O:-YMOXN2]VEOHNA^5/[:T2W'[?_P *KB^
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MD61#H87[W.1(IQ_(U\(_L_?M%_M+^$_@GH6G^$+[7HK>WN)Q&MK+.%$2F(#
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M*M_-JT,<QZ/M.J:MG=QT)R*_ICAG+1V[$YC,46,]/N#OSZU_+W\7-9TC0?\
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M[3?V1KWPYXSEM;C1M3\KS()_(11(8YU!5L>=V<XK^A*^-W"EN8-PCC9?-QG
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M,_WJ:WY8W7371^9V2FO:4HVYFY3FE&VCG9J6K?O/7EMJM;ZVM>^ MO>>._\
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M9D@9/#NKM$[L$_>)92E<'(YW%<>Y_+T::)Y%B".5V$9VXYP!]>G^2._Y(_\
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MQ'\/_##]NGQ/XMOITM[-KF-DE9@HS'JNJ_Q>N95R.36M^T[^V@?VG4T3X/\
M@#5CJ6L6LNGQO96\YGD"3/:8'E@L1E;5^W;\:W?V@?#'AGQ-_P % -<T36-*
MM]1T\ZA;+]EEW; 'UC5-WW6SSM7W_.M;]M/X#>&?@!\6?#OQ5\$>'8=&M[F?
MPY)(UN',16*6S\SEB2<K<-D[L\_4#T*N+PM?#\-X6&'C.M]3=3#UZO*Y4^6%
M%2B^KE)R5W'>VNQE/#XRG4Q#BXRI*HHU%#2%1-Z1M_+!)\O:_4_5K]A;X?>+
M/@C^S-K=KXSM[C3[ZY@O-:A%TIA8H]E/,KKN"GG>ISQU'2ORR\,Z]/\ %W]N
MVQ75+A+S3K:+Q%:'SI5FB58T@A .]B!Q%C!P.PZ\?='Q9_:RCO?V-K?Q/IUQ
M!#>W%@GA7;$Q)$TFFI;[Q\Y.\,<C.1GM7X^_LC?L2?%OXU?\)-\5=+^(/B30
M]5DUZ_GM9[1;,&."\U"^)1/.LY/E,<2@9'/K7A9)2GA)9UC<?..#KU:LZ46E
M[D*T=(.V[3T;MHWU1KC:32P\(\_L*,8U(7]Z<E*SE"+6D;/2-UI?4^C_  +X
MQT7X/?MZ^&/"%O=06>D7T\LT\$<BQ0%SJ6D/EE4A3S</D\]37Z3?\%/?$5O%
M^SAJNH6DBD742RP$-UB>PO"""#R*_"G]J/X!>/?V4O%EA\9=:U?5?%&J:,T:
M_:=16,YPMM=,3]GA@Z_95!Z#CUR*_5W]K/7H_B;^P9X,\<RR*&OO">G3W<"?
M<6:2POV*G)9AC9S\V>N>E>YF<<+6S;AS,W-N=67L)\K7LY4H*,H2BEM*<[K6
M^FCZ&>&I5*V&JTYWC/VBG3E*ZFTVM+O1<JNTWLSX0^._PC)_9W^&?QN\'V6V
MY\(:<)M8O[*$AXGFNKG!EEC4%20B]2,\5]V^-OB%H'Q@_8.U6VM[N&]US2?
MUV+E?-6::.9+B0@,NXN#B=>OKTYKV3]EKX4Z=\4/V3+[P5J7^D6FM:2@$>1\
MOER2XV\>K'_ZU?@/^T!XP\7_ +*&K>/?AZ]W<2Z'XF+Z?:Q7*C9!#/'&W[HH
MJ' :V;KGDG.*<_8X_/L10J5YN>58B%6@Y.[E3JTZ<I<UK-KWG3BELDK]0Q&$
MKT*3JSG!*O%*<5%M^XTHIV=N9M)MOJ[]-/Z4_P#@F[%+;?L_^ K9P0\/AR!)
M5YZ@QY!SV.?Z\5\'?\%H-6N(?$7P,@MLAUU*]$>T#.<7N<8]NO\ ^O/Z'_\
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MT--?>O\ @?-G_!-K6- ^)'Q?M];\8M!-XS-_=R6[WFW[6=UW(7VESOZ)%T]
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MUY^OZ?C6M0 4444 ?F7_ ,%!?V=Y?CA!X6DBM9KEM)W86(RX&XR=1&P!Z_Q
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M/2+UN[ZK\S6&!HPE"25^2]DUI=VL^MK6TM_P_P \_M&_ ?P_\?\ X6ZQ\/\
M7(%%OJ*+)YD;-!-&\43A/+EC9)$.2#A6'0=^OX"^+_V)/B9\)_$3^&_ NI^+
M6T*9Y<^3J^K21JH*%0I^T, H\UP #\H^E?U U$T,+G+0Q,?5HT)_,@FO-PF;
M8G"4:E"#;A.I&HDY?!);M)W5VK+MIMU3K8.G5<-7!135HKXKVO=Z;VL^C/QB
M_8+_ &"+'X;ZS=_$[Q0VH7WBB75#=I-JU[>7<T8:X28JGVJ:0JFZ)?E4*/:O
MTG^/OP3\/?'3P%JO@?Q!:1365]%Y?S#:R85Q\C*0RX+DY!ZU[RJJHPJJH]%
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M-.FU)2O!WZ?X5>[OK_P3MP>!IX-6C)S:2BI25FDE:VF]_P"NXM%%(S!5+'@
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M?*GO&0J=S<8]>*_I(:W@+;C%%GJ28UR?J<?_ *ZK#[-=+-;JL>",,%4#CCT
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M+YT?S.NX;@HY)//L>W\Z /6J*\E_X6EH@_?FY00O\B'<,;^F 2>N<=_Y4?\
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M\@9<1.A</"X((VKTZ''H,:7@W_@G/K_Q)UF&/QWK'BFXLK:4CRKW6]7:!T4
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M/3@^O/YY_E^5?DU^V_\ LE'XZZIH=S,U_<)#KMI<R6Z7%T(40:G:W!/E+*$
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M4"61]V[+9W3MGGTXX-?4GDQ?\\H^N?\ 5KU]>G7WJ,VT9F6;: RC@@8(X_\
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M2>]DI.V^WH5'#1C"-.+:BD]%YM._RLD>$_ #P*?AE\--#\+V\3(MKY(*MN)
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M=+^=K=?6W8N,.;[45K:S>NU[V['JE%>8/\4?#YM1.ES'^\R$^;^+&0!@]?\
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M5:=XP>W)&4VI/1W35^W3;N?N#+<PPH\DCA$CY=CT%8MCXCT2^N98;2]@EG7
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M.*VZ];O31IV[>F3B%8B\P&U 7);MM&X^O3'T&*Y9O'?A>)WAEU2V1X\AU,B
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MX2$S;M5M?-B8HW[R/*LAP0<MG((_#%/TWQKX;U6X:WL=1MI[D-M$:.I8\@=
MY)Y(Z#C/MBOY,? WQ_\ VA?B%\7O$'AK3[K7)[$>(=4MT$33[55-2:! "@!
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MG''UXQ0!Y?X9T[3-2NG:\T^*:?G=<MOW-PQYPV,YR>G4_EWG_"+Z%_T#XO\
MQ[_&N*\)WDBZW/I\:*;6,$K(%!8\2#E^2?N@]?QKU2@#G#X3\/ES(=-AWE=A
M/S?=Z8Z^G%,'@[PX$:,:9!L9MQ'S<MG.>OJ3^9KIJ* .;/A'P\9%D_LV'>@P
MI^;@#IW]A^0II\'^'"KH=,@VNVYA\W)_/Z_G7344 <W_ ,(CX>S&?[-AS$,(
M?FX_7\?K3H?"?A^"0RQ:="CL<EANY/Y__J[5T5% $,-O#;C;"@0>@J:FMGH.
M_?T_S_GG%.' Q4*3<W%+2*U?F[-)=U9ZOOH A.,>Y KE-6\3^&]'GVW^HVUI
M/G!$CHK?>P1\Q!R3D?4D>U=97\QG_!0O]HSXBZ!^T!>>!_#6JZC;Q#4(H8H;
M2:1-Q?59H57$9!.0BJ/_ *U>ME&72S+%2H^T<+0YXV@I6Y;)I^N]^EM#EQ5>
M-&$7--PG+EE9V:7D?T:GXB^")KA;,ZW9R7&5Q'YL9;+<#C>3R1^E='=>(=&L
M+)+^YO88;-RJI*S*$)(!4 YQT([U_-1X$\"?M%:AXXT+Q!?3^*!9WLND2RJ;
MG4/)\AMCLQC+[!E),DX'')Z&OMG_ (*&?$GQ;\'?V9_"MQI%_>V^J7-_IMLT
MJ2N)GN)(;1=A;[Y)DDQC/4\Y[>M'AUU,;0P4,7"HJLH^]%II)I<SLKZK:W?8
MXI9HZ<;SI2L[)+JV[6[Z=6WMZ'ZPM\0?!\I$0UBT=F(POFQ]<X_OCGG]:Z>.
M\MKZV$MI*LD> 0R$$8P>,\^GZ#VK^1SX8>._VH/$OA^X\:,_B*2VL<W:N#=F
M)K>-I9=Q .TCRX<\CD>W7]?/^"?G[6>K_%S1+[1=>O1-J5A/)9.DBQB026UU
M=6S@_*'W H >?;G'/?F?!KPN!JUHXJ%:5"7[ZB]'%6BW?5VE;5*W0<,R510C
M.+IJJY1B[ZWM&S6RUVNNQ^K%CK=C=SO ERAE@8QM&""=P/.><YZ CCDGZ5FR
M>.?"]K=2VL^L6RSHV&C:2,%3@'D;@?S]?Q/XO?#']J'QMJ/[7.O?#.2YF?3?
M[;O((H2H*[!=VD2A3MS_ ,MCC![YKP#]IQOC]X1\;>)O$^E3>($T:*Y:7<DM
MWY")Y*D8&?+ )7],<]:RJ<+JGBL/A9XB-'ZQA:5:ES*WO3BFH=':^G,M-?(F
M&,TM"$JDHU''F;:B]$G)[K:^B[7?4_H5N_'OA5XI-FMVRE5ZK(A(/7^\?\]:
MU;+6-(OK&.]CO(IH8(]\DVY2%'3)()Q]X?G[U_'1\$?VB/VB_BKXQ\0>';>]
MUZY33[LV^V-KDE?DMCCY""/]=T/KZXS^]$.K^.OAM^S!XQ\0:O/?QZI9^'4F
M>2Y>4R1RFXMD)!D.5(!/IQTKFQ?#U3"*G%5X>VE*RB_=O!M1;7=MW^0HXY3E
M/FB_9MI.SO\ O(VLU:WI;_@GZA:?K&GZI$T]A/'<(.C1D-GH.Q/KZ\_K4MYJ
M-K8P">\E2&,G!9S@8[GDC\#^-?E[_P $P/BYXC^+GPQDUO7KN>[4^;Y4LQ+E
MMKP\;L=MQ[G'X5Z5_P %$_BKKWPH^$-MK?AZ:2"YGO'A9XA\VW=$/3C[Y_.O
M-P^4^US2GEB?+4JSY7-JUI<CEJM+O3KJ=:Q,GAY8B5E&,7[EDV_>5GZ_9?2]
M]#[WAO;6\M/M=I,LD 4N'0@K@#=ZXZ=>>G>N5D\>^%1,]M>:E:Q2PD[D:1=R
ME>N06_V>?\BOC3]C[XH>(/&?[*TWC/5Y99KZ+0]0NQ-("7WPZ-#<J<D?WR2.
MIYK\$[?X^_'WXM?&+QCIOA>[UFY@MKW48(XK0S[%6&>^5=JPD*#MB[>GI7HX
M+A^>(GF%.5:,'@*D5*H]%:7-=MVT=XK1^AE/$M1HU::M[2+YJ3VDHV7NW[<V
MRZ/YG]8VD^+/#^LW;6NEWEO=%8SN\MU8@#.1@,>.N?:K[:UI-I?)IIN(H[J;
M++%E=[8P3QD?WO0]?>OQU_81L_C1IFNZS=^/%U?R4LKIXOM_VIEW@7!4?OMP
MZ[<#_ 5R/Q+_ &E?&6G?MI>#O D=[<1VMX95-JO$;J/[-'*<@X$AS]?2LZ'#
MM7$?694ZM.4,-2]I.497;=KIK1WV:?IH:8?%.2ESPY%S:65DHNVCZ75]7?KJ
M?NIU'!X(X(]^AK&U+7--T<;;VYCB=N0KD#((],YJQI,[3:5I\\GWY;.WD;/!
MW/$K'\<GFOQG_P""F'[07B?X1>+M"LM#OI[:.YTV&5EB;:"Q"'./4YKYZCA/
MK&(C!+W_ 'H)N[5KVEIMMOY'H*4=;RMI?36[^S?R;ZG[16MS%=P1W$+AXY!E
M64Y&,D?TK*UGQ#HNBA(]6O(;83\()65=V<_WB/[IQC/2O"OV;O&>I^*/A#X/
M\0:HS,U[IC322N#DD32*,GZ#_'DU^)G_  5T_:O^(?PWU[P;8^"M0O+823VZ
M.MGE=^Y=1SNV#G.U>OI7O95PYB<SQSPD7&-.'+[6I'WTHR:5DDK-ZV:TL<F(
MQ=+#Q4IOWI:173FZ7>EDW;4_HYL[FUO+:*6T=9+=T!C9,%2O8C'^?PJMJ.KV
M&D(C7MPD/F?=+L!N/XD>_P#^OK\4_L(?&*Y^*?P6\(7FI79N=9CT*%]2WL#*
MLX\LOO7J#^\'!_PQX!_P4_\ CSK?P5TCX?W6C7TMG+JDUTK^6VW?L,X ([_=
MQ^'3.,<..R:K@<SJX"27M:4_9J5FKP:YE*UM'RKMMIL2L7"5+VD4V^5-JW:4
M5.W>UW]Q^KUC>PZA;K<V[AXWZ,O(Z \=1WJT5R "3QWKX]_8@^(NJ?$SX!^&
M_%>JRM-=WAC\R1\9(-C9R\\#O(2>GJ,"OL,$$9%>96H)2E&?O6YH/=)V?57M
M>ZNCIA4C*SB^BDKJVCU3_P _,8"%9AG  S[#CD_H<_2N7U'QGX;TR\%C?ZC;
MP3[-^QY%#8]>6'^>>U:&O7+6.D:M>1G#VVGW4ZGK@QPR.#CIU'Z5_,=\=/CU
M\8?'G[66I^!/"M[JK6-EH=U.D-D\RKYL,I53MAQUV$9Z_P J]7)<FECY58JK
MRPI^^Y6MRJ6J25]HVLK=^APXS&2H**4(RE*32C=/GY6E972U>[[=[Z'],MIX
MJ\.:Q*+*TU"WN)7&5C1U)..F,,>_%6+G5[?3I-EXRQVXZR-P%QS[8PN?P7TK
M^8;1?VC/CI\ ?'.B:IXMGU2WL6U&SLV%^)6B*7=S!&,K<;EY23C@GHPK]5_V
MQ_CYXB\*_LWGQ_H,K1W-SI%K>>?"B[A)<Z/-<\$+Q\RYP!CC';CV9<+5Z=6C
M#GIU:&*IR<:O-:*<;>3N];I+=Z;'GXC-XP:]R2G!^]!)M.$E'G3Z7BK:/^;=
M=?T%'Q"\*-(RIK%KNC8H8Q(G&/\ @6<YXZ=3SUK9?6K=;&2_LG2Z!P1M.5()
M_P!D^W<_TS_)K\.OB!^U-XR\)ZIXYTK_ (2*[+W;3VQ074D;18D<$*,IMS&!
MTQP>,<U^F_\ P3P_; \5_$_Q#K7PV\>S_P#$VTN9+7[-<Q1I+O)A<A@8PV0L
MOX=>E7B>&98:C6G"M"K+#P]I5HK22IQLY)I7:LKOIOTW,</FJJU:7/"<74G^
MZ]VZO)I76NS5HOMN?M%!>6T5JMY+L@\Q2S=L8.._KM_2N9NOB!X*AE$=UK%F
MDL9QM>2,$'GCEOK^=?G!^WK^UK>?!:VT_0_#U['%J>J1I!:P((F=YI/M1554
MJ6S^Y[<]:_%Z+6OVP?B#?W7B Q>*(["[D-S:M M]%$T9P%*A-J$<GH .*\W^
MQ)+"T\35J>R]L_<@U9ZM-)7M?W7<]J6,BH\\$YZ\O*M;26KNUM977XG];2:_
MI]_ILVH:5/'>($W!HB'#<CNI([YX//ZU%9:[!_9D5[J!2VWM@!\@9VJ>YYZ]
M,^_2OPP_8<_:Y\6Z1XOO_@]\3;V1-2LI([:*WU$+Y[LZ!F!,X,C?ZMCR3T/H
M:^N?^"E'QK\2?!;X:>"]7\).]O)K'B*&RF-O&.(93"3P%..&]/3'%;4^&JDL
MTR_ N=ECXITJZWLX<TE:W\U]GJM;]%$<5"I%UHMI1BXN+6EW)-M:ZVVN]+O7
MH?I=!=6]Y"EQ;R+)&Q&'7D'.T]N.<C/USSUJ61UA\R:1R(T0LV<8"A<DD_3^
M0P.M?+7['OB_5/'_ ,$- \0ZQ+))>W(B9VD)W'-E:2')!S]YB?\ ]9KO_CIX
MIU#PE\.O$FM6#$36VB:I+N )*>3;,0P_ND>O&,9%>)_8\H9OB,'"WM'B%15[
MQC*<+IMI:)[W=M=+FTJ[E"D^6^BJ1;DXKET4KJW2ZLM=&^B/6=.UK3]425[.
MX280NR2%"#M9"00<$\C!K%O_ !KX:TVZ$%]JUM;3<_NWD0'C!/!8'H?IS^?Y
M._\ !//]H+Q%\4](^*$NH7TUXNCZSXEBC>1MYC:TEU':@/.-OE# ]J_-K]J#
MX_\ Q:U[]IRU\!>$]4U82W,U_#%9V<TRAU06: B.)AG <]CC/K7V>7\$UL94
MS&#Q"IK 4:4ZLK<RO53DEIT]UWE^1SXO&>QC2GRWC*5VK\NL;-/T\OZ7]0=I
M\0?"-])Y5KK-I-(>-J2H3G.W& Y[UI:AXHT/23&=0U&&W$R>9'YCJH*'D'EO
M3T]O6OY_OV=_ _QTM?$]A<>*+GQ(MA))%+*;FXO]@WW*,1^]? ^4MW]CVS6_
MX*A?'OQ[\,O&'@'PAX/U/4(K^^\*6TWD6TK^9*[I$N]E7+,2T@P><Y KP8\.
MSK8VEA%54Y7J-2I-RC>G%.S::NM>VG<TACDZ52<HN,HQORO2ZTLNNMW\S]]E
M^(O@]FVKK5J3G'$D?;_@?TK?N-5L8[+^TC<H+14,GFY&PJ,C.<_J.G\OY;_A
MY#^TOJVGZ'X@O7\3?9;P)+([27P3 DQV( Z$?F,5^M'[0/Q.\4_#;]D;5M92
M>XBUZT\)7$\3MDSF<32[<EOF)PO'K@UTPX<J3QE#"T:T:LJM7V3MT:2<EUUB
MKM['/7Q_+!J4.5J$92=](MM.+OU6WE=M:GZ%6WCKPM*K2+J]L1C)_>1_+T[[
MO:MJ*\M]7BAO-.NQ+ "3NB(96[<X)Z9'3\Z_DC^&7Q=_:E\4^"H_$>G_ /"0
M7,&H62W+2HMRX"L4&X$?*O4<KZU^E?\ P3__ &OO'7B'5=8^&7CRXD&HZ$8X
MHX[N-!.6E6,D,TBB1CP3ST KTLSX*K8%5E2KQJSHI.<$N515E)J35^67+>RT
MOJRJ./IRA3C%3U3YIR6B?+=M;KXG:VWIL?M[=&+[/]HGPJ6^9&+= !C+?YX-
M<D_C+P[JDCZ;::O!]N (,,<B%P3D#@L2>5/;TQZUR?QE\6/X8^%'C'79)?L[
M6>@W5RDHPNW:J'*G'!&>O6OY4?A)^V7\2)?VGLW&O:E)X7O]8L[2W\RXD:U/
MF7UW&5 /R<AX^G;&.U<?#_"U7.*>+K4YJC.@[QNN93Y8ZWTZ;7Z;71T?6814
M7=MM+G;T>EE>U]+_ '']<YUG2_#%@BZUJ<47)/F3.BY#$8_N#^(8^OTS37XC
M^#&C++K=HZ9*D^8F/I]X_3_ZU?!W[9>@^./%WPXT*_\ !%QJ?VNYL;&=SI\U
MPC'S8M/E/_'NPZY;MT]LU_/[\8?BU\??A#KUCX3U#5/$%N^HS0K;B:XN_,:6
MXDCC109'+'+2*  <_P JYLGX:6:XM4%75.HH2D]+M05G/F6FL?PO?2P5,;2I
MM)J5W)13M:-W:VNVM]&?U\V?CCPK<L(=.U.UFE=AB-'0DDGT5L]3^IK5F\2:
M;!>PV4ES$LLRAE4L V"%]6_VO>OYZ_V/8OC[?>)-$U;Q4VO/97,,=VGVI[UH
MGAD(D5B')4@IMYY&.GI77?'?]J/X@^%_VM/!GP\MKFYCTZ\LXO.B5>"P.BH<
M\?\ 3PV>>YS75C>&/JM65&CB(8IQBY.4+=;)/2]G=/\ )'/B<>Z5-2C&\E[T
METM&UX^;=_R^?[Z7%_Y4!F10ZXR".<CKG_/6N/N?B7X)T^18+_6K.UNC]Z*2
M6-6#=2,%P?3C'Z5\L?M+?M(CX$_L\P^.OM,,>L_V2DJK,L3;BUG=2@E)589+
M1KV/IG%?S[>%=:_:'_:4\4W_ (P@O?$L>DRR&YM_L%Q>VUN5VHHVI;/''U!(
M 7'TYHRCA66;8+$8JO*&%HX>I%1J5%?VDN>,+6>D4G\,OYEWU,ZF/="4&W[5
MSBI.%E'V=TI;]^FWY']96G>)M!U*":XT>[@NR 3^Z96ST_ND\=/R&<=:T(M3
M@$)N))%50-TH)_U?('/?TY/J>M?RD_"K]LG]H_\ 9S^+-AX.^(4>H0>$]1U:
M.T2YU:V,@:TD6-B1/=HS=89 6#'!!YX-?T/^,O%J_P##/?B'XDZ1=NYU'0TU
M*UEC<E5$D\*@Q ?*N<?P@ =N2<<F99&LM=*#JQJQKSC"E5AJIMN,7%)=$W?F
M5]=.R'2QDL5+F@^5TH<SC>^EOBTT=W[MMK7ZGT18>*-'U>YGM["^BGEM2/,2
M-@2,]FP3CZ\=JUKO4(K.)9IB$0GYB> %&.>>W-?RO_L5?MX^.+S]I+Q'X-U[
M6;B:QU344M;6.Z<.ORHY(3S!\O\ J_X<?J:_HB_:'\57&@?!_P 8^(M.E9+K
M1O#MSJ6Y",Q^6B,'XZ8R>>!CTKGKY3/#UZ%&IK[2,I-M644M-?736V[L*CCW
M-5:B3=G9P>E[-+W?-?"MDUK;4]QL-?L]1NGM[66.4*,[D.>S$<@D'IZ5O5^1
MW_!._P"/FM_&!FFU.\>Z4@X9R"3BVE?J!SR/SY-?KAN&<9Y_S_G_ ":\O%8>
M6&J>SW?+&6SZK\G]^OH>CAZJJT^?FOS2:U5K/^7SMY;[]Q.'4@C*G*D'N#_]
M:L>X\.Z-=HT=Q8Q2([;F4[L%NN3@]<\_6MD#'2EKCASJ$>?65O>]3<YO_A$/
M#N]9/[-AWH-JGYL@#&._L/R%-/@_PX5=#ID&UVW,/FY/Y_7\ZZ:BK YO_A$?
M#V8S_9L.8AA#\W'Z_C]::/!_AP>9C3(/WOW_ +W/Z^P_(5TU% ',GP?X</EY
MTR#]U]S[W'Z^Y_,T[_A$?#V9#_9L.91AS\W/Z_C]:Z2B@#F?^$/\.;%C_LR#
M8IRHYP#^=?%?Q3\46?ASQ;>Z9;:-"\46[!VR_P#/64=00.@%??5?GW\9KXQ>
M-[]/LT4F-WS-%&Q_UTO=@31:3TBWOJDM]NGW?D;4I:VE"52/2"<K)W6ME_5S
MWK]GB1[OPW//,09%E !'H99QW&>WK7T57S_^SY:K:>&+A%<N/-7D_P#76?\
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M&VGQRS9(,BO?W2D$G@_<]NI^E?>'Q6_X)^?!Y/ .L:_';V]OJ-AH-WJ$=V)
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MU;W@-%C\)Z.B_=6WP/\ OMJQ?BU_R(VK?2/^;5N>!O\ D5M)_P"N!_\ 0VH
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M7L;4Z-:K+$<D8R4I6EI:4U&:;46[/3=]+]3SS1;G6_A;_P $^I/[2DE:75O
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M?^"IWQ5TCP_\ O%7A*RN8+W7-5\.RVD*[@UP)Y/M!4*JMG=A./D[_B)O@+H
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MQ]W\/\__ *^:GKYU^3OIVV?;Y'<U:VM[I/9Z7Z!1112$%%%% !1110 5^?\
M\9+&XE\;W[I,J@[N,'_GO+[BOT K\]OC1)<#QQ?A+AD7Y_E^7C]_+ZBKIJ;E
M:&C];=5U];&E)5'*U-M2M?1VV\SWW]G!F;PK<EG9_P!Z.6.?^6MQ7T97S_\
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MV$FHRYXQ<I*R:;=M;W5[:VW_  .P****0!1110 4444 %%%% !1110 4444
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MMR3O)):1LU;R3O9W[Z+0_GYT?X":_;_\%!=/\:/9W2Z>]T\S7)\[8-VHZ8^
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M^#-*\3VRP^(+:*\\JX\Z$F.-BI5@5^^KD8VKR".<XK5MM L]+L%L=.3R8E*
M* HPJ9P!M"CC/I_A6V89S_:5"A0J\T91]G&;O>+4+)._5VUU^\Z,+0J4ES2G
M*VO+3=M$]KONM?O.@!R 1T(R/QI:9&I2-%/55 /Y4^OG7N_4[0HHHI %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"I?G%E=$C($$O!Z'Y#7F_@9UD
MGNRL8B N9<@9Y_>N,G/YUZ3?$BSNB!DB"7 QG^ ]J\W\$.\EQ=&10A%S*  N
MW_EJX].>.: /4J*** /-OBU_R(VK?2/^;5N>!O\ D5M)_P"N!_\ 0VK#^+7_
M "(VK?2/^;5N>!O^16TG_K@?_0VH ZVBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJ/_'G-_NG_
M -!-7JHZC_QYS?[I_P#030!YA\/?^0MK?_75O_08:]=KR+X>_P#(6UO_ *ZM
M_P"@PUZ[0 50U3_D'7G_ %P?^57ZH:I_R#KS_K@_\J /)O!$J_V_<1^4NX#F
M7G<>)/\ /U_.O:*\9\$22_V[<1[!Y8'#[>3Q)_%W_P#KYZ5[-0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?G_ /&2_MX?&U^CVHD8;OF(/_/:7T(K] *_/7XT173>.-0,<.Y?
MFYV@_P#+:7U%5'E;]YM+NE?JNGI<N"BW:<G%=TK_ ('T/^SS:-:>%[A&<.3*
M.0,?\M;C_P"O7T'7SM^SG-++X6N3*Y<^:O)_ZZW _I7T34D!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!5O=QL[H*<-Y$N#Z'8<5YSX*6=;FZ^T,'8W,NTCL/-?CJ>W%>C7P+6=T
M =I,$HSZ?(>:\X\$QM%<70:7SBUS*0<@[?WKG' _"@#U&BBB@#S;XM?\B-JW
MTC_FU;G@;_D5M)_ZX'_T-JP_BU_R(VK?2/\ FU;G@;_D5M)_ZX'_ -#:@#K:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *ZW'N:^C:D@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** *E_@V5T&)"_9Y<D=0-AZ5YMX&6)9[OR
M7=U-U+N+YR#YK],D\9XKTF_Q]BNMP)7R)<@=<;#7F_@8Q&>[,*LJ_:9<ACG)
M\U\XXXYYH ]3HHHH \V^+7_(C:M](_YM6YX&_P"16TG_ *X'_P!#:L/XM?\
M(C:M](_YM6YX&_Y%;2?^N!_]#:@#K:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.H_\><W^Z?\
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M'_72<>IKZ!KYY_9VMI;;PO<K+MSYH^Z<C_6W!_K7T-4D!1110 4444 %%%%
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M+KR"BBB@84444 5[J8P0M*%+%<<#J?\ /\J?%(9(ED(()&<'_/Y^AJ0@,,$
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MM6^D?\VK<\#?\BMI/_7 _P#H;4 =;1110 4444 %%%% !1110 4444 %%%%
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M)RNK23NEU?K?N!6MKAI_-RI7RY"H]QZ_X'OS5JD"A<X &3DX'4^M+4 %%%%
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MLVY5*<5+=2:YDX)2T]=4WL85,6J>LHMIW46K-/16Z]9-I'^AI_:5A_S]P?\
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MBU%_P^W_ &=-I;[+#P<8_MR'W_Z=/;_/?_)*O/VC/C5'-E/B)JA#9.=MOP"
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M%<4,'[3GY:4G:RMSK?3SVOU[-]BXTYS4'!77V[Z7U6L4[.UNNB_ _P!;V/\
MX+@?LYR1)*+2+#9_YCD/;_MUIQ_X+??LYCG[)%_X/(?_ )$K_(\_X:*^-B!(
MT\?:KM';%O\ +GZP_P ATJ.7]HWXWHVT>/-5(Z [;?D_7R1_+BN>I@JZYG&F
MU%65VXNSY5O9OKZZZ;W"5.<6VXOE4K+YVLF]5?6SM>ST9_KCK_P6^_9S;:!:
M1?,<#_B>0_\ R)4TG_!;C]G2-RGV6(X /_(<A[_]NG^%?Y'9_:(^-2012?\
M"P-4$A8 IBW!4<<_ZG&.3W(X]*G'[1/QIEN)%;XBZI@1@JY$'S';]WB#CD8K
M&E0JN5-RIRE&TN=6:OR\J;5[62;[]5<R=U+>R5TXO>[:Y>E]K]MS_6[_ .'W
M7[.GEF3[+%@9X_MR'M[_ &3^E4HO^"XO[.4DWDK91 X)_P"0Y#CCOQ:?T-?Y
M)*_M%?&YOW1\?ZJH+X/%ORN<9 \GO]/7\9;CX_\ QFMID,7Q!U-RZY) @X+
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MO)9%P -RV^AN>YSW^G6O]5[Q(0/#^M$C(&F7F?IY#U_E5?\ !S@EO+^UM!+
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MY.2.BDGW5KV\WN_PZGI8>K)3E"7+>G",4^^VOJ[V]=]S^TC_ (,_H8YOB?\
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MC!_/\/SKVBO%_!#0?V_<KL;S@/F?/RGB7&!^?X?E7M% !1110 4444 %%%%
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MV0(1*. <_P#+6X_^O7T'4D!1110 4444 %%%% !1110!B>)03X>UH 9)TR]
M'_;N]?Y3_P#P<QF2U_;"MTF3$;+J/R-T(-GHO)XYZ^O:O]6#Q*7'A_6O+&7_
M +,O=@/&6\A\#H>IXZ5_E3_\'-0EE_:VA-^GEW@&H>2JDLK1_9-&PQ;C'R;3
MT.><UW8&'ONK-7HP5JCM>W-:WS>MO1D3:MKO>ZOW77Y'\UD$:BZBECXC RS#
MH#D<8/XY[5Z!!+;NT+-"NX(!L.<R<CYLY.<_GU[<5Y\@>&(8'[K:-S9.X'&2
M ,?7'/L:ZG3[E)H1(3BXBPL:9&&49())!/7';T]*_>^!<5E/(Z,TF^:-W)+G
M47R[KJETO?L>*\)7KQ57F4J:C*$4VK-;\\E?W6]D]'I='275E&8'=8P^_G=G
M'D8_+KQGKG'48X\YO4"W*YA^X_0_\M.O7!S@YY/!X]:ZBYUN=87MK=0[/Q+D
MX"GC&,#D'\,URTPOKF>+,:ARPV L>O/?;[GU[>O/I<48[(8SG2I04]E'E3O4
MDHK=K5.^B76R6NQC1HU(-3TE*-XRE*5DO=7)'LTE9+?OKN=SH]U;16\BO&,N
MN,<GRONY[CWQUZ^O)YS5[>&9VDP!L.5/3SN,8[],Y_G77>$-!_M&WU)IV"-;
M ^:,9"G]WTSZY'7'MTQ7&ZZKQ7:VT.&BC8^4Q."_+9R!D CJ,$GIZ\<N,Q^!
MQO#5#+*4/95DW.#47&:]QW@[Z7O*]GJVM-3:E/FJ5))WDHJ,HMZ)OEU33VZ7
M6USDE!:X8>3MW C:."N<\]> !TY/'Z])"\R6R0I&Q48.\#AN!QUSSCG..O7-
M4Q87(D:9U4<$L >B]3CW^HY]>:LPZDJ#RBORC&"?7&![X_E7R>6Y;+ 8*;JJ
M-YQ;2=GH[)OYO67\NRL>C[:$</3DXJ4J4K2BM7RVV3WDK[N_33<9)"V5F$9
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MI-K1JI9WO?\ >S5[;+M96[V[_0P=X_=MJK\L;A1117$6%%%% !1110 4444
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M##7KM !5#5/^0=>?]<'_ )5?JAJG_(.O/^N#_P J /)_ [YUVX7[/C"G]_\
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M]8?46[D?KUK_ "[/^#C31[/Q;^U%)-<310:C NIB%I'1%VQVFE#&UV4DG8H
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MOZ[6Z'F2CR746[JZ7N^GV7JKW]U:\KN^J+-GYD4A8.N[=\IX( )Q@G/7U_\
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M5M'NT[]>5DUJ[5./+#G<VOW=[2222YF^MG;?6R;5SP!+9FF6$D* <(#@%?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!5OMWV.ZVG#>1+@GH#L-><>"1,+BZ\YUD;[3+M*G( \U^#@GG'
MZUZ-?C-E= G:#!+R>@^0UYOX&18Y[L+()0;F4DC/'[US@Y_*@#U.BBB@#S;X
MM?\ (C:M](_YM6YX&_Y%;2?^N!_]#:L/XM?\B-JWTC_FU;G@;_D5M)_ZX'_T
M-J .MHHHH **** "BBB@ HHHH KW0<PN$(5L'!/ '!KX:^,)N(=067!\E')E
M'.7^7C;^G0&ON6Z4-"P+!1ZGZ'_]=?)GQ;TV&[DB&Y589P.?GX//X?R^E?&<
M7-*E2;NDN9][VCIIU:=GOZ:GVG!=_P"T$E=Z^]96?+9WO*VMU?2^E]$>*:?=
M_P"C*\Q7.T^3_L'_ &O;GIQ].M."SW"2-'(@SRXR#N/?;EN_4@5@W*R1%;6,
M'!^0MT"\9R>.W';/-=79V/V>*WWR#E>A/W\@G(SU)YZ>F>>*_&<1%<SNDWSN
M2BY72@]+[VOS=]5Y']%T53^JI6E",U%1^VWRJ+:5MEI\M[:E>R$MC#(S8+2C
MY!@93H3N'/7GT[?6LFY-Q<D(2"Q;]Z<<,G?;@\D_4_J*Z&\V*9@ISN'S '_5
M]>?3\B<?G533K/S) Q.4!R& X;CI]2#TXX[$],^9VD^5<T)P47HU[T;MN*L^
MMTV52Y(?O4[1Y7S.4DVTK6@EW6BNKW2T[DMK$EO;HC_ZK(")GYP<  GO@''4
M#OSUK53<(@#)&&Z$D\%3T'?/\_7TK'N(6-XVPD+C[H_AY)]?3J?Z55O&$1VF
M<*!R""0"1@XZ9XZ?6NF"Y/9)N4G.4I+7WF].6SZ73;[::6%5I.O2E]F4DY<L
M>D;QMJMG)/7^?3L=($4<[E95^;:#D[O7Z9_^L:I75]+<DVL;+YQ!5&'W0H&,
M'MGZGMVYJMI:FXS(TF-P\K9ST(P6^G(((S6DFDQ02?-,IW'?ORQ [[3]<D>V
M/6L\1648PC&\THJ6J>C6L_>>EE]E?=N>/4IPHSYX)NRFUTO!\MW>UE;HE9/H
M<M)HUV'+R/NM\Y=0.2<\D8/3&>@/U!XJY=VENMJ$.T38'EL<%57:>",#G.,\
MCIR.]=(7B1A$7Y.1MX.[MGK[C /\ZP=6L,VLDK2[%W9#$GY>.!QR.G3VY]G3
MKN$:<)6O=2G*+Y9:6M*R=]'O;RVW/9PE9KV:<N5Q<>1J]Y;6AVLG?FZ23MJ0
MV,<-MLW@,K??QCGW''TSQ[UJS%0FY\.I'[H _<ZYWXS[GD#KV%9NGP+/"JF0
M%E'RG^\,CI]._/Z5H%!&K1;O,W<,W:/H>?Q].F372L1"49J-V^:\;/D<K)2=
MV_.]U\]3:LU*K>3DYJSG'79\K3B^CV7=KW5V.,U729KF:*6U*JN[=,,#YNN<
M<@\\<\XK8TV&:W*QEAA3\GMP,DYY_/'KZUKR62)&&$@8D?(!G+?GU^I_6JXA
M.(R#M+']X.?D'4;AC'Y&HEBX\T;M148Z*UFW*S4I=7[WNZKK<V5:$J;@N6VL
M4Y0][I?72^UO_)>I,\TD,Y+L#N^63&,%>X'7N>.M8ES"+B[)+*;8'*1Y^<$'
M//.<=.P[U>O(F4\'<@.0PZ,<_GS[\=#6;! PG:X+'#9&SG(///IGG\^:SJ5V
MXI\SBY4[:-INKS1;TZ;63U3WV(I*+DK1UY(ZI64E9:M6]V2Z7U2OH:L4;390
M$+M&<Y'( Z=?\^QI?M2PH\$K;D((11C=YF,!L<\ ^W;&<U 9/+_B"@]_7VZ>
MO K.FAW723;\@E04[\\;NPZ>Q^@I>U:NI2DE))0DI;2IVO!M;K6S?7Y!64O9
MR?33D2CJI*VSW;[)*Z1(5NEM92SJ'9B4)P (_F..O7'J??VJMICH;E9%*BW7
MB5.-S-N!)&<''WCT/45KW]JLEOY*.!N4'(SC.WISSGG!'ZUR-BDL-^D;EAR?
ME(/3(R<].>,]\FMJTFZ:J0G&Z47&+LNGO3\W_*].ZV*C:<4WS6DE=[.VE_-/
M3O=;]3NIDE>=?+= 67,1.,*G& 3D<YZ\CZ5D)O2YD60C.1N_VN,Y7GG\,UIH
M(GD14F4C'S,,_(V1P>.H_'_'/GMP;I) XQ&3Q_?SW^GI]*X:;DG)?"_>E[VN
MT$VGKJI)6MUVT,O9QE.G/FTA&*LERW][1W[M[K?J<+XSCN"L>P@G'[LKC"'Y
ML;^2/7J1_4/^'5Y<WNLVL&]5-M+ME+8P^%&=F3[\8W=_K6UK-M%/!+&T@_>+
MC=S^[SSD]3GCMS6!\/;6.+Q#&HF4>5.P!.3YORCD8'.<GKCZ5]%E<KUX7CTC
M>*6D4TG>^VOPV^74[,VE%9+5B]9<LE%6<;:7<ETOT?5[K2Y^H/A)6728,D;-
M@VKW&0IY_P#U=?6NIKE/"(']E0MNY*C*_P!WY4_R?>NKK]NRUIX+#M*R=.+2
M[)K\/3IL?QUF?^_XOO[:=].M_P ?7J%%%%=QPA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5'4?\ CSF_W3_Z":O51U'_ (\YO]T_^@F@#S#X>_\ (6UO
M_KJW_H,->NUY%\/?^0MK?_75O_08:]=H *H:I_R#KS_K@_\ *K]4-4_Y!UY_
MUP?^5 'E/@=9_P"V[AC(AA*_*@QN'$G7DGICZ?K7LM>+^"(E_M^XD\U=Q',7
M.X<2?Y^OY5[10 4444 %%%% !1110 4444 %?Y<O_!T-=3']JCQC$2NQ;NY*
M\$\_\)'=GG\A_*O]1JO\MK_@Z"EB'[6/C2/>-YN;D%<X(!\27G/0^OO75A)*
M,IMR4?<T;MOS*RL]P:OT;[VZ+J[]/Z74_E8AO)A(O0N0@8X."I X'/7&>_MS
M73^8#9[F'[IN-F#O\P_Q=,[<]\=.]<S;)!'<>5YHPH5MW)!XS@<#G@ ^QKI$
M>%[=I-X^560(>I/(W].AQGU]:_3,EQ=:6'J.E+EJ>R223O%722;C?WFK;Z6^
M\57DEK!2=H6ERMQLER\L;]7OJM6E;S7'WAFM[G=D,2>,'. <=<$\CIVYKI=%
MANKI,$;D)Y4#+?>/3OCGT]^O%<X8FN+G ^8&0X.<]6^OX>G%>T>$-$:"-;B9
M1D8PGKSD8Z>GY5]UX>9)+%9XYYC4>)4$Y7>CDV[\M]>;S:V^X>$P;Q515.1^
M[]I]'I9RO:]NBZ^1,BK;VBV<CQB:1-R'@! 1C#<D9^8=2,>G%>4ZS*T4LT2E
M2&8;R.<^XY]_?UYKM?%+&UO&,<NX$$X4GY. =OX?3J*X)K>6\9B@WN>W<_S_
M !YYXK].XXH86OAI8/#X.#J1A%*I3BG)<MGT3;44KRWOMZ\^)J5/:^Q5ER.2
M<;--J+3OY7Z)7[^9N>#O-M[^&4.@/F90GHI]_F]1W]N>M:?CG7GOK@1!E+1O
MME(/#'GE>W_CQ'!K T.*6&27<2K*?KM/R\^@X_GBL;5G\RZD)<DJY[G+<GMS
M_3/3FOYYK87&Y7D>8<]2:4\1=Q<K-1YM%OHG>ZNO+:S/1P&:5HTY8)2TJ<LI
M-:2DTTM'I:T%9[7?3<J&9^%!X3IUX_E]*3SGR6_O<=^GMS^5.-N3")4Y+@^8
M.,IZ9[<^Q-,MHTE+QEAE 2N<_,W8#ODXZFOS[ZQ4G>;E-)IZW=[)Q2M'I'LO
M3Y=?UE*+?,[1E:W]Y>ZM+?RW?E:VX]6<\$_*.@[CC//.<=SP/\'"-W'RD YY
M^GT)_P _C4+!H6^?(=N-G?![^@ZUHVL*N,%L*!G)Z'@]/R_^MZ?291A/K,J;
ME3E._NNTK<S?*TY2[1L]UIZLES]H^12NVKWYM5'1QMV3[6T^8L?F%5C7 &X$
M$C^(=^O3CU%2W,MU;2(S2(SA/E(YP,#@X8CL/I[9XTHK(/;-*C!I V-H/S!?
M[W( QQ[_ $KG[L'<5+Y()SGL>X/7OQWY'KT^ZP^5K PE4IN4)5(S5:*GR\TF
MDE9KX4M;;J.]M3R<:^91:2LI/IK=N*^?G;R%>[O+D&+.Y3SM7.?R! ]1^/X5
MU6DF1U1&*I<#[C-PH'^UD]<@?Q?SXH:':12LLFY2PX\L@Y;YB/0?W1GGO6W-
M9QPW:JLRH'7+$;L(3M^4\=<'C'I[5[V29.J:GCDYS48N4I.=][6E'LNR\CEH
MM3DT^:/+R\K6FM]4^]UOVON:S:FB6ES"[*57"S $Y8]MG/89SUZ_6N )_P!,
M$L6!EU*$]!CU^[W_ ,FB_F\J1T20L,]!GYNW'3U]?ZU0\]% ;=ANOOG]?\FO
MF,^S/!XC&2YG"7L?9N_-K=27NM:MW73HW='LT%**M+1<R=GHI:1O9Z+FW5OF
MKHZ6YD@D0,FT,H_T@$CYSWV@_P# >F?TQ7.74J2%47"QC_5+W'U_+C@=JLK'
MOB:1W"<94$\OTQ@ ?S[C'O4*6(F\N0.!D_O >J #OQ@_AG_'XW&3PV(QCJ1B
ME2Q%2,&E*ZBG%).U_BTM??6^QB[0J5)*TW!I032LDTI-N6J;2NEVW*D-M.LF
M[&<C!;'!&>@Y/X8_EBM:*1HG7^%000IR&'YD=._%;=C!;RNML7'[O#!CG#L!
MTZ;L\9Y]>QXK'UU$MIG='7<<C8,Y7YOI[GCU&?>OJ*51Y!E_M\/S1E4=H*_,
MI62UM:_KIJ]>AE&7,X2G&U.3D[R=VF[./K&VO172VLBY<73S.T:2)]H"?.V?
ME*8Z#D<X!Z?3':J5O="))HI5Q&5;Y>AWX//?@GV[UBV.9IV>279CG))YP"<?
MR'XUJ791HC,A&X93R^Y XW#H,'&>,FOF\/FN,GBJM:I*:52G).4G\',KOD>F
MG16O9?(FG&,[\ZO&4H\THI\R>G+9I7MOHM'H?UE_\&J1S^V;X&('!%^0?8W;
M\?I7^G[7^8'_ ,&IS_\ &8_@52.2+X_^3<O]3_/%?Z?E?&XR3E5YF[MIN][W
MUW*Y5%))W[JUN5V6@4445Q@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?GU\9KJ[C\;Z@L;QA?F^]C/^OE_VA_GZU^@M?G_\9+"WF\;7[O="-CN^4D_\
M]I?0&JBXI^\FUV3MU77TN7!Q3]^+DNR=OQ/H#]GQ+9/#%P+9BR^:.3_UTG]S
M7T!7SG^S@K+X5N0RLI\T<,"#_K;CUKZ,J2 HHHH **** "BBB@ HHHH PO$_
M/AS7!ZZ5??\ I/)7^53_ ,'+*$?M6;7R8_\ B9'<?O BUT@C''0'W[ =^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG]/7I@>I?'#Q+HNJZN/[*&/W5NN JJ!CR\]"WOV^OK7E>D6L]U,RQX(6$O\
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MATQ=/)@O)@6MHU02HIRY;(SC()Z*W\/<9[5ZWX@UVWLAI.EV)C2UO+*.5E+
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M=K?6T=RBLBR#(5@01^8!_2OS+^ WPUL+SQUK<FCPPVD.FWTQE:-=HG 6'IM
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M<< CN#C [4](KF:";RV!W8+KU+?09'3&>A]>N<SAA#9_9B=[N-Q/)V'GY3D
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M:,%+!3M![#G([_Y%9[1OG Z@\'&>._T./\XKZ,U+X>?88%\QT!E(4#YL_-@
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MNJZOSL:4U-RM!VE;NE^+/H+]F\D^%;GDG]Z.O_76X]A7T;7@'[/L\$_AFX:
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M7CA@<#CIG&<=ZS+S4H(XA $;,AV* F2I/ / X'7G&,]ZX*=&3]Q*W+)4XO\
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MIH[;KYIG31Z9;MI<<!/^E!OG7'0':/8\\C\ <5TWA..QTR;;<OMC3#(V "S
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M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>C>#?@)XB\465U=6=JSQ1H7D<$#8,Q\GIQEL=/YUS^J_#.[\-W$MM=LL;1'
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M/PB^&,]];!+V:ZOY+7? !N!D5AM^<+T+_@./>O*+'[1I\=X^G-YBI9R,J[L
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MHV7[RS[_ +V>_:VUCV(Q<8Q[.*Y=;Z))!1117 ,**** "BBB@ HHHH ****
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M &RRN[4\"XMY8<XSCS$*]._7I7Q1>^$_ ?P+\8GXB>,;B.&UU^X_L:W>:*)
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M>_\ GG9L+]8HHX6!RLBR[N.QS@?A7*LTL*JA \T $KSC;@'(XSGKVQ1'<LQ
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M*$;Z4(W;=[OFF<\'=-]VPHHHKRBPHHHH **** "BBB@ HHHH **** "BBB@
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M(ZB-FRNT+Z'! /4?IGCL.@];^$OCG7/#>N2W8^T&T"A@JM@8"R\8+ <9 _\
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M?=.I*7X7L?I$FG&G;^7:UK:_U^04445PD!1110 4444 %%%% !1110 4444
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MRKE1DG?@#=@= #SG'I@U36:6-3&'VNQ+!\X"J23@MT!P<=>O'TA>Y0D2DY(
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M/R$C:A/(/S<[2!ZC\L_3?@@+1MYI^4 D,1C<?0#&?SXSBLZ.T\NX:=6X;.$
M/'7V]\?0<5,W"JGR)\ZBI*7\ST7*EON_^'5[Z4Z-GS*RF^6-6^L-4G:/16:Z
M7M:S\^AND5+5-[+Y@Y)R#Q\N!G/7'L?KS7.-#YUT'+HT2*,*&R=XY!P.>OX<
M58O^;?\ >3;,*V"2>>F!GU]_7'7OS^G-)]IW!B^6V;0?X<D;L<CWZYJJF%G.
MG%QNYQC>46]$M-%Z?-OS-Z-.R4>?FDY2E):148Z62_1;G1RRNVU,D,!A3Z*
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=1_X\YO]T_\
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M<,R+NQ&""02"<<9R.W/7BOAN'L'4H4WSR4G"I>$)7]I>+UE>[5E==--;L]'
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MOMUZ]?PZ+QQHMMX@$9MT66W+AH]@WC>3G/?/K^7.*\=\4:9#8^$_"=W:,@N
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M\_XT >I4444 >;?%K_D1M6^D?\VK<\#?\BMI/_7 _P#H;5A_%K_D1M6^D?\
M-JW/ W_(K:3_ -<#_P"AM0!UM%%% !59;:-9FG"C>W?OW_\ BC_GI9HH 0D
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M,[SU/MW_ !SGW[UTLND2W)$]O"[)*0JJJ'()YR0.@Y'/'7K75Z3X+N+Z-(A
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MP,UGB]8R>7Y70\KQP.>?Q'.??IVJE>7)=$E#?N"1L(SM!!['@=U/ZBK,,KS
M.G,V )#U^0#GI[9]_P"=>A3<6J>LIRO"[[63LI>45IV=]4=-.G#DYGRS;BKV
MD_W;?+:]MGNGV=DM]%U&=1&"B$JGSEATW ?=^I__ %4W2]06_C960QLC;0A
M!(4L-PZ]AWJ*\W&$B+_5\Y QCS<<_CNR/RKAHYK^WO  6#DDCL=F<GVP ?U[
M="8ARDU%62=IN5E:*A9Z-:V[=_RM47.E%0Y5RR;3<FVGHW=?S=7V5CO]1GC"
MF,<@<%O0@?\ U\'OQ^6%:P,]]'<JNY8P%\L?Q?,#G'0CC _R:HK++>3KLYA
MQ+[-D \]."#ZGKUZ5O6P=95$(PXQC'I_GIWZ40IQA-.,5%:+36[TWO=:;][N
MS-E#EI\JMR1@[W^U)V3N^D;=M2P][)/<Q68B9?,R-_:/'KW'^2.U5M6N%M8]
MLBE2@PIQ]\]>/_K]ACCO<MED%PTS](R?-)Z>P_G]:Y;Q1.UQ+%DY"$;.01U.
M/\X'^'4E!4J=E*-Y.,G;=\_-:/I?3;73R(A!*M&,(KV<8IO7X9-*Z75W5M'L
MM5J:6GW :%V*\2Y/./E^Z?PY]/6M."[:"()Y;%3GYAT;/I]/PZ<^E<FL[A;2
M.$\,!YO_ (]GH.N<?IVXKHK@3BU0+G.T^7C'4D9QW_SZURXB@I5H2<.5/1RE
MI)Z)*RM;?7U5EN:1H\L%"K'XZCDM7M]EKIIIIZ^IRNMQF6=[B(Y/),:]4&2=
MQ[8'L3R,8K:T^?S--BAQ\P_BQU^5>A_K[\XY-9WV6?:LA'[Z5MLQZ_)U/KW)
MXX]^O&W#:&"&,H"$S\H&<9XZ''TZ#VX[<:44E2UFI3;@FDKN.DU)K:+>W])[
M.*]V_N\K7(]4T[;:VO\ J-1)22"AW#.5]!@\^_3-!C(5I-O0'YNN2/X?7^G\
MZM-]J\UO+W>9M&_UVX/]*H2S2JK1DG!S]-Y^N><G_P#5VPC)PY8^[)--I7U2
M;5X-^>E^UD0JKT37PJES36UIJ[EKI9=.^M]1MI*98Y28RA4MP>K ;N>/\.]<
M)J;337!M@"$=R3+GY5Y'7OQDYZ]*[./[4+>0OGS<DITSM^8]OFZ8_"N-N#</
M> ("8-W[SJ1N^7KWSG/OTQ58R3]R4G34X25U%MN/PN]FO>?27-TM;<]? 6M4
MY7'FE;DB^\;.]M[:Z66K>KV.NLV9+"-=C-Y:!1Q]_K@@=_\ Z].B$D,L?R$B
M7DL!_J\8ZY]ASQ4<4LRVZQ9/FD Q^NS'09&>O\QZY$ZW!RA)&V/B;GOCC/'^
M'TK&B[N-.5U[12:D].9V]W;:TM=.GXYU(3?.H\J<I7E9MZ>[MY.6BZM^[ZYF
ML@3P2K)%MVJ=I./F[C'YX'3CUKG? ^Q=96",;]\I$C 9$6,=2<>P. <YK>UP
MW#6<[)G)3]QT[].?3KTY_&N/^'/VC^V9=F[=YK>?ZYPN<_I]WWKZ; 6M&+23
MA."YFVES66K\M-%LW:Y.8THRR3$2]U.-DDI-OWE&+Y4[W:W?9WZ'ZD^!8Q#H
M%G$IW*J<.!PV0N??BNSKBO .[_A';/.=NSY?3H,UVM?N&!_W/#?]>:=WW?*K
MM^;/XVS9<N9XZ*^SBJJUWTFUKY]^ST"BBBNL\X**** "BBB@"K+,Z3PQK&S*
M_P!YAT'^??\ 3K5JJ]Q=6]JF^>6*(=C)(B=>."Y'Z5+'(DJ+)&P9&&0RD,#]
M".#0!7@FDDEE5HV54)VL>AZ=._<_YZ+%,[SS1M&RJGW6/0_Y]OUZU0NM=TRR
MCN))[RUB\CEQ)-&C=1U#,#GG_/:"WU:+6=)>]TJ59?,7]V\+A\D$9P5)['CD
M]>* .@HK%TPW_P#9O^E;OM6#]_.<X'K[YS[?A6A9^=Y*^?\ ?[_Y_P \Y]J
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MBXM6M)JV_P V^K;ZG;DM_8SNM%7ER_9]WV<+/E>^F]O._4DHHHKYP]X****
M"BBB@#FO&5^VF^$O%-_&3YUAX;UR]C5 2Y>UTRZG3:!DEMR#: "2< #-?P,_
M%?\ :K^/7C_6/B'\1=(\:7?AU?"7CC6-'ATC4M2DTK4IXK;4[VW1K;3[N2"Z
MFB(T\%7BB*%9$(^^N?[U?'B/;^$_%VHJ&F^R^%/$,PMQ_P MC%I%VXC ) )?
M9L&>.1GI7^;[\:-,N?BQJ_Q1^*,MQ_P@\_AOX@Z[81^#+HE+K5UAU?4(Q=1+
M:^9;%9!8*X\R16Q<J2!EL '][O['GQ>CUC]F[X6>(?&VI1Z?-/X1TV74=5U>
M86MN\["4O(UU=%$;*J3NW\A23P*^B]6^,GPTTW2YM4_X3GPM+!%MR\>MZ?(O
MS$@8VSG/(Q]:_)WP)X5\4?'O_@GQ\// ?A:.?0M5D\&Z9 FH;_*&197T.[="
MS/\ >E5NF>/6OQQ_;O\ A9^T#^R+^R[XL^($VK:MJUMH LC/+:W$K8$DDS?\
MMI8^R8]_TH _LBT?Q%IFNZ3#JVF7EO?6T\7F1R6LJ3HZ[MN5,988SQW_ !Z5
MM0R>;&D@!&X9P1@U^1O_  2*^.&H_&G]GCPGJ.K?:C=KHLSS?:B"^Y;F-></
M)D_O/7'ZY_74   #H.E "T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 5;X$V=T <$P2X/3'R'OVKS?P0CQW%T
M)&#DW,I!#;O^6KG\..,5Z/?C-E= G:#!+R>@^0UYOX&18Y[L+()0;F4DC/'[
MUS@Y_*@#U.BBB@#S;XM?\B-JWTC_ )M6YX&_Y%;2?^N!_P#0VK#^+7_(C:M]
M(_YM6YX&_P"16TG_ *X'_P!#:@#K:*** "BBB@"E>132J@A?80P)^F03^@_S
MFK0#!%!/( R?IU_SW[]:?2,-RD=,@BE)<R<7>S[:,$ (/0YQUI:K6\!BW98G
M)_QZ_GT]:LTHN3O>-K.RUO=66OY_<5))2:B^9+9]RM=!FB95.UB#@].Q'7MR
M0>/3Z5\7?%I)&U*$AODC8B3GJ<$CZCG'?K7VG<QF6%T!P2#U^A']:^/OBI"L
M<S"5PLH;]TA/S2\')4#O@XYQ@#\OC^*N>%"\9)*7-?3XHN*3CONE=N5MNQ][
MP"XK,9)R2=HV76_-O_>2[='9W/'49VB(+  #Y>?N]<9S@#&<_AGO3K6V:]=2
M#D1$[CV;'<$=>O&,Y_*L:>Z2%1 '_P!< K,/^6?;GOQCD#Z]ZZK2?+M845G!
M#@!&[/TP1WR<$U^28C6E)MJ-TU**>\;K6*ZZK>WD?OTXM8=6O'1>[>_-=IZ+
MOULKZ/7J7;:)K>:;,@\KC8N?N_48R.?7'MU-.O(9;R-5A?/S?/@\,/0>OX],
M>AJ$V[&2X;S /. &"<E._/IZ=\YS5BT9+%(@[A@'&">C''3Z9]\?SKSZ,XM\
MEI.$'"R;UFN5:N^MXO1O_MTY%IM9R5VE=/5-=/O74Y?5H)K&%0W*L=JJ.2I)
M !V_P]1SC@@UH:8CBR6,G$H!9G)&"#@XW$^F>,Y]LUJ:[;^9$+Q,L7ZQ#&5&
M1\QS@=&/3/(^E06< EL%"O\ ,,L3R,_[.<=L$= .:[:;C&<->9SFG)I\J3^S
MY+K==]&=%.I!TTU=.4U[1V:4)IKW>5ZR2U3:M=ZK1:YP$AD\M3E=W('3.>3P
M"/;)^M-OM+>8JJ,!(0&WC& N 2-WY'%:=FB(TIDP9%5L(>NWG#<<>^138)?-
M66,DA=[?O#G"C+  D<CJ1TZUU1E3FW%RNT^5J^EEM%.Z3YMO+=HZ7.TIJFU9
M-.3UUE+ENXJ_V-[)>FQSOV5H+I"DBHBC#KD#<PP2??D$^_3O6NK%"&1@3V(/
M;W/;^?-<]JP$4GG"?#KP(P<%NG(_ #\"!UK8TI4EB4-(&$@#%CGY3TV__6'\
MJTA&$HRYI-3M>%E_+;M]W9'4E%4W)MMKXHVNN5VU[7WLNNQ9\QL,-WWOO#/)
M^F<9KD[^WE:X",=P=L*<YV9]><+^7OC-=1+"//#*XVQ=!V;.>@]!_*H;?33)
M)*Q?(<G)/2,8'^!Z?H>O31A:%[KFY&Y4ION[*<;VY6NW6R>S%+E7+*]HNTI.
MWP[*S75J*3\]NAG/8L/LNQE!CQOR1\WWOYY'TQQTJ[>W12,0;\,XPO)X/7/H
MO'TSGO5AX+=,>;<I'Y'"YR?,],?+GGG\JY75S)+=6PM,S+*Q\PID^5P>3D@?
MEGK^%<51\JC*4[ZM-O[-K6MK>[Z=[Z7-(<E1V4I3<8MVE>-M$XVD_P"ZK].V
M^W36-LY@VNX=U&XL"#D =CZ^W6M& ^7&'<C8QPHR#@]!QU&,C)..GUJE86_E
M0-&\@RBDACT;@<#WXX[5)($2W65I%&3]WD8QCGM_7H*X:R3E&4964N65N5WC
M96<GVO=:.U]UHC*W.W!M_%%)6=W=7LI:[]]4K6N++',9GVR $+N)W#D=0,YQ
MT[9]@#5#RC(&F+<#*8)&=WKCT_VNGOTJU"HN\D2@*!][GG@\<56(*R-'NY /
MR\\]@U<,Z<HM7D[1E&2]U^[)/WXN6S6W4S4*DJZM9Q2H\ZMHXI:M:O1=4[ZV
MO8S[F<P0/"SC>V2&ST7TSGK@XP>GZUSELCF_2<D^2I(9,]3D<A<Y.>>V#6UJ
M=C_HLDAD .<@DGL,X]/;!^OI63HLGGW"F0%-AP$;^+!QGI@]!U'?Z5TU5&53
MG45)1C.$US1[1::[O?5'N)TXT5.G)3DVU4BE[.6JBKQ=]+?RV>OD;TJ2,K(N
M1)(=T3$<*O89/3J.#CH?2H;:-H_,>4_*F-_ ^;Z#/S?KC\*T+@-)*L*H<$9+
M\ */0]^_ICY<UAZK?K:1%<X=, *#R^<G(]!]?>HHN-23O&_N\LE_+M:4;[Z6
M\[_(FDG/563J1CS*][13CJO7;;1^\REK-X&MY84=0TB;4Y^X>3D]=O3Z'ZUB
M^"7,6JQHAPRRD2D<;S@9P> U9[1R7BRNK$[QD_['USC_ ">G8='X2T]8=0MG
MD<+B3()/+C'8#TYZXZ'ZGZ++?<FU/5*I26W-=-1LM$_5_P##7WSBE"GDM?W+
MMQN[37NRT2EKV3U76US]+/A_D^';-L\%.!G)'"=NW.?S],5W%</X "_\(]9D
M,.4/R]QPO^'/OFNXK]MRZWU.@ET@M+W>W5^>Y_%&;W_M3'W:;^LU=4K)^\^G
M_#^K"BBBNT\X**** "D)P"?0$_E2T4 ?R^_\%WOVWO'/[-8\ W'A5=?MK2>0
MK?2Z?9Z@\1W-.!O:WB9?X1C=QQ7[D_L+^.K_ .)G[+WPH\=ZB\TEUXBT%KR5
MKA668M]KGCRXDQ(#A.C 5^1'_!PAX'T34?V<9?$ TJ&_U72S:_9H0B&=RSW.
M2FY<<<9.1Q7Z+?L/?$;PUX!_8U^ \GBF]BT&&7PRQ9+C($2F_O.HC5_[C<#T
M- '\QG_!2?\ :S_:#;]K:7P?X"N?$VF>&]#\6S6>K7"0ZE:Z<;>..])+W'EK
M T>YHAG<5)Q@FOZ?OV"?%4UY^SCX?\1:YXCL-0GDL=]Q*NHPW!B.RVR96$C%
M.6/WL=:_*O\ ;6L_V;-?\.?&'Q2WBWPY;^*KT277AY6BG%WJ-PT\&/L[+;D;
MF7S2-[*<*?6NA_X).Z/X]\2_LF^([*ZDNS+/I[IIWF.Q)_>V9&S#G'R@X]OR
MH _>[2_B[\.7M$-WXY\+6\N2#'/KFGQ2 X&<J]P&&#QST.179Z7XFT+7U8Z)
MK&FZHC*=DMA>0W2'()X>%W'3GCH#GIR?Y2/VM_V8_P!H+X:?"3QY\9;#7-09
M/"^CZAK<VGPW,PF2*V<2<;F"=)>/F'W>O<_2W_!"+]IGQ+\>?AMI=YXD>_-\
M8T61+UPT@*Z4'.<2R?Q \YH _HWMDD@MR)B69=[>IQR?\C\>YIUM<"X5F 8;
M7*_,-IX)'3CTZ]Z8LTC7+PF-M@'W_P"$\'\>PS^GO:50HP!U.: '4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U'
M_CSF_P!T_P#H)J]5'4?^/.;_ '3_ .@F@#S#X>_\A;6_^NK?^@PUZ[7D7P]_
MY"VM_P#75O\ T&&O7: "J&J?\@Z\_P"N#_RJ_5#5/^0=>?\ 7!_Y4 >4>"(Y
M?[=N)-X\LCA-W(XD_A[?_6QTKV:O%_!$2_V_<2>:NXCF+G<.)/\ /U_*O:*
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MR_>4</DD'D#'IGUZ?X5VNK7=LRF03J< Q;!G.1QNZ8Q7$>7'+,8P^0^YMW.
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M5*V_5=3R*LZJE%TU+FC)-1OOS632TZ+7LW<\,_X2&UNU-B\P*V/[NS7=T"=
M!QV8]O6I;?Q MH\/ES%9$)^U8<C@\+GIW[G-<E=:>--@2]<C_35#I@@XW#N
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M"JNI.2>FJ5KP6SZVDVWS::Z=CUCX0:WI?AW5A>ZI+''IT,O[YI& 4,)%?O\
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M-_R*VD_]<#_Z&U8?Q:_Y$;5OI'_-JW/ W_(K:3_UP/\ Z&U '6T444 %%%%
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M&$E.*E'5-7_X'J@"BBBJ **** ,K59Y(8X]F?G<*V!U!8 _H?Z=Z^'_VAO\
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M^=Q\6O$6TAMV!_PF7C'C(S[=_P"5?U54 %%%% !1110 4444 %%%% !1110
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MR')\ECY8W??^O][J>3GI5JWARC32?*\@Y4?*%QC& ,!2>.1_+BLJ4+J<Z?\
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MU)N*;TL[OOYCJ*0'(S2U\VFI)-:II-/R9(4444P"BBB@ HHHH *^4_VU<_\
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MD(8[O^6A'_+:7L#_ )Z=JJ+BG[R;79.W5=?2Y<'%/WXN2[)V_$]^_9^^S?\
M",W'V;;M\U?N=/\ 63_Y^N:]^KYS_9P1D\*W(9-A\T<8Q_RUN/8>M?1E20%%
M%% !1110 4444 %%%% &-XC3S- UE,9W:;>+C&<Y@?C\:_S(O^#CKX&>./$G
M[1;Z[HFD:A<Z4IOEDEM[2:6/>]KI2K\R1MSE7_$5_IT:I,MOIM]/(@=(;2>5
MD/1E2-F*GD=0/6OY=?\ @I)_P42_9D^!_P 0G\*?$SX.^"?%=^TLV9-9;41*
MVQ;5F($&HP Y$RYX[ <9K[?A#/JV3K'4:.&EB)8R,(<JDHQ32:3DGO\ %==K
M,RK4X5(6>DE).,K7LEJTO7^O/_-.@_9I^*$3),F@:SR 5/\ 9]R!@X(Y\H$\
M=_3VK1U/]F;XL6BQ07&@:R/MD8G7_B7W?*MQ_P \NISUS[GID?Z%/PJ_;R_8
M-^(7AB377^ ?PVM?)"XC235-N/WN/O:J3_RS]>37R_XS_P""O/[#FCZ_J6DM
M^SA\,;K^R+F2RBD=]:)*1XQ]W60.1UXQ]>H]&IG6:-5:=3"U?WMHM\\;W;5D
MFW9]%UVVL<C=-:0FERR]Y.-TU!1E+;?1JW=V]#^%V']F7XJP.)$T#60PSLQ8
M70P#@G'[GI_^LYJ+_AFKXFW3R$Z!K!=6)<?V?='_ -H^F/4YZ>_]Q*?\%B/V
M&V"D_LU_##H3C?K9[?\ 89/^1]*S+?\ X+'_ +##2W*_\,S_  N3:<9WZY\P
MXY_Y#/O^0Z^OG8BOC,)#VDZ&(C2<+?O*L)7;2DY-?.W^&RW.F*I36^MDX6VV
M6_7T7=>A_$E:?LP?$5Q,DOA[5C(V1%G3[G).>!S%QQGU[]338?V8OBG;N\?_
M  CVL#^]_P 2^ZZ=O^6=?V^Q?\%B?V&#M8?LU?"_(P0 ^M\>W.M?Y].*NI_P
M6%_89E\YV_9L^& 95'\6M9/&.O\ ;/OU^OO7F8:MB(5J6+=*<J/-"<U[2*YO
M>C;XMFEHNWR%5C#E:E;E25]'?FYE9^G7R[V/XE4_9?\ BK%;QS'P]K(C+#8?
M[/NAS@=,Q?3GI[$50D_9<^+%[/(1X?UIB%);_B7W1P!D_P#/''/).<YK^WV/
M_@L9^P_*B1']G#X8[ V0I?6SC'<#^V?I^72I5_X+#?L/1RN%_9P^&*Y4\A]:
MP>,<?\3CN/8=>]?H./SW&8S+:4*>68BGRM\E98BC;E5EK9W36VO<PI8=*3Y9
MQ:<DK6LN9I2W>]^KZ'\,]S^S1\3X(E+:!K*J7VC_ (E]T.00O:+U[=>??CI/
M"?[-'Q/CU.W7_A']7W2O&.=.N1\K-_UR)Z?UQ7]LLW_!8+]A9T0/^S7\+W&_
MIYFM@9)!SC^V.?\ ]=6K/_@L-^PTMV!%^SA\,(FCA$J2!]:R"@W#&=9QU'IU
M[FOA\1F%2\:>(I57*%54ZD958.$D_AC:[]Z-M]M=3T$I1:FE%KV<5[VOQ+>W
M5.VBZ>I_&Y\2/V4/BO;PVTX\.ZP(C!$^1IUSC)CC(R?)S^?X]L^50_LW_%5F
M$ T'6/,(&W%A<Y/ Q_RS^G^37]QEQ_P6;_8JU*W*WG[//PSF1'6(*7UG&T'8
M/^8P.G:M^R_X*N_L(S31$_L\?#%&D0-N$FL@C.T_]!D>N/ZU]!E^=8C+(1G1
MP=914)I6K4[*ZC>2M:W+>Z>MCR:ZC-<M2<)5%)P7-"4E&S7-&.FUK>I_"]'^
MS=\7+FVGM!H&M&,2%77^S[G&[!!_Y98S@_ES5J+]F7XL:$(@_A_64-V,IG3[
MD9QGCF'IP>W'K7]Q=U_P5L_86L1<>1^SO\,F(D).)-:.X\\G_B<]3^'\JZSX
M9_\ !4C]B/XH>,-+\+M^SK\-0UP75'C;6=T>W&<9U=@,[NXZ5W8'C[,<#F$,
M;3P\Y2BI?%5BYRBXVM)WL^6]_EY'.J5-04'5IJ/-&Z4):_#:WGT3UZ:L_C.^
M$/[/_P 1/"Z7NH:IH6J117&Z3=)I]PN5_=#[QB_V/7KQZY\$\6?L^_$S6_%^
MJWEKH6K/!+>226[+873+M[%<1' .3_\ KK^[/XJ_\%4?V*_AS?W.CR_L]?#B
M:.%O*VR/K(SE2W.W6!U_7UKS2X_X*Z_L*VD6G7$?[.7PP+WJJS#S-:^3=N..
M=9QV&?<]^,1F?&M;/<PPV8?4)0J892YE&I34:E[1O)]N;7O?4UH8.FY*HI0D
MU[CDHM25W=6OHM-[WV=C^)VW_9F^*MNY>XT#5]DO#YT^YP1CN3$/_KCI5B\_
M9K^)C(@M?#^K"-"&4+I]QC/3C$77&!Q[^M?VGW__  6-_8@A:6,_LY?#*4)C
M&7UKK^&LC/\ ^KVJO#_P6._8>:WC?_AF_P"&*Y<#;OUK Z9_YC/OCO\ G7Z#
M@_%7'8++/85,FG*U&--588BBK>XE%V;YE'D?X:Z6-X9?2G)SNW%:3[J7-&SC
MY]/ZU_B,OOV:?BG).S2>']9W]Q_9]R?4Y_U0Y_$^W?&CIW[,WQ-F1(W\/ZN8
MRP"9T^X^\>/^>1'7&?RK^V.7_@L-^PSN#']F_P"&!W':?GUKH<9_YC/![UO'
M_@KK^PQ;V,-RG[.OPR#,P.W?K.%(*\_\AGWS[?I7Q'_$0\THUG5HX1\M7F2I
MU*D9*TG%[1>E]&[[_@+&8"*C*+DH.%I7:<FHJVMUN]MO,_D=^$/[$_QAU&+4
M;N#PSK!,-A<3$_V;< ^2L<C$Y,.<!1V[8K@;[]F'XHKJ-_)_8&KF"UN;B*8_
M8+G DCD9<']UV92/\*_LQLO^"WG[(>AL\&F? 7X<6\<T#12!&UC#1LNUH^=7
M/&&(..?Z4C_P6/\ V*I+&XN7_9Y^&F99=\J%]9^=Y'8ECG6<YW'/XYK[SA?Q
M%S_+L)C/^$:K7IXCWY2IXBE#E;6C][^MK;'BQR:G4UKUH34GS0M"6C=KWOVW
M76_>Y_$EK'[/OQ3N+L0MHFLEAD+_ *#=?=& ,8B],#]*YV\^!'Q1THKJ-OHF
MLI';@1S.ME=+B0')R5C'H>^>.,5_;L__  6!_89:\C#?LY?#$LR@F3?K0QG;
MP#_;/X?7Z5LZ;_P5@_8,U=I+.X_9S^%RPR.2P,FM<GU.=9YX; Y_*OQ_B[BG
M%9IBZE>I2GA75DO=52,FM?>2Y=+-.SU\NAVT,II0C3G>$HZQBN1Z\]HJZMTU
M=]+:,\/_ .#4GX?^+?A_XX^(^I>+K'4+1-9O;.6T:]AGB$BJ]@&*F55S]T_B
M/S_T!;2*$ SQ!?WO.1SZ#K^ K^>#_@E5^VM^SU^T5XS\0>'?A7\+/"7A$Z3<
MQ0M/H3:@S-N-OC<;F_NAP91T Z"OZ*D544*HPHX KX:;O%-QDIMMZM--/TUO
MU^?JCU<(E&$HJWNRMRI64;)*UOE?YZCLT54@ADCEE9I&96)PIZ#IT[]C_CC
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M\\CU<_Y- 'O .0".A /YTM XX'0<4TN P7/)H =1110 4444 %%%% !1110
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M:+93S[N&,IMT9\XZ$G)(Q706ERUPKDH4VL1R.N"1_3^?I6@%RBBFEP&"YY-
M#J*** "BBB@#XA_X*->1_P ,7?M#>?C_ ))KKOEY_O;8>GOT_K7X)_\ !N-]
ME_X06TV[?M.6W=-V/[)?\?[U?O9_P4:D5/V+OVAMT8DW?#77E!.?E)6'YN".
ME?@)_P &X<;CPC;.5^4[\-_W"I>/U_SUH _K9HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZC_QYS?[I_\
M035ZJ.H_\><W^Z?_ $$T >8?#W_D+:W_ -=6_P#08:]=KR+X>_\ (6UO_KJW
M_H,->NT %4-4_P"0=>?]<'_E5^J&J?\ (.O/^N#_ ,J /)_ _P!E_MZXVX^T
M;?FQ]),=..N<?X5[/7B_@B5?[?N(_*7<!S+SN/$G^?K^=>T4 %%%% !1110
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MF(0?#[0A=^>F\+I=IN\O@'.(C[_X8Z_RAR_\%NOVPFD('Q2UP$ <".V&./\
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M]N^[Z']2LO\ P;=?!\P''P_T7=Y__0*M?]7GU\GT_3WI&_X-N?@ZLR[/ &B
M;.?^)5;?>"_]<O4_K7\JLW_!<C]KT6S)_P +1UE6:5B'V6^1DC"\QGI^?T/-
M8T?_  6R_;(FN1*OQ9UTH01M"6O5L 'B$]^^?Y<>-7S/$U<8ZTO8\U*4[24)
M*"BN75)O:5M%OU"C0;K4(+G:G/WKZQ7-96E%:M+HEYG]9&G_ /!N!\'_ "I/
MM7@#1-P<[2=*M!\NX@?\LASC''Y]*N2?\&WGP5^WVNSP!H?D>6/-_P")5:X#
M9'4^4!GKGU[U_)C_ ,/J_P!L:%#&_P 7=<W.=P)2V) .>,F$8 &!T_J:</\
M@MY^V")H]OQ9UMA&NTKY=MSCOQ%C\^OX5]#/C#,,7"G2JT\!R4HR?M'2G?5*
M.JNV]%HUU-\SP"PO)&,O:MUHINDN332]^;>,5JTGKLMC^M2]_P"#<#X+*/\
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M+M2VW=%U_<YZ;OU'I7\BMG_P6]_;$AG<R_%;7&4KT*6^!UR>(@1@G^5/NO\
M@M]^V#,P\OXKZVN"#\J6QXR#_P \>>.:]:/B#GU:A5P49894)KDFU"KMIK:_
M;1.W7N7&A2I^ZI1DISYW'EV;6FOE>RZZ^3/ZOS_P;<_!M]/P?A_H?V@(Q'_$
MJM,[L<8Q#G.?KW/!K(M/^#;;X1?V<PG^'^B_:/M9QNTJV_U.[T$73'3CUK^5
MK_A]]^V">GQ6ULD#D!+;C _ZY<Y__7S7:?%3_@L=^U#X%\:ZQX4\)_M6>'?C
M5X?T>;2C9?$_X8Z7\1M)\#^)Q>Z3I^IW:Z)8?&;X9?"/XE0?V->WESX?U/\
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M:_1[42,-WS$'_GM+Z$5<)<KORJ7DU=;HNG)QE=14M+6:NCW[]GJ[:[\,7#E
MF)1P%Q_RTG'H/2OH*OGK]G>UEM?"]RDHPQE'_HV<^@]:^A:@@**** "BBB@
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M<RRI4(.HDEO!J#=URV;GNO1O;EOZ).@ZT;2=YMQ=OLVBURKR2:OZ['L?QO\
MBIXB\?>+=>DN-9U ?9[D?9]EU*@;;$N.%<;OOGUYX-?/LFO>)RL:IKNK2&/^
M'[?<MLQGH/,^7D^GK5KQ%/YFJ/>6;$BYD#(RG.>,<=CT_GVQ6>YE6-Y+4?O%
M&;@KUSP#N]^1G'Z5\XU7HVY$]>L&]M-'ZVOYO4ZZ--Q:BY).+YE%=59)WV?Q
M?=L2'6?%3D%M9U5NG6\N#GV_UG\ZA;7_ !,':(:SJ@('W?MD_P O4<#?UR#4
M5IJ5PRLK,VX_<R>_H.O.3_CVJYIEC?7U\&V,2?\ 6<'[IR3VQC)_IQ7K4:>(
MQG)%1JQER1BVTUS)\MN7T7N_X=2:M:-%5=4G%<R3VE97^=E=>32%BUGQ&RY?
M6M5YZ?Z=<#GMQY@SS[>_I3KCQ!XEA14;7M7X(.PZA<D!2>H'F_Y_#CJ]0\):
MA"BW0A=;8<H=OR\8/'&>X_GQVY&^MWNIM@5C*I7< I/ X_#I@_\ ZQ7L5L+A
M*.&<9TN2O&$8J4?B<H\NL;[M^5CFPV:TJJ46HN5KRUOR1GR\O/?;E^'YFM9:
MSKT\9EDUK5"BKE6-_<=0.F0^>H/'/?BJ<GBGQ(Q>--;U3"DX47MQM(!/)&_L
M<'/?K5B:UEM=*#NA2%I O((S(1Z$>I XJEI]H) P S,V67C!VD'..,],?AST
MKJP6=.EA:U#GJ+]W[-QOJ_=M%V6EU>ZTU>^QO7JT)OGHVYHK5*RAS12<HJU[
MOO=;/8CM=>\1S38;7-6V\Y(O[D$>V?,SZ_E^%6$UOQ8AD$&OZRLFX[-FH762
M.O:7GDC'Y=Q61,DL4A2 $#<=V.@;(/\ ///?Z5:M'OFE7RA(UR%PF,EB/0#T
MSUS_ %%? YC*4Y.I%JWM5%).ZMH[Z]'U\^[)6)_=WO&%G&2UZ75U-=+===C^
MU+_@T+U'7[_XJ?$L7]Y>7R)J%EYK74TMP5S)IW0R,Q4\\\\\]:_T=Z_SD?\
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MMR0?+8MCCC)TJ3O^(_SS0!_6C1110 4449[=Z "BBB@ HHHH ***,T %%%%
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M/,'B6$Q9QC(L8^@X]3T].: /E=/VS?VC@;O_ (NY\1<N3O\ ^*KU@[?N]/\
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M^A5?GW\9KV^B\;Z@D).P;L=?^>TOI5PY[^Y>_EONOUL:4W44OW=^;R5SWO\
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MRDEBG ]1U.,^U_\ !!/X@?&[QQX1UZY^*>G7=DD>IW<=KY]H;8-"'O/*(&Q
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MWY=M+[\V_3:UG9^9PI7['((XGV&8@*>?W1/H3G'3C=Z]CTU) ZI$_P!H9FB
M\SD R'D<XX/KQQBLNYB6:Y\Q&)$C#S<'[@QR5_N]./K[U,EN5WAG<@#]UES\
MPX_/N./0&OR!U72J1<).5GI)KI9<W?T7](_:<+0IU(J<G;W*;EIN[Q2BMM%&
MS:OHM>Y/(9I6$B2L!/QM'(CQGD?GCG\:>^YT-MYK%HOF+ \OCC;P/;L!C.?2
MH8MR+LZLW$H_YYCL1R=A.!T_2FB,1R[MQ*#_ %;%B=[<_+DMALYZ=*Z?[0O[
MOLDU'X5[NNUKZ?/^ZM$=7L:+3]Y)0YN1I[OG35_1^ZKZM/F[EE&$<"F3D/\
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MVQ(4D=0"1]<5E+<W1MY',9#JY"C!.0-V/Y#_ ": -:BHXF9HT9AABH)'O4E
M!5*WNFFEFC*%1&Q /8XQR/;G^7K5VD"J"2  3UP.M #)59XV56*DC@CJ.:HB
MUF\J%?.?*.&8G&2,#@_D?3ZUI44 %%%% !1110 4444 %%%% !1110 4444
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M*)#M89#<?(.P'ITZ'H/8U@VLJ17^]@'5&&X'H_0=OIQD_4&H+2[#1BT=SMD
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M_$.CEF+'^T;/DDD_Z]._MZ5_K-?\&Q/_ "8!)_V-2>O_ #PN_6@#^C^BBB@
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M<7VDL#;2SN$:)OE.97/4=>".YQP![X&G>+[_ $O2;C3+8?9TN$V2LN1YP!!
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M_P"VO^RAI_[5OPMU3X?ZG++''?&':\)0.HB,IXW(1SO[CT^M>::G^Q;JEO\
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MM^?L._M0^&_VI/@AX8^(F@ZI%JJ:K"\AN8KA;D. L+9WJSYXDXYK[1K\'_\
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ME?XLW[%!@/[0O@_R4*CS[+(/][^T;#GMQUK_ &F?V0?^39/@E_V(6D?^@R4
M?1]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5;XD6=T0,D
M02X&,_P'M7F_@AWDN+HR*$(N90 %V_\ +5QZ<\<UZ1>[C9W04X;R)<'T.PXK
MSGP4LZW-U]H8.QN9=I'8>:_'4]N* /4**** /-OBU_R(VK?2/^;5N>!O^16T
MG_K@?_0VK#^+7_(C:M](_P";5N>!O^16TG_K@?\ T-J .MHHHH *SQ)/)<RP
MLA$6T@-SWR#S^'7O^-:%'OCF@# GT97M;^#?(1=VT\)R[''FQNAQR2#\W&.G
M;GK^37Q?^"NN?#'XE7GQ.\*K>R:C+;311E))Y59V?S%CV,S*06;&W:>.W(K]
M:=3ENK6WU&Y60!8K2>2-0#NWI$[#D=\A>!@\5^(/Q5_:9^+1_:0N_A]BYE\+
MC1YI[)0MRT<>H^9L@DSYIC(5MIPJANO(I-735W&_5*[7I<:W7J=SX"T'XH?'
MOQ%97_Q%TNZM(+"YCCA)MGM$>&"98XW.Q45R8[>,[FSG=US7Z[^%]+M]!TNR
MTN)O]3:P1 ,V3^[0*.I)/;_.*_*[X;:S^U!JGB[3=/N/$4::5=2QS)']EO5V
M69D1A&3]NVDB)L9QVS[5^K%E"]I86=QJ!\V\CMH5G< @-*$7S#ABS<L.Y/OW
M-*FXN-3EE=<^VGNNRO':^F_JWT"K"4:WO<K<>92EUNTK6_)_YFO>.RPMM&3C
MIC/8]N]?(/CA3+K8@89CD=_,)'^KQT(8YVY]L>]?6[N\D#.& +KN7/!P0?8^
MV/TKY/\ %\<LFO@*P\LNWG+TW^A'Z=<_A7YWQHY.G"ZC?G?LU*]]HZ*UUWOK
MM?T/L^#&WBWRJTM=]'NK7W5MGU^1S5O,\(>,H%$>1$0 -W3KZ^^<\<C.*X:Z
ML'EU)IUBW'S=S\9VGG/K@G ].N*[&^\Z.:) ZY) BQ_#UZ^O0^G!JK9B19;@
MNPZGSC_>Z=.PS]#_ (_E%6-13E--6O&3B]]$H:-;J^W=].I^U49>QE24)1E*
M4;S:;MK;W=K[^6^FPEW+*+2,JOW%^3Y>OX]^YJC:7DHA+2*/,;AQ@'  Y/MU
MZ]JUK@-(L:Q'$9.(QUVX]>?PZ#TY[X=Q#,LZPJXWY_>MSAER>,?CUS^':HG4
MYE""NW4=KO[-K7OIT>FE]-;]NQS3C&FK1<VY>B4D_6]UKLKWW-AG+6Z84;%.
MX$#KC!QGO]._XU6CDD:;SDC!9\(5V @#&,XP=IP2VX<^]2%F6+R!C:!P,$'(
M Y/;C':GV(E#%E8!QR3U^4 _3L..OTK.=+3FY8J4DW)Z<MKQU5M>:[TTZOYS
M4I<\%SI1DHS::U@I-P=V[;[:6>UM>EQX-H,;C(*^9N[[R,[03SU_A'':J-L9
MDD*NI')"J>A7UP>.GJ*LW=T9"JK@*IY .?F'&>,=QG\/8U7DO3LP,?:,?*W&
M O<>HSQW].#44TZ<+-\U[WI[6Y[*%[Z/]+W$U4A3C*>JFFG3TUE*UI/3=_:M
ML2W%N%_>1J=G5CUPQ )&?;H<=-M9Y,J*QV\YR, C(P>:07LH0J& C).]>Y)Z
MX_$GMWX[TXR32Q[F89'"]\+SC_/'-;J3?)&+D[1?,TM7HN62N[/73_+0:J2E
M:*;?+S:JUW'E7+)WW=[K?H*ESA"I (?EC@''ISU'^?K38I7!9]N0O(XR#C'4
M?X_TJF$>2:,(<1C_ %P/.\_7M^(-78HW8F-6')PGJ,X/4_\ UJ%>UV[QDFY.
M.NJBHZWMT5]-;Z+NU'F:<FVXR4G)QMHU%1U7HNFM]"4$W.9 H..6X'RGIT_A
MZ]!^IIFT<':/KCKCCD]\5:MX)85E57 Q_K?]KD9[\=0>?3IBLY1)YC$G]V3\
M@[#K^!_#'ZURSE*\K^]RJG:/7E?);Y7:??F\M5UX=RE!\SC[BCRVO?:*MM\5
MG?3IU)]JG/R*1UQC@8[@=!BN8U5I"ZIY:A%8%2!C/S9^\.O0<9YZ\BNCE#MM
M\ML,#ESZCTZ_SS_C4U!HE@4S $#[@Q@JW&"<Y[X]P._J)+VD6X2JIPE:*:TD
MFO>>VO\ -T3>C-6K1336K\[]M>]^F^FKM8C@N)#;Q_(/,X#+MR-N  0ON#U]
M15@7#K<!'7$9C!S@@[CSM&3G&2>.G!_"MILGF?.Y7SC_ ,M,<% .!SSP/4G_
M  @U$RK(C;AY!<#;W#Y7GOW]ORK.G*5.5"/+.[<H^_WE:[CO?EM_DC5Q5X0D
MN1>ZY2ZZV?2UDNCWLW?H;VU'4JZJR%<[2,J0<Y.#GGT/^/.%:Z?#!>!X(U"[
M\E@!N'/9L9'4\=OUJVLLODB'=F5ERK\_*,=.OH?[WY\54M6FA9I-W[@$[T88
M+'<>0?3@GI_2NVUYTKR=Z:G=NV[Y='VM8J--PC.:?.W:$8K6ZG9*:OU[7LRW
MJ5R[7L&,$K&%"C!W#(Y*@'/X]1Z=*)(MH < I-RY/\'L,_=Z<XP,\<XJ%[6>
M:872L 1_JSV5<C@YY[?3I4TLOFIAAE(_]<!U<]1CI@\^AI)>S@]92M=I/[6S
M=M>WY7+@N6-.$.1J"49<M^9;-75DDU)WCJ[R7O:7,V:>5&'RA4BQLP%&_C//
M'S9YZGMGC J]I<A;4+9U^;S7RXY.S(/&,X7MQ_C5>X263RTW<-@1 _P]??'Z
M?G1H2/'J00GE9"&.#\WJ1]>_Y5Z&6MO%P2?L^=KU34(RMWU>FZOW/*SN'_"?
M)J4G.-.;?+KS)RUOMJF]=>C/NOP2S?V);*0 H7Y3CKT[]_\ /H:[&N/\%!O[
M$M23E-OR#'(X7K^?^>W85_065\WU'#W6GLH<O>W(KWMIOL?R_C_]\Q%O^?LK
MVOO?SZ]_,^+_ -MCXG#X9?#"ZU1K*ROO/@O(T@OK6"[A9OW*!3%<1R(=WF 8
M(YS]!7\YGP\_X*7:GX0\>:%X/D\$>#M,@U+Q5:Z>LD/A+1+>3%[J*P!UD6Q5
M@Y\S(<-NW$G.37[]_M\>,OASI7P[&G>/])?4(;LSVVG,)HHUAO)9;:*&1O-M
MY@0LYB8@;<A<9&<U^4G[)O\ P3B\!?$GXA0?%'XFW-AJWAO^T(=5\/6"0VWF
MVUQ;R37=KNDN$G0E'^R_<BC)VG!'!KKK4JBG%RBFFZ;BK_"N5WEIWT:6O=[&
M-&HH/WUS0>ZTWZ/7MK_D?LY\8]2U#5OV;IM=T^62UFU'P(^L"2V8PF(W&C?:
M!Y1BVF,(6&U5(  ].G\7R_%+4]!\9Z_XHO?%NKS:MI'Q#:.,7&JW,K1VR:_(
M)%"O*P"+%$HQMP  *_N_NO!&FWGAG_A"513X97PY_84-J I(LQ9_8T4#;LP(
M0!]P*>.WRU^<S_\ !)C]D>\DUS4O$OA6-[O5=0O+^61H=*4&>ZFFF+?/IS$_
M,X/)SU/6MN9N$$I*4;<RMWEO\_Z],Y*S5FG=)Z=+]'YKJ?5W[*7Q]\+?&#X;
M>%[C2=6@O[FWT/2;>YV2QNPG6W$,F[9_%YD; \]1CK7UI7QY^S/^R=\+OV>=
M-N+#P%9?9K5[CS8P#;@*!<33(/W,,0ZN>WZYKZY>Z1+A+<@[G&0?;_/\OI2)
M+5%%% !1110!\2?\%%F8?L9?M!J$#I)\-]=23*@[4*PY;)!QCU_^O7X&?\&Y
MUH8/"L#1@^1\VUNH).E2]\>__P"OFOWR_P""C F;]B[]H<1/L'_"M-=W]>5V
MP\#!&,X]Z_ C_@W$NIF\&6ML3^Z4M@<YR-*D]_84 ?UIUEZX2-'U0@9(L;H@
M>I$+8%:E9>MY_L?4]O!^PW.#Z'RFQ^M '^59_P '1T]P?VV]*8PJ&%EJ  V#
M!']G: ,D8P3CG)YY]J_EW:"5A)-M.T,V<#@')XX^GI7]1G_!T>+P?MMZ3NF7
M>;'4=C8/"_V=H''WO3_//'\NS7<Z)+;[AL9R6]SD\XS[DT 2100-9R2L<2JV
M%&<<8ZX_#_.:SZ=AL9YQ^G^?\/:FT %=+X0_Y&+3.W[_ /\ 9&KFJZ3PA_R,
M6F9Z><?_ $!J /\ 7Y_X-['<_P#!/3X1HR@(NGS[6VX)S%8]6_B_SZU^[=?A
M-_P;VK./^">7PB+L#$=/G\I>Z_NK'.>37[LT %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 51U'_CSF_P!T_P#H)J]5'4?^/.;_ '3_ .@F@#S#
MX>_\A;6_^NK?^@PUZ[7D7P]_Y"VM_P#75O\ T&&O7: "J&J?\@Z\_P"N#_RJ
M_5#5/^0=>?\ 7!_Y4 >4>"))?[=N(]@\L#A]O)XD_B[_ /U\]*]FKQOP.MQ_
M;=P2X,&WY4QR.)/<]L?YYKV2@ HHHH *JWCR) S1IO;^Z1GU[?Y].]6J0]#]
M* *OFJMKYEPJJH0EU8#;@ YXZ=,_7KWK\VOCE>?L^>,];EM8)-!T_7=-E47K
M61M+6XEF"NV9S;^7)(VV1.7W'@>@K]$4WW\>HVMQ_JRC1K_P--O(^I/TK\IO
M#G[ 5L/C%XF\;^)9C<Z5JVJB[$/E!0L7E6Z$%I#(O_+-OX>_3I0![E\#O^%*
M>';F*#1_[%U#5+@D3O.+:ZFBE*IN*M)O>,@+CC!Y]Z^_;5X)8(WMPHB(R@CP
M$QCL%XQ_3VKY T+]E3X3^&_$<6K^#[7R9_M!EO-I@?<S+@\QP1XR AYSTKZ_
MM+6*SMX[>$8CC4 #Z #^E)Q35I+1V>JWM9K\D!YQ\:L_\*H\>8.#_P ([>\^
MG"\_A7^-3_P6#:0?MN_$$+(Q)GO!G<<G.MZMQU/KBO\ 96^-7_)*/'O_ &+M
M[_):_P ;3_@KNT*?MO?$0S(3^]O"GL?[;U;:>0>^.W-=N'C'E4[)R56*3[76
MW?5_?Y6N)WO;75/;?IL?F+%93A-P0ER,GCMC.?J<_P"<57W2("&_O?CD'IN^
MO;..E=/IU[O5D8CS I+,<\I@X'7T_+%8>I2"1F>$80,<CK\X/7MW!]17V.$E
M4@HU)N\^6Z2UV2OS^:OTOY%.:Y>2TX.$6G&-G'>-W>^[ZW5]-'T*L-Q,)PP0
M-\I^4J/0#IC]<=_K542.?,&  6)) Z'/0'M3[62>2Y 5@K!" 3Z 'Z>XJN[,
MI="<@L<_7)Y_'->"\55GB)2NVH2CS.?QM7O:RTY5UM\M1\T>=RYI^]%I.VMV
ME9/HM5;S_+J=*NY(F1T'S@#  Z\CGCJ>G;I5EV$UV/-'WSEO;CU['@]JPXGD
MM?*96'F,@9#T"J>@Z]?3_P"OFI?M,CL7)!*GYO4DGW_7GFOOLMX@5?#*B^;6
MDJ:Y=;-.S4=KZ+9_F6X2<;72BXQY9_:YE:[DO):R=WI;N;\ZB-"[QA?*YB^7
M ;KU[,/TXQVKC9Q)<2R3(N.?FVC '8GC@8R/PK9EN[BY\J!WXX$>,G'YGZ^G
M7\Z<*31FY42#"DB3@C<,K[_X\^E?+9QB''VD.9W?*Y2FM%'FBTENVW>VMO(B
M5*"<$I.[^QNHK371O=OFMV?J1K.9(8D91F/."< L3[]2?J3^8JTD[1([;<LZ
M[2",A<\9 / QZ_6L[8S;&7[H)V^WKZ=>AZ?3FM:U@,\BH2,Y'F'^\O4@9SST
MZY'3)XK?+.;ZK4<KJ#2E!1V:YHRC>]K7\NA<HPC"4+64$KRM\3:34E;KJE&]
MM.SWH.)A&LA3Y=V0V.O3OWZ]^G)I&N)6N)&\H F,*1M&,;2,]._T^M=.]L<F
M(D?9U7]VO&0W&"><<?+V':L"6UNDEDD\P<@C.T\@9P.#W!]>_-<6/J2JU4E%
M^TBN;7X?>:T3\NEM7K?4\ZM-\OORCRN/)[[:;:MRK1.Z^6Y5BN T30,JC]X7
MR0!SDG&?PZ9_2N@TEWEDAC)(4R(-N<*1NQG'T[D#VKG$LW=/-W]9MA7'<\^O
MK^GO75Z;93P2P'/S$HP8 \#(/;GI]/>O1RJIF.#A.O@E448R;J\NEYQLY1=[
M^7*UYWL>YDRH5\9A\/5BGS2325KR5XVWWE'I>U]G8^G]!MKRTTZ(V>](RD;&
M2/*D-R3\W'3)(Y%:OC*_U&3P\9+HNQBCV*7W'>HC8Y.<YR.I.3V]*U/A[?1M
MIBQ7BCR0%# ]^6&?FW8XSU'?K7-_%'70(SIL)!21-T>#PJE" #@X/+9R !7Z
MQPCAZW$.)ABI4Y*=*&CM?WI625W;56NNFMO3^E\XSK#9/PA+#T9\E>I15/WK
M1>L=M+KG[+1:*[[>'PR^9,@('SG+<=,8Z9Z?KZ]*]T\+6LTMA+)L(\F-FC&.
M'QMQZ _>.*\0TRS=V,N[Y4(WJ1R<D?7\?_UBOHWPO=B#3]C.F60A<?P\CK_+
MJ/YU^Y8>EC\#!>UD_8T81<5JY+F:3;7PZM][WOLC\>X=EA<5#&5\1[LGS1Y[
M+K"-H[I^\WY^]*RTU?BGB;26>_\ -$>#+(3, .A.X$$#@=!Q^77%>=>)+81!
M8R %C'R'H6.>GJ>GN>#7M&O:BIN[KE?W;G?R.<<^IQR>W3\<GQ7Q+>&ZE7G]
MTA^1>N.#DX_EQ_*OA./*=#%8"=?W??\ =<)K2#4=VXK>Z37=L^8Q].G1Q-:-
M.\U%Q<5*RBN:UK*[O;F\M3BEF=(V!&0X*$$9VCU&<X/H1S^=46RN,<+G(([G
M@\GK^&>E79LX^4_[PYY _'%5@PP >4_A'<'MUZD$#^?;-?RO6I4J.+;MN[Z_
M!*46DKV=]5OIV\CSY03B[2M*44G.RO9<J?ROK+ST[DC$X+A1N*@$8Z#!YQT]
M?Y56,[?9_*VX DW;L#.?3=Z?UJSSCK\X'S'U7T'OC'?T]*K3CY-R<+GD'^]Z
M_3_.:>,4JC4VG=*,U%Z6O:[C;3W;J]^^G=Y5()QO=^XI:)*[?NW<NS_G\WI<
M_P!#?_@T6V/\,KIR<.NIX"@]?^)IK8Y'TYZ?X#^ZZOX1_P#@T2DB_P"%:W:,
MA\W^TSAN,#.JZWV(SGD=Z_NXKP<55E5G%RNTH)1;ZQUL_3^M%8YY2YK/F<FD
MD[K9KHNZL,D!,<@'4HP&/=2*_E1_X*M_LI:S\:O$<7A.^FU6^L?$;S;;%[R\
M>!PD,B86$2[.K'@*/YU_55=2&*VN)!UC@F<?5(V8?RK^4K2/C9\>/VF?^"FW
MACP]8>*K?2OAC\*=>N;'Q+HEV+N9]52XCM)(?))O$@0)]H/#6\HX.,5YU7^+
M0]YQ3DT_/1.UK==GMN)=?3]4?D-\!?\ @F;XZ_9?\=6TOA>?Q1X>_P"$IU!=
ML6GZIJUI'<>9Y8PT<=PJL";4$C&/EYK^[SX"Z%?V'P+\#Z'KDL\E_;Z#;P7D
MMU)(\[2JQR9))&9RQXY8D]!7XH_\%J-*^/7@3P9X1^.GP2\9:=H&A_!RSB\0
M>*-.\BX,VJ6]FVJ^;%%+:7MJ(V;[3;X+1R8V<CD"OU?_ &(_BKK'QS_9-^"G
MQ4U=RU]XS\'V6K7^YG9FDFW[OFD8L>BXW%NV?;N7+*"IIVU<Y2DM$[6LK7;3
MTZ7_ $1^6G[<W_!(7X;_ !>N?B5\6+2P>[\3>(K6.4HES<,9Y$G)"F)9<-PY
MXV^OUKY _P""1OPI^//[,7QCN_!4OA>]T[P8UI]C5WT^58%CVS6Y*O)&0"$C
MCY#9QCFOW7_:H_:]\/\ [.W]A17UJTD%V\@F7[2(1A?,'(V$=4SC'TZ5@?LS
M?M[?"W]H'Q/-X8\/Z9;VVKP6XGDF%S!,S JW&$MT;JK=6/':L0/T80DHA/4J
MI/U(!/ZTZD!R ?4 _G2T %?*?[:N?^&;_BAZ?\(EXAR<=/\ B27_ /0FOJRO
ME/\ ;5S_ ,,W_%#_ +%+Q#G_ ,$FH?TS0!_/M_P:]RR1?!CX^PQ$M"_Q:\1E
MV+!\'_A,O&'<@D8RW&>U?U:U_*S_ ,&NAB'P,_:!$8"?\7;\19!QDG_A,O&/
M3&WW['K7]4U '"?$O_D2=?\ ^O"Y_P#1$M?XT/\ P5P9E_;(^*K(NYAXGBP,
M9S_H*?A7^R]\2_\ D2=?_P"O"Y_]$2U_C1?\%;M__#9/Q5V':W_"3PX)['[$
ME 'Y3W3,T\C.NUBQR,8Q_2J]6;O?]HEWG<VXY([FJU !3D;:RM_=(/Y4VG*N
MYE7ID@9H Z30I_M'B71Y, ?\3"R& ,=)HQ7^LG_P;$_\F 28Y'_"5)_Z(N_3
MBO\ )KT*W:V\2:/&6#8U&R)./6:,^OZU_K*?\&Q/_)@$G_8UI_Z)N_<_SH _
MH_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\_?C+J4T'
MC>_C6!' W<E5/_+:7U!K] J_/_XR6-Q+XWOW295!W<8/_/>7W%5'EO[S:7DK
MO==_*Y<.2_ON27]U*_XGT!^SY:K:>&+A%<N/-7D_]=9_\_3%?0%?.?[.#,WA
M6Y+.S_O1RQS_ ,M;BOHRI("BBB@ JG<022R1LDCH%/(7&#][K^8_Q]+E13LZ
M1.R#+ <#_/\ D=>U #;BXAM87GG<1Q1C+NW  SC)Z"OGSXH?%#P/JWA#Q=X7
MT[Q3:1:[<Z/=001130^?'*QVJ54LQW JP^Z>_'2O5O%MC/K?A#5+$M)!-=6^
MS=&S1R+\ZGY74AE/'4'/;I7\M_[37[/WQ]^&OQ6UCXC> M3\8ZD'DE-O8'4M
M5O+*0BZN&5?LCSO;D;90,>5C '!Q0!^]W[+?B.#P[X-L/#>N:_\ ;=2BD&YK
MAX_-8M#&@!"!!]Y3VZDX'I]I)*DF-C9R PQZ,,@_E7\V_P"R1\2)?&/B+3;7
MXF:_?:-\0XKJT;4-#^W26/EX#'YK&-XP,S+,N/+YVX[&OZ+]%AB:TL[F*1I$
M:SM@K&0L& @49.3R3GD]SF@!_B,;M UE>F=-O!GZP/\ KZ5_E-?\'.4*V_[8
MEF%8OE;\G)S_ ,N6B<?3!Q_*O]63Q+C_ (1_6LG _LR]R?3_ $=_\Y[5_E+?
M\'-^P?MAVNQRXQJ&23NY^R:+D G/?_Z_.:49SC7H)-J#D[I.UY)QY;OHK]=]
M7T$Y14E%WYI7:7DM[_>C^:V:Y+21X38%0# XSP.><^F?K4CN9RL3N2".,_P^
MW'M_+DU7N9)'EC\U GRJ!A0O& ,],=^IZ]:NBU@\^ ;OE,8+G<>&SSW[?_7[
M5^AX3GE@*:IN\Y<RD[WLHQ3ZO>[\^IE*M)*I"^KOR2EKRWLGOKLOU\RK' 8O
M,9@Q13]P]']<X';/K[U%+;N71]Q 8@@8^[U]O;]:TGN!-=PP*!Y<;;> /F!_
MO=,XSQG/\A7KMOX,TZ\TQ9DP9'BRV&.5.>HYX]3CZ>]>'BL%*K64Z<5*<8>]
MIUE[EU9/9W;MMNSG5.2G*<I*W+:^FMDDU9[=[Z76AXA)=RI^XB<H&XD(Q\_U
MZ]>.W;OWT8-6C@LWLYHEEPN$+9^0]\8(Z_C]>,56U"P%E>7$)S^Z?:F>I]\G
MD_YS5_3](74%5P-TF<N,G@<8X[9SW]:RCAUAJ\(74-(N4K7DG[JZ[)MZ=[W7
M6W5&A#ZM'3F<ZB:DGITOJM5K:R[7L6].T^:WL)M1M[MX&>-@RKMPR@*=IR,X
MP<=?YUABUO-1"M$9)Y2PR@&<<YSP,YSG],]S73WUB]M:?9V:14&=BABH9O3@
MC.<?IP*T/A_>PZ1J\4DR1R[Y(U>.=!(H4[@2%?('!.<8(XZ=1UXY24+PLG)*
MT'9:Z7GMJGVT3W.*2G";CSQJ251\J459);QYK:)=^GW'&-HUVDSI>))&57(R
M".0,XY SV[=ZK1Q^02K9^\0 1^&?KW]*]X^*DUC=:ANM(X88-D+*T"K&"^%)
M7]WC/(QC/?%>.7L2/$LA^64':%'R_(!UQ_7FC*'/VU*-2*5W&7-IJHVT5N_E
MM>VQUX>4E%3Y4I645'3[5DM.W=?J-0A4W%N<9!/;//7]/6J,T@9"5. "?E['
MW_GTQUS3'( VY.PYR<]P,]?SXR:K+&)(F(8F3/"[L\<_PY[?U/O7T6:\0^S@
MH*.D>6*L]+:)MK9M;Z_%UV.BM)4H0<H^[.Z=G=J4N75O3W>M[][[#[>,W4B(
M3P2!N&.,D#&>GO\ 7DU](:G\,;*U\"KKL4C-.L0;:-IW99_3_=_#VXKP&UC$
M7EJ@X.&=NZMG/WB,CZ>U>W6'C*]U#1O[$G<M BB-(SC!&2?09ZGKTKW>#L#5
MSG%TY.E'E4DO:-7:6DHI*UF[]=[:'S698V=.DY4U?EES.\K<T8M:MN^ME?SM
M9Z-G'^%M"&KW45G-*2)'V@<97[O3C'<\G/>O3];\$QZ&;,1[B>!SSOX;'89X
M'8=>PK4\ >#8+S5;:2$L6,P\P+(1MZ9Z'@=!C]#W^DOBYX-L]&TO0M11<R0P
MQN=QR'/[X88,<-Z\_J37]4<)Y70PL(4,12C>TM)QLNKNY/XEZZ+9>7QF+S>-
M3$*/M)I.2BU;2<G%:6Z)*VJ3U];GS7?>%7@T--4D#H\J90'C9C R >N>?6O-
M+2SEN1(TK,7128VQS(PYV],$=^.3Z\BO0_%?Q!O-4TV/388XT%J"KK'$BXR>
M^U1Z=QGVKSO2+S4[EK588=QMI5E $8^?&,*V!EE]C7NU\RRO#UW1C",N22C>
M,E;F5GRWOZZ;;Z=#MI4JLZ:;:Y6T[/=^?Y;/9WZ7/H?X._"I]:NEU34Q+%;2
M;#A^$4%&8GE.HR.OID^_$_M):%8:%J4EMIUR)HT"#(*G/S("#C(XY''>NBNO
MC_K&@:&FAK!;V<X7RW,=M#%* RI$3O5%8$8.#GKGTKYD\5Z_=Z]=22W5Y-<+
M(_F;I96D)+-NQDL>^, =!7\Z^,7$='&4)8'"5K.I*496LU=<O.KKX6M+.U[7
ML>Q@<-5H5*<ZBY8NUE!\R:25E9*ST>_G=')B0?8\X&3)MV9XSC ;L<YJJH8L
M(RQ+ME@^/N@<E?I@@'Z"KCQQ@ @Y;D!.V!P&VU973[O[,U_Y3?9H_O28P!UP
M"V".2#W&:_EBK4<L13I:\L>5R=WJ]/>76WEHNVQ[LEI%QC>]-3L]7JM-^W5?
M+H8L\(E7S -I7Y=H[^_/K@>W/N,07-MY C*ECN4,>.A^HZ?YQ5I;A2#,2-R-
M@+G@]>2. >F?H?:K$YC7RXSRLR>8Q8YV[N, D\8ST[\5Z=&K4BKI^XI7E[VK
M5E:RWM'?=I;FE.4XPDG"ZC9=?=6C:5][+5/SMZ_VK?\ !GI&S_$?XJOYI4+J
M-B"G #_O=-Z__6]*_P!'RO\ .$_X,^8H?^%F?%0^85*ZC9;5W<,/,TWDCOU-
M?Z/=<E>:GR6OHG>_5N3=[];JWY];G>MK]'9I=E9:>1FWZR@+,DC*(L$J,8;J
M/3/<>_I7RA^TEI'A/3_ 'B+XHKHEK>^)/"=G]NMY&\PR"5I5BSA6YXF;&,=\
M'U^OI$$J,C=&&*^0OCOX]^$7@#0O$6C_ !$UZVLK+Q+;^1+!>WB)$520,<),
MX4<Q]O3\L!GY\?\ !.O]N?QI^T+\5O$/A37M)6UM-/TR66(K',N#'YP'+N<X
M\L#H/KTK]MC:;YVFE=GCQD(0-HZG(/MD=_PZX_DH\*?MG?#;X!_M4>'?"GP!
MN=#OQXR\00>';TVD-C>2?9+JYNHV.\+(RG:,[E(/4^]?U<Z/J>I:AH5G=W,1
M%S<Q1-( NTCS(HV)X  Y8]NV: /Y7_\ @L_\(?BCXQ^)VLZGX,^(^N>'+65X
M1!IVG_8VBWK<0X4>;;2OENG)/7I7TU_P0U^ 'QH\$^'-5\:_$+QQX@UG36N9
M["#2M32U6W8G[7MN1Y=K%)N.5/WL=./7>_X*:6>@Z1XEU/66O2VK:4%U);1Y
MV96EMI8KA$:$G8RLR!2A4ANA&,BO0_\ @D7^U?XT^-NGZOX6UC2+'3='T*YN
M;*W-GI=K8K,+)KF".1WMX8O,D985)=MS,3DDYH _=2BJK7D"W"VI<><XR$[\
M8_Q'YU\K_M)_M8_#C]GC2)9O%>OV6E7^1Y:7-Q!&2##YH^64]PR'IW].: /K
M*OQR_P""\/R_\$V?CA*?F5(M,S$>C9-W[9X]B*_47P1X[M/&'@[PKXRLYDGT
MKQ'I%MJD%TA4QR1W&2K*R_(00#@CCTZ5^6/_  7=D>3_ ()M?&NXMQYB"'3#
MC 93S=]B.W^?0 'G'_!#.&5/V>M E=FVR:-.5C(&$_TJWX'?'!QGKGVK]W:_
M!O\ X(7W\EU^S[H:2+M,>CSC  &/])MSV^OZ5^\E 'S#^V5&)OV;/BC&3M#:
M&O/I_I<%?XR7[>]IY/[2?CB))CA9+XY&/FQJNH#!X[]J_P!FC]M D?LT?%/!
M(_XD:\C/_/U!_.O\8[]NY5D_:.\;F21LB6^()8@L?[4O^#D\T ?#AZGZTE*>
MI^M)0 4Y3\R\9^8<>O--IRD[EQ_>'\Z /L_]BF57_:%\'%8A'B>R&!GD_P!I
M6'S<YYX_6O\ :8_9!_Y-D^"7_8A:1_Z#)7^+1^Q3)*_[0O@XN@0B>R PNW(_
MM&PYP,>@YK_:7_9!_P"39/@E_P!B%I'_ *#)0!]'T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!5O@6L[H [28)1GT^0\UYQX)C:*XN@TOG
M%KF4@Y!V_O7..!^%>CWP!L[H,< P2@GI@;#S7F_@B...XNQ%(9 ;J4L22<'S
M7..2<<_X4 >I4444 >;?%K_D1M6^D?\ -JW/ W_(K:3_ -<#_P"AM6'\6O\
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M6NOP[==>?TN>)$6TFF$<RMDR$@,V>B]?;'%:M_"[JC ED.W')QSC#]<GI_\
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M2;+4#N^7*_\ $NT#CI_GCWK^7[[&K6\LY<[E<C!QSR>?T_G7]/\ _P '1\$
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MD1@D_P#+://Z]N]?ZR/_  ;$_P#)@$G_ &-2>O\ SPN_6@#^C^BBB@ HHHH
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MCWPSXKTRP_LKX<:=X2>-+:,&T%VK#$S)G]_-)R"N>?;(K]<:" HHHH ****
M/B#_ (*-F$?L7?M"^<A8GX:ZZ(\=FVPX/0_S'^/X)?\ !N,UK_P@]HJIBXRV
MYN.1_9+^V>F>]?O=_P %&I%3]B[]H;=&)-WPUUY03GY25A^;@CI7X"?\&X<;
MCPC;.5^4[\-_W"I>/U_SUH _K9K*US']C:IN&1]@NL_3R7S^E:M96N'&C:H<
M9Q871QZXA?C\: /\JG_@Z.:S_P"&VM+(B;9]CU ,N1DM_9^@<@[?7/8]^>:_
MF$#VGV>52A\TN=AXP!EL#IUZ=Q_*OZ??^#HZ=#^VUI3?9E %EJ(*8;#'^S]
M&X\Y]^"!TK^75T9B\@4A=S'H>.2?\\_TH D2ZE2!K=3^[<Y(]_\ )-5JO16J
MR6DEP7(96P%_S_GK5&@ KI?"&?\ A(M,Q_SW_P#9&KFJZ7PA_P C%IG_ %W_
M /9&H _U]O\ @WK\K_AWK\)-B$2?V?/YC=F_=6&,#'&/>OW=K\(_^#>QU/\
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M!N5=F<'R^/OCUKFC^T%X4:TM[N'RYDN$#XCN5.P'/4[/:OF/XM_L_P#BK3/
M'BR]T_Q/J5NRZ=*[!/(._&!SF'OP>*^7/V1_@[XO\:6OB"TUSQ3J5X+59%M1
M+Y'[D+]DQMVPCIO8=\[N] 'ZR>$OBSHWBZYEMK*(HT9 W>:'#9] %&*]8!SS
M7S)\-/@?=>")$EDU*YN'W9D>0IE^,#.V->A'MUKZ:'  ] !0 M%%% !1110
M4444 %%%% !1110 5^=OQK,/_"=:AN1B?FY'_7>;_9-?HE7Y_P#QDO[>'QM?
MH]J)&&[YB#_SVE]"*J+<7=)/R:NMUT];%PDXNZBI>4H\R^X]]_9YNVN_#%P[
M(J$2KPN/^>LX[ #M7T'7SY^SS:-:>%[A&<.3*.0,?\M;C_Z]?0=20%%%% !4
M;Q1.RL\:,RG*EE!(/L2,U)5*Y6X:2(Q.JJ#\P*Y)X;_$?X>H!R?Q(\/P^*?!
M6NZ#<2/%#J%J(7>/<'4>8C?*49&[=F''>OQZ\*?M'K^S%X^G^'%])>S^%M.<
MAKDKYTFP2R6Y($RR-]V%.LW<]#FOVOOI(MJVTREEN/EX_P _S]:^7/B'^Q[\
M'?B!>ZAKFO:?>/?W<3^9+'-"@&YVD)Y@9OO.QZ]Z /RI_:4^,'CO]J#Q9X0T
M7P!9*_@S3O$^E7T5\Y%O=R1IJUI<N'\BW9C^ZMTR&G(^8CUS^Z6@QRVFDZ!"
MC,UW#HNDP7",QVAH[&!'/?G(;G )ZY]/FWX2?LN^#?A]J"_V7#(^E6Y1[82^
M4[JZ*X4F39SP$Z <\]:^OHK2"-A(B\JBQC_=5=H'Y>WI0!F^(2Q\.ZON W'2
M[O(ZC/V=\_A7^6+_ ,',6EQ7'[5L5R_RS*NH!0O3'V31N?O>@Z8[^O7_ %.O
M$N?^$>UO;PW]EWN/K]GDQ7^5U_P<O7T\/[5"I,09#_:.UN<!?LND=CWP1CH,
MU]GPF\-"..J8B#DHQA:6GNIWOOWT^[S)FFX-1U=U[CV:TO)_X;_IU/YD;Z-(
M2IB=G4*,ECG' .,DGOQP:DM+B(1^><&Y0[40XVE?4DY'4?W3[=*JR*\UNTX8
M;1]Y<'OGN>?7V[]JHVBR3RB-&VD]ST^F*]/%9M+E]C"NU&%VHQTV4;+;KTU>
MN[2(Y*49<J<G!\O.]-;6=UI^9TE]=&XLF\J./'_+8[4!4\XV\'KGMCTZ$USW
MG2S[+<#:>%&, '/3=C&>3CCMU]I\SP1SQ9&TD;N/RQS_ /J_2HX(6$\!5@&9
MAM..GU_'_P#77+4]M7C&JY-U%%.+EM:5EKI]GIVDNQ$J*^+EO%>]%OLWRI[^
MB]279<OD;$'V7()&!GW^Z/7WIUS=7!CMY6C38I)0@+EL9^]\O3VYQ^M:<ZDP
MS"$JKH/WY(R'.1G;Z#!'7/Z&LRUF26!K>=0=N1"1V.>ISGW]*\RV)C:/O7=Y
M<T?CC!-*76UGO;^:VVHE&E%N2BHVB^_7WGUTU_)GINC:Q =$E!CC\[R3O^5?
ME&P<@@#!R>P'UQ7&S"WEC69S_%E#C)+<$9SCV'7'./2LBU2_B\^.$G9Y9W':
MV"OUW =.?PS59FG6! S?(#D+@Y[=><8XZUM[7%U9QYJM2-+W:4$]W%13NUK'
M=:K>^MC-./Q24+SDG3DN;5J.GH^GWEDW\D-T\IC3=@ #"X  ..-H&<'L/2K!
MU":^,$4J*(VG12P"@X+#/.,_AD5G6\$E\[DD*57)^@'KZ\?YQ49$L.!D?++@
M9!^\#][].E=].M*C1NZDJ;=-*3TYG))+WK+=/?;7SL:PCSQ?.KRC!M\KT4M+
M_P##'>>(-%TNVLX9K:1C=&*-MN,+RBLW\9[GL#Z'%4-!G=2(6C0QDC<Q W9S
MT&5[Y(Z]0,]:PKG4KAU19F#N H4C(^7@8P=V3C SW_2KMG=B&>(*N$.TL.!D
MD@GV]3[5[/ 698RGC?WCE54JJ:FE?F2:NK=+IK?LMC@K+W8*E&\-N:79-<S^
M>T?0]$O=/O[.6"XDC5;22+>,<@C@Y8;2"< YS[D5B-9S7DK&V4!2<NPPI'I@
M@=N/_P!?3V'5EBO_  Y96R,HNI;5&1P/NKM;CCG.2,\_3O7$:6T6E[TN/F8=
M2>-W?(Z_7DYX]Z_HRG'&XUTY4ZM6%"<8.2T5KV4HQT>MM+?\$\VM4K07[N25
MER?]NRTUWT5[V_$Y^7-OY<<B*TB\+P#N;GJ2OYY]A7>^$M*DO+VVBU)/]%NV
MVDJ"VQ2,_+PN/N]B.N.M</JT;7$ZS1, NX,N,G &>??U]#7TS\#IM U:8)K$
M3.;(E24=5W8$?(RC?WS[ =:]/.*F(RC)JU;!3]GC(<KI3O[]K1NF]N:5O=MT
M:[GS.=XFKA\)5JTY2DURNH_M0;48J4?)WTM?T5S,^+*:9X7T/1;73((WAA#F
M.5XE$CDY'SEMQ.,#&6(]J^8;J:X\2JGDHJS(WF/$#A-O4]!C\-N>!V KZ\_:
M9ET(PV$.F1,L.'$:M(&*\ODG"KUQGM]>37PQ9ZC=Z1<EH2/F^5\C.5)[ $8[
M\XZ^W!_#\_XOS'&X9X?,L34K2]@TZ<]WS-2Y)V2UB]K-:)*YZ_"LY8C 4I59
M.I.ZE>>LG'1N[\MGUZ(=J=M>1S&W,:(RG!V''?'/ ST]/>I5MX+>S"NS->$'
M?%R4 P,8Y(SU_@'YDU<34%N+J6ZNL,K(=BCLWS$=1[CJ.>G>O8OA9\(M0^))
MN+JVE$?E0R2D^67!1(Y' X*X.U/7J>/?\,Q^8I54J;<>:3E*,=W)? ^UVG*]
MK7Z;GOU9\CE"T(4;Z\E]&VFD^O+O>W=6TU/%M#=4F,5RH$;,2C #)<DE5Z#K
MP,9^@YKUG2/ 6IZZZW=M:JSA"(T"-L92" 2%4C=@9SC^M<AXN\-3>$_&-II%
MRV4BNHO,^4IE5F56ZYQGD\YXK]*/@W>?#^WTRQ:^B#2BTA\P^?&/FV$$?-$>
M?0DGI[44\1]9IJG)W@I*<8OKM??6ZM=:KM;OY^<5<;36'EA91:DU"HUM"$K)
M-=6]'>_8_/C_ (4YXSGNF\NSC\K<V23+N'/IY9]#U(Z=,<UP^M^&]3\/7+VN
MIPK'(,D 9.0.N2RC';K7[-'QC\++)I"+,>6"VX&XAR3R<@^1[>_MS7YM_M%Z
M[X>U3Q,QT:$QQLCE#O5@ 0N,[53/7/ [<42C3@F[<TDF[/I=))+S3U737L<V
M&Q6+JU>6=**IWY(R2?/)PY92GO;JK[/?30_K'_X,]\_\+)^+&$4J=1L<DXRO
M[W3>G'?VQ7^CC7^<;_P9[[A\2?BN-RX_M&QW#UQ)IO3O_P#JYK_1RK@G*ZAO
M=)II]'=NR^_7SOT/KJ?P]>F_^".WE^MSRWXT^+]5\"?#+Q5XKT2-)=3T>P%Q
M:1R8"-(9HTP2T<HZ,?X&^E?PE_'?XY?MB_$_XP_&+XD:9J]S86-N8I380>(;
MFVMX$29T'E6\-I'"F[S!P(U_08_NL^.>AW/B3X6>+M%LW$=S?:>(HF9=P#":
M-L[<C/ ]:_A$^-7[(W[;>E?%;XP:;X/\:Z%:^%O$;116-M/H-S++&@F+MF1=
M4C1CA5Z1KTK,T$\$_L_^./#B_LY_MD3^/O$.K>.?&GQ.TC2]>\.7WB#4KG2[
M:S>."\DD@MYKV6TWB349@-NGQ'"+AL8 _NJ^'>K7?C;X6Q:A=1*+R\TGRMO!
M#,UA$0I(4 @LY4_+STK^&7X.?LO_ +<$VH_L\?#GQ+XXT2X\+^%OB5I&JZI;
MIH=U'+):11PQ2HK/JCI&2(%^;:V#V.*_N\\%Z*OA'P78:1$=[I9PQJV,CS?L
ML4>2 ?[RY_#'I0!_.K^W=KG@7X-Z?JNH:AX?T:'QA;75[=:I<0Z?8?:#:+<H
M^XW!C$C'RS*<,HY..,U]'_\ !&7]ICP9\<?"&O6WA2%0-.U>[MKF1[:VAD%Q
M ]VDBJ8LDJ&B8#D9[ 5^?G_!8CP#XNTKQQJ7B#7[M;S0O%=S'I$-G;0O$\2W
MEU!:ERQD<' NE)/EC[OY?7O_  0W_9;M_@AX4U/7M+NV.G>(;F;5'M9?FE6>
M_%U.WS# PIF(QMX]>* /Z*B 1@C(K UWPIX;\36[6NOZ'I6L0-UBU*QM[R,\
M;>4G1U/''3IQ7044 4[/3[&PLH-.LK2WMK&UC6*WM8(DBMX8U^ZD42 (B@'
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M3I[>]52GS1DO>C%M;V7/R[/N]]/F3752G+E2C-QTONDW;E:\EU_JW2. (_D
M"JAV@#@8!Z ?TKXZ\3VJR>*);B,LPAF/F9SE<J,8SGKWZ<U]C.PV,J$$@,..
M<<'CZYKY(\5[;35KV9<E3(#(/XCE1@@G(X[YSGG\?S[C6RI4U'GE)NJTG;V?
M.J::OU]W?\GJ?;\#R2Q]133;E3CI'9M2WU_E>JU6J5]CC]23S8YFD #H,P
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MR,.IX7KP.QS775QW@G>-$M"Q^4KA!W'"]3_G^@[&OZ"ROE^I4&E9NG#F_P#
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M9.__  *@#^L^LO6\_P!CZG@9/V&YP#W/E-BM2LO6\_V/J>.OV&YQ]?*;'ZT
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MD_X:5M'*]KM9@8]^ ,<E\<'K@XX[#^M?=X3-<3&+C"M.,4HZMZ1VO;LUJG^
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M3'_0U)_Z(N_8?RK_ ":?#\TEQXCT>1\9_M&R!P/29,=^O'6O]9;_ (-B?^3
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M)O\ D7M;_P"P7>_^D[U_E3_\'-5P1^U>D&T-N74<28.1_HFC\#G!Z]"!BO\
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MM-5+KYKH*_I_7D?O5\-?A=-X'M(8#>3S/&>7?;D@@C'RJOK_ #KV]00H!Y(
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M_P"@FKU4=1_X\YO]T_\ H)H \P^'O_(6UO\ ZZM_Z##7KM>1?#W_ )"VM_\
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M_P#ZXH _ /\ X-=IHS\#OV@%^6-O^%M^(AM'\7_%9>,?7)Q^/<U_517\J/\
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M *^ ?C)IRS>-K]S.Z9W<#;C_ %\OJ/\ (Q7W]7YW_&ID'CK4 9I%^]PI./\
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M =N_7@UYKK>IZAKNIR37)<EV!8,1QR>>^,<^M?#X;$58.5*;<4I:N2NK:/\
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M,QW<1E\R EKDG[T[KSP>A'''4U^L'_!LM#-#\"M4D(*!])NRC<\?Z1I?Z?\
MZJF5*%FZ<9>TCRI[^Y)-)2OLTWT5[/?L#3B[.U]&K=FD_OUU/ZOXT5$5$^Z!
M@?Y_SCI3ZJV3,UM$6.X[>3ZU:KDE=2:E\5W?UZ@%%%%2 4444 %%%% !5'4?
M^/.;_=/_ *":O51U'_CSF_W3_P"@F@#S#X>_\A;6_P#KJW_H,->NUY%\/?\
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M-B/Y/_!O_!NW\+-&OHKZY.K^?#)O#(R1[C\G7"<\ ]3UK^B71/AA%\/OV?\
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MVH _@5^.;0G_ (*7:UY8*@:[>;U)&6/V_2\D=P/;_&OTO0QBVD$@.\C,9!
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M]T<?ZVX']*^AJD@**** "J5RUPLD0B164GYB6P1PW^ _Q]+M'X4 1RE!&QE
M* ?,",C_ #_^NOFOXP?"+P3XG\/ZUX@UJ<V=E96<UW=2P6RR.D2'>Y4&2/)^
M;J3U[U]*R*KHRO\ =(Y_S_G/2N)\9Z5INN^$]=\+O<QQ_P!L:?/8[-X$A\W
MPH/?CCWR: /R"^#?P4U^_P#B/_PDW@BZFO? /VF%[*ZG+Q3.8WG?!A19(U!B
M>$\2GDD=LU^U&F)+'86<<P_>1V\,;=^4C53V'<&O'O@YX#LOA/X,L/#C-&(8
M9!L>9560L8HHOO$<_=&!GO7MP((!'0@$?0CB@#$\2@GP]K8 Y.EWN/K]GDK_
M "F/^#FI)H_VO[?S1AB-1QC/_/GHOKSTQ]/K7^K1XE)'A[6SZ:7>G_R7>O\
M*B_X.;9DD_:VA#C=,$U$!E(( ^R:-P1@G/XCG\*]# 74IRYK1BM4K7>JVOUZ
M*^ES&IS*=-I<T;N,H^K5I>BZG\ST8+%&!RH !ZY]./R/X@=!TMWD,\\L$> &
M,8V>ZCN>V>>G:L^RN4BD"SKNC[@$ G]#@^V/K6DU]NW2A<.AVPGJ%3_:]3G'
M^>GVU&NJ]/DIWQ%2,4VW:T4[=K/R6CU6MM+JO4C[KA3Y;R7-R[W=D[7?P1TO
MK=>=RBL<T,%U&%4J"H<Y/'/ ]^:I2VTL")(^,/RN*TI[@O!(8\#=@S9&<GKQ
MTQVZ9%54>6]:"%B H(5<#IS_ (^_IVS7AJDZN+E""<'&K%2O]A^[?OK=W7F]
M=R(34DW9JS::>C37KY6?HQD"3M#,40%<'>3G(^[VJO:&19EV@;MW )P#SG!_
M'_#UK?D0V:M&A!!R')'WN>H';H/I6*^89%FCP,G*@\\]_P#(JL;EM3 XEU74
M<G*-VXM.W,HI\VEKO;_(Z/8VA*5E=\LF^K32]ZSULE:.FOEJ:EQ<21-*S(/-
M="& /R@>QQUP.E97V>?8ER0-C,-ISC)STQZ<_P ^M('FNY)7=ANVG=[CCT('
M?_ZU7_+G-G#\RF+<-JXY!^49/-<-*I4Q,U35XQ3C"S6\E&R;MTMOTNEY"J3I
MVTMSQBE/>R6EFKWU:UTV_/2MKUK8*&'[S RN00 1CJ1_3C\A7360?4HCO&(Q
MD@DDL7P<#'/''/.?;ICD$M))93N89V@YQQTZ>N?K[=.:Z[1!)#&V\CRLD%3]
MXD9Y!S^7'3U[_N/A_A%AZ<)5W&T?:25WJ_;<MFONZ]7Y-GBRG%0E"#BY-QFV
MM.39V5^GKT_&L+26"Y#;%+C. 2P4KGG)V]EQQSUS27EVN=BJ!%CYR."''!XZ
M''/.>W;I6KJ%RA#+%C[1C"MQM QW''J._7KZ4F@^&;G44>:5\Q9;<NWD\MT)
M)]"1[XKUN,)T<O47@J<U)P4G-6O>3M*^NUDF_+9,SEB/:03<DI/EC=*TI1V<
MNBYNBZ::JVICZ9=":^C?;_JAL3/0C(/)_I^N.MM%C-^[%MJDY?';D=,$C_/O
M5N738M-6XC4_Z3YC>4V0=J]@1C)QD=#VK%@$H6>=G'R$9&#ELXZ'.?8]>?3-
M=/"6-I2A"K7I24(1YDYK5SLM=-+:IK\D=$*ZGRTKN"LES+1N]E[33OLW;;I=
MW/6;#5;*&V"2@!P,1=,N<_Q'(QGGU[>N:\7UZ-KZ^N98L!4D+2#/ X[#CCD?
MY J6YU"XS'ANA^7KQSW^;'^1Z5BB^D29R^"LC?O>N3^>>O'8\G/6OGO$+/(8
MK!U,OP[<8U/?GR_$XQDE:-_-<TNG+>QV4*?LW>5&"Y6O>[OW6GH[^]'5Z?B3
M6D<VI7-CIMN@\PNRQ$_Q'&3GCV]Z]R\4?"'5O#OA'3?$=]&J>;<(KC#[0NV-
MLAB@R06[8X'8&O+?#CV]IXCT._4?N1<%BI(_N,.3CH<\C!]<\5^E_P"T-XN\
M'>(/V>? >D:!!Y?B*?7+>*^E\U'#0M!9Y C1%92"'Y+'T(XK\<P^/PT$Z5:D
MO:?NX0?*^>R@HN3UMRN7S>G7588NJO:P<8J-3FE4MO\ NU+5+UZ:W\M#\QK^
M^NIH$BAB0P*WRN6PQ/ P1C'3!//?MS5>(VZ,9)SMG9<.JC*@8/(/KS7HNN_#
M[5-#T^.]DG0V[G"1F/# G:!R6SQN7'R_3M7-6_A2:XMGO)95W!6=\* "JC=@
M<]?\,=N?+QWL,/.$^2/+.3YKMNTFX_#9VMVO?[[G1A\32J2;D^2+C3\Y;:I[
MJZT^3]#B[RT0D3P-NC+8^88.X]1Q[].GT-$?G0S(0H)V' SVQCW['/\ ^JK#
MGS9Y+2'B.$MD'+9D3.2.G''OG^3X!NE$+D>=GAL?+MST([D@CGUX]*[\'BJ,
MU3H*FH3G%1NT[.+MRMZM]7>W?7J77E5@HJG)251N\=W=6M)].5=;/Y&<T,\D
M4D@0"(,<GG(Z],_3'Y>M4F+2,%QRHP/H/PKM+V!8;<A"OE$?.  26P2<$<=<
M^N,\YKE&BVY8$9)^7V'/!X_E7=F6'EA:7/-<TY323CL]%ITT_E7>^Z.K#PG7
M44YIQ27/!6NHQL[;:7?_  ?+^V;_ (,]#.OQ(^*JH@,9U&QWMW7][IOW1W["
MO]'NO\X3_@SU$_\ PLGXJ;64)_:-CY@QRQ$FF].>.U?Z/=?)UI*2IV:;46I+
ML^9NWW6VOK<6SEO;FTOO:R^04445@ 5B^(IKFWT35)K0!KF*PNI(%9M@,J0L
MR M@X!8#)P<?H=JO,OBWK%YH?@G7M3M#A[/2=0N6R"01#;L_.".P/K0!^#/[
M4W[1=QXFT;Q5\*/%\L^F:[/%J^G8M9O.0+>,\,!#'RVSA0<8&./:M7_@BE^R
MO+\&X/&7B^;5KG43K_B#5;Z,7"L&6._N+Z=0"6/ $P[8X]LU\+^#5MOVP?VC
MO$VEVFH0:;KFG:G,US+(XDC9+:XOGQY6493BU?JQ'(K^A/\ 9=^'=Q\);6'P
M_=>(=-GB\F/]S&!'(SA67/\ K.Y;TYSUR: /O.FET!P64'T+ '\B<UC:EK=O
MIEG=W<@+I9V%S?M@X#I:V[SL W(&Y4(!.:_GU^-?_!8#3?"OQ2ECL_#E[9^%
M]&U"XTO4))[MA&\UM/%"TGFB%40$Q3, 5; ^G(!_1+7XX_\ !>(@_P#!-CXX
M+)@0-%IGF-U8<W>,#'/7^\*_3;X)_$[2OBY\-_"_CG2'1K77=)MK]5243;!.
M&PI<!<D;?0?0=_R]_P""\Z3'_@G%\:9"<VB1::;A #N;F[Q@YP/Q!_"@#SK_
M ((8M)_PSUH(*@0C1I_+;/)7[3;XR.QY/&>U?N_7X/\ _!#R[2Y_9UT**U!0
MQZ+.%W8)'^DVYYP!^?X]N/W;@#B)!(07 ^8@=3_G_/>@#YC_ &S4:3]FKXI(
MGWCH:@>_^E05_C)?MY17%O\ M(>.(RBEO,OM^3T7^U+\''';%?[-O[9LC1_L
MU?%)TX8:&I!_[>H*_P 9+]O*6XN/VD/'$A=0WF7V_(ZK_:E^2!SWS0!\+'.3
MGUI*4YR<^M)0 4Y?O+GIN&?IFFTY?O+GIN&?IF@#[._8H6 ?M"^#O*=F'GV1
M)(Q\W]I6''?CK7^TC^R6TJ_LO?!0PJ&?_A M(P"<#[DO]<?YZ?XMW[%#0']H
M7P=Y2,H\^RR"<_-_:5ASVXZU_M,_LA?\FQ_!+_L0M(_]!DH ^BX2YC4N &QR
M <CJ?\_YQ7S'^V?S^S'\7N,_\4K=]?JE?4%?+7[:H=OV7_C (^'/A2\VG&<'
MY>U '^=3_P $HVN%_:G_ &C5BC5D;Q7JF_)Y'RZ-T&.?\,_A_23XCNA:WMN9
MHTPW^I^Z6)P1ST QCCK_ %K^;/\ X)-I<_\ #4G[10+KQXJU3S..3\NC9QZ'
MWY[^M?T>>(XY;N_N!*PV6ZJ;3C[I8');U[]!^7.>[#THU5:I/F7(TDM)4]4V
M_P"M=;B=[-JRM9Z_:U2LO/6_R^0_[=AYIFC0%TP^,8"YSN7CD\YZ_P JR+%+
MB^OF:)%\A &5B?F.,MR"I'89Y^E1-'</96Z^8/,\P>>PSAHP.5 SU/?GO6G:
MR-9_ZC 5AM .<\C!.>#_ (<5T/E5.S4975HMM_#'EC"<O*SL_4=HK3F;E>.V
ML4FES1UUYKVLK_,OV5\\FIO!'&OVD!5D7H  "N01ZC)^[UK\&_\ @KY:WEM\
M3?V?)"B>4WQ:\!G.>=YU[1>/\^WX_NQ;1M!J!NHSBY8KO;^$@D\ ?0GN:_#3
M_@K[+=W'CW]GN1G78/B]X"0+@_>_M[1!N'/KBLIU)*$>1)0IQIT^9_$G)+F7
MRMKY=VK%.+@Y7B[2<DN;I;E^Z2T\OPM_H(?LL-<-^SO\%S. /^+9>"]N/3^P
MK/V&>,?YZ_0%> ?LL+,O[._P7\Y@V?AEX+VX&./["LL=V[8KW^N&I\<K<N_V
M?AVZ=?OUON2%%%%0 4444 %%%% !1110!5O2PL[K:,MY$N![[#BO.?!33M<W
M1N%",+F7:!W'FO[#M7HU[N-G=!3AO(EP?0[#BO.?!2SK<W7VA@[&YEVD=AYK
M^Y[4 >H4444 >;?%K_D1M6^D?\VK<\#?\BMI/_7 _P#H;5A_%K_D1M6^D?\
M-JW/ W_(K:3_ -<#_P"AM0!UM%%% !1GMWHJDBW NG9G4Q=EVG/\7?\ $?\
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MG<VFH7-A%]NVJ(77Y&!PQ;!ZC XRP'7ID]!7':IXNU*[E<*O))4KYAX7H<<
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MYW?V6ERW:UOHFM_OL?Z$_P#P:*KGX=W#$G(U0\<X/_$SUO\ EVK^[ZOX0/\
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M:W/Q:\1;V8[2&_X3+Q@/NX/?..<<5_5E7\I__!K[#<1_!/X\-$P^SO\ %?Q
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M-^PS^WE!^WC)^T7XB\+Z;?:+HOB+5/L%C/J6H30SV+:S83V[ONTS8I-O8)D
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M[_A_C_LU?MHG'[-'Q3ZC_B1KT_Z^X*_QC/V[Q$W[1OC7SG88FOBA[EO[4O\
M@\_XT ?#QZGOSU]:2@^W2B@ IR_>7C/S#CUYZ4VG+G<N/[P_G0!]H?L4ON_:
M%\'?N/*_?V0QZ_\ $QT_YNI_IUK_ &E_V0?^39/@E_V(6D?^@R5_BU?L5-,?
MVA?!WFHJGSK+ !S\O]I6'/;FO]I7]D'_ )-D^"7_ &(6D?\ H,E 'T?7R[^V
MBP7]F+XO,QV@>%;O)].5KZBKY;_;4C$W[,'Q@C8X#>%+P'\2HH _SI?^"42B
M7]JC]HMTN=H_X2O5"$XQ)\NC?[)_ITZCM_2#K[*U]=HKB,[5W,/^6?H<XQ_7
MGUK^;S_@D]';P?M3?M%1M(P9?%6J+& !\V$T;K^!/KV_'^D'7HD74+^1V*^8
MB;^!QQVZ@_\ U^]=^%C%VY924KW?NZ72V3MJW&ZMKO?IHG:TK]%[OF[I6?96
MN[WW2U1AI'LM;<&ZW#S.)?\ GJ<?<''?\*TF3Y X)W9^YZ=.<8_'^?OEJL#V
M5H@=_+28-&Q RS8  /L0!TS6CG!&>I/([ ?X_P#UZWQ'+**;O"-KN/PVC=62
MT^)_R>5[71479)6YDU:+[3<HN35M^5^MOFRW9(L\VUY?+VX._.-Q'..AR.W;
MUXK\*O\ @KR@_P"$\_9[Q<!<?%_P&NSV_M[11NXS]?\ V6OW1C51,I!8+N7&
M!U/H1_G\>E?A9_P5Y6(^//V>F9V$G_"W? 0VX!&S^WM%Y^O?Z]QTKFO+V=5V
MM>5-)12;5/:_6Z>GO=>X.+CRWDG\2MS7U7+=VOUW_$_T%OV5D*?L[_!@&<S9
M^&?@PY/;_B167'1>G3N*^@J^?/V51#_PSO\ !CR6+?\ %L_!F[(Q@_V%9D]S
MW^GTKZ#KDGRJ34&W'HVK-_EU$%%%%2 4444 %%%% !1110!5ON;*Z&[;^XE^
M;T^0\UYOX'79<78\[S\W4OS?W?WK\=!TZ5Z/?X-E=;LA?(ER1UQL->;^!A$L
M]V(69U^TRY+#&#YKYQSSS0!ZG1110!YM\6O^1&U;Z1_S:MSP-_R*VD_]<#_Z
M&U8?Q:_Y$;5OI'_-JW/ W_(K:3_UP/\ Z&U '6T444 %%%8]_J(@=(HQNDW@
M,#P -P'^/^/." 6S=,DTJR(5AC0N93C:  Q)]>,?KQ7B_BSX^_!_PAK(TGQ1
MXYTW2[VX40K8W GW.7(0#Y(F')('7OTKU[66QH^I2+_K!I]PW'7/D,1Z_P"?
MK7X2^-_V?+KX_?M!ZM%>:U?:=_9.FW=]:1PJ[++/:R,\2-\Z8#-$H)&< YP>
ME U>ZMO?3U/V/T[6O +:>WC+P_<6=];KAUNX?,PPFW$'#!#\Q7T[^G%=EHFN
M+XDTZ2>V/E$-P5[Y+@=2W'&1]>YK\&_%_P ;/&?[-=K#\.?$4$TFE3ZK8V,5
MVDLKNT(NDCB;8T0 W+<J2 W![GJ?VX^#YAN?!.C:E;,SC4=+L+PAQ@_Z1")>
M>O\ >_J?947%JI?W4JEEVEHG=Z_)_P!,SQ<J_M*;<7=QGS/EU27+9W:NW;;N
M>DO9P-Y<TL8:XCC($ISD#GWQV!].!7REXL5(_$CA7\LO(V4_YZ84>HYQTZ\5
M]8W%S'&NU\AMC=.>W_ZOSZ5\B^)E,OB5Y9B5*2-Y('.X;>2W3!Z^O'?BOSOC
M*7-[)0<6U*=^5W;@X\K3BM&U9N_3Y(^YX)A56,E-75Z<+IJW,G+?ILKWTTU>
MFAPL\2/J.689$@PY_P"69P>?KZ<?AR16G*OG[D63!0X8]?./)R>#SS[>O3%<
MG=ZC%'K<<"-\K3 2G/08YP.YZ?0_A75[(X7+;N7)\GK\P.>O.!T)[^WI7Y/6
MERPYI\JE"32M:72ZBU:SO%=5I=I6W/VBFZ<XR4Y<ME"4(N]KWCU>K3ZJ]EJ^
MAD,ACF,9R,]_^>7OT/7ZGZ5KD 0[#)G'/G?\]>!\G3_V4=>U1R6ZR,9'^5SC
MSP#G;V!7GGM3%$4P%NK$QKS&V>6;L" <@<#U KAG-3Y&OM+5+_EW[RU;3O:^
MR>BVMM?2TO:*24;I<SC_ "KG2;6C4DT[I:JVQ46Y52(1(!@\IG[O;=Z9&!WX
MQ^>HKQRQ[$F!VKDS@_?X^[QGTQ]WG-<;?QM%>L(^92<2#^$+D@D'N1S_ $]*
MV,)8V"R%V,94[3R26.,C'M^/Z8JE'F=6+?O07[M;*;DTY36V_*M-4M-CJ<HR
ME%)Q@E\"TO)Z:VW:_ETM*]^@Z6]B4R6[2[2=V%'T'S\5B(LSR&"*8R([EC,.
M=GS9V]!CTZ'H>]9($E_=EU)#<KUXV9//U[CCVSVKL=/LXK?:C'<K %FQSN/]
MW//4GOV&*QO)*-7FA.5Y.UU>#?+[^B^SU3T731FJ3<?WD7%QDI6@WTY6G==U
MJTM_Q=I( ;<N9,.HQL_O<-D],<X]?R-,@\NXD""4@#AF_NG(XX!_/H>QZU;D
MC2&)MY(D/*@="O..3R"<@XP>O;K69! MN6VL3YA+G'4$XZ>O?V/TJ6H+GBIW
MG&4(QO*T7%M.]]E:[TOHM=+W*BW-2Y9.S;Y96VTCMI9I='?>_8LNR1R^3NY)
M&T9^^/QQSVY Y]^:.><YXZ>W(%4IO*-S"SLPE7.P#HW'\1[=<5.EQ%*S*A)9
M3\P_7C_/XUUQG34$[<UES3D_=W_=JUK77,K:WM\6[N4G9V;737JW9>E[]_EY
M$5S;/</$RR%%0_.F1\_WASQGOGL?PJC)F"25$;"O@%?^>'OV],=6_#MHW-S'
M;IEC\Y'R#..Y//IZ]?Q[51MO)N$GD).]@/.'/RCC!![YQCM@?C2J45=SC%)\
ML+**NI*\;N_]UZ[KFMK=-EQ32YK*<%+EY;_:<4U;76W3L]-M!P"QVZLT^0I!
M+$_ZW  V]LG\!UZTZRVRW!E64!#U@X^0<Y/()Z'U(XX'%4O)R#$3B ?ZEN<L
M_& 1GCC'0GO5B*S>!-Z9,KX5EY "]"<\]B>PZ5K2C[%-2DFW*3OI[UY)QMV?
M+>Z]'8M)RI\K]V7M%&/-I96]YMZ7L[:]-B?6=*AOXREM+\P',P_B/&5Y'7@C
M@#KZ&L72= CM9)&F?< &VQ,20#\V)> .GUQ[<XKI+>,6Z")6+ 9.2><D'C!/
M;CGOUK/O9F27]SS*1MD7)P(SU;..2 3QCKQGL-/KL8Q<4[\TG>RNXJ+5]=-+
MO1]GN1"4XTW3;7PW4N5*3EIULK<WEM:VA((L6SH+K@.,2?W &^Y^N/N]!^-3
M%<W$;?:#PG^JS]_ '/7/(&>O<\>F5E NQ7?[.QW2.?O++DG:!W&[<,Y'K1N8
M$29(NEXA0'Y63C!8GIQL./<]ZEWYG:I'D?.Y74?=:4+:6UMN[WW6KN8?+^OZ
M_K>]AT;?)&)2VYR?.S_JC_<Z=><]&]B>]F4)!&DA;<$'S*3S,3WZ_ACCIWIL
M*1"V<N3EVW2MC)5^>%ZY'7TS@<8I+T1_9UY/"XC]QWSQQSGU_P 8^U[M]6VV
M[^\U%>6D=-+*S>AVT8^]24E.+OR22O9K1I];/O:UE:2L]3/OY)5M99K>8_=R
M0"?W>/4%>/S[CDUS/P]NIKO6[GSLH8YGPQ_Y:X"8(//7/MT]:ZI((VA>-23'
M*")\Y^4<9QC(R>.N.O3M57PW86UCJX\EL[I3MR ,\=^G\S^ KLRYRGBHR2?)
M=:-M)K35ZK[6W1Z=SASEMY=6C*,5)-V=DGRIJRE)+65ME]KJC[X\&<:-:G.-
MR_ZO^YP/8?C_ )SV%<=X,53H]J1]_;EQV'W<XY/>NQK^A,IO]2HZ:>SI<O5?
MPUUW?Z:6/Y<S'_?<1O\ Q9[KE?Q/HOZ>Y\2?M=VGP2\?^&$\%?$;6=*M[UY'
MBTM+TSAK?499H4MY(S%&_P Z7,<1&Y2-RC((R*_$_1OV%_AM9?&W3[#XM_%6
MQU2#3=8TW5=$L]2EE(#?:C<Z?%$(=+B.08[9$W$?=4;NI/FO[87Q3\>WW[?N
MH^"_&)NM+^&^EZU97&GW]K/+(TKQZ[J/RM \<,2#%M:Y(G;ASQ\O.9_P4.\<
MVUG\7?A?K7PYU*^O+N\U[P/:7449V+Y0U#1XG9C TQ.8WD+*5&,8/6N[$1E&
M=&.C4I)RM:7NN-_^'[.U^QA3<E2J\J=W:,FEIR=4_G:U^E[:.Y_4/JWABQN?
MA'#X2TZ-;RPE\*+HNGR(?D%N^FK:6\Z$D?*$*LN5/^[BOYI_'_P0UK]F;XR7
M]S=_!J7XQ6&KW^I:F(V"R+&;N9;J./B]TMLQFZ"#EL;.I[_TU_!N:XO?A1\/
M+B_7-Q-X.\/2S!CN/F/I=LSY)P?O$]0/I5GQ%\/?"^L:E%K6J6%K/+ ,#S+=
M9"<A!U/3A*UC).G#1\W635F^UU_PQC<_GG^!EW\9_'/Q1TG^POA1JGPDT NG
MF00K D*@W-NHSNO]08;0'<?-_%[BOZ-?#&EM;Z'HHU'_ $C4K:PBBFN7/SM(
M.I.W"YZ=!V%5M+\*^&+>2.[T_2[.W>( !HX%C;@C!R,=U'3V_'L    !@#IC
MIB@!:*** "BBB@#XB_X*,KN_8N_:&_?>5CX::\?]_P"6'Y>AZ_4?RK\#O^#<
M6VB7P1:7 ES(Q8&+GC_B52<XQ[GOV_"OWP_X*-+"?V+_ -H7S6*D?#77BF!U
M;;#@=1_6OP#_ .#<,M_PB=N"3CY^.W_(*E_S^M '];59>N<Z/J@SC-C<\^G[
MIN?PZUJ5E:YC^QM4W<#[!=9/MY+Y_2@#_*M_X.CXO^,V]*'VS.;+4#O_ +O_
M !+M ^7[N?;H>W/6OY?_ ++$T$LQF'F*Y 4]6Y;YNF.<9[=:_I]_X.CDM/\
MAMK2@)'V?8]1+''(;^S] X SSSGN/I7\NKD@N%)V;CCZ9X_SG^= %F.YC2UD
MA,09V;(?N!@\=<=_3M5*K"6TCPM. -BG!^M5Z "NE\(?\C%IG&?WYX_X U<U
M72^$,_\ "1:9C_GO_P"R-0!_K\?\&]BX_P"">GPD;SM^;"?]U_SR_=6/L.M?
MNW7X1_\ !O6(A_P3U^$A5F,AT^?>I'RJ/*L/NGO7[N4 9FL_\@G4O^O*X_\
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MRD4_D^9X?O5$X_Y9$A?FZ-TZ]#UK_&P_X+'V<EM^W#\0X'O3J+++>?Z0>_\
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MRP4&Y<S4KZIKE2?H]%L]R5+-Y2S32[5"$^83@'C[HQD]<#H.H_#)<+&K_-N
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M]Z"25FULXM]>B:ZF=3$VMR.$7)<KY;>[S2C)[>6E^J>FY<N]/1S')!D12N
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MP/\ ]9Q3#; 6[R9RJ'#@'DD9YS].PJIB9BTL*';N)!'/4GCO_/L>U30W4\3
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MUMK'GEY:_?LMBW8F)91YRDH<!!T(;WX/?GJ/2OPH_P""O30_\)]^SVI1R_\
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M?^%9^"\;,<#^P;+ X+8X[<5] URSES2;Y5&_17LM.EQ!1114@%%%% !1110
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M,O:3FY/E:2A#3317;T3O>]M;>0^FW7<\X^,TJS?"_P >VZ',G_".WO'OA?\
M#\:_QQ_^"NI:R_;?^(HFP")+W!!XS_;>K>OOP?ZU_L;?&B(1?"WQ_<1<2_\
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M"L29,888DZ@] >>OIP1WKCK>/?.H!ZL!QG/)_F/\XKK?$;VT4"10L60, &8
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M *Z[6OZ%R%)9=0232Y(:.^EX1;7G9L_FG-'?'XEVM^]GIV]YZ?+8****]DX
MHHHH **** "BBB@ HHHH ^(?^"C4:R?L7?M#;I!'M^&NO, <_,0L/R\ ]:_
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MV.&Z>9R<'U_/_P"O7-:H89-L\3KF4G*\DC&>O0=ORXJI-J!N8$1R08P OO\
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M5N7F;UN]&KZI:=6>A2BZ,:=-JZ>KL]%?=NVC2^7^?%Z?$B3YE1VY &W).02
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MRK<'3INB_P )^E ']5Y\V6>*:&1&MBH.1\P8$@Y5@<8(!_QK\?/^"\L23_\
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MM;;H%N;:-?LS!BPX= ?F+#C(!&<<^^/Y,DAWX60'+9\DXX0#@[LY /7J1UK
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MZ6WDN&F4.J9'S*>,\''?O_A4EYIS6R(006'^M4=8S[],_P!>U &572^$,_\
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MDXM)/)*J5D[,.H(^M7[5VC^\6J@Y>[UYO>N^MEOW6@=_.U_.VJOZ/5'YA?\
M!7=XS^Q3\1EE1B_EV/ED#A1NN/O<8!QZD'^GZT?\&TDD#_ ;]U'(CC2+K>6!
MVG_2=.SMRH]NYZ=NE?E+_P %=M+U1/V)OB4QL)#&Z6)\SY<+\UQ[YYQV'O7Z
MQ_\ !MG%>VO[/P>:RDAQHUUL)"CS/])T_I@D^N,XP :K$5U-*$&^6.[6BEHN
MG2SOH)7W;NWWUMLK7]$O+0_J(HJ*%VDB1V4JS#)!ZC_/^?6I:XQA156YF>+R
M]B,^Y]IQV'^?_P!1JU0 4444 %%%% !5'4?^/.;_ '3_ .@FKU4=1_X\YO\
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MMKN=)8:8MIY-W+EX5*,RC[Q.001D'C(]#_CVGB#QE;FP6SMD/F>6JJ0-P&$
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M8>&_#YCBU?6]+L)G94\N[O;>!]S%5QMDD4Y)88&/YBMR_N#:65U<@%C!!+*
M.I,:%L?CBOY/OVZ?VN?BMXM_:2\8?#;X=Z)KM]<>#E74[N&R>%52UM7GN)'R
MUT@QY5E*W Z#% ']7]AJ-CJENMUI]W;WENX!$MM*DT?(R!OC++G'O[U\P?MJ
M_P#)M_Q/X.?^$2\0XQ_V!+_^N#^!KXO_ ."77[4-U\3?@?JVI^.Q=Z-<>']<
MN=*NWU,JS(UA]ICFSY,DWW3#D\],<5Z_^V1^TE\%;_\ 9Y^*%C:>.M+GN?\
MA&O$-J8D$^X3?V/?Q;.8@,[SCZB@#\;O^#7NZ>'X*?'ZVE'F,_Q9\1%73<5
M_P"$R\8<$@,.X_B&,5_5=7\B7_!L]\6/AAX+^!WQY'B/Q7I^GSW7Q5\07%N)
MA,2T,GB[Q?(K#;&>"CH?QK^FR7]J3X$0D+)\0M(4D9 (N.?_ "#0!Z-\2_\
MD2=?_P"O"Y_]$2U_C0?\%<"G_#8_Q5WJ67_A)XL@=3_H*?7^1K_7Q\8?M*_
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MRP#GD#_/X?G0!)1110 4444 %?G_ /&2;35\;7XGA=I/FR0#_P ]I?\ 8/\
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MN7&>1&.W8?CT8>-.?/&IHK<RDK)KEZ*ZZ[?D4K.RNU)RBD_LI-J[?6Z6Q_C
MV7P,^+<VDW$,7AB[:$O\SFTO\@_/P!]DQU![BFC]GSXN7IBC7P[>;U0*@^RW
M_(XP?^/0GC_'G&*_V9+?_@FM^RS!;B!?A_HP4@;@-,L^3SDGY>3R?Q]:H+_P
M32_9CCD9T\ Z,.?E/]G67 XXY'J,U[& SBIA$H4JU6ERP:IRC*,8QEI9R3CK
M;IYJ[,ZL(SG*27-%M:2^+2W7[_D?XUL?P#^+5LLUL?#EWEB Q%K?<>G_ "ZC
M_/YF]-^S]\7$^S22^&KL!<&,_9+\[N3V^R<?K[YZU_LA-_P30_9B=BS?#_1B
M3U/]G6/^%64_X)L?LQF-TD\ Z,<#Y,Z;:<?0X(_$=?IBO<I\68BU-8C$3K<D
MKRM))R3M'M\*WMH[WWT,/8+6T5KWZ+1_U;JOF_\ &<N/@9\4T^TN_AV\ .21
M]DOCC) _Y]?Y_P!*QC\$/B:PM0/#U[\S-Y?^AW_)]_\ 1>GOUQUK_9O'_!,G
M]EUF'F?#_12I^_\ \2RQ.>/3:/ZTG_#L3]E8/(P^'NBX S%_Q+;3@^WR?7WK
MP\WSF6,]G&,JM2+J<TKR34-;I[=%M]_D12PS3E*:IZRO[JE=QY>776UW??UZ
MV:_QI[;X'_$V">99/#MX',9#C[)?8"\@D9M0,Y_EUKK8/@?\4CIT.WP[>&#<
M-C?9+[EODP.+7Z8PV.?85_L7-_P3)_99= 3\/M%$A.&)TVT/RY[Y7]!_^MY_
MX)G_ +,(C,*> =&$8&4 TZSP#Q_LCT_^OUK]&X1\0\OX<I0IU,-6K2BFI352
M*;M9:>ZTEU2_R'+#7V?*K<KMOTY;76R5^;?U6Q_CJC]GSXKW-R9(_#=T78+E
M?LE_C;@\_P#'H<C!)Z?UKT3PU^S9\49;.\67PW=+"EO+('^R7Q/FJC-M_P"/
M7Z#W]Z_UY[;_ ()K_LTP '_A!-(#;N<:=9YQGI]P\8XZ=.U='#_P3O\ V:8(
MWCC\"Z0JO&RL/[-M.2P.>BCN3_GKOF?B7@\3B,35HX6=J]&5*+=1<T962YF^
M6VO965M3EG@*B45&IK&\(RBK12;7O6=]DNU]K'^,7?\ P'^*RZE<R#PW=D13
M31@?9;\<!BN1_HG7 [?AVK('P)^*8MY5'AN[V%RS$VE^2#D]_LGY?3FO]FEO
M^":/[+\D<V[P!HWF2.S9.FVG5B23DK[XZ_S-5X?^"9'[+JN-_P /]%\O'(_L
MVRY.>N /Z5^1X[,L56K.5.M.4(W:YFG+F3O%W22=KN^FMM#T%"22MRWY7>ZO
M[UE;MUO?3_@_XT+_  .^*;O!;GPW>"0QC8!:7_*]B?\ 1/?T^GI5J/\ 9V^*
MQ23/AR\"G[Q^R7^1Z?\ +IC_  Z5_LJ_\.R/V6][2?\ "OM%W _NS_9MED+Q
M@#Y>/H<8JQ_P[2_9A&!_P@&CXYW8TZRP>/\ =KULOSKV$*;KU)RFERSBI))I
M+7HVK[>:-4I-1BY)1479+I*246M=;;OT/\:2?]G/XN6I@F?PU>;20R'['?X/
M/<_9/7BJO_"AOBO$+EV\-7>)LELVE_D?3_1!_6O]FH?\$U_V8G1TD\ Z,V!\
MF=-M/T.WCZC'^-$_\$R_V8&X/P_T;!QN!TVR(/J2,5P8[&1K352E5G=2UYFM
M8MJ2Y596Y?GWWU:C>ZY[._*FUV5EK?RV^?D?XT</P*^*12T4>&[PX9O*_P!$
MOCN/?K:?7\O>MQ/@!\61.\O_  C-T7*C>OV.^X!'7(M.G/\ GM_LAC_@F5^R
MXN,?#_1!L_U?_$ML^"?^ 5./^":G[,8P?^$!T?)X8_V=9=/R_P#K5[.79[3P
ML%"O*556L]8IN_O=5T=EKIIW83HTGM=-MWO+2U[1MYVU>O?R/\9K4O@'\5&;
M<_AR[4,<#%I?GDM_UZ?SSQS63_PS[\4FN'@'AV\\Q%WL/L=^>",Y_P"/4=@>
M/\17^SY_P[/_ &6FR)/A]HK#^$'3;/KCKT/?W_2H#_P3+_99 #CX>Z-YI.&/
M]FVF[;[G8#TX^GX5YF+Q]/$U)-5*D8RG?EO"RO9K[.T=5;S&X**@KJ<HI)RZ
M<JMRI+HTKW;\OE_C+0? _P"*-M;H6\.WFQ;A0&%I?@[P1@?\>@^A/XUU!^"/
MQDU%HU_X1Z^(\K"J;:_(*A0!UM,9P,]_KTK_ &07_P""9'[*SL0?A[HI382%
M_LVSQYGK]SKG_'WJ.W_X)G_LS09/_"!:,"#A<:=9G"D].!TQCCVZ&L<-CH4X
MN$IU4UL^:-I/HY:;+IKIUN14;<THQ;AJTWNMM':RUM_EJ?XT=S\ ?BI;PRAO
M#EYLWG>PL[[(/)Q_QZ_KGZ#KAS_!'XH20Q6;^'+P&1 T?^AWW*8X)_T3.>3_
M /K-?[+]Q_P3-_9>G^4^ -%*G)8?V99<G\5/\N_XU%_P['_9;.&_X5]HH9%V
M+_Q+++[OI]S'/UZ5U?VA1M%JM6^U=2E%VNDETV4M6NQG"E:]DH\UY.][WTWU
MW:5ENC^+#_@T@\'>(?"OQ8^)D.L:?<6A74K-6\V":,9$FFD8,L:>G)[XK_1B
M!R,]J^2_@K^R%\&?V>[O4M7\ ^%K'1[J_=)+B2SLH(7D9=N"3" 6(\L5]5DM
M/;'R\J74XR,'K[_3\>AZFO!E)U)^]+>3U>J2;_);F_1:6+5%10*Z1(KG+ <G
M_/\ D=.U2U#5FTG=)M76S\P"BBBD 4UMVUMHRV#@=.<<4ZB@#R[XC17=Y\/_
M !];SH$B;P=XIPRD[@/[$O@"!@>O!]?SK^)7X*ZIX+T#]BK]J'2KJY$WBF;X
MM^*&LX[A8_/VG6O&I4)F3S,9>(<(1T/IG^XGQ!I-QJ9O[8NHM;[2M0L'C9U
M;[7:26^""1P?,QTQS7\WGQ/_ ."/?Q4UGQ_JL_A);>U\(:WK5WJU]:+J%E#'
M,]U=>>7:'[0NXGSISRN?F.0-QH Z/P-XU_:6^'/_  3?N/$GP2\,'Q)XX6SA
MET7399[Z!98?[/U22,"2VT^ZE \]85^6)OO=<@"OPV_:.^(?_!83]J?X&>*O
MA=XI^!\%G8ZTD"NZ:CXCN3^[:3&4/AF//W_[P[]:_NH^#_P?TSP'\(/"/P[O
M;.+.CZ):6%]&-CHT\*R*YRI*MG>>03]:ZQ/A=X4BPL>GPB,_> C09_#_ #_+
M !_ Y^RY=_\ !7;]FGX?76@Z+\%(IQ%92Q6H:_\ $5N6+/$X&#X;<C)C/0GV
M%?0C_MK_ /!:RXTZVLY?@%;+Y,00G^V/$ISC/7/A3_(_3^V)/AQX88/&UC"R
M= OEQG XZC'K_GI5&'X:>#II)8QI<(\LD9-N@!QCH<8/7J* /X?/'OQQ_P""
MQ/Q$\"ZGX9U7X(PP+K=O]G7;J?B*3/SJ_P!T^&%SRO3Z9K^?+XG?\$2/^"FW
MQ?\ &&I^.-2^$OEW>KF3>@M_$<F/-GEN#\QT%>\QYQVK_6?'PT\)?NU%A 3
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M3^^'<.O://9RK-%FTU"S>WF3&BZ/R89T1U^9>XZC\*2G)<K3MR-N.VE]7_3
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M6\I,C'/\ZZN:R\M(+:R94CA!41JP4CK_  Y]\_\ ZA0!L11K'&L:G(48]?\
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MP<\@\]AQQTKVNX^"VHE!%L4DY"$.AVYZ<[L 9SZ'\ZM:7\'+S3;RSEEC4JC
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M_P""D0=(&^%K>8ZAE'V3Q'T/_<#]QTZ<]>,J_P#P;Y_\%)(HY"_PL;:I&?\
M0_$7KZG0_K]1V]?]@8^$-%,BR&UCW* !^[7H*<WA/1G#*ULA#')&Q:UKX^CB
M(8>,Y8ENG",9MS6LHI:QM%6U[WT75E04H2;5DF]6EKRO=*Z=FU===#_()TS_
M (-^/^"DYGMGB^%3,0P9!]C\1#)Y_P"H$?TKU&Z_X(.?\%+].M%1OA-MW)AS
M]E\197D_]0('MWQBO]:B+PMI$)4I;1@KT^1?\_2K$_A_3+A=LD"D?[J_X5[F
M1<7ULEC.G'VDJ4IQE\24K1Y=+\K5W:VUK&[G>/QS4DVTURZ;).UM^7?5W/\
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M'^/H_P#P;Y_\%(HE9V^%IPA&2;/Q%Z]O^)'W_J*T_P#B']_X*3S1P[?A40H
MVD6GB/YL9Q_S O\ .,=J_P!?I_"&BNK*;6,ACDY13_GK3QX3T=0H%M& O3Y!
M_G_ZU30Q/))SJ3J\RMR.#BK:J[=UKIM_2)=K*R]Y2O=K1+2UO.Z]+'^/>W_!
MOW_P4?D,Y'PL8^2?G'V3Q%\ON1_80J(?\&_7_!1XI W_  JT[9R0G^B>(OF(
MX./^)'@=/\BO]@\>#=$'F8M8OWN2V(U'7UQU[4@\&:&%B7[+'B(DH/+7C/IZ
M?A71/'0G4;<Z_)RV^*/-NI*_N6TDK_A<GE]+WUNG_GZ^7DC_ !]?^(?C_@I
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MM%;>&+A8I!(/-'(_ZZ3GT%?0-?.7[-Y)\*W/)/[T=?\ KK<>PKZ-J2 HHHH
M**** "BBB@ HHHH *CD:./\ >/@8XW'W[4YMVUMHRV#@=.<<5DS,?L5U+?8B
MBMTDG<JW_+*$-(S<XZ(F>WUQ1<#5:1$7>S +USVYY_ES3E8, P.0>0:\7\+_
M !J^'GCV^FT'0M62YO+>=[62-9;9F$L4QMW7$4\C<2#T'IZBM7Q7\7? _@+5
M;/P]K^II:ZA<PK)!"TD"LT9*@$+),CGEP,A3GMD\4 >J5&DL;EE1@Q7J!_GW
M'YUBIK=I>Z9!?V,@DCNTWVYR,,,D=02.".V:+>&>)HIHP&$W,V3POTXYQ@=<
M?7K0!O45F7>K65G-#!-( \QP@!4\\_[0_NG\J6^EN0J&T59.[<]!@^F: +[R
M)'C><;C@>YJ/S &))Z=1Z#_ZW^/O5..)KJ.'SRJRQLK[5;)R!W'4<Y]NN:JZ
MO=1V*H[''G,(^N,;BJ_U':L:M.4W!QFX\LKV5OO\[+H)MJUHIW=G=M67=>9M
M)(DB[D(*YQGW]*/,3?Y>?GQG'^>^.?I7E?Q ^(OA[X8Z9I5SK=U]GAU.]@MH
M&+1J&EGG@B09D91R\Z#\37H&F3VVIV]GJ]O()(KRTAGB(8'*3()$/RDCHP/U
M]JWA:\N=M)1]QK5N79KH,UZ*:S  \@'!P"1UQQUJM:M,5<SJJ?,=N#U&3ZX[
M8/\ GA 6Z8TB*RHS ,_W1ZU!<O)Y3>1M=_3=['TSW_SZ5L1O-;-,X6==V$!!
M'\_3K[=,4 :=%1/-%&RJ[JK.<*"0,_F<_E7"ZSXEF\-6VJ:UK8%OHVGYE><M
MMQ%N50<N$3J>"7 [T =Q'=02RR0QR!I8L>8@SE<^O%3UX;X?^+_P^U*&R\0V
M&KB6V\2.R6)+V^)&CY8*1.0<8S\I.!UJK?\ [2?PNTWQ)<^%;K6535[1/,F@
M\RURB[W3)7[1O RC=5'3% 'OE%<EI/C;0-:TJ;6;"\26Q@@>X>0/&<1QQ>:S
M':Y4 )SDD"N<\,?%_P $^+L_V+J27)6:2 A9+=B)(W9'!$<SD893GC([CT /
M4"< D\ <D^@JK)>6T49EDE58U8*6//S$X XSWS^1K@_$/Q/\(>'=4M]#U;4$
MM[Z]6,PQ-) I83%50@/,K')9>BD$D#FJ_B7Q1X6T338CJ=_]GM[Q[>6*3='\
MWGE6CQND4$,'7D$]L>X!Z:K!E#*<JP!!'<'H:6JMC+%-9VLL#;X9((GB?^]&
MR J>,CD$=*M4 4H)7G:9)(V55( +8^;@=/3KZ#VJX!@ #H*  ,X&,]:6@ HH
MHH **** "BBB@#*OK&2XD$J.%VC..>< <?CC^53V3O(G[R)D9/E&['."1D8)
M] ?UXJ]2  =!B@!:*** *5M:M!+*Y<L)#D#L.G3T''3Z>E6':*!7E<A%'+,>
M@_(5+7-^*;L66DW=Q*2MM''F9QU5=P&><#T[B@#SG1?CI\*=7\6>*_"NF^,M
M/O/$'A01GQ#I<8G\[2Q*1Y9GW1!/FSQL9OPJ'PO\=OA3XK\:W_A#0/&6GZCX
MBM(6EN-*B$XFBC#R+N;?$J?>C8?>ZJ?:OXG?''[;&N?LZ?\ !3?]K&*^O[EO
M!'C6ZTJWLYI+SRDMXX3*9#&LF(NL0'RR'CKR,5'^SY^VEK_P<_;0\<_&GQ7?
MW2?";QKHSZ-X%U&6](BO]>GNM0EM[<>;MM06ANK8_N9Y7^;A#QD _N:U#XD>
M!]*U;^R+_7;6WU0NL?V5Q)OW,YC4<)C)8$<G^E>?_';2/ OB;PKY'C+4-/M-
M*BB>Y:6^5FB$)$4K.0L<AQM4'[N>:_D>U_\ ;L^-/B7X\^(_%]_8_9O!>GV[
M:E97*:C*P<6TE_= $&V2( H(,XE(&[VR?N+X)_M:_$O]N/PMJ5GIMFT/A^VT
M^]M;J_BO))REM:6\PN9 8X=F42U)P74 \$B@#]POV7O$?P/M-*U'P9\*O%6C
M:U)%?W%S>6NEI,GES*\HEWB2"'+!MX/!Y!YQT^DM<\9>&O#;(FM:I!8,[*BB
M4/RSE0J_*IY)90/<U_,?_P $_P#5+OX-_MS^)_#UOK%SJ_PS;PKJ-]J.JSS\
M6_B+S;HW%H$W/!B.1G4%IU;Y>4'2OT"_:N_:3\ ZIXSTG1=/UUT+7]EO$<]M
MG,<MGNRJW&<=>O8'\ #]D()H[B&*XA820S1K+&XSAD<!E8>Q!!J6O%_AS\5/
M".O:5X<TG3[_ ,^\DTC3P%WPDD^1"G(65F^\P'2O:,]N] $$EU!%+'#)(%EE
MSY:'.6QZ<5YG\1_B5X1^'$4&J>+];M]$TZ%1--<W <QI$-^6;RU9L94]NU>@
MW.FI<WEM>,[*UMG:H'#9]3GUK^?'_@X%^)?BSX<?LZZ_J7A<RB>/PU)+NBF>
M%E;_ (F'0HCG/RKVYS]* /V]U7X_?"/1?#NF^+-3\9Z;:>']7MDN].U*03>3
M<V\A8)*@$9<*Q1L;E!X.176^'OB+X-\5>$X?'.@ZY:ZAX6G1I(M7BWBW=%*@
MD;E5^"Z]5'6OX4/B]^V#XS\3_P#!/OX#&QO+@Z]#\/M*^UB*^+3&<2WN[S"B
MF0-AAG<@/L*]S_9;_P""C'Q6U[]@SPW\-OAE9G7O&G@S3[H?$!;C47$VGQS2
MVWV=OW%O<S9;Y>)XX/O<9XH _K7^+7@[P/\ M*^#6\-6NHZ?JUC*7+%U=HMK
M!2<AHSV [8Z=:XSP)XJ^!'[)'@W2OAIKWC+1/#@M9XX(+;;<"-IF6"S5%"08
M!,B*GY=J_G ^!?\ P4Q\:_"KX?\ P^TW5X/-\9^,_$%OX=M+&2_.&O+B"W5$
M#/$LIS(9!@1EO;G%>R?MV?#/XL_$#X>>'_BAXIN)]"UJ?4(;R&R@N)_GE6ZL
M+N.,M)%"?FDFV?<)P3P>A /ZC=$\2:+XCTF'7-&OHK[2IXA-%=Q;O+>(H) P
MR <%"#TS@TRP\4:%JEY)I]CJ$,]Y%N+P+NWJ%)!Z@#C![]J_*_\ 8P^/L/A7
M]CK3G^)ET;#Q-I^CZFC0R3HSF.UL$6W<M<&"3+[0>8\#/!-3?L=_M,> ?&ES
MXF\57^MNMPGB;4=%MH7FMW1E6[N8XR&,_4X7Y0.OTH _6FBLW3-5M-7M8KRS
M??#-&DD9XY1QN4\$CD>]:5 !63'I[I=_:#("H.=OY?X<?A6M10 4444 %%%%
M !1110!4OQFRN@3M!@EY/0?(:\W\#(L<]V%D$H-S*21GC]ZYP<_E7I%_C[%=
M;CA?L\N3Z#8:\V\"^2)[L0.77[5+N) X/FOD<$]Z /5**** /-OBU_R(VK?2
M/^;5N>!O^16TG_K@?_0VK#^+7_(C:M](_P";5N>!O^16TG_K@?\ T-J .MHH
MHH **** "BBB@ HHHH *C\I>?1NH_P __KJ2BHG3A/EYHWY7=;Z/3_(:;6SL
M48+,12O(3G<<@<'T_P /U]>:O444J=*%)-0C9-W?FRISE-\TG=V2^222_!!2
M;1G=@9/>EHK3Y$7(_-C9S%N!8=5_S]#^5+L&,>_6JPM8XIWNB3DKSSP ,G]/
MZ#U-312QW";T.5R1^(K.I34DWR*4DK)/1/5;V]-/N >44]1^%&P8QW]:Q]>U
M>WT6R-[<ND<,9)=G95&U1DX+$#./<>G<5QNC?%+PQXFE:RT6]2XO$9E:/S(3
MS&2'QLD<GD'&1^'>E[&E_(NNBO:[M=_AH.[[L]+VC.?T[<?YY_\ UTFP8/UX
M/I[?YZUR5UXCBEC-KII\V_SCR\@@L/E/(+'[V!T/7UYK&UKXF^'/"M[I^C:]
M=?9]4O+=9EAS&,@[1_&Z-U91]WO^%*-&#C[U.-W>ZU:5]';7LA7?]??^9Z*(
MU!R.G4_YXIDIBA1I96V(@R6/11^6?\^O-1V5Y!J-I%=V[;H)UW(WJ <9XR.H
MJKJ<$UU&+5 !%,-DC9.Y5.<X'<]/\]#V,.;X(\J6CN[IM6:\E9(=WW9>C:*>
M-)(V#QL 0PZ,.O?_ #V^D@0#/''8>E06EJMI;PVZL6$*A0QX)^O7O7 >,?BM
MX.\"R1Q>(-1CM7E)"*98%8D9_ADE0_PGM0J,+RO3BHW7+OK[MG?S3O\ F%WW
M9W=S=6=EY7VF58C,XCC+ _O'/\(QW-6]JYSZCI]>_P#A_G'G-KK7A[XAZ39Z
MOH]]YMO;2"ZA*-&Q<JJN 0DK?*00<\UW.GS^;:B9QM(49]@%';\,T.E!./+3
MB]5=O2R2Z>>VFP7;W;+NP8QW]:7:,Y[8QC],_P"?KUK-NKTBV-S" T<>6D).
M-JH06/IPH)_PKF-%^(/AO6=9?P]97BR:I#$TLL(>)B G#<+(6Z@C[O\ 6CV,
M%*-H1:MJVW=-)<O_  179W&P8QW]:78,Y_3_ #_D_P W44_8TM/<6EM=;Z?U
MKW"[_KSW$(R/Y&DV#CV_6G453IPD[N*OIKMLT_T"XSRUYXY[>U(T8(''(_7_
M #_]8U)14/#TG%QY$DU;3[_S'=W3N]!JY"C_ #WIU%%:1CRQC'?EBHW[V5A!
M1115 %%%% !1110!D:C:V]Y+##<6HG1LY+ %5ZCO^O\ A5=/#]CN_?1)*B']
MTI PG^[Z=_SK>P"<XY%+0!Q]]X2L[^ZM[B9$9;=\QJ1G:/F&!P>FX],5UD42
M0QK'&H5%& !4E% !03@$G@#DGT%%(PW*5/0@C\Z (OM$.T/O&TG Y[YQ_/'Y
MUSOBGQ?X<\(64%YXCU2#2[6]N$LK::8.5EN9BJQQ+L5CEV=0,X!SUK7;3T,"
MP[C\C%Q]<Y^OZ]Z_G;_X+_?M)_$[]G_X.?#K5? ]BT\=M\1M!EU*1;N6V*6$
M5YICW#DI!*#B(N?FVKV)'- '[ZWGCKP?X9LXKO5]>MK:VO3$]O++OVR+<[6A
MV_*3\XD7''?WKLDO;(6<=^LR_9)HTGCFYVM'(N]6'&<%3GI_2OXA_B__ ,%4
M_$OQ9^ GA2?X>O\ ;/%.F-X0MK^T74E)5K8VL6H9,"RR'88).L8!Q\V.:^\?
MC-_P6<\/^!OV>](T32[@77Q1_P"$=TN--,6_M\-.ND8F!96>?(N'B7_CWSR<
M@$8H _H@^*'A?1/CMX%UGPII.JVLJ^>\%Q,=^R&4131%&PA;(+GH#T->6?"?
MPIX#^ T]MX>O?%&FPZC?_)';)Y^^<JP)_P"6*@D8'4]?T_G>_9U_X+(:'X6^
M'.J6>OW3#QYXAO?M\6FM?6YP\XE78"Y6;'F/&.(>^/:N<_:^^.7[7.B?!C4/
MVE8?#'E&Q-K>>#[9;^]7^TK::22.=F;^S_E"F)\>4)0>^* /[!;:Y@NX$N;>
M02PR#<CC.".F><>E4;+6],U&XN;2RNXY[BS8I<1)G=$PQD-D 9&X=#WK\X_V
M+OVL(OB+^S#X,\4>*G%CXO;P_)<ZI92SJ?+NENG4('D,4C?(R\M$I_V<#GY]
M_86_:]O/''QW^.OA_P 9YLK'3?$&H6^B2&X\Q9XT&EE"HD$:\B23[K,/EZ\\
M '[9T50T_4K34X5GM)/,C89!XP1QZ$^HJ_0!S_B'Q3H/A2T%]K^HPZ=:L2!+
M,&VY! _A5CU8?G6!)\4/ L6C6OB"3Q!:+H][+Y-M>D2^7+*&1"B_)NSN=!R/
MXA7XL_\ !=GX_P#Q%^ ?P&\-:]X'LS<RWNM?9KDK<RVY6!M4T6%FW1PR$XBG
M<X.!@5^!7[1?_!4CXA^%?V,_@Q%X6B>[\3W/BRR35H?[2*2QPSZIH"REMD,D
MN%1I_OHHP"3SG !_>!I^NZ/K.GG4["\CN;!5\PW" [ H7=N^9<XP,]*X'QAI
MNE_%'PIX@T#1M4A;^T-/U#2I90) L9NK:>S<-A,_Q,&X.<5_-O\ #O\ X*NV
M_A+]C/2-1OIBWQ!U-K2WFL/ML+%(+FQ4,_F9\[(9SQY(Y'45R7P _P""NUOX
M?T;4K?7Y-FLZKJC?8;9KZ'<\EY=W'DJ%?9)@M-$,JAZC&>* /U?_ &./V7_A
MW^PI>>)_#VJ>-=$MK_Q7XBOM>^Q0FZWR->:I>:B=P-JBEB=07N>3Z5^L=E?6
MNHVL-[9S+/:W$8EAE3.UT.<,,@'G![5_*G^U;X]_:1\1>&!\?VTC[%IEC''-
M:(EY= 2VLUM]HB<DVBKDQ6:MQD#=P?7]A?V%?VF7\8_LX6?B_P ?.NFRZ3:Q
M6C[[A79F2.X;(,WD<8C'3\N* /T?75M/-P;5;E6N"3B+YLY'ID8_+M@=<9AU
M!8KA"_GK&L(S(3_"!DYXY_B Z=_>OS5^$'[1L>O?$7Q;J7B&86WAW2;Z--.N
M?M$;++%(D/)#E$7YBXX<]B:_1O2Y--\0Z4;ZPN/,M-3C+1R!D;(SMR-K$=5[
M'O\ 2HC#E?NMJ/\ +ND[MMW>NO;8#?M"AMHC&XD3;PXSAO?FK-5K.W6TMXK9
M&WB)0H)Z_CU[U9JP&LH;&1G!R/\ /^33J** "BBB@ HHHH *HZC_ ,><W^Z?
M_035ZJ.H_P#'G-_NG_T$T >8?#W_ )"VM_\ 75O_ $&&O7:\B^'O_(6UO_KJ
MW_H,->NT %4-4_Y!UY_UP?\ E5^J&J?\@Z\_ZX/_ "H \F\$1+_;]Q)YJ[B.
M8N=PXD_S]?RKVBO%O XMSK]R1(3/CYDXVCB7'//N/\YKVF@ HHHH **** "B
MBB@ HHHH>J:>ST?S ;MX ST(/Y4ZBBIC%1V71+KM%67X %%%(S!06/  ))]A
M5 +5.2ZMA.MNTP69AQ'@Y/3\,\C\Q3TN$GCD:$[F4, /]H @?^/#%>&_$;QQ
MIGPS\.W_ (^\97/V"TTUI /FC7**DLH.9FB'W(<^G/IG$RBIKEDM/NV&FUL>
M]$9&.?K_ )_6EK\G?"__  47\%^+?$L^F:3<R30K.T4;^;"05#JH(V.PQ@]?
M3IGM]>?"7]HWPOX[U>;0S>(E_))LMXVGA.X_(#D>8&'WL<*>![TN5*2:73E;
MN_A6RW[_ #\Q'U$DL;EE1@Q7J!_GW'YT[(8\-RIY _S_ )_&LQC::;'<7TDH
M$0!D=MRX & 3DD#CZXY^E<]J_BC3[/P_J.M6MPDJVT(E.V2,D?.HYVDXZC_#
MM3DN:T6KQ;][6VS35OFA-RO&R35WS7Z*VEN^IVH8$D Y(ZCT^M+7R/\ !#X^
M6?Q!U_QM:S2;8?#:Q-,WF*P4.4'3(QR?4<U]-:-XDTK7H?/TZY25.OWT)QUS
M\K,,>^>O%4,VY)$C +L%R<#/<_Y(_.G@YY'0UR7BCQ%H6B0VLFK7B0I/.D46
M)(AND:1%4?/(G\3@<<\].E6;O7;?3A'<W3HEE+'&8I2ZC<'4%>I"]&4YR>.:
M .DHKRGQ?\1+'3M*^T:9-'<7!? 02Q^@(^ZS'OV!IG@'QO)JVB7.IZQLMECG
M$:YD&"&DD1?F?8O11SF@#UFBH(KF&:(312QO&5W!E=2,$9'() _.N9F\6Z58
M22Q7MS'&X<A1YL62,XZ%@<_G]30!TTEU!%+'#)(%EESY:'.6QZ<5/7*H(KV6
M+69Y5BM[8%H6W#8Z]268D <CU/0]ZXB/XV>!_P#A((_#CZDG]HSW MH(Q+;G
M?(PRH \X-S[+^&* /8:*YW5/%&D:1=6EI>W*1S7K;8%+H-Q(<]V']PU<U'6]
M.TNW-U=W,21*NXGS$SC\6% &F\B1[=[!=QVC/<T^N:M-5T_Q)9)=Z;+YJ*=\
M; K@D 'DJS>O7WK=M3,85,RA7[@'/8>P[YH L4444 %%%% #2@+!L<BG444
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MWAF?5_#7B73]<T4QGS+R$2>2 &7.0\:MC)4<*3S@U_(%X(_:S_:!^-O[+O\
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M&@&%\T?PX_Y:3_Y_#->_U\[?LYQ2Q>%KD2H4/FKP>?\ EK<'^M?1-20%%%%
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MX&,G)_S_ )- #J*** "BBB@ HHHH **** "BBB@ HHHH *Q?$5@-4T>]L3M
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M\6_$/QI\26OB:%M!MWFN+:9GG\J2%(;!24&TG&YVX('?CCD _=3X/_&OP_\
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M#]G#QC\'/AGJ=[X_\#>(-7MF\67.EZ?:1:+>:A+''YTD4#B&*"5UC563Y\!
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MO9J\:\#RL=<N(_)(4+Q+Q@\2#C&>>,GGO^->RT %%%% !1110 4444 %%%%
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MU#Q5:76FSS0*AL;HJ7C)MH3SL9EX)(X;MWK[_H **** "BBB@ HHHH ****
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M_/% '\CO[?7[._[4GB;]O+0/&6A_V[=?#;3?$MC>);VTL[VRQ0ZE?NQ$*MM
M\IH@?E[>G3]AO$7[,/BKXJ?#K3[V"VDCFFA59HYRL,I4QV[N&21E;NPY[Y]\
M_J[J/@CPQJMT+R_TJVN+D$,)7C0MN!SG)4GJ?6M*SM8+4FP@M/)M4'R@!0F
M".@]E'Y\9XH _,#X=_L=:OH?P[T+0X;6."6QOVN&4R1*0WFQ.3]_')4XQV]J
M_1+X8>%[[PEX:@TJ_(,L>S&'#X54V@94D#C''^1Z$D,<:!$0*H.0 ,>_:I*
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MU]!U\^_L]6C6GABX0N'S*.0=W_+2<^I]:^@J@S"BBB@ HHHH **** "BBB@
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M(K<VPDC<QAP <RKC/F,3@?KBNR^,/P;TS4OAF-/M\-/X>T^.+3D$.=WENP
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M*** *MZ6%G=;1EO(EP/?8<5YSX*:=KFZ^T*$87,NT#N/-?GH.W->C7P)L[H
MX)@EP>F/D/?M7F_@A'CN+H2,')N92"&W?\M7/X<<8H ]2HHHH \V^+7_ "(V
MK?2/^;5N>!O^16TG_K@?_0VK#^+7_(C:M](_YM6YX&_Y%;2?^N!_]#:@#K:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YQ_:!^!%G\<-$CT._U*
MYTV!)1+YMO&9&W848P&0=%Z[J\/^$?["/@SX6:H^NP:G/J^H-#<VX-Y9@,J7
M2NCD,9G(PK\<<@#FOOZB@#XM\/\ [&O@_P /0:E;6NH2LFJ7TNH2N;55:.2:
M:68HO[TY :9@#D=.F,BM7Q7^R;X6\9>,O#7C/4[MA>^%-)CT6RA-L)%EMXFB
M8.6+KM.8A\H5@,\'T^O:* /R=\=_\$N/ 'BGQ6WB*W\27VG/>RF:ZCM;$!=P
M4  E;A01A1G(&/3FO<?AY^Q/X8\ >%?$7A>RU6>XAUZTEM;BXDM0DFV3R23C
MS&W8\H#EA^&*^\:* /A#]G/]B_0?@5KVNZQ8:O=79U6>2;RY+?RU&\0=_,;/
M^I^IR>/3T/6/V4_!>I_$?4/B9,ZRZM?2)+);26BLA*!@ 9#)DC#D_=KZLHH
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MOTKVROD/]A[2M1TS]FSX5KJ*R)-_PB]J&CER'5N>&4\@\'@_CVKZ\H ****
M"BBB@ HHHH *HZC_ ,><W^Z?_035ZJ.H_P#'G-_NG_T$T >8?#W_ )"VM_\
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M-Y>J_P" :4O:<W[N_-:VEMKKOIN>_?LX.S^%;DLV\^:.>O\ RUN/<^E?1E>
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M+[0M*N98M2:SCFN+=A+"^U2P9<\@XZ\D<'CG\-IK>-H/(*C9C&.W_P!?K_\
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MS_Y^F*^@*S2LK"E)SDY.UWV5EM;8****9(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5OB!9W189 @E)&
M,Y&PUYOX(DCDN+LQ1F,"ZE# @C)\UQGD#//^->D7Q*V=T0-Q$$IQZ_(>*\X\
M$RM+<71:+R2MS* , ;OWKC/!_&@#U&BBB@#S;XM?\B-JWTC_ )M6YX&_Y%;2
M?^N!_P#0VK#^+7_(C:M](_YM6YX&_P"16TG_ *X'_P!#:@#K:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %? ?QCO+./QM?K)&2PW?\
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MFK6Z-]X%<9!SE2>.C <T#5H&B+A@6#=!R<>NW&<8YSZ\4>RJ7@N5WGK'3?\
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MMDK/3[/2[W7>&O<%S7JZ-J'+[*^T7R*[CW][?I=VZ(LK;Q3RO)YI$A4[E5\
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M,+.)WVEPQ82'@[B<9!'&>V?Y4_R8KB9"TI$BK@*'ZCCDCG/'YX]^*V(^=O\
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M]B?ZG%=N,X&>O>O#Q$/9R4;132WCUVU?Z&F&YK/FO=J+_NW:U:_O/>2[E6^
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MC[NO-IV_\EU*]Y.BDM)M>U\UR+XNRO\ CH2&*.!YT\TGS,!PSD[!@8(R>/P
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M27Y?K^.QU54=2)%E/@9^0_R)J]5'4L_8YL==I_D:\:6SWV>V_P O,L\F^&T
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MMDK/3[/2[W7>&O<%S7JZ-J'+[*^T7R*[CW][?I=VZ(LK;Q3RO)YI$A4[E5\
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M'FY]=;;VL[=M?(G,4,WDQM*?W?$9#\O@'J>2?UZ^U.,4<#SIYI/F8#AG)V#
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M[E]I'IVY;Z]KOL.^R0QQPNLS[5?<I\P_,P' .",^G>GK;Q3RO)YI$A4[E5\
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ME53:,JV<9P.1SSG_  J3<OF[,?O/*W[]JXV?W,YZ^WX5&9)?)1]@WLY#+L.
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MRJIM&5;.,X'(YYS_ (5)N7S=F/WGE;]^U<;/[F<]?;\*C,DODH^P;V<AEV'
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MA\&/'F?,?G^G][MTSG'O7=I_<Z;JZ^!?K_Y/JKF":O\ \N]_Y?\ ITMOEY?
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MM967Q1M;Y?#VC=7U!M:_P]I[QT^.-[ZZZZ2[RU&'[3Y2]?/W'?\ =W;,]_\
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M.?/W#9C;G9GM_P !_3-//F>:F/\ 4X'F?=QNQ_/KC\*C$4ODNAD!D+ A]Y
MSG&[H..,9[8[U(5?SD?=\BJ RY;)..NW&3WY]Z-+OX+>];3W=HVY5?2]O<[2
MYGK=7WTNU[FT]6O[E.]_E\71JUF-/G[).OF;_P!S]W.SMM]O3VS3AYFZ'KLP
M?/\ NXSVW>^>GOFF&.7RY5W_ #.Y9&W'"J>Q/\)]CC'XT_:^Z [N(P1(-S?/
MD<8&/F_#..M#M_=W?33X8VM\_A[3N[ [:W]FM7O'_IW%OKT7Q]X:#1Y_[[.<
M\_9_N_AM_'./PH/G_N<9SQ]H^[^.[\<9_&A8Y )\ODR9\OYC\GU_N]^N,9]J
M&CD(@P^#'CS/F/S_ $_O=NF<X]Z>G]SINKKX%^O_ )/JKC35_P#EWO\ R_\
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M;<9QGG=CVJ(1R^2Z;QO9P5;><!<YQNZ#C QGMCO0K:?#]C=:[ZW?;^?NK==
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MI77O*G&K[SE;KI:VUWMT*GC8P?-)R=.#B^5RTG*<8RO'[V[OMJ[GZ/\ CO\
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MN# _$54\->!=%\%:-IW@_P *6L>G^0;>>Z6)4B5S&%$I++@$G#=\GK7XX_\
M!7GXL:K:Z?I7P6T6YGAU#Q!J6AJZ1^8JO&TFG+,&<$)RMV006R<UX=*,,35A
M2B_8*M\5.%OX<&KO_N*MGOWN;5Y^QA[>I)<RYJ3M=;V2^[KV3Z'K&H_\%-?
MUSXK\JU\1P'1(YWMYG%W^Y!$B1X+>9LZ!_PSZ5]+_M"_'[P]X)_9?U3XE^'-
M2A2/4+*2_-U:SCDR6%[-N+HY.<QYR>_KTKP*?]@OPUJ/[,EA'8Z-9Q^*M1\.
MZ=J(NMMLDGG2Z5-,[F7</F\R5&Y.<\G')KXW_9':\\??LH_M%^ O'$AU%O!/
MQ$U;PU;0W+&7RK:TM-3C$<?F'&T!L#9D=LGFO0]GA9T(NE']W2Q=.G)0M^]=
MXKFFTM5%ZO5?+0\MUZD:JI2:YZM/G4Y7TAI>*6Z<EHNO='YX?\$]?'_PM_:B
M_:9\;:IK]S#JEUH^M0^8T\AG\MW6R&"6+8SOXZ>U?V0^%=.LM$\)Z?8Z&BI:
M1VY2V$> ,;V.%'MDX[GZU_/?_P $9_@=\-=/\??M":C::+:+<V&L6),BP194
ME+ \G\![U_1#/ HB6WLI$2*($*JL $')Z#I@_P!36..E"5:-!+D]G-.=]:5K
M1DH\JL_-]UJM;(]K MR@U=0IQ3C!R^*]DY:WU3;:5EIMW,JUM8X)S+: "64Y
MOR  2W&<_@%S^'O6F?,W3==F!Y'W<9[[??/7WQ49M]GDNDB[@/WN&&6/)./4
M]/YT\K)NF(;_ %H B&XY0XZE3RO]>M8OE^RE:W;6_.KW[];=?9W776ZGQ+X+
M\J?O+6W/#5^7_MUF(//V1]?,W_OONYV=]WMZ^V*</,\U\_ZG!\O[N-V/Y],_
MC3!%,(XD9_GC<,[%B-R^@_O'V[]J>%?SG?=\C*0JY;(..NW&1VY]J3MK\/6U
ME9?%&UOE\/:-U?4EM:ZT[6GO&Z^.-[ZZZNTN\M1A^T^4O7S]QW_=W;,]_P#@
M/]*D^?S/^F/E_P"SM\W'\_Z5"5<Q+$)5\U7+,?,ZKG(&>_&1CWQ4N&$GF$D1
M^7Y?WC]_^]C]<X]J??X?M6LK+7EM9>?V%K;7N&FNM.R]HGS1ZWC?FUU?\W\S
ML,'VGRFZ^?N&S[N[9GM_P'^M//F>:F/]3@>9]W&['\^N/PJ,1R^2Z>8"[."K
M;S@+G.-W0<<8SVQWJ0J_G(^[Y%4!ERV2<==N,GOS[TG:[^#[73W=HVY5?35>
MYVES/6ZN-KFE\'_+R]U_=A>__MVUU:S&GS]DG7S-_P"Y^[G9VV^WI[9IP\S=
M#UV8/G_=QGMN]\]/?-,,<OERKO\ F=RR-N.%4]B?X3['&/QI^U]T!W<1@B0;
MF^?(XP,?-^&<=:';^[N^FGPQM;Y_#VG=V!VUO[-:O>/_ $[BWUZ+X^\-!H\_
M]]G.>?L_W?PV_CG'X4'S_P!SC.>/M'W?QW?CC/XT+'(!/E\F3/E_,?D^O]WO
MUQC/M0T<A$&'P8\>9\Q^?Z?WNW3.<>]/3^YTW5U\"_7_ ,GU5QIJ_P#R[W_E
M_P"G2V^7E\":''S-TW79@>1]W&>^WWSU]\4T>?LCZ^9O_??=SL[[O;U]L4[:
M^Z<[N) !&-S?)@<Y&/E_'&>M,$<OEQ+O^9'#.VXX91V!_B/L,Y_"DK:?#]G=
M7?P)/Y7^+O/71"BU9?!O#[/_ $[6VN]M5VA=,>/,\U\_ZG!\O[N-V/Y],_C3
M#]I\I>OG[CO^[NV9[_\  ?Z4\*_G.^[Y&4A5RV0<==N,CMS[5&8Y?)1-XWJY
M+-O."N<XW=#QD8SWQVH5KKX?L;K7;6_E_/W=F$;>[K3_ .7?V=?ATZ[[\G9<
MRZDOS^9_TQ\O_9V^;C^?]*C'VGRFZ^?N&S[N[9GM_P !_K4FU_-WY^3RMFW+
M9W_WMN,XSSNQ[5$(Y?)=-XWLX*MO. N<XW=!Q@8SVQWH5M/A^QNM=];OM_/W
M5NN@)KE7P?\ +K:/GIU[W4;VL[DA\SS4Q_J<#S/NXW8_GUQ^%-/G[).OF;_W
M/W<[.VWV]/;-.*OYR/N^15 9<MDG'7;C)[\^],,<OERKO^9W+(VXX53V)_A/
ML<8_&A6]WX?L7TUTE]KN[?%WC9+N":M#^'M3VC_?TMY/7E[--CQYFZ'KLP?/
M^[C/;=[YZ>^:://_ 'V<YY^S_=_#;^.<?A3MK[H#NXC!$@W-\^1Q@8^;\,XZ
MTU8Y )\ODR9\OYC\GU_N]^N,9]J%;^[LNFOQK?7>V_\ <T!<O>G]G:/_ $\6
MVNU^C^W=EZPSYL.?]9D>;G&=W\6?TZ=^E=V.@^@KSRWCE:XM IYC.)&R<-\N
M#S_%U S^->ACH/H*\/'JU:]WK?1O16LO=71/?77:Z1UTDE3BU*+NY745;E:=
MK/S[]W=BU\!?&/\ M+_A-K_R,[/FQC/_ #VEZ_Y_K7W[7P!\9+:Z?QM?M'<*
MB_-A2ZKC][)[UPFA[]^SXB1^&;@1L77S1R6+?\M9_4FOH&OG[]GO[/\ \(Q<
M?9\;?-'3'_/6?KC_ #UKZ!J*=^17<G=)^\K-:+0#D_$2I(521BB%>6!(/W<?
M>'3BL9XXE^S,LFYD!$:Y!W@DY)[' ]<_D#6QXC\K*^?_ *K;SG&,[?SZ?A6.
M_D9M=F=^#Y'WNF3G'X>G\\5]!A/X=+?X);+R?X=_*YSU7\6][?95Y;+9/2_8
MA$<8$^'SY@/F_,/W?KC/3'MC]:#'&1!E\>6!Y7S#]YZ9QUS[Y_2A?(Q<;<8P
M?M'WNG?_ "?:AO(Q;[L8P/L_WNG;_(]Z[M;_ &_NU^!;^=O/X-3&[OO5W_E5
MOX:W\K[V^VVO,=M3=.=W,@ E&Y?W8'0@8XR.>,>E-\N+RXEW_(CAHVW#+MV4
MGJ<^_P#6G?N]UQG[V!]I^_T[?Y]<4P>1Y4.,>5Y@\G[V/,_SU]L4*_\ ?WAL
ME_(K?AI'36%GY"7-IK5WCO%?R)N^^E]_[]UJ2!4$SR YD92&3<N%'J!C _ <
M?A49BA\E$\P^6KEE?<,LV<XR.3SQC_&I!Y?GR8_X^-I\S[WW<'.>_3.?QJ(_
M9O(3/^HWG9][[^>>O?/]*$W>/Q_8V6FVEO\ VS:ZNVM 3E>/\7_EWO%6^%WO
MU7]_L[(EVKYN_/[SRMFS<N-G]_&.OOUSS48BA\ET\P^6SAF?<,JV<XR>1SQC
M_"I?D\[_ *;>5_M_ZG'^'_CM0C[-Y#X_U&\;_O??SQT[Y_K0KZ6Y]Z=K).W;
ME[M/6'=_>"YM-:O_ "[WBN]G?_V^][+N2E4,R2$XD50%3<N&'J1C!_$<_C3/
M+B\N5=_R.Y:1MPRC=U!ZC'M_2GGR_/CS_P ?&T>7][[N!C'?IC'X5&?(\J;.
M/*\P^=]['F?YZ>V:%?W?BVC:RT^+3E[V^SM=Z: N;W=:NT-XKK+6_6]OCUT7
MW#]J;H#NYC!$0W+^\!ZDC'.!SSGTIHCC GP^?,!\WYA^[]<9Z8]L?K3OW>ZW
MQ][!^S??Z=_\^N::OD8N-N,8/VC[W3O_ )/M1=_W^FZT^/\ SVW]^ZV!.7_3
M[IO%?\_/\M_[FH&.,B#+X\L#ROF'[STSCKGWS^E.VING.[F0 2C<O[L#H0,<
M9'/&/2FMY&+?=C&!]G^]T[?Y'O3OW>ZXS][ ^T_?Z=O\^N*-;;SV[?\ 3R/X
M7L_^OBBNMT>]IK5Z_96O[R/GVVZ\EW?2PWRXO+B7?\B.&C;<,NW92>IS[_UI
MX5!,\@.9&4ADW+A1Z@8P/P''X5&/(\J'&/*\P>3]['F?YZ^V*D'E^?)C_CXV
MGS/O?=P<Y[],Y_&AWO+XOM;K7XHWOY?S=I60-RL]:NT_LJ_Q1M;SWY>\6WZQ
MF*'R43S#Y:N65]PRS9SC(Y//&/\ &I,*)A(#^\$879D$;!_%@=_?\:B/V;R$
MS_J-YV?>^_GGKWS_ $J7Y3, /]>8@!C=_JCP.O'M]*3;MKS?;^))=8WO_P"W
M[).VX7>O\6W[S>*[Q_2_)WU?357"3IY2L=A8;F#<@Y&1N'3ICWIZVB+,D@;E
M1C;ZXQ_#T/OGUI (+:!R,!"?F[#<3G^9Z]^*C6X5F"?\M3RG7.WZ=.F,>E3[
M[4N3F4%=-VU::C>_HK7=]K=Q74)4^5*::<Z?=17+[2*]=+::O3:PXV4;"7+L
M=SEB03\IQTR,D?[HJDTDB$,PPUO\L(Q]_)YSD#=CMFGRW.Q_-S_HT9VS^@D7
M[V?3@<?SJP-EULD7!*C,6.PYSUSS@5<9.+2J/F32;[QVT:6UXZ2_NNZZ#=3V
M3UC!2J1<U%-7<][.ZZJR7GIL5%)Z1Y/VCB<YSY>3V_NXX/'TI+N"-$57E>,(
M,(0[#</<@C/U-6$DMXC*4P"#^_Q] ,GIZ\]_3UJKJ!M[FSD#<RLG^B^N<C&,
MY[9Z]?I6D)-UH1]Z*<HMM*\K-I<S3_E3MM;E5_(Y\3^^@X<MI13T>B<W!-Q;
M[*.E]=59=S\'OV9O#MKXP_X*._MD:/K_ (?TW4],631DMYK[3X+DN#R3YLL3
M$\]><<^E>->/],O/V/?^"@MAXM\(Z7!I&C?$O7+?PA=?9;5$MFMKO4=1W*J;
M?*3Y9@-R*IQT(P*_<3PU\%?#?P[\:ZU\2-+L8+;Q5X\D0:Q=)"J7%P8,[!*Z
MJ&?H<9)(I_QO_9N\(_&.R\/Z]X@TJTO->\.:K%K6ERRVZ2SQ7T)5XW1]I8,'
M8G.1SGMC'K?6J,:N'4YQE0E&KAG:UW6YG&-9K^6*6COI&VVQYD,+RT;RC&$G
M*%9)?:A%)2@V[6O+5;IKH?S8_P#!2?\ 9XO=;_:=A\?:I93Q>%=2U?3W;4/W
MD<7EOK3RR,)00HVI.AR.F?<5^AOPL_9>_9%UK6/"VJQZSI^MZQ;0:'.MO>:F
M+T17D,,,F$BEE<*RRKT"\%1C! K])?B-\ ;/XR_#RR\(^,M,CO#:9(6XMUD8
M#%L1]Y"<[H/TZ5\K?"/]@#PEX%^(L^HV6B+#!;O%- PMV1!)'Y[#&5VY!(Z<
M>_05I+$MTJ%-X]4%AU4IS=&5W4@N6,)SNUHTG;=*[Z;0Z;=2K+V$9QQ'LTE+
M>*BFI*.FK3Y=.GD?"O[7.@77[/'[?G@']HOP_:A?#G_" :%X)=S&)=.CLP;.
M(NL<@:V1TA8L)0F\8SD<8]3_ ."A7[8'ASQS\!=+T?P?J]K?S7TWAAKR"![>
M4)<M]E\U-B [=LK2+@8 ((P,8K]2?V@/V<M ^,'P[M_"6M:7#>3VCHMNLENL
MKJD<<<<>W<A88"+C'&,#M7R#\/O^"8/PPT[0KF#Q#X:M"PU&.^B%S9!N8KF6
M>,J'C[ KCTX/'%3#$8%PP<Z]93JT/:8>";3]HFU^\W>WV;/7JQ2P\G3J0]E'
MFJ\DZDDVU3VTTT;2Z6[;(^//COHGB'5_V.AX@6S=GBTG36"K&=I']DW3$E=N
MT_ZL9X[UZ#\(_P!KO0-(_8JO=-M]5ME\5:+:?V>EGOB\U&CLM0^3R]N[(?8"
M,'MZU^MTOPP\!ZM\/W^%5]963Z;);1VRVKPIL,<,$ML@\K8!@),?X>AQ7Y]Z
M1_P30\!Z5XPU!X?#<">&[^\DN;E!9A;=FD=,EE";3\F_UR,\>N=;&PQ'-0KP
M6'5.M3JT7?2?)9IK9WG\+MU7<TH4%0O.E:2E3Y94^SEHY='S)6NGT9^47_!/
M_0]5_:#\%_MCQ:M!(]_=:GIDUA&BF-I]D-KN.V,(7(R?H. ><U]G?\$^?VH=
M(^''B#X@_#7XD:K#I5IHL\UA:)=/' 0A739, R88_>D.?08[<_K9\ _V6OA/
M^SQ=:L?!VD:=ITGB4AK\6MK%#YI0(H\S:B[N$ RV>WI7S-\<_P#@G%\(_']S
MXG\3:#X>L'\2ZJ&GDEM[-//DN0BH,E$W%L!??CUKSZ^,C6J5>?VG)-TY*I))
M0HSBU"]]=$HIK;=G;0IOV:]DES>T7M4M93I-02T^_KIO;4XW]L7Q1=?%'X1>
M)-9\, :AIVA::DNE30*)%EA68*I#(#O'[\\DG.>]>%_LS?&2P\3?\$^_&G@W
M4;U(O%6G:%+%<V0=(YHG:[L=H,:@.I.&&,<X/M7ZA_![X*^&O#/PITGX;:I8
MP+G2H].U&VFBQDJ58K(C+DD; 0&&>/7K\T^'OV%-#\)_$3QT^B:''#X:\2>2
MLJ16P2VEC#!B-JHJ$%@.V.G7&*ZOK>%E3^J./LHI1JPK/:<H583<ELN:<EW^
MTWO8Q^K5)5WB8N[CS4H1>C:E[MX]^5/Y*^JL?E9^SGX+\3^(_P!ECXIZ;#92
MO=Z;X,U>\LI%C<2W,ZV\.R-W'SS*VWE"2"2>/7Z:_P""97[4=E\-_@&G@7XD
MWT.AZIIMI=$6DWE6CI(FE)$N(W"L#YL('J2#WZ?K-\._@KX6^%EC?:+9:=:V
MNC:A9M92QK J0O&ZA&5EVXP0J@CGW]*^%_C]_P $]/#?CK71K_A3P_$R7ETO
MVAK2T&PQ/<AWW&) "-DC]>@/?K6V)Q-'%QG2KSY*$^6<*^G+*:LY*]K*:T2\
MFWV.:CA:^&G*4??JQ<U*+NN>[]R;:Z<E[^=NFI\&_"#5/$?Q[_; ^*^LM9"\
M\(?V3>26.M"W#&5HK76GXO$4%L;(P!OXW=!FOK+]AZ"/2?VN/$6AK(TD<&BW
MTF9&,C*4FN00I9BP Y[XZ?C^A'P _9Z\"_ WP8?#FFZ99V>ISZ=-;3A+>..5
MFN;9X6W_ "AR29'&,]21CJ:U/A;^SOX;^'WC+5?B1%IT%OKNHM=0-<B!4F:T
MN))'(\P(I((?)&<=/K6.*QZJT*^'4>6#A&&'F[KVLIM<TJ?1P22::>MPIY?R
MJA4FY2]G5G*2MLFXOEDOEKV?<_,3_@J)I<^L?%+PM);!_)BU'22TT>05V2Z3
MQO7!P=IXSSQ7['?"JYCF^'WA*,G;)#X<TF/:."=EE$I) QDD@<\GGOFO,/B]
M\#?#GQ1OK;4+JP@NQ!<6\C.\2R8DB:%LY*GG='^!YS7N&F:;IGAS2K'3XE2)
M[6T@MXP %(6*-4  &!P !^GTY9^R^IX;#1YY5(+W8V3E%NW-SI/2^GR7J>C[
M.HZM24HWB^=J$;WNXP49+35-;.W1Z'X6?M6Z->ZS^WI\/DAB9=/&@H)Y(U*C
MS/M>F9!=0,9!8G)[5S=H+^\_;5^"]O.C26FDW%[&A<%AAA&<'=P<9QSGG.<"
MOV(\;? SP[KOQ"TCQ^^GP2SVEF(VN3"K,&+Q.P\P@D<Q9//;I6?:_LY^$K7Q
MQI'Q"DTRU%]I;O);7)MUWKO #;9"@(S@GK7J4\=1^KI1C%^TIJFU)V?/"UU_
MC=MO0S6&FY^_3DHPCJXZN;FK)Q3MK%N_RWT/!O\ @HG;,WP/U^QMURU]H,L>
MY?OQ;C/S$PSL(V]5*]>HS7J7["EH^E?LZ_#^W8'S8O#5LNYOFDD(*<N6Y8X[
ML2>!VZ^R_&'X:Z9\3] _L::U2[MY;?R9D,?F J3)P1M.?O?3I]*Z7X;>$]/\
M >%]'\-0PI;PV%JMK;Q*FP*%Q@!>,=^.G4^M>;*OSX!4I-RGS2M2TY[>T4W=
M=K;O^EM2A4=?VRB_=<5=_"X**A=-)^\KZK3\3L(+?ST>64L))>&7/W<<\#'&
M?:JRQ%9A&[-Y<9#1L21O;'"Y/7CUSWS5V6YC65U'5 /-'/3MGCO]?SIIE@D6
M&1\"+>/*ZXW]N?YD^OTQS1E4U;C+EFO=5OANE;E\VMK_ &=3JNN>2Y%[LES2
M5M'RKDE?;E4%9]GW)(HXVFD<OB1E(*9&%R#T7H/7(^HZ5$]G D2[I3C>64[N
M2=W0G))].M17#*;@M:G]_P!9=N2=N<\^V,]?P[U&TB2LK2<VN1Y><E?,'Z9W
M>M)1E[LE*25HMQM[WNK1)>=WR]TF^AHES*&TTE=3Z\WNV:^]W^7<MX7S=^?W
MGE;-FY?N?W\8Z^_7//6HQ%#Y+IYA\MG#,^X95LYQD\CGC'^%2_)YW_3;RO\
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M^%#O=_'O/I_=C>_FU;G[14&M]!\UV[U?MZ**_EA:WGOR]&^;:PSRXO+E7?\
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M/]G^T7?V;[OVJ7?TZ^:_]:X"SU.BBB@#S;XM?\B-JWTC_FU;G@;_ )%;2?\
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M_E5^J&J?\@Z\_P"N#_RJP/*/ \40UVXD\P^:5Y3<<#B0_=/3DD>_UKV:O&/
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MV_R/>C6_V_NU^!;^=O/X-1W=]ZN_\JM_#6_E?>WVVUYCMJ;ISNYD $HW+^[
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MP4B\;_L8?"WX.>+/"\T0N_&JW+SK+:V]PLIB$AV[)XG7'R@X4#\:_'[X4_\
M!=3]KOXE^*/ \%GI2/H/B#7[33[V2'0;(1+:S .[!XK0!<*5Y&WK70LGQ=6C
M&HW&T9587LO<]E4=.4'&WQ2<7):7U-5C,)5Y*5FHJ"]YKX967*F^L>JOO;:Y
M_:IJ[R"UM;BTD(D:9-X49)7>F?P()_\ K&M/5;E(;.*6V0+=NJK)M)+C(3+<
M]QECT]<\5^%'[=O_  42^(?[+/[.'PX^+&DB+^T_$^O6&G70GL[>X4)/>:#
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M4_/]?[W?KG./>DNFG1?:?_/Q+;IVLMOCW"W]W^6W[R3M^\3MY][]_<V0UI%
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M.&)/WCD$YSSP1S4Q9?/C38"S*").,J,=.F._Z&HTDE%N6V .A"A=AP5SC.T
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M^N<X]Z&>0"#"9,F/,^4_)]/[O;IC&?:CY7_[>:_Y=IO7\>WV'H-;_#U_G?\
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MM*4796W:]YZ^ES9XZ[C#D3G)*TVU=W2M)+O9:6TL]#]M(+6.%CA NX??'O\
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M?7N?T71,+R&TODD\@%29(UX"=1@Y.?P_^N*9?1&R3^TK24R&$>:Z \28R,'
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M\_9)U\S?^Y^[G9VV^WI[9IP\S=#UV8/G_=QGMN]\]/?--\M]DB>:V9'+!_\
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M/XS\*_#Z&*V\-G3K**2.Q"K;^6KW[CB+"8W9/Z8KY5_X)':=J_BK_@G%\;]
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MMMHEW!'9'E61$&;DY(8#GW-?2?\ P25^#VM7'["O[1'B$170E\:^#9+JV78
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MR4D)W>>7S'TSY>??CI^.,T\^9YJ8_P!3@>9]W&['\^N/PITBEXPBN0>#YO\
M=Z':/;M^/%(58RI)O8*HP8N?G]\9SSWP?6O(36_NKXM.5V6D;673;W?Y7S-[
MJ_J\RU<E"+M4O%Q;:]V"=[;].;:Z:2V&'S]DG7S-_P"Y^[G9VV^WI[9IP\S=
M#UV8/G_=QGMN]\]/?--\M]DB>:V9'+!_^>8/\'7 _'OBG[6W0G>V(@0R\_O<
M]_O<X]L<<T-K^[N_LOK%)6^?P]I7D] ;BKW<-Y?8D]J<6U]WQ?S1]W<8//\
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MVQC!YHU[RZ]%K[BNWYV^+KR[:Z![W>IUV4?^?<;;OJ]O[S:>FHT1Q@3X?/F
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M6YT^2)62,9VL2_RLHSTP:^NET[2(CF&!47^%$"IAASGY5 QG'^/I'<6*O&7
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M)WD:9Y7TZPA" LQDR3$<<GGJ/3[;O-,LWD:<V\3MP9S)'&Y8=MI()!Z'WYX
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MI^Y=UN-BYD!*MQF+ Z#Y>_?/;WIIDE\N5MGS(Y5%VG#*.Y'\1]SG/X4_<^Z
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MD#MSD?G[U2N;B[CC-P49HYSY'DCHBD[,COT8'\,^IJO<W\\%S&D W6?F* ^
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M[L],\8SUYI/9Z?SZ<S?\O5[VZ7^._D#7E?X_MR5[N&O]V_;['0@68+"\JQ*
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M(D81^41\JD<;L8S[^GTJ\LSB1[<\JT#2[O3()"\8^F*3[6\T:GRU$FX!D &
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MYJ0LXF1-OR,H+-ALJ<=-V<COQ[55M6K?SZ<STM&/VNMM7_?NT_A,?M2]U?\
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M\L H\Q, $MP,CY<=<XX[^U-VW)AD;=B0MF$[1A(^P/!/7W'T%=F=,C,J$CY
M!N7 P2 .OY'O_2D_LM?+D4$Y+?(<#*CG@<>_O]3V%B7:*=57]V[L[ZR7-T_E
MWW^92I1YOACRI))6U33NODNG9ZHXY/.9X@,A5!^T# ^<]L<?S!]>*9FX4RAC
MDG(MR /D/'48'?)XQ^0KM1I<8:(CH!^\X^_SG)]_Q'X]*:-*3][GDG[G ^7I
M]W]?7\>*/K/7VBLE%6L]^=)_^2=[]B?8^[;E@I7WY=.7FYK6]=?\6IQSK<*(
M2#SC]_\ +]_J3CCZ=<]/?-.43/YS#(CP/(&!\AZL3P>OMCG\Z[!M,4B+KQ]_
M@?-UZ_F/3^=._LR,&7'"L/D&!A>1T_+U/X'BCZR[?Q5?J[/;G@ET_E;6VU_G
M7LH\WPQY$GI;6[:E?;:ZO:_Q:G$K]I*QIG][N!F? PT?< 8SS[Y[#!I[>:DS
MEN82,(F!E7.<$_+CTS_B:[ :6@2/KO#?.V!EEP.#[=>P^HIW]EQF5V(RA!VK
M@8!.<'Z]._\ 6F\3KI45DGI9[J45&[]+V_I$^RO&2<8<S;LVM+-IV?=]^[LS
MBRMUY*'=^^W?.Q7@H3PO )SM!'4_X/0222''$(CQMP/]=C[W Z9]LX[UUYTM
M3$JY.X-RV!DKQQT'8>@/Z9>-,C#Y POEXVX&-^W&[ZY]_P .]+ZRU>U57O)K
M333DY%M;:_3U'[*-U[L>6SYE;5N5K_?;7N<,9[A<VAYG<_(^" $[@X']TCO2
MSQ&SP1DVQ&98^A9SR3G;W.[U]_?LAI$6UF(_>[\J^/F ST'MC'\)XX]:EDTN
M*21-XW1@#<F/E)P,DX/7KCGCMVKH>.@U;FM>3D^5<J<DH6V\V[=G=E*,HV:=
MFK;=/^&.+2&:6!IE($N[,!QPL?8$A>O3N/K212O>2)"00D61<<'YSU! Q_/-
M=H-,58I(U)&6^3 &57G@?TZX]<9H3288WC9%V\?O,#[_ +G.><8[@CW/%'UV
MGS<U]5>*TLE[JU2VO=Z=G>3\W:>C<M8VMU:UOI?MO_2.)::>U9X&^8RY6W(!
M^3/3/';!Z8JXIFBB"YY8?ON"-Q]N/H?3C\NG.D1.96<;F/\ JR1]P\?=QT[]
MC_*G/I:,(O\ 9^_P/F//7\_;_#&IB83CR*247*\VT[OW4U\D]ULW=ZD2I<Z?
M-9OH[;.]V_GU\KKL<=;I(LLLJY"?\L1_=/?/48_#\^M/E>XDD0J?WH8>:V.&
M0=AW&>>>>O?MV/\ 9D8,N.%8?(,#"\CI^7J?P/%1KI2!(P/O!OF; RR\<'VZ
M]A]1WB-=)INHE91BE9\JBX1;5O*5K>:[(2HJ+IRC&"<;<UE9/:[2MH^S[:=3
ME96;)+#(Q\J\\-V)_''ZFH?]+%N@#8E#Y9B,@KD$*.N/ER.O]*[/^RXC*[$9
M4J0JX& ><$>_([TTZ6IB5<G<&Y; R5XXZ#L/0'],N.(MRKVB=W%RNGU2<K+?
M?HOQ'&ERRF]U):7W3[-]5?;LM#D!YLTI8[O*$>-O?S<?>'&,9YQC\>U5M\X!
MB+$W#,/+?G 3/0^^WCJ/UKNQID8?(&%\O&W QOVXW?7/O^'>HAI,>QB>9-^5
M<@;@,YP.#QT['^>''$[7J*S4%:SW=E*^FW5[W1<:<=ZD5*3CJXJR<HVY'_V[
MT[')2,\.UF_U0 WKCYBV/O#CUSQSZ ]JELFF!,K\DD^20.%3/ /Y>W/:NK?2
MHGD0L,H -RX&TD  D^_7O_/E/[+01R*.I;Y" /E'/ XZ<^^/6E'$I)7J7<G'
MG5F[W:4DE_AW_4;A3<8KV<4XZ)I)>ZK./S4KN[.&5(Y[_P ^%=IB8^<!SO8X
MQZ$?CG\ZLRW;K,D=U^\#MB'C[O\ /N#Z8KK8-'BA=6 P#_K!_>Z<G/IZ<=^]
M12Z*DSLS#.TYCYQ@\]..N?J.]:/%1G44I5?<A%*+=[K7EWWM;IM83A:,H6C)
M2Y;MJ^W++2ZTL]]GIU/Y_?\ @NQ&?^%4Z9.&96AT^VP$8J3^]U <8Q_>KZG_
M ."-S*W_  3V^"-X YFFAU#+O\Q!'V4#.<DXZCG/6O ?^"W^CQW/PILS)(=L
M&GV^4.,/B:]'/'O['^5?4W_!'&RMW_X)]?!J..,*JP:@(\<[?^/7)'N1[GVK
MV:^(A')<OTNEB*G,UI[LG.R_PW:=KO;N<')3GBZT8?Q94X\[=W%)<FB\^SMH
M[==#]!T*&YO6V'[2T#"63'#)DY XSP<GN1G%,T^.8QGO#@E%(Y!V\$_IQCUQ
MQ7;)I,*I]W]X_P KN1\Q7J0?J<^@_"EATM(F8#[FT[5P, D?Y[\].F17D4\9
M""JQ3]V3O[UF^B3B_LV3=NRNCT52I*A&'+%RYUS*WV4E>]]'?=[W>N]SC8S,
M 4EP922'8]"A/ _+Z^WI4L,+PRN(LB%D8[<?\M<$YQ@COG/OUSFNJ?2$:->3
MO#[BP')&1P>/3/\ #_\ 7L#3D#Y'W?+QC QNQC/US_M=.,8YK"EBG"I53GS4
MIIZ2N[O3EM?9K6W;4SC3LG?=RO9;):=-N9KXG;5VNV<0'O C1[LS%\HV. FX
M\=CTP.O^%2N]PLT;D_N@H\Q-HR3QR.,=C76#2UV-DGS-^0V.0,G@<=.G\)_F
M0\Z9&94)'R #<N!@D =?R/?^E4\2N9VFN5N=KIWV@XZ^KE^.P*,^62;5V_<T
MTBK16O=W5WWV..#7GDRD-AV<M$Q7[J=EXY_+'TIK>=<&)''RIGSP!]\]L<^_
M<'_'LO[+7RY%!.2WR' RHYX''O[_ %/91I<8:(CH!^\X^_SG)]_Q'X]*EXA-
M.\XO=)V>W)&RUW7-?\]!VFG3Y6ERN\K7^+36+Z6:\G8Y!GDC1HT^\>(CS\IX
MZ].>O'_US5<02P&.2/AVYN<Y^<XY(X^G7/3\:[4:5'^])Y+?<.!\IX^[^1]?
MQ[JVF*1%UX^_P/FZ]?S'I_.B-=1LO:*R>MT]G!/2ZTM*]K/SU$H22E=\UW>%
M]6KVOS-[ZZ^FB.21[EFF?/[LC]R,?<([]Q_(<?C4;O<RJD6<MN!F.,;T[@>F
M??(.3Q79_P!F1@RXX5A\@P,+R.GY>I_ \4P:6@2/KO#?.V!EEP.#[=>P^HH6
M(5^9S2=HVT>B<8N3\WS?C]Y7[Q1A&ZTE&4Y6U?*DM.VVB\CCU,MO*^!F C"(
M>JL0<$\8]#ZU#Y$ZJLP.+EGS(QSADSPO&2#MS_$1S7<?V7&978C*$':N!@$Y
MP?KT[_UIITM3$JY.X-RV!DKQQT'8>@/Z9I8IWC^]LY<G/\7O)KWDT]=7;U\P
M:DY2;:::T[WZN3ZW?X''H)'D)&1"(\;?^FV/O=,8SVQTXSVJ,&Y",F<SE_W;
MXX"9Z$$ YV\=?7UKMQID8?(&%\O&W QOVXW?7/O^'>HQI2;&Y._>"K8Y R>!
MQTQC^$_SPEB6[7J)W]GI9[MI3OI?;??0S]E:,5:%TUS.VEHNZY5;1K[+TMJ<
MBXE25#_RP"CS$P 2W R/EQUSCCO[4W;<F&1MV)"V83M&$C[ \$]?<?05V9TR
M,RH2/D &Y<#!( Z_D>_]*3^RU\N103DM\AP,J.>!Q[^_U/86)=HIU5?W;NSO
MK)<W3^7??YE*E'F^&/*DDE;5-.Z^2Z=GJCCD\YGB R%4'[0,#YSVQQ_,'UXI
MF;A3*&.2<BW( ^0\=1@=\GC'Y"NU&EQAHB.@'[SC[_.<GW_$?CTIHTI/WN>2
M?N<#Y>GW?U]?QXH^L]?:*R45:SWYTG_Y)WOV)]C[MN6"E??ETY>;FM;UU_Q:
MG'.MPHA(/./W_P OW^I../IUST]\TY1,_G,,B/ \@8'R'JQ/!Z^V.?SKL&TQ
M2(NO'W^!\W7K^8]/YT[^S(P9<<*P^08&%Y'3\O4_@>*/K+M_%5^KL]N>"73^
M5M;;7^=>RCS?#'D2>EM;MJ5]MKJ]K_%J<2OVDK&F?WNX&9\##1]P!C//OGL,
M&GMYJ3.6YA(PB8&5<YP3\N/3/^)KL!I:!(^N\-\[8&67 X/MU[#ZBG?V7&97
M8C*$':N!@$YP?KT[_P!:;Q.NE162>EGNI14;OTO;^D3[*\9)QAS-NS:TLVG9
M]WW[NS.+*W7DH=W[[=\[%>"A/"\ G.T$=3_@]/->0D9$(CQMP,^=C&[ITS[=
M.,]JZ\Z6IB5<G<&Y; R5XXZ#L/0'],O&F1A\@87R\;<#&_;C=]<^_P"'>E]9
M=G:JKMSL[;6Y>3I;:_33J/V4;KW8\MGS*VK<K7^^VO<X@&Y",F<SE_W;XX"9
MZ$$ YV\=?7UJ5Q*DJ'_E@%'F)@ EN!D?+CKG''?VKKAI2;&Y._>"K8Y R>!Q
MTQC^$_SP\Z9&94)'R #<N!@D =?R/?\ I3^LZ_Q%9<W1ZM1A;IIJY6^>O=>R
MNI74>9WY=%HFDO>TU;M[W=)'&;;DPR-NQ(6S"=HPD?8'@GK[CZ"E3SF>(#(5
M0?M P/G/;''\P?7BNQ_LM?+D4$Y+?(<#*CG@<>_O]3V4:7&&B(Z ?O./O\YR
M??\ $?CTI?6=_P!XNJ6CLO=BU:ZM\5_\EU;I+W?=A_?TWNE%V]5H^ZT.*S<*
M90QR3D6Y 'R'CJ,#OD\8_(4LHN$6)L]!FX^4?/USCCZ=<_CS79#2D_>YY)^Y
MP/EZ?=_7U_'BA]+1A$/3[_ ^;K][\QZ>OT?UG9>T5M$]'JN2+T_[>OU\QQI1
M4FW&+7,FDEJE9)K_ ,!T\EIKL<?&9)?,D _=G_4*1]SU)X]?H?YTSS[AC%"I
M_>(X,K8^^GH/_KD^O-=J-+B7S0HPI'R  87IT_ >I_ \5&NDQA4('S[LNV/F
M8>A]NN>F<]?5O%*4G*51+2"BK-67)%N]K7;EOW=_5Z*-.*G%024M8NUFFK**
M?=*-U9>7J96CI<_VA([-^XP-J8.0<,.O3T]^GT'85GPV?DW#2*2$/\...^/Z
M>O3MS6A7#7GSR4KJ3<(WLFM;:Z#LE;E5M%?UZE6]W&SN@IPWD2X/H=AQ7G/@
MI9UN;K[0P=C<R[2.P\U^.I[<5Z-? M9W0!VDP2C/I\AYKSCP3&T5Q=!I?.+7
M,I!R#M_>N<<#\*Q ]1HHHH \V^+7_(C:M](_YM6YX&_Y%;2?^N!_]#:L/XM?
M\B-JWTC_ )M6YX&_Y%;2?^N!_P#0VH ZVN7UE;C+8;J?W>!]TY."?P';'Z@U
MU%5[F!9T((^8#Y3Z?Y_SGBM\/45*HG)73T;MJKM:KTZBDKJQYPLETYCMBW[U
M&'FM@X9/0#UX[D]14T[/ QW#,1&(UQ@JW8D@<CI^'XUUZZ5&JQD?ZP-\SX&Y
MAZ'KGOV&?4<4YM*B>5F<;EP=JD< \X(YZYP>O\N.U8BFDTIR;YG-.[MNK)^N
MZ[)6N]F^6FY)NFG!P4)*6LK:.5MTKM76O1'%E;H0(VX^<6R[$9!3@A1U.=N1
MR?Y"EB9YI"R[A"$P5_Z;8/S<C&,]L=..E=D=+4Q*N3N#<G R5R..@XP,=!QQ
M]7+I<2N=J@(4P5 &-^#\WUR3W_#'-+ZU9/\ >*[<K.SM9<O*GI:_;M;S(]G3
ML[P7,VK.W?XKZ[RLOZ2.)!N0C)G,Y?\ =OC@)GH00#G;QU]?6I7$J2H?^6 4
M>8F "6X&1\N.N<<=_:NN&E)L;D[]X*MCD#)X''3&/X3_ #P\Z9&94)'R #<N
M!@D =?R/?^E'UG7^(K+FZ/5J,+=--7*WSU[Y^RNI74>9WY=%HFDO>TU;M[W=
M)'&;;DPR-NQ(6S"=HPD?8'@GK[CZ"E3SF>(#(50?M P/G/;''\P?7BNQ_LM?
M+D4$Y+?(<#*CG@<>_O\ 4]E&EQAHB.@'[SC[_.<GW_$?CTI?6=_WBZI:.R]V
M+5KJWQ7_ ,EU;I+W?=A_?TWNE%V]5H^ZT.*S<*90QR3D6Y 'R'CJ,#OD\8_(
M4YUN%$)!YQ^_^7[_ %)QQ].N>GOFNQ&E)^]SR3]S@?+T^[^OK^/%*VF*1%UX
M^_P/FZ]?S'I_.G]9U7[U65KZ/5<D7U3^W?KOKL'LDN9\L=UR:;:<NNFNFG^'
M0X]1,_G,,B/ \@8'R'JQ/!Z^V.?SJ-?M)6-,_O=P,SX&&C[@#&>??/88-=M_
M9D8,N.%8?(,#"\CI^7J?P/%,&EH$CZ[PWSM@99<#@^W7L/J*2Q/>HM>7=/1.
M"<NFOO?C?U#V2M"T8Z-.>FCLN73L[:+LM#CV\U)G+<PD81,#*N<X)^7'IG_$
MTTK=>2AW?OMWSL5X*$\+P"<[01U/^':?V7&978C*$':N!@$YP?KT[_UIITM3
M$JY.X-RV!DKQQT'8>@/Z9%B?A3J+>#EH];I<VF^]MM_/J>R7,_=C:RY=-4XJ
MR;]+NW9>IR">:\A(R(1'C;@9\[&-W3IGVZ<9[5$#<A&3.9R_[M\<!,]"" <[
M>.OKZUVXTR,/D#"^7C;@8W[<;OKGW_#O48TI-C<G?O!5L<@9/ XZ8Q_"?YX%
MB=KU%KR:6>[:4[Z7VWW%[*RBK0O>/,TM+1=U96T:^SM;7N<BXE25#_RP"CS$
MP 2W R/EQUSCCO[4W;<F&1MV)"V83M&$C[ \$]?<?05V9TR,RH2/D &Y<#!(
M Z_D>_\ 2D_LM?+D4$Y+?(<#*CG@<>_O]3V%B7:*=57]V[L[ZR7-T_EWW^92
MI1YOACRI))6U33NODNG9ZHXY/.9X@,A5!^T# ^<]L<?S!]>*9FX4RACDG(MR
M /D/'48'?)XQ^0KM1I<8:(CH!^\X^_SG)]_Q'X]*:-*3][GDG[G ^7I]W]?7
M\>*/K/7VBLE%6L]^=)_^2=[]B?8^[;E@I7WY=.7FYK6]=?\ %J<<ZW"B$@\X
M_?\ R_?ZDXX^G7/3WS3E$S^<PR(\#R!@?(>K$\'K[8Y_.NP;3%(BZ\??X'S=
M>OYCT_G3O[,C!EQPK#Y!@87D=/R]3^!XH^LNW\57ZNSVYX)=/Y6UMM?YU[*/
M-\,>1)Z6UNVI7VVNKVO\6IQ*_:2L:9_>[@9GP,-'W &,\^^>PP:>WFI,Y;F$
MC")@95SG!/RX],_XFNP&EH$CZ[PWSM@99<#@^W7L/J*=_9<9E=B,H0=JX& 3
MG!^O3O\ UIO$ZZ5%9)Z6>ZE%1N_2]OZ1/LKQDG&',V[-K2S:=GW??N[,XLK=
M>2AW?OMWSL5X*$\+P"<[01U/^#T\R27(!$ 3E,<F7'7@=/;'3OVKKSI:F)5R
M=P;EL#)7CCH.P] ?TR\:9&'R!A?+QMP,;]N-WUS[_AWI?679_O5=\]G9Z6Y>
M36UKI7MIIU'[)77NQM9\RMJW*UW==VM==3C9&G Q$0)\X1\<!,\CC!/&!G/K
M]"Z:,,FR5<QD9D7');'49XQG.,^HKK!I2!&Z[]^0V.0,G@<=.G\)_P 'MI<9
ME1B/D"@%<#!.!G/Y'O4^W6B]K[J<K?%=M*#BO12<M-MR?8VB[64[WC-:27PZ
M2>M]M=[I)'&(+E;9T4X;=^Y.,A4YP#U/4]L?3K4BR7#O!CI&")Q@?.>V../R
M-==_9:^7(H)R6^0X&5'/ X]_?ZGLHTN,-$1T _><??YSD^_XC\>E5]9W_>1W
M=G9_R1MOH_>N:<C]RW+_ '^M]MK[*]V^Z.&EBDD=VF)9P?\ 1B/^6; <9&.W
M/3'7VJYM<QQF;)9!^\/][UZ_GW]>U=6-*3][GDG[G ^7I]W]?7\>*'TM&$0R
M1C[^ /FZ]>/IZ>O&.''%<LDU-;J^CV]G'7_P+K?TTN3.GSQG&5G%M.*2MMK9
MVWNU]W<XU4E?SGR=N/\ 1QUV$=2>H/&<\#DGK4#&65!;ODR$XN&QP\1ZJ..I
M^I^G%=V-,1?-'8@;!@84\9(XZ_G],U&-)CV)Q\^[YVP-S+Z']?3ZBE'$).3<
MXJ4N75+?W$[OO[W]:(J-./(N:"Y^331652R5WL[)727;0XRRMU9VM2H^Q(NZ
M*,CYE< \YSZJG( Z5_+!\5);FQ_X+!^/9()9$>7^P(Y 6;:8RVJ*0%5A_"2,
M'C'M7]:D6E1QW4DO/ELN F. 2&Z?GZG^=?RF_%33%OO^"R7Q!M@2!"OA^3(X
MR =5?!SD<XQVKTL#B83E4IN;Y94.:>CW:3DH_P LI.UVK7L>;B83Y*2J^[:J
MX\R^!1T47RK1M[K30_IDT"!AHGA].6M7T33YMA S]H:UB._.?[W/3\>QU_/N
M$'V3/[YB#&^#A8P<XY![$=_PK?\ #.F1G0-"+<A=&L4 P",BVC /U_'],5JC
M2(MK,1^]WY5\?,!GH/;&/X3QQZURQQM.*C#=J<?B7,[\VK^?V]-3MI4JD4U*
M<91WA:-N71:>G;M^!RMQ<7-KM<\VX4;T Y+8Y/4>C=N_;O L,TJM> D7!8^0
MV,[(ST7M[<9[8-=M)I<4DB;QNC &Y,?*3@9)P>O7'/';M2#3%6*2-21EODP!
ME5YX'].N/7&:%C:6GP_8O[NK]Y7YN]OM=UH:<C[_ -=/ZZ>9P]F6>XS&I4@G
M[3G_ ):'@@@#(_/TI\EQ<0/)$_S--E8"!]P]B>/8^G^/:II,,;QLB[>/WF!]
M_P!SG/.,=P1[GBF'2(G,K.-S'_5DC[AX^[CIW['^5-X^F]^5Z16L;NRFK+T2
MMY<ON]$'(^_]6_ST.4E^U*MN0WW0#-Q]_KT^7Z=<]*(S,\DKG/E''E \[<=<
M]00?H/Q[]>^FJPB&3\OW^!\W7K^GI^II?[,C!EQPK#Y!@87D=/R]3^!XKGJX
MB$[VE&S6J:=OXD=4EHM&VNWR&HRYMTH\MM-)-M+6ZZ+7SO9^O&LTY:-8SAU8
M&5L?>3N .!SSSWXZG."1IA,[/S#C")@95SG!/&".G;]:ZY=*0)&!]X-\S8&6
M7C@^W7L/J.[_ .RXS*[$90@[5P, G.#]>G?^M3&O&&D)JRYFM'>_-&S;[M7W
M^^Y/LY.FXNTGLG+5<NEN;HVOQ9QC+="%&#8GW?,V/O)D$#IUVY'7\*E22=Y2
MPSY0BV[<#/FX^]T]?;\:ZPZ6IB5<G<&Y; R5XXZ#L/0'],O&F1A\@87R\;<#
M&_;C=]<^_P"'>J>*NV^>-VYVM&T5\'*MK;7TMIU*4+-645'5R5M7)VUO^?<X
MC-SM92<W#/\ NY,<!-W(P0#G&!P1_(5*XE25#_RP"CS$P 2W R/EQUSCCO[5
MUPTI-C<G?O!5L<@9/ XZ8Q_"?YX>=,C,J$CY !N7 P2 .OY'O_2CZSK_ !%9
M<W1ZM1A;IIJY6^>O>/974[QAS2;MHK)223YM%=NWO=[(XS;<F&1MV)"V83M&
M$C[ \$]?<?04J><SQ 9"J#]H&!\Y[8X_F#Z\5V/]EKY<B@G);Y#@94<\#CW]
M_J>RC2XPT1'0#]YQ]_G.3[_B/QZ4OK._[Q=4M'9>[%JUU;XK_P"2ZMTE[ONP
M_OZ;W2B[>JT?=:'%9N%,H8Y)R+<@#Y#QU&!WR>,?D*<ZW"B$@\X_?_+]_J3C
MCZ=<]/?-=B-*3][GDG[G ^7I]W]?7\>*5M,4B+KQ]_@?-UZ_F/3^=/ZSJOWJ
MLK7T>JY(OJG]N_7?78/9)<SY8[KDTVTY==-=-/\ #H<>HF?SF&1'@>0,#Y#U
M8G@]?;'/YU&OVDK&F?WNX&9\##1]P!C//OGL,&NV_LR,&7'"L/D&!A>1T_+U
M/X'BF#2T"1]=X;YVP,LN!P?;KV'U%)8GO46O+NGHG!.737WOQOZA[)6A:,=&
MG/31V7+IV=M%V6AQ[>:DSEN82,(F!E7.<$_+CTS_ (FFE;KR4.[]]N^=BO!0
MGA> 3G:".I_P[3^RXS*[$90@[5P, G.#]>G?^M-.EJ8E7)W!N6P,E>..@[#T
M!_3(L3\*=1;P<M'K=+FTWWMMOY]3V2YG[L;67+IJG%63?I=V[+U.03S7D)&1
M"(\;<#/G8QNZ=,^W3C/:H@;D(R9S.7_=OC@)GH00#G;QU]?6NW&F1A\@87R\
M;<#&_;C=]<^_X=ZC&E)L;D[]X*MCD#)X''3&/X3_ #P+$[7J+7DTL]VTIWTO
MMON+V5E%6A>\>9I:6B[JRMHU]G:VO<Y%Q*DJ'_E@%'F)@ EN!D?+CKG''?VI
MNVY,,C;L2%LPG:,)'V!X)Z^X^@KLSID9E0D?( -RX&"0!U_(]_Z4G]EKY<B@
MG);Y#@94<\#CW]_J>PL2[13JJ_NW=G?62YNG\N^_S*5*/-\,>5))*VJ:=U\E
MT[/5'')YS/$!D*H/V@8'SGMCC^8/KQ3,W"F4,<DY%N0!\AXZC [Y/&/R%=J-
M+C#1$= /WG'W^<Y/O^(_'I31I2?O<\D_<X'R]/N_KZ_CQ1]9Z^T5DHJUGOSI
M/_R3O?L3['W;<L%*^_+IR\W-:WKK_BU..=;A1"0><?O_ )?O]2<<?3KGI[YI
MRB9_.89$>!Y P/D/5B>#U]L<_G78-IBD1=>/O\#YNO7\QZ?SIW]F1@RXX5A\
M@P,+R.GY>I_ \4?67;^*K]79[<\$NG\K:VVO\Z]E'F^&/(D]+:W;4K[;75[7
M^+4XE?M)6-,_O=P,SX&&C[@#&>??/88-/;S4F<MS"1A$P,JYS@GY<>F?\378
M#2T"1]=X;YVP,LN!P?;KV'U%._LN,RNQ&4(.U<# )S@_7IW_ *TWB==*BLD]
M+/=2BHW?I>W](GV5XR3C#F;=FUI9M.S[OOW=F<65NO)0[OWV[YV*\%">%X!.
M=H(ZG_!Z>8\F>D"IRN!S+CEN!T]L=._:NO.EJ8E7)W!N6P,E>..@[#T!_3+Q
MID8?@80QXVXXW;<;OKG_ &OP[U+Q+M*U17]_ET?3EY-ENE>VEUU'[)77NQM9
M\RMJW*UW==VM==3C)A,8RT9Q(#@'T7/(X]@1V_&N@T6.X7!1ML7&]2.K9Y(Q
MZX;_ !]+RZ2HA= QW,^0V!D#).!QZ''3_P"MK0PI @1!C@9]SCDUQ2J3FDI2
M;LV]?.VGIIML7&G"'PJ[6TGOK:[]=+>A+5'4?^/.;_=/_H)J]5'4?^/.;_=/
M_H)K,L\P^'O_ "%M;_ZZM_Z##7KM>1?#W_D+:W_UU;_T&&O7: "J&J?\@Z\_
MZX/_ "J_5#5/^0=>?]<'_E0!Y5X'6X_MNX)<&#;\J8Y'$GN>V/\ /->R5XUX
M'B8:Y<2><2I7B+C XD/&,<\X/';\*]EH QM;S]E&.N_C\N/UKCY#-@!.)R0%
M;' 7//'TP.OKZ 5Z)-"DT91QD$''L<<&LI=*01MUW[\AL<@9/'0^W8_X=.'F
MH-OFY6Y15M=8MZWMTL_\C.I#G<?[KOKMNO\ R96]UVT.1<2I*A_Y8!1YB8 )
M;@9'RXZYQQW]J;MN3#(V[$A;,)VC"1]@>">ON/H*[,Z9&94)'R #<N!@D =?
MR/?^E)_9:^7(H)R6^0X&5'/ X]_?ZGMTK$NT4ZJO[MW9WUDN;I_+OO\ ,2I1
MYOACRI))6U33NODNG9ZHXY/.9X@,A5!^T# ^<]L<?S!]>*9FX4RACDG(MR /
MD/'48'?)XQ^0KM1I<8:(CH!^\X^_SG)]_P 1^/2FC2D_>YY)^YP/EZ?=_7U_
M'BCZSU]HK)15K/?G2?\ Y)WOV)]C[MN6"E??ETY>;FM;UU_Q:G'.MPHA(/./
MW_R_?ZDXX^G7/3WS3E$S^<PR(\#R!@?(>K$\'K[8Y_.NP;3%(BZ\??X'S=>O
MYCT_G3O[,C!EQPK#Y!@87D=/R]3^!XH^LNW\57ZNSVYX)=/Y6UMM?YU[*/-\
M,>1)Z6UNVI7VVNKVO\6IQ*_:2L:9_>[@9GP,-'W &,\^^>PP:>WFI,Y;F$C"
M)@95SG!/RX],_P")KL!I:!(^N\-\[8&67 X/MU[#ZBG?V7&978C*$':N!@$Y
MP?KT[_UIO$ZZ5%9)Z6>ZE%1N_2]OZ1/LKQDG&',V[-K2S:=GW??N[,XLK=>2
MAW?OMWSL5X*$\+P"<[01U/\ @]/->0D9$(CQMP,^=C&[ITS[=.,]JZ\Z6IB5
M<G<&Y; R5XXZ#L/0'],O&F1A\@87R\;<#&_;C=]<^_X=Z7UEV=JJNW.SMM;E
MY.EMK]-.H_91NO=CRV?,K:MRM?[[:]SB ;D(R9S.7_=OC@)GH00#G;QU]?6I
M7$J2H?\ E@%'F)@ EN!D?+CKG''?VKKAI2;&Y._>"K8Y R>!QTQC^$_SP\Z9
M&94)'R #<N!@D =?R/?^E/ZSK_$5ES='JU&%NFFKE;YZ]U[*ZE=1YG?ET6B:
M2][35NWO=TD<9MN3#(V[$A;,)VC"1]@>">ON/H*5/.9X@,A5!^T# ^<]L<?S
M!]>*['^RU\N103DM\AP,J.>!Q[^_U/91I<8:(CH!^\X^_P YR??\1^/2E]9W
M_>+JEH[+W8M6NK?%?_)=6Z2]WW8?W]-[I1=O5:/NM#BLW"F4,<DY%N0!\AXZ
MC [Y/&/R%3J)8U1F/SXS*<'YSWQ^F?QZUU@TI/WN>2?N<#Y>GW?U]?QXH?2T
M81?[/W^!\QYZ_G[?X#Q%[+VMEI=V:=N1/3RY[]?,3HI\VB6J<&E9QLK:O2^F
MGIH<DC7#>>V?D8?N>!\F.I/7/X8_'BH@UTRPQ[CYJN#*PX#)Z <<GGKFNU_L
MR,&7'"L/D&!A>1T_+U/X'BF#2T"1]=X;YVP,LN!P?;KV'U%"Q/>I%? ]G_(F
M[]];^5[^I7)*T-K_ &W;1[7MVUV[+3J<B9)TF=F.82N$3 RK$'!)*\]1[_C3
M6^UFW1=W[TL=S8ZH2#@8Y!VY')(]179?V7&978C*$':N!@$YP?KT[_UIITM3
M$JY.X-RV!DKQQT'8>@/Z9%B?AO-:\G-I+:WO:;WOVW\Q\KYGMRV]W35/35OK
MKMY:''1(_FY0$0A02I'/G#^(8XZ^HR.F>Q?<27$@"AOWV0$89P$[CL>F!U Z
M_2NQ&F1A\@87R\;<#&_;C=]<^_X=ZC&E($;KOWY#8Y R>!QTZ?PG_!?6.:49
M.KK[BM[WVFE._P K7WT1#I.3C.5G4TYY6^*S7?JDO=?0YCS)(5 'W, NO.2W
M<CCIG/Y]N\4?VAE=Y2"^X^2><+'V!SGG/IC/H*Z]M+C,J,1\@4 K@8)P,Y_(
M]Z:=+7RY%YR6^4X&57G@?G[X]3V2KJR_>^]+EYGJW=M*5NWNK7\ 5&*YHV2I
MO5+K&>GO1_E\K=NQR'[UY4"<1C_7C'WCVQZ$=>G7.<4LID"L!]\\1$#&T^_3
M)')Z^GUKL%TN-6B(' 'S\?>YR,__ *Q^/2FC2H_WI/);[AP/E/'W?R/K^/>O
MK&L7[7X4N^_,HN__ &YU?_ %[#W4O=YHM:VT<4T[-?C_ (M?,Y)4D1$W?>QF
M7C[Y]OTS]._%,59G\YLD)C_1QC[IZDDX.<_ASZX!KL'TM&$7^S]_@?,>>OY^
MW^#_ .S(P9<<*P^08&%Y'3\O4_@>*F-?EORU$KN[LG9>_%::6UBW?3O>[WKV
M,>9NRY;?"]=;IZ;V5];:>]J<0OVC$0S^^5P97[-'Z 'N>>N?IUJ<R3I/(S<P
ME<(F.58YP<XYZC_]==:-+0)'UWAOG; RRX'!]NO8?44[^RXS*[$90@[5P, G
M.#]>G?\ K5O$W;]]6L^C_FC;5>5_ZT!0DHRMRJ3DVG;36WQ+J[>NNIQ'DW"H
MLH)%P7R['.UD)R%P,GIGJ2,_E4ZO.\ID&?+6+&T_\]0/O<=L^@S[UUQTM3$J
MY.X-RV!DKQQT'8>@/Z9>-,B#Y ^39@K@8W8QN^N??\,<U/UBR?+.-W[1K1V^
MSRWTMW[?<7:3E%MJRBDT]7=6Y;/HD<3$)6F,MQ\]R-R1N!C;&>-O.3]W X..
M.E</\3-/LF\ :W%-&S6<D%VTL0P"SM;7))!P1_$W\)//KS7M']DKL;D[]V0<
M#(&>G Z8]OZXX[XC:3%)X0U6'^ VEUN]\VLWZ\GU'UKJPE>$JE"$G"4G7@E[
MJ4;)JUT].NG5:G'B*4I*K*6RC))];12Y4GYMOFO\2ZV1_*U_P2"!N_VK?CL\
MK22)8_%[5K>T!9F$<*ZC;[4Y8]!_=P/:OZL-2>1;LOR(5;]ZN,[O<=?RQ7\P
M7_!(O28-,_:@_:$0-YC/\9=88$\[!_:$.%& /7&"/TK^JN[TV.X=3C"G)=>S
M'WX_P_')KU.(G3P^8TO9<L*<L+!MI?$][WMO?\+=#;"0@Z48N*4)2CSI)*\6
MH\WX7.,N)E,2JBX>5?W1P/EZ]<#V]1^!Q586TL/EE#C=S<\']YQSMX],=?3\
M:[1-(B"N&&2!B,X^[[CWZ\X/XYYD;3%(BZ\??X'S=>OYCT_G7B/%*\;57&*>
MJU2E[J:=K:^]MYZF[ITXZTXI3M;F]'[OW*W2^ENQQ\7FJ)O+&(B!Y Q]P\%L
M]<_ACO[5$BS_ +O'^O#@S/V:/T&3U[\Y_G7;_P!F1@RXX5A\@P,+R.GY>I_
M\4P:6@2/KO#?.V!EEP.#[=>P^HI+%/6]1)OEOH]4X1<K]_>_'[Q6J:>]J_XK
MU]]:-KYM:(XZ42-,QER8<?NU Y5SD@GC'IT /;KTB\B=528'%R6&]SG#)GA>
M.<[<]6/7\*[C^RXS*[$90@[5P, G.#]>G?\ K33I:F)5R=P;EL#)7CCH.P]
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MHQ\WR@KC_72^H_R,5@,]T_9^*KX?F2V=I(/-&6?)8?O)O7/OW_*OHBOG_P"
M_P!GLM GMPZJ6D!P2!_RTF[<>OZU[S]JM_\ GLG_ 'U4QDY*[BXZZ)[VLM[=
M?ZW GHJ$W$ QF5.>1SUI/M-OR?.CXZ_,*JX$]%0?:K?C]\G/3YJ/M5OS^^3C
MK\U%P)Z*@^TV_!\Z/GI\PH^TVY_Y;)Q_M"BX$]%0?:K?_GLG_?5'VFWSCSDS
M_O"BX$]%0?:K?&?.CQ_O"C[3;YQYR9_WA1<">BH/M5O_ ,]D_P"^J/M-N/\
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M_>%%P)Z*@^U6^,^='C_>%'VFWSCSDS_O"BX$]%0?:K?_ )[)_P!]4?:;<?\
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MKWCR(,%?)CP3DC8O7\J/)AR&\J/(X!V+_A6HSP0Z3XD$4TO]I7687,8&U.0
M>OR=?\:D_L;Q&7MU_M.ZQ< D_*G&">GR?C]*]W\B'!'DQX8Y(V+R?7I1Y,/!
M\J/*_=^1>/IQ0!X(ND^)&%P?[2NA]F''RISC;U^3W_0T/I/B11;_ /$SNO\
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MUYF[MW4='T:5G;U_KR\$@T[Q&@:Y;4;I@C&/:57!RS+G[@]/U'K2OHWB03K
M-3N\2CS,[5^7.TX^YV#?H3VKWGR(,%?)CP3DC8O7\J/)AR&\J/(X!V+_ (5T
M.A%NH[RYI\W*[_"I**VZVY=-OO#K>W9=;:>6W5W[_<>$3:;XB>)IEU&Z4VQ\
MK:%7Y\ \G*'GC&..3^%/CTKQ$%6$ZC=$W>2'VKE,'C'R#Z]^N3[^Z>1#@CR8
M\,<D;%Y/KTH\F'@^5'E?N_(O'TXI.A!J$>:?+%MR7,[S;BH[]+;[O7H+E5K=
M$TUJ]TU+>_=?=H>"Q:7XC#R,=2NR+4YP54[L!>OR>Y].A["EFTKQ'NB==2NP
M+KG;M7Y,AN!\AST_'(]:]Y\B'G]U'\WWOD7G]*/(AX_=1_+]WY%X_2J]C'FG
M)N5W\'O/W5RJ/S[^OWCMK?K:WRO?;:_GVT/"VTGQ$R/$-2N@;0;MP"Y?..OR
M?CTZ=/6HX--\1K&LK:A=-]H(BP57Y<@<CY!SDX_ @=./>/)AY/E1Y;[WR+S]
M>*/(AP!Y,>%.0-B\'UZ5"P\.6$>::LXN;4G[UH\MO*^[WN]_)65FNC\W?5WT
M=[K7\--CP8:-XD%PT']IW9$7SYVK\V-QQ]SOMQ^/O2SZ;XC=$NEU&Z7S&$6P
M!<#!"EONGKG/7C!KWCR8<EO*CR>"=B_X4>1!@+Y,> <@;%Z_E5JC'G<VY:**
M@N9^[RIJ[Z.][NZZ*]PMJGU2:^3M_DOQ/#!I'B(K]E.I78;9Y_F;5W=,E?N?
MATX/Z00:=XC16N6U&Z81L8]I5<'+%<_<'IGKW'<U[WY,.=WE1YQC.Q>GITI/
M(@P5\F/!.2-B]?RJ?J\>11YI<UX.4KOWN5WM;I?J%E[RZ2;;WZ[V>Z\K/3I8
M\&?1O$@G6 :G=XE'F9VK\N=IQ]SL&_0GM3IM-\1/$TRZC=*;8^5M"K\^ >3E
M#SQC'')_"O=_)AR&\J/(X!V+_A1Y$."/)CPQR1L7D^O2FJ,%)23G:,8J,>9M
M7B[W;ZW]/P':]GU5[;]?S^>QX9'I/B)52$ZE=$W@R'(7,>/3Y?Q^E0PZ5XCW
MRN=2NR+0YVD+\X&.#\@]?T->\^3#P?*CROW?D7CZ<4>1#S^ZC^;[WR+S^E-4
M::YOB][XO>??FTU[W[?Y*RU_O;[]DOEHNGJ>#3:5XCWQ.-2NP+LYV@+\@.>!
M\A]/U%32:3XB97A&I70-F,EP%S)GU^7\?I7N?D0\?NH_E^[\B\?I1Y,/)\J/
M+?>^1>?KQ1[&GI\7N[>\]^:,M=?*WI^!;;^[M]UM>^CZ]==SPF#3/$21),VH
MW3&Y/E;2%^0D#D?*.>>GL::NB^(_M#P'5+LB$>9G"_-C<<?<Z''ZBO>/(AP!
MY,>%.0-B\'UZ4>3#DMY4>3P3L7_"G[&'O?%[R:EJ]FTW;7OZ:>H6LV^KM?Y*
MRTZ?KU/!Y]-\1.B72ZC=+YC"+8 N!@A2WW#ZY_ U-_8_B''V3^TKO.S[1YFU
M=W3.W[GX9QUKW+R(,!?)CP#D#8O7\J7R8<[O*CSC&=B]/3I2]C3LH^]9-M>\
M]Y6OU\M/TN'*K16MHVMKVVOW\[[G@T&F^(D1[IM1NF\MC%L(7!R2H;[@],_B
M*&T7Q']H2 :I=@3#S,X7Y<[3C[G09_0U[QY$&"ODQX)R1L7K^5'DPY#>5'D<
M [%_PI^QIW;M*[NG[SM9J*T5_P"[IV_)];]=%]U^FW7Y]=D>$SZ9XB>)YEU&
MZ4VQ\K: OSD \GY3SQT]Q3X])\1*J0G4KHF\&0Y"YCQZ?+^/TKW/R(<$>3'A
MCDC8O)]>E'DP\'RH\K]WY%X^G%)T*;7*^:R;?Q/=I)]>VW_!)Y591ULFGN[W
M3OOZK]#P:'2O$>^5SJ5V1:'.TA?G QP?D'K^AHFTKQ'OB<:E=@79SM 7Y <\
M#Y#Z?J*]Y\B'G]U'\WWOD7G]*/(AX_=1_+]WY%X_2G[*%^;WKVMN[:)1[]OQ
MU';6_6UOE>^W?S/#)-)\1,KPC4KH&S&2X"YDSZ_+^/TJN-)\2&*&7^TKK,SB
M,C:G ('3Y.O^%>]^3#R?*CRWWOD7GZ\4>1#@#R8\*<@;%X/KTIPIQIIJ-[.U
M[MO:*7Z#6GWM]7N[O\_ELM#P<:-XC,\EO_:=UB-2P.U.<!C_ ,\_;]149TOQ
M(L"3_P!I767D\LC:F,;@,_<]_P!#7OGDPY+>5'D\$[%_PH\B# 7R8\ Y V+U
M_*K \(.A^(6E\A]2NFC,/G."J?,-N2I^3H1Q]:[SP78/;QNVTQ!78.N,"1MS
MY9LCJ3SU'/&*[SR8<[O*CSC&=B]/3I2I''&"(T5 3DA5 R?PH ?1110!CZW;
M&XL91'E9@/D=<;AUZ9!'^37F$$.JJ+AEEF4P\C&!OQMZ_+S^'8<5[,0",$ C
MT(R/UJ/R(>?W4?S?>^1>?TH \(N-+\1L\3KJ5THN^=H"_)D'@?)GM[]1ZU))
MI/B)E>$:E= V8R7 7,F?7Y?Q^E>Y^1#Q^ZC^7[OR+Q^E'DP\GRH\M][Y%Y^O
M%1*G";3E>ZVLVOM1E^@;V\G=;]FOGOU]=T>$P:9XB2))FU&Z8W)\K:0OR$@<
MCY1SST]C35T7Q']H> ZI=D0CS,X7YL;CC[G0X_45[QY$. /)CPIR!L7@^O2C
MR8<EO*CR>"=B_P"%+V,/>^+WDU+5[-INVO?TT]16LV^KM?Y*RTZ?KU/!Y]-\
M1.B72ZC=+YC"+8 N!@A2WW#ZY_ U-_8_B''V3^TKO.S[1YFU=W3.W[GX9QUK
MW+R(,!?)CP#D#8O7\J7R8<[O*CSC&=B]/3I2]C3LH^]9-M>\]Y6OU\M/TN'*
MK16MHVMKVVOW\[[G@T&F^(D1[IM1NF\MC%L(7!R2H;[@],_B*&T7Q']H2 :I
M=@3#S,X7Y<[3C[G09_0U[QY$&"ODQX)R1L7K^5'DPY#>5'D< [%_PI^QIW;M
M*[NG[SM9J*T5_P"[IV_)];]=%]U^FW7Y]=D>$SZ9XB>)YEU&Z4VQ\K: OSD
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M#:+XC^T) -4NP)AYF<+\N=IQ]SH,_H:]X\B#!7R8\$Y(V+U_*CR8<AO*CR.
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MY,/!\J/*_=^1>/IQ1Y$//[J/YOO?(O/Z4E1IKF^+WOB]Y]^;37O?M_D66O\
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MA%L 7 P0I;[A]<_@:F&C^(0/LO\ :5WGR_/#[5STSM^X?ITZBO<O(@P%\F/
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MZU%;:7XB*O<-J-TVQC'L(7!^8KG[@YXSU[\^_O'DPYW>5'G&,[%Z>G2D\B$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P3_P""X,,,GPKB:21T
M9=/M]H4G!_?7W7!'J?RSUZ_47_!&G/\ P[]^#.>ODZA_[;5\P?\ !;]XE^%<
M:NI+'3[?:1P!^^ONO!XX/^>GT_\ \$:<_P##OWX,Y_YXZA_[;5ZE9Q>6X?EO
M=5'S7VO9['%"-L;4=FN:CUZVE#X5V[WUVZ'ZE4445Y9VA1110 4444 %%%%
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M898T;)\PX&!]>/K[GU_"L*_M4H^S4N:[6VFNEY7Z+I;J6K/?;_AMO-_EJ6'
MEC9"<;N.#COD8IL4:VT6W)(7DEB3V ZGZ<GK]:;*LFY#&P"_Q @G/T_3_.:J
MWNJ6-H4BN+B)&D8)AG"]>O!//N*UH^U<%3G=M-7M;WK+XO6V^RN7R:PMJI]%
MNK;K72_;\31CD610RG(/^?\ /OFG$9J&W,1C!A963L5Y'3_/XY-5KK5=.LCM
MN[VWMR.HED"G]:<HJ5TDW'L][>=O,AVN^6]KZ7WMYVTN:%-9@HRW JG;:G87
MJ-)9W<-RJYR89 _3/''T-/BGCND?(PJDYS_LDY/X8I\L^1RBM(V5WLKVM?KU
MZ$MNVEK]+[?@!M$:=9]SY'.-S8['IGV'ZU:Z@CZBL_\ M73Q)Y7VN#<."/,&
M01@8Q^(_SUOHRLNY"&5N01R#[U/)*"BE%*-M=^UU;];ZV&4+2PCLI9Y5D9C<
M-N(8L0,8'')]*NRLB(9'^Z@SG_/^<9IMQ-#;Q/-.ZQQ1@LSL=J@ 9Y/X5YGX
M:^*OA+Q?JNJ:#8ZA9O=:?(8)8TN5=RV(SC:%&#B1>,GCZTTJTY3DUS0BHV:6
MJLDM>GEWV'*5]9/717?DDHK\+'HMK#&"TZ.S";YL$D@9QT'0=.W'?TJ[3(T6
M)%11A5&!3Z!!1110 4444 !..M%!&>#12UN]K=-[W\^@!43R(&6-C@OG&.*)
M91$A<]O\_P#UOQK@_&?Q \,>"K(:KKVH6=I%&,AKBX6$8YSRP/7'^/M:I3J*
MT8.2;MZ[-K[BXI+WI7Y=4FOYK72^]H[>"U6!Y'#,V_LS$@=!W^@JU7F7@?XL
M>$/'WF?V%JMC=&/(*P7*3$D;./E .?G';O7H<%TD\DL:@@Q'!^O^?Y?2B4)4
MWRRBXM6T:Z6T(N6J***D HHHH **** "BBD)P,FDVDFWHEJV N>GOTHIH&3N
M/X#T'^?\^CJF$G)<S5DW>/?ELK-^;U?HT 4@QT';M3'D"%00?FIV.<C\??\
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MIR48W=DKKWO5I+\?S'@ # &!1T'TKAH_'^B2Z[=: )XOMEJP5U\Y=Q)R1A"
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M ,X_+O3JBCFADXBD5_\ =.>O-2UG&'(E>*C+EBG9/HNE^G;N4%%%%4 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[.WB']I+X?:#X0\-7I@CN$GAN9;=V<;3([Y'E;MW..XK^'S]L;_@GI:_L/\
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MQ(5S\KM[CI7AG_!,'XTZUXN\!^(]3\<:K)$;77[Z'%V%&Q(GN^T>[[H4=_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'X1?\%PUU>T^!NI:UI[JL&FZ5!+<(R;F<?:+I<*
MVX;?OCL>_&3QQ'_!(3]L#X<V7[!7P;L]?NK6#4K:/45D22^CC9#FV'S(T;$=
M^_;\*_3W]M7]DN/]K3X;ZMX"EUD:/'J=BEFTQD,> LK29S]FN>N[^X<XQQUK
M\"?#'_!O)\;/!&@0^%/!G[4>JZ!H5@\K6%C:WD'DP><P9@AD\+._8#D_UKWZ
M-;!_V?3ISK\M:$^?DBI)K1QUE:UWS>B1Y%:E7^N2J1I.4)P4;NS@[.,FFKZ/
MW=&_OU/WN_X;F^$T)EA^W6+M"A8XU*(9Q[>63VSU_"K$'[<?PHGMEN!?6*AC
M]PZE'D=.?]7GOSQQ7X3:?_P0,_:0LW::X_:ZURZ)!#*;RTRP]#_Q28SU]1]:
MF/\ P04_:/DFDEB_:WUR&!U*I +RU*H><''_  BC'C(ZD]!TXK*G2RMV=2L_
M>W:YK1E=-*RZ)7VNOQ.J<L2FU3BE^Z3A"R]V2Y4XWVZ]>Q^[2?MO?"=R1_:.
MG@ 9S_:49[?]<_\ &C_AM[X3E-XU&P(#;<?VE%G/_?O%?@VW_! O]I@VRPK^
MU_KHD#%FD^V6@)!.0,CPEC@<=^M.A_X(%_M+19W_ +7^N2*5Q@W=J0&YY 'A
M+\>G]*N=/)E=PJR;MHGS=U:[\E>^NOWA3>,<7SI*44[?#[[=K6WM;6ZTOW/W
MC'[;OPG+A1J5AR,Y_M&/'KC_ %?6F_\ #;_PGP6_M&PX.-O]HQY/OGR^W/\
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MPPA_Z"4>3]/W='_#;WPGR@_M*P.__J(Q_+]?W?/<Y'^%?@^/^"!O[2VZ _\
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M>Z$8YZ5_1WX8\ Z%X(^'TG]BVPB<V"_:694RYW)R"B+@G"]<G(SZY_"KXC_
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M7/W>/[;WPG 1O[1L,.?^@E'D?7]W0/VW?A.2P_M+3SM7.?[1C&?I^[K\'_\
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M?M?:YY:KAD^V6GS,,<G_ (I/OC_QZF'_ ((%_M+^5,H_; UW>[ED8WEI\@Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 T$[B.V/\/\:=116%"3<9W;
M=JLTK]$GL-_HOR04445N(**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image00024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $+ K0# 2(  A$! Q$!_\0
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M!Y]J /2Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"\MU?7;!V7S+RU%M(>?[@[4 ==139&VBH_,7Y?G7+=!D<T <O\6?^29^)O\
MKPD_]!H^$O\ R3+PS_UXQ?\ H-)\6& ^&?B7.#FPE_\ 0:7X2_\ ),_#/_7C
M%_Z#0!UU%%% !1110 4444 </\;O^24>)O\ KT:OSDK]&_C=_P DH\3?]>C5
M^<E "4444 %?2?[$W_(UZ]_UZK_Z%7S97TG^Q-_R->O?]>J_^A4 ?8-%%% !
M1110!%_^JO(WOH[37=77P[H-UJF)RTL@8!8I<8)3/>O6^6^4]Q7D,.G7<>L:
MXFA>)FC2&5KB>);?=L)[ ]SQTK.ILCMP=M;LZ?X<-8-X6O'TX3>8[2&Y\_\
MUGF]]U? 6KDKXAU(J<?Z3)U[_,:^^?AG;PQ^&+RXM]0_M#[2\DKRE-A#D<@C
ML:_/_P 0 C7M2QS_ *3)_P"A&MZ%1TVF<^)2]HTBE.VZ0GC\*BIQ![TVG4=Y
M-LQ0E%%%9C"BBB@ IU-IU %BUMS.V%K16PEM,3.IPO/(I/#_ )?VQ!,^U>O6
MM?6M315\F-A(.YKU\,J/)=NS.RE1C[-U),CM_$!#YFBW<851TITFN>:_R6R!
M@<YS6'&RKOROWN,G^&H+P*DG[MMPQUKJE4J4Z?,YW1"QU1>ZC=NO$<A8J(H4
M'0[5J)/$,L()BV@_2N>SFBO->,J7=F'URJ^I8N+@W,YDDZL<FI?*A/*R<#UJ
ME1GWJ*.(4-7&YSRO)W9KP:I):P/#;22(C_> /!K,ED:1LL<U%FC-37Q#JI)Z
M(S4$G<#24$T5RE@*#2J,TN*I)@-HS2XIS(5'--1;U0#*_1[X+_\ )*_#'_7D
MO]:_.&OT>^"__)*_#'_7DG]:D#X)^)__ "43Q'_U_2_^A5C6-E/=[A!$7VC<
M?I6U\3.?B)XB_P"OZ3_T*NW\+Z=IR^&42ZQYDH+F6,_,I[ UT8>FYMOHCEQ>
M(^KPYK'F%O;2W$ODPQEVP6 '8#K5[6-;N-1L[.VE*I!9J8XXD'YG\:Z;7=*C
M\-7#+93F6X>'<S=E![5R$UC@1NK O+RJ]"*PG9RL*E6C52D;OA_1HH9DNM0C
M-P@3SA G?V)KM_"?A^TU.&;5;];F&7S,-$AVHJ]A4/@N:+6- O5N[46\8"IY
MPX V]<FNCCO[#2=/BCA9YX^"/[HKMP:A57O:-'F9QBJL*:ITMV4/[!%AI]Z=
M-8R32[E"GJH^M,\,'^R[&V>^6YM+BW?,.Q>']<U5U+6KK^WU72A\DR@2 <J/
M>NCM=1>VOYX=0S)IMO#YAF R%8#./QJL3&+]]GFT%6;C&>M]3S3XO1P3ZY%?
M0!(VN8P7C"X.?7%<%CY<<>]=)XDU1]96>[G9-QF)&1\VTG@?0"M#3].T=O L
MMY-<*NI>?MC3NRUQPC[WO'U<JR4%H<>L:8R6Z=CQ2H\8<EE]@*[?6M#L=$T[
M3=4M8C>VDT7[[<> Q[>U<YIMI;:C+<QQP3%RI:!5[8ZYK7V]DDD3"M&:YEL8
M;<L:;GFKGV<;7+L 5['K50C-34I2CJ^ILFGL)101BDK 8Y:V?"9C&O6OFC*[
MP,8S6,IQ4UM.]O,LL3%74Y##M2DKHBI'G@X]SVS5[^ULKHR3RN45<(@^:L#4
M-)T35Y9I[1YD<QA@C+CS']CVKE--\17:,\]S&MTN<G?U%37'C:\-L\$,42*Q
MSG;ROL*=2->44IZ(\2E@*E%^X]>Y4\1Z,VFF%9)4\UOX0.@]S6[H-AY.NZ=;
MK-&[;-Q(;Y<XXS7%7M_/?3>9/(S-[FMWPZ[SE(;7R4G!V@N<%_QKHH4>>,H)
MZV/8I_N^6575([2+5]<L9A:BS@N'G8J)%? _'T-,N=>U'1]'N(+B5[?4=Y=(
MPV0%/O6(^L-9W\O]H7(WQJ0B6H!0GTK#O=6GU.U2SB0*BDLO=F/N354H-1M5
MEMT,YT</*HYTX6N5-3DCN;U&\R221^9I&_B/>IU N9DB!>& C:AQ][Z^U9D<
M8\TB1]N!G/7GTKIM,N89=/9[Z]AC$2[8TVY:N.O4O*\454;BM#0TV.XLKI!,
M8W'ELH5QP1VQ[UJMJ>HSQM;31,ZQ1A<A.?Q-<I-XBCD18Y(VF"'"%NH KMO"
M/C.RM=+GM+B%9))LDN>2/;Z5C+'8FFE9'E8JG-+FY;GTY^S><_"VP+ J3+)Q
MG_:KU):\Q_9YFBN/AK:R6X B::3;C_>KTY16W,ZGOL]>A_#6@ZBBBF;!1110
M 4USCM3J:Z[@: /,O%GQ U32->N;&UM] >&(#:;G41%(?JO:NL\"ZU<:]HHO
M;M+))&<J19S^='Q_M>M>;_'C2Y()+*^L-$MY(IF/VV\BLEGG)'W5(/.#ZBNP
M^#3W4GA'==:?'8Q&9_LZ+"(2T7\)*CH: .MUR,RZ/>1K$\S-$RB-&VLYQP >
MU>*VGA/Q9=0:")[.> PHL:[KK)M&$FXLV/O KQ7N[+N7!I N* /,OCG:>(9O
M >I-HNI6MK;1VDAO(YH=S3KMYVGM70_"8Y^&?AGG/^@QCZ\4GQ8_Y)GXF_Z\
M)/\ T&E^$H_XMGX9/_3C'_*@#KJ*** "BBB@ HHHH X?XW?\DH\3?]>C5^<E
M?HW\;O\ DE'B;_KT:OSDH 2BBB@ KZ3_ &)O^1KU[_KU7_T*OFROI/\ 8F_Y
M&O7O^O5?_0J /L&BBB@ HHHH C)Z$5X?'KQ\/Z]JUEHFI:3*LUTSF*_<P21R
M$\\D?,,U[?CY??%>:^,4N'FN!J6G:;-:D'RY)( _YGK7/7FH*[(EC%A8W:O<
MV/ ND'2?#UVTMY!=W-VTD\SVY!C#$=%Q7Y\:^I37=1;G'VF3&?\ >-?H5X&T
MF#2?"\D=M;0VT<BM*4A)VY(]#TK\]O$<K'7-14G(6YD_]"-=6'E%QYF4JOME
M[3N4+B;S6!P!@8XJ"G'GFFXSTIRDY.[&%%&*,5%@$HI<48H 2G=:3%+0"'AB
MO2@R,>IIN:3K33:*N^A))*SG+&FYR*;2U;J-[LG8!UJQ,(A FS._O5:ESGK5
MPJ<J:%8.*GE2-8@ROENXJO2YI0FDFGU"PE-IU)6;&)1114@.6K1DC,6"N&'<
M54I<UM3JN"L@%S4CS%HPI[5#14J;5P"OT>^"_/PK\,?]>2?UK\X:_1WX*_\
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MM*\@,?\ 8#7GDY)'!1NQ]CUKT3X/V(TSP18V+W\MY=6J^3<>;)YABD'WDSZ
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MEKQ=_P!!'3/^^F_PK[1VT;: /B[_ (9:\7?]!'3/^^F_PH_X9:\7?]!'3/\
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MXH **,TFX4 +12%@.M&X4 +1BBDW#- !BEQ2;A0&!Z4 +1BC.:* "BDS1D4
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MOKRTL;N*:ZLW"7$2GYHB>F17DNM:I>0ZUIOC<6]N=,6Z\DW,>_SWMV^4*4[
M'FKMUJ4,7C&3Q)X;BENYC(MG>PQQ%=T;_<<^NTT >GV&LZ=?W][8VEU%+=69
MVW$:G)C/H:;/JUDEU<6OVB-[N",320*=SJA[E>M>=^");JVOO$\&@007=Y_:
M :;[2&C#9'+!OXN:W8Y[9/BS(HC"7<FEH)2L9PQW$X+>PH [2QNH+RTBN+:1
M9(9!E77H15BN/^'^]8]9 /\ H8U"3[/].,X]LYKKUZ4 +1110 4444 %%%%
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6B@!NW%&*=10 W;2XI:*  4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image00025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #Q Q(# 2(  A$! Q$!_\0
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MWAT'_D.Z;_X$I_C2_P#"7^'3_P QW3/_  )3_&OSEVQ28 &<CK4,5L@=BWS
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MX^7S>AY[5WI<V'NVM.G474\E_;4_Y'S1O^O#_P!G-?/%?0_[:?\ R/FC=O\
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M%?%.A6@B\1: DJE6BO(2"?\ >'%?:R]JTQW(YVB/*W>#92UY_)T2_D\E;C9
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MJ*Y\Q?$W_DH?B/\ Z_YO_0C7,5TWQ-_Y*'XC_P"O^7_T(US%>2G8]<6DHHH
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M+$D'&X >HZU6T;58;WQ7+KM_>+;W6_$$,:;6ECQC QP.*POB-86&GZL)-.U
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MO]"^VP:>D<UKIP<\G!W9;CIUQ7GH[B+XXZ9%J?BG2[8_VK?2?96>2QLH"ZE
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ME@;R,$>:>?F^M4?&9_XJW6^G_'W+P!_M&JIU)4[V,O9:WN4;V]-Q<&1 L0Z
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M+:[M_LND>0PNHC&7(EZKGJOO7JT5C;PS&2"WABD("ET0 D>F:\^3_DX.7_L
MCI_UUH ]-HHHH **** "O*OVGO\ DC.M_P#;/_T(5ZK7E7[3W_)&=;_[9_\
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M<>IKYO'%-5B,?G2ROO;)K1)6N!LZ7X@OM/M98('P)!MW'DJ/:OI/]C*^GO\
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M XDC),I 8=*YC4/V7=9U'4+F[F\26'G3R-*^V!@,DY.*^L\9I  .@H ^1?\
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MCUR>ZCL*P?#^DKI'[0-^L=U=W/VC1O.8W,F_83+]U?05Z]M%>:1C_C(67_L
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M 4444 %%%% !1110 4444 %%%% !1110 4444 -\M>>O/6F+;Q(KA(HU#\L
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M8(QTSF@#<A^'7AF&&2.+3=HDVEOWC'E3E?R//UIG@[P?-H6H3W4]U')Y@(Q
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MONZ'=7$WNL>)K7XLW>OQ^!M6N+-+'[ FR1,N0^=XYZ4 >XTG>O,O^%C>)/\
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MQI(TXVM;,F<>7@8P<\].16)I?PXU!=0L+G5K6POM@VE3,Z_9F60L'3'7@]*
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M&T&YDOGEL%/VW_7 .0#TY S\N<#..M03?#WP[,)O,L6S,Y=V$[Y)*[3SGN*
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image00026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $/ KX# 2(  A$! Q$!_\0
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MR#_"W_8:@_G0!ZKWHH[T4 %%%% !1110 4$XZT5!?7,-I;--<R+%$O+,QP*
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M !11G%)F@!:*3(I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\_\ :?\ ?DT ;M%1Q!PB>806Q\Q' )J2@ HHHH **** "BBB@ HHHH ****
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M"O!O#7_)UWB,=O[.7^0KWNO!/#/_ "=AXC_[!R?R% 'O=%%% !1110 4444
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ML/\ J-0?SKU6O*OC_P#\>'A;_L-0?SH ]5HHHH **** "BBB@ HHHH ****
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MR@D;^AP2:Y#X4ZM?:U^TAKU[J^EOI5VU@JM;2-N*@ 8.?I0!]*4444 %%%%
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MY'2@#TA?NTM(OW>:6@ HH-)0 M%&:2@!:\J_: _Y!_A;_L-0?SKU6O*OC_\
M\>'A;_L-0?SH ]5[T444 %%%% !1110 4444 %%%% !1110!G>(K ZIHE_8+
M(8FN86B#CJN1C-?(_P //@1XNTWXBVEQJ$2V^G6-QYQNPW,@'I]:^R:9)]T_
M2@#F?AZV[19F/>[F[_[5=3FO ?'GQ,F^&_@>.2SM5GO[Z^G2/?\ <0!N36]^
MS_\ %.;XCV%]%J5JD&HV;#>8A\KJ>A'O0![!1110 4444 %%%% !1110 444
M4 %%%%  WW37F'BS[3H7Q&L_$=UI]UJ6F?8S:J+8;GMI,Y+;,\Y'&:].;.TX
MZXKR[Q9>OX?^)5EK>LQ7TFB)8F&!K<,ZQS$_-N4=R.] %WX3Z;=0#7-0DM)+
M&PU*[,]K92/EHEQR3Z9/.*W=9\%Z!K6JKJ>IZ7#/?!0@G)(95';@]*Y[X20W
M*C6[D0WMMH]U>&6PBNR?,"X^;@\@$Y->D(?EH P(O"^C1:V=833+==3V^7]H
MV?.5Z9]*CL?!_AZSCOXK32+6-+[_ (^0$_UN>Q]JZ2B@#)T+1=/T.Q6ST:RC
MLK7=N\N,8P3U->->&^?VK_$>?^@<N/R%>]UX)X9_Y.P\1_\ 8.3^0H ][HHH
MH **** "@]**#TH S-=@N[C1KR'3)4@O98F2&1AD(Q&-U>/_  6^$_B/X>^)
M;V^O-<M[VSOD8W,:J06?.0WUZU?_ &A?B@WP^TS3(=-93J5W.KE",XA4_-^?
M05Q'Q:^+^H-K7A*?PA'=S6,:QWUX88BRON_Y9$XYQS0!],Q_<%.JII%['J6E
MVM[ &$=Q&LH##!&1GFK= !1110 4444 %%,<\')QSP:\]U;Q/XYM]3N8=/\
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MB!BR@L,/CYAG.#Z4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!112-TH \1^*4E[I/Q CU33-2\.6\CV?DO#J>23SU%=E\)]5OM6T>ZDU&[T2
MX(EPATK[@'O[U6^(&I6=GJT4=UX,N=<)3<+B.)7"^W-0_!O3+FSMM:NI=&71
M;.]N_-MK+^)%QR30!Z6@PM+2+TXI: ,CQ7K47A_0[C49HIYEB&1'"NYF/88K
MS/3OBAJ4_P ,7\12Z>BZG/?&RMK4GA&+87=].]>P3#=$PP"<'&?6O$H/ NO'
MX9W5A'%''JT&KMJ,$9; E ?(!/;- %@_$SQ%8:7>Z9JFG6?_  EL5W'9PQQ/
MF%B_1R?2E_X6;KMKH-Q97]A:?\)='?KIJ1QOF%G89#$]ABLN7P7XKU>UO_%-
MY86MKXA>]ANX=/$F5*1\;"WJ<43>!_$VHZ7<>([JP@B\1MJJ:DFGA\JRH,!-
MW]: /0/ASXLO=8M=5M/$:6]MK&DW'V>\\E_W?J&!]*YSXZ7UM<V7A@074,A&
ML0-^[=6SR>U7/ ?@^YO=,\2W'C&S2VN_$5QYMQ:PR$^6HZ#=7%_$WX<^&_"'
M_",7^A6LL5S_ &O FYYF<8)]#0!]"K2T44 %%%% !1110 4444 %%%% !7 >
M,?B+_P (UK!L/^$=UF_.W<);6+<A_&N_J-O7ISUQ0!Y,_P 9A#$[R^#O$J1H
M-S,UOPH^M<%XT_:<TN;P_>0^&;2\AU9EVQ23H-J>I->]>(;O3KR"ZT*;4+:W
MO+R!HUC+@/R,9Q7R;IOP*U#PSXD;5/&5Q:P>%]/<RRSNV3,N3A0/4T <]X)\
M53>+[>X\/^,--U'7=/9FN8FLDS/;2$\D>Q]*]H^&_B'0_AYILMEHG@KQ2S2G
M=+/+;_/(:V?V<]<\#7::C:>%H([;4FF>2177#O'GC!]*]OP/0?3% 'E ^,@+
M@?\ "'>)1R!G[/7J%A<F[LX+@1O'YJAMC\,N1T/O4I/H 1_.GCIZ4 .%% Z4
M4 %%%% !1110 4444 %%%% !2;1C';TI:,4 &/6BBO/OB'XQU?0/$/A[3]-T
MY7M+Z[C@N+R4_*@8XPOJ: /0:*\9O/B=K%EKD]]/;VI\-1W\VFB,9\_>BD[R
M>F"1TJBOQ5\0Z?:.^K6]C))J-HMUIOE@@1[I-@5_7J#F@#W2O!/#/_)V'B/_
M +!R?R%=?X=^(,NG:3K[^.I+>";1)ECN+BV4E&# $$#KWKSSX9>(--\4?M+:
M]JNB3&>RDT]0KE2N2 ,\&@#Z/HHHH **** "BD;H<5Q?B?5?&MMJK1^'="TZ
M^L-@(FFN2C;NXQ0!M:QX7T/69A-JVEV=[,!M#31AB!Z<U=T[2['3;1+6PM((
M+=#E8T0 #Z5P8USXF]_"FC_^!QK'T#Q[X_UY]133_"FEEK&X-M*'O"/F'7%
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M-W'//_UZ-Q/YT +BEIN[FA2<X- #J*** "BBB@ HHHH **** "BBB@ HHHH
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MK):VB[F^888Y/3CTK%\3:'XI_P"%/AOB)J=[IMKI<RPVEA)",W!/0Y')P,T
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M\%^*_$%EJ \,/<2( 99&DVF0?W3BO"]GR%@PQFFJ,D=CZ^E 'U!\3/'EY/\
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M]/\ ^?ZU_P"_J_XT 72,U \"M=),R*9$4JKE>5!Z@'WJ'^T]/_Y_K7_OZO\
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M[]R>:ZC^WM(_Z"MA_P"!"?XUQ?\ PI;P)_T!0?\ MJ_^-)_PI;P)_P! 0?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image00027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %/ B # 2(  A$! Q$!_\0
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M\ #IVI+] >]SB=-U&;0YM2U*PNM6U;2[2U^SS7%R\DRWEZ9  T:C.U%^8,4
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MLZYT/2;K4$O[K2[&:^3!6XDMT:1<=,,1GCM4-W9<596.&'Q!OK>R^UWEM9-
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M1"T>_B>'SF3RAH5W&<#/'G%MG_ L8-<W\0[JX-_XGN/M=Q!-HMA:W.GK',R
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M_P#'NGTHC_U\WX?RJ.WA!A0[Y.G]XT1PCSI1ODXQ_$?2@"23_7P_4_RHNO\
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MG- %^LZS9@QQ&Q_>S=".?GJ73=4L]361K&<2B,[6X(QZ'D<@]CT/:FV/WO\
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M_"?2@ D63SHOW@[_ ,/M1<+(('S(",?W:))D\Z(Y/&?X3Z47,R&!P">G]TT
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M<CC(_'I78UQ?@6)$O966+Q'&QBY_M2".-.HZ%5'S5UGVVU^V?9/M,'VO;O\
M)\P;]OKMZXJF2BQ15/\ M73_ +*]U]NM/LR-L:7SEV*W3!.< ^U2F\M1=1VQ
MN81<2+O2+>-S+Z@=2*0R*Z_Y"%E_P/\ E5RJ=U_R$++_ ('_ "JY0!'<?\>\
MG^Z?Y4]?NCZ4RX_X]Y/]T_RIZ_='TH 6BBB@".X_X]Y/]T_RIY(5<L0 !DDU
ME>+Y'A\*:S)$[)(EG,RLIP5(0X(-:+Q+/;>7)DJRC/- $O7I533_ +]Y_P!=
MS_(59B18HU1!A5&!5;3_ +]Y_P!=S_(4 6Z\E36H]$\2:W!::K +-KQ[N=I-
M':18B72.0>:)AG:Q&3MXSZ# ]4OI'BLYY(C&KHC,#)G:"!WQSCZ5X==ZOH6J
MZ]=ZM9QZ?<M'=& VZ+>;YR)%S^Z4^6Y+!6R1S@$]*(_&AOX3W>J;Z?#)J#W;
M[F=H/L^T] N23CZ\9^@JY10(R]$T:+2O,*3S3NRK$'E(RL:9VH, <#)Y/)[F
MIK'[W_;2;_T.KU9UFA+'#L/WLW3''S_2@"Y<_P"I/U'\Q4M5[B-A$?WKGD>G
MK]*D\MO^>LGZ?X4 ):_\>Z?2B/\ U\WX?RJ.VC8P)^]<<>W^%$<;>=+^]?MZ
M>GTH DD_UT/U/\J+K_CW?Z5')&WG1?O7ZGT]/I1<QL('_>N>/;_"@"S4=O\
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M7_KPNO\ T**M^Z0I S&60A<$]/7Z5QVA3ZAXB\1Z;K8L)K73%M)DCFDFC9I
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MAQ#(=\GW3_%[4\0\#YY/^^J6X_X]Y/\ =/\ *GK]T?2@"/R?^FDG_?5'D_\
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M..B@$D_E5V-@T:LIR" 0:QO&$$8\):V0O/V&?O\ ],VK1M+>(VD/R?P+W]J
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MAH D_P"7H?[G]:AL?];>?]=__95IVR3[2/WO.S^[[TS3P0]YN.3Y_7&/X5H
ML7,0GMY8F",LB%"'7<IR,<CN/:O$K;P_?2W6JV4$,%ZD=\T1O;'0+>,P?=)2
M-I)@1MSC.TX.<9KW&O'-;O;:S\1:U=0(D$L=ZJR:>-5NHKN^;"#S(XUD"8((
MVC:0=O)'."/Q?UW0W\)[&.E% Z44"$;[I^E)'_JU^@I6^Z?I21_ZM?H* '4R
M'_5_B?YT^N.N8O%9\>6KVDD(\-;/WJDKZ'=D?>W;L8(XQUH [&F1_>?_ 'OZ
M"GTR/[S_ .]_04 /IG_+8?[II],_Y;#_ '30 ^F/]^/Z_P!*?3'^_']?Z4 /
MJ&[B2>$QRKN5B/YU-39/NC_>'\Z .6U"QDLY#D%HOX7Q_/WJF>E=K(BR(4D4
M,K#!!KF-4L&LWW+EH6Z'T]C0!07[J_2J^I6%IJEE)::C;QW-M("&CD7(^H]#
M[CFK"_=7Z4Z@:;B[HXE;37O"B))8W$^O:+&P5[.5=UW"G3,;_P 8''RGGTKU
M7PCJ4&K>';*]M!,(94RHFB:-OQ!KGDZ?B:Z[2CG3H,\_+4J/+ML;5:WM5>2]
M[OM?U7?S^^Y:HHHJC **** "BBB@"E>$B_LMHW'Y^,X[4^ZDNUBS;P(SY'!?
MM3;K_D(67_ _Y5<H Y?Q&VHMX:\2"]AB$'V.;RMK9./+;_/YUO6CR_98?W0^
MXO\ '[5G^-F=?!^MF-=Q^Q3<?\ -:EB2;*W+#!\M<C.<<4 +OE_YY#_ONO(_
MBH[GQO8KC:?[/)(SU'F&O8:\@^+5U;VWC*R^TSPP[M/(7S'"Y_><XS45/A9U
M8-VK1_KH<M=2.EO(=G;'!Z40*ZH"R N1R<\U#)J=AY;?Z?:=/^>Z_P"-+_:>
MG_\ /_9_]_U_QKFLSW^:/<] ^$+.+WQ!A >;?^+_ &6KT'322UWN&#YYXSGL
M*\]^#,\5Q=>(7MY8Y4W6XW1L&&=K=Q7H>G_?O/\ KN?Y"NJ'PH^=Q7\:7J.U
M.VDO-.N;:&XDM9)HV19X_O1DC 8>XKF-"\%I:Q,=4N/M-RL@D@EA:5&@P!G:
MSR._..1NVG XZY["BJ, HHJ-IXEG6%I8Q,PW+&6&XCU H DK.LY%5CG/$LW\
M)/\ '5Z&:.8,89$D"L5)5@<$=1]:J6/WO^VDW_H= $MQ,AB.-W4?PGUJ3ST_
MVO\ O@_X47/^I/U'\Q4M %:WF00H#NZ?W31',GG2GYN<?PGTJ2U_X]T^E$?^
MOF_#^5 $<DR&:(_-P3_"?2BYF0P.!NZ?W34DG^NA^I_E1=?\>[_2@ \]/]K_
M +X/^%1V\R"/G=U/\)]35FH[?_5?\";^9H X;XB72OX;\;PBS,>W1=PNMA'F
MY6;Y,X_AQGK_ !]JZ71Y4_L#2Q\W$$/\)_NBL'XCK>CPIXU:5D.GG1F$"C[P
MD"3>83[8\O'T-=%H_P#R+^E?]<8?Y"H^V=+_ -W7^)_DB[-<((G.&;Y3\NP\
M^W2N8U*Z6?X87#_96LC)I!;[-L(\G,/W.@QCIVZ5UDN[RWV??P<9]:YK65NT
M^&EXNILC7XTEA<,GW3)Y7S$>V<UM2^->IQU?@?H:7A^9%TBTSN_U,?\ "?\
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M .FID?WG_P![^@I],C^\_P#O?T% #Z9_RV'^Z:?3/^6P_P!TT /IC_?C^O\
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M>^,K'[9;0W&S3R5$J!MN9.<9KO/#W_(V:Y_U[6G_ +5KC/BE_P CE:_]@_\
M]JFHJ?"SIP:3K13_ *T.".@Z2BR$:;9G(SS O'Z42Z'IWR^5IFG^^ZW7_"M.
M3_5M]*=7-=GO\D>QU_P1M8K2;Q!'!!# NZW8K$@49VMS@=Z]'T_[]Y_UW/\
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M3NVRJLZ?LXTZ;;LV]5;>WF^Q))_KX?J?Y477_'N_TJ.2(>=%\S]3_&?2BYA
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M\Q]/I1<F7R'RJ8Q_>/\ A3I'7SXOF7OW]J+EU,#X9>GK0 _,W]R/_OH_X5%
M9?WF%3[Y_B/^%3^8G]Y?SJ*!U_>?,OWSWH ;F7[2/E3.S^\?7Z4S3\^9>;@
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M=Y@]&_[Y- !%]W\3_.G5%&XV]&ZG^$^M/\P>C?\ ?)H =1110 4444 %%%%
M%.Z_Y"%E_P #_E5J2-)$9)%#*PVL".HJK=?\A"R_X'_*IKN<6T6\HS\@844
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MOK/P_>W.EM EQ#$TFZ8%@H )R .I^O%9K7^IIK\37'G1Z4QBB1HS$5=V7)W
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MU&X%K=&1513;1R6X08F,I(+ ]1C&1CWSFNMO-+L+J"XCNK6%XYF$DH8?>8
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M63$@B8G:V.X/(.,5M4,$%%%%( HHHH #R*\NMHK+PEI?BIQH9FMX]922SMS
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F>IZO812IIKV<-OYLD+1?:)59R2 P!.T$#)'? Z5V%%%'D'F?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image00028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %< >(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZIHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBJBZI8/(T:7UJSJ"2HF4D8Z\9JWG/2@ HHJ&>[MX)(XYYXHY)#A%=PI8^P/6
M@":BBB@ HHHH **** "BBHX)X;@,8)8Y0K%6*,&P1U!QWH DHJ-+B%YI(DEC
M:6/&] P++GID=JC^VVIMFN/M,'V=3@R^8-H[=>E %BBD1E=%9&#*PR"#D$4M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWE_.@!U%-WK_ 'E_.C>O]Y?SH =13=Z_WE_.C>O]Y?SH =13=Z_WE_.C>O\
M>7\Z '44W>O]Y?SHWK_>7\Z '44W>O\ >7\Z-Z_WE_.@!U%-WK_>7\Z7>O\
M>'YT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 44C'"DDX&.M>?/J&RXN88]5F?3))8-]R+PN45BVXE^/*)
M.T;1C'7C-'6P'H55]1_Y!]U_UR;^1K@);W6X[&QOUN9'62!XU7S#E@-_SE,8
M)V[6WY[8[UT]AJ#ZGX5,\"J"$>-B\GFAMN02''WLXZT :L-C:>4G^BP?='_+
M,4U;&T\^0?98,;5_Y9CWJ:+SO*3'E_='K35\[SY/]7G"^OO0 OV&T_Y]8/\
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M]]_TS_6@!GV&T_Y]8/\ OV*/L-I_SZP?]^Q3_P!]_P!,_P!:/WW_ $S_ %H
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MMSM_A],G'Z4S5?\ D&W7_7)OY4R&^9W9:HHHH$(44G)4$^XI/+3^XOY4ZB@
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M3;G,3C]VW.1Z?6K(_P"/H_[@_F:BU7_D&W7_ %R;^5 %JBBB@ HHHH ****
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M9SNZ8P?7.>>:[#1]8T[6H'FTJ]@NXD;8S0N&VGK@U?I][]03L[HXO5? YO\
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M]N+J*^=+M[L*',@1 .$^7&S8>/7GG-=75/\ R(3*#:18M;06YMU,$*E(TR<
M$8/U.">>O)IOV&#3M$N+>T0K$L;GYF+$D@DDDDDGW-:-5]1_Y!]U_P!<F_D:
M0R6'_4I_NBD3_CXD_P!U?ZTL/^I3_=%(G_'Q)_NK_6@"2BBB@ J.V_X]X_\
M=%25';?\>\?^Z* )**** (KC_EG_ +XK#\.-/=ZSK>H3>4J>:+*-$!SB%G^9
MB>YW]O2MRX_Y9_[XK'\(_P"JU7_L)7'_ *%4O=&L/@E\C=HHHJC(CB_UDW^\
M/Y"JU_=;(PD,R12O*(0SH6 8C/0=\?A5F+_63?[P_D*JX?[/"Y\T2/*C. VS
MN,\$GCV%'0:W0><20_VL;"8WQY7\)XQ^)_*HY9)/(=?MJ[O+==WD?Q*>3CV'
M&.]:5-F_U+_[IHT"[_I%>VF@CC5%=CDC[Q9N6Y')[?RI_P!KA"EM_ 5FZ'H#
M@U+%_JT^@IU/0G4KMMEN0 K,$W(_ P,@'!SST]/QIY $\8 P C8'Y5+4;?\
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MW\J)Z.P4]5<M4445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDW\JE'_'T?\ <'\S46J_\@VZ_P"N3?RH M4444 %%%% !1110 4444 %%%%
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M47_?D_\ Q5 $MQ_RS_WQ4M49H;YMFVXA.&!.82,#_OJI/*O/^?J+_OR?_BJ
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MU157RKS_ )^HO^_)_P#BJ/*O/^?J+_OR?_BJ )1_Q]'_ '!_,U%JO_(-NO\
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MZ"I[CQ)I<&IZ18-<AKK5@SVB(,[U5-Q8^@QW/K0!L45'+/%$R+++&C.<*&8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image00029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $& ;4# 2(  A$! Q$!_\0
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MHV*X;FLPZC/_ ,]6K0\09%HF/[XK%X(Y'- $[:A<[O\ 7'%-_M&[R?WQQVJ
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M96DC*Y4UR6H1)/&KH/GZCV-;'@&1Q-=0MG  (]O:@#>\17\UAI_FVZAI&8*
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M*R-FRC,KQMN4$\UI:;<&-RC<)(,$9J"0[OQJ!SM; [52,9NYUGASQOK/ANZ
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M*M+>1H-21),\8:1VZ#-4GU0>SYM60Q75WY162X?>6W'' _\ UU-(D,\WF!2
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M&^YK*22T-B[:/<70A]I!Q3UE66:1\H!*H#;^Y]JS5*+9Q'D;N&SU)IL46Q@
MV0IXSVIM6-(5$UJ78P8/-B23>ZGYSCJ/05<MKV,RN5A$J[> _P##BLJV_=W!
M;'LV31<2(;S%HA 8XVYH*<D7[G4B[SPP"1;9B"B$\ ]\52N#Y_W7.X#'-2LB
M13I'.QW*I.!VJK,RO< !B8AU/>A+4RG+30M:;.MM'*KG+L.O>HI<,S-\P.._
M>H)("]P64D1D87CG-7+>U .^5V?:.?K56,M1MN?+NHS$QCE4;E;."*^I_!=Z
MVK^$["Z;.\IL?/7(KY7F?S+DH@#,W!/]VOH;X0^*+>_TV+2I$$-U;)C:.CCU
MJZ;U.;$1NKGH$3XC"G&?I6_X9!%Q/G^Z*PY%[J!6YX8;-Q/G^Z*Z+ZG%<O>(
M?^/#C^\*YILYY&/?TKI=?!-C_P "KFR2<]QC\Z3=@&22+&K/(V%4;B3V7UKY
MI^*7BQO$>O-Y+$6%N3'$O8^K5Z1\>/%<NBZ'%IEJ_EW5\/WF#RJ>E?.@G8MD
MG)Z?A7-)W9Z&&I67.R>9<N3T-(D7 P.::'W\FIXFV@D&I.Q,9MSR5)VG/ K3
MM9/)C9TD8!Q\H4_=J/[-']G$QFQGJO>G)%:"UREYMDR24=>OM0B^:S&-<6OD
M[,D@') Y!-4IDA611 ?EQWYI;JS>%HVWJ%E&XJO:F<*,*..U#(D[D;1_,.U!
M.WC.:5SFH.^1T%!#N6?I5>0%9 1WZU.#\H/J,U4G?# CM32)9I^'K]M.U:"Y
MC8JT3AL_C7TL+O[9;13Q8(E0./RKY2AE/G9]3BOHOX9W:ZEX9MB6R\(V/STK
M&K&Y$UI<ZC2I9(Y 67G/-=-*VZ%63OUK+CL\D&/OVK0"&.#:3\U:8>+1PU)7
M.^TO_D&VW^X**-+_ .0;;?[@HKN.<K>(2!:QY_OBO(OCAJKZ?X#GC1MK74@C
MX[KW%>M>),?9(\_WZ\"_:,$J^'M-8']UYK _7%9SVL;TE[QX 9 >P'':H\Y-
M1!NGK2[JYTCTF2>88P0.AZBHEE(-!([U&_M3>I-[&E8W($BEAD*<X]:BN9=\
MQ(X^E9XE9.E.$V>].V@^9,M%^"35'RPY8GBIV8XZTS<!0A<Z1%)%C&VI%X&#
MS2,ZCO3/,7UIV$ZG0:1MR?>KJ8V#CM5$?.X J]&1MY^E#)\Q6.5Q5:09*@=.
MYJ>1@HJE<3<;1UJ4#9'(PW8SG!P*]0^"*L;R?&=I85Y2W&.>O->Y_!'3FCM5
MEV\R<FJDC";T/K?3_P#CQ@Q_SS7^5<ZY!DDQV;FNCLQBSA'^PO\ *N9G8"XD
M'3YN:V['*]SRO]H&:8:1IZQC_1V=BP'<@5\_:I]H>W# &.$?+N'4_7VKZY\7
M>&[/Q+IJVM[OQNW*RG[M<2/A1IRZC&\<C- ,%XWYSBN=TWSG73KJ,+'@.FV5
M]JFRSM+2620C&V)<@_4UO:GX)O-"TV*\U>(6Y9OW<6<EO6OIC3M"L-)4_8+:
M.!6Z[5Z_C7D?QZN9_P"U+2U=<6J)YB\<$GJ,TYQ<473JJ<K'D\F)B RJJ^O;
M%4I(-KD*V!R5SWJPR1C+2%SG[H7M3Q9D[?,5C&PRKMQCUJ%MJ=378QFGW2!7
M!4+UQWIUNY$IECX .5S5^73X1:3,&=G'W..OK2Z7:^=&8P &QNRW\J+H5F);
ML[2-)Y6^7JQ]!4$C-@Y0*">O>KEF@7+>;M+$J:?,F9=A*G XSWI7'9]2'R95
MBB<$B/=G<1Q4Q!D:1@YXYXZ >M17$LTD/V:$,47E@?NC/>HU+M$5'*IP6 QD
M4]R16V><7B #+QN'<UU_PMU?^SO&EHTKCRYOW+>O/>N/C=$5O.4CC@>]7?#8
M,WB&R2)29#,I3';FJCH14MRGU\$ 4X/ K6\*Y^TW'^[6+;JR11B0#(4;OK6[
MX8(^T3@?W:Z5M<\Q[FGKC!+$D],US'F;<$8 /)SZ5T?B+G3O^!BN*\2^:/#V
MHFVSYP@;;CUQ4SV"*N['S/\ &/6H]>\<7+P/OA@_<(0>#CK7#;:?<28N)!*"
M6W'=GKNS0,9ZUSVUN>S&RBD-!(XJ5)0J_-S36 --VGM18+E@3Y7[Q%(9 /3/
MO557&3D$$4QVW<YQ1RD\^I<,FX=>W'-2;@1G-9RNW2I$<C-'*5S7+3+NJ%N%
M/O2A^AZ]J7RRTC9& M*Q+9)G$:YXXJG-R:FE/'':JY;-4A,(1M8EOPKT_P""
MNK_9-::R=LPW"XQZ&O+BV*Z?X>7/D>)[-L_Q@4IH5KP9]5:>7" ?>V\<=Q5B
M0C=]:RK.252"O0C-6II&6,MW%%-V9YL]ST?2_P#D&VW^X**;I!+:5:'UC%%=
M5S,H>*F3[%$'?:6?Y37D'QHLSJ/@2ZVD-);N) *]8\<*K:9$&P/W@KB+J.#4
M]-N;"Z4!I$*#'?T-*2NBX.TCXZW8<@XZTI<!15GQ/ILNB:[=V,RD>6YP2.HK
M-9AMV\FL4CO4[DLC$CY:;NXZU"TFU:B\W-.S!ST)WYZ5'NSQW[4P/FI84Q\[
M=^E-$7N-4NF=QSFD,M.<Y8U7<_-3%8E4&0@)SBE9&5@KJ03TIUN&7 CY)ZU9
M>.1742J0>V:5T@2LQL*;1SUJ93@U$'VY'7GK36EQ4V-+V0^=JH2/F10>_6GR
MR9%5F.<MSQ^M6DMV9RD6;&U>]OH[>$$LSA1[5]0^!K2+1-"1G!.U<*HZD^OX
M5Y'\,?#WEM_:%XNW/W0?3U^M>AS7LVIWPM;5GBMK;'G2#C [+]?6L)2O+0AQ
MNCZ:TJ3S=/MI,YWQJ2?4XK FC\R24X'#5N:+@Z39E<%?*7^58TK@2/C^]77V
M.26C((SQMZ8H4C<Q'6FSX\W=G [TTN <+R/6F(>W((/(QT]:XKXD>&AXAT&5
M(DS>VP+QG^]_LUV>X\$#D=*9*&'S*3ZG%3*-T7"?([H^-)3);W$D<T;H\;%'
M4C&#2O*?(R\C$>F>E>H?';P_/%J46K6-L3;SKMF$:]']37E\3!5!D0,S*0%Q
M7*TT>G&:FDQ/M)<83!0\U 9?)D (^9NG-.MW!*X487H,4/8AKF4.3M8;QST]
MJ.AHRS!"?LSR!590PW<\_A4<=Q;J5< ;E8D9.<"JTSRQ@!5Y(P.>*8;6,V_F
MOPQX8 T*)/,Q3>,99-GW6')'2D\US#M*$(>K#O0 %^0KM&.,=*:PFVB%6RC'
M/TIDMBL^8_G!8#]17MGP<\$0I;PZ_=R+*7SY4?\ <YKQ."WF>ZCMR.K "OJO
MP38_V9X<LK5@ (URQ]2:N".:O/2QT1?<3N^[BM?P>=US<GMCBN=FD9Y B9YX
M%=1X3A\H2*?O%1FMT<:+WB,G^SQ@<[A7//AD8.H.>"OK6_XH.W3!M./G%<MM
M+GESSUQ0U=6"]CP'XI_#2:#4)M3T%?-MICN:,=4;OBO)+B*>VE9)X7C9>NX5
M]NE(U0@*N".XKGM4\'Z+J[$75K&&;G(&*R<+'7#$\JL?(4;%C\N2,5IZ587&
MHS+#:Q/)*QP%49S7TQ9_"/PU-.HN+9EP>JG ->E>&?!F@^'E#:9I\,<F,>9M
MRQHY2I8K0^*]:\+:CI!"7UM+$[#.UAC%<\T&TG/&/6OT$USP_I6N0"+5+**X
M4?=+#D?C7CWQ8^%?AS3O"&H:MIT,T%S:IO4!LK^(HY;"A7N[,^6@NT\T]L 4
MCC.">].& .:BQU+N6M-\H74+7986X(\S:,L5[X]ZM>(+FRDU";^RHI(K-<+$
MKGY]OJWO66TN.,U"S$\=J+"OJ(TF<&HV:F%\#%-YIV%?4>#G@?C74> +9I];
MA<#*JPYKFK2WDN)0B*2S<8KV[X9>&3:P+-(O09)]:F2N$YJ*/5-#FW6_ER_>
MQQ5N0[MP[5EVV<$H.5J_'(9;8G'S=Z:CJ>9)W9Z;I'_()M/^N8HIVCC_ (E5
MIG_GF**W$9'C:!YM*C5!DB0$&O.I=Z2,7)65>GTKTWQ6^VQB[_.*X>^MHKO/
ME81U]:H#R[XE>$K?Q5:&YM@$U.,<#INKP^^\-ZK9RLDMNQ(X.*^GKF%H');Y
M)@>#CK43+9W1V:A;(9/[P&,UFX:W1HJK6A\J2Z9>#AH'_*K-AH%Y<R#=$RKZ
MXZU]/7'A?29DWQQ8SZ'-2V'AVPLY=_D(3V]*=F-U=#YKU;PQ>:= D[V\@B/1
ML5@22%CCI7U[K%E;WEBUM)&A1N@(Z5Y!XF^&@DN&FT]68=U7M4.ZU-*=1=3Q
MIBQZ4](6<X49:O08?A_?;L?9)2/<5U&A_#>X+*9XEC'OUJ>9ENK$X?P7X9N+
MV\C,B'!/2O3_ !!X(M;G1TBV".<#Y']_>NNT?0[;25 @0;@.IK4*03*5E0X;
MJ:GD9C*IJ?*.M:;=:5=O#=QE"IP#C@CUK,=\\?Y-?5>M^$[+6(&$D0  P"1S
M7$R?"J*.;=$5*=03VJDFB_;+8\+M[6YO;A8K>)BY[8Z5W/AKP-*DB7>JY* _
M*@'6O2;/PWIFC-OF(EFZ"-!G/UJP&FNBV D:#JW\$8]CZU$Y]!J5RC;1F$I%
M&/WG1%'1!ZFN@T?3GO2;: D1+\UQ*!]]JKZ/IQNYO*L\_9S_ *ZX8<R>PKM;
M6-;&S%O;#:A'IS2I4[N[(G/HCUO34$6GVZJ,*L2J/RKF)G FD'^T374:?G[!
M;G_ID/Y5R<AW-(W'WR*[$C >P!4YY!J-0,X(YJ,/@88FDD=@PP>U,1:48(IL
MCA20:KAY&Z$F@@[MS]!S0 RZABN8VCF19(G/*L*^;/BKH":'XBF6V4I!(=\9
MQP/:OI5CO;Y>!7/^+_#EKXETYK2X #C[L@'(-8U8WV-Z%3EEJ?,'A?2+O5K\
M6UJ!YV&8 ]Z34+:YL-1\B]C974893P2:]^\&_#VW\+7#7?FM<7!&%+?PBHOB
M+X$7Q&IO;7"7T:;0>FZL^1V.IXA<UCY]NI2V%*@;3Z]*;"$=6'"@<U>U30M4
MTV4V]Y8RHP[A3@UDS1M&,,&5AU!&#4[%JHF3^2SPM*V3"O!;/2H;-#++@,0G
M8^HI(_.8% K[6(Q@9S79>$O M_KD$[QYA*?<+#&::U(E42-KX3^%;77+J:[N
MW8K:'*CW[5[S&FZ, <<8 %<AX!\+_P#"+V+1.X>6<[I".E=E$<9].QK:"LCB
MJ2YG<6TMW,@>0]#77^'T(ADD/<X!]JYF.3<VU,DG %=C8JL,<=L,$JH)-604
M/%QVZ5STWBN2,VP#:174^-&VZ/GU<5Q"X/?/%4@+IG9QZBI$90H)P#[5164;
M<+Q3X9E4_O/SJB3=L;K:,2#*^N:W8M6MTC #=!WKBOM&6RF,#WI3. "3SFE9
M#.V&JQ21G85#=@U8OB]1J_AF]L7 )NHF0<\ XXS6*9&,8QDMVQ4TLK(@C+Y;
M&0?0TI+0<79W/BW4+>2RO)K:=2DD3F-@>Q%4VESUKV7XT>"I;F[?6]'BW%P!
M=1*,DX_B%>(RAXW*R JP[$8KGL>A"::)6>F,YJ+=Z4 DG&#05<;NW' YJY96
MTD\H5%))/89K1T/0+C4Y OELN>G'6O8_!O@46MKYMRJJ1T7&32OV(E443 \
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M6ID$LP'F$(G79WK+T]X]D;KT/\0_BK7$J\DCG' ]:AJS,Y*Q,J +\BC%-O'
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M#S./P7JJGEX*E'@[4P>&A_.O1\4AP*/JL ^M5#R;5K6TT2XB@UK5]/LIYO\
M5+*^TO[#U-,ACT^[U%--MM;T]]0;G[,)/WGX+6)^TTX_M#P$(9+9+D:NA4R
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MDGSYS)$!YGKGUJ.+P]I")B/2[)5*E"!"/NGJ/I[444A78^/1-*C6-8]-LU6
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ML!M?7K2XHHHL 4=Z**+ !XI <T44[$WU'4U_N\445)1S#>"= _X2/^W38_\
M$U8D&XWG/3I]*E_X0_1AHMYI(M2;&Z8R31,Y(<GJ#[&BB@+D.B^"-"T.ZAN-
M,M#!+;ILBQ(2JKZ =JDT?PCHFDZS<ZQ86?E:A=Y,TH8DOGGFBB@#<DCCGQ'-
M&KH?FVL,C/K4IP%/H!VHHII".:N/!^@RZK)J7]G1QW9&^5HSL$G^\!PQ^M6Y
M?#6E2ZNFIM;9NC$8<EB%V$<C;THHHL,S-4^'7AC4K>TAN]*B:"S'[A%8J$[Y
M '>NECMHA8?9!N\CR]@!.3MQZT44 8>A^#-!T"\N)-,L1#)> B;YLB3UW U/
MIWA72-+6Y6RM%@^U_+(R'G'H#V'L***+ ,\->#]#\,SSG1;(6CSDM(48D.3W
4/O71(,9HHH =2T44F 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image00030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #' N@# 2(  A$! Q$!_\0
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M/+"964>=LY+ 'DC^=>E_LY7<UY\)-'DN)GF=#+$&=MQVJY"C/L!0!Z=1110
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MP]Q]GB\]EV-)L&YE]">I%.M+:&UB\JVAC@B'(2- H'KP*L44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444$T %%)FES0 444F: %HI,TN:
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MRSN< #WKQO4]6M(]9>VM+^_DU.YN_,2"#4E6V\K</GST&?[O4F@#V0' W$X
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MJNWBEK.6YN+.W%[+>1D-'YA#1#U%<R\3&3_09E,J?,JR<'%/AM2DAN;R'<<
M"2$X*FB&+FH7E'1FM7*<-*:C3W18TEKYM2-V+QS*R$N[#+KGL,U5U"";[/)%
M)>R$;O,C23E7/MZ&M&&0WC*L<@$L0^5S\K,/<5%-<RI<-'?1(T+#YD]_4&LE
MF%123OL=RRNA9QL<Y9Z9/<7S7";5,; 20L=I=?45NI#9V]J\XWI)TC*MRA!Z
M4VZ81LBN#(JC:C_Q >],2595*$(87!4JPYY[UG4QM2I)W>AT4\NHTHW2NT3S
M27=Q(D\Z 2$ F5%QO]*L27K0QQ"]C66-A@.1AL&H(VN]+TU]/=EE@)#QEQRI
M] :9,%* RK(=JX7/.:R=3:QM"EIR=3J=2UJWU);+1;J (UO$)+.4]9$_B7/]
MX=JPVLO)N!'+>((ICB-]I/F<\ ^AI]O>6D^B1VNHV\@93F&Y'#0MU!'J/:B[
MD%S<F-W4221!>!QYB\[A]:4]7<Y*:E2O$SYI)'N)=KF*3)4JQZ8^E.$I18@?
M,=#R'5L]/>FVP*&22-S+-*,MD<ICTI\8\R$C,9WX&<<_E4-693DW$TII!F)G
M9%FQ\LR.%8'L?0_0TR:6".2.YU'2H+@+.F^XB^0CG^-?ZBLBXMVC9U*@C.3G
MDJ.W%/M[N8&-Y7#Q!U41YZC-#;M>QQUH7B[,^T=+93IMH8_N&)=OTQ7G?Q-U
M(0:U!:NDFQH=V4&23FO0]'Q_95E@;1Y*8'IQ7EOQDUF'3=4M(WGAA=TSENN,
M]JC".U:[/EZL7*Z1C12R/F1VDB4\JLA Z>M0R3WEZOEK((F'!DC&1]!ZUDRZ
MUI>D8:ZN'DC?YL%@W/K5&[\::+)="))R(AR)%&.?2O;4E\1C[*;V1U.FI=1J
M(I+M9=AR%"[ GN?6GSM=I,\R2DQ,,=1GZK7'VOCG39;22-K@H%.T;DPSC/KZ
M53NOB!!:G&G6ZMY? ,ARI_"J52.[8UA:K>D6=I8OE62.TG:.(Y69Y.96SSCV
MK3M6N;R*[.HR?9X2P$>TY(]O>O-D^)ERT0"VD*X.!E.![5:D\=WUPZ-IMA]I
M95RP)"HA]J:G&>ET.6$JQU<3L(K6YMYID:Z)\SEGP%4#L<>M;.G:/9^4#<SM
M>,W):3E3^%><-XUE1"+W2[5+B3YF=IMW\J6V^(,A9X_(MI(H1PRR;.:<Y7TN
M9QPLWK8],=H_/6-DB6(+M50N3CUQZ5FVJ:=-J<]H%$][C*;> @^OK7"ZAXX-
MW(MO%JD44RKN+)#Q_NEJQHKZWM+J6>+7KJ(W(RYA 9MW<GT%"4>5^\5]6G?8
M]?N]+GU:Q%O=QK:1IPJ, S$C^*L'4K=M'58IM0BLM/(^8C#2R8_D*X<^(-+B
MM\S:YK,[L,B0<$'T]*YN\\0:< [V]G<3N3M$EY<%N/7%8^VC!6N=%++ZDWL=
MOK/C9=0:'1] /DB<^6TEPWS2\=6/9:\ZNY0EQ(DFZ1E;8T@Z$_UJMJEY)?2-
M+)Y2S,HP;==H7V-11W3+-&T[>8N,%0.P]J\^M4N[(^FP6&C1CS)&O;LBS0-&
MGF,C9"M_%CFNFU/Q=);*D&D1Q06Z+F1R,L'_ -FN0^UV[!W#-!'TY7+ "E34
M-/$#//$K@]W;M5T:DH1<8$8JE"JU*IT+FIW][?:@'O+QYY0, ;LA<^G:O1/V
M=U;_ (3J=CU6U8-[<UY;)XFTB".$6D6VXWE9I8\89/8>M>B_LV:HMW\1KV&W
M5_(^RL0S=3S45\/5Y.>6QPUL91]FZ458^I*\C\7ZM?)XBU.S2^N$MMZJ88YK
M:/ ('0O\^?\ (KU6XN$MK>6:8[8XU+L?0 9->0ZEJ<6O:K?O:K''&TB!TFT0
M//&,#+[R>PP<GH"*\T\D]7TR5V@5&B>-4"HI9@V\8'.:*GLU"VT2JY<!% <_
MQ#'6B@"S1110 UB-IW' [\XKR2ZM1JGB*YL='.E3RR7B7+WHN5+1A3R/+QDG
M'''%>B>*UD;P_>K%;RW+,F/)BX=QGD"N2N9A):VUO;^"]2MS"\9AD6.-3%@C
MG(.>G7UH [ZX436[QD\.I4G'3/>L1TOET66TC0)<PJ%25QE'&>,?A6^@)4;N
MO>LKQ7=/8Z'<3Q ,R8X/UJH:R5BHJ[21S]U8>=HLL-]%'/<*"5\L<_\  :H6
M-O/ILEI:FVFN5:4-YQ'\!['Z5KV=W*EE#/=Q,'F(.U>0N>E0ZQ+"UVMM.L\,
MRH72="=H/OVKM3>QO&<[\K)'NX+*>\O[F3R+<?>5^C=LBKVEFSO89EM#$;=C
ME1&00<]37)_8+R>(QZAY,EF,^9GYA(I_D:O6-M<>'[&*?3[:.Z$APT2-MVKZ
MCZ"JG3BEH]2ITE;3<UM0TK3T#YMHD)0B-D3E1US5",Z5J#10QE1)Y6YW8;<
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MT^.WU 6S21X >,GY@*T9M.>3SF8*S," ">*UJ*KVDKW!R=[G#S^#Y9[I$DE
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image00031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #\ B(# 2(  A$! Q$!_\0
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M!TE%9%]J3Q3Z<MI MS%=.5,J2@*@QU]ZFN-0MH4NML\<LUO&TCQ*X+8 ].U
M&C16!X?\16NJ^';+6)2EG%=+E5F<#'.*VXV5U#(P92,A@<@T 24444 %%%%
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MW#-.\Q6.%=21U /2BXM26BLO4-7LK"01W=Q%&Y&0I/)'K2MJ]DJQ$7"-YGW
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MI95&6"\X%+F0<K->C-4;W4;:RMVGNITBB4@,S'@55T_Q#IFH2.EG>Q2LC;6
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M]L=:T6U>]UNZNEDO(88R1$L(? #8_B]0:Z&+PU:RP)>:Y!;K)##L98CD+_\
MK%).VK&N6+NT<G:ZPMC'YDLTU]/J2B**)#EE.>3CTJSJ-Q) &DL!(^D;@LZ*
MO[Q)/]G-6](OOL]Y?26>GPP16\F%CG&&53W0^GM66\MS';W$E^Z)&LV;%B>
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M1A8W>T2*P'R%A_(^U:NGR^(;7X@6"ZBUPT4S@&1#F,CWI\K3T)JP23/<)?\
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M:CRMLA\4>+K:>WLX["Y9KV8AUA PPSW(]!62NJ:VGB&'15OY#?\ F+<2,?\
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M4KAT0"YD4%V]<<5C:YK<.E-#&\$]S+-DK'",L .YJ/P;KK:UK-SLMIK>WCB
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M=(-KIMUH\UW#>0J5N)),X9NX(HY&U8*D)/1'H_Q!U>TT6Q.FZ4T>VX0Q(D
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MA_LTPA+D[ 4Q[FKO]HVMU!N;4YQXA=P8WB^2'S.V1TQ4]I%%I;36.JQ>6;@
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M_P!WWK2N/#,UQ-8RR7S>=:_\M N"X[@T^1V&ZL3"U[PY8ZO/!()HK>9EV*5
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M1H,A&[[!6T=)O=/FL)R)A="-UG;9O\P'I63-X6U4II=_IGFI,DC'RI%^2+W
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MSN8+_=)]*TEMM/MM*D4((954 I(V0S=SFES-,4:$;7-G4/C7K?G*+2RLXTP
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M$TJN"T:#<4&>N:EU[5HI-2#6Q:.,E2)/[I['VHE=E-MF9XR6UTC43:V:2&0
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MF@-LK%MQV C]V>U/D8*I#N8VFW%W,US;0)&Y+;VV<,&] :CM)$3#06DCS1R
MN?X1C[VXUKZ7X-\2V]G#:PVWE $LTA(R<]\U-_PA6O+IMW:1Q.#))O#%\!S[
MT<C'[2/<X_Q0%,Z212K+%-+YS;?^62CJ,>HJ9K*TAN$Q+((I )0Y&"#70GP)
MKLC8OK-7(AVGRC@?A[U(/!7B?8[/%$;>3;F/^) .E7RNPO:1[G-:?>FUNPL,
MX1-QE:1UX9AT6J<.H+97D]]-:?;&D?+LR_*GKBN\;PEK^H&+[980"TB0J8^
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M,+@64B16MP-NW;^Z()-7=)C$>O:7Y+W?VEKB,LHB8*G/(S22=Q3DE%ZGT?\
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4IJ7%%D*[$ QTI:**8!1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image00032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %4 =D# 2(  A$! Q$!_\0
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M+]-\):2U[J;DD@B&!!F25AV KI6[5D>(["TN;&:ZN;6&6YMX)#$SKDIE3G%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME]&88_,T =3\.;G[7X$T"?KYEG&<_P# 171UP7P-G%Q\*_#K9)V6X0_A7>T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /.?B-'X.T"\_P"$L\2"W34$@>W@>1L>:,?< ]:\:\)GX(ZUH4>HZU9V
M>F7SLYDM7F)*\GFO??B+X<T'Q#X>N%\46JW%I;(TP8C+1\=5]Z\N^%'PY\!:
M_P" X]0A\-&9=\GE-=']Y,%/!_&@#H/V==3T+4-!U@>&-&&FZ?!>,B,&+"<
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MUOALWL!@[2>#0!ZDII<U%ORJE""IZ%>12AL^_P!* )**0&EH **** "BBB@
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M ;*@\_X5)5+39)9=/MI;A0)WB1I!C^(BKHH **,T9H **** "BC-% !1110
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MU+_PA.B_\\9?^_K4 =!YT?\ SUC_ .^A1YT?_/6/_OH5@?\ "%:+_P \9?\
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M^^A6!_PA6B_\\9?^_K4?\(5HO_/&7_OZU &_YR?\](_^^J/.C_YZQ_\ ?0K
M_P"$*T7_ )XR_P#?UJ/^$*T7_GC+_P!_6H W_.C_ .>L?_?0H\Y/^>D?_?58
M'_"%:+_SQE_[^M1_PA6B_P#/&7_OZU &_P"<G_/2/_OJCSD_YZQ_]]5@?\(5
MHO\ SQE_[^M1_P (5HW_ #QE_P"_K4 ;_FI_STC_ #I#/'_STC_[Z%8/_"%:
M-_SQF_[^FD_X0K1_^><__?YJ .@5T;.UE8#^Z<U(M<AX8TX:9XEU6"W2=;0H
MA3>Q9<XYQ77K]T4 +1110 4444 %%%% !1110 4444 1Y] 1_.G@9'-+10 T
M^GM2*!N)[]*AOIDM;:6XF.V*%&=S[ 9->&'XN^(DTV#Q8^D6P\&S7HLUP^9\
M%MH<^U 'O8I:@MV$L:2(<HRAESW!YS4] !1110 4444 %%%% !1110 4444
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M;3/\P.U=WX%CG\5_&.]\9Q65U::1'8+:0M<H4:5N_!KV5HR23N(/MVI1'@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ P*,"BB@!,#%& :** #:/2EP*** $P*,"BB@!<4
M8HHH 3 /:C:/2BB@ V+Z"C:/2BB@! BCH* BCH.^:** '8%&*** $VCTHVCT
L%%% "XQTHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image00033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00033.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &@ KT# 2(  A$! Q$!_\0
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M:E%,#+_X1[1O^@3I_P#X#I_A1_PCVC?] G3_ /P'3_"M2BD!E_\ "/:-_P!
MG3__  '3_"C_ (1[1O\ H$Z?_P" Z?X5J44 9?\ PCVC?] G3_\ P'3_  H_
MX1[1O^@3I_\ X#I_A6I13 R_^$>T;_H$Z?\ ^ Z?X4?\(]HW_0)T_P#\!T_P
MK4HH R_^$>T;_H$Z?_X#I_A1_P (]HW_ $"=/_\  =/\*U** ,O_ (1[1O\
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M$Z?_ . Z?X4?\(]HW_0)T_\ \!T_PK4I:0&5_P (]HW_ $"=/_\  =/\*/\
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M$99-HR3CL/<G _&L70_$6N:A8W5W>>%9[*(6XGM4:[C9Y\]%(S\AQZUH^--
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M_'6O:+X'T.R@U>QMGBL+V_DOM7)F-XT4[*(%)8'=^9QC HN!](D =64?4T'
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M]#^5%@..^$-YJE_\.M'GU]YY-2*.LKW"XD;:[ %O? '-=A2X/H?RHP?0_E3
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MM4(**** )+?_ %\?^\*Q?%&DRZU;P6:W#6]O]H66=D/SLJG(4?4XS]*VK?\
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M!;CDY[FK5%%D,A%K;A]XMX ^\R;O+7.\]6SC[WOUIB6%DBR*EE:*LC;W585
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M0 4C*&4JP!5A@@]Q2T4#*&AZ/8Z%IZV.EPB"V5V<)G/+')INB:-8:);S0Z9
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M>M/7L!)J5[H^B7O^EZ>\*SEY!=+$#&S[&9AP<Y*ANV/SJN=7TF.PN)GT>Z2
MR+9W:&%/W6-H4.-W3YEQC/Z5+?\ ANZO[R^GN]2BD$J[;8&U_P"/8 @@#YL'
MD?-P"?45''X7NOMZS7.II/;F1IY8#;E=\S#!D!#\$  +P<8SUYI:@7-/.BW6
ML7%K:6:-<:=&L9F\O**#D;%;/)&#GTS3KJ30I;.2(7>GQ"3_ $9765,JX4J
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MN ) R!7I63ZFC<>>3SUI<H7/+1K6JP:8)9M8GF22XB0HJ.DZ$JV\;C'T!VG
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M)2&C>&)HX$(0(H:,-\X '<U4_P"$2NC$N[48!<212PW4ZP-NF60H6898X;Y
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MT></^>,7Y'_&HJ*+("7SA_SQB_(_XT></^>,7Y'_ !J*BBR E\X?\\8OR/\
MC1YP_P">,7Y'_&HJ*+("7SA_SQB_(_XT></^>,7Y'_&HJ*+("7SA_P \8OR/
M^-'G#_GC%^1_QJ*BBR LP2@S(/*C'(Z _P"-,:4;C^YCZ^A_QIMO_KX_]X4Q
MOO'ZTK*X$GG#_GC%^1_QH\X?\\8OR/\ C45%.R E\X?\\8OR/^-'G#_GC%^1
M_P :BHHL@)?.'_/&+\C_ (T></\ GC%^1_QJ*BBR E\X?\\8OR/^-'G#_GC%
M^1_QJ*BBR E\X?\ /&+\C_C1YP_YXQ?D?\:BHHL@)?.'_/&+\C_C1YP_YXQ?
MD?\ &HJ*+("7SA_SQB_(_P"-'G#_ )XQ?D?\:BHHL@)?.'_/&+\C_C1YP_YX
MQ?D?\:BHHL@)?.'_ #QB_(_XT></^>,7Y'_&HJ*+("7SA_SQB_(_XT></^>,
M7Y'_ !J*BBR E\X?\\8OR/\ C4D$H,RCRHQSV!_QJM4EO_KT^M)I6!#C*,_Z
MF/\ (_XTGG#_ )XQ?D?\:B/4T4[("7SA_P \8OR/^-'G#_GC%^1_QJ*BBR E
M\X?\\8OR/^-'G#_GC%^1_P :BHHL@)?.'_/&+\C_ (T></\ GC%^1_QJ*BBR
M E\X?\\8OR/^-'G#_GC%^1_QJ*BBR E\X?\ /&+\C_C1YP_YXQ?D?\:BHHL@
M)?.'_/&+\C_C4GFC[/GRH_O=,'TJM4O_ "[?\#_I2:0!YP_YXQ?D?\:/.'_/
M&+\C_C45%.R E\X?\\8_R/\ C1YP_P">,7Y'_&HJ*+("7SA_SQB_(_XT></^
M>,7Y'_&HJ*+("7SA_P \8OR/^-'G#_GC%^1_QJ*N0F^(6APZW=:7+]L2XMY)
M("YMV\J25$WF-7Z%MO.*3LMP.T\X?\\8OR/^-'G#_GC%^1_QKFM!\8Z%KFC_
M -HV>I6RPK"L\R22J'MU89'F $[35D^)M"%I;W1UG3OLUR_EPR_:%VRM_=4Y
MY/M1H!N></\ GC%^1_QH\X?\\8OR/^-9MOJVG7.HS6%O?VLM] ,RVZ2@R1CW
M7J*S++Q;IEWXD;0U6\BOMKM&9[9XTF"??V,1AL>U&@'2^</^>,7Y'_&CSA_S
MQB_(_P"-144[("7SA_SQB_(_XT></^>,7Y'_ !J*BBR E\X?\\8OR/\ C1YP
M_P">,7Y'_&HJ*+("7SA_SQB_(_XUP/Q@;=!HA"A>)^!]4KN:X7XO?\>^A_2?
M^:5E56@T=]-_R&M7_P"N-M_.2HZDF_Y#6K_]<;;^<E1TZ/PA+<****U)"BBB
M@ HJ$W5N)GB,\0EC7>Z;QN5?4CL/>F37]G!'"\]W;QI-CRF>0 /GIM]: +-%
M0B[MV:91<0EH>90'&8_][T_&F27]G':+=27=NMJV,3-( AST^;I0!9HJLE_9
MR26Z)=V[/<*6A59 3*!U*^N,C.*LD8ZT %%%% !1110 5+<_Z]_K452W/^O?
MZTNHR*BBBF(***B^TP?NOWT7[UMD?S#YVP3@>IP#^5 $M%,$B&9H0ZF50&9
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MF&QA:"UV1$,59U8F3G!/R <8ZFC7L!JKJ>B3R6BW)LUN9I)%@C($C,P8J2"
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M\\5Q<1R1M)NAABW^7 N -J[B3C//7O6Y;_Z]/K3^SJ'4C/4T4'J:*H04444
M%%%% 'EGCY-5L-<?3;*>\N+3Q,HMUWR;EM9 PW[1V!3/%>G6EO'9VL-M H6*
M%!&@'8 8%/9%9E+*K%3E21DCZ>E.K&G2Y).5]SLKXMUJ<*=K<N_F]K_<DO\
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M,^X$7V:#_GG^IKS?XT(J+H@08&)N/Q2O3:\S^-?_ #!?I-_-*F3;W!'?0?\
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MHVGTH ;13MI]*-I]* &TYOO&C:?2E93N/% #**=M/I1M/I0 VBG;3Z4;3Z4
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MTNH6NHB:S@F9T!#P-YB+M=@V6)W$\X^Z>#5G3?$VJC2;=9]:T^*<0W$[W%S
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MX48']X4VB@!V!_>%&!_>%-HH =@?WA1@?WA3:* '8']X4N/E^\.M,IW\/XT
M&!_>%&!_>%-HH =@?WA1@?WA3:* '8']X48']X4VB@!V!_>%&!_>%-I<'T-
M"X']X48']X4WI10 [ _O"C _O"FTN* %P/[PHP/[PIM% #L#^\*,#^\*;10
M[ _O"C _O"FT4 .P/[PKS'XV?\P7OQ-_-*],KS/XU_\ ,%^DW\TH8([Z#_D8
MM6_ZX6_\Y*O51@_Y&+5O^N%O_.2KU*.P,****H"A-K&GPZL-,FNXTOC;FZ\I
MLC]T&"E\],9('7O4[7MHL/G-=6XBW;-YD&W=Z9SU]J\N^,^@7TT/B'6HE5K0
M>&I[':I)<R-*C#@<XP#7-W'PPUV[T6XFMM.TVUNYKV.[L[6.YS;VN(0A=U9"
M) _)*X!'KFIN![P;F 2-&9XA(B[V4N,JOJ1Z>]1M?V@M[B?[3"8;=2\SJX(C
M &23CIQS7CDOPQUP^)-=O99EF-VMR]O/'.L:J98-@B9=F\J#T^?:  <9J:V^
M&>J6,=Q9:9':6=EJ.EV%A?&)\99#_I#X[LR_+GOFG=@>D#QAH!TZ\O\ ^TXO
MLEG;)=W$NUL1Q.,JQXSR!G'7IQR*K7WCKP_96=G=R7V^VO+26^@DC0L'AC +
M-^1Z=:XG7/!^M:E+XAT+3HULK*]U:UNVO9$W1FU2)?D4?Q$-&%*YZ?6LJ7X9
M>)VTU=-DN+2XCM;?4[:VN,^7N2X ,?R_PX8MQV&*5V!Z[)K^G1P:?-Y^^.^E
M6&%HUWC<RE@&Q]W@=ZNF^M!&SF[MPBE06\U<#/3G/?M7C.D_#37K>6&;R-.L
M(UU*UN#96LQ:-4BMVC:3.!\SL0<8^M1W7PEOX_ _ABRLH+47UF7;4XDD13=,
MR,@;>Z.I90>,C@=,478'MS7$*SK"TT8F<;EC+#<P]0.IJ#2M2M-6L4O-.G6>
MV<LH=01RI((P>0001@UY!_PK'68_$=C-']FEA2:QG74[BX+W5HD"@/ N%&X-
MC&1@<G(KOOAO975II>IS7EO):_;M4NKN*WD7:T<;O\N1V)QNQ_M4[@=91113
M *<WWC3:<WWC2 ;1113 *Q]9\166D72P72W+.8C.WDPEPD8."S8[5L5R?BSP
MK-KNHO<1W<EL!8M;IY<SIERV1O"X#)V(-(#6/B'3!*L1ND$T@8Q1YYE"J&)7
MU&"*MR:A;I9K<EP4;& ""QSCC'J,\UQ\OA"_:=YD^P*TCW'RAF B62W6,;?E
M[,O3CBF_\(3>;Y_]*A,7V>(01_,!'-\GG-TZ-Y8Q[YHU [&[U*VM85D>0.K'
M@1D,3[_2DL=4L[W3UO89XQ;E0Y+,!LR,X;G@UQ@\%Z@+V]G$UFJW5U'<[07_
M ' 1V.Q..C [CT^8GL>*T/@C5$LO+":5"5A@MS!$[!+@(Q8NS;,HQR " >G7
MFC4#OH=3LI]0DL8;J%[N.-9GB5LL$;.UOH<&K=<=X)\,WF@7(>Y^QNK6BP,8
MW8LI61V &1R,.!SC[M=C0 4444P%7[P^M!ZT+]X?6@]:0"4444P"N4\=V\T\
MNDF&&23;]KW;%+;<VL@&<>I('UKJZ6D!Y';+KBZMI,$MW+I\*6UB+3-O.^5"
M+YJG9\@).5._IFJNI76JZFVM^7:WJ17.GW'G6OES-Y<HD38I+#:6QNQLXQFO
M969@IV]<=">#7+:-KVO76M:C::AIFGPV^G[?-DMKN2:1MR;AL0QC/YTK 9OC
MR.#_ (2+19]0_M)+&.VN%>2R21B'(7:#L!/KCW%95K'KL_\ 9YU.&Y>[5]-=
M]Z' <;]Q)''IGTKK5\;:/]G$@>\60S_9A;_99!,9-NX+Y>,Y(Y'TIX\8:2;Y
M;4O=*6,JB9K9Q#F,?O!YF-N5P<\]C0!S7PY.KR:S,^JWS^>(W%W:/!.,R;^&
MW/\ )QT&SJ,50O-2UR;Q;(^EP74,_F74#Q,DQ7:L;>6S%OW>&95(V^N":ZB7
MQ_I!AA:W%].TEQ%;B);9PX\P$JX7&2IP<$=:G?QE86_R71G>9IKB..&UMY)7
M(A8!\J%R",C/;T)H YB"2=K72F\.OJLUWY=T;@WD<@87'V<[=V\ ??\ 3Y<U
M:\ QHWB6>XMSJ<D9TN%)I+U)%_?[W+J"X'/.3CCGBN@NO&NC0+$QENIXY%A?
M?!;/*J"7_5[R!\N?>K&M>*=-TB\-K?-=&981<NL-N\OEQ$D;V*@X (.2>E '
M#QV>JWEI(9Y=5B-OIES-$D99,W G;8>!RV,8'<5)#9:BMS>ZNIU%+]KZP^50
MP1E9(EE.S&".6R>V.V*Z]O%^D"YN81-._P!E=8YI$@=HT9@I4;P,9(9<5)?^
M*=+L;I[::2=[E9Q;>5# \CM(4W[5 '/R\\4 >=7<<R7$5QJ/]L12_P!GW:6[
MVT4F3/\ :28P=H/.,$9XQ5RZMKV?4M-N=>AO&6VU.V>4HCD*3:$,<(.1YAP2
M. :ZE/&MO]J6U,4S2R1W4HDBBD:-!"^P[SMR.>O'TSQ5_2_$UG?W,%I#]HEN
M6ACED:&!VBBWIN&Y\87(Z9Q0!PZS:N-YMI-5;6/+N_[21T?RT 5O*\O(VGYM
MFW:2<=:[_P +6C6>@6*2R7$D[PI)*UPQ9R[*"V<].>W:M;)]324P"BBBF 4J
M_>%)2K]X4@$HHHI@%%%% !1110!SMSXBO8;B2-?#.M3*C%1)&(MK>XR_2MC3
M+J2]LTGFL[BS=LYAGQO7GO@D?K5JBI2:>K-9SA)64;?>%%%%49!1110 4[^'
M\:;3OX?QI -HHHI@%%%% !17&6WCNV;5+V&YCA2SMVE3S8I&DD#(X0!DV\%C
MG: 3G%:<?B_2)+9[A)+@V\<0EDE^S/MC!. K''#'^[UI7 Z"O!D3Q/?^.?%U
MY87-]'IFG7ETEU*][^Y:'[,-L*0XR&#$-NS7L/\ PD>G>62SS1L&5"DD+*P9
MEW $$9'R\GT%9D'C&Q=&)B,03#32-$XC9?+\QBAVY8JN,@@=:3 \L\+^.-:\
M.>%;:+6M3%Q;/X>M[^VFCM0\MN[2>4 Q8_..02S'CFB/XG^)/[%LKJXOK)(X
M=6DLKJ2.&,SSQ#9L:.,G:WWN=O.,$5ZO-XPT&.V:207&U?E:/[$Y<+M5L[<9
MVX=>>GS"M/5M1T[2H(9+R$_.28XXK8R2' R2% SP.2>U SSSP'XW\0ZY\0;_
M $Z^2UBLHY;B,V;!4F@5"/+?&=S!@><C'(Q4?A;6;._^,=]#HWB6YN+:W2:&
M\M;J[WB>?((6&/JJQX.6_#FN[;Q3H27A#2[7P-UP8"$&8_- ,F,9V G&>U58
M_&'A[(EC$JO\Q8BR8,@#*I9N,@9=>?>@1U5%8>J>(;?3]2@@=E> Q-)(T?[Q
M@VY515 ZDL6&/:J*^-=/DU2")!-]D>)F>5H'!BD$OE@.,?*,AN3Z4[@=517-
MP>+;+4-1MK/2F:=VN?*E+(R@(%)+J3PPR ,CUKI* "BBBF 5YG\:_P#F"_2;
M^:5Z97F?QK_Y@OTF_FE)@COH/^1BU;_KA;_SDJ]5*W_Y&/5<_P#/"W_G)5_
M]?TI1V&QM%.P/7]*,#U_2F(3ITI*=@>OZ48'K^E #:*=@>OZ48'K^E #:*=@
M>OZ48'K^E #:*=@>OZ48'K^E #:*=@>OZ48'K^E #:*=@>OZ48'K^E #:<WW
MC1@>OZ4K ;CS^E #**=@>OZ48'K^E #:*=@>OZ48'K^E #:*=@>OZ48'K^E
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M?7MM;LUO;D++*J$C,GK5C_A(=#_Z"]A_X$)_C2CL-FE16;_PD.A_]!>P_P#
MA/\ &C_A(=#_ .@O8?\ @0G^-.XC2HK-_P"$AT/_ *"]A_X$)_C1_P )#H?_
M $%[#_P(3_&BX&E16;_PD.A_]!>P_P# A/\ &C_A(=#_ .@O8?\ @0G^-%P-
M*BLW_A(=#_Z"]A_X$)_C1_PD.A_]!>P_\"$_QHN!I45F_P#"0Z'_ -!>P_\
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M_P"$AT/_ *"]A_X$)_C1_P )#H?_ $%[#_P(3_&BX&E16;_PD.A_]!>P_P#
MA/\ &C_A(=#_ .@O8?\ @0G^-%P-*BLW_A(=#_Z"]A_X$)_C1_PD.A_]!>P_
M\"$_QHN!I45F_P#"0Z'_ -!>P_\  A/\:/\ A(=#_P"@O8?^!"?XT7 TJ*S?
M^$AT/_H+V'_@0G^-'_"0Z'_T%[#_ ,"$_P :+@:5%9O_  D.A_\ 07L/_ A/
M\:/^$AT/_H+V'_@0G^-%P-*BLW_A(=#_ .@O8?\ @0G^-'_"0Z'_ -!>P_\
M A/\:+@:5%9O_"0Z'_T%[#_P(3_&C_A(=#_Z"]A_X$)_C1<#2HK-_P"$AT/_
M *"]A_X$)_C1_P )#H?_ $%[#_P(3_&BX&E16;_PD.A_]!>P_P# A/\ &C_A
M(=#_ .@O8?\ @0G^-%P-*E7[PK,_X2'0_P#H+V'_ ($)_C2CQ#H8.?[7L/\
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MO_"0Z'C']KV'_@0G^-%P-&BLW_A(=#_Z"]A_X$)_C1_PD.A_]!>P_P# A/\
M&BX&E16;_P )#H?_ $%[#_P(3_&C_A(=#_Z"]A_X$)_C1<#2HK-_X2'0_P#H
M+V'_ ($)_C1_PD.A_P#07L/_  (3_&BX&E16;_PD.A_]!>P_\"$_QH_X2'0_
M^@O8?^!"?XT7 TJ*S?\ A(=#_P"@O8?^!"?XT?\ "0Z'_P!!>P_\"$_QHN!I
M45F_\)#H?_07L/\ P(3_ !H_X2'0_P#H+V'_ ($)_C1<#2HK-_X2'0_^@O8?
M^!"?XT?\)#H?_07L/_ A/\:+@:5%9O\ PD.A_P#07L/_  (3_&C_ (2'0_\
MH+V'_@0G^-%P-*BLW_A(=#_Z"]A_X$)_C1_PD.A_]!>P_P# A/\ &BX&E7F?
MQK_Y@OTF_FE=U_PD.A_]!>P_\"$_QKS;XR:UI=P='^SZC9R;1-G;,IQ]SWI,
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image00019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $$ ML# 2(  A$! Q$!_\0
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M ,"G_P :PZ*T]G#LA<S[FY_PE_B3_H/ZK_X%/_C1_P )?XD_Z#^J_P#@4_\
MC6'11[.'9!S/N;G_  E_B3_H/ZK_ .!3_P"-'_"7^)/^@_JO_@4_^-8=%'LX
M=D',^YN?\)?XD_Z#^J_^!3_XT?\ "7^)/^@_JO\ X%/_ (UAT4>SAV0<S[FY
M_P )?XD_Z#^J_P#@4_\ C6G+XK\0CPS;2C7-3\PWLJE_M+Y($<9 SGIR?SKD
M*U9?^13M?^O^;_T7'42IPNM$-2?<G_X2_P 2?]!_5?\ P*?_ !H_X2_Q)_T'
M]5_\"G_QK#HJ_9P[(7,^YN?\)?XD_P"@_JO_ (%/_C1_PE_B3_H/ZK_X%/\
MXUAT4>SAV0<S[FY_PE_B3_H/ZK_X%/\ XT?\)?XD_P"@_JO_ (%/_C6'11[.
M'9!S/N;G_"7^)/\ H/ZK_P"!3_XT?\)?XD_Z#^J_^!3_ .-8=%'LX=D',^YN
M?\)?XD_Z#^J_^!3_ .-'_"7^)/\ H/ZK_P"!3_XUAT4>SAV0<S[G9>%_%7B"
M;57677-3=?LMPV&N6(R(7(/7L>:R!XO\28'_ !/]5_\  I_\:;X1_P"0P_\
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M265A/YUM&@4 .F5!0G^YSWKS*BM886,9*2>Q+J-JP4445U&9?T#_ )#^E_\
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MU/YT_KU?NON_X(O;0_E_'_@'@O\ PI+QE_SQL/\ P)'^%'_"DO&7_/&P_P#
MD?X5[UD^I_.C)]3^='UZOW7W?\$/;0_E_'_@'@O_  I+QE_SQL/_  )'^%'_
M  I+QE_SQL/_  )'^%>]9/J?SHR?4_G1]>K]U]W_  0]M#^7\?\ @'@O_"DO
M&7_/&P_\"1_A1_PI+QE_SQL/_ D?X5[UD^I_.C)]3^='UZOW7W?\$/;0_E_'
M_@'@O_"DO&7_ #QL/_ D?X4?\*2\9?\ /&P_\"1_A7O63ZG\Z,GU/YT?7J_=
M?=_P0]M#^7\?^ >,:Y\'O%EY'I8@BL2;>QC@DS<8^8%B<<=.169_PI+QE_SQ
ML/\ P)'^%>_W!.(>3_JQW^M19/J?SI1QM9*RM]W_  1RJPOM^/\ P#P7_A27
MC+_GC8?^!(_PH_X4EXR_YXV'_@2/\*]ZR?4_G1D^I_.G]>K]U]W_  1>VA_+
M^/\ P#P7_A27C+_GC8?^!(_PH_X4EXR_YXV'_@2/\*]ZR?4_G1D^I_.CZ]7[
MK[O^"'MH?R_C_P  \%_X4EXR_P">-A_X$C_"C_A27C+_ )XV'_@2/\*]ZR?4
M_G1D^I_.CZ]7[K[O^"'MH?R_C_P#P7_A27C+_GC8?^!(_P */^%)>,O^>-A_
MX$C_  KWK)]3^=&3ZG\Z/KU?NON_X(>VA_+^/_ /!?\ A27C+_GC8?\ @2/\
M*TM/^#WBR#1-7MI(K'S;H0^7BXX^5\G/'I7M&3ZG\ZEC)^SS\G^'O[TI8VLU
MK;[O^".-6%]OQ_X!X!_PI+QE_P \;#_P)'^%'_"DO&7_ #QL/_ D?X5[UD^I
M_.C)]3^=/Z]7[K[O^"+VT/Y?Q_X!X+_PI+QE_P \;#_P)'^%'_"DO&7_ #QL
M/_ D?X5[UD^I_.C)]3^='UZOW7W?\$/;0_E_'_@'@O\ PI+QE_SQL/\ P)'^
M%'_"DO&7_/&P_P# D?X5[UD^I_.C)]3^='UZOW7W?\$/;0_E_'_@'@O_  I+
MQE_SQL/_  )'^%'_  I+QE_SQL/_  )'^%>]9/J?SHR?4_G1]>K]U]W_  0]
MM#^7\?\ @'@O_"DO&7_/&P_\"1_A1_PI+QE_SQL/_ D?X5[UD^I_.C)]3^='
MUZOW7W?\$/;0_E_'_@'A^D_!CQ?;:M8SRQ6 CBN(Y&Q<Y. P)[>U?4%<E;D^
M?'R?O#O76UQ8NO.LUS]#LPLU).R.7U+_ (_Y_P#>JM5G4O\ C_G_ -ZJWZ54
M=D>;/XF &>E&*^=?B!X^U+6M5N+>PNI;72XG,<:1,5,F.-S$<G/I7+Z?I^M:
MG!<7%A;:A=0VXW321!V6,=<DUZ$<"^7FG*Q2I-GUEBC%?* TG73?6MD+/43=
MW48FMX0&WRH1D,H[C /-5K.#4KZ]%G9)>7%VQ($,6YG)'7@>E5]07\_]?>/V
M3/KC%+@U\D_8]6_LQM1\F^_L]9/*:YPWEA_[N[IFFW4>IZ=)%]K%[:R21B6/
MS"R%D/1A[&CZAVG_ %]X>R9];].M%>(?"7QY?_VQ!HNL7$EU;7)V02RG<\;]
MAGNIZ<]*]OKCK4949<LC.4>5V"I#_P >R_[Y_D*CJ0_\>R_[Y_D*Q8+J1T44
M=:9)S'Q(U.[T?PC<7FGS207"S01B2*,2.%>5%;:I!!."<<5CZ+X@\21W&FZ;
M<6!NKB_NKK[--J.+606L6PAY453\QW,  !G )QDUT4.J^'_$TUQI<5S:ZB\#
M"26$9(#(X(.>APP'0]15R2739_$=O"YC?6+>W>XBX)9(G(5F!Z8) 'X5/6Z9
MHG96:. MO'FI16#?8]/CO&BM;[4)7N[LAA'!<,FP$)R2!QZ=ZU(_&]XL=Y%>
MV%I!?!+22TC26243BX#%4PJ;C(-C< 8..M=-'X<T:-'5-.ME1X9(&P.&BD;=
M(OT9CD^]%WX:T>\5UN=-@DW+$IX(($6?+Y!R-N3C'J:5I#YH=CF-%\;:EK;Z
M/;Z=I%NMU>)=--]HN&1(/(F$;?PY.<\#@CO6EX/\62>)+LPBQ%O]GM%DO"7R
M8;@R,OD].<!&.?<>M:5EIFC:9>VMOI]G!;72P3&W\N([41F4R<C@9;:2,Y--
M\*Z%_8<%^\T\=Q?7]T]Y=SI'Y:M(<# 7)P  !R2>OK35Q-QL[(VZ*,YZ$'Z4
M51F/A=$DS(ZH"K8W,!G@U!Y\/_/:+_OL5Y;^T(2-%T7!(_TJ3H?]BO$=Q_O-
M^==M#!>UAS\UC6,.:)]@>?#_ ,]HO^^Q1Y\/_/:+_OL5\?Y/]YOSHW'^\WYU
MM_9W][\ ]EYGV!Y\/_/:+_OL4>?#_P ]HO\ OL5\?Y/]YOSHR?[S?G1_9W][
M\ ]EYGV!Y\/_ #VB_P"^Q1Y\/_/:+_OL5\?[C_>;\Z-Q_O-^=']G?WOP#V7F
M?8'GP_\ /:+_ +[%'GP_\]HO^^Q7Q_D_WF_.C)_O-^=']G?WOP#V7F?8'GP_
M\]HO^^Q1Y\/_ #VB_P"^Q7Q_D_WF_.C)_O-^=']G?WOP#V7F?8MS/#Y@_?1?
M=7^,>@J+SX?^>T7_ 'V*^/\ )_O-^=&X_P!YOSH67?WOP&Z=W<^P//A_Y[1?
M]]BCSX?^>T7_ 'V*^/MQ_O'\Z7)_O-^=']G?WOP%[+S/L#SX?^>T7_?8H\^'
M_GM%_P!]BOC_ "?[S?G2;C_>/YT?V=_>_ /9>9]@^?#_ ,]HO^^Q1Y\/_/:+
M_OL5\?[C_>;\Z-Q_O-^=']G?WOP#V7F?8'GP_P#/:+_OL4>?#_SVB_[[%?'^
MX_WF_.DW'^\?SH_L[^]^ >R\S[!\^'_GM%_WV*F6>'[(_P"^B^^/XQZ&OCG<
M?[S?G1N/]YOSI?V=_>_#_@C5.Q]@>?#_ ,]HO^^Q1Y\/_/:+_OL5\?Y/]YOS
MI-Q_O'\Z?]G?WOP%[+S/L'SX?^>T7_?8H\^'_GM%_P!]BOC_ ''^\WYT;C_>
M;\Z/[._O?@'LO,^P//A_Y[1?]]BCSX?^>T7_ 'V*^/\ <?[S?G1D_P!YOSH_
ML[^]^ >R\S[ \^'_ )[1?]]BE$T1Z2QGZ.*^/LG^\WYT!F'1F'T)H_L[^]^
M>R\S[$P1UHKY=\.>-=>T"5#9WTDD"];>=B\9'I@]/PKW_P $>+;+Q9IIGM@8
M;F+ GMV.3&?4>JGL:Y:^%G1UW1,H.)U-I_Q\Q_6H:FM/^/F/ZU#7+U%]E?UV
M"BBBF2%%%% !1110 4444 %%%% $UQTA_P"N8_K4-37'2'_KF/ZU#26Q4MPQ
M17CMYI=MX;\0>)[[1+); PWEC";R.(R&SMY4_?R(#D?4X.,Y[4Z3Q;J(?3H[
M[Q#<6.ES/J"Q:DMJF^ZCBV>3(04(&26&0 &Q[U//W+]E?9GKQ= <%U!XX+#/
M/2G5XO97NJ76MVM[J5MLOKN30OM*-!P"QEW$ CY3T/J,U=LO$'BR+2+*_2[F
MU&[OK+4I%LWMD54DA;]UC: <XZ@GYJ.<'2?<];HQQFN'^'.K:CJ^DZK+?7T5
M]$H40.'5Y%)CRZN51!][D#&1G!Z5P_@>[LM/T_P[>>&X;J6[MM,N)==CM5<A
M]L9*!PWRF;?C;WZ]J?,"IO7R/<**\33Q)K.H:3?O=:S<I86U[ILWVVVPQ2&1
MCYH+^4H8*0,X4@'()(K=7Q;J,WQ"L+*QNIGT\WHLIH)@"SQ^26$X C&U6."&
M+\\\4N= Z3/3ZEB_X]Y_^ _SJ*I8O^/>?_@/\ZID1W(J***9(4454UB2ZATN
MZEL(Q)=+&3&A&<FG&/,U'N!%K>LZ=H5FMUK%Y%9VS2+$LDF<%VZ#BM"N%L;K
M7-2T4?VOH]G>()U*_;,1]#UVD=1V-=%-=:R/%5O:QZ? VA-;,\MZ9?G27/"!
M?2MZV'=%\K:?HRFC8HHHKG)"BBB@"2W_ -?'_O"NMKDK?_7Q_P"\*ZVN>OT/
M1P.TCE]2_P"/^?\ WJIS*7AD1?O,C*/J15S4O^/^?_>JM6\=D<,_B9\>S1/!
M/)#*")(W*,#V(.#771W]AJ'@*PTPZN-)O-.FN)GC:.0B[\P#:04'WAC;\V!@
M]:]1\<_#&S\0WTFH6%R+&^DYE!3='*?4CJ#[BN._X4QK'_05T[_OF3_"O:^L
MTJD4V[-&T:B-VS\=^'8K_2K]KO%]8);644GEMA8'2+SCT_A*./\ @7&:XGPC
MXDL-)\;:;>6YGT^U\]_[0G\UG6X0L2#M RHZ<#-;/_"F-8_Z"NG?]\R?X4?\
M*8UC_H*Z=_WS)_A6<?JT4US;ENO<@C\5:9'X),:7CK?)ILFFK8B-OFD:X\U9
M\_=P!^.17.>/=:CURXT:X%T]W<1Z9##<R/G=YP+%@2>IY'-=5_PIC6/^@KIW
M_?,G^% ^#&KYYU73L=\*_P#A5PGAX2YE+^F)U4U8XWX?PR3^-]#2)2S"[1R!
MZ Y)_(5]3'K7&^ _ -CX39[GS6O-1==AG9=H1>X4=L^M=E7#BZT:L[QV1SSE
M=Z!4A_X]E_WS_(5'4A_X]E_WS_(5R,2ZD= .#Q16)XRUJ30= DO;:!+BY:6*
MW@CD;:ADD<(I8]E!;)^E#$E=V1PEQH'B.33=5TW1K*^T_16CW+87EW&2TGGJ
M[I Z$E8W3>,,1RPQCFFZ_P"%=5OA<GP[I#Z+;OI26Z6S21@@BZ$CQ?*Q'S(#
MWQS@D5T6L:KXET+4/#]K=?8]5FO[V2%H[*#[.600LP&9'(&&&<YZ=J;_ ,+&
MLGL4N[?2]0GB2S-_>!2@-I$)&C.[+?,0R/PN>%)J++J;\T]T9?A_P;/]OT :
MG:W+Z7;M>SR6]P$C6!F,1B3RXW8;059@,D ^G%9UGX/U<+<17=A>Q2&UNXM2
MO;:[3S-5:1P8C'ENJCGY]N/N]#70GQT+"#7+F_6.YBM]5DM;5(Y$B9HEACD!
M^8Y8_,>GJ.E33?$2S53+!I=_/:1VEI>S7"E%$45P<(2"<D@]0*+1"]3L<G<>
M%O$LN@R01Z:EO(-&U"TA2W*0Y>26)HMRABJR$*Q.TE1CJ,T>+-$;1;J6SL[6
M**RO[^SDM;::13;SND$GG^8&<#^Z>2-S 'FNGU7X@0Q2ZG:VUE<*]K%>'[0&
MC8QFW'S,T1.0"2-N[&ZJ^H>+9+K3]62[TU?LEE+8QBXD2.;S&G\H\Q,<#_6?
MA]:32&G/JC:^&"6<7@72XM.29+>)7C_?!=Q978,?E)4@G.""1C'-=37/^&_$
MEOK6H:C96MF]L-/D:%ED= X*MM_U0.Y0<9!(P1705HMC"=[ZGE'[0G_(%T7_
M *^I/_0*\QT@+9^&[G4H+&WOKL7:V[>?#YJP(4)!V],L>,GIM]Z]._:$_P"0
M+HO_ %]2?^@5Y9X=MM6*W%UHU]':-$A,K"\6!@@(!)!(.,D5[.&_@+^NIO2V
M-36=#TZ*228F>VDEFMX%M8@"L,DD0=@Q;D!23QUY]JN6OAS3K2_NV9KQ[>V>
M\LY5N(E#,R0LPDC'X=^AQ7'QS727*DF6;$XFVDEA)(#U]S[^AJUJ.L:GJ^H2
M7$UQ=,Q9PJF1F6%7/*CT7G%;.$[6N:W78W=.\(6][>6A6:Y33[N*W:.5V0,D
MDN<(1@[C\I/ Y]JI-X?LULB#<W)OOL<]X,(OE 12,FWUY"YSVJA<7.KZ)>W-
MF+ZY@D@/V:3R9F"_(?N@CL.WUJ%H[\:<M\TLHA9S:+ECN.X;R /[IR?J332G
MOS:"T[&SX-TBTN9M-N[X7,JS:BEHL4,8=1@!B9,]CG&![^E22^&=.ATF"[O-
M56">>-9Q&J[QM:3:5"@9R!DYSU&,5SUE?:A8B=+&XN[?</WJPLRYQ_> ]/>I
M_M.K6T)L([J[\A2LWDPRED!.&!P.,]#]?>AQGS73!-6V-\>&+<RM%'*ZVD\E
MNL-RX63>KRLA9",8Z8P1G/6H)]!TB&&\F:ZO3]CM5GGA0QNRN9O+";A\O3YL
M\^E9EKKNI6^J1:C=237;(PR+EF*OC.!GU&21Z'FK&M:QJ6N?NTM[M8H(6+J9
M))G:,L&R[-R5!QCL*GEJ7U>@[QL:L7@J-KJ_@>YE18_.-K*2H\T1Q>8<KR<C
M(!Y Y[U)_P (S8W-S-:6/G0!H[#,EPH<@S;<E2,8Z]._2N:DO]8M?.@^W786
M0"658YRRL"HP6P<=,#GZ56>^U"2U2)[FZ:VC"HBEVVJ <J!Z8/(I\E1Z\P77
M8WE\/Z>UF;_SM0BLUAN',4D:B8M$R#CMM.\<]B".:98:39P>.]*L)?,N+&:6
MW?:X 9DD"MM;M_%@UB7FI7]U*\E[>74TIC\IFED+'9UVG/;VJ_?:3K%BOV^=
MP7@\K<\=PKR0[E!CW '*\8Q^5.TEI*6XKKHC7GT>PU&^LI#/=)-J GG*)#&J
MQQQ,XVJ%QESLX  'UJ$>'M.733J4TVH+:-;Q3)#L02Y>9HR"3QCY<@XYK C_
M +08^;$+LFR&_<H;, +9S_LY)S]33]2N-2:ZNA?75Q-*=HG<RF0''*Y;)! [
M4<LME(+KL:7B?0[32EN19W%S*UK>M92F9%4,0NX,N.@ZC!KH;:*Q.L^'[#R-
M-=7MX)9(#9?O'8PEB6DZ,"><5Q'^G7TRQ?Z3/+<R[@IRQED/&?=J1+B]AOHI
M$EN4O8<+&P)$B;1@ =Q@4.FVK-ZA?78ZO3]-AURVTJ^O[2VT[_29!.\<?DQR
M6\:!V<KT&#\F1UW#N*J:IHR3^,;"+3H[22UU-XYHHX)#Y(R</&K8S@$,/7I6
M%<ZAJ-X\LUS=7<[,GER.[LV4S]TGTSCBH5ENML"JT^(V)A S\K'GY??H>*%"
M2=[A='5>/-+@$4&L:5' FDR8@CE2+R3-)EB1Y?\ "4&%.>O![U+-':I%X;M$
MAL/](CM7E0V1\URS_,3+C&#Z9Z5BD:WK-G+/<7T]Q$79'$\[$EHXS)T/HH./
M>J@U75C9Q6@O+XVJ8,<.]MJ[3D8'L>?:I4'91OL.ZO<[7^QM,BO-6U'[)"UC
M?VT_]GPL.(76-VD*C_IFR;1_O"L[4= LXO#-JJFW;4+(QS7PMGWW&R7[P9#Q
M\A* <_Q'-<FMY>!$*SW&R,L%(8X4O]X#TW=_6K.FSZJNK)<6/VI[]R9 0I9I
M,?,2?[PXR?I1[.2UYOZ_X8.9=ANE0PR^(K*#:SV[7D:;91@LA<###UQUKK9Y
MK99O$<]M:Z3=/8QXA1-.V)&3<!>5(^8XXS7#*\WVD.AD^T;]P(SOW9SGUSFK
M-EJ&HV$TUQ975U;2O\LLL;LI.3G#'Z\\U<X.3N2G8[2RT?34U-=0U2"RLK9K
M*%IK6X9HXTGER"%ZD$(#(%[$BL?0]/33M>UJWOUMV-C:3,KW$/G(""NU]G?(
M.1]:YZ::\N%99GN91(YF(<LVYL8+<]3CO0UQ=.7E:6=MZ")I"3\R\ *3Z<#C
MVI*G+5-CYEV.GMO#J:O:WM^\J0L89KFV,$8CCE6)>=L>,@9!';GUJ2'PYI:B
M:<&^O+'['-+'/$R#=(BJ<;<94C=RI]N37/W$^JZ5]KTO[7<QP0R,DT44K>5N
MZ'IQS^M/NK[7;?4(C=7.I1WMNG[O>[AXU([>@(-+EF]I:#NNQDGJ<9Q[T5;L
M;&XU W#0#/DQ/<2,QP-JC+<^OM52M[]" KH/ >NR>'O%-E>JQ$+.(IU'\4;'
M!_+K^%<_0 2P"]2<#ZTI14DXL35S[+M/^/J/'(SP:AIVE@C[*&ZA%!_*FU\U
MU.=_"%%%%,D**** "BBB@ HHHH **** )KCI#_US']:AJ:XZ0_\ 7,?UJ&DM
MBI;A7&_V]IM[XMN9I;*9)-!\^V>[:X3"J45W(B!WL,!><<8-=E7(V/A:^T_7
M=:U"SGTGS-0FDN(Y9K$M/"S1A -^[E05!QCG)%)W'"VMS2G\7:!#"TLFJVWE
M*T:%URP+2+O100#DE>0!S^=-E\8^'H;*TO)-6MEM[K<87Y.=IPQ( RH4\$G&
M#UKC6\#7_AW3]&T_0+G[1#'K4%\&EM]Q@;8PE=\$90M@@#!7.,]*LS?#0RF.
M>:_M[BZD%T+Q989%AF$\GF,%5)%( (Q@D@CK2O(OEI]SIM9\9Z%I(U$75\&E
MT^(RW$4*,Y0<'&0,;OF'&<\U.OBK13<65N=0C2>\57AC=64G<<+D$?*200-V
M,XXK%D\&7/\ 9GB'28-3ACTC5C+*$^S$RP2N%'WMV&0%<X(SCC-1W'@:2\\0
M?VK?W-I<M.ML+R%HY51FA/RM&%D ';A]V",CTIWD*T.YJ0>,]*O/$UGHNG3)
M=S3?:!(\9PL)B R.1ALDD<'@@UTF:XW0/!]YI6HZ0\NIPSV&DBZ2UA6VV2%9
MCGYWW8)7U &>_-=E35^I,^7[(5+%_P >\_\ P'^=15+%_P >\_\ P'^=#%'<
MBHHHIDA7'W-IXG;Q<\MM<!-/)^4N=T87'0KUS7853UBUEO=+NK:"8PRRQE5D
M'\)KHP];V4GHM=-5>WF-,X?Q=:Z\SLSW%BTK/'Y$TMLTL"Q@GS%VC.'(Q@G\
MQ7>:>$%A!Y,<D46P;4D!#*/0YYKAEL'\*Z$)-;\2G3(7N452GS)N)X7)&<G\
MJZF72KR3Q5;ZJNKW*V,=L86TX >5(Q_Y:$^O^%;XR47:,972[72T\K6_%E,V
M****X" HHHH DM_]?'_O"NMKDK?_ %\?^\*ZVN>OT/1P.TCE]2_X_P"?_>KE
M/&U[?0:?#::*MRVIW;XC^S*K.B*-S-\Q Q]U>3_%75ZE_P ?\_\ O55P,YP,
M],XK9?"<4G:;9R$?BF\N(8[RWAM!9AK-)8WW>8'F;8ZY!P-C<=\X-1^'/$%[
M<06+W2MJ%P]K+)+'9@!@RS!,%"P&0#SR#[5V6Q!G")R<GY1R:%C1"2B(I)R2
MJ@$T68N9=CBGU2?[#K5\NIS?VQ:FX5-,WJ5B520I\G&7(7#9[YJPFHVMC=:*
MT/B)KRTN9Y!/+<72,I_<LP&> O.#MKK/+C\X2^7'YH&!)M&['IGK3#:6Q4J;
M:W*D[BIB7!/KC'7WHL',CDYM;$.N:A-IM]/J,5K$ZSV8E60-,2NU(D W#;R6
M(SP>YJ+1=>OQX=60S?:[Y]9-@9;J%HE >7'"\'"@\#VP:[)+>".3S(X(4D_O
MK& WYXS4FU3_  KUST[^OUHLPYEV.'E\5:DEBPE@MGN[F"06D=MD,TPF\D ;
MC@Y^]VQ@CGK6>OB;4+26U%S<+%=6=C<I<P:A\K3R1O'MX4XWNI!&,_>/!KT?
M8F0=B9'0[1Q]*1HHW(+Q1L00060$Y'0T6?<:FNPY&W(K8*[@#@]1[5*?^/9?
M]\_R%1U(?^/9?]\_R%-DKJ1U3UC3+36=,GT_4H1-:SKM=,D'KD$$<@@@$$="
M*N44R3"LO"]G;7%A/)<ZC>3V,[7$$EW=-*RL4*$<]MI/'KS6==>!/#PM(8Y1
M<P6\:-!)MNFC$\;RF3RY?[R[V.![X[UUU<QXV_X^O#'GX^P?VQ%]HW?=SM?R
M\^WF;/QQ4M*Q<92;W*\GACPUJ-]<R0796[6>:XG^R7NUT\Q%216VG*H5C4$<
M8Q3H/#OA=M)O!#/$VG26UO9SR)=@HL=N<QC=G (SR>]<AH_@EI]*OK[7(IH(
MD;4HA;V5F5NY4FE;YF;.7X^95 QSWID%C>O:Z:]]H3W6@:=JA>5(=,^SRWL7
MD82:2U_B*/QTYQD"IOY&MNBD:6D^$;F^UB]FNM2M)K*_:X>^DL[YG^W12AE4
M>5C;'CCY@3RO'4UU-QX+TB=[@L+L1W"VXEB6<B-S 5,;%?[PV*,]Q6;;-:-X
MS\-MHMF;*)K&\,\!M_L[+#N39NCP,9DY&1Z^]=M5)(B<I7,C3_#]G9:U<:L)
M+N>^FC,/F7$YD\N,MOV+GHN>:UZ**HS;;W/*/VA/^0+HO_7U)_Z!7D6D7L5I
M;ZLDV[==6;01[1GYBZ'GVPIKVKXY:7J&JZ3I$>F65S>/'<2,ZP1ERHV=3BO'
MO^$3\1?] +4__ 9O\*]C"./L4F_ZN;TW9&K#XD@>^5Y;N[ACM["."TV[@L4H
M5%<E48'D!N0>>,U-KOB2RODNQIUU=6"R7<D[HL6!>(P3 ?!X(*MP<CFL3_A$
M_$7_ $ M3_\  9O\*/\ A$_$7_0"U/\ \!F_PK7DI7O<TYS0\8Z_8:SJUO>6
M<,D<,<[,]HRX1QOW;^OWG'W@>XXXX&P_B^P^U1O->7MXOVV>XC\V''V1'B*(
M%&[DJ2. 0..*Y?\ X1/Q%_T M3_\!F_PH_X1/Q%_T M3_P# 9O\ "CDI62OM
MYA[36YNKXJCEFO5O;UFMIHE1C:PR12RE4*@[RY/< [\@^E;VC:C)<V)N=*D>
M&2:58XY"C[(]MLD;F;8<;<Y(W<=37"?\(GXB_P"@%J?_ (#-_A1_PB?B+_H!
M:GSU_P!&;_"IE3IM:2&JAL_\)/:3Q&SOY+R731:6<"PKT5XF3S&7G ) ;#=3
MFK=YXLM98VBAU"\CDDM+BV:Z5'RN^16C'+EB %(//!/ KF_^$3\1?] +4_\
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MWXSGY@"#@YYK4B\1VJ:6()+NZE5;:X@EM#'^[NY7+%9F.>"-P)R"1M&*R/\
MA$_$7_0"U/\ \!F_PH_X1/Q%_P! +4__  &;_"KDJ<G=L%.QT3^.'^U.8[R]
M6#^T+>9% QM@1,2(!GC)Q\O0]ZEU+6K6VT2R7[3,UO<:?<*FGK'^[9GGDV.Q
MS@%>#TSP,5S'_")^(O\ H!:G_P" S?X4?\(GXB_Z 6I_^ S?X5'LZ6EF'M#H
M+GQ;:M8WT=D_D/-+<LRRP,XN%D^Z3AP PZ?,#C (JQ_PF5L=2O[M;VX$]RMN
MT4LT3N8?+7#1':X)4GG@X/<5R_\ PB?B+_H!:G_X#-_A1_PB?B+_ * 6I_\
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ML;+[5:6EJMJDH AG/+-$54C & #C JA'X8U=YW-U?/)O(,CB<J)%W(=I &>
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M^,='2)2S"Y1SCL <D_D*^DZ\?,Z<854X]4=F%DY1U"G'_5C_ 'C3:<?]6/\
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M]5W''7/3ZTTL6"AF)"C"@GI]*<*;B[MW"4DUL)1116IF%%%% !1110 4444
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M(<SQ0_969E>22),?O N#MXSC-7K_ /M?4O@[:2WT=Y=ZE;W4,TX\H^?)'#>
MEMH RWEIG@<_C7IQ8GJ2?QI,G.<\T[ >0^(%M/$M]XIU!I+ZUT><:=%!<RZ?
M,\<LL32.5>' 9HOF4-P!SUXJW>BXO?@K*D&BC3I//14M+2%T5U6Z7]XD9&Y5
M8 M@C(!KU3<V<Y.?7-)DYSDY]:+ >%^+M,U?3K7QOJ>G6UY<VNK:C/97EJB,
MS#E/(N8U[@'*-CL0?X:L>([*.;7?%L=IIUT_BJ;6;:32KF*V<-&HCAW/YV-H
MC #YR<'D8KVS)'0FEW';C)QZ9I<H7!OO''3-*O\ JW_"FTY?]6_X4V VBBJ6
MM7O]FZ1>WHC\PV\32!"< X'<]A36N@B[2,H92K ,I&"",@URFI:MK&CR:?YI
MM-4^TB61T@7R=J)$7.UB3D>GK3!XV23<]KIES-"S;(9-VW>^Y5PV1A1EN#D]
M#5^SENA<RZFCXCTW57T>.V\)7EII%RLZ.SO &0Q@_,NT=SZUO9.,5RD/BR>1
MHXGTAX[F=S%;Q_:4(D=7*,"V/E ()!YR.V>*9_PE\TEP(;?1I))!*ML^;E%"
MS,7 7/<91OF^G%-QD]PNCKJ*Y.#Q<UU:+>VNGAK$20PR-).$D5Y-O1<<@;AW
MY[58\(^(+G5H+5-0M!!//:_:HW20,LJAMI.!]WDC@YZ^QJ7"25V',CI****D
MH='_ *Q?K6Q6/'_K%^M;%9S&C+O/^/E_\]JAK0FM/,D9]^,]L4S[#_TT_2J4
ME85BEDT9J[]A_P"FGZ4?8?\ II^E',@L4LGUHR?6KOV'_II^E'V'_II^E',@
ML4LT9J[]A_Z:?I1]A_Z:?I1S(+%+)HR?4U=^P_\ 33]*/L/_ $T_2CF06*5.
M/^K'^\:M_8?^FGZ4OV+Y0-_?/2CF06*-%7?L/_33]*/L/_33]*.9!8I45=^P
M_P#33]*/L/\ TT_2CF06*5%7?L/_ $T_2C[#_P!-/THYD%BE15W[#_TT_2C[
M#_TT_2CF06*5%7?L/_33]*/L/_33]*.9!8QM1TG3]76./5+.&Z2,ED649"G'
M45F?\(=X<_Z ME_WQ_\ 7KK5LMISO[8Z4GV'_II^E7&M**LI,3@GJT<G_P (
M=X<_Z ME_P!\?_7H_P"$.\.?] 6R_P"^/_KUUGV'_II^E'V'_II^E5]8G_,_
MO8O9Q[')_P#"'>'/^@+9?]\?_7H_X0[PY_T!;+_OC_Z]=9]A_P"FGZ4?8?\
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M] 6R_P"^/_KUUGV'_II^E'V'_II^E'UB?\S^]A[./8Y/_A#O#G_0%LO^^/\
MZ]36OA?0K6426^D62..0WE X_.NF^P_]-/TH^P_]-/TI/$3>CD_O8<D>Q1'
M ' '  [5(/\ 4G_>%6OL/_33]*7[%\A7?WSTK/F15BC15W[#_P!-/TH^P_\
M33]*.9!8I45=^P_]-/TH^P_]-/THYD%BE15W[#_TT_2C[#_TT_2CF06*5%7?
ML/\ TT_2C[#_ --/THYD%BE15W[#_P!-/TH^P_\ 33]*.9!8J0_ZU?K3:O)9
M;6!W]/:D^P_]-/THYD%BE15W[#_TT_2C[#_TT_2CF06*5%7?L/\ TT_2C[#_
M --/THYD%BE15W[#_P!-/TH^P_\ 33]*.9!8I45=^P_]-/TH^P_]-/THYD%B
ME15W[#_TT_2C[#_TT_2CF06*DG\'^Z*;5YK+./GZ#'2D^P_]-/THYD%BE15W
M[#_TT_2C[#_TT_2CF06*5%7?L/\ TT_2C[#_ --/THYD%BE15W[#_P!-/TH^
MP_\ 33]*.9!8I45=^P_]-/TH^P_]-/THYD%BE3E_U;_A5O[#_P!-/TI1985A
MOZ^U',@L4:0@$$, 01@@C(-7OL/_ $T_2C[#_P!-/THYD%C M-#TJSS]ETZU
MBR6)VQ@=1@_F.,4Y-&TU)VF2PMEE8*&8(.0N,?E@?D*W?L/_ $T_2C[#_P!-
M/TI^T\PL8=UIEC/;M'-8P31MD%"@[MN/Z\_6F6]E:0K&L.F1Q*A4H%11M*_=
M/X;C^M;_ -A_Z:?I1]A_Z:?I1S^86.:_L?36GAE;1[?S80%C8QK\@!R,?3M4
M^EZ;8Z?)*;#3X;,R??,:!=W/3^OXUO?8?^FGZ4?8?^FGZ4>T\PY2E15W[#_T
MT_2C[#_TT_2ES(+%2/\ UB_6MBJ:V6U@=_0^E7*B33V&C.NI9%N'"NP'H#[5
M%Y\O_/1OSIUY_P ?+_Y[5#6B2L(D\^7_ )Z-^='GR_\ /1OSJ.BBR D\^7_G
MHWYT>?+_ ,]&_.HZ*+("3SY?^>C?G1Y\O_/1OSJ.BBR D\^7_GHWYT>?+_ST
M;\ZCHHL@)//E_P">C?G2^=)Y8/F-U]:BIQ_U8_WC19 .\^7_ )Z-^='GR_\
M/1OSJ.C!X]^E%D!)Y\O_ #T;\Z//E_YZ-^=1T460$GGR_P#/1OSH\^7_ )Z-
M^=,56;[H)^@I#P<'KZ460$GGR_\ /1OSH\^7_GHWYU'119 2>?+_ ,]&_.CS
MY?\ GHWYU'119 31S2%N7;H>_M3//E_YZ-^=)'][\#_*F460$OGR_P#/1OSH
M\^7_ )Z-^=1T460$GGR_\]&_.CSY?^>C?G4=%%D!)Y\O_/1OSH\^7_GHWYU'
M119 2>?+_P ]&_.CSY?^>C?G4=%%D!)Y\O\ ST;\Z3SY?^>C?G3*2BR GDFD
M#<.W0=Z;Y\O_ #T;\Z;)]X?0?RIM"2 D\^7_ )Z-^='GR_\ /1OSJ.BBR D\
M^7_GHWYT>?+_ ,]&_.HZ*+("3SY?^>C?G1Y\O_/1OSJ.BBR D\^7_GHWYT>?
M+_ST;\ZCHHL@)//E_P">C?G3A-)Y1.]L[AWJ&GC_ %)_WA0T@%\^7_GHWYT>
M?+_ST;\ZCHHL@)//E_YZ-^='GR_\]&_.HZ*+("3SY?\ GHWYT>?+_P ]&_.H
MZ*+("3SY?^>C?G1Y\O\ ST;\ZCHHL@)//E_YZ-^='GR_\]&_.HZ*+(":*:0R
M*"[8SZTWSY?^>C?G38?]:OUIM%D!)Y\O_/1OSH\^7_GHWYU'119 2>?+_P ]
M&_.CSY?^>C?G4=%%D!)Y\O\ ST;\Z//E_P">C?G4=%%D!)Y\O_/1OSH\^7_G
MHWYU'119 2>?+_ST;\Z//E_YZ-^=1T460$TDT@VX=ONYZTWSY?\ GHWYTV3^
M#_=%-HL@)//E_P">C?G1Y\O_ #T;\ZXO6KW6-1\:CP]HVHQZ4D.G"_EN#;+/
M),6D**B*W  QECR>0.*K2>-;FVU<VTE@LVFV^HQ:-/?>;LE:Z9 =PBQC9E@#
MSGG@8%+0#O?/E_YZ-^='GR_\]&_.O*+?XEZU<:?#=Q>&K39<:;-JL(;4,?N8
M6Q(&^3ACQM R/4BM2X^(%Q%>W,D>D(^D6;V*W4[7.)5%TJ%2J8P=I<9Y'M1=
M >A^?+_ST;\Z//E_YZ-^=>/6WQ*OM-L_L\]G+J]_]HU"9\;@WD17;1)'&$0[
MGP,#.!QR<FM:X\>ZE81:U<WVG6C6\6KII5@$E?<SLJG,H"$@ $DX!.>,=Z-
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MD\J.9A%(&9 _W<KUZ\4E3H/9(%"F^AT/_"R_$7]^T_[\#_&C_A9?B+^_:?\
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M#Y@7[D=. >>.M.L]:M+F6UC:TO+9[IRD(N;;R_,PA<D>V!WJUFT%HJ?X_P#
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M^C_^$9T+_H#Z?_WX6C_A&="_Z ^G_P#?A:/K\>P?6H]CYPS1FOH__A&="_Z
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M4T?9(?[GZFBBB[ /LD/]S]31]DA_N?J:**+L ^R0_P!S]31]DA_N?J:**+L
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JH^R0_P!S]3111=@'V2'^Y^IH^R0_W/U-%%%V HM80<A?U-3444-C/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image00020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $X L\# 2(  A$! Q$!_\0
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M9.)[?B'UB![[17@8^->L?] NR_[Z>C_A=FL?] NQ_P"^FH64XA] ^L0/?/\
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M/^@98_\ ?;4?\+KUC_H&6/\ WVU']DXGL'UF![Y1_GI7@?\ PNO6/^@98_\
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M*".]6XM3C:X%O.#!.6V*K\"0A<G8?X@/6E;L,T":BDD %-DDVCDU1ED,C8'
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MA,4HQK24-KGK4FW%7)J*A^S1>C?]]G_&JVHQK#9R/&7##&#O/J/>L#0L6/\
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M.AK1MM5U)(8HY+0>;YA4F7<?E['('4U>^WWB16KRP(C3.P8;&.P#[H^I]>E
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MX&=IQTXJCI>BZK?ZO=&Y^UQLLP9II78*%7<-H'0DY!R.,8%=MH^H7%W-,EQ
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M,DT =5FC=7+7NM7HD,:PB(Q2J'.&( S@[N.A[8I8]<NH\,UM(S3.NU"I 5<
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M;7NJ1PQ*$1%O'PH'84[ F=2UI:NJYMH?E.5_= [><\<>M#6UN\;![>)U9M[
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M#DE\;0,X/TY-6-+M)+.&1);J:Z+2M('F(RH)SM&.P[5C:YH4M_J,T\<B(LT
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M?HJA]L'_ #WL_P#OY1]L'_/>S_[^4<K[!=%^BJ'VS_IO:?\ ?RC[9_TWL_\
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MW0>PJ(\*ED:::260[I'8LS>I)R?YTVO=_P#A2.E?]!:__):/^%(Z5_T%;_\
M):T6<89*R%]6F>$45[O_ ,*1TK_H*W_Y+1_PI'2O^@K?_DM']M88/JLSPBBO
M=_\ A2.E?]!6_P#R6C_A2.E?]!6__):?]M8</JLSPBBO=_\ A2.E?]!6_P#R
M6C_A2.E?]!6__):/[:PX?59G@]200RW$T<%O&TL\K!$C49+$]J]U'P1TG<,Z
MK?D>F%KL/"G@/0?#3&73[4M<G@SS'<_X'M^%95<ZI*/N*[*CA97U#X;^'6\-
M>%+6RF/^DMF:;V=NH_#I75T@4"EKYF<W.3E+J=\4HJR"J>K?\@^7\/YBKE4]
M6_Y!\OX?S%2,EL_^/.#_ *YK_*L3QEJUSI.GPW%M)%&GG*LS. S!.^Q<C<?:
MMNS_ ./.#_KFO\JCNYK:/R1=-$-[A8_,(^9NP&>IH Y&X\:W$1E5K!4$%PEM
M<.SD>6S,<8&,GY=K<?WO:H[7QM=O);0S6,32R--O,<N JHQ4#G^/C)'H:ZNW
ML+/3X9V5% :0W$KR?,2W=LGT'2J2ZG%,(2FG2&29B\2E5!9<<O[<$>] '.-X
MVOVMF9]/CA!C)619=Y#&+S%X(Z8!!]ZUK'Q+<7=GJL\=M"39*=D'G 2.P'.\
M'A0>U:4VHP1V'VO[*SPAF23:H^4*<$__ %J<VHV8:])1=L1197*@*V[CKW [
MT6 YG_A-+B\M6:SCMXF6.!\L^78NP!VH>J@$C=ZU8L_&5U>RPQP:6 9KEH4W
M3#*JH))8=0WRGCW%;ZZCIAD ,EOO6/(^7HO!P./IQ3)=5TZ!3(K1,6*R$H "
M,D+N)[?C[T <Y#X[DD6%OL4:H]PD;.)=WEJX. 0!G?V('3/-7O"OB>XU/4(K
M*YB56:T6X$@;)?)(/ ^Z!QUK=>YL(_)=S"HD;=&2O4^O3]?>F?;]/CE@,<D>
MZX(2/8OW^OI]#2 U**H2:G:(T:M<)ND.$49);!(_F#4>I:M;Z>VV<.25# *.
MHW ?IU/M3 TZ*Q[;5_M%XL,=M*R-N(FR-N%.TG\ZEAU>S=$+3+&7#%5D."0.
M<_ES0!IT5BSZ]:0PRR2,RA!D#J7XSQ_C5@ZM9BXFB-PJO",R!@1MP 3V]QTH
M TJ*S!K-@8V8W4856"D\]_\ /7VH_M:W49E)C&]T)8XQMQS[YR/SH TZ*QKW
M7K:VBMY4S+',2 RD<8.#P>I]NM2C6+,$"298G(9MKGD $C^F<4 :E%9C:S8*
MJ$W*?,,C@Y-.;5K'R1)]J3:3@$'.<8[?B* -&BLY=4M6G6%I565CA4SR>3^6
M<&DDU6TAG,4\ZQL'V\GKT_(<]Z -*BLJWUFSN)IHXY>(ADO@X/&3CZ"GG5[$
M;2;N+#/L![%O\_A0!I45CQZ[9&XN(S+@0[ 7P<$L2 !W/2G)K5JRR,TFP1NR
MOD_=VYY/Y?6D!KT57LKF*ZA\R"02)G (JQ3 **** *MP,R1CU#?TJC(NQSZ'
MK6E(/](C^C?TJ*XBR*:=G<'JK%#'K2,NY2#3B".#U[<4W_.*ZDU)&.S(D<JV
MQOP-75<'D56=0XP>O8^E1)*T3;7_  -82BTS1/0T&^88S7/^)?$<FCLR1P+.
MRP^>[,Q 52ZH/Q))_*MI)0161K&AQZI?+-+*5A>W-O.@X9@'#J0>V".?4&DF
MNH-::#K7Q/I\T$LDMPJM'($8#)SERBD>N2#TZ8-0KXUT9TD:*ZED*LJJJ1LS
M/NR%* =0<'!IJ^$].2XM)X_-#VID*Y((?>6;YAWP6./3-&D^%+2PC@CCEEDB
MMIDFA7:JE-N=HR!DCG&#Z57NBU-G4M4ATS3VO+MG2'*C !+98X"X]<FL4^)$
M.K36OE","!)4W B0@JQ)9?X0,=:T6T^>73)K.ZGFE>5V8S84X!;(4 @@@#CF
MLZV\&:?&ZS1O<QW*1"%9M^7,>""I]CN/'L,5*:ZCU+-AXHL9[Z*T+2&>3:"1
M$WE!F3>%W^I7FC6M2M]#NK-O*40W<CBYD)Y14C+\#OTZ55U+1X-,TUUM6E$B
MRK+&Y.=LBQ^6IQW './6IY-(MM4L+6._:68Q;LL&P7+(4)/U!/XT70:D-]K&
MA6FLO?$.VJO#';;X86:1T8&15 'L"?:K4?BS3&FM8H)Y93<>6$*1$@%\E0WH
M3@_E5:P\+VUK?QW)NKR>X5T?S)6!^XA0#  XVDUFQ>%;S3]<@GTUXQ!%Y<<<
MLA5ML0)+J5(R6.3R".H]*KW1:FWJ_B6PT[4%L9YC]K)7(53A2P.T$]B<<"LN
M34]'\2:?IL=]87,SS$7$$7E.'BP<+(64Y0<XSGUJ_?\ AZ*XUS^TXF9+DA1*
MNU2L@7[O4$@^X(IVG^&HK,P-;W]\K11^3N+*2\><A&XZ#)P>M3=6T"S+?A[[
M+I]]-H=E9+:06\*SQ!/NNK$Y//.=V<_6N@P!DXK%TO26M-5FO9;J2?-O';Q[
M_O;5))9CW))K1GGV@XJ6]2DATLBHO'%8M]<]0#2WMV>0.M9,TN<YKIH4')W9
M$YVT$FEJHQ,D@1,EB<4V63/ ZULZ%8$8GD'S'[H]!ZUZ$Y*E&[,HKF9I:59^
M1"JXYZM]:U;88,G^^?Y"D@CVBG6_67_?/\A7C.3D^9G2E;0FHHHI 07ES%:0
MM-<2I%$OWG<X [=:DSD=>OI27$$-S"T5S%'-$WWDD4,I_ T/Z"@#F(_&NGDP
MM*LT$$TLD*2.O *$9R!D@<]ZO/XGTF-Y5>]C!B<1M\K$EB2 !Q\W((R,C/%4
MX_"NE3^=-OFG:X+^9+YVXMN&TC(],8J:#PKID-PDZ+,'CE66-3)D188M@#L,
MDG%%@)/^$HTTZ3<ZB)9C:V\IA=O);.X-MP!C)YXH?Q7HZ22HU^@>-E1E"DD,
MW08QR<\<4V3PUILEO<0.),3NSAO,^:,LP8[#V&1FDM_#&GP7/F1++S.MR 6X
M$@YST[DY- #X_%FCR78MUOE\YG$84QL!N+;1SC'7CZU'=>*K6WN;R(QRLMJC
MEY<J%9E&2J@G+''H*D'AG3@V=LI.X/\ ?[^;YG_H54;GP_H6HW]Q.;C?+*SH
M\<=P-HD=-K<=F('Z4 6[WQ3:V>KV6GS1S%[I$974#"[SA01G/7TS6C'JMJ\H
MB,RB1G**I.2<''\Q6=INGZ3;7S3)="YO+:(0-)-,KR1*#GG^[5Y-(M =R*W,
M@EY;^(-N'ZT 2-JMF'*FZCR)/+(ST;N*A_MVQ\Z5#<(JQXRYZ$G/ _(TD^C6
MLBJ")  S,=K8W;CEE/L<57?0+%$W.\H\L@HS./W8&>!D=.2.: +KZS8JVW[2
MA;(7"Y/)..WO5FTNX[M=]O()(\D;AT)JF^C6I:-E$B-'G:RMC&6W?SJQI]C'
M9!UB+L)'+MN/?VQQB@"Y12XI&H **2,AERO(/(-.H 2BEQ1B@!**7%&* $HI
M<44 )2C@444 %%%% !5/5O\ D'R_A_,5<JGJW_(/E_#^8H EL_\ CS@_ZYK_
M "ILUM%.8_.A23RV#IO4-M;L1Z'WI]G_ ,><'_7-?Y5(TB)C>RKN.!DXR: (
MKH)]GD\['EA27SW&.?TKFK%].F2T"W-U P&Z!GE4%5P/D!]"".#S72NT5Q#(
MBNK*<HQ4YQV(^M9/_"/VP  DF4?=8 CYEPHP>/\ 9'ZT 0?8M/)C4:G*JB=I
M419E(W9)/!'3)_"GFRT9EF0+#LNE57^8!9,'('Y]:FDT.V=XF4R*(AM*@C#@
M-N .1V-,.@6ZQB,/-G(;<&Y&#GY?3KVH 9-9Z62L$MS^\1^,RC<&( Y]Q@?C
MBJ]S9:-!9W;2W&^#'[^/S0?-*G=EO5NM:4VF6<LTBLY$LFYRNX9P2,G]!5*?
M0K&&,B6ZDAW*41BZC"8.5&1TQGWH =);Z9<?95$C/*"$^5QO((Z/[<?I4-K:
MZ3$T<BW,D>R3,6^4#;M)'RC^[RPJ_9Z):V\WFP[LA@Z],CUYQG!HMM%AB5!D
MDJ<K@8P-Q('_ (\: *KV.F23S$3>6;B42M^]'S8&?E]!W^M2F+3=1N+6-I#<
M20H[1,6W!@1M8$CJ>:<N@6J@A&F4-&8G&<[D(QC]*=I^GVMM<6TL5PC@*Z1@
M;1O8GYCQU/% %JRTVWLU@$",HAB\E!G/R_U/O5!O#=G(8S<B29T"A6)Q@*V5
MX_0^HK7EN[:!E2>>*)F^ZKN%+?3/6IPP/0T 8\V@6<OWO.4D;3M?&5/5?I3+
M_1$N;J.1694\]9Y ><D#''L<#/KBMS-)N% &%%X;MA"/.>5Y0>) WW1SP,CI
MR:G71X78&<L[+(TBD?*!G'&/HHK426-W94=69<;@#DC/2G!@>A% &1<:';3(
M$)E5=SLP5N&W'+ \=*:=!M&D=@CKO7:PW?>ZX.?49X_K6U10!DP:-:PXVB1F
MW;RS-DLW/)_.JL/A^..>>3>ZAA&L7EG#1[!USZGO7044 9BZ3; $E78D@MD]
M<'/]:;+HEG(9M\;?OEV. >-N0<#\A6K10!@GP];89?,NL$;=PDYVXQLZ=,?_
M *Z>/#]FGD[?.Q$3Y8+9"@\E>1T/^36W10!BC0+;R[A=\_[X*I^?)51T"\<#
M]:5?#]B%E4)(JRDLZAN"Q_B/OBMFB@"&U@6 2;,_.Y<Y/?\ R*FHHH ****
M(6_U\7T;^E2.,U&W^OB^C?TJ:@"A<0GJ.M5/9NM:[ID52N(.XJHRY1-7*M-=
M ZX84[VZ$48Q72FI(R=TR@XN(),EM\?; YJ6.YE;[J59Q430]XSL-9RI]BU)
M+<DADF:4!XR$'?%4K^6?[?$B.R*V 0#Q5CS)$&'_ #%,RLLH=L%E/%9-/J7<
MH7C2J[H99/E;'!K4M/M)TI#""9QV;C(IZJFXE0,DY)Q4R\>_XTK"U(4CN9SL
MNHCR.20-M3PV?E]6PO0**FAD/(8G%#'-(8*!&/EYHSGG/'I3<^M1LZ^N* '*
MF6R?6IE8(*JM<@# -599V/3(JDG+83=B[/=!0:RKFZ+'@\5%+(<G)JG-+BNN
MCANK,Y5.P32U3EDS1(Y8X&23VK4TO2BSB6X&?1/\:[I3C15V9).3T(]'TTS,
M)YP=N?E7'7_ZU=7;Q8I+>#;C-6E7%>35JNJ[LZ(Q4=!0,5';]9?]\_R%2U%;
M]9?]\_R%9%$M%%% %/5;5[VS>WCN9K5GQ^]A(#K@@\9_+\:L*/EYZ]*KZM+=
M06,DMA:BZN5QLB+A-W//)]LFK(X7)&..10!P<GAG6)='@L'FM4C@ED9#'(X#
MARQ#''\2DY Z&JFM>&]4M[>>6&>6Z:=]LNR1LL"P*DC/0 $8'<TMAK^MEXY>
M9FO+]H?*EB;;:Q9P&/RCV[GK6EJNL:P=4O;"TMBB1S1QK<!#\V_&,'V ;)^E
M $9\.WUU9Z/()#;O:Q.@CE<E[?<FT,&'WF!&>?6H[7P?>I8K'/>-YBVLD4>9
MW8+*Q^_V[?EFB+Q/KDC6!&FJHN9=FUHWRVU@K_[N22P)XPOO3M:\5:I8W6K0
MI9F1H9D2W\N%G5E()(9O[QQCC@<4 6]*\+3V-_)*ETRPR+-&0)78A&"[ -Q[
M$,?QJC8>&=8LHX/+DL'-K-$\40RJML5E9B<9!;=G'/-,M-:UZWU(J\8E2[O'
M"^<K*L2*% C7 Z\DY/7%/TOQ'K#3Z;;W<4+2WBM(TGDL@A$9/F*R]<_=P1UR
M: +VG>%7MI-4O&F!OKLRB,J?DC5B#CID\CJ<UJ1Z9=1_:-MRX::%D)+L<.22
M&'I@'''I4>J7MY'?1&VCD-K&F9G4#DL/EZ\\<'CUJA!?7?DQ*]W<-;,$\^Z\
MOYHG(Y4<8QG'.#CI0!:DT>]26/[/='RE(QND8E.F6'J>HP?6IH]&N4M+F$W3
M$31JN&<M\V,,>>1GVHL;W%[+]MO)$V,(XX67"LIQM?..2<U4U"[N@NH;KJYM
MY4E6-8T086(NHWC(.3@GG]* )WTO48V>*UN%^SO("/,D;=$H8' ]<\C\:'T>
M^C??;W9,G'$DC$'Y"&S]3@_A4-K>W#W$:7-Y/%:[B89O*P;@ C[QQQ^F1S6A
M?ZJ\,H\A$>-H//5F!^<=P,>W/- %73](O8C'-/=$R+(I"B1B F#E<=#VY/I4
M>EZ5?E8Y+R5HUSN:,3.2QYY/IU' XXI%UZYD5I1;HL$@22(LKY","0S8^@&!
MTR*9%JU^ ^^TF#"7**W\2E2<=.@( ]: )AH=V=S/>/N(;!$K +\J[>,XX()_
M&HO[%U*2^:>6YCR2VS:[@*2"-X&>O3BK"ZK>K=+;O9QY,NTON8*PXZ9'7D]?
M2FS:Y=1W#1+:H668QELG9CJ/F]3^E #]*TR]M;V*620L@0APTS/SVVCMZ\YK
MH@>!FN?BU:\?)6T4LJRNZ?-E=O1?0DU4?6KXR6^;9 D@5L1EB6.XYY(X^E '
M69HS7-PZQ=RC='9HRK@E_F&\9&=N1GC/?TKHE.?I0 ZBBB@ HHHH **** "J
M>K?\@^7\/YBKE4]6_P"0?+^'\Q0!+9_\></_ %S7^59/B>QO;M=.ETY(I)K6
MZ6<I(Y0, K#&<'UK7L_^/.#_ *YK_*H;ZZF@:V^SVCW DE$<A5@/+4YRYSU
MH Y0^'-9-ZLL=ZMO%-/))<(CDX7[T>WWW<'U%.\/>'=4M[FP?5+V:1(/,:1?
MM+$/(<8/;CJ<'IFNNNG9;>1D7<X4E5_O'' KG8-1GDBLMU^$2X.Z67RQ^Z;
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M,5/10!&L850%   P .F*=M-.HH ;@\4W8?:I** &A2.F*393Z* &[?I2TM%
M!1110 4444 %%%% !5/5O^0?+^'\Q5RJ>K?\@^7\/YB@"6S_ ./2$?\ 3-?Y
M5)MYS35@VJ LC@ 8 R.*7RC_ ,])/S'^% #B,]:3;_G%)Y1_YZ2?F/\ "CRC
M_P ])/S'^% !Y8Y! .?:E*\$9[4GE'_GI)^8_P */*/_ #TD_,?X4  3 P#^
M.* @ XH\H_\ /23\Q_A1Y1_YZ2?F/\* %VCTI!&HSQU.3Q1Y1_YZ2?F/\*/*
M/_/23\Q_A0 ; >M&P<8XQ1Y9_P">DGYC_"D\L_\ /23_ #^% #L4;13?+/\
MSTD_3_"CRS_STD_3_"@!Q7-)Y8_R.E)Y9_YZ2?I_A1Y9_P">DGZ?X4 .Q2>6
M"3[^U)Y9_P">DGZ?X4>6?^>DGZ?X4 'EC_\ 6*41@'/]*3RS_P ])/T_PH\L
M_P#/23]/\* ';12;!G/3Z<4GEG_GI)^G^%'EG_GI)^G^% "F-2RL0"5S@D<C
M-+M'I3?+/_/23]/\*/+/_/23]/\ "@!'A1U*NH8'C!%2 8IGEG_GI)^G^%'E
MG_GI)^G^% $F:,U'Y9_YZ2?I_A1Y9_YZ2?I_A0!)FC-1^6?^>DGZ?X4>6?\
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M\*/+/_/23]/\* ),T9J/RS_STD_3_"CRS_STD_3_  H DS1FH_+/_/23]/\
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M%%% !1110 4444 %%%% !1110 55""2YF#%OEVXPQ':K500_\?5Q_P !_E0
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M]G3_ &_^^S_C1]G3_;_[[/\ C4U% $/V=/\ ;_[[/^-'V=/]O_OL_P"-344
M0_9T_P!O_OL_XT?9T_V_^^S_ (U-10!#]G3_ &_^^S_C1]G3_;_[[/\ C4U%
M $/V=/\ ;_[[/^-'V=/]O_OL_P"-344 52@CNH0N[#!LY8G/2K0Z5!-_Q]P?
M1OZ5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%00_\?5Q_P !_E4]00_\?5Q_P'^5 $](W6EIC9SQQ0!P=CH_B2"2:=;V6(W-
MYM*!O,,</F,=YW'&<8'':E%IXI61(X)9+: 2<[%0[@TK9;G/.S:<5U^FWIOH
MI)/L\\&R1H]LRX+8/WA[&L_5M8>RU**!8F:,HS2OM)5#CY,GH.1^M '.._C5
MR%6,H1:E2XV$-+QA@.QZ\=*NVUQK3ZWJFG1WAF@M+?>MP$4LTKKA4(Z94@M[
M[A5[3]<N;MA 8XHKA53S1R=I92V1[' Q]:GM=59--MI[B/=/-&)7\N/"ME2<
M9]>* .=>'Q/>Z?/;WT5SN:W58_+= K.&^8N>"#QQCC%6;6+Q9-<%;JX,,)N^
M2D:?)$ V-ISR#\H]>M:5UX@=(V1+8I/E2P9P0H)4<>IP>@JQ_;\#M D:%I)B
M, N %ZYR?7CI0!SZ'Q?P9%<E9XRR ( XR0X4CHF,$$\U!(?$^F61N&=H[>WB
M):/:K#D2$GUR#Y=;4WBC=87$]M9RHZ*YC,Q"JVT'GGO[5:DU:9B$M[82,)4B
M?+A2Y*Y.!V'3F@#$TF^UJ^T.TEAGGN)!>,MTT2IO1 .%7/RL 2,M]:BAM/%%
ME')'"UP8&D:0JNQGC!D<X3/'0J3GUXK9;7U:*,6D'E NB@L!ZKN&WMPW!]:D
MB\2"6%)/L,\:.2JM(0 2!D?G0!@B'Q;;N'AAS+<7$<L[AP5VA4#  ] ?FZ>E
M4]6U+Q+I=JBWMV\/GMD2%$R@&_<!V.!L.._2NK/B11L46S22F'S2J.#C@$C/
MXT1:]!/=&*6 O'N(1\;@2%#84=2>?:@# >TU^6%VA2X>*:-S&F5"EC*K*7'4
M$KGZ=*Z?PO\ VH!?KJ^YL7!\B1@%W1]OE'3'3WJ'4-<,4=PEK"_F1PF3,HV>
MPP#UI3KQ#SQFS=7A*JY\P;0S' &?3OGI0!T.:,CUKFI/$8$$TB6TBQH,>82#
M\V,XQW'O4TOB&*+34O98B%=L)&'!8@#)SZ'':@#?S17-/XBZA;1@TF\1,\@
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M6+B(R2%7! PH/ZYQ0!TN:,USO_"1+NVM"8SAAN+!E++U /\ %]>*5]=(BWB
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MP"_,%C/\'(_'VS0!JVUQ:2LB121>;MWA 1N4$>@Z<8IOVJP^Z\D"D@L48@'
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M@*P4_..">@JO<:[86\DZO,#Y"!Y2GS! 6V\X[YJBOA:U%O##YLC1PL6C#8.
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M))/ZFK>>E<I<1:HPE\XW)MC!A%8@MNXQNQ_%N[CBNI3/&[K0 ^BBB@ HHHH
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M$([MXWM]L:N%+,V"@R 2X_A'/% '0T5S]OKLT_VIT@B*)Y?E 2?,^XXR?05
MWB69%Q):(CG!4F3Y<9(.3C@Y!P._% '3DXH!S7)3>)YUF=UMU\E00$+?,#N
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M2BB@ $UN#D<'_</^%!GMR,'D?[A_PHHH #+;'.0#NZYC//Z4UWM'4*Z@@,&
M*'@CH>E%% #C-;GKS_P _P"%(9;8C! /.>4/7\J** %CFMXHU2/Y$48"A" /
MTI_VJ+^\?^^3_A110 ?:HO[Q_P"^3_A1]JB_O'_OD_X444 'VJ+^\?\ OD_X
M4?:HO[Q_[Y/^%%% $32K)<Q%"3@-_"1Z5<'3FBB@ HHHH **** "BBB@ HHH
(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image00021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $- F<# 2(  A$! Q$!_\0
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M*X&K;F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ3J)RDM.G]?J2T445YAT!1110 4444 %%%% !1110 UG5,;F STR<4WSX_\
MGHG_ 'T*JS'_ (FEH/\ 9D_]EJ]5-62$F1^?%_ST3_OH4>?%_P ]$_[Z%244
MM!D?GQ?\]$_[Z%'GQ?\ /1/^^A4E%&@$?GQ?\]$_[Z%'GQ?\]$_[Z%244: 1
M^?%_ST3_ +Z%'GQ?\]$_[Z%244: 1^?%_P ]$_[Z%'GQ?\]$_P"^A3MZAPA8
M;R,@9Y(IU B/SXO^>B?]]"CSXO\ GHG_ 'T*DHHT&1^?'_ST3_OH4JRHQP'4
MGV:GU7O#CR/^NJT))Z"+%%(IR**0QLAJ'3?^/*+Z?UJ67I46F_\ 'C%]/ZT^
M@NI9HHHI#"J&H:O9V,GES2$R]=B#<0/>K]>0?$*TOKF/5;6T!-T\P?:6VF2/
M.< _3%=F"P\<14Y)NR+A'FN>F6NN65Q,L0=XW;A1(A7-:9( R> *\@\/1WEG
MX5MK;56WWB@X&[<5&?E7/<BO2]32[D\/2)"EJ]PT(5UNR1$01\^XCG&,T\7A
M8T96@[ZM?\$J<%&S+=KJ%G=V7VRUNH9;3!/G(X*8'7GIQ@T^SNH+VUCN;2:.
M>WE7<DD;!E8>H(KY)O[K4[.#6]/T:ZE_X1=KE1<M:[W@0D] Q&<=O]K Z\5[
MK\+DU*VN3;6R6!\,+91-;O:NS(9"225+#)8\EL]#CWKS,-4==R6BY?/?6VG=
M'LYQD\<MI0J*3?.]-+65KVEVEKMVU.Q\4>=_8\@@9E)8!BO7;WKR6TN=4_X2
MZ2R-N8[9,LK!2"JCHX;W->VS[#"_G8\O!W9Z8KE(A ;H"0M]FW=^N/>O:P&(
M5.$HN-SQZ<M+'1:/-+/IEO)<?ZUEY/K[U<I%P%&W&W'&*6O,D[MM&3W"BBBD
M(H:?_KKO_KX;_P!!6K]9^G_ZZ[_Z^&_]!6M"KG\0H[!1114#"BBB@ HHHH *
M*** "N+^+>M-HW@ZY,:3^9=?N%EB./*R.I/X8]\UVE5]0LX-0LIK2\C$MO,N
MUT/<4GL:4I*$U*2ND>"_!WQ%JS^+(++[;)-9W!96CF8E0 I;Y<GAN.E?05<M
MX:\":)X=U"2]L(9&N&X1I7W>4,8(7\^IR:ZFE%-+4WQE:%:IS4UH%87C;_D7
M)O\ KM!_Z.2MVL+QM_R+DW_7:#_T<E=.&_C0]5^9Q3^%F[7B_P >-!@M;F'Q
M-$BO&4%GJL"D!I(&.%<#U4X&?7:?X:];M=5L+NXG@MKR"2:!_+D17!*MZ8_/
M\J\@_: =QI>I?PB3[);)G@$^87-=V2\SQ<>5^3]&[/\ ,RQ<;4W=&9X7\?:I
MX-T?3]'U^VGBMD)^R7\\3".X@.#&,@''!/T& <8KUWPUXD@\1Z;-/;(-JJ07
M1@R'CL16E;Z;;-H=OI]W!%/;K D312H&5@% P0>*IZ'X9TCPS97T6AV26<5P
MQFD1"2"VW'&3P,#H.*,3BL-B$Y<EIWW6SU_#\?D*G3G#2]T?-GB3P]>Z=:6-
M[<JK6M\AFB<.<'@?*1V//XUZK\!3JRV-TLUN$T=R9(W*X_><#"G^(8'/8'\:
M['PS-%:_#S3[JXB$L=O9B4K@$\ GC/>NGB"K&HC4*N. !@"O/Q-.U><O-_F>
MJ\>ZF'5%QULM1U8OC+4[K1O#MUJ%D(&E@ 8K,"5() [$>M;5-D19$*2*KJ>H
M89!K)G)%I23:.*F\9S:9=:G#J=IYJV[LL4L! #$"+(()) S+G=Z?2M&^UV]?
M3-&O+"*"$7UPD#QW*EBNXD9&TCT/UXZ5T301,6+11DMD'*CG/7^0I5AB6-$6
M- B8V*%&%QTQZ4K,T=2&C4=3D[7QM%>WQM;&Q>XD^T^0I250K+M=BV3CLC<?
M2JUC\0(KMK()IL^+N0K$5D!RH*@GZY?I_LD^F>Q:SMF1U,$6'SNPH&<Y!_F?
MSJGI>A:9I4'E65I&B;Q)S\QW   Y/<  4K,KGHV^'\3&_P"$M4>!9-?N+<KA
M3F*!Q(5.=HR<<8)YSTKQ7P7XTU^/Q)9*FISW44LJ1M%/*S(VX@$')^7KUKZ1
M^SP^2\0BC$4F=Z!1AL]<CWKB],^&&@:?KBZC$L[A"&C@=\HK Y!XY.., TFG
MH=&'Q%"$9J<=]NOR.ENO#VC7>H-?76E6$]XP ,\ENK.0.G)&:\J^.D-FVH>%
M=$@A@ACFN)+N5$C #+&HZX[?,WY5[37-:]X,TS7->M=7O3<&ZMH&@C57PFTD
MDDC'7D]Z]/ 8I4:\:E5NR3MZVT_$\FM3YXN,>IJ^'R3HMGF.*+]V,)$FU%'8
M =ABM"O&+SXNR:=KT]I;Z>DFF6X\A S%79@<;L@$ <=,?C7L-E/]ILX)]A3S
M8U?:>JY&<5P2FIR;1V5<-4HQ3FMR:BBBD8A1110 4444 %%%% !0>E%!Z4 9
M\O\ R%;3_=E_DM:%9\G_ "%;3_=E_DM:%7+9?UU9*W9G:UJL.E6XDE!>1SA$
M'5C_ (5SJ^)=2DD#)#;A/[F"<_CFNPDBCE7$J*X]&&:R[S0;68;K<?9Y>Q0<
M'ZBMZ,Z,5:<=>YR8BE7E*\):=BMI7B>UNW\JX*0R@X)#AES[GM^-= #D9'(K
MRY/!]CHNL&\:"6&1BV"CDPMGKQ_0UNV=[=6S"/3W:;/2$C</_K5K4PT9>]3_
M . 8T<7.'NUO^"=I7+^./&-MX06PEO[2ZEM;F;RI+B)<I /5O?V[X/I726YE
M,"&X"K*1\P4Y ->9_%[1=1N[-+30[34KV?5)O*D8WDGV>W'!R8\X XZXP,>N
M*\VJ^6$G>S7E<^@RRG"OBJ<*JO%[W?+9=[^6_P"!MW?Q'T6/Q1IVBV3-?/=
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M:HYJV&IU%V?<OT52UK5;/1=.EO\ 4IO)M8RH9]I;&2 . ">I%5E\2:*T8?\
MM2S .WAI0"-PRN0>02#WK!1;5TCHNC1EN8(F999HD95WL&< A?7Z>]'VF#Y/
MWT7SG:GSCYCZ#UK@M=L=$O-:O6DUNV@:Z^SW&98XW19 55!O/56PO[L]<Y'6
MJ36>C2V?FCQ98_8$NVU+9Y,60=W."3D#>.,=P!R.#JJ:MO\ @3S'IRLKC*L&
M )'!SR.M+7&^$+C1?#NDBPAU.::$AM0::Y3 C29BXWN%"@G)QG!/-;%EXHT>
M\U!K**]C%P'V(K';YI^;A/[WW2>.U0X-/0I21M45#=7"VT8=TE8$XQ%&SG\@
M#3+*]AO!)Y/F QMM=9(V0@X!Z$#L14\KM<=RS1112 *#THH/2@#/D_Y"MI_N
MR_R6J7C33;C5=":WLU25Q-%*T,C;5F57#-&3Z$#'IZU=D_Y"MI_NR_R6M"M5
M-P<9+I_F3:]T>?:IX>U2XO;34-*T^VTV>&W:W6$2+B-9'82?=XSM(?CN *T_
M#WAJ>T\.)I-ZT1L%CEC-H$^]F1BIW@],8R,4_P 9W>J1:KH=KI)F/VEY?-2)
MT0L%4$?,ZD#'TYKE]0\3ZGINI&>*4,D?VU1;SEV$[+.BJJX_C(R%[#GBNV*K
M5H))KNN^E_\ @F3Y8MW+EKX3U..XT'?:VY^SV]E&\_FC=;>26,BKQR'# <?C
M6WHWAZ73=%\1V4,$<:7=Q.]L@?(*M&JC)]20>M9M]XNU:W$DC16%O;&\GM8Y
MIUD*QB,,?GP>K8 &/?KTK/A\5ZH=:G1E*+>K!BT?=YMONMB[,G;"L.<COVJG
M&O43O;O]S_K^F).$2[I_AS7+>[L93+*BV[62"-;H^6(UAVS#9G!R<=NW%5M)
M\*ZYI^GVUO$[JOE6K2Q_:B5$B7&Y]HSP/+XP, ]*?IOC&_1],L56*X8V*M-)
M<!D82_9S("S9Y4D $[>_7(Q5C0_%6IZCJ^B)/+9V]O<QSK,AA8!Y4=1M1MQ!
MX)(()!Y_!R]NKW2_X:_^0+D*.G>&/$-O"\*;X8@T99?MA99"+K>64?P8CR"!
MUS^-2V_AK6K.*VCM(KA7BU*2X<F^8Q3(TF0S#<&&%/0=P<@YS6AKOB2]M/%T
M:0+<'2K1XH;LK#N0M+W+]1MS&>/[QS5.7Q;JD]C:7,5QIUKNU%;>>)HW9K9#
MO&)<GJ2HY&.M'-7DKV6NO4+06AJ^(/"KZWXL@O+AA'8Q6T:EE52[.LN\ $C*
MC@<CZ5G7'AW7?L<30SSF]9[YI2UV2%WI(L(7G  RO3I18>)]3BN+>T6W$IOK
MR:&W=][[2DY#[CV C^9?IBJ;^.-1O(+Q[,VMO##<6Q2YDA;'DR2LIWKN."-O
M/(.#T%3&-=6BK67_  W]>GD#<-R]#X<UNSU!+BTNKI_+NHF59[YW0QF'$H()
M.<R8_IBH-'\/>(F,<>I33QVKWD<\D<=XV53RG$BAMQ;:7*\9Z>E)?>+K_36O
M!$D+!;BZ96N2["7RRFV&/'1FW''4<=#6M8>)=2G\1Q6DUM;K92W<UHN WF*4
MC#AB>G<C%$G746[+;\@7)<C\!Q74NHZG<2W4\^GV[M:63.S$2)O+LQSU()"9
M_P!BNJU#[L/_ %U6K55=0^[#_P!=5KBG4]I/F-DN56+$?2BB/I16)0V7I46F
M_P#'C%]/ZU++TJ+3?^/&+Z?UI]!=2AXA\.6.OJ@O_.^2.2)3&^T@/MR?K\HP
M:I7'@S2IHC&#=1!GD9O*F*$K(%#QG'\!"KQ[=:Z6BM(UJD4DGL)QB]6C!D\)
MZ7*<21R-']H>X\LM\I+1>41C^[M[57C\%Z='$-D]^MRLBR)=BX/G)A2H4-_=
M"DC&._KS5G4M<DLM2DMWA0Q$PI')NZNS8*G_ (#R/7!IUQXBACB1X[>>4M&)
M=J[<A=I;/)]%-"KU%]H.2/8H)X/M[BZUZ;4BK_VF$CQ"2I2-.AR?XR0"3TX%
M7K/PQ96FKC4HY+AKDJ!(7<,)6"[0[<?>QZ8'M3/^$BVW126TE2% !*Q*DQL7
MV\\\CD=,U+IOB"/4)H8X+2Z7S=S*TB;1L&WYN>H^8=*'7J/2_P#7](.2)!+X
M0TJ66>21)2;AYFF&_'F+*!O1O5> 0.Q&120>$;&!;0Q7%ZDUJ[,DZRA796QE
M&( !4[1VSQUJ34->>/<EI:L\IE\J)G("N1(J.>N>"PZXS46K>()K"6^B\B-Y
M8RGV<9(\S@%\^FW.?IBCV]3;F#DCV'S>$]/EL;:U#W4:V\TDT;QS%7!D+;QG
MT.XBF)X.TV.&-(9+N(Q- T;I+AE,*%%P<?W20?7-32^(HX6E#6\TGE*[NR <
M*I;L3_LX^I%%UXB6&Y%LMK(UP=@V[UP"712I(R,C>.*/;U/Y@Y(]ADGA/3GM
MWA)N-CPW$!Q)SMG;<_;KGIZ5&_@S2V>^*_:$2\0I+&K@+D@ L.,@G [X]J<_
MBF)X)6MK2Y=QO\K<NU9 H8D@D@8^4^_2MVUD,UK#*0 70,0/<4*O47V@Y(]C
M(G\,64M\UX)+J.Y-VMYOCEP0XC$>.GW2HP16Y1142G*5N9[#22V,_3_]==_]
M?#?^@K6A6?I_^NN_^OAO_05K0IS^(([&9-_R,UI_UZ3?^AQUID9&#69-_P C
M-:?]>DW_ *''6G1/9>@+J<A>?#OPY/9F&"Q%LPC:..2-V_=AA@X!./?ZDGJ2
M:D@\#>'[6S474#3&.((\TLSKD  9P" .%49'H*ZNLKQ/%++H\HA!8J0Q [@'
M_)JX2E*2BY!&$6['.IX:\%I'#&ME&(HF5D4F78"N<=3CHQSGKWZ"MJU\+:-#
M:6\5K Z112_:(FCN) P;:%R&W9QM 7&<8KS70K*^LO$&JWUS=K)9W(_=PAB3
MUR"0>!@<<5ZGX926/1X1."&)9E!ZA2>*[,9AU02<9WV_+]#6=*,5>QF+X#\-
M);M"FF(L;!@0)''#9![^C$>U=';0QVUO%!"NV*) B#). !@<FI**\]R<MV9)
M);&;>G&N:<3P/+F_]EJ=[^+I%NE/^R./SJ"\YUS3O^N<W_LM2K9,6.^7:O8(
M,<?6J=K*_P#6K%K?0BDNYR,YCA7U/)J#+3=6GF]< @?I@5I1VD$?(C!/JW)_
M6IZFZZ!9]3*2TE/W((T]V//Z5,+.8CYIE7_=3_&K]%*X[%,6"X^::4_0@?RI
MXL8,8*LWU8U9HHNPLB 6=N/^62_E2BU@'2&/_OD5-11=A9'E?C?Q/J_@7Q4M
M_J4$-[X7NU$<4<**LD$@&>_4G\B/3%<'\'/ 5UJ.I>(-4O+"6UTS4-.N+>S>
M60.I%S(7;:.N%QUP.M=[\1? W]I7>KZ]K-_)>6EO:'[%98VK"V.2<=?7UYYZ
M"NB\ ^#IO"%QJ4,&IRSZ/,X>UM)!DP?WOF_STSUKDC3K*:F[\MWU]/P[(^EK
MXC+Y8#V=-1]MRQN^5V:OLNTEIS2LKZZ]_#_!?PD\2Q_!CQK8:SIZ1^(+QX19
M1;UW,+4+Y>"#CG! _,]:V+'X>^)M*^$WA6_AT\S^*]*U@ZW<V0<*\P=VWQAL
MX#%"OY5]$T5U'S9Q7@+5-3\2P7UUJOAN^\.VZ2A+5+J;]],N/F9D_AYX'K74
M&Q_N3N/]X U=HIW8K(SVM)^@:*0>C BH&MG3DVY!]8VK7HHY@Y3'6XDCX$[J
M?[LH_P :L)?2K_K(P_NAQ^AJ^RJPPP##T(S59[&$\H#&WJAQ^G2G="LQ\5W#
M*VT-AO[K#!JGH_\ Q]:O_P!??_M*.K,%JT<N7974<@XP0:K:/_Q]:O\ ]??_
M +2CJEL[?UJ&NER?5M,L]7L7L]2@2XM796:-^C;2",_B!7+WWPYT6:XMY[;S
M[1XYEG=D<L9"HQR6S_\ 7R2>:[2F31+-"\4@RCC:1G&12C.4=F$DGT.#N= \
M%(RP2VIE"N&XDE<9'3G/(&!CZ"M&W\&>%KQC/!:AWVA-ZS.&4!BPQSE2"2![
M<=*T;CPY;[<VA*-_=<Y!_K7*Z;I-_HFJ3R7&J73HY)CCE ^7GLW<>U=BC"HO
M<D[GGNM6I2_>15O(ZB\\(:+>0M%/:L8FMTMFC69U5D3[F0#@E>S=120>#M#@
MNK>XALMDMO()8R)&&&&[!QG_ &CQ[U:TG4;B[DV/$K*.LJG %:U<L^>#Y6SM
MIRA47-$*SM-_Y">K?]=D_P#125HUG:;_ ,A/5O\ KLG_ **2ICL_ZZHT?0T:
M***@84'I10>E &?)_P A6T_W9?Y+6A6?)_R%;3_=E_DM/UI9WTJY6TW>>5PF
MUBIS]1TJY;+^NK)6[+M&*YL0ZQ9+,JSRR1*$*A%#D!I&W!2V2Q5<8S^O2J=U
M!K-U!*&%Q&TT6&9, CH!QT!(SGWS4%'88HKF;5M:^V"$DQ6R3[2%B!Q& ^,,
M1C!PGJ03VJL)M<N6\R2.[BCQ(%BVKU**5#<#@'< ?U- '7XHP/2N;CEUN:Z,
M9,L,9D(=_*7Y!\^ F>HP$Y.>3^ =>)JMWI%N$WB[:5#(K9C5?W?(RA!V[N^>
MOTH Z+%&!Z5RD#:R\D<4RS&&/R2 R_,X!C));IG[^1D_XQ>=KEPXD=+N./\
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M?_%U?)"*7,WKY?\ !%=]$=#17/?\(=HW_/.]_P#!A<?_ !='_"':-_SSO?\
MP87'_P 72M2[O[O^"%Y=CH:*Y[_A#M&_YYWO_@PN/_BZ/^$.T;_GG>_^#"X_
M^+HM2[O[O^"%Y=CH:*Y[_A#M&_YYWO\ X,+C_P"+H_X0[1O^>=[_ .#"X_\
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M0GDVFIP*\K1P:A-%'YDC.54$8&6)-#A#E<HO;R_X+"[O9G1UF:/_ ,?6K_\
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M&R6.1G';ZU/_ ,(!K7]R+_OX*?'X%UV-75/+59  P$@^;!R/UKW)5,+;1Q_
M\6-/%7U4OQ+);Q.&0'53\SE.&8XQN]N?N'ISTJE;G7K1IDAU*..225Y742D;
M_F"M)GIC/7OUK0?POXJ=2K7.022?WB\YSG_T(_G5.QT/Q#J$=TL-QN2&X:&0
M,Z\NI&?PSCV-8J5.WQ1M\C9QJ?RS_$)KWQ'##/*VJ/MA#$C<VXX;!XQG\3Q6
M5_PE6M?]!"?_ +Z-;\GA3Q1('WSAMZE6S(O(/4>PJE_P@&L_W(O^_@K2%3#+
MXW'\#.=/$/X%+\2E;>+];@F5Q?2/@\J_S _G7KOA_4AJVD6]Z%VF1?F4=F!P
M?U%>9P?#[5WE59#!&A/+%\X'X5ZAH^GQZ7IL%G 24B7&X]6/4G\Z\_,I8>45
M[*U_+L=^71Q$9/VM[>9<K'T+_D(:[_U^#_T3'6Q6/H7_ "$-=_Z_!_Z)CKS(
M?#+^NJ/4>Z-BBBBLR@HHHH **** "@]**#TH SY/^0K:?[LO\EK0K/D_Y"MI
M_NR_R6M"KELOZZLE;LS+O7])LX+N:YU"VCBLY%AN&+C$3D A6]#AAQ[UA>+?
M%.K^'Y#<+H$5WHJR01F\6_57_>.J9$>PYP6'?FKFN^#=,UJWU""[-PL-_*D\
MZQ.%#.JJ >GH@_,U1^*R"/P%<(N<+<68&3G_ )>HJ@H[*BBB@ HHHH ****
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MO_05K0K/T_\ UUW_ -?#?^@K6A5S^(4=@HHHJ!A112;AZB@#"U/_ )'+0O\
MKVN__:5;U8&I$?\ "9:'R/\ CVN__:5;VX>H_.M:GPQ]/U9*W8M%)N'J/SHW
M#U'YUD4+12;AZBC</4?G0!STG_)0X/\ L%2?^CDKHJXJ>^OU^)$071KIH!9M
M +D,OE;3(K;\]NF,=<]J[3</4?G6]:+2C?L1%[BT4FX>H_.C</4?G6!8M%)N
M'J/SHW#U'YT +12;AZC\Z-P]10 M%%% !11D>HHR/44 %%&1ZBC(]10 449'
MJ*3(]10 M<]X.^[K7_84N/YBMZ9RD3M&HD< E4W8W'TS7(?#^^O;B76$N]'N
M[!#>RR[[@J,EB/E !YQZCBMX1;IR?H0W[R.RHHR/449'J*P+"BC(]11D>HH
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M+*SMKA;B-G8S%@000.,5Y\GQ@U5=5EOQIECYLD"0%=SX 5F8'Z_.:T?VC/\
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M26NXXTG?4E_X2>R\S;NGVYQOV<?XUL1R^8BNC[D89!!X(KR&;0;Z3Q/#J:7
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M3Z***\0]$S]/_P!==_\ 7PW_ *"M:%9^G_ZZ[_Z^&_\ 05K0JY_$*.P4445
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MWFADU4+C@#',?M4\OCR*T9=2T[1([F]OM.:XNXX-YG\R(82-L)R 6QZ@$G&
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M9?"VI6MF6CN0_DVDB1QP2LI1\2':O&6!+KU(.1]*%%/J%WV.V2PMHQMCL[=
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M@@AM;=8H"#&/+7Y6'\0X^][]:DCM;>+;Y5M!'M8LNR-5PQZD8'4]SWJ:BE<
MK0T__4'_ 'C6?6AI_P#J#_O&HGL4BS1116104'I10>E &?)_R%;3_=E_DM:%
M9\G_ "%;3_=E_DM:%7+9?UU9*W9QOB'P-'JUMJ\$=Z;:/4KE+J3]UOPRHB]S
MS]W/U(]*Z^",0PQQ@LP10N6.2<#O3Z*@H*\]\=^+_#\D.N>&]7M]3DC\H6UP
M;>,8/FA>%;/!Q(.N.^,XKT*J-YI&GWL,T5U9P2QS2+-(&0?,Z@ ,?<!1S["@
M#+\->*M-UN\DL=/6Y#P6\,X,T>T/'(H*E3WZ@'WKH6(526(  R2>U4=/T;3=
M.N&GL+"VMYFC6(O%&%.Q> O'88''M5]@&4A@"#P0>] '*WOB/0]8TV2QD>\:
M"_BDB^2UE!:)E ,@^7A,.,/TY'-)'XG\.^'])L;=[QX;.'35N89)(W(:W10
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MDJ$EF103C<1UQZ_A2L!-141N( I8SPA5;:3Y@P&]#SU]JEH&%%%% !6AI_\
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MY^[+_P !&_\ CM&-5_Y^[+_P$;_X[6EBC%'M'Y?<@Y49N-5_Y^[+_P !&_\
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%*@H__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image00022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $) EH# 2(  A$! Q$!_\0
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M //"+_OD5-N]C1N'X^E $/V2W_YX1?\ ?(H^R6__ #PB_P"^14NX$XYHS]:
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M37FHRW\.F:0/)*D>9*R\8]J&".HN];L='LT-ZIVL<!L9!IEY.][9*MCMABD
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M[ZE1?<=(19LOD1L6Q]Z0=3[5&74JC;Y3_?ST!]*7[1.S AFD'1=W.*B7)Y&
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M<Y]@/6O"K6\O[/Q#<?V5>>)[6UN+T3M;+IBF(;B,C.>GO6M&ZNT<]2VB/8?
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MV;?P.#V(J2,  XPS,,_-VI4N9('+-\RXX9JTE!4WY#;YO>1]B?LKQ>3\,WC
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MFXEMK7SD5L/_ /6I/"^B&>^;5-<M]UQ"<*#UQVS7076RZ66..,(&^>,8[BI
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MRG<V.OUJQH=MF]=LC$))!Q3>KNBN:7+9E^UTZ.&-9KQMTI&=N.!]:66<;0B
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M\<R #)DE'&?I71>)8IY]&MYPYW-&'X&&)^E935T5 S?#]R^GV\>D:GF9'?Y
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M,7E-\']26*3*_P!K1_._&3M:N":*1E,DI/'=CR:[/3MI^#FH^9_J_P"UXO\
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M>L@<"J.>>K%HHHH$%! /4444 )@?UI<"BB@!-HHP*6B@!,"EQ110 8%&***
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MRE[XIEGT]WTNT9Y%MC/)N.#'[>YKHM.E>;3[>63.]XPQR,')%%@+6*7% HH
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M5FZUK4;.2>QDF,D@N4A^T!!E59<].F>,46"Z-;_A'[>&X62.[FCB2<W4=N7
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M.&6TB:.(?(I'"CN!6G13NQ6,^XT^TFMTAEMH6BC'R(4X7Z#M0MA9^4J"VB"
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2K3P,=***0!1113 **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image00023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" +* B$# 2(  A$! Q$!_\0
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MV&1)HDEB8-&ZAE8=P>AIU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <=X_P#'
MMGX1FT^Q2RO-6UO46*V>FV2@R2X^\Q)X51W)_P :A\ _$&'Q3J>H:/>Z3?Z)
MKU@JR3V%XH)V-T=6'##D?G7'?$Z:3PE\8_#?C;4K6YG\.KI\NG7,\$1E^QN2
M65RHY .<9^OM75?#_P ?+XV\0ZM_9&D3KX?M418M7F5HOM,O=%1E!('K^G-
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M4!W9ZY&2>.M<S>_'V-[61;'1'CN2/W;2W"L@/N ,XKVZ:SMIWWS6\,CXQN=
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MJ6H-+()KV4;CPH_HHKEK8J-/;5G?A\#.JUS*R_%G3RWHOX;&94*+]M50"><
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M*00",X(Z&@11AV8(NYL;CCDXZ9H X&\\=7&G7-[%=Z?O2*YE2!H#GS$1MOS
M_=Y(.[GC)Q2>$?$D6H>)IVBTFSB6[;R?M=O*'+2*KE@6QAD/EDAACJ,BN\NK
M6"ZMY(;B))(I%*NK#@@]:;8V-M86L=O9P1PP1C"(@P!_G)H Y*U\=I<ZMI]E
M_9DL<=W,]LTDL@!25.'7;@DX;*D\#CK43^._L]Y<075B)%MV?>T<@W[58_.(
M\9*!1RV?O<8KN=B[@=HR,D''3-)L7=G:N<8SCM0!R$WBR6ZT>PNX(AID=S=F
MUDGO0"MOM5BQ(R!]]3&,D#//IG&OO&-U;Z;>W:W6D![=-T=L86S< 0[_ #UY
MR%)SC(Q@'G->D21I)&4D171NJL,@TC0QLVYHT+;=F2HSM]/I0!P>L^,HXM>7
M^RIM-U98[5I5@MAYLRYX#!E)R"P *JI.T,Q/&#N^#=<N-9LX9+M(U>2RMKOY
M%9<&13E2K<C!4XSV(K<CM;>)E:.")&48!5 "*=%;Q12221QJKR$%V Y; P,_
M@* )**** "BBB@ KSS3Y2?C5J<?G9"V*XC-V3C(3I%C ]^_(/>O0Z\UM[F=/
MC1J=M;JLGG62^9MG3?"H5<2%#\V,Y&!QGGGG !WTTR6[W,LF=BA<X_&I;>XA
MN5W02*X]CR*R;^&4:3=Q74@F?R8U<[?O'H?S.:Y^-GB<-$Q1E'!7C%,#O,"C
M KFK37)X\+< 2KZ@8:MBVU&WN1B.<*Y_A88-("XX&VE(&#4:JZP(KR>8P !;
M:!N/KBA8O+\PJS'>=QR2>V./0<4 2 #%"@8I #CK^E1R2%(BR!I2IQM3&?U-
M $N!60H_XJ>;_KWB_G+6L>!DL />LE<_\)--S_R[P_SEH UF X^M*0,4V0[!
MEG 'J>*I7&JV<&=]RA/HHW?RJ92C'=E1A*>D5<OX%&!7/S>)8=S+;1M(PX.X
M@8_#K6-?^)+EG\OS0C'I%"N7_P ?QXK">+I1ZW.RGE]>H]K'7W%Y;V<6;B0*
M>R]2?PKDM<\0_O=T(EC)'EA(V+.X)'\/]>OO63'%?WK':'#$$[(_GD;ZL>!_
MGFMO2_"LZDO(Z6ZN!E,;WS[MGG\ZY)5JU?W::LCOIX;#X3WJTKO^OZZG/[[J
M:;9Y;6\9&[S#AF/MZ*?SJ6.&&W.Y0S2,0I<Y=SGWZ_TKM[?0+.+[X:5O5SQ^
M0K1AMXX>(4C3_=4"B&!EO)BJ9K!:0C^G^9S]C&\>G:>)$9#]M!PPQV-=-65J
MD*QS6C@L6DNT+9)(X4C@=OPK5KT81Y8J)X]6?M)N?<****LS"BBB@ HHHH *
M*** "BBB@#FO&SZF8(;?2I)X7GCF420 ;A)L^3D\#^(\]U%8]C_PFS7<PN!&
ML"71CD.5S+$(T >+^[N.XX/0DCI7>T4 >;V?_"1)=(;A]72R$C-%)(5RD627
M\T9)R%P%ZY()& <5W>B27$VC6,EZ"MT\"-*",'<5&>.W-7:* "N"\0R>)7U*
M^DT=YV:S:4BU&U4F0PQ[%!/\1)D(/3<N#Q7>T4 >?:X/'?\ 9=\+$0.3L,!C
MD5)E4<MU!&3T.>Q..<5/8SZ];ZR$E6Z>.74!S,, QGS2ZJ-S#8JB,AAC).,9
MKNJ* "BBB@"KJD<\NFW4=FVVX:)A&<XPV..:XMO#&OFY6:VU!(&61G9Y)G<S
M@DE Z?=78ORC&<UWU% ')1:'KR7%\9=7$UO<6C0HC$ADD(X?('J3P,<8ZU0&
MB^)[*QMH;"ZC$:J$DA$HW.QD&9-^S@!<C 'OVY[RB@#B;70O%422QMKD?S%F
M$@R<$G(&TKQALDG/(., "GWV@:[=Z3ID3:@IU" N9+DS.N,YP,* &XXR<$=>
M><]G10!PC^$]1-BX$D1G:-8D07<H$:^8S'YNK%1L"D_W>:ZO0X;JWLF2]=F?
MS7*;FW$(6.T$]SBM"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *X3PV%G\=ZK*NOV]T(Y)5^PFU,<L9! /SD_.HX&0,=/2N[K
M@[#4[H^-[T7<EU]ELUN&\@6X1(QE-K;\ /NR2,$D=Z .FUL%K&_"L4)1,,!G
M'/O7'*+KG]Y&<' #IU'KP:ZR]N8[K3;N6+=AD0X(P1STK!CMYY3^[AE;Z*:8
MBGON5QF&)_\ =DQ_,4&X8?ZRVG'T4,/T-:@TB_DV[8Q'R"=^.1Z5+_9$YD>(
M/#YRIOV9/3G'.,=10!D_VM)$H2&ZD@W'!W97;QU&1C-7TU^[95$-Q#+SR21D
M#UXIUOI-U=112[HU3;G"R[ANS@J<<''K3)M#N1'NFM(9#WV8;^F: )SK%\5_
MUBCW""J_VZY^;$K+O.YMF%R?4XK-DLX874>3+$['!*%EQCUYZ4")_P#EE=R#
M!Y# /^'2@"W)([_?=F_WFS716_\ R,3_ /7K#_.6N3Q<J.)87_WD*_R-=7;G
M_BH6SU^RPYQ]9*&".9OG=[N;>S-^\(&3GO5*2ZC1S&@:67^Y&,D?7L/QI][$
M\UY/YTV(_,;"19 (SW/4_ABI[.SDEQ#8P;AD9"_*%'J3_DUX#YI2LCZR+A"*
M<G_D9WV62ZFD$\8B#J%(B^](/0OU_(#ZUK:9H<XA2[BB!MW< Q1+AV0'ECD@
M[NHZ]^E=/8Z/':"-TDS.&!9RF<CNH]/KUK7W"NRE@5O/<\[$9J_AI[?U_5S/
MM[=T5$LE%I'%+APT8;SE]CGC.>I].E7\D!C@GV'>DC8;12JPY^OI7H**CL>/
M*;EN16@8H96\X&7#^7*1F/@?+Q_]?FIN?2C</\BC</\ (II60F[NYGZQ]ZP_
MZ^D_DU:-9VKD%K#'_/TG\FK1IB"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "L&S\+V=KKD^IB:XD,OF;8)"IC
MC,A4R$<9.[:O!) QQBMZB@"O BI-(B*JHJJ%4#  YZ58[U#'_P ?4WT7^M3=
MZ "H9(,S++&1&^1O.T$NHS\N?QJ:B@"**-HK=4=S(PZL0!GGT'%2GH:BW2,\
MBM&%0$;&W9W>O':I3T- $<L,<\>V9%<>XS6/<Z!"VYK1O*9N2IY!_K6Q)'YG
ME_.Z;6W?*<;O8^U2#I0!Q%W97=HS^?&-G\#+R/Q-;=IN.O'S H?[)!N"G(!S
M)TK;(!!! (/8UDKQXGFQ_P ^\/\ .6@#'L=$:XN'^7R+17(7 QD9Z >E=3;6
MT5K"(X$"*/3O4K=OK2FLJ5&-/8Z*^)G6^+8****U.<;']T4J]_K21_=I5[_6
M@!:*** ,[6/O6'_7TG\C6C6=K'WK#_KZ3^1K1H **** "BBB@ HHHH ****
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MI##8>I6;A'XERV<;N\M>OX_H<E\'Y=;U5K^^N[VZU72[B9S) )2)$<?=8DD
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M "]_K2XIBKUY/6G;?]HT #=OK2XIK+[GK2[?]HT +BFC[S4NW_:--"_,>30
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M*@ CW'6NVH *!P*** "N6GTGPSIGBU]=>WT^#5Y$6.:X8XD^;Y5XZ#.TC/7
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M(\@11(V S8Y('3^9J04B]_K0 M4G_P"0S%_U[O\ ^A+5VJ3_ /(9B_Z]W_\
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ME8=.M$5G\PA8@,MN#9_-5/X"M&@ HHHH **** "BBB@ HHHH **** "BBB@
MHHJO=7<=N50AI)G^Y$@RS?X#W/% '&ZSK/B&UNO%$EM;N]M9*J60" [W,2-]
MW&6PS'D''&*CM_%^L/IOVA].B*(J!IMDH61F#<JNW<!E=G/\1':NP6.^G.Z:
M5+9/^><0W-^+'C\A3C8 A\W-W\_4^:1CZ>E '%3^-]5CBN9#HDB-"Y4H0Y &
M5P,[>6Y/''/KQ7?QMYD:.5(R V&&"*JM;7*<V]VW'\$RAP?QX/ZTD-ZRRK#>
MQ>1*QPISE'^A]?8X- %VBBB@ HHHH *YKQL]J+>-;S3(M06.*:Y".^TCRUS@
M''?.#VQZ]*Z6H9K6&:>&:6-6EAW>6QZKN&#^8H YR*STJZL+^]GTBVWV\LS,
MHYWD $GIW 7\JY"]U;1HDAN=2\,/#>L?/BC#[!*I'5@<$#E^HYV^]>FM EE9
M7)LH5#G?+L"YWN>>G?)KA$\6ZI:Q6O\ :>DM+)*XC1WA:/S26QL08)S@YY '
M'XD @L=8\-Q64$+Z'(DI0(R2,C$%QD L6^Z1U;HO ..E,TV_\,R+:P)INH7$
M4,[.K3D,"7"AF;GD#@ >G2KVK:WK$Y^PR^%VF5QME/E,R%<@D X';CZBK=CX
MBNX-3T[3[G1(K-;EE1 ,@[=O  V_PC@YP/2@"A'JF@6,EVJ:!L-O/):AE*[&
M97.,DD8!V9R>!QS5>;6?"4UC&ITEHF^S-(XA50T(8%" <\MQ@ <XYQBKQUCQ
M3;6*FYT:.YENB2B"(_)QSOVYP,D8SSP:M6FNZVD</VOPX9WE;<'@!4*#D98,
M.#C'X9]* *VD^(=(AFGFTW1Y(GAL&F<EP&(B"@( "3MPW#=.#WS5VX\<P6D2
M":W6XF+ DV<PEB,>\*SA\#."0",=2!WJ7PUX@NK_ %&.TN=%:S=D=]Y!4+&I
M &01D9+  =\,>U=,EG;)-YJ01K)L$>0O10<X^F>: ./7XAV9N;F$V5R&A9%X
M((<L/X2#@\^A(YYQ5J#QO;75GJ4UO9W"M91;V$^(U+9P5W?7OT-=4(HP !&@
M Z +TI?+3YOD7YAAN.H]#0!Q%O\ $2U)9;FRE4J <Q.K!\\?+G!//'3U/3FM
MG2/$T6HZE]C^QW$#'?M=RI4E3@C@FMP0Q#;B-!M&%^4<?2GA5!R  ?I0 M%%
M% !1110 54N'E:_B@CD\M6B=R0H))!4#K]35NJ<G_(8@_P"N$G_H24 5=2T.
MUU(Q-J*1730Y,9EA5MO3IQ[#\AZ5')X<T^66WEDM[=I8&5XF,"90KC:1QVVC
M'T%;+?=/TH'04 8?_"+Z9]JN+G[+;F>X.Z5S"I+G())X[D#/K@567PQH5I=)
M)Y-G%(@.P-&@ SU.#] ,^U:6JZ_IFDWUA9ZA="&YOW:.V0J29& R0,#TK'MO
M''A>_DL/*OHIC?M*EL?*8[S%G>.G;% '.W^H:+9/?1CPW=W"Z;+'!&8[6)A,
MLGWFCR?F5<G/I[5U46@Z(9(3''9&15"(/+C9@,YQ]<]^M7_#^J:5X@TJ+4=(
M>.XLY20D@CQG!P>H]16AY,2D%8D!!X(44 4]/TJ/3K?R+!EMX<EMD<:@9/4]
M.M6+"1Y$E$C;BDK(#C&0*LU4T[_EY_Z[O0!CZHGB%FU,:>ZJ&\O[(6V?+C[_
M &[].<^OM6K;&[DDG62:(;&  6/H"H/7//6KU5K;_CZN_P#?7_T$4 5KK2XK
MF1Y+E+>5Y(_)9GA!+)G.T\],\U2/A32S'/&;*TV3,&<"(CD$D8.?EY)/&.I]
M:WF[?6EH R?["M/),7V>S\HQK#L^SC&Q3E5QGH"215>'PYI<.?*L[!,AE.+<
M<ALA@>>X)'XTW4O&?A[3+C48+_5(()=.C2:[5L_ND<X4GCN?YU!=>./#-F+[
M[5JMM']A,7VG(/[OS?\ 5YX[YH H:-9Z/JNIZG$NABUDL76V,UQ9A%F4!=IC
M.>5&Q1G_ &16W'X>TY)Y)([2Q$DG+L+<9/!7U]"1^)K97:Z*PP5(R.*  'X
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M;CQ"0NP.N"I*KCG;@9'!.,<@>PK6CL?#<@TZ*758&DM6D2!0RQG?(!@X&,D
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MJG)_R&(/^N$G_H25<JE(,ZQ!_P!<)/\ T)* +C?=/TI5Z"FL/E/)Z4H' Y-
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MOJ-GMXG20,.!'\^?P&:SU2_5673XVCM/[LQ'F#_KGGH/9JVE4*,* !Z 8I:
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M*3;@M-%U.\JZ7_Q\:E_U\_\ LB5H50TO_CXU+_KY_P#9$J_68!1110 4444
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M>W806S$H "W(7:")",D_>;J:FN+F_P!<6_TR2VMM6/'D7<28M;:;R\,')/S
M;PPQN.6(ZK0!UVBWFG2S7UGIRK')9S>7-&$V88@'(]00>OL1VK4K \->&K32
M"MV8HCJCPB&:>/> RC&% 9CP,?S/<UOT""BBB@ HHHH **** "BBB@#AOC!X
MVNO GAJTU*PT^+4+BYOHK)899?*7+AL'=@]P/SJ7P?JWC:^U5XO%'AO3=,L!
M$66>WU'SV+Y&%V[1QC//M7+_ +36CW6N^!M*LK.RN;W=K-L98[=&9A'\X8G;
MR!SU[5V'@GX>^'/!4]W-X=LYK>2Z55E,EU+-D*21]]CCJ>E '64444 %%%%
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MMM9I#;7\TWF01I(UQ.C21R8E+.K8&1DQC'T(Z&@#3MO%FJW-L+F#0I9(2OF
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M2QB-V7<=I91PI(QP*U:C\^(N4$L>\'!7<,BI* "BBB@ HHHH **** "BBB@
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M>E 'H]07W_'I+]*BUFYN+32[F>S@-Q<1IE(@"=Q_#D_05DIJ>H7,TT,^FO%
M+6.3S#D?O"?F7)XX_7% &Y<RB"/>8V?G&%&33T*LS 8R.H[CBF7%S' K&5@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGGG_ $GI[_=IWVB__P"?.#_P(_\ L:RO$7B!M,_=P6<\S/$S1SJNZ,/L=D&
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M=,M?+B!WN%,KELEV"A=Q]\*.>^* N<;H7A>^F@LVNDCTIH1YHNK0_P"E7#L
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MQ/+N?O,>V2>3CN35J@14TO3;/2[7R-.MHK:+)8K&N,D]2?4^YJW110 4444
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MCBFC5S$OS+G#)SSSWH CTJ_M]5TVUO[-B]M<QK+&Q&"5(R.*M4B@*H"@ #@
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M+N))8O)P85=T ! VN6R.O/J* .]\Z/!/F)@8R=P[]*(YHY/N.#WQW]*\[O/
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M% &)!H_V&[N;IKF69[JYCD(/ 4@X_'K_ "]*W,?7\Z@OON1?]=4_G4^?\XH
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M#^2F2-[%CR<]:JRY;WU FU/_ )!MU_UR?^1J>'_5)_NBH-2'_$MN_P#KD_\
M(U#J0O3I?_$K9%NOD*[QD$9&X?EFI GO?N1?]=4_G5BL&+^US?71O?*%H;F(
MVXP,A.XX[Y[G\JW?F]ORH Q]8&N-?Z:=&>R6S69OMPN%8NT>./+P<9SSSZ5E
M6:>-PVG&\FT0A6F^V".-_F!_U6S)ZCC=G\*ZM=W/3K3OF]ORH S/#HU9=*MQ
MXB:T?4P&\UK0$1'GC&>>F*U*8=VX=.E.^;V_*@ ;[II::V[:>GY50MM)AM]7
MNM11Y3/<*$=6<E !Z#M5)+6[ =8_\A+4_P#KHG_H J_6?8?\A+4L_P#/1/\
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M<P+C=-&,G RPY.<?SXIL=Y;2('CN(64J6#!P05'4_3D<T 3T4 @@$<@]#10
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M-Y:\CH.U #;CR.GI0 YBJJ68@ <DGM6#=:E:_P!L>4;F0%=H*$?NP<CO6MJ
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MYX(QV6M,QY^:]2#CVOVVTT_SN:HV*J6__(0N_HG\C5#6(=9=[PZ;<1JCVZK
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MDKEBN"PY7<1T%1^&EO;>;^V+V*QL+6XE>>YO[F3$TL3%MD)W ;0"5(;IM &
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M9QD]3D\UN44 %<UXN37'EMX](>,VTR.DJM%N*N!E3NS\H.",X.#M.,9KI:*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432300084096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Chemomab Therapeutics Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat
              Atidim, Building 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">,
              Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6158002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">284,094,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Somekh Chaikin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel Aviv, Israel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">1057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat Atidim Building 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6158002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Sigal Fattal<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">492-5563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember', window );">American Depositary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMMB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember', window );">Ordinary Shares, No Par Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, no par-value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432209020320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,292<span></span>
</td>
<td class="nump">$ 13,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term bank deposit</a></td>
<td class="nump">10,492<span></span>
</td>
<td class="nump">26,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other receivables and prepaid expenses</a></td>
<td class="nump">1,037<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,897<span></span>
</td>
<td class="nump">41,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">22,151<span></span>
</td>
<td class="nump">43,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">1,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,423<span></span>
</td>
<td class="nump">3,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,838<span></span>
</td>
<td class="nump">6,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current&#160;operating lease liabilities</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingent liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,154<span></span>
</td>
<td class="nump">6,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2023, 2022 and 2021;Issued and outstanding: 284,094,700, 232,636,700 Ordinary shares at December 31, 2023 and 2022, respectively and 228,090,300 Ordinary shares at December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury share at cost (11,640,460 shares as of December 31, 2022)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">105,675<span></span>
</td>
<td class="nump">101,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(88,678)<span></span>
</td>
<td class="num">(63,819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">16,997<span></span>
</td>
<td class="nump">36,223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 22,151<span></span>
</td>
<td class="nump">$ 43,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289408352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common Stock, No Par Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">650,000,000<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">284,094,700<span></span>
</td>
<td class="nump">232,636,700<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">284,094,700<span></span>
</td>
<td class="nump">232,636,700<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,640,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432294590816">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18,381<span></span>
</td>
<td class="nump">$ 16,977<span></span>
</td>
<td class="nump">$ 6,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,078<span></span>
</td>
<td class="nump">11,556<span></span>
</td>
<td class="nump">6,033<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,459<span></span>
</td>
<td class="nump">28,533<span></span>
</td>
<td class="nump">12,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financing expense (income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,238)<span></span>
</td>
<td class="num">(353)<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,221<span></span>
</td>
<td class="nump">28,180<span></span>
</td>
<td class="nump">12,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(534)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24,221<span></span>
</td>
<td class="nump">$ 27,646<span></span>
</td>
<td class="nump">$ 12,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per Ordinary Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.103<span></span>
</td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per Ordinary Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.103<span></span>
</td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary Shares outstanding, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">234,998,859<span></span>
</td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Ordinary Shares outstanding, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">234,998,859<span></span>
</td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288781008">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Treasury share [Member]</div></th>
<th class="th"><div>Additional paid in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 34,497<span></span>
</td>
<td class="num">$ (23,695)<span></span>
</td>
<td class="nump">$ 10,802<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,274,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EffectOfReverseCapitalizationTransaction', window );">Effect of reverse capitalization transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EffectOfReverseCapitalizationTransactionShares', window );">Effect of reverse capitalization transaction (In shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">152,299,702<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">58,637<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Issuance of shares and warrants, net of issuance costs (In shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66,381,520<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">134,240<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,478)<span></span>
</td>
<td class="num">(12,478)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">97,639<span></span>
</td>
<td class="num">(36,173)<span></span>
</td>
<td class="nump">$ 61,466<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228,090,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Issuance of shares and warrants, net of issuance costs (In shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,576,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,970,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Sale of treasury share at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Sale of treasury share at cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,640,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,646)<span></span>
</td>
<td class="num">(27,646)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,218)<span></span>
</td>
<td class="nump">101,260<span></span>
</td>
<td class="num">(63,819)<span></span>
</td>
<td class="nump">$ 36,223<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">232,636,700<span></span>
</td>
<td class="num">(11,640,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,636,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Issuance of shares and warrants, net of issuance costs (In shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,458,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Sale of treasury share at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(638)<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Sale of treasury share at cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,640,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,221)<span></span>
</td>
<td class="num">(24,221)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 105,675<span></span>
</td>
<td class="num">$ (88,678)<span></span>
</td>
<td class="nump">$ 16,997<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">284,094,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,094,700<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EffectOfReverseCapitalizationTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of effect due reverse capitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EffectOfReverseCapitalizationTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EffectOfReverseCapitalizationTransactionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares isued due to effect of reverse capitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EffectOfReverseCapitalizationTransactionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>it represents number of shares and warrants issued during period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432205905712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (24,221)<span></span>
</td>
<td class="num">$ (27,646)<span></span>
</td>
<td class="num">$ (12,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Change in other receivables and prepaid expenses</a></td>
<td class="nump">903<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(2,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Change in trade payables</a></td>
<td class="num">(1,172)<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Change in accrued expenses</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">2,823<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Change in employees and related expenses</a></td>
<td class="num">(737)<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in operating leases</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,611)<span></span>
</td>
<td class="num">(20,370)<span></span>
</td>
<td class="num">(12,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PaymentsForInvestmentInDeposits', window );">Investment in deposits</a></td>
<td class="nump">15,882<span></span>
</td>
<td class="nump">19,601<span></span>
</td>
<td class="num">(45,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_LongTermLeaseDeposit', window );">Long-term lease deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities', window );">Sale of asset held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">15,879<span></span>
</td>
<td class="nump">19,533<span></span>
</td>
<td class="num">(45,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CashAcquiredInMerger', window );">Cash acquired in Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Purchase of treasury share</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTreasuryStock', window );">Sale of treasury share</a></td>
<td class="nump">580<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Issuance of shares net of issuance costs</a></td>
<td class="nump">2,924<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">58,637<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">3,504<span></span>
</td>
<td class="num">(808)<span></span>
</td>
<td class="nump">61,074<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(4,228)<span></span>
</td>
<td class="num">(1,645)<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the year</a></td>
<td class="nump">13,596<span></span>
</td>
<td class="nump">15,241<span></span>
</td>
<td class="nump">11,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the year</a></td>
<td class="nump">9,368<span></span>
</td>
<td class="nump">13,596<span></span>
</td>
<td class="nump">15,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CashPaidAndReceivedDuringYearForAbstract', window );"><strong>A. Cash paid and received during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxesReceived', window );">Income taxes received</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_InterestReceived', window );">Interest received</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">972<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>B. Significant non- cash transaction:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed, net of non-cash assets received in Merger</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CashAcquiredInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash acquired in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CashAcquiredInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CashPaidAndReceivedDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CashPaidAndReceivedDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents income taxes received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_InterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_InterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_LongTermLeaseDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term lease deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_LongTermLeaseDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PaymentsForInvestmentInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payments for investm,ents in deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PaymentsForInvestmentInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of other assets recognized in investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432204110688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">General</a></td>
<td class="text">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 1 - General</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.</span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics Inc.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company currently has no products approved for sale. The Company&#8217;s operations are funded primarily by its Shareholders. The Company has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it obtains marketing approval for its products. Continuation of the Company&#8217;s development programs depend on its future ability to raise sources of financing. The Company believes that its cash and cash equivalents and bank deposits as of December 31, 2023 will be sufficient to fund its operations through March 31, 2025.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 14, 2020, the Company (formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and Plan of Merger (the "Merger" and &#8220;Merger Agreement&#8221;) with Chemomab Ltd., an Israeli limited company, and CMB Acquisition Ltd., an Israeli limited company and a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;). On March 16, 2021, (the &#8220;Effective Time&#8221;), the Company consummated the Merger pursuant to the Merger Agreement Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. surviving the Merger as the Company's wholly owned subsidiary. In connection with the Merger, on March 16, 2021, the Company changed its name from &#8220;Anchiano Therapeutics Ltd.&#8221; To &#8220;Chemomab Therapeutics Ltd." and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.</span></span></div>
                <div>&#160;</div>
              </td>
            </tr>

        </table>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd. option was assumed by the Company, based on the same exchange ratio.</span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For accounting purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab Share Incentive Plan (the &#8220;2015 Plan&#8221;), with such options representing the right to purchase a number of ADSs equal to approximately 12.86 multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in $ thousands):</span></span></div>

          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,427</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Asset held for sale</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,000</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid and other assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">236</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,187</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net acquired assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,476</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288942320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
    <div>
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 2 - Summary of Significant Accounting Policies</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div>

            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">A.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Basis of Preparation</span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</span></span></div>
            </div>

        </div>
        <div style="line-height:1.25">&#160;</div>

          <div>
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Use of estimates</span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></span></div>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Foreign currency</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Cash and cash equivalents</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.</span></span></div>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div></div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">E.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Restricted cash</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Short-term bank deposits</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">G.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Property and equipment</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Annual rates at depreciation are as follows:</span></span><br/>&#160;</div>

              <div>
                <div style="margin-left:36pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" rowspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furniture and equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" rowspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement</span></span></div>
                        </td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>

          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">H.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Impairment of long-lived assets</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">I.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Research and Development</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages. </span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div></div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">J.</span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income taxes</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">K.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Fair value of financial instruments</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#8217;s own credit risk.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#8217;s non<span style="font-weight:bold">- </span>financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></span></div>
          </div>

        <div>
          <div style="line-height:1.25">&#160;</div>
        </div>

          <div>
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">L.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Share-based compensation</span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</span></span></div>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">M.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Government-sponsored research and development</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">N.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Severance pay</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $86, $142 thousand, and $116 thousand for the year ended December 31, 2023, 2022 and 2021, respectively.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div></div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">O.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Concentrations of credit risk:</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">P.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Leases</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2023 5% in 2022 and 5.2% in 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Q.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Principles of consolidation</span></span></span></div>
            <div style="line-height:1.25;text-align:justify">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div></div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">R.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Earnings per ordinary share</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.</span></span></div>
          </div>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289209152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 3 - Cash and Cash Equivalents</span></span></div>
        <div style="line-height:1.25">&#160;</div>

          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,718</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,663</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In NIS</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,574</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,756</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In other currencies</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">100</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,292</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,519</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>

        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*Less than 1 thousand</span></span></div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432299319680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">Other Receivables and Prepaid Expenses</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 4 - Other Receivables and Prepaid Expenses</span></span></strong></p>
    <p style="margin:0pt">&#160;</p>

      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government institutions</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">289</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">459</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">748</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,307</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,037</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,766</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289282544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 5 - Property and Equipment, Net</span></span></strong></p>
    <div>
      <div>

          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">68</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furniture and equipment</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">400</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">399</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Website development</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">529</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">532</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less - accumulated depreciation</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(226</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(165</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">303</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">367</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432299319680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
    <div>
      <div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 6 - Leases</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter &#8211; &#8220;The Agreement&#8221; .(According to the Agreement, Chemomab Leased a space in Atidim Park, Tel-Aviv for a period of three years, through <span style="-sec-ix-hidden:Fxbrl_20230131233234992">May 2023</span>. Chemomab was granted an option to extend the lease term by additional three years.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab returned the previous office and lab space to the property owner and leased a larger space in Atidim Park Tel-Aviv, for a term of 3 years, through <span style="-sec-ix-hidden:Fxbrl_20230131233722905">October 2024</span>. In addition, Chemomab was granted an option to extend the lease term by additional three years. The annual lease and management fees are approximately $111 thousand. Pursuant to the Amendment, the bank guarantee issued in 2020 was canceled and a substitute bank guarantee of approximately $77 thousand was issued to the property owner during 2023.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above operating leases are included in &#8220;Operating lease right-of-use assets&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2023, 2022 and 2021 represent the Company&#8217;s right to use the underlying asset for the lease term. The Company&#8217;s obligations to pay lease payments are included in the current liabilities as &#8220;Operating lease liabilities&#8221; and in the non-current liabilities as &#8220;Non-current operating lease liabilities&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2023, 2022 and 2021. Based on the present value of the lease payments for the remaining lease term of the Company&#8217;s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $392 thousand on December 12, 2023.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the years ended December 31, 2023, 2022 and 2021, the Company recognized an increase in right of use assets of $392, $17 thousand and $345 thousand, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023 the Company concluded it reasonably certain in the lease agreement for additional three years and accordingly performed a reassessment of the right of use asset which resulted in a new right of use asset in the amount of $392 thousand as of December 31, 2023.</span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, 2022, and 2021 operating right-of-use asset was $392 thousand, $227 thousand and $345 thousand, respectively. The operating lease liabilities were $392 thousand, $214 thousand and $343 thousand, respectively.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As most of the Chemomab&#8217;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#8217;s incremental borrowing rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was 9% in 2023 5% in 2022 and 5.2% in 2021.</span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of lease liabilities under noncancellable leases as of December 31, 2023, are as follows: (in thousands):</span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="margin-left:36pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">115</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">121</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">121</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">107</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total future minimum lease payments</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">464</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:88%;padding-bottom:4px;vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less imputed interest:</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(72</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of operating lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">392</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289448816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingent Liabilities</a></td>
<td class="text">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 7 - Commitments and Contingent Liabilities</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div style="font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exclusive License Agreement (hereinafter- &#8220;the License Agreement&#8221;)</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (&#8220;Fund"), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee;</span></span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(i)</span></span><span style="padding-left:24pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to certain additional terms set forth therein.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to pay the Fund the following non-refundable, non-creditable amounts:</span></span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)</span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$100 thousand upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;</span></span></span></div>
              </td>
            </tr>

        </table>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:35.45pt">&#160;</td>
              <td style="width:35.45pt;vertical-align:top"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(b)</span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-indent:36pt;line-height:1.25;text-align:justify"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023 no payments were made to the Fund.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition to the payments described above, upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (&#8220;IIA&#8221;) for the support of certain research and development activities conducted in Israel.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In return for the IIA&#8217;s participation, Chemomab is committed to pay royalties at rate of 3% of sales of the developed product (linked to U.S. dollar), up to 100% of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology or development out of Israel.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab did not receive any grants from the IIA in the years ended December 31, 2023, 2022 and-2021.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since Chemomab &#8217;s incorporation through December 31, 2023 Chemomab received $1,227 thousand from the IIA, which were recognized as a reduction of research and development expenses.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, Chemomab has no commitment for royalties payable.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">B.</span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2015, Chemomab entered into a license agreement with subcontractor (&#8220;the Subcontractor&#8221;), under which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediates and active pharmaceutical ingredients. According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with Chemomab's specifications and timeline. From time to time, Chemomab and the Subcontractor have been signing additional agreements for additional manufacturing and final process lock of the product for clinical use Under the agreement, Chemomab is also obligated to pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2023, 2022 and 2021, Chemomab recorded expenses related to the above agreements in the amounts of $4,832, $5,222 thousand and $2,590 thousand, respectively. The expenses were recorded under research and development expenses.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">C.</span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the bank imposed restriction on a bank deposit in the amount of $76 thousand for the purpose of secure lease payments under an office lease agreement.</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">D.</span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2022, the Israeli tax authority ("ITA&#8221;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 2022. The ITA raised several claims, mainly in respect with the recoverability of VAT related to the Merger Agreement expenses and the classification of the Company as a holding company. In July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued an assessment. In November 2022, the Company filed an appeal to the ITA&#8217;s assessment. The Company has recorded a provision in 2022 that is inherently subjective due to the inherent uncertainty of these matters and the judicial process, therefore, the outcome may differ from the estimated liability recorded by the Company during 2022.</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="color:#000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023 the ITA rejected the company&#8217;s appeal on the assessment. The Company is expected to submit an appeal in April 2024 to the Israeli district court. Based on the consultancy of its tax advisors, The Company estimates that the amount of provision recorded in 2022 remains adequate.</span></span></span></div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432368830560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Share Capital</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Note 8 - Share Capital</span></span></strong></span></span></p>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:34.9pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right attached to shares</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:34.9pt;margin-left:36pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">1.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Voting</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Dividends</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since its inception, the Company has not declared any dividends.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Financing rounds</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately $45.5 million of its American Depositary Shares )ADSs( in a private placement transaction, (or "The Private Placement"). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately $4.5 million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $75 million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued 699,806 ADSs at an average price of $22.75 per ADS under the ATM Agreement, resulting in gross proceeds of $15,917 thousand.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000 of its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float. During the year ended December 31, 2022, the Company issued 130,505 ADSs at an average price of $2.11 per ADS under the ATM Agreement, resulting in gross proceeds of $275 thousand. During the year ended December 31, 2023, the Company issued 772,900 ADSs at an average price of $1.83 per ADS under the ATM Agreement, resulting in net proceeds of $1,371 thousand.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 19, 2022, the Company entered&#160; into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with Dr. Adi Mor, co-founder of Chemomab Ltd., then Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), whereby the Company agreed, subject to the requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which the Company received on November 14, 2022, to repurchase up to 582,023 of the Company's ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the company repurchased the entire amount of 582,023 ADSs (the "Treasury Shares") from the Co-Founders at an average price of $2.0848 and for total consideration of approximately $1,218 thousand.</span></span></div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 17, 2023, the company sold the Treasury Shares for an aggregate consideration of approximately $580 thousand.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $2,863,664 of its ADSs in connection with the reactivation of the ATM Facility and pursuant to Rule 415(a)(6) under the Securities Act of 1933 Form F-3, which, subject to certain exceptions, limits the number of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, the Company entered into an At the Market Offering Agreement (the "Roth ATM Agreement") with Roth Capital Partners, LLC, (&#8220;Roth&#8221;). According to the Roth ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $2,863,664 through Roth or the Roth ATM Agreement. From October 30, 2023 through December 31, 2023, the Company issued 1,800,000 ADSs at an average price of $0.96 per ADS under the Roth ATM Agreement, resulting in net proceeds of $1,553 thousand.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold">Share-based compensation</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Share-based compensation plan:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company maintains (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;),&#8201;which was assumed by the Company from Chemomab upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, a total of 28,443,060 of our Ordinary Shares (equal to 1,422,153 ADSs) were reserved for issuance under the 2015 Plan, of which 3,445,520 Ordinary Shares (equal to 172,276 ADSs) had been issued pursuant to previous option exercise, and 6,826,440 Ordinary Shares (equal to 341,322 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 6,394,160 Ordinary Shares (equal to 319,708 ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $0.30 per Ordinary Share (or $5.98 per ADS). During the year ended December 31, 2023, options to purchase 16,634,300 Ordinary Shares (equal to 831,715 ADSs) were canceled.</span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, a total of 23,061,380 of our Ordinary Shares (equal to 1,153,069 of our ADSs) were reserved for issuance under the 2017 Plan, of which 23,046,660 Ordinary Shares (equal to 1,152,333 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 3,689,480 Ordinary Shares (equal to 184,474 ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $0.20 per Ordinary Share (or $3.91 per ADS). During the year ended December 31, 2023, options to purchase 3,739,320 Ordinary Shares (equal to 186,966 ADSs) were canceled.</span></span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The expenses that were recognized in the consolidated statements of operations for services received from employees and service providers are as follows:</span></span></div>
              </td>
            </tr>

        </table>

          <div>
            <div>&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">407</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,084</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,763</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,882</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total share-based compensation expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,491</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,211</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,019</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

        <div>&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The number and weighted average exercise price of options are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="line-height:1.25;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average</span></span></div>
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at January 1</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.38</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,003,260</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.12</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">10,455,580</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.8</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquired in Merger</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">609,535</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,970,000</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.08</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(134,220</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.32</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,240,120</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.25</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,712,275</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,398,400</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.8</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.62</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17,784,640</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9.79</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at December 31</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.33</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">35,191,540</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.42</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.38</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,003,260</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.12</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div></div>
            <div style="line-height:1.25;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average</span></span></div>
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at January 1</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.33</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">35,191,540</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.42</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.38</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,003,260</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.12</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,970,000</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.39</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20,373,620</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.32</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,240,120</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,055,180</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.86</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,398,400</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.8</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at December 31</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">29,873,100</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.99</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.33</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">35,191,540</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.42</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>

        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair value measurement:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows:</span></span></div>

          <div>
            <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
            <div style="line-height:1.25;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:27pt;padding-bottom:2px;width:84%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023 grants</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average share price (in U.S. dollar)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(a)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price (in U.S. dollar)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.06-0.09</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life of options (in years)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(b)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.53-9.46</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(c)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">97.79%-112.94</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(d)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.71%-4.43</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>

        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:72pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(a)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The weighted average share price is based on the Company&#8217;s Ordinary Share valuation as at the grant date.</span></span></div>
              </td>
            </tr>

        </table>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:72pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(b)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:72pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(c)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</span></span></div>
              </td>
            </tr>

        </table>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:72pt">&#160;</td>
              <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(d)</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</span></span></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432209323648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 9 - Research and Development</span></span></strong></p>
    <div>
      <div>
        <div style="line-height:1.25">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consultants and subcontractors</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,014</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,052</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,894</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,362</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,867</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,789</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease and maintenance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">245</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">114</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">407</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">461</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">365</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">400</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,381</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16,977</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,334</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//985-730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288994208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_GeneralAndAdministrativeDisclosureTextBlock', window );">General and Administrative</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 10 - General and Administrative</span></span></strong></p>
    <div>
      <div>
        <div style="line-height:1.25">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,545</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,435</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">943</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional services</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,139</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,596</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,695</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,084</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,763</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,882</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fees to Directors</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">258</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">231</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">244</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Insurance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">648</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,084</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rent and maintenance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">81</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">29</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">323</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,423</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">216</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,078</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,556</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,033</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_GeneralAndAdministrativeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_GeneralAndAdministrativeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432297690560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Note 11 - Income Taxes</span></span></strong></span></span></p>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax rates</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ordinary taxable income in Israel is subject to a corporate tax rate of 23%.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company&#8217;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.</span></span></span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab Inc. is subject to a federal flat tax rate of 21% and state tax as applicable.</span></span></span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:36pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>B.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax assessments</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2023, the Company&#8217;s tax reports through December 31, 2018 are considered closed to audit inspections by the Israeli Tax Authority (&#8220;ITA&#8221;) due to statute of limitation rules effective in Israel.</span></span></span></span></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company has not yet been assessed by the ITA since inception.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

              <tr style="vertical-align:top">
                <td style="width:36pt">&#160;</td>
                <td style="text-align:right;vertical-align:top;width:36pt">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">C.</span></span></span></span></span></div>
                </td>
                <td style="text-align:left;vertical-align:top;width:auto">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Losses for tax purposes carried forward to future years</span></span></span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2023, the Company and its subsidiaries had approximately $165 million (approximately $159 million and $143 million as of December 31, 2022 and 2021 respectively) of net operating loss carryforwards which are available to reduce future taxable income with no limitation on the period of use.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></span></span></div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        <div></div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. Chemomab Therapeutics Inc received $351 thousand in December 2022 on account of 2016 and 2017 and received the remainder $183 thousand in 2023. Accordingly, a tax benefit in the total amount of $534 thousand was recorded in the Company&#8217;s statement of operations during 2022.</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px">

              <tr style="vertical-align:top">
                <td style="width:36pt">&#160;</td>
                <td style="text-align:right;vertical-align:top;width:36pt">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span style="font-weight:bold">D.</span></span></span></strong></span></span></div>
                </td>
                <td style="text-align:left;vertical-align:top;width:auto">
                  <p style="font-size:10pt;font-family:Times New Roman,Times,serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>Deferred taxes</span></span></strong></span></span></p>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In respect of:</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:72pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2021</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net operating loss carry-forward</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>38,258</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36,550</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33,396</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,163</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,774</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,147</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research and development costs</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,041</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,858</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,449</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>9</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>13</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>38</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross deferred tax assets</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>43,471</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>41,195</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36,030</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="width:64%;padding-bottom:2px;vertical-align:baseline">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less - Valuation allowance</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(43,471</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(41,195</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(36,030</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net deferred tax assets</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized.</span></span></span></span></div>
          <div>&#160;</div>
        </div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25">
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company has established a valuation allowance to offset deferred tax assets on December 31, 2023, 2022 and 2021 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2023 was an increase of approximately $2.3 million.</span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        </div>
        <div></div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px">

              <tr style="vertical-align:top">
                <td style="width:36pt">&#160;</td>
                <td style="text-align:right;vertical-align:top;width:36pt">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="font-weight:bold">E.</span></strong></span></span></div>
                </td>
                <td style="text-align:left;vertical-align:top;width:auto">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Roll forward of valuation allowance</span></span></span></p>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:72pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at January 1, 2021</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,200</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Currency translation Income</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,425</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax assets acquired through merger</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>24,535</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income tax expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,870</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at December 31, 2021</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36,030</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Currency translation Income</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,316</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income tax expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,481</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at December 31, 2022</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>41,195</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Currency translation Income</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(3,295</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income tax expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,571</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at December 31, 2023</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>43,471</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left">&#160;</p>
        <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px">

            <tr style="vertical-align:top">
              <td style="width:36pt">&#160;</td>
              <td style="text-align:right;vertical-align:top;width:36pt">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="font-weight:bold">F.</span></strong></span></span></div>
              </td>
              <td style="text-align:left;vertical-align:top;width:auto">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Reconciliation of theoretical income tax expense to actual income tax expense</span></span></span></p>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A reconciliation of the Company&#8217;s theoretical income tax expense to actual income tax expense is as follows:</span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:72pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">202</span>1</span></span></span></span></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Loss before income taxes</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(24,221</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(28,180</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(12,478</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Statutory tax rate</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>23</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>23</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>23</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Theoretical tax benefit</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(5,571</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(6,481</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(2,870</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Change in temporary differences for which deferred taxes were not recognized</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,177</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,696</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,332</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax rate differential</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(101</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Non-deductible expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>346</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>744</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>239</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,392</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,879</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,064</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Actual income tax expense (Benefit)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(534</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;</span></span></span></span>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px">

              <tr style="vertical-align:top">
                <td style="width:36pt">&#160;</td>
                <td style="text-align:right;vertical-align:top;width:36pt">
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="font-weight:bold">G</span></strong></span></span></div>
                </td>
                <td style="text-align:left;vertical-align:top;width:auto">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Accounting for uncertainty in income taxes</span></span></span></p>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align:justify;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:72pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the year ended December 31, 2023, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company&#8217;s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</span></span></span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289448816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties Balances and Transactions</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note 12 - Related Parties Balances and Transactions</span></span></strong></p>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balances with Related Parties:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following Related Party payables are included in the consolidated Balance Sheets:</span></span></div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:36pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">490</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">891</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued expenses</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">74</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">58</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">564</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">949</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 19, 2022, the Company entered into a share purchase agreement with the Company's Co- Founders, see Note 8B(4).</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:36pt">&#160;</td>
              <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">B.</span></span></td>
              <td style="width:auto;vertical-align:top">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions with Related Parties:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:36pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following transactions with related parties are included in the consolidated Statements of Operations:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;margin-left:36pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,795</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,409</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,255</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,304</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,466</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,775</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional Services</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">258</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">231</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">244</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,393</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,142</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,310</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432205197136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Ordinary Shareholders</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;font-size:10pt">Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders</span></p>
    <div>
      <div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:36pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands, except share and per share data</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(255, 255, 255)">
                  <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24,221</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,646</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,478</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(255, 255, 255)">
                  <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">234,998,859</span></span></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong>227,589,288</strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong>207,468,650</strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(255, 255, 255)">
                  <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Net&#160;loss&#160;per&#160;share&#160;attributable&#160;to&#160;ordinary&#160;shareholders,&#160;basic&#160;and&#160;diluted</span></span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.103</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.121</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.060</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;text-indent:0.55pt;margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="margin-left:36pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of shares</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding options to purchase ordinary shares</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">29,873,100</span></span></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">35,191,540</div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">27,003,260</div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432294416448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">A.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Basis of Preparation</span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</span></span></div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">
          <div>
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Use of estimates</span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></span></div>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Foreign currency</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Cash and cash equivalents</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25">
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.</span></span></div>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">E.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Restricted cash</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShortTermBankDepositsPolicyTextBlock', window );">Short-term bank deposits</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Short-term bank deposits</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">G.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Property and equipment</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Annual rates at depreciation are as follows:</span></span><br/>&#160;</div>

              <div>
                <div style="margin-left:36pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" rowspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furniture and equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" rowspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement</span></span></div>
                        </td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>

          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">H.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Impairment of long-lived assets</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">I.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Research and Development</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages. </span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">J.</span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income taxes</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">K.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Fair value of financial instruments</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#8217;s own credit risk.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#8217;s non<span style="font-weight:bold">- </span>financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text">
          <div>
            <div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">L.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Share-based compensation</span></span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</span></span></div>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock', window );">Government-sponsored research and development</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">M.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Government-sponsored research and development</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SeverancePayPolicyTextBlock', window );">Severance Pay [Policy Text Block]</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">N.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Severance pay</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $86, $142 thousand, and $116 thousand for the year ended December 31, 2023, 2022 and 2021, respectively.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">O.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Concentrations of credit risk:</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">P.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Leases</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2023 5% in 2022 and 5.2% in 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Q.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Principles of consolidation</span></span></span></div>
            <div style="line-height:1.25;text-align:justify">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per ordinary share</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">R.</span></span></span><span style="padding-left:20pt">&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Earnings per ordinary share</span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.</span></span></div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShortTermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Short-term Bank Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShortTermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288943376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of net assets acquired based on their estimated fair value</a></td>
<td class="text">
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,427</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Asset held for sale</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,000</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid and other assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">236</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,187</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net acquired assets</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,476</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432204257600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock', window );">Schedule of annual rate of deprecation</a></td>
<td class="text">
              <div>
                <div style="margin-left:36pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" rowspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furniture and equipment</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" rowspan="1" style="vertical-align:top;width:88%;vertical-align:bottom">
                          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement</span></span></div>
                        </td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the annual rate of deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432204369808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of components of cash and cash equivalents</a></td>
<td class="text">
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,718</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,663</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In NIS</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,574</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,756</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In other currencies</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">100</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,292</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,519</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432204362640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock', window );">Schedule of other accounts receivable and prepaid expenses</a></td>
<td class="text">
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government institutions</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">289</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">459</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">748</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,307</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,037</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,766</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432204369808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, Net</a></td>
<td class="text">
          <div>
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">68</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furniture and equipment</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory equipment</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">400</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">399</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Website development</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">529</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">532</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less - accumulated depreciation</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(226</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(165</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">303</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">367</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288880464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of lease liabilities under our non-cancelable operating leases</a></td>
<td class="text">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">115</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">121</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">121</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">107</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total future minimum lease payments</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">464</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width:88%;padding-bottom:4px;vertical-align:baseline">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less imputed interest:</span></span></div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(72</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="width:1%;padding-bottom:2pt;vertical-align:baseline;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of operating lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">392</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288860320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of the effect of share-based compensation on the statements of operations</a></td>
<td class="text">
          <div>
            <div>&#160;</div>
            <div style="margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">407</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,084</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,763</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,882</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total share-based compensation expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,491</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,211</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,019</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of number and weighted average exercise prices of option</a></td>
<td class="text">
          <div>
            <div style="line-height:1.25;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average</span></span></div>
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at January 1</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.38</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,003,260</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.12</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">10,455,580</div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.8</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquired in Merger</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">609,535</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,970,000</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.08</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(134,220</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.32</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,240,120</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.25</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,712,275</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,398,400</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.8</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.62</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17,784,640</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9.79</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at December 31</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.33</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">35,191,540</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.42</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.38</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,003,260</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.12</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div></div>
            <div style="line-height:1.25;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average</span></span></div>
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise price</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">of options</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div>
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining contractual life (in years)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at January 1</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.33</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">35,191,540</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.42</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.38</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,003,260</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8.12</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,970,000</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.39</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20,373,620</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.32</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,240,120</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,055,180</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.86</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,398,400</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.8</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at December 31</span></span></div>
                    </td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">29,873,100</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.99</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.33</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">35,191,540</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.42</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate the fair value of the options</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:72pt;line-height:1.25">&#160;</div>
            <div style="line-height:1.25;margin-left:72pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                  <tr>
                    <td colspan="1" style="vertical-align:top;padding-left:27pt;padding-bottom:2px;width:84%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023 grants</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average share price (in U.S. dollar)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(a)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.07</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price (in U.S. dollar)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.06-0.09</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life of options (in years)<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(b)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.53-9.46</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(c)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">97.79%-112.94</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate<sup style="vertical-align:text-top;line-height:1;font-size:smaller">(d)</sup></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.71%-4.43</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432204346672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock', window );">Schedule of research and development</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consultants and subcontractors</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,014</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,052</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,894</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,362</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,867</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,789</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease and maintenance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">245</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">114</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">407</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">461</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">365</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">400</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,381</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16,977</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,334</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288894640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock', window );">Schedule of general and administrative</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,545</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,435</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">943</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional services</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,139</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,596</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,695</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,084</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,763</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,882</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fees to Directors</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">258</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">231</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">244</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Insurance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">648</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,084</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,024</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rent and maintenance</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">81</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">29</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">323</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,423</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">216</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,078</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,556</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,033</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432203438032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the company's deferred tax asset</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2021</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net operating loss carry-forward</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>38,258</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36,550</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>33,396</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based compensation expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,163</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,774</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,147</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research and development costs</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,041</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,858</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,449</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>9</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>13</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>38</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Gross deferred tax assets</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>43,471</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>41,195</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36,030</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="width:64%;padding-bottom:2px;vertical-align:baseline">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less - Valuation allowance</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(43,471</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(41,195</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(36,030</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net deferred tax assets</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of roll forward of valuation allowance</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at January 1, 2021</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,200</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Currency translation Income</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,425</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax assets acquired through merger</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>24,535</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income tax expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,870</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at December 31, 2021</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>36,030</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Currency translation Income</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,316</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income tax expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,481</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at December 31, 2022</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>41,195</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Currency translation Income</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(3,295</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income tax expense</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,571</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance at December 31, 2023</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>43,471</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of theoretical income tax expense to actual income tax expense</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">202</span>1</span></span></span></span></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>USD&#160;thousands</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Loss before income taxes</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(24,221</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(28,180</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(12,478</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Statutory tax rate</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>23</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>23</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>23</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>%</span></span></span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Theoretical tax benefit</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(5,571</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(6,481</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(2,870</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Change in temporary differences for which deferred taxes were not recognized</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,177</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,696</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,332</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Tax rate differential</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>10</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>20</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(101</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Non-deductible expenses</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>346</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>744</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>239</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,392</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,879</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,064</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Actual income tax expense (Benefit)</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(534</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:2.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289222960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock', window );">Schedule of related party payables</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">490</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">891</span></span></div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued expenses</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">74</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">58</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">564</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">949</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of transaction with related parties</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">USD&#160;thousands</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and related expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,795</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,409</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,255</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based payments</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,304</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,466</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,775</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional Services</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">258</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">231</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">244</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,393</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,142</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,310</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288985552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net loss per share</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands, except share and per share data</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(255, 255, 255)">
                  <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24,221</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27,646</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,478</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(255, 255, 255)">
                  <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">234,998,859</span></span></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong>227,589,288</strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong>207,468,650</strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(255, 255, 255)">
                  <td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                </tr>
                <tr style="background-color:rgb(204, 238, 255)">
                  <td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Net&#160;loss&#160;per&#160;share&#160;attributable&#160;to&#160;ordinary&#160;shareholders,&#160;basic&#160;and&#160;diluted</span></span></span></div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.103</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.121</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
                  <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.060</span></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of weighted average number of shares excluded from computation of diluted net loss per share</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;text-align:center">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of shares</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding options to purchase ordinary shares</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">29,873,100</span></span></strong></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">35,191,540</div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">27,003,260</div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289375232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember', window );">Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger', window );">Number of ADS issued and outstanding after the merger</a></td>
<td class="nump">12.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADS issued and outstanding after the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432368827376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General (Schedule of net assets acquired based on their estimated fair value) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale', window );">Asset held for sale</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued liabilities</a></td>
<td class="num">(1,187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EstimatedFairValueOfNetAssetsAcquired', window );">Net acquired assets</a></td>
<td class="nump">$ 2,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of of asset held for sale recogized prior to the completion of merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EstimatedFairValueOfNetAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated fair value of the net assets acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EstimatedFairValueOfNetAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288820928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfMonthlyDepositsRate', window );">Percentage of monthly deposits rate</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PercentageOfMonthlyDepositsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of monthly deposits rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PercentageOfMonthlyDepositsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432203136704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AnnualRatesOfDepreciation', window );">Annual rates of depreciation</a></td>
<td class="text">over the shorter of the lease term or the estimated useful life of the improvement<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AnnualRatesOfDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual rates of depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AnnualRatesOfDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432294375920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 9,292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 13,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">6,718<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_XXX', window );">Other currencies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than 1 thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_XXX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_XXX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432208500512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ReceivablesFromGovernmentInstitutions', window );">Government institutions</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses, Total</a></td>
<td class="nump">$ 1,037<span></span>
</td>
<td class="nump">$ 1,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ReceivablesFromGovernmentInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ReceivablesFromGovernmentInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432205913408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property Plant And Equipment Net</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Website development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432209342336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2020</div></th>
<th class="th"><div>Oct. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiry date</a></td>
<td class="text">May 31,  2023<span></span>
</td>
<td class="text">Oct. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, option to extend</a></td>
<td class="text">three years<span></span>
</td>
<td class="text">three years<span></span>
</td>
<td class="text">three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AnnualRentAndManagementFees', window );">Annual rent and management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BankGuaranteesToPropertyOwner', window );">Bank guarantees to property owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ReassessmentOfRightOfUseAsset', window );">Reassessment of the right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities', window );">Operating right-of-use assets and operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Increase in the carrying amount of the right-of-use asset due to impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Incremental borrowing rate based on credit rating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AnnualRentAndManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual rent and management fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AnnualRentAndManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BankGuaranteesToPropertyOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank guarantees to property owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BankGuaranteesToPropertyOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating right-of-use assets and operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ReassessmentOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of reassessment of the right of use asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ReassessmentOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432205847936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest:</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432205885408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Decsription of occurrence for payments</a></td>
<td class="text">upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_MaximumPercentageOfPaymentsOfRoyalties', window );">Maximum percentage of payments of royalties (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized', window );">Cumulative Amounts Of Grants Received And Recognized</a></td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royality expenses</a></td>
<td class="nump">4,832<span></span>
</td>
<td class="nump">$ 5,222<span></span>
</td>
<td class="nump">$ 2,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Bank restricted deposit</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember', window );">New Drug Application and Biological License Application [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Description of application payment for licensed product</a></td>
<td class="text">$100 thousand upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct', window );">Royalty payments on sale of product (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember', window );">Capital Additions One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Description of application payment for licensed product</a></td>
<td class="text">$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_MaximumPercentageOfPaymentsOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_MaximumPercentageOfPaymentsOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty payments on sale of product developed with funding received from the IIA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432197912352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Nov. 17, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Nov. 16, 2022</div></th>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,863,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options to purchase ADS cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,373,620<span></span>
</td>
<td class="nump">1,240,120<span></span>
</td>
<td class="nump">1,712,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTreasuryStock', window );">Sale of treasury share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember', window );">2015 plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockReservedForIssuance', window );">Number of stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,443,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockAdssResveredForIssuance', window );">Number Of Stock Adss Resvered For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssOptionsIssuableOutstanding', window );">Number of ADSs options issuable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsIssuableOutstanding', window );">Number of options issuable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,826,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssVestedAndExercisable', window );">Number of ADSs vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsVestedAndExercisable', window );">Number of options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,394,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,445,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options to purchase ADS cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,634,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod', window );">Options to purchase ordinary shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember', window );">2017 plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockReservedForIssuance', window );">Number of stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,061,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockAdssResveredForIssuance', window );">Number Of Stock Adss Resvered For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,153,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssVestedAndExercisable', window );">Number of ADSs vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsVestedAndExercisable', window );">Number of options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,689,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,046,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">The Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's</a></td>
<td class="nump">$ 45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfWarrantsPurchaseUpAdss', window );">Number of warrants purchase ADS's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStocksPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember', window );">ATM agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement', window );">Aggregate offering price of at the market offering agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,371,000<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,125,000<span></span>
</td>
<td class="nump">699,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,900<span></span>
</td>
<td class="nump">130,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStocksPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember', window );">Repurchase arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RepurchaseOfAmericanDepositaryReceipts', window );">Repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares', window );">Number of shares repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,023<span></span>
</td>
<td class="nump">582,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts', window );">Weighted average price of repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts', window );">Total consideration of repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RothCapitalPartnersLlcMember', window );">Roth Capital Partners, LLC [Member] | Market offering agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,863,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts', window );">Weighted average price of repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts', window );">Total consideration of repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,553,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents as a aggregate offering price of at the market offering agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdssOptionsIssuableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADSs options issuable outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdssOptionsIssuableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdssVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADSs vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdssVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOptionsIssuableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of options issuable outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOptionsIssuableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of options vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfStockAdssResveredForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock option ADSs resvered for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfStockAdssResveredForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfStockReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of stock resvered for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfStockReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfWarrantsPurchaseUpAdss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants purchase ADS's.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfWarrantsPurchaseUpAdss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ProceedsFromSaleOfAdss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of ADS's.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ProceedsFromSaleOfAdss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents repurchase of American Depositary Receipts shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RepurchaseOfAmericanDepositaryReceiptsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStocksPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by the company for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStocksPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stocks of American Depository Shares ("ADS") issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Total consideration of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents weighted average price of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RothCapitalPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RothCapitalPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_MarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_MarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289034288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Share-based Compensation Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 1,491<span></span>
</td>
<td class="nump">$ 3,211<span></span>
</td>
<td class="nump">$ 2,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="nump">$ 2,763<span></span>
</td>
<td class="nump">$ 1,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432208780880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice', window );">Acquired in Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">0.39<span></span>
</td>
<td class="nump">0.32<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning</a></td>
<td class="nump">35,191,540<span></span>
</td>
<td class="nump">27,003,260<span></span>
</td>
<td class="nump">10,455,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger', window );">Acquired in Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">609,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,970,000)<span></span>
</td>
<td class="num">(134,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(20,373,620)<span></span>
</td>
<td class="num">(1,240,120)<span></span>
</td>
<td class="num">(1,712,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">15,055,180<span></span>
</td>
<td class="nump">11,398,400<span></span>
</td>
<td class="nump">17,784,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end</a></td>
<td class="nump">29,873,100<span></span>
</td>
<td class="nump">35,191,540<span></span>
</td>
<td class="nump">27,003,260<span></span>
</td>
<td class="nump">10,455,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
<td class="text">8 years 1 month 13 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Granted</a></td>
<td class="text">5 years 10 months 9 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of shares acquired in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options acquired, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432205910784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average share price (in U.S. dollar)</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">97.79%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">112.94%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.71%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.43%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in U.S. dollar)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (in years)</a></td>
<td class="text">4 years 6 months 10 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in U.S. dollar)</a></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (in years)</a></td>
<td class="text">9 years 5 months 15 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The weighted average share price is based on the Company&#8217;s ordinary share valuation as at the grant date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432288939472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development (Schedule of Research and Development) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ConsultantsAndSubcontractorsExpense', window );">Consultants and subcontractors</a></td>
<td class="nump">$ 14,014<span></span>
</td>
<td class="nump">$ 13,052<span></span>
</td>
<td class="nump">$ 3,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salaries and related expenses</a></td>
<td class="nump">3,362<span></span>
</td>
<td class="nump">2,867<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense', window );">Lease and maintenance</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense', window );">Share-based compensation</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other expenses</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 18,381<span></span>
</td>
<td class="nump">$ 16,977<span></span>
</td>
<td class="nump">$ 6,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ConsultantsAndSubcontractorsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consultants and subcontractors expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ConsultantsAndSubcontractorsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development related rent and maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RentAndMaintenanceResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development related share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432294376432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative (Schedule of General and Administrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related expenses</a></td>
<td class="nump">$ 2,545<span></span>
</td>
<td class="nump">$ 3,435<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">2,139<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense', window );">Share-based compensation</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Fees to Directors</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense', window );">Rent and maintenance</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other expenses</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 7,078<span></span>
</td>
<td class="nump">$ 11,556<span></span>
</td>
<td class="nump">$ 6,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative related rent and maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative related share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432203242720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in the total valuation allowance</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ReceivedAmountOfChemomabTherapeuticsInc', window );">Received amount of Chemomab Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc', window );">Expects to receive amount of Chemomab Therapeutics Inc</a></td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(534)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Capital losses carryforwards</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
<td class="nump">$ 143,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. [Member] | Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount expects to receive of Chemomab Therapeutics Inc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ReceivedAmountOfChemomabTherapeuticsInc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The received amount of Chemomab Therapeutics Inc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ReceivedAmountOfChemomabTherapeuticsInc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432209027600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 38,258<span></span>
</td>
<td class="nump">$ 36,550<span></span>
</td>
<td class="nump">$ 33,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation expense</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">4,041<span></span>
</td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">43,471<span></span>
</td>
<td class="nump">41,195<span></span>
</td>
<td class="nump">36,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less - Valuation allowance</a></td>
<td class="num">(43,471)<span></span>
</td>
<td class="num">(41,195)<span></span>
</td>
<td class="num">(36,030)<span></span>
</td>
<td class="num">$ (6,200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289469744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at January 1</a></td>
<td class="nump">$ 41,195<span></span>
</td>
<td class="nump">$ 36,030<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CurrencyTransactionLossValuationAllowance', window );">Currency transaction income (loss)</a></td>
<td class="num">(3,295)<span></span>
</td>
<td class="num">(1,316)<span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance', window );">Tax assets acquired through merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxExpenseValuationAllowance', window );">Income tax expense</a></td>
<td class="nump">5,571<span></span>
</td>
<td class="nump">6,481<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at December 31</a></td>
<td class="nump">$ 43,471<span></span>
</td>
<td class="nump">$ 41,195<span></span>
</td>
<td class="nump">$ 36,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CurrencyTransactionLossValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to currency transaction loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CurrencyTransactionLossValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxExpenseValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxExpenseValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432205667312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (24,221)<span></span>
</td>
<td class="num">$ (28,180)<span></span>
</td>
<td class="num">$ (12,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Statutory tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax benefit</a></td>
<td class="num">$ (5,571)<span></span>
</td>
<td class="num">$ (6,481)<span></span>
</td>
<td class="num">$ (2,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized', window );">Change in temporary differences for which deferred taxes were not recognized</a></td>
<td class="num">(1,177)<span></span>
</td>
<td class="num">(1,696)<span></span>
</td>
<td class="num">(1,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Tax rate differential</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded', window );">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</a></td>
<td class="nump">6,392<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
<td class="nump">4,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Actual income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (534)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents as a change in temporary differences for which deferred taxes were not recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432208705184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">$ 823<span></span>
</td>
<td class="nump">$ 1,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,423<span></span>
</td>
<td class="nump">3,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related Party Payables</a></td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">$ 949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432209382960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty', window );">Salaries and related expenses</a></td>
<td class="nump">$ 2,795<span></span>
</td>
<td class="nump">$ 2,409<span></span>
</td>
<td class="nump">$ 1,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty', window );">Share-based payments</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty', window );">Professional services</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty', window );">Research and development</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total related party expenses</a></td>
<td class="nump">$ 4,393<span></span>
</td>
<td class="nump">$ 5,142<span></span>
</td>
<td class="nump">$ 3,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to research and develeopment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to salaries and related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432203262112">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EarningsPerShareCalculationNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24,221<span></span>
</td>
<td class="nump">$ 27,646<span></span>
</td>
<td class="nump">$ 12,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">234,998,859<span></span>
</td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">234,998,859<span></span>
</td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.103<span></span>
</td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.103<span></span>
</td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EarningsPerShareCalculationNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Calculation Numerator Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EarningsPerShareCalculationNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140432289193088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding options to purchase ordinary shares</a></td>
<td class="nump">29,873,100<span></span>
</td>
<td class="nump">35,191,540<span></span>
</td>
<td class="nump">27,003,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MR_9Q3767)8R _GW%N=H.S%N*W5NIY?]02P,$%     @ 8C!\6)@L?'O= @
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M(#@2$.P# BG #X\$#/<!0[F%Z$A N \(3QWT:!\P:I*U4[=)S32EZ>2JKAY
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M%'Q(&,%A,._Z/1_M]].62C:UY2U'F2A-S5>#'.;>VW&T=(/:!X4$.Z#4!Y$
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M;.2!E "=X:5:2*^XNA("D7"H*O:"!8\KEB[9&DHOW"S0T?,[^K[-O#]<GID
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MB[+^N64T9]("S/.U$/IP85_0G859_0U02P,$%     @ 8C!\6) ./5$C"
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M* 0I+7I7,I2)V9!5>@U_,_3Y!OQ5\Z72VFPD<PE[M L>"!+B.E.QT+;*%Z(
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M;C!.Z= (WX5L(N)*9*(1QU'?1S(5>)O RTAJ>'S  GH'CI";O+*E0BQ0D8'
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M-$%;![I?*WK7UK !NC&<_ %02P,$%     @ 8C!\6 >DTRBH @  [04  !D
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M\*HL2BE2D@4NCHV-MB)S@;+TLJ52H@*FVN YR><)K?WANNT60H4+AS^Y+[C
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MZMXAP/"B0,PJ<;JV2M%6L5LIJW0K5U[9I^*[;UXN%@?'OKIG*;^;'^^)RU8
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MO;-:>:HS<2*+#-]2:@J*PA)DH#!_T0@H: :,K&%:(H^J\)HD)S&R044DQV'
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MT9@9D6V^M-IW8+%%S:%K_WHPU1E.=7[I6KR5\&@&8DNDC, +8/"C9T)<II<
M.A##3Q'&CZ?]40NU\0U[D=Y_?.C5$B#\WV7>4+8$#KK"W EG8,EP]M1WYEX0
MXB+B&_AN/$'CGOO.S)L[EXD]BL&2AJTXY_S?U%^XDVCBO&D?AYCI9X&[F#'[
M=L88A6MS7$-?  /D*]@++I6N>7P4TO@P]MW W@V\<$+79@$Q@PE?^S,]L.'Q
MP=0)4/L7X#.^4<_WIJ&#G?P,=6X:^\["FRT.K>XE!:T9.='$#19@[3')B,/C
MSOA_"95H^-%'SBFH?*?+]E P$#D&B$'X%ZC$OAO-T,G"%B^/,;&//\%SXOJ
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M*8E TP#<7Q9%W?Z@!;I7IE__#U!+ P04    " !B,'Q8VMA\@+H"   S!@
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M0XWRTPI_"F#( ?=7&F_3WJ $_6]F]@=02P,$%     @ 8C!\6%/6[NKK"0
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MRE27=4M1BI7K3#X<BCHO+QJ)S\;)J&6T XY"(G@X$.GLDZ[C%S4:U2ZA#,T
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M\./R*^12.=N$8$\/ I9;RKKD$C>F;BSL'AX"HIQAHM-2?&YK,3AVRMH8M1&
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M#K&XZ\6$Q#::Q.:=V\_O VB4V#-!J&_)^HOJ>!H;)36<QMXS?AO<HO]#GOS
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M?9.&K ]Z-U&S'YY>J(<GW:*31Q-NIL6H,#0PQY5EP>FL8!#&,P?%7<0F$PZ
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M>4K+WRR:Q+"X9R7XLZ8O*I@$F9*IT9H?N( ###6WILZL\U6ZWVJJ_@E2ASH
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M-T96N'4]*-YQ:I^G:H0@OX>:*3/R1'^07-I^C,)V_.HU_ &%Z\KL+23YMTT
M#5/UUA8M'NYMQ0]RSPE]@!OV#+DE\L,@< PL1'"-Q=O81BKOQCU1^5)=C60<
MB?@5H8Z389.(C>37M+G9U!R3[WS?-4R^Q08<7ZGR=9('#OP*!N06P,.039PE
M;XYO3+WB]^/YU<ZRD9?(X[?Q'?PK>?.\>UQ>X/^H:RIDD-&6M/1\^NS)"=5)
M_$Z\?*! Q.^A+ZJFJ3;\Y]IH2I1X@'Y?5B17_P$;Q/\SP:M_ U!+ P04
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M4BN-9%"_K.A&!.,2Z+S4&O>!:]#?L=E?4$L#!!0    ( &(P?%C,_UAQA0(
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M7W@_HNZ9J;FRQ+"BU.3D_#0"T\N^-YQN@]36VI%PP[*A28G&!]!^I;7;&;[
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M+1HZ%92'^1<@29:=W?&U!/MJ'B&!^J.HZ &6'4#Z#$"2LFNM<&O9!U5"^3=
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M&-(X'N[W[-<V=\QEQ11<B>9[7>IJYF0.+6'-^D;?B>U'V.4S,7R%:)1=Z7;
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MG"GU=(ZLLV>J(-'4"Y,IB5(O27P215XT2\FJ9 K.;4T6S@E(%<R5.CS:.9#
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M8,I]T;;U#3Q$UDJ+J@6;""K*FS]^:'78 X3C(X"H!43/ <,C@+@%Q"\%#%O
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MY[*C/G->C"?%1K*EN;"G3*KKWRQC-=(!UP[J_9PQN=GH -60&/P#4$L#!!0
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M$RU*VV560F//LL,,_RH@30#NKX70^XEI7.U_*OX+4$L#!!0    ( &(P?%B
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MU=!43^.]Y.HJ57DR6'"E""X?$4DC]/9G3C,U1_(*_:<4='&O1!/E,2"V0H;
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M;Q/J:V$*@Y5[;!A<PN(2UML)0^<R:J7!98<SE["Y(U@C#6'POIX1V!_09 F
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MI?I< *X#U/B<,?G:T05F_0$2_ -02P,$%     @ 8C!\6$F]DY)L!@  BQH
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MM'2&:C:J.<;A!X"94VVL=384W1/OYZ&/SD>U -5"5)NC6H1J,:6)&6[[9,;
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M3R6=C#A;$ZZLD4T-M)@:C>''F<K[3')\&B-.3F81Y4"F-(\E3<C^#.LJ7"9
MV)SH1T=*U)!,68J5)JC.U<6C&H,X(/L^2!HG.#HBMS.?[.\=D#T29^1GQ):"
M9J$8F1*]5'N90>G1>>&1\XI'MD.N6"8C02ZR$,(Z@8GA53$ZFQC/G59&'X)C
MXMJ'Q+$<M\&AZ=OA3@/<?SO<;HG&K3+F:CZW+6-E6J[I$_:@)&><TVP!:GRX
M24](4/]-9N-_$!Z2LY0MT?KN!U*22PFI^-.4GV)_KWE_]2(Z%3D-8&S@FT8
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M ZX,\/F<,;F9J VJN^'D/U!+ P04    " !B,'Q8 =WX_/T$  "A&@  &0
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M0M"L:L9 9$)0 O+[FE+QW%$3M.]'_K]02P,$%     @ 8C!\6,%O4523 P
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MWMT(Q95-7]Z\:+&K.]6UT-CWUH\9_LN - #\OA%"'U[,!-W?T?Q_4$L#!!0
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MI7=R2FFIUEG;#LK:>LU"(CF7;>;T&($R 32_E!*W';- _[S%_P!02P,$%
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M==D<\EGWN<3D$U!+ 0(4 Q0    ( &(P?%@'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 8C!\6*DX
MCY[O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ 8C!\6)E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !B,'Q81INNO&@'  !K
M)   &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ 8C!\6((EC\<!!@  H1H  !@              ("!K \
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( &(P?%B8+'Q[
MW0(  *\)   8              " @>,5  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " !B,'Q8I:"\A*8$  "A$   &
M@('V&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 8C!\
M6*3H$IB"!P  FRX  !@              ("!TAT  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( &(P?%@3F4*A5P<  !<C   8
M      " @8HE  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" !B,'Q8D X]42,(  "P$P  &               @($7+0  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 8C!\6-\E<M7($P  *C<  !@
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M970Q,BYX;6Q02P$"% ,4    " !B,'Q8"7>]D5<+  ""'0  &0
M    @(&<5P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M &(P?%A&./P%>P\  #XM   9              " @2IC  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ 8C!\6-K8?("Z @  ,P8  !D
M             ("!W'(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " !B,'Q8&MRIW=8"  !R!@  &0              @('-=0  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( &(P?%A3UN[JZPD
M  \9   9              " @=IX  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ 8C!\6-D Y-!Y P  70@  !D              ("!
M_((  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !B,'Q8
M%K#P$$8$  "J"P  &0              @(&LA@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &(P?%@.8(S<%14  *5    9
M      " @2F+  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ 8C!\6!\VTG., @  ;P4  !D              ("!=:   'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !B,'Q8S/]8<84"  "'!0
M&0              @($XHP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( &(P?%A=(B^:<0(  &P%   9              " @?2E  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 8C!\6+8%4O5X
M @  ?P4  !D              ("!G*@  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " !B,'Q8]QKJ\;("  #=!0  &0
M@(%+JP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( &(P
M?%CZGK-LAP(  'P%   9              " @32N  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ 8C!\6*/+4Q7)!   L0P  !D
M         ("!\K   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " !B,'Q8Y]7I<L8"   F!@  &0              @('RM0  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( &(P?%CK;9[;XP(  &(&
M   9              " @>^X  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ 8C!\6.1P7;:U!   P0L  !D              ("!";P
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !B,'Q8KTP<
MK?X"  !<!P  &0              @('UP   >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( &(P?%@.&.J<5@,  ',(   9
M  " @2K$  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M8C!\6,>FX#QF @  ,@4  !D              ("!M\<  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " !B,'Q86$OZ5:0"  !7!@  &0
M            @(%4R@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( &(P?%@IT&(VL0(  ,@'   9              " @2_-  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 8C!\6&<./! K P
MSPL  !D              ("!%]   'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " !B,'Q8$ :CK.L"   P"@  &0              @(%Y
MTP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( &(P?%BV
M$FZ5D (  +,&   9              " @9O6  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ 8C!\6( #F7#, P  <!,  !D
M     ("!8MD  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &(P?%B9QF&.7P,  "<.   9              "
M@0+[  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 8C!\
M6 '=^/S]!   H1H  !D              ("!F/X  'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " !B,'Q82S>$?9@&   7%@  &0
M        @(', P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( &(P?%CRW98Z1P,  ),*   9              " @9L* 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 8C!\6+H>VQ*+ P  &0P
M !D              ("!&0X! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " !B,'Q8C(5\9^X#  !+$@  &0              @(';$0$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( &(P?%C!;U%4
MDP,  (8-   9              " @0 6 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ 8C!\6$(*_<1' P  /PH  !D
M ("!RAD! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !B
M,'Q89?3,DBL$   I#0  &0              @(%('0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( &(P?%CP'4R4T@(  +\)   9
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M;',O+G)E;'-02P$"% ,4    " !B,'Q8BQ.MQI8$  !?)0  #P
M    @ &.,P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 8C!\6 P_D/SE
M 0  ?R$  !H              ( !43@! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ 8C!\6(_AMVG3 0  -B$  !,
M ( !;CH! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $  0 !W$0  <CP!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>100</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - Statements of Cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Other Receivables and Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses</Role>
      <ShortName>Other Receivables and Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - Research and Development</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopment</Role>
      <ShortName>Research and Development</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - General and Administrative</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrative</Role>
      <ShortName>General and Administrative</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - Related Parties Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions</Role>
      <ShortName>Related Parties Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0022 - Disclosure - General (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralTables</Role>
      <ShortName>General (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/General</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0023 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0024 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CashAndCashEquivalents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0025 - Disclosure - Other Receivables and Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables</Role>
      <ShortName>Other Receivables and Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0026 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0028 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapital</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0029 - Disclosure - Research and Development (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopmentTables</Role>
      <ShortName>Research and Development (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ResearchAndDevelopment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0030 - Disclosure - General and Administrative (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrativeTables</Role>
      <ShortName>General and Administrative (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralAndAdministrative</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0031 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0032 - Disclosure - Related Parties Balances and Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</Role>
      <ShortName>Related Parties Balances and Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0033 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0034 - Disclosure - General (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralDetails</Role>
      <ShortName>General (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0035 - Disclosure - General (Schedule of net assets acquired based on their estimated fair value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails</Role>
      <ShortName>General (Schedule of net assets acquired based on their estimated fair value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0036 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0037 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0038 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CashAndCashEquivalentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0039 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails</Role>
      <ShortName>Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0040 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0041 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0042 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails</Role>
      <ShortName>Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/LeasesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0043 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0044 - Disclosure - Share Capital (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>Share Capital (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0045 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails</Role>
      <ShortName>Share Capital (Schedule of Share-based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0046 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails</Role>
      <ShortName>Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0047 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails</Role>
      <ShortName>Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0048 - Disclosure - Research and Development (Schedule of Research and Development) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails</Role>
      <ShortName>Research and Development (Schedule of Research and Development) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ResearchAndDevelopmentTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0049 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails</Role>
      <ShortName>General and Administrative (Schedule of General and Administrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralAndAdministrativeTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0050 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0051 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails</Role>
      <ShortName>Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0052 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails</Role>
      <ShortName>Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0053 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0054 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0055 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0056 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="zk2431185.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0057 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LeaseExpirationDate1 -  zk2431185.htm 5</Log>
  </Logs>
  <InputFiles>
    <File>cmmb-20231231.xsd</File>
    <File>cmmb-20231231_cal.xml</File>
    <File>cmmb-20231231_def.xml</File>
    <File>cmmb-20231231_lab.xml</File>
    <File>cmmb-20231231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="zk2431185.htm">zk2431185.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cmmb_img01.jpg</File>
    <File>cmmb_img02.jpg</File>
    <File>image00019.jpg</File>
    <File>image00020.jpg</File>
    <File>image00021.jpg</File>
    <File>image00022.jpg</File>
    <File>image00023.jpg</File>
    <File>image00024.jpg</File>
    <File>image00025.jpg</File>
    <File>image00026.jpg</File>
    <File>image00027.jpg</File>
    <File>image00028.jpg</File>
    <File>image00029.jpg</File>
    <File>image00030.jpg</File>
    <File>image00031.jpg</File>
    <File>image00032.jpg</File>
    <File>image00033.jpg</File>
    <File>image13.jpg</File>
    <File>image3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="542">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2431185.htm": {
   "nsprefix": "cmmb",
   "nsuri": "http://www.anchiano.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "cmmb-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cmmb-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmmb-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cmmb-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmmb-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2431185.htm"
     ]
    }
   },
   "keyStandard": 214,
   "keyCustom": 70,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 11,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 100,
   "entityCount": 1,
   "segmentCount": 34,
   "elementCount": 453,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 542,
    "http://xbrl.sec.gov/dei/2023": 47
   },
   "report": {
    "R1": {
     "role": "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets",
     "longName": "0002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:DepositsAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.anchiano.com/role/BalanceSheetsParenthetical",
     "longName": "0003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "us-gaap:CommonStockNoParValue",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "us-gaap:CommonStockNoParValue",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.anchiano.com/role/StatementsOfOperations",
     "longName": "0004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.anchiano.com/role/StatementsOfChangesInEquity",
     "longName": "0005 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.anchiano.com/role/StatementsOfCashFlows",
     "longName": "0006 - Statement - Statements of Cash flows",
     "shortName": "Statements of Cash flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.anchiano.com/role/General",
     "longName": "0007 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "0008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.anchiano.com/role/CashAndCashEquivalents",
     "longName": "0009 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses",
     "longName": "0010 - Disclosure - Other Receivables and Prepaid Expenses",
     "shortName": "Other Receivables and Prepaid Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNet",
     "longName": "0011 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.anchiano.com/role/Leases",
     "longName": "0012 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.anchiano.com/role/CommitmentsAndContingentLiabilities",
     "longName": "0013 - Disclosure - Commitments and Contingent Liabilities",
     "shortName": "Commitments and Contingent Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.anchiano.com/role/ShareCapital",
     "longName": "0014 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.anchiano.com/role/ResearchAndDevelopment",
     "longName": "0015 - Disclosure - Research and Development",
     "shortName": "Research and Development",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.anchiano.com/role/GeneralAndAdministrative",
     "longName": "0016 - Disclosure - General and Administrative",
     "shortName": "General and Administrative",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.anchiano.com/role/IncomeTaxes",
     "longName": "0017 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions",
     "longName": "0018 - Disclosure - Related Parties Balances and Transactions",
     "shortName": "Related Parties Balances and Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders",
     "longName": "0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "0021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.anchiano.com/role/GeneralTables",
     "longName": "0022 - Disclosure - General (Tables)",
     "shortName": "General (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "0023 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.anchiano.com/role/CashAndCashEquivalentsTables",
     "longName": "0024 - Disclosure - Cash and Cash Equivalents (Tables)",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables",
     "longName": "0025 - Disclosure - Other Receivables and Prepaid Expenses (Tables)",
     "shortName": "Other Receivables and Prepaid Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNetTables",
     "longName": "0026 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.anchiano.com/role/LeasesTables",
     "longName": "0027 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.anchiano.com/role/ShareCapitalTables",
     "longName": "0028 - Disclosure - Share Capital (Tables)",
     "shortName": "Share Capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.anchiano.com/role/ResearchAndDevelopmentTables",
     "longName": "0029 - Disclosure - Research and Development (Tables)",
     "shortName": "Research and Development (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.anchiano.com/role/GeneralAndAdministrativeTables",
     "longName": "0030 - Disclosure - General and Administrative (Tables)",
     "shortName": "General and Administrative (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.anchiano.com/role/IncomeTaxesTables",
     "longName": "0031 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables",
     "longName": "0032 - Disclosure - Related Parties Balances and Transactions (Tables)",
     "shortName": "Related Parties Balances and Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables",
     "longName": "0033 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.anchiano.com/role/GeneralDetails",
     "longName": "0034 - Disclosure - General (Narrative) (Details)",
     "shortName": "General (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember",
      "name": "cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember",
      "name": "cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails",
     "longName": "0035 - Disclosure - General (Schedule of net assets acquired based on their estimated fair value) (Details)",
     "shortName": "General (Schedule of net assets acquired based on their estimated fair value) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_20210316",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20210316",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "0036 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:PercentageOfMonthlyDepositsRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "cmmb:SeverancePayPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:PercentageOfMonthlyDepositsRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "cmmb:SeverancePayPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails",
     "longName": "0037 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
     "longName": "0038 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)",
     "shortName": "Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_srtCurrencyAxis_currencyUSD",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails",
     "longName": "0039 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)",
     "shortName": "Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "cmmb:ReceivablesFromGovernmentInstitutions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "cmmb:ReceivablesFromGovernmentInstitutions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
     "longName": "0040 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)",
     "shortName": "Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.anchiano.com/role/LeasesNarrativeDetails",
     "longName": "0041 - Disclosure - Leases (Narrative) (Details)",
     "shortName": "Leases (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_20200510",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20200510",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails",
     "longName": "0042 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)",
     "shortName": "Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
     "longName": "0043 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)",
     "shortName": "Commitments and Contingent Liabilities (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OtherCommitmentsDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:OtherCommitmentsDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
     "longName": "0044 - Disclosure - Share Capital (Narrative) (Details)",
     "shortName": "Share Capital (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_20231001to20231031",
      "name": "cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231001to20231031",
      "name": "cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails",
     "longName": "0045 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)",
     "shortName": "Share Capital (Schedule of Share-based Compensation Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails",
     "longName": "0046 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)",
     "shortName": "Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_20221231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20221231",
      "name": "cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
     "longName": "0047 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)",
     "shortName": "Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:SharePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:SharePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails",
     "longName": "0048 - Disclosure - Research and Development (Schedule of Research and Development) (Details)",
     "shortName": "Research and Development (Schedule of Research and Development) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ConsultantsAndSubcontractorsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:ConsultantsAndSubcontractorsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails",
     "longName": "0049 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)",
     "shortName": "General and Administrative (Schedule of General and Administrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SalariesAndWages",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
       "div",
       "div",
       "div",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:SalariesAndWages",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
       "div",
       "div",
       "div",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.anchiano.com/role/IncomeTaxesDetails",
     "longName": "0050 - Disclosure - Income Taxes (Narrative) (Details)",
     "shortName": "Income Taxes (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails",
     "longName": "0051 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)",
     "shortName": "Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails",
     "longName": "0052 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)",
     "shortName": "Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_20221231",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:CurrencyTransactionLossValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
     "longName": "0053 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)",
     "shortName": "Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
     "longName": "0054 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)",
     "shortName": "Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails",
     "longName": "0055 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)",
     "shortName": "Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
     "longName": "0056 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231",
      "name": "us-gaap:IncomeLossFromContinuingOperationsPerBasicShare",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
     "longName": "0057 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "strong",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "strong",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431185.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognized liability for royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less - accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r119",
      "r349"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r492",
      "r603"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid In Capital [Member]",
        "verboseLabel": "Additional paid in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r374",
      "r539",
      "r540",
      "r541",
      "r583",
      "r606"
     ]
    },
    "cmmb_AdditionalWorkOrderAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "AdditionalWorkOrderAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional work order amount.",
        "label": "Additional Work Order Amount",
        "verboseLabel": "Additional work order"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r34",
      "r83"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AggregateAmountCommitmentToPay": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "AggregateAmountCommitmentToPay",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount commitment to pay.",
        "label": "Aggregate amount commitment to pay"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AggregateAmountOfCommitmentPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "AggregateAmountOfCommitmentPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of commitment paid.",
        "label": "Aggregate amount of commitment paid"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "AggregateOfferingPriceOfAtMarketOfferingAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a aggregate offering price of at the market offering agreement.",
        "label": "Aggregate Offering Price Of At Market Offering Agreement",
        "terseLabel": "Aggregate offering price of at the market offering agreement"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r256"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Shares [Member]",
        "label": "American Depositary Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AnnualRatesOfDepreciation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "AnnualRatesOfDepreciation",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rates of depreciation.",
        "label": "Annual Rates Of Depreciation",
        "verboseLabel": "Annual rates of depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AnnualRentAndManagementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "AnnualRentAndManagementFees",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rent and management fees.",
        "label": "Annual rent and management fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding options to purchase ordinary shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r120",
      "r137",
      "r171",
      "r174",
      "r176",
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r284",
      "r288",
      "r299",
      "r342",
      "r411",
      "r492",
      "r504",
      "r548",
      "r549",
      "r591"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r125",
      "r137",
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r284",
      "r288",
      "r299",
      "r492",
      "r548",
      "r549",
      "r591"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r284",
      "r288",
      "r299",
      "r548",
      "r549",
      "r591"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_AtmAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "AtmAgreementMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM agreement [Member]",
        "label": "ATM agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm Id",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "cmmb_BankGuaranteesToPropertyOwner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "BankGuaranteesToPropertyOwner",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank guarantees to property owner.",
        "label": "Bank guarantees to property owner"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of presentation",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r486",
      "r487"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r282",
      "r486",
      "r487"
     ]
    },
    "cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of of asset held for sale recogized prior to the completion of merger.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Asset Held For Sale",
        "verboseLabel": "Asset held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "negatedLabel": "Accrued liabilities",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514"
     ]
    },
    "cmmb_CantorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "CantorMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about Cantor.",
        "label": "Cantor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalAdditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalAdditionsMember",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Drug Application and Biological License Application [Member]",
        "documentation": "Contractual obligation to increase property, plant and equipment either through construction or future purchases."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_CapitalAdditionsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "CapitalAdditionsOneMember",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FDA or equivalent agency marketing approval [Member]",
        "label": "Capital Additions One [Member]",
        "verboseLabel": "FDA or equivalent agency marketing approval [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_CashAcquiredInMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "CashAcquiredInMerger",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash acquired in merger.",
        "label": "Cash acquired in Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r117",
      "r477"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r344"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Restricted cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r90"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r73",
      "r135"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r73"
     ]
    },
    "cmmb_CashPaidAndReceivedDuringYearForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "CashPaidAndReceivedDuringYearForAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Cash Paid And Received During Year For [Abstract]",
        "terseLabel": "A. Cash paid and received during the year for:"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a change in temporary differences for which deferred taxes were not recognized.",
        "label": "Change In Temporary Differences For Deferred Taxes Not Recognized",
        "terseLabel": "Change in temporary differences for which deferred taxes were not recognized"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r121",
      "r122",
      "r123",
      "r137",
      "r158",
      "r159",
      "r161",
      "r163",
      "r169",
      "r170",
      "r180",
      "r197",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r299",
      "r364",
      "r365",
      "r366",
      "r367",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r399",
      "r420",
      "r442",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r521",
      "r537",
      "r543"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingent liabilities",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r50",
      "r343",
      "r398"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "verboseLabel": "Ordinary shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r539",
      "r540",
      "r583",
      "r602",
      "r606"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r399"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 228,090,300 shares at December 31, 2021 and 9,274,838 shares at December 31, 2020",
        "terseLabel": "Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2023, 2022 and 2021;Issued and outstanding: 284,094,700, 232,636,700 Ordinary shares at December 31, 2023 and 2022, respectively and 228,090,300 Ordinary shares at December 31, 2021",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r345",
      "r492"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of credit risks",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r104"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r479"
     ]
    },
    "cmmb_ConsultantsAndSubcontractorsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ConsultantsAndSubcontractorsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants and subcontractors expenses.",
        "label": "Consultants And Subcontractors Expense",
        "verboseLabel": "Consultants and subcontractors"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Costs",
        "totalLabel": "Total related party expenses",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r137",
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r299",
      "r548"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "CumulativeAmountsOfGrantsReceivedAndRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.",
        "label": "Cumulative Amounts Of Grants Received And Recognized",
        "verboseLabel": "Cumulative amounts of grants received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "cmmb_CurrencyTransactionLossValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "CurrencyTransactionLossValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to currency transaction loss.",
        "label": "Currency Transaction Loss Valuation Allowance",
        "terseLabel": "Currency transaction income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental borrowing rate based on credit rating",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r582"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry-forwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r582"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r582"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r582"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails",
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less - Valuation allowance",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term bank deposit",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r32"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r516"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "EUR",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per Ordinary Share",
        "terseLabel": "Basic loss per Ordinary Share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r156",
      "r158",
      "r161",
      "r162",
      "r163",
      "r167",
      "r297",
      "r298",
      "r339",
      "r354",
      "r480"
     ]
    },
    "cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract",
        "label": "Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_EarningsPerShareCalculationNumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "EarningsPerShareCalculationNumeratorAbstract",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Calculation Numerator Abstract",
        "label": "Earnings Per Share Calculation Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per Ordinary Share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r158",
      "r161",
      "r162",
      "r163",
      "r167",
      "r297",
      "r298",
      "r339",
      "r354",
      "r480"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per ordinary share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share Attributable to Ordinary Shareholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r164",
      "r165",
      "r166"
     ]
    },
    "cmmb_EffectOfReverseCapitalizationTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "EffectOfReverseCapitalizationTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of effect due reverse capitalization transaction.",
        "label": "Effect of reverse capitalization transaction"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_EffectOfReverseCapitalizationTransactionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "EffectOfReverseCapitalizationTransactionShares",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares isued due to effect of reverse capitalization transaction.",
        "label": "Effect Of Reverse Capitalization Transaction Shares",
        "verboseLabel": "Effect of reverse capitalization transaction (In shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate tax rate (as a percent)",
        "terseLabel": "Corporate tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r264",
      "r278"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well Known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r113",
      "r129",
      "r130",
      "r131",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r168",
      "r181",
      "r182",
      "r211",
      "r249",
      "r250",
      "r251",
      "r274",
      "r275",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r315",
      "r357",
      "r358",
      "r359",
      "r374",
      "r442"
     ]
    },
    "cmmb_EstimatedFairValueOfNetAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "EstimatedFairValueOfNetAssetsAcquired",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated fair value of the net assets acquired.",
        "label": "Estimated Fair Value Of Net Assets Acquired",
        "totalLabel": "Net acquired assets"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ExpectsToReceiveAmountOfChemomabTherapeuticsInc",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount expects to receive of Chemomab Therapeutics Inc.",
        "label": "Expects To Receive Amount Of Chemomab Therapeutics Inc",
        "terseLabel": "Expects to receive amount of Chemomab Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional currency",
        "verboseLabel": "Foreign currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "cmmb_FormerChemomabSecurityHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "FormerChemomabSecurityHoldersMember",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents former Chemomab security holders.",
        "label": "Former Chemomab Security Holders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Equipment [Member]",
        "terseLabel": "Furniture and equipment [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_GeneralAndAdministrativeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "GeneralAndAdministrativeDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of general and administrative expenses.",
        "label": "General And Administrative Disclosure [Text Block]",
        "verboseLabel": "General and Administrative"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "terseLabel": "General and administrative",
        "totalLabel": "Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r422"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Government Sponsored Research And Development [Policy Text Block]",
        "verboseLabel": "Government-sponsored research and development"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "IL",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_ILS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "ILS",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILS [Member]",
        "terseLabel": "NIS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r80"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss before income tax",
        "negatedTotalLabel": "Loss before taxes",
        "positiveTerseLabel": "Loss before income taxes",
        "positiveVerboseLabel": "Loss before taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r65",
      "r94",
      "r171",
      "r173",
      "r175",
      "r177",
      "r340",
      "r351",
      "r482"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to ordinary shareholders, basic and diluted",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r93",
      "r95",
      "r132",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r158",
      "r161",
      "r162",
      "r298",
      "r339",
      "r600"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, diluted",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r132",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r158",
      "r161",
      "r162",
      "r163",
      "r298",
      "r339",
      "r600"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r188",
      "r427"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r427"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information pertaining to income taxes.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r260",
      "r265",
      "r266",
      "r272",
      "r276",
      "r279",
      "r280",
      "r281",
      "r369"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails",
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveTerseLabel": "Tax benefit",
        "positiveVerboseLabel": "Actual income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r110",
      "r152",
      "r153",
      "r172",
      "r263",
      "r277",
      "r355"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_IncomeTaxExpenseValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "IncomeTaxExpenseValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to income tax expense.",
        "label": "Income Tax Expense Valuation Allowance",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r261",
      "r262",
      "r266",
      "r267",
      "r271",
      "r273",
      "r363"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Tax rate differential",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theoretical tax benefit",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible expenses",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "cmmb_IncomeTaxesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "IncomeTaxesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents income taxes received.",
        "label": "Income Taxes Received",
        "verboseLabel": "Income taxes received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in trade payables",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in employees and related expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in leases",
        "terseLabel": "Change in operating leases",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r535"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in other receivables and prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cmmb_IncrementalBorrowingRateOfLeases": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "IncrementalBorrowingRateOfLeases",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents incremental borrowing rate of leases.",
        "label": "Incremental Borrowing Rate Of Leases",
        "verboseLabel": "incremental borrowing rate of leases"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_InterestReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "InterestReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest received.",
        "label": "Interest Received",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_InvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "InvestorsMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors [Member]",
        "label": "Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Lien [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expiry date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases",
        "terseLabel": "Schedule of maturity of lease liabilities under our non-cancelable operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022",
        "terseLabel": "2023",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest:",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease term, option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r137",
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r285",
      "r288",
      "r289",
      "r299",
      "r397",
      "r481",
      "r504",
      "r548",
      "r591",
      "r592"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r92",
      "r347",
      "r492",
      "r538",
      "r546",
      "r584"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities assumed, net of non-cash assets received in Merger",
        "verboseLabel": "Liabilities assumed, net of non-cash assets received in Merger",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r116",
      "r137",
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r285",
      "r288",
      "r289",
      "r299",
      "r492",
      "r548",
      "r591",
      "r592"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r55",
      "r56",
      "r137",
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r285",
      "r288",
      "r289",
      "r299",
      "r548",
      "r591",
      "r592"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_LienOnBankDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "LienOnBankDeposit",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lien on bank deposit.",
        "label": "Lien on bank deposit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_LongTermLeaseDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "LongTermLeaseDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term lease deposit.",
        "label": "Long Term Lease Deposit",
        "verboseLabel": "Long-term lease deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for licensed agreement",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentDescription",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of application payment for licensed product",
        "documentation": "Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.",
        "label": "Losses And Benefits For Tax Purposes For The Year For Which Deferred Taxes Were Not Recorded",
        "terseLabel": "Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_MarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "MarketOfferingAgreementMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market Offering Agreement [Member]",
        "documentation": "This member stands for market offering agreement.",
        "terseLabel": "Market offering agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r214",
      "r325",
      "r356",
      "r389",
      "r390",
      "r448",
      "r450",
      "r452",
      "r453",
      "r455",
      "r474",
      "r475",
      "r483",
      "r484",
      "r488",
      "r493",
      "r550",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "cmmb_MaximumPercentageOfPaymentsOfRoyalties": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "MaximumPercentageOfPaymentsOfRoyalties",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.",
        "label": "Maximum Percentage Of Payments Of Royalties",
        "verboseLabel": "Maximum percentage of payments of royalties (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Merger Agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company inclued proposed merger of CMB Acquisition Ltd, wholly owned subsidiary of our company.",
        "label": "Merger Agreement With Cmb Acquisition Ltd Subsidiary Of Ours And Chemomb [Member]",
        "verboseLabel": "Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r214",
      "r325",
      "r356",
      "r389",
      "r390",
      "r448",
      "r450",
      "r452",
      "r453",
      "r455",
      "r474",
      "r475",
      "r483",
      "r484",
      "r488",
      "r493",
      "r550",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.anchiano.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r111"
     ]
    },
    "cmmb_NatureOfOperationsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NatureOfOperationsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature Of Operations Disclosure [Abstract]",
        "verboseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "negatedTotalLabel": "Net loss for the year",
        "label": "Net loss for the year",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r75",
      "r96",
      "r114",
      "r126",
      "r127",
      "r131",
      "r137",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r160",
      "r171",
      "r173",
      "r175",
      "r177",
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r298",
      "r299",
      "r353",
      "r419",
      "r440",
      "r441",
      "r482",
      "r502",
      "r548"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant non- cash transaction:",
        "terseLabel": "B. Significant non- cash transaction:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpenseDirectorsFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoninterestExpenseDirectorsFees",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees to Directors",
        "documentation": "Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing expense (income), net",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Financing expenses (income), net",
        "totalLabel": "Nonoperating Income (Expense), Total",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfAdsIssuedAndOutstandingAfterMerger",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADS issued and outstanding after the merger.",
        "label": "Number of ADS issued and outstanding after the merger"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfAdssOptionsIssuableOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfAdssOptionsIssuableOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADSs options issuable outstanding.",
        "label": "Number of ADSs options issuable outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfAdssVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfAdssVestedAndExercisable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADSs vested and exercisable.",
        "label": "Number of ADSs vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfOptionsIssuableOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfOptionsIssuableOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of options issuable outstanding.",
        "label": "Number Of Options Issuable Outstanding",
        "verboseLabel": "Number of options issuable outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfOptionsVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfOptionsVestedAndExercisable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of options vested and exercisable.",
        "label": "Number Of Options Vested And Exercisable",
        "verboseLabel": "Number of options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfOrdinarySharesConsistedInDs": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfOrdinarySharesConsistedInDs",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the number of ordinary shares consisted in one American depository share (ADS).",
        "label": "Number Of Ordinary Shares Consisted In Ds",
        "verboseLabel": "Number of ordinary shares represented by each ADS (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfStockAdssResveredForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfStockAdssResveredForIssuance",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock option ADSs resvered for issuance.",
        "label": "Number Of Stock Adss Resvered For Issuance",
        "verboseLabel": "Number of stock option ADSs reversed for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfStockReservedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfStockReservedForIssuance",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of stock resvered for issuance.",
        "label": "Number Of Stock Reserved For Issuance",
        "verboseLabel": "Number of stock reserved for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfVestedAndExercisable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of vested and exercisable.",
        "label": "Number Of Vested And Exercisable",
        "verboseLabel": "Number of vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_NumberOfWarrantsPurchaseUpAdss": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "NumberOfWarrantsPurchaseUpAdss",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants purchase ADS's.",
        "label": "Number Of Warrants Purchase Up Adss",
        "verboseLabel": "Number of warrants purchase ADS's"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries and related expenses",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in the carrying amount of the right-of-use asset due to impairment",
        "terseLabel": "Increase in the carrying amount of the right-of-use asset due to impairment",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails",
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Present value of operating lease liabilities",
        "verboseLabel": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current operating lease liabilities",
        "verboseLabel": "Non-current\u00a0operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "OperatingRightOfUseAssetsAndOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating right-of-use assets and operating lease liabilities.",
        "label": "Operating Right Of Use Assets And Operating Lease Liabilities",
        "verboseLabel": "Operating right-of-use assets and operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_OrdinarySharesNoParValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "OrdinarySharesNoParValuePerShareMember",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares, No Par Value Per Share [Member]",
        "label": "Ordinary Shares, No Par Value Per Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other accounts receivable and prepaid expenses.",
        "label": "Other Accounts Receivable And Prepaid Expenses [Text Block]",
        "verboseLabel": "Other Receivables and Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDescription",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decsription of occurrence for payments",
        "documentation": "Description of the nature and terms of commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "verboseLabel": "Other expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r605"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to Related Parties, Current",
        "totalLabel": "Related Party Payables",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r492"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment on commencement of agreement.",
        "label": "Payment On Long Term Purchase Commitment Commencement Of Agreement",
        "verboseLabel": "Payment on commencement of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_PaymentsForInvestmentInDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "PaymentsForInvestmentInDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payments for investm,ents in deposits.",
        "negatedLabel": "Investment in deposits",
        "label": "Payments for Investment in Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury share",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "cmmb_PercentageOfMonthlyDepositsRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "PercentageOfMonthlyDepositsRate",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of monthly deposits rate.",
        "label": "Percentage of monthly deposits rate"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "PercentageOfRoyaltyPaymentsOnSaleOfProduct",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalty payments on sale of product developed with funding received from the IIA.",
        "label": "Percentage Of Royalty Payments On Sale Of Product",
        "verboseLabel": "Royalty payments on sale of product (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred shares par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r206"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r206"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables and prepaid expenses",
        "totalLabel": "Other accounts receivable and prepaid expenses, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r183",
      "r184",
      "r478"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term prepaid expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from preferred shares",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Other Equity",
        "verboseLabel": "Issuance of shares net of issuance costs",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cmmb_ProceedsFromSaleOfAdss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ProceedsFromSaleOfAdss",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of ADS's.",
        "label": "Proceeds from sale of ADS's"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfOtherAssetsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of asset held for sale",
        "documentation": "Amount of cash inflow from the sale of other assets recognized in investing activities."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_ProceedsFromSaleOfTreasuryStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfTreasuryStock",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Treasury Stock",
        "verboseLabel": "Treasury stock at cost",
        "terseLabel": "Sale of treasury share",
        "documentation": "The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r604",
      "r605"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Loss before taxes",
        "verboseLabel": "Net loss for the year",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r126",
      "r127",
      "r133",
      "r137",
      "r144",
      "r152",
      "r153",
      "r171",
      "r173",
      "r175",
      "r177",
      "r180",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r283",
      "r286",
      "r287",
      "r298",
      "r299",
      "r340",
      "r352",
      "r373",
      "r419",
      "r440",
      "r441",
      "r482",
      "r489",
      "r490",
      "r503",
      "r532",
      "r548"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r105",
      "r108",
      "r109"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r118",
      "r350"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 30.0
      },
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property Plant And Equipment Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r341",
      "r350",
      "r492"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r105",
      "r108",
      "r348"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual rates of depreciation",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property And Equpment, Net",
        "terseLabel": "Schedule of property and equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r212",
      "r214",
      "r244",
      "r245",
      "r246",
      "r324",
      "r325",
      "r356",
      "r389",
      "r390",
      "r448",
      "r450",
      "r452",
      "r453",
      "r455",
      "r474",
      "r475",
      "r483",
      "r484",
      "r488",
      "r493",
      "r496",
      "r547",
      "r550",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r212",
      "r214",
      "r244",
      "r245",
      "r246",
      "r324",
      "r325",
      "r356",
      "r389",
      "r390",
      "r448",
      "r450",
      "r452",
      "r453",
      "r455",
      "r474",
      "r475",
      "r483",
      "r484",
      "r488",
      "r493",
      "r496",
      "r547",
      "r550",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "cmmb_ReassessmentOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ReassessmentOfRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reassessment Of Right Of Use Asset",
        "documentation": "Represent the amount of reassessment of the right of use asset",
        "verboseLabel": "Reassessment of the right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ReceivablesFromGovernmentInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ReceivablesFromGovernmentInstitutions",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government institutions.",
        "label": "Receivables From Government Institutions",
        "verboseLabel": "Government institutions"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ReceivedAmountOfChemomabTherapeuticsInc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ReceivedAmountOfChemomabTherapeuticsInc",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The received amount of Chemomab Therapeutics Inc.",
        "label": "Received Amount Of Chemomab Therapeutics Inc",
        "terseLabel": "Received amount of Chemomab Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RecoverabilityOfVatAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RecoverabilityOfVatAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents recoverability of VAT amount.",
        "label": "Recoverability Of Vat Amount",
        "verboseLabel": "Recoverability of VAT amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r319",
      "r320",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r416",
      "r418",
      "r447"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r319",
      "r320",
      "r321",
      "r322",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r416",
      "r418",
      "r447"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r427"
     ]
    },
    "cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to professional services.",
        "label": "Related Party Transaction Professional Services From Transactions With Related Party",
        "verboseLabel": "Professional services"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to research and develeopment expense.",
        "label": "Related Party Transaction Research And Development Expense From Transactions With Related Party",
        "verboseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to salaries and related expenses.",
        "label": "Related Party Transaction Salaries And Related Expenses From Transactions With Related Party",
        "verboseLabel": "Salaries and related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to share based payments.",
        "label": "Related Party Transaction Share Based Payments From Transactions With Related Party",
        "verboseLabel": "Share-based payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r319",
      "r320",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r416",
      "r418",
      "r447",
      "r590"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Balances and Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r370",
      "r371",
      "r372",
      "r425",
      "r426",
      "r427",
      "r445",
      "r446"
     ]
    },
    "cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RentAndMaintenanceGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative related rent and maintenance expenses.",
        "label": "Rent And Maintenance General And Administrative Expense",
        "verboseLabel": "Rent and maintenance"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RentAndMaintenanceResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RentAndMaintenanceResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development related rent and maintenance expenses.",
        "label": "Rent And Maintenance Research And Development Expense",
        "terseLabel": "Lease and maintenance"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RepurchaseArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RepurchaseArrangementMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Repurchase Arrangement.",
        "label": "Repurchase Arrangement [Member]",
        "verboseLabel": "Repurchase arrangement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RepurchaseOfAmericanDepositaryReceipts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RepurchaseOfAmericanDepositaryReceipts",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of repurchase of american depositary receipts.",
        "label": "Repurchase Of American Depositary Receipts",
        "verboseLabel": "Repurchase of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_RepurchaseOfAmericanDepositaryReceiptsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RepurchaseOfAmericanDepositaryReceiptsShares",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents repurchase of American Depositary Receipts shares",
        "label": "Repurchase Of American Depositary Receipts Shares",
        "verboseLabel": "Number of shares repurchase of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "totalLabel": "Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r258",
      "r599"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r259"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r536"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r527",
      "r536"
     ]
    },
    "us-gaap_RestrictedInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank restricted deposit",
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r83",
      "r346",
      "r360",
      "r361",
      "r368",
      "r400",
      "r492"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r181",
      "r182",
      "r249",
      "r250",
      "r251",
      "r274",
      "r275",
      "r290",
      "r292",
      "r293",
      "r295",
      "r296",
      "r357",
      "r359",
      "r374",
      "r606"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset recognized with corresponding lease liability",
        "verboseLabel": "Right-of-use asset recognized with corresponding lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r491"
     ]
    },
    "cmmb_RothCapitalPartnersLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "RothCapitalPartnersLlcMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roth Capital Partners Llc [Member]",
        "documentation": "This member stands for Roth Capital Partners, LLC",
        "terseLabel": "Roth Capital Partners, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royality expenses",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "verboseLabel": "Salaries and related expenses",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "cmmb_SaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "SaleOfStockLineItems",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Sale Of Stock [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_SaleOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "SaleOfStockTable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Sale Of Stock [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_SaleOfStocksPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "SaleOfStocksPricePerShare",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by the company for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stocks Price Per Share",
        "verboseLabel": "Share price per share"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r542"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r215",
      "r522",
      "r542"
     ]
    },
    "cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ScheduleOfAnnualRateOfDeprecationTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the annual rate of deprecation.",
        "label": "Schedule Of Annual Rate Of Deprecation [Table Text Block]",
        "terseLabel": "Schedule of annual rate of deprecation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Number of Shares Excluded From Computation of Diluted Net Loss Per Share",
        "terseLabel": "Schedule of weighted average number of shares excluded from computation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of cash and cash equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of the effect of share-based compensation on the statements of operations",
        "terseLabel": "Schedule of the effect of share-based compensation on the statements of operations",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Significant Components of the Company's Deferred Tax Asset",
        "terseLabel": "Schedule of significant components of the company's deferred tax asset",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "terseLabel": "Schedule of computation of basic and diluted net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense",
        "terseLabel": "Schedule of reconciliation of theoretical income tax expense to actual income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ScheduleOfGeneralAndAdministrativeTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "Schedule Of General And Administrative [Table Text Block]",
        "terseLabel": "Schedule of general and administrative"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other accounts receivable and prepaid expenses.",
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses [Table Text Block]",
        "verboseLabel": "Schedule of other accounts receivable and prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/GeneralTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of net assets acquired based on their estimated fair value",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ScheduleOfRelatedPartyPayablesTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party payables.",
        "label": "Schedule Of Related Party Payables [Table Text Block]",
        "terseLabel": "Schedule of related party payables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r423",
      "r424",
      "r427"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Transaction With Related Parties",
        "terseLabel": "Schedule of transaction with related parties",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ScheduleOfResearchAndDevelopmentTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of research and development expenses.",
        "label": "Schedule Of Research And Development [Table Text Block]",
        "terseLabel": "Schedule of research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of assumptions used to calculate the fair value of the options",
        "terseLabel": "Schedule of assumptions used to calculate the fair value of the options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of number and weighted average exercise prices of option",
        "terseLabel": "Schedule of number and weighted average exercise prices of option",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Exchange on which Security is Registered",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents security holders of Anchiano as of immediately prior to the merger.",
        "label": "Security holders of Anchiano as of immediately prior to the merger [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "auth_ref": [
      "r178",
      "r179",
      "r386",
      "r387",
      "r388",
      "r449",
      "r451",
      "r454",
      "r456",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r485",
      "r496",
      "r552",
      "r601"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529",
      "r551"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cmmb_SeverancePayPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "SeverancePayPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for severance pay.",
        "label": "Severance Pay [Policy Text Block]",
        "verboseLabel": "Severance pay"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Ads Forfeitures In Period",
        "verboseLabel": "Options to purchase ordinary shares cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Ads Outstanding Period Increase Decrease Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price (in U.S. dollar)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Options to purchase ADS cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price",
        "documentation": "Change in the weighted average exercise price of options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award, Options, Acquired In Merger, Weighted Average Exercise Price",
        "documentation": "Weighted average price of shares acquired in merger.",
        "terseLabel": "Acquired in Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ShareBasedCompensationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative related share-based compensation.",
        "label": "Share Based Compensation General And Administrative Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r252",
      "r253",
      "r254",
      "r255"
     ]
    },
    "cmmb_ShareBasedCompensationResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ShareBasedCompensationResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development related share-based compensation.",
        "label": "Share Based Compensation Research And Development Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average share price (in U.S. dollar)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84"
     ]
    },
    "cmmb_ShareholdingPercentageImmediatelyFollowingMerger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ShareholdingPercentageImmediatelyFollowingMerger",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shareholding percentage immediately following the merger.",
        "label": "Shareholding percentage immediately following the merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_ShortTermBankDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "ShortTermBankDepositsPolicyTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Bank Deposits [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Short-term Bank Deposits",
        "verboseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r136"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Website Development [Member]",
        "terseLabel": "Website development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r121",
      "r122",
      "r123",
      "r137",
      "r158",
      "r159",
      "r161",
      "r163",
      "r169",
      "r170",
      "r180",
      "r197",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r299",
      "r364",
      "r365",
      "r366",
      "r367",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r399",
      "r420",
      "r442",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r521",
      "r537",
      "r543"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r19",
      "r113",
      "r129",
      "r130",
      "r131",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r168",
      "r181",
      "r182",
      "r211",
      "r249",
      "r250",
      "r251",
      "r274",
      "r275",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r315",
      "r357",
      "r358",
      "r359",
      "r374",
      "r442"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r386",
      "r387",
      "r388",
      "r449",
      "r451",
      "r454",
      "r456",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r485",
      "r496",
      "r552",
      "r601"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r168",
      "r326",
      "r362",
      "r385",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r421",
      "r422",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r497"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r215",
      "r522",
      "r523",
      "r542"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r168",
      "r326",
      "r362",
      "r385",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r421",
      "r422",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r497"
     ]
    },
    "cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "StockAndWarrantsIssuedDuringPeriodNewIssues",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents number of shares and warrants issued during period",
        "label": "Stock And Warrants Issued During Period New Issues",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs (In shares)"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "StockAndWarrantsIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock And Warrants Issued During Period Value New Issues",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "StockIssuedDuringPeriodAmericanDepositorySharesNewIssues",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stocks of American Depository Shares (\"ADS\") issued during the period.",
        "label": "Stock Issued During Period American Depository Shares New Issues",
        "verboseLabel": "Number of ADSs issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r58",
      "r83",
      "r364",
      "r442",
      "r458"
     ]
    },
    "cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options acquired, including both vested and non-vested options.",
        "label": "Stock Issued During Period Shares Stock Options Acquired In Merger",
        "verboseLabel": "Acquired in Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Options, shares",
        "terseLabel": "Exercise of options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r58",
      "r83",
      "r228"
     ]
    },
    "cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "negatedLabel": "Exercise",
        "label": "Stock Issued During Period Shares Stock Options Exercised 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Sale of treasury share at cost (in shares)",
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r83"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r58",
      "r83",
      "r374",
      "r442",
      "r458",
      "r503"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r57",
      "r58",
      "r83"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Options",
        "terseLabel": "Exercise of options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r19",
      "r83"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Sale of treasury share at cost",
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35",
      "r57",
      "r58",
      "r83"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r77",
      "r401",
      "r417",
      "r443",
      "r444",
      "r492",
      "r504",
      "r538",
      "r546",
      "r584",
      "r606"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split conversion ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Roll Forward of Valuation Allowance",
        "terseLabel": "Schedule of roll forward of valuation allowance",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplementary cash flows information:"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "TaxAssetsAcquiredThroughMergerValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.",
        "label": "Tax Assets Acquired Through Merger Valuation Allowance",
        "verboseLabel": "Tax assets acquired through merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital losses carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r545",
      "r589"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "auth_ref": []
    },
    "cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Total consideration of repurchase of american depositary receipts.",
        "label": "Total Consideration Of Repurchase Of American Depositary Receipts",
        "verboseLabel": "Total consideration of repurchase of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock [Member]",
        "verboseLabel": "Treasury share [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury share at cost (11,640,460 shares as of December 31, 2022)",
        "label": "Treasury Stock, Value",
        "terseLabel": "Treasury stock (11,640,460 shares as of December 31, 2022)",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r35",
      "r36"
     ]
    },
    "cmmb_TwoThousandsFifteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "TwoThousandsFifteenPlanMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 plan [Member]",
        "label": "Two Thousands Fifteen Plan [Member]",
        "verboseLabel": "2015 plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cmmb_TwoThousandsSeventeenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "TwoThousandsSeventeenPlanMember",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 plan.",
        "label": "Two Thousands Seventeen Plan [Member]",
        "terseLabel": "2017 plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "USD",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r102",
      "r103",
      "r106",
      "r107"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in the total valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, diluted",
        "verboseLabel": "Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r163"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, basic",
        "verboseLabel": "Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r163"
     ]
    },
    "cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.anchiano.com/20231231",
     "localname": "WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents weighted average price of repurchase of american depositary receipts.",
        "label": "Weighted Average Price Of Repurchase Of American Depositary Receipts",
        "verboseLabel": "Weighted average price of repurchase of ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "currency_XXX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "XXX",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other currencies [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "985",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//985-730/tableOfContent"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001178913-24-001124-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-24-001124-xbrl.zip
M4$L#!!0    ( &4P?%A1@SX(/!0  #G=   1    8VUM8BTR,#(S,3(S,2YX
M<V3M/=MRVSBR[_L57+^<V:I5G#B3.9M4,EN*+UE7.9;+5C9SGK8@$I)8(4$-
M -K6?/WI!@D*O$&@I$RH6E:E8HKH;O2-0*-Q>__/YSCR'BD78<(^G+QZ\?+$
MH\Q/@I M/IRD<C[ZQ\D_?_W+>^$O:4P\ &;BG1_'LP\G2RE7[TY/GYZ>7A#F
M+T/"DA=^$I^>O3Q[_0K^G630)<"GUR\2O@"0EZ].?_M\\Z"HYH#OHI!]*T$_
MSWBDX5^?8O&,"*K!L320!8()_.8T*RQ (PO=WVZ L$DTM "'3$B0=L-$C>E<
MQ%=OW[X]5:4:E-$%D31H)?[VE"<1/<W!-!:G\U:,7TZA5 ,&=,6IOZ4&PGU5
MR9SX<D2?5Q%A1"9\?06_"T*2C^1Z144S'2@^Q6*T\]GHY>M186E@(2R;0U#_
MQ2)Y/(4"Y18:T$]2)OFZ&3@O+".DG(-;MF'DI244^NPOF\&QI 3*2.B+9EA5
M5 (6H=\,"@5E0+GB+9!04@)-147C<R)F2MNZI$R9RSHDO*P"M1$MBLH*8VE\
MUO0YG;T$E4G*1#B+Z C!*"<2V@LQ.L/V(D?W@Q9U^T%5V 4AJT99L2 'EH0O
MJ+PE,14KXE.7]H9&-*9,7B4\OJ!SDD:@IM]3$H7S$#ZH7__B>>__.AIYU[?3
MRT_7OWFSM7?YQ^BWC_<WWFBD2L-XE7#IL<9*VQJ"K&F\27RE$PL*_AIIO!&^
M&KTZ@\_GQ;,(3DZ[,K!I#KLQH/$Z,M#<O#I6K1&PSC>[B%MM&UWJC3@O86'E
M;U'@5[_LQ8*CV$;U<N^J[>VV*SLFE<L-D8[<M;3L34R(-G!\&.%#YPK+O8-3
MI2:*_K%CY>6.QJUV$Z?XM5O]1L_E5'<!KYYVJ]/L 9TJW2!DC[M5N^E-G2K5
MX/BP8X6;3MFM1@VOGISK;.O9K74V=I&G-)*B(-.=@4W X%:WAL_JQ1ABERIW
M$+I><3>).X0R;0Q56F0[F>Z?=1$AN7W5.3@^[.1W1I2UA]OA&^?JMP\AG%3?
M@*E^"X,'PE@B%1'\B2]6JY#-D^P7_,8(Z!UVA%/ ]/#AR_UU>WRINLR+Q$\Q
MMM1_QRRX9#*4ZVN@S&-5W8D70@CL!*EYT=P$=!ZR4/'\$L;&WLC3Z.8C88&7
MT?(,8N]/JR0JQ%-!@PG[53W#&%$ *86(X]X<.0>Q(&[(=T+S2>2GD;VZ_*6V
MR%YV>@#1U"#@'#[&) H#C/P^D@A#[H<EI5)D5G* L]OH# Q3$(%GDXZ7$_(R
M2H.!# .5='Q'(!B22RI#8",SC*7<;I#7[@;Q?BH1_MM@H*8O2$SFDY7NURI?
M3;G,;IB?;8;94/22N;>A.9BDQ23G2\(65%RSR]]3Z CJ=JD"V(WSQMTX.6$O
M9%Y&>K!1FXV(6%Y%R5/#5[,ILMOEEXI=*J8 *MX<R0PV,&SPB3)H/_*.1/^P
MZ_E_,;X*A1\E(N44?N1H@UY-WT[CF/#U9/X0+E@XASX3PEI?95)"MKB#]L(/
MJ79V-UB[5?Y1M4I.%7W?H.MM"'N:\F XPW#83L#X _]@D_U((FQ!,D.UE-D-
M\[9J&-42X;A$/1B$!CL8=IA J,GOJ4]!.[.("M#[':<K$@:7SRO*A/YX'."L
M]GGULFH?1=$S2"ICY40]374PEF&L.YY &"K7.' '?UYAKWN+67^T4%NAW2RO
MJF;19+(AO2;T=P](#;8P;'%#2?%QY,]V39]5-9UA#4HU>X4DCD.I@DGL !+5
M@<*OFY#,P@CXUQIW ;2;XW6MO]B0S+J-@JAG4!W,949?2\+I.5F%4H>VI3=V
M _Q<BZ00U\N1!ST;>KX'\0CW,2BZH(\T2E2;G&F\I<RN^S=5W6LJRO,-.H,9
MZH,XT/0XB(%A(3$E]$A+H[IZJ=T4O[0,\Y0ERI0&8QC&N&;P2*?D67<)Y@N[
MRFLCZPS54[B#DDL-3X3IMCO"L>_+4]78XTXY88+X1@+6#=1NF-K@.B?JY51U
MLCSKH$W"@]4,JT&H?I,(<4>YZE+'4O)PEDH<9$V3"0]"1OA:%2V3** \MV!W
M-+LU:R-RJ,##&CRH(N_MS4H\F7BZ&L^L9S!NYXS7+IDOMPS866W$Z)X!\W[2
M3\/$5D-@,55ID%(TD;^R6Z0VLM0AQ$\9^J#L[A^0:8M.&'93U4:=73Z>P9JN
M>633>E8(N[5J0]36G/)@G-V2RZ:AG*'M1JN-;=T2S8,%.V2<3;/90>RVJ@U^
M+=GGP4#M:6C3'J4W=O77!L(9[J#I;<G.4G10?V_7>GT*V4Q\#LIWSX":9K!"
MV U2&ZBV94,'VW1)BS8,9]I@K/9Y79LZ;D^1#A;:DBLUC5)_;;=#;>1OYDT'
MS>^<0"TW8^X(=FO5L@+.R=3!E ?)JIIFW179;N):-F'7#.M@<4O'=D$E":-R
M1Z;?V>U3RQ\4B;E;PK,.ZV_>3SFM0?<-NL=C.((THI,YN/98""K%V(=A(<<M
M,:KRZ9*&_%+(,,;&[8J$_-\D2FF3T?8F9K=V+?%06%M7C%D^!I\H475[)*_<
MPTWO@9<P3V+]'M4,>'/@P'M$%@8_V2>;6WQN);?8$=?N!;641I<,[] L',3<
MFP]]S%A*HGOXF,1D?J'.H0D5MSLX0@>J=A>II5VZN(C9EF1\>!P9P=\F*X,'
M=9DP*+F#'<1NVUIRQS)E8)JR%6RPXZYS"R6;NH/;[5O+%;G.+IC&=L,9+-]I
M3J)D[BTP5AO_7,LW66<E3,-:  =KVB8PF@.TEC*[]6I9*CVI,0173J;8A#F?
MB4QY*"$N4B7&*O@O+*!\DO+;A(U\3")%V(SE>Z39(B/48,J#T[:[0LN6B_(W
MJSG!9U5N+O?W%#<>L..5^?$*AG*B@U/MO*6C''RYP]N-O^,&CZ&=Z#03VC*R
MMD'8S6;?%C)8IY-UU/-(I9? ^S&L5'PT1L@[X-DM6<N'52QI-L)&A9Y9XQ ,
M=[&V3F/<IO&,<F@^O])PL90T&#]"9[6@E\^4^Z&@=SSTJ3HHI9X*.1P]NW?4
M\V3MWI'5KQIMS8&7L^!I'KR,B>RLEB$!TM%CQD*DL5*;^ (U3Y/SG"M:),&U
M>2VMQC[4[-Y23YFU>XM1NX?5XZQ7P0"FV#WDPE-L(#R^R9D9?*;+\IM---]<
M7G*4_4C8O:-AWU#; A[34=J@!B_HMM!G8\0VB*;9N#W(V+VAEJ*S+1<R_:$=
M;O"(K0N+2B9N>&^UV9M:RJV\M&@(^MT-L?F,C+DDC*D3EA_T!<^$K<$R<\HY
M=,_D64V&MUEP;X)VTV]9558:)1B38QL&=!^>L_$_PM.,( U/L3+X30>_N4^B
MZ"KA3X0'DSF&28J?<10E3YC_VNXGC@3L?E%+WK7[!=;GY17B[Z)*KZAS<( N
M#D#]A/EAE,TD3^;3)4UX=B)I 9\/S*?)V)=I_;V#DQRN$KLCU1*!%D<J\81O
M#*X,/)V6P*%%QEI#X>!R>ZR)-?VD %_?D;6:+ZV,+ Y&S^Y(M=1DAQ6U92_;
MH*T]S</@+@=Q%^/MUU NR]C[^(T38;L#-1R[LY,#&24>\E*E,[C2@99P;ZR/
MP64J\Z[J(Q&ACXF*,$I![3G9DG/].579W:V68MU]>7AIJ=*&/_RI.,Q2*!F/
M136#&Q[<#2L)^"PQ#@,S!#Z8 SI58G>]6K[V,*Y7R_[G,P-Z!NF_Q^7P/YPN
MNZ=S3]WE^ XO&_EP(L)X%>$=D.K=4MW1B)=BCO1==/\!45\\QY$&0?*6B]F4
MPU:UDU>L2>27=]GOF@0B:FT4=$^GFOGL6I1#" 5FZ"I4V7+]$RDBLZXB 0J-
M^BD-.'Q7:2K?R*%E>G]JW+X#/TIW\[S/+VQ4]P5].!D'@?(4$GU-^#=HJ"@?
MQ[@V.VMK4=3_6& R):D+7-_%"8,&BJ^O)8WQLS[QR S3S+[\<#(GD;I$5@$"
MWV$23!5JD&:73YQX(@7H4*;XZQ-/TI6F&P*]$X^%D5J>].%$\K0@-<O"2J!#
M9Z',+R.J2+A8<'498<;S9JW,-($!BBGF%L#>R.IS&K@)JT*N7(H[$@;MTM8A
M>R.N@VDG\SE4S!9JIGPR'\O/A'^C4K\> QC='"Q:EM\=]Q@T$D-U/F$7=)6(
M4.I 2'RF&$V8XF\!S&0MKB5^%R0Q"=F?(FVC7&W[4DR1VF%,RP'?8-8?+0E5
MEY1])@QB/75_+M4;:DU9FJ%ZXX>VADC&Q9=3=[Z&PIXYW$?"OGU*"2=,@LZA
M!\C7OT^>6$F4+7#'8*J/J0@9%0(Z@!D,4Y ^9HL7+/R#!M<! (;S$$F7-Y:"
M8QJ+2]72%'B)(/^B47"5\ <245-3W[6:O16=W1$MOU_3?$CYS]6-MN;*X;'O
M SN5JRT.KG>'>OMB"(O#GP/YA-=:I?)K]_;(K/Y[-4?Y<C =B8L)HPW\M\+T
M31BQU&YVS3Y3OJC(T53<FY:T_0M'QC%VAD\GVP%'@XL4@XW_HX1#2S7.F:S(
MZH;B%L+\*>93=])=LRG%BV?!#!<AQLH4T_O LK%6@HK;1&X:&U/NW6D<@R/
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M.DK"0S4-ET/H8']_I>Y#^X@UBL-$=:5G$4+OK\D=:!Z%!O/-TR&35*TG;5N
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MA'-.15Y:C3BO PE^:U77&.&N PE^=X[[.EJ\!NL=[X2,A?CKP8+WCFG(1'V
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ML'7;R#E^IWC!<4B2I5N 8;:9\^CD=H8X3BZ(D-7-H++*L%4#./?P]]?=Y@!
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MIZ/NSDFE2@%VK+;>_/G 5_8^3C..>89S,O+ZS!XPI^OL.<AAO%S?5*!Q68R
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M5?.&]H1O<!+U?$&$@FS+2,%6#*IT8^O5:)!75SM5(J!"5\ZO3]EL"E1;I>7
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MRFU#)X'9YS/*QLB@A&L8X6R7WK[1C\JCW*)EK6#*0VJ,<1JN:7?X*^E_'D]
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M W#[YF9^79SI;2KJ7)K@)-^(V/KOB/"$&01DHT+O'N-4($PPZCB7)KC*[W%
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M*F"#%EX.7G94L 8MMC#?A53P!BVP-#\LJ; -6E#AOTBI, Y:5)%YQ%(A';3
M(O?JI<+*$&!^.]^-R]Q#J&9>DISC1!.N1K;L@!=&N#X-1XI^S(K5W%SP>%&:
M\TFEXG,<T?F6C=3<5,\XBCTBA*%[&\N;CS&]E7R9L6>998U3.T<0X!1M,AIR
M<H14,^L8C^P\]CP_/SN?@._=1T5:%B$";CVGRY/?-BB>:7Z-"'JW $5$S&''
M >=7<+J\!#[>_NP>U;C="4G6;I$&I<PPQSD6]PL[78(0M*)7(@H!LZQS89Y1
MDA'+1#WO)D4T05RF@,O>X67D?=I/"R4:?J7&N@6AU@WX$?[(?N%S7HGZW4)6
M:X15/*ULCVNO@6ZAK]MQCO]-<9X.;AXSV,$WFG>MN+$T18MHW99R:&U&MH9;
M<G]R$YK;BB9E+9.2^7_F#RFW:; ::%>JKQQ9NR.]^>KH2G7>BG*X;0;M^0O<
MR"LF$K?8ZZW:48[$W9I^#:37J.X2/D@[QZ&_%=GW;M\@<GW,W=#*;74+]ZW]
M8-:$E]-8M\#ANN=WYT+R#'W1@:W<5K?@X]KG5Q->3F/=PIJW ?P(DSPM)4UA
MR,&R4ZX>WMQ %!FN)FI/(<C4!)U,Y!@V0L%(,)1+]L>-81'>C)>ECK(KCH.0
MVF9P39JKDP#&4VY9%NZ@)4*1\LNRD <M43)U9,9C'[2(^J/CH+$T DD['MJ@
M?SL%7$V*.DNWG_)\*2OL+ M*HAOXCA;/LE@E&K$V:/8L"UG2!FPK%9]ED4Q4
M<"NK!RV+:M(;UJU2T;)()\J(VR@B+0N T@/F'0VF;>%0M/-BEB[3MA@IVOD3
M4ZEI6PP5W5/.5&_:%EY%^Y0S]9RVQ5II@_Q *RJ*K&+ R_ SC" "P0V]B ?8
MK&/A,\0)2MTD6P63&"?DT"??0?0*'R1<#66JFW<^=%?02P-(A90:>1EI 5DJ
M'B44"ST3Y5LQ[HQ6/BD<N^22GS_<$C@L,FI803G]B" [R;MT754T# OP%XB6
M$(V7I%UZJGSSD]4D?*GU^I!XL_0%^YX/T&:ZF*8(DV4Q6<$P#E^83FG:VCZQ
M2=/HUX914L-#_MMB(?\X61R*Z>(^\OQ7WTM!P-@TS+).ET0=K:FDBR0[<Z@0
MMO+7\SA_.L8<^Q:MJ")C;)T\LDF^6L%+&5'BOW*-)']G2%351.1>V]/%N&#)
M8_+Y/@PAV7L)##9/1"9"\SC?LGSB.S3I=,FH8O>::K6S69-&95.JVLZE59<<
MGF ):T-[%P=!_(.^?LH&ESE3BNT<R4-R1XG_&"?Y%72V#OQD$D=4]4*&_)D.
M?%-.Z[9-*?M-,B8KC^!$N-=.A@G2&Z:ACKS[Z(;I.R515=D)4D#EV"OT&X31
MUFP,XT5"]RAO,<FW4/=D-.B (2F?LZZ)2B+PZ?EKJ,%O'D.VX&VM&P>'9'F,
M^X*YG3X/4I0WZ$<UB?'V)?;H<0U8G61'RY[GW1OL2[G#I58"F/!"8=>6;XFA
M8?/+W51.%7VWJXZ%J<1ZW@>6NQ>UDQ!;7Z5.:A2Z7+,L]5[JL!PD;VZ6>B]I
M "YW"Q1X-)F(:I&&82:5SOQEE"4;J$>Y>\K"R$"\E82*["YD2Y,3_@:N$73]
M[+0[BL7J"<5$GDLV3P$E._+HAEO+AL805S9NK6*2- /!*SE/RY2<Q?':!EQS
M2YJL)<S5P5*:,"L8CXJP7>+,H9.W$O*;,!XK@4G.I\U\DZ=H;+.4MK7M040I
M$MJA)&H;1T0=>U/"'"I:9.*@--50I9RQE1_ "TVU$Z.-F")^!>,A-NY21!AD
MBB"9VCO_C7X2AP=A5])CZ%.@_P$"G,G2]^$:Q:]YT"DA $XM/68EJ[;GOCGI
M*'*BE 3!N">H,VB[E A=QD#(^DW?#+EVDRZSK" 2L"^!P[>9B,$K;I(=T<-:
MXXDD^8K8=X24@1T*N[0W V?+-2<$5B@R6:H<ZS2S7!G+4B58)\!\F<SB1[6]
MGUR2FG #&K )P"MJCB5_**&O(*"3=!1UUE^17?5YN>4I<MP-QZVS7J0331BZ
M'Y;QZ[E;-)C35?ZWI:O\QAD'0=&Y#S'S/L0K;I;>K[,;'GWD9[/TW#_,>/20
MGSOI#Y7I^>.//WCTD)\[Z9..L;Z.$V&T^3 >)Q. T,:/EMFMF*<3DZGO_'R,
M:^1?\8_X" ^MZWOGLW77O"8:]Z1\_@ENUWU&1"P#6G[XGP24G&]8=O-JB27G
M.<8O57(N-AUVC>4N-"JGO"RS.OX=J;S1U2]SCS#YR^8_,,.SZ><K_1N>K4&D
MS;)UA-0;F@S/IBG7;>?5\]Y)H^'<M _"+%XD/P""-_ 5!K'<8F#6,6[VUV\V
M-VWX-V\V/S*NSX@?MYA?T7R&CK'KIF&:O?W8]7U<!S 3-"-O'-(\Y'D(+";Y
M',BZNC#_5I5)"I$4V\PQJ59_@WIJ%O]35.HH8%<T'>V(?-9I@A3);V\VLTW1
MHD@[XQ[,E"=/$"Q7_K14J=$*L%"V';#!GQVNGR,-6_K8I1->OO1L/&"O7@>'
M3B>UY7K*7EQ7*ZG\!$'KE,N'=O)U61.%%"\X_ SHL+.C"C_2(+:)_PJ/HKM^
M@!A#F%%R [&+_'6!3JBX%M0TKK5NID>DJ.;4^LLI:&A.01)..$,;O^.HQ_)=
M,27G)Z"/;K/M,8<HG"XFY*Z/@,M3GX@K&W_]D]%P^[;V4<XB"<_D!29K*NXH
MYF_L90[R4-?S^#9C-HISL%O94<SLR']?"S,6^P5$8)E)W'>0G7^24T4U'S.#
MJ$\@^OXY!30V/&ET'I>BP/1'Q#9Z<"LI*W89E#V3B2 \'U/ T\6SOUR1/U\Q
M')-OF_:4N))YK>KNJA)CD*IG/B?R+CD//GCQ W[^<$8-70'_JN;WAH:&YFKN
MVF=OLE:-*2<TUCP)Y,H.?)3)]WPK#*^:<I;CSB!NX$MR']$ '92&>W)^((@3
M^H[P/G)1+EKF?SF0Y!NIIT(V:((0R_M,C0Q/Q#XYDX, [NX8_>54.A3OQ?SR
M8%](Q--V7NQXZ @N(:<'NO'>8JER3^O<'EQN++5M*(.6N#)9FH6P'53A-<S2
M-(3MT JO=I8F'VR]=X670$LS$&H"O'-IM#3U8+N5W/K":6DR0DT3?G@WM34;
M86O :C=744Y"$^_KXS#T\RRP]+%+G 66S(R*U<(\BBUNFJP@JA'W(&&%8]8Q
M;G_;IT1D>6LL;]QC_R&.EO1>\)0B=T66Z):@3YL)6<++F(8BI2-:EO $;T1:
MMF@1<@:50G?OEBV:?U^29P4N\S^+/?*;*VB*4+K?^#2"_-<9S K&(Y1FS*)*
M,R'YLF&_O/$W)?8L?'.YY53=#+H8.X]A)C=*[^W79QY]Y&>S]$BX/2@:>X\^
MGT/*NJC'<GDZ*?(&A$_5<ML*6O4 ?^;""" _YJRPQK*:+)HB,HL>OT9X#5U_
MX7,8'[>\67+O8@1=@-G/0MF%AS:N1_(%8PHW-35!*^&H5M\9'?NZ*@>&4\L9
MZ;D/;",L3Q?/\08$R>8);++>IM$,%&_9O+31!T^Q!6>DYX7Y%_#FAVE8[[CJ
ML2"!XZLB5]L9Z7&SF>1.\_XK'(<TJ0CIXS.U-N!GZ$+RK9>E5G'C9>3_"9M\
M[%JTXHQ,.]:,71>ET*M&+Y>PJ/GH,8YRT4OPYE=8W1D9#T///$KR26AU"N55
MG9&B3RIK]^8+=QIQ[H3D$Q%V86[SJ:[#S-W<ND5G9-IGM3AM;M_6,.)Z.^T6
M=$::G%&7!/J22%#YG&X':!Z3463ZHW)K.2,]/JE[O5 _A+*?)^ SSQE!->=2
MCU]JJ4PB$G.,OD^IBIZYI?@5G$L];/#!A]$THM;@&[B.L<^DY*"@<VE:#Y9E
MY_+=+(W8*_F<L2[>ZF\J[USJX6^4Z[Q"5-@9IXO? ?MTY%=P+H^2%9IGTF#9
MW!BVA)-S+F0";1Z7]K8(Z[P0-4!2'2.1U<(NOT8->)H'B&G].''\0F.+K>Z#
MNA< RVQC82A/ZTZ)0:05E^0J#58B._.&[Q.YMZ_YAB2[3C41L0QHN0WJ)*#D
MYBM+,W-W6&FG=C(PC6,6L@D^O1+8%+.J6W4Z]@F\YM4Z]/7,-,4=,4D29U;9
MY#9 XYGN[&(:8G+9\ ZM?78^W](S=9:_Y&JAU9&V')X.9(%]T=*77 I 6Q@H
M+7W)I0I:WLIIZ7LN5<#J)E)+GW:UV,>R]E-+GW=I/:RW!E9+WW8I'U^=++*6
MOOIJ,>6'1EQ+WW*I3K#8(FSK(ZZ.2)O,RZ('6X.!RK-85R '+EDU&L,K<,.5
MH(26\PKCP(4FKC&^ LD0D R\G9RM (*%4:Q3Y%*&]T(N_<^2V/W^P'G^R"RK
M^NQ13 ;K'6-C.>-OV3)='/2> $HV<R)=8^!FJKE/F_HO@B>+\HT<%9_P'=9A
M86UO]")25/0L;UM&4[?/<;(J]AK%%$&$'P*73P:OCO$'@EUG[S@>[[/T!?N>
M#]"FMKT%6XA9QWBLTUK_CR D'VL[6C@'XLJJ>!A+.V??,6(_&FTJ9GPPGY#_
M2A;E4P#RNYSPB6MS!=7W@"POS22LKI+\<3LLJ2G>ZS-<%Y?=,6'^T5*"%DX5
M3?%>OP#T'9++RP(B/UI*#A&WDOE$7GUOVR,=I:5I8Q( C"6/4E8=\^%)ZQ0(
M)^&PL'F"9V0Q0SQY(JU!A*"7$2/.F,BN-;PQ/U)"P0!$=.N)$LC6BCD775YE
M=R%2G+AQIZ RH8QC>OXCGJ_B%(/(PW?^(H$PHAWQCVENI3XHF\%7&*G3UE#-
MN5!D;T>;X*,EX70A)-.*XO ;U25$R>T;1*Z/&]\*RE0S_]!N]]#,U"/X'N.T
M\>F@N)+Y1W6[M)#;UQ1E'-C+DKT_0921)PV&U8#R SNMRXL.+HC<S+!<IW8<
M>?D7U%B3?2.Y\.0;5'Z%)WI 5HJLY*I!^Q\G#$F6>3=0;4C7\[SZ^.42Z]AK
M#//.*:WK.5XV-?F6NTFS02"88V\<DC\NB KM>4RN\]GF?(0_LL)L763+]G0]
MX'M,*<>9+HH#$9<FR:]KWACS:^EZRE>[G>!LK7$.%7X%Y:=]@M'*NGB&&*)7
MZ-W%J-S5HO%BU=/UAF^G'SH5I*]7<J8HT\BH6W_9IX-.VDT>@3EC8U03/DT3
MG!#!B&P%$:7\VLZE(D<4T-J>3AZ->K1B94^_0YQD_C&%8,,S0?#J.)=Z>$]]
MIMK0QJKG7.KA+'LSU(9$3E7GTK0<GQUVG^@S(IJ)&$88Y&;+2GWV:;,M4KBC
MC'\ Y!4H:DLSYT/[D5B_01JEEP"EML8E+.7G[+#E*0J.29=SI<FVUQ8$6<6Z
M!_:X!#E7ILUY##%)+&2I->!<F;9T==T9A#DO8):%&]]'.:8>]V%#;\Z5'M&E
MRV*6&X0^NG&N] A$6UL'87J[LC] F\SQ==T8&D*AMG.E1R"2ZRW?6=THSMMP
MKO0(27LG6G%[[3;R7=ITKO0(6?,X <&$[$[?@WD"EZZHVK?H7!G731]<]^>4
M?Z7DQJR@EFFHZ5QMI3<#44QXGDEECW%ST9.+6L($N#L.K=R0K'M:V0Z%>"0L
M#S?23&K#0M_SCQHX&H&;E87/U7M>GU8_9U<\B'C.7/9%O)"BF@%4QMW+SITJ
M1WK#SCUT*3L=@$(O-$M?RK:>S$8_-TM?R;8&R7>@L_1Y;&NT0K\\X\]CY7EK
M/T?P2;%6GG/?$2/%B'@KE^QFJ,W^@'8R&P:MC#GDNPO:%V1#\RR>TG[<=TBT
M+[@-DU(^H*WKHIT[KH'.!F8H]'X\%7 ,]TF+[]'MUJ.E47H4M):R;IBG@)#G
MI6G9+:,S/I[CIF5WC(ZK5<UWT[)H/*KVA5;>GI8%XE'%S'8=M2S>CK*QJ(.7
MJ67!=U2ABUU5+0NLT\$0>.CT:EE@G;:3Q_.;M2VD3B>,'+];V^+IM,4I]MJU
M+:A.6Z1\OU_;HNNT1<GR'[8MLDZ7]<KR018%UAD*1H$3<P5S>.*/-1[(U1@.
M5(XZJK-Q-7C#D]'4'9 KL,,3VGKV,]ZJ3@8W,GTY'U=#,E"I4-YUN4(Z4*E0
MU>6YPCM0^;"K:W2%?Z#R8S<GZ@K]\"1+!?_J"B5#L#0<F#+[?/:R?T 7@8IQ
MFW"5G?W;;\-U$&\@G$'T2G80@X4$6>?%&BM#H^=<8A+C6OC0DKH&?WC-/:E&
MU.R>NCHG#7K-E(N3"\LU8#R4Y<Q=02^E^T?/#+$"D_;:G_$0DN2*$8>P\MQX
M*&@4Q%GBU+(%@3!&#[?>$4)Y8DAXS&H<>3?P%0;QFA)5["5AA#&)VL81?881
M8>@!(6GLA803X22/9BR+2:J^H_BJTM+5MA\@ZBA>)?H9&T/BD68@AKUON&FS
MC8U.7WR%[3 RM'=OO8]4\\3PF9ZU#^8$9"MAK9BCG7YQ0JJ;P<IQSY."+,M<
M+780[&%=2WH/FKYNIV$(: +L,<9IF&M^OY*S;1Y/0.#2'&#P#O@H\RJK;%1'
MN82W5MS*W+N[-V[\JIW1(Q7T)S?A&+\RMQW2:KW5EF3O08Z$G1J_XF1T'NC!
M#J&\R$%90YIYAV8\NQ"-7R^=&K],:5X*.93?8YH5D:;W>28GXQ=R*(=I:&X]
M<HAPC(<K-P M3[MYY/'-B7!,Q_;5"NW9Q]_O$(3WY+Z%($Z.L'HY))C/L]([
M,+,KET.":OH2N\:VW)(W-(4]D7,I,-/'0;UOU4PL&@T/0FR8!4[>V-"Q#]64
M,,VC@U%2&QGRWW94:!;U9TH+PX2P\[LY:ICJYKT21B@JSE0N33MES%"5GT9\
MJNIE-&7QT3I]QTFUD.\OTH' ;K93[@CI:UJ?'5O"(T\Z"T8?W1TKT=()C-S%
M]7%5E5H4."RC25V)8J>FMG?X?>E4+'MI;&P\^]*Q6/:R>8#KDZ]CL>PU]:F,
M;Z5CL>S%]N#&EZ]EL>QM^&F,;J5GL>R!^N!&EZ%P,?WXG>NIT^M@:M3#L!_4
M#]\A1\/H[$[ OMK(.G>; P(9]!\$EK3C)&J@[Q# ODYJB!#V%5@6>K@H+B6K
MX^49.!J8RC4+IY9-:TOFW46%9MT9:L7H7%Q;X/^5^ZG-P5N[YU2,%"A5JS<^
MIK)%BN #Q_-*6$?5H4J>+)8]C%M>C_^4P!Q1^0[.7!@!Y,<<.U=C63-4%AU^
MC3 1V/V%3T1VEM*96]XHM7<Q@B[ "=?:TUQX8*.JT8HANUX_PWB)P'KENR"0
M6;/[Y?5XUXBHS2\S];[Y(\PJWXE:#-T/R_CUW(W3*$&;G.#BGRV]Q1?._4/3
M057]:)"2KS,.)5]G>GQXC,W@<2Q]%7,9I\DJ1GZ>JX5CJVNNH,DVWHEPR4=I
MAU7,$T_ZA3CQW4F^6(6/ QO+#WO,C[/<;Q<+Z-*7'Q5=5*5'GT=%KA_XN4"=
MW$$:G"&@O"&E\2]W"G/ :FB];K8V,R2DXPF"GI], $*;18RR"T-(5QH'*J>6
M<V':>9*J;:LW;S]H:,2;(A(O77@8PV2RHG>D^TB(2[4IYT)/NL8LRL<K+(9P
MNIBL8$@VRLM\1=;*&J9D\V.R4%AW!,GJ-+*X#FISO3B>QT6_+:E6;(:&<#_2
M@5<\%/L$(W+OY:T?1@UG])-)VX#,579/R2"Z:IY6&DD>T$/U(^MB:YU&B4ML
M R[.-=@^93>76C:X@XNS?1EEM$V;U;KQ+ANOX79N7^I$(<4- #D7>@MW((_:
M/7925PB<!)),H6"AC47KJCNE T2LL; W0QR'9EF06]V&7=M/BN)FD$PUB'TL
M7?]$VISK2>VJH5E=<CH#(E"J6.9)W0%H&RV+97[.;:_8"IH:RSR/VR)NH>6Q
MS"NXPTKGZ(,$SKD&W"Z>(8VFXST!E/@0?P(!W8EX''FUK,%XZ\I4*[YY ALJ
M=1TG\$Z=D!JI#Q)A=415S0?-:1S>^@1\VNS\(OUT6J$]XZ%XY&@3F"+E&SDJ
M/J&-[+#P4>F5"+^Z7WAPXWLDZV,1M[$@Z,$'+_3!$4U_G1+AAVN8$M8U'K)D
M[+HH543!K&,\*,@T(6*'$NV,&K4 ' 9??4CP,89$TI9!G(P!J/- -(^K$C>R
MSG+4#H5X)"RU)_%)%<.RV)C4\TQ:JH;J?B[*,-B3 \WCQY:IF[J#93-P@6[)
MP%7\$28/,<9EEMYQDB#_)4THRYG'4^3Y$2CR,*_B@-!:NY;OI52J,L=F.:..
M$QBW"C@L$^CVH+#Y'#%1XGM^D%)=] RZ*<J6Q^V;&Z1D%FFF(OK@ALP&G>WI
MXA:@R(^6V\D2.95I:=]\N-QR8H0JAYV"QL/2=AS=3YOF!D2QK?KKU9(1E K=
M)*IJ'$N5&X%F$\NC@PL5&LPZ)S435F1=:3SM6<*)IF/3IKPJ*O@/SM43S&ER
M +&7I2 X;:V]C?<,6V6L=XYT.R_S,H3S[WY-#,#>&[Z=JZ-U5I'?SFF'-,;<
M/_\?4$L#!!0    ( &4P?%C1E!I@!YL  (R]!P 5    8VUM8BTR,#(S,3(S
M,5]L86(N>&UL[+UM<^0VDB[Z_?P*7F_$'3M";;M?W![/[IX3I;<>W56K="6U
M>^9,W*B@2)3$8Q990[(DE7_]S<0+R:H"0+ *!"CO1.R.6Q( /@^00": 1.9_
M_*^711H\D:),\NP_OWG[_8_?!"2+\CC)'O[SFU4U?_/G;_[7__P?_Y$FV6_W
M84D"*)Z5__G-8U4M__+##\_/S]^_W!?I]WGQ\,.['W]\_X,H^ TK^9>7,MDH
M_?Q>E'W[P]\^7]Y&CV01ODFRL@JSJ*F%S<CJO?WEEU]^H'^%HF7REY+6O\RC
ML*($.G$%RA+XTQM1[ W^ZLW;=V_>O_W^I8R_^9__(PC^X_]Z\R:XN+H[^W3Q
MM^!^'9S]_N9OQS>7P9LW]*]%GI(;,@\HNK]4ZR7YSV_*9+%,D17]W6-!YG*(
M:5'\@/5_R,A#6)$8/_\+?O[M1_S\O_%?7X;W)/TFP))?;BZ4;'_9:(M5^L$5
MQFM2)'E\ENT'=JNV8]2W55A4!^!NU7>&_"ZOPG0OS*V:SM!>D?WZMZ[GKE]A
M323[]6M3TRK::A=I[\[<Z,44_WT)W]] 1EXJDL4D%MBPIF9AI0W3!1G;Q%;S
M:*.]%!?GO-BD&BT6]T#GW?NW[]@*^V_XF]DDCA-<R,/T:U[\-BUB4DP6^2JK
M1&T*F;8YTU>8O64DQP/HW=@ O;<#Z.&AH'+/6CW)%XND6I"LNLNOP[42E;;6
M[,-XH?TT!+3IO/G,=9C$AMBVJ\T^CAG<SW;!3>=S4+K9PW611/##I/H<%K^1
M2OQZ L4(?KL3KFE#LS^_=@*_O'8";W^TPV ![49A=DJ6>9F T;:^?0P+4GXF
MBWM2*.%J:\W>6M(X@V"SI'RR;!6F-S!BY70.GRI(E-"-EQ*6JL+LK27M8Q&1
M):5C$9$E7<,^ /-GDL6?PRQ\H)/IG)"R Y.LRNRM)25C&94E[5(MZM6F8\;M
ME)R]M:0@#L)@9XT_#K/?/JW"(LPJZ%VP?(I\28IJ/7W.U'"TE6;O[*S=0R"S
MLW(?K\HD(V4)9L]]DM$I?$.B_"%+?B?Q10QCE,R3\#XED[(D53F)_KE*"A*#
M+%_"KY,4S'12PM]6"_@E%ODK2>/SO+@-FXWB#K$!OSE[9T=K_/'ZQ8[N^N/U
MBQT-:A/CR:HHH$+[#U%4K$A\]K(D6:G6-4Y!S-[9T?3_'7O.CC7RW['G[%A,
M)Z!3\T)OI[3+S-[9L9+Z?]>.9702+F%_E8ICM7*:D2X0B@JS]W8L(IN([%A"
M-A'9L4%.PO)1S)>+[#,I'G1@=LO.WMO1^8?CL*-CL6T\E(.U Y88DCR1^'2%
M9RU_)V$!^GQR7U9%&"F/;DSKS][;T6SN\-K1)^[P6EK%'\/L@5QD=V2QS(NP
M6)\F>/A&LHB4\+E3 C^ &-Z%+Z2\RJM&+2D)[-O@[+TE_3 B1I8TSW@8?;"D
MN6"I7Z45:.D2!/UV=1_E&17KO"BYG:+$WEUU]L&2-AL8I24--S!*2_IOM5BE
M8-D^\4NB<CK_A*<RI5CEV(+7);B]6IE]L*0SO6"WI#^]8+>D2^E6)EK?P:=*
MD$HP$"_SLOPU3%=TCS1)T_R9>X\I8!LV,/M@29LZ1&Q)6SI$;$<;GH5%!O90
M>4T*>M5U$J81%<X\.R59OL -=(ZFTG%8)M$5J2ZR*%\0!"6J=!EA%C\Q^\F.
MQGQMK.UHX-?&VHY&UT"Z6BU(@0T=0&NGC=E/=G2\>]QV]+M[W'9T^QD8[5$U
MG=\0].,F_"PE^9U^M;4>*S$;UI_]9$>?N\-K1YN;?H]Y7!R*FK4R^\F.7O>#
MW9*&]X']HR4]75;) IV!S\.D0".(3.>@-#8/[I6032K//EK2K0Z06M*'#I!:
MTH"P:8ZJ\B[G^Z+:(?*1+/)%>'_W")I@2595$I5@1R@Q]VMF]M&2'O2$WI(V
M](3>CFX\!SL3-DG,N!17=2"G*IBJ\K./=G2?/3QV])D]/'9T%&P(P*H30G%+
MHE615.N_YFD,RD9_YV50=?:S'6TT-$H[FN@3R6!.I9,LGL2PWTK02L:SIM.D
MC-*\7!7DCKQ4Q]#D;RJT/9J8_6Q'*[E&;4=#N49M1S-]RL&&R]#;\7:99V4.
M*ON&E"0LHD> <0H67IHOZ7N#/$VB=3>%/=N;_6Q'5XV'CQWM-1X^=K0?4QMW
MX4LCTY=)1BXJLE#N-W1U9C_;T8+V<=G1AI)OW*&_4@],M/SLSW;TGCT\=C1<
MW3ZI;TPZH31%9W^VH[$.16%' QV*PHY&J9OFMJ'YA4=WS=F?[6B)83':6?F'
MQ6AM-2_H4XDP/<Z+(G].LH<;^OKLDH0:M\RN>K,_6UO5!\)G;74?!M\OME;[
MBA2DK+J7D\URLU]LK>[[?M_6NK[O]VVMZ$_0:MZUH]PJ-OO%UDJ^W]?MK-&7
MX7U.+W?69_]<)<ONIUO*"K-?[*S(-A'967]M(K*SXEXF))MF^#B,OYM5(MDN
M./O%SIIZ (*W/]I9-B_S[.&.% NZ&'>AD)0%(';63PM ["RD%H#865'1NX"@
M3]XQR<@\J= K$RREZU4!WZ$^FMP=^.MC$CUN^&M^A26>^VP6L5H7V/L"D+:S
MD+\RTI;TQ^LB;4=%*:(\Z)6"MA) LZ.K!H%F1VD- LV.-OL<OB2+U>*:%!&:
M^P]@XE^':_Q0.9W?Y.LPQ8=H:HPFM6=O+04!<036CFYT!-:._F1/E6HA^YI4
MCR>+>WK)7M+W79<5>IF729R$Q7HZGZX*7)C8)=-]AR!;:!N(VM'/KX"H'9W\
M"HC:T<-78;4J8'I,E^BKAT\1FZ/@+M\_D[H U([N= #4CB9U -2.7KU:H21-
MYY.XO"C+%7W,,%U5&)@6H^%.YA4I] \VS5L T'8TKEO0ED*XM#Y93I=T7/'3
M>-/2^K(!8$UM &M'\SH":T?SMC_W*RDK.IIG+Z#WDU)W\=55#P#:T9@# K2C
MZ<2']A]J[3!;TE+#@K2DH88%:4D[;7YJ'Y'45 68=G738##M:J.A8%H*F%%_
MJP!9JD,EXBO8!+]ZD9TJ=U(&50&F7<TS&$R[.F<PF'8USVV51[^A&KDAY1,I
M"$:OHBN,YH[:I"X M:N!!@1J5PL-"-2N)J(?0P>RXJD_2$D] &A7"PT T*[^
M&0"@7<VSC\J1ZQI+(2X& &97NU@$9E>?? T+&EO@>E5$CV%)OBQQG>B")J\%
MX.QJ$<O@[&H.R^#L: M^AI,]W"0/C]5T_J448>RRN/X;O45MQ:Q38=ZK,:!B
M1Y^,@HH=S3,**G9TU*81>95?A^R=GWB*K3^%-JL-8.WH*S=@+06=F%:/I)A$
M$0WYPKS&:!3*++XNR#),ZIB2G0[]_5L"$G;TG6<2=G2C9Q)V="B_>IQFPG=&
M:)PF7PC^"\.0T7+SSD02^[<(I.SHWI&1LJ.S1T;*CO86-]^X#:'.H/C3A<B<
MH51N'=4 GAV-/!@\.UIV,'AV]&K;Q>%SGE6/Z5I\ UW.E?#TU69O+86%& R>
M'1W9_@YS"UG7?B(9AGB?SJ^+/%ZI;VS-6P#0=G2B8]"6=*!;T)9T7)%'A,3E
M>9$OV!=T^TIY:0!C23?9 6-'I]S I@9LI9+IK*WMCPJ3MA) LZ-/!H%F1Y<,
M LV.'FDL8BHRS4/DBZRLDFI%+ZG4$ TJS]Y:"N[@!*H=_>($JAVM4D<TW2]\
MC&%U@&M'GSB#:T>3.(-K1]>@YSM(&SNS6D_GOX:5/NFJL@) LJ5Q+$*RI6DL
M0K*E85*:G3LLJG9D6K &YJ!":%;<6U(\)1%;4UI%2O1#;5=7D[#V":!M2WN]
M+MJ6PCV\.MJVM*H4DSQ2"C_6L\S_H&]!1]C2V:^^(VQ9 Z^^(VS9&5)PL ,,
MBX2^AN,EQ&FWY5[8_T/0!;9LEU?<!;9LI5?<!;9L,SDRO"T\#DO\"S^@M4R]
M]P> \J"VWS@I#VKWC9*RI: O=3;H)*L(C?6IBDO8D02G=T- P9;]YI&"+<O+
M(P5;-M/VE[4FC#D!;3, WY:EXPF^+2O%$WQ;%L:2WV-/T(GNP>!%OJ8*P+*E
M]2W#LJ69+<.RI3W%-Z;SR8(4212*"^JP6-,SQZ7ZAMNL]NR=I:@]CL#:TG!.
MP-K292:?TR>=Z-,& +>EP9P#MZ6[G .WI+7RZI$G%$&K%@R5\C*-.E8R31T
M9DD?V0=F22/9!V9')S&G /I.Y;(KE+*L+ "QHX4.!V(I/DZK\?(:YE/M76R
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M4^O\]3S'[.7P5WWRG;[M  &+=I(? K:LE;RHT'1LI<0M3<]7#>H"4%NVP=!
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M/@L+C.)<BMRUH")6>C5CHWWH%^=6UV&XC]?R!A2[%@=?A3YT;N/1R!$ZNK0
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MKC6N')QX)<]4[*0Z)Y@%.Z61U@'#>J-P;^J]6H<^<:W?7T.?.+<=%LLT7Q/
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M.M]<4$&VV2\(_)'^1LMLGP:!N7-M+P7Z-2P*L)>T5HJV(C!Q;PT,Q<2]]F\
MT>6T\Y&KH@9@=Z_W[6%WK]T;)+=ABH\M&F76SY>Z;U/ UKW>WX9XAV&!5\6Z
MS^(FJ0E<W.O[P;@XCR0X)!?W%D$+$6)@L3_*LQ=21$G9L9WIJ M\?-H)7$$(
M.*:KP78U8.%!Y\])64)GAFF'<^=V44#K0:_/DR[_F*80(/2@KWLB]*"5>R+T
MH'OEYW1&AP4==8&/!^TJQW2\OH//=AT!=M<&3AZT[-"<G,>B4Z+JEUFS3S/
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M2Y$RNB-PK[+.[&?G63!J+$S7H)+-,U0PIAQD]8"'<PTL\!CY>NP4!L3.M:@
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M13 *'KP,_Y!=)I4>_L&@]<6@^630_F; /AJ(KP;PV:#UW8!_F)4+\-,!?#O
MC_M2XH-VJ-0.V!6Y/\0$/%D5!?4-;OX01<6*Q)BI)BM5!D4]&T-6.DA;\@)3
M[YY/2"9ML%$N5]%C\)Q4CPE,Q(P$:Q(6 4Y3F*-97BQ N^/B%F(@E2!:1RDY
M"I)YD.893-@CG/%4!/E.*T1*+"Q $(-I9G=&_\+&(J/;O=B9''8/A51;[P[
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M;VBYW) 2>HE@F@^J/%3.J@W=$JORB<JLF(*W0:\'$MZ*/Q'5<M/+**T:8-U
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M'N@2]=[1+UR(O]$&YN"NZ9H1_81C!+.D[?%QS5)3F4P(^4I?;#@3\4Q77J>
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M_=([$8XOW\;<">0[$0#B2;05A*(Q$&9"[?[PI<ZM+29YQ7!X.U;KW3'24#A
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ML[A M+YXQ)UH7WG'L85!I!X4>1>%-<&-B>ZCC:_Z \Y7WDFM,V!Y^+K:$WC
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MT=;3@:D6[6M*C&JSOKV!'X2\%8LHG<AZX26DB.LWIZ8B=+ /8IP0B+K\Z47
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MRE'&FR]AQ9',&D'B]FV$*7?J-B!$8)RUW+PF,N5/>VT8X5#[[6>/9Z8&JMN
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M30E;J!\5RI_Z3%FW%<J,^DP)W]'VA+9]064J#X>ZX)N1[?"!2Q/[.:!'.,Z
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M:S":6TO;I3(N+=UKRQ+7Q?HR*L4BE^O)7&U6:$O$^O#G)UR#>JA+EK70V>,
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MV AF.Q?BNKBX$8<VT'M)MLKP-2'#96F==FSQX"*R3CL.F;9W!/X3K@S+4!\
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M)>W! 0YBH:#-9.=P3DP;&?26QUG[&KR'\'? N&+A($>#^'QO,9NNAPT_PV>
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M?:!SJNAXL>HUUYAT$A+-ONF!00N(N<AB,!_*.56\.I?#C>3Q%^O<NS[SG!&
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MZ<_OGXXU8]Y_.GK-C3^[T^%MP#(A>^AJNPO@'H!'@)[Q><:P1H(4C5QDB[<
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MY^R^V+/_%_]]SG%R/B]R9N8[<V?F>U_7-1G*;\HBX)J^CIX.X-RY<X"G9Q\
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MTQ?5E*X(L5$ :IOJ$MH"7[YU#"8S+'IC-G?<U'0N.XGP*9V[^(!Z_V+(*_#
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M<!)GP[R+7N:..21=-Z^^<>/$BO'^@8'4%:Y[!=EY";GP<=3VS7=D!:+ZWLL
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MWUJX;]K<(MU<3+VZ@B12 +EJGKV$7PJP4PI 33UUBE?ODO@Y_G$P'BZ9Q@,
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ML8/2L8R>(>8EE?Z>EN//RB&AA844@-F>'6]W9UU(@JM9JM.V\)_RS)"CS85
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MA"^1P)=K<[@?[ZD100R1V_:/QE?]-)@?C/7K\>,<V03H(96A$4,1/R%8 PH
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M!L=>!HA22PR8]+5%C*^7(,XW"O\1T&5U=DCC+[JT<HJW\J+?>Q[8]7DB;O"
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MKG!?'5B\:NHA9FH9]6#M1:JZQNW',#!R_&1$-,[+[[M7@MI>OPP[S 3Y;G>
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M& !.NM11C:8KX4W118N^T N/W.*(Y_9ID0W@0^CL,2C/]ZD(D4+O*USC\PP
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M5ZJJ0.X B<5 *Q?/2?LH< X'#GCD$:=G$=\F/?;57+8F]:'=9.$[NFSP%8X
M3TQZ)CZ6A*CU\MK=BY2)#-2-&'>CVM,QM8<*MK8TO=^%.4%G>#Q#/6S>"0,
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MA-<:U6NN(6_-"_C4>SJHW^R:T:CV99L:!_/<UUIW[;*0)R,#J]%*D8%>(O9
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MBYB-\C>LX^B,&S*'#I3$-6>-[AE4$\7J*1<O\!E=,.%^E:$JY7W%O()>J]G
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M;+.(3GTE=@UJY#M2/MNDN!*&W<#2F!R3SMZL^JYL_XH_[M0'(<[;A/['WH_
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M;*ZK?3<E</V#7MY5W\/F$*T#)# &"AAKD0C):6L5XJBJJQ\+?)=76VN=F\0
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M"YTP^!8*^B*2(N=R]!86M4^:+GCX\ZC6,+]^_&TO&-N4@R$0Z-#1DG<<C$,
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MC=K+=?=6E>/C\7-H!K\;43%*5R7<*D*JPT\29PM>DE'F2\U+-;C\,9YG'NV
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M1%KJN(J8&^4O+G"FVMO3D3"C3%6"T!21I [Z/:CDL!)B[88$"/X0"\92BH.
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MHSER\I\W#)09YPS<B&DB]T@[VC'7Z6+]QI5!-<23"NXZ/B,IUH'[(>%P/)S
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M23R6PC*%O=]KYQ/T1' R/',9>H,!PF,J")[)S"F-YA$-J\]=@Q&MEZ:V#,<
M!]N=L$<0LBF&)H_JA)T-QK=!!6@)\P)PD]@PV2OIIS2ALX:%MZ>TX T(+-*#
MP?^>QBWZ:<Z##IQ^0L)R/%MTQ>A]W]S8ULWD1#Q9NW,V,SEU7[2LIZQF7X>I
MZW8@YJ:=J&<55CATZVT\8IOU@J\IF"TEH'@Q(5H-45[6EDQ%>A?*I5WO49ZH
M>R'R]=E R"9['%$.P9>3'RQ'(7QNT,Z"CNHP/6<C$%59N7;*9EKYV;AM^T-
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M:O1;L-9;T!/A(H/:!IXH&M8 5^.I)5P3K1478R-XIHCK>EZA>,7.<@;KZ"'
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M)MX?O_&#&;+[2V4T'$2!?] ]%8PSIBR_JQ&F[>K(!/L\\0]X073BU.[<#^_
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ME8_JELREE5!R!>E1=I)DC_D15)2A^.CZV/+"*2"!.GWI/3<69M1%=7WQE>]
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MCH_19%-H1\,I *!U)^P:Z9(P++G.K5(DM-OEJ_YGX>AFS;H']Z^?V:-S3:]
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M!D55AW:_K,7."+U-A,9(W>O7$]<CAI27_*_\EAGS(I#*IWP*$+%8AI()&:<
M'45H5GV:8 _7@8C^K5D4[5X&]3RTS(C*I_C_:U252.)NV@EEO+]B:=45 A$4
M V%8[//.QG 37U)X_?QA,@R#>'Q 5W%_O214M7Q2N3"@51(^YV.[,-6W&"E3
MR7)6[<VR/,PPZL0/L;M"=*8U[X(<4"0AVEYBF*@W9X'0F(9PJ='YQC?#CG$B
M$OO?V/+>NY&\<@9_)XG&/7Z6G'Q!59A'>0/M:13&!C_RG-GJS8GM8$%$C-85
MZC95YW1\/R%N?[$5D&\@I=@7Y%GL:-WV(EIT6XG<S'=-[WS$D>2HYJ(L'B>E
M*8 *@$=T3=?A [Q2U/),8(JC"0'-=I.4N7UL(B/\J8\ICTD;%J2XY;9W1*NC
M\KBJU;J<@/N%MJ"<1X7IVO*;X5N]YX<JN._CR YQNQZ.EG?CGKVQ&SX;PZ/Z
M3TV@_6@3R]0."#I8@<<=IERF:HQ6(7._>'Z-W)>P?)M?&/=9L-HRHO<2DZ86
MDM8"08/Q[M N$#M5%6^1HG4G>%)+=/^00IF52!%7LJ)F9DZD6S;@3YA!@SS4
M7*[N)AF6U_\6[P^I'6X7E?5HA5H/&_A#0EUI6O&\$%%9XN<?!]X)])OYZ?]V
M?IC74+6<"!N+>R11X(X5@>UI/0'Z08.I$NN2D^BBV8K'8=*UM^3V'O%RG^/2
M],W8975[ >V0/P6X;TDDHO$MX+27-?)%X ;#V-TCM*;L;"6T4N>7S+3G4G:'
M9ZRUZ/O_6N4+[6UP-W[:"-5:/]K=.O?F?L][7J$KAP@G($L[OWKJPI4_;).=
MTBM:!1-XAK:^(9^GHWCSNID+W+G4R-Y.JB4@8.]?R.?_HLY[N&*J-H5OY/S]
MKRJ_GH[X1G\H=PKH4 "YY]L!<I<@*(&._9V_>[U!(_Y$^BN_"^V!)"1%,2R$
M!BL0(J4LV>D\^1"6A D(O+'!DIBV7GJTT; !WKFL=8.J;E]P]8\V%-<I3OU#
M:T(M?H(R@_XK?95B,5JW(]IO=<']521;.[.HC_+S=PW]K6:_O9"?O/4.P3T2
M]2OU@W8+A8@N2WOK@MY+< ]KSZ7D_ED"=!*V"G.'OJG>T8W(1 _+-5T=#O%#
MPS?R7FZI;A?J%@98'$0 E5CEU%AA2T<(G /]\O0IX)S4).H=SQN,UF47;O)D
M/D].^",;YYM^\0J7IQT\XLM[=]LB^A#K W9G1W0:6\84=:_<K"H8XO_-.FLE
M;#(P8%JJ'K%XO(( SZF8)OHL"!:*BR,HC\W]X(YM]88CY#DJ1:/?S9'T>?QX
M_G*22JE$CYY&?8N-Q+S42[H!/ZP#E% @1LL-"RT)>X8OJ(1ZS!BL!A*F.^0K
MKA"&B(F<=DUSO@4%ZZBQ6/I%3TH :9 X1A*[4+N\YIBKB[0Q>W?=,>LB>\1)
MO\:N(MW:Y5Q(<1U>/T5(XR//*<#O.K-]FYP1> /\)YO*+D._;+&2,KVWC(UN
M/QL$T23+?$3JW[+Y,'NG<_YYULY #6)^\V(/Q&G9Z7+_HY+7'[IZ^2HINCK+
MF?-SV=GS)\"7G<&9UG\+@%S*8G"!9UMO,RLY3P&5(.#1!:<7Q7$G4)E3P$LY
M,?;QD[=*FJS0+F"F#YUU'-BMQ?9'T6I?>/RPQ:U),]! P!(*&VGS"Z@O_^^B
M[;[O__M1_"B0'O:)(R.@+G,TVRR<[('U'U2]XYOL6CS_LS6ZD,\)OS>BZ+5_
ML2)8^EWRF\3HI[1=>AO4Z+E?19-XDQ!,(UCUO_G<K!R4G?U0L*=WT<J[!NP?
MA'.M%2K]A[76$ 8#KS*"CFAN;5JCI\Z-V:;QUQFW)MVYXU4:\WF5# A_0#;K
MW7PLP8]J?/K.:2/FI5#>(1_;YWUFR!%)EB&4&;P864P%T;+:64B#AGC8QVWP
MLG!50EEQ^^<&XUL9/E+%[%]C^'3[T0_30UC=9@9_>OC_>U'&ZF23)?5XP6^\
M\L>!$9UGL5)L(&]">/"RVU.)'MVBG 2L$>C+">/)SSLR+K\ C+Q1<!=OT15N
MS;+CP&WM]^>A][H^\.JML+0^7KT&A"^X ]0SDF"O1BN$"+H)J!.RBDL;)SS@
M+6XN:ZF=)<&)[\^GIM]G53L\ HR? KC;A8/*5V")1S(?0X[6UGIZ:WT5QW_J
M[1+*OOPN.N\S+Z<C1&_U93<ZIQ1WT4PW(.+]V;P51JRH$(>@NGC4Y<7] 85J
M.3U%!7<],0DK:T,*V+ %.;.UZ!U<^<ST1YFRB3M2;/"+YDY?:V$X<-D1&YXS
M>K[^H\@4_A+X*8]&BKUZ(+^;16<S_UZ"I]0AF/4)9J:26NYRONY!WXX"^LW[
M'_H<3>]Q# H^A$6#:HUZ1I(7I$?KH$Q! 13+Y%TR3Y76B)O&[*O@L[7O9%-E
MDXU(F&,+1G[N,/1(J): LST'GJT'Q&>#1,5_S="?D%&@(),"AB-$T^7YTO9Z
M"<GAH>9Y^FA+C0]%]\4-AL'=+S#I4B+%MURJ\K6T/U])KI>_*HX4R<DQM0@]
ML-H?M%-HWPL-@?70(QBWF*;5(.5=PE_CQVQA1BAQPH!"[KKIK<4/YZ1E/_"#
MSH K@#5.U&NSRX$](A%T81+8;#1.-HO#:I"5Y57:%P?0Q@QJ5+ 3Q-3.%V3:
M-6,?PQ;M)V9J&'''RKKW[F^NEX%./*)K_.H']A%.BR,L+DL&R5$E5FDI1TI]
M,".C 91(Y7* DSC22=P[7PPT_[1_YK)T?R4R'!;J$8K=G.0:R,,IZU4*?<JQ
M-OHBL54_1(;]RN[%DI33@5>"I/<IG<WN.PM%61Z$[C1FA]N)J8!GM>GA6GF8
M@Z%E*$DX=B=S"<6^%: &ZK(+"3W?F*["Y\+=8ZV8NAA9>F:1-0J' V_+:$45
MVJ+7;%WJTWNUY].?5!0)3&DA!^:H2J0 L%\[^Q]K'8VLFA2A@M"CO1WRRDU[
MT7?XW$\F/NZ@>&*(#<+-7^UU5^.SLH-V?Y%BH<GD26@A;K8%U!.[;/0+F@AF
M\J0/$02[LF>$.ZF]$KE6E:0KVMXR&@<%H1:\KZM<C@E<7U8.+!+YG#35!&(;
M--C!FRB**[3C5CL+!)/3/W'DQL(O-NU=/ZD>I"/Y6T6V 72?6DYR960.DL%!
MMZCN%"%2L[OIDD=,Z:8 *_*J=RCT:NT@IW/RD*!"FOCW")YA(Z8_&%P3,&[J
MBI_7U'\=_>:EA3=S0G\8%+<8N8^P<7<M3%CD74^4"?$V6C"VLPUK#Q_I5)_5
M<>DFRK75EITX14>GA4;R^+ :V3=NC***4TAW8%0N.)B6VRYD'<9.F&RY&\1F
MUQ#IEJ]OW/@JS<C)F_/^U\QIAQ?]_G=ZV0S5WJ!R:'++MVNG['[:M 3<UXN-
MO5[RF*E?E8?*9H^\0C!ZK6%!MELE!N('TGL46SZOSB0BCK/7.^ZIX'YM%(=S
M7WO;)!T>"9.\NT41W19_)-;^+L,TPT:!>J3QO 5H(]7=&6,%>HL5+%E(3VRR
MD&^?I&<_IE6T7Z4ZX;-[P5>G@@H[K/-N5J7YNU_YOKY@]D7N7]/)2M]2#9O'
M%,*#]1(:>M #S6/^'SVPR"^? CX42.,W?J$^JN4^77JV_F$(R7*2]UJM3$ZO
M@TV#53W^%/!H).84P!DF1K#I4M(2P2<7LQ8[^+N=Z[04UGWQA5W?YPLPJ$"^
M!RK]KBG<]H8T\O(G^'EMGY(?*NW6>2A78GU;W<012.=;/+R?S=&$(S$]6T9Q
MC0=7]/*HX2B<S<1Q1/!_JU730\9=>"2'AHV8\6C7)X&29X9!-V$ OF/%);U8
MX6<#8E8M ^K"#:V9K?4'8V7SO-IU9A6'(;ZB?MMU6/=0#XOP-+YJ)E6T*"A;
ME0K2H^LPC RNR:!A^^2UQFTM:QGH24#J*<"PX,L>>)(VU)@'\.T8 =*KJ>@5
M<+\,E5^IC&U[#R[HQ\8-)A]F4PDY9,GD/(EW*FH^98,CYN+NA[KP$RP&$3B8
M^$W/3&1>4?K)&L_)#HG*H#]Z@ #7^ )Y\E[QBPM_9'?>RQ;D^1YM3+:M+&96
MY9900TA./RZ]3[YJ/ZQ?,G<_U^.[* +PR@FX&I0=XRZ5U<OK\%_M;2&VDG#-
M$#H31I,+N4V^@7"KP.V.^#K=U;N<]\G_3G7'(J'CB"I!X;C;7_9F/Z?.C),3
M3Q^6JZ_"24Q7S1R?.$-T- R>"SAOEC=I!R:"NYS<*2[(8RJJ$4NZAZ)RY5K2
M8*< QY%8AJ]S",F.M<3/6&(56Q/WV,C\K3J?+5]1MX/_/3Q"++,M&R4@4<"@
M0C,"]..1_F _,A?>G*Y>EO/T8]_V*H!V9OZPZGC9"(WEI=J,^=&4+4,3$NQ$
M-./6O_"_?/ "<LP4S2]KA]H>H4B&/:>5:80NT9@ZK,^O(XH&P\_=S*NO'_W]
MLT>H%.Y[-].X(5!T; N<CEFJR(AR<Y#]//"C=7RN3"UK([%HSUF;W/*/[H1Y
MK-2S[E_ZHMB@0V7&@WO5=8 Z L]JUXDB@3H+[A*2?EL[16X[3DCOVCD\^QJW
MKC[]'B#Y*F]U,67<%VPL2N70(?Z9J'S57$MRK&HK*3P7^.)9\U/Z3;$_SQ*+
M9&Z7\9#IT 7F;?53P 5ZF!#)9FGO(@EC'B.,L6:Q&1RT^<8NH6*YZGCO[P>@
MK""S(HV?%+AXW!7.\GA4P7CIZOD/F7!K2\%;/#6#+F<?\1PRWY&'X>PO."Q'
M.R_]'&32T\ -*+85KAE//\[:LZDD2Z,1'_I7#&V1(G-O88+_9FM=B79^!Z"^
M1UWT2QD4#X8&_R[3!;S&L[84-^I)FH_ .'VEJA++#Z =]U'N]R(>XKOL3DYD
M:"G0M+P-9N=>K?Q^Q!']%!!C@_^7VM71?"&4_34WR5289(7'_8E:W&$N :WT
M@N!'"&Z6Y0 W0Y],/6^$H:])HK"H\TY16,/<*(+MM;A5V\J-W)KC NK(T\J_
M="G4=?H-J@'I:O@IX"*J._SFGO:X-.O$A]U+E=AU8>;!^\RE@H?$*@F#.AN5
MZ/UC\#*:E[@:>+@%QO$R]$PT Y652:+$*'P)BF#:&?)$;+E2;F#=C>6JUL53
M0+#"LX,GYYQCAFU7HGHU):@;$"'2K1[H)>K3TB#!9>'H9I$V^/R<M8&3-\=L
M7XJG1._#Y.?W;XOU=2"F@QYWSUUXE76+_5$2WY.UBRH#YB8F?^NP]EE4MO2A
M_4M++I20Z]F"QWG?JR8JX08:.W]#M&[<$LFV3GB!;,GYU2.N5SN+RII._ !4
MGO#>R_G?I&PR$&^A:;.(36G5Q">@<W"Q':E#5VLWN8\E?W"^#\[2V:<3=D%D
M[.\\+_BTL@1D-3+L3_ AV6%V;A&CONKZ9T%X.,'7U]V;L^SNB/L=*[G$6['V
M/E[,AIF[!.#5)97D?*L7\?"X,MU.KNMC6>;';\CEV&&L_,C 0;%N;X%8TVC)
M>+!-B(VAT\8\2)YF@EK\#L.;R;!0!6DI8?J$C$5B@TO%@C7)G$QD<O?*6'>L
M28V@9(\L,'\C]B$.SI)&"($]V+K8;BGPLDRBO]NQ6L_<<9*;QCZ/V8A8]N5D
M-$\_?T@((>6;(G;69ED:B;^QM2B"" T.?AT('WJUXRM4(ZL['BF']CS3I@Y1
MW.=DMZXL+OE<4>8O^^SN4XFFHM?O <.ZU*$PPY>_>+1X2JL_SYJ_B,\MM_+Y
M(6<S342-.,PC"B9[=39)?C@M3Q^%XWSEP8'Y;+M3 )L>>;+2I7C:9L;JQ+&F
M.K+HNN'%G8*059B]O'T3?H7H0$(3!NYAEC9B_:_:KS\U%W-Q\Y;=2$X3V]4Y
MT8#T,OA<%+68#)&E56J\OE!(4'Z(JL:_I7A(^E]R+[CGJ)UVQ=$Q\XJ3W]L"
M%3IL7G3;C2'<4DBR%&'[GL"2*<M-;86+Y?Z<'&<YH\9<R2$6AD[+)4SWBC]V
M+A9M3L#9YO81WH-/!U8S=$6KVR1SV<U50C['%36=_%!5U[)3I]=O4V#K"0Z,
M2P[1&B3SHDFOEYG>:QNF03,B4G8#T:0C+@48_ODI8-;CP!L:TTQVQR4)4)WV
M[>' #2[Z+RB^ G)K49EZ9^;,"$WE*78+#=<#D\R!K&;7-?B_^H V.K6@AK!A
MU/WRY05?29/NH0Z]6SWC-;JS69MDMP:HX+S5C0NZ,[*9X_[VYBWMS0JP=6A*
M$H;*X4;L^.M7ON-@3_*MLK:T?#(Z9R"2&1*?5BII62L-Z"QH7"$@/B*^P1Y,
M5AVZZX;E;O$F*K.KS/QM5IH\;_0X-4A0PP\'WG$@,"W*=$'Y@Q[;X"OH'']V
MEB=VA.J#30:$_:\+?KOS<>46:N3V*0 (;MB@WL+A#SKK(4HDV))E@5N<R8&)
M\Q)[C;:WY"] ]2'5]P2#]<I.>%E-^OA:7O'<AO-HY5!0R_Z_U>UL]Z,C#<G!
MN]\N^W8OS;:^S%171[NU>)X"S@"[RKM*L%.Z7\R>EV6^T)%*O2^;8N\FV)5#
M1"T:6/-#GQ4L7]I>M7+8_Y*Z=DL\:*- JW%CG A1Q3]I/T^*6F9CG8N-UQ0A
MNOEI]S&_K8K2.$/5U/2VQ'Q8<+96N#P4^=4[;V43="5<XJAYVDX2PRSYY/4E
MWRJSAC5WT2'_?0A$I]ND>[QCF0L84N2@<B!3RV\Z.2L!.M@<V=NC7\4S$"LN
MB,.6Y.^^"/W8+AT)Y!PV&1T8V"<JYCSZB^9[[9!YG->/9L*!,6TQ0VTT)'*G
M92]R73%']-RUOXV+&RAFA-XI@'=DZC'##76RS9AV:(FV8W;K*J]W68QM-#[T
M>=4PS3]:Z\',DA25:B@+8S2VE)D*)6;C83LL^/*'XU2I\H<_$OA%9B[97QKU
M;5<QJU].#-Y8'W8[<4I2 7-_6JGFB4\6Z"TV4+1H03:93X)C/6(W53V4DN62
M@(XL SEZV'=D.SA4_008T/HG]O)P2PK HQ?*1F\L_EPCVM=$/&(8;/]CG-7]
M&<7?WUTB3**Y.GXM$K;R0D,.*W^?E4V6.(AA-BP:+P3&:?*/9V;MJ(>C__2"
M65QQ"B?V"]'WL_Q.>C7;--E6,'_\B@5=-N!:TSPEX24 ^HO7+6,:=##X8.;'
MH&2!Q^C]+Y2IK9ZG>L9E*KKP&T4Y:^W8),S1-(]%=^\GFYJP_34]M5[I4X#+
M HZQSUKEWG5?3E\'?>Y-W/CWOGJE'C"R!![BIG(=T%D>+H&GRSL:R&R=IX!K
M5JX",D_2AXF=MS*SG,&#_JD\WUZMN%6I,A>H6?P[IG*5$Q&84\!;MFG?7AAG
MJT*[(SU[:<=Z\\X!,.>6U1>C ;,C8VSU/WGPFB9A<.5"&^4QZ=B2%+MLX$H,
M]B\OVYT9=9E>UFY,[7N@W;_W7G[L /35RY,9,[PY5JD=+1SU0804!\:V9>6U
M5=29U[<(:"G?M]3SYSLL4W/I9%D*K"^W.Y[=TP014V@M6O<AXS-K='CYULW*
MC^TYNF^36>(*7PB]Z0E(#P6> NS"X$0CD3L:8VWS2R?%P9]U!95-&X]$548P
M,]\^ +=+WCT1L/&"8QI.T!X+7VH7YL-+5+X_&EW0NQ-SP<8OW<'YA1J-68,
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M.ZS+A+/. 4<H@KFWE&[<5!L*+EW0JRXU&-452OYU):)?J""J+8B'SC5XG[=
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M@;OTOY\"KM>7@Z5&^N>UAQ=V\7/=E*J61[)H)J"T//J%/&Y3XA_;M 2QDY1
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M+_@VO=OG-HEI\7C)#)?%P_MK?<JABOFY!68Q4D[U JI#6M+0]F%^T4S";T)
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M )1:I,/K7_XKF&L+&VO75<%\AX,G5,2\'>.'+[5W-6[E<QB9%>6G&I[56$&
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M!M>N2%:LS;.'N\]@:V*FTNUU# \DLGP-2/GM^Q@J,U41U.2R>U@"_@6JO]"
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MY%,:ZX+\0L((AK)!T=<0$%N(PL/$75F?!!ZJ5Y'5VX:,2;#%KHX37DGREM*
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MN06)G>- O0_L?8&6,[2$-4P05U%-_LY6V;U]=U1A@:<VT\!^II7W'D04_IM
MG(98\!]I07^(%_JMS,_59"-H5(CB1^ZJ7?$/UY>G.CR_.%VC 5#D4%15N GP
M-?TO57HS- "G:A\F;8XJ?D(#&*DFH')W"!];[ ?N\65XL_GTKQ)1A!V84?6C
MZ''\,S<OU(EW6'M$A'\+&I_PI-A8N<>OG@:8S4RQ-+$;ILM9X"0-\&B?J/!N
M#.C2>NRR7F!&FNVG J,@=F\C!]:L\+DTP(6?[L8O<)X;@URUPW*LS/WW'ZO'
M8+8QH!G[,K&+=':\7D8!(K=! _.N[\JB?DM.%\2S*QM=VIZ],P<[/@4W95D1
MZH4RRV7TAMU;[T7%#4[;W)8?T;?\5_=[FQ#NOE;;YTTX*'0:'HE8^@*J_P"I
M W9*^?7+.EY]9G<< 0VQT3"&C9!0(\^W##AB"V,2FNW=4J(H-O9&LPWJ&<J3
M;CO7?-U':0 E$%':)9YL7T6=[1#%_4'M66E31],C<D?2!N?6G<);"<>$U28.
M8BY?VM;A%8T;KOV EDWN-^R4L(+08P4"D'R#DQ #FK4EO)\F0[P.2+,?: #9
MYA>=KY$C_; F-:NAQHGB#/CL1O)OYX>^H0EL#F$1[F<N[V29U^=5F4P\;DP>
M!9TXPL/ @CXD#4ARM/#5HJ5B8]UR&ZU#^[ Y$)["U@)<*@#5'/T]0=F[(/RH
M\9?IMDH1I^%'<O=9[)3Q0]4"",,^:*?N['KXK;0EEY^@B^%JV?%ZW[8;'U3J
M8[V.P@(^YOG-^PWV>YZ'0&/(O*(1)0O@"9N\EF]]*9R?X=E-C(HFCOL^_7RA
M8,2VE.#'<#F7*$/]17D^B1@CH-CV%O@S?!/)7B>:]$NCZ/L4^U>QJ8!?JZIS
M"PV5T%P2U#YUM. RF[;YCO;3,A<)NR&\H93GPB(5YM7_E&DZL[F4;+U,,$G4
MGS_>6BT!UT^L"K+>Z9S$=OY6]A<<J3BP>MB.WBM7]22)-F9VY'A1K*&6Y9I%
MI,*-ZOR"''YUA>A=O[@-9(*:RH_?,"^D<3ZDOUTR&-%=D;#C[3>Q"=IQ$XTI
M4YH9STU$S61I0XTM? Z[284GA<7?FM-6V5BKY<KF#ND_P^\_HA-Y/,JL:9/2
M0 .LE)4K6*06*XS=LUI?WZ2X7?(.K/^VOY&XV8<_7%6OHZC2 "DF(P+>08%T
MA]77S$RV6-[X?'_JZV^=X8U^I'HG&')/_8JUAA2.NLY6U@7[OI@M##MI/N:/
MV,&\*"]]=!(@7N>>:;)>9]SDU;VOO-/'5U<+:G/;+UAHF#JE 2RE=W(>Y%?/
MZ)7L--8LS/PN%GUO8:EC^D/H_<7M?J,,JB,0YQ?SSA]XGOI'@#F^:]9.Q;Z]
M-_GCHG^CEE80^_;G5W_*F4G))O-Q-( AFJA/5F[6(>0W&JFTO =>6:@@OJ0C
M:";$>0YXW3T'U!\6]B%;'HB55"__&G/JUJM$:@J@ ;34'$DO$3JXP2E83[K+
MH(G6T\K%5).-M1.O;T_P<A9<SR6ZY_,V)F\=^=;GV 3JGT)["Z)*I.8J[/2B
M)8(]?\Q-P&U.YP@<E")'2C+"]0KGRK-X++-7J2U_:R-;[AM[776Y F!&>$RQ
M[HF?WEVG;T6I.F]]3KA@_X6&M\O,3P-CI6PD*WC?B3F?!4"Y-ZD:CGP!=,C0
MPUM:Q_SRO6/>L^A#"!_/R+/)DNY*14^LKX&]TE<P+^JL]!-R?-.^K1V99$R=
M'IUU'%*2$$L%Z 9?\#0-P%@/_!A_\:V=*V'UM<>?/Q6<]H4%2BL=6TFC5=U/
M^!N_\_GSL:>JTP!(?@0C7;TO*J9Z_2GLVG@8%/'^'N)XCAOI<'Q&+7S=;T.]
M^\O5K#"QUPRVUY5OK7VM;OQ.-2+V3(')+%5@?#P\MKG"74JZ:5$%D8(DJGRD
MIX?Z]M+J?D\(-YT8K2,@EZ@_,"3NOV>_>07K%J%[>#\:P+,6I:UC]6?CLW[6
M^GK%3726[,T[(#:+H.2=Y,,ZW+:[O0HW1_R>!:]* /?Q-F8?/>%M/>@GU 0J
ML%UY(![>>(,ADA3&-VT<C>U1<6+W/%2\M>QSXONU[@BSGX<J)XM,K.+9^@09
M7_OF]9;N!-;HPCXQSO>U)>6YS)&!]?GZZ<$.F7<>CF7<7JPZ=NTU6-8_+1XE
M@]CUB^J4QO6,+"1:]8>-0"'2XB4TP ;$71#G+MU]Q:4SMMJ-)[%H5"=0JBBQ
MR)(!,5VP.A^A(B!YYAMP^,Y"Q&^[DP; 6*TBR>S"!/^Q#J;P?W'@FB+;W@UW
M%8N\\<^K%LKWM7M292$)U! ,Z#LAYE>BD_*YMS['@I10JL9*2/E,B3CG^;.6
M.C?%18Q.P Z<)'><P (S3;QD&F>78D=P-[+@A]JK0X8NVUHVOK2>>:=^2(D(
M2Y)+P-OX3[_QF<RQ^%NT$*A/NCW24AL7/M;8KFR?F86!2!?TU]  #!&SE[5N
M6/[DR*](V%;YO$UGF3,D13RUWBVZXG=6&9OMY;^?<A9"OP ':0#JY?&?U(4"
M,</Y7)(W$)M\K.Z.KZF"96Y)[)G47YD_8H0>SL&K@<[ I?9,?: GDMUXPRE1
MVZQ>\/0E!*F)^N2./Y#2O/GBVG^L\YY HT4J5)]:@ZN0KZ(DI<_!!M+_%=F;
M]^!]36?+:."ME1QOZKAO4=Y:6<76;@,%N)STZ%ES4%OMQ(/U',(4R^?MW(](
MA#&.7TEPEY_N0+(^=I]QA]]_E*K]KC IHI*=@ZH/NJ3&P-F#C%6Y]V'WEFVB
M:1=0D;OO[&,,V.]O@1X)&L !313GC$)U"=;NOY77\EY!Z4P(SS/99\8AU@+A
M2+*C9XGX9>O!X0)3*PAAWW#L6.U6,8]9G*%FEZPK9K]];J?%]1L)&F*BQ4%T
M);S[JW">N%CL^$!AQ["IR[F6V=U,+Y*?4.T""12WI<([-J;K]MB(L/"?1$'J
MI0+(ZC\TP&NS.>HU$1I@(C$?DNSY(TXM:%6Y*7P8OG-.VO=QGN-7L@QR G9V
M@0;H-.M,)C!1OL;8=UPUIBC1E0D4 UK=C'B)<E##YZWC.'LXUZI]4D603U9'
MG], =.1TQL5SX8B[6K?[]@(4LDZ4'2%=-$#V0;@ULP$3MU;I7.!IQ4X')+JR
MYEY.3GY1EM&R2,+U,K(.HYH+<,VE@ ;PI]]4HDVG8OLODW9[:*@.?GUWO'#G
MB68NZY4#UFQ&3/]V#M'S6>-0L?-L)'>"-ZM, 36_!N0&Z93W&/>:<UE^\W%.
M!KXUPWB.G?*E#;JCKBYY[*G1$_8$>FWX6Z(B8BYP$1VZ#UO AS#59DID*)NO
MAV\7#T_)8V'&!Q%LQZ=$E_M>@&#U_%KDUV>I?I.?^\+6J-S5XQOLLAXL5MO4
MT+/#([@JT>45=DGPPGU?P.@;V0O>D$"54ZJ(5;$JA\.'OXT<Q! IZZ]']*^W
M->>ZD^P)0'M#;>;V=,O6!6MN/^W&3,Y:]JRXZ94G!0B1>^@)]8[/\,-RND4E
M41=S)LB.>,6?)*?L2C5252.W<59B[MNYA("!U8EMT%;LBJ$1\LE8@&H%YD-3
M_"XG5.X3@-(3J2S"B#SL+X:D>Y$Y ]WYO0C+>-'>C"Y#YDEGRLI5;;64^>M,
MZG5YR>&"';@3)K57$>?&78OF\Z1OD K#'E3F-*6IJ6W4B[\OS5U/;8W<T,,6
M52($!\@1'G?M[ 8#/#X<BKB"32@$:522;\@ YKC,?\N<F-L]ZX_<B&@U;VA\
MCCX:(QS.:12\Y9N.U)5O]9(Q_GS-[W@U&>0U\04^MD\4[=\5I0&N3.%S#<>F
MSW;1,SP)5I_G$)3'6S\8?6F L!JR"NHH"1)O?<\@UJ^\K/1O1>9?NY6G[N"L
M;<?#A-JT'D=AK)NBH.NP_+<%PA2BC@K6.?F[\=0HT?+ :#1SN" ^=/RB*<9F
M?->3/U7$2LKGDA'XN1_2C :8[H7HZQHX/4\@MT= 6!<P&](S@DL0LARBT_AR
MN*PLJ?_A][IZ= ([X?4Y>UF?"134SFHR[@(#8QIH@+O#$23;.]V#RJKW34L0
MJV^SZ@XXH#8!+;M&87H/;SA-ODPOO@F/:/3R0AY_/9^KY3V>]9(5;#;J0EY-
MP).F$V]8I8;^S]>D+4HN.-V695X5HO[H-YFTR!DIP!?F.UZK8?J!% 1A\O D
M2S\S#R5DAG2L;0!LVX<<^P:;LZ#K\FIP'WJ8C,%8N9;.I3^XB'0TJH@WU:O*
M:;FF?\JHWO#+^F\5.WF@L:R8$02X">KL)_.QT1<E.PT+%J>472A]"B;L#_[Q
MZ1-F#*0!MB<*VJQ.BC#-/J!$$,X&^8$'U4L#S.CT@'E&L1O-+:E]'F67Y)I8
MGRW='E3BWNYW.Y%E";!C=8F$:UNFNS\R."C3R7Z].-W<'5^R('$RSIKK:=E>
M7%)FC3 &"I/SVF1I@!>3HGK(?#YV0V;'5+9,K$#()J,7W(@^J7 @*QQR95<6
M>\V89?$9'Q@[18',;"97A4)[05&S65W2G&X%5U%"J>.GJF??AV5E%>5T5Z,[
MMW?DR)B1\)@:*>5/+4L%;;X7]Z'P3=#TYSMM:$96)U1CT;>5DJ(&?4PN;F)O
M!^QBVO;]<])K/1B63UBL\L1>ZC1$<-&*S$M?I/.<H.M$>QK "5%['G)IWGKG
M%41.-1IVL8'1<^P$W(E!KH-FG2'9XF2>-:S/F2N1&IX/>X(;N(PT\2G?; I/
MV:?+RPE/1!81+1UM"UWY/KEU=B,GH[FY.5>O&7W6OVWM[&K5.5ZF?#A8'.1N
M/><UL?[%*H]L:XAF57,^=*2*<-)1\?8Q :X-5R8VYG;P!=/E*5E7F@8X,L%@
M09*:U-/,1LJ:0@-U7-4-PRSIYU&,C;!RB"'BJ.B1)L(AI8A9V"UXT*_?A)+E
M"!+>"8PQ;\PQ"#Q(D- 3YE8/^X?-9#>$ *]">(U"<8O0^@]&/SWQJ?^#KO>,
M:J(+WWYCQ0HV1&I40)J H$@G-D! B'2I41#I(+UG;. C5;K2HO0B1&JD1HH@
M($1ID5X"A- 22AII)_[?<]9ZSUGG_3 ?)BLK:V;V[.OZ73-W[IT8P8VJ-=UM
M^J.NWKQC_FBUC] #Q4JSR*KP?X]H*7@>)RF1.#[*%"F07)^7MH#<UE^D)RA$
M;M=SB;RH/Z0AN0FK1]UM9-ERM;@67=OS5N=::*K92(M^\>3J68+J^:&[\EU&
ME_1.7CIX_F#B0^<2&I /CJF['R@JU*-?'W_;U^5,I]#%B<^6EGH\7LY<Y>KH
M80JYA% JD&<-OBIBO&F+_1C1<%($&4E4O;"B1+/>[@$OE(\LB+BH8R9D Z@2
M"_FC5$((%HY?H9W0@B,-BGY^:?R4NSD49SO3WX98/O""I^B<*>Q8^#_K.Z!:
MM=&(9[)O5'W^\SO^K969]H=30*YK]DW5*[Y*7TV"=Y)(5 S29_13CP?7G1 C
MPW85OD'4=W6IOO=0D$PT3<V.$D4*!&IA[YCA@7'FY7$VD@QH.OAC\T!WR.F\
MG* Y=A#;RU9_S]!Q4O\*J*5)]W;BJX5;FKB24G8,>N0MFU?$"7!"G!7[6)T&
M+'IAZ5XK%"//\Y]+CX:HM;7X7@VYO&RB0<:5>+#_(P'*72;(VNQEBM6;< 5=
MWP V7\#.IE*G:?H%8SE5%<FHLQF)1+PO[<KDHY-W+?_<\%J<A;6[IW(3A,GP
M%. XON[).HJ>>\$!D4PNM)T*]>U$"UO=SHV -C0MR)>P))T1Q*"UC348OKG@
MN@$.=MBP*V&"@NB!X<C=&GA("6IO&6B7+'@'<8;$G)$].?#);?&K*0>D(Y,W
MK<8!D;'Z<8TY\WHWO*;\SJ:%/1W%-32MT>2;/I)BSI\IV,"+Z1]M: Q?S5CM
MA^7U$*I?W P120S_MSS$&I$VJO9E_T#KX-S1BZ=G42C[\.4Z2]0)W+E5MK_E
ML[2"*(DO7/6WSGN[XA=_AFI65[]*Q)?N>_GBVJ%SIC89Y]X\/6VD"WJZ*F2<
M6.%%L8V7\?.6OGR_<%]Z>LP1K=,_<8A*X".5*3(^W\K3,5N7$*\A&B\4_G.K
M]HBEN1_#OB5'>A&W.P 4/QA22[O(<Y#,!##8*2R]!&C__?L=X-XJ?=W;X3<<
M3##C'NL _/7\M,'0@I9$3I&[;:^FPC/<LZ'IO<FEX?9?HAH?O.Z)"^J:_>FM
M:K"J76W57,,SQ]RHE5HR3_'$TGU-I,X#B.\XA ?#E7VTVH7UD>$3J0"]#GQ$
MNO5H^V7OKFU@_F')\6>H:P:\-G>J[%U?SA:' SE"C%KVT<_''-@3Z.-%[K>?
M8NO@D T65ZCM=K6$V(4XH=]E[YTN3B]_'6[+L%[DSK=D4MC3S]";GW]5\A34
M8+-6!R:(&-A=UG^!"/HA=P2%KY8#&G);NU/J;N\>[K;[]=]NZ"H+.-DZ6P&Q
ML5.\A7P%F?L\6_\&4@/^#CD?:9*EDGQC@,^\Z5+VXRZK8;\4OI*B*"(, V&*
M1$M4L[\#9T^87>"RH'S B9*#0+X]"_*A1V7%Y=REV%]?0\.3\='VNFJ&F@Z&
M!BI4P;'4!)E>':N"0 8 &X(,$"E9M&B>;F0"6Y96=O E@"(?[V^_X)5,*?LU
ME7<]<0J>8QW=^K'9 &6\%/GF503[*?P"T:;MPO"S".GBQF].QT[X8+1<JZ(T
M UBRBV/;,,\FA;@3V8>+2B?',\PQ1#L?@-=S;WCU^<^:/8]T29,;!)GB)60'
M:L.'G8WX;T$.JC0P(CLPZ%?6?]2?(*=2W.36Q,5,%C_07L<!\6JIXB 33FSL
M#UOMMEIOWZM(@0EG@W/*T]W\F>'7I$1./%Y #UO?_1V(Y'4G$<)5"JVLKLD6
M6I'*RR^7=KPXM^\[K@BXPIUGMV9I5R0@AR*EYF>3!D)K>A=$=88V4OM!RZMJ
MFSJ4A0@@T%D0N:9SO"'#*?N^R,YDTF_VA1_ ]2V?)]8W!_PN)'G+_BYN#/+-
MT*I4L,A+G-%?MW%1-^\PCR?(!AA(>6H69C2%S+(O_,Z/E5M,NB>='POZWS>Y
M;4WV,0;C!'*CDW1>\6@VLA;H4#Q<6[HYCH:XQ4[&NX2Q>I 767+D[A8.:"'V
M+(G1K:\E>IC! >FB:!Q0WO0%0_(U6JQE67]&D7K9;?HL6:GK[L10NJ:#L:T)
MI6:& WK)YAIWG?YW X@K,K[M"LTKLWO%+1,;G'/R4U1>@,#TP3VQZUR&VI;V
MFH^U_MBWN;@A-=L \ '=;;-<7$VMM6-/<$#G;)9V]F'K7YS;BI_-<5:G[FUE
MT>Z:W4D1S+C][E%"WL=%5U&_W96(9^AO+1J_JM6^9&279]8%.BUYAQ6X3?I4
M308VK\*E<AX:J53PF&XWZT_X3^PA@R<\FC<9NQJ*/"83;[L@1R8/T\UA-=\Q
MH*-^PRC["+^)_ZDK?"F0RCC.QFQQ0"$=/I#MSR&PQ4-S:K8]/8Z\36O+G@TG
MVW\*I@EQ,8E(NW*P+61=D0'I91&/-G) ?='3\$LX9U_^Z%8.Z#\&85.S:CJI
M:6[/(ZOR E-LP*.IN7V/3/^?@D+:)>H^V$> 9)6OO^ZR!>'A81QX!$F/ QY@
M"47P9T"[[7/ 6?$='<>68;ER0/>%FK?1] MSZ/4K2>R,^#7@6!$'E(Y8-"JW
M/Y[T'_S:U_2&+VT7V\P62?M2#PR#\7GU5RH\FL2OWD3BP\I-EMK;M9Z^A]X>
M*Z/%07<BN9DL/_.$"F,G>?+,V;6<1'5V?MVE%[?=J*K^]!A)*3Q%L&< T8E<
M@(*G&TTNASXH?Y/VI4!/P<R6]8$#,L)_IIGXR1HIIXFAJE*+ZI<&A(UJ4):>
MU*D-M*OOFR'X;YB0UG52L8W0V05AAA'D1IDF?%3MM=H<NT"-:S3>P%P6N+J7
M%8=VA1Z)E&) )X":0%'9W_>MGT5F/])_\.^_CMJ>S';(7$;>H:V26,#+-Z9I
M,VE^K;GU"M9QZ &V^MZ&T,$V/2<;<]]I*NL0\/5FVC%"EG_RJX;SCY/NR.-X
MR,@E-'] [+?UB5S^FX2[>?:MA8V6'-!/5LCESQ?F/DV9I14(KU48.VX.LL(S
M^8,9B!UVP,/I6Z[QI4YM."8;/ET^<$7'>QP"Y7X.2QGHU\M4F6AKJ"%N:W>E
M6:;\X=]X?$WO7#779 %%G]%GL;(QYTQU0?I77]UXIOU2?!NWHV6I:=3][=FA
M"Z!0J1SN=,'OYK-'JQZ"?C4_NLD3Z:__57QM0&?\EO&'BXE'(9BMO9$ ]DZ*
M8>]DA@.#U=4H,<0P:\TL:F*R'4+D/#+.9Q5]:5!-EJ"@CID]RG$1O=]^\-1M
MD;QIEAS-D -ZG0NXE,1&*7;!3D0>UL_ J@I%#V:[8UEV/LGY+R+R3#1V>I'$
M0P47<_(**1S0&O8'@)+JA!R@=<[Q=<G?[=H[E%<6X/IYIO=@YJFN#>'C[HES
MCC?%2WQO.\Z8)^PEJO(Y!!A>RS&/?XJ+J$.?Q"BWRHPEV$:6GREOG<ZM1*?X
M^O;\Y("$@T?J940(*9-&KD%/MC&G#]Y<H@L^.G5$'8SG-V,/^=:TSN;\-HG]
M82]R[:+KQ:7[^-F<B%BJ;^(9]PRT6-N5\?%)?=^3>=6A%U^"+!\J2C[\M*][
M7\\!'K0(-L$S>,?#*O5(>]S2XW-G7W=#O?!;R+5?#2@*@G?(XTS(JZ69C39K
M]( B30B1BXU__JCQCM'?TA%K[QT;PA_?:4GJ==998 [K8.4.<5V;!^#8$R=>
M&E6K[9]0-(NB87AVY>C-7+6Q^M=,>Y9RB185,*_Y7TMW.B+C0S?<;52-;L=
M5_+3]/SFV<ZQOZHMYW*<S0I2$I N5 [(L3GB_4)]3&R!$&]-3&P^U:)A;!:8
M8B;MEM/^D/H-:2_G!CP-&[^BOC4WUF5(BST23ZNXX;7OT$OQU)'3L&[\A@WC
MNN=L+3&![*UOCG*M&R$^2P&]_S J\,N)9^8QZ$3;Z]EX:ZI(G\B3&%WX,_8T
M4!/+]/Z]J2CO[9SB^4C215)Y7"Z/]^ABXNNA>E)<UU7]0_@ZNXK^Z*[15^63
M?VR*A+D$U?Z74ONK'MMA_/M5VESKWZ**B0U"Q=HDOHSY6N?3E>B+\6>V/[4+
M:A[?M[WX7(D8#[;]Z1F1K1YBN/Y]I_<)-BDRW'6R-4*Q"Q$=3NTX"3P:(B<H
MK-[V! *3?SV1/*.2WB#:=0+TH7V=Q\_1[L36ZN(WS>#<9J@3[S4_#@C;K6G-
M$)S'"[I$0M.?%,FN6A= +<T4;?1X&<7U4="NK4>'JT\.;*L,5"0U/QO=W<S[
M\9^J@_Z;GQ>=M:@'1/V(Q$G^W*MG>C2Z!U+\,"7%1R7(NQ6ICCTE2;6'=)Q=
M3[2^4\-(01Z$,&7=Y)\VOFF,_!EF=O_GYO4\3W*DMDJT8:#0(N'*2%5N$YG
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MNA@37M^3'-N[VN2S:I&785 A64 ,6@-::%7@M/.N!LW2&^?([C,ZMB@D;AE
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M+< G9!-_H9&=9;NAT5+&$Q2&@=M$TS@]"-)CS3XFZ"K+GD'76<32)G$2\B/
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MO<782-ZW9#Z(Y3Y<A3[9[;?<T2VC@I$47L^+FW8$@)6@AD[7!*TSI?K,>"$
M2MV:!./YV=P 3C+@!9R(T70\6T)(YR@'A.0GP!:-B[B$]X;87M,H*0RK_JY=
M*X7KT2&SFQ$D@\M\ZT](+8D(4M(*C0/ZSE^Q56;;(/R47A\[[892G5N1?NP
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M:35J,*HBA41 IPP=29_TB,;)OP(1\G(U )V>;\,2![IUCB;HV%@[#G>>7I7
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M$$5>35@=>O#B?<CE;3EF)OR:VT1(#/MFY+W?\]4W&ZQL?XS<]*,_.7W:1^J
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M_C#5<K3RF%Q-TS LF<4UK_:O?VHB+R'"IB*7Q=#;W9 U3(,GXR:* S+E8P5
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MW4I*[E$,RXO$1F2Q/-E5F.DL$>>TF9,*;;GGY3_%BD"K/OS8QP<=T!0#PPH
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MT>[^JI[^O^&.Y^QU!JR=O-H"Y_QJ6TTPNC1K._E/QR[/7)'E'57O6<_CUZ+
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M&;K\2$R9)U,R\IA$D%E8T%YJ2<@+Y4]67<21G,,2%\N@IS7W*]'" 9CQADC
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M<&JC\L%53-\0"R=EM'B$<F-V=08(#V /8Q0R_-EQ_Z_R-U7_30[Q=>]\F3[
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MGIV"@2L\SP*Z(:.[H%G)Y_)/B W9#H-GQGA_-)I^7SA+OQ[5=-1 6+L)3W\
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MJ4"6%F!0>_9BV]^^,9L<>XYU,'XB.#*CU*N'IJ,<4>\UJO)YF'UV>Z]>%OF
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MS-T'3>>CB_ ^APQ;OGRZB;O MFB8:73D(15+M>5O<1ME.H%)/JX\C *?5G2
M^K^<X+W:4-<UBF:O:IO&_A>VL?GL%!B84;BO<[!DJ6F@I\1,G88J\NJI6?P(
MV3JE&"T'YU\#80ID-C 421T=7#6F[60-#4>*=Z+@CS%!PU-T,@'>:?FJ7*'2
M[4K+*>5.U2/L99M-QTZB27HJNI IX-E^%4%F0FSC(RKY&OJG=_H7AD6G5L\M
M'RMM9_@UG ?HT2YJ:4+!UGI)FN[6O?MXU,W59HH-R78S,C%R>J(IO%"J@0BX
MI(\_*6\UC_W7(F#,I,>KS$"$*O->D!+6G.$$Z>(+Z%@O,C!APU;3CR=MGBWY
M>2HMS85OE_0M5TLS5L>+P5J5C@0D_?(QMC4,9CMU::P/6OAY1_#)M/SIZ?9R
M,4W1Z];21Z"S&D&B&C+T;!; G?-C$Q]%GO8X -,,$4 I3D*2BEUX!SIYPHKN
M^PS^%"H;]^JFODIG6P59_T=?K >K-"0A8B-NDE40Z$?3R< ^Z&D0R1I)N9:_
ME$D]Z$1_F-0;JT*Z),VX\ U:EAQ(\-KM_M814[P]3HP;:SH(#ZBXE&BW,@3O
M^;7O '0B-!A738ZZ3I-V;U8MK&KWZ-\U7XP&UPWI8&UM;0P65AY=3BER4\GZ
MZ@XX$-/,\\7#VA"ASC1NR"CP,LA^*WKVXG97F,?KLG FEZRZJ]%54_8$VW0,
M/?KYT0YPQNW55Z7J?_#(WX(%20N<@'6L)O^V;$F*:E\TXOQHR>#71*7HKYZ&
MG??/Q_VCZA5N!79NJJ]*>!DGD0M-,U<+H#538_6#S?=YY6ZV>OE?,(,;)'=6
M"S3Y.B@H <N:4&6',S>2[TQCTOTBQ>(Z<I+3ZU:RQT!C7<S3;&MV@H-B3WM!
M.?:O'H=%9<,V3U8,BEPZ]7.BG2CH?NYX9-;:X2J.AYH2)Q0K'K/-&#-K7IU$
M_P:1V2 <ED(W941XN+, \Y>5E!)L?F>_2#@^?Y0[^J3V;4W[X0(U>P4&C*T?
M-Z%SM;/\%$;0O;CHIBME@[Y"J1]EGM^21%4%BL<G7Y$YU:WV:<X;,PS\DT8
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MGC1* 9[=F+8M3D/-]K  <71.$*[N>@XZ,Z[V_RV ?IA$;E-F9#5) *GO;%F
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MBSV"US@R)Y3%F,\[*-Y4)@\#9IGH-B]5VM$'O46)-)]:]BSF"]#3;FM$COJ
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MJ-@NV#EU@G5W*2=#117'G--AJU%_?/7[*71W&IH]/4I^L AZAKHGQ4X[8!+
M!A/@66FW^/N:JB'1^R )BQ\?''G&[>MOQ[FJ+,6A\8534S7%^QQ]=O@N()\5
M#!CY/8O!,$[0:'C($SQ3DUP?<'B2\?GV7<-R;;U9!3#BDP;BZ?;:J)HN../B
M#*S[C:\F_R_[[8RP.=0YP"K*4E?1=GBU.CV_(F[UP:]+EW<3R#L/ GEKN7TO
MST5S]"C.8)&8'VL(_2/Z_?Z2E_]<OCOH>TCS)\#KF*Q,VE&Y$ROA\=*.XXFN
MIV2D4VEL2=#P/LCS3QXXWT3A:I_QE$%:=0S"+7@73_F@Z%:KZ\3:U_Z\(5S0
M^^W+A/B@,G8/I@52LS@!2[G:?/:"V-7?J0QJ:SRQ<5$(>.SP,_GX@8"/_DJW
MH=\,$;LX-QZ;X.H &)QW4(,3*[+)GMN;?)?4I17:S@&<%GY9*F^T67Z_FD]6
M,PE8*E(GEYX@N_EH\4K'C(OV$6T&Y6#9-;&;RSK&FW=W:HXQWE5GZ)\+6YT+
M8IJ)I9_],<DS%17-V. 4Q-#4"AG;5"I7IORAT3]&T$#K<7SKCH:@^Q$I<*SE
MJ\#T8]ZGDR>_YL/>J9TM%6&'6\3)<>< )R:&(&L\:Z;<8(D+N43PAFBUDT%!
MWP)LQ]>!1DT*NP%Q[S!XR_Q"ZY)=(9,23R7F-/ <$*?Z)/ZE1]/4C7<=HI@L
MIAMBW@**M=L"M%#!4S4Y,^M&OHKG'5W?BRST/$8B&IFG:O*3P.6LF:<GTFC]
M?YC'O T2W76N"-SY:?PF.3FO"J.GS&/;+G 2#$T?D11&?KTILE_FS\]G T-A
MQLUTC?.OH ^^J1X)J%,RJW%I?05,4)\:%T$2UJT=?_@ (<P+FE6&'<\AUY]6
MRW?<_Y9X016>!1]TGG@K<"]OM1O%MX8"QK%T^B&Z9Z_C0R5)@IR=A5_,;X8N
M/OTW(39](MB?)'Y 0VB@(FR"G^\\EV4<H]6OBJO(M:V#VUW#/\\^G"BI78;K
M$*1M> 9D1+O":1D@-Y>Q=V*4/%3 N*P!\<WRPA8'5DFI<+KOA .;P8)R(4(5
M> IN,I-WE#NVJLW1?A] H$I/>%RS3<Q$=<+T.2#[8!W.M(H"47O$HE5O:@O%
M[L5+7TA* 1YO,75G!^Q0&."_[,X!"VI[L]D++F9Z9Y?84A-:7Z=8?[^Q>K5Q
M58//"^]Q&2A#^(*^1NQG>N:7]E7"T=!@S458*(_%9RMY=Z60G)#)/4=K\W:Y
M0ZBN"G++1[ME#)X]0Z9?#HC2VV24L9'((;TE>E=H%N:K"_V XHBW$R3>[[%)
M\K=:797)R/ BE8XFO.])%5G)$^.YHBJ=\&O0GQ9+':4R%_K7C,_?XT?MA,5U
MY&Z+N5CD;_].WJ;:< ;0DZE=QQG7--\F+VP__$#NP55:#"D*C+C49K*$6#LB
MH=!OQLN^Y;DZEGHZDX/(#)A5[7(C\#_,!J;_I>\7]\=KE8@I<;DJ"F]DKVLX
M&&9L>A2#$N8"O7 G0>UI4OJ&$P'')U&EL8'9PZETLQ%\:[4.SLJUL:D.:CLY
MRI:6ENV"![JWZ2H[.5-\!1/>?9>&XL/^UPF?*43OL]LE<>T- ^'-/EF.*5R!
M/_L%-&.O/%[V[+[3N$^JOA5=0B_/^OF[<?*)(>26KEDPZM;5Q1?ZPQY6*&=M
MD@+R?CJNMN6,K\4D.5@UZO&=1*Y03> :MFAI@W1GCDK]DVRLQU53F@M(>TVQ
M*_6*BE1/D059*[)I@/VMH5AQ7\[:#839494?ZO15==SGH)C0]\E0\ADOH"$8
M1!/12*D= ;7\1_B?HF#K1EC6,^GN%Y@H0H+9:-W8)Y *Y%3S6.-RAN+GE-[E
MZ%C0TM_BE1,VS!<& 7S),!58)Q_>!/0!7I.2_O(4]?%P0(A"4&QJM'!=.+C6
MD[?2+IWH\<P/K7YTBKF,X&F;G 8K9#OY,YM=__>+"/YWSM O#BL6V]:#7X>+
M36)$.F+ D<AHQ%W'"@>VB?SCX*1GI3QT-1M]DFF?7$1]DK>A<.O!\"CGNA7:
M$:/2Z'7]T_(O_U\_S_^O)A?[1U_FH<*KJ0GGCOB;3505"\2R]#G;,.-G?W0>
MN3"!1KC.L*:XVZ1Q/L12VN;0L0-_7'%.WJ4;PS71];*^-M"5\=42O=&54GU3
M)Q6AFF#D(26!1(;-G /P3]!A?'62'2[ 1=8".\9T]P*PLU0^JZG4R1O7IJ]*
MY*V@,$!W_W1L+2F8.C6:5%46.XEH98"84 4T=($,-=)]/&LVX97^U?B=2G"&
M+A:U,8P:N6TW6584/\U7*&5CO;@;2EW,0=!FDMY",-#$B0E-^'@[R1<;] :D
M_Y6LB"CL52SB2^I/S 0GY1&<#L 8C'4@S%3)79%]T<G(VX5#H\1XF-1?YE+7
M?$R*V_L(K([;OIK?+3Y+ NXQ/W\Z2)^XGI;+\+W#0<+U@131NSM@G^SY[YBJ
MI(>1-3*M:X.1]]K'Y0\AQ]H7D0M_3[\</UA4V!+ 7^OBY6W$W&OA7?=)0M-_
M%-15L7VB',]TG?%9@#>Z "Y_#J@%DKAD"DC0O?+CCS4JZS7INE]M-)#A$S[O
MIN?_\::A'?<B00^M4)T<7??-6V#VN84K@=N(Y-/@[OZEGPY3IF'M&H\S)CW2
MK.\C\ASPU_@^;IN.OF;B>*VB-9W_*I 7?CJ7_%JW0M.KO^;;LI< AH.D3"E$
MU:Y3AW>X,?]AS*+#U,\LEUB@]A[ZQUH4"GH.N)RF>T&0&!W_B$:^FSOC.)VT
M-"5W. YAKD+9T9KJRS3Z!$R9C*$I7+L/S@$FWX<_1<&&NO0ZM[;%?:=.3^"L
M5]V+9L#?==^&)'O&X+(>!#@((XBC7)*<,8S^_!_R$BRE*LRY#T+&ET\#.2FC
MJ,5;XKMJ,T'/%\P3:2<&I1+. 7KAP50X!SN0'ELHU4>]WN.2[V69(K-'S^\#
ML9QKV5%*+CH>:>09K=Y).@IES+>V=BA*]:[AD+[VS($"=*+994J?DLFTA&C+
M9J2($+=F-GGI\5TE91)3*P.QV?X^-_HNC,T*TT2_#?:<-JL,XB/'GP,<F6X%
M:>-W0LJ(M!V5&VDM>?1LABT1)>]C%9)9(B4 !N^Z$]O'4,/"_YW^< E"=#B[
MZYC*Z1;M)0'L&-9]^]JLL28RJB16L/7F595".)C\&G,.>(6:H'3M<.% $<K,
M;,\?^!7JJMA[V3ZZ= .@RGW=;^.PN_,U17"5I62L(#13QUE/T30ZT5VO<)AD
MJ&:%XF__8V"R6&2A)/P[O4%_R.54ECHI%7$KU00O*BJYM#!MSO+@-3L8[+:?
M;U993D&FI_I?ED;2=8J+7Q6F5W_IF4P;!AE&;&V<<09)$UERG";U,Q>VQ1;*
M^*-DLRS9W]='/@ZGO>?9*I!52V (S[3/GWSRPO[FU-3#G-M1<G3%WP  &IIO
MW2<LWK>X=X3WT'\+AWR !7X:]*2'U"4'F>AD3<X.R9./N8!Z*GR/=&GUD_*<
MM<_472VL Y%0C3F0P9TH%<=$D61#Q5%#68-:D^LO##1M :V$(EK!D!"]R6YA
MOD6G=<5!%4KR@<U8K?,/8DEGZ?&J-@)7.*N9X]BEQO<T54\5R6>N8%;=[5-9
M]JKBX4S8_D&<_@Q(8"X6&E"J5?SJ4J'6;AQNBJ2$>*:R':P:+5:7FZT@V51;
M[8OM(=VC,C/)3[BC19D<0]+.)SKH-8X@EBL_2S07-&%OWEK=6;AM^A).=PYX
M$ PDO"#GW[N/F =%J N)N+GV(0FLWZ49.B*4SN25-I6# :NHR?3.+";\7,R6
MX! )E/_K^\:^O<WLHERB/(][A"E/<'-I!WPA%NZ@UDFE?(MUCI?FYX <\+ZV
M8/81;SZV/M'A2W1:0RFM,*U#3YKV1$47>X8<_9N[5PONFT%KJX?FK*E13)R?
M@_7SU023R5&H=L2M?\Z\<X3/:$WFKWWL/0>DOOCCF?4N6 :R24-=>E?P9I&J
M3&?<?E#M/?ET[T)(M]W-YN:9FKIAFM701]K)E@=\!;"L<T [#VPP/0S>5O-'
M.O\!\&7M?*PFZ0<!X8$O"E.5FW>1DT70._F<FF9?ITL9ZTGXQC$/B,I#U'KM
ML;&\K.YH;BJ@DQUV3O?5&=L^]CGK:WOQXD/H^YOK-9HF&H"U-/$53(.><UH#
M#&173'6&MO\=WW@0L0TMFMG,!JC?&1_O%,0:K?M&,AODJ51S.;72?;]V*VF<
M\U2]Q)F5-2TS@Z#PI[RS;-W0W.IB1?YU:D3T"-<J]G89N/LD.B&,?^'R)M;A
MG]:ZX!-FA BW6!2[9+DZGU^*)30[4OW!3V2\8T".]NTDJ^8$'@O;=E'#*[9:
M_'C_"K;GY R4DWQ-H %^JN.]=$+V%H/9S^5S0#<2OD$U8I;>9W=AZ-147X54
M($,-AZOK6DI@)+AOI"GQ]\JRAU[]W:^1PAE)LZ4*6\%GRKQ,[1(T>U6U?&</
MU_80#1&<J^Z_C-J4!OJN&Q R^BT%D^K2+3%X9(AJXP7#ZE+%SC/2AF+?<8,O
MJAR]JDMAJ"/Z[]&V\EWC17?.\H[(1MH8ZMB,3T_^^&T0UK%>5-GUZ BQQ6*]
M5!432IHU[UF+589G8PO>PJX0#>:9 %-<;E?]/-J?10 ]AMF7>#,%GO(TBP_[
M1+MT\P .$2G=KTTJ,06J&FO*@?4J]6].@VK. 3(3>?K)BK.?WQ0X8*&.QE7)
M*Q]E*AAI%[;_5M_;<=GF0,,/!NX4&[Q3+#)+-WB<?U)_4WM6O/H<$"'_7WW
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MM,>5!]T@> &<#8@W8R(*F.:<";=D\_W:I@%C+U$<XR<WS&26'%*1%+6GQ,V
M[#=+"91O;KP[86$CC,#3T55>1:($?FI1?8[X+TFJ"/=!?7?J=I25 T=W6MR&
MS2"36M<+X6T6YUB]\OQ#G4FO;>)43K>11)&A\4(OG_TE#.3W<FV@[QSF#]4E
MJV2_X^-M$J6QWJ30[3&4-S ,JW4E%'=\_.:AJPIP#T,7@>?S][@G+;*N_1P3
M_RE=SOVNM)2>GL66G?LT>@U1_O<0YFVF<\"E&>JRMVP+*(S(]^/3P-R7=+$/
M57I95?>/;IX(_\?/RZY;P3)1E)>4VU1,*-%=1+%N3JYD-1*@T+,2(2W#D4L:
MKSW8KHFPGW2_&$99])"TV^9_U*@UY6_.CO*?Y@^[;)2? ]24L]4B%W:=/I)'
MV=NDL)ENXH=0D-YI,WIA$F,8 8ELP8AU%46'=[MF)/20@I5:2U,4ZI09VKKI
M]WJB)^X-%H6->V+W"8>(;6=)HNSDXA5.19*6<;R'1B7W4L73&:@B]<D*L!7L
MV;>J;X+4'Z'5PP95J9[C[\? &W$7]%JT#@0_VYX*GK@U#+6D[!\I 4>C-;3&
MWF^",U;KG9I=:K-B<7G#,^C%;'/L+=/1[?*\!"V?AX\5A9-B 6K^!& $R.H/
M!4"RVAL1:;F.KT.6.G6R+-=78=Q<[4S7WS7=:(B.Z7AU4)/5#/Q1?HO"(),-
M&IEO2>]PX8\<_3&V]NW-P=DL[,O2&"H/,BY,N6J SR98$_WA"Q!6/SO=/19R
MO_GGQH;JL(!/K[Y:,>SUP-RD/ \8O^(&_+ZB/LE"%Q+;VO3S[9EF2BPGGVW4
M*T#%X;^V3.ZSG3;K!.W;#,KFUV_[?+?8UQV5(>W#Y[.S\7ISD7 >F,(&G+'E
MCI\F!!.DYOVV4L_7,V].T+DLO<KF58SR6BG\"(7D&Y^C,)"(=ZF8\FQ8_:Z%
M93EY]">R_L',>/>/^DA=IJ/=Z)N!WN@"V)X?A.!&E%O@T9"+8_03T!H^$AF7
MMOKE<E'K"K='@N@E)MCHCDZN8EM(VSL #]51 P'B^_1+40=6PR;60280V]5I
MQYG)&QLLKF/(DZ/3:=[+6:P9=E<J'/X)&!LS]&F$YCFHY#FFO?X$=7M1Z$08
M>_Z(_GF9S] ]IX]#1N\N*].? _X=E>1[N$\4Z, _+2A(>M;TU.128I<ZH%LX
M^S?6L IVP 7B6*O$;1OJ<OO>Z+U4TJ!T"UK"S>+Z[1R0#3X!>V.<]3V<3=C$
MG':;40A4R>BS:W-!TYC&3\EI=513(H(FBIMM;>_UVY +F@)+_."_E,G;^0UC
M^7NZ+OG.,L\VL?JMI=W71"_Y<GL=(OKZX1-)A/B?(7?@$39"_P#6SFA->EMW
MS^*Z2>+DSZI/SJ2";NR9;#6$-\ZK\3UOS/RZD@:U]/%YK228\B%6^[@B&&Z'
MFAB202X4AARRFJ*&I\TV.(3YECR\V;MD,@38NQX8#2GF(QR"C\CZ="=J='O.
M3DI*2IZR.P@'3""TGO*(CPEH/S<I!.?QT[ZOSDM,%.''WLO,=[EF!!#K#=66
M;^>I7XJMI=3"\7HNMPSQ:UL&> &-T>V"FI$W0??VK*;07)WW7-UVIABXWFV^
MU:27B85BRN&OW":H(7V?GPC-T91UY1&T%+<U"9D/Y4?S];6$#]6X*+2?NE0D
MY(.['8HFA%-=7&Y^B!7L=?G.#+BLK4HWOU@AV>$NH7R]P^BS_;.\X@*A=-\X
MB9IMQ%%I&4JR("Q3>PB:XO[<77NGWOIHUZUC)#?JH6?6%:J;!,8$/4DT-'"S
ML)E4S\:O?9> >5#CV,A+PK(#4L76D2FC49U&H"P]&35DYX]<39C8RA"YREE]
M4Y_V(NI9*9/-GYKLFQO5&P&CT;YC;'0;<DT]'#SF+K:_0KACI>*<?XYX;3Y)
MGBPXR<%Q!;7LO\Y=NBOYH0C^A&31Y'(F#AL*ZVZYWX0D!BZZ21SU;PB(YSBG
M6P1-QVJ@!K*:@@,.5X^8)IX08D??S.03_1??/?[136#]KOGH'*!/62/%PL=W
M0!.W"+Z9JVF0\#0:;?'JGM6^*4^I3= .HW[PR<932.4Y8&NSSSA(]L\#^$8?
MEA:__R#@>""X>HG^99M13K_LQC#!,RV1O.1S7.Z&,VKS-V7UU&>-SAA9RAL6
M+2UM(>#VIRF!\/GQ<T X3([HCK]XVM_%>9>2X-/UKT:PD[OSFGQE7*.JHV>\
MYABJ1,)."U,[HQS(H-\U2YCU>Q69^S-:ZV>"!:C/ _@)B&VV)0HO%(6V\(#E
M4L,.Q=581ZN_E-^)E5-B7_\85L0C7EG_I9UQ_D-S)<43-Q4+7=PT\Q9#&M0;
MIZ\U-F^EX=RP*Y5;W_4LGKE*/5^ILO8Z3FE<A\M!ZN"DZUSSV&W1/5H+8K(O
M[7B% YO"G<FQ+J"DWX<?EX6>]')S^Y*H/@5$%'$@W6I<S-XZWLLSQH/:W6BA
MI^$A3BKYOO*3<J0H@UM*#&[,D2%S#'\W:]<M7.?O:/687F(1J)R/Z\8,-P&[
M^*J%?T&X9ZPVU07Q\@DEFVQ71:#IGQQY'P]^\*S/L<L*#C1#?=YC51!=,1;3
MEXH!.?5EQ4'+8>0XX(UD@T[3&)T-8X-0;3E"<NW),75 @9WMYOCCZ*!K7(\6
M9X0.])H^J;^$6(+>+ '6/ ;87W2!, =E3D$:;U(6'PG:?_%0D(2Y8Z=(U"LU
MW:80%(95?/:VQ.* F27^^^0Z*[+%*?::I3%=^I_BKJ[HM_Y=X@<6\/GATF\A
MH$BK$ R9_1RPMP>I6E U:3-J7\@S^CH2:I0Y-W7LFI5VC$I3?X:X,E)J6J[O
M:HQ38-_=L9&O:W!:VX3?VH/^*>6@CSQ8"]T$H$_4-'%C'>IWPJ]R/NP]>.71
M'PLJA*<B"^!0X-Y5ZVX046OJ''"!"F63AZB]J_9_SX"_*KY41 KDHP!M"IC8
M'SSW,'5?,UUM/GF3TC>;'>$)/[(IP(!U>A5FQ-V^DR7V'?:2<C:RA/?*>ROQ
M*5\]2R%6E*U'#O1(R0.:QJL7&[GIDSH#C]LDQY.6BCZI"_C9:8VJ,BR:US3;
M/0\7_QH;6;)EGJ4U&NGPR9'=;HZ& [&#(OQU8AZJ*F?205JU>[Z?;)AN6#P2
MK'"IV'Z>PQB;%\G[:"0,$]OT&I7/QPCK@5SPNE+&.[>P$\&S$@^Y[UU=Q\CA
MLQ!R_14WP@XBE>F'4-4U:NNR.;2GY76+>/J9JEIP,P6G5D<;KPS6(FIJ<Y@+
MO)K) J\.9^7G2!7G@"_9$W *0Q-1A9R,/UZTJ4 ")_<TG(JGP=/FWRY:_] Q
M&2UB&+&[%( 7/ZTD&N 1;:@K33RY?D8/A\O*C'1KHL:U+UVECQ6(N<[ZZQ=0
MDCOM2$]!OW:X_$YEU0?^VI"+&LQV=%&7J32G"'B9AZIU<K]3'90Q#\_N@2<0
M5X'2G:_EUBQ93$TR\B=772;4/Q6FOZE36W\>+2KF-5Q4UV\_&CP7Z<%,IT 3
M/ZKV>MQ*M3XF.?Q7=!9QB41A*;!QUA'KM>!Z)G;#(+;_U&V5V4!#.C1*Y-O%
M_U<3K5BXD1E[,51;[5V.]7K#.NT:=GOI[#EP:VE>Y=/"&RS?I/SNFX>*K2E"
M:\E*&Y#NM0[X#<E.26YGX/47$5O[SKY&U@VQ/].>B%_45PY]A,9>XOR;$?C#
MAG_8.^["HZ(G[MS5'9L<-**VI@JTL? +<87_P.7!L"D&*9;+VM'WAZ8\E@2X
M?<\! FG4L(!%<5\-\>=<U/GBR^VM4R%G+W@.\->Y^2FJ&K.V9G>@+]HY6&#V
MOG!78_,<T'#8>'!V>*^_^-O'QS]"6VU_K $A-O[=&'R7V71'LI(PAA>U?%B:
MX@^2FU!P6\N:0&.SYB+ W\M\M6NU<5-%&#ZK0.RI==+C[%$W.O=HJY>)F-PX
M&!IE=V"E6\*YE[&R-5)1D:WL+"I45M=2VE.76"/U$]"R,,ZH=@ZPBLT>^^Z4
MYCFC+:,KVJ4O#>I/(JMGS1Z]G/2\V=-X;=FNT)UJM Z9I_SM&>X4BR'BM;9D
MLMK#NN$(Y\.5J\*&SW5N6=65>",AO@6I1W/A!3;F_1-=^!2\#EK7NF@#47":
MO',7"LVOCF8SXV<%+"6%43R[P?7J:2M/=05$XAT$BE2YJ7:1..C>J7:Q:^GM
M; =Y![>Q>SKDZ2OYY<>WE^4A/UU;EP/V3HZ7AJN\Q8S<CY/3S-)UA@,"QS;Z
M5SW[.7,7BYYDL1Y;>:V8@ONF#F=G="YK#BTYZGP]9FK>2#@Z/2:+64+;O5TW
M[XCHTJ#8!1 8FB(U,K'4ODXR^9X]%;\X?G7S_0D\&)#Z:HMT3)!FWYEF=D>J
MNA\=';)_)WQVIS/P&L$I:9P]G2FH74Z)M/R^Z:-Y0^]QIN(OD?ZY*6\N!:Y=
MJ-,P0<)B)E1]0"S5QE]1O0C%>PYXJ+99T%FFY_GA.5MQ*TW&*^^EL)[CI<IB
M_I=*DYJ0C#V,^MQ8?J*VS'Z)J_IQG72@'764<9U^_H5/N-LR=:33GG]^56\S
M68"8P02K:^9$E.I\MH8XCMCOU.SN*+@VIYJ-$^ AD)KNZ'.  X+; CIV[)NJ
M_.^M#O6NN^ZLPR8@&C'WC$,$#DB D&M(3'L1"UWIBWJ^X*KA6HX5UJXQIR4+
MH.\E8<67[UE?\[M/53# V=M.E<X!0P[5<^L=- <^F\H4/K*')$?00_S*4?P?
MN7X<@_KD@M"9JG3?Q[?/=EC:#@%V/-7#J$A5IU/)^9^Q+#*J+09MKPV"]LNO
M"*,9?[CK@7=]$2Y,Y7V*X?[!<OH>A)&[#FSE4Z[RUL.X(C<U^!\V$+9F]T9'
MDI-OPK1E'<?=R+#+M!FA^7A--;CRILLOC2NP##(0<8!845B@);$ S8E&\P.2
MVB,Y*:>K8U=>^MM_14II$3*6I7I;>XX%-G!/*-?<BK?OI3%'TRK=Y(5E-VQ
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M#4&QUGYE4-JCF&.Z0*70 RK!7 JTI&/C,6QE_("J[K8IOK08S<752I6O_<<
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MI,O>B^W@MGBNU6:QQLI$MHNZ!8N#;> G!@'%K'=A$_9-*A&PZNA)3N^K5PJ
M)B-' % >U!S6:M!\8@W(WGS%W6?YWBV78<DD8W]V_8;><J=:Z/V3&5H8@50(
M'=\:?UDF0Z+CFQU'=("/0KGYCX_O%@E:R<HYH:UVPHI%X(V0;V,@\@1KM_+#
M';M#MY7\#SNO'62GGT'W>0B@S[XKK_%"6ZJ63AD#0WK2VCT?]NV_GMSGW-OE
M'>$WV/Q +J8+&$<]3>MQCNQ(J(@IELTJDAOF^(GC#FSCJYT.BUE"' %LMH6H
M44> E[4L'6IHM3:S'''4WZ5S7K(Q*7,H"M^NJ<V!0*SSM_ 4O8I(Y8G,Y "&
M,+%_=:P:?9#\>+#+)I2*6,"@EY;5XR%?SMY*L=50?$U%EL'X\=@HS_->#5^>
M.,5=C0-B#?/S=$PO+3XY[4U6/Z"Q() <AZC5%[D9/%ZTC-0)JYKV*55JWP'<
M8?UO[I#![0/K(>X <MCGZI%>W7W,%*;F098J'#/]-=:5,)#Z:7CC@HL('K<&
M[REED_S\J7P1QJIMI-=G$Z@?*<N6JCRSQW=:B?<(D'&NWOB'L!(RL'-@L+I!
M56(WPGOY6S+[3(ZHGL803"@G(.T-WGMHOSPP4-7O?BI_"/4;B\;X#0<D,%;H
M4Z 859=:Y*/Q;JFF!ABIZ3?Q(,"BI79&E.D ^%X%WJY4;#RY*OTQF;'\*E0B
MALTO0@5FGX*)Z?L9<@XZ9IF?/91>[)AS;<B=FUC<@%X,-LDNKC*T'?+S;?C0
MWAW8-['9W,TX]?N.0?XN9K)\MWM?B1F!1B+4PNRG;-WOCG>6[;/)NU69E[?+
MOFWA_P#OJ5&XJ&]0'F,M*ETH<^;:W;Y@F<Z[N8=;OJ"<(\#/U'7@G%%4L]2P
MVHLY=2FKK9'$W+R\>'?BS!O_MR,.M$5T6N.+;6_1V2?%'!_?R_:W^2'X _O%
M)G6&K48UX.I5&@T?9,5>^G)<ERS<F1#O&;*R)]F'P1&@+4/O/YLMUZ?/#4&%
M\"N#\,OLNM'Z/%[2M:R/+@3LT4*[Z V# 0V24D.J.N#9Z%XF?UZ3XA?FH@M6
M0L]AD3[P\PSN%=#Y70DCMF7?._?NME_Q-&8/+SK__"I&F:9MO5NN)NWC8)?7
M<O)UEAS<'K!)AUA1B)A&I[1M0W!,G^_3B3\%5AV&^=R9D#C#%&6][;R3>R8V
MVOH12VM_U$ZI"8EI9=SD?RIJKNLZ9(DNI<.NS)TRU3D\'G$"33E?N$TU^:1C
M(._VP6'PBMDI@$/=*JSMAWZ MA2@>S5TB43>'&N68BV."E3V(D9LI'J;C2"X
M96)&TX;_Z@J7CC%@8QWSCI<@W'WI!E6N2U>T(IVHDZ^\_BP_.-P_9L;;0JPR
ME'\!BS^2569V!6ESU0A+X\SL)8Z0&N'L043.!KJOOTVV,M$05Q-(AWW;LB**
M407"-2B]LYG.NKO+PJ._4)V_2T*\%1)^/F N6_>):)(X^#'VK_H<''4Z=8[H
MAN*[O4:5*<NE2HT^.=/>_->K=5E[:0B-JB5F?TRJ@GI]GWE+N?SV$ Z)7)<,
M=@)+?E)+!,\)T0VQR(-^:&;;M+@O\&P/8D0F1>*ANUKQ95-3XX6:!AYUZ5%8
M.[^EXIWVEX*E4@VM81-5-5B&@!TPQL.((J)(O/#,<E^OKE506>> N P;<%\]
M K3*0S5L/<8*#@VZAY^V+X5_BN'UQBIC0$BU173%MX!^]?<'DI+-]K 1S2-
M!XD!&2Z=&UYDZ:VN5M6UOQ%/"5FK42;4&/4TY]P]O.^;I<%;66B@N.U7)SP,
M]BYK"H/P!RBYG"5:Z-IW/Y,JVQL]%';RWV[8NW_LSOE2@"UOC;:EHW:_XNPJ
MQ&2YC!.%XEF5%HSZ,WQIQ7OBPP85;]KX5,X0XL[<>FJN%97C7@:886M#\3XZ
M^>3A+5$6U?LFPW]<XMV18'G3#,Q;4M#QQ("O@6)]V:XL?AM3=O#]\VVT4*SL
M:8^I>U;Q3',O<J5P\\56>;NP8;+#^DC$DH=N%1BD_;TZZ-+3-^6^B89R. 5H
M0>_207'-ALOB"CWTT&6K>'2Q/K%81+EZGABT#X&!)/C\/MR*30NVJEA993?1
MO/7PWU'Q=Z9N9686]7H27LV<;!_V[M6)^0O_7H4T*3]<M8L_9#0_[E$;"W:?
MRFSP1B1L6Q%?4R_0;M$KPD7#Q;;EM"L;RMF\[]G_/2WM(6[$-<6]0=TNG"'M
M(@DDQKF\(\#I(\":2O"?I#WKK=Z3?5FP/W-\&@;?2"SY&Q%-Q=21-UJ?4SG%
M'W3*'#^V-I100MQ@.S0H1;4STA_PP@]E;&@,#ORK?IFGPLHOBE3TP/ZBU-+:
M*A?O1^_+KGVY99[YU%!/RGY]=)BB\"5=(RT  I^???&?_X3^E=TX=K*M/_GV
M,%9Y73+B?(#=6.MOQQ/X+; FT>G6UG3V9>C&K7?;FQ@$DC"$'F.UDS#8F73^
MAMC ""P'387!>M4"R82Q2L^ =&\9&EW.:'+RGN418.P.715"BCJ$A'MDAIW.
M#!A5<,P3Z=MTG-@]GA%]_,_>Q=JY^7?F6$;K=EY;F*RAR=!$CJ>H&&SF50TN
M$:](?#:;+\1I4#,Q=P0(\^4W)F.&T#^QX_I[=RFZU)LA.B$VLYU)+BX("4."
M([./7!=)N;?0<\-_DQ)P.+-2[?OF>57-J]='@#LOXJ3I3%;DP^&YV*D+?C.O
M/P.GN)CAH!4*;N"EOYJ]+!#=,9+!>X PZ*Z"9A3W6AP!+L1K9;&QG2E\F*E4
M&U;XS'Z(N.]1_:YZ!W-#P_ZNNM+*'R;, F4T[0WGE4M!,2ZT0[;?$?YFN'3%
MZR*]8:$;[BF)=I]--#D$_T<A\?_6?[G$_X9F>!X!!&DPQ.RS^N9H#^3R_J'A
MCROZW@431BXJ]>_-^#K O)G:^T\):()-)B1*G&!J[.NS[W367TR2;[>ZV8!]
M(434KY0GN*9Q<Q"]AG XH- KT#/I09#8W4-D>\2-] 9<XK.^RS+"7^<%ZF$?
M,QP0LZ /(!Z8"_X:%$N*W([-_(7.ZI_?C,1M$.@)W5@D!;<?Z>L$#HS7X)S'
M[/]6)"'?_:MD^">X%8[*F=0MOF7#\_)7>(V,B]* 3SL\V6K7*C)+93%<,*YW
MV=G"=F>5=;08M?0LS\N^)JBJ"<CVM:]"]*6@=8"I&:2-6Q2OO^(-6C.C(%$C
MDHOM&E9J^3/F<"P+' 9EX4!]_>R5*B M$S>^2T">/#9\'Y$C\$D0XVSWG'1D
M[$OX>51ZDWEX:^/'Q=K.J>\10WBZ+^CL,T8/&O4DGR.UM3[[^VS\'RG "F,)
MM]WI00T6/S1P'(]4X4Q[]N[%V=P<[OZ')GK=N1E(_-9&^&VY]QYA*LAQ1?&:
MV"$*V EMP <WZ\I+/,T+Q\/.;OZ%P(QP:85NO!53/^H6[\108Q@@PP@EI'<S
M/8FA?J=[@:)O>N=^%Y5]*0&^%SK 8M2>EO@O!6*DC:7C5E"NK9@@_<1,1EP&
MF":Q\?,(H ,52%$Z K25<5_U&:S_'#WNO;FV,!R6]43)Z*J[>PJ7;IL4D>A1
MO-.,]?Z]3;3LU8DRKXL^10"0L3>6:H:'^3.+JJ.E2@FQ+P58*(;*0C@OXT8Q
M;KGJ7Q(\?+7*/+D@1NU<<RP%1.4/#]H6^71G7>W1K+K61)O;H%/"NI<@$]?/
MCG+[%K(&W6-?>L_Y>).S#;%I/=S+W+YNHL5=FE?4>2/EK[_\)XF%\Y"V'(3_
M&BB>DK ;W?9(.KU]4=ZCH?-RK%BGEZF?[KWLZ701$ED]'/%!YG+9P8JU6F+3
M:#VXJCX<VX<=YV&<[=UF[F@&#@<:?9HPZ'6[*&\&A#,7>;8X 0.8_NR=1A>A
MWX'.-DINI;8'V?-O$7,OV3PXZ;'S^/N\J$B&2YG_(4Y[UONT6SU'B4RKVP5G
M(?-39BSSQBQJA_XQ?D"-/P^9L"_(1P#@4A6,:?L(\%$9R>- +Y.["BP>LDTN
MT*PR[)Z679C86\7^]LLX]81/7:Q-RA2/%*RB,>QZ<'/>0@?,2WO\4Y25%08'
MR #E9";?2UU4$CG)ZZ/->\'Q,(CF81]%FQK/33,<6&D:KD*I#X#"TC8];/)7
M\#BC7Y'L)@\TSP_[5H7'U>V*Q-%5Z:J!1,OG^ 61;_O;6!QP:6NMWP!7D/U*
MKJR_D[Q3']RB#F2B,:R;^(G1#65 [ &OV796#C"2(Q?1SXE)D;(O+LL,;_$0
M=1*'<+\_'_"*+^JTKEI8QC^3'<UN^5Q;R$.<_<5G+: &/E;3VX.C.;P*H[&$
M_!>G]'+ M=#W75J2GN7XYA+B_H5_D8R:QI<8I.#JB&T&)R.+K,!NYK4W* &S
M3N+<P5MN;)95KSC^(X4WQ7\?\+:$OKK$!CL"F"QMK:Q8BIWI:BU,5918J%'4
M7S]I_%USXOLI/B6Z!GPL/SO*?&Z6Y][\/GB_HGX7D+^@_82M+?/)'_55]_J>
MZ>YC$E.@6Y$IL3:E#+NNA4S!&S+,(KQ+AY#@PN0W3'QL:A9NI5\L3RZ]S6(%
MPI$''$Y:H^=4 1*:_6-C=.B>;9WRS1[\O<9N6O6U*-%\YW]I2?];_U])RQ5M
M6/)_O;'VOZ!O-Y_'F#N^QAQL4OQ7C+)?*?-D7C7""8E8#$MZO1%(MGTHQ(@X
M H#&OC:?WRKD87V=S_H*EB-BY(T(#UJSL^GFU3[YRJCP>"=G1(C]XMC[N8);
M8\".N=3^XVCQF5_^(S$6![PVEIL>$ CCZVC^@G,),2>Z*C?=JCD]#V;V ?8!
MRBX;"O^3YBN8D!Y(R* &_RO%VE*;Q;)5SJS"^N4^AE:/H, B@]B=,\IKOPGW
M?RS,2_3*36FLJ<[32G;H[<TUK9%$K2![IN)> L]0+*<U0U &*F),)V5MLC/V
M@$L(]^7L-YS7'66$/%HFB@ $Q(+.]NGG!&6^RF,/(R7N(>%@L78IJB#_AZ6%
M@)QM;(^IP4K3-+WI'N^MX?3Y&(M=WZJ)"OR# R[,"B,D+]]S27DSPVS5304)
MG^B40:5]D&@B.#F3(;1^OI322="-["@)D_\1J7=3R(%9[7BQ'_>=.]>;-QTS
MK+H%#K51I@]_"H4-)=LFZ=82-Z72#O;_6.GF3C2,:Z"1?XTT%2&O#"&P+/*5
M'N&N)_P=;[..  BCSA2CH(NUU64Y-595G9E[E?RR/,P)F!T:FOZT4.R;A:I_
M]R$4=3@08_MRXPA '"V*>QTP65V-1V.M_BTZ3R9-=N/_UO\/T@%P82#68DKY
M(VD&G7L1R-K_$8O^_U(7J,6/Y(I/"[)HH(=IAX=VL?=NV-?^,Y/(,;BF;9&>
M28S]X.36$4"ZZT2:E9" 7B!'<@Y7L:[=;;C%SU.WE:?T-:_$."8F-J5Y=","
MF/[G$'H331=W2$I^JIL"<;WW5,DY>[>,5P7?K^A?N0\ ^&.KY-.#;IN:&#1'
MUK4U&IX'R.#4@=A9>XFY^&C\!2A7%VSV[K87/(>+K4=JZ;VL;];K>2/[,$85
MQ>X(<$K_F$&F0A3WI+(DI=NL]K($ZY/[^3J":DQ2/WTNFGT3&ADJPH415*#9
MP5H?H6>. 8H=[1D6K=LH7.8.Y;R,BFD;6WV1N1"BRGV'D/ [S&IDGE<Z#OO#
M;H8@IA?]5F_,U*#T)7FR%/VHN]-9WF?4-<S)25C*.?.O=-70*&@'.!S-X&'>
M"W!ZKG';E27(Z'HUX@C@Q7+\8VN9^A[H=@1XK;+X@S\EA_9@$(G<<)R\V&AE
MN;XQT $XT8=)C% B(+VW^VLHV]3')0_0LZX>2S'PW=X2V(H)>24>>@JRM$ZB
M^M!"*8+;8>W3RJ.-H:6K$T$)$1Z^"B6IJ<)"3YV?<1FN9/"U7/*KV@V!L_FK
M*+DH]9B!J;\7)L(T0>2*@U6_X;D+)PH*2)WB_?F;U9D0^T-I07K*V..ZR[8/
MJ7,ICSK7NL2GSMS8YXV!*GQ'O-Y%SL7O&1X!WGY=APJ&X%N!%P.I[#]17]T.
M P=^J/\^HZA3KK/^##!S15<24PH#P<XR[H8\FJMYO]L4W%;_JPS)0<Q0O%*%
M^G0C-O?^KZ?%-8*"S1ZSON/WI.\4KF_+9XHG[B>"5?.\)@,&H:J9?\*]^ TM
M;BJ*^R?:3NYTCXNBC\<3X?TR^S-OS!#N*^03WJ+RO]JG^M^K_"_,:[K=FO:&
MW8%,(Y:WR^?X!!]4A4U9[TBHNHY4=DN(%YB,S"=@!'!YOI?#72E@.?;X7]QA
M=]=O?V2\[D8(A(JP3X2Y'@&*#TYA3;,;JT$Q1X"+WX\ -G,1ZAJ5CX$9R1V4
M\:T!H[JYTF./8;(#2/-+-_!*.P@%D9E'79&*592:K<,]5R(Q7/O%G0J5[%O]
ME^_T^0 Z,OLAO'+:OE<,SK/$=BZ\Z+I!C;JOK\F%L7Y97_,H(P*8!]"(6@S$
M<H8$M\=R>ZAD-B7I30I>U8FN^VEX>M'>YZ+]4"!1Q#9Z8&CS5D,\=?#GB\G?
M<&N%]=.__IDK#LQ:EOH6XL/MIPJ9+\<ZK;HLTAZ;^MQ7^ML^8CF=4+H"(?YL
M'"J;:ZSQ2GS<FLP0UZ&[LDDUI*'^T8B9W9B"BQ^'^96.78 5?%6 0XTESTBX
MZAC@/<%+'U-"IEW;Q?@>G,(8)@]Y.^*SSV=%:H;*PWFAG)K[-"L$JV]_!W#,
MQ$RD$_Z^ CP^%ZM>DR$E$IT(\5]T2./V",#U]AP!"O@1FDXKD+'TDDE,8/Z4
M=N#)MV)"GEQ/ V;>:+J; K*C7+W.JC$=HX=*JE!N]G1%$RH".-L2R-&^AKY,
MXYEM@%=X6"]DQF)ZJ75YL3:+@#@NC,/3#P2C]@>OPLT0CCM V'4CZH'Y=77#
M*%*80#2<K8JG8'V=INV@WI%GJ33DVBOC\ K :F2]^W1>][(=)X</EU&!^IG#
MX4J;_.:']9#\- %-=E/._VRI#Y2XU,XM5,&X0SP>8O;*"KW=DE"A9<4D2'B?
M\G=I\$!^5,=PXZ,\]]^YA^"_5B9*I^SO69[D__!^DQ%1;5%S87\7X>(Q^=!\
M;J$G;;&*N'# FATEQLYN8KZY20SHU44B\Y]*@G'A0W5,)OXQB3K,B2S6@#K-
M4#?*X-8?51&:,#=T'ERBMEPK&'.,;=:QC'LTV9A(&(=;CU')-AN]T.@+J(>Q
M>'MH*F\54L6QI!+\"PYPQUV>6&'<*J_-,N6XHIS]LB/CPLM'^*C=QX$)'+\W
MM)E2/CQD@]P96T%^QARW\)5H266XI3^/X"D^FXP [ %_$Q4G64PSW-**]!FK
M+VMR<5.A+R^D<'S@FK_&DB>?/JZX_.8(L!B,LDH6B,5?T 9QN+4S)MN/ !@Q
M_%8]@_M*E)H9PODA!PO\NM"NP)K83K='#V-3^_"[NF74C_S5(.NJDN#Z\!5_
ML.B%Q,Y'$LQ=-]YHWT*.O#+1?.3K>[%$6FU#,.KNLZE: )O9_:LF]G[0.S3@
M]9<ME+@6NVM_;I)R\ U*D[$' Q'%OR4W;M9'BKSN2-!A%D3>?#U_*8S!?JJ[
M(+O('F^]LJ7>/U]\0?2LBQ\ X&>DM'+_VG+9.?R<]QNOLK'.BT$#^OG@-S?O
M.$5?C7FNK-P?[+IV2^+'A1)F"=8'+#_83VU6YQ1D?_[,)/**261961Z LLIP
MQU]K%E@.1AB.JFD[N(4@3G,YQ]I"3[72Q;]11K<&M0ASF:HLM5D"#&5#K*9+
M6?1]M"&B<-#>%,ZCP:5\\WA67E$7^7@$$!,5X(%RR;'SBP_7L.9@/\33/OT;
M0_+.[A% GJ78Q-8P<OMJ*T,H8]*U?C1OM[W$IY>GQC; ZG:#^^=SH@5>4C>K
M(I<R.WRUSJO6 )A674^X2PP8'0_Z^?*7X=K/I:(]+QT,;DQE@#MI2QJCRW>/
MC;2,T7F6*,=G@H'SLDH72MA\'IR\_(N[]+?ME__@R,-6+=T6]M^KO;67S"\D
M+0/9W$\0EI' ,:@HY7K[OJ1;L<>>9? YG\%><3&6WPN=0%[+^Y2IK8ZRV;E2
M5?[F<!"V#[-F<'L]$?]8HFR9#)'H@<T&T61;O"EZJ/6KKZF4)M\)O=U85=.*
M4;!#X\],*<D\X\%>K@LE9X['75,RC'5_TI3\'\;&@8OZXU[!NRQYZXEY:8TU
M0Z6-.F==_%\!EB@?]^>A@GFV;CWNIE'U<4< '+F 9\0J!;M=/)N'0EY@B T3
M$LY:6F;=>"#P3 S<+$]3:/@F2:29('3EWXG?PEZ^8W0?D%2J;^#UBJPB?M[C
MJ]>L?G3PE4<W+L0UOF?Y<=)\]]7_HV/A7$&E^?]<#QI!B(B)\ A7-A\&4?]S
M _3_;&]*J+VM7J>97AIY'@$,\72O.G:F("UQ);X(%1RI]9BE_ARSU%<0HXW!
M7+4U!@<+I6HH;$W^U53S8W?E?H:49)K5G?F5Q894H%+G^+RI NTJS34H^#I1
M(ZR_$=8K]%>% .]=A> ._H5EMPIL&>_2BYJ!JW@6H7)7V*R-/)3W2J76HW L
MY%QDD*" A]HE=$_SAP]^D&\#]]BO-^A)ZJ$."Z:$2IM+\_(GLX)>?#S,X[)*
M;>IIZE)7&-J@AZW-0SG"S2F#!%!\UCT<S6RNWWW?O'I46KCNS?2JF_!32VV7
MMDUGSG:F5\J8H<8N-Y.6/Y\@";]]-#)@6=_(?^I_F[7?^ZRB^&TOA24NNF6/
M'XUHLGSOZ[W?["T7Y]L)8]LQ@+F$1+1]Y:VY>.ID]NRI#:4U*2>/NF>':U54
M>/SBLRJ]K^-C_GY[%>XRS;1"R>OCU*J?G;"?K[)>P.3>$G&[:SC$4CIP?%#?
M*_@2PZ6_=F\J*;Z=ME3 HTW5)86W^6/]XTG$%1-;G8EPF/,46I"IGE\; 7O"
MT,AN7N)H_^..^GLC:3$-W5 1U# 95MIX:&,D,X<0@<(@*[T#8[Z[)#O(WS82
MV>B";33QW**-ZG+<LM>/ET@>L0,=)W$MUC.MN_O(C7C&Q3EZ0_X03=AEBXJQ
M%U?Y4AHA:S.I'198;RRL0] \+Q0S%4+(]Z"XOPF$W]N1>I+A\N8T1& ;V?0O
M-?BTV+; ^R. )_(])"*KRA><WU^VH@&N[YJ[9]EL<2.V)8"  'GB9OEO;T'/
MLT66QL1QC14_4#@KTG, #D,^6J]UN6Z=IVL:6"=HJMM=U9>+<QJBXQ(8;=;J
M.^XJ@9D[O*5_+_>]\SOCFX =0GUKR^!7/P)@O2$[FY%IN<'-3%O^&-&OU9'/
M[5X//.UD$DE*6EL9:Q+?N):E7O3+J%SP@'E78Y269W_5U.BIO56E[M1MU,I*
MQ4$ 7>2BA;G9F]%!]XO[]<?-Z*LHX73D'1JUT;$^LU=Y36,>OLCR.\RBJ&_E
MOY[W_C?(F3Q5\\_[[X0_,_#4'$SN\DWTS5+=PX#6^H\M(E.Q,:>NWV0<&R7P
MD#K2\D9)F;_*#M%.Q!SL;QY .5*L3B+-'(\ I4!9D:X#\\-NO\UMNZ<'.7O?
M**#2<)TM*42VZ\2[,47%>TD=B;\:_"IS1 4]I,L@<1&'4.-GC%8X1\ CX;40
MC%G2@F1-0#N95(M!SZZ!FDF>(5V!?\\LA_Z[3SQO<;Y!0KORZU>KC^D_U^7L
M:O5ZTA=-3&,.3.OMK"<'PU%7C?V#P.8+5A'*W@BL_X$6/0?*'6Y  0L7"5QS
MU]^+SGU+#^B-G3]\$@$<D%CVCD27N_P"7J,(Z&X[0N5',MSO;3UAEU^B!X1A
M-'P)IYL<&.?X7$ZF0DP?GD@H^M5"[CV$'3;P2Y"O[SWZ^9IQ)L3D]H/;\E2I
MQMT:8S;@4M;HJL/*8 ZW; JB+T?QO'5WWAK=]9*W/1ZW<B"0H0&@1S7?#@D&
M#9+#T!SN<K_ !=98(4_']EM/2LP7S5J9,^*70%4:[.7I3W[+KXG][;YSZ99J
MC>G#5_[=2U%CW!'9KTZ*[<S$L7"N3![WLF7+N;NG6;XC+Z(F*RJ68T]WY?TN
M\TTP+Y7D9G&6ZD_" W%D@5)7$QVV=F^*N$ALH^[LYM40_G:M$:\[.4VXQZ9?
M[9+!5([)YT2GC>\SVPE957O:ZS<#B^PH?,(CR-RF%,+%YH>ZBPID9^ \[G@[
MW[(XZ(!*;IT@=GM? O!P80XOSC)2]C9I5^E?*:SJ_0TR;+ #1W1IP,#5%&[3
M>93@M;J&J6/OX4/-##3*1).CCX5T3-:G'FW#HN6!/,OERVE-HXGR-4Q?N/@>
M=/QDO?_B#]Q>"3D$HXA\01:M'C\I/UEJOVK3D'3N2Z+E'4,0/3OT"'!Y#?0-
MN&5N\4SCQK)>^P+)"[T;@:;@5I"TJQ,WT*<"1FR9YI&"]&-_.0C+&T3S0";"
M1\V);OZ;+E4YAT> ;]V&9BGN%;Y^"_MF3:6Y(&EP_>32C_WG30Z^"R<]77CJ
M,)0P!QP:,EQ@*63TE4P^ @AJ' 'H+TS?9J7TT*I(*DE@B6)5]P9.J$C"W-9>
M^:TK?'=$G 0+;H8(3J,301/2F&D5-(50MOQE6K"YHCK"=)%ST.FSZ.F9 H$U
M]H!5=8T4NB<EAZ%)=%#7: 4RWH*Z6(@RIX\ $ZS[O2^N\D'N/_7-^)L1=V9#
M[M^Y]#MADSKMM)ZUK;L=4V;^UGK \Z2@%9SW"MR%ID%_#Q6CZ6\1WS>PQ)*5
M"/51RJ\ORC$W,5\00#$-P( ]3=:3C+,'VT:&:?T\G9#TC[=CT[\QGC?!%LII
M'F2C/<W*2(WS%-N*XKKA]>Z7<HG/>7'#L2Y>&,DK21F[?.Z^"K/*AAK]0J@H
M.^X*?'^HVV]1\<8B"W%_DJ9\:?7';;;7 FP*1H 0.>VA0/UQ;RGP=PFABJ2Z
M. )../ZADGI$N?VV@<%W\),7(2U$!H0AOSICHEMG8X7N6CXW,.KL>D=*V+[@
M77S76*R+>_N]ZX"8-[%'@.]ISV$JP&I/QMWM3>)9C]DF"5#]4$Y=0T7-94VA
M5WZWXK,;(W18\B VQS0 9(C6?/@^EK-=EMLO7&1X2;XQ\9O SA_R#/3K4AS/
MWJ=C_&QW"@G7HEY:A1C.\\+8E0GX _@CT&^!]\\C:1(Y0A_Y> S?^B6T]H5O
M,T)+K4V,?8/]['=(#'0Q9_.SHI\9DWIV\O.#@58-Q-)Q6D%(TF,*C@H,UQTF
M-Q33G:FZPUX.7UX:8)(MQ6KNZ3H+! 2NQ"VB0V%.H E,._QZP'F)"&W3&M3(
M3)0JK+);_"#VA@5GZXVD) P7<<4&5GW]=:.$="N>W=T@9Y*G:]V;2T0FG_R"
MZ<9;U&?_O]P,3Z"3:OQE)&92Q[/J&['D*BC6>I"O338ZDL?G#"=QJ$%L.-/]
MJF\\VK [5%*!1"(KV4Z)F42G%QH:**V 0W-(>/(.L,+'CXGOS,F(BY(//."5
M-B[(!%9HL_4(>8G_^[^DY*FE4SR2@B8-?&"B<#*LQ4J!-L#  5$?XL)="%-6
M;1KL7\B.@TAGZ3WGS[2?.EW^E?SC2VGT/GHA5$ZDS?LTR%;62S$H\;$R@+9L
MM,V!?>)+1K9CQZ6&>N>\.]%\(4D6/_4+I!U&\F/T?K20I)ACKG"Z9/C"D4A[
M;KALQCR2,W>BFBY/&EE BNKEJ?BE1QONV055$0O)++2KO7NIVP+1Y!$*#'GG
M". Q;/(BI8QKW^O3%]FG=[&P(X"E)G3NDH-G3$86W/X(,"Q0"I-%LS7??+2E
MOP??OK#EMC@]$6&]RMDVRWZZ@2?L]6^'U_CA-$8L@R^D/-QC-NQB@-2IOR;Z
M<6SX^U-:V@(@1IU]1J$\<4/7?KK98PP_^DLOV8DM*#C9\<!E3-+&" @OG'K[
M^:(DN]7-,0X2CF@1&.BTQ38G/)K<?VI$Y2'*M/!F0O/P,>+'\%X%/<0-' &J
M J#!+0(?!Y=X4(%<1X":KT:[1=&H;&*8KBI$1G=<<5QQ7_! E>)1$*Z_O=\Q
M3E,0B*KBB-NT<GUP5>_AAW17@349S,$N<L0&2Q&I^:5/U5?7DN9>O6_DS?O'
M,IWK10,<'[0*U*/-T+\B<X9AKJJJ6L:+!J'*ZJ%UG<K #ZL25*:MD4L&LU-<
M:0JJ)3?4U:V. $C[%/>B2V\]TC/]12?^Q@KCRO YVL+"*H-)!1DOYS,X1D=+
MF^!+PQO +YL<%&^"R'K[-K/AR$:5I(W9T+ISE-M4'\/^S\+?<>&,"^(D/#^9
MVD"]S1BV#NZ,/S^IWC?8'@R^<G]YX/SUQUP#01GS)$P!T1IVO-6WXR^L"9P-
MUP^\]\T35^P0Y%#K.E+_\]WG1QQ"STEC:":@(S;:&M&.CS&FJ$R'&E1-H\I3
MM Y.="L]">2+4PE&<&IS?$C."'6ZJ)QJ5P^#?TTJ/K>%$,_HSB=;T[/&#HX
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MQ]:24\]&BT^G*$L$C*E;]N^N>/>N[>B%%*4(K@M?&Y'LR7&SFZQQ6?A]!+#
M_SEOBZO"1_(+)-F%_A_MG5=44U'4YZ.H6"@"(IVH@'0!*=)C P2$4 2D1D4%
MQ-";E$110(J$(J" 1.E%B-30 ]($!(0 H8<>(/0:TI@XWZPU+_,T\\V:LGSX
MK76?[KKW9)^]__^;<_9YFJQU=?#RQU+5\R4*=6B'P!W(UW?33W&A]+X,#FRP
M^";^I^G#IA^1%1H\T$*>Q/-"M?.P>D\'(D$R!(FE'@&DZ#P]4KH/:[=S9[])
M5H(/80847_IW6'&*3?+%]!<VRDKFC0E>6-A&GRWGV_AX0QWN5M2S$/NDL='&
MO,P+ICKR_\>_N?YGTU:'KGZE?]NS&ED?Z/1FS?:!Y<<5=:]%?2W90N8"8]8_
M+93?B7OBB(X,1; .Y^.(1L6]CK\];KZ?YWT4$_6BP+QY#LO='1E=+.8;4/,B
M*Z<*%V)%%4)Y0:^Y3GKEE-OLV+N.;^SPN'=7[%AL6*FDG%7]?5\[W:*P..!,
M9;K<B?81S2. P52JB4<4Z<EL2J8S2L.ULJ_9G20!36I'PG,F.B_YA-A<X4%9
MPM3^'BR.&MP8(9O*-<N=K>;M13[W7$[S53Y\? 0X>2%T9>S (&$%K')JZ)O4
M9W% L@@"&ZOA@QK$CVSUTT\'/&A70:Q2-%E\:$T=0B":Q=IB>9[4 S5S+Y,H
MK^7,V&@PR8VV$[9^!"B&%R'-,FX)9WZ+%#HC$\CP!]M!V"0[%?TYY,X*G#^Y
M7E+'7F-JK,AA[&#C<4[OG*2NJ:=;9^,^SFC_CY1*G&3'(5TWP^M6QZG,A[U>
M'2!"E7K04/L8&IL')](%S;W[;[V8*@O2N8KR74217\$NP)LM9.:0K0[,G]^?
MTO)]R-4.^K.A19,FLH\ [?M?:K*43KT8]E!%K'=?+S@"6&:]AN=-2\]A2-+@
ML:?#FGS0%XMJSW''LXY;,:_ZB^>+I+-O=M@<CD]'-+&/B;0U BG@4*K1*Z<7
MG7'Q]I.Z "EV:CDST+P/F))E>/!)[TSG+4EI_;4RK-/!JP,UVZ*]".D="=7F
M-G'_GJYQ:G!]W[)UO>U,KOD';^,C0-.[W(Y9#.O.%W]CT/[F6S+-==,/-'IC
MOYGC'GM,I6 &<DN^0:N!8056\FSHG9BJLY+L<[)ZC(?^%+:\HDH00H ^/,DW
M1\L-7WX^M!L(S1HWMS:V\M[W<E/1OTJ;/W3#X<<W5.5(4MQ[&3ES(=R[Q%_7
M%)2. )IFIY@.?@1R:GEF8')@2'BS>K(.22PGD@T<5T\ =1#IL$9D**2BKP42
MF7%R4 8*N_2B?(5GVVY14BS5^K.%]8V=:^QJS+$-Q(,Z^IDQ/M@9EZ!Q\4X'
M;^0<W1?[/J<[-"R/;RRX= '\<&F#0%YQ#$\"NYKJ>Q6@E4\U+&1:8: 8;0*>
MY_W&18XJI%T(" DVWDWV_!49$3(1& )/4E\63;YR)20/1R7O$F+I'ZOB.P4?
MW1M'H YWESN 'UYQ(F[(;JS7E:0N-V;HO?H\"S_DJ420-ZN/ ']8X4!@Q5YE
MS\':R8"JWT^V]PC/7\;_G$A'[J1[#V!^0"Y\:10:!N>\.P*06>&7(16V*EE;
M!(?RJM\W6 LGLLVXT(0;JG;"8,A+\FS#]R]WQGK-$^P*EY6#&AB#%C[87IBX
M4%GCOG$5!1L&Y8!&Y2#]+[7/D1R&-ZQ+#=^ORK1(]WY[<Y&8<8:,<!O:G=ER
M#P\-4U]/Y:L&+DL.[@K!S])?:5^$]0 K+Y;/=+,:WMR"[O+?W](3JS=UL"^4
M4G>[>9R%15*034V(6(VA)6)>2KI7'#[9RLV^$K4B>17HUBB097:#Q3$]5AY6
MV1(9$Y*=FAZRC'Y:U5 ?I:_C+3J^X+ "2Q//! 57S"TFU\3Z9)PQ7LI0K#&8
M$Q2FQCBAB#9#"YA3/EKP%B2KIG0F*75AO;+['-?%+(_5WNT>PKWQZ!N_C0>R
M3C485*\?9G]?NUA\+0&;ES?A7 5VW5WE_ER4H$1!'+!O*^=9I[9 L24/8V95
MYC:53:U<_%U"5H5_T_T9UBB:#[_?_L<]XUGHF"S84,8^*G_DSWPZXM;AUA0F
M6%-N%LXF'N[S$&_S@ZW6M_K2Q#4OKA.,;) Q1-VDCUD&XM_#G:-#0"W^LDX%
M^J^>";*5.#Z^_'#PO E!HV;:E^J:LP5O!H^A?L*8W2_D1?G>J*PJ5<PVG7+@
M^J%7#_CJ^'5N!<1^^Z&18^"/J(')DC7T7MZW-MZN#^JQO46)=88P9-YL[4.:
M-JT,)AG@A9^!O-]]Z'O.-K)$QBWIKE<1,(.SH8$,WZNA6M.B0$[LW &863/2
MRD\SI7'H(SMYEA:IA.\182> *;Q,,;@>?O$8F%RPZ989"=AJT[ Q=JTD+'F\
MAG 8W=A[A],S<<2;;+4;2>$(9AZ$<01<5]USLG[6$&.47GH$>/C:]R47%G^(
M*U"=V0RP$ --Z=MXTIV<5VIM@\;["MIX#>J7MSN]]&9J25 H, BS_9+R<^3)
M%/=ZO&[>2GYF7C:3X#%#B!*U2BLI2'IEM832^%U"7# C--&C5['GCH_!N)W\
M]'NQ2V0.@?/.N!]]'4< DI0QBAO_SJ?AQOW!XI[?.),V47V):S=$0D\+QNJ)
MQ,&_;(P([/N'G/NIXB!3\\&ZTO!T=Z.:N];%.PFZ<%-(++Y2+I8*GY6+#0Q/
M*B":=V>-$,VNVW9ZBN@6"+5('-,?4Q7U\)#>[]CWH15H7IY&A64 ^]W=UJ@4
M6PUGO)RP5UR8UL- J^H?I/P9SBSP9^.)WK'1L>Z\^&:UQPNV8P8KPP8A I:6
M50?V:PO/_\KRDQPD)Z?-#@MLL..SEU<R*):1\_$7C@>WNYP1]9GW J,":?:T
MF'I31Q25>[,H9Y7+O@KYW($[3NDU+?UBU]X<-82XX[V_2JJ< 7UP8(WM,ZZN
M2IX=.2,R\LO:GN.UIH((GU $KN%5"I6SO%WXAGL4=,8>8ID*/3O >EM55O@5
MO_)#Z'..DW>2!.[-'0%P-D_D SY/.YIEOWJF']0?J/T@9:[F"_]'%]R+],,L
MBU&]0X?4*AK<R+YO*3=*42?X<#DL>(]B<<K]-9SC>#I7-@L0O/O)=<GF$+N/
M<B<Q?HOW"P(L2K[-NR"7B-1:>&L$:>[PFP&UI&N]M[MW#-C%O$J'=5#N+6]/
MW"LXOW7B[J_6DTQKC]*K5)N(6* !O8DJ.XM@0[ YUPSO;IY"0JOYL(@4C.=R
M&YQWZD*$6?U6^S>V#R)7R\:^9PX[=[*5/#V4[T[0=O-07&L+J;P833'3<6+]
M@GGO&\;9JAEZ#26?K]=U:NKM>.XI[8RA8*4BU4Z;]"?% K2Z[<F<QOW*(X!Y
M=XY:NT-O]M,%-4GGU03+G;'A6@H5XPQZB8EUX!O0%G E*_&'%?>T#EM):7ZV
MZ+6YZM *EUN Q(%*W5<GBZDFI/<8CF+,W$"'%<^)A(Z%6(NX.28A-2+1UD&(
M%@MWQD<%^B0$1-LWU$29>*7PW'#?C@]EV^OP O6Z[C/M2]*0OH@WVMQI!D.]
MR_.BB<GB,J^=9)@]K0U\?E2[_$Q'65=D9PSWWW ] E@UQHR:%YAS!/Y(,!U.
M3TZU=Q[S6R8M%QQPZG:?4(AE\6R/6"GDP0Q\+#JY@.G#YAED%$Z*(H1%H'D,
M_9HN+-T57JQ3D9C@'P)"$4M'I3P3H5/KFG5UMEC,I\2G-G8)WI1(!)C\?(A:
M0I] N>938=78KB>Z@XX"[WF9I6-I(%,B9'!&G[-]7L,-Y)1V!-!!'S;-8I+<
MQ_/?-VH[Z)]=0ZYEN4Z' E\K((S5]G8UK6"GC#.N0 UD1?=&G8?KX"UUZ:3\
M.R,V1GF\8SPKN_CU1KHM\ ]JM1L5$'2?!)X9U]^+/IT=VS5DH+G"RW%Z;1Q]
M!+!IV NVG?E*)=;ZBP-"<M2TWZ:G9[@>+FSJK8Y3S .*?HZY%<R@+D+&7<K;
MN%HX(?;MA3&?351B0B8<!^KB*>*PD=LA"HB8/=FXB=L["#3^<3QL<\'#&XLO
M=K1,5ULO;"M,*$>/#KD6'E(;7?XDYF?FG-$Q-UWP'["1T[)*U-ME/MG*8QH)
M7=#/?'2VWLDK+O"\GMU@GOBW#N5Y^(D*=HX UR9UW:39Z)2ZH;6UKX:?YYW\
MG!XV/3'<.2AWJ+/SO814NC8V1M0[^'+7N,3X%HUY#Z5"^GD[6'WKLMOMD?O@
M/SIB@;ZO(MIO\\QT1$:'].?U(2E[8G9".49PF2SW!HZN3()84*>K?Y"UCSW[
M7/L1P"X*.*:N.GT[@L[)HG+J#$,#,X$(5S HS+MSRATMJ#-=Q:]?7A+U[ELW
M9]A&6"@F[CFZ8A#DO-;_=1+X7FVNNO8((,)-"PL6.,?3@F"YJL<?#(#C\X\
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M@Z3"*U"K5E])P^<^@/6P@RO/'.XZXU@7A?5$8L(9<9.RPN.0F?JK^"#)EK;
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M_O&/?_SC'__XQS_^\8]__.,?__C'/_[QCW_\X_\7X$>C_P502P,$%     @
M93!\6"M)@BWW"0  K H   X   !C;6UB7VEM9S R+FIP9YV1=U33"1+'?X&0
M0):E20=!J0&D2!$I2U;IN,@2P$#8B(L%%90-'2FA2.A=05%@$0*RE$@)O>@B
M2%,0@D $,51##64A8,SO<-_MW7OW]H^[^\Z;OV;>S/<S TZ 'P$A.RM;*P "
M@0"7#@, WP/F  S* ^.!PF \,#@<QHL00B#X^!"B H+\0A*BDI(2HN+BTD>5
MY:5E%&7%Q8^=.*:HHJJFKB8EKZFCB=111JHAOPZ!P.%P!"_B" )Q!"DM+HW\
MGP4^!X1Y 0/ AQNB ' )0[B%(>!+0!X (#R0/P7\4Q N[D._<%X^Q#>'#10A
M@ O"S<T%Y>;A@4(/JQ&'=0 JS"-R_.09V!''G^$*>%'=Z,PB7L6S-2_$T&^9
M2GJ>?C%\"'$)22EI9155I)JZOL$IP]-&QN86EE;6-K9V3LXN%S"N;MC+5ZY>
M\[I^XZ9_0&!0<$CHG=B[<<3XA,2DK.Q[]W-R'SS,>U)<0BHM>UK^6VU=/:6A
ML:FYY?>NE]T]KWK[^D=&J6/OQB<F:?39N?F%Q:5/C.7-K>V=/W;W6/L'7[D@
M #?D+_TME_ A%Q<4R@V%?^6"< 5_;1"&\AP_"1,YXPC_&7]$03>:5_1L9E'-
M"SY%/313S-/O+4)<29^NO/D5[4^R_PXLYO\B^Q?8O[EH #\WY/!YW,( "C@H
M;6[U%8NHUC8>LAQ;BJI3[\TLE8'&6'F<[C48P7S'! &.I8GV'@D$WI*Q5E/5
M]@1LUD9 Q@;+Q@L$B@AN(-")!X'-0+&9I-3\RD8)K%R-K+!:L+_L%>11!T&<
M\L\A*QR+-2].N\>^4VQ*R?TXI9'V'L-$<]STF1LER\&>- ?E>:+^9"N0H?M\
M3[23F3$$ F<Y=2 0.0<"LXP.(1!PKP:!"5L0V/DI</BMEFNKJQBM?5#PT(#\
MMO8*:F\=Q=$JBN\>QDEVO"A=QA1<K<=8=$NSDU6"8G-DV65)#/EUPY$F7V($
M:OU(&0A\TAVSM.SN?\_7D(<Y!0+TXX6<N"]>G"^O0*#[+0CP\1\N^FMLXZ?*
M_6(VR6W/J'[31[>J*=:>6EK@I*-SPKL#I1;3L-I@G#E%_4_/*X)=J"V];L[N
MX<U(?+CI&XY6 N]4-/LN+L+92GH@,-Q9"0(S32# :KDBIUGK56#R*&S EAZ1
M+OHVJDM=4HY/L@OQJ6+0] P(*%K5@ "N^/#VPJ,D2>HM5Z?;ZGO?F35WQF^I
MLA4:SK4'W\Y-V>905H(XRQHR,LFMQ/?\PO75$6)6#EODC [1FT&=S(*;9NKO
M%J_KMY\^%][7M*V8)6)PM.^$C?SJNR8?/?+YVY_=ESKN7J@L?Z/1O"MC7#9S
MJ=,IZ??-K@J6H=M$_P0E_.,2);QG7$Z%-3U7Z2ZEJ3]Q'L:WM:8PY/1E"56^
MPYWNP;KO6\8V8FD3RF[8/9]"4C!! _T;72;RN*+T!IX;)R1J'A];"&VH7]L^
M[FDTIZ:\7EWF2U=[XA8XU1O+4=%FFW-"7^&D:YOZ,[JHLN-]!'BD>&/:SKEI
MNVV7UIHT(_8#-F6Z+8XGL6]/S)T^W5-$+TS-.="Z_]OKX.N-BV_0DG?S=&P\
M,4KXF(B$JM^N,N^5%IDT5;ETHH\G93GZI:4/'BR["3L3 YW2[LXVI1.5A+<R
M"+-.96D"!")V/W>VIR9P-CV1-N#:OR&*UC_)XPGKS85^,;M@L-Q9Z],:0!#I
MTZ.C76VOF2(1A]\4TQ%(DZ+ZC;W_GJA*N^!XKGEC=;DP(N;+>35QB\MQ@:K#
MTJR5V:64C?"PV8'BDK;.26D?W_DX3]B+/1)J0_8RATN#]"7GUD7"D>6#*BIY
MWI5V:VIMJ]R?RD&,Z0T<-1:H7/"B=5M+DIRR-!;##(D)<LHIV5$R:*6"&0:?
M>_"'4\SVE!Z-(2'&C_VGD>.VF:QK'<Z;A"0#@FQ(W6>)KEH;GX6V?$VTPH^#
MRMEX+?_>CW(A (8TP7F]ZS&)8APL#.T^_&%1U$/-?12>A1+&8.!V^:2$_$>?
M,G7(1CATZFI807;EC9:7*CC5'^O;4P*]0W.^1RE>C)@5W)<V2#]8D^<DI+4E
MT\NZAN18WJ_R<,N,NO<T4C_I98P+;3B;V O/3-G=(>,VX>Q4Z5=?@M)!P,+:
MS>XNTIEBY*_2B;[OYAPW7_44!&B*.$XWRRM,U =Z$%OUQ/^-H#8(I,6@I/>U
M/EM0*_6/FC@W)>:>I[JQB4/\ETW.6U\>$MOQ71.F^XJ%M*)'J@(T#=8#/KO2
MK/$*2-V3/3HVGT0CK[44BH<;I3NQ+'WI#\2^78MK,:@K0$46%Q!HRO%L1,NS
MD+P0K X&DSW>)SE>K#Z:O5JOQT$LVW4 S\RDF.\N];R/E\ 30^,%W$VWJ5XU
M8HLS]1N)9&UR0)7(XN"D3*#W0\7M'/ON)H_64<!P">>[ND^?D0Q!.;4_&]<O
M/SZB-3XH(N5XUX]L'F4[CV<AEMB6S*7NR!.LMH/2,E(;5C^WGS]574AS..KT
MFU 7QH:E]E4'";6^"DVG3K90H>E39,GZSD0%?0;"=JME3HECS7[-P?KT+2:@
M%QR)F]G9*;%#51Y,<HPV1X*!)2<%OC99P^:WB83J5HV$_B(N8WYI:]"6>]-@
M)T$2$ #(^JS]$N\/QY@!6(?X$WF,I:8+A0(5%%$1X\RQFGW,=Z;A*PZ3?4HE
M?S!8>0/?2N,7,;=\PC>9%?8MK?'=>4VUWO64D26KC-[RA;8DJ_4[3/EHUP/!
ME-L!#M"5.V)1 8]<<E"G+MVQ*&I$[OE$[PQ517S+''V.+8AF)GN,5J^=\L9F
M.7S.7W:8HB5GX)<)TK.10FS),?KF%6Q\\BI/>VJ!<II*(,'X!_:O40[<Y0>0
MB[GCR#[J/5KMS0]!(!#C%X9(/&,=?/!XO>97'$N&SE_QE%$%*R;;BU!>W+=U
MC=^ AD4R&=D;T;1JEI:]^1D6?#9LQ1NV]8>::7&(BB-%MR:SD;RIP_8>)ESO
MY&,]ZAXW-NB(+J.,D6IME5*47/8GHM-L5CNK@B[*,"T(S*=5IFH5JO>NUDWB
MZV/05B9]1Q/Y"7:+.;IF/;KYC^Y5CV>! -&J/W8WU?I*97HAX=K+P,WYO5.[
MJ-O-,:]II]D+*=5NSL^FQV.LYW![/<A(Q6^2-X3<< /%UW.>:5U* X$"X\?:
MT"S\/H8/SZR8%8PU6&AC[J!_,OTA_%&K%,QF#^W?N\RKN((]6"/W>$@P;I%N
MYDC WIQM'2LF"DT829G*/6E1]W.NKNAQ]'[]T#Q/?]I0@J#@$%6@N!G9.-N:
M6-9&I22[G_,;\E5>')MZA3@_%_NAG6C_C2N5(O.9L3I7O[UPP37OER4N_9_F
M\6/V5]E<3+FBC_F"CAQ:FE)GVT-;URDSJN-S)?SC'+(364,F(9FL:JOA$T1G
MH*XU[R&03]KFGB*?) %_E^#D/P!02P,$%     @ 93!\6 )\>UDW"   WB$
M !    !E>&AI8FET7S$R+3$N:'1MU5IM4]M($OY^5?<?^IRZ7:BR#3;V)MA
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M4^GT0.F/X^ENVY%8S1[_^;33V?JR;TI?EBSM]H.*(AQ3M+?4.:&:>Y_ QB+
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M^S;SS+/#SJ,=!2H*)S__!# *&*'%&[XKKD(V&1V7__O.7W0=SKG'XI114&(
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MC.A,U@[#!!$M6"05BH4PD2I (7.2:AOZ+$ G'%CY3)&()9J[,5QH6D6G5:;
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M*L$,5$.8DQ'3:27LSJW>+Q[44-@74IHQWMNX2_:,0^7*%/*,+'RZ86B^<29
MV38UW7OOYCL#U?\<S==X..]ZI'L-VI53O"14CL&?SF6F6#7O)GIY\=K#RV&
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M.=$1YW-+N(=B]EK+VGWURK%!Q@5;L[-=0*OPW$%30D9XSAG@=0LK4R@WCCC
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M_Y-!EO;7DUNW;?9%N:K,$BNC\;]7\\K>R'*.L)O3# 3K)VAQ.P'U%0NH3Z'
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MT2$U0RW(4:$_SICF2ZFK]S/K4.1=6#Z>A^OKP<U1@FQ&7V_Y:Y$1>-+S<K'
M<F%XY?,RM7O[R3A;#T]+LD3[!R'^#SIT#E=+\_EN %L;-I .[T#R^E=266"
MYQ30D&/<XY0Y D6(M((Q<>"ZW-YK&!JB=,?5;42&L#1;HJN<> <6441;B$RM
MGP$]4&ZX$/BQLCSX^Y_;CH?D^ IGN;KR9DSYHA!8YO<&V0E6^\WGV*?+$+);
MN)'"<1P>I(#)M_5HDU&E]F[)-7IT<#Y K+9B\.F!PNM1N-A!%#KJ08W^HEFY
M))P^E<R=1:C!O$*_[8)A608>BR:$PPI,1OV>V[/L)]B3G2%3?)Q-=C.\Z55
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MQ6^AS\9R9O2O[[^9ENF:_CAK%CG\\?\!4$L#!!0    ( &4P?%A_%"QR>AD
M -J9   0    97AH:6)I=%\Y-RTQ+FAT;>U=6W/;.+)^/U7G/V ]E=VX2M+H
M;BO.I,JQG1W7<2R7[=FI/)T"25#B#D5R0=**YM=O=P,@08KR)7$NRL@U-9%$
M$F@T@.ZO+VB^GF>+\,W__@]CK^>">_0)/F=!%HHWKW]6_^H?_]9NLXO %5$J
M/);%KY@;+Q(>K=1E^CN-W7PAHHRY4O ,;LO3()JQMS+FG@R\F6!7UU,_" 7K
M#SN#3J\SZO>'UO,G<;*2P6R>L=YD,F)MUN_VA_;C[;8B]F=-[6LG]E;,F;EQ
M&,M?]G[RZ6^/I=DJ%+_L^7&4M7V^",+5*_:/VV A4G8IENPZ7O#H'RU&O[18
M*F3@'S&Z.PW^%*]8KYMD1RP3'[,V#X-9](J%PH=?J)]7[*<N_1WM*6KPP4=V
MJ7I4'>Z]@8'@_:H5+[@SK(:/ICV;!F+-$0N#2+3G K\ I9W^2)/^N%[5O4O]
MN!.''A#R.D=:\C=F+E[/):-.?]F#"<^$+%CJQ-(3P((HCL014]_:3IQE\0*(
M23ZR- X#CSDA=_\HKF=Q\HH-ZQ>+(723CR5KU13"HW#/3,9YY+7KEVR>*/*.
MV(++61"U<9I>,9YG<?&35+W0;S32LX_SP DR-CGH]'#0KQUI&/_SPY-@.OP"
ML\"^&TI.?CU[/WU__);=_GIV?7QU]MOM^<D-N[@][90DUA:^GB0Y<UYV6PS_
MVX>&KJ87YR<?V+OI-;L^.YG^Z^SZ YN^8V?7U]/+L^EO-Q<?V/'OQ]>G9Z?L
M9/K^ZNSRYOCV?'JI]\4F+GS>B/?>_/VGWKA[]!@>_SM/L\!?Z3471![P_!4;
MC)//WH=[)1OK?3_834T,/=0M,SV>S,4"?G+8[5Q(GH@\"]R4761>A[W,YH+]
M_:?#?A\8LR;0*LM#"TJ\_(H%&7#*Q;:5-M S1RWUCO;9G*>,>W&"VB";!RF[
M A'@KJ -R:Z%&]\)N6*QS\ZD!(D2YVFX8L=+#F+#8]@DJ!N>!7'T^02JCFOT
MM4KM(WQ?N%EP)QB0#!1-W2QVA&3]%JJAP><3<%9T< K*L49(1ZU)=L(3>N!/
MY)>0BQ1T*'P,H@KWG#P#"9RQ&&B2RR 5S!,^K!,/A*H4<#.7HAR9N0:_WR %
MP,U>KU-9_E]OHV7< ?WOBC!,$^X"//AEK[M'WQ/N>>;[\RCP9>!E<_S2??$8
M;<[<D*?I+WNG-U?O+H(TNT52]UC@_;+W9V\PY(=BU.63B3L\'$\F_F X.NB-
M>&_H^_V15V[GDN^OLU)6JN^>&9BF3.UPV .P$7EHJ -U61!7D:>?+==QUC/O
M :*4]FPDZI/DV[J4VSRV=5QR)60:1RF[R9U_P^(%.IC9R7E%0>ANJN.#K[(V
M,_ 3SNL/JU9N+3F1SGD8,IXD(%6!<3P"\"68 QTB+L>O(@))[ K:E" 7W%Q*
M!/!X"2XL0/Y-?1]0OTP[[!SD"FQ1%" MAM(0!/0BR#(AZ'[\Y6T,HAN05V$5
MZ+XMFH".1,_I<AZCI")19KII45MI[L[I65B")+#LD9 P%-!+% %]GD Y20+.
M6=U+EGHND A#06(&*9@IV'AG)_X>$G_] \?U#EQ_R/M\..@>'HZZ@]'0[;J^
M,YZXA\/M$'_][1-_%0RTDX&?+P//([2; (6UW_*T#C*E< 5<\E 4 D#E/H@6
M$B!5[-9A[^!JDLLD3@6!14O *='HP6V&Y]#8<AZ 0+NW;VA HTM#A<:&>@2.
ML$4=V,6:M&,E)5&L7.<AR@/5V4R =(0'5RR1\5W@";B;9Y]*@Y:Y&N7CK[V#
MHY3Y($1YB (]B#WFY1+UBNH?;Y<B%'<<],F[(.*1&\"MUR*)86M%,\.=]X*G
M.2@!Z)MG&:?1 7>1HM0/A ?C";)Y#(A7BAF*<9C$Y5P@\J4^9A(Z:,&&3;%5
M?#3A*_)"T;R(^T<<NZ#R4FNF!:@,>A!XI8:U4P\/JH=#UQT-G-ZAUYMTAP/'
MX9/>Q.T-)X",_9$W<;9#/0RV3SW8)K2]KG>*H>;\J"S_/C0%[/M$O^WZ3FKV
M?9TKD2GN4!:1/(&O)?>U*$6Y)\5_\D"26QV$M4@0$W.0E&D&6@1%6<L6OEH?
M2#7U+?C  4W#M)&D7R09?$#@BVX UXVE!Y)7D! MS/\A:),P7JIF21ZC*/09
MMGZON*1A ,4/N6M:H*! %Z7K>+QD0 G,Y_RNHMRH%VF6M@^#JFH38Z6 K*\:
M*6P9YR'9..>+1'(W4XJQ4[J:"EU:\+R!3<05U(!D)J7H9\5K2O_0L(!7M@[B
MI0XVE(AHQF>J^04HR3CR<A<I+L=?.F]<3DX>& [<E\G R3.U&-2HB5#2:.@U
MP]^LI4%3W4P9W P?$=70W6#1%5JX>#PE PQC,K;YA,O,>*00ZH#HET&FH8U\
MBMO.X)02CRV#,"R9@*;?#'&51$:0C;HR/"Q0AHH)P<6[.,RC#&A!+$>K!8;!
MQ"()XU7!((U@9G'LZ;UA0 Q<]'+5B[D+&)YF,E?8SC09E(^\1!B(>RX T< E
MW8(##X,_A'89[NM!XFU)R&'MPS8$5+(@+*(&#4]@0S,IU*05R\SL:=T-W!=D
M:<D>#IP( QAD:ESBSR6T]MYTOKZ7?4OA3<\9=T<CI^][A_YP*)S)@3L8=GO#
M[N%DR/G(W0YX,]P^>/->N7A@5Q@!?L0N8"=F&KQ'[#37/J([4=RS S_?'OS<
M;O;#E7- RKB%*A*$7MTKURH1@>WN@[5@*R 4F@^#$661+CCZ#MTP]T1I5(;%
M<D(DA4HZ4,:_BW@@#-5*JZI&):U+X6PLS>*R?R^*LB" ? 3Q4@0+!XQ4I3G@
M$42(2MTY*Z5UR)_*TM(]5/%' /=;!DW JL('$V1LEBFE'_(EW@1D^ZDHS.8'
M53N?@;&>ZB 498,4EX ^DO1-;&M0;G7^ :WD %;CZK#+.,/I M"B'-=X+VAZ
M,8OA6P$U2SP%^I="_"6F67>25/EA Q3M+DD)3#P)[/ 0\(:W,@^M0:IRZ G,
M9XY0%L@PH'S0'1I&W'#I\$BD[>G'4$!G+LU*O]OM(P^GQ/ "TAY+R:.90G,*
MH?%%G"O_QV>3;*-O-T@"[5>AZ7FP<=QP +5A0WN!0K15]/\$.FT3R1$6N38G
M*P%FI-M:15\1/VDD\?;ZZMT5V !O@<-_',/_"F3CAH)+U'/9O$A3H1P9)5'U
M+T56C>JNDB[0U$71? *_M!W\J4U^+=#JX9*OTHI:QA2?* 8)[,$3^D,MRZ>M
M,8'*SUFG6>7TT-4*V#(JJF_G]9A<A8:\GB*;:F-(^F_MMLX<P]%>Y@M'2+"!
M1/8"/K_HOWCQ0F>&[1!L,X+E@_Y8^'P@_)XW] Z[$_@XZ7D'W8EP^][!>#L0
M[&C[$.RQ!P &)D/NW')/BM> C.>:=2CF$23"AP2@(<A\A)/:<&^(^AJXAP&%
M'$">5,DT,4@ML-FQ<0,L:4Y2%@D7\ .7JR(;B"<  A*IL F %N\N2&GC(R10
M2D4%?SJ82E5&O4$OM3$0H2&M")4ZUV1D*@A?#,L:5&5(%3W6X)ZRO$T:NI&;
MB>A2WD8I?. :/)":A" -=[37H^!50X@)@(36LH8;5FNZ&1JP<1!944D-1C6T
ME.(N@!G7\V-1K1B/;BCAYL"7 %H6']TYPACB=YK&;J"A9$6_-R&YAAE%CGB
M5U+ZM@#5MIX;4&^88)]ZH!K0,VPH>(1N-#!;8+K ED@I8PP3*W16!8&JT.0X
MM+3%86"K@54T9^A]*QP\+>Q BCF(#B'5$)1C2XA4+;.2=EQJG@C%#!<HMT0,
M^E%SXB>M%"G29-TBP*^ MI#3"T#18',!G,IBZ!1^*?K46-2,7A/>PNRX<HJU
MYZNV(,LAXU#K,[:+ISVHKL?#;H\[W4'OX+ [[ Y[_, ;^,[(Z8X'HW&?\^U0
MU^/M4]?G1B#OU/53U75=09-0T/$5X[PQX2/4=*@";4^X%><PLJ=)V$<F,&)8
MWF#!PR<00;4^2#VN-QAD:\J/ PU>&8!!Z;K(%Z:C BW@=;!/,7<!G1\@Q5%#
MHVTNL,.=F'M0S'6Y>] ;]T;CKN,/G<GHT/4/AI/A9#R<'/I>=[ =8NY@^\3<
M)>9!>6(1!;Y.L#QB\-M%P!U (]G.@[Y1\-6C\!B_##0KR<$9*(E@N66-GQ1E
M21BK$.UCW-:;7%N%E1*A,4)4V,A2H;E0$U-\2_A*^8ZU,]FFT-?11Y#>BR!?
MI#K.'$BOG7"9K=2@2+Q1/!/Q)8ERR[]&F!0@J4*;0#K >171]7.3T*ON+,*Z
M28P"%</1L0-SI['[6L38V!F7A%DKGN+28+O/&Z\&MQ#H-;(N:BRM0^K*AE/L
MI'P$?"8T&\(R;FA* 9\CN,Y#\EYR5Y&>@8'9$/+>:8('-<%DU/>%.^E/AD(,
M71<@+F@!?S 8\(G3.^QN"> ]W#Y-<%SFV!^Q,W,88*<$OI,PZME'5R09G4@S
MT:V2]_>=?+"EF@X*X2D\G>=E@V4O!C)1C5$D5'N34H+S!@47QR[,\0_XL:4R
M=3:'HCKL^4,NOZN@;<D"HKDA)!C8N7<HH='D\&&\&>#\;"E$]3R=B4]7U*^=
MSAWR#!.$E7H -7G'@["%/BN<G757BUB+45M)=I^:8%=-':P^H?+><!;+X!AI
M@C)/O'%L@4E-=TE9K]EU>JA&!3_BQ*_E#2RR#4W>&!A7T#"P*?"#]4.-):!R
M,"YK^]8L(].61=9RQ*E&;M-Z5/EBA':H2V!0R)<*$#$T,U&A(]MT@)+C&(E=
M>O8>%^?7ZYO:M<//1:P2P_,5UYA)ULM56D'Z'84055"MTD?#87,C\1H?WJNM
MC.KY9*-[ +4N>%@](ZM_VWO3;V#(7S/DN8.)3><,#D1WXCJ^YW$Q[+M]9R \
M&%M/]%QQ>.B,M@,F3K8/)MX(4B@[7/B <\ *(M6T&Z99VYC*$86'5"L=/P]#
MC!UJ/Z/6-: UCDQ*$B"Y>;P4E/5?SU_B&$,L8E4%'76T%Z!QGT>&A#RJ' !&
M!7G'L49+F=)<#^XH2[YH'].Y&P:SX!]MIVD1,6I9^AR7^(+3^@Y7#?Y7VW-<
M]^9B["PFI $8(6UV"5<\M8C_0,L80[Y,^[..7S1%LW;&^\-2V>F"Q3[R)X>#
MX;#7=_G0]9V!/QX<PJ?)>%MJ(W2W3RP?XTXI3H'<EB'POY",_MS%H 2W<O_%
MLF9&HX% XJC%%K&G7;SER9-:HL9R'ALIRM!QRI109AETITHJ4#(E?#-<1[F%
M%YM3H#'L7STX8_5=E9YTT*?B!C9FO7)FJOU+J9MESD6($I4.._,GY61HZ_JW
MSLU..CXH'07G?=[K"\%=?SB8])RQ$,/QR''[[L%P>-#?$NFXA:5C3K'N$3D(
MTIT\?!)IGU[DJAY@KY:Y8@O!L9:/J4+5/2U.&VA18]A_[&8M:@%O:O?H9&L>
MSKBJ(R:D(*RFG7.!.OHOL4/3X%/D65&@H:G$@?4\8G@E,Q6,K<%CJ3(*Z)@"
M:!-*IU(.J5D>J/P]4PI-^VMOK+:AO3H32 ^EJ3Z0@KU]V5%],6G^VI&;FS+;
M_8?;"X0I&C= &7"$U7I:IM]5W(M?4[?^X&$4,XO/')!H4#Q-*V$#40T.^6<G
M\!YV%(OQ^<,T30*G>CZL+ (9Z[I?*F?7; 5*,S7"<L,)_?-4<A$&NB>49!=\
MR48'HTF[-YE,E(0F/XPZITWHVSJ A+A;X^]O<!3Z1Q!PA9VT4<A5UK@5G:RD
M%AO;JPC;<2>E@@OFH!E&[XKD?G0)_5METVMYB5Q*!+'*RF6& =[I?.PR97TW
MP4\K6?I BM+&>2].]IDY?ES9+0R8W5/=@[R<&'057JV;1P1558B4K&%'B&JG
MM,HV]^M0DV0F%[4T&BI:F5)6*+S,N*T8/3V?2-'.^$=LDH+LC9+M6V;,_Q#+
MUB!BL"(V+E$+>]OW6VNV-QD,E2)2#NG=-#QM&N[9(HVSHK+TZ'K#]D%U#KN'
MJO%LQ 3X&T@$["F1 72>H$EH2BBKVDJUHSA6+;OUZCBEG:<)2X$D26(#G7TF
MRU)Y^\HCQ^9F^RC,/X^/KUKL_-WU#;49Q5$;?_J9?BG[+A\MA<A28+0$5%H6
MNW_@P%Q=4B'.D-KRV!"(IRR77[6@Z8^P4'$>&E?D;Q&=6[_!]9!:%15AF0F$
MID7Z:=.RV\W"TV8!-T+C+-#)DL+S46X562\E67I>+.M!NUK.*XT<EQ-V4SRT
M 2+^57-Q!KM<G-W>?>S>M<OM-6[BEWR?]J$RT #%(SP7H#@#NRX('3H@;1JH
MJ#ZLLT"=IU:)"N3G-;F5"M(K@^!1-6O*3(JB(&,1,,,W5;P,]M5IX:*FHL"B
MM&*19"_3?:1']_VHWEK0'C3HZ;<B"7T*HK'M\B"#AT_!8P6E])!IA)M\QTI!
M1.,!W^ *!D*<_6I:JF+=71"'*HZY#H?F\0(/MH&4E%0BJ)2HH.(P"AJS2VB+
M#E7T#^DE&?W*D16L*)0$D4Y"J32'_Z8B;)@.R_5=F978T:6!'VZUI=6SG=#Y
M>$Y5:T\J-NF3'N:,/==\H_HY:K[JTV5(?'+W98'(E^Y^G0XL.@AKC<I%$B.*
ME%,P*=O_R6$S4F(M1H]UQ4A5D% EMJAH@ ,HQ@]TX4<'WZV%@,;.@*T? 2_/
M?N-I'KB1BBD(D36>V^R/*3!\TF'#;@]V_<O>8!^':?W>P]^+I&LK'[84 R;"
MLWT@:N<$?XH3_#Z_S;?PAK?6LOEKA7A1*+E-&?M4AQPC@P!4(OP7UCS6 D$(
M2D-;-QCS1#LG5>%S4[3<KLUPCPV=ZFQRVW>FSJ>](FVK:IK;1_0<,;/KKY&'
MU*7W'8$PT<ZN(](5^&8.O"R\ZM5*1HLN]T[%,X1$GYDZ(JB*P:LSA'"_6U'
M*-9 $(45I?,%8A#TXJFFK!?[\,@GI;\<*:'O[3_F.(3%(RM2?#N70K0_P$IA
M5Z;&O,;:VQF'V F]IP@]O9E^D&B?X*6$0;E1R4(S_CL5CQ'*,K<*91(CR,G:
M]):R<5$0<:.S=LU+^XA-N>V[[=/>__=%=U^C5?AM-Q_LL\VG$[\,38T,Z'T[
M!I@5^-Q;OO37@X)=HD^E1;9*GBB0!+K?%T&&A1"P1H&JG5XJWJ*( !9(KY7=
MJAR^JU?(JA:64M!F8UNJ'IH*_6-=?6[$"SYKU8POJK*W@)51GFJ;*3#(5']7
MYP;;"LOA3P0+T.RWZKJ7AHLU<-6 -?RR/'SY9%/1 OODH;S_F (8H88WS;6-
M-QP!W=^E/GR2P\NR"3;$LNR@@+3>UU ZN]Q8DB^LR?NR@-LEPOXHCJSJ0JK^
M'Y;E7?>"5]X4H=:(G>O-EY4-9)&4&IRNR '2A93:3,$:?LK#%:1IOND=$LJY
MI^R@@O*BKEZM"3/\QI:@6^6K*B+VI?.%EVUC6F3!T4!M'47T4E ])AJ*.6,L
MBMB^MDW@/DSD!BX]<.?ZVJ@OA*W=/]\!:-@BR+YFL7U=\%XJC\=Y*7 E9TBR
M*DTFU-M?Z%UM*QA#RH+%0GBH6>BM0>95-YE^<UWI'=<%)*P,+*.I]!5]9$8C
M>69G]-546K48*];*T>Y4!?9A%ZM$,/.=CJ^4 S?JSQ3>]! 0D%HL7G^4SLL<
M'W.3UUIW]6]XY1)14V$CY:3YZ-$) Y-M3OPI<JN1,;G,6L:+&<LRZQOK<U*T
MN!RX$WNF0E-:(:E&1CELBY[.\P,Y+5T>-IENR^*Q:UO!:#X>IK%YP8)"AQD
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M4'UG-=<KSI8715J08#W_L9+54O2P:_DW<.#NC28<N)5Z;=6(#P>B6N# 6.8
M+,2KS<#OLUH0WY#+C6SOMAT<^"?J#!&\<UE,3\.!MTVMJ<<TW\'[K'"@/?)<
MX5H>#DC^IL,&)U0\2?3>JF_?P!\O6/YIW9?U](F64IS_OD KBC88PR1X$?Q[
M !BK"LV GOPZN7^DS8#M $4DCT-D-2/L5-?MV_07LONYS,7.VG\(NQ$?0SA
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M=ROYOE1E"Q=SG;\_-3M0H! 7YS]:;C<+,!!">^HT5\>(YM$=\3Z3XU$NU_,
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MGIDS I695N*9WR ?LA]!T(ONO/0P[]>=(Q+3T:EM+Z;W9/>I[!^R0"56:W<
MD\^>=S#8YJT/=8C$HB53<MJL%;;H1"EW#ONYQXX)(#R>%N3DZ3N5A$JHHAME
MYY%^HX$(?:-J\#%SH>';21^A%-ZJNB9:_ATVP5$[O:*'6NTRLE?C!<6$X+Q!
M\#8)+NSM27!!-X:&&?9]!\?40I/N%<4V4;VZ24WQ42LOP]!KQ85DZU7+BBGA
MG:*"O<S#1,88RW2+1Y+-Z%9PH,.ZRO_%T#+4!S6_)=T*ZFQM:!LH%^L8Z6(4
M/(X&\JX2=SXN9B\?=/6\%G OFFQ=>U+^3I8_C$N0IV-_#=0J?)8/V@_>4K!/
M&W HT=6U_IC8K;VK3CAOQ[!\G>1U4J3Y2'!E;;<)'09^DRTZV^&>M1[G+B+F
M>!ZK'";/ZY'([OV!WCR<#M*27,WQ$#W"ZPB:-"D6M0F[%_ELORTKB%!'X&BR
ML.S+D5]TQ4"O<\>\\W#]@-JP_79YH0ALW]\F%Y,:>767LZ2RA'Y,(&F G@ [
M)JY]Y(C <>.XD B=\WE3<7V*MXMX]O/]HO<T 6MQBFC=T!X8_KG=B#K.X]27
M]UY(G*+Y\O0[RX:(T69N2-P>G=U2^F*S(RBJG5;KAQ;.)<4;= %YVYU!>3>@
M></ 9)'B1EF_HGQT=R=4>ZJ-."E&)D.F76">VO,E96+K[#*@W]D.<#A&*F<^
MO7\T5',"JPWO<Q,_,ACBWU%8M)T?=?$6*"-WC%<X7.H<9<"DH7!_PS24Q,*>
MV&V(N][GNDA6/H!],5E16)C?D3''^O96[^/2/'1&F?L.NBO%)%QP@$L?9E@7
M!^(>&7Y7M\>A?_9E)8PR^F1/\85IC-X-R4EU0]JV&QR@P-D+T?E,VBS'XQ\-
MR_4^*Z"BATE'XOMR-AV_*-!@C-"*\97OL[6B.>3P"-NPA0/I=UY^[E*ZOV/?
M=]>[JXP@E*6P\V[$18>/EV;3UJ0K-!^MD+/A--=VP>,8S*?D??N=+F\^21]A
M_FC-R['7U.RYC?M"(1S\W#NLA4@CU^]KS$(7].,$R7"&_*/$#_3&@UD?S&K
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M=0(T>JJ\[)2EN1(_\!&J2 -V'C_OR'4_?^7&'7[)/5KD-XR'T4Q&6*X>0PM
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M 4SY[.-1NB/LZ)5KU:G[61-P:F Q_KM,E35$QHJGP8'&-A]P[,TJHD8@)KJ
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MJ1$.CZZ-JMD&T=.W<""**PS1":N"UXE64J@JOX=.ZUN.#4WRRSTMX"9&P\!
MB9)[T$6TO=#TNJDHZ[A20" 95RE4GHG)VXHQ<1:U(OC6ERX&R7$>NX>JRE2>
MI_EQC90CA=R[$XD'.SLIA_WJU2%2? P<W^0Z%N8^MSD>]+G$L\G'O51BFI1_
MP?#ZY$P"%EAH+=*>G;])H*?HZ-*K_2TW.N&%IEC.L8&C[@,E:$WAF(F[TGY
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M>BKX&$T[WX1$\, !&H0\H9^79-ZD!L,,V\ ??(U3G:$LQ<QP(* )#CQ3ODZ
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M8.BT&S]9L!0TYNV;2U*0D;('US>&H[<A\!VP^,>J5W595S^@H$6/H;3P+I#
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MJ,"6,:!0[P(_BU5-)C.WHP+S%=W;J%EELKOLDP+,QCJD$5XQZ[".LREK+M<
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M8\0M'+Y)'@0AQLDM5_"^U.K5T@*BX/&]2RUE\ZV,2?U+N4L%$JZ&\%:1ZD5
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M-6A:UH2TLOHI4]!&0M N?<V!0!^3:0MW:\:P\4 ^ VJFY3C[I:"OHJ)>BG
M/C5,^\R%_U5OO$&-_UCWM:0]B"U4:TF^]LENZ,0K)IG/7QI.,#;:O4TR/Q:1
M?XSLX%SYD.O5_D7R$.,>$$!G3C&,++@6'7G3,L.$R;9^#S@HN1&YO9:]/@"V
M586'SA\]'_)X?%1[O LK%JQ0[DS!D7)XB%]QS2MXM@>W9Q[9T.I286I_"_HV
M."WZXLRD$Q?X&T3XA:H[R=UM]NT%X;+&M;&R5_KD"G-W1=N75=Q(J2<7_4A'
MR=)$ _O!+]XA82E^8GF?QHX246&^L(YPQ#:XDW,F6O/MFC3U'N 7N\2X/^4Q
M[_7S7[>Z#S'/=X$_BY=PFFL'U?K%_)W+$SHI0"Q/(MY_>H9 .W)ZA<IG$K'!
M$:;#0"(2T5[-S+ QVO&\I[(#@?08O38)5ZN#B_J,XQZP:' 1?'V6<K[@$4KX
MF\[%Y(,1V^-O;"0W36 B:IN_+)L^40FM@#L<'@_RV7DQQX-/O7JDI]%-OBGN
MK;]@EV@G5I)^D_. R,WXF[%B-W3U+SW<A^]NT [SX0_NTAI+T8T;YYC":?P_
M"\8\9^F'(Z#A/%&?))AC%>\I93@-[L$=_;PWTWPARM69_6"YX,[FF9C8/0")
ML45['O*P*,#^_'NY?^>!S9N7+V??0-\+0)6:;*"HN_!M2F*=D[4[Z=7:W-R4
M!%F94AR9!W7F\\VB"$&$^BX/ FI7;OP(VP\[88%U%!=?D[6&LV\.")<E_C*"
M&:SPL.[(F\U,,W^F/XJ\)V&E*&00 9$-^_/QWO3,KL&NP<&:8&2R&-1&S8\$
MF:X.V ^:SLWD\"7QMTO_ U43<BZT5MD0P2>+9WZ^7[OC,,]!%C.* OMALRXN
MHTB]K];&9J3K$*.ZP@Q?BF-' &>[3K=;R65\)HGDLJ[PT7XC,OWNC?;7^GJ3
M>X [PL48>^B/3M<"V:P9YV!6JE80?GZK/_./J/)ZN^FQW$9=T';$)%W^@90U
ML6JT3:W4[@Q,^J3\=#0".7^[U#_0U8_"SP:[@CZ0]%UDY**#M203O P:PAHV
MOG-6><#I2^86TL"DI'1BPP_%33$T[4#J!LH42;XDU)\.)7H/^,]4'>>Q2YV;
MGH;L$1F/O>786U>F8+;& [CO.?7RV:,(QC/E(=&V'2&\9FC(#9TT7] C22E)
MG7Q0M&/^+YY??U#Z1002>O:]SV/DP:F0DE =@GIW ^(IWS4B,PVQO(0":X=9
MP8NS(HZ6XDIL(5T&+%0"J651U1,1_S;W/__Y]+>K!_C;!6 ;,_9ZII&U<Y6,
M*9$5U/'2$6]1D$^B<:EP:PJ]3$<"*2/"V;KZ-<F^,(DW!^.G*$^3:QH.:(0K
MMZO*S']^>398/+F5F"%Z^;5FF3I.R'P6DC3_(>CCP5G:4(UY1-M6SW>0@>:J
MLLWTMA_1X;;4Y,".#RA%W\KC/]-1AS( RA&&*?4E4-*3 [E@,9J.YPE-=&MB
M!%W(D'I%J#<A@Z(Y"''!$<]N4UHA[4S\IU^J_H.Y;I57/'71[@K829W8IW>G
M,K,11VEAM\MVF)!+:<'9KR%?3N)I>45?^73H(HPX8@5X#9[?'*MYDYC?T=71
MJBJCZ-6(,%::ZYO-EE9*\I&8/"M@Y,\=W\H4_SH2JQ?&&^-T*+O5SA\\H.TH
M%^$C.)MY[8EX9$M]B"*MDW[H\@I$_[AB#CG4M=E%M.: 'ZQ?VFV))4+E&#K
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M8X;[0K^5U(%^B)?Z1[_;P7 C/;^M-,%DRV1.3,44WPS<MN$)7F)?''A-$:W
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M=Z$WT;H_],=&]_2REI0OV$\M4.=YYHKF*@I<?35;;+/T/HDNI^R0(QM$SV5
MEQ2-5ZE.*DJ_+,^V.W=N/*7# "-,(/#?4"VMC!J?5;.;#>-W54+4Y'&* +<;
MQJ;]LC01B=E']4^MDXW/VA8UT*9Y3O"8SHB9#N0[!!%,/CIUD87:.J/,V@)
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M7@9&N+*^^>JM2RZU2MP B1O%]H77K"4=N[G^3RY'C[7S#_P5%BR!@R%H.86
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MMPC=NJ"&ZM,25KC5EOD/UN\6WRHMA^<SA$\U3WP233N5.B&-R6HB_/4F6F0
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ML2;JP[I</&%V?8M--E./CLX@?)KGG>!+\<T27Z@MK@:]91H!-DEZ9MV6VSO
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M$M+,-KKQJ+?#5'5@9N(^#\8%4+2'+A6M?U[M>#7K9H1JZ!Q5;;.\#!A7\!-
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MK02I@IUO\ (R&+,>F:UXX@@!'/C=K..<TI^(J5;/&JM?)&P:O9Q^4J!;U&%
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M%7,?2$>H#G"F+5C*C&Z_R\-9^L>"6F9[:X7NX*EF]D51[^@!@"+QB.89)0^
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MPK+L2/.4#V31^.A)YM1OQ58[B*N+0^N^5G*MR$%!?''$>H.CSV4KXE%5C7F
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M''Q2''^B]F&.9M>[D<N0?<Z4@@M&*<;>UU&F,4@A7XB/5<HVT@^.R?G):^$
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M,)X,,OC@O]L4-TBO=Z@WA=N]7YF?96/F#Q/+R>.X2L#<I*[#?V;U"9]"Y0=
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MEM9D'L>VJEW_#$WX\KREN_$!4+M]8:JOFNZX*7=]).6S+4QWXPC#-?O2LDT
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MYWVXO[KA.O5SA3,"X?.+C1XF57.3?+=K=SAK=K;Q-<:P:FUQUG?J% 86D(R
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MM"Y840EV<+(Q<E8X3!K)E;0,XNK%1POY$\O/WDZ^06/"+H'6MSIVC:/0%I<
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M    :6UA9V4P,# R,2YJ<&>LO 547,VV+KH([NX:/&AP".X6-+@FN 1W;21
M< LD0'"GL> NP2&X)8V[NUOWX]_W_/OL?<:][YU[QEL]YNBJKEJS:JZJFO.;
MM68U[#=L%<!1DE.4 ^#@X(#WSQ\ M@!( T@(B$B("$A(B$C(R$@H:#AH:*BH
M: 18V!@XQ 0D),0$1$1DE S49.1T%$1$-&PT=(Q,KUA>D5*SOV9G?LW _(KY
M+R9PR,C(:"AH^&AH^,QD1&3,_]<7K O 18'#?&$-#T<+O,"%@\>%@_4"U
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M(JY:,0-[CM*-^O4$".A+-5$.)>^CHM**6#+E5=36/ TXTCUY[ZN:BC;RA6
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MB<5QUX8' K4NV-@QV/)5OU<Q=%Y-3Q<;.WZ9*'T3.:RLFCV_KRQ+H/O-'9%
M0^)?"=-:JW\;7I3;1>5BXWE-1L*  #0P%PR(+,R! 59J3ZE5VGP6G]*HLXD?
M+]4>=C5V^IX5 #[TGI"!H([T?_>K#4*@O^G%I/A)KOQ_E&I]T<C!O3L#C<O
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M<O?U&XYJ)S+4#XG1[_.3T:VKJ"?FCC*/9FM1+F]L:Z?P!+"A]?;O,$G]9F#
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MG)WHU&7*K1^KQ./5Q-64=A%6&-7NA&Y]/"IFUC*:1!N;!FTR@4'S%C!@4M&
M[Z^M\$$U'1A0.00#\I**A,4/RG@#,,F8\W(^2.[)(A<"__;"+YOI,<Q!?.GK
M';NX@?Z*4K.ARK*/$>,<B]L5)<M6#;2E1N>P58XU ^> 2)F[_'P([Q,+KG0"
MF=PB08,RH9&Y>)52L0=2K0=";EBO Z^>U=L7;^ &)!3& B[4-7Z;16T[&!H\
MO/^43%BC5A?VF4(.?@-#[K5S5@$^!(Q:/Y)Z01]WS'Q&H]=0I1FE)0 ?Y 6
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MRY52O)'0'B+59:)/4@TLR.Z='<:;'(K@&\T0_G:\BB_=^H'>OP<Y-"Z%S[S
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MJ%K9]T*L>94L?@=7MXDXQF1[.40.0#-&A\XT;</C]5Z,Q[C=T3_NOLJ;BGW
M)6ZJTW2DRK_(=[ZBSGRO]R\9@)T@X[GEW451V>?D7X> +'RCN$7_$C%QGWGP
MB@#0D),O*?@K43_N+7Q\8'I-T 0U:RQR3126RY,'4E1^+P;P&$7T/!PL1'I\
M:IT\/L19'N%X",EG^'PG@?S=-X[56[;%-?"3P E=35Y,_%_<RM'1_N+\W!#
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MJ,PRET$(IZ6,BR:HL^*.M%G'3K:E5VX'RLK"9R,ME)($W7!RATM&^9JI"*J
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M$#"-2LEQR*B7"?IJXW[$2GDR>_)0>*:@A)7'[J0^AEV').UA*N4))3\WND5
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MB&38]85BX77ASRPD671EOY)(LH*5#Y[$T;-I17@"H@1\O"1[YEG/BO;_/EO
MLE@?_8O(;Q0U/KW("=Z3 J)V<:=03!OJQBQK?>D0D-"J>LFY=!LDDF QH4K
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MHEFH 9E*C6(]^26+9#;#VZ3HE.VDYQW[RIW_.A)!!+;P/P!02P,$%     @
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M9F&],[(/'K,XY"PBOUG/_T7M/YC]GQ$+^W_%[+^)_0\O!  /#>4?\="( /*
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M\CUMG#]JC"6;CV%2Y-M<5[2C.3776PZ+A$FK)1Z5W348888UK*WAKNA\M,5
M.:2L#J1\#P+?3.X$?XM559%YF(M% ^K!>><T'CCL+UF2< B5-[[/G#(WGEV$
M$Y=I1L73VE<<I'OBVZI6#<TYX"X9B(OM.']G4DA&Q77HTF]-X;&R4D<$IP"1
MKZTF5E[FDAP:>Y>M_XQZ88G&,B)D*O$BN*LR.U%+R9OIO!<'F-K@[M*R;<:
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MD(=9MHVN8'X;2;2EN=1!0=-)C-7)A@-AY*M82=*7IAVI!D7X=-Y;:I7[/>1
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M])XT0"S=0;&@@6D-<7 +$R(@8_$A^GS.2-$"IW,P* >N[EAX.97N7LZ<*_+
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M310SV1Z61GC^T7@;Z^&^1K-3)B'V%C9>DZ>%4)5XY4X$S7(9_&*);*A.R)<
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M[[V9U @MRXSY0/=+I(]C9-0W](!R3 Y]Y##OG=D@EJI^LTO<C5JDD'Q$2,*
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M-8V.C*8W0/,52U>?BBP=^6(K&>] WUSV4R%)%8N2!C6!&P&O-T\*.*>GS0I
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M7M#V-U"__N&ZIDG!?P4C['V4DJPP'-8H33BC[SQJE\KB HPZ7Z'H[R\A\Y^
MA)_/87_4.I5?)8O?68J#P3'FX;07%[;HPZBQEK  FB78.JR[]D0^W,T)$_OV
MH[("K;G4%%$7FO0SHY9 ]SW1T?MGNQ*F^5)]%KW%QS/'U\2%E@:+Y%(OZOZF
M_0GP16Y(4395A!?H^9J^H-[!P&!B%7R&GM" <'/K>E7<.N\N=+:#\'!,OR*.
MAPE*+-CE'+7<6!A9'!Z(^=K#3;&K,IB_.RYQ*FMG&U/ .#0  &Z4TTMA(R=H
MB6@-V4M65Z_XG89PMH618-\:M>-2D)H2(VX$D"UF<6*3&9ZR&[\3IY5E<,Q!
M6TL#'2G^FKE\-=?%;%1Y)W\9.69+I6OZFYO2'EQ0HG"M<;G+DD0D8[E]9E*/
MPK2^H4H7)*B/LT5"VH9'G6ZV]D*3X\[/6$[FX#"S,6'?U(K0J2&&\^4 SO<U
MC _0ANT 7CX^/^)+-JHD+5V)TNIJ'5WP;LQ*=O6D"<[L(%-\?8WS)[3NP9=H
M$-#BGDT4))B%.M'!RJI$MX-IP_*U-5!2HAJ[)WAFY(C><)&O>\\PF2<L5'/A
MN/(NFHT@R..PEV8) "[!$P%\+OE6'<+!"XM>L)_F6(7W($HWTTS. PNK\AYU
MM572K  K?>#L*IAC</"X9T(C-5U[6G-H6_1%&8B/;?$AP ^*N*NRZLM;U3AA
M.AEY,950M>R7Y<3F\.;K B>)2A//!29H/&.<OQTE1 Z'%&8\^#W4:;)<GWZ*
MD]?TY#-IT(S4J(2X,OH&0XC!1UZ$N2/#!)OYI#TVI#1I4 R%!>- /B[L#D%%
M"AJ:3?EQ3\0"4^F0G-/.MWPV"T/%;.L"  WA11R450X0DINPBQW&WAZ9DWEA
M86M"XKDY6TL_^B][11PP6;0:K\UVIZX(M%.E#?TZN\V]%>%^.SWZNXGDYNS#
MXS66<QC05S]I$J7T/6%B $7BMUXMJ-J.@J(%<GM1_M_< *)&I",G)\.MK)4?
M*DX_P)\'=B("F[Z4K/M>/*4(A\H@4S=)8?IAR&^XR;6T/C  YL,O /"C/PVL
M=I+QNLPKNL^.$T9K.\\A-7626'61THCIST P]%8*E*Y;FC15.UT<<GZ-0)EB
MJ AFV@YVW,:CB+,Q/.!I+_PNP/!:OK)ZK)29&?_75YW8K0A#U]Y2SMYN?('?
M3)0X;9_6 V%?^K% JT'U;4Z]WKKH,L%TKSR5-4U7"=:*T382/#3)8K7P:LD3
MN'<"A5^M>:L(WR056O%&:*>@4@H:']B5E$ZI2T;R&^1>\\Z\B-3;(=]08&;_
M[,'2J[(8J$)'RVS%1Z&-26],3Z]J,DQ3*<ER8M&9($@WY5IL<4)4]LW-HM$B
M2!J@0B+AQL.E("3Q/N+PDQD5'Z=I;:W'6%CL;LCEC^O%O:"Y*">Y+CWNY]=Q
MOCU,]A^7+*"D'-AOY)X%,W>6<6[F^]=C32U[LMN0(*MTMEHGN5=$4.7V\?F/
MC4?%APIU>)$4E%D6YO,4[%W.^O?6J.?AY[R=\XY/_NA/-6A!T#2HWQKUR]D
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M[>P]<7#%#M1GQ1%O!X],UGV TH)!S60Y N<>"B@1QWUFG]Z75E(S$]5&G"0
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M8I&O+<5L$J,UKQJP1;SF3IA4NKZ*KJN[6T>^)P^;O&' ,#@8V?7*V>>YR+E
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M_+C(M[_TZOUZ])U^Z11NXP/A/3#CLMNY752W9V+$J#@3.?B_3;]R[\&ZT_"
MS/F%G-G'E?&%;<VWXJ@^@,9<1T#@J= IOB[@?188X2V_D"L=K&WTGC28B].9
MXKTR%#1RZ_6KF*^+;V/_/KKF=4T\P_<8XL0YFZ,CD/I<.?M=P/W!O"458YR&
M,S?\N]'=;IQ2GAV4)H@$AU*,2O^K 3CZ9-2S3B!@5\KTYDUA2=5404,ZQJ=T
M K$_%,$BSN>B\4^F6T%HR[9>HIAMI 7*G"V9C.466$4+#!S(X*;![?8 <GLJ
MW*EWJQ9?R=8.V?"WDQ +_><V1.'N,GM$"!MG/$@_ZZ%!?9 ']Q[\'DTN'5U[
M^-6\!XG]M*=3XRB7NF=ZR;]^3XOEV8@#2_EMSP=35YEK77QXG>]4;H@]LP68
M,7TWQ^[48X6'90;R]E!*MG.H"E)B^/O!8W>RN:46FN$,K%V$.@M8+1#P78\!
M)B] MU^ASP$0<5]%%4<E\UFLSG$Y)/8\T(./[TB6-]X]S\E<N"G#NRJKI'LC
M&(]_P%5I*C[(-NB+Y?E"Q*F#8_7U'99^.BYU*A]V2O_DN[.02S3.Y>F:H(8G
M%JI@W3OGM@6.'MB(.IVGI@)&0IG>UR5'8U^YW@KFS;]H_+IG-N(!TKKTX>5H
MTY'WX0P%NW417R2>J=@$BDQ7W^BXSQ#/XB7+#$91!828X&\7G53&%_-5$)6O
M$NPW-;9-,E?:PTW;N*Q(DJ%MXN-JJ30CN?J^/XN=C_L9]<0T@RIA<RGU^Y(+
M2C,;N'..7(?R]S@6,WG"T?J-^052#V$N>,FFL-X+4QH9@?-[.=8+<!S;OWV.
MV,[@+SEM#H4ZB!.UZEHE)O&-^OT)'BWL(M;>%7F>2_?8<GIGJ*M/P*7.74\F
M39MI#=0K?RL1-2P&K+C-G[&<D%;J,;*Y(C1U-2WKEW_<A\N!T70XV3L']ZNY
M8$H@_#-4?-&"T&2_?G+,P/-:E)PT(=1<B+.S@!8D;(N1V556:\@**<RU+?$$
MBV7/H+I1 ^RBP46DC.8=)HG'TZ()72Q*J)-F0L+G$SH%727JW\YK-58H-K2I
M8KVEQF"%2Q4MI3U4!'3*?.?.IZ_]CFYC!YE-?(9A0Y<ULJS.R[\.;8*WWI%G
MX\H4J(%C.?!)<N/E@.WE+9)DA%+JE!TO-C9W"1J:>R@%CPP9!DP"^D*AK,_V
M7Y8Y;%G4C>RNY7>Q"+2.NX@0WC=L ?=]:A<0:-[OEKJ/0:\,:/OXI[UL_N<:
MYB8)F$_JT%C_ =AXVSQ3C_PA[HY,I\U,^%99H4R=0I-B&S3Y&L8_+@3D:=Y4
MV\+6L)53;8I.90H7'YU<"7C?X1</QG)>OO][C%[<;J%WM].>FB/TX!Y^EOE'
MI5.G8SV-=E\3D2A2"=U<9<TND.3\MCB7>3S'W,8G,(YDQX)FU>]2Y)Q%_.)0
MN9)CO]<(U,&VM/Y[G&D[A(2GN9%(BX?6<9(SY$N/Y_:*63#7S$"&?*^ES)G>
M"LDGC$_.2G/";B/^^>"?V=0Y\5ROH;WUPKAQ/0<%KH*#)16PSX=(6>1VHNL%
MH3RO:8VFNT[T8/JD(.F0YDCE7"'EY]\5#PI+S/A0<2>W:FHQ]:W>H0,6)_6,
MK6IK-+))L3+)97"[ ?"<Y_U^J?\CZC/T6S>1J'_PNZ>H@4VM0T&+*#.$54W5
MH>1=_"%'V2>WC*1@_CCU?BT!IR\%TZ>J-<3-*85:0U?LB1C&:LW\)=07S\DH
MG$-"O%-,6/<<9U_>Q(]K5U,Y#/7[1J_-<MFABL_[^65:#RLMKX3WX"U#/8/:
MP9P'.H2-:9O5*'?61&/LM'7A/?#L[XBS=JP@Q<EW+F+OH6"NKZ$VG_2;IKEL
M8*QEUD(:3XWM+Q2A%^V?*YT(&MMXWR?5]"=&7!&+L92Y<D*%]DD6*^Q> $QO
M-3]/Y'SA@VA1D371FEB%7':F]&><'HN<^8+YT_IR^?)JT9Y4CE],6F,>_(QM
M/K%:;.^=1F%@A?:)P72PXE<##YJE*Q>K7 QO4S^0/A2C8$M)!5XPB:03'*D9
M>F\K1#B\MS1:5U?F'3/_T1T9;JG&.8+1] "9B\1MW:2\_4:JE'JHE3"^/7CE
ME8Z1YB$28M[U6^S#@%SJ8W\@D:+ V;&>^=JWF1&,RB95*O:<MG?;(VK*D[=[
MP:Q!W5TU\HWZY8PC?BK1SWYD?*A0FT^@8"\4CR=Z\[N8[XI(0^^:8%*^<=7@
MJ(8-3KBMPW)GXT7Y$V,SWAJR:](D1M?4+1,P\$;0$J/#>8BL:/V,B(QHZ.+]
MY5Z"4Z$_3"'OW+0Z+B:T<14JEOO._*(C]4J:-,V[8HPP>_(\AER5B"3P",_
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M;<X1T-0JKH@M_!?R>,"=RG<;L<@VP]NK;T3(GGON,K& G%#:S-65%^1V$(R
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MVK]2'5EY5OB/@C;9W@'[Q55V4Q"$ FLW.531@]6GQFN6AVS/?^1D"=/^^K\
MQU':AQ'_97@T2O>_7[?ZMQ7[?3MEIB%8JE*]WT @#F(3%6A6R.#.H(GKUXQ
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MBG7*?YH5&V@M+'6;^O">4X'6^1$M=L1$OP/Z3=\&B!G^%GJ\O1#)D!C__:!
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MDS*M[= XTB5Z 5>?J+(\/_6JW<ZB(=36_XZ40.^DY>F+DG$Z_Z[8ZS]C <^
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M+F"#%M]7JN^_[)I$57"*[4L!G5]\*T9N59O;_!1\ TP[(8\NG:IN@(-[C3>
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M!(4I!G>FYLZD1_.5L.LBAZ+6EE1>-WGYOR[H(7JRXDR2?V_<GJ7& >1ZY$8
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M'+N'%-]Z-P:3-<"<-JSNM!Y2FZ!,_8::[1#F9N>GCE(Y#7V.94H4*U;TJ_C
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M\H=^1,N&)>])($MPV:S.E8N=J>N^=T\?V+ZN!+1SY91S?^5BK^4&SVWNG^>
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MPMWFP!*S"9UI3O.E Z\2X+VO1,7WDDR[+Q-=]O5'"W:M+C$CAR=,<D83.MX
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M+ABG4!,[E@;,2XH.H'@2&*-S^_K6W66DP>Y-EL5AT0-."6:W<>#TT4ZYTGA
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M/%,EAR(4N$ZD<3?^ >3+%7]=DE7MU+3UNH46S;S94.<(D$S6=N;X8+ZBVMK
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M: N\\(=WFZ*8)T_ 7 I)*\+<>-Q7L8^>FSFHEJ_(AAC^WSXKV7N^DW5 <%N
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M Y3.,,9U'I#C_U+Q]135>XIJ?(F!R_.2)?&!\4FF;7_LYQ.U?TXM@P- .G"
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M-AT=9Y&@0<,ZS&@L0F-P^32N;^EJA.,2(RGG/=WL*F_CHZ3L[5:P"4T3D3S
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M/<H5&BR Q.ND91X4.&V*8Y>I+WP]5\MVF.GK9-<9["3")Y08C8QKL(22RAU
M(C%,]MU=FZBSU?YQ](5REA9(BU7#/B484LZ]#W5:/LP>9O$;S>X*O!P#[U7"
MV[4TK03D]Q7ICW!B?^29C$:&@S@174@&Z)EZL\_S^B\!JFD-&F$8S$6<-5IW
M><"6BP[KZS=M;HO,)W3Q8;FY.[94+[;\2%TL&'XATC=NK3%\%24'4B)#CXT2
MK'ALWK6*E!O.O7U&(E3NLW[6\4H42$/!Q#3HE+)6IJJ8Z]L(H@61H9"O%AZV
MX3+YCE[\)IACU=@B[@#VLM"\6]SXX>\KL/RY6-X5X  -O\ L-NF3$S0)4-T5
M8\',>S4U.=H^WO;Q(4?&"24F+K):[7YO_51\T"JS>W])#]&WQKAQ3PX;%_VF
M-['V,W-N:BFH-[K<AW_MR7AP&:L:G-R10>:H'HJ,W\KNYI<0'X3<^F]O7?+1
M7@7# 593MB[$K;'4U?3IZNLA\DPLFP-2 \RCZB-.BY'HV0%=/!F\Y0Z\2?'J
M2.YK-KW]M9\.TN7WO/F.3RZHL'/+\HU*4O X])T[]0S<*.-Z]V[E1BY0JKAD
M^&?)A<'/:<Y%)YCR6 B8]0Q_'-=+[V[+F@D@D3L9A:V\P9AUCVF=C=OGFL=4
M(V1+RY^W0/*A *4>-P=O-8VOPJ)'Y9)6J7=(7U3-@U?.<TL>X(! %Z$B,.>I
M3K5_="Y'^F=,RRUF1ZBS.>:9$$URI/= VL\SU<F<P72AZ9);&CD[FKC%K,-J
M>Q!WP9%"<K*695H 8QZ.GV(VQUP!E]K<7(\#<Q=NO.LVLB (^)H_BIA\+:IK
M2[&GL4WB&TF4_T_6?7O\%RFCG 2T;U\%^&,C4<E?'LULM9$JYO0W\9VDMO-Z
M8B5-5W&1>YQ=W,AH=<$<(63"4BL0?/<Z1<E60=,JE2;O+;M8I:4EM'MNW[/B
M,V4UIN 2DL+06L.NX1T73&J7XX>FW*+ONEB_E?,+9[%^7E9'=NZ.OM.G%EXF
M-7'W?SC7.1_B(_RJA(]>OI)*O,N'D!/3XR=@ 0>@SZPR:R0EJ$<#I9,OZRE<
M2BX&L[9Z:61Y4[,8TEO+E#[#JL-YXUK?GI&_VE&9F^T"Y4&_=NJT,.-')-Y-
MB8$+R ;DK+7$(WL"7<^[&KWX&Q0_B!!?6'PCE8<I.UA*%EM5PP$FWP[&NTS)
M8\4617-+KHV ,-G>?MTTX?*8>ZLWN->A[ ^"DXOS>K0^:ODD6W<S%WG7(A'3
M&WZT+*R)+'XM%P1KJK%%&O)>%!<?LR1V3*J.O[I?/&";_GQ_5>YRU^\6<N?N
M3'"B%&A)?4+H&UV@%7**^Q2>N#L8@]Y8C5%T;UE&L+@%F+%YW*?B/BK3V?**
M;_6:M!V[\ZPO/=LL3[L)RQ^ECK+Y#DX:732-QAR(QA!#39>_4,9;DGH*/U3J
M:NK#>_E73"Z_H6AQA:.5$5^C.KD*RPD3"7;DC-M8CU&W\*58O)@Y0^OJ>]RY
M*.6:$#DM%S:R,,8R3I9CQUV6O,NRN[IR[71:+-SSX3O>#'2Y--37AE77'E'*
MT>R%QY7E6?%ZYA2["8+;W5Z*+<33=XO._,3"_EU-R:2,)P<L[7,0YIA;Z>LD
M? L)C*N/6:P0YG$K,O2&C"<;C*V51XM0F=5UO?FQV;5YO#6V8_1;FW\KQZ/8
MY)$35\4##OCV' X8@2+LQ/X=<!!L&$.OJ%!@%9P"$1EP@*5VX52<S]C2J;1+
M\]T3#C+0 =?/*SW3!U.BZYQ-;LYSU500KZH+[O=VEJ9#MW1.>"%;7R"W!-XM
MQLH^[<:GQ"=\#_9/&=B[G]@EEG]_+G#2'*9]\N:KMXA)B5S!F^ <.;,Z!8+/
MI@YA&2%.(3G'U2ICZJL8T]>*,-5,.=-19<Q=N0H!O^4"'P^2TN95#5$B#"#?
MU])2MM)Q@BH0\ >=V >78K$@OH2KIE=UA%-UC8/?<(FGK9CK[P>G^1=N)A\7
MT<GCQR<^;:X<L&6LBE7EB0J/E,,!HE1W F5I+-N0.>5'F0$RJK,5.* RZ6;U
M%R=NK)JJ.&D3%2N/@A/^*AJB?P6?N)>V]BJ%L6K-&>MAOXJMF'!A@\+U%!I)
M%TV)*TLQ<#;H:Z313=32^YIPB=YTJ\'L];CX+CI/MZ2X4K.%Z85MSQ1Y,FSJ
M9Q5OF"4HI%QG">(ZXW+WL(O9^W1*JGXR!$<%(WE."'#O892A\F87. Y9$7)'
MN"Y3U5-)%5/(M+LEZ)&[X@UV(JV_,;CUT9Q+Z%C-HF,PPT.3FQIA2\OC/(+U
M'!T9&OFMQH9/%/-XN=171I[J)RC;@Z*\J?0TJ%*=!J.3-X2V%!5U4R^+LMP=
MX0!E#V$A!X?+FLXMN>!>&9BCX&'DK=2H)'=Y0Z#DR_2VM*[%&-GQO+$WA#KV
M]M*:M2]$,)576;9=%&K??*)4E_6Q_#:XE'&>0WQ:Q,6LDD('6B!>V)TH&:_:
M^&#=!AQ$6"VR$;@L67IA"0?,Q?0!<5B<-J!1%AF_>_"SS\<7;>@*QJTR/829
M\MRK)B5L\FES9V9?!_CR.VR#AG)JHF7,HWZDANLFKI=?T$Y,-=57P9)^R^\A
MD@O+Y%%-%D)1>Q>?T]QH02U[,VWIG3-786:V4!7+_/+\?8>DQ6.SKTU3;&M1
M;M2I^]EK_,4/N OL+D+NAFY%-<A.H9.;:2/7D Y'C.:%;%N9;K>/E.DYDNDL
MPZT-R=]#W822VY"+Z$:C-KCNN_+1A3[7I!,MY6:(LDU;,_"CGI<(7.R!^C)
M(->J$=D./0]MYD)PT==FJ:!#C1 [01Z3*HG?=I[GE *:%0X5,JG^+;UOTKQ"
M$Y__JO]V6?1('$)RX:ZVHCOFZEJFKAN"D0;+69F>@>438(E:QZ0XZ PR*R<)
M4J8JY'-[@J&.,G2_JR-9&>WQR1&,QNXXZJJJ5Y$--JB_XH4B3C:\ZY#_T3[2
MW9' K%U=6V;_D)@B6E+FNRI>WA&T[75!,&&<E",*9*NG1$$VQG':L/NV=*IR
M+P,'&)_" =O2M2$[__<(:4 TDDF*-U8%92CX@N1\9U:60EH;Q )Y6; >;:-D
M<3KSLEDV O# @DLTNWQ+>9%%.QG&:D?:C4#C:7'6DL=<L;&Q[3J:/R^2[(DU
M>I ;OZ_7U6:Z3BGH4K+TDEIR98__D.LR<R-(YK55W#K:Q\LIWL&[>3M69<K6
M_+WJ4Z/N7 M6#9/C,NDO%!^X"Q6WJ]@=PRG94V'F\N68'=:SBWKSK*K&,C#U
ML).(Q <0WG7!G2-G<YC'+I^; -.$O1>I8%Q)>4IC0+W$XY2JKO5;#QYN=:CN
MLTR3FIAP&$Q*(<KQ:'Q0Z7#;EGD@-(CLZS3 7EKB2//W(/,^KS)=\GP9"PG@
M3EO(U3QV>6YX:F)Q3:(A7D1P5U9M]R4M!^^HQJDV#<PI^YPB4(%U2(BYN_U@
M&6_VVPK'&L.KD 6UV,PM@DSJ[)BX$8/S[)Q/<B&_HV3TJO-^ CU(1 ISY,A+
M2'IQ,5T^[G;&:0H497^( 4FJK?7I)"*>;?EI]+]A6+0J'NQWE!/3$]]L%#:W
M>*'11,;>WDF>E8V@XS?(#.(-,T=1BD//W6!U[] IQTFPX]LS2'R_X Y5GZ[F
M"/GLW83]R5AY/N*ZS9OJ9NVO$EB[RO(7XBZ!LOS#(#&3&#C  ')9XJD[L:&H
M$;UKH>RTGB2O)VDL,#S-M.T0SC7 F9)'48"P*PCY!@NC:G&=W)ZL"T_# "?^
M0BXAONCN<-++C0&#LQ5+,&#-(0+/A/(6/X1N!!NH+H>Y]BE[)2N:DYB/V6IC
M47=>T&2@CLW6103?:@67N"?M28?HP_SO_3!;FQ;*_1*TC-;70K;B9!2K)ML%
M^LRUCD6C5C$566&&'+I]BS*F=&%?+6,=92A06%C6Z!8"I]H5=<\S*2<,I(E?
M/.M]NU1JM5'VS:Z!KGCW4I0R;;.WK]\49^"J$XL/9WJU1G_GQ12G['[_?L>/
M"$?0:!SA=N%I?#&,YSC;ZEJ_?:J)<IRF%C;#7&3[MA]1^K&=](@Z?67J6V@U
M:;05J5:1LWO0B,0W4Y&;;2XCI<R<L%D2@JE7!=VOSDOE5.LWW\.F%R:%.7A3
M[5R$8]H_!QDS/1?N.R]U(N897005%>S@Z!KFAULF5B@.">P^+[4.]SS9TQK=
M5A0%>;6M1&79CY1K43S?,THXKEAH^%R7$&CGW?RZQ+0^R!'E.CO4U&D;S#)0
M,D%H>;]_XW%3/D4PYOY=KOE8J_IYD(<)9VN"UEG&7"VQ*1C<8<'"]SGI;5E9
MF7DXBT+]-ST6%9-P>C%6GQJJR0*\O0"M[R(7[=&],TGO=)/OVB=TB5Y(E'Y3
MC?V8-PR65@VW/%)"%(&@]_WLZL3: )AN/6MT4AQ['2!7%6R5G?GFK:_/C<B9
M$;@ F#DG-W:4)8ZK&B340E>Y8TB^2%^AR#LM/7CV_++B/"^XO9!+W:%V8_-E
M@1Z3>++!1":I3O4+P@V)A7!,>T4RYLKZ3_7D%R7&>)P?V$JU'MC-XAR["R+>
M4!0]CYXNK?X6!JJ5<<I""];XB!AS>V:4GCG;09CZD17B?/BV?T%_L:$[=T)-
M2<E3.\ORN#>>E_W&W=^_383IT_R.<JJN?FVX!<0B8V*[POI$-)3NLV[9BFI
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M=I2I@.+G:[M%'GZT;9B8OQ2=^&IH2T4Y *&/D_E03[$Q3P<?^W4+F$">H6*
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M?6.CJD%[A.?N[L:4O20,+<RJ'RZ:*D><8:D+&4JLQ 31=#%1^=BEI=4%I>G
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MXR8@"@H*RHN4#)24#(+LS.R"_^.#\ F@NPBBO=!. KH.7* #D="!"-T -P"
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M%+IJ6G:_^Y&;5E=13F1-VK]M2SAVB-TR+U6T/@6HQ$\(,Y];- OE\S(VLB0
ME1::W^ "Q3Q>%;E=*3292]]%..4U&JZ8][YDO)JD^"-CI35JF;_8A2+6<4MR
M@7Y#3NW-9,8S%3T*Y(<,K^6TI\U#P48P^G46Y ^?G<)RU16_O84+;'HY/]VS
M:#6@+=H:'5XIYH!@UJC^A1$UF" (_G?M[Z'YWST(_DL/\H]7"4#I:"&2$OOD
MH\O7(BJL[8-C2^.CIXCI1ZM$BFC1P47!7(L>U)]XQ/2E.1,G&5>F^2G_!X$Y
ML!:P$L!5O\W\7'%G91<_X2%;"<*N=G]IY\!QR=[>-O8]W5P?520 KH"SCDO
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M2$>V]%6(*7.%CW<=ZW@7GMWHN$( UAX0TY(D^4R0 +QN0'.?7XQ'+KXD "&
M!T1AS.E0CY(H1^#-UTB^[.0_2HM<#:!8GZQ'TA[,I*I^;B8W<7S9)[.Z5Y;N
MVZ.DE*@R;KC\":O.8*'!V;,F_ZCX2Z^\,7<7-ST"/?5)[K:<5W!.<YUI%6/O
MELA2XJ"847]34\P[[][D:CV5.7G7'HT.S]8^//U"./+@6C=X^S>R,PZG'7"-
M  Q'<.,I1'&/63,R5;W?0H1P@6/=U3AV";4G99V'NB,9>EH'X:S505VT<>_M
M9(C=W3_KLO\T0VDM ,L=:0A9!U_AG9#XKMV5M*>8F8#9\.;;'S>QQ60^;I^H
M]2V6Y&BC7XQX$:9U&NA[.N$2SOXN/:.<T0M"U31U2:<3+?.N\]1-_XQC3,1Q
MNZZTV-UVQ''7^6P&+HI6[>,;ILC/ZAP=%=6]:4_"V^,S#N$>WI%DR\FP#7^F
M3KGS7#%4Z-O!;B3[6P) !>TV7%]K3CON_8H:SZ"+LO;REY_Z^%#Z01>0=M5N
MLE6+]L)FWU+ZQ&M7=:YR\@I4-%W2I[<4_:1'WP%3,(."JG7^_'I*03I1#EUR
M-'&=[KJJ]]ZT0UU@-!G/[-P"SYHU@_XP1W9:$=N=XJLN[\U^/!,C?K@(E Q7
M:5+7@=7Y%5)>&0XYXFATQ_(_RO-S%-YP?3!/@97*S9]%Q&YT7FQ50Y4X:!:&
M?:W.^J2S,!FH2+(T%"7J$65E/-8-<W$J@TESV[7N08\#LE\=5+@MYQ_6?4\.
M)671[U>K(@G8GJCYLFVB0+%XFCHGWMW )5:C#>^@L_1N8/[8KY>4FS5G">U>
M"%/BP(2=\;*<,)55$:LT_%-JQG/7(']JP)^RMO8?A.\%EQ@NB@!<G/SH"%[B
MG'09G.NT,&VX=@;O*)J9*E1T5>9Z2 #87HO)#RSNTN?92XM+=E JU7U&C!VE
MC:Y@SG\JL=6VAAG;SC F9J$R\J;:$*&[NJU!F_=3]>L;6EM?Y9H.!)Y%VS'M
M.:=BA/0Q0Q$<C[#O>LJX6,9F!V[O3(N+Z#+2&BE?/0[R>RP=M;VC %ZFEC:8
M<C]ZWA11EB@^HZ''Y\NM=107BK\VC.>"54_;9U!BM24*W6L&7/;[X79';E,*
MU)XI,84A6;$SAK ,3:8I&NQJ-''(&>V]@Q[ 6QG7?_D5T3VO"'4>NZW##686
M_IW!RZ\X^E:*G.*Z1-15=@T3UT#<@QER/OHD(8PT;__W>JU9:\/9=M.^!V ]
MS(G<WPT/$)LXH+V"\]4;<__EJ[W9N-C8^O:LB'7Y\H8]R;!])5LK+KW,#)ZX
MH.?BX"?)>8:RC[8;FH_4W?-Y$C]:5-D#O;)^%'M2UQ:=X" 5Y5'P^\DKKG4I
M,B0D:R50<;25H0N\Y\G%2P ^OD1>LT*&!? ,%,+D3G$;V@C^$7[3'1'AMV^?
M?+JBO#G?NK^4'"ZQP!@PBCHJS7EH5YVHIU_QJ$*#1($=.%'ZKZ4&M3572VC$
M(91]QJ&<.\Q=6.ZDZ\EU6(66U,XR(ZBN# %5F7S.X("R2M_ZY$0M81W.E38Q
M)Z]=->9$/]DY>E%X^)?- X V_X6-)2YUH3,%C*=@[QM6\%T^]SYD'#N[F9]4
MU2@U&M;*N\))S)3.+++.:%HM\WV][=V(5F2/0)Y/YL&854>8LZ1\.C^;9(MI
MN>B@7_]3_XWV]XIK)(:1<(;8F_<&!4'V?^B- G&NB9\GJWU0VK7VV\E=R4GF
M<4=OW2Y*E5F*7[7AFAVF*)<4BWOZB6%WM+4++=KKQ/O)IY7=LZYP@_HV]I(-
M8MA)=CO3?#5 P10>((AS+42$==$[2$D/;R=O5?4_SI!>)J59ELVBF5I6G&^Q
MQ>P;-V,&'KA<B_Y@,!7PE">TKUVVPN[(LFWJD#M,_WOY;^W"XKTR)A,J?88D
ML"&BG !0K$DK<>.4CU+ROTV9#%G?;J#7G4EUNR:S^G'=&$_YBKMSB-8OVZ1?
M%G#_'2M(TM(C+.TZ!#[WD6;X/7P!G93:DL*8MCA,4O3O!!=[TIMABD0_C1:L
M<1RZ!;Y-"QDI<ZRX?D6X(*O;Q>_P0G-EV+'<^4KZRWG^EM&="N;[1>[[[T@:
M77P6 ^[@''8?3Q1.2D2XIW9',@4]:WT+<OSZ^15%547-$G^\ETWAPH;T,?-+
MS>)O_'1F]6LYGTB DY-ABJRBSD7W_#R]9GG#84 -)G6RKZT*2+NT@5SGTXE-
MV\#5HR%+DR0_Y!]/7SK.0[/P'AL3OZ"U%&?!9\($P+H(G [X5/K\93E"7_>6
M++]&#HSO2576++'G4J8=JN/'XI4F/MMS,Y]Q5B+>K/EX%E4B&TM"64UX/RIN
M=A( F&C4R7E<1*6"<([V$8?]FTNV$+Z7ZLJ^E,!)NVSNN\NJU^6"HTN?&7T>
M]"_]63E-88"5' JO1'_8>3X<K9KG'7&KVO.SY&'*%3U+[.?#+(H_=*#)(/0J
M7MX!<AGK.B)Q688M2_^87E>\1?'"U$@=%KGM6KIV#+XB7+9=!A[;I@N84')=
M(1EQ/;<G&=3"-?1"Q!O&%X-V=+3UT[1!:KQ7B5I1D<P_#,NB5H=-[K+(I)W=
ME'KC\**++3W%("3>)'UVJL?<8S7<63)5T_T:DG'+K^7:1;"@@K5#;_(2D@4^
M?Z-MU.EI2ZH)1\J*U-O@/LO][X"/W6=?)X:E;\D9XECF.M+>'VWY;>FISMX6
MV<NC[;DX%RR%&NY57MU*^!:5G>/'+UV]_IO+4) ?/58OZDE[\E=V1^/N$&GD
MK?[%Q2("P)YJT(HU^70.\1?2:PUQJ1CA3[$/_2GT@W93F9.V9R$:(O$1E^[K
M5#@W8.M4./2KQY$E MCQ=X-:(50,&B=:10N@\WV_+"V5$S32I:JN3GWF$L&E
M%N$R>\P]V[RMGS5X9LO0_7RH[K8)]46HZ_N;=+%;G0V'<Z&G^>P#>V=C.P.E
M>OYAU?S#B/P3V2KI@A888T?#KDNQP!"IX(CDJJ.*H$A@?P5GE?\%#?.0K:C(
MJTYXWH0?M#F-%Z<2/W_AD)[92<TO9+'FO+M;T3WBS?Q=B JEWO+BTH'D>JT^
MA< 2+9D9 JG7&H0VD]3<M:6?'?+,CLZCHHI- T',EC@0PDB'S"M=<*H7#R1^
M=C[(5E[T9-H]^T=K1?===41#>VBG"IWK?D(YZMKTNHQ@#<.((IB4E]N-$HOS
M-"73#*C QUUESKA(!=]\A%<WBCG,#]<RD5;F=[YP/Z P\I=H^^T?TW[V#1@X
M:_O@B)-WS==9KJC?)ISHN%=>> $L67U5.>)7_KBEZ/3L?997_2AQ'!;B5H13
M^RH:\P+GN=Q=RE]\C;X][^DO$;$W;3Y896XC^WG940\7=H=YUMHWZ2HZCV'>
MK+(;%&-Q@TV5P=OUN[T[6Q<JJGCI?0!&DTQ5#-@4$YOKCVX3[6EP@PLF:-RW
MV(&]CVM6\_Y2J81[$L"/B-SO]GF</WOB!I5O^S:F\IJ!;O\FN)-8K+%8>-]7
M)6;HAA+=?MVEG0]E.;X>PK\:U&QBWY>YA&0R=-0H4?.7+@LZ9R=K"SGOWKHR
M!62^2P8C3J;2OV-FT,F!K==\"^W-PV:V7=+*DNJCFMJM0V4590[*H SV 3>)
MFE>) \U?Z%N 6G>[+95$?U_\A9Y*_)=/Q.P_[G.)UEZ2YZ85";NEZ1JP[HE;
M/><H/B, ^3X$(*PNRLE-O7I\ZZJFDQ=]_VNN;I,ASXS+^*\8YV!7UV4+EC&1
MUR_,M=V>5M]9&"'A<DV;&E9B&\M4'[E=]CSAYK,0J0_7HZ]G9G$*DD"(_$<N
M,XB,K[ALAG/)VR  ]!*5K+JYVU(&3&(A:'4\,_AARJX%SR_7WU.#2K+<=-:X
M:9NL=?/M<1^1@DYW6X-P&VY_MSB7R4 IO"*\_8+<493MLJQ(3NM8@47_6:/7
M)2.%"G^9BE5S7/J2$XGZZ"'UTQ5M;2LMQ2.T1IQ0[*([NMC/$&=MN_RE]I)S
MVNT4I\[6V*X/-CL%34.Q8P@6*"8;LY*/II;6:PMY5?_TI;70YZN^KLKL\W+8
M\92P3G^];B4RC4/!"]5:-]0,;7CA=T^6);^?7<)21!Z*!DL;H<S,5873=+C>
MF]+S"R7,A*VK1[3"LQ&^BRTS" K#44FRVH93\>ZAH VUJT4[WM\?GZ<'7$-U
M87Z9=$O[Z";;/)U_>'G%R8OMRW-N(V66=C(_32PR3K0.)MDBI.$^)TO9?STZ
M#*868/#;N"]$2=9>B0_[C(MK[&#[H0/5-H=+-)#JDSBD-8TYCO(#/6GP;&>?
ME'B=L32_V)O@M,^GD*!);/[ %_UTCH;BFH>F6T62CJ>^&2X=G]67='B'<7>K
M(=F!26S]N^4#W+)=[KH</I<YK/A.,U78KQC&LZ^(RKPG.D6!52]+&UPW_+_[
M+2V[XT)8^K2%&70FG8VTQDTM57FBZ1AYSC9H9 XJ\ZX91I:85E&"_M@9P??O
M]N\459+&P.^\1AM&7SFYZFHX[*-/,9 B7 V/R\,9^\KWP.&_ZVCI/NB'O,A[
M][LE2-ZDX(PZ9'2AFV'&7 ^>/130IQ>JK\;;QT<R([F.%NQ*WAL7?_&-)?%0
MHIB]-TNMA-$=>$()O%/:%KY^/G_SSYU%?[=@^L>NM78P >@+^^MZ:A;MXUU5
MQM@7></ "_CJ$*JESZ<CU!TNS*U%SC0>__I8V1VZ$U?N$C"6(3*E(+#XO@"#
M7\M8@8I8Y%_MKMOG[.AI.=VEF,,A>SP--JLTDQH:&UWFE?L:)4!]"%&C^I'6
MQP4.)GC7H$G;#]T"-#\4A28#A/ST,-#(LWNV1;14BMWAH"2U1-@;I#NZ5=2N
MW_1.+ZSDKKK-YKHRM[[?0^ROGT3Q[#X0!\!6-4?YG)+I+>[,L9P*7(TK=P=7
MTX8KJ)9..TR>=#>PF+N3/63XGABJJ"Q0[C>PM$L/#^ <V9UZV$0W#:E,E!#Q
M(N?*UMNOV/R,Y&I57Q*E0CXS0YEI5C6H\JK'!*_)#5/,?0H>'IUZBQ\B '05
M[=<1#NA5@R 9%R?;O9]BT4+/VTSU01!;K-#B5)B"?XE*T<937]]:JS@^"JZG
MIU,%(\I7@Q&&8ZH87U@&9UTH1ZFO<>S(UZ"EJBFE]D/L4%<,10_*J\?"M[3?
MY79>;=H TD/V5F1@>L_[0Z:CJ>C(PM#=%=_4J&>AO$+:H*[ UD63+I_C[B%&
MQ""\[9+'Y0]ENWG3I,*!6VZ?GLI*@-:1+*VV7KZ8)5[,\[SGM2QC_DWEJ7=O
M)>XEQM[/-+?;.E^LP;)T'4<MI]ZLJ#U];F#K<?/ZPV-]O<>5UY@A8CC[SA.X
M18Q8Q:LPQR]-MERON>H.7+:JT#,$@*FOB+_8]\6^&4#J\,KZEL\3F@/0NL"2
M:%"&+YN%<CWU,^#UJUB*RLIEJUG7V_;TDA=+I(H, LDT58%_N6,\>L04?WMR
MNU4V:W8C>>;;%4"K</ZI+L#U<YB\7<TU _[9[[^6;43WF-;;:;#YF>%;.W/;
MJV,5MW]><B6;OCB2<)?&YTDPY/'2P(#!J1$NTLB#XBWJY=)Q("U)=A9MUEH)
M%)6"))9P<P*P\(LH2O2V=<!X9#EREUAV8P#S-WY=9[*5M.<Y"IQ+;9!-K?$S
M:,7\CYG?47:D=Q8KCL"^&>G5\&F+1V.G4'.[PKN5N*D$OV<X5XKN=*VO=MAG
M4E+UFN&+9*8N.W/V).'8^F LS5 /G@UZ^<?\AIQZZ/*#(+0Z6S/%+O/A<J2.
M*IZ;-K;^Q#D[_[>7$4]38[-X_5JETM'LZH^X<M_=$"Y.[JXD.?^=.B=_5_B5
MB,*[@G>?>&Q:*E5ADI=ZJTJ_E\R1G3H.K4C$SV_/SK<A)$"?$&#T49G2342D
ME>X@;LVM=\"6.TE#+2YD^;RD'Z>"U24 :HE]+.;G[SKOR7_QHKO4.73>M1L=
M\'@=U=>%O&2^;F*T/F62S++.P'J=/4.Z7F;#'_XU@,%/<H(;TM: "R:IB'<O
MT%\O*@E)5'A&0N1'BD^BD7'E"+ 9DDGWBU=^C65+8Z^U0K1/_.B'TWM6"#TH
MSJX EVF0LK(R=<OQ2:15CK'-%]YQJI%ET2 (^[A[(GPIW>OTKI>CUMX\&_,#
M_#I;L8(8QNT>]/+G',2 99A)3=V[O!JZV=_W>>;NL1UFT4CW(FG0DZTL2P+#
M"H]=K)<\4(Z3VU%5C8GUZME,!\FOM^LX1&G7)YO'1V8W[G3SIMCW,O4O>TDN
M0AG:&2 .QCYJ$8OI-KHU&'R:N3VZJ>4VWE71;7T=LK1T>5K83[9P9A.5E,F?
MSRAT=9<Q%_Y&+ 587RL!HWS^,UTFB.D"KCT@ +_Q=02@HQ0O 7*/'J>]4#?Z
ML+_@@6')+V]]GT#_#>YMQ3\S2O2H(), @"<[C@^1O8&WMX:@A9.MI>C=3F&A
M7BZ.EBBML>W;APV)0[$_16;K QSC-R$?SHL+"<#08>7Y.12;YZ2G]YD Z-5Q
M'TT0Q\O$""PU!$N J:9AQ\V0E <OPC.\W]V+#_\=N[Q0KFV+.?Z4"-NVMLV#
M):KQBB6I&MM2-"G59C(?.,GW9I"-U^9WU%LD9-BV7/IT7?4G31O6<F$+NQ2%
M)$>P(>M$GU@]/?Q6$Y;&P"5S>6KL]S 9]#4WR<$"944Y?X<=O$A/<N3TICOU
MKTX:DTJ?@S:ASR>ZB6@K;:NJ!CKHQL6JKY]>7#CH@5/KZ0'(PO\$"_IW<TMK
M$MLZ(*X6:DLJM/Q&?G&\ZB2> $R6=/PY'_\"<)W$WP+L&9E[7O@G'KFG>GH$
M(',3>GK2L:S,4J.JCY\8^XS&CW'>N0'%EE8U-Y,;4^4]N_*2&I#[[[ZGT@B-
M:.<;=Q=2E)M2CKPIZ6^XNE6_+7W2^.5G"ZW#3NDK7&F60W-YT@?DTA(C*N.=
MN\C3AK=+SPG LQ0 V85D@CB<0'*YPWMJV3/>O9AL<&*;8>/%-:VG_&J7VT!Y
M]*8OO:+)AMUD[Q;1>EA(22M0[H2C_=P@G 6/6A:RIYYO>^$LLHUVJU,_?JDH
M2-2B0HO7LW5?1U,\[.\C=KR.'G,\W+\I?R 7[R-C>.$H-=D)1S#F&KBWL0-G
M.$]* +($\*I(;"Z>L>$5>.TB>'?S#Z#=FW_UA1W&W$7WGIQJI]Q\&U3][?4%
M=4@=)BD7,V3!)9&I^LKI(BPN62;]@87FXJK2NR/ULYLN%UR)NE,W\X 8A-ZW
M?JP808":I9#DN)(8!*QQ)689,MI1J_/5//RVFKFUG-,;9,V0Y+?U%(_>8L_Z
M(_M*H9M/\NLQ0KO:0T$0\J;:!-JM])8W12Z2L:,^5Y^W)G9FDK>"<_R>N]!N
MW#B4ORFQ__+5%\.8C ^,H'W)G61O6^<:RYYJJ:>!.Q3QN,F&5PHWO=%SGO.]
M$SF1_!X,.GROC"6'^'Y.S2(Q^7X73*BS'@R,7]A"EM\Z8\10KCX/9K>KF&9S
M^\T.M&".U3&5K_S S._RH#]*2-K5?5_/[LYFP(OP\Z/@-2%K O#J$EZRAP!T
M)F$$SD'W"$ ]T<%,3'[K)0*@3/P7"3VS)ZG[VZLED"XP[@.FCP3@TVMB?J([
MEK01#/C 8#R^ S=" "@M/B$/2+F/#XFP!<IMMIFHMH1J>Q]RRFD\OQ\=NO2B
MJU%AZAT.OL3=U4;2TS%3W_R:7J/B6>@E$?T\G8S<E/6_W*X^@@#$$S\93'9V
M*9J3T9T 9/R!.[(/!7[=ZIJ3+@YIKT[@\>(M_TJA=FB4$K6$?[6X"UI_WG6O
MO3K&K$&;=S97(6QVI75H<;4+2@FOS[@FE_'>#NYD:(%HT/B4YX#@]#')1O[5
M9XKS<R0VBV;JU%>#F#_E87A2 =S(>5L><MBXBP!<8#B#1Q+S4'A1[^0"[>D)
M 5C^(SE !&#X"G)AB@@ L+5@.:H'1M63-()A>MC2R9H^5]:D2_2FJ>_<>8(4
MPRL5_Y+&X!-0W.G)64#=[%K*XX*( HMUE.-U#GF/:7:2-$I@^)_IW@H[-#CL
M)Q;\VD6BG\]T]4UI[]"QBA YVQ&ZV>$B13G@[1F\R'9H)=]-TJ=DH5?^A4.;
M*2V:B8F1K,MCB$D_8*@=1-UH!@G#'Z-2P>D^/_3E*,V!/2(/$0"B"T,5V<20
MQJF?$65$( %8G=(G!K6OTCPG4"$9ST;\&[F_681<M"&&E8H +()_'XZ#,6*;
MDT59M#<(0"@2PWUVLL&-8SU =H%QM'A_#]HS*I_#Q![OS#Y:=@?\Y=$#>!L]
M6:/W[@.C!P,)(X&:?>UD@"$WH$!.>^:S<14YMCS%A#E>#/C@581[IV!@791?
M:Y(OL7?L**WRXW"EH6XW,N751ZS349ABC;F9Z<SL= V_9TW:'9?"@Z)6<:R
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M^0?&D,TS'<.9#:D&,87ZJ2O:E/1LH\K*O!7PU=76L%X(#S8&&VPZ=O"AMM&
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M5.$JH.2.!6X>0AN@B5(A&Q>Z?.#E>0@"<IA7-@=2!4RX,D/9_A-TR=_]4UI
MI K<S84A]L#;]9B')>/_'X#RB:_\,6UV#959X=SGWH=DXC;XWUL?$/Y(_7KI
M8JC2]IK[#=#\X->8D(!DC7&>$^&X8CNJUT,3/Z(";BJQG$J1.SK'SF.!F@3H
MAA<>;T?]ZS4.IICER6V=\U@L(&EY!%I6\<1DHY6.:'@!@QI?"@Y6ZYY\+,#(
MYGN4@Q[UV962KKY=A@K,&\%YALG!,^A=($8)*LX_)ZH[&Q!L7^][3]KJ\>\&
M\9"3KVC(8>8V1FIA4^;J&AAU !V 1BNY[*T>7 >]1]S,FR_6\\$"6_ ?&JA!
M0*LV64M\=:L?P Q3/'S$4KK,87-T?UC=WP_E.+:+-$2H2WOO2H54&TPPM["-
MV2+M/K1,SX7TPTZ,'$*"[,XJ8V!M"]7;L0WPO;*C#,)XE:#:J:LN;=W*V^?C
M&E2F:]^>DN5=GCER9:@C-K1/L)^+"; 3#GC\WLQE)I'--Z]99W_%0NE555W+
M^.D"W\1MI*;G^F-@(35UO4QW(I1'<:_%<@X\?W+SQ7RX[]$H0@-A6G>**&!%
M'F*!9O0E4BP PKG5AH614#'^ZWZ%%\,6K^1'A!B\)29JD#:A<TKXV2&V;?UV
M[.GC(!2[A0#.$5%C@1_SH/W\V]X)R]>IGSP2HB$B A^>F*_:EG%O^0SI;7*5
MRN\F3&"!+*5T^WM^K[0.5DLK"^W!4TE)%S8U+] B8OV5RE'2NP+M*;M9OQ7C
MS=R3-Y&-8P^Q7A?:H(O-EJQS?06C]2+#:>&<XI(<G V*Z]U;5T#F[N'4Y(0S
M<-WIH+#<VH_Z52IO?SX1Q->+R8JL+]N>2)$:3_6]XBUT1'2'IHJ4^ZU 0MA/
M0;#XX#YOI=*/,\PWQ_W>44TDQQNGT%$Q!J+TEX;R#CED_GG6\?HW8.R,<,O6
MCYCKPZ30KU;#& Q)^[YF;.:VR9,Y]$2B7<B1Y6S%,+OR:O* <U.Z>Y1AAK\
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M8!>'!V.49X;>(,H61D<W%0:>LD#GZY=G4%SX@W]C\I:_-901#?='3H+$CK$
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M]G<'7XA0G].=FO?R%OH/35UO^&\?EUC3<<0_X.3FY+"=523JM!+$ H=7+)?
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M';VJ<RN/^F1:HW#ZP Z&.4Y/(P[*Z4$[^67#? JC]Y>DAE2)CV6JAO9..&X
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MOV"%C67):C2;)+2O5'M-/*W,@3[^",&6@AJ.Y5JRFL7Q+2!C%46#5N,AAC?
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M!8(6\0CT5X%9[R?/TCFOC^;]R!)]1T34AZ![5$:Y7$K01,]:P!O1 VJ'L)W
ME2_B=]_!Q]ZB<1KB_PVNR\#\9[,KVC^1-?/M69[4\H A60;BH2C!/\Y8?@U7
MZDYTA9,!28!/[8IAPH_^M]#$,^^VC86SOCS:L!;LLY9Z'U1 _K<,T#_/<'D<
M26.?@>LM[^G^K9L6_YTR_ ;P3C*IG4WA,[H=FH"X9(8YJCW<=>D$83+$!7<?
MN1TYG\I?I636DSK\_<\@L8 .\)V6^M^Q<P0?I>[^'-I^DOO?EP')O[9Q&">T
MYSVVSS]7*@7]+@5P^[]K!UO+C+PTC9)@QBY!WV(J_6>--:\A14^R,1M$_5H2
M>.U11]#1!BLAJEX?X'6)C#D'OYV=B BKP>]9_2[?C2\GHV2(JG6@\642AI-5
M_6M-NC*).]BI*1$=^:C41H/9CN!K&SH252 @JTSF:-_5O=YKT.#2I20)F'B,
M(EY>NR :S6^ ']C6,S+1K9%D]U4%0MG\>$?\D5#1J:^?O0ZG":.S?B0MRHAT
M\J_(N^:_&"$_UF%)0D"-C>:A&)W2F8%<>B9Q_K HL2'E<-Y7SJ;C8<4UXAVU
M-WC-^IXP&?Z+B.6T,;@=NU*2^*BVKDRWK//@O6C'*Y=06!&FG1MAV)LX[(;4
MH(T^$ >T%->@.UDW\]NFKJMC.EO[L"?%$R.C7(7KQ-<W@ AOR]DJN#VKWD"B
M3U"A(27R"RW.\G51O-W9U7'U#=!RZQ&[U!1*0ZSXWDHZY$T1JR<SZR\C/,K/
M52B3WYA_\0F=# ,//#J^5%N.N,!CC)M!1B36W "/7H6[X58IQ-BC$=N%'SDA
M3LBAM75:;R2KJOTM.WGWNXE3?HER=<F[D*)3H3<),Q%%G'^K2;:+W83?%KE4
M&"]?X).FD#<W]$(Y#.,&Z"G4+_W4K Z>5>K/K@G'\LZZ7MO9M1:N63@:F4%<
MWY6F(+,7Y4A?O:5T>?=\P3UF+Z^H,L/&/-K\A"=X4H1FIO>5GJ<)!E#Y=I="
M25'U::Y/=O9TWE[Z_-(].=E/HK&G#J+)Q6G[VNMQ47]UA7CDN=SLB!0WXX][
M6;US ]S+P"3H;-;[]1(W(*#*K2B)_&'>I_RRW%5Y[^J#3Q\UB*UXPSL=7S!P
M7Y@T>\QYSS@DX'?>&4U#^'[WF>*/XVWZ)"*BB>%VK&!YBB(T$)\A([(<XZAW
M"\WUGM)K":ETR\@5H[N)"H(>[]S@N)DU_AM <SY]3XWDUH#21WKXD&_S>L:N
MRWO@%&743\$_)-O9569FU=/^,D=1H_M0+>>,&]JU'OA ?><_%A$ET),*0NEG
M5Y*C#1?:])7<$O32L-$8$X%2+MM_)"^4H@,OCYU$G'/Q)=O%;</_MIH.K9(
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M N:)%,E]/R8/WS7YU!>>.UQ*9%6JB>*[6+BTJTA*8P]&2B;K1[DE*[YYOH;
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MREPDQQO9DG*[@J+<C6N^<<G2.3U'[85/_7*:Q4F9*-XF=;9<U_":<1M]Z>L
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M6OEKPL*\IA1>A.WG*B/+6)T^ZN<H.RA840O(N6\)5:0_>Z;?3/\O4$L#!!0
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MU#UA'8TNF@M5G)1_&>ONO9AC:=S/#:Y)%-@7%NWM=V[HB;9-!';6V&6'N\A
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MZXX9I-%J)85?LZ4@0YNP:V&.@AANJBRHK<I/5FWN_$RX$IS_TQDR\/'-AFW
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MD"Z^BR)\V:5)S!!"ZP0,*!QG=X2!KD?F5XR;5^GU56SRY+0=#JZ]?@&8O)%
MEYW-(B6=DK/=8A-L':'?R"_?T+!1D[W/6%EPRYXJG1X?@S_,;5:MU-'>F-S
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M& N_3Z"[S:E8EOQ^6>CV288KG>CC"H(.U,)\R6I,&AL4Q\Y7@A9W1'<'B5Z
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MYB20<Q&&!#7Q.=K;4ILVN+O<\33T?9#P9Y& SI4I!'KXL^^CYE"^3]AXE8(
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M$'Q6"%3]/#YMB_=G[UP%W(W(EID6!53@(3T<L$R_YOQ]ETQ+:*&)(%^0ZUE
M[#*"XML_Q4.R_7FP[3PLI*<1$;WG-^\AXM'%@MQK+0L?QHDEZ;_+O?/_(3A:
M8=A\UC=?PODG0_D+P>?2N[7/'[T@?9X*VBL$FF2T_A#CST%A1'B':"^)! Z-
MN&LU4KF;[ 31)Z"K!-$_>4*X#B*=?ZCX<TS^F;,I!-V^W$'[,'Q]-MVJ6W@
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M56MP=Z4+Q"2%$&T3JI[ FD!=-M..6^ CL23U,V_<#\7LQXJJ>^FMCO8UIG!
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M ("$AO0_ _"_!A(RRLOS8F!B8;]ZV5#[&H",A(*"C(J"AH:*^K+J^[(.0"5
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M[7_(_M^!!?S_(OO?8/\WUSP !P7IY>6A$ "D '<6.G&*.9$YY@V.]KQ[ L\
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M_NE"#%E?#P]PB"7'ZSW;:[UKRKKN-QT(R9I!TH.8$-+CBMO*C_+H;R]V6"&
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M^#-@@]+A:?5/<Y1+?8@B2>7V_7I+."*XZ,[/?SN2TMY$D0'1= W<-V7LGV.
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M@V3#BL;;1T&'ZB26A^? B*_\98L6T]D.L,D9"_*")3H]-)G+?HA;<RQ;HB1
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M#_J&V%XRGUW[-_O#XH0^BNJ\MX99HYEZPGV/)CG@ MZJHT<NADKPP7UI%*S
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MW6MC)XD:=[[Y-.6)>-I[+_"PW[0>G4>">N#E>:-%I)+BIL!W+4V[?#>1=V-
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M\.9DV62T,-J&^X%=P57$0<H;XDNQ7?5]3#^MV+W#4Q;U3[>NC0\PJ35KVV?
M^:;;K5[TH+?[RIZ% D8CD&:_,1F+=AB1\2=O/8YTRN! ]51*U;0N2>RBUV!<
MDF[.+C67A'?>..>O<TGW#U-60NW[>GRHEM$RFJU"^$7IA/CWZQCO$UM9XMR#
M#Q4/1=N->_-ANXEM/F$&'FCK5;_"N4*? 5H\X]DW@0R]V<B_,$: VS O42GO
MTS]M;%KNS)$TWR!FIZJ5SX!$_HG^4"[X0V5<R\RAZW_6VSOY\K3_IJ5,SP3O
MBD$,3X3B?K<()MJ3.*-G )R<8S2HY_ 9P$5):Q@!?_-R?_3M^-UUS%,11.Q4
MJ.&_\S3]NM0=G@$2T/-R42X&_,OHV[$X#'Z1;24$U.PN>R=RO5CGOVU:^.&E
M& ^5B2T(#$<C(:HT68M6GG+)[KOL78P^W< G?94/DL+5M&?'0E[5+-1V+%06
MT*[H<LFNEW5U1#'32^J_!)4]M.V-/OZM6_I,TLB!^K;.QCGQX]4#KF:_9.>E
MUA1^CSW2,X [B1AZ4B7X#+B]:'PH'IS+A:^\2')\0"I<RM2NK7E#80KJ.OWB
M%A:[+]B[KK=:1NNZF5G0RL534Y5MI3TI]L@C2TPU4J@=N,\DL+LF.J?F?JJE
M,F!7#XL?XR,D8DR[A5/EQDG5(B*9]%;#I,@&%!MYRI-!O_+4C+]A/]HQ.%#^
M_B:A+]Y1:K?B2;[EDF]!O'BXM]SGXL0/L &W<VW4'XYMP.MP5>:7K&4O)*/-
M<)D](&N)B!W<326EVR[5#T:/1\% @>7&H-V^]EV^.% ]DNGX,4,WX;YZ/IZ^
MY)F[Y4_AVJEG9;4S! Y+%$_1?A@JZ3_FW;.3Z@ZS\-:!@7ZNUG.I.;"H_FW\
MO'"4F@/*Y00$F/T\D[W,!2=V&D.5RUF9)BMTY1YZ1;0&1J3+<J>%^7,DZF5X
M(72RL09W<4A>_2:-@M'-&7%QC7#T>*^,-M=@*M?EG'U:ZZZ/<0E#?_T=!R4F
MQ46+X[)WAF3QIW/8U;,*MAQ<8+(S*,33GY;J,.QJAA.VD@=0K8O$XZ6",N_M
MGP'T/5*7!U(7%&? CQ;=+MKQ$9?EIO4#)RV>^U=.CXDM'JZ8?5IHD=_6KQ1H
M\-<MKRQ5J.PWT=A[$D>5KHK;#(GB )<HX\5=?_@IR1"QND!MJ@"OK0;C6G'+
M.;43)8=7<IC6=3$!SX"#J4L=S!\ @L-5A%B!E7*,O#RO]+'.I%#LJXRKGC5?
M[=0R^V@WJX;[@8EAO$(LK5D+(<(NLN,-HE%V6RD??YR?6C>I7KM*;3^%$5FC
M!HI?S7"^E13O /X6QY*]\7 ;L5/,0YB)LF3G=^/6]C8K,/!S&I\O3O\^$AV)
ML,1NEB=%H<.[-)5;2'\B/A7>=/K]4$!^E<]'AF"1RK-AG@QM;AW28VM46S4"
MRGR1/_'W5:(N-IB14B[F141WI:;);KFS#;3^DELU+P[:CMA>+D^X]>K5I;M<
M#T])&#*;A@>0/K$?\CPU/0.4A]W@=/>Z,P%$3N&")>?W*[N&&M_O!(I:^R >
M/4ZW@(@7R6J8@LEN6^W'OS/X#6#ZS4B;>H813R$DZ7FAKZAK@D;$1/?5WF$*
ML=)R8][IT;^5]U<0#'+Q1,^CY>:71VCR4/M1N!-9?<24T#+X_L$UM6H 0^TB
MK%UX8F(Z_!L:!P$JCI>0H=SC-4I87:].,H&_^)2Q5_2N7!.N!W$4!E#7<G'1
M4F=&E(QJRA8/<JK<]2%WN+-C=W%2G<0+#@0'W*]G6]Y/<@1:L;SS0O[#!J<O
M$^T'OL*Y+&8L&3N-G<[QK*;TUFG1_MH.2?>0\:8Y7Y..QMUMO^ST2R ^?N4W
MT%SP#)@!_FGU//!R<GVU;O,0\.([^__)[$D 3E;^[B;E&4!7['=W(!5;+BD=
M;ZQ??YR9B+_*R:W^03LV<!0,-0P5W1U1QI=P]MV/.?R28&6>K!7]">+T]0H$
M&X[8%I528WL'B)+.2B,XZ/:U+<&FZ:<M_= MV*?1#%+/ [R31J&V$UF3AKFO
MXI?R)4E8?D3%#=3@O3@<47V#$N&J4?')] MRS0#C-K4O.Y9Y)RT?1JVA([LP
M6A+JZ;[F.K00%&*9P#A/RXYH+U6@!W001#T##"MK5;Z?BI07%M,8LQ8"^!?J
M"TXH"J5+_Z:!!90#.[97QI,7M,W2IX-&LOV/!CWA;_QW0'O%S*O*:_WF'-JU
M;+6LU4M<X&< YE^_%X$E> $^#F5MK$5"'MMIR*4G'LG\V,^('5>C*)KXH-AB
MO-Y5X\)XGOW*"8K&CGMVO#DNB%A-0H$!*HI5<27M-37P=!K[<32.)TLI>S:X
M7VQ743'1ZAWF/+^OP+LWG[<$8B.<\4L!KN/YIJ29OY>&'CMZ^6DV<'Y:,!?#
M <FYIF:A^BY+[&NWZG]S;0J$,CQ)-CUQ-WN'Z[.+H]:H#SCI:D2IS!!2R[U\
MCQB&!'/:7V5VT.7%M7!R&&.T[\>X] \+(PJL9#IH%(_5$J5KPT09\5QL^7',
M J%Y2ER"NG&<&^?1TCI:2/I4\9D<"DS.VN>[.D9^\_CDLC/4D4(57(JI4AVZ
M]8%2&XX3+^$ 2>5]M!P J=K>\$MXEJM*74S<:4C?#XR6Q=CD/,@C9,DEO ):
M3O&\1N4@M#UN*]DO6?15+W6VV"H<Y4<?AX]-GSR!=] ./$\17H_6F%_8=<(N
MYV2XJ;@#E*E&[_,=4?T1OSN?@P%BY7:/80LJ(Y3LA8L^?9N3F,WF8OP0N_TF
M4A0]_LLJ4 P]O[G%:^VU&GA4T3324%I^/MY>G+PD7WZ/;_==4&RCF&&*ZV#'
M".Z$T_?&PC 3;)<=&4^RA_./%0?>DU7I+WD9$G6S*_O^X'TW]5MM?DF2?$>O
M#>P"*99RP5^82WN\(DS1$NMQ'X)9,1 :\I]<T;5ZQ90X1J7A$&Y;=ONLPU;7
M/G8Q -;#GG-VHUCAQ@?8>A&/%A8'LS<T6&K#=.)%-V%C*FN9$E(%T7?F-7KE
MU-%L1Y]]E+>5_NO NV\I5DD+:B$8/=!;-.EG@,FOLW(I@!GA[%49SJ=3?'6,
M$WQ-I%7S/'B^P >JJ!YW&+%-K4M&$DWC$<2]@!5#E"R7Z@>T5>TC&FIE?U:O
MO(($@>:J12M?E?8JOIV9'@NW;K*>+:RBY[/_0+ZP>. '[#.42;/40">:2R='
M<2WEJ'5_M@HI0S-CG3J-^9Q9U_&?:":MH8*%.*I-S-V0JX<BZVCF^&'Z\-:>
MJ0NK-.^) ==:.&KL647!WKPKID7F"(&V*YWIBU<6UT>\QL[,FEB/,W*3?!]1
M_-BW55>@ 6*T>NLHA77PVNP&C+3]2!M[HQ?/SO:U8!B.W.I(LK1V:4V5YI/N
MRS&H%<>W;XB@J*J$!RXM0H8B>I6PNR]AP#YPP$J0MJY*^#H#H,1BJQ3-='_$
M.>,0AV"@X[Q6O564,?: MX(KPD&(A>D'PWRFYV$OYN\#!>)B-E$IT;4??U9Y
M$CVXB2] 8OFJ7ZL>YMB[CQ(.+XNB](?H$P8=FT\[A50T?WO5,I]Y*'$XFA=0
M>NUJU'#6U8^AW\H$]Y<+@?7,65$B/(K^N!GDGVNYH,V^ ]GEM(9Z>*,@54<!
M-"+ 'QC @PP <*],DK1:'QFH+8'WMC%[9\ >)K]+.NS>A>S) C1<ZL"A'_YS
MHDB-:]*LJ>W?Z-CL:Y?..X)<@S8O.NMHE@,#56N73D[DYS WH!Y$DD-W^]C1
M8F6I,\W$JV3Q.%3-=/K@2=2NTW\2A1R6%Z&0M&P.S +G#0L0QZ<N;(Q00<0S
M0%4JS[P( _M6C KIT.@[H;%GO%J_NL"=AA+WMPA['\[C[_0X.Q9Q4IX<<%*&
MHYD_#S+/@!BZE[P+:+ET-2%K#^G'.HG2_7[);TD#S1 6P: +BXG1VQ0;+!//
MT#T0/YJ8\IYX2T41CZ8]!<B*:KG38I*S0I2RBN9]3OUBHIB@C:<@91C99);9
M/I1OU2GT:CN*[8#%?BEF(.LUZ1'>11\@ AOJB#AW9@.0B8>0[8"5KY$CPJ/
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M92P9%/W2/05+\._&,R_&#5]+O]2-[9ZU"+NP+ A867@PC(ZT_JD"7BJAU_\
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M*'B8C[P..M%%%BBQX;T?^Q[/R9KJ2]NG^:6ZE4!Y>W.*UP.F*** %IW:BBA
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M,T'0+RXDTRQ$,EX")OFR)/7<#4^G>%=(TM;E;*T6#[7\LC(><>@/8>PHHHL
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M^68><Y>#$]OU#,"_.GU[J $W/$@?BT_G9VQK;(BF=&79VW$L]'!>Z:)O<YK
M&LSV)NJB/V0?\0.>DRC.^[TI!=V1Z*I"7=1$=^I#%X@3.%C&O?ZJ\]_-IWH9
MW;G[R9RM/-&H<730)GP\TH]?A'-VMO'O??>TA@)\_#O[50W<RL2? <>^(8:9
M7_<C0C]Y5(FL757J/'S$<**UW32(51J)'C@[,J4_*)?>>#OE@4?R]':OB_Y?
M!5MV+\)J?*\W'3J7;6E==*B;#I?;&_-FA>F'D5F:MM#OQ=H!'G V;^"+W<O+
M7?B?XQCB6*4_3@]Y@PGM&5+Q"AQOC0L PI/S@YT$NFNF=R&;[7S_RM,/#7_;
M<-:_D;T]WAUZ56*I='G)NA=_! IXR_DT=DY'Q?1HLW86NW2 KUCTQL3[2SWE
MYU4A=:R]^7J O_9E;XC<"/D)F5$561Y97A8O P'#3Q\^GL]_(_Y:7I4(8@7\
M *DWEP38RD@B1CDY")2"] -"Y"AY2;>6]?(>T8,XN?MH\.H,J:9L/<32(^U=
M=E)H]1BX?#^A58U)?%*PR-*.X)U=:0B\2_^:RB,/2#?85 (JD_W1NKNJ)+A;
MOW'Q^W &;HPL\'HD/^ W<F0TLZV^"$=''*3O/:JL$CL2WC'-W>_*G8T<U_[+
M+(SO:UT.%<$92."=$4"Z\H33+L18QIJ?09L^=X2U<PCCC6,$:2>QPE5X1*0R
M] 9!/]_Z230'C1MVWBF8]E7+%XHK_?F+%KJPXG'955&F.;-[EAWYQ+"_BOEV
MJ?CLT9-GJ?]X6T6=;)Y9O#H=<*] \8O96M\Z0D$N#'T]6>KNX(.>QV5M.7_/
M.V ;41?[]8#*WU851^PE/Y99YCMG5_:[]JM/\U9HGJG%JZ95?GNKU4]ONZ&;
MIV]6#H2?:.J9YN3;&V=.F%)\"UF4^<NPV9''U45S<$N)3Q;3B+C>626>(-&.
M^$O:T_7TB7'N=OKG+:UUPY/CM"3$JVN=!JF? 2%^)04'0D+9& *G1(9U0Y7R
MF[R$GE*NEF_'Z<W(^GGG6D?\V7O(/0> Y(S_ZML[<FYLG8LX0@(3%*(C:WP2
M;)#WW5L;O\@NRRH9;Z.A81U=E?JDU$/T;87%DL>VL<P=0G:21,QRW ],^>[L
M>A0FI:VK-U6A7/XJ3T^F=!OPG9F=2R7,8QQ=WICWY:?H()E2YMY_0J1NB\<D
M2H:_P +-%@DP%33LW\W,L)B_.;AY[MR4,E05@9YYBZKEBX<S!2;^M5SO=&G\
M:Q_+H/:_O2#XRA+*[/XP:Z382;T1'\<;%!.B.XUG /I,=R53)>Y2+\<B__&V
MM*1_F;@I&/\JFVIBT_=W]IU^>(G8P>#XIGM/+(-L?G2G"N >;MCJY>E=V_V;
MMXD_,.IJW$=[N"N)+TZ&#,5-\%)LG_B)Z:ZQ&'[7P,J<0H/5)5&59J"869OP
MAUKIR?T@H#9Y>?[E>WIS,7EG8E>_]ECV*(O+E_KS"0VB(4\(^+]Q[:^M+4_U
MC(1(I!_]IV(AA%\G-!*7)$M57H1,VM>M;"--PKV3V"(V$,LKSJSEF-!4,\J0
M@0U-C??XI0A*;-<#.2;G?N?).!RVEP7TU-\NMCVIZ\!2OR3'5.4!\CO!V4G8
M%UY'RK75)EGYA6K_N77UA])MJY!K.7Y /;0@[SO](F*BY) %TSG#[%:0D1"
MDZ0A#R#\/_$A$I>X][11> HRD*GW9',@G>BH!,'H$&CMT&TZBXZJOQ+E-/Q
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MC?:X[GM4(@N=^;<%FKJ;S!K QYS=UY.T0]>MZ$8C.I:G/$Y@F?!I)3B?A&E
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M?BB8TSHP.!_+?[&]O=6]R?T,XPI:+]'[EIVI6F"ES!"^]Q['+P?X+LRNNMB
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MR?$4RFD9CSUHHY(3,Q& &RK5)QE/_6= EMIC&8V1YA/^IYS$G7?(-"H+L&?
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MZYC=:EX_4?4719!$T&LCUM& 4YWQC"2M#P]Z([XH'K4\RW3@O5U  S+-QV>
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M+:8H?*\V8@%^+\MR'W,UE'6(E1S*;NTQ;JS3C&6\3/TJ7&+J9H@N>IPNX?7
MO.!DSP;6&ZG><I89OE<?$WF7UV)!^_J#"OM#7>VX;(V3#N^2&;V &:.JS+\
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M-BGA!%5KM04#AM=2=L?5FSNQYQM;^+79$FI3>)P/=3H7]6F:I[X+H6A*,UH
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M=,J90L@_=M,-4OQ E)<2G(5]FSO_>:[]^A\@)K)6%.:T._CM6NKI8J-NY6<
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MK$6RN>(342"XH$4#EN)<ET*15'$(KZLX,AL;P2L%-@ 8 OWVRB'/W-&</A+
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M&&KB*^Z[AW+ID9Q=J,>C.,)X9NHA']HBBUMCV&*&%E6HL8)B4\!]D7J1F(!
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M/@?0D/\7=J",V\7W_[F"'4@ _1@8W=^#T*G-;GDR@UP9XQQCV>H>X(AA(IC
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M)"[%>5JJ $[RB!U!:R.24Z;N)A*B6S.#/MY-2_>_@_3WKWP,,W\C6H*J?HR
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M>D/"<RC/;$-^7N-Y$ZG(*6,W<N3F-:WTG(:_,]FOB]9#$Z6G/J?:!5FVC$"
ML]%ZN(X?_32BVM=4S5P#^X>!:23B$Z-.D+=VEU"BM8_?L\5%TV456WCD4#,W
MO2S"97BFX&!$Q+JH8T(PCWSWM.M%HP=J ,ZOS*]X,+\_YG^NSC@SI7#Z8ZI-
MGYJXPHJ_J)!^0&C>E\W0SW.N8Z"IC6=R>9C7/"P;M[ET;M=".&'YZGUAI!:3
M5PL%QF?=AP]1" B_-8=\TP6?N#8$X^B'&T7L<^'N&8:,7[C,VR&)*H%;J970
MJE8NL!OSF_JL4B4U="1DK<8D,+PQT%![UH _JV-TTQ"0NHO8 ]DKU*>YX"B"
MZ?-?&Y.UN.+H7PAF(3N<]7_\6O9-L83IW]LLFV2X:BP.UOK\/#Q6O]=?FLY&
MA2/=\0P)GO-HT)U/1%V4 *N=O/9;MSN?QI.Q;]X(T,I/,9@<;)BR5QG<7;K7
M6ZW?^GY0?%:LH_JI.7F>RE\QPO,^CV@AJF3.7;4W$O<,;3RF!,1385NF# (1
MM#>(&Z7^Q&LD6KL2//QP-N)Y78]H-1+2^Z["&/R-PD5S] >2=$'57%)L?C/W
M9+!E329-66IN1*65I*+<-\FYTJJV$9%[L22].O\M 8NV(S45*B^<6_NOY.1P
M+2JPQ*/]EKMX_[1;+FN"--07\ L;DFHU=2BD-GHD4"P+K%&_9^9?I-5K:I+^
M%&0BD]O1_:7RX+VB F31TM.ZF..2H.:N\2_ ,_A-9DLBQ]%_?G7&Y!">*I5@
M1T^X27_N$\1P+]C@]PGX[+,&^KT]S...')Z'4Q?25@)SH%9S1VOA%SW?-2^)
MX2YJG;2@*HA1=);RFPA\@FW??1EDC:>1QUU8=)F[%@O2KKVZFQ'PS_G&^TMV
M]=%W;J5AI.35)'/2Y,R:T._8,36O"A]1Z&+'*QI8;I;D7.';@ =,.O?E5(PO
M,R;%-6[XK05B4A,9_.&6+Q\ZFJL@M*I9+OCJY+"V:\HS!A[9]STB4I"34KNQ
M5$<;/#MUB^4CH$UFM_2L1P^%M )3LB)4Q\A)O#5'8;7:*M[CRB&@,F0'B)*
MEUE!@H3*MA8VR;X(/],80/P%F-3LF<1?1B3:@L6_F@E+!=-\MD$O50ODJ/AQ
M6/>]1=Q$/S[^(B4=N$$:F*G?\VZ,B3YGO_Q4/K6X>?4R=_3PM4/6[QBM.4#B
MGSOO/O?X@-I;D\.^Q2#'-&+CH6;?=*K_ 2] T+_ %.TW^S?[4BLKN7[19N@O
M!Y1/S2'D[A[4-L;BWJS.M[:VU?2;J34+&*+5<&2&/?@3 =2!V.*R+'^RTU"&
MX\B\?>A\J$,6,3#N/QKLM8N(M7U+R='T^%KFUD5H[X_*B_[)_E6AX6BACURZ
MOIK6&V,ZX+9R"X/S #L,T^:Q<)N)Q,,]PVHK/'93MJ\RGJ/NH.F?2N@FT)]&
MM1K<X.H-* LT).5C!_B'N#4LUTNG:QJEQISF^AO $:1?^79B<8JFEM/:K/IU
MQ>W(LE<!03DR'.>?:I;'*<IK0NW%E;@VKZ[&J0VUN9T=&+-,W8'Z<56TS7]1
M:PU">T/G32X6.)S\ZGU"_2M37]1NM"U-)5LTELYH@7DE^8(1U4?A7/QM';W%
M[<V]MLU*<"2S8?PCKD^U3ZDQUW*]C<VUQI5XNIB1+Z(%U:<_.[?[/^%>M^#+
MG[7I4$QV[GB7<%& #7C,UA=W<7]MW)G9)B5ERFXICJP]*[KX/ZA+=27]NUSY
MD$('DQ%<$K_>JHJ\KHC$1_=W1%\2K1X-7?5K:6*:6.$*T!DV,@_O9KS![VRN
M=,2[$DTNK+.1,K<;E/3![XKLOC()!XK@VP.X\G>P XD _AKS5(@9I9'_ -$D
M+X%N>O/8BNR$58TPR7(C1OM:O@B&S1;,CDFV7#OCN37/7U]<WM^);J2X9I#M
M=G7_ #Q7L_PW\+PR>;JM\T-QN&Q(EY5/7FNN/A72VDF:2!9(Y!CRRHPM1[>,
M'8<J\8.QX)HSQVDT4_G;55@2B<;R/[WM6XOB#3Y+P7MS8E4B);9"/+4OVK9\
M?>&="T722=.F$<WF!#&K;MQZ\^E<"WGSVKI*"0&W $8W5II-7-8)35S8\3>+
MK[6_L\5U:(T:+\I/+8-6_"E[<^8]G=WHLK"[(5X@@( ]<GO6=I=D'B6X^TI!
M)!G,9^\J]C[UW]EX3T;5M(2ZU&^,%_-'\VU\?0[:F;C'04^6"L<[IVG26NI7
ML*7BSZ3;MYGVF-=YB';'O6GI=M'J]K]OM[7[+?6\GEP2$Y-TN.21TS46DV6G
MZ=JMS&]Y<2^'H(@)"!@2R9[XZBI[S2=/A$"6,=\NG^:TRN'^9,CHH]*QD^Q+
MUV*;6NK:3(M@LDJ6ETN2C\A >O%=+X)\0Z;IGAUX-6NF@BAF,*33)@8^OI7,
MZEK=O8>4EA?33WDF06D4LB+_ '6]ZJ3WE_JFBVVBSVXNHW?>T:P8/RG/4U,D
MV*4;JQMZC/I-Y=ZM-97$-K'M"K<NA)D./X?6N3O+6X?1LOJT/V9'S%;1#;+D
M=&/XUU-K<WUSJ2S16=O)! /)CM650%..6S[5C:3X8O-42\NM*57F$I8I=''S
M]\>WI0GRK4NZBCK?AIXR&I6YTS59TCU&U7#>8X!8=JZ^YTJRO=3L+JY6!9('
MWI(,!B>WUKQ2[\,+::=/>7MC]@N(9-F2^\ESW]<58\)BX;Q=HIN=3CN8S/EE
M28D@XX %+V?-*\7H<]6&C:/3/CVBO\/YO-)5!*A9E/3FO+O#G@^_7PO-XCDF
MP(D+PHPYD'K[5ZW\:H3<>!YT$/G?O%R@/6LGX=:M:ZQX5FTV_E5S;(89$88.
MS'I72YN,3'#MQA='E=M9M;R)]JMVC%\OR.QRI)&<8%<]/ID\#%'C W-V&5!]
M*]5OO!4ME<07^AW4M[I1DW;/O&(]. >U9PTG5+?6+2 -;7+ZB75<#,>T=3GU
M%5"L=OM(S1YA]AN4F$$T+!$^;,BXZ_S%:MK%$(&B\S]QCYS+Q^5=QJ%GJ-PL
M>B7D"%[#][". 74'U]Z=<6[7'GVVL:1;K=0('MD0A%=3_,BM75OH"5F<XL=B
M861MY#I@.IX! _6JUM"Q6!Y=V[J& X*"M[0[&XU"\ELK!H[BXV[<!<I&3UY]
MJGU/P]KUGG3?L,CQQ\I<0C(QW'XUESZFO-%.S,>Y@CE!V0C[(?FD+\#Z_6G:
M9#8;SJ-NSLQW1*I;Y?J#6?<&XM5:VU+[0D8<%UVX.ST%7[JULW&_292+'C<A
M&'3\*;O:Y=TR"XDFBGC2&+R5C(+Y;.[/7/UK4@CLKI;@M(L'V;!VOU)S_#ZU
M2C9_)8QJORL,E^3CWJW#=SWLTT8>WGCB19(]T0!+?W0:B6H-JUD59((TO&,,
MOVVVB 9K@#(13V-,V>3"UO Y\N0X;8<!P>>/2DMRL<\ILR]I;W!^92<H3W%5
M90T$MT8YEG0,% !^8Y_BHMH2GT+=K;W5UF>VV_9K4Y&YLF1O<5I:;X?$LFCZ
MGI\^Z1[@//#MQN.[MCTJ+1K/3QI^HWU^YBAB4(((WQ)*_;\*[/X>W^DM868$
MZ6GG2[8K9CERXZ__ *ZQF^QE5?NLZ[XO%AX U KQ\@)S7GVB>-]/N/!]M9WE
MJQ180I_V@._M7>?&TE/AUJ1!Q@+7S[I8EGN=.2(*D;0%\?WEQ6RBI15SEPB4
MHZG5>&8TNO$3"UD$ME)$7260 F-?1C[58OH_L4\MW:NACB+'S$.&+>HJSX.A
M2QTZ[^SF-Y)EV[(UZKW!]*;K"RHT,<9"+.0<!<K$OH:RE\1Z$;;,O6T6HW_A
MF35Y]7D;4XP$M@S8*J3RON:T([>>Y<V-G#-$+B)6:%C]_'4D_6L:^LY;,VUE
M;,MR(%$S,&Z$GAJW[=X-0U&+[3-<PO9EH9O+&-JD?>^E#.2<.34QM(N;Z_UB
M2'2-T(CB:":$$?O5'7/;\:N^(O!30V8O+"=M*EM+8LS(W#L>U/L;73I]2U"V
M@NYK:\2,FUFSA#'U))'<TR-;N>"S:^O7U>V64M-&K8$(!P#[_2E=IF=VWH<W
MX/FDFCCM;^*\>UAF66>-UR&)/WL>E=?XL6;2_$$":5+Y$=Q#M,07DY_NGI6C
MK>MZ597#6T;H7>U*>8#T)Z9/M69J<E^=%TZT^UPZG+,P"WB+N>(>X]*4G<-6
M]2B;K4(K">&***QB)$,5JL>[S2?X@WUZU'=3W]E<6MC)<RQR^:N8E7=#(1UY
M[5+J/G: MZ8[A[BTMV1)#(PS(3UV^E7-0O[W2_#,DEY)%=&]PMEY:?-"#_>/
MM4I)E.PS%AJ,US!JJP0ZP6:50ZXPHZ9/O2:'J,2Z#<1.!>F9RL<(&6C?MU[>
M]8GA_2KVYAFU.\V74$3CSW+?O"J]O:MT7%MJ-^^L:9<KI86V*A"@R[]OQHDN
MP271$_BS3X[31[,Q2+97#2+'=RH?F4GM68'@GU.S_M.^29K>5;<OMR_MGUJ5
MI+NUT.Y6<_:8RR22S. SF0]OK57PLL]QKEE))I_EV_F[&=0&)<>W]:E:;B::
MB[GO$("J .P ^M24R/-/KI1Y844E% "T444 <UXVL;V_T4Q:?<&WEW@D@XW+
MW%4M%M[/^QXK6$^?!#\K;^3N'K[YKJKF+SHPH;'.<USEKX5>RU*:YM+Z2.*:
M3>T!&5]ZQG!RV-Z<U&-F8/B"SN[:_DUJT2V+0Q[$!&,?[1]ZI:+K\D&@C^UY
MIKFYN69E2 ?,B]S7H-QI<-Q#)#/\\3C:P(ZBL>+PF()Y6L[DPPR(%$>S.P=P
M#[TE!VU-(U86U.2AMSK,T.G7L\TMFV98I'^5U/8#O6E%X7MH+=H6G,MVTHD2
M0-B5E'8^HJW+X 5T=UU.XCO%?=#<#[T2_P!WWK2N/#,UQ-8RR7S>=:_\M N"
MX[@T^1V&ZL3"U[PY8ZO/!()HK>9EV*5 9LCT/K6&NVRUAH[>T1;FQ4NTJKS/
M'W'L:ZU? 5KY\LIO;H.TOG+M; 5O:M33/#<5E;S)-*US-.Q,DKCEL]O85/)(
MI5XH\QD6XU+1EL]*R\-]<M/,J_?MD4YX-2ZM+'IKZ?=Z3>37>V7RY R[O(4_
M>ROK7<+X*6WGN7T^]DM#,FP",< "J<'@.XMI8)+75WC:-R[CRP1*3US5.,K!
M[>%SBYM2AT^/6+0+(U[=E2'5-HP>G'8TZUM]4N[J&RU=66%E(@FEP"<#UKT.
M;P=%-KT6IM<,"% :/:,,?6DU'P?_ &D2;R_ED(?<@' C'H*7(ROK$$<;JFNR
M2Z!!::G;RQ7+-C=C*2*I]>U:YL;?Q%I=E=[OLPB.8T4\(%['U%:FN>"3JL<,
M7]HR000C"I&O?UJO%X$N8H7BCUB5$D7;(%3&1[>E3[)B=:'0Y'4I]NDWVHBX
M,(F<BWLX7R)E7@\>]==\,=%%A:M?7!+7]W&I<XP$7LH^E03_  PLY=+^R_;K
M@2H?W<X^]&/05U/AG1Y-'L%MY[MKHH-H=A@D>]5"FXLBI6C*%D<WXW5+C5$@
MNYTMX5C)C*XWES[^E>+SZ7'J3:[=F^=K^S)V*1\S@>M>W>,/ J^(=42\%WY3
M!0K+C/ ]/>L"[^%4]RBJNI+ 5!!DC3YF7^Z?6NB#:W-:->$(V9Q?PM\;VNBV
M-Q:ZB[B'(9%49(;ZUT7B#XD7$L<?]A+&B8R\DHRP^@J4?!18H52#5"#G+L4Z
MU.WPA<QA1J:^C#R^M)PBW<OVM!N[/-]>U'4?$\GE[+6W9"'DD7@R'_&J^B:C
M;6^IN;BU>26-@@60X7/J?:O4[GX01-O-OJ+Q;^N5Z'U%.D^$S31%)]2$A+9W
M>7@]*TNDK(M8JFM$>:V/G:GK$GV2*+<SG<@_U1.>F>U=K;/;Z=JD)FM<:I'$
M6GA?A3#W"]LUM7'POG&CV^GZ?J"6BQ2><[*G,C]LUJZG\/(]2CADNKR1KQ5P
M\@.!)QTQZ5E-79$\139YCJ"RW\<M]:VUU:PW,HCBC0?+C/0^QJI/>7,=S]EC
M66UTZ.Z DSEFB('7/H37LUYX.DF\/II=M>F%5 PP7[N/2I9O"$9^S-!(!+%]
M\R+D.<=2/6I$L5 \GAL9;6]BWRH92^Z)'X692><Y[U:\4:[=C79]&EG5+1H@
MF$&&5ST;(["NTUGX>3:K?+=76HKYB(44B/[N?2JVC_#&XTZ'=_:PFO"V3-+&
M&.WT^E+E?4;Q%-GG&I2!]3MFF*RQVB#]U Y19G'?WKUOPO>6MWIYDMEC0D[O
M*4;63ZBLK4OA;_:,T<T]]'&R?PQ)A0>Y [&M)O LY5X_[0.TJJB4#$@ ]Q43
MIN6Q,JU.2M<Y#XAW;Q:[IY@,44;KMNMWS,%)[_XUDV6EZ)!X_P!'_L +-#YX
M+%.?+;ZUV>L?"F&_N5GM[Q[>1@#+R6WD?7M6IHG@'^Q-6:\T^Y15=E9XV3(X
M'./3-7&+BDA3KPY+(G^+,8E\$W^ZY%MM 8.?4=A7B=JFH>&KQ+W3)8YGD@61
MF!R6!Z@BOH'QIH!\1Z&]@)EA#,"789XKAK'X2O9W:3Q:D,Q\A"F5)]QZ5LG=
M69&'K0C%J1#X7\>:C=PPVLV@.9I%9HS$0B2 =<5FZ+8ZYXB\17=EJLPTZWMS
MYPMX1AHP?NE3_.NVC\&ZC_:UMJ;:NIN8<J(1%B((>J@5L:;X;-IX@OM4:Y+F
MZC6,18X0+Z5DU9:"=:"ORG!>)/!PT>&XUF"YN+^2%"?+F?IGJ<]ZX:5Q<&RF
MN1(FQ]LK2/N+*>A6O??$>D2:GHUQ96TX@>1<;V&<"N)M?A8RS2O<:B'62'R\
M"/H?44Z=[:FM'$Q4;2,7X7W*P^*+J*U2,6-PA*;1\RD>M=SK7BC2-*N#!)-(
M]RART4 W$#U-<[I?PMN=.FCDMM8:*>-]PD5.<>A]:LZM\,Y]0U,7R:JT$S']
M[M7[P]*4J?-*]R9SIRE=L\Y\?ZG%KVJR2VID2*)0B;A\SGUKGU2XT=_/>)IV
M)!*CD >]>JS?"*9F?_B;97^#,?(JW<?#&[FMS$VK *R;>(ZV325CHCB:459'
MDCR1W$F%EV22_,W'4>U6?[)CCA@AGN)(=067Y8SP)!V(]:]'@^#L3*RW>HNP
MX"E!@BE_X53?&9&DU=)HXCF)7C^9#ZYI.P/%TSS"\>33X"NJ0RJ)2?+!3@GN
M36;'<Q7 1^ Z_*%7@\=R:]4O_@W?W]P\ESX@=@S9",I*CZ5'%\$9E4!M84]\
M^7S["J5K"^MTS@K;3[G4;IK2P"3(O[W<&Y5O?VJY9VD%OKFE7+21!UN(XY1"
M<GS,]O;UKN[3X-R6\@==6V9X?RP5R.];6F_"^VM=2MKF28,+=P\:*N!D=SZF
MLI+4B>)@TTCL?$^D6FMZ2]GJ"E[9BI90<9QS7(ZCX&T.[M&BAMEM9@FR.:/@
MI7?W0+0, .HK+$,G]PUE.4D]#CI5'%:'B6L6NK^#=6B:<+=6<Z["Z+U']*L,
M\<S%+69HGF3>8R<[AWQ7?>.])NK^QCCA@=@0PW*?N'U([UY[X=T+7=EY#/8R
M^8B;HY&3 R/[M4ES*YZ5*O%K5ES2[2S?3+Z,3Y/D,Y<=6V^GTKH+.\BEM-.O
M+&\B2VFB6VO9W7#?_K[5GV>DZHNARQ0Z<P9D(&5PQ8]?I6CI6AW&N65E8S03
M65E9@&>/9@RR#U]14V9G6G%]3!U.UVZG;:CI\<4%M!)Y2V3O^\FP>N>F#Z4^
M?4-,O-=O//#Z5#&@)M6.TO-US@>E:OBOX>K>W,$UD;B$&=?.B#DJRCN/0U8N
MO#5M)KEXFJ:=.]LUN(HY5^9F'?GU'K5]#)3C8Y.^$-QIEK/+!&E]'*QECB7(
MEC'0GWJ[I;RZ7J3W,$,L<TR!K/8ORR GD,.V*[3PYI!MKZ[@EA=TMXEBBF9,
M;T[*?4^]8&M>&]1298K">[%H[; 2,M&.N<^F:G<I5(O0S-5NI(8'LKBPB;4?
MM#2-&RED*'JU+:W,6CW)OKGS+W3KY/LZ1H,A&[[!6T=)O=/FL)R)A="-UG;9
MO\P'I63-X6U4II=_IGFI,DC'RI%^2+W ]322'S1>ERSHOA+5;#3[V?3;A89[
MN0M]GF^9&C/0$=C6!J^F6FFK%#)*H> B9T+9/7HH]":ZC4]4\1:IH[06%A<V
M6H!MA=TRLOKCTJC#HF[$5]HUU<7JQ &3T<>_I4<LKBA-=65C"B6UOJ9F,)EG
M$Z6Z'<C@#HX]:TM!OM-34?M4EM=07,DP)C/W8MWIZYKG&\/ZT6BB^S744<<G
MFS(HSN&>U:]E:ZM'' J:;,T-U+Y\JN.4PW _*FX/<*DXVW/;(S\M/J.'.Q>W
M X]*DKH1Y@E%%% "T444 <1\2O%-WX7M+.6SBCE,SE#O[5QEO\2M:N5D_P!'
MM8RJY48/)]*V?CD@.DZ<TI"Q+-\Y/I7F/VJ;^T#/;QI';1X",>Q[<5S5).^A
MU4H)QNSNK_XEZG%$B+%;QW2X$R,#Q]/>EA^(^MR0S2?9+<+"<MNX.,>E<CI=
MG8SWUS<:G=9N(>2Y/&3_ !"DLI88+DW"1&Y21V#,YZ8[^]1SR-52B=G!\2]0
MED&(8MN-Q!4@@4MY\2=0AN)E%O"D6P-'O!W9/:N,GECNHT-R\EMY!VJ2.7!/
M3Z5(8Q US-?1F6028"%L'&.#1SL?LH';0^/=7,T:2Q6\:R1EQ(P/7^[38_'V
MKFX=I(K>.WV#82I^9N]<LJK=&X(C-V\:@ML;H,=,>U23:A;V=H%L;E[KS8OW
MJJN3$WH/>CGD'LHG5+\0[Y)RDMHLBH!YCQJ2 #[U/J'CC4E=GM;>-(/*\R,2
M#)>N3T&\N$\/\F!9;F39*S?Q)Z#_ &JAU&]F?2KBR@>*XM$D\L;SB2-1R3]*
M.:0O91.OM/'.IK):SW\=NME=96/9_"WN:H:Q\0]>TV41OI\/[Q\1.QP"/>N4
M2^^U"*34'5M+BC"P*BX5VQ@$^]4]0CCU.P"7%PP>%_+V!RQ//!I<\@]E$[B^
M^)]U'"ZQ6L8N%4;N<A35:Y^(7B:*ZMXTLK5RZY90#D^]<5-I_P!HN(+.U)#A
M245.2,=2QJ./439V4U['?++>QOY<MN#SCID4<\@]C$ZU_BOK,+/]KLK9$WF-
M60YY]ZZ/X;^.M4\2:W-9W]K''"L8=70=:\ANX+M3!=RH@L[AMMR5'*>AKN/@
MUN_X3.?S)V++ 56(# V=C50FVR:E.*B;GC#XAZEH^K75K;00OY+[=I'./6L=
M_BMK*J6%C !Z\U@^/8FD\8:]-+=K&\9'EQ#JP[UCW# V%L\=[$\#'A?X@?>E
M*<KV+A2BT=W)\3=?CBM9)+2T$4PR&YJE<_%C7XF"I:VI=FX!':N*5&\YFE)>
M%.B[L9'M5/5C(D@B8*54!HRG8>F?6KA-CE1C8]*'Q:U-[.0I9PFY1N5YX7UI
MNF_%'Q!J)N?LEK:-]FC,LF>X]*\WV-YDD.GR.T!QO9UYP>HS7H/AW2[+PYH=
MQ=7).ZY3)3UST%*I4:=D6J$;:HT['XHZI))%,]E ;.1-WR]1ZUII\2)66X41
MH+@ &-"*X30;:![6;S'8['V)"!G.>1Q4L@-I9SP73QB3AWD/+>P6H<Y/8/8T
M^QU]S\0]6M((9Y+:VDC9MK 'D4V?X@ZVB+FUM@QY&#D8KD8#9LV9IS'\N\JP
MR0>QQ3&A1E#1N"PR5SP#FE[20>PAT1U+_$G5T\S=%;+L(YP<-]*W]'\8ZE/I
MANKVWACP"V5/:O*M5EN],U"WM=01! P#C'.<_P!*[/2!_9?AU#?*297)7OP>
ME3.I(4J$>Q/KWQ/O+1H6LH8I8F7+Y&,54NOBQ?*\#P00M" #<9ZKGTKAM7:2
M.2W=%YE#95^@/TIECX8O+^PFN$>*,*2%'_/0?6K4I)7;)]C$[F[^*FK1++Y4
M-JX4Y5L'!!Z5T?PU\<7_ (EUF]L[Z.!?(B# QCJ:\)DC\BQ0)%*UP2Q9VY4C
MT%>G_ :UC@U6YDC<EYK8,^>=IS6D)NYG4A!1T/1?B;XGE\(^%9=5@@6=U<*$
M8\<UY0/BKXO;2H]1^PZ?'#-)LCC))9J[KX_Q^=\/I4)"@S+R:\?\.ZEIJZ58
MOJ5P'FLB3';@??)Z5=636Q-&FI1N>EZI\1=:M;>*VM;..;4Y$#G*X1![FN=T
MWXO^(&UB.UU*TM(8"^QI5!QQ7,:SXKN;IECC*V<6_(<C).>U<9KD_P!AAN[!
M=[R2G<68_=[UG3G)K4WCAX]3UZT^,>J#69(;NU@DLXY"CO",\=C6G9_$?Q!J
M.M/!ID%I<6H0R*<88^WUKR7PM=6%]=0+K$#6\1C*J4&-[@<9KH+>SU1-)GU>
MS$EI"K$1L!CVP:J4G%E.A V]0^,/BFVD"165G(=YC. 3@CMGUJ*X^,7BRU*>
M?862B5@J$]#FH?/1-+M- TFSB2_NOWUS-.-P48R7'I7,W \O<%:)GC9H6:1<
MH0?XAZ5<:C%[&%MCU'6_''CC1--34;ZPTUK0J,M$23D]*S;#XO:]-#<W$NG6
MODPK@X;!+>@KB+?6]<A\)_V"SI*C2Y69SN8+_=)]*TEMM/MM*D4((954 I(V
M0S=SFES-,4:$;7-G4/C7K?G*+2RLXTP 3(2<&M;3?BYJGGJNJ:=&(B,K) "=
MWX5XU<VSP,;I8V**^5<KD.?I6OI-\M_JL5WJ^H7";?D_=#!7Z+TQ6RCS+4SG
M24=D>X?\++M[JQG;3IX/M*QLR1R?*2WIS7#67Q:\;7EA>W-MI-E,MJ<2;>HK
M@?$$LKWCPSVOV5U4O'/+\NY3T-4;7Q6-.TK^S5:>)+ALRR0#)<]P3VJH4[;&
M+BCT#2/C?XDU"Z6$6-E%NS\SY&:V-%^+GB&[U>VL[K3[>,O*J.5!/RD]17CN
ME64JW"E6C$#$^5%-_#GT-=IX5UJT@U[3(9%\L12JB@<Y8G&<UC5YHRL:<D>6
M]CZ2\2:C+IFC274"JTBXX/2N-B\<Z@_WH(A73^./G\-S^^TUYC"O2N:M.47H
M9TX)K4ZY/&5Z1S#%DU,/%EV>1#%7+Q)FK2+CI6'M9&GLXG1IXHNB?]3'4J^)
M;H_\L8ZP(T^M6(X\TO:R'[.)MKXBN2<&%,8J1=?N#UB2LE(ZG2*I]K(/9Q-+
M^W;@@9B3UIO]NS@<1*./6J@B_.FM'UQS2]M(/9Q+9UZX!XBC&*AD\32K,8ML
M(DQNV=\56,>>H_"J\ELAD\WRAYN-I;')%/VTQJG$O2>)[I>/(CJN_BR\'W8(
MJR[Z6&UC:2YFCBC'=V KGKKQ+HL*Y-_&_?Y.:I5*CV#V*>QUTGC&^&0((AZ'
M!J*/QI?M<Q(;>$!V"\=O6O-;SQWIHWBV@GGQWZ"LN#QI=7&JVD<-M%"C3("S
M\G&:N,JE]0]A97/J:,Y4'U&:?45OS$A]5!J6O16QPL,4444P"BDR*6@#S/XT
MH)-/TY6C\Q?./R]C7D&GF]U2>6WTFT2<6KX>21MH7_9KUCXX_:!IVEM:;TD6
M?_6*,[/J*\4T=]?T;Q1=R:>T5Q]J^>9#@J1ZGT-83@V]#NH.T=3HM2-]::>J
M:OI1AA7Y?M$)#!OK[5<FM?M4<31Q+&A"A2CX4G_Z]8T-GJWB*6XEU;6'C10?
M]#C^7>H[#VK9M[)[06KHAC#?NXP3N7ZX]:YVK;G1I81Y ?,>Z_U[83RL9  Z
M8]ZMQRPBZ%O<V,K/)!NES)D@#H<_TJ:R%M;:Q;)>L02=Q;;A=Q['/2K%NELM
MK>V,T9:[DEWB?=_K$STSV%,5K$&G7WV*WCN;:$?:X28VW' 9#W/KBI([#RM2
MDNXI(I+I5#Y1-JX/<=B:=IEI*^H?9[>4-$T;>6I7J1_/%:MO(/L:C466VMU7
M".%P !]YOK0)D-K9275O-J<3Q_92WELLD?S*_P#> HT:UMK#4M4\^-)C%$ 6
M#;@6(Z$4ZXFMGO/L6@7CSPR  (GS ,1]XU#<026=C;QV6(]70MYH1<B;'4D^
MU)IDW*FT7.ABW559/,+(D:_=;^[BI-/AMM.2)IK87.K21MO4C:H [?45-'/8
M6^I0:U#)%#!(AY)R&E Y(6JENUQ]CO992/+E<R[77)*'N#V-0]RK& VUKB]O
M;<-:I(ODHAXP3UIBW6G)):?9].;[?$OS$KE9 .]6_+G'G0M"MV%42PA@25CQ
MP2?44V*3[,C7L3>; Y#+N&""/O9%4P*\-SL$ZWNQ0]QO$>?W;(1T^M==\*[>
MQA\=3/IK&13;?,=WW>>E8>YTT6(2:?#<?:2TGEJV2H_PK;^$<<4?BZ<2Q2)<
M&WW)V 7^M52^(RJ?"SDOB+8M<?$'4I0P"H<D'KBLJWL8I9)+NV55@(V@'G)Q
MVK?^*$T<OBZ])4H,[&"=7K&O1;:<MNVCRR,2FYD89"'O3GN;4E[I4GNGMH+>
M[E5&VCRE7'7WKH='T2:^B$PLF>-OF4[N-Q_BK(L-.22U@DOKJ,P2$R*(SDJ3
MZCM2VLU_INKV?V*^EAMS(H*,W##--OL5)'0ZUIT.@:=8Q,!-?2/E1T4GU/KB
MJ317TMS'=ZI,TL8(/E8P!^'I70^/K;S=6TO]Z5Q&65%&=S>U87B'Q%$MO)#$
M9+BZ10 ^-H0]U/K137-N0Y/8J6M^MG;W4HP)1,SG:W(4]J-'T*^UW3+S6[AG
M6VMV_=I_ST&>3^%/\(^#-5\1Q&ZF/DV;97<_&[UP*]JL--M]-T>*QC -M#%L
M)8=1W)IUJD:;2B)3MH>!,P=9A*5D42C:2<-M]![5<AADN'/D2NMM&>0>V:;-
M;&XU22*Q@\]S,RA$Z%<\5>GBNK6Q6&*WB:6-LMN/SCGOZU4EI<U4E>P@\,WB
MZ6VK:I<D6B'_ %;\L5S7202IXC\(A+&4V[6YSC&<XZ5!;7:?;/,UV^M]ES#M
M\E1N4'MGTI/!%S]EU:]TR=8PMR-T#*,*V.PKFEJ$DV<A,)(U#7^Y3R54\\BN
MG\/EDT^3374IB'S?-/\ M>E5O&J6=O/%Y.YV)Q.C<<9YQ6EJ'BG28-'1[%LW
M!0(D97) ]Z<[R2L3!::G-Z>P%A=VTRB00LRHY'45V/P+F6YU&Z>,@*L.W:!C
MO7GTVI6RV$HCWR32-EV X4&O0?@? T6M7OV@K'*T ,<*=-OK]:NGO8QK*T6=
M/\<98XO LWFVQNBTJA(UX);M7S/80!=2D^TQ_P"FI\PB!X;T%?5_Q(ELXO#A
M.H,JP&11N;L:^9M36U@\9L-(C:??%MCSG#N?>MZCUL/"?"="=,MG\+RZA)=0
MO?;LM$Q'[H>GUKF;R7[++=?/',]Y $+R)D(>V/>IM42WU%(062W.W,RH?F+C
ML?6J.EP->^<RF1_(C,O R-HI4XK=F^QM> ].;5+QK*VYB5/,::89\D@<G/O7
M<:/XE^SZ%/I$EBUS-&ACC*KO#DGJWH*\HM[F.*YW6\\T5O. 9 &V[\=A7H=I
MX[L-&L1#HFGQ123H"\TIR4SQGW^E*M3UN3)FQ;65_HFGQZW;Q07FH2Y@DB9>
M0Q[)6'XQT:TLD@5KYH]49?/N59<@AOX<>U=)9SV6GWMH]KJ\3F%#+.;ILJ'8
M9W**QDU73-8C\0S:O]G-TPQ9.6Y;CJ/09K."E<%<RK=M 7S[RXN)([>W0+'
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M;!$0/G8CDX]*V_!%IO\ $R0W" PQHTB*W0?2K7C(L/%2A59@%&%!P!FARY=
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M/3TTJ\B+_9[D+M<@G) Z\US'B8PWGB*>80>6DGSF.,;L5O1+'-]N9XC%<3R
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MVMQ$9F\RX$7D0X0D9+,>HJE>_;9+A&*3,B+M7]R1BJ\]N9PBQ17/G."\F8F
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MBM#O04 0"(22@I*!DI)!B)V97>A_W4X^ ?04H >@;V 0+W"&'@2F!YUT CP
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MF:V5CFC,$BLOX%ZFXBKRP=.M\R;7X'4HV)00YING+E7@NQ"S-)R;[)*6&?[
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MW4/FH$8G0*&TRXW#B8':,(EMS.>OIAR)+B)C(4]<&RL'7 1#JAZWKA:<+MZ
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M][/V6G7LCZR.E2[OD">E)WE]$\D0THF:Y6HT9IL0RYI7@BWL"=]U(.-WQ;B
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MM4Z9YM<*,8@,0ITX\_I+'!W:*UH5#0$:(,R-P%YN]ME*UPI!PXI=0<8SF+*
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M[!^M.ALL,_*8 FM""Q@-XY3U[0#1/M&8J-]W"%Y/%!1^5'L&"#X#4@).U*=
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MR:RA/@(22+JHC@YU5[K<JR)Y(7%(\?.MR\AQR4XFJ\; 1?2,NM2"6&HU MU
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M%_3>Q.^4DVJ$47Z-<CY$CB2+ ?C^D+; !/Q#HSQ4[<MP^,MS[OB?Q#]:-9D
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M^>@B)+1+5&:3U:>:S#!=JQLNXVN7:7S6*\\)YKJ-('Z2_K 8%;!+K;D41\T
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M/Y#P+.(D?Y*#4':9!U''",D=K4Z\&5#";P'-O.,U9\DAW0%V]N?'.J.H3%M
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M$_XIV;.AM# [.L$:BAE:WH A?(/)*0_>MCQ,.#..UE#:F2PSA#S#]1/.9@Q
MRRUI 4O0R*5F'UV#(_.9U2>6)'E'38^+S5JQ.1,<!8!WO;]E*.C*F2\C&)#]
M.^STGOJ!C7V*O2>;#QUUY>Z(QC6%2KP-WQO6>*83S'S-+W;V@;<1+I #I]:
MB!\3&3I_H%U!HTO6^6%VC%M6L[RD+RG7LQ*3PQ690:^E\D:<KQ6;::A*^=S9
M:4:V$/#C+$.XE7=Z<]U^\#'KB:U2L-C7GR*A=6\$[%/NF)P"NB\'+++<J]\Y
MYO@-DRV4"%#F.R.+:[G*RIZX[Y?DS^@<#0U:.= \HW,0U0Q^$G].@%&.$=JZ
M',HS.@=._U'B<X3@_/\;6!5;!^<H[7\A[S]F] =BRWX]3.*8 ^\OLMNG#J#
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MNHVZJ_8J660^T:HB?E\SBS BZ'@ZG<>_+(LN9'L[K-VS,MY!L<T;ES.J@@A
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M6^(&O:H!Y6MOAH>2[V_>4TOY7M%ZB^>)X3ZCG<_([?N\4DM\N/^@_2]D_WO
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M:W[0]4/W@Y5<8_#-8'KP[B4@[2Q)[D)AG/^$CCW5DUFS5;GQ$O#^2&6^4GG
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M>P!^&R;T9HI^8&T.L]X;8*?+\'LHE,2(M[\$7#?&)2>21,.T&O<A,=*BAC/
M6)^OW'K"ZZ&&ZTL;S%]FO@PTW7WZN>;F"NRMPQF'>S>7[2WFFE^D42."^%Q6
ME:X38B9@*Q[QZ<4'8=3 K#P?359 EDQR@ZZ'N =X4['5YLE(D]MWC%N(Z%HS
M-F](J1X! ]F_,F!__?ESA"E7+,QK;E[U5193H&3AXTZ&GF&>ZR_HS.-ZCQCQ
ML"NUD8Q'+R.\VF.7G.(]RP6:_U2W^FT'=.Z2)0W)^1R ONH_IS[]DK#>G$.Z
MS4,PW.:B4&*4SH_SXVX9;QF!:T4G]-@$+Z*>-K[GCDM?C$K)O8UJQR=C7;\Z
M+I>J"?NSYR'T/:0F)I&.8P%JG3HP5FD/KJ21FCC]^WJR(\J3V:*<\ D%*/;U
M?K?.I-C1-I31V7O8?:#RV4QTG=_? ;A/5D\7[=)19R"4EG0E#9;OU;YU5IC,
M*6Z&5==*AB=M"=44ZJS54M@GN+M?*&_O,YQX7$3Y>\T(_-[$?>HZOP3$BTJC
MZ?L#'V5NEF]->C_R\4J5S,19:]$[Z*6@'@=UJ]I"(@;0E<^A59D%*XK;UJ;F
M:%16NT57U[BT[O8^K\SI,P]9(YUO:]VJ*:T<<AB)_L=RYOJ1D):H1&7>PO2Q
M!$>FHM/&/?1PB%S<T..FYMV7+ULLM5*G0(T(&\QV_4E2(^$%4>$/ZLTH"GAW
M\[XO+Y**;W#V\2^'5_"'FARWV$G2?YR!U5SMUH'FJ-'J/49G)EDF8183:IU)
M??//-*G>I\TAN$ET)O)>$+"+BPOH@;&-GF*=;W3YL14XT^MM7SP__7Y-UYV!
MWE+GPRN)?[ZI0<N-R!F!1:]$B)U;(^0C*]-')3V9'+A4A,-I=A<L_':&=OE^
MQ)2WY(H$FI+G]M,C+C X\JU1AV&[\<_O1G2Q)^D/-_8T>D5T,WL;^\Y%;##-
MPP($M>8U Y^^Q]F?PFI!G=L!\TF3A]OVYQ-)9OE\V?Q:21KT(M^OFX,5W[-<
M#[\Y&.35L9#,1:O"\4.F8MF#?GZ#XB;?N&CF*\V5R.C3J&X $J)SMJ=S\<-3
M2GR:K<WVOKC8'^NY(,/)S:)T[OD#"^OGS+%L('[N\=!\.60;))KK#HF'-'<)
M8 O3]5^>L^_(G+]7,:XU75@UCCPB^#(4WCK(,;=+*!';*%DU[7^%C_#;LBM=
MKFY[Y68,,P%5KRZ)F#NGKIO4!NR$&'497\PZ=\^77._+QGP5T;?.>D)  7_0
MDD5,_"=&?"-F'#B%_GQ B&>P@B">B3QWZVYRQ!P$!@R&ZV3=!5$P8 ;99BIC
MS W&.XR@7^04O?//3K=M!V*Q!@0*MX4J\:ARD@!1<JKII7<QWF00Y:@QY>]6
M-V^6T 2BFNU)DM/GT%8RW3;=D<6=VR:BJ_9B>">030OT%D$!]Z>8?! =3*K?
M%]:ODZ6@0^HI.4+]RW,Q K\;S,("C.2'J135:I5S2_0-$P(L!,H_:8Z-?6?H
M,"[:N+T[]4%8M=6ZMVU*?Q!H?51;@E5Y=%%*8L4#NP+GZ<>;5 LQKC*5PKKL
M4R\*'&OMRVCTQ[H@%MMAH@2U,!5<1*F4M6Q'MNC$RGM2,O5Q8W\O\#>7<K+G
MWT[(8\C="+:@J!4X]@SGU8;&9.^$.,4B=SINN90L6'91_%A*ECGD5QU2\;(M
M"EU(AMP)\R#0A3W#&ZU ;[JI<%\YS0^U70V!L<<WO:1%+C2O5^>KL7_T?),M
M.,1':*4DQS!N+=?9BG]7OSF[@2U;6N&OSWJ2]? T/53(W-R]NE%I+=]-H3RP
M@*6+M6TX6X<8=RBU4PW6G;;\?B&/W^A6X<('PK7*7+-D3CX_QU",5@I#OYJ2
MQ1U_CKCR_9%-KV%!&/7:*:G&+V(>\*'>AX[^9YI@GC%$A-R555*/$,3'7!%U
MJPU/Y-;R_"7@!3I2OK#6GBJ%=X8%&,B\_H;]?"/);1N)%_#OW/U.D,&##1OK
M\]=W5_O7I0Z4$F.2GDQ\3<;1*YYR7E6D4DWNVXQ28](C"?WL@"9'O@#,6*#'
MJ;5)K3)?MM9,:5CB?+H(?PM_*9]SL0T6:>V_$^Z((U]&QI"X^'*V0Q)A61BQ
MY>J/5L]3]C+?&#^S_MM__RV L[DA?T5C\M6DWW:XVC5.MB\_LOEM&S:%8TQL
MY"GNJK(,N>V'DFXO+$,8_C4,MU-1<YZ31EF4?)?JG0B/1COKV0S& @MV>'P^
M6S[ 1?5($ZCW=2V8N&Z%<?GS1J_'MC8\/ZABKP)Q?F5/& *;\+*GX:=*DGL%
MERK#&CET9XSSQ81?\AXE>([J>D!#S])B!QQ-$#IB0G*#W5\OH#&]71?BX7U
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MWH.A)P:F26D@_E&L0W[)WE8$TIPT?0FXO2?V*G*A8^;)K<);Z4W1Z4Y)VG:
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M3< )KMD(ATA!M$UD3:9J,J<D%)0"7W1[LU#<W7Q(:6*H$%EX%P(+0B>1%(+
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M%17 VU3\3$S[B!L\7?B5:/)+R]](>G7'8FS<U]W>6RZB:ES#;%L"^(<F1J>
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M1(<=[00WD!2P]J(PHF= KF]9P,DQX/G'F"4IS:>V?K3F]REFBX\^%'P+RZV
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MU1@+$OGA6:J$ICU.O=F#@K2K:_WA:I1-X,SLM5I>,^J=+=/;(,!,U:>F<-5
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M5NH:_M:!) ?>PV_?-'#*T;;JR9D:DCQA0:EX%36&>R4H@U6X?NGR'FPGY%7
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M%*MUF38P/8N(V]Y1)&]^EE4JU1WY;%,P92;?M',E>*X$Z,\GN=??H7YP"N"
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M@IF8;Z5=NK-CI<G9EJ9S@^7U)R?\EYST*AXZEXT3&3"KOJ:#W<SV?S#@D%/
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MX(?7Q\L:14KGYV,*6*XOJ5QXUW8DL%:2#L.6L>$HK.$/6$R(BBD=R@]?TO.
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M2V2;;VFGW6OR\G6'#2WI@, 3K4^ [B<)],X*],]EM!L0)JZ+OSN]8H]Y/\T
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MK2M<_^C3/R_;,.!EQG.&QMK6R/8-D7B65-<+0I8.:.8^\6S=U!.W.UL(V?O
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M[U&6#J71".V)RQ[N>*E'9>7G,.0)RM#L/2E?0ZF"^#<V(6AKE\DT(9M]H_#
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M?\C#&5TQDLF\*=@%$F[IO],U5JK1U%K),D!:A8KK$EI+782'0FP$W*5W*D4
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M[Y\J>[^]!9[:P%2,J*/W%?0KNMCSX,B,HX3K?:-6UC?31T2]!"FX]T@[61^
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M:SYSV>JK,7+@8UN8TQJ<JK>W>CSQ(/HU7"I<8%X(IZF%U&G=![/98A9LR+-
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M BFZB/RC?6HW&S;7,X/*FX<U(E_?RTCN'%P ?$Q31Y252&+E*4,N<;^^7$W
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M=EDND:1'X(JNHKF%;PL2+;(8@<]M]$4?J)-\N0M%YWSB;Y.SR+D4&GO(, J
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M>G65E!Q)EFWOB7 ,>DWW^SS[OHBV(I=O#)?+GX#-;4L/CY<UT7??_>.G<F$
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M6V2$QIW@9G,R#$)/DA@W.3/+U$VAGW4*^=)?O8Z/R9)M;$@E-O;E+U&^4@:
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M@WP#'*>9@-.#N9_/'I+2SS$!JH4[<E2@=383P"MW]G. <U 8JTN^SZ\?7/!
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MP=]09'L!*(+]$&9BMTUYF%:R]G# TK'66Q>[LC],X;XZ#%T>D[1<W=QOFH5
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M[_P,J9Q!N5X3G(8+^I;[U"VK!K/=.AVY9[3S8C3A4/*RIK&BD58L!VL^;?I
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MH'74.3/2(U>B^+PM[S.U%46#[ 6&T=#4U(/@I5)VSE\>^Y]T3\T)9N.+@DS
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MR&_#4"1:!;/6;?RN?MC\_M@W_!UWM;>+>'"VU91)]C7?ESS IDD%>=TY:#P
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M5$!55VD?<3M!KZ&AN;$I[HNV9$JJ@IT0U]WZE?L[5!/,2,>RX>JCT^ W&93
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M7+%.01>)!L7!;LD3^R#;Z-6951ISM> X/@WX+W@*>2CB<^"L_[/0_W'.7^S
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M/1!!JAB_V7_^'L$Q>H2:K,X?LTA'= S8>6U5^/0A[AYY7^:6RD[3T=?<UL&
MIQL%GZV7G7JK5RBZ*:@ZL/P1JQN(3,Y;&B[=1R7;.L#'48I:7EE* 4]6<XG:
MS5N34\.F2TD)2]X#SL0WW1W'1=LI^D!>A;AP NL2TR '_\)D3LW8!_F7(QR6
M;,PF8P'<=$B20C0R>G?@WA>6E[8)<97AM1708P3="87>]%=O87Q9[3V_%_^H
MN2R;MYSO'GF44#Q[WRL)"^'K$DFVL!@H\>]?]Q2J5$0^=JQ/\UX @^==]Y.'
M(]QX@SWB06.Q(^W7*WIGQ"NGVX#[;'")]GK7'N,GY+]YG#6 4USU-.(8]8PR
M8NJ!/H^_FA=[UV +O<X0C0:=T)*^ZZL5W5V7\&>8S%H*/('+V1.U6IX;I$6-
M+]:].V0K3,P8WZXGXHU<>[6*YN<7"\GL?D%%L@TQ#I-8B)]LKYEFVJ)S3CE_
M0:WO7[I%"M*;2<$')V"G^\G-^W<RB]$6S$L<%'BR2:%8;)D_4F/18(G;.H>L
M)!-70BR*'\HBPLM^G\Z0Y]G59A'!:C]>56VK4575Y 3,*P6D^"#!^[7Y%!\'
MBUNY,]7NA4:)BFLI1&VJYTE*GD0OCT3\*N-ZLH[=1=A[8C6IZ*W5'V'A3L'<
M$;;LP,-F>H5MI.^J_!"E(U6/WILN]F\6&RWH>+-O^-T-T8SB:VS2:KA_&SUR
M0N/3<#E^<VB)KTGRSF,>6$E+0NZPGO'^2*26L%8_,5XNQ^&Q0X'IOGV-K3$V
ML^".N[3^C5HUG[@..HSM]JI+\."OK&8!C^>755DF%^W._<8#COW:?/19%1KG
MKC*%V'J@ZJ[BTMB)FM(G8<9WUO$/:AE1[4M\,-/B'+['/(D\.65Y8QON'N6E
M\& 5<^W1SAU"W-.5[*+2R89.@6P-TV5W!\$5]F^)O(#+-+OH>O *_#2_XMN2
MAZDJOQ#QBU%4S_A['B=ZSH =156WZ;'"9)J6[(-$-@1)'NJ#"VSF+/*6YA.4
M67Z0S(9.#"=P\RH"28I;;JX#'FEY5]J65=N$NS'URC(G6!#E;99+JTRORV/_
MTHJ4;3W0ON6N?%Z\6490Y3-SGYNR?S L%^9]4'4Q.?9/=JKC[+F!#QK'2$";
MP!,)"^='@3<-';@Y)1A.HN*:23]/0MJ58%X>\<](-Q/:][>GEY=WBN][:'8&
MB4REU!?WZ6**\S4M)OWZND?;C#!*[@]9"AYWA\#4@ZEKE2M>#1+1,X6PR[R<
MM0*(AX>_&^,5H7&G+VCL-E93%.E?GB;2 ]3$"M$#@XQ4I1,[_Y B=S?I?KT+
MO\O"][]&3=#6%>9W@:1*J?<;>\.R=2_N?TD,-/IU8?ZP\>G\:Q\DJNK(K-_!
MNS[ 1I$[("?;2'/JV&UC?&%PM3>'.7[HZ[!5B8$IN"+%VUJD?Q=6)!S\_4#3
MW/>;N%ION.L^Z]7 ?ZD?LEN<6ZUW^?UITC6/^9]=9P#_!;TM.*4 .UXRC+K&
M.%#B.S>PFG:B*/<NA-TQ9/V@@3;F3R@Z W#:9*K>,0/_^8^I_ZL;G %B@(V3
MRD=7"H;^V^0[D^C_UB,?>.__IE7M#/CO=?9&8RF]0WJ;$"(]S?C<@A*]^7^I
MP[)T?+K5R,_@P:9)C(?:+1\12XA?#QX]IDU7)?1:M_C<DX^X%8+&_L^.^7\C
M)$7DA/TZ1.PT7\'NIL!OCS6M#3WEC;A)5,C#DX)3M8*3BL:9);ZWG.4Q4=Q3
M,NGIL6:R7)RW;'SZCHZ)IK>TQ-.]#?8E/<:W!004FPMV/.MKA(M/E7,&::8/
MZ[YIU%^+?1_->#56EFVW#7;L8ZW\[3IJD;/&0_KU^C;3IB]N8K\=M-LSSG-S
M(M#&^<]']XG8 !P]'0J@U%;S,L!F,GM*R<3^,C2A8YJ0V0:'N^WTI-RS> 6-
M3JQVA?'$@S;--)^00@(+/',:-DWFDW\9^GW,Z9IXER(BZ#FTGC^4XRG5/L5:
MM.9O+\:+8)MA@S0K1&=4%Z>H?EI9%E6;YTVB$]J/ 1V0"=-89AQ+VAR9;O'2
MBW#DKB=V=KD5IOY!4BU,JBI534T453=OA\$LV$)F%S4%30/(WP8#DBXL^&<E
M>)Q4$M-[BQIF9T4]F0V,YX/7Q^ <R=[U6(^OV#AQ_O$Q(60,2]K+B8C0&S<1
M,CQ.B^P:[1CF!;F>HCNE+W,T'!]TD)5(Z) 0&[?R3>T'EFUBW54W0'?0":%^
M-$[0CZHGE<F;W[Y/D2M]3LX '(%SC2!2)(O%@<OKC0-9N;@/AGD@OD[OT1W=
M\CM8H?5*K-*3'#VW59,4[GAPJ>[/LO6%X"^VC:G5,^O24S36%]^5'/51D7":
MI\'T.*H<0\H(7"^^H))8YEEAR,00N  +(;5XN=&]B'QEGP+F[PJNU>O&?R<=
MSOTN=]H6SG[<R4^N[O:&^9Q*$-)H@44?VQ8".=[@#5WT;OK?$Y#B<+][Q LK
MP H5XM7/I9E& 5\GEN5U\TEE9Q.TU7.*+CJ53^MV?7*:59F5@Y .X7P*Y$[/
M=? TIE(Y278\X7(24)CIFVP7U*E2J84@E*6IW?;*X9P \J1WA/%0=L5M>[W0
M.&-Q03(-.CG5V2J@G@T3T4NQ'3;\&H3K3RHZ75@K$CJI##:M( TA-_2ZY!A)
MB&T<>&)#N?F/#'@KEC'P"'[E#* <];PYTQ/]<#PJ8P-VQ%B>Y7:UJOG=4];.
MI0!%91%:)6; @46OL"L]"0BB4<J*>J8%0(;4!XK#J,(49>?#.\5C]8?E!OUM
MDPE4=Z6W[8O,KX@ CPNWE#_[4P@Q!H83W1#W1Q(:B%DE0V!3T\SLYU4EU"A)
M2X!KKY=?U(7.SEE9U';=&]#.<0;0(J\U3Q@W:/ "5V'AQ$;V0XYZ)0I34B'#
M8\/TQ,>&$B8_,-V]3^)-W6:U+3VRZLL5D&Z+!BX"?$IIDU58=$;=1UAM=^Q;
MW(("U8J\=8')X(#&/.3R1-U8C3^%;DW"ZWM(>0*1*^3>]MRG")<[A24>AG]C
M!,.3#S_O<$ZRDNO=>YW89%P+Q+]#NF_67@9-)VX2Z1%0F%E]O/U*&@H([%43
M-DS(V"_/X>@NV0(ZEP,E#[.ZN[N&TZ:-CR<]QX[3>O-^6%C]6<TQNR9Z82'&
M';G'BK=IM)CY=\(ZMUK?IQA^V&'9/:X_ W3^H'GRJ[^,_8570:=7LBO"0XKT
MM_N?N8]X-!R>AG1BO^%+%3BX686=KL X'==[BP93:H:+)GV7)OM7^PPCR\JL
M.D>7<K(]G7XL3EHN%D<G+VKP/.LL$X_9"=4XQ,._GP&:H$X[K3XIAMD?#;Q^
MQ^QJ3\!#A&79\[O:&Y[$3?"RZNN)$%@ (4HDCMVKK[[45=.]3SAN@GZG:V11
M_A323@(G_'TK%IW]-DE05:,Y1^ GYDY".4U("+[;T";<EV>H1?!R49$L3-#2
MK79-UUKVF\B[7D9YLNK$??%W,^L24/F3<K* !=]]7MM9?96KWBS!]K[KK>XC
MS9X"1;_!QW6B=DCY<X3<U4T4',8AP&G]LB)UDMV?+2H<:)N^O!:PR[J/_9EC
M,,\:4OEW6\V$_3NV)\>^O!Q+R<7:?#)(D?B >6"4D%"7,>:!4_I=4<\\,-91
M#?;=EE>+YQT['T1%)^;*,:K+TF,([/E)]7U?GD2:M#A8+BSYSVQ/A\%KAX6B
M'3-0FGYVR/C )E[.CF"I/#^#'Q(/'WPRZEY[1O):$@6CQ-T6-PZ+Q0/RR_.U
M7(PQ/ N\&SX"#>JY&<Q8AZTG2#OY[8(VPQC)'VAQJ/=H#LSS1_]2B'G(AFL<
MGIH^\Y;^@FTL/&I\\\CL*)AX^/X,T)R'/P.PQLR8<,>+Q-!TNT_UMEM#, M!
M'N(@D\#T6I?:J7VB=[6QH>9T37FU=?+[?WF5Y3^GU T/<JRIC6D["FO;_'C8
ML"=!:[#=BS@\(BX)!8><V/^J3&\CKNT_EY9O,-0[V4OIN_^S"K/^A&A/'8+L
M5'N!]::_QJ]F--Y>8AK=%$KX>^_\Z%>1-*#R[D"(C^TS,UQ(:5C)@>F\> E:
MTJLIG%9!&FY _$]7D#^;RDIL1/KB)/@9('O+[-#XWYET/U6GFI=OV9T!OL1-
M!&\\(FIPL_G23_]B/SP#F*!ODH[IS"?$&T<K4SFF7BPV=G73&-_%/SRV'E>]
M'W?M\0$8-]>&5]TCQ<-\T%;WF?F,D8[(E-):@E-%E+]?R?WL%1MM/4?D85&_
M)^=QH,N6)6<O^D-Y11_Y'KA4\Q$;CXY7]B4\$/^=.E4&4=2$R+<-6MWDXRF)
M3I55)HS'X*KG?YT!-+[<M"3KJ] XP(,DUL[Y6W)>\M>?4GO;<CS?>#[(F'V!
M8"N]:\+C=0G8#B:FG?H(%NSJH/1&!2SZ:CQ\K'X?U%@K#=O4H$#22&OE0M6Q
MPGN25(?5&53!L-89(&]U^JK"3;>YI5U=2^.XHB+?^&J(=8O'.,(A$:(P<P:P
MHKQ:$7.Y7S]_]ZA\=0Q25_6ZMPEQD?=*571]:=\Q,9,"=0T2/WC#XT?XN[=^
MV[+PL\S#N*!2+N"KD5^\3IO,'=@G!^K?F9A=!\Q=;_/HPD524MFX>#XWC=>'
M+A.QE953 >YA* >;'(M$@L=)J;]!E.78/7_32"V9K</IA<T;J+<%H.TD9?]]
MK8GAL*^)R6/.\VA3AX/<19+ML.!LW$L_[ZZ+A=\7LF/>?1.L.M0\+.ULHP<6
MXUO0ER_%S*:[>ZCKIX@E=QA5V=%5[[.T$\>R-YU"(5^M_2S=Q3X.RO%0[W]C
M=KQ\Y^9V&0CJ>0$.,VF\%X!I2:'=(_B:Q\4)F@R_?1/G?SZ@F9>5O@]%FFI4
MRXO3[_G]K4<2Z6#Z4=B1<#H 1@06P3U[5LN&E!8#7%<DE_D]^$6#2J?W74!"
M'MA>8>,T6Y?ZN.V7I=^,VY.WSCWDK'X+#A,+96(_;76R7EY:JGS\F2%XB94;
M@PD.8<KQN_^Q" E]>RN:D/SG^_'*"/WC0(]ZGVED)+II3&8/E\>.RKX_U6O-
M>*B>F.T3R_'\GO)3 &R'EY4&)B&D+ +SN_E>9*BJMAG4ZGOZ4LD;ZSGK??M>
M!U\J^?NCD@8=%]S?9.TK[)828"/SIK)I@/3(MJP%WK"6<VU,BEX2Z#^9%6)J
M _3XU+#OYY*>^N"@X83PN/8BJ')++R>H'Y)<TA^3ZG&+[1TD@?S.?D&VW6<)
MN%CU-4.YX_?M*F5GP>P;RA^V[B&VJ4C4!+%CJ,B62?=U-9NK=EQMD#AHRG^'
MH,ND^G82>Q'J#?6Q6',=-JT_]!RO67$(=$9T(5Y)W$Y8">3$5IX!+&AI/P?H
M^!ZYCYBTS:C!4)>I!]!AU\XS@-!5\8^/O=1YCK91) )+GL[B.)FKK-Z$*'\'
MRF;OA G:)"@J>K!G@I+T7*Q;@_?C@$^J?QS*K:[[96'4?(XUY7 @CIVR$MMK
M ]1 5?/ZG?*:Z=*P;J@F-WKB_ L9+PT% 'B\0?7-V&5!3%TBLK-V_QKB$H!A
M/@P<D[G>JGGO,_?Q->%GMB2K"NU0;W4.U.B1'>*KR_#F(H\W9M_I%P<YNNZ(
MT6VYU,KQ^M^) E:UFU;Y[)SBIF7Q)X1#9GZ0R];RCP\):T5/<Q:G46/"Y-P3
M\<BV[1:Q>LKJ"V^9F4M-?QBB6IP:E#FJL.8')/:J&)WH*TSQF1<;9"<:&YH5
M4"WD/!I:>DGN%T%*-MLJ/SLSARUJ4J+R/2H\=V5'^;.->(15.2&9JV=X)6OA
MPFI[ZM^@+$[89@>UU<;@6U^BRT"41FUG:^=ZH4<2U>W)@-:8TFG@Y*45HPSR
MW?4KF!H7H?@!G!STM/VB.WOR<L,0GQF-"_":_G<''OJG(9E(E1>R3K=SD#UN
MYV5=^-W$&>4HM1HE+V$?H2QJM054L./MH]U)7K_1\#@KP:5))3S)#NE!8F&#
MGHMQ/0SF:6F _A[V^9"&./J99S[I7'E0-KF<BW$0%%DWVO]1=.]2D:>?F*Y2
MWJC[>)]VJBW^^E/^GF=O<.<3PGS:\T@8O?:LLE^_D]G7N2]P\_LQI(RC4DF+
MW(W!%PW3+CO&??B\8A8_?^,#E [AM DD#:/I'/X\,9VXD<_H@]R>5)=E.82[
M=7?Q4BFMVB_C=7MA^4:ENI;9A5-C4C#VJKJ7F6JNXKZ';[,X+&&]6U.=TU,K
M.Y([GWMD) 09>K1DQR:N1W!SLY(Y)N6/4I)UY[NE \P$]>!-Z!Y[R(G$6"WU
M6I,<\3-7,N7OWK95)X,03^Y3G2:U?&UXVX4;Y]A%Q0[,SA58NJ79$RQLS:U:
M[W<L/XV?>D6#R,IVL)"Q]"O_[LJ5/]$<DN2[F[<-#)(4,\8L=OR.;6QC(B):
MU!K+#$H+0%8E1@>S3SUJ!'8_CA-AW(]P(16X CZ@;:+(1JPH<(G^W6G(_<&J
M^&&<R@50F\R#'(^/MC4QW^8AZYHYK]HB';Q>9JB\8SCO$T[$<$14-^5!+%E,
M!\SC7E5W/E;SV4)25\#+T]&I6"/A3B=M.K,'4E>+#) DX-1),9]L=Y?\$G:,
M[ U.S.(97PS>6B*4+)173$WY*Y<V'DCL!:BWK'^]4E]RE/0%87_RMX<@MQU.
MH=HN+=B2KYT!+L%4;QXD;>IT%"T69]J5CN^G.0/Q(=O+MDN[M@ES_#7E^9.8
M3J"ZGHU;R/Q8( ?RCF%0@66QYZ9WT0GU]8](@?-__D,O]E=3#J3-+$ON=:3P
M0-K^VGC.O+F%]WOH"#G6J184"U]L .,5B-FVL8+%E>?-5K?F&:M&H&;I :P_
M7-9.$GT-(,(SAYU*;CL=;$YI@%VM_Y!$^$.4LO03'1+7&>"1<E%0Q*:-)FE0
MB, I*[3 @!3E(G-75L[N8+&\*5U?D&%>3'1+>CO86-H3J^RT>-8&&FD>]5Z-
MT=^O$[BBYD:J*C&(8M%LUNK"2%!8MCSJUBO6CCC!S8S@=I KOWZ,2"M\04#>
MLI.R@/7IL@2I+. ")\.%U2>I[0H[[,]Z->_T=SY]KE6H_L[:.T"V8TEI3YY6
MUMXH+MZ6_]+5ZX3S&V.PH=J5>=^.F5/7AH,^G=D'BG9[.'K\UAD@XH F8-WE
MLXC@ONBW-AQCXJ+I2X1,+^*7$,K'^=X-L?5*MJ4PD9-KN=/7BXJSB<\>?+E@
M+QIR<'"!]+JSV48TL%U?;NB@Q[2B234!G72%+;FI2<'WZ/;AVU^2G6EK<\XT
M"D,@ JJL+#Q!XH&LM$=/$$'NI/'[/N4:#KC@?3KDT7[[H]^(C)5J;X&G?)JV
MYK*M;@OC(**H/H915:9GW' A1F-47BD%ZC+N+?OF\+[+L^U7-[I'&* T'CL
M42+O56IJJN:6RD1$];L=Y>_LZD%F*H^[=<4JHOQ*3A>YJ/R:'?25UZ+K3_E[
M*'=$ 1WFHEZ7?&HS>:-3J<UT6\4C1A"'*]*)LYWL<L_Y<2&*(E-G  BAX/'3
MV@HR3SU2:&/'-D4([9/1=_]EW/>4A=CSQ@S4D2O-' >[S(.:=V)88V_ILSGQ
M^L$@JV#\0'79([[>/UYG /]*/1U[GW;/[GK?9/]@US>#GT.^:'"1OW/'8 W0
MKMWW<^[4I^E67OB1,JHWI5>4L792,1(P9JKE%5-%NMPEXDL;B+%L+/5WFUKJ
M%+A98\1]4Y23?T]1+"%6W8ZP236O66@[UKQS2R@Q*;7QL]( B!Z,V(X;#):K
M[+_B.'ZYM8VQO7D,T$XORP8^>8%$0WN2)_2N9:ES6V8Q5R.84A?H+J;0R;9!
MSRM2T/$$R'UO@]SO\8TRXM "?RAW'-\ XFZ!BVJM=4&!HKPO =ZQP_KF]7<Q
M_$E)$VXV(3Y L72$INAF_>=3[,.NRJ.Y '[1:BXGU+-5I7(CT._H@9=O<TS:
MWJPPO(8P(7R(>;86E5P7D6W/_Y%&JP? -Q/"ZGV;"9:/'5C;K@Z[8PBIEAAC
MXFQPA#4?R+VZ8IUEM-8UP=HT'0L^ TB3]![ZB_TY _Q<K_.;7!ZJN;U+-8C_
MZP-.H%4YK3&V0IT&R<R&>[N<7:],/NO5AH*FF*9(;(P@>" F>^JM=,";&'GE
MK;[77B@,1H<&:9;!&RI12DJ0:#WH7<-=6\;T<7M?Z2Q&QT%+=^_&4J'[B[N5
M$K1C:U8/IXIC+OF2#(/?^^D+,T=^9"!G7'[!54V/^Q+'K0LIT7<8-A%HFVG"
MW2%W^S#.V,_=H;<SC=JT[;WD?*(G]GZN/XX>XKE1$/2S-?TG%UUL-AAI'VRK
MM11I5;H7:09RE;88[?1>+J_V])104%@IBZ]-S,;<'5@8Z/+?<C\]9LNN_%7?
MGKCZ/.NU'3I=*95EGE%%$2<W/"A- S-D)-YL?RUWQ)C%O'A[Y;R[01I/"%_V
MU=N+$YS@3JX]G%CL.5:L$2%CIC0FH">J+"%:H0X^$3/7WACL5IS!NEWLC-%5
M?8K)!YD.6[KE8BVM.8KY;W]XXUL4( >.IPS;Y$_M._;S:&5&=EDZSR"=X@@
MSAS[B=%%S[)VM%B OMHE<3ET4TB4I]8>[6U%FS'W(EN8)3O4J1@>4O1B\>4C
M2/.47A?L7'AT.TH]6*D\Q]4WL1JS81@EF2B':81AMX>0?<CZ41A0R<.R=;35
M?^T,T.J1'KCM)W,Y+7+<PSV>?>#W2J'61MT_\+%+9BD:3_?3?#%/5?;:[%B/
M&X3ZGPA$#GK,$=:BQMJY+S;[ DHEO%3.&2/MH3?7K=T;LO8HC^T>1/PC_P77
M,]1[8Q7E2>5>%(/.Z4!EV'&%MFW*SN1'\QJCR$1;@7FK9-M[XF#]D%Z_FK$.
M7'59V*) *-O:F#^X#PV"MU.H5NNA@O%ZMV*MPMV]F@..1PP0>^QP6H; +]%#
M+ZUF#4?;;WN\J(,C1H&X#:DQRX ?]N"$QX37B)-&_BV0J*CQKJ+;DG?JUMSK
MN6ENA,<.V%5,;[*F/C&^86RY(JR7%Y\\!_$S\#.<5';$P@(K/9,CEM$?GI\!
M')ZK/(Z,^KMT)_@;#5,$,>D\4.PO^R:]Y<?P:RG !GWJ,4+*@20=HZR?=M-]
M2F1.S%,9&QYJE<'H0GV=MCA<0J@,-F> ]C2S5?3"Z7]]/_-#_L=\"XTAG ?;
MZ:>$,\#WM/K_/@%L,T4T;MT=/@-0"D*61(G%Q+C_T<$>>O7_<G(LV/UOXC//
M.'1G/H8?!R]45F;$I(IM13]N8R(?!$.HS',T>F?&1N],3MRU;2".T)(AR[Z]
M<P+^?ZR>)^^?L#.Y.#:6>R(PMY111/^'1#IGSHVX2?MPU,3\C-E1+/'P7R1I
M[K\U=@;X:Q+0Z5?Y37C-7T:6FW9+OI"TL(Y3TY.=N?]%4TU?5Z97BMEM:;]Q
MQMCA<6\7%>*T6%QVO-M',W07FH$A#Z,6DO2CHK5OJ%W&8X/=#!?OEE4V*\M+
M/V,=T]^?WVTFQ[0/1!7&"DZ]?K%PT?IK>,:,DR*0M<U+T<U5TW!OA,^(_.F!
M%],$^SF.*E(Q;*Y1:[:&.=\@/0>7<U^SV)UG(KXV83Q%CV*G,>#>QF<<(Q_>
M[_*DR+<!6B\]Z/F).EO5^ EXY>^OI>K#[E#9CA4H.H]BJ]8^>ZHUT.FPU1_\
MS(Y.(7= 1=8FVRXW!!6D_0>J$V%2'MO6?%=5W@\9SV;'?H65?+*]*UU>(-40
M'\=\.O/Q?,5TXCF6&;*L F.VW49O<.ULHL 9P+DKH&+Y#\< O_7M^,A(/;^,
M#"SV97!X@H/QU+6T;""</4.C+-&^>/C+-,Q\+:BUV$)/<3XSY=RK @[ORZOB
M0-+)7/&!)^B7@??^]>.#,\ 0G\XGG(Q]\@/P=$RQA$V$E^07R:^UB]:$P@AH
MV+6[8X=<[WC9Z%H#:5_\'?=EGC;E.9Z.=NI?HI^:.0]2;)0[39;RUAPN .58
M^+2H=IU0)Y?SQ[6QK>@K:3/PY-=(=SYC9/:NAT#RL(6O7UF*M3^P%V0I+U"M
MD.N9$?%-]))$>#N0VO[,+?YF,T2QV9%_/"9>;+\&OHJ20]LVW;96*[>OE(D/
M-/=,1_I0"(B0H\-"AP%RY+/^5FYF( \W&X3R_N2 IK[!^+03+%OG^.0C,_X#
MQ'[A/E3-/ZBSOH$=.S6^!.ZF-Y4P,;YC9:CE2K4N.[*E.AN/56C$:88-(+7.
MS8*7 G@VH]UD!6],2F2)15W21XD'-G$K92@EU4O5EC47<_O@90TE=F8V#UX?
M&SF55GX""K.S\$2:2O)XFI'CQ= >;K-N7LAE[=G@>4X1)SXMD=':@DKFAO2B
M/;$6G]:JW@;7KU-ND*?CZ?W3"TX>$0KCZT[BOFOJE<KDRB)7"TF!*JU6?08^
M=NW7F_AWI$9/W =MP0L=OQO^:/#DM<G=1-IAB)5V/:MTR!]* \^NA5>_VE=D
ME.AD(6.D)#.-A+WUO<(7$MQ,$\*C"/"UW=&E+YE 4/;,6E9'SOV\@O:4Y!7+
MXV(*)KF'(IGW:&OAZ6ALQ$6-&5X%L@+Z7?"CZO&6RNW)H2\Q(E6QX@\(6)UY
MIQB,Q<=<M*YL\Q,3;D1<&<(.L1T>B;OWP/X11,GR$R]7>,(!VQ:<Z4VKCR-2
M-S+J<EN8B5-WKP#/:2=/40%H3X-X4TOJS;VK>=(#8,\I+4J:MC8PV+]OL!][
ML>ZX+UY%EI5:BUV._L91[Y9;6U4>:*B[>B?77N%\43L=:OJCEQ^"+B,TO(HJ
M.R,,$@_@0*&3/*TZZ2SS5('&+2AJ^#CV< =;-%O\L$6;MZ7?0RO[:2^.$L"3
MAJB;.PY.AJPFY>7\B$]9O]OO(F2KO83-J0BNEBENL&O0!-!6R< +_LL'$$ID
M;BW'R\>?#8.##_Y!\F/O2P%*PPQ]WYZ8WUB7W<+)P0-V]CFUL#>?;7I$[3DM
M-BGL+C>?GL/V;)8:M0XFF?&L "?;U2:R>MEW2FJ6LPT*\[>?&WP%B2$$R9M:
M9EH@:4W%!@JDNA2Z\6U& S\Y"_, (.V9;";!,47J>S^I<ZHZJ8_G5$;AEX%[
M2M^.-E4G##+5K>)XG\HEXL!5$.HTIPYA8%C@8]0ODSE@XAYX1%B=%]5:<S0P
M<&=9MES>)'?<S#OI>_IR/1&4PG9H\G0+UK5R6CP05.*Q#Z]Y!<_I#-,3O642
M2"_+VS@[?D@>UM5V6+K]2<F.30[*>$7Y]!TC:C?/Q<Y3^+3I@^\?NM"NTZ]@
MY#E*3)$^JLO90?1',EW!^R2N>0ZD'XF39 M30VSKW+V;.&[Z,X>9,R99:P]&
M*:_#KKP IY?OF-;9>3C(BT"*_L%YXE ]P[BBM&7JY<J%9_A@#6JH8NW1D>&T
MI>Y;Z1XE.W3B;00<ZL1>[U8X$#.B+?%\A%^C"\5(P -FSJOSQG25ENNX:G+Q
MWN9SO#"KUAP-7#^@L1<42,^F!3J:")H6YT<I.2MFLF(#U3N=4SQC82#MJC8<
MM<$ZL:S4OR%R;:H6/51Y<C_-Y]@^X,:Q;<BR)?$HU.PP-*0YC^1)39@QH2TU
ML(MUU 81CT*(I)'&:.GR:M^*%EY8 ]6==N=?&O9F^$_Y8@EL5Y)>1=!N%[WP
M^:4L0T>K[?U?YL%)1X__ERGF$X)9&W$NP#K[L.39?_G:[S%MYW\M;>1/2:BO
MM&Y83_5*$6A\A$Y,<#ZBVPNJM<0R6,EEJBQBZ6DU>%KP-^QW 3)Z=&S,TO/:
M1&&MSV),C;?R\ 0GQ?:%<>S_^8*NX_^JKY:-'Y$&@#_D.J\'@.0OADA/=#,^
MX%[H;%J1Z/4.%MB\NL3!1(34?D)(IV)T_3KB^=ZIW=G$>6OND'>_,_:_$NU"
MAD_3'PT0/P0Q'43QMM@RCE/X'@C5]99KQUN>&BHKV!V$G@'8S&K[+HE\N>1[
MW1ZZ7!F^_9YRDG<&F%EL<VY\)R [RKBH/7</$2LD:42)/@.0BT+RB9\E3C\6
MVF'WW!>5U_\2#\W_I7M<)#WUR]LSP-9T=^.8_(UW.PH)" ;:!;3%TH_Y+,-^
MPZCZQ<EJS[T&R_#BY=8!XO[P5Q?%X@3=G7K\XN*#G_$:/[R JMUQ2%^2HKJ^
M+ MIK$S2LI&[Y>Z^C:;O5P CXZJX*%="TR$<+JYVW>>>@29/',LGM2'\;Q(E
M+J']@%CH8G.GEH,3;I5_N'D&*#":]"NE2YB@ E[[[F*GJGQ$ G,-+K)LXUB"
M35/^]I37<2#'I*9H3GA2_L]*;;7\J>NV-::6A_4GM6DV(L1R6Y8,X,-/_B4#
MB=F'XQ6B/I7<8(4U>D[;YP(H0KFBT=^TI&2,IZ=<3N*/M_HBN'N;[)O+A*HL
MO<T+::K%F?9]G]P&:B<V%Y+:I&=\XG:6X!*F/$,Z1^X#$ZKW2U^^9 %.$EB7
MH_U##/"<!1LH,[8"[A;3</#/Y>$"?P=^JR^CY;G%X)*:(>CR8N>I^<_G5]IN
M1@@FN.NE::>)0\=Z&\9LR!4G0@?ICAYUFCY%W"$MPYH\INGT71/N>.!;-6DD
M2=GP$@--8)/STZZ\=F)EU0>I^#4=OM-#NPXK!B146@QAUG$76C0W 8_D+NMI
M9?G$39^W/ +[AQPM[GFYFI:6B3S\.Z,F@T;^5XN*#68#BW<!M[ZK98W,7^"3
MBS?.$38E\?)D3Q*S](P3)%$VJRN:;:+Q5K^^:OH 5;<%(,O%7^2SRC9RTWDC
MZXPNYA=SQ;\N+@2-#)8Z?&:=@3%.:RTU/'S5^X.R/EO/RI!@6?(KC8,.+97(
MGU!>O75P%":+$U=BLYYT3HO:I?Q(%:+J?+@=*OH@LUTQ\!_@'6Y(F7.SUFZS
MLQ[Z]:M3P<KKE,=G FOXM]''<K8D$CA>E*9I$Y!>SFO_O0PJ Q..*JZ_$B/%
M3PCKK_J;9#OI_MB^*,O=M<&)[F=KX<@*AU^EBX*A+.(?K'\(#IVX2XJ%GP$,
MKN\4>"^[L4RD7ZC=3)J,J:6@"<1<^KP@KTWAK_DKI..G=ONFE-#\[W;=^.=3
MIPT-Y0M0U<)](_'VL+NWS@!B:_231V!\</UO6Q'UCS])I9#+4O*:-J"QJO%T
MS,G%3,+5^*^Y9$95Z0%=JF.-2W&-K5EPO9BCVE7C%I/W32\0<00%<,P9P!38
M:IBAX]>3J9,*%&:Z-D@%+H>)>@GX& @!XA;TGSPWT&<+$T.0Z7[1;P*IJ&"^
MD9;-KN\O>Y.56X"\H3 (+:D"'C\C[HOD2A$PTSV1,)WW7ROW<U+ETQL;+)!Y
M?*\B&2(<7^9)T%5.K1QN4Q]=>W"5FSND!X#GWIC#5%3!5).N5H#.-2_1*\+U
M%@YV1J:>&>;GOO[^O'H&P\*#BI ET6]V%N:J)>#> <YQ.+/-'#'*!S,?3FSZ
MBC'S7AE5<K?0VX_7E2V?K+2G]KOXP8R7VL!3708@LWWXLOEC;-=Z[JG@J]"R
MU5+^6+N_[C2:W#'=^,_E \+ GM[.]\U23WQW\RAA&N%W=.KBKMS?[*(F0?M)
MMU\3RKCN#?>A1J*FABU'<^YV,5J*A[?)(^V J_+!DK]8\F^T>#]/-_(VA1;Y
M1AWSNK/7N"V"S;09%BXWV(\EBI1$1UH<=IW4[TPT'\[Y9L2N\L8$L9T!T)MS
M93^29=*I5S$B6TDLA\#C::S*.M7"(CF#1U^=+?)2SRJW IG(TJX70F".KBA5
M]5B+O)9T^)X7 -VAK(BUSZ@ZI?<G06-2.T_,YJ/F9GN*UH7SQL9=P"]NLWKS
M&Y959V79,@]-U>8T%!2GW8.PJ_!\DG>^4RIP_A5 HFO6I[FY3;G)GM )*8OZ
M\_9%&TZ&,903=$+7Z[1<T6JE!T8+?;ZJSNN?RR@77UVD_87%FO^I8;[^+_PY
M604(#XF7G8(6SN*_HLDG33 $R909Z:7N35KJFN8Y^[YU(20I.;?ZJ "[48:1
MM6!_T%&7M1UEXI3Y]+/4&>#J\DVW/-*5[Q61NG+;';#,V %)LW/<5@*W-/DE
MWC=?(#&3E=D]3T3R5N32G:D>QVMK"IDL=-"4)H>NGVV*<)\18O?PT6(6P_-Q
MM;@LZ]".[H=JTS&I ==C0;"C'2DC:MI":U/\ZOKKP![$> 0KD)NU"3\(,\/L
M?AY*NC:0!WR"#=".S\A.S.DM;5BW&>X['%(KDAOBUXZ_6I;))^PF7Y]H9K(_
MO56IE 1F+EU5V^J<L+*CX^:>1J)0X11S0ZND,OAFJ63(4RLFY.M8]7=PL+75
MT6GC'FQ<M+.-C1P[PD5:;K<%G5:9"]MH:KFS;;/0A]6+J]OMXO6TCE<=E4?F
MK]Y!/L@ &I5!&B4-ETN"TR'R/T$$/3,6G&AD>?; 0F).^1IVWS7$V7;#:3QA
M4V:N<FVSUK $IS[9DN9T!L".2]&B36C>(1M.?<H;)30A>X :QBYN.542AR9'
MG@'4_GA=V<$V\ZN/#A9)IY&1N3L$7?:&]<874Y']YE-[Y4-IIA;*^,4[1B9?
M<#"C CD?$R[,@S&+%2-=YS^13PMN_&^?U/Z_C'.F!TFE-5P>CZZ %(-?M :V
MASFX> A_59U/JDX\%RH3O-L6H!P%55Q^XP0I<ZC[XJ6XQV:&/.##N*5G>66R
M6'67,9)Z0]Z,A2H^___5V8[WV $8J(&'_V&I;(8K35SH9VHNSN>*,Q/#"?2'
M9FV-+$)=DWF?UQA:2A%S2F((E#IW^"[VM[#VYU=MXB.*('E..UJ(V)9(J[H!
MA"VP2Z,=Q[/U@8^.KB%@YZ2 %% N4M \IMML'%_2/R;@?\0);CKI%DT8:K.*
M2WQ;G1XCOE@SZ5)J#6=Z7'$ZKX%+M^ P4W3@)K#B;4[K^353'T4^?_;DS3;3
MX:*>PF8[2 SI6*"Q_1WQ\9S1):7@#7:54^BIP"/88L:WI[NWSP"EE$HBO0>4
M[N0,<*_HZ;&+S<;7>!MRW:YFP>/A/8(;Y?<I:U@6U64@=WS>RW.JWSLOZ)JG
M"3%UU,4M)RZDO!H1]!L9P<Y#;==KW^F%% 6 ;YA,2OPRO\%A /O-WN9#2%@+
M+/PJ8":F+LC/*I'$RY70W$P+^?8S>'AO[(N_;?W?8N\[#M6L+'A9"L(_+S+$
MS81G-6VXJWO*FM-MOP]_#Y0DXZII(UY*G!H8DSTIWQY9,E0[-N)-; (?XT*W
M I:8/$^@Q7%52?P:W./1=?^"'BCC,OZ3"V]2MGZ#"J< >1'/RT+'[K>/G]44
MF@A3_<25Z]XDRS,C'/)7T3C87(IXK4U?]_C)))]+OEL*R7U_;,H=%:*49Z%;
M+@+%=>$4_1N.@N^^RPE\-[QV>5%QO)+!3@F-/2!\*K@3\)E!J7]K_R$T+GPY
M^G0%;CXEX&5U/5V%OC$U.N/H]CB*ED1^,K?HUM?56-?]U"JC]@H=</49FY=Z
M'P1A['"UKE>@1@\E-*J276WE5[^O[32XNS1^4TW81?,/;GG'KU*JIEX2FM7O
M7B[KE! =NC6*8P2'3Y>[FG?)U'XK28^^=WR"X,@JEM_>P;E]*OU5$ZUZ@Z%E
M7A*AV>&M(CMS5!D\*6%]V\KJ;\4=59'*:PG1BCX(%#Q$#H=X_/@>\#F_AY!F
MIX^0R22VUL(2,_/F<Z9NFT%NTJ!%(EL:6%.@O*+(9:$A/46*E3D\\ 4"$7<&
M$#S>H>#995E/W&ZMG+Z475IIY-^/W6XZJ0FN%S -F(\^/X)/#Q<.^1 =Z@^D
M [9#9[ \U3*_OMQYRJCPZ\K?VY3E!/1V+_0J\DYFQ^F4V\Y"@E_TJ=_B4D)C
M9NY],=_O/[#K/-GKD&PC[X;A[0K4)L'E&/$.SRG!4/%,R0:,I%E7S>_-Z]@=
M-EE]#$_DYFS$.RS'*S;EK?[(2'&^%G$&,,=/'CEA56@^Z8ZC#0[ZER.^51VW
M'Y0NKQ/'ZM)V7-7*\VV$UU->9A4F&)F:NOPY6DD(>220[Y9V59/G<#Y+V(DW
M.["<TK.:LK7B<"WO6N?G<1\^#IM+=I1M)$<X$4W65/QS&C?4WO/SP.Y$W?/:
M8?1_*?]:1XI\ZUI1V#]TU)GA]XF7Z"0KW"0POP]AVYHH,P"X_^/=WH&*ZDJA
MD'6JM>2OKNRD]:&M<N?R&MV=+<H(D=XUX8.KL.X;%]=J8^:$<:JG4Y8ZVEPV
MP21N2J@JX;S$(*#W$RD:&JWG"=W]YL%,Y8ZZY\505(M]LQ5N8PZ_T.<:_=86
M+5#G!!#QF_'6XSV9JRUZ.+]EO*O*E8"*MWOL)1]R=$S,8;%-S<YTY=?E]=LQ
M]8/O+L)E%!'PNY- G':26H:66$.49/D:%:,.@<M(%_=$5=Z\,<)B,!W=F')@
M8G5ST"Y3<0,NL3LSU%YCQQ4$,  /VIU35]AOVBETJF=Z:+]XHT5L[3*E/9BT
MI'QUKH!E:] @*?%1UCVWBH5-E6GM>@52%L6)K/_A,.M>5]%%YVW(UZ$G^Y[:
M_L3?:,B[M<5%#1#WN\N_$[A8@'2YLNU*Y:47^O\ZCQ.Z&21P2GK=F(:+MH8I
ML0B1=< ?!@;Q(U2$HB(<;_"*&-O-G=-POL5G,:Z3'1RJN$F,=L.%-0K>C=Q*
MS&T0-JY?<"^.AX;\Y7<W_L<Z!7_,32B2N^:&TOR&K&U.=T9?B4@%S)<F&;/W
M9]Z,5@Z V1$43H%[Q<I_];^5VU>93/-L)<>!>U0CG@<TSWA+_&5JLSSP$$J_
M*A%^G)GP22'^P1E@$!HL53ISS&<_."=[H?OA]J?@V::9F\0#N/PQL3H1A"QH
ME=]ZGLTLG911]*"U."6Y\O"=SV+D!_$ZR_^#N?>,:B+\_GVCJ(@B*$B3JH T
M :F&+BI=B/1>%)!>0V^A*" @" @H!()TI$1*"*$CTCL! @0(2 D0"+V'</V=
M>^\ZY]Y79YWS?W%>[!>S9F:M6;/VS/>SG_WLO?W?-'AI&0O45]IM5\#]IV$_
M8+26L(YT4_:[)-S\HE*:OV'/B2!MC6/Z+SA__![,8FN8\R*(4'9<?JN.,1K7
M$8_.<Y)L42>K#<SM4]MJ]F/'9R[^_;,+_H73OO_GK\WK+P2:$#+NG?+P6_$N
M47ZB9!Z6M]O'[<+M_Z>ZR4B8-GPF^=7YTY=7272RN+6\PR=.#3E>/>M)4#?J
MM<K/$3A<L*9JX3,_6;+>5<Q@_J*5/]M_/XM,U.]9] P*VS%N&;EBO=)Z":!\
MI29*DC).2$KW0TRTW>FBN@1\2%P+.EO:?=PZ'MG:WTVFB3O7#!M7%/:.7[F-
MC2R6AP:D+"_LHG.'S71F1UI(_1F]QU(%1:>G?KI-K1V^)V><?;P%]*J:IZ]^
MO>D$]C!O!.<(>6A'!UKZO3*A4N-F!Z/Y_KV]RJ X5R;=VJN+E&<O<]5>CO!;
MV'&<]F[(T7:,*7(X5F_(K?+G\2^+TTWS<55QYRXEX _86P,6FJH#,F+R'38=
M;G9_ATCH@KX?M%J/;!HZ!YOI3H-K:]%I"+_:@Y8&1[/J^BR->F1+YN"HK>'U
M !Z\QR"&N8L97Q2&F)L]B<,953D:A"X>[SQ%Z3T%<<LL)6D.['[0X"U3<\X?
M^"1]P$WDO[9+I%7$Q^W=]-7"\O.T73<<TMD?9P2RT63+GH&M:][T/^PP9+<R
MZ:.+D4@)&?V0[\ \9^K;:#RV=NR%FMUQ_GSC-+2G:]*ED@S_N;WAYLR48JKF
M1:/%Z-W/O-'_GW%3Q19!5^;KM4)?&.:87I5-( VB'3CUY#AW!TVR##//B-+V
MK+\71#8I>@B8^D%UHRO4RS;NW9E>GUN^$:!)UALN^W'3S9JGT%W),F"K\^R2
M1_7*MB.I,NW,=VL/2/)5_\ON@XV?%#-K#G0O)QYBEGT463EGF,+%TQ]V240U
M*G[GN 0L$:QJ.&,JGMC6IZQUM3KV P*G:&CEV4+1$62V@.(/\!R,KG:NF#@M
M/WVX1OOR/CF08 6OW'AV?+19Q75#['SX&ZD5E)&#* <7FS&8)Q3WRX&!M6,-
MYN96\^D.TW8F :O 6SEC$N!B7IY3'R>T#@:Y;TZLRP:&6IBIR178F[H-&7[U
M/%7J^*( 6K1P:TLANU5U8<TC6^=8^!2Z%*$V05YF$IV!W->[-)1$0-8#P7[#
MF&85]WTGS/-9?M98(Y8A63P%Q9>P'#+VS9M.U+G6=*=W<)U9P5RM686>50,'
MC4O,$=@%%[^B96*>QO.U8 [1.'/!/L:7>5-XTVA>Y4V/1%-B\>TV^>2>?Q^O
M,3?[K.><Q->^*D'*MQ-@[#C;)+'*Q[U0B.FL6I6J6_Z8+<%3Z>QPT&)FD*WP
M)FO,8/</O%*12^]@=9R/XU"YP%SCGJK0]SGS3&US?T1#W;G3WI?B7C--08LA
M@O]VEUE1AH-+AI3IJWAZU<;\V7(+'\J$2EH9PA9ZK,9#;<:07772D,+C=;C8
M/P7%8VK+N+]1BU-SA41OU_LP'Q#.=E_WS@1<+% ZXJ\%7816$=8S27]-0QGT
MJN&JSMI(%M/2X+H@X?*Y\I2ZA"-^?7?Y[?>U9J<N!%)919Q8ZH-[49B2+J5A
MJ]G@OW5<PH* ^^G<Q!V- _P!:=_TRGO!-M'^U!P4 9L$WU^*FQ\;\Q"[J5P?
M.N(MKA!:/WS-N/#+[^H_FA_X#0T*B23:=#VC&C><&KK1R/P7/N7CDFB@GI'>
MF(#5X-PZL7)S"(5(OO?M(3>W%_/OBT!R]H53BF:/\+???7<3/&D64[?)$$U<
MX[4G5?7,J:Q#@?I;R5.)2KGE_?5\]A\V6>DO3"E+\)5>(_NX).?NV !_!C8+
M-H$7A[Z?BVKUXN+C-,VPQN^1Z*+OJ+E.C?.6#4W9UAH!#0]?OT.LG<-IZNNQ
M>E5!*H4 Y0LQV,!QV<CK+38350Y=WM:9(P(F9RD'ZGU5(-C7?H8V4]$=Q0GZ
M$]8:T?B6ZDOLB*?._=0$/.:?9GQV2%ZF[[3EN(&4-&35$7<2L!+3*"ZVU,Z$
M[.V;\(R_:Y3,]$"W!@L=\#"E"$G&)<BW(SGGAL,F1M:?_5)G9(D9*&#O+F,+
M!8\'Y30+T1#G*K+Z[5ECWHA#1)K_N<X[=O$SH![I^ET.Y6O+2Y0YP"$UI8R@
M\S@3_A5@K&Z\M]X'UE7-_E?;'.?.#:Z\_<S[SBWW<=H,B+763OR>;/8+XLR8
MQ,?K4W<-? $+=@N[4'RQ*W@P\.)/9XXV:J;]DY)5][]PN9MC0FKE $E'AX,0
MT_@2:(!+<);U[2[G\L?RZCQ/Z&W9I_!AM&Q+% ='A$37<QF3!E_^LL8NO10-
MD@9/'KPAPVKNUN?<K^1A#V%)K3[R?EVF(QQ^^/T2<*-X_]P^X'Y.HT=+Z^X1
MZ4+.9\MZXXKU*L6_4R4)8=-A-[I?6U\Y8/*(V@Q<S[P$@#9(2DR[W9"8GS5S
MQ(3T;<R!LLI]8Z[_JMUI5UL56B35/$.\PO3FLL,@6;>'MU<.I<[H_S,8UH/X
M:+?YC$>SS7TY16FEJ:6K,BLSHQYQT&IX-C66E9FV7M8W7'B@L'WDATK'_SX6
M%ID]S2<F*DW.TJY;OS0>QM7,U1K-,]>;%-#12GHK$0KP(\8C4C?^V[BYUSZF
M=_.IRZ@?A-Z_\K%"V9<CWI_FVPN+4T@]C]V-63D[OP,9>,]VG#4]^>D):Z?L
M64#7T+;A#N=TD=9YJ&+75F$P2-;0L_H5AHLNZVE(^CJ:X?R!JC+E#SC/2<TB
MA-;RA+O3V'C&A[Y/,BO]^J@&C\T"73%J^!+P,UQ1_83B7"?DL2+3Z%:(0+ZS
MF5OAQ)^G*DXA#DQBO8*OOMN%*L[%4 /Z:)37!\.BL0/(N\JR%].+B?:7 +]7
MQAS966.M_.3;I%O(21W8W]LLN<A/HN]@F]Q<7=SV7Z&"FVM>[5L;0H=6;8*F
M9ET?GL;-,WO+L,1)O2257(V)W?.Y8T<1=9$5&!D .*7MA>\A+@%1607JEP"7
M1FNI29<*)-9*_-8'QH:'@L]GQ9D *]$WUV=:)X3^Q-KMD&O#%UJ^!Z'6$[#U
MPXO6*_K_6./I>O3P47=MI%/4:=6&"%M*GX13'M2!W7.*)&<KM6UGXFS2L$UK
M9%%5RM]9MH=DLL,&EW2='6#T!2L*?2_<W$#XF->6\M]$'U^OR#>@RX.B7!.6
MN'+B<!VS#H@@7*P4-OAAP;K?8TE$4W6BD5[;%W.*:SNHTT1PU-E2^&B3\"7@
M_EQ7B;T^C_9>1PI+S#:-&@!<@V(/R_N%.$^6&HR>;ITPST/J_XKJP^=VLPN=
MP3^(-\B\-Q>L\H+5%+-T414.,S09^[O-U;X^E=<[0C@5ZIY7.NL(F9<44Q9W
M5FQN;;N!)WWAE%,SCOGF]<S:/X8%&_=,0E"4P.YZAN691%C(#FNL0_QFN]:C
M97L#2/"="YFE4KCY+@><+[:)WJ78J6??PJR]*OFI5O80I'G$H16<DQURP])Y
M8VPR5'I5ALXR6KPBZ4L*C>P91,S"0O_/A",ZG95*9<2J$X6.=!9/V';46/=;
M"93QT1EDBOJAY[.\/+LRV$OC6RP\#H5:PO.##A$)93=Y7$I%.G*E!TRK#=SE
M:<35CAM]%5S\M#7==#L2A%3#7B92<OZAVAXNQL2UH;=$>-XRJKLDWG?8ACH
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MSBG#2?\+92:)C7Y(R>S 93=+*%=GQ"8C=20DN@G7UE,U[,>HS/],/$4UX((
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M]]Z(I_BG>"72B"4V+8VA0'0X1[,*!"X:[D$G('4S<P(3HA+S?0^6!A5;OI=
M^QM^,OSG2X!6ARP\UMTPDUV:5N:WD-R]9N./;S0(4P](+W<-<(QD@1"MQI.J
MA7/LZ**VB.IXP:]$)^ZTW,C (GOS1_U"="FYM[AYE@!>SSGALFHQ(0([Z;_G
M^%JNWBXUNFGZ6_6!AO2+7(_42CL+FY10H:DG*3S(I#ZWWD>?WIR5A\O"_CQ5
M^@R1Y408;_4T=*7M#+<SBI8XS3],Z@IZPC0*<O%U$?N,^/SX\9U5U1C*OJ_!
M^P3K$8<H,EHQ8K%_FH=71%XN;T!Y6%@DRWTS<$/#=9^PP4^A]6<LT(IC<EF!
M7JO9]L#<7XIL\)_YU0SC,\5;OAXE+ZCJZLY#W)?I(^L:GBH -S[8<AF?509$
MO%PS:WAZ:J[3I ][21%EO7I^":!\%,*(A#QP4;J7O,4H1-FH&C7TT9VE %D%
M*&?]4S' ]R6&S3@_K:^A<^SH_FG!2ODF[HG^Y\EX'?>&34_;*L^.%_+8H:/$
MV5[W9LL#%*DRY)G^WT:[G8OB08BL@'I5(S<OU>_(.0L(%246"%? D*1$LDLV
MWLRF% UMJ!?UR!CK[O-3<D8'+\EC:L+ZF/R,8/2NBK,_2T=?1P$H_&G!W2]Q
MS,QE, YY&2^GI0O=W-B+#-WZS U)Y8ZRK=.O-JG0Y)R+,^,CSICJTF\+CGJ=
M+VYIWF+22E.1$]BWG#N'>>T!R]]]=-#IRZY$973V7BLHGT_<FO; >V]O#A8%
M0"PGX.6(<QBO<N<O>S7:9(X ?PO_!0=,YIYU L<]M"3\@64AM+'<:HOBE^$5
M?0>>D#^^%*TA%V)YC1/RXF3?.)"'D$^R808'ZBTZP5O]:*F2,M;7O,+UR;YV
M@TF+DU8+2^SP\2_S2+DC=I?^W=MWHOJ?'O+JN".L3'TM>GWBR!OKA5OC!T]-
M-L ?'J\0!RM+]Q".9=,>CUN.^G-8?B&:=JW2G%FE>SWUI,E[IVZ8G*;]]3/C
MZ1:&'<X8'_BG!B,X1+8P%F7<T,=U,Y*OG<631H,S(&+8V\N:]>39'UF_;]O"
M?9RR3U]K(WE!_5OM&\##P\=(J5:.#;/LWIRN]?&7D6T2(L3Z@UZ.*(7=6<S?
MD&=)A?KT\:4B#GR:WDY:BUXKG[,;X3&C(D@9B6?Z])8E^WI%>;FG" MD/%*;
MER<''IIS=+Y]-+B;T3'HHC'J(TIE\5*N*)_13 II)(12[HDSI549"B7LPW1W
M-O-V<BEM'GZ:F0+0PPB):B=OHOXPF467LC5$-7Y>*")!%?^"]WUDNA5DSS%S
MC$IWRDEJ.PUWG&?,59KB6/B^UHZ4EY=>$T\[_2;&M]I&2$V4@6/K^8"_GQ05
MRE8GV J.>:V$[3D)S6]K^ :9':LQ\5HHF.A;]PJ@X,]8544F+<JVUQI)0B6.
M1W6C66D9Q[SJ>L\I ]K:VP^!&S1R% 8'K '$QW:43YB)S LJ]2LUJ=B2]8/*
M27,-'JWXZ&C5VGV'CTSNJFO0'UQ^+-WR5VF7+(W#R<PN'$_-H]%NA0DJJ^K[
M]U9^J,QVOOZ,\&8 L8=E"TT>38>:30C^;K)\\#7?43JSE+'"WD71=W1^9M.O
MGY.9O[T7W)47[V_\N;Q":EHIWK"BT:4K??2)R(_;BN\L*[C?WNA5IN0,.>[9
MZI) ,VR>B?X!W<&NSQO^^5DC^%%EP%H\O /V#1Q>W*K;&8B+5V1U/E/I$)U^
MG,T]6]W$__ZY,2M2W%TW"KJ?>">PJ]CA2$N5U7L!FL9:Y]GM<@]ZUU,,N@/>
MZH_^_.3JSYT-CB&/[P($)>]AGS'GPJVZ](TA090;]>^0FFQUE)+CJ1W*'>6#
M[>_73C*>J"0)E%HHS%B&$[7N7@ND5KOP_1<M7@CUKTQX^&QI0VIZ[=XK6DUB
M&R/&PR%P'53YS?+MM+^WV1)22MSZ"C.@GJ#GH4DZ7F9&^N7BU197V4W<WC/?
M$I=;2AH^W5]8RO_0N>0T3,^O*ICW#Q2>N92U]$UN!J/"0*H)G+P:&F6-!OZZ
M1IJCEDPN2+C;/2QV39%[(E-HY_W='_N\7*BIGU[)>TN*)#\V.^.&@)=_Z)UG
M= KS-I[IW"E_SVKHT!M:P0*([I)%OL8(Y9/41MPDW]<*RD\M"I[$IG1S[7Z4
MJU>\!*0%"KE48YV]Y[']U4*]6KF43H9O(^I]*5>V$R<.<-AO%H]US6ECCOS3
MMK:%!)WX]["@I.#C8+]34O\=642QRF_))=")KT"%@_#C4]8M]G.R56]%"$^P
M-8TE8:7:+J'G$B"PA&=GK>>*. W"]/H-7[6<X^YI$U3LP BCZN4/E)(P4MM6
M7"=MEX IJA^28^D& @\?:5?DA+-=5U  _?.IMJCVNYE;?<G>Y<F5R@^39+!#
MLH>;+J=8N6&O^U6I/E^=.K+[O#X>Z6FH(/WM\_UFSVDX.S1S'L34N?7/U:1H
M[!4Z/B/SI)KYFC7>+_HBL=<M%QWV_1+ =0G0Q52/TDVYBBM.==WDH0$I0-B"
MSC#TU,E"7%ZI]0ZS#D6JWJ&-NY:=^:_>[0>\$M@K"VE:2KG"LIT3=889W>DT
M,2JIDEI.3?E<7)B'?W_:.#,GVRR)<YV)J87*/-#N&TLP_GTP"3(>#";+.KIO
MN#AY1HQV';R^UST[(T.X4**W\@*SES0 OWS[U8ZK=_4AS!+9U4[6I :*%O+J
M5H03:92O';"!UPE3AMIF3RL>; I:B%Z[J_'0.Y "7L)@X1&;5ZH78%8ZG%PJ
M>>BON1X8]CDM?>$BZZM@,<-VKXYEH![B$M"QXK+=@-(9:4?,2 ^TQ[XBTRFZ
M:U"BV9O/W\'EZS8(K&(S_=]!OF$;-Y2[QRER%)R!#\U5[C5PBNWTM7L#WND\
MHX[ 8.H$Y;YS[X]L\1IZ=CCHXPCCX*T#>$R_\WC%UBGVV&89J2ENI-%2.=FP
M3Q3\*5@.$\QX\E#X6:K>#*$&XQYS5/R?Q%U%Z4G^KLEI3,"XJ_R/I.;ODK/'
M!$QBD!_\(!"^'WL)B%)<B2$S>G3:BZ4,EDRYR8DACS,]]!2W(/G-(='"2"G_
M4(=+0&%CR]DEP%+GA"3FAQCS.^7*BQ/ZDOM?Q'U7"\F*G;[UBV'#(J#<*9?!
MIMO+GXA_:"S#)D3^/E\XA2>W*Q#&X+&,_BK1SR/U5"62?V&R3AZI+]<WBJG:
M7MUXTQ8I'H)A6:;>)TM>V3#XWTOEZ0K?$WFP0(^*%L.VGI"CYBLF7+(BW.]_
MZ09?V2MU+Z ED(/##6':&OC]^"_>-/.S;/^9=<G:*6N5(?(YV"NPV-SJ(F7,
M*09V]TN2H/@TRW:72]F=O>@UL9Q@:@=8(?@L*59>YG9+=@GA@7WCK.KH-Q'1
M?Q1.=Z? U?]:Y#^R++[OD6_\TAQN$&8^%\*^X]$-CQW5]BH9SOMWB^P3([^%
M'_]$3XQ<)]:+[(8T6Y=P,.W,*C*.NDEFF5K]E=-R%![3N,&2?O]FP0*43G8/
M4@&NFV?=@41W$()"_'Y:64L.TJ8;U%::^ZWPR?#)#)=N1ZU)'_L=B_%\Z6<+
MSU7BOK$A,5-3R&'(V]HRLU%A[Y%<^=BYMA*:]C=#JQ.^@@8)%6'\#*4].^Y7
MX@)[W_VQ2\"OA=638CQ2%)]8EP=];+BW'^W![_=V2&,;>PF8R%&L0HZGG FU
MSLG&!YJ)LS"[=WFJ+ESAN* MA7\A"_?>'7^KSR*R4J>(:TPX/-B^D(%___LU
MAU&XF/BS.GZ+]\Z#.N2A(BX\M_ ;0J@6]0B.R*J9&=IR"@TSSS$,YO%63K.M
M3<)Y*EH7\V'KNX+PF67Y/P-A+>]*4X_ 2:WKT"^R]!>;2^CD7W1R66X_L_P$
M:-.$6CF^4_AI+% ?;.N:]7NX/T]3FF75$,)@$WQDEE*MX_]^U3^R(+I[I&M@
MYU8U]M5 <B[S%ZQ*N8]0.Y])>E%QNNBY"2$A<S56RTM FZ3(%I7O%P?'59V
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MXT[3SY+N0,#/I4@@%Q[FCDN_(W]*1;V,HFJ.3TUDI4R ''8C]) H$[1/;CK
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M*=/1:-!CE/+V#%I8H#C*:F^YOH/K"":@<IOHM,M[!O<%'VMM*@4/R"4^W,+
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M@\8/UL9D:@1F^2S@?4#NDT\*LO=(&T<Q#A[VQ;CR%->X8./$V1SX0RNF;4!
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M?ES;V;6JDLGU_ESBSV%5.;J6UK8@C^=L =C<J2N8/XOWO"\!GV=H&Q!F4Y<
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M\"WWCNMZ5LC3E:L/\/RE/?6P.W\\JLMI/55UQQ89%G,]#JOX@,'RJ24OM+V
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MA:;:3QHG&^84X_RD2RJJGT.@C]LY;9Z6ZV"8<)LQI/=&M_7[-@0,EBKN?T.
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M$P\\YYU$"4Z,@D8*7S,=U+NEQC5L!](K*4Z5'W>(=KZWD?ZJQ7YH@3V&T@S
MDG9A]O$*_)@^H,X]:!',><* ZU'@M.EL4K'0)>#V?.WYJ=&SN^HJNL[FKW<F
M&O2TD>N6IYNKGL96;(UCRXOR5YGJW[;/M" HV9K%YU8:<!\,J'336!EIZ12:
MPWH&0L17F($^K$K>;Z_V"7%"[6X@F#AR+>(7S4B7 (-*L//,M,ISH/X0MU)"
M'1O,!ZD#7+ZE?8-E.*%^-+7D53I(0RH692EI1:RK',<5?$FH] M4A.B-ROXI
MDK[8_2(UB[>COBZ?;E>=; "E\X"26<)D[<>HOR15P=7<ROV[U$OOF0]0OAUV
M6X+7MV]"C]N&0&F<1J6<.IRY H^E!S ;@"6VW"&2\48-@9O!J$##TT7(=;(*
MBJT;-)XP5[&3'2][%&O:-]TK=W;J?'^WTDP.\OWB[3]-*NX-6ZZ4OWG8>N[A
M\V0@#($/^ZIT_JCTXYF#_QW:"/Q2B.+D)6 #N6&]N6\->S>.U:CA43E]$S?K
MU[B>.43CO>C;$<.#Y/GU'_MK]R%4S(6?+@XYW+8;-Q=7_T_ A?^A# ?#,3$T
M--BAJCFEZQA_WT5_O9WS$C 4$#8MJ;OFM@@1VK3,N$I]"?"?LX.,XGQ63ZV_
M'])M$YTFX8SU+Y</>%99%PFC7ELAX+]\I*$C=]^P&W/ID(T!%N(E(+V.;6.T
M!5K\^'\Y&L2-B_<("-[#&RJ)K-I[D17".I"ZSUFX$R1N7AAWS!#3/W7<MGM3
M:[($ WZ.IG_"'?!8Z+E,#W+MX*CNQ.[,-EA\?S?R\[[5MRSIV'/=!]'OGTYJ
MOLK._B)"VQ-3-+/9]_;YEH?U1,[Y\.R,MN3O4BJ>A@!SX(ND'K0"F( ]FL"0
M'Y[@5/;6TC-7RL1P?]AH,';[U\;2WCT4JZF.H?)(H9W_DQ?LT(9%LGP(U3XY
M[F2O5FK/T5P^G#G^4BZ,WY77_?%*LJ:V1-C>9'7\IVW(7J< -(_^()&:XE#R
M0LO?R#B[@\R<I:>5_%=6/OD>+)-=I\YQ,&!PQ0ON93WT6MHLX\\NPXGGSM&,
M'H28(VOG*,J<=]?RC]#YE;:0!70)YE!A^?#N7S.)5Q\?9+QE4Y R^UU_+AH#
M</S<#J$TU1W?K/L0HD47\T\W$DYD*B>70J=\?P5D0Y-<!$3:/FBGQZ@BY9<"
MSU9:)ZQ_?[I-:<JY=%MJ+SD0\-A3.RQM]YREP269C*GU\^CGBA$/9,T 4ID[
M->C#'('H]W9S,:>W(H0*$DIU#8J*"07WYU)]<LOQWN>^,KB).$60@Q^WTUD9
MKC"C)NW\6"FS[]WXSVUXKW*:X*H,7UND4E#N2UH=F7/1K*.PVR[2#Q0!X]7U
M]L_ I1$"#B:UE)REX6V)M"8>25J-ORHFO+LG.1Y97DLR$@@>(MAQ4+*&Z'@L
M-/ '8?;.]:9 !4UH 9TW>33AM-?;.,X/S\ZKGL#9[REK6!PZ.&DO+-[.E0;+
MS8X$Y,K%9T@86.@7ZW8A^-2[-G=F4,[FADVU,KA-GV=Q>8FM>=3<0@%=%+B3
MC3)EMHR@IV@^_HHM$5J##18L\/CT'8K7]<GX1MW4=XV--3)9Y[TC\!B]Q>^K
M5./4_@@L<TO\,"R#0H=U,(@MO-6AS1T/=""*2NPG??HQD=&(%(,:)@=*5._\
M7"N&/RIMLME4P2RJU7"!-R<O'NEH2ZLJ+/<U0#@;S:.G7CR)\.%>W0X\7+)3
M4, A+$-'.7UL&Q)MV137:74HY8((0:$,'5N@1UOFG]P$-1_<\$JG807NA-T)
M."H6J#Z+,]+TKKN%?S+3>[UW+P#-'BV/&78O=XMKOPB[MK(Q%%6L(9F?[692
MRK71?%JZV]"_Z65;8$;>WN+J@SS%LJ8<U.S4SOI:Y6HV[=]N#V=<?<<NFNT\
MU==S"3!QIP,<_]/;$MFHA( ?S<V_[#8RDT*->O0L#>Y5PVCS<]^G;.)/+327
MY^5?A5%$/6_EW/Y&2J@6&@Z062*V;>PCI2<?3PC5J.UJY^?:-61RJ+>\^58=
ML8Z#2Q=ODHS;'*??<="IE,N:#&I4IH[%SO"JF_%)HT+-I.UJ6Y[(J#R CC]=
M'<_2T%/G+#_T-9NVFE2P8GUH-28O_+:H9DO]Z%O%KYAEB[2WC/PU)G#*I56[
M6<F-K+(2$[!4'%^ 3NC(<X;44B9N;[:WW517S.42^N+!<\00>FQG"V#4#>Y6
MW06MPNN9?[ )^2;" L4V!Y/*P#BL#KW9X&?(0U ,%\_R"T%7XPUF=4:2.([D
MA1U9^:DZ;O?(AZ4$00R4[34K-QP<#2PNJ,T965_BT4?R]E5O>35ZO@R>=!9*
M'U/U3<OPPFOR"C9=WXL_UJI/ET'6*(>;6#TPK>5JR]PSE<:3' T?)X6+=M'*
MIX\M=X==6W2Y0B&?<8\T^_2*.MU7Q[#ZAO<'8Y/UK(YHO4)HUELQ2T[;^P<4
M5XW[ !!2MF+>-TI6T9@CZZC%.V4_AN?F5.R]WUPMG^#Z(-P]YX$_V;>*TE6W
MS:\PC77/*7!SFK4B&!LE![Z_4'2,C.TP+) &RNBMESZ4DSO0R ;=YH8@"T\7
M)_9RZ>79Z:)7]BYR8$=[\XO.HA8YE;_+[HF<5=Y9;+3I5S2:40W.(C4:MHX7
MYI2YNMXJ=O$-^[F D#_/9_U)&T).^WL)N$N<3;A[DHF0%KS/VZ#O 8Q\8:%*
M2('2@7XT5=@&S=:&W]M0@P)FST-HF$Y7-PY*T/**8JCOX44-#1:0ZW^X!/5
MO+/>-0<5NS8<P+<&""%'Z:%G6#\:?GZIW7T(!-N,8F6/"JO9KI'C+Y/7(OS\
MGB=";9L?5D\+9!I24 Y%!'.<J&-SXZQ86L9]Y&Z>@4-H%_L?/H)ZFOWAT;]V
M^W[&DP?/M2Z,9398^9<3HHZ&G<;:/0*N]%.Z^LBI/_>-]U1*5[IQ$>8VR]'.
MQGJBX[C,R@&2RH+.&/BF:-]X76A*N?:%KPWVR0I\L,"]-&?YR.W>-9V9A=O$
MM/R5'?CIXJDY.>#/5\3G5)Z1O &KVT7CA:@_A0W)QLZ"Q!JBD@!9Y%QB7&+
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M%/GO178U6;'YE&@4J#*^4#&.:YC_[CM?=V;&?A7<0K'/]N,4\1GOG?/"NSW
M<YD\(*(-)8CEHBB8WQ" 1TCIJH_3CC'6<X/)#%>LDSYL)GRE/<&.(8"2IQ\=
M]S5?67\R-H.L?[)!I0/W=I(<6KW<I:\P$@68X>C)EIO[=9]T!9#RRE0]][WD
M-"KB9C_P#+3=_'@<FJNQGVZHP]-A\+.PQ"MHXEX-UKMZW5B#;R%'I[%;/#YP
MI,#LN@K?W<*5'6(:C',L>*"F'&/)=!'XCT]S1S04N<XMGRK/H-+BEYMN7P(4
MLX<=;Z,]B'CKOV/6&PR7 .J0?ZOT9'Z9U"N2S )0 BE$(M K(9A="\Y_P0K>
M?Q\\H3& =G5)#QDKY@U]6''Z.LL#X;8V,UG;BEF]KZOL_E_-1__[P["%:GH>
MX*Y%OW2([@[Z=Y9[+^7]'KY4H=7NS[\SV[I6FML9+VJ5$"KNX'U]YA8](9 N
M$9-]PO1 9J>CFXMZ74]MB+W9*R*W]X,"Z+_3AXQ/5,"A_^U'CW&_2X \>_<P
MY71X\;LGAB\$?B\!9#A3V@ ^DJ3],[^3EYB52T!G_E[\1RP=W11X\F'KC/OL
M'#A=ROC:L(!6_ /PUZ]OL5OB$;O6H2YW:@;BYE&L2,FFD=) \>]OPJZ 2;B+
M!O*-8/6]H3^L_.@'+5SPQ9<8M[)J#GI-H-K"Z?JU/A14Z+YF\@ON^,Q\4E9P
M^>A??)"2-D7 MO#VVAX:6Q?MH^DO>0F(D568KRDOOO]F&AG[TY53JL)*1&WT
M;G"_UQW#&P_K&3>MAX6B638+G&V=J9(%(TMZGK;L[3S5[F>\5R\M?XS<^*$T
MG?<[[%;PJZ5+ )/V_@WF1KFBP[*70099!W+E<67M+]DD+<+7 I>R+DY/0HIS
M-#MFY))-T C3)UX3W9'&?OK'%?" <YSLO=146+(^=.U!BVZC,='<S\K!.$<V
M.>\^+,!NAW^W>\POQ"?PN&X1,Q<^7$M+5PS<#B*W1@8;[L?(A"[>HYGYGNT)
M1W9ZYITT#RT%WCA36<:F,UWIIAY]H1A-,W:^;\UR;@L=*C:E0W6;\/E]M8$A
MQU@O 5? :_XE^=^C8Z!&Y7@B9$88A'+*24 M&0XDP%A3'9DU0'UI?IB5@X7>
MC?C9S>277^17@<$2=NY<0?8'26/$LOVS*2G$58/=[K,3A0@[^5/*L;D)]>>Q
MVQ5,XJT4:*7&P1VZM7%?-$. V8,D.]I[?4 6;"BU_T[@<3L6#M[??O6F9(.:
MA.4?+USS7BG;*Q,BD_O)GQ!ZBATPB]3F5%M8JH5M6K*9#VHLR&5^^Y6=+2#Y
M%;3U]%?8I[-X#QB\>6M%KHJKBOY&HB6*VNHKU5Z@]ZZ1[>?\05);RH^-G0]R
MQVR+Y!+(L/+4]$Q[I7@N;&,G J-D?0FPNI.=*VA2PQCTFEBS@Q$S.I@^"O13
MX=/5!VN"1J&HE]K.8X;L4;/2)35)CW6>&MNTJ?[":T$C#B@(EP X#$/A==18
M9IG$5'O=6'#PVIP_U?Z8O-TIQEQ64^36SU>MU/*$;_!\[TL T4!D2D L5_27
M\3IMH"C3$DN(*G;7*KK&*U7?*+91-X0S:UW3?LS<K:)9>!['JZ*7^@C"W=\@
M8U>(:I"QVL(L##!'O04[L[Q*[&W03?9;NCW%"I#?8/LJJ?TN75(T>F9;DV;P
M2C'G4MUS=P\,DEW-:NTZ?4HR ,H=3"L-I7L_?N^J*&-G#O05$\C]>ON,_Z!Z
M\6^,AX?1L85>Y 0I&[Q 6'LG4IAW79K-L7]-;GOU)]&-Y%K>,G^AV8-:?[YZ
M'IO8VYG.$?Z\C7L6<#I^^U'7 'U2\^":1_<;CW97]"P24R:B80R.^'+7O2+L
M/LR]S5MF"7IZB,M\$AF<J=DZP/&0,Y?H>)MP\0(7KW"*X71YI7RMA_O:8J^&
M<:-E0+41;H+![T'M*N1%EU1PG"G.+39H88%PK.L,:1,]($!)$6>K?FB52X"2
MQI?,94?M:7KWKW]A=$VJ( I<N+@I7:F 9XGH8W0'+5UF[BO\2:"7<=JG[C\6
M=5F*=KE$"[M<,GK<KPS;O]E%*[Q0I>TT/J%Y4%/V(P_L[3LWH(%'<#U;F8DL
M*TD;;>G5#,5SW7](@7B>#^V0X68793K+)\S[G_KL&I99&G3_=!_H<-U"Q.>?
M!N9NZEIHW%U^@[WC\Z1BW4XIU^HP0RN93DJ* G:[;QS96JB82RXW2_9VY"^<
MF*V3-B\8P*ALSQGAMP91&GFQ"!Z>XOQE9_X#4YVTH^;L37N8NO"J$[ZWN#_F
MNA]5<*^<8\[44;E+9W_61H#2$PZ7>]U*TG)J;'F$H;'0:S=5%IQ)SSE%&>="
M %UABN(Q@_%C??7.$_7OEP'R/D?'Z&$/?>D;Q03NP1_Y!>=#RKWI9ZTG/D&;
MH+A<L<KLM3ASW&T]WP3E=RBKR:J#OZY)>A/2E:2(9$\Z=B%J+PP;&C?@%4>7
MX\V"DE#+N\',[;_*0AM(9C&,)4,N 0%2_?PVR0&;'W.MPRQ\=H<V![AG_*B%
MTZ>KV9=[F"NZCW%9)5]-!V$6KAN,"[INKZM' H-G#Z3S0#VJN5D@O=3T)-WX
M=,U#\QR6RD:(5F+;6YT?'X ]1W_E#&N,SF3DVM & F(Z\OA!'28F],E$4+Z!
MTTB@;)20^ =W6EF?'C33!G7QX  SM<H@M7R+Y[S,X1'9*HW>NK'@NM/:0[\J
MD%1E:-VDV:+R5-9=0Y>AI&E>U>3-F9%65%Y!S4SH.]7/ZTG;,Z-L]L%OH_?V
M_-_]E3U43*LJC-)^0JE6D"2R6>\0KW[V+3GH"+B+SPY\$M,1L&9S4]1V[KR5
MG^7>^3X\5V.MVM*RH)&_:3ON5Y'.:7L[D!'-%DT3TYO][W(-K=7S#.O/234G
M$Y-)R-=@/6@^XH99]6AC@M@F"E79DD&:]:JMJH'U6V8[V6H%<+W<DX-1+,+Y
M01WS@TBJ2/1.05]BVRY)#9N;3;ZBCIV5C S[:<9IR[-*L4JE*'Y6Z86AA(N.
MR;.<&J!85UKR'%$6 6[M&\=-;!%*T<#=.>/6CP7 "<2[;(\W%J5I@P/JK0I"
MR)JAAQ(=$Z?-&DG0- SGV"A>V6H^Q<QGLYEX<7/O%9.$IK/,C9X/B/ F85>Z
M$V,["\>/7]6_S_0"%W*]V/TB#U<:92_0 MHV(L5_T,=O1G!'QE8(0M?[!B^!
M]WIK:[\-+6KK!/,GFO"+1;K*# L![?^_?R_47?J\1IZO3_$G="]+>P)33H+"
MB!6CS5E-UNUWA8\N?L-==CB^-LP!4\XOPOB._H^Q*"$W!LX^(:E#Z1_>V8$\
M"G$AB#Q)EKFEQ<)_"6#D8,'OR(;PDWQ/B,L),[O+QEVYM,XSK9^);MLZ#W B
MRJXJ"(%$Y5O%(HIO39DX+&;KA#^(*2B'F=V9(5$OKX;T</=[C3QGP9934YSS
M'_ ?M32>\&,)7 E=9@*AW'N)=*RQ9>B9EC'&KR5/3&[L_&E##]*TWJ<@]>RU
M+A^C6R.L&0ZUC;M"N8+P'%UF*4.%75F_&F_>KY!Y4<F;SZ,TDEO$J!"(.0Q:
M-G7(??DK.3CS$:> #K?<0UAN,=GPQ'#/[K=9!IJ.Q1\,FK#)U:G;$UQ,<?3R
M-W8X?74OTM]7/B[BJ+:+J$_XA=8B$YS5[S]PGU7I[6(<OM-,T_L#A> 2D.#@
MY54,*FA4]P[:/II9%%ES/G!^U[AP"1!*E\"=H\*6_H+%6FMT8C?HA0?\/*_L
M6$1< JXS#%-!5^T>$V@X8BX!NBZ7 $&W$]D;O ^/:O;SHRR^HQHHQ,<4.1I7
M?;&%(<!=E;M6Y<75:8>^QBBS\E*C!RVPN;J1@,8R^7)D\7D%\\W,%HMTG^=^
M%.V,6!A6_A^C$S]7]T7&V?LX4+]EHZ/AW/,8I\ HZ8])SI[H0KCM8[8,OKPL
M7B"UD]1FAW,1D\WO3S0[Z[(D, BCZGC_"/R'+WX5AH,J'!S)P--X& :7^4Y7
M0!MHX*4;]PU1,J$L9,[]TVK@>&3V%>9[VF#)1IHAD_Z;F/"911=M//]TX#%0
MA\YES.E!QX+ZP?K'-LB4T:#*0_GE_4TX?]&#!])W%/,?<6Z9FJ;9OWN?_+)6
M'!;HMVLE&;3.A8OT''G%S_=K\$;I/I0@7NW#4#_S:>SI^\1P!M4TN/DWFGBY
MD #D:.5[:NM'&B9;!ILJXI\,"OH>RKS@9AT]*=\Y<C;'.#NZT;RP68Y:_\1U
MOR38HL[7,] EIY: L]-\L_?G@M 7Y,;<&_/["=25%(!=.PV\$(49*2:/;HXU
M^7W>+[:YT1WI-0SEI\LF$)$6(\'&#M_]71W3E:JU8=4V0MO+@S)M@R%J[>4W
M#OM6BB,/C>+ +(Y*(KKU;*+MZ$M *7SB4% /\?4MQ\>2$DO5+!&_.,EG*<<I
M'KZQJ+IS2G0)5J.JU TLFY SJNNK852-FF[P]FVNW3*I5R5DMB\D0]%U.3D-
MZ/E5=E##KI5?&(()FDSQJ\MSFJ2)K>\AH>+A.?RC$K]SCJ?RW<3IW]C1O//8
M4D7@<'HX,FUK9?R,9G?6Q+-V: -C*NN\5 J&!GZR,9KQN>]V^/)QY'>0>-<*
M"Q=O=8YAOH.3I+-+W<*9^$2[O8_7#7WTV0@"I!LW9QX+Z=3$LUG.NA4D;9!9
MQ.K3[S+#]IEN_.8E<K/S*#8P'4L,& H+K+G[[3)=)4PIB;91.9[GFA$7;SO5
M^KY1,\U[EQ-J2_%, -(N3S<&!]_\[>N;;7FKZ(%\9=\@Y^.]/,IR5=9 S!I)
MAWZL<VVX35O6!W\C=&)!3#M_MF[Z.&.N;LO'>#ERFQLX 1IH$&08\ZL]56RV
MZB&1]'0\E-(KQ1F$J)D2F#BXUS>'".7KK(_TF=59/H?Y)+^."8L&XF8+Q0\9
MNB6<H/94]H>418>NJJVZ"[6' S8O4-<YN5ZFI(PEM>U.V2'6K O=CQR(%BSD
M*F'(HU[C#*F*E#5GXKS5D%.!6W5"TN\W40]^0'\4:/=P.Y9GZX!VC5#O=>-I
M-#.#^TO.^Z*PG*[,J$N ?A)IC.O:9UN@,U,[%<6Q5TJX+)&2-="G--QPPLU$
M9?;*]T'5MXN',D/8T6(7T9L!B2HKSQD=4I.ZN_[E)BRA#VW@"!W@UH/SZ1=N
MJ>@7SH*3)&9:^D!QIKY;#':,G3,NQ01$W\-FM;)'8/M+ .WZUNLR^GH50GC<
ME@%AH1ZM9.&C9-91GVG19*Z3F<Q!"MTZ; =2^9#?H4HUI_+J])\N=Q1="^"D
M&/=9BD=C&#<MK5*6=$O-%?:\3>9V>KIGKOUU5U"U2]@\;D#2=A32W?[<V?NP
MH$>V_(:T-N=%SB2^K&!D:_+O1I^SO(.ZOOJ?!A[$A,HFVB>HSF<3\>Y\<G)!
M'?+N27@)1;,81=@/XGN_]J.?SH?3-EDR=[!!5ZYQK.$P<%F_+MD+.8@.R/+1
M<GMFZ*L/'Z2'T&_46.4<B;L1G'M5G\0<AX ;2D\VAZQ?_).UB8.)"9;%ZXP8
MCP)CZM4&,Y!>I2Y4$F.?.WAF,B0>I\5JK'&G,754KY:P%@,YTCU8-'<KA.?X
M%D/DP8_IZN@]*;P(A^0C=UF/^ DCWG<!3Z= #/']]P@^J_'SI_!0!-SGO$]]
MRI7K)HL(]RV%($>$5F"HG+H/:TU1JN(&S 8@HQ42$I*@<6H1S?H23@U_.%5X
MJK%98Y]:CB_,,'*VNL"[JO6ETV?(>D),S37SD=P+&!?,HI&/6WF/:^R]@08,
M<[?KC4/YB"&%EGH<6M2/>[9\QB;4B(,U 0-C#PT[14M-A([QDQ+"OZ4-AMH-
MWO>149"EV_.4X^I6Z4UNLSEBZO+G#%,J\$6=F!$=0/EV-S3DTSTULS/Y"8CF
M,O T B5=8#YOG%J^QIR?DQU3F:UQ7#D?0*H"[?2L?_Y-(?9C9Q$:#B0KYB20
M5NH;$>E43LSN%%^7CM%,%_PC0FYV59]?T^[=9Y?PZV87YI!9LDM8LWA0A/-#
M+0/?IDT/+]DX[K>=^S.0<A^-Y&6\S>X<VT@+*A!R$#)4,"A,+SX"#1P21OG<
MB[75&Q6MS 4#<I#V-76.I+]AIKE[+DGL>]-LE%>C\'7H<IWS$'4T\I^4Z91<
M H2%3R2UQ,@S"P! \BV_Z8U1/(H<$M;5.B[5FG'P1<;69L["NM+,[[B@A!!J
MY41LD.%X&'10(*Q9\$U7C5I\1_U\$]RM75-2A0\B\UR)X2G\CS"5-;SU$1?*
MFL7EBDPM<J!K26FMNJ6P]67IP24 RQ79M"#5ZH>Z6S%/2 [;J&[Y,*'\1RE
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MI<4>+A5)LT]K0IRERAN:$_,5.P/&GQ_^TRHT\123NTA_IEM'"8>T25BFFHJ
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M@J!%=10^I^[,9;/JPJ=7WM*0/C\=>)?@%A7'+MV7O0HN9#ZUF;^HN:4T'XN
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M!],EV6<1,U>9!O:%P,D<CX9=\<]MV9Y1N]SZF K!6$)/)(O1N_8%/Y/.IE/
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M3(_S;2>2K-)A,C\*0Q:J,Y^HN#&I5BUJ''O)[PAK#Z;0W@"W_?\X<EZ1VT]
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MT51<>YS$\]^\$05-^(:44?09 EW\S?G\'Y;N]B,FZ9X$*>]P_0"['BL5^U/
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M0)MA>$+^Q%-NC9V2#U""?=%5["Q*U1&PNV(=&5H\VE<P=\-P27+H2GP!LUZ
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MT8V;I*YQ9\,)G27<O<YJA'17&X4$2TV<:FE0WKDD>V"N(=;9(<.?T8B;[-@
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M0PLI!8V!SK1MTVI3@A%\9)"P2_A&6+:^@WB>L7TIWZG7A=%=Q=^1'A:Z[L<
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M3:;!"[:E];?)*."_=93E.A*/GVOG-IH8AEWNF$#@BX'$G#Z5=>^QYZC,OGA
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M#%XM*]^FQ4%G!DIU2CWC@3>228Y1P-K[+52/L)"Q-VJ/*/TL.QRT>(D,$\;
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M CH!$ NC_X.^J"SJ^E1 K#QB!GAZI7CLOSS\9!0G!%$!=UW<*/5P2BA]X&8
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MV)@<[;D/K78RY6R-.D"GVQ4@C2ZE(A>$+MEOXD!PCRAHE+[\U;QI,2/#@@J
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M62KTQ,OD%_D'^*'CDSL4GO&7,]'YWL2X#(>8-VNMF\A2B(>?S8X):L*\PS*
MIQ+1?O_>$UV^\1@<2H BH*PW3RHN(3A0 1<UR!&4!_[MVCL-X$$$_5-+5B-_
MC-D,][0#^]@$W=:6@JDO;6PE)\,;.A<EI:4'1<'&;U<>U$X-^U4N-5&LU17R
M=%15Q_)S!CCRKH!VIF9#F-'Y)12IYNL4%!7 I"2:4A]6E.T<]]RC7F?8Z?A:
M$ODOL4OL2#EP%P^]L.NP0=R5LM@%%P> LIU1%^#QFJY];[S[X.66S]P9S@1-
M&:(!&(78,>:9@,T/D =CQ38.=Q8<Y]V$W\>61"]I>\%?<4%LS/>U8PG"L UA
MIUN9'CP;2SLM3>O%XOLRL 1?7(Q/AB_[L3*AXUTPR$*Y7WPR?)3_:JJ]J/WM
MQ%%GZZ%&J*M+$-;0G$W!5>M7(A^Z=O'7:-+,&.S72!#6P9:0"2?_:!;"U 5]
MHS&=%&/,5%FY8%LGP4BI73,1 [Y#1$9'B 0#BR__#7M9'](E-1+]',W&&72*
M/H)"SLSZC1QQU\D66)G2+OC$ECT$!)LOB:8"3IM^-P)W7FU/!)3B((1W5$"8
M< J-*QE$DP]9EMJ.H0(RP:&ANZ9<G_J4O[Q(\ZQF&S%^$_&K=(N?]=U)8@#/
M?%FR;)B-EJ=7@X>Y7GV*]'O<RL@IFA#=3$X#"_8H2F?QC/L=\TP>"XRND%^N
M[*K,[.84@/NQS.^>?2,!BU/[ #]&ME1V<90 )C0[J9AHF_(O =!MT4'^(:'U
MF *'@+*[SI"T;EL@*5?Q1#J+B79/:"6L_4Y_RR:V9%Y#&$4*"]G?/#7M@'0\
M'7@P[N,XSR-B;5<T6L0NK-FYR9IWX$JDG.]Z?2_G0=T#.7-3IY["8I!/ \9-
MZH2+\)3(3'HS^G;4=6YG\,^+1ZS,S.1T=\;X\NZ.Q?:,BUP-;VLYMB?#%Z+6
M9?<@KYV7KUFD1^0#7]>UQ,NSNT-\)A-C=V ;77V4:P'$NZOO=YR@Y\"<%DAI
M^IL?.5ZUJ_55YZR8*KV)D%LY-3BS,!4P\5N;XVL*.0M\^YV97^^70VCFHB__
M64"L>*!P:<1!UEU68-^?5!1!K=@ZBQ>;6+0@^#2I.N<845I:OH"\7V!H?I@M
M(S!P[8FY+&B6#+=RFUW9Y2\!HQ WMT0[1'Z!^,.>4 $_9T*&/DA$-(D#M5;<
M5"X$ZP]'K3\ZO5\1A_G(.5ACJAUYKJ?G%3)[.TNN$^)Z-B$N?B2'F>^)8\^B
MXD;_SQ^R^*?LF!8@!AB.7K-0<".QA![1C4UI*\9.HN8]VWGC6WI*/4-T?;+\
MWS- A$B0K[4%+&EOUTV+M/Q-3;1GC'GO5Q_'+PT/*"H'UW-52::]_"8_>R.F
M/&HQ<']*:'U&QF]X2JK];(T<A8931 @07&S$:<K7$I]KS\;=WB]5@28<(C1^
M'YV+^F'L=:RW  0>7*R*NDZW>Y&\+<]YRH#X %L)I5PQ)H+ *)LJTVB2ZCSV
M"^2:$O\\<^YTYS6][$<_^S'?FF4YTHG9K8G>-#]AJT4L^D\*VV( L+#T1D./
M^'27]1$=H(X;>F4]UO1RXIL'Q4$5<"$3_0JM\1.;E<*-(>,[81I+26EJ]F_=
M"WZNC2!L*7(MQ3XW-!4%!GZAQRS7KZJ]_OUJ!\!'N5F%EE/CL[NH%+C[EQA(
M-/K0_4YS)) S.N[$J ZEE>?89F%;K52R#3CW]P"E3 7D"QZ5*SUHG<GE[[E8
M_T%3;A.I]))F2T#;/\WL\M4< 0%.SY FH1IHD<6Z1./W1TMJ0AJ+[AJ'1](I
MCUJ7]NV_GUR.'@SG>/2%(U+9'2!0>'R\4QJ$0[<C+H- /S-M=,.<V$.[ALNV
MQ6_.9/1EA H4. ..":Z\Z> N6EL7H,T^%;#.0I@\\_5:4]@(Y4K#;LF-B^V=
M^0%6--RN^]&X YG3!E#0I=\/J\E"J]H.TL("*4R7Y&6O^]'9[7^29&#0 >M0
M :U^]V-L" *FG52  J"/3\'#(7A!B0/Q@K$L:/$J8!]+N.O5*K!Q^+/>=L#E
MMI= &7C$#8K, ^^BYQU(UX]?5M:1H=Z714IQ$:TYNNPC?BA*@FM CTKSC(+I
MUE>%(D"6GA; Y]^5=C8X2-3L[1U.-]%J/[JKZ97+&LP<KP37U;U.T%%6X$F;
MJR(BST?K!Z*Z+'_>GW_<?8<IDY+K-=R C830BC0&/?SFPQ=VGR^U:_IU3^/A
MDX"6+473'AY6B#V0<9)@G#;,E6[R[J*&W&O;D^:U;?3N3T;/V*,1@N9#$4F\
MR<.H*WR6^7+L6PM-H'DHDH<VV* J?K\]9?Q80ETPHDJRY(-X &_K%++Q7?-U
M,A1A[\:(MZ8?M:9(^0BMCW1PH>[*:CS:D>B2H)S1: HSB64(S/[DK].? 'VE
M,+7'GM?<XO:[#[TH.H"@%GE S&>:D^&_<G/>G(;:'UJ]>OY;W3S.F1#=)LK@
M9.P]*ZQ.N,SR+"T1."5*&3@&CXE2,H/1E.HUUI5;IL^B/UYHY Y?E%FF7/*)
M#ZHHC_A0EW+' 3I;>\8D'G,7G.D-VO3@,\4;QV%RJDZ:@BO14P'W:A*H $M&
M2MA8^/_^3L&7M!;_(5HN2/V,%S!95:6H-5\@]"P_+7MFATHM P\&X3AQ\@<;
MJO@,--:K6.G%;ZV$Z7_515!*=7 /#AM&OR"\E#JMW7C#B%3@A+S#%4XZ.(!E
MH?[LP'2O]OWP$@N:'Q,&(D)\1XH.@X53M<6Z%.(\&BJ.88["94[>A!S_M;+"
MD[:%Y<DJ0B2OHA3PSK%KW1%2Z8!SW#4IR"YX+.GO(5%% _>%AI,,#D?#<]>A
M%V3H.LJQ,Q?F*@"I;P953U1"=SK-AIL!,VJ=4WM+G^ON\(@M=F\2FR%*/C"4
MAQF=\-_T]MY#0X)OS?1>94W*$ _L#:'A"@MK5.::YJ3T2**E08HD8K)^J3H!
M]$M.0S0GLF?Z? ^E,DM<GL=Z)D10[#;O_C/5%Z3/'OL^M/LD91 FMJ7H$P:&
M$=6,(%$!7LML6T]B@&(K>D :>\D76%#MY55CUL4[LH4G@0?')"\;( 6&\P'W
MW,=QR$V"N%_=/VWHE!WQFUZS](D7=<,6:ST")>5BEE*D3&:\(3MZ=X9U*H69
M8Y4$L5UR4QZHOW&QE&KIO$I@6@N'7TC16H.OI%26URDQZO"0P.'^_9=ZD&?\
MI8O3[Z=[+_,QP1%*1+*D]H[Y NO,4<_4_7/Z5Q[_1GYJOX(64 XRI ),R_>2
M<,_EA==+8#V]\4VG^5.KT?-= <I+E]_"-@UTUV:PLVYY:2#U*4IL]]9<K"!+
M\X54,PZ>_;[H(R6?0Z#Y<O4,DEL3Z&#5_&YD+P7@TZ4KR8BS486U"I=?D\5L
M!0]K7R)/WF5\3LRDU<ULB!J$?&*55-N361KL3WIP%:#7+\L)@SUFD#\NBU)2
MCCI>4="LYF=#GL! #0@]_--?X>Q+5_6+'GK%&[Y,>I27DZ"I7:DU YQOO"UX
M8UV"X[K#U/D#/@8(MQR)5C]+X=JK\<N?W"4E5["T*K7+3;J8.9$.@5Y6^(L]
MK@5+9.**'(]8,RVDMR9ESK[[I0K6TZ,+K <Y HV&/8_(S]G ]>A-SEB![B=-
MV[O]:7 ]]5$4\MA2&RYX:"HBZ]2YUR.V5*$-DO$!KPRFO'!QO?"9C$L\;"'5
M?\2>CJ?-8*8Q*@NY#^X]UE!R*#I3BO@NX:EW!$9%C?*FS;X?8/Q9]"&M$ (J
M%*CJ"[V/AF\?P_VNWB7B!(F#/V@%6^0W/$S)D=&9\OL&X54I(KFEOW2<RA!7
MFT8F\^KKI'#3\55O L>7HEWL1CP\C8;QE9989<8?+G>E;+1X+HDO8F(P_EUR
M2'F5CE.TB4N\P9\/2MVH;70TKA!5X+:#U /5D*'+UZ0_'2V9V]8#ZU+W:%4K
M:0O8U]+J"H(9ZK[TGB'4"#^.)WW,[68;O.Y-6B^TEQGE$MC6%/22\<D;.78]
MUG9Q<TV7<O(/C9?;*[$T<NS,NW@%DWN[)G*F=SM(V_KHY+#DQOAVT(>[ L?*
M$@B![+4L8#;+<*-XNC[OQ?T/?3M2T>?E.$]7>.:M6T-VM +N,Q[UA9F^9O),
M?8KJ5U%;@<.<HTG,C2[C5(!K72]=,AG;+]\-;#BB6%?-G^6VX\44,<E [$;!
MB%JZ4H]'UG/3^-SBGD(!?MK*I?BH^NJR;6S/H9+G^-:@7'2E9,2@L1=YONL<
MTC:V)6VQ\>DW-8UXFMJ KYEUO'W=/4<X>=Q'3-JI".6RELL'6>:DM[V R0\=
M'VNYLII)KT=O(<Z]^]BA$^#>4=%7U]BXB9HFAB_11(/K+D78[47G^(AJ]_2!
M:DK+H'TA"@U-#.N6'M_G,];5;RSQL[*U"C]_P)<'(I<:(DC7_)/3<Z^I<A[A
M:U@>VPM=/MGMEC^5M;'V,+)K'CGDTI0F3'*OU0*N:[8_F/.:CM4E>]EH.0,O
MK1#%4BXNKE[]+)3'X/EHBP@U/"S9IJ>@(O/7);!Z7DH5#GZIQ$N2\ZAG;&<A
MQE#]C>Y;?4:9Z7*"24WL#V0\ZED]UKHI5@7!O91D&[ @TCUM*YVYPE;8HT(%
M.*.&,2[TN0JF7TCB[QJ9.A5%=VLO0NH77V<$^9V^:U3LD%T^79</=8UYFOI'
ME:T557B,7U4&K3/>#A:O'9V=G73-%[]\/I'#8P005T4%!)WN6O+Q5)+[=97Z
MB 5F 1$2L4SG6J_M!7$W>H(+QHH3==-U5/?^QI3KW#^P["5;F L,G6;I6G2<
M6',;=IIT]'IUC&:@9::. H.%?;8*=GVFMI]V6K;\O?N57?6'[Q'2$E? %0O3
M*F7Y&VX\0C]TY^0#QA6XT?SH&$?+D^R!GD7/O2"DL_K=N:^Y)#X#G%#RPG#1
M2Y/8B'3C"0,/T?2ML6#L##=X[?(5I!P*5B8<9>8"<<Q[H&)JP%FD>+^4G;BV
M[9*V[1LX,2O=8NM>T?KW=QVFBO/0653(0&=S9W.IP' -!>A9)H 'U:@ \Y[]
MA-&=VK+96L0ELQIHGJICR_+=3\BBP:'0D1AEE4SA*MC(WII8L>$GS2"Y3L>2
MZBA?N/9[8I/)ROZ6DT/JVPPKG-!(HO6IK \%;'$SF7*I+N@UKE\UF3L5A2 *
MP*D :_NZC_4Z5^2[+D3HABB@>R#5".0M M.<(HQI:J+=PR_@XEBCRQU/8U32
MC3]7^P;QT>3 W4ZP4/!- FX7O\ 84Q*L22XJAKQ=5]C0>CC,0E1H0<?6"HJG
M="%I%$\9&,[)C"^OS8R:F)J ?H,MB# (X9;<@\ZQ;^H#/!ZZ%C)@,S6EWT1$
M0(#4Z;L!EAX"2#_I(.26<+P.QK'&$-40)IGN[3"H<,-3H]/[5HJ(>YG6S:D.
M3X6Y.#(0FN=XL?=!?LJY3RL)CQG^GY/Q"SR$!^@X*H#.BO@T@$ %Q(/*3@(H
M1Q.!00>4:H( %7 )%Y)"N6ZATP >29X9\056V.Q2#L%'D%:U7"/R5X2CRU"D
M;+ ,.I$9FI@4OCP7DT2X<C9HO@O7]FC0=$EQ!WM\-24633K\R8A_]W]2/%"X
M#MQ=D2464 &J,H'_Y4'ZW#+/?_1#@]W[CVUW ,M_J2 T70\KH@+NX%&G9[RG
M]X,2M(4*L*?,UF)BJUQ.R@\2N.3P&9 O0<K^B$_\-IO$"%+>-*WD?NVNP,DI
MQ6?S_T_\C*XH:#Z,$[R8LPY$G9P>%D5VR2E!]RG@JK%O+#_&'CL0D>/Q\:Z:
M;APVRV4( ,L/HQL:Y]1T_5M@RWV4JV>+^ 47@@[1(EB]@9#B,6_%:[Q[J2@H
M'1]> <_RC3R\7_]VJ[M?5>J%KM?TL0R9CO1\C./)CGKDX6<7F&WNM&[N@<%'
M]P#<_BG1]"09TOH2,E=&!51AVX%3^*Y9UAVW#A&]%W]+LA8M)C&YEU@FBYU?
M%AK8VG8X?K!;^9AQR%WS_+#@:_Z:7)MAX5K04.)/7/VROI\S]JM4X?B@2+'U
M6E[I^%<8=!7\=QVQXX)N36E2=9NCO]ZZ]#3#R:3!;]YO,<+CD 12VZ?0UQ/N
M2:=^YF&LNNNWDK]3;Y6_+?;!*R(60;"%[86+D6[AC]J<+O/<K&YYS'EY,TR.
M"B@[T]MXLO,H9,<"AJ'=>,/807;\D_B("A"EBX/60[QI1VT1P\VM!@.S_)[M
M]$*_&20+UP;D9T1U75PQXVCP%KP&)2CD47^<YJ8GG=9,]#N!CKF1GCKM//ZU
M,K_UV:9OA<)O\D.DZO0I2DY9RNSH#']!*^2>C>S\5C@B )-Y_R^GZQF*9"6/
MCY@"&5)%SYGZ:B'#XNT223KCYX58!)=:P_C5@>OAO"<4EDPJ@+&3#&N,M.5A
M/OS43PP-\#W13SY1WSKUIC3AE\M')>3D@27Z>>S&WNLR&U/NC6E#^/P8_);T
ML(>'3FX39BWD/7&KQAP21S:!DSA<=BRM6JF 6\1G>\'EB#.8M2CN\D"'_<.2
M-<@<!A)*>9\/##^]_[?=D=)?K>0 %+W70O$AE5F=:3P/R'O:5U$D@_&7ZMSC
M]Q3!N@K[K#@TW.O5'TBK*Q7P7LF29A=DH6)[OL >UA?MW6%)D<>O1?5=^5:$
MNJJ?%V[P]>7G/)V&.LT'32PCIO7@+T).DU:P+[*+I;Z49>PA!!^/HM W$NZ4
MMR^3@']5D:A,4?0A>8@20BA1Q!(>;<_M6^HL!0.'E$J1[Z3[+&VSH/7'/5W"
M)V9GR\JG*<J$P;V/NZ:6BH&4+4S6R8)H8#05\,W>Y@SW>\A[1S,4223311::
M&.#;Z'.FN%6P?3O$2*1"^U)%QX)*L=ZE$\/$HH'5.O,AY^JQV:G*!T*&"07]
M(SJU#<" 8FO!O""9WWAL$=G2$M(*YZ&E;X+_N_KU.7:0Y)2<U40%^"0@8;CQ
M%%TJ(-0%3'\ECY6'\4"YP;-NN-0CPX,*>.@!?3,8< !;7(+,G27NFLLQ%X&W
MJANS%2.U+6N"F)=L=^<.\!J('0LLAG&3^2P:KH$L!/GLC7TMWFCV7.#AX]%M
MAIH3G%,GC<KJG.:7R3DI2G>&&T#Y33Z'E:OO?R;:;BO[14$8^JS)QY@ZLN_,
MV4?#(><1E3E[*CRK0$>1?5NM*I2B\KU!!2K 1JNG^@RF*X4N,I_YS)R/WO,#
M%XQ!T9NNT+IM,N,\*6_J;+@[\#U/N2H3(:>D4CA,<@/>1W>W];P$DG..H6"J
M*I;$*G94;V9)!;3UCPW:3K'V?7B-XT",[6<UU9VBA]]4/@QJM]:FOZPF8C54
MN)03-@!,_@IJ_JPE7EE0_]7+8!+E(C,F:'VTW; *,:CXA]6&MI_VS&)6LQ#R
M^5+(V JZYX"LO,9!H:\C*%2*H@".'][_FU%8?S&RYR&P%")4"6GU!(*&WO\S
ME;J9B=.K\$FWN'CQQJY ,.3I@*WZV7RJ(%?<K[L!Z\STSK[@<@4T]N?< C.V
M&9+"+1.,8C9EPVM/[!LD;O)?>?"@S,K S<GB.>)ECFK]Z)VZJ0PR'L\R8._T
MW'EX->4'V<Z)"MAQ_5>B)J17[4_S;)IS4T"KBD=T@994P8GC!(<(+4)W7%9:
M;>!3&SN7PA<#; >H@$CC,AH['Y67['BH]2$IE0IH7S^;(8XONZ@ 5I^!0;_S
M!A/?&?Q[/K\^]W'D-,W]+()GP1/W'(](9N,3:@U:)[[3. 23[3Z>8/H7%2U%
M9RDX7*QWKD=+$CPTG'FHI5!<<V N,XJ5:GDHQF<KYCSCF+\FJB/== */-BD5
M*.NS/1T]"\I0=Y5_C:>>[UP*4TB :U<?"L#B59H@IY-#D-9:GLM*J\$HP&JS
MQ74>"G_RA+(\L'[MU'0O KMCR8.YD)M**"C=48/XN2'1QS841/8<A"#*N/EI
M@0MQ\_"/:=$5EWW((C/%8]O:Q55Y8 VY+KTS$9AH=Z*<:_@U*C[:8LEU6]VM
MU7(EZS9/?7*#RKMX$S\7+Y52K+:BLA)J_9ARMX[P$!70T'+[_KE[C(0D<QRG
M+4_=Z2F.=JH0TB&+O6)<VG86FS5VV[S:-5Q2T;$"9]#B@7-P: VGGC"PT\6-
M3O><MDW*&A%J.WKF&!\4Z=;Q47L:VP4(BT\G+U!<.QBNDF4BMRJW;;Y$4OW6
M@A,VSM.[(I0D&#12I)6C/RS(5P:5J6[P72L+B\O6J=W7,5?HK)JVVX#A74(4
MWD,L%$Q)')$[YHH]YKB6VSS)Q8DS>>8X/[V3I;558!O,'T:A[R'P>^0^EJ8"
M *OOCONY7^N(CM;,#/F0!P-=R>IYD'LUD'_3^0;[=-^NA:6]\-^\9EK+K'L7
M7D.7].K/W(T%3TB)[U&$\:!/C+W)R.A0*D I )=VF+/ $&+^Q?*F?9C1_;K[
MHT*;^34(%V:X]5+7%R'P>J)=@8H?MU6Z.6@I2+3^1.H4 =QQ0;7"1W; /*L0
MQ\L=D([?(XKE71(,7E"85VO)5SW"(\P\ZY'7%0K/*L*1:-:U*80AZVZKLK[P
MQHTCDF"$D./-3X'!)N,]--]O8*(93Y<&(>1@M-.N(>4:%_$E@;6K'OE%28!H
MXN^',PT_"*C*L=\%SL>D[')H[@ C.[<2"M;]0+]>!;\CV._$+ACQ3*#A*2H\
M9RZ9YR,$S5,!LJ;#U5<.()M6EW3$+$8I8BRI)J4&[C#=:'NP*]AD.@G]T \A
M9K>Y=_->4S?<+EW+9-MNVV73I=Z2L@F92X?N:* N49! =F]&+H)-6[*"UMJ?
M?I4AT!M.#FNU_<NS$>)^S-->-D,A:8/&E+_RT[YD28]3B!;E&61N&H;QP]%N
MFF8C@W9I.]!IJU&K;=ONY7,+1/W/\<;J^I=)Q:<DF!B+COQSG:Y<2Z-XS3UD
M1>5F4_T5Y4T?AS<_K_L3FY (^ DE<5WW!#6O;9F(Z^N/=_)2%!$!B85AQ.Y^
M84=:/R@9>'+E_E[;BUW. TM(-?[PS(DF'\R(EA9Y5NT2MGXU[D 8'#>>&V:7
M)7'ONM$QEX+#Z1A_U:O-:-V.O@?M\L3^$$:]_5#+!F?T+=9KN;EWBA^UB@W4
M>JJ%2"$+5J9IZA^R:#.W7$@X*,S^(:"SJLK.&^M:'0Z!/(ISNB+D2A?S>PGY
MG/_FSF7*+O!+L#'Q&7A\2K8E1'=*V.QA-0>QH3@HP+LN-8$V4UK"%<,9>0?8
M;-M#X4[]R=B$7X1BPHZN,4X6+'SK;+T:V@:^RR[ (S$D0\>(XHD1'@5?"38$
MW@KFIXT$][' ,I<RXUPG9+/?!_<C>;F;A'N KK7Q;I/I"\X:V8D$!\MNX!$M
M K5&"?I+N[]_QKGKUVM8@9<HR@_[\S<I#PF?VZ%-E11F,58<^Y%P:-8AV=9T
MK^[L;SW( @L2!P%[\Y'^2<%"3'WP?(,GE*#=:(:T9*A;RP)>I12N O(U[W5$
M;[C_EM217/ OS0Y8?AW7E?<C5O6#W@$L529VJF^>X4NII:/YRE?I(,'LQ*?W
M=+QNB/>&+2K]7-DY?4D[JM]=\:L^HY@NU!(:RQ<E=@7/J')!VRU9X.,W/)IT
MQA#\HRAH!.#F>[V(V]S,GRXNP0$0#/*$A,_:-=UT(:K8^ <9?:3<=7Q1\13^
MIK'FI-D>N+^+7R.MTB22T^^/E"GYE&K;5][O>K&YB/,.AZV<F,ZH$)81PLT7
M*"/0RN44G+*S!LDO^_&GKB<>?FX?9#514BOGF\MY:L0V""TLA*_9UU_1D2LP
M/*FU9X3T#"[+4^(31CC$88M,!:0LNVS'6@;:-@5/%E(F@.<VLR,W&T.R!X?_
MO/RU-4U>^&G[GG)&911VK<OGL-P$!V2: 0':;OIH*O>2_GO74DN-'"6<4']=
M"[ O#Q!H?'/4I;<TVHXFMO"_<0#&)A-[FQ1+T*VF/Y/LRZ@S,.DD,NA #0&D
M2-I@VG&@@R!]7GJL!"TE2'OUN25_[W9OWN+8^&J]IT?2J%%5=5J],O$HL &$
MH+.4?YR:Z,[*LS?LL:HLO"IT@C_RJTY&MQT+/FAG5Z=\RSAE-#^]]?/_*Y2.
M'DH#//@5_?<28Y05;F>V?C>Z.\UX_TZ79]OLDTLJU103Z(Y',VQ!Q/1H,&QP
M_<P >H_K\[M%MN[7J!E5#;75=,_0N-]<X1J _(9$++XZX++'L.D\VHT)N<"8
M1@4(PPCR80L@!(:[S^H/*LDQ9:=W]3$-F?FY6@\7<*P&PBTU$&3&[^Q=[N[C
MU.M]LK#\J\I#QUI%IQB#F+8UFY)MJM:BE/)\SKI&P.'<:*8&YHOUF$$O)P>1
MOC+78AA65CM[+ ,*.*F I]8.HD7%('A:38Y*T^^> .6-"M'-)_,_0OUX^P$9
M'Q-B5^+Z\6JS9[JO,^[B)QI!0U2JD8.<4F9O4-#N<-DJJ[G=;9G)I)S;;?W!
MT7'+&^W>JWJ*$&@UN"&LPZYVG6#.E-=;M&"[(<)&$GF"#S$?G_7;DWN;N\1?
M.E-7U9CF>YSB,WQ&6JZX;OETWV0J60_E\2?7S.$ 6<" @^--;(Q!B)MUE$W"
MJ]$PC;4 V8'#OOV1$3B7L.^^R;=HC8T&2QY%/A]V/,K:_[!,:!DW6*=BPPOI
MP9*(5$ &IXVAT*^U>=XGZ<4RK.S25;J]XU;>B**A\'%1L31)PPHG$+]W"5$Z
MN6];K:FY>D%=U/35V&74 "4%R'/"')-3@ B,"H%T['9_],DT$N84%7,X*:<"
M:):3[WJ^36QAY#U.I14HL+1M5CXY_OT+^S+CR9-RIO()=P_4_'8,A&R3NGQ0
MH)5YF\W?Z*57K$A20H*%L(VU US/L&)(R\,WP4!3Z[BB>H.$-IY1Z5J&_B8D
M.R7IEO]V!0:'U."6>([W8Z!)3K/KW/<^)U$FQ\[[ EUJ%U>X@E&6@4<D=Y?\
MYLI:/Y?6J'D4;XR_<L,N@4?+_@CF)7'9<I-V"57T?O>3<G-6]=$/Z]NO+.,S
M=HVVP6XN32?V#MLVSZHJ-[I3RE>,S4$S4?K5"?&:7K#]P-PA7N?F^[.&1 =C
M5 '&5<&'EMMA#J*G?[,>%?GF;E?U[XL/65)M++WG6%"I_^[4'[.K0P1 .4@#
MM<K@+0:55"3$NEHP;,_QB=S;,,NX5HX8H'4S*>W$.5'<[ O(4/>&9ZANGQ^H
M+FA*TX<"XQX7S_,=\8RV9YW"LC26C94><Y6EWR\-**@J+EMOAEPX5VAYT.<0
M*UMVQHW+*EQ)J@O:%DF1P>HEA30\>S<:V+H4P >X'9*"<1,7_Y_H<GX[##X:
M)D^61X%!J6.3 @W]P8L9<2-^N][;&8?XP9#FMC+M)VSF1D7/=74\Z[36JOFY
MIE:K&P[@T*N):960=ULV()VTH;3(!;&;]"M$R*NXON#?4]]&7(];OZ_4>!'0
M9\G1(<8G]G+PLZ'JKO'#Z[N19J2^GE3!DTN/*K_+6^,.8?'\Q.<EWS5.:/LN
M*BR*76  )XWYVQK4#1]:N*BM38I<PO%*M,5\H$F(Z=A3KP'AO!X6O0PMC+=H
M+93UZ7NW4G_@YFIQRK>J,%25N3QMU3SP"RVTIUE\NA'$<T;!H[+N[1Y_]5D3
ME<E\')*U& *U'RWD>*\=P]*UW1P2,(=&58!F!81OYS<4:]A2>.#3-?T./_=5
MK/4*2LUW;U+>%1XGO]>H^RXIF;$2[3%Q0 DI-]NR?S6KK4_L9*\51BO1-&#C
M,L!)^]],<UR?'>(O'8VHXT$G3;KUTM/F7^-UQ7X\]S'1Q#KLAF!N<#ETZJJZ
M.!B[9KJ),H0@QB$*7\[4&3.M8UCE[_.T,T0[*D!,OP6+OC-JDI;4+BPLY0KT
M$D#\Q _J$8Z*T^R_'1[NN$1K4@%FK<0"OJ,N24@!"UZ_(*++\[E:B7T/6\V(
M9<\>)F4H"#$_FE:=\]QX3("E/V'*Q/1DTBI ^LM7LUT.41OSL8 U2J:[_"8R
M50H%1^0IX#JX^;^P<%B/$>YL*'SI.:>Y3IM.@3 H-#UM,__\ /Z$U>)-+Q="
MC$W)(PMWLHN):X8'%=5<M!5*FCZ?T(+;63OCLGB6#9.V^0?S&0[:\8UOV(K4
M%SQC1<N;-T]>+;>_J_J==^O7$JC/8D\MN+'Q&),R?Y(V;C[8I/3.3*;TY:\R
MXV]DY$L%.Y7 4*0RX;>G?T%'M+7T^.$+03G]((^J#WI\;AON7MC25VGC%E8/
M%+,US!\W?I*ZR_TY\+O<;_.0G]_%::0>F?FW3JD.RJ%>@#D/RDIN>:^] ;U<
M*43X;4R[%1^[L-KGC6U5C6V7-P56W3]9Q:0)&Y5D#]S,^%4:U'QLH1RQZ;/-
M-/"(PW*L9C]>;$N5>W)?"G\"9GDC@[AU][LJ#"]\'U?Y+MLG7N$H)4L#N31M
M\JSGH<'-#]=EN296.>Z<L<!][)I)*?=)GLT##?1=]]2>M\J  ]298-:WH4GM
M-4PHNE6Z:62@NSZEB!\ZW-_J>06=F=W]DF%7O>;C(S,\XS-!&47,_6U2MT$0
MBG8?VLQ:V]QSOF4-LM(1:;7L*?"6E&)1VD<I'<(._&#[<6=*[_&;\90%OTX_
M\6E^Q%%2RM17M=ZZ?>GI6]WL*IF(JU2 6BII8*!!#L5.!0!7\)8I\3/[]\FS
M5D:L0O4A25L4B.]! :M"\EBO,ZD^EYS!34YSPEJL:S^_:<QU]^6T;O).CW3!
ME1M2Y7(MQ@::\KS1#,[.;;L/;UBNFI=(G+?6OI9KZ3/]]P_;,4H+<)+0A:WQ
M:Z$"PA4R!Y,6("Q.]=Y')<_B!OS<F 7IC!:E&/P80H35Y^&;03MN"YWX28)8
MYVUPX?IEC%N F\2^RFO6Q?<K0OZPY?:CP2&( SW- C!2#ZDV\JN!^+P=1?[5
MRC#BOF@GS\8NC#E@F:0"6A4:A7=,N[B5M&&3.1M^"CZE_2Y@[W#).XXKWU&(
MWH>TUT0]@[Q_,JZ+=9PVCL]>V 7_47EJ.Q\">?D1259TDDVYW$(,>!V*8=^V
M66D7V%3>3<>Y=0&Y_+L)T [>-FN6W5GXKP$/%T@ ?8DPJ$S/\7JJG4;7C39]
MU+%>-NS@TFY9>HALFQBS$U-.>@^)MG1MZT/PLED51[%G[;JF;Y<$"LU""0F4
MF?U"5/+GQ?FU#( Q&RH2N_ .%!/H=DANS3;+Z- ,R/RPK='92(J&7'INFE8Q
MO/ GXV;0/&.7&R!8B)P:? V'8B$D&>IQLY?7-C<AFO<E!*,63+ /MUINQ$G(
M*S=)V"1"=UYA,>U'/H1J(B#8?"<E+-@ASV;=/"/0,_>EC;E2=J@5@+G/!7_\
MX<[U .ZQ]68.<AS)8A=+N3)4X,]H-0QS$SO<O#T><F_V%5^\:45\NR'\Z6T6
MD:H?HX!+\BRDG3,S/X;,?5?A); 0>4CJNZT[G9O?SQA&96ZR0^6/\TO+K[6E
M7T-H2P$0;9N=IPWTDM@CGYV9KDS9C,K5RGC,\0I9B DM,$(*@$TK%OO$Q9N\
MT^<18##RXSRBB.6#=F"4R]KY],)'MCO?LCGLOS[)Y#,05R5:"D I"*5]FX;A
M.W'L;':R+QW/R[G>@ZI87,*@:664/<W'87G^LKJU8V+6<B(XG3V-#28C.[ID
M.<X,TQ;PV7KZ"0H>M*9%Y^Y02G'TEZZM\@D^]'2N&:IM;W00&CDOV?WXX"?C
ML)FJA :MP;?8WD;AA9F.&C!#"#Y!(*ODE=V7=]\TM^0N-2O\$^NEX'[?FG(K
M39P-0XGG'V,!T^K6'DM('Q*Q!^,EG$F9BYKD']5ZC+GZA+[V_G"/US(6AGO)
MT5D7.KQY4+,?@$\1[Q(CE3@*4S-J0ZS]7#7;I7KUK#,]8IU/)1$L*G1GUC6
MV,,8"0;^V;LIX;QFU0(7Z$W&O*22V9!9\GT^5 #O5"R)Q?3(J>:EJY+3_(Y5
M<.=,\=1>KAN7*^-.W&.>0AGCS=!IOI/WA5TTUYM4%_W6QA&R2CQGN)3)F8TN
M)4_S5V?%_Q;$JS-M?#6&!Y?'V78-20#]3__5[)'9_AY^U8%HC!RF7[EEH:PV
M*>JR^+3.6IZVUSC\ H_^X]O_>2_Q_^YGW,QG-G-=\MF-.5M@2]"_:P9FM;_F
MW/M\;_DEP JQ-X8L4/*RC@MIV/"S !_'B:HT,)8&(#\%4P%55B$YOMM5?7"5
M+!".YPL@\-O_G<:5URT;<E_T'(?K*D=2?.:YQ7:KQ\,#KG[+YE'LNY?QFGO1
MXZ\WQ7@KY4L'XQ(4RFE;)@XI ^8%!^Q^%"41K+R6OLUZL-/DV"HKBTL,-PM_
ME: "C*-YV777Y.6*/1O,MH-F1'S+#X*!:C+./5J)SF*1!7[\;.L8JWM'0\6G
MF<S!!G6.T[^?=)PW]9;(H(!&CRF-8[&,)./ZQH!A_>N.D6Q[.6QW8#37NJ0H
MGJ"V1D4'#W<^LW.BV'6I;A3 5EE^)M83Y%'E]#[R45^-$^.I*N#3*QS?P0&;
MDB^G.VA?*T,U*H_#P-.G;I/+IITO+P H/'EBM6U[,/9]J=I1*[U]Q-C^MI=;
MKN%24M*IC-W!S.0V# %IZZGMR\B7F_(M !8 %XF&>AT-']F ]S=B'A5P$Y#K
MPFWS-8U[BS=NK1$;%[VZ/%"'*N%-AH^FHMS>83\P>(WP6#<!.4WI:F/EHFR:
M,V=P]W-/?*I^X9;'ZH*05@J+M89BB1FV:JPF42XBEG46U8B4>>+IQ/'NKB2>
M#NGP-+1<35>.BQ9>:A*ZX#(=!TOC'=PG76OI:5TC')#*K2^W$1Y7W*"8K:&Y
M&GQ(9.6UNZ"B J9\TJ>&L" _G,!Z !5P=<"#V^]"'7Y4L]898Z(IR]>8E;RG
M5Y.F<KWE 5]AIQE>T:Q(6("+N\^&$,2CBMI5\$_A=1!Z$A^EMM5>T"R!-^O;
M53MHF2MY:X!S/M'PS#TD%BB?.UXD*YF:?+(7Q]V7-)5;:\2-(/"$M&\Y6?<C
ML?<>L[IZ'?NCGHZP'9?5*SU/.UNT.[232%<-0+-[(W:;O@U?5)CZ5JK9Y/'Z
M72A=78OGD"C*_HS3$#>>IZ.XHS9&Z>ZW1%<W$<F")3Z[,G7#KJ# $>A"V*_R
M?HRAI\:SUVJ-A:O@;7E>&&()9V&6R7_A\OEOI!T&^<,M1AAAI"%YB<?I[36Z
MSM"NP8DC?+?\9HRPX^Y]]]%<O*9<F^0G/6U!Z]FBF;SC!$K1G%V=?5AN ;N(
M7<DBSN%!PZ%3GFOW,2TASZ-^@I3)F-;)_$#O17 .I^\9*1M]NI#W5S+\51=D
ME!3WC<0P(=^-XAZ;FX\P-8SGC)4F'JV=>+SL65:*.]-DR79L>LN7@%)HC(Q>
M1*5C7I^Y#LIT6UF$K4? K7H@2*1)S%9S)]FR#/<DO3+:0-M^"\[ONN=*;U$0
MMZ6]"S*4/_?R/;&]5S\Z\$/.'E)&2RSZ=HZE;DG<9YQM@'[9EG@ 9I"!MH@,
MZKDEGVMF?D\5B(_1LY;*FO$_(%VT>VODQ#(H1<F1QV.=!A7/$MFK,H=.]EQ^
M.=WBE<2WZ,;CQ)_3-=KS#7X;QPJ%.V$6Y@;1[E7DT70/G=(4R4 W+ILTG=,@
M-$D$L^>;%+%Q4A<C%0O^49QLPU+V+EY/MI='K&]/K4Y1EU88Q4L27O'YM!C@
MJFLG$JE Q@9SXN078-<4L^4R0A<Y T+<+0@AQ$+<_G+:0H9STZZ4TWWR>+66
MEF!@-2R/&*/$D5R]_69-=5]+6&=CK#2_L<=F5^6#6Y2L! ;99'OCA[Q5W$Y>
M&,,C8D(&1.C,IM=4Y@;B*OOV_-U$)8AMM'T9WH-R!R3\\HR9VZSQ9,-@;_B@
MYAZ!1#S8W#20WG9QN]&+=#UTU>1IQ*UE03)M3B<CM9/&BKUSZV#;*B SA#:;
MZ(V^_%_S85\;M/22/',W@X"B*6L86!,5T#;<R/I$_M-YBZ4G<1EE:@PSC;LQ
M@5'IAH2\ *;GG\N&<_CU_><XZ<[]39AF+!-> 57Z0 HMJCBB?X<Z68-?%D/_
M>J%JG''70CUNUP3_/-^3W,7F@L)#T2QI"^]=1D,:%WX+ZF7V3DFG"(<<U%?#
MZ]9$&7KY=5.V!'_'?4J.T]':GG$]\JTGC:_4PSNY5(WYOJM9N'5S2ROY<89"
ME]:RDJS=OIHG-&K=4DYMC_L?Q+UW4%-?%.\;!,4.(D@1B B(=!&I0F*E%T4!
MI:J@-.F])12E]RXM*"7T2 T](+U&NH1.@- "! @$4GC\WGTS][Z9=V?N?^^/
M,W/.S-EG3M9>>Z_/=Y^=M5AXX'M8%%Q'M-/=K=E&O(.O-JQK%HY<[-;Y46BB
MS1R> 3**G7>=S[3$K:]O#GJ 1+N?IXP+RC<6=NKBGXGHV4]M3*3LS_0I\:3T
MIU+3@X\$.?:Z/;9^C:.:R'86F-&EPURN@?(*4=>5+QQ=V)@+LOOS%#6V3]U+
M]N,#?_,QG>%,@PV/;OL<]&#WT%#;X\//=0G6LY5/[K1%9?I\(+O&0+F:[:X-
M4HF5[8G++1)JL_]D74G)6/[T:<DEK2]"0 V6C 1'3&$!IDI#J433[ 253I2^
M?K-OMT[&C,/V58:V>OZ7>OT,>R-,00KJYL0)T(<$P3N6\?\XE]:WPOD$<'!
MKWP*$%FSB]Q]]$7\\C!X)<U\ENK4?";UY\8QAEO'KB[M*KK>]V5A'<V=>:F:
M]CS;->!+W87=[&8/2*S+N6L9-13R,2P;NOLZEG$3(D92$#ID2S2;M8F?,^<8
MX9<\2:U.<WAU775;YRF#3[#Y=V"%*CZ+H#???7@*N*0;?)!*&YA@F="C<8]B
MO+#D%[NI^US#^5=O<8>*77_*/X%R1BWDG0*8:7?]0"3P>5S[E./=YI8$7^-1
MJT;GV@2[^YF@.8]CO?Y,0M3DOF0)Z:@3=;F\A=?OR:Z%B?'9%4A^I-1]O8Q>
M<#GE2''P&TMX%%3J#0_^[YVH#\AFF["HI)_ZR/M=ZZI51Q"@W'3_=M3#Z.45
MCCZ1R6!2ON>A?KJ]L1T0 _Z&T=SD$3)N>7U^&:.<E] *]@AOF>5I#6..8!=P
MRK7F=I)Z!Q$B#2Z &4UD"JI*C(VTZ*4,TQ^![S/L=M<NPC3V3P'7-GA%QVD7
MK(TRQ9W\# M)%[KPG.KL%U:Q*NITZ+E9G)P"3GXG@J()9C@%6$N&F]^24:/Q
M7].SN]4T'OUK3F,KZ)_:'YZ?,0_XWQT>=KJUS=WPL"7H#+['C_VQ5U O+"Q9
M2^G_248MP*(A[(2Y7[4-U_,=O;[WT3;>+>,@Z$4!XED$.[S$'XW@=^F0Y[[O
M1]\':YS/IMH=MY#4=R>Q.W]. 3$G9I&+3TM4?ZI+>>N-YS\@>-M2CJ&2%]29
MQF ^M&\4/FH^%0:'_GF.(AMO$8Y;//P&R3&NV:Y9]6CL6_6YX?_V@ZA8#P+\
M7IYA'Z?WS4,)ZL_:._;SU]P7IEYYE/]S\<;M(5KG27*W=I%!]N*U4<(6C=9H
M2E >3<P*><Q&QITUXSBSU&(DRAHJ=(;/WVT0WFGHF>GK4/0(ZAQJ8<98_4V;
M!U( *!YI$?/0K>@QC9^R_P0X$?T_D"M[=NU_270I_?^BL?_/X_48%#OD>*1+
M"[(E_L]S:_H!T!F6]A@;GP+*RTX!.>UFC68O=X]HSS#S5'='Z@4N(@8@\K_N
MGT&,7WM#>SH)([:= I(!WJI! JEDCR7EX'[ZT.G>)=VE_VH3HS4.;0D(!G\X
MV06K0 :!S-+6A;"C'*< KD.C_YFN(O?1EP"NK1OO8U]R*J.,ONJ)%9;G,?M?
M5\6I/X+8LO+S-41H>AG,"89?8/.]'@Q*CDC*\KPM<_Z:N>H]K)UW?LY!S<F\
M(_]@RZ-6"0@K:6\FX9<YD]G/SP+,%TWB5.]012G>T(4RJ7LPLJW?T]\BE:4/
MS9*] 1Y"9 L#FERO$AQJWH7Z%XR]6>PG26A'7FXXORCT]Z,=Q0V\@$ 6G@*0
MP(XOS_<<FZ:'%+CF$,'38Y 7KN96?]Q-Q4SQ$H:/JM4Q!@8^1*0]Q..N@8%'
M4_(,NZHX&RP905-=(6_H">ZG!#UX]TUT!3[;2Q_=Q.U).3'4MQ-^P+K'+Q5G
M.;LB>=).4>@"!4":10-^.)0[Y+G/##3AE.OY#ZA@D>&*B?*?JD%6CO>!23>[
M"'&*V!:%GB-$3>=J\NZ_J;GK?YWTAF=5==XKRZ4:8]#;T@7'LW*/>]MZAV1)
M[H8VWE^'BPKGU.AC[]YI?:"_%^<<4S>-YCEQ5RA_+3E[A8[E U(A6N>Z.O@/
M-%_;MW!.:;I?UJE-%^P)Q[;RD'U6BS#&:,7J;Y"M"C'GOXD'!^AC1I"$?YJN
MU$#1JV1AR=F_#39"PJ[-!I&SGE6^/E76?^2@K/QR=C5V8P:V)P>H.75OYT?Q
M#%[#^JUWPL:XF55?,7*? K*3OXST_3T64:-K>^B:^0&[ST\Y*'L<K;BJZ78]
M-*D/>.CD/&;%L:;RV, _Z4:W?,S3O2"&X./K4*:^*#"3[I6TCY]!ZF1#O&TG
MXKM#;D%3/U%0H\]68B]:6(B-X IV?^\M-$ 6)TNTJY"Y>6T;"H:S,GZ[[B0H
M=$\>&W@T4F$*'%)!/H&Q?E@'*=@ZL7CR<,2XBX?N<G\: ;8?&.5CJ.P2UW=7
MY.G'@5G_7J$#FM^G%E1TE;!>7]'*J]PR6[?Y1^QJ79)S^Z.IH]NL#KF7"I'R
MW6XU9AL.<_9"^=4ST:7B;]6F&#YX^V%!S3XX"C9?\<ICF[OAX70_6IVS(P/4
MNY%C/LX1Z ;'M+NX3]3A'F"H$.@4$%@D3G\!E+8,U%U!0_^@A/L>R"2_4\G5
M(+[-2)V*B1:J+=\<OJEA0FGJ;7&P9UF7#-GL]X0_KW^Y5S;!\5,EW$G_\(+8
M$_3<G4088KWSDXFI[K6.O-: Y"ZEFBX%'BDB'M8=4>7H__#7\]M L1M('NE1
M?@K-;W1GH2G#K<Z^\_K6X2OI]?5_'L1.2*I9EOR'>E9OA0_U< T1'77!_HMX
M*,GW:T32IRR<S.V7@G/Y99[V>%_CB9-WN,\)[^T/CS5_]V?B.1F5'UYPCLG$
MIA_I?F^Y]IMPOB)E6^9ASE<)YU;)H?E6=QY=%(B3>_1NDT!6MA4HXQ@8?@H0
M:O9E#U32>G1%!>29ZO+T4LIE#]D]9]CANZMTZ^;9$_DZCPCNMJXJ(GHK-M:9
M]E90XW^'>]8C^KD&C0F5KJL:&[*5W[)FDT_\#RN&*"]&RMRBU3!& <57@M[B
M&,YC%8ZZ.1"*U;QOL[_0,WO-2&?[!*A</-HQ"US:+"1F5'G?9(P5,PV<D7O
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M>EP+,U^#Y@-469(2;#!Z%@X!6'K* ?"O^ZJ[(SO)8^1S$/9=$.:=L5N8*1V
MFSNHE1!,4\@G6*:>.(8X9F@9)FS(NS(#'Z?,,)JI8PEM")Q0-]<I /\2"\:
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M_-LH?FK,<LQL!1KW-D-+4SCNYP?&2_LWZZP0+0K+)\ R.[1#&4!J>9LS+HJ
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MNI@> ^B1*"6WPC]27D<][S_U6/>> M['S^]O79!ZI>D9&<_\Z2--5H 2W0W
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MU,]XC1SW",H3SA% T,%E]=9M==HBA<5$MB6>3&4.Z*D\IRHD?<4X_S.79AR
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M9I*^BXLL=XS'N)L>;@HUUORG^,H; X'>?1)G@P*>BJ^K*YNJCWQTE8*)&XN
MLC':'*"V+'I3OEYFCUF?125VA_J?'@XJT$HS8?T-9S<950T1B.+22"$-OCS\
M@4QY37RB?IU')E;_-/7BC'NPKH^'9#/^3E+-;,MP9]EDP9M.V!KRH8?EM?-\
M^ZT-62@5+DTHNO[)-.[F^_PW6[0 AA/">L,6<>*KC5C#]$BT^;H!V A5L83B
MK-)W^U;@8WS)-CIU[48\%O;.CUDZ[TJOF'75:OIQ@Z>GV$GS/4WIPG19F4VA
MV0,XJ2K]0=JL;."D)\I$*O2S^[?#*\ACE9N29(73I0.NJ.]N?.*.7U_]94N>
M]E(*72M",,L>I\M-2-*LOF)06[/+5F4T#EV>TL^N3D.Q7 MD_I*<$Q@1#[2;
M;3PNW)W@^_FP]['&0UU]^3]E3KC&J2G;83U&_?8[,$72GHZ=.32O, V;F3$U
M&Q9GF79UBHWUQB]U>Y6$;SX*:PF@L3_L06TN!O+,)PF<JMVJPR>RV3)P^]M_
M(**?2C2E/WFHO5):RZ%FWS#*-?EN;_%/]^MCL4UYFH2B!11"UZ?]A0'X]/=R
M\]P7:SNCEB^V8BV-A\YZ"2+'3O,I$X*!9=G9,'>KFMP ?*6LA^P5T7>75R_0
M()R"V+N!1^^X]\KO!*TJZPWS&=!J3[>&A7U*G$UX1P5GASJ]+7]G,A!IZ7#I
M"1/86)T]VCO)=R(^5W<Y?]>QJ4Z\RZ?+2@,\?]-"@L-[1ZUY\.6C;^8B?3Y?
MFM&&LVZ:J;)C:'S-9&/LG8V7\.P)OI6'OJZKR>:CX67^B$Y27DF$656]1HH2
M9]_5DVC1D)R6EMF@,J&"JM0KE\*.2#GUP&7[PB"8>'I'8)KV\=Z,;B^-\'WE
M@%LY"IB<"Z=G .'1W:-2T;'K5WDIRU!)R1Y']D:&'_Z<<+ _045>&"HL,P-C
MEHC1-#->/;0J\&AY;1PG8F><VK#4S]S$\0ZO*JN[ 5>N'D6YFOU]RN9@M/)W
M5DZ!?1B%H.-T+<RE.4@LI)O"!BIR'NV-_U9%7,-D77G][P%>845GH9XTJ[JK
MC2,P&V\Z6-COIUQ&7O*Y%J[LB]K 7&[@21LU3L#;9*86SN+P,LGQ<%QXM61>
M5-A,WT&<CDP^VD59S']20G\J,T^<^!F:8P#P)$PO\;8$K=4ARGRB%LH(MJH?
M>/W>=\7-RM4".2"?!P,9F%:9=-V%I&8X>J'^O6M\1]NJ+C);[*!:-)N]92:D
MCYVW7\'CLF06((30*U@6?MDRN@-Y6U<X+_79F&]LX HTE5 SF0Y?]5GS*]82
M+04'R0H.3@+]+67=&YIQ<LTY1>@S (-C$H3AG^YRNL-)U<:GM:V-A/ZRD!O>
M+73H1O[JMQ\NP-X='$.&5[9L4\&4M'V*P9>()AO>_H+4%&.KP #X ?";].4Y
MJ98TRM(X&"&]#,-<G_>,!"N3)1&[L"]B[CO;5D.$BX%7."$A%7?GCP7XSP"$
M140.8P1VU\#SG_+CO=K4^?S1,+6<^[MKL3Q3OV)^U5E.^4_HSSRGO='6U!\6
ML2F=$X7P0LSG'7,I5!*EQ?/FW?HQMEH&L?M'&I6FSMGNZ"FCVU%Q5/.7_@IM
M;2JH?<5Y3HFC',H/J@31OOO4'?^9_.#U7NUWKE]'=]=+_5V*7'O71 L7ISS3
MWN8E6A3;\2GPUIC'FCX<TJ\I\=IP6"HKJT&OVMIF2/UT6BX8^-EWDN47T#A'
M*CVTRL5H)<A>!7."AT,^C[']<*=K-9<[-4Q]_]+B[9^TCZHM'VY[+D"/R>>B
MZV- F,T>L M[*<QS@LH[6WU:&/<[Z)],X83#4^$V9^]%F?<::^3I6QAU%A?D
M=1RHDHNKHA)(UR2=%]2<MJ/0=*L0[9IL^[70Q5PG5J28C_<5_39K+0" .D@E
M/2?S62,2TJB<Q(=[7/A6-%>-O^_=4L>?_4XC,SH!1\5>E>S?REG9N$*SIU]3
M*_X"VLKKV]HEK3"I,G-E9<<GN)$^G:[3S<99U9Q((%& !6>TY,E*';43)H:7
MNLHG;7Q9<G>:4K S?]OT+4Q/M3+2)A6S4DM7 S$.2/JWR:2]Y^Y48T_+-1\_
MP^V1#4>M'6]KD&X0:8\"=R>LJC82-\$B$TW9.C6DM$',H+=,7:6N2@5'<)*.
MZ=!M-J-XPBE#8\A3WU7,*C\DXQFH<?"KCR\6]G3LN^!_]50OD8D\NUM&1"[$
MS1KX=:W))K4IO+,WG[ #M.=8N;;!)CZG60FUD; MMG2.\"[ BG/%8JTC[K[X
MT?"&5&0PLU3AZ?8NP]5EKMFXP#- +6+[9Q%U$G'=WS#Z-*L2R;D7[=;^0NDS
MM"BN1TN9E&!8%EQ81+J[F78&8&RY0^3MX.*9J+8&T:"1[GZU4?1S#P9#1:[6
MM9X,HUEVW$E?4!D JN_KO<#(,)Z]+T>3]1,Y:$D8\<O+<-FB:976_?6NYYK/
M/18?2M:I_5MM&:*\WVZR+*7V(=@\J)QE_U $56;-K'<1)V5"#17 1LE]@P'*
M>)932R61< :XF/27F!OJ\OLM>B@O;]9@T=;#6C,B(']M:&[\Y&]OOR<T^R=X
M?F,(H@=TY/Z7UP&L@K5SLB_@LG_U^[I=[_IMI^TK._] -!@> +NL$E<BJ<[=
M5H<+=3R?3<%QZG7B^/.]WWLCN_RI47DR_;Z4O",CC_+W:7-RN&N\6\@R< ND
MK7)_UG 7H95&K(#+[07#J^"!1X*#60>H %\L@;)S'LBQ1-XV+W WEKLHMZ,V
M78RQHRQ 6^_D>ZQZQ9O'-4A>;"SY\;F<]MG!<;>9I1U-[;469UT:"AIS( C6
M<8:\H",DOK"UT7)Q5YW(%PW8TY'YM'M!L^#;VKIP2!]*DA)7XN#!_:JQ[S2!
M?Q_(E4)#GCM_JAKG.JX:P7@&<( D*$$^R +9K=Y.>;KX.=4EFUJ;2G6YOUH2
M&K_?XQ9QLE0/ZY'X MKU&4J2R<02GU %!3'R>LOAF79LF(I:>\?ND*4]6#<W
M4>EE*16=867=>A]4Z<J>XKS*:SCB@U39]PE:RJ#:_]E9^'!-CPGN7.H<C\!=
M U '/(#S*[EQ(/3UE3"#"6I_1"XQMQ<WSJ*XD7N0T5-_/MRT%J63<AYB;@EN
M1BX!=^(5>@88'BZR2R7[R1Y>7E5\)G3+G#Y"V;I(,-<3-%7E_%6E?%WN8Q!M
M#0#B!V(X_W$8*Z7*X SPJ6@Q?#AQ50+=1 FOQ0WO>30<#H.0S>''_^UC] &O
MX;FZT:"8VLO!8',ZN^=I@&7NP_B0\XDQA62L^(.Y_1NF9'Z_X;(^@>O!;' >
MP7S@B#( I&YM6YGT@NAYE$_D64CXG,%0?+<DXX\$3T/L@L?3]W]K TO5@I+C
MW7#WR-SG(PGFK4F@7AW?#9BQOM\8;5A_4-Z E7M3T;WC);E=>FJ.O_3_C_UJ
MF4I'DC@B=,^$YWD.)N1_VT#:+)%%_FUUD6\)GP$\9[16Q.<5T[.1,<!AU 'L
M[?_2M\58NX[7'JC;69K-.ALSQT>7RTUO/'OF_DV/,2MW1G$M8H/JG0%(%(Q:
M'1^\R.H0TSC_L?[^7@]O&1BT!5:F9("9@HY!DVOA##<\5@_UBN6F[YKPQ(L[
M*,QF5P@*9IEO:.;=B7X>6'N9A[.ZZPTM+\7:^^-5%<)RN X;]Q#L?9/OW>][
MI,6RHDX8+<;UU&V+7V9#5F$G\9ZTY^L(MGCM#QQZT-L3L0"*/='S7/NS[\57
M,+?$00IE#OHTZK6^>/,\GG?.454BG(9WN7ES#MP:O'I9_L7+^&^\*N8'_^B^
MB!+P7QKIN2[O:M0FO/8LJ7Q^=-7GQ?U8.XN>?8": QZ#@& -Z:YJ15?C%6X)
M)L$_;&67&C=G^+RP*9,=*NO'RR*RSP# %Q.K8*F3H@7/>#(,<0:X@ML9\)^-
M/+^0)D(^C_F_[>M@#.(FF3('R0R%LPXQU)6"57V)BXA_MY=>NLNW)W!UQK]Q
MWL7M_XDH86))S#@#L"<01<JROH(QN;?NYZP4!2TW"YCQBEZN*5UVH%DWI%40
M:!8M'BN*+<()*LP%KGD<&085N*O 1<I_AKKB'9NK(0*'9D I,1G*YG@?@O?"
MS43R,S^.FXJ\^VR_/=R9T!?8U%,:')?HG!6HN6G"LVDE]\5N:Y9G1=(IT%V\
M\"@DOB4W\JFW!-IF;9-1A7[-<WQOV(!P!#)I-^\D.1KKI0KVN@DJA\:X5(7[
MGUSXL<+HD^_HA/<C&$Q5G;@.P$W8OL6 5Z^L%4+2[5(=WWQJWXID2NMC4,,K
M'*UK;8R7R6G7%3O8/%(16E/@-%PY7Y\V?_]\HSFFYHGWYX5QKQ7!F)??["8=
M[7E433X>%,E/2E[QLKU3H^]7"Y\9RQ8J5O()3*[^,37X%KWOT8<:5=5G?, T
M&OS*FQ5;#6$!YQHT(])6DST2)&?HODFO.)<K#'.OM2AV/?WY)&F6Q[\O_@KU
M>$")FC=6."%($NMG->?8@V8YT&(GS#<L[YIHYH"N?8LWL&A[&>'M89BAVWO2
MDEW7#-W4Y"B7SS+);>8C))F--R=OU!"F(ZRU33]VLBAV3JL-9F.C@!P!)8TV
M6_8<N*\%;9*'1Z<!PYL:.H$^'J:,*;0T!S?5S@!VAH)L9 6NJ$JF91$9J?O]
M7@V;#8=K+9*'R.>HH<6BJ%9[<,.]P1+SI%A]79%LN^ONQXU;)0W,FP]?IV[T
MP@LN^0<R.ZR@9BLGY4.S62?>/ !^\TQ)5#-\H6K@$]RE63LU/J/W/DKNR8.E
MTMN8A$+)\WE=F\@,'JGT>+ZKK0"$G7"Z_8@EF#T5?B*7>*SIU12^T^SEO7&N
M0P7<(Y$FJ2X'?9D1*9F$ZC?X4A>93-L Q8=&C3Y5;JD*AU-[^%!;U_&-/ FZ
MNIJZ??8+1E\[[G.\HIT^7 \!<Z D@]Q[^^S[10.66(<,MPAKA\6RU\=%\R,W
M0^*+<AZ36Q &&LXR9:M2WRKVUSP8V? S"=2ZFK!"=Q4)93^GI&(8WR^\OX>;
M7R4B!Z4J+!6IZ/NRVK$OC]^YU]G=*J"YS-FYU!5S^XZYHDIVDW,.W1F@=.-D
MLOG>E;5FBS6VIZGLS<&TL 9NV,AJ%V\<M$\WN"E)H1N,/UD#9@>F/<$^VA2Y
M5Y1B;W*35*Y#*YA%L*&JI?YK)\I#NQXK-^J:Y1Z$#HG,G:_&W[?'2 //-B:S
M^%F+^H7Z7$1\M?2.T:@M<'0%F6^,MV*/LU3W@XZ_0]_2BC3/Q0O*'QG'U28)
M6EV<_BKPZZQ\7773ZM]?DEM>V7#L7PY^T"2R0/CH)I]6&:/_TQ0:7*+>;<&X
M2']9DL@P+;N)N/6S;MRO,^MO?9!8^P6D<@4[)]+3!%FD6DI0R;WQH:]J4[)D
MH^!A,P]7Y0N$]#^X-<@V$%A:;W[IZ:4VUMA!A3X%6:%!$5^^S!57E G8%1-&
M=9C@CW2N?_N9],)SYM9Q"UZ!##>_TOBI H3_'C_YE>TZ$YU!R!I&%7';.MV\
MQ1&?<3-L^Y%BZ[KD*3C,K[P<W_XW**I-X%-XCD5>_TG00#V?#RNWT3BGR*F\
M_&F+R(/V/RV!Z55)+UR'#-/.U6'D\<8O8&K%Z$"%XJI4S17%QWK?]UNLY:;B
M*<'OEH^J B?J=E?^>'H0'HH',(MW,RW[J=DI)1PWJRJ6&7(\+OB&3%SQM#DA
M:0_1*)P!% ^W[!R9R1D\H0KF?4G V:KEE<^\.4UKXP6OW.9X&A,?: K6.R.E
M&)]NQ0-%40<!WL8M(,+GI?D%W2*9VZX;W7J9;MO+U2!(^L1(Y\*4->E$U__5
M)-#I")JI7^J_LN%6)NZ=,>/UY3N]Q?X))C[; &CHX[W54XSS9YVOBI?US,H"
M*O1]_7%\FJ265V#:PH[K_.%0H?A"#8\ V7TOT5'Q0?_A>L' $#;D8\C!35H^
MHJ:>\*MT7(]$]A6RS$$S5CU/LF&LY;FS+;V6FV'Q4A*WS$:KL['_IM#6WYO)
MC?GI]B$*8OGU!X\*']#0358D#Z.XR& S_ZL/H@1$/HBWYTV42T[0X#?&$1X>
MW;@RFVCV%#]CA265(\+I9-G3ERQF;2JIQNQ<KX:\D9SJW5ILW/&*,&.V^+OY
M)?W<K)"K8[\RIDR2=*_A]4IM-T8.7E\;@3B2AI]E''O V$#[Y,8SP(] \KU'
M#FH .+#5W_R<6I\T8K<V<#C0+ %R%;'[]@^ + /_EG6KA#L=I51>JX98DZ7\
M,U_]UIEG6>!A&WQ/WT[>737<?=\Y3R#+Y5]OS26_HR\HC15,7P>?-X<GK]\S
M9Z#&I81UD67N"]2)W.O@!V$O)ILNV?_9& OZTE$'<0BU][_YG<\AYNC$7< W
MQOS':DMSZM.N!UP)[,6G4E\A3T%(0?)=Y_:,M>VX13@(';A@&._IYX9[8 F3
MS68:+<NXH6O)DR*!9EYTB1KU^+:_;+7DJE]NS@QK]MN9G$JL,U]]3 &"1R'5
MJ Z)?VO/SIDO JDTEU[4<8?[;5RYY_TO*UP><CNIAN0JCPATL^]"8*<J^R*B
M8_A&V./=F3W;MU2A<9Z)/^(\K_E\.B2TS(V?,C!<$4 ,=QQ)[;%T,A)%ZA+>
MR4K$<+,10 QON1EJF-.-1GA"KY3YEX:^9G#?T1A@TC4SQ-F%%<4A A0Y4,>H
M74A[AE:'1(3:[5U8]*S#6)CRK\?.;S9]RNB=5^Y'?%3$X0EYZ7;N 2MUYWP*
M6:=;R?WO&$%@IR$#,:_]GEH,__SH6N-WB:1'.)94:F+<_$?)5*-I/Y@U)5*-
M]ZU2/,S[5_"4O;&^JI5VVZ?G5[]<= =EXA]NQ5,))RZD$$@;2$5B%['(W06)
M;,1V,#*ZU;70Q$I4N*;'_*;\,L]P,LD5/A7J;7U'P[IIB$HZ5Q_B;CG\E$*J
MU!:(.]VL?DS&W5K;*:']Z.?=[ADIPR"YJY_2::_[Q1SH!D%#DUJIU;_SC2*-
MU@'D2#$ \WXNKO0,((#=>XJBWI*XN02CT$B< <I%-OM.#(\FSP#)GL0<U3#^
M1:YFQ*(>&%@..2=_"&(>50J3F,]%;@4?K-9UP6[=H=?T_A\KER329A^H2RUU
M.S$_QV9;7#+U#@1'PYLK9TBTMGO0D<8'(YO922Y!&0UF2T]__V"XO0@BQRB=
M 2A!-F> ]1@W\EO(?#D[<*%23?@DUY?*%.2;:U@A -$] SCB8R#[?%MG ,*"
M[QG@%S]L[\?YR.L?&6*X%TN9Y^AB%D_"(2/&[X'"'K7!^\$07^]N565PJEU1
MPZN#GK: "\B5P]]"@*)"^7(\O-Y951+__(?#KO*>.J=FW#*D73_O1#G@#/#6
M8HFU.VS]#&!S:G[:<RXO*H#[KY@@TU.YIP+X<>@IZD2*Z,ZF\C2OE)X;QRY]
M!D@<0TRY46_$+!T!DA%D4YWS?R9.K::A</\?',<&F+>"6,\ 59 %.<0!N>P,
M(!?H_Y_'"W8RY(9'DW>)DW#J[>RG-UE(6#GV_[J9N?Y*#O QLD5[EFS;\+(I
MZ^I>A^M3M4:P55E2'0MNJ:FZN3(!2')-%ND4-2I[@-K&^\NB(G?LWEP/SBN$
MK)6UX@]A/UVU_^?X19Z_S%[_M<[,U(2!X'E?*B>P&_92>JW_U2>1Q/TD:>SI
MR,7 ]!>6&#U?GR=/F7:^UCZZ_)_1*X,HV(6H%MSNE>ADQU\G8@QW-0O" 8)*
MM;GY-L.K5PMLTNHCL<I+@A-9.0VP!ECU:,G&[0U4OM(,LM*&X4J/*H/W>#/8
MBEA$O0K?=;,AYL'"#/; Z?R#?S_J)0%J7_P1K/^6M&_=.V=7O]%S!#@%M0/9
M@$Y!-37C89*OYP>55KXS\11.NYB->;[I>Q\LR3-,Q[J&D24@,,]JTU!WKW&Q
MI<GIYP;VOX)[QTM6)^R++.1& RM8MJ<<:_:BH_W8C)?U[B1J<W6APH!-3U.J
M#"(/MK#Q$3L4M7:L?M7'[DFY-L\[WII%''QO;VD!&.[0C+T7"OJ02;V%LZTX
M@#C99MFKG#"$A(?ZD]W^<S/.KSDE&6(N3^8;L5D0 #_$9SXX_O(E0GU!FQV+
MFB(+%)=HHT*[1,)-54@*ELRQ(%-%G99K-[Y^<0+0;<AM/ZJI.*SR7]U[E-E=
MCDGQ250'5PZI3A@;BEN]1Q79:4%\((_%\+VT+?C<>E*5I+#.>"X8IXY*Y7W[
M<%?] )];N85.HHM;V8:7]-[&QG]\3/I%P]L2)(AI6%?R-=F,[6-2;UWP9D7.
M@A;H]C>54-C18H77(#[V&C6GE5]59KK*^']X_PK3APAW_=H%5@U9AXSC=^BH
M4C>LW?::T[N*I>)>*FCM9-S^X$&:X/71^HL.W&LYD&$KT,,5K725XHM[*"SY
MF#E$)1*J_=B76DI)QA^N%2I1>1>E;=PM)U\NW:U9<2O%G&?QNX>3!#-%0=/'
M!YKC88.6^,HTK Q63^V_[AZ[\MWF+7>G!F<SJT4/I)6% (5/&%/FF548-(%J
M(CC8YS%8ER=]^<\_SX]-IC5:_A7X(/G?JZSE<)PNU>F2QW8)$[5&<_JW/P6U
M.0OR>K=?T$)A%<D: 95DD[WP^$3W&ZD;=Q,:GGA\FZ?WOZ#>#!<J_U->F<#G
M>&?%+52^)4Z^CV"U.7M8@Y[DYH?V\W\9R ,EC1B(]<+M"I*MWS4$IY+\IKH]
M:A8H3[7AUJF6-_[X+.=Y2%ZB#T;[_%AJ4;+/6)3=ZF[('+(P>D-_+47CA=>_
M;57DR6 H-EK%T7'1DW%N _U+!,M?"M>U"$.Z0@'SM3Z,D"T0T"VQFDFV^AW"
MF7'_]S#;NY"EO\-L6\00"U0^LQPE)3/36I=1H]_A".\!%TOXV2ZOH61J;)Q*
MR0PYX!L#17>L-$3[>CFG#[1RT+Q_I,!:O%1/Z4F@C;Z1<W4IRX\,%)\T?O86
MY!'<JLA%$)6\>_+A1(?V[5K.&CD(;[52XVZ<\F!\+4-7:E3<S;*\"3$8:ETQ
M-5_2O>'+ES*9;I"P9U=0+%Z0&C7WWA[@%80TB#A)'G+]7O>U5/L.CBXY7G&-
M? ;(<A%E^'/AJPZ'ES<4DMLS7B7\F"_T[Z?]IOW@-N3:L-51Q7?.X&[9!Y1_
M^W4/UW_"$!YE_THW:IIP1E_B%,96DEZD:O4[.N9;5[503N_81SD&H9PLWSNR
M#CU6RV)$\@*'2QLG5$H5<$31CM6>7CM#P!)OQ;"-?[G[CJ#.@Z]_9SY?L(=*
M%)G@],5DQD1Z6#]V"-*Q"NX1BI*6#C@8'F0K* L*ZFO(%0Q@'Z24A8:6FF56
M8HQ=QR,+AOWYDJU$W)R=]\^7I$K5"^U'3E7\K9UO=2_0T/U<^Z'8BYO>F_L3
MY*!7MG4D1X^ Y[Q)NF3C79-@)TE6^T:Y<3?[]?CB<\?L*S;T]LD;T[C3-[ @
MJ1UW"=L*!-L%Q3HU3?D+1?6JOE1FDN-5I_J9>WXKPDGYQ7:!85-A=<LHNU+_
MPF9&EKO%FLD>PB;&C5_04^:H$\2PK:S=\%YH^U>BVOBSNR,EP9D-(FE@]F*J
M>/;!#.IOV,V]^'27?)E[2=:/0KV@55KL0@.N^9%>ZJ<D?Y@0,7UQ=$GZ-?V_
MA^Y="/Z/#AS)<-7P]ZH'@\$:'3,;NY2,,=MD>Z9'/7V'W7<BSO/&(N)QW]O5
ME^LF 1DIZ[_KE5TI$YNG^5D@6Y [V/S6);ML+KNW+X\&#P;=KM1)^.=CX<Z%
M%#6[#WNNH=<3F&;F7$8[:S%?!)-^LSQP5F%F/5SB'+8ZX 19!6_7?LZ[>*/I
M63. E@]W. S,+7NWT89?NAO(EI+SK;?CT?&PE_*%8+(B_O;ZL=6SYP5_9VIU
M<2<ZK+1\OE$*PZ"Q%E_HS'X8RY2@3)Y[L%^Z=()\7DUCLZ&]&'1IYXE1TB>>
M07FP75IM+G.+WL"!)2CLIY=BNC>?__W#=2!'>"CJ>2+/_O2OY?L*W5*2J/%$
MI$&6^:.1/GN2ND<8KKYM*Z>EGMPMI;Q:(#T7_+GEU=#0E:$+N(U^YZ^0;D3*
M098MO:8TIEV?I+G&[]B'J4ERF>T#.I%F3KN /K<RX\;B8.&\[&Y%GEW__,9V
M"N7)H_>GI=-H6Y3\3G>!B24!R7T"AF*!S#:76GE5ZW?"AP5W2R#OLF_-"RZ+
MZC&$+)^N38R[ESO4I6A'WY@T" ^!Y(Z/Y]%939R [V)YJQI=_I5B]7K7RT+1
MF'N*O:6^RI8BP6+F2\44.*0M-TD;RT05794\<)53CA]-43Z<R_+.0IW*HTZZ
M(&TY^S9Z>R*+31]:-2?>/8_(JL 6TL2#LR'7S@!:5B=_?.'Y#0T9<<]0^P@W
M5;4EB^:[,5;HTJU?@>!PF6W3IOJ/8W2-]3SVGSR<5-S9D"9XD%10PE$Y42S/
MK>[>W:+%4O9PO>=A-JVH$<UU:R_VK[7A(8==X=<7XU1KW!G.  ::Z&/)=R8H
M[D>JRH<$[B%$I 1&^8B+\M<3,O]3Z2AOX0S -NBYN]:%'G!Q<Q#UI^5X\6NN
MZL)&<;[HU:O#7Q6W?6UH@15;C!C:><//_E] #%9!1?KU$YY.UJ%O-5:JM!U]
MGD2RUWDHJ"I2_;=:)$?$5 P7;GAJQN\XZMMKMU0P/56)7? 4RQ#K65](?._U
M].%%CE>[(B?E1-LSP,5,8MG"<"SUXEX[L5A G]UZG*"\GC9FTTMOG3V16^.=
MM)8VNZD!,;CG\?UN>H%5FP]]^JTN)@\:]9F*7X>*^"$I</WJ>V"T!%%(GGQ;
M>1'2'FYHM^?98<MNO5<SE%?LRA(E]AP;])&/A:7=)M\\P>?S'1ME\4GV /KP
M45 E]ZYG)_9.D]BN"(@(V9/NP.XF8"5B//!YE>Z*[QC3;JPS\.Z/S-^(N$]#
M@=B!Q<!C"$;JG6'? F+S.[ZO/)IZ,3^@"[NY 1;+:ZO<<88D9>+60G3G4N#B
M\&4M1^:U3+&F&'?^JJ2&KVF4 4DN;8^6IA&ZJ?_94R:NG $N+1@)DF^[+849
MTS_;<\G$C&<.42"\H(H:(NK\XJ:E-?5JP=[PZQ.5,@F?8Y4Y/Z"A*^# D,CS
M!4B6GHO@:N5-T,C2;%/O(9DB3"9;6B9)"% $8O?)J!?0&<1P4LX&K!"8KE<$
M'6:"&8%K8XB@W[0K6(RJY1G *3?6-8]OW>W#%C6=SC#D#'#.LIA.0T^2%G%6
MY:]%?PCK334C2C&DIX=J2AT"U;Y+X-Z>W-,9C[*]H:V6N_'"%[3$2PK6]_4F
M:1,7G\PK)I$@=*G4"02?__$/QL@$$T)^@6+O<!D_X,X*J9^Z2_7[SQDVK-\!
M?#Y"A^:N>.Y=A+L^/Q]O$7RDQ5\7AD6;<?B22RD%9P '[A,YPX^@(QX7[E/Z
M5*HHMN+Q>^I("^/^B]\'VY6,QXCJ=XHXI-49P"7W'QU5/WD^G?+92HL:P0\(
MY_[?=1\^?UVR7M3('J7E>RQ^69I,5Q.,^,BY7-\H)?1$W!%P"7,&$+,)\47*
M;K# X[)'3*+V^=L.E1E$AL+N5)4-HM"LRNS? Q*G@V%($TPL@'#M_XM%;)C)
MD'_@;^6MNV.TOMC[!T1_/'$JDHNX^OZ1X&@JSG,>R\,2,-[NL^V]VKWNW7N?
M/&-?Y!%"U0\#$47*PR2)J<%[RNVEH0)Y8M6CFL8Z*V8!$$G[Z8&^QT[=LT7Q
M,[$4EXF5QIJZ"0\S];LB.LMQZLIU^08=B5B>(%85\T7&+A#:>7&4DB].Y7ZS
M"KH>Q^6RG2+6K\65M_KNX_.30BGFVBSAJ*V>_,EQ<V_$RW)407>=79'OO!C=
M8C02<<L21-88VRF[_[<A7D&G-O19T*OO]G%#71H^]G70G7=K@3:H+43D(3R<
M3J]R;-&3(/?W&:V<X<Z(T*:.*F)(9!^^4%M%>N&:(S[N1TJXI9EA.E$QD$A)
M(P18?K_UR8$"=WD@T.V-49L\K7"\CK:PG'&E&VR*1S-GM]Z7^<DRH/!FL)]A
MF70L4UQ?/[&2BE)#AY;W[:%//3>QZJ57->N:^V:"4PJF<"+6^Y!5MSEE4;%J
MAZ5"Z>DC/.@^<>%YX_2'*/M$[  ?I!3YA'7-([P"#[*&-WV5C@(T[MCL>CT^
M4INFB"R? 5B0HAG$:QW]XG,^A]AUK0T4,!(<V!UOD"6>!P[<GH"%Y_VJ085N
MU5 8J^:[Y\3V2_5L#T-+0?[NN:#$0>N!W6CH#R.N9\\ \GY;6_BLO9XAD:C&
MO\'^ MEO9L)FA[L#<GRW/GJI*BW"V?%*BK_4MY+4OW!WH&"PIQMM);5O--+F
MX0Q%0\"YC?&_PR-G@(059GLC Q-]J[WD+]AG/_.L2W&SAYO@24V[[I<I_&RZ
M1DUH#S1F%DTZ\2QLM^T7JH:64+I.U.P0">#5WV@[71ZQ!PF2]=[OO0#+)/\M
M=$TYK7;%'ZU;R9^1MO6$M=UU545\M#=]OU)[N?S:<=D0FT\0<@D%C':-F5A]
M\1'NSUE.'2P+W1C=*#B<HL YQJ$NI1J##2'\?!1/__*^XYEI9S&/;T85!O/J
M6U .9\0X8LDT+TDS<TB[S;F=>?H*+>O0HX L)DRT&H''R:+I0]P/KT>/>VB3
M,=" HNF8IW?-:)!\A!-UH$%'/$)WR*]Z=24V)=DGQ >]-VEMY]8LLTGU-4Y7
M85$R2H*BW2P>RM,%X%K0ECCW$)L@N0AVZ,<6IQU2S]"(H2KDDS?Z-X8MZ4EY
MOL^3XG5S%%U\SJ\_L[-LUTKFA7/4%4^BV98XNR&,]J;+S<J/)(^@867=%XZY
M\E0"#^<G3 RR1+&R^)!0ZYP^EI:$P^;.26T3:%%)ALOXN*7N5/)XX%%9A5A7
M/6A.L\C93-6K\X)F>".''\9RN2\6Z:G8T\K+2Y?Q.%3HR<_WT.3FT*20I3W!
M.K#R.#19CVOU=6+[<?M!P@%2MC$Y+/%+<C5(6L_\UTH2O IEN#_BFE_PMA K
M(5>"\EZQJ0R<G=L"?RP8NED,B%Z)IT$6J6J=G(Z_26USQGQMBI=BD)R )!R6
MO.;2R;OBS?I?53;E853=X@W;6/DW]F8<68*_AQA-SLGQIQW*8R_)PT!I\U=>
M&6X4I._Y:V<B.,/'O;Y7I[<;+<O,:?YKH^R0_^+,JOJ/I;3YL*(BPX6M$7#A
M]VJO@(1RI:5XPS#3TB#^2$=3+TEJ':5<,W1O@BM<Z4U5BLZJI."Q SGB[Q:1
MNX.[S&?(N F&]RD)2+ S[_5,18>?--78!@4^?'R@0(I5J6T^BJW%,F<?;DSD
MNF:18[5L[#_$S_NQEMN;NEPO"7:]9<%\WQXH!][=&O'."=D7R4M1=M_'T#/8
MG"88((:!2R8OWJ9=D@:HDR)8A6=>9:VUJ+;B-_F:\ZT_E11=M7I8QI=QG(,^
M \@_FX-.EFK(3,&&*#5X<.9&:<WG^?JO&.0^H_3[_CI>#\!%B7K5< T+%H8Z
M&DYO-BC'?$3]0;7#&IM@?!9W>VVFX/>#!I#"&:#_N=<+!CJ5756=,\ 5V=O"
M/7'UP9=:,3-JYCD4"D)X**O X"5OOW*=$(FRXE:/!UM#DF2]S3_Q-; TKH@W
M_CNL25H_K@I<]W37,BXOZ3%7UN[[ZIL<D1/.2#R(="OJN#0?Q/L"OF]!4^_[
MKR)Q8@]#*'43;=&.#G!T[$, A9 &+=$D;"ZS\61A9(8^MOXB7I-5-)#K\>%\
M3NX8W#UXK"E[HW@6[G'B%U[V)D^_73HC#(>^%3NU&:#K2@FU&Z@KMH';M4&9
M*B*O/0JDC]=][TLD<&4+)8G]H /DSS0 V[:ECT-\H?1[0\(L-3DND6-_+T)*
M55-]%!37ZL8+]$5;7%]'&0,)K?Z^$_:%C&I1279#C):Z*!=@354 JF[%9[[!
MWN#FLNM539NZ56M9?X=DX\#X\GV[HW1IIYR7K_<CM2NJ:#2ITL/<<L&;H<[0
M:\T%/=8O:OU/FE#]\08#$=W2D3@D<3+T4YJAF+S7]"U:LFKXWBG8[ZWVWN;C
MJRL.//&,@YM:*,2*7905IJM-</L$3=!_(E47;I=9>JSR9X=[-U>@0%!A/#.L
M\4!0S+.VN-E_?;B1S#1(B7F7#_@)-HEO5CX^ ZA%P>\MD>^PDY@FDE,P^_0^
M"G:(W!/<M/GA7?-! H?J5$X?1S.N!Q;JTH+<IP(I![<\3T@B:!)V& :17CQG
M(?M%+Z+C;OO62S<1$;S:]9ZQZUL6X@M.E+Y+DC9:#SCG7K'R9E$N011S&8'S
M!>C<3RK!/X/4#"\&*3^/,-XS+<^I?+H@QC3WW&Y3!."?^,XT(E>:I\-C1F=(
M'TRA8KFDB+X%8<KW A,.TR=XX-(8EP&!6-FH?4OW7U&:!^ZK%T57!>Z[]]@X
M.,N>Z) $S@!M"DV7]@07[W#? 0O,3+O.L5-'HDUW"1^?NJ]B;*Q[96?+-\29
M_/BYMQ$^0KUH+ZW+C5O&OXM8A HS"Q=AN^7FP2Y8S;3FN6X95R%@N._CG6IL
M'JH6L0P>"K.?J+EA?>21:3N^DC3EKM6:\.>JV+?V-_+WY-%T*6_0]E<LW$WO
M U25("S]>WHF(V'.,.*OXZ[&)G1MXMZ-/*B-:YU4=4 OK(?O!4P$\.6.KF0=
M "!"0C3N:F8&+^02GYC>(3J&*5(B;_R^IEUU%V*O0>LQ<$6=V^OA4ET_*&OX
M'/Z_41+Q?"A9"2:BF3Q\TO]Z_XG#6[^"RZ'%A=_JAHLD@=(1O<,F4[6K'C=U
M=8WJI.J"/0^HS=))568NLX)%>H=@MV)"X';!WG$[EE6-/<AN26?R!Z*A;N0P
M,S0[J7M;T-J;/K,6PO*=G7;8*+Z&4! 63)*F]F*O(YRSY18[6LU 3C6A"7*/
M;M1?N]0Y?O\<TAG*0\$-L'*[#:8%L1[E+ =NSP-R2TJ,V/]=AW-/D'S'\ANX
M&U1][Q-#4I@\ROCY;^47?Q3???5. %&;P9<A;0U348S76D<CEL,PUK_Y-HR/
MD8@S "R#LG\&^ B]FOE?#[5.P[^0]FI4(&$EH*.UC75(=6N7EWJCL_%[$YO;
M.\.=E%HZQ9ZQ_..C.S04ERF[>NU1PI/+VA6-]T,2K[\R*W#<"J8B)XYVP1V^
M$>MAA<@M=>Z5<ZJGTS+T@K@W/X0*LUJZ FY$7(0XOZ7EL[^XE)43? 1;F?V1
M^BG97?FIG)<"G6"\6DXJ11/2-KJX"\:$&&RD!U=,!,@Q7J=D__ ^;@8.JT#$
M!P.5^&I)4=T^UC/+!U!2LCJ3QL4;SGQ_O(5K[SASV)<#&0\RAHM>5^1XGT)R
M=X\*1VAL)3X!E]^,*X// .<H[[I:FK\;389:.84$(\\ ZJ[G'X)RB?(5,^<1
MK:IV*T_H2F,8R=KCZH"9JC41,5P&QJ$6Y,GLZ*H$HF!Z^X-M>BW#W#Z[+5(I
MQUHR""[SO]V3-^74HJJLG@'\S@#K K#_Q[OW*AT+>')D#>)T$WM*+[M5LPQB
MA"R+E9T!4&;G6/X:9OOCPF_7W'V&IC- .2.YA/)B$KC,&7R^NG*?O*!+"7J@
M ZGSX)U6^:L0WI3#1Q4_ U#"#F%.,/9=I1F(^PS3?%O=RG,?A>29(^3):G/2
M_ZJ35!JTST<_6GA$W6 CX*CARI,E3T<H0A=@&:5NJS;")9_X)]]CWC,$;8P#
M[9JW#MR64M>V3Y94/:PM^$;\*('ZJ1I;ENQZUC%.UW#?!Q'I?'&USU:.N>A^
MP$;O8"%<>6[>U#]YFHA=&4S/:?(AK,^3 =QJUK'$$M/DN6@9-Y1:ZOIK^^G*
MI>LLJ1Z?[G[M0>P/(J(1!BDT.R!:Q()N4,"JD QDV_;IRWH^@X,O;L6_4DH\
MA,<\@WJNQS\*/H8AW.VNOHK#M7_^W'=E]S;K-@L48NAZ0ON$DJIVF^C9Z>U*
M9:S9=R8]3CMP^7 L+<XHV<8E=8'+=ZP%45T3.S2G'*3)&Z=.NPZ@IF29F"6-
M_MNLJ\D@?^7RWBL%[I:H!$=$_&?.P:ME20 C(7&&Y+LW\KEK\9TW*R4%0MNR
MD8)*<V5(DZW8,X"C9QQH7U<E] SP!H??/Q=^[(9$$?B3W-KCSJ=2MTF8]APD
MR=,,'4S7HNQK6Q^$3#7H[36--:R9FB5 (*GE@J$86Q,,.)/[6X6EP6VO)S;0
M'&5[Q=.L,T"6:?C8?1Y$,W&9*[.EN2H^=7P#!9],_'QP(6G M^_5O/\AN<(B
M).6CIO.GU[0<\0@%U=! N@GSZ05^XVNR G@UZ_R:?R(')Z6'B$0#M_2D\8A/
M5MYQ68%QLWCXEG^X3/BUOS//!>EORO>!C?-&&+Y1O+%;IL_BP]K>T[S1H?TY
MK!YJ@G/(T?O*_/'O$QJU]]Q%]24[ P4C61^10)L<" ?JXYZI\^>4<O2GO(&U
MO9I0=+^!Z1163&N0*U#<A33JHNP6D)J\7F-V0&[,%M[1_LY)-P1HI87QYBCE
M9#>:IK^6G3[0PBIZ>JB&<C&Z=L0LU^Q_MPB&?OAZ>*WHQ]9_5=YA&>DX*646
M/J:B50)?+@25XX:OG+MONMOW974JJ;#!O\I@4,MMO1;RW8/)NV;L"S38^:@A
MM7RY*:TR,,2Z :'T>03>S=*W*I%.TTC8[CA<XBR-R]+Q%DU^L)2;^;:5,V;I
M S2AO=817M^P_R-PZ0.7E/=)+JP(-)3U4,9IY5G$->WDC_+T, 3Q8 ,DEO6&
M(SQ?,1LKDE)8;;3Z1<<#$UA;N__@Y8\LIF0XB?UWF>QH,V:USGE3L^H[3PR;
MIOW0U5910X0Q.)_ZIHP/QZ3LWJ^$NP^-'&8#[$IN$?[@H!@V\+J@9QVLR"ZZ
M:#QCJN;]\(.?O(I<KZG[A/O.*H=;B>."L5C1U=,R+9'?,@67.#-6H7FA:-3^
MNDW>E?87-2E,365[<LG&9ELE1LW5V\<_%E_?ZS%9F?TZO36. #>?^KC<6S2K
M3VSZ<17ZD%U3LAIZB#\\11D<(04>:/V;A 0T.<BS"F9Y[Q]QEEZPMLY/TU%I
MZ^%5-KSO3!LQPVU'1MU5RR^9U-$@:9>[@[F#RV[O;[C;U4T<E.KOD_831!($
M6]#NI3YEMQM//$QCYV7T:843YEAZ ;Y)WKD=A1#==9GT8(<H*6V3!S<:VA/A
M;,CQ!EIT0V=5H*$\Q+*6&>D[#(-MX&WM,AU5F%I]#YB@K+2M/:H-&X?',"WA
MXF_S"TI$?B--*0^8>'K6NQ66T!.?FK50KM7GO\V[7^\2WN3*).M8[9O'U<T9
M;82"G.TW*)?1^^,&G__AM?LTN[7W\^7YR#-^O;R)5BU2B F'W;VD=3AKWG3!
M,><FKWURUAIOL:)JLXC) N[0O5#4/%;EZYU'JB>O<S,#%(:-L&6^D#O^([Q*
M[_CN),IK1;07/P$H**C4^@"83Y%7%K:\&018BTV2LH7>XB A9CJV&%.W\@S,
M^"E(8>CO/^ 5/4;-L-1-HY>4+8TMSNK&M>UJ*Y&6.6[Z%H>>*]R*_=[CK!LY
MN3"8[K'A=:M!L4^5[WA[XS(DX[G9O=<9YQ1@-\=%9Z?[X2M/Y(LYLA()9 CE
M34O<;O-TA.'TT'<''F^R2CRB_S?5GY3&E0:DO81SH,2Q:G2Y+C=DZ-?L;F)#
MYTB\>SN<:2S,](YA6G#!0:Y0\;]Q>8W@ S#X\$_U)+$HICKM/%'):$6(?AH
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M5'+S=MZ=T^8=\NEWW>JDXNN;^-Z';OVA@BUP"=1 *<=E"<EODAI KT.(S7S
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M\R'$%%PK\^9GA7+J>S07) (1=+#QT1P4^7NT5(L)]]DG'CW%-3 WI?<*V#6
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MX.N';J>](4FQ_G'EFB511\XL70^ZGDVKO#89^2)S;#&/.# 7#=/4/HA7%SB
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M10$=.=LV=0%497:Q7^)LW',D\?*6&8[FLDWPO0L '\O7"X#-I:+4^D:/Q5T
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M/_)K!%W2>P%@(&H?ZKAR:,>(^2''JEX^M-"7\5QP_G4=]XD0@*P,.27>1F.
M\7XC,9D0^L..$H=2_@S:6\V-%C$?UAP?+:K67 "8G.&0^O]6?BJ= YHX.;M9
MGS!0%T1MHDVB9/-T!12GPE)WY#%!*@U0RKIN!_@)%*5O43ZVT[@$5"4R4T/[
MH:ZJG?_AC6.C"3&Q_.;,YZ[NUU28M)6,KD%>C3RF9T=RK?.=NT^(_RZ&^0=?
M %3=B[[<7,I-S@3PFL22[R$N=0Z/$ZD0K!U* .ZV5!M>==,TSW/.'>B_H_RQ
M"/V>E\*GY15[__8_*;O9AO)U-\NP-J$_V0V%?4J+[--L/,J,G[UG$3F>>)%
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MJP*46SZBCM!+K=+KK$%59M//=U^:A3./N1MCX5WS@JK##&H/C4+BQ]:M)LH
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M'9\KS+[1;S)%>A?/GTX-RI#T=)I7TH'"SJ:P#'C!O(GTWDNOO>]C/@#JF\$
M&>Q[EO8MA2?MXX]:196>\,<4* E>"OW4*8\%A2LYF+7S[C?P/#;H/:7:W$2>
M="F_^K5H&UBU:,O53#]/EC4*DAW-4=[.+:K3?*P 3(O3F*^:4SA"#W7_@LM;
MR3;G7%T0&-'0N$CF'+B(IQ;"F"&6LEP;+^N86NS-/@'IW0S<+\4O3"^?IX]'
MF#X5BY,6H_;Q'+8+6(&U/$.9=C2,EW/HVK_=OA3&S;VZ:$/CHR4JL7!04@NV
M9EF^4?^R^F(F<=>/#A4GMG;NV447Q)"QB09/BHKR(+8IC74:^75;M3("(CXW
M$EQO->1-2PY0 E2&#S3F%"E#QL(\,8:CJG71'M<65\-'K[<!40U,$9.>ENK=
MT\_T/+9$<_W?ALQ<@ 4K[7<320+G #H3,V[^QJ0)%G;ZQB8S&'!(%072.OSC
MZ'PON458T9Y##0L.A"$LM7R/*_[VN7=C+8#Z)89W^9B!0DP5=OQ(E;+J.A+C
M8)E>]?WME<1D/G*3D.2"4L#,+O#$TW45^8^ :K,(8-O%/PZ1$10&;F48S6UN
MJ8W2TSXPJ\6H?YJY&TUJ%E8D6,MBR]Q.JYW=90<9 4VAPN)N5_V.#P\D#U!M
MZ]6W3-^F_'F]UI/(RV'D<SDP.@<:>$8UV2*_G,_-WUMBV*X]C7W8MZY%(9>Q
MY1^M);;,>#DU[ /G'Y5S73<L ZIK>C3"\<]KF(M4>A<TK$;,!XA5*0YA!PKW
MT*\_28??7@-:\C( @5Q YS]8:A9KA9(UMJ)R>?6BE9^E/?,V?^@87?6';79F
M,FC>"FRB,/86USK?T?U@%)1Q9ZT.B=P[X;O1XIZQ8*D9*.90.+=^GS>;>^W$
MBANH%P!0EMN'M<YR=>Y31 ;<ZQV^#%1*"FA,/5U'@0?&&_AL:Z(P@^_C&C9W
M2E<CVO02363C&Q-QI6E>+H1^!_1/CJ(92Q6Q.K&?XFD<7SAV4=0*"@H;!G6?
MY@<$?DLNT02:)U!3,Z]$'U*H3N*-&'7,HHI<RG_U]?CP;RV(<:C4;P#7YUNB
MEAPZA%XNJ]4WUB:HK+[DR3VQ:W\%4Z'^5"^GCR["+NP,0*P3WQ35<3H"U<7F
M>@/I:S >+660U RRR1[PQ7 8VV9O$)MC[ND>(0!L.*;?52W]YGN71Y;R@+HH
M-6\OKU'69ELW)#3E,)V[S32C<1/L_*%TZ5K,):ENO6N7P_2DWSK(4&IZ?)LZ
M]7VUNZ52E/KM_FF,&CA1MS.T,]Q,<X@?\JT8A8>",^GQ!_WW6B.>_ASE$CW9
MA:>^NQPXPAETG:^@YNXNETE^4>_\#77WJ,V:X\D-M&GY) &'8W*OGN0T-E$J
MDKP1XWQ-O5=RHH6#,$4BG@/"@%C@=FK_;WC?[#1/?[WG^FKFRW%8NMB@V^E"
M^"&(WKREO. &\D$OP':%KD$PAZ,1O36R"^_H?_0M2FSUTTQ(_1>>/0_Z6#P!
M/PAQIHSX$[[4:#.*C62+=?>LTAV^I;H9C7^#,M^1<W^5HW6]R5/MT=:I!4_<
MOK;!F"52BHTIJL0HR>MGT4*<N-I^;V>27L;11L7O!4WZ32X*[3&*))@9Q:ST
MQ)N-/3ZZ@N UGP8^ZH+FQ$#37$DLA/I -6*YM#"H^B.8WEPM_X!P#MA80XST
MU?,)%+IZI3@>@%WZ">@A,GUYP<[A.H+(79>\Z=D/>4I$&.SP=8HP^5:\BN$=
M/PB@<G=D_WYME"7G-<-(GZP8Y>JIT4[R[@(V&1^U"\+2=XM\9;6O\'QGXV*=
M,/5\F2W5R??.(R].@V:IV([4YO:V&.AS^/9O;,87SV7ML SAD8^S*IY!!1$_
M[2W:1%.DAF:C=Q2<B*^($V?<D!E_HR[7:%;74))3MBG1[(_S74.IL;_2XOVL
MUZ-J;2WTGMJ$6<96J \,:U^FH"@R.\N4(6CM*XKB+ET9-I,U4&OT:4M 9_+\
M@_%RKR8G:=C-7IY/\T[3SM)?)5F"9PK^N$6%=P,H&ZT<&VB(%-'L7K8W0U3_
M(%_?3#OMX+L[-U1UK@FN:O>CU"DL$#K(!7JONXR!;^WNX/ZTRHP(RXLLN7XU
M52XI-LO_XLU>9:K$+J8>B2J6558-@3B7A4XM(YI05_Z6+'%=F7*\P[&=Y-9=
M%@V7WJI4B:.B[.%VD'D J"RBSJ=AT2K4'U)2^(&3:R1[-ZQF C]9Y$Z7^>XH
M]'T=_UE,>[0JLE\\31RF)3,8Q'4.N&Q'SI=GV45VL![6A3W4>8JWW,:LJ=36
MAC]WIY[+C<P7C,O^^1;(LG4% H&V6\M3+^,%D*S)$9)G-<W#S4:>G+&WTJM%
M&/_4)>N8)@O:NKD))\2OPIM.@@(N?EJ:G(2G7//5UT=7-]7*@B-<["<X)ZU2
M##)(%EH+HFT=/R*ZYQ5\L^C_%@8K7^LIO07NR&#;E6PRW3SE3"Q]-F<]7NI,
MX)9W7N53T4=RR+I;7+E+I872KOQ5%:I555U76UD38UU7\XDG<IX9O9VK^^!:
M)%6; 8"J"R();0\HC;J :E(427,D=[?0SS%%U7Y^H'3ZBV_TB@@* L/ZWZ7,
M_E67FR8NCGH"HE[OW\\&GMD#46BB]M(S3L>+EJ?-&;@CSQV,AO-E#<XHJ6EN
M)1.><X!Z:/)#IJ^X)LYT3<B6T1(-Z?8?M7, [6%6I9UH.BM4Z-D*?<WSZ#1R
M@-$V&1#8?F:O:DU.H?#W 'B])!]P9NX>TUC64,2MZO(&QBBCEC*)-M'WXHX]
M%F^5D(L*V>')"QC$=-U1?_3@F21)-T;KYOL/5*##P_]0,-MT5D#@>;$1H>6&
M&LM(EKX8/=*=R6#%N_]A5/AX2"O(D1]0(#)O?C K<3 HE8;P\QQS0XT]I3H"
M;^G\@F/NM\_K-\$5>^*F>USQ;'1 /E@-90STGPO;S@'W7*>RLT#5(J'-N7:<
M04G/@2>(ZM+_M6,AT]J\/!%>X,MN)K0E)& 15_ARZ\9S>?*HMK;+Q<-5^]GJ
MV$+.)8GD&:OY@5U>O J;2DW4<8>)ZUPPT\/BFB_XYTL**AJA!I\F4JY//8EU
M8_:X?7AG_[C]5(=F[, H@RBWS/D#>]>P*KJ;!4S;2OF#E5.1-\K^_W%'Q"_8
M-&+$YU_5TV3+W?)#?GK=O;PYI!33.B8\G . 2Y[(4*=!:OX>_Z_M$;<#=&@*
M_W>HGB66:Q\YL[VIYXX0%,X#J2[Y$) NAR>=.U^67>)W:;"4FD4+IPY%MM8Q
M(4&"\-6"PO53K^,,+[V^5JM4R:)4AQY1^3V9=:L<V8S!%VC=T5\OS4U05(IC
MKWK)4%V"52BBQC5,\3%DD")?3TQ??-S97NQ7ZWR]^L>4PI^0*%?8^R&:%"VQ
M,42Q,\_,B)#9EF2)1A-(#?&>P$)2($HN>9;X!G3,L\#_Y)_V34[@JULD>=XT
MQ-Z)'/@E)RS?M2+L0</-=&#5Z>@PWBR0_\$_E]]V7-!9Y-(ONKOFKW@Q#3H
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MLZTCFTVK+1EH(R?"^[$O!DG2?GI/]UG<.F\&BXW?R@W(R+2<*.QW]_L8+_O
M2.8RG1J//WW6D&^Y?G\<2Z[A6U7].!GFHX--Y*J%5'KA5JWQ2KL2\)EL>-MF
M]#$U-\GWV->^E;/Y;N60P>/"!G61JE7=@(^$XNU!OMT7.J&!L1^NUXQT63B7
M-^Y?KZQ>-['0K1-FXWYPU9PS:S\T=BC@DX#4&IM-Z\?E1[>(J@%4:6\980BR
MHVOY2H//2?B6#1H&S3H'<$>VU\>]NQZ=&0]QAWF>D"'I)VO-K<)YGXD[";-
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MY"AZWW^]K&SJ;^(]<H(-C5R7LFO2AGRM^2G>>0&JG]VRB_C*$8C"^]5W&]T
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M*O>GGPQ6_$J^8/\.3H,"2\H-WJX5EJ;F)L:S6H^N/AC240D#PFG6X= /:^<
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MWL0,[-:VOO(.7\ BHUF[,M."MQ, %DSW]6M.U J+!FZHJ^O !7SBZP1&A>>
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M4!^_Y?1&@?&WN4U<6U=@=G<PJ!M)O18?@L+!"T0P;(GOBSCGA VIO!@Z3M
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MN\F9TVT_I,://1 2\)5.:VQ\XHY\>D3(S!?>9Q7]BVH@G.U(MI8CH9R];<&
ML32HIT-1%BH@A2<ZC7VLWE=*C*Q<:WKE,*8N?92+L3A,RBL@:%H64HQWY'R^
M"&I%.-$.=7I7V]=\ 4K=O-BYC41SLXRT":<*9:2GB/(E#?-,'J=>-GK8U<G(
MJ2IS!+M9-QB1[];#LR_H>RW'^#.*EL/&^ZS^?3,R07YN[GLO:  7][O[T6?Z
M^?ES;&Q\,5B$^RJ1W=KM^T?=9)DWK5(_EWAV^'JZ#]&J0+^/U;-'()<_6",S
MN'#[NSUQ*+MZ!B(](>HH[2C1P&!?6UN(X11PP_?[](;['R,V)C7NATJ;%^Z=
MK;GB"=>/%H7#:':7JJD]H98#%I1@,(&S(7L%4Z^&A6>^SRSP4%KESL JNGL<
M<I<'8-.F=P,KI(JO=DQ5F:H\J[>N*[XF=][?6L'&$];055?"J"I<DKK(R[9?
MU'FDI?7:@=" 5BFOW88HV3*=C$L5F-CO-R2L),_^/OIX>."\/^,5<-_\31NZ
MK+#/BZ=RD87=3)CGKZ+*L"^!(H?^4?U"KMTXQ.J<HA1A6P:7=L*(4GHXG#/R
MRL!(6"^X\<;SH!U$#YB=[AC='ZK?4&]OP\ORO<J:Z.\J&N,6<RZ*ZK/4Y%+=
MM]%SA=]=/WDD+B4J"H&K<I+N&5&MG]'R5"I?3"XAR:M9+KAI&!VZ)/,59KZ4
M5F!\)!A;S<2H_1URLA?_)UMJ@:4I])F8%FN,B&6Y> ;52_<=:[HPVDI\/W'T
M<'. >'#RS>_C8&E<J\>!.]A"$71R"M 2F,]?T85*%/QR %W=KE>4-IC[9;CM
MMZFN,RQ%%<0?%=CS.F]0&QWDL0DJT\M?ZP=@%J!BLH-O6W"86^M=ZSC%$V\4
M##FLF>*H,/&M]A%XZR!A>OY&8_S9*:AW\.1XWUT;QG'$=0J(9".3'EIA(]3>
MQ,ZF.AAHOTAPK*FI[>]X0]"_F>Y\"X' YCK+0<?*9S3$VZTSD]2U ,YS4BIN
M5%7GIC?"]PVKQ3^U,N@5K?DJS!^<'/TJ@+]L;_P6)YYQ>')X"@!^'&&CK@1_
M(*%6N@3PG?ZG@)--N;H?5E93J^"-56SR:(9N=3)A8ZM9I$GHX<BR;GP'WX,T
M9P.WD6Z*4#/VA!G2FNO^D!C@FJZR5 SOFZ,^:YBD(BG^U#U'HM(_>6;9"NA:
M^8>6"4GQQ+G,-Z:$@=<!1SO]H*;;NPXE[@'3Z+BYKI*C5]/I-<-'^LG)Y7!T
M\Y)9<*GVD_R,$X :16!7E7I9FN04>)XHOPAA]'W3 6$D"RREE[U?B?+%2R-$
MG)_5*9C,/8^!\;DJ  LA?K OMPQMO&[!:8->:$=1:4#V5RWGN1I)YN17V03H
M7F2TYY00HZG7;O4MD ,B.,_8M"HP]I?]7B<-NQR]+!<T(QR<Y%M"I>_8O4/H
M'/2,CP6=%_K8=&41=_M&J1C10M]>2!B',>HT6)M]+%,7_>F0JX;R"-S;S(A6
M8-X56#B*:'I:;.[@WY_XTQ1C,3>S15)N7]/")O:\>(UJ9E&M@7#,[;YD)#X\
M!6RUDL3)6D3T3V)/YZS$6"!WF>7TTP4VD:6 "8-9H^K[OVJ/,!G?VJ5;W?8[
M>V45]AU)KW9].D0N^2(7:N/W1-KV7RKPE=I_VS )C+WI)E/]%??,RE T9X"-
M0=G3(,;JF/M6VDKR]DQB: -$T9EGIF8D" 3CWMVA7MY9M.1:FQ4@ZN392_F8
MQ(7]VF!U<^BP%KGY.L2[V^P7&2D&TY7;FP(^A+2"\-J<]G,U605Y=JO;Z#\5
M$YV=#_,HG2.\B[^G]>.G]3A5G6LVD;5 ''QI@"70K9'HE4]4;6M MCG)[?QM
M&,??,9=R4N^<B5GN^3A0."#A@GC-!*_($+\Z\Y1B0/G2S!#XJ&JW -X.N?S<
MT2^@%,/#9*[IR(KY1+++=YD]'GG<^GV)K96/I5_\\-&MN9M.&2NL?*,X]N)'
M5WPO-%E)\@9OJRD&[QP6KP%@2:< )\MCJ5- %)# [QNY=PKX\N GI!!T^Z2R
M^0VE!K(\1>4[R]4_O(L<D/F4L_!># 8!_HDL[?- -$B["\?6+D13\/T[JGN0
MCO=+0+,,L&(?1)^%7'2&>&#>,.E6[7BT6+90XN+ Y]!<Y\NJY <6CY>#];R!
M?SS2J"5%-.'$,_IP7PMY"K!@!9W<-SD%W 82!?Q3*)5*CX([U/840(]QU/!D
M:L_<_]W];P+R$1+5V'6&),*S!+^-0GY"CS>? ).E_X\&N*-'\K3['WE3W5H5
MM8]/1F\"WGSSD8.]^LI?_2%8+HAIQHFLD9=;<=?AEBK<+P^4#"E-)=]A/@4\
M.,='B54;H=;]LP#\$2AEW/0\+U70E*0RD* %04./4>JG &,848H/M-O"9$O]
M]!\N@&#L\2#=(41_^Q2P-+Q)1:R>?>ED\*@&*Y7Z?!SC=@;#TX)!P7.QWB;)
M*/+-$9.7-3]B;"V;YMDJ@"?@'_M!O7M9D7QQ38;K"PU-H0\^:=1S6K7PX(X/
MIK]>E(L+@R/ IF2SRML^Y)NP]BGA!]^@>T*'/SZXOY:DIN_S?W#Z"=R>#_"!
MC5Z,DMTJ8!;_XCNAXH<7?(I?<YL(L"W7XN@N),1P+E8[5<-XH4(-PK6/KO(+
M.Q;4C-B7K'NM3Y6W'VWO3P8+3T9#Z1X%5@S(H-AV,I8D#3 8GR@^364<.>+X
M]VN_";:NOSM9,VXX_8*1,B$G]H15'R:^'1_6!PKXJ?KT0GEKF$7A=XE-QT:&
MZ!^#^9"ZR[W-[SBEOVZB9; ^VCGE1'UPJ[IV5D8V=W%U6G(>V-QI)Z"V&3/=
MI>Q1L K'F\"'-RWY1L=N:)Y+. 7@^JFN;.RZW"AV-G:N#))AYRE@5]=T$G8*
M>*^HI_S@0Q1FO;<DM/\\A@SEYGPZ -8,<K&VM^9*EC,SZW=^!L;[B-,>Z5K"
M8#1 =2*4>OD*:!+ROL\V)>!]=>/C^JX/KK43!G]EV982G@QHFWV \G:I7WT$
M<=!9,0A=J1U/'LM>][)V*%-1E_;W='>R,/#G"[HUY&_N6# P:TF4KB]P(?*Q
MMHE+!0[(<6!AY& )[7?DDJ-K2,:SY)B3Q6"I]%V[PP;ZST:>[Y>+G@+N7F4>
M/#?'"5*GM, $@__G2Y7_^P,+!HO9]TC'PJ;[US.GK]:= BQ%SC*(F^4(#_8A
M.]APR8V>2U,F3?/+_/N%])Q\8O6+'VXS:NE][%^ +/8<+1!046=L3!6QP Y"
MJL"J$<Z^W$=Y,(I7W9'DH5,@A:0XC?)8B(Z,$WGHEQ=C33714M0N"*+YGVZ)
M[G_OQ^8KWOR0G_^>X?+OOXK*@#<UCQMJ,%>;76;YIN*I<+BS &M'UEWX[M$G
M+X172UV\^LAJDV]23 ,JIN@O-U^MLN:B:EW5H,N<]F=$N]L'ML&K'?!SG:[B
M\6Z6F> 'E%P%Y85)+\@U(JRMJJM@X[K&>S>A;KZ4BI>],>T%@W<#?V8G88>#
ME0:(BGOW&;]8 ,/.L+NCAGVZPY]E#J"0I0( ]/E:9LED YYE;Z!%)!K(<'](
ML/HJ%^%/_Y._MV;OB;[=82HRRVS[95TNT^^X]<++T_!YLI?AFXW2<W1[M+<!
M'?^UC7#!OS;".=F8D[E/0.&?%X/ J-SLG%7D6$F[K7-(:04[C683C_\BG215
M#[CKD5311WJ+N6DI0@_.?QL'[L@ESZCALCL;=Z]G8"62_#AX!_@<2XPG'7W6
M:@*,:U_56I2L0L0-7=7NW$W$3O]<49'YLPL./@7@$>R^5I2N+^H+ .L,&RJG
M.%734X#@MF*JOFC@^68U@]QT31Q5+L>5'?O>(4=_S.!N""N X$HWN^$_[Q\D
MM[2^_K9,F;^#3V4_OF$QPU (%A"@&C C "^,?\[)5%FYWIW2H^%O"<V)SB)C
M%2!XXFJI::7@$+MX%;?KS"A$6RL[DKTHA9_SMK*NOM+>89^2<8JRLA[&L)AZ
M9+G'*4,NZ?,JS'AW$[$Z[&90D^9C_B9 N"P@UZ?AR-3<(CK9TSM@[J]IBN&/
MWK=;T]YQ2&SYH_D$QD<SKZ^3OUSS/T!]W".21J6&PZ->OSL0DX%LN\MRQ($1
MC2?/+QJWZ'?UNX)2C\E5Z%<WISIE-?<;/*(;B07;)5 7OK$RX:;HD9FJC?J&
M_)FL$NC&M^J$<ER=O/9E,3%&16U9_,FHM"[+\1M9_)9* "/TN)-_UC2T79B-
M(6EIF>, O0$:$.T+8'\1V7-A+$3L[4J_:K=?)SW="/NFI65,W[IZTD/59/ZB
MIT7Y,#H6?@&H7>VP6Z.!H<J^1X34<=Z#%2]>F_DTLP9YD*:$H19F-NX.R!//
MQX[*44!KY+4ZNL:50_O.I?/^?DS#8<W!]0,[Z)^6,"M3<'YI:R$F6"1YQ)9M
M)G1FG_%-QC797%.UCP^8.J^A6GF NF)(BR<[Z+#U]5TJ\R;>7C]*%[KWE.<X
MTX@'8V*N(K26%6W=6RQ@E[F##H Z6B(W=B:>&2C.G^<V4(#<4#CD#ID>I0\2
MU/W"3-1^DR"Z'G,*R/+8(G69X+[=B[;GOO!DPU7,CR]!17O4S> C[N!<J)WW
M>0@Z2PH_3_4C0:%TZ)V"[XMVG9ER!EJ9]3.I$F_3M,;'3G@+8;\>E!X/1QM0
MW]<B$"S5)B8[ST;3$EXR2>K4C$KD<:<HOEP*B3DYP=;8FW8(C3)Q! Z%+&<B
MQ-$*^ 'MW7+7MOLS/&I<6]9V;,>=X".+["5,XY6K!FQYCE(A+Q( #)&)[*CR
MG4 LW0&LJ+OB:_OKY6)>_L(DFVHLHCP[Z-!\C"!:HG'T1B=>3A<QC-G@/P5$
M:PHUS#D1?^B5C0BFQ[$YH\!*4." ++[LRGW!\A<M4NS1J@-7,KQ:"/@C21C7
M%R^)?;-T;R^5V>A.'N#3S<1IVZFTME%)%KA];L(T-_;RI179=337="(QZKAT
M/V:_YT,23DN"EP\GH?;@J/:$#(I_D_ETS UZ:XLRJ9JKW@^*B^_>6)L8V[F;
M I*$H']3-L\_]E]BX[ &+7MM-G$OK7_T%+)53[H'S]9*86M=2/[Q#,L'>W4&
M?3I\__2X]L8^>.$.3/KZ>&*)[0R,!+DZ*F>^XS)[RU@-WIKWI./ PD=VMP7V
MA/GZ*M@S#4V$);EWY(UEFS_ @F9Q^U,%:8-K.<H+&W\4QC.6,\>.!1,,'+5?
M'IH"5<E21&WK\K4;CHFO6'M[Q#+S@[D-[WIA5RF*':Y<<K\'/<T-5F>LO;]<
M;#^'OO=)%20LFO7]D&VU>(VJL,?ZZ;!Z&&>3*73]G;'^Y5H]8=FW_N>FD!97
M_<KAQ1NWMZ$\:-XN[PMA-U!\64244LTN\:.RD:QNNINZ2;U B=TI0%LZP-C.
M_X9N4H'G:,Y#<T6K^42XB#+?V!IU05@8EV?@^')20]:L8EK*]?%C15"R0:TG
M4V024T:">*AIT?(>.BLR2B/[P0PW_)5\I*&M!>++\P0Z=%QS;HJQ9ON7E:=P
M^MA@KWNJ"MD?\3L9AL6:<K@^Y;([7D!,N-..R=%(33G!4)Y?[7F:&/']=KVI
MD;1SXSX"LSF^\L7E.G\0$D%WJ6T[ DNSV7(*.&>,UGW*4_'R%WA^+JS+6<P?
M\N4('_NC"6Z@Y0YVV<8O%7/-]4ATOBU0LP"L_WN7'[2<]N7=.[:20HP6Q''&
M>=R@M@+7<^>CZ3+V34Q"[/S6XE8Y?MW1ZV ]B!'70V4X#&57XB;K)X752][A
MS)3I;; #49%8R[4=2^R54\!%?^V[Q&][.KJ">1NWY-,Y^'8DIGWP5"ODT$93
MO8I.E4.WH=N!X5S/B.>'HP!G@H&EC_:3O-W<J) +OI$X>D?.@3\#[#MQ:@Q@
M]O$9 X7M#Z;\EV@ &1EN4823@3&)GJL6G5CMT9\:Z?)%O*&KK/V3=Y,OJ\?&
M<);FA_4!(+3@>Y3B)N9=EY=5J19$OT5-;<.1)J^BW@>A$!&A:W6?I.3+;(+J
M6T%2HAEO#?&RIP#:(4JMYPXF<2$S]=L"XOF+1(U/L]V\34GU^TX_?4<Y.H!W
MGT\I1GAGWX;8#$SX/!GT M[P/5K0CN"KK#;MT_W0%$#)-?I;GZ9[O^Y-PKQH
MFQ=+-_7/' OHO<M-Q]OH"(CM&9^$O*P9=G;&E2,K#'8?39MTN5W)NU/R1>MI
MU-,6&I@#@*)"I_"?*CT?,FL"[QFJ"?T8Z!+)]FUQ1 K^+LQO*N9H6X"@@KP#
MFD>(*4!V-;7C!*-\_$PL>(&MB=Z*_V$T$$F^7O<LNVH\C$F GEDY0Y[YZ]RZ
MP73(5 UXSW >2[Y>^X9O:V=A?Y!MBG0KL.L4H @:+CO>I- -(WW7:%8&IE2S
M)_,6LVE/ >VQ_A#T- M5-!ON]P5B-W?[^"]*W)*6LPWB8+GO>PJX? JPA4P)
M*\<3/A)SMQI'[1R3MR##\_-HXE_J+)I>!,>[](5IPLG>Y8D.&;@G,2I+FD$"
M=P'$UR3/W"2\@G564M)_]&,%S@+[T[4LFQ#-[P:@BI#+ )(&X9%Q).[*_(YD
M<GRFS5,:H @A.9+S&$9(IGR%+$\JT4,F(O(A:V*&Q&IP!S^<$+'KLT.>FYOD
M.(&TH[2/_1GW!2AGH.6_*/J2SAUJM'(DJ HPIBG@R)"!I>'FMY0:GGWD!\88
MIO>?YBY;<!0_:ML^Y$X[26DVHM1,N6PA]L*W#D07Y <227,^46<<[H'+)V!E
M:A32 8*)7B3[2U4%.:1I1[FX*_1\<;TA)$\_RA#T\VV QWCSSCAH/B8+1)UV
M_!&H%OBRU25AB>'B=AB.#SJ2W8UX3J67=AVBC@*K3:,5VXG0-V<8-<O/G,T_
M#J)40^'>Q*QT;]QX.&(6$E)WH;U)FB*!Z]J2(0L,Y:E$0_L>)!:KJ_=-'O K
M0V\=FIJZZF0DV@NHZ&CK-0L(&#?"O6M!R9MS1&[#>+Q ,IR+&W$#U!UEG8'C
MF6<"C\JTK$;#B-R6<3DOAB(_BX2U=/=N)%YXST9[CA 2=QV-%^"">[ 0O]K'
MASX1)2,;ELFG (B"[6B<G/[0(MN'QM3>$9#_]6R%L!^,??L4ZBG@U4&_O4Y,
MDM^##"=6F;I^4=U&BZU,O$^5X3H\/<.,9Q'GY3AY(/3QT&&#JE$.&SA^;TGD
M!L7R?&T)? XA./U427>6IN,N/@6\Y"ZB=</#$J@BU X+84J2DFC@M7KD^ XT
M:G,1%OKTPO;];B5$X0+C3M37%]G0860U0D ORTDM2U/QVSFZKKMOK[UT:?+'
M;XZL6X8#=PTISW$@%J1MTJ>I'FVB*=>Y:_->_8VYYQ':2)I:-YQNJ-YBO>WE
MV3ZRV)'-^D,21E[)<0<+2VJV:XY5,L3:FTS9>P6]&?,"#?H03.LTXB<WYT?N
M_P;ME@7>::J8-D;^+FV555C.R/) EP7@?56WVCC<J .@"TW5](T+J:$] 8D_
M)P.RCF$^,(EW_UT.J$$.BMITY0W\XDYG]E%RE7I1E'V[]U$WTC[U7IQ[(+I?
M9BG+<=@E3K"\V7RN+G4%?\S(LDJE<T*SVG;MBWJ)]%!V9I&*VA;5YS;T=)0!
M?O .V/&-&I=\2%^)1\O<OH ]"']6\-><C"#_G[:$ *_JLW^RZ.)LWVOS)K]\
MU\BM\!Y2",D>GKEYCK9V72ZW6\R0;H^-FG=\,L[X)5 @SQ>JF?AJ_-Z!$">[
MT=4?F)[JY0:XP]K,N(2M1XV.AJAB$D,B\?(!\CI9>3<SN0S_#2V4.VJ!\2U;
M;#O^Y!YA?67_1L+RN:S#<XGSC!%*-+NT5=D,4Z6Z?0H)S4O,TM_W%6+<O_'M
M_86@%-#EAMVG 'K63E:E^UE'QO7UCJP-=0&^*_25&C[)O:^DXB*DOO7[VQ8$
MR1TQ"77_N6\56;(7<A1T,$W5%W742ZXW1YY5K#<.%8X)FC.CH>G[ZRXM<2N+
M=N^[,X15%\^M_T5I0QV.N3MPK&0>G4B#6?.FPH$KG7XGB5$GJUL78G?3*\4,
M.?W/TO 4$*FSSQK[+1^MD/]*O-'* N(1,C+R5?X3RS'Z-G_ 0SZ[3O&$]&@=
MLS*5/J'M],8@Z4F@9:O/R5S3]LEFX<9X',EESCKQ1XYT]$H)@_2.EJ^S[-0(
M9[T\LDS*./?Y8\RD>V S> =P$(< 43R/G"I1S$\/N(.63@%"_D<#@0<C4/]W
MR;2]\71B7%"J\1[^%'";#+W1]\NP4L=!S4+;J+!I3@1Q? 1RRD]KFQ7+%E??
M$&K6QS%YQTYIEJEBBEYJQ#?)IL<WB<GY7W^YF84/@T@PO\JSQYC>*))]-/G7
M&GV7@0:/\C!-K:2D<!8G /H7!M('M!"J%@ 4Q 2[9>V8GBWY%>=R_.$)91*+
M!7AT^MOL3:%__)&S@ KQ\61(.JMO+L(-FVO]>2L,8CAL<;+O?+9GZC5^N AX
M^2"]<H-N5-Q1N6]$@'^_)!S \G=-GOG 9\,#I[_-8+,J\181(BN/ &>2K$?J
M1G[H/KYAS4"G9$<57^]: X?!.*+**\%[ Y/BR9V]0;-Y$(M30$ QJ3G#4%+_
MCFHRPD'-]%=-3>UZ(_S7:(&O:E[UH_T#@;45=;06 ?X!+6(J5OJ>5M[8M'^F
MS7;ERK=62[. VU^+WE5C@6_.:EC!!>JS9I7I>B67(_#'+;(<F--^#@O$D@.H
MZO'M!**A-B_1)]X\P5;_4L'E;^!]0@("CQBUM-0-'W[TZB[@QR49YPG%AH"H
M*%FGQ2C#">^2;W?_]D@7T?PDX$M6):QL;'@[%Y!Q( M$B:2UK3W/XZ]%I%=&
MIP!CU"Q*EK/NKL>@0442SWS>G>='9GUE^E"X=P%X>\ZOU%[E3<HO8?4^R>VN
M]6&")L['970P1O!7^3E J!Y7&_LI +0\JJO)\:V[-#__[<XR0XQWO^A1Y/':
M'G=YA]%?0[H,8.(!-JO)%B;)+-TC2@(]S8H4L^9PIP,]:XJK+](TKH9)+"X.
MU^3ARESVS$U()MTGQNML[IT6&XA$335C2;M9=..0R4SRB6BHJ1?I\<3<8\KL
M->\8Z:O]])O'!YN&-/>[Y)WDDZXN[S,JUO_=-+;__LI=03[EU740-IZNB+!S
MU( OL5<ZRA TUN\$4OT)V#C1K/D/#?<,)!:<>$L+^/+@DEJ&=."2=%/GQ* _
M<DJF]9V#49656GN)AOZ0UL IA])XX0T>]VLT[Y_PW?M]:>?O/_")NE[6K1#K
M5+W=R4:XNZNZYL#MLY)+&U]RP1>E9'(6$;*'2_7SBV6Y+YXFWW3N]%D.G, "
M+1219J-J!^I[!I3I'#5,E[I8U&ISBJ9 (4;-_FP!S25&]0ZU3BP& O*G9D_F
M@OR?S9K_"E?FO>*VF<(W>)+=731K)NA>?OTX)KC*+5YPZ:Z[EC8HWKD^+:#]
MA4&*8J^I?3R;P">@E/BT!U&W6F?NQLK/A><_GFS.]5!$1_9*]5GY"_'.7ARP
M6R-N-0D-PQ0Y.T>MP21KGJ4>B-W*;O=M(2FM6=,Y:SEVH=X?1A/WZ%S_=EEW
MR7;*G1R$H255-+ZFG@>4:G!\Z@1P^-,,*$V0J^ K'4S59==UPUR2!_K6VL$(
MCP'U3]U!<L:A#7DOM9Y?![]IA%H@(]E8UA:*U/46_"Q>%Y;=V:^3.ARKKK=V
MTL5L%D::\6VM>SR4=2_J5#,NXYRI00>-QZXWV'6B;>&A[;UK'3??H1526A5?
MSKNZRJ+ _F9#T*@ &[L0AI[O7;(8,14VZVR+9J1Z_]Z[J]:"WY[QO.@^-L\.
M2QSE^K$MMZ=#=)H4C.OH<A6//WXWH(6:RX.8K'ERO$T,>Y-HUK_>F5]>FK(N
MOY%>67]-.T4L<*AI5);G&.YFWVC1)?TKH*1@\O!NSH$W_Q\("J6=X9:)0+V6
M'X^-[B#TW V[;.3$B:+C0FI%4QX]9'^AV7SW#B<(6WPHLW[B6201M/1&<WW_
M.-(JXX-"V+;:!J3,0I\>Q;9TA6_ B[^QD7?'I=' 8;S!!(,:P.KE_];G.&:M
M>F,B4'P@L)7HHE5;N>EH1,INY055. 73^5I^)X!\H$N4( _S6+=9>MDA)Y7I
M=^!3P!'1TH.JNC*!/KRE-S?JNC&NGB1(0#; "C<&-+57/T)(J]R010T?,#(R
MP'.";/1/;W8*:!6@7@6/R47[=N[.MBX]]71A<G.[ 2<]L^3=,@YO9PN1HBKT
M?NMTW'\S#R$SHPB5E%2((_,>2',O*YXO=*?<,TA*@"9G6G#3^B/Z5DRAUZC4
MK<?3/P>28\):^P5P(L1'MK@1D@:U!RQ>E;HP\ ?ATRFGV%EUH51W\KD]C^[%
ML<5:@!^FX,=Q;A+0S+L4&78*J-7&&>\AS7?[T-%*YXF1;2?FRVG/&\R4;2K^
M\-R0[R$A/LP'7V/#GUA#-?WJZMQ1F<7F!0UQJ<DGBIX;8[@ =EW-PKR_RVG>
MR<G#!_ZFYHV3V4/ B&W>IMW^:,?BZT=O[+R?$93OL*P&Z#&S,*B]-H+3R>Q8
M)IP"X*I;J'DA:X.&O<(<WR_T-76U:1@UZ^D^/Z>;@I/O0D+I6^GB$)MXPS98
M@->"T.U51]6JYE2M*N87WMOAB 87N@N?=+[0I2S[=( !D%;SPWC,M8YR+]"G
MD[@J2.$5U:N%1NG6P R"=Z/9E[QGQD"_LQJ+KEAL8([)85>&]PT5EE;OP#Q8
M&_%*R6?[8D_MHIXCBA=LR,5'[.2DK9+>..X6\VCI]17-S+P-UU=0^-[I@4*
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M\I(ME4E(''@P=T:8'59+"OY3-.DREQ6D]*\'\M$_'62OY>Z.97B(?GB8=G8
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M+T*6/YCXE%!3$%!2XQ)!H(!M//A^,%2< @9>SH!V"@0HCL?3E%_(^6@@XRG
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M,VM(%,6&6#4_-TG2C;3<L_Q"YLYSS.(?><<\\QR$:1[L-WO(P&27APW@8@M
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MI5X\(XT#99#2@?\ESX00?R5FD][Y;$,R 1!5O,4.5=$9LCGK0KDU9E4R<PI
ME0U0 OI. ;F88%"(99S3&9\+376T,'ITL=$/H<9N3:"(\/C03)$=#Q$,5IBG
M=^7_]MI<!W"%O_4Y@Z>;8)M G]BS3 U-=S@(?YSKF!IE#=H?I" UCD\!T;#
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M9XWDQEYCI'%%27%$ W@SS1PX@[:2T-?70*/G"?&&&Y5[@4;+UXN\.Q[X*.,
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MKTSYLQO.!-:;:J0<NN4A(,J_<CWVG725/[K5R.'!ZR>2+K3K=DIONPOL%S3
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M'/+<[%39H%J/^&G/ Y@,<F8=$S;Y=%G\34*M$V>,.J/CDQ!^"CE2]LU5_P>
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MIC6&C\8$A0.]?7!;E=>-/ZJ(!X()<".?Y+X#VE)YYY[%>V%Z7?;MUW>&E
MVEFV1^-)WMJA:?UK;)1# )D8KB-5F-LFZMY$5TH<2T4O0 :6PFQY^9PRFM,L
MXM>5)9H5/0[L*SM>-SK%:TS9V<MZ<M'Q/D+X@O[U*4P<_>815+5]/@1$D_;"
M>CIMPNVW+JWM,6?_:&\H'$G)2?=];443^8]/999ZV<S^ZAS00RWG7>B\2R^T
M-!C03_G1L*W&\.-*<^=J:6$/"40<<=J_RGUH<BRP?LGPVH7<)WM(:SB\'=.D
MTK0SJT?7G\:,^<Y@&4%TX]V+C(R/\+7-+0>!GY,4E[GNM"FFF(6-OUV^>AR5
MHR.<D?$ M#5\"#BID2E]"+B(ZLJMD8MBO'MI[(=;V45\)J:&EQO>;11)K% ^
M"#AK\I#W\G^',_..Y<&_GE.T#V OXX\D.Z^Y@$F?0(U-D+(I'3?#(&[_]E^Q
M2X9$.0>T7@G_X*OSG^4USTGMO[CH8E\WE-K-K^5.$"+] H3F7S"Y(^*Q[<Y\
MX&&] B2Y36\IT^.PQ@QO$%70 OC_DW-Y1]CC/UZ;L]!D%E[VCY-K,9R[I0%0
M9F&"\,.G3M3Z#]RNN,H;<UO&604+X-0CXX$(W@6F%(6V!?E^J7\DW 2?KVS0
MWF3",3'-OJ_J>Y8[];I0*IL=0Q)3G]F;7*:+))Z$>4\'H#[^"#T$P"K!/!3<
M7G@+A4&[N_K'SMT2&[1GE!L4X2IT<ZT&Y2ZJH8M3<U!X\#DECS5/)/V,W>H4
MSMAL#V0TWG8,&Q8\U+U_,6B<&&O=%/[S5JX/&^=9>D^$.M7'-O-#E>R'VROB
M#5HF9[KL#F383*=]4L@;[EM>/8< 00T7FB*V>XOPX['A]0RM"D='7JR!9.L]
MF5257,<'@.G&F[IGNC9"85/)4<N"L.-_L1FU"HDZ!M_:KO1R4Q]<M3OZW6%4
MF//#GO*L?=,R9ZR5>!!BX!#P",5WDSF2ZQ/D U-8&KLVY!)8-=.P$6HPV3EK
M,])[:4&EGR=OD2MB>P)H="*\9*%'EZX[;S\D*^H,(GRY$)KD@T;PDA-[?OI4
M8?H]$M%0'!.!*@F/7W"6IV0L96?<$ VY[-?DL=CX2*2C+6@!J8Z_X1=VC>WB
M*!QL&3B''T3'_:E_N8E>3&Z>RS9_.F!H:Y<GD],H[XO[,KB/-K3+$9+:%EU5
M?7DD_?ZAN@L;# $'QHI9Y%40-AZFG>#B)Y.2Q<6C4%JS[7(V^;-%%T*GO47#
M*V_QY.WR$UB;5W9![P+"1-\->2X-[(32.PD(%6'VS?45^[3Q+"E5^& )^^U*
M5_^6>(O:-DOS$JS%-*,P%ZXR8&33\#C]ZJ;[K*9=I5;YGE5'S/TK28X"_2C(
MP=+F;S(55N+^\;@ZYZ<^K2 Z>2X\'[1G@JG7N=;2WZMS8(-' 0A>#I;0,+,+
M#V]=7/W1V]8[N93[[;+0FT[RL28712WMCI$QV8.@36EKH[V.@;\-#9B1D;TX
M/>T5/Y5#P$V"7GV1J:%Z27E#S\-F\ZOG+O-K? %O>LQ^XA>F]!%*$4+5:WIO
ML,T*4?L46IL+&AB4AQ&$"#X,_:[E+,[#/7\ZE9VM6>@08*P_\?WIA-2[B=XG
MZQJI3_&B(KCDE;@2$1<+:=IO^U;K&\VWEQ0;Z!6&IFC'LD'Y=%.?M_;'1G9"
MW3VP3%MI2=SG%:\79M=:#>KR)TQV@2#>]_$*_0YQCE?5,Q6X L,GIWX[H@O^
MAHWK\MC/9)G>]VT/GDQ#89KP4YH5U>BUA49L0I DX%GU,)XQ31J%,F(D!0<D
MQI:CET+4;>W.[-"HLK5CFGR& N6&??LI/CZI&9]Q1A;YF( * T@/5I>E4<:I
MN[07M>D]J2DWK D1?10UU/3Q<GJDRDOF2C\^$J(56TVT6$R\\J$Q54RC5)B#
ME&1\.2\JX0A>QYW.2C=[?#7.-L@+.(Z'(R".NV5NIZ$W@_*<3_7NU-E8&^U/
M6FT:_*T?V;\I_<L@T^A7QS-K#]&&3%?_H%E&O,R 4(?1AIZ@-IA"]T%YWB'@
M<E0)JGAXXV7S&VU%?J?5;V7X?>-*[-L6F?$Q*_EA6GN3YYGQ3Y ="(6W]<E7
M/+[^R_F7*B@(,E-AA;$9Q,[B+FXLB;N\Q!B&-CJOA.T?A)RSF=+L_C%TY>%]
MTA<=U'ZLADM'&/![Z4"V6,:Y;XA(2V9PV-YNGP5=_=7T=)_G)T=2R@XGOEF#
M&DJFAYD+>EV?%_^8UAY)B@5)X(^+'/2J.X!OEYM8^B68AG^KB6M);?/<9&"J
MB#G8&24;,X.<06_3I24DUL?0VM8#78OV8 -43U7</N"X*V5,G08H[0W0V>SJ
MB-(UTP(6C\^2HY(_^J7UBQ>019/8> T&^N7.OV>C9A*DZ [GH"I]]\+&WG^=
M/3[[2;Z#-^OCL5UQC3WQ;RM6(\G5AOIZC3?45S;M]'IG8-(;[<+Q>H,PR7WG
M]0N.OTHRVI=GLVH;VI7$Q_U+O? W/&1_LBEP+V@XAP@'BT:J42_UC/B?6G=*
M^1+1>7+J/,\=D-*U.2Z839A?W(HT_N+?JQ92)XWT"&(BMXP]53?':S=?.F7M
M:PQJ3_*)'U,8JTW2/;Z=U.;R#4VL3K Q0][.7ZM:*!PCHPW:@2[-9]/QAFB/
M<&73)7TCJX":1N7,\8;HMU+6:J>K6!/T&)V"&^ F6CL;WHSWUP^/O:COD'(4
MKE.(C+KL@O#K^V+Q6*8GB*8N/*)*&Y+1P[+YM'H/ZU0*9I^[KMMB=^4.V,+H
MUE-HWFN5?<U5VX/\<IT44K.MSHSK/:RUM>=FQ'C5,E"62&4VML=JX\1>F$[E
MP=1!J\G[:@$$3<$)Z)XS^W'7*QY=;#^+27*:5"8_'A[Z^L;9!M_%I2G_RH0,
M<+!=LW"$PIO>&[(/("YVQJ??,_K"M_M4CZ0!/\UNG>S1L+FIR+M4[#\R^.MO
MX)_D=CT](QEZJOZ>NS;,6FNO/J/X*UEA<S'#PSEGUG'?]X[X?C#Y1#"=EF3H
M!^+V_-(ZOA&^5I#DT@T\<(_,ODS":,UHNI?KBKZR4Q3KD[@:3E@2<N'O'\!7
MJ>VNFX<K/_=PK$B^5MMBUGB9<QL')X$BJWXV#P:7#H@/!!1Y7*\;6^T8GQ')
M'Q9::LRR2"CB%9O)3PTOJ[BA)^WLD85=3>[0$.A-=/-+'&(B:'G<SX_44]X>
M;U^PW)._>\41C&:?B8AI?-ILZR5F]* 7^:::Z]J*+]F^VS8(\B43E*4 W)_6
M/@3T0(D9=.-")I3P U8_ ^^2!5*>:_!N"SX;J=RTTXDW,$"KN$=H/RLP"!&5
M.VJN9M-W3C ]<5#^5#_B!T-PCX_BX;S=:/R-TKAMT?<DRG#\]HSE@]K1DO1(
MG)NR6KC)*?^FI+M)D^=]@ ':&\4'B/5WV\9]C;C&C:(Y)']NI>Q\1U;E,QO7
M_;W:(5'];6)+\N!O#>\?41?'FZ\&SJ. LJJPK<>;0E//Z+84^\IPU5$$0F93
M<9,5:_M08*+C\>CMX/SL3O3Y[-E[@T\<^37=6\\):/L[%IFF^M:7;#3AF,#:
M>AJ_F>^3\AUXT*N!$KCX$V9@/=4.JPX;U:J<CQ>$17M3#(P2O:2N;17^;0E_
M#[[K277#6@]'I^Q$WQS* &TL(',@0/K9<>1+KX2L?67(R1)*S_,*W*I5=N+;
M_NK<YLQ5%4K[R)1<[N>HS-YA.'(7L^7I'H][!^26D<4HGP]6[Q[YR;^AY;@2
M^/- G&WS_"AWR;-MOF[<:>*E=*OQLN?N&M\XN>5GG,2OL)FAHRL=Q5:Z=7Z-
M&S[KP-AO]2J#H) W61 !NM^VCA[S.\6D/%SL]VGXI^.2Q^Y]GIXJ'28R[L;\
M%N[[1;=;0!;9<[IZ>!7\+3(Y!.B.5GZ]&N>>!5+754MK/ W-9WMN7H?DH+R8
MU=W89<@,SRP 3B:=2&P291,5'O7?HX<!  "62#7'+Q(LKPK_T[Z7$L_DD&]%
MOMC$"N[/6FA=<N]C'.D$8%8!D0P<1+(BYZ:M7V5U7<PZ9M/?\R8>"EHP%U?I
M:]Z<VD+@N"D2(]\A+PX!6+Y?+XK#%3%Q#@$>W^8"@./(?U9PT_*XK0]3;XVT
MP.J0_IOV).IO-G+]LU""FE:I0L+$-&F%]H6P1;3*R*ARI D^F>FDG1@W;DP]
M8$BPTBL@<W\I2+S2;L'>S^6AQ^J'@-9# ,\ZZQ*M>>]OF-\X,NL04//CMX%<
M=DC<X@E-Z\R#%L<\ET8K)NRHXV+=(2 &.Q*9LA>1;"+ET^^UQF"-5$"I;FAE
MT%N:+S>9!GJJ4%V223#"G8N.S8G23M$_!"9K@$W\&@%]$*,Q_:_7ZI)/&P$F
MX&Q$\[^ JJSOP!TYUSR7?4(RA=52\7]CL-U'%YSX9V(1&B[FI0Y^+<[ T'<8
M8\G?B/:M 12=(Q8@OX^EG\?,7[%PO((FS!:'EVM4<+>$83:6 "_=03OLHTCB
M(/X0\% 1DGT(6-_EA&W9 -\?-.V@]C+?C,)R&<IF>#BDM;]/D9FGAJ*_#1#:
MI0GW@J'6E@?)3%R%UR& ^SLEN7F:I>R5H+="VMZ,63*S(R)"TLIX-BF')*D_
MC?J25[6"2#MP4U>WHXJ[VR/"@']>;C,^S*MT"1X"YOE&[K!6:?6PH=!LXM ,
M?0GZ^XD!F;6&('*O7B<_(*FIXNTU9O]6WF)>,L>*9/(>N.\DMXT+9@5;!I19
M5C(7N^R5G=)_&<JFD20YDI1BV58VN*H_OIB1U>Y5>[2+2YJ[OUW+?<R8JI"Q
MGL0YK8=->1PTN!MPO' 5?Q8T?S1-+(EH6&M_H0E!M-CK+?L)ZFL54:_+1UB9
MOI?"\R >IL!O,I'$IK$]7L21.2 J=TV@497UXW0>)Q1<I[]2VJJ6DKJ4D=61
M7PF&MJI(>^9/B(L/DDU-XHI$S,L[$#0L%C/S%_7+BR)9_ A6K?S# ^TQ)9S<
M#UFJLL)#L_$(?F8(P_,0$.5ZWJO3A@$?'DX)V(&@0+OYH.06M0ACNQG)'0,F
MQ]8?0]KY\(=2NL^%DS,!\S'$)+UAT$V&VU''5YF3X&/+?"_]BFV]CCMP[^:K
MJRP2&N'X\68YSZ!D^8;&T%<E0X(ETMC&Z2[LSA+&NF._9KEEI1+SI>4UQ/2)
MR4.?]Q+_M1#_PTL[J>@0(.(':8'LGK<L_V\'=T2>;^TS[V%QC  OQLE+9.R.
M[/^W$N-OEB>*Q@=L=A ,&],<7.H&V^%J.P14<=-+60?H7-D83\%U@4'8-"3H
M@VHO&WH+/](.;;/O.LVVQQCR\E('RCLN"1DD %%;="+V/Y,?OZA)Q9EW.FLF
M:L4!"/7N[N^ADK204TF]-X0KLX#MWS,W-)%MFA1$/X3O$-#U*-S+\6@&GZ.(
MWZ68!95/!(-):SE)B MR:PW)0Q]F7<0M[N\<5(S(?+W%[86!\ Z4ZA38Y\LH
M9NY^)W*^[KE_45OH(_^^<"+8 8P"U7;_PMO'CP3OC ]/!U<M.-=_?"/VH4-:
M51NE/"#&7'WD@;I/O"/RQX5F$6S=\Y$B?#O";9(<H7\D_>O])S+H4ZH-PW8W
M6'E8;*X'MB:%0MTWA$4(ZVK^RI[3NF^2C1\> H!FF$9]9A@]Z%\F(>79=JW1
M: =0.Z<C2JMF!UAG[.-YY4U1KB#OE4^AA3Y- <1>XTVV;O-QT#SK2-J/%.F&
M+Y>/;4C,%)\*O,S_TMP1&EJ*SS'Q]<T+>8W@/V),Q9'04$VE!N*HV]X.!K%[
M%+6 "9=MPR6W!Q^"TI:#P>0'>.8S'K[EOS-JNYKN]->@N>H]7VOP-.CL7!BZ
MM&8HA/DQ[!#P@V0!G#'*%M]X@ZJ$5!]MWK6G* ;X_H*7WRF!^\N:X-5=>C(8
M/H+LW6>>/FD.\H"]%[^6BVH;#L;3O,RIR22R(D9;\7Q]86%)8''&05T-9LA6
MK7#4U,<OO*RN<?R7W4H@Z2A>@6UK4G-/>[?%:C+:(]B,M\M&-"81FTT*+-_"
M8.V_CS2 _Y\78V)"14ZLN 9M-<:-0I6+0V#2<NS*E$@[!(ZWFQ'BNYTEA4YN
M^;(9Q.<<)IN53V[O/G][Z4*]J^2 TGAFG=>83OOFZ+/U<?$[:6R#4:W?\&*^
M;$;YJTLEI:D7T\ $,V9%,Q%E[&4#@S_R74S(VUZ/8MQ<K^Q_$YW_U#')6\>&
M&L@(1E@EO/J=X%02V)[WXFMJSG)H0\N0.:%\HD??<SPPW8: NJ'U!SW;$A:^
MVWS%3/-[G]3L4_LL<8KJ2N?Z+M6<_5EAR%6]H"O/TR8. 3 2T<K(PZDE<?_;
MLPL:T5SWMSL%"(> L<?O/68\O_5YBPZJK*H3H(5M+2,9H1]*&T;J,BKYAV 1
M_GJN"+S_F4'CF3]Z7PJAZ\4=^V%3&[<KL1*I8JX/$F]U^L&FG:"A@7T%1(IY
M;;"VPX=F-O=;1]LH<AT,NGO@8T.)#,]]F@?,38K2:DNC4,?;TR5J)/6-?H?.
M0=73T U&(&XWZNS%06=KWH$+&0]Y);LJE&\\FZF4'MS#4D-OII1IDWGST_1W
MB$,1'B/44/JF38^O,THN,N1U<A9"_-^MNTH6/]'SGK6IJRS<#!)C5J?Q$<=?
M,@M<$+"E2OH$]OD& )WU@_8EY:MA6$_S$[07U\,3DCZ+' (("(*]<;:#Y-)$
M:=.@3]LT3'U2V\"R(;5^8[TJ5U.CGIQ@6&+>U*[*4QN?F16*,UCQR*!.K%U!
MVSTU=4GS'[X3W#3(I:H1."">MN_^:O(AI^"YZ.#CG[IH!$#Z8B"5RTCS%,$C
M0)ST*<77QN&M-Z#K.!/);/EKGCZYGI<1O^S\?#\>XI\0NHW!Q-&$&KZ<%HPV
M@DL1]'IMB+.M;IC5.D,XL ;GB$F\E%XV4\*O?4-LIA(4])18F;.+<3*I'4W,
MP."D<B/9DUB.P*.ORH\ZWENY\,RPXNZ%M2F,E@.3LU0]1%BUSPB7=2)$@D<Y
MT[<[*?A /F38&&1?Y<9_S=(CM?I4& V:%W$'D;@PW<=10M;05'/+DV5_*+VT
ML3,X;I$:5E*X[H?N<KSYQ[S$U!#.KKF1HV>G&52?L]+2\$X5-YQ>#9(3UYA+
MFZ:%'HGR4<M;K%)7ON#2V1C#>?["*BBMM[ 0X,<#O _ML[]HZ0 =F6%YXM*#
M:TFW%-:)%/(OL$ML@=Z"K;EP/G5G=H4H W75Y$V0,X] BOHF5-[&ME@F-)M.
M;=M>+*&%R<H+-'0(.;[@TD!MTW7YRWWOK Y^[;N<.,D4:3N*,JJ5[>H.UY!+
MI8> )VWS;_X?VMXKJJFH??<-@H*H((HH4H*"(KU)+[$! M*;$(I21'KOA* H
M*-*D2@W2$2%20P^(]!($)$#H!"*$$&H2((2#WR[GO_<>>YRK<Y&+9&6-D;7&
MG/-]?EGO?)YNW[5#VC5; [9S_; OL+F$S:T0?Q3P&1GN>]V(MS,5G#NM#@HT
M@0>.Z1"Q9,5;[.7:',F?O.LKMT/T7:GR^-\N%8T1"M*73@#'B<NY,%0"SF"'
M8A1$LS+=BP$D<W)'X5Z="^15.@RDG@"8XPK>/;X@=+S8EQAB7ZR(A8)LZG9X
M1_4*UTK[-EO'IW62,VWJT;I-<V3Q0*-8]P$GHJ"0I5:_!'BC!9WLIN/U,I")
M8E2B@)6D$54/0TPVOJ_PW(C]O..TF1T?? *X.E8D?<W,1SHDK*WQGV56P=S>
MY3>WHT"_Y$/HDECWX?GMCMM!+J;\G#J97C668/6*VN8Z<BLYU-EEQZ=DX.RY
ME<%Q^#?75,&_>V#5/J.A%=$QG;I'5U>O1@0=%7"J>BFQ%&SU>5654S$1=H!#
M-M1!SVBSSOXI2C#C!IBU?]PXU;9"'9S+J^UXPOY"X1&JCT^Q6T.!0%FF.N,,
MWMTQ2M*Z]Y-9?/ZB71O+*R+$3W^)'.]BJB@H;IV<8@?WJYRHGZ+27'"'[*<E
M,K\=!K"ZW B<=L#]^.?C6#<_AVQ1HK%"%WYK\B\2?M*E*F7@&OYSQ';N6IC9
M7>I(D\Z,64U;+L+Q".F(@,:L3Z2;5#0QW\MOC!!N_5,;&+ #'OQ:D!I0G?LN
M7..[X0-@U&D)A%*O@KOGK]"$;,(>40*WF?$=B.N['RW<BN,XF60"TG4;>;CI
M^KC-9;:424S'16%BRT?NC[N1P+HAUT<U02MRYL:67XK9TL_)K/RMDIK=.0'<
M)&%];5L]N3WC_E9$?OYL@:Z?>&^@]-V-4&=AXI \!L*AV>F&7[<!;^I'%8SI
M$C.XI>PL=A/[JX2K!%^H7E>500',=T\+VMGGQS_:&*E7Q\5IO*>L9&G^24V4
M4HRCL;5J510TN&O<^FX-7NOC3V^NCURY'GA1,NXG+&6!F9:.>QX7MPKC2N8'
M/VO$\;6X-7;+8$#I%=#;T/ITZI7=9<\N( ;TRY9+19G=,NW3-4)\2;&E=9_?
M;==/%\HJ/S]]SL,N\Z&#7["-Y1X]T9-RM^<G],-\#7DC9PE^O>[]^KK:_3^R
M$NR3?Y_\&H1A+EO//S!\JGY#7KL\(RL/NP_BHHW. T$NK> %8E>H&+C#YE;=
MJ*7$Y5^(^#0[*5<21/V<W&R-^VL4I]7R'-+U!&"G XP+5#M3MP7K!EUTSN0I
M?N_.DO4JS5QF5G1BPD"VQ4A:U]6]+H?_T8/9N$'IH$H$";,5^.X[TI$8H\$C
M-^2].!OP6!B<YWG?6>D--Q9Z79'ZFGY;GG;I1>X.GN1&Z?*&NI'2];>O&@<7
M0%L</-DI/QH51)7B-4*W;?_X0X5LM]Q8X+[R'9[Q''#FKBMA1F@COG?+=I3F
MKIC"%4T%3N):;MVQY0CC^6T)VI,<**U%'+KWI(YV'[1EM@W#\"^5SJ_\Q\)Q
M:(WV]O\:K.W-]"]8.__1(^A/?8ZG>T?,!HPKNB-=OR*A&;O K(GR<?(MAAVF
M/J'FMQ!A9H#00[ZW"GS8F]H^+YJBCHJBPC/R+A%9>G<HGS0#[?Y%9N]<[2&<
MEB_X?L:IF+:#8ML%EH';IH*T#\VD4_KL:U9_;OYK6N%=$G*:P[KYX#>N%?H]
M@<IU%49Y<?Z4PAX;0?]^0E;\?YH\1LS'[ZA MXS=;0"K#A"?[=AHF@4,L085
MW-HC1H3XP\?..P156'TE]+,>N!(I$.CA?.8)@'N"[?1ZQ2=:ZD59FH-;?G0P
M$@YM'BQ_IM"N'=I\X@(_=5#P @5(2FJ6*:K@,%3]9XY N_G;9,M5<\^<6=<[
M4.\ UX D_,NN(@%L8WYNU?2I-H3#%HQ2Z:=J.%7J_10]#U;0N='X$1J$[[*R
MNIN9>P>[(Q('9_P3/.RB1<H*ID^Z_'67B<:V7L O"$=CBF0%HFZ(I7 (FP0_
MTY!W\,X-/17<<)OW<A/ )XVI\#_W1P-UJ59EF,IOJ!_6365C<97?\UKQH67:
M:QL5@= O:U]4C/D@T0 IXG75$'M8B24%26,6XIB?,C8%NLQP3&,/<@H/W,-M
MHLMPFV1"![S&X2-#H+3,90'3^3=D33??>63)1)O4J6C\^,GWZ-YZ*0^URMW_
M!P%;/^#!J@"(/R!VASJ*VSKISAEY6(UG.Y<)$+:FX+7[KB5V?JMD?[,X8D%K
MZJ&KDQ_,] _LE.6W/%^B_OD[IM\XWE.!SM _H4%<R1Q(%N3"W& "19"QDT]3
MS0]T^.*WU*'YIEAP]>IJ6/_PX9H[Y!R[H?K3_]7B,83Z.M-QNSN/XV^WFF<Z
M#?,?A\=OIZ6)TL>2.2>'E.D?$!Q*9#R6^^?QR)'<').TL=E4V?73\%-+7G&S
M'!H+H3M24ZVAV"U@A$QW-1EI3?H;(G^9#S DWZBG86(^U1H&!P4)1ZY>H1#7
MOYE)_VTKEA#GV[>#7HS&#RX'&_P<'?9JWFY!Z*DA2TH>VF8#MPQYG$S'PJXO
MN'O^1!MFM;)V2;K(LW4U#CR^T)7XQ*V0'J5XNVV)4O3-I2DP0N5A*25\3F=6
M[X(NR>MQI$!2<%6LN(6YLI;*CX6;-'\U*=KO>>"><M:]EI=;)1;HO2%[(R7_
MU/?C 5T7B4+3QJ^*+GCPP>\TGZYP>[ZDH./:K]O/)I1 '_P"&]H"WE[I:'-\
M%5NY)!#_F(P&A:H&P\>S=!HV*_(:;!-UV7V$>?.>QBSX\=#;(5.'^$GIVYH;
MQ\L2S)22KOF:_>ZLXB"XS>B>JW_#1TZQPI;6J$%M.5>^MW'A<=D_^B-K]T!C
M:1F!=XL*_RI5E.VD&XWZE1.KX+R/9J<?>EW-F9P4P) _'GBC+ &3VV*_W M<
M P996#Z'#&J2=5LB2"!]*_2!\6E=' IQ8*--5%F!SY1>-Y@KQ*;)9<J%V'\5
M+%7QEZ65J]U^T,8]\4HH0R,A&&84/HP#VLP705-!5.Y6432P[OO+GI1OLFS8
M[$O+&YD**)\0ITI%@DVWZ9M#7%U-C)=6:/^:8$OFSM\G^3/Y?S;A11NP^69J
M*'!P_-&LVZRVU!=8*N*B/2.B;)D[\N!/CMJ+4OM$CW>PC-#='H8]?'R.:F@Y
MN+I=^RMF3E^OA;43%F9B]HS??26LG?40:4.;1VT-A>Y7'P99ZAG&I"K>S<UL
MO=9H'*AWM%%1O*PEM#-4<N>ZD$CICK*(=;.@N]P)0 H]T7=FTS U.>4$X! :
M"\TV\S!(6=@_0,KLD4X JOZYNT-:^9]E&N+^F<';C_C&A\::!4ZMQ#_%#-S1
MZN5<1 Y+P?0[U<(%+\200!8&*<NN][I<%4K5N]I((;9']98$X::8%;+:-=>B
M"I@<#1(X%OJ5W\%NH6RYQ# ![GL C7N-83=Z$Z4!#5+5K(>BU(HS7!Y!"N2.
M/EU-.'3JSU7D^;>B@KN'!^H4!;;Q!%H0-0A>L&AUULW/D; V-*!90\Y+,G-W
M6YJW^5A9["\EA^!_9Y4NLH)H'KK71U@I.BPI7AEH5>7N$>!DTUX A,3N:*EX
MOU6DKW-Y#NYTE=0ZMWICP#N6#L5;DGM 2[P0C9A+Z@Y?8RJ)BYN,U^3?YO8;
MLO*S=[PX>=?,.WT=O.D]S CM;EN*9ET2LLMKA:DJABH^ZOM;N](Z.JTLH2/[
M%8=V,721T2W>H UF$B%CA%=^Z1.C^J]JGGA[:/;GD '2OMTA+)%YH"BSZ$+]
M,A<YTD_=$E1L%9_]2^]<F;[V'L$VX<FF;$NF  YWY+H74EQSCOX$4 D](V5Q
M^*K"N] J>/ ]M]Q^V,7DI(X'IP)[^/RPR"3*)SJRLX?-+-LMR2"UXAM" )X/
MS41FX+J$'F>RC-K^,K)L7 LJ)[MCMMQ(0*"SG!)+,G/!&8(G!S%#<]C>.!8"
MGH&AU%0]/78P+>\[4F"IR'?TV4[C>YS 9;,PS24>XU\8AN(''ZX]NGS.!/"U
M03#/:I]Z9 =IW%@\DK3;]-Z-+W\SPJL V)&:W!T*RCC'?TTX#NW[_AXJ*6?Y
M7D]&46C/=^N)>D0N84V;K=9NU+UQ5\2:P.@H,@4Y3EHWMMO6$O ]]_H3S^P;
M@5 <(EQ#7R7>NSC(1%O2Y^G4/'T;Y'"W9VPL8-?@X\).5\.N=@(L&\'@0)TK
MR8T$O??E"D3PQ^/&,-2$=O3[KC\_?AN7Z+G(SE5[!UA]TZH$R[7B_/+K0VI#
M@L+N9V\6W-M5*'>#<ZF&6H S\'XV*>!:KR\C9?3D#/[5]:#E^+DZ'N14C)Y
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M]7--*],%"-]LEK0TK<FZMGK-+$DF4C/=ZT_C-*C %E TMS>1)KN=0&4WP)P
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M:Y\ 7LUCI&4D_GU?\E':R/B9$&C/#$^(.:4O?"YM[.&15M#2G31I,YW9H<1
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M_]:*%+&8/I3(R&"/NB[--S/K0:<P-;:YC;KE/5H!?2UG%2$'HH:> &I#-T\
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M&KHP/,1IC79]/_)1$IVL(.S^:,=+F7&:E;"SB1C[^T)$I'\@?P'Q,2TOM*@
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M>7L(Y9(F$G,W##L$)&0 ]I1OY;Y1G?H_:X9*01_!VT*NN).?DFE.B$ MFH]
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MMU'_XUV$:NO<-NDU&G.R-G-R46X=O0#Y_^RX]OG,-U?$+C,M2TI92-_)CT;
M"[Q!5( MZ/@1, W*^UF9W!T#4Y3ZO:QB?,5O-K!_:*<]1!N*BUQT++7574C^
M LU,X!/D<53=2>N'=31F_-=C"(Q?OLU(?G+'27%WLN-=SU@1C.]Q[@/1D$*]
MZ_H%@H^Z@Z-DP-: KMJ0;+)XU[/3CTN PITH)?X%WM@] 7CWC_$GWZK?VK6>
M3?MV/-G.U74H*+V*-3LH[OX>QW&/41%PD=$?8"&?\3GV<MOKH.Z.^'4<X]U1
MI%W^&7G$J_,B:1U.[_!GBYXE),TL5S?JNM!51=Y\,6T)EMY&[!T_=MN4#U@(
MGC'8DY"8G@J_%W34<>N)^C7B',\<=^M1Y#L\/5-:6O,)[M^]%*<;4:")Z'G!
M !)<?CM9 T@1"L8 ]LGGW<@I37(YH4([.WW2<SU;88K65 "W,5&LK@"[B=ZY
MJ,=_[-1XH_'!*-HQ*7:(AOAW*-USM[@*YYL43W&5F%]UQ=MA=?X.KB?A67ZD
M$- ':4UP:K;)!V<!1F/\)JEN;[W6BT]B4$%GSYKF0>CY<A%O@@^7,CI.A!_K
M#"PL\\*!BWWA"%OS]>*_' ):7#?:LAN9-; F0\C/X,1PY/ON3+E;%@,QIG&!
MB_:]NS-&6U-;]:YFT0E??I1NC4Q4;VV@;4*Z2%)5]9]NO?E0E6LX60M]G"<#
M;S#2./N<3T:-A7B8R[^37OO31N6YNG/&]_Q+S<\ RQ< RR@DV'I.8'1XW./1
M[[4/K#MI'7=Q]+A5A(GM;^6V%POMPHHO!--(JA0AC.)ZPCYJ$''U*30@7?A/
MFZA/T8:S8&F.^X%KWTZ 'G)F25SG9H&U:<S-3+%#7_WN$S$Q<(7S]PD,XFME
MQN#+<GO]^Z\[4X6>\DY<]/D>[G"'Y8:1[W#6'H/7#<N/>,47X+K#U>%99^2:
MJ(>-K0) F\'I';N(_9VI\S2;[KL'^%[Z@QL,]=TE^\;9NLQS7.Q6%.6;^:2?
MJ" _T;B!N)N]/;XZ8]9NY:14.;\I(N:C7?SM6U6!9_94(VZN(N\)[_V#)Q.+
M,YE<"PE2#W,;P:(K4C^RQH.NRHE'_@3PGF>9QH;?[5.FV/;%>@M>DZXY^VG,
MG-?F@ OE,.1774=#0'*:ST3-[EX2LA!XL#V*GGVY2/Q=P65B]+=F>#GV;IU!
MUJK@R92*6SBJ=G6HP$+U9P+W89'PF'67C<Y$A;&?;[#L)MU%DV:AY4YWULW(
M=8JV^WKXS2<>?']F=2N/GV9T>@($>0+Y$-:8(FTO)%R2'^0U*<K,L\SC=^(C
MC7V8-2OWC7?6[4N*@+.TGQ-7G_%22 Y^Q6WS;OB-7*!0NFAHJ7[LMF#3K:^>
M6Z=-Y*FQALQ;*WU\NR;O"WAO[MML94&8M@X:#[]<+>!AC:C9HP_=3(MJ;,:7
MWB6&_[1;8UV[\G9.1S@@XKS!&>_<YK1D%HQ^2\2/N8$%ULVS;]QW[ZEZYV*6
MD^!#VWD5.?H]-6+>N\N*:K!O1ZA?^#;3]ODUG>\QCY5L<_("MV^]0-4-CAI/
M-Q[JJAG<EWYT=!28M53A$A)'KIOHK/XVIN=UI;AC]N<D3]%$]!_GE!R0:=#1
M#\&;2KJY^4*JEX..J #^G8-EU$B#(7.>&T?YQ'OINJI=0!]@@T%-ER^]UZXS
M4\7N/"- _DB1LQ]$LP*S8LN*L1SB3OH<-]\[]@J;I[I983,S>M HV/**H:+R
MNQ:)Q^K=%>CJIDV,S4F&1-;?7]V/CO-)/S2:N81RP63;G=4:^_-#GYZ>93W"
M@:7=Y1]P KE6([S7;<L?F,K(YS:&@?M1HRB-H(7TE%T R/=T>CF72&-<"Q#/
MSV$.I<<Q^-[?>8*E^<.F>HUI(2C,8_<5G4<-2K7#C[,#318'Y,;0;LB1J4#T
M_8$?/F+12SP>AZJ[4 I:ZXT/P R']"7")-$O]$Q#HG2[2WW3)DA4 ,+#+<2?
M:?E!P#%,AIX$%2BDZS>;]!'K:\.9K_6DM,MO"TO,U.5X+/:Z[5?7:2N+WLF9
MS"VW_7[4\"--SW4TCE((S!0""^P,L\RMM^!G)E"-5ED/KD]S)+"*+O]6I?!B
MBHHA[E:]?2O]V^^PQIF*9"@5H"B7AA-"PE#HH-3#\B).V57TBY%-M_S\B?7G
MXP9?0ZM6^-="4F&?]+\]_O+<H_Z-L8,:IG\YQ\PRU3@<>G)$21_5]F(?][DJ
M&N/#P%-U)KEV>0BN<6QI*"Z3KF*GOZ7WQ-J(>1SB+U07@GTL5W>P"6LMZIOZ
MD&7ZIQCP^*+/G5<JLV&P?HYW9]0:0?L3E##R=_Q//6Z!ORS/<E]&3=I>F[Q_
M47Y43>'R*V4^WR1O8IS8HT._";=TG9Q;'-=<U.1,W>S#_-:YU9>J3 *BE[UR
M91K".0M+Q/S"P_ZSN9C6<DZH:FT,ZR*O236+]_?UT(.#0]3V>4PTF"C[JM]C
MMJLDZ^KNA)D/J.I\\0^\ZE$G%I]%V1-;$%7V0!I;>L$"MZ=F+"SW_Y45-?]W
M65&Q7UH=,KGEP;-Z =7G;#-_KO\:57TVAV'Y,#]RT"CYR]G)6'+K<!HXV6[)
M_3S%2.]9)'Q)S(<R._[$SC;"JN5L>81RVO6K6'P<Q1CCB1A?GJ^.A[E(<8;*
M$P._NE7C^)C-A[?FRJ'FIJ,CRS4IN[@'THM/]">9H]GIR)"_KO+*!753+D<!
M1QE;=%<F]--T.SNY\>*U6$QC:,M_%S/-+E-8I2[C08=G,90:<"0JGH:33 CZ
M$JYM)O*D"HDO"\RSA<)L:P=+9\Q$?R<^._RPU)\F../7FM;_T-L><_H\?!!R
MSHL*<$;$797/51Y<KJ4"8MS:Y L%V;;88(XS[14?(OKVX-\^LW1L$^6V5N>(
M(CLGXR9+=TE/=E@M#=OO_:?-T!5Z9CSQC31DQ!]V$T)P/VJ'O^%C(O+N+$#A
M[<'A"#5<.^2RK<V[F+9*&6A]^Z[8I;)<1F50!Z:P"^9J''DYN3ST_B![2O*%
MFF4:*_P!YH7^_U1"-2-)\N!VN[4GL#FA>'Y_\(K( 44'@\-V@"I1S6&07R<C
MY23-P3-RGWY5I-?^0MQ\I+3+ M. +/SK1NDY["?6/WXT_Z;@R]H=UP!38H90
MDMNK4SOMU#/W7C4\#_:]!WI_=$OU6%[$?/(5BPD)D_Q-U.W=V0H]_K/G'>ZI
MU19?K=KIY>G;/2M\_H_&<6,L<#I">"@Y8LUFZ\U9\EWKLM5U<6EE1?&^L_%]
M)M"%'2I@]&!3[U!1NRWEN!C-GCPYF\P=(9\+Y<64 %ZNP)F(V;HOZ1C(7YZ#
M0<JJA[RGN),N6$L9>/?IE4 J(*X(O*\],XCIIF_-D#>!K%R#^W(ZCY1<,5<I
M?W?X(=(QO>-,:G!:Y)"JY;_>TRTU,UR4RZ%@<LR0_FB#=\&XG<&\U7-I181/
MA8;O;HYF0M3??B59.O+]_U&]9?D&O*E"D%>Z(K1#22U=;[2\QE-*[TPV_L)A
M9#P.GS5L4[C3N@/4"WK(=BG2TQ<A$0L-6VD\L/X,?B>5Y',/-ELP/MC!"-I<
M;^Q>OHC=/'G:'1V=L/QY>13S4"M9HAC8E0R?^@D6QA-K>$^>4X#5B\ .K[>8
M2V@X4?BP8EX,QD'S( [5.,GY0+X AFOC;E>;XU5CP,9]F(?^+'&@<X/3HQP[
ME&3K3:N>2-_3U/Q9\)9O+O#AP;I=69P5+$X5;9>_Z0QD,BQ>[?6KM /38=-[
M17I2 M%'U8;*Q5[(3WU1#E&C%OXO#&.AMHN8J69P+!!4]-I3((G[Z;<)7MU,
MG AVA[=I<GFW-"Q<//1ZAH$;$X1W54%R0\#)Q+MK ?\A.&"S#U@BOSX?^\M&
MK,PK#"\A,T7O8>$M#P2"=IN/:*,?+>WVT(]ZD[G@8[\M6NXJLGODX]J_/&PD
MG6@G9:I@8JANL3!8/7F +OFS>NO!(/<[3K9:C61F?!6 "X]9W"?64QB%;M62
MW_O?NZ+!555[ ?G-HZI&HL,[B@Z/$_2%F!ON!,Y^MV6"$8WW _4NF#^5O+,,
MY&=CA@H,K4+X_NWWIGX[]/8P[,6FUX-!DF.AO6U8ZL*%/+8M+BN TLO8HS#E
M48Y;/???%XCH%>:I/_'9$W,#F;M!ZGCF%+OVQE92 Y?0/U*]"L=U>XR6M_M)
MW'\O_*<T#$@)^:^F3%<PWF['B[2_70KU(>K.HHA"\%8/!9N=PFPG5=_[%WV8
MHGS)L7E"+^'>\%9T^!]8JQ'I4@=L#CSXZGSX)M:(EF5F]K[HJ?3T?9NQX+='
MW\6:S0Z_$#EN9AB_5=8#; I=HT<8'\BMA%\A9L[">9 ?YSS"ARP?XN4ISK8_
ML7WQ4U;A[*B2NL,U8* V!U<Z_=L>P'(RN'_N^,_9]_^C.LU#+M0C7.CUN'&V
M(#T5H%9 !3RE I3) %2_5R+K)(@'\K[:&8)8^K5W>AQF^)C=IK*@NWZ<;+GJ
M,YLGY-*3;A,",5LQ'IL>=8,P3>8WG]_3?4@%]-M$SZQ#[N/Z9BIR!GOGW#+2
MXT&R@?TD=$Y(L.6 G.#_:#Y+.SC51?[M.CY=7^F$*4=514Z2<Q^&HRDV"()W
MX"\4+Q1S6*I<FI9O.YFO:?;(='KIGNY897J?0R26P(9#<5"0%5II[8(REP:Z
M$Y(N])F_N=""1Y:$:NX$'O(3I78"VU/<<H4)N8AODZ3%@MR^<;.]'QJUWKE:
MCM7/B/O/\$:A.T5?JV52R]TRO]:M5R^85I37F_K$&6_DC]>'>69@B<UCH1>)
MU?)IWA?M.>M?&I#Z/*1V6?J;0<^QCT+B7I(1ZI+V'_(@S-->CQFC-ZI)27=@
M^#^Y8&R. V8L=8;"4'(JWN+)#XD]N6-Z?E:V1]U826AQ81<&LOZ,(1A*C24I
M<0TU*]]97@2/C=HR*RX$)^#*(OI$GUUY+3KBXM/RW2<AC[/#^DF7XKIGKNM&
MWP\!I6X]7VUT?I.$!&[[&(2W 36#XRUZY,H(B]-6$6W6,]XT:$GFD2@O]F<J
MCMK;3F53B:X;YUH2R*FDK87#4R$0JBD8=WI#@<2F>>@0(#[#LN]@;$;^Y$CA
M< +/9H,JN!('C0$K6/J%OFP7[)]9>)O_B4-C=^B3MVBYMVU&U8(H,3TAP4V^
M&<;I<969L(MJ4:,#UD<KE;"1.E0V%<#5 X]$L ]M2E)X&P +*8<&^(1D\#*.
MEFKZ'>"SZK=_HNE;<9B["IF46%@73;]JKV[C>-W(V5@2F]"AW0L^YU8R>]$I
M+3'%RY3P0R\IE0C"AO&8E6J".M]*#;TTK*UJ*'IS-RQLO;5W[Z.C6HZC*/KF
MFJ_^KJ&F#;):NWIF05O\KI%I%O(':JO(#IN9:><1&$8.'D/M(*N(H!UYAJ4G
MJBI0G@Y->#GDJ11_2O:CNXC%T;J_ZD"2J;*?2J@*].FDO,*85*U7&GT\I/#.
MW^6_EJ?7%/X-[HG?69+Z@%;,W+LA#Y:>W&/(']C)-&SV(Q50<2'A5R[=0,Q3
M)\#0#P(+: -N3,%8D[EC0C5[B#[O189;+4J$"POD3$7JG[AL568^QG3ZM$*<
MNTNZ-S%&-G;NZ<?5!S8@_'>P<W_<D<+M!R0%/[NHQ? N6&*-*A6 _=+9(H0\
M0&D1<!MC.SHV*NV9K8$&C#8]_+!R"-O2][L>5  <\OGH"'6P7$7C&S=*[QT
M;.[L(+WG\G7_7.]<Q*N=)&6_33L>,(%F <8*+TPKDICR11O<?X K/)3$F8.%
MMXR/UYN<Y^U9V-ZVC>2]_E0\D"Y<;>*K8V'PL<G&;>R)C5D&E/&=MDYA68.
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M\[;[?!_\J[451$=>69;P(VY95+\J,%<#;+W.-A?X^N8O+/*7 !AZX8\S@0H
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M! [X^/M$5D I/02?1?-U'U0%YD9&^/S*M&LY;T,$+\[6GOX] ,[DNNW64YB
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MO^U6T)3AY1G[O6:=2?V)?K[7A28G+C'Y3>?OGETV^X/8;+NQ<:U<]R2:/[O
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MOBB&M=((.__\#2&2*$YD.2CH5.AM$R78\91%?4HEG(/2 B.\6R$MC3'K*)G
MNS]3 3%W-<<6R1EJ]4?XGH>>!UA48_#[/26-6YL[#"+:Q?K*MSR]RJ>F8D4,
M#^R" ]&'VQYA++N7XBD7Z&E9+90X!&+,]KW!'Y;99M5"CSBFP^_C^>&AK53
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M\3>HJC\&X5?^-R+B;CE[O49>T-&KH.'!BYAR1/E:207,@V:((JH#K=5S)HR
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M(_;XYR=:?[FMW+P8]O7)QU8ZJM7)@7\24TYG+32UV4S_MRD217H9"KU@P*C
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MMI.TRF!:7!*AWI-$M[Q#8\$]<@[HK>"2W!).%*.G2:_Z,CQ8Y &5+&*LI9A
M=0#.BCIX_T)I/%4%<[W@KE\WQ^+/ 6.>JHO*^D.MUR@R%/LQK%7;L>U'V+P-
MJ[@HA#.<=7[]:=!TKF?F"$I^Y!#7^/0)[ZI]>ILS;3L  NZ7L.,D ?&+6V'+
M$JU##HC6:7_-\N.G.S+?WLZUT+@,T_:/+1Z;_R"+$-._ ='2V)(/.']E[26#
M@8EE[2PM:B2ZWK &]^SXN2=(GO8A7CNL^=3YBO. 5>.6?Z5+KF/?%K.[5;3-
M<8@,?67]$O61(G*!JS\8N[Z7FK ,I;4*GX."Y(!LF_+*_E,S/>@FSV]5;V*U
M7GG[OV"C3LD.,**84[X8P7EPK7'"P0XC>307%J_Z^&N$G"?P:5V#Y;;O^JV6
M!_UO*AK^],S=T%]R !O#P$NP[!/X&]7 KYOJ8H2 ['+7DX+:,@8U.;DDZ^$/
M/X\XNU51NBH_/B(%% 1/F\FLMNRE)%W".2#Q2S-1I@02:!+=0[=J/0N)"-(R
MSJ^BU&B5'W5:]V;UN[H\T"00]BE\Q(X3[+B3T**0NN/<.B5KXVT]T6#5)5/3
MVZC@]JW/\68;PY0HOWR!GP:H$(I_8A<'8MUI\\0C,(UOY,R^X[<ZKN,78'<E
M=]''B4<M/OZ[R?$_N1F@0&CH3"MYID']U@3"&4D-R>VV7#!0D:9A:(C,R4</
M?M]#KPA_%^%[AWQV5(;P:!UQ[P<!R$P&Q;^1<MV0UFX%SIMYE-?C)FSOS47V
M\ZH>GIA7A(\O7)^0E9[5O?^NE\)SUB-4PN6)ES4R8X'K_2N@R@53JVFHUQ.5
M,!:A!DM QKD!T1QA*X&L=P6^(ASQ59<W\W\L9@:;MG?"?G;:5S?L7D9.D,@W
M.D+/<F5#*B66#S\>@7Q/?OS8F%M3BC4)>BJ ?LF^_Z3LV9*#Z#^.4>\TF/YM
M?^2_XIL=L\65I[KMU2H:34E.%C&VA;OZE/6>9D85:P:<LY]USO#TS_BH-_35
M3L."2)W@9 1:B$Q7CT5<S/ Z1#^,93WXRL@<SSMK^;P@-OM/3BP/+/JNYY?&
MKM'.3#?_<Q'/T#MAX<993C@C4<40?[9$4(@BN3I7N:5]_Q8[O8#JXO*6W,O_
MU8RBVTR]>$^G:0'Z,<;:LT;#V)"2<X#UZQ_%PZ,Z!E+89$+KL=_3TMA0!=F=
MTH9,BE2Y.?:B>^T#(&F[]]!T#5#W3C38"9Q\LMAKS ^YY,U(C%7$D93"^)Z.
MV ?Q%S7736(9^'!<"4.WRSK]\H<W) XD#NV)0EC@;!R9#NWCE,M1SIEV\(50
M JN9'@V2CK:3GJU,^G:G[2N#C?SX;\#+Z$B[<<_&;C@%R@Y9CB:&_U!!OQ&3
MW62SSV?:*K]V5W-A_AP0/]6L#H*\<#?>&JIK#1R?K!7YI'VG0IWAZA>?# W1
MU$D*4L4YH$N ?"GT^6E@7P@XH<6HGC/>_QQPE0A[,@[W=Q%-OJ).WC3)F.((
MB8SI'A9@?27HD'JP#TT]!RS!S@&<V^'@]9/,_N/]<M&F?+W6%*S&CL>8,\MS
MYM^LZ-*'4"V4=&2;Y+*,VG1T$=K2Z/'0;9UX9)=*N*E=>X;20?DW3^SDMO"D
M]ZU>/[3,-X\E+T&6NY<E^YE#UK@*@<D(YYU99#\"*)>B\&3&R3QV6M$$6#<@
M-:G/W-G=K"H>F=;=,==2T_[.O+$EI=HM/?+Z-J6H;T$.4D/7B'S@.WJB]#G0
M.]WA!>P.>5WH&/BCSC0:T+DBH%E(TU;=+R/T%6C^O&A/CMAX#J#V/RM0-3B]
M#Y$PQC?&;95,7D-\-]"?9FZF;SR,U>+#@<.""8/\FX<RUM7N:*=+CR]KW_JI
M#Z >$DT-#H]JHT=C$9TI[KUWB"R;_<K:.PDX+XZ^U]/ZN="ZM]P.5-WFPNJZ
M/V]2$K\3P>< JC'B\?*' Q@]I%%W2JKNLH*52]9/'I?GC7;"GS]'#4:\N'<G
MM;W6)B[V'/ "D02N\0"QPE_@1VLET_HJ]"1?-\FBE79X.!HR%*#R*J;OT5'7
M%.]2#:Y_G#E0J J?!M66Q!"TR.Q]VQ7%7?"&DA,_E.S#EYST&4I:\?'(P9#<
MDWX@D"C4KR!YA1SG[E^"%I?/4TV__R(;,A?ZW21]!O:>!T#6O9CQ\-]@S U$
M>>A%_4T,52L[YA%-DQVQTML1O*Y'Y=-S+3#UF3+ FCKQ8/"P*IM,/_:)/+:@
M2CQ:A@)"%2;:'BUPC(4^_3SW["P5=>!A^%[]6J-,"J$P,FZV\K+]NUUL@\3)
MYCB)?7E$_G5CS;A@8V/]=8.P<BX3GPCZB+:K@/7UF<0D<Z+]DJ?;6;VGL69-
M,T+4IR6#*SF'\1E__UW("^/)7[38]G/ 5CJ!<P#$6)>4S_RRMCJO.XMC#S4L
M&S >]N5UQ<N6*PPU\JOO7BG9&B\_0VP=G-*2M/!K,3F24>AA;ZP=SOJ;S;V8
MY53<:G::S.H<A>+.3&5X DGGK*R#C\1/> +A[46]YY%,Z3T\\7\_GC8W)/<S
M"J7X]H:>RH+L'XWC.+7-#3BE>K9?(=I-^3[AF<5&>E^9MJS&&\AV$:L8-WV0
M.6WZ0H00/CQ'/;]XG<.#7BX6YNKZ"LC[)8HM!7EJ=U=A9*$U^ 4U8.M@;9/L
M9_P?[17_->@;>QE4/O<(:HH)<0_^=A\A,0O[/K/Y4'0GTO_F<TUN=??D79H+
M(N+93\*8C?Z-;(H743PX!K*O"=!E?FEJD>3,,%M]1 .8/YWA7B++4FS(7I!<
M4&,?_)BYWKL8.E+AU[FX*^$*/N@\!_SUM(!R(%9TICK2SP'RE4A*Z&!E\3E@
MAO(<\*D>X%_W^'\>9/C7N,9-)?#F.5GV-]9BQBV"1G\I>.)O(?#'!1N)@_J,
MF4DJ1,_E&/P63]Y(.01N5-V<U;VP\9B]OO<P?7!/E?E[JH@E7: O&T!?T+R
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ME&,EI./N&-X<K[\9_=!HV77/&B5$^Q8CZ/.*Q$$^#',_M!NFX#9/Z4S["2+
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MA &>C&Q!+U=N$]951C^[!#O*?QS;V-N$OBV@%M8_JYA^^!KMY_$(OFWLFGA
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M6#Y+;485UKF,'/F&FR*Y5L[&!LX!5FU)EGAH;+B8];.AK^M)$CU"?>1TSZB
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MST?D;#'P8B.LE79;B]\_D5BFGX 1OA[<JIZNX8YR-\_&GYU"AS=>7$PV?U?
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MW[A]K#7JX=:2^C*ZB=19V)<1*7&K[PP@,$PA$O!YF-\_6N ^K)M)QN3NH0-
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MDM)\6ZD&SZ"?]:'V\IH/4UK];)X+7B)Z+5G%W)=I:\<>3XI3P8@3(E[P7#X
M0'I5I3D*#P @Q:E4'L4AJ#64,3#E;NQ.#-,2\D&#LFUTBTG;R725YM'OJ5(
M%M_F';)<4AOTU*J<1M#A$=N@B_N/[];ZPN1E]KN/SJB4 7V>MP/7F+YJTY!Q
MA7X=/KI,2#X A/5M0%L4SWIHW?;Q[ $]-#,F</J'>3+E0.R2W"XD2\K1,[SJ
MHH>I+4/TJ30&VS 0?J%PE?(J&[\#2V-MFX^>J:9R/SPF<7E<@I(E__SXUPM/
MG>,ND6[:<"RX&H@[$R]+Q53 1\Y^GCA7TY^Z+%.^I>D&P[^\8YS]L)K%^O.]
M2M6.IXXX>6F2_TS$"A->EJ!+%.,/+MI^U9??4E35>I7W(\@V A5# <,E41=]
M1RPWX^=M>)ULZ=>:1A#4XV+[)O;P"IM0*D> T899>O0TTYGLB5M0GD)/,8F<
M'KM+A23#<XZU+-_&>5TO<$V=?NVP%SRPIH"VM/$\ "BR?>LY $"93:JXEXGB
M-)OJ3QR8 :ZR[C_U.?Y%BQ\2+GQ2_7+"I1Y*V&KY'^*=JXX< :-O^T1?W3A[
M,A3,2IFQK>PWLCOGF-.T+%A4G '=S7ZI7[/>D7%2YJ<X=6TBD<W;1,6D(XE^
M\E&;+RHTV:NF=O_V\T?N0M]D8R1("[+NYM$!Q\IJ 5-O+WU>C'F]NVKN//7<
M9TWH>117RCNU"U70;D/%"*['P?(:D5<RF"2)-$]]4;)X.X94X>3#255VY*=6
M@R@G"YG^^C7Q#,;*GQ:;?VY,J5!;4 @;E$M<;5N6HH'3"KG$0JK$O^/T.F-)
M]]K#O*ZPA<I,_:+ 0#3ZH%!W-%\!\5Y<2G)JPBBX*TEC85;T7<>7)BXWP'PC
M-2M807"#%E8=I@X 3+<*3(R76$KMD_J76&HJ]&UGD^V>7&EJ -/E63"J:K_M
M*(:P4CL;V?!)4?426'GMU;#U,/&WVR97M#[&6E>]S+*8>U4R\#:BBS48!1Q8
MQERAW_1&0C<T8P ^^6V.,P)0%H@=RO]J\I*LR:FS+KJ 2TYGF,,X.MBWYQN0
MT[@5G6G:#QJVFI\M';*ICC O3QR>F='4C7.,[^3#?G7\OAD\%S$=N=\>"2 J
M$=PIK[9!(<:$NJ*']KN&-OKIZO4U@N0*SE9N<CMJ#U[0B1WXMA,SHO/9#]X:
MJ#1CU5NZA.[G*S51MRUZGF%!][HS3F26@MDKI?VROB8KQ>-:6&%6XN!XN12/
M</^3OK5MXFJ3JR-#OQ:O.@<+N97C17M;;U^/#SKBQY::1LX-9&3V\/6*NL[B
MXK7'-3"VBE$.VUF;$S'B(;$AS8H:%!%:(I>@*OPX,T*.'Y]O4H>7:*_SSUDZ
M%_9&4JS-SJ[ZNJO*Q5[\M=,)X^U XU%*C.(C809J5W)X)C1K.2FY%?.LAR_&
MVV'V!JE'C/5PSU5I,6:BX8+COQ:0OVK]&3B8&J_BO<A0S(A@0FB<MZB3[Y([
M-2CAR3^NHY?_H,.G)WJ^W4TAFTR%&U?\XW4=\BOH9VOJ=6H?SRDB>BK%)/J:
MENQT*'%7^9P7XN001J*;B=7H<KO2DX\6^2/59T]2/TYY\'<> )Q:\:A582SE
M;(M?4*9__BC1IJ61=3C7WV[6L=O1TMK_\MP=@)41UUQ=/*08NF'$%,)SD8B;
MAH<EJX9Y%-:-C@LC,1*449/;/95_U*MFFLJ*76'73=QDT;3D0!4'>02-@8#4
MRP&RQ(CL2:+S[>&ULP;?ZH6S4$(IUIXN-X:]$MU>GL-( 813]U]9,*K/!(,5
MPQ2K\MN$@T&,4T3OJ9-R/J]T^TMX89LF*8N/$RS+=:[=WZ\6XJ0_F8K-5Y@H
MF(HA"B0ANQ&LBYT(G\<8=$M?%QQ39?G@#>DJ)Q+W^EPG;U?&:W)O@PQL1/'X
M > Q$W>:C#,+9&'WMJ.-FMUM=8[3)/1K.;BXUGZSMWJOB@JX).0 8"',H[41
MT[:AG-.;/-0SUYJ8LZH>D!2'AXU]E,L^OT<CA_P9')F5<Z:Q82::LQ5$+ZX)
M/466+"L-!['8(][+2)1D?<2\G#EAY^A--RHNM9STCFEM\^:ET*D 4TI!_7W\
MUG1"6T\9IZ/;"97HJ:JZ+=&+)KWL+"] X!,'@.M$1.LZ:X!=$D%D4(@*\&E1
M&IHTQ'.WHN\5G3.;PX@^N6'5??B&*HJ0&FC*$PA35*$]+F1D<B:IU8S)".^Y
MEE3PF8;$^/%%O'G+=8Z*ZNN\HUQM?YC2DZ7IHW2!P / X2$:_;Y;,N? @Y 0
M!F*REX\<Z#W&V+1\=^'N4SQ&+4/@P^K^ :!5=0?Q/N@B]+-1D$3+#$6,>JJ)
M<11"?*Q9345[>:J?M:[DVP(]-7#+_'QB^.91OT@R9D.8?)H>J_IEG2UH,$B\
MKF\]7ANO76$3:/5>B<,R'#/(_2*J=>L$]-CZ&+I-:K+<D"RPSJ&^ 7WX32(/
M+5%7T7^=<_\R55E]7G?QG<'1!_O16VP OQ_7 "J!1G;;60)N$0UI1'=N+#@I
M_7S_A<;J*.G8>[-+]"X/F4P9FS0(720F D]_!;<8X2G1H#:R(Q[Z1=C^'-B-
MVR2=0^?\AH]BC/W>YG_-"A&"O@))&&^^(A?=)+ KI[XB:[F\9UAJ&$6\"(96
M.?%-R)5*:XW!^*@\DY2G'H@G_UHN"L<PHQ-WOIDI<>&E+\0I,^2?A]U:_BSQ
M^,>93_S3><^RETXOL>FVG4")W>WDNO;,_93.;?<!Q*+9V_[KA]U4!&=:JX6\
MF-["<,/E"QD,W)HMR4]R\TWM2D=O7ZR.:D5V X_KR-GL#?.$_5BR("J,D%\X
M9FO5?XKFY5_;JU+T@*8S>6@?U3G4= WJU/1J;S*L\7+ I8TGSP(%RXA95 $C
MMJO<^IVO]./G!<(. (GT<3>Q<M^ "WE5V4;+B]:7TA+JA[=$3W=^Y!*6(]<
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M2S  F=$F\]/K)P< 8N<C9ZEHQ/C:\Z?> 3EPTJIPAL0>'21M\APYAJA=<?(
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M?X0#[8-2A%;^3*[ ->(>O@TLX6\SOA42QN<&5ES!Q076K#_8&$HL8<KO(AP
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MQF'?NEU&YR/9M +=]5J4K]%&QAONWY19>N%S8)62H,J2W=<]$M5^%+$-,J9
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MK%BA&6_:Y#RLGITR$<FB(R>$-S>P=?]G9@)?A\-GAG%).K\F(N&!S)..U&U
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ML_/Z9EI>@E5[O?7$O?(CIL_;GZ?,25R^FAC(LP@]&3EV _1J5OOJXWW")OL
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M5&=T_Y^*E7H8Y#Q*51O?3!5K(#C,S:91??V&T(N^X2D]AE_\(33O5):!@[R
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M43:7:=KSJ1F%;*<V=OX#VBFPD^OYGPYQ>4'L@:]0"'AXCILV$]L<Z-CCE!]
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MMT]KEOUOF?"_M$RX];"A-.(0(GW@M]G$7$^[G/TUXV#?*[F1F*_<"K%.;4>
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ME)_8'&^-UKV>7)?E);(D:'3WP&+!O"*X0FAZ>E&J*'7(6GM4BO.YI=[F7V)
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M-<N&,WKC3C>#N3ZQNSUT^T.:?]+CTT]S1?!B!9>R_7H6V\*IR30(78,:ML@
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M\*PEO ZOQ<]N(U!S[31E[!J6?K"2V:8MK83C!CK39M59@.2MAUC*@4<ME05
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MV[W!<;HZ>705>S#2\35CB5U>_G-/HU?!Z)GGX6P)'06".JGGY):#(WIHDSM
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M\M3+&W3N3P^$<.BO.?*#"GX2(0Y!AJN6#:D>1??/-D0_=.MM9FYRS#;B*D_
M1SFF+,A<!-@/6Q.CR[-_UAS+VH,<ZH.OW60^2Q7E%CEZ1PYN]'H"'CX!JD9'
M:0'_J($3UV3MUM.BPP?7/.#RVSM'.H_=XNB7]872QY_\O)>CEYAVHUB8([K
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M'8UO#EI)ZW8"4^>Y"4^1'8Y,BY1I;]4/= PF20<UWIS9Y-AZ"'!FS-9A$VK
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MVLQ,J3P$'+PHW/80<.+/"*;SAL'G/X _[ZE?SD\)"0,ZM&\9?IP[XNYTKI]
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MK;?^N=7-R[^5H.^5SOWW$?#S[=K8:-M&22VCB$- F08YK%R1_!V((1\$'@*
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M8P/-OWRZ]U<-E@9)P6=N?5OG;'T */)2)8["WA_S4L+PQ%E(4=3$D8,X34C
M[B7,@E?^X]H*G>!2+(IL1]U5$X,KMA2WSTRDI\\U5&',,4LX@X +%M8!EA=N
MW,WV6'R5\PN]1Z-+KGR^91LSQ!V(3^PFZZ(ALRA])SF1IIZ\C]GG;@GSMJKR
M=/,3MBXE:7PI%!%J://8ZF>/S0[=2N@J1\]1W2UD7;YY"06A U;=JU,1I8<
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MMNS2.98WJ'(/IX^[^5WB8<-=8=%64(0%"J,6I)\?<[\H8G';4S;PJ9C?CJ-
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M6L_+[;_[:Y1.$.72I^9@T)3[NQ+S+W^Z&6RV/N9PM._DM?3C42\+K*P,K8)
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M,BI&VQ7JL<;CW%9I/D?L"!>/3.L517TWSHO^&+0?*::?4+YF>G:!-6AC6G?
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MM;B8'UV :BQ[&I?X'>HB@<)[J$=GU!*#7HJY8]HE7F JZQ)1MY)>X/8V^U'
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M+PHJ6XYKJ'/,."1517@%E';YUSL!A9OMO/5\',C7'I;8EA?RENC&BK#+9 N
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MAO[9;_&+U]XNQ-T'1)E=5F8#G(5)K<)FJX!50\ET0]: 54#[L6&G<='-4OO
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M+EUV@Q4#S<@:7H:)9+W3.=/J5NW)'_4#[+]$ &3OX.);1R](#8U$?CI!2]8
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M%2Z_]F ;J*D_I#:[R[)4[G^.&EW*T$/C^ED;-X)ZEKLE'4:02N-R/],IT)
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M^&_'36/J+I!ZS?%=^!$JET%C\YB?S-7^WY,_,.<?K)^F5,/""GIWV.^<Z%W
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MYL[A%TMJM HX?>GRWOX'_\5A'8A<U+HG?8]$=3T$WQ%,V$?+,^8L;0Q\K^,
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M@Z=['J<^'^-EB+-QCFNIB-M+E,8?JOVLO)3/[P2R.DM$0[!*-:;L0[&EVL?
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MYX7R!!S[QUW;8::-S+<!Y?<LNN)\0[;'%9-W:59/#\\A;E(T6(5-WC\AR!V
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M.GPIZA+1OV>BV[O)4%?+RU0M^^.TU3[WQ#!)!E9D2B*'\\RT.J77SK9WS_3
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M!UW%9DXHE.->W)L0_ 4D"V]Y_T+TS=?/6,LX'$[_MV>CV\ JWIP/>$M37R_
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M-Y)8D$[E8+4AKM-A[\)5?1DXR$;@H31D<:4;TX_!_SYL?.C*T'7*]89<*QA
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M"=K:LX:_< (*:HL^2"E507G"GPCH,6UPLA;[R.$;]6O?C8B)V>H:-;?SA,-
MA52.&:P Y^J_#\^RLG*!)T/VSP8IC^B-N[CVQ,SW3,QC/^2\_U6Y</Q5EB^H
M<;RU&53Y+H@:'&N]4:34]MW$ =+//D"5886IN=ZX0\4S4U?N(;?Q+9/H'7)B
M7FJ3/6V?4 Y$YM1DR\%\0E2H'ZTT:-+B[KWIJN5>19O:^8 0_*> -3N^'E<
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MP2"5 [4L7!#L.2>0<.EH!G<J0&[*'62+]&,P./ZI<T571=E@>/"L1" /1AH
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M4^(BSV:8<&G* A/]TEF4"MM:2?N81N,#7'W@TRLGM=LQ_;>*\XL\#+14%_B
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M7ZI")8JF=3D[?QL?4(ER:V1@;42)L$0?%J-;8@OH^9#<HS$!]S9X32^Y@]4
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M@88X=GB+RC/]F/;-NTHFB]CS?,!=J8)-9M6W 6NT]830V]YQ3N$X4HM9ZGS
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M82OQMM/3=QFO;EQRZA&45I[W/0$(N2FY$85'7O7WG<<SF;W.S\D^"#BR*?L
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M^FIY/JQ-/=0RN*QN;W@!$5/%"DZ.COMMW)0[%=@N?K@YCMY3/@%<Q)//8I9
M^%9"\R)#$N3;2/$HT9[#=>AQ"%?+T_Q8$.?OBJH%Y2LW;P*4S\$-<Q0L#6]@
M[BQFM2FD#NX-Q1^)N.#_SDEEX&T/_'.T%?P+=/4/TX4N.#6:X1[DA*T,]<Q4
MYI$:CW5.:2GK5$;]I>H0QKNFDB9W2+&[M8<15%WU5+=K,(A-QQT/65S":R9P
MZ72)U$K\VR[0"U_Z1R 8/>6\D+2%V'6P)L<M\K_^C<4_R&C^.8Q+= J)\'$0
MZ;CPJ)HEV]<QX*FRYWW[[DPJ&VZA*YHB VNS@G*12WYM2[VMG8(Q34RW0:Y5
M/SS,0N4(+]A&P*I>Q5^E7*8MT5J K]5AI$FRT+PJ6-T0K*YP OB%XFEN=FGO
M@9.3US%W'KU4"*W?:*\*&1WIW1W*>[ZQ-U@4UY)K*6TN5B+HS/-QG5,4^A%?
MEF$35VX1F.7:2!$U4*K?11\%+X@2)*VD BQL63K1'TX NYXG@"2H&'V0-,=T
M5TTP\$&8OGGZS5&A6JV8A]C<2N3;"C^G6];*?5<[X9GJ8(HO61<!6DR*HC,3
M^/_<#@,_0:*3G[\LU^.]&9_CBS$=0_\M613=(B[L3#*0\&38+N5)+F)G5NEJ
M@DC#AZ,?,R[,-(%'T) <UKG4+>!0 0G<D )[+WAY^?.%#!"C:T7?!#^B^Z'7
M,!],(E&L=REC^%LO$6%AFJ9L8C;T <+5X[8$UJ]#C!#++$TR[\*?9+I_5&BR
MG9'&Z1#"^TQ'J%<J78\-MK(@*YTU1Y:#$)8S>RO<O,GC#6IE:^J;1YVTQ!9N
MPE0[NA81ZX0FIY<'9C[,[I08GE"=^@S!4Q/4Y.YQ&"F<L?-<ILX80.GT(:C4
M:*C@;D@7].;PO*X[DJ(3:-3X@K[JM!+^\SS;@48M-?($T"9V O#PX O5HS5I
M2 :R=J@\D;5I7P+]T)28>= A7CO(Q5_,CH4%SIP K@\URK6(2'S6&P!G>6#W
MA!&\OV-+5\3+)Z<<?=-;B+UUM[H@VA+&2:(M)'<?8U??0P_<][HU.H9W$?UN
MW*1Q"+APJX;^KR;]6U,=;97\QCC#XD@V.7F:2#W"ZY BR)I%X.LNG'3Y84BM
MZUQ?;$\''8Q6N_I$9S>/ADJGBISN5 <X7S+'#W06G++O0)W9-<SQNP)QZ!I7
MN"[IEFH3:<K>=_4VMK]+*OK<^' 6@04K2@JG-1^$,$F2$C/;/[4OK+%2#,S]
MFG?U $8XGI>&-5=#9X[W;:]$W5Y?6"[O4?E9(I&YLA*;XZ" @!S9U#6M^5C\
MQ>FVA2A1!G3KL'9;C29V'J!6O .-V[+C&&P%^D[[!JS^^@$CLJ-AW0%XC4LX
MU? 1AR [FB1ALT-PUTHF0D. 5E*+F#P^-!Z^G?0T64BEN1V(:=HTJ@/>:QC0
MK,8HS(=.'(>>4N;YQ=,&?A>((=70/JCY+5YIEH_N\A<XBVIY?F')4&W-M_D2
M@#4FO6W?VC"T2J.%9?%<%\<) *G8L3-5WYGJXM+=&6#Y&UC#NYEN,.26U9@D
M)U(#G'7&]"02!S\L-'EW6[:/UNKYKFE7*(M 7?0DC-*RR$[#S4E:Y"?[XLU[
MY5IME('-E H^LZ_P]*GQE9$3@-4)X"Q59Q?38< SW&''/O)M%&G3%[@:=3Q]
M[V/<$Q%/Q4B/-$$]G)HMX7!!\;T\VQ#5<HE?]6EK*N_-!E9.2,>9)&D%OHQS
M<#M) IRD0CCL. %,"I'.#1,]DC[IO%J44FW/:CT^4DQ2]N'XPHN-D!I1P._?
M+]GURB-2EP(C3AU(V2DF3P Q&FH$Y]^JJAY;,N<VLO"-X%SO0.ZEP>TJYD=:
MSA()/4ZPN!- 92>S8(F*O!<K@NN1VL_B GGI(-$^X]:YAL,I6$IDEH6G&UOC
M1HAVVMNM>6))P)"<9>BL#7SMT@)<(-"RR]K'#<4]6DD$L]OBO0!A[Z$>V3AS
MI2.;O0H*+%;@8M.893OIF%;8U)=2_CH?=.]3;Z'S2_N67W[;JI9[YT[KEG-:
MMU3JTV&Z!A;:"^222IFS'H$08XP71K#X^R7<G^"S[>?XXF+^=".*0D_W>H'K
M]/HBJCTMY03@WLK:3K_\,\SD]YI=[W6B\LWS.X-.FBM%+;^HPS^.??!&#=Z%
M/^^WBQK/7O9U?-,X79'FA"\N(QUQFPY(CJS8]4JXR^4^!0>:1J*#>#=%)7M$
M$.T_:>/3H>:[9S?AN[$]BY*W$#V\3:X-:7_]WY4(WIF]\KYGYS_=Q\E (I,C
M%UGB-%AH670&\NJA%HK WD&R1M44W;4Y<+V=:!*NTV#U\*[((X6I/K)O!7QB
M9]&9RI9*BB+W00A]1KN&N9"%2T\03LRM94_?U&0M7M1YHR*GS?R';_X^<W#.
M^ (+OMZ9L(HA8?OKTID.D_PJP^#ZP[B6QCT+K:AI)5UH[QLCA;+>]KGDB1!N
M$//@\_57&^:KI04,$@%Q:8X7BXQMD 6!Y=LSD?:*97?*2O7NK>H:^%B-N*H'
M2YN-P-.')^C-L/E/IQ"%N>P M/(#([KA'$2,@)5;HG.C?GVM;^Q]D1^J'X(A
MW\Y=J_>&P@SA_] Q:!=@A,;5$9'A%LTE@_OZ:*MG)NUR_2U/[Z>KOE9/.\2Q
M4VG0/_:"&A+0WA/ S\-8C9O0?RK\Q7%AQ8%ZAR;_4GJW]9/DQP+56C$^$'"-
MAMG135E>+2BSJST_&GP"F(JP(W\A"/VR4/BXT'I[8\FXVK5VZD- '9/;=W\=
MIPWE%C[):PS!@[NC=WM1"B6UQRC62VZ^8$5VGEJ1!SE.6(I<:.Q8 -):KB"[
MZ?ZR<:[5**1A0*Z%QTTAUMZQ>PX$]JN;6S-=\. G6W8UO=X4X!J3JH6HIU5/
MM[7<.L='W2@A1QK#%W4^?$6E/H/83>%)\[7]*.&YJVZ=^O5]B9?S/AS\0:R4
MT!G;*:'D$K,QC=M0S!PG;##4?.%)?>W/Z_97.K*".*;K5I-O^@DVI^96!/-9
MXD[Y7I)^N8S0/@_$]RS-1= O#6E_"[I[W_IYQW'ACUO)1(C)K)J$=>\O_+NP
MZ;P)Q)V2*R,%=K7<9@;#\<Z\/2$$K[A4T),11\G@P\;6MZMZ1BNZTCH2=<V>
M;GICZ$!\\<=I^L+!J?@3O$*$0.VOK,_>'=ZN79-=7?]S9S_USL/[GW\O?\X!
M\))!;@&Q*(50N=TGJ^.==A(_!K?-Q%VJSG>^>_N2FORC[<_.^JF9Z::RPCL%
MZU UA( NN"#T_MHU5XV+T>V'*BU2'(@P[X6W2)J]4>JAS_K8H!=.<\A0+NQ"
M:!N!@31(*_Z/_+"9W2A6,K>#AV*T+TAEC#>NU1T,&7+%EUYZEWA%><2GI%[C
MU28F6'RW9>[!=_/E(JY]E81.R7H!<X1.0 #D@4(B!.,JAJ5^EW4M[?MBKTUL
MJIO+*SELFT=\1#&0H]\>0IG'\7Y]@1,%/6^% ?=FDO?S3ZF";N[0 ;\6*C)/
M+H1WG'9**I_> %Z#>MY\VF;9@LXGV(6.1Y-%<?AV0COI.>T[>N%TUKC8/#U5
M75*W_%RD*^4_RH"RU8:Z2AWRL'.(''@G7 ]$EN:DL@MUH@#DY@662/LK"WDK
M+<Y%DUR.(6-(8Q%:5%R]5Z*XMN)<:D[>EY*8!>L)ZX-OQCT+FZ:K"2[6_KFI
MR_X6+\:'2,'-;\W51BU,?(FY"D<%SCTB!4V9?I5;F,VE=GLDK"V):RY!IMU.
M>8AHJYG3)?65D[?OHUJUADN:<]"5\3*$L\V4LVQINOZS]_]@02 OXI^E.7:J
M'+1M[BIP_BL)QJ8FLI0QB)S",+I]>KZ1VHNE':1(V,U8VR:=2@PGN10AN21B
M1'IW)>QMWM6?([A=3)0?$^2)RM]@\P94Y/,FJ5\KO[S9DAN8]<Z-QUM&)OP:
M/C7W>@4^HX;26)=*;DG7L?6#/74^*1CDDEEIC@DH0];2?:S&]BV5PB\:0]4M
M" 3IPZW'=UX/(YN-F#J7IUH:W@_<1][W5S]#E;SR^P1P0XU_R<7]SFYQ+:0B
MSE%*=#*"VC"5LV.^W@I3(3N?>O%%>PXRB"1$_HD(E!-2C+E;@5^NT4I?%/[0
MY$1;]OK3OHW04B.QDXU/V8&+UM#B2M#H6QK+)C#0!(UWWUKV@?DR5R%#V@\8
MC"DCD9EQF6N7!@(WW':M? EI*Q)>WCG.C-JR-2;>.0Y5%-& VLS>834S<8,N
M2/DFIWS?!1=1<#-4!M9"+W(@$W;S#=SLF8%QR(4J[-^Q<9X@UJ!!PW<<"3%)
M[@_;YI-M!3_2[Y 5VTAC];.WQBJ14Y(H".[S4PLC9N:9V.Z#;=D\ UB.90QL
MON!42O"CJ6PE75"NX;=VH"LL,<>1Y7I^5J,<HY#/X3_C+![_,4Y8VD=,S9$E
MY_#=B_9GJ%RTS-/FO=S<LY@4DQ0"7NX.6TE2>9"[N_U1J/XZWZO[W4MV1"A;
M.O>C@8K&U6] /Q'>X=75./WG95@)RTWWTKT-IWY;X;2CL,(@3D7DBIM:_>2,
M[3'XY_&74XY\,T(U)2C.@\*E_R.G);V&[,[K'&,/*K__9B4Y88ZUD.TN%CVT
M6<_1 ^"6SB)3P(+,5D2Q&YI#[95,3&V"D$$>'6<UXH^L![X9W%H6FWW&,9]Z
M6[:K8_49[@?=!^B*QD8OL6R= $[KTT?674*SNQKU+ZH[=/B/A7/+% +5LOQC
M-T(GI49[9B1/ 'T:,YL;( 8JA+Q"2*)?DBFF/MY%)0'&W7WY[2#:+/6&X:K&
M7UTRF?L>^%?H7N\!FIU[=S_"UGZ#"-S:DEHNDO@2_LU$/[VGL'7M3L540HH;
M%KSF6;&(KDLKXF29IH#>#'OYM)B)0)/3;#S,FN %<S4Z5/;,>5PW.L'N%ME+
MNJS8U72=%?-66-8P<O8B6G,_:/A-!I*^ME*^/TYGYJ=]"PW:[5O@?*<&V8WH
M&(=<.$STM55P0;;QWOW1[U5<OFP8UR[9L- :B%B6I%]J*Z:/V%^'N4HYV))M
MW>3Y@T$<,YWEUM-NED:=;-<VK#_GIB\@<U!"%,TSR= UAK+N ZG3:M36D:/G
M0631S';*J2#C,!*-?TOU^#83]@DD_.=-E+KRGWT!KCF-E_Q"ZQ'CL:<.[-_O
M5?$N/;4)&]/V-6Q$O(>QUL96TU0E?F0U$1R3KCR<IIQ5&6#!.69 06[#VUM;
M%8 .P/ED061G<25%U8J<O;CS<5P3K=#D&E@K(K&OUA_2]'CY;H%4K4W5Q>V(
M>CPF7 VR8,_SO/4$$$GL"W/[ASZF>%*T5ST9_L9-WZ.JCA\U0'N -V 0E@18
MC4Z,AP8OV6[P;HNZFZW>1OV_U;EG/!]E8@XFV?CK$KU2@$+V)<#=1QYD<5P7
M2" 4G$0*)B>4,$I'U=[)]L:7]7B;Z!N$3CQE%ZZ+C*&= /A5S]FK?EZ&;Q&]
M)"KS6I"5YPMX_/VS5U970P?&(7W?#I1>&*RW:1@&]DCV4*8K)7MLYVPM<S/6
MZ$OK59L\F=[L9F]2)RQ$EH_#L7_&!LOU!"\K7D^.P,RH$U(CQ@F"HM").20#
M50P8T5026RQ(D$V<>29[Z7S(EP]S'=JPE<^8GJF<RT>A=^PMN6,*H@KZQ,=*
MO[%E-0TJX(=ZB.J7S(WCE^L3X[*?+!\DMF;[#_NL]>LO)H4_<.U'E5=A)_MR
M+GS230G[4:&,X]NW=<JNF-C8U0HH_IOI7R--+DY2M0(!XN<IOCO#XT=FM81#
MO"V!Z =D#PQY_-ZW@\GG-;YL9O7)P[@_^F<+5J$=R\SY: _J!0)#I^!EH%,V
MD#5P@SW">HBJ>/50MJA=:3\^^=N9Y2<.74N]$=UCJ%39!:M7SH:1W"JCJ^O#
MOD5]?A8OJGK'4$E9-(Z2;)"@"F)VI8BK9U^^'&E^@-:IK\K4Z"4P=, NDJTW
M5-5#;.J&J^ZHODY\=>?%NX[WM8QTUEED9:AQ\8;G8[]"P\RQH1^TK2 L6Q5^
M&J_4QOU+V(_8O;=_:J@2X$A%/'!1$GV=?$4O 1DFX12BRVO4\%AL^M>RENMM
MQ WFQPK!86$XDC2M!GKG.162.N_<09._6QPE'/E&OSN'^V/6'*]C..MAY3'N
M9G#.Y4-)LD=<P;NRCPF!^JR/4LKM+V\\SKIN9)H-7ARV"?)]V^\4NH[]%U?F
MHEOI>*4H?^P8F5M;.TEC>!%8HXULH*CW+WO)WA1[.7G74&'9.8<P5+U##9OO
MLVDXP.L\KXTBY)[5O!G6F?/N\Q$CM]+.L>7\'/X$0'E.?42^16!_>Q"GE:V?
M:A0EZ0J=(' ZC3R18+S6L-9#U8F(7:5R+IV:W47ZSY+ 174),=_/*=U&V30-
MW&WLS(6_'\ZXUM_B5/?**TD%<2^,6G.[6WWNK1>YVLU<OF_N:10YPJ]:5P]7
MP-A47K@[V86H1KY8DK;2EEZO!]NT9)IE'0G^D_FH<9/L\_N21\ BTR,F1=W&
MYYVM!]^HC0(&S=?]PZ$O^\(M^19+AM3"%A#7\OE93".,@NX9OY[),('N7F6#
MMFX>'9,W*7KDOB71!"3ZO<KYUY*5G$_KT"FP.K9^6E8G[R/_;TIR'=H^</-^
M;S0+5(WJ0[Y".'6(+ D54I9ZC7E8D0QU/2N69.&Z!:Z"*6TYAQP^CU\]W.Q^
M+<J="S\>2+X6U>/"(G.ME<PMI"R*#/M'@IM]I*R;ZO^NT0<-"]G,;)7U9TM)
ML19-MC*H)--CFZ!%,XNTK3\,>=T-5-53F%@VC50@-[5;6G-OUIGHIM?4%X=<
MS3M#+4_9':CT6&)BT1V]Z;,R,V&%N76>'_% K..LRAZH1.\(0YH@!,2$LNX^
M?C&B)L/3_]U&YU:DG0/C;RM;I;[OR@S!I93:H]DKXGF2RNTOLWQ7K O%,.Z^
M.!&.K/$%ZQ((R 2YH)V$7%U-JL%E9MH"9=23"N<66:)>UN61<*;AO$JR33YH
M#R'4F4,<?]DL#P&5O!C=1.]K3%Q5NG29L-T.8,M#9;<V^<M3?X=*TDK0+BP)
MQRR)H?<+7 CR8Q\(C^_G:OM$1+HK8%DC5F5>^-AE4X3I$^A3\45(>D9V(# 8
M)@[6ACFI*\Q$4E,NRL58Z5J]BJ,D*F$,H] @Q$*B!-N^_>L9O<]J=V79\G'L
MTL]+!PJ+T[-:S'*3&)BR5/:-<+J=S<V2M9)B^S*2.^@PS-H)P)B@ "_0DN^J
ME)M\S/4G2$Y3X*N8* .\R,<?QDYE*OW*84TLW)>5^"GZI>''9CS"P\=>A#XQ
M2#49.9#DA44K^(_?613KG.KW)RUXCW-+F(@_]DU*C8^8CJ4:$N#Q0%?,>TYK
M_QK$^IC]I(^^T#<#:__7WU_P13A]?1GO1PT9'W ,E7S\H'VPG._9*[L2^=V?
M.;:&;@'N$LSX$L9>@P-1SJS1WZ-IZMEIKT A(0-V.RU#% G2I(RZ.\Q$U/9G
M]#.(R<:;\+$'<KJ2SFY? 1F_>KJ%:D-ER^A3]BP(#8G94'GZ2$VLZB56SBGA
MCD*,9W8 I\?1(?]KP9#$%D][9I22VPF  _VFTJ>#(SF=P!=\X2^>(<N*/6.@
MGYQV$Q@V$=:V$29Y5+,K@NY$\T+_92$F354:&L]WDLIB>AI0+Q49:^*CUE!Y
MC0B/2+)TGB)[8H9H'M#,3_GEX8> $@O=XJVE[R'R3IFF><7^TZY=-U;2RKJ\
MTY&3/I)$9!9HVPXV;(F?(<B8#FHP8,EQOWS4!S/$<_1=&&8N_MGNB/39:PY)
M3%^ [SX33% 9CVMA6%0'=?-4)//:0H_Y;"-Y;X@VXP5VFM@"3@";^W".KX2=
M:+3C%7T0W^2CS(QC1\J]&RW35T(>1<MI"7[%=T+-Z;UT#3(&&!$* >\N/0W'
M@9(Z@G]E631E7301:6:*C,6^]#SW<MFY&" JZ)7J:7B%MZUA,L1%]ZZ_1)K7
MQ[:]=FPA_+Z%3_6H!P?)>BJKSMERT\RL0*3&Z#"_2#BCR497,7#F<)I>A[07
M).MT*%X<UQFK1%2=<93M1/L;?6I?->>[YCJ>I[([D MM<MPN.\^9=/C2DY*]
MG<AX(?C'!BP7IGP"J&; \R\AF$/#AEI8EOY@9S=-\G!BTH7)Y[C'A0X'.W."
M-E0 /MW61-"4SA(Z <H#'=*X$<7XF>RT-\ ;]S%CX5^2@OIM(X6@$.;S*7"4
M2K!EV]#N1N%^EM7K2@LC1'1ZL.FA\G+9J5_HD505Y=Q7;PJ*2RD1+]6L%Q&;
M,]_=L[=T50R1R;01;.%$R?T[:- 8++/K=&5-(*AE_R#DQ9\-]R*VX8KLAM1T
M"S=_Z&JD!_ OZO1QM3,5S'D*8DX "'(DQ9?^;U9T%_<;<=$^4$1C]/L&BJT6
M_82B&\.1@M7N>Z KY!QXKEC6'#:?.U?+D$0])0Q>N\"NP9NI.D^[F#;U4Z98
M!-X8$QGR@)J&\&BN'&U=&_D"\1"7U^P2@3 _<1GW4FFG<3EOUX:J:G_M'6[*
MG*,HEX]]<J7'=IE?4Q-ZX3O04X1@%Y,:%F_7X<'UP2948=4GGODS3OT223ZU
M*E1WUR/R[W5RM'7=\!WX&:'/&KJJ/RYVOJ**HMTE=TM.R4N2 %J,QHN4KF4T
M!2M\+ J,4LIZ'"+DQ!XUD6+\$JN<_<WC67*>NBJI9?<$T"W(=[KS%A$/MR9H
M>J#&B!W]^5,M3N5;)@P,=\RV&59>L,Z[&G<,MK^6_,[LZV!=N*%WW=.[C"<T
M&3VY&E);@035@>YYP84B1_']SCLAL0;EKO[;*<,]]TF/=0@[46I/JF$O-SZY
M@:[U5:A6-W8+5R,<X!W.W-_'T==#98IMVTO<>'(XQO=Z;W,,\*%6A<_LQ9_[
MI&,W2IVA\M**-62HW+1O4G1!<N^ X!;BAGVG8_&SI@\IF>)L%924IZSN5T5Y
MGQ,P_*B?M":-V^2"!6WT_ E  "[KF_OX=!8\O?TEC7'6Y*].'W)>3PFCM]-%
M]K$_D_W2NW>4-\I!3_[':%H!QMA0=D574E*!(I/\85^11QJ\!%D'BY7V8HG-
M^N:#K570A2)B<\>XQ 9D]&J4^Q2[/NOFNY:#G<WGP<[Q+8H5+PS )1N>+UX\
MY.J[X=[[=J99N)0/HDZQ[)[EIWU],+4SF4]9Y.GU[U_ /]+WWGX?OUZD)1'N
M,U-LG)-G"-YW)DF1APD!W<$RB1K"\K&H+VS0.R%.X!Y[[^?%A:9%C2_F[VB\
M5@D#_REHDU_15RRS]F"NWGKVXU^9*-=0N06K5UE0+;A2QJG69;TD*8ZD9U!F
M%I&; Z%6BLSVK%<>NI.&#TUMR*GS.\Q4;%<MQ)$#G[U\0W#V7 ):(L\;=CRS
MJ?^04!*E9BR8_<UM[#B<F>!Q*-A10"E&9V:CL:#%\6[X#7)2VW'8C_JF(;]6
M;;%]F%A/75.*""#HYKMG0O7S8"*8='T0>M=E4*H^$;*4*,Z7YMN8X;#"[8R%
M!CIP3_2-P!$(.X\VMNJ6.JZCU[A^4^;OPQ]R;I2.F/J'-OOO5%%B\U[A^1\4
M\ X8J-NF&(A+S;4@\C>+,G ;\=[=8G<4F,(UNY6 R]#TO6Z\).49V6?^8N)X
M<,&O0PA7AJH5^Y?"Q[P:#UFXMH!QK6'R?,;KNT^-Z]]D+.-24X<1)X#OZ"\R
M9,GN&/I--^ -9*4$5E!&"W+W5K*[\ OZ]LU+\5KUPJRC32S!!*7[PE:S8,-(
M-SW?@DNGNJ710P1L59Q=;TL=J'B&UW/;EBKWL9JT+3JD1^_ VTX B?2KY,:%
M9@,'0W2MXCY6K0_"\P?!RS0O\_>%\S=!V<W-+"HO.9WR*%2KFE87>GW!56/*
M^1MHR4;29.7UM9YS[>+*'?$3YYUY ZGE]2> \!!RR)(A/.SK=/:3['8/B'B>
M97.V=_'*U >*QA@&V'719S/VB('42[B#_@H=09W/?O8SDNBU&'*G3O.6[7"0
MY?,+HUR)#(>Z!_.QM( H)=[+^WFWVX;2P!)6;YUY3+Q\"E0RK245V>H-#M I
M:I<<:#GBV@7Z&>4E_8:*.,B=]-&C-XN'UJTL&[-SBZ(?"NY-&E3:Q-7]OOM&
MMQ&>D]0\<1DOU%J?HE1HQ58QYTERHQM![X:ZT<I;SBU6LG9:9[SW$(Q*67XQ
MH]=4-/C*O4\EXL?$^0%\X]$O(3X<%PU'RT I3U'=R9(%Y.*.QM&ENKN[S1<%
M7EZ+]SB?5Q4T=;!4LLJ-NU31Y&:V,5)F:%Y@:"Z<_[5(I)>HUZ-=G!*FFE<H
M.U[.HRM,RSIT#)N3'-WI[PF307\ALL2@Q,E7?@<83Y(C.BR"(7^K&1UB7TE;
M/^I\1"W5]F;$)06/#:DY+]#\"$5N]V;% >4Z#6^N/1?\S,S(#U.AJM/*J4R$
MG>X\*0-]S?!9R3"Y$P!^2(;T89"^H;SL\'LJ.>=Z][J]!I69AJ +DSF7WL*8
MU4Q=PMF::Y W1*@I"4,&7FY0B\@SJ[)S!YW!GPW/1,E<B"G7Y\1[F8F%Z)I\
M^";AF9[Z8BAV4-X_EVCYL_!G76EJ;(*B[S0R_2C-5+_"_? GI95P B!]W,7]
MFKDL96F6=3%#]S(7OU7LXE/3XH/-55R4.I,1^18%1!9</(R:>I%DBD2FXN=>
M/U5HRO#^6_!NB/GIN9TP,*& ?AD/(PCL/QIRVMUB',L,_VW;M?J4;O/1=Y(W
M,K++$W> 4#D%60!9<NE.4<'S2[<$)W7+;6Q?Z)+*LIF%G;WJ_YQ[QR(2+9I7
M.PIZ_V-__@NN!MK;(C%C[J.KA[?. FGG]>SL.WEWJW@OI[8,9QD%^Y0VE/9;
MV<Y9$(=78:!+$OHW^J\S)X8_G?!U=)PN#-.6Y"?";M;,B*:>O<%CL28+?P1Z
M"-(<*OF7GS&G-?053O.UX/C9-T(GW-*"PF8OHI6 \U_MD<2Y7QZ,]JA<EB\!
M*STK[Q73="F\3Y4O=Y>S8-#*Y*O94GFNB<]YO.*+Y.\LK_3U,<KWB\T4KD R
M3>M:';7COL]4I&?JB%;3LS1BR.L$C_9DLJ!U[9":YM7@#@WO0N.+^W)U^[[3
M15#2--_XJNB6%"&D"Z5"WERT535N;FH8]JW4=/!>O/?Y3:W:)UVA5?4+H>H,
M"5!@(*(M ,XJX]O)8T#:+#V#:O#^I\L77YA4'<GPUKF1>Q'U_C2Q(#?KC!K"
MN45;VO+U(NSLDSVFE=@?^D8**YH'N'/KLVC'MMU$UC-M1Z,!BBK)YFE%TC:2
MVFH_5NL2]#"(Z2"YSGU]%H4BA=&%XD10D[6-C21)Y^ 12FAXN0GLW_!T5@'+
MR7 W\-?.N/(2OWKY S*Z'=M1'VR>47X)%1EO(A'-<C6"^_PG;<\0YW O>XPE
M7H3B034EVQ)B[:\^=_7JE28^QU? A@M!]T.?M0O]>>O](;3Q4!T\ 7S#PDG_
M9R=-8(E7,U_,O2UI<TG:N:FND]C1&$_[),,$OB88U(C1(.Y5[Y)\UX8[1CJ^
MLY5$%9BPYLP7X-U*]>YY^P\96HQAF_VDN8@8*]5^44[?QNR4VL5T;(N):]'@
MBV-#EDMD+!#KW&%9N9C]K5 GZ$JWB[4L:YDNU$@M8:8-*+>G))IL7PC;S0[T
M\K!\2@F5*<^OVGP&_,QX(<!WZC#"[Z87!KW(G$W1"4Q<(E6.MPAY.=Y(#CG_
M]/=\2O>;QNFK+W<MA5*WP%_(E83Q17C[SI2@]M!*M?$"WMD*.3R:,/W]FV-+
MBTEH#<#$'S\/',%=C'<^.VI^+TUXJ.PN*K!12PGALC[9EVXS&ZUH[E?=VN^Z
M)-[KQYO4+#[LE9:1TF)>7VUB8Q4TY00]?A&8,6Y@F6W^RM$MUF8@=7M!4YA:
ME'2.>XDJ82#4&<P9(W5A.P[&3OMY5VTB G_$S!7:VY((DZ!NTQI0P"FJ"AET
M8=FPI]3^L4B+/M\W8)AX;:)L Q_M* S(7+L,K''NW&$/=" 91RP*- L>.PYM
M!ER7'%C^%(-@MBVP0[U</LN MB9X3M^RX7W,I-1EYJ7T?8?I,3/6N%QIHV(&
MWLHN2O"=<@CXB/S>GEM_Q6"@;R:>J"N56^D^M8$9@7@L8L+5E+]+?ZD$9]3)
M55^\(O8I)^6BAKDZIAC(,S/< OZZF8%V^>>1/U+="_B@\%24N_T"+=@'#U^M
M,2##"?JDQ-$6\T6P?.(LIGU_(Z:A]?7SYVK;2M<!&L]5@H]][(V@OTX R(SR
M\M!GT0N)+7\]-,8#W)NK0CL]JJ=[OZQHXB3C?9+<#N\#F9W?_UJ4-:X4-V];
M<+"_KKT[/.,=,$1*SP(]P1<7>W?557(@PH)K&4KD;,<V&RDUK<OO4+\3ZE5#
M(I Y 6M>='9R,B4(.H,2I>6%VG)&';1>7"0MKHY@+B4J3<:(%;ZLG>:W>K<^
MLK1)T1N:I=7)/QW?JFATFO:68_W!M1V(J87)S^V:SDBK/R:E[+9D83N9X[/,
MP \B5H'0ORGF=1%[X5[-PYNF"Q;G+B0MBD1U#Q99Q*_[6$,/95I2#^T.K37Z
M;!64?WXN,RTL+#+7<#0$I9>(7M'U[G09::RWWC;;S:2R)2W!HQ.28M4T=RGF
M&MPM4W</][7<7]894*"0I@PJ?^5D\RK:&7J!/H;E[$0 9LF?&"N=AK?>-&3P
MQ_.*$:JF@ZK]/PD4?$/T8K ,MF1>#PK/[+J*,(6JAWU[!5(W-*U!D.I9&%N
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M56C6[]X=Q:-*193"A2LR_OKI2G/NK2&"S;H4CU!1;QU28AZ &T-*<ZZG^9P
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M*8IV.R-L340 -'SH^S^8[F7!2YY#_X=IM/W,_O3R?QGZ?V@FR_]!TWLEX.E
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M3LD+$3=6MHH;'="><H.XI$\&%#6,M @H%/.QZO>I3!-7K4R,3ZJ),50Z58^
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MJ.<,$'_>_Q%=9P ^L:X<PZX3R<U>F^$==BD]2MRW!N2T][7+/VFNG& .9$O
MMQ7A$;FW\(H'N<ZVZ!B041A"XW;Z/)M3P^V-:F2ZR:T7K3[,_I2;'OB@YQGC
M72U!=+E,6YRAQFR:406<.N4<XLI7OZZ<CI](>3Y_H%@2_B(NZ8YM<E0!#517
M1$2TWBS9&I6[Y7\\XC,M'W":7"-[X6\][96)F<'"SRM?<DW79S;J\L3I^+N]
MB,3EPQ@J+0;O[7,=B@ZR-2ZT)OLX1-K9(.0N][M__-A@GB[&P3"TQ!@N=;R#
MH=* XQZ=(I9)#[][5+LWZ:0@;1X3Y=3NO>X.-'P_N_-*R/-RS7IBW!9H4O 5
M-Z+S7._92B/?E<]3PX4>U+>RUY%$;;Y5UGWLVO^\-_33>A?@?_0.W'9KZ8>%
M?%D]4T2W))O"X[!>3$)F_"Z'Y-#WR=FQ;!\.5ZE7-5(,N,QRTUY+*_[,>.F6
MD+(,R;'OU#H@0$L) B"ED*4IMN-4P5?6I@/8K8'F<N.=N;+L9.$F9;,E[2\6
M%ZM0E&HMZD(Q[ <0EX:%)XS,D-PUU;=/5HN43.[FT'W!Y;X2=A)(+_ C!,SJ
MG7JL)"4*U')T#\>V\6,@/*40 *II@MOCE'W>YO8'Y[VGFOG!)3I5UC[TM]3#
M&7]-($FBNMOURZB87)FL'EMJ4O!7='CQW*:$CX(.)+6YM;%A[T?)\725N( "
M;["FAP9&(&(0S)+MKZT3K<STSH/)2E&BV"K G.A](RI[_"5ND#U#WC8/PI-#
M-X[=%E/5TG4-\?.O?3E7 P^:IR!V:VN4D_66UOX;\?:^^*G#Z0VCB;<J?RV)
M^0QPQ3=ZJD4_WV8#?ZR<[.;[*5APYP,LZ,LP8-UW2)DQI@#V@+F4,R)\$G!Q
M/O\ZZ_'^&)[/@U!-I2O')W6WJ>(U!T@/'V;N.Q@^D#XT?!'Q2LY528CGC^S"
M-!2[<BFW]A@=\WD:["C2.52K-X+@MC0W*NJTU0V;4A:I:MVMW%[*4\5:*G(-
MVN@/R0Q_4=XY"-V>SSC02CF-.LC2@S+\39::Z0O--#\>BD7(.*=\ZM7U/O7
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M\R/#[C2.155(IQI]V!310+^Y=:8>]8PPXZ+1F%:E:9-_$*-GC@U8I,BI6P'
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MSKOXUY1C#N)^FF.J1\-NBI[YXKA@Q:MT-J +!P:DF':E"@/ZC0DGF1Q]*]R
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M:\?0,W$&@MI9_3CY+C.HS[Z6PB2!\A2/Z&W.'*3RG(&Z@L)>ZH>N&$%BEGF
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M;41Q#<)PU:JIN_+GJ^S(VI+"703WX%+*\A98):RR(\'26N;K;4B6HVMQ:<S
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M7**IR*$TKG5/KY19<]T]ON*7GVEIG9K4%4:)P/)]Q*>7L(>[JH\8P[O7S![
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M?:?<F^Z'@=)M1A?$#>MY%9E!KDL*HIL8-Y/PY!'HZ7F O*>'\Q,M/E"ODJV
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M2A%9WJ5XFX])!AR5M9\L\X>++X[*L[G@$B4+O=("2]E?QDDH,6C+<C.4:J1
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M"J=:H'WG@[;''H*CT?7Z=O6Y8(/9>Y#Z1;TRFX;,$J@UW(C3L^2-Q8UE)*/
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MGM4?U,?KD2GW&RF*N$W[M]N=?EI\*?=^SYJ3P3WYU1*1T=AV?M/>\^.:1$3
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M1=^\$+SAH>B$X\P4ZEML%U(JFK=[]D<^RZH!/&OB]CF7J=-VLN1-2Z;#%DQ
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MCWT'F%LA<8[AXWEE[9B]).K<=H(,Q&)&E 2V-2_9=-T4_E$5]-RR?N'XT@:
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MCOMSZ(\ /N:FL6RXX/,]K@9(R>1+<?]04#JQTZ(]GD5*Y)M#8Q7<HQW@''5
M2C.1TC2\W,O&[/(;XRLOWF<I!Z+^XEH!_86Q-S/RDGZM7N^S!'MZ;[.&(@9N
M8<!ION@-ECZD+=(U,.W/%U\%5?FB P"&CEFU5*>L?@<UJ<4F/!)?!V)T*$ O
MUS"C_!.$09%.Y&Z^"C3A#HHD<46C_!DQX9'M1+H@1Z 4ZL9-_CU=)$-JXNIZ
MP0T]0\2<0!NH>G"EI]F)O#Q*('$:@^&]7B=N\R2,$P&GN52DC,51[N5A@K+<
M&!X)M&+OM;JWYA)V*?[T"37B[Z<,-?XIMLVG@_]A-,9GNT.VIX^2S7B[I7(A
M_^#8.^1)(GULX ZR^<<;SD'" *;!<&!U"R:[!:MM7,LD!C_AGN;L#276YU%]
M7##C[;91+*)R2&O%?2PR)&TR$*HTG"UC_28RD&]2W2^M#"^B5#^;'H_S%>;5
M$>F-<X G)IW2M*/YS[9VZ#?G))]*JB.O/ 2#:*1M7'$RW@J*8\RE%1OSGEGH
MXHP.!63V]G@4'P#TN]\B._FP\7#-6@$BRD HF_IQ,\URW!WJ.-KZ(:@"+6<O
MSF8)"CT"B0LRZ<]B)]QW#)Q"+YI3IO@/3/Y$3<HP%C+YAW#9%WAUW*.@ *<V
M>V9K&!2%5R5,R  IAC^<XKL%2[I3$S9!VKW^1$\O9D 6DF&,%_@Q]JP=Z!C2
M&&OH4[;IYB*I69\7^.+&?];S0D.<BXM_CII&3B[015:_<#3YXW.*9D[@7"=?
M"6SNP8ASI<&UE0U0H:>V.JX.]P@A"V6_V_1(Q2L'^,OGE=@_ASR<Q]:5HQR!
M3_>)EV9%WV9[-H[!S#W8 8(&T BCF 9CKC2%+S;$7+MO@DHD2 A2]S21_J1#
MDE?.%6;Y1#'ZRW/(D#I?@ZL/$5D%:R)<ZT$S5=8AKEOY\UB^+D"HKYA=S%]O
MHC 2!+*%&C7G?6K*O>+P[;)Y8N<!2B@&.FS#E4T[Q?MSR-B:XC*EOKF3^#GL
M]) A21*/;QY7'1$0!)(]!,+OXLV9 \++1/E?&4JVD*;";8%D,/6&:OS*?4-\
M=P/%-4 =QS[K+"@WWT%FKHF'*NX@Q51RCA$[E9&A^I/+?%$?0;<$ WG=-1Z=
MF+U(^M,YP$5?A#!2; Z^2@*6ULX-FLF29 B'<-M[C53@4-13J(TF#7F??V1*
MDL=1O4:Q,6]O+I\&.K*(3*^5\ 4'G?-YF#&D@$KI]TCU033RI A?-(ISB/")
MU&"3N 5C^'*O0"$,LF((WPB(XZKYRH!8MMZW&M"2QC\X\F<^+^7=U-K]=IW*
MA%+KL5_+ \=M)_29::N(H")6:RKN((SG]=_-]GQJ#P<JWE%V[W]H9E6"?H\;
M,G,*';^G9QB6\%U[1R9[=]T)R^,MJ423'?Z<?PJO> A,F#0E,$L!IQ?1F"6"
MTD\U.+31K_?4I[7GL?4EV]RA(WD7J.*/-N35.OY),[PKM>,!X=$0QN=!Y*MX
MZL\*QV1U)B 55J!'>^/>U?+%QZF-_;>713;U4W%35/KPO 4\%7^24:R=8?>Y
M4)--"#O$7SO9YWKD,]2O8S41F577Z^)N.TQSJ7X<46GWF&3"U1X]S/V:JR7;
M:Q; RE%*=K<)>+#KVJF8 $TUZ8H=;0.3(3_RV+> F+<U0PT*(:^4$@]D^AG(
MW]Q1&:]7'Z&E%G8]=U6A0/:>4WLS;B$#K<!Q8:?P"OW I)R%-#/A &PXL\6+
MK!_]=^)T)_EEQ>;IIBFA:Z$_M:LJ=;XN25?D7)-GQK2GL%"3J5UL*OLQX%/$
M:V]J=G\(D?N3KP1_S<BZ:_@+]OSO ,['G7NU/[BEJ&4M%FI*!^#MW\VXI/4M
M['$OI3[IZYE?GQ>=Z!SWBCCHM)#F7F/MG&4H<29%W=Y07:RVZ,063#6P4+T(
M(-XOE+S5S]!^7+LO@&JOWP^ E?;B3_QFXV^Y1'][/I_2<T8ZLH<^[S3ZO.!Q
M@'N274P%YX"5K,?/T[RE_S\3%O_G=2./1M[GRST*G03]F=8%Y?W5H4@X7Q%:
MH+42LK$1&RY+>1WR *WR%?H[,-6KAHK2^\H^.OU<5!=U_)RJU^[7?MS%_X-<
M,3 *%CF90H_CRHJP^T%RKWXF40#;O>+F-LQY"LU>/XLDURX< \1SPKQ'58?;
MQ0'B*8C(I,!Q09VS^X">C&?HC*._BNPC2J*JK)2\OSOX/0^9&R&457@N*\;P
MLU^BJ0GEH;D>Z-C2@&L%JVNZV$N/IGZ,1YN9&<O_?"_[$G<E5GD9(#&"N%(+
M[ >\OQN/ \MLTS^+;_&QT';.WN;41I+,%/]C:U8G)@FQAVO)V"G0H+ZA-WN3
M.O9RXZ"TR 0F4@AWP=:P]7OL]J[63R5AUPS#HYS&8K)DEC=S6[=@;@]8E8PZ
M[G#2OODK>S-"6]"/:SL&5(HUA5'PK(KT/G<=72JS-EI%(P88^/RA\)IGXX[:
MF$IM@]_M'V,4G#ODHSH3XN'"3HX9P-JD>\Y%@Q>7?73=[%PK5OP=JQ;2BVYZ
M-.Y!33G.!H#_,LS)7%D27ZP/]&8?Y#UK#P /(SZSV!Z\/ LEO"5Q<J/+UPBT
MH1;!691N1&IK3C><B;EW4X 1ZPG'>PCZ0._=AO7F^M>O4SQ'AONZ6Z.=];IZ
MC=YB7_T>X,JCV&<$5EJ6V"E#.,G=!VT/8.DI,6JA"8XY+L4&Z$WK4,6QF&=5
M9!0PBAVR(20@"Q)@5F_KVKV8<(6N\:'O1V>F@B_,O2U[N_ZM-)ID."W,4^#5
M(>E_YT_TDK(ZX+Q:8J#^5#,3M8+B^.%0#!"RO0&&=?G*# KH48<I0C4>G7/.
MHB)E"))0G].(F3%S?#BP;4QS4-^QLJ*FO"RN8BG_;?';& 96= MV^?I<@PA7
M1H:5LFKY9TY!0((K_@*]"X*8'G@J:3<WCHY1#L4T4%(MA'#R-#U%E!"NJK-8
MLPE82.X0@\2["<( NX#Q/A!(3QR?(LK/A<HWMWXK>8$)17<]=X]9O72\4'F?
MQ\X)_JSGU8K#'Z\KMG"3ACXR@1S <+'O2'^9/?QN51YS[,:95^J7#]RKS+<S
M)-2LNXFYCGRM2:HZ%/AZ\TYE:DU2KW7R2908KUW'VI<JLG>T1L)*4XCA,%)T
MPL\EI8'=_^D\S\-$&Y?- (!?K9GUI;VO<*<-4L;:32MG%EOYN:V9F4TI%X8,
MXZV]BXZ[U_U+&*F8.X7O\W[!?'):ZPZW37\E2" J45S99?9YZ,]"' 9(7-W^
M/RA[TZBDM_!MF,YI5B,S9Y.38\Y9#N4 ITQ-3<UYELP<D-1,34V$!F=33YI:
MFI+SB*:"I*+DG)GSC"-8EHH)I?1+$!]Z/KWO^W\_/ ]K\0%8:[/AOJ_[OJZ]
M][HV#4PA\^B!@2'3B'L\D#G@ 4PS%6D/LF#TK^!8 A\R^!AWPJG]'--AN(M=
METR6U"C'8Q*XAT<,- ^WE3FK+EZ4.!*_?9VC6TU<6^*Q^IE,[O''RY%061?4
M#1YB>M8AHG<-S!C>?1@P5WJNG'Z6<9%*Q_*URVWL!A+2GT#/NRU&1O02G=#*
M6"J=:1D-?D*X?'<[7;#M??K-B4!2XN>ZEY@[<$#V*^>T$$L?>V44+8WI\,J%
MQV>@[""GH4K 53B@N-7A8F#'++:=Y%B+)AI$:Z2WG^=)BXCD=OF- B5F3W/;
M6+!!%.U,:+>GW+A:;>#@B\'#K[P1(B[Z[WVT?K[K>G:_,L;[B*JVJKR>@8VU
M^J<"F;A(*^=W^Z!JTL[4$6P>^&G/S<($7&H6O_&-J\6Q8<S#:C3-T/?]GV<(
M=.;QFJHAEQM,,;B?;9YY)G<L $LTJ\JJ&,)='W%04G;?>5')R=\''3G,L6%^
MW51AJZ/''D $#(PKOF$:%>G!3*%E3 ):'DEQGO5A?F6]9FKTUL6C(5AJ'(&>
M/!H YY%TOZWC0.Y7-R8I^_@H'.7/XWY%/95S2QPUIF-FZ)X;$,HUWN3COJ?
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M"(V$]H-1[?*H?QE!F558"6,,+7IC8Q#>RXCL7'*:RG&8@)XE%#2RTRX^B8R
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M]H:A$MD$=$.9B+FI[9"Y3)O?RKF;G]H$=CMBMWC>SIQ'4WQ1JG3I3C33RD%
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M#OEK:IO55N=.&!HX4.^)63)$8AF5+0^SGU<Z/.U\(?/P0CK0U+?]N?M<Y2I
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M1>Y^RS)P21]KC<U@U6)P457#B*6AR=]GMT(XK.9UUJP#'A?)[L@\3:#JVXZ
M#75#U[S*O9#V \OVN_57:L[!-X<P%C4CE/B"#;TLD=9&_)2T\XV4:M/]%%.Z
M0U1MWLV9%>^.% @+*_4H=_$O=X<^8>5!F,#/=D\KK?$EQ)QS@NMYT\O6&A,6
MS!E*\VD$_&-C6W+PIS<&65.H5=B,LEO*H)/0DZ>71) 3OF U(2+3R4N>5H!H
MS>LXR&RYFU6VHBA4Y(>UM;'_1::.EN>_SC?($3F3=@/B=LPSDB$-GA);0)=L
MN[KXCXV3FP;+1"T>FF?&7#88Z,_,-B#Z'W%(&\?DJKZ^2C_UR?IL?G52<&/D
MBNCG(CV]S>?$E\F@A)O2YCCGUT5T_8KK!KF,W6O]1CZ!*^0/"A5%0(6Q'&Q>
M7:]YO;P,95Z:ZXZ]'_[Q"IG]N[[%T?7E>@KA6BG*BZ[9G64(=<]Z="OD4_?.
M>SAU:<0KP$>L]=O;3D2]'X3+0/7@GRHP=_<V?PMMZF:]6_>-J#E,=, 1QUIV
M<R8HCF5@W))AE2E$\>^+ \LK[!C825UMXN]=\,HS&JFX]CA^H;4DY54&K+=A
MP[]!'JL!#"ZV^O67$ZP4BG-EY7DRZJK;L%?V0P[/>5[BA2&+=!A_) >8_)8U
MKVU<8X(\RW=38%H76QK3+TTO&?_$-(P^_"8QU3QEUY%0QM?K*?8Q%ZC >/K[
M<L ?@K=3F+ !(M9[\9GW*'395-94WW>LQSLH;6H>YK[@"I.34-$M,K*$\%H4
MU\[( R2!Y;*ZR^3!UD_DYM2*0=&X+S93C->?5U9+VF%E.?K?B3JYBXLKPP9
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M7NZ ;K 4(9:!G+CW[9%W>7K@*_\>QD+ 25C<Z^= UUQ!H9<XE1*4SFCA,-^
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M@SG 6;=7C"*<VVKA#)Z1QS,N-3Y<-<K(O?#&?J,3H2D]*%VTT5]CN>.IM3Q
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M-&4ABJSCWB=_L]&^<65RTH*5^!:ES!8GP:^DC4Y8CD@D=Q!!C:-2(_,0KI2
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MSE;.!J?ECSG2"-&@$%_#N^9PK.#VJX"QO@GEZLKKYG;ES9 /YUC%46&-\"M
M=^;AKE)7BUKU_H)'O9S!J?  !WD),UZ+(K@L6'VXQ$(=[3YB@@EP6J%TO+?R
M[>5__VTL?:C(B->P3#5_4$:_*.7XZB<,"D-GW  76T[,-9ZW%Z;WAFN 9>/[
MQ5_/V0E;)3W[\+>946OC\[/SDDXJ)-(<)Y8VW?.WY.N_P5PQ3N\>O1Z^GUP1
M_[:LPK>\X>JVHWT!K8^13%_J$-,=,:(', KF 7^E)W!-V#V XG9:+Y 0W"5N
M3?&=?<%^8N4OO_D53/?["+R3$+T,O^*AI>!,.5E**7VA[J3.'L$:7?C4I]3@
M1E$R+Q ,NJ)P7;#T*=9Z0T3E6N0BT\G4_,IS6K=WX:B4!J?,"RG!'Y4[CFLK
MAE*!)?WZ3S\TZ^KG,$P]O['K3:SWC; 86)-]'A8J_,Y=Q+[,U0N-F8&H)W.5
MW?N<#@N>\QE[&3\6]>!VY%^O3SP@"*4ZG]7G?YNO#N[Q3K5UOJQ#-DFU^^ L
ME 4M'+%XE7=UQ+ X"SI>7#X"*6X"'?OEX[#8FQ___M^M[?E_WM9WQ''L;JH\
MQ]Y6BK)V,";] -1M'&:BJ4%''"[M]-TC#G/C.+DI"OK8!X/8O8UZ[/);2S>T
M6;VB1QS/W^>Q;M]B11/^0WEI?(SRK\,QBK0#>&9%R,:Y9MI=6,D&HOL,5*,Z
M-OU;5O=->K+UI8B$FYU@B7>?R[O.[=4PKA]QI"BRDK37?FG]A5XIH>7X$>\J
M=N5X68YM&YJ9C_H?8+6^L^>VJ+[&GZU61<(MWDET/O=4G4C$VZQ J$4CII/D
M]ANK<3H/TM]@HF\^J.?WD2NQ$2@PUNR_@@NZHVN=?LT@"3AI.3>V>\=[9TE/
ML2]51K^P]/F?FQ,4TV<RFR7WROS4G$O'5_U3=D-@<Y@(?TO\#+";U3I6:QFV
M9214 ^F%RV?PGD8KKURVGH=!7LLK/=KLH;^/#9YI%M<L0=G1>:(_MHS40D"Y
M_$6V*Z2MY0?KPP=&57B#EZTZ6:*K4=EK&VCA')_3OY;>0L!U?"2N\Y>)@ N@
MFQH:3?C^\:91CQW1&)68WSD?1R[DE!#R\B<'8<%+IT;F= Q"GDQ<DK)6P-<[
MM8U.8$ILN%4!@M#=5RX9)V7F#2!0_)G0SE.UD1-F(Y+(;+CNZFZH]T6HTA2T
M0W/=.?%I'6]$HZ7QG1#3R-KENUOQK/VFAUDYC[^IG*1"VZE (*SH1P>SB>A7
M)G(K0['1P%I]-%$^)0-A;!R4B>F'WI-#I&U$H9SF@-+&1+RFSD+-6$N_EM5.
ML (U@/O&R"-(9KTLEY./'\-?S;(NJ4_>YL,PI!8K7_U$(7];3)M2'^4_P^M^
MU["S/\2YY!?8-5^%*!E+OI>-1+*N[]^9O?8[@;SRG4&<7I1.>)9%Y&R"2K;4
MO:-"N$JV-0-O^\-#OR&+5G:Y^KMW6MLR04,K:NP \IG?K34P"%+,\B5,ON!)
M4]KA>,#-:7<2>3WFDS'%BQ<,>N*Q3<& 88#,TF\OLZ26QE4@2!_HHHQUAHF:
M4$VYSW?GRJHCCHQ@.\$^WNA2UH<KGS(T'(W>VM0$E@FDFC(#:DB/-IJ-'!]$
MR#W[W$B(DADHQX_L^GEE&P?7DH/&RN"^<J#A EI:-SXGK(D99.=SSNI4<];*
M)LN5/5H=RUCZG6)6U< WZ(AXZ8^@;D=H-[M$!]R8^\/,Z[3TNP27:AW91K8:
M+8N#'1N:FT?6R[?<WZ5XU)&";DP8-67_R%*1*5+7":I/.QPPCA87KPPQ U>E
M3OTA?Z@F0X4M!F_D _'$S" Y:_>P =&0@K4JR(\J(T41,-R?I0SKLD367/AK
M3,-GCG5WYD#B"<$.\*1Y5)ZJL&V>1_UI:VN[O%]:_@VVI3SQWL!J+YVX[Z]S
M+=;_@L="6KF4]<'8%;<>0_N (J_ <H%&?.M$,A2#NS<&?9DKF\KW5J!47T9+
M7RFP]4[1R^36 D[LS3)?W#W"DQC'*$.Z'7YJ*')S ,+5''=S*?(OL;IL'RG\
M6$2MZJ_D.Z;L=4BKI+H/(N.5I)*7SDM;:(O71Z@/(@A2*[\KXARN2D[#MBAU
MJN 8S^*=/7&P$,D@[^*RPBEW-=Z)QS:/.'M^O[YU?G26*3?'<C*K0@L@XD+"
MP2JLL6VU9+$7\R;-8(7NEO2?$[TOJVQ6-N]KY"L4U>7X,U&U=K0X>Y(^4Y""
M1-X1MDJ&&YCEHI7G3>O,JP+K>%,A H-D%RNU],8MF\"66,K@N"><\BS\!NU6
M?2W.M,83V),*Y-+/*:S8]4DV7"-7UU6,IJL&/2T0L3#5-W?>\).-=;>PQ(_X
M#*_LNMO([<4>ZM<&XR?@XL20AX])(OM]1G>=XP?R@YQ/Y2S\8&1E]4@F2:L*
MO5L13D>$G84[BJ"D!^.>+.;@-Q(TG#]-:*45N=^&VN@6?.YU++$V<LJ:_4[V
M+*9A?D4TIC]J"/X4N\ G!Y@2O5/QO"',1&TL4%R8-IT6J+@]Q06N:A.BDT.J
MB1UD45Q-MX"WI"Y%@B_M8J> GH*!GH![5^E-T=C26$%!$ST=\W,%TM(<')Q@
MZ82=/!+4K*8@(H(DMU@Z.35Z1:HXCR^HE=@T#H5K%=@$F?LH+[@;I*<^,S4R
M^0!'DH<-R0-D*: 8V[&>:3P?8MSEX$[$ >6=Q@.06JV.OEHD9%# E9&'<!^X
M)W I[RLA^=>TCOR[\3T1U(WOOOU_6V^K O[R'ZL]XHC)K0_<KVI.MACU_R-1
MQ^/^[5(L\;%"_)R^8]:E=8FTRK(W?T7,!;=LH#]5IVL+C)J6?/WT,3G\6>BI
M[W@\8\I^T) [_<3Y;-\WV9Z&6]]-F5E>!D5%M8%-)$B=MX4VMX889N6I>^7R
M T@V["],N]CD\)2-GO#X8FVZ>4U.[I2G K!"X5K#.]V393[>^I&Y%J$XHZ':
MG.N39.@K>$*>QW +]511[5/=$?5._3Z1F]!S_V9/R$N8O[T86PKZ7&']K$0[
MP2\]!CGL]?A0SG)X?:KB(.=6D5%>NQ%O,WRS&^@,:Q5:_\Y:PQWK%\%3$0(F
M_YSZOS;+W]+M@^03\X!H].QQ,,*CU[:PB WS42TN)O\L3Y2&)07 87@AJ\DH
M:DZTGX?AWM0X!G2)[=$T7$I'7T;DZD+BEO.YRR;AT:?^U=FV/LWMI!Z;R$OJ
ML.PT23Q/6Y>.\8GCE:U*0XD+ ](7MO(C&<]*2UXX6]XN4-<M*P*/8,R;JI+#
MG;O?]@Y_Z3MQKK)$.K'7[(LIPQVHB]576=4UOU,D:F:2#YH,+OHQ[X8/)/!I
MSZX3F%)YW4<<_VV&:>>9X&)X,8/F>&((O 37KZB'L\:Q]J=INE$*S?.:013%
M6 4X/D>BJ\DHL;A=JW%.B,830_7ZU#BTW8R<Z!IN<?Z\\LV+ ;]!C9I''XKD
M'7&<C&9]:C$\\$$@&8M,*BVJEW"N[2R[W\8A!H<Z$43GZ6R:"=M@2QXZTM6B
M*EKD"FR87@_IG"G0D J$4X<-3W3 QL55K>MUJN0 7 P0=;O(>G+%K X//Q9<
MQ8*"6Q@WR[TU=/N4 PWLD,"^S63-;C!ONJZMTLJZ 0(:$G-''!Q_T!?8VFXS
M%U RR#EM?H1Q]_099!^:Z_ ^$93S-WG#9K06P(MXL&1,FV)7R[N\Z4Q&*+2K
MW&N@!D"N>;'#MY^>IDD<<7"&'PL\:2T-E P30[_'/L=_H(M2H4=UQ,L?:HQJ
M73S\BU:?Z'_OB.,\(J6;CUEF,1+ (XYZE-)Y=SK'%;M,OI&)0009T68B\/?R
M:CKG_II3Y+.=(!L[.V/<^=$AHR;_ !9YCCA.ZZ';KQT/-0I=3T@@>!B_/N[2
M0-(?SJI1'Y&E8W>P>I3Z-WACP;PH!V'@-E*1ATGH9$L-'RH63T\O6]C+- P#
M44Z%L/WPL\ZE*[D28[4X?$A3C_HZ^ICAS0YM,*42>XQ_+<V2>@;)O8QD&B!:
MZ_*A :LPHR-7D!E .^BY^S)+.PYUCY;888@L!\^)H1^UU=<3->Y]9JYVO6I:
M^[EC-4MX\YA6D1+B _/8SXQ&.X&>_N6P>' \3&UT.Z>6(N+A_$R"]FS^3-5&
M!\MK#M !>&NYU VH%>X<C H%-!!1AK3.N?BUUR@].M](Q[Y@85-"T:P#8+*:
M&=?5%!^1MM ;I>'@-R?F9)NL*6P9.6]XQ/%8]N:)0^LV\6/S'RN\6>S,:39O
M+^U$NT.]=$\_/Z4N,]\!H=7W8.P&;2D:S^)ZT! )N0RR _2PY6CK-?03_T09
MU@56#Q4,MQ@Z*492Y\)(#^"J<A#$'.O%$<<;9^W9=X!:8ZK=@2L*P&INN_YG
M^C8SY.!VZ " UQ_]5@AP$?]Y)T34C#E#U^L@E>"8!IWBIUL;DXD;7>)BQGQ%
M"55TT:YOK/R/#F[$K*@W4LE;3TD;%S+8Z5KJK"2T,T_,M,Q0BQ]=CN'(R@V]
MAB!U9O#:,9$]XNI,.=I$=Z[,3\^/>=2GDW^FKY(.53Z[D^VZU+27>0V=@DXF
M#1Z,.DKWV[.@4*@C_%1:/+8U+:<6QHTO*N2=@$ ZWIP5N/B@1,#D(\449&[R
MY>]_Y?_/TG3V<\/#&]\/[+"M@TFR@Z?)5Q.\;O@/?/NT)=C2:";M$1-E^X'7
MMO^(X[6&].>^TLE)-\;<ALUKZL;&5>CS1J_;?4"?DTE?/Q&W_&]]8_0%Q"X4
MQJH&6WVN:(K]/.!#5$Y%=Y!7\HQ!>:4WGH:WW=2U"_F#&:HHV8:_4DV\/,H^
M@[!8F;Y4N^Q9&V,!SEI<F0+^SJ(]N7I_B4=6<@IV_F^Y9V?@YO:ZN>0YW1E;
M.*F=^P5Y90\4;Z]>>T]]?=T?J#7-8'S?MU[GVS'*]E/N>5%7KV3?[T&JFM3W
MO.9WOJZRL ;L\,3$[E;OBWP,/C7%4$4[1.5&D=R673-^YM$4UB_+ZHI\#BLY
MKL5N=C+TE-N?G+3:5T ;PTGFYE+GS$64V//T+6BR01'L;D-C5N>#^F!7NP=C
MVUZ5QBA_-*B'=+[>0."%-35V/+A>\0K6BZ^>+:2 S5]M QAZ&7TPH$PX0=$%
MD(D8J?JH)T,;6&S+1+A!S(MDR!X0T]"6=!A11SCQ=1.567P@5&IG937ST,\K
MV!7N=^HW'WFJ6T/I:X;JB'2&/#^GV:*.)%JBP%G_WS.S%C,.;S>HM-'BWZ72
M-T/7+;,36Y&:3@+SXLWN^#;MIZDB#/6L=R;^Y+<D#;C1.EE=3A\.+O-=;[1/
MWXL<[,T2[,FNL)GNY>[O9_6\6]*ORKJ35MMG9S2'C%'@VUW+:P"J)3%T;X.6
MZPR'=3UUVGY;9(F7:_#F6[OSWX=))62J=!<G:23I!"%+?_7[E8']O*OFD'O^
M-5<VP7+ !6QMBL'I#,FWEBUC6CQ,Z:?X6GQ8AZ$,7&.'WTK#R\]'\,<[,"C(
M4B3<<GB2E^'_^$9:%LRJ_N&)P@MTM9P5 ,?"ZXV\SOUM1OJMD.)YG6&)8*RS
M;M*P27%_:7"*1F!RC"(VU_G?K\_3QVTOUA=OF9N=N-<P6A:5LI1L:DM;1%6&
M-2U";TXUM^VFQ^[IYZH*+6+T6RQE6P#RV* [?T9#B3$[@;LJ@<OP&V,])5A$
MED$V9*,2BZ](*7S(,SZO.[J!0VECR)/V,N]$16]?;LQ=N(;,S(7VGH6?!+[Q
M"72DI55DE"T+\T\S$S8G3.Q4IZ<"+K'[A-)@Q<M>GSTX%;=;70;.>@#_3?H4
M^'H]727L#^ZL5AQ=ND/53=%#X50"H?R^+]DSWB-E$/89F@)=,DYGPR]-E8'1
M5Y,H=;%@^$G5,R,G@I02[C$(? K^K7[_''&$1PZN*19VD347L[TX7?BA[U:J
M=-B9?K*Z*5/N)2?]6GKN!43^*7^N 0..A5@8;1;<-9_#22Y_'S$IZKM4!@\R
MF8)DUK4!S9=6E895"BSB DT92;Z)*JZ!4VLS#<E0,OF@Z78Y@88.W^E'ZM*:
MWI=307'W#.Y- 1XCW3KU.#/*IZ>[?;\G/ZZ_P4 ,KRQ*@P6^G^AGU%O&13F<
M6$UG-.768%8YB43@@[X#?IWAWPVUC8B=F\3]Q0Y(1'/8S;G*GS@O\R(>$0?P
ME<B_7(6(C7]J_WMD[&LHW:46Y)X%9Y>50I;_@/9>-A-$//;+5EZE%$U] *.]
M"@GDP^;53 H^6!JXB-J"9*U(#&=ZH-0H6.EG!F=Q0/\<LZ?*Y381@Q-X0]45
M@-(P^$TW'#,^'@?CNEEUTL? JV%/=47*GL0;A:H.N)YBXE,B[J8BA#';JRB2
MT[5MVEOU1VIH>KU2>I/2@M.WK3$"/TBUV74 \2TFJJ1E=.S$+#+$5>B$?T$3
M!H:ZO\8AJS QXFN,8'U3R^L*JF/8])3\FR?T[K8>Y/M:Y,LP:.Y:*&,XF+OU
MU4 4O>;AF,*UA$W2@>JT<R:?M:?M=$CI)9=W_^P[D1^M>-H3YT3=9IN:&Z'V
M ZK_:G9](B/O;=_]W40E9CD.^6<C06&S#6W-?E<LFUS2DZQU^.U4,8&>Q5J/
ME*KJ3^HM]H'6JO9^L[EI%464;*KS6@$<8C&:3%>1#O[=]+*JYHWMV+K_5P6%
MZX\76@EU#7%F#?6;P-_0I2TQ";,PLTY+0GWGIA%D[-/_P]Y[0#6Y=>VB<5M0
M 2/2BT1%Z46E"I%L"R(@78JTJ(@0$","$B4019H4V5(5A$B7&I"FM BA"$AO
MTDDBO24T7R#EONYSSKC?]VW_>[\][O^/<<\X/V-D#%C ?.=:<\YGSF>U=QB[
M(9DQFI:,+PGH5E?8'+R2_B(]4X1!LS7/KVW4R,Q(K,DU+$L+L"Q;?K-^-Y)R
M7M2A(G[A6DT8)K7:3]MN6OWE$O^=P[$Q*$GK.V&4??9MYZN+C7GA]_,?+5#;
M=<E959EN(G?CR&UQ_9G$@)$=,ZK9JQ/%'_HERQ(IRYOCPX]/16NI]2[=.[)\
M5=*W?Y5BZ[(LW&!9@R=%"6,&+>A.Y>&/X95-2:BC&[4E?IN7*THK!.+U%0IO
M*27]L>:@\-:T=%!= 9.08&6:47S75DSVYIR&42&,1_CBF3C=@PF15^M4WA'<
M],W[&VT$/_0L-ZW38\PC9=>E#K2:!L2>G]5W5[P_FBMH-^!9-J'C.7>04<>,
M(TZ=G*!9X'>*HY@FM2<(O?._:,PEP[8.8U+9D#N*2#:$H$PJX6ICKH6P(8MH
M6S;D^KFA;;]_.I#V/V:RSU!P(ACSNGC\?;H1,<LE?N:$LN_#5VU:$*,VMYLV
ME.F+NQH>Z$B4:UM(5FMMAC'?R?M#YWCFAJT#=IH2JP\-^Z63*;WN+=*JHM_J
M]K9IW$*Y_W'79>R[S)$I-D12=84'2&^NS-]N?E%F.V:TNO1#?5CJ,<_U<K)(
M1*!UPLK),VD7A-MT^!X?8Q77B0M0-9*XQ2:4&SIE6S(EW^NK]-%?3W&TR=PB
MJZ7JAT5[6(>%N9H9FF>:2IT"=%\XJ-_44#^J#6LY;=*)>?GV-OU!\@VSMH=X
M%+^F:5-_1J9EK:Q)K*N??G@6U3#'JH$\FBK,RG2=*$^H<U>S>CELS+?@^H:Y
M_"JMKCAL>>]%U\3X-P\REB9;?I,9S5 [(*%ES/SH#T7:->])1$9Y 1G"Z@F5
M O$#W6(1\N&W"!/VT5>,;I>]>I AP%VJ/NV='?)\B3G,^ ;?-2(>Z,,AMCW0
M ]@?_7VUXRJ<.BC\9:E3BE"\@LQJJ^_X+9W#R$ ]1^[44O;K"]>C'J_VDIKB
MQK=[/"J!)[!(4A.1OYA?PN$(>?N!<3(9-<5_5%C*N47*_*@Y3VM\PLL3O&-K
MBU%#40>QM@":>O>E$C>&J$NLBN/O-8JF+HJD6IZZ('+W77E%@X!9:OQHSK')
M5\\=PI'/HS%F;@\_V)344]WNOWASZ/IR9-''/7E!MY@]RG6$U%IA5@_Q,.MH
MM8A/Z#BU,47<+#65^"J%-2#1-^3PZ>PQ$[5FKFG;6WVOK>2UI>"T9U?>+M":
MW#:&KBPY#85E7N*5+HSUB-TZO2&Y?;% 7M9U(.E^\YR8*G5)UU+HONH7!]L#
MJK"E"/R"T%L^VXJ:T+;<W-?#?'$;R0>!.6\OJFC9=I7.XQ\DD&F/'P;BLA33
MR<GZYS*N6U;UWI432+_='&%\SXC*<[->[GW%B!%?Z=F/'>?W$84;R6>LN73L
M)-6AMIPO4J4.ELKUQFF6?J_4/ZLWG]\[K)>59*B\+;'K]4W/:Z>X_&W#2=0B
MZ]>RK[&6 OER704<FZEF2;'VR;U6U7?>WHDQ_/G.Q6;K_[W7>.2V:.4#R]5(
MRE'C1LUBYS[LA5RDFU55RZG[WK:?RCA#FQ:+KF9]PE"NX26/_4%H$7G&Y!A<
MZ_+*PW-@HBQI-9MT;S+3RJ3;V8>+*V;.JG>N]XMZQ(<W2W>.?SJTW_NNV0%6
M(.VHJ5OX8-5&14@+,YP-2<!;;;Y)&+CNP"@D](L-KLFZ#S>//K!Y'G\GOX8@
M*1BWL8G=J,FL_E23H)[X8G60P8>G6*9.&@]UZM&L0M!./1M*$=JG2VDOTWW=
MY$B>L*![\LX#\ OWHX];72U3"1@T_'CG9I/PN+9C_.\X*.,<!<:/Y:0KA?A+
M,N0&,F@K80RY4S53I9L/2TU<3Z?GC<Z)-!:!_I(Q;[JOK/;#IQLGXF74I?4<
M7UYF1K(A :^Q&G3=!NAS<4XZX?EZV]A#*AD9AO;VP^GWID5/ QAGZUZ;UK7K
M9:5!-JBF.&_N_!\!JLYA+=-X-WGW"EI:CS$?UF# JW,O('6Q'WZ)XOYP?L*@
MI]1>;< W*2^IY<M+%4SW@0 ^=,KTX\U+Z-]:Y/-SA"683ML:4UOGD0>923D)
M%B2K=DR G=LET8W'7;'.IRZJE%A;8HG7XW6,.:5SYTRN9UOJ#^9VJH?.:-R-
M>]ROHZ@/N_YD3;5-\(DBPFVD%;6ZTVKI%[4X0=9M2!:E6H&N$LR&"*BTZ926
M ,\GF1(- 5^.M#GZ^' DO/\6,*&EZY1SR0?->_H075>T0B%QJMH/M2L$Z\+3
MW"$$\7?Z[C%[^M#XQ\FP=H!C<A]PG 8E2]7;5KU>)C X)B,E=/H5T]R[#?/N
M1?^P.%U$3@TQJ?H8(/S[;]84O3-KE"@15]-J+DTQ]=Y/XL0+VREN#)KU/?Y#
M,NVW7AEEK-K<&$=Q)=XWBTDQY_+&3)7<MXS-A(ND2LDHWAW['EOH-[#+XGI1
M3X[WC9YLV98\F_1 NX%$)?\?94OE,^/$HL[P^ZK$H.'.X/L9SN@]0-I\_6>5
MG@[Z;&7IX?E*[+55!JDEQ?TBW^_ZNF(NH=_L\S8+_!_CZK07%7E_![+S2F^Y
M*S$,4JTO3D8[S%SKGOI8R?WJJ9F"3?N#<[#&YY^9W(1I&"]M_?2H;T-I4>N9
M;'EWS543P )KR0L-:U2R>%%@F[0SV'W/WZ/A=!!\!B:"DJYL=5>,R3'BE\5-
MZ>FS_ 3JP/19EW+ZGT#BEVM-<]M;SS?'_EP7*@33[S=M;3!J<^A.OM5*/P\7
M'V)#OOV0_GFZ6.Q[,QORD8I;Y.5E0[+NPHH%05F+/V]9JZ-Q_I05N- '-]$F
M40HD3&4VW<PW#9*J7G</Z[7']C1[*OK(F];$!;;Q-X^G4/6K:F+NY&5=D5@%
MA?_U7/,\D7?=S]>ZBV(,'<YDCO)>M6F?#CNR %>X[Z3S2<9-69<OYG(+_,4'
MK1>*)R;@9YIV/ Y&?"2$2LCD>J3X)C69QW<;PT+[Y^.98U5EE22N[Q_RQ=(Y
MSNER!,;>XAN)N9XS&SWHMN3S?=/?S^_];.4>ED*7-U-___)W0<U<8XU$LF1?
M?J:]*Z>$<*A-VZ$"5.Y%JDX$,SU27_7&<<R,V'T"74"&W%O*/"?L72!F1]KL
MWMN146*MXX'V2:WCKJ^[0_"XUS6FJ??@E8,?_MJG/ZX4S2>8-0_,XO>J&B1T
MK\"M"C.WT2_7K'L*%40H=WU1!?ZDVV"!G.XRT-3:,[RM9[9\<>&!PLRKDP'6
MYWTOT#@"J]42Z'.)EZW[3P884/U4F]ZO)3F]<N^KS53ME3=]W%MY.<CQAG.*
M2=74H_M0MX#TNWUT<[O(O%6SRFI97;?5,M3%5KUA]?**( -AVXS3?1-GK:IS
M5VMM7E4:4\RJG7SVU4PY9]9ZN:%#';3["KC+W^0!-H,-Y<IC2(?74Y5=XTW;
M0W><WGY2P]^N52O74XAP/Y3WD%_<)<),[\&39-BD??]2S<9,6-EQMX+QT7<^
M/<N%JIR/Y:FH#X,GEK6N?J]*MAF5#^ B'<W5D; CR1<-]MR$_/FUZRED$L(!
MV=5E-F#V56[U?<]4*M^[ D.Y6H.A3UKEPQ_B?AAT6(V?\Q-=L_0DR+6,WV_Q
ME![OCHPN 4/]^\Z5T2LAM)FZVJ/597TJR4<X?1>TA.Z=^'36^/@0=\4W5@^M
M.GBH[(![^"6/]Z%[O]/AK]J4)3ZD= C=JKC QZ/+Y:K'0Q)I>AH3??&8Q9YH
MO<_?WR9&AU%B9]0?MYH_*OL^FIQ@4+Z^JB6Q_X+-X0C^%9?&4SYN-9I5<K7E
M!Z73,MZEA4E#_LZ'4*_T%+F*1X_XL-J?U^.V(UE?XG:JD(%("'%*>Z)\A9G$
M$<B&;(@R7\EMX,! ^HZD-#,3(ZALB,W](]J>H8A($G[3E(S;X#B+\'%)"V.\
MVS[]=W7(=V-#H"Z);WVZQU'QT4?UH24.':_DU3WK]]_9MPI5G+-1MXB6.>(4
M+<-S,C*N^^I06J*[5E:O)2JKMWO,M4HE<<V*5U^_1Z^PW=XU?]W?:#PDQ'7B
M-ZPJ8FCD]X]X4D^HPSAK^I3O2-74%[4?2I[GZZ\IR=>]NGD6/I!Y!ZG6_]5T
M<)</;8'"$9B==+T;_69110U7U'YO)6?!<R[FB]<:6LS<9M18/G[8OLU._ZK"
MKN( T:N%#0)-2OG2A5\<Z6?L/N#+GAMJ]-D-1F1DGO(AU+AI31@ERCTTWA62
M-!UA+^/2EZ/.J9&GDTDKM!?Y8%/@XP.4#S9KEH>G&6=.H*PV_;&5CTH<?0IL
MQA.J>@M2VY,KJPNXZW]/#,:_MS/P?BA9%2\8;SQ^V<QU70[!#UQJ>++Y%+T'
M.21@H^G>IWJWHK3<JWO)&W8N>.<5G-/#0S6#-M+&Y8YSY_I067IZRWTE85LR
M*K?3T3,'%:\^*'*'#4'U3E>6ASV6GQFV:J] \4>@ ZY8+0Q4AU@#@N0AUMCC
M#&/O?3FJ#9ZH&1/\DIJ-F?"K9??%/0\4&@Q.ZDN41T\;4.]*O)3FLWESTV]
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M2]08.F_2Z8?#Y2X\F#]=$SCW.RP-Q!9_#F;Z.H%O0?PTC1#F+\PP!RY0<1R
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M<@OX/<PBAC"E;2(2#ZV6FS1'NRLM?9KDG!@B4K5CQ#-/U9:D X*?MP. F>M
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M;%W9$'X\LJQL<()20<(?_#;W2)L?>.BM<:NOU;[M44(1R==;M3\H$ MC*$T
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M2-25,-XFG$ 9;A%QR U'B\?$J:+YW,)S<,Y N&[_>@VG2'8$P\![$\%]PV6
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MZY^MJ2.C1M7ZBA8=Z[($KC)L\(_5'SFU-48G%]YI3(GU._/4:,B-K\(P)/A
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MR3<A)AS [SE<6\=W';_[OX_>=X&7N1;[8!L"9CRJB,..^VS'O:=E//=XY!\
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M#65Q#R#F>?G0*5,QT29,",3W'H -EL% '@:AIF8&%'E,?ZQ1?2T*O>WMHGU
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M7L2E5L9^9Y'JM/P^C2.44^!2/(JM>OWSV<?\YB-:R$WWO_N_[68E]4HJ8_/
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MP;)1P?14=[FL0.LWE$!)5X8X<L-P=J9I<</2B5]ZKCML$[TG8^HW+U3X/"V
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MK2V*;T:KLI\LD2L !)VX;LPOUI4?R\/F):_CX4O8TYB7Z,=3QA WU:X?+$+
M:E@MR=+" 79Z2XN1T49*]Z$O!RXRFN0D:J,;Z3C;:Y[CK1]&+:!A&"E)!M3-
MLLDTM#GN'.WGUT\!F>.WZ6@#ZTSM1'##NINGD;N&%1H,21O=W6*QE'"8: DL
M)K%?/"%%>;!!4;)!U[N4PQ7(8W</4+K+"V:5\ZKT\ZH.IW[6'=;AA!O!VI[-
MT$(OJ>H65.+X&(PW@F)J\A$>%PK5EM3'.+8%_/MV[O!6BIX.<BE.I0C)L9J[
M-NT$[-9.2-.5N;5DDO+7GDUERX^CKPF9+HG;9WU%#$B4*/H(G[2K<V6L^^21
M+2FT-K1'])<F]N7N'Q#1**YH*Z[$73WANE57O4ER0V;C[%D8WDY(1GI^X*M7
MU(AT 94&QA$9J8VZL8[7#9W^HWCYH=:YMIW/,"O(U$>ZWDQ<KWS,\-:BSK3]
MN,?R1[()[.EZR]T7.ADR&.MH]=!,#C3+$O:IQS:9?Z0V9DV_D1Y?A<KU":*M
M1+=O%36=UEAR)>-['J.+H9F,G<F!F585K+GA@GRUC<P=C^^J7BT%DO]87.ZH
M^XYGU7KSK.-W8S.'/'?[IMBB2JWBKT^2Z@>7L0V"+;G& =#G$,\AA)';EM;F
MT@*3(\^ZDP[IJ?F8E7)!(_F.&\QOCWOSJ.GPRZBT FJLI="A]9'98\-S"W)(
MDF[]\?(GP9G6+Y #5V/EO"FA;#E.LU:?-.M\US"]%*ZN>F\0@T@CW.'"(-KC
M5Q9*D?<%Y9T\8%;0<>JB)8O3\BI/-4%$\QF=J;4>ARY,+J:<@Z"1H5)<EWUF
MTS,>]M7=CI!>6VL$+(C(IC8?8"^5)\[3;DM2:?QP5_R<)X7#VT,T8@(2)H^K
M4N2LH,+!(7#I%G,/(&_GLRU0V-@CGIO_YJ:M&LDJ'F#&?1?=S>U2X>I<U"DP
MZNIF*?*)J\K99Q2_W>!!*$*4!LTI1&</A'(_<JY9$#K%<@G;869_B==W/IKU
M.K3U0JE-+I@?U*GO\,ZOPP\RX,]:V^.6#VKG,BTJ.ND"A=%O5K(E--*,VB8D
M;=>PW_'OFG.CWN&7+@V6;H+HS#CPU7E>_]EG2-Q4KECYH?S-1,%Y=E:DZ6MF
MXS6=#"G$,$PY4 %Y4MY Q#A]ML_V!">JW./3Q[=E6!J :@93OO0M2(E=>J-;
MZ,_5 \4B#B,;>XZ_=(9,2"52U/M8\5C/LCI=%/%FE.Y>LP(X(#JZ-OC5K^G!
M6KRTMR-O769@%B29*LEOKQ(]X9 8O!]"V?XO6L0%MW2PDUDV=/!Q:B\E&9'C
M P$=2N_O :&LJY?A^<>L,7I,49R;&2+'OI'4#!/#=[E0ILD!F.EO?05U_NM=
M[ZR" 3<_[HD R@!"DELVN%#SRE0[-_.7=#]2<+1=M.?<*-Y/YZ:&]CI^X5PG
MVH(1P\39]Y-HP[B,0;*NA*:UAW&'H4&G(><7)0>?4B>9F +SG1!>&SR"'5H3
M.?!;J<(HGOPX9"JP<NO4*H<U_6TENS^J^I/()&2\1WPS<C5ZN$-D5?.C-TA2
M9NT-_WRD?2K;>M/$>4OWG*'I7<[UV!)F:695HOF0&>*-&]9Z8M?X8M'\B[@>
MFXW?)OVS7)U>G6H=KI%L@T_]ZL@I5OW0*Y!&%M\/F&---D=]7F2>1F$9*X>>
M[FV,,"LNM6@.$W)$D3.\#,EI66I/I2ZJ^BJDN$;#/2^Z""<EJ.)DMR$I3URO
MP!PBJ6?\MG"*<\+K#'[:)TU4-]-.5FDB7>16@?9]?X.GG[#0GOKXI/^:#;&8
M3R$>N"T]6JI>7F@Q5^H\(>MWH<S09M!RU=1#_U(PT_Y&:JZE+IW&J0?\B+_7
MA^KQ$'=L=__0(XOT$"K2_#H!I;;M98H]'8B)R:1W9A>1B:.OCT'!AY!S\Q?<
M@4C!&C]'$_UZ7[#W(WC?89'3A;JB;D- ?00(%%L]<"RSRBE<P%,AJ.ZCZB&U
M[KYC@ A]#H0S>@L2-6:]Z<)]\W+8UZ4I\0O$$J2G^9QDOK_(N5;T'E"N^4S_
M+Q>Y&[5KQ8^D,+%FG7Z=<HUL Y7JAE!K*EV51!B;,=U^4*#:\3G;G]$R6W#O
MP-OBHF]KM4"]][#X(K')K<I/I8H5.XH=]-9:XZFTTXN&HZUI22L-L5@_I66.
M[Y9B2TQZI'-])FS/RNN<_RP:FU)9Y9#8<W0W"5]Z)+R&_/Y:T"/JG%+]*OS"
M;[)^N"^CIT^96SCY^6[_JM.VU>OG)Y=+[?AB9C]_PUE61U-P/,R32@/%_ARD
M;QS[]CIQ<O9SU,2JJJ%LBPHSR;Y&"CND1;H:"TOX%/Y@C!UV/0$RUM-1U4V=
MJTX60C[W8F@FJD@<BQ;J',N=(%>XW]8SE1I#);>D=9AB09SE[YIP/:6'6OM3
MZ>(88CP,\9Y)JI7Q6D;!\+@==<IA'%^8%50)C1H*.88(-(9(2L:B*&^[4TF(
MN*J%1FS#8L10HAPUO3J5&IE1VIG=4S$I_EI =KWOL&&R47W2U80IB,_XNV.?
M!(+HPOHOB\RIJP&9D615U6ZLN%NF8^\YGKM'1-,ZUO11,[#XI-J9[Q$-9M&>
M2_D3H'_1GF+\JA4FI9_AF[U#!<I-'C'0[\G4<9%?R8IUIT_J1],A\[$8&_E,
MS5M6EK$<FK3_*JRZF)BTARA%06L,>YY5:.>]*7"*Y+7AKOFE/G.\P++RV\2_
M<=FQBKJ=H6QZ/2H3KEVNW@(-8V]<3C3VUE<:G1RP1)$54>J6&Y<%3IKW=ZS.
MHV'LLHHB 6*"F0*2/-0W9HJQJC02W)K:^K05+L4[EP;;O:<QF2X%TU$?!8S%
M%?-H-7Q?=DE\"#+<>C))GP;(F#[^4F"+!+INU?ZAPP0T,S>(4,=]M\=UX]]/
ML0[!Q044ZS)3%28:/6XK^TTNU["5496PJI #JC?X@7UH+,IKW4;P,>OK29]$
M)&6.ZM,(8H@"5IR19W<*C_ZN:D9!EC7539E*1FQ6 1G+E46/=V,UN!C'FW-&
M6R59C*T_"R8:<" VY/HG><%YBP9L?#VO9SWOXBV:KC3&CX6,\;D-BA=:O0>\
ME":OCA;::5<OAH0)WNR5!QCR'+@=F!].]V69O]-TX>(?$&KF^[0I-S%,=PS/
MT]YO&*^_!Y!RQQ'W ).]?MMKQ=^ 2OLU VT(886JY;<JM*8@X^ E3^OT1UNB
M>V7 /VNQ71KN3WM>KIZ%F>EE>&7JNTB7G@.OI/P%RL*X%*GS*\-[WX<>.)5-
MY<3-ZJ=F\ZX?N%0H?0]D[8(++?(:3DL"K07%%=9])WX5SYL.2)XJ9"<T]/6P
M?2%G)7%6\F,<@;R?HVL)*.WWQ3O'RD)AH##7\U\.,L=)Z,]:G]5:@AB56]J2
M!D-4#Q21+C;IW[CX!'_\'5T?%+"T7BCF?5OA\M8^1D9U-?>I4PY9(HV+@=Y$
M\12K0K9S!4]U<?IK7PC<SSQ(>$DP-D=,[N,!)_9"Q3L>)Y\RW:(#/Q<-NCV?
M]UIN!1KCZ3LVYTY.A?91O5/E4:%\WLDH @H8)<(@Q-=%7,O=([I+L.J@S,79
M:G&,^</W];J2)U+#C^(')HN"D$@O2+L0\F^A=C5=6&'_KB).JZ%).?NKB-<Q
M!CT99)5%1?L&_GW1>^3'K5U_+=N=##=?)[Z;);3DI,RR-"->9&9D9E5$]&PW
MH/\\#828*R >E^'KX'Z4WI:9^^Q "Q!>H_M6M5#6@"=1+CZM2SME37DRE53O
M[1GXPZ.NM;&R4C\\+!OI8=@0#@O/W^5P!6?=%;'UGVA%1>EDV5RX:J8PYZOO
MN7GG=P9#XR@<-21IL<>?[FV C\;"[T"6Z-T7]*#CNI_MMODSTG_^.93+YJ!=
MFV240IEW7>1@8:"(NYT9B^CBA--[P-^6W+LGT UGF7L -Z93[?IQU(D4ZYI(
M&.\6^65T0*'$RZ>S";T7H8U^IY8IF^_>\Y^HNM!ZQ-35EK!T.+_\R?]5%A!"
M((OU59;VI=+KN(9IE0[JG58A1BU.BY3=ZB;^1?.Q694+']%R9 VE$=ML@;B&
M@<>FL<I,%U?*&J>9^2AB]R9:@52_^/^?-?) WS73P37H2W(QAJMD@G8.AI(M
MJ<?QL'_$+;F0--#T,TPN[+00%?@=/=NKA!6KX7T/Z*0!2=YQF(BE.6R+V\-F
M6;MF3ZLSRV^-'SH*O=:1'@L_9KL'S)9!K]^I55,XC2)C*2UDG9LH!!8&0,Z)
MQ*_C@&19P\++Z2E:!"^).H9*7]NUZS^(U2IT.LM,U0>#'?R,/B?JN%]/01U0
M*MR +:&SYPV%"$@TL 7N.JR8% :!_8,[O_#.MT?\24QRX,:+J^ETS1(42)H:
MTDJ%]UXXTQM;-,[#;_VYZ7$_.\,"C)+9T]WS47G1X!#FF<3N>LJ5UUQ7'_?U
M3E-16"J=R$6I2'"Y*NC.^/*D)@DK1E*SB'^<KE)JP2.KHS&O<95*-VC#JF>4
MBO:Y$7_+^ ?.[5%A[ZFS87P%*P>%\T(*!I8]^HQ/&0(_QPCD$L5,Z00&DG8L
M<%SI#(M1Y 6X_\147)#3?!MZM,GNFL51)D+37C+\4B6D\+#:GI!6JU"K1#E/
M(8[M#Z"4UJF!2,E6[Y&2,XZ>*764:96J+YFM"U>CZ:AT5ZYR[UC,>D>R=N.%
MR0'Z*AW>,QM#=!U_NG</F*D8S,<2I3R_O@?D'F\[&1LIL8I)?1S8P_C/V-1^
M2AJ0V7IR>R=6H:%#@'R+?4;U\^&XZZYQ#0N]N\7L/0(<Q-C:WXC<V^M9/?>K
MQ>O@;"A7D%/RC&'0Y_>B._9@]"J6-";+0WXN3H;XW"(]H/OG:"%(6X2;)==F
M'[([,T'L=ZBY8_[)!1L!FZ2D7,G%U!Q@A'Y!3"ZI%5-H0JBYI8>$L:9=UG2N
MB';,/[N\171@F1*Z_72'#A;1G/3?S%D<TG:R0R,Q]MGHHW[QN/ @@MC"/E)?
M0N<TG66-'-?IE'1M"<@\T>$CP_;8-B>7]P5/<T6@+]$9UJU!4.W%K%7V4 X"
M<.R/"D>E)X 0P&I'?'\.(1U['.)P#'(@9$(&R??[["?R7L)-^)1_XVOYQNK7
MYSB&Y8^QYS=1M\*HF#BB_G2<K>=V74N G38K^>;KE0\79--8!,ISW;P'8.;1
M@$K7PX-93577L7W)'S5ANTQ;LYEG1T'W@,</4CS0OO(>X&JX(YXR[)B:$=,]
M9VRCV6"B^II%3/N='C<EQ],29*>VX=N^@)@?>+2$)?< 0DS3ABE]F.0C%^1\
MT;3;D6)1&8/X/]H"9$6P;SAMW55JB2/O#XA%S:)&PYC6?>%J?'N''I_&K^X!
MHA5ES6:>)@IV\%JW01!\40@:L%'-X9GI53!,-U-[Q8O&'DY]L_-K?$6&7G.F
M%A9.=0^0V:+K^C3JK,JV'N2IP9?K=KI\7%$>J8A]<:MT#[ HH;\#&WW+.E]0
MV1W:I7IER/]CZ*OLTY>0-Y]>?^XG5#F)E9$+(NSW#_A)57^#"JP181VTM :S
M-X)W.PT=OF6U$A0EH/8,>&>WP>=;L$THQ^DW[^4#7O(YT(P:-7S@P--,I9D!
M%%;4*_O@6,8I<_[AE[[-BBDK%YEU5T-%R_R4)\@J&2;[ BD\S*-VK'>1V'.,
MUGOF-"BFI'RJ(M7,KJ==\KU:O=M\YH8I:<,78W-AIC<SZ_3'*18%:6W[,JM4
MCS4RU3N?B^6LA1BU91Q\\^HEUB\,ZLUSHS ?O9_H8<-,Q<X_/._=FMP.V Y7
MQ_"^ID[&Z3 1\F$OTFF\N-+$4P^^Z9WV$/3D&BHFYDME_<NF'9.=Y.TX6<2,
MN*U+2:HWJ4T"-K99CT,7"S>K5HKJDG4\;K5K=_?KQ:4H@/\7;V\5% <7-&Q.
M$A)"(! (&BS X.X. 8(,!&=PE\ P&6QP32! \#!8<'<&'P9WUS!8@@9W=]_W
MJ[]V:_^[W:JMO>BKTU>G^G0_W5VGNVZ"8[D:K47$(]S0>UWPQ0LQL#/LXU*2
M17]7PCLM Y"PN@ZXJ=^^=]8WA T+.\G#'=\G4B28"IL&&\T5L8'P\IZ6O?KY
MLL?U8B3F=*[B? S3EK"CG+>C!C9.-U!3RTV_3IOSG9^92;ELW!JC45/3@K?Q
MQ[FTWLU,/WC,HTERG#N8EXHOSVBG:W-J35_P^41W99H5KH:'DU'1&GO3SOS/
MH*@*0Z=Z*N\SZ<W,TWT-I0X8L;VI@L['Y\D+@25%:S7\U"59;L!_WGH, :L5
MV-LGY*F:MSHE3BN]%%P)^NY\[PGC'K8M.C:J6SF,EQ1S#.0<6SC*N95WM!3K
M 3]2D:OQ%?2LP '1=D8PJ ^[:S5Z_CW;6_(=WNTQY47BE95\+EMWC.:VPWYA
M&^SBL/ S)>[^1%P"PL=W^G:N_T98\=@VI%E&^B\'UU^''QR),YJ"S8A@"BFU
M!R!#L<9<53\Y"5JP: WV[,]F9F% P"- OR+!$A)U'SM!JCC)T!B\'US/9"8*
MU,J##3RKH3)G%:U FBKR]MH\L>%5P!3UDFI];0S:NPWQ:\*4/L?7+8^OR$/K
MUK5&/P*2$[S9(I$4K,R;%=N7<SYI4>?U3[X:X_LU>GL'Q AV0I)&O-W((X@2
MQ7KN"Q;;N]8"_0N_.L_1)&S-'+QDV-WNH^BCWAWPY7F9U/W]\EBM4G'"%^@G
M=B8X.K<1OG5=<5)%".K,]>E+7!(U>,"&PU[^RZBGV)ZX.^ZK0,&ZOE!B!5UY
MG%/L_N=RE8?KI+-H)^[8O1=Z 7?28]=;\-FBX:K7.<[!JPV/ ,F ,6=#PEE6
M:H*9F7/:,4SRV^@T:RNTV0.Z<-706>2]\_G=?=O G=TSKHM=90S=K4*A#\P&
M9VNBO\2,^B,D"/C=-H=5"M4'.F;HJ&J0KV_^^2R&3YPB/* Y;Y6!*BA:T?YD
MC&K$#;ZR#W*3'*P4Z[(@3CY)'- ASWCC;ZQDD/S7BTL):/YJ8ZX_RJ7C0_DO
M3+CFAG9<O'8MS,8U/6ZJY2Y&-AI?\'TA6YB)Z4 ^+./F1K*Y*5-C^[+Q,\H.
MW6C3[>&^UX/+)*>P(PJR$K%;HU:N?%;?WZ,(MV\"S65^PI=Y2"-X!)AX,7>&
MMIC8:O(HTF'6:_Z[E#CL?C+>^ELIC+_NK\ M)Y>W$T@?R:&[PD)I-=X)Z54#
MG5#@O'9CM;_]SH4/],;@7&2GZ^^HAGHR5]O,^8QJ-/T#=:%(+[ZD>*0WK5K;
M8.M^10B*=.S^ EM: WI@>,:W=/V?LW9Z!%S2G5Z/W74%S#O>=__'.MZA(?]#
M/+ MZ>-KYGL?Z8>HD,;9M5K:J[NXAY;,1X!"EPGL_^(B9[&VN^\.TOM)#S_"
M:Z J_[,A**KOOOH_]"+4A0%(DI'\!5&E K9$7,G^XYF*I-4)TD%/#-VB5D2!
M$5VS9U6L7E;C*! #&"LQEL/66@,;F AX,I^2W"2K?EL]-YX$,LT77'0RO!Z@
M?0<AQ0$B'#0?JD9Y/,7'U,3P,Z86.O*ZP6I35,_2\+$;)'DCUU:/*J0P@CKA
M"D349=8N[9$PQFB=3?*.G9<K34-^E@LK+$M\U<2N0(OQ#EWM?A$V)<E*-=&*
M']%#XP%&%;N'T@JE(\/[/L*GVYMM 2,TT&)?G2LW*SAGGL=,8]E/<46.%(54
MSJGJ1J%I'#<&&;P._3>&9+$XM.P\/3"[E)E07Q-;R8U@5P>M67#@#H4Y8OH
MHVNRE41Z4M+H%8XK_WZ!^)L1%)%'0-YZQ>GV?*]+_I@K]44,<(RQ66\ZB=,/
MBMM@X? )>Z#^Y,E?J@(EO/#2%AV$>KZG>->LWK?:V_[W;4E:K9,%T7X*#V E
MK! LNW\AN*X>^N;?)8+E)!#B_6,,-"0>*7EQZPF+:74P-.JZ93(Q:4(A(R4C
MA#[#"$^"AK25OH"Q_E3!N99D?^2"?L)P=F2W$0HN#;"N>OJAC_F_*'AW<VJ"
MW2GO>OR06ODSA%-Q^-E[GH>1%C9R_"RA5T'M#"+]),-F.U5*KT)H(_#\,T-4
M_Z/<%]\:C@=!Y/.<98[,\,A@=49DQ+.YRR1-[OO:IXDD9A0A)TC5^XGH3,;B
M=2LC?3RKI/NGTZ;H(!5_-'2DA70SK1-9X1FJ/\5%L7"(@N[F6(NR<7%9I[T?
M$/EX*D0?3?(!]RO[1)E A&<.U^#3DD3+#Y3@)Y^9 YV(B9S$7IT0X(]Q)0LD
MHK/ZW!P9Y)VBG8;8TL30,O6$@>+F*>=#G YOPDZYGTDJ2+_QOB27<"]R.($=
MS#D\.!SFWR[=M(P(Y)+[\D9:(N]*6-F](+]/R:Y&CJ[35]"A9@UA!O$F<GE/
M\%+5%H[#'*R28ZM.$L/( _'GCX1<,PFOK'J.YEN#W3\C?G//[G-QKM6VU!G
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M=T4NO8G2.)HPEGG>TSMQH=,$CGT$!%LGP-\P?TL\R6L_C*XORQ5^+BX.E^E
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MP-&90[,N&\OC5?D@S2((;*L+?D_"6^-;T?%%&.N92K:!5Y/IE]KO@)[J86,
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ML\[T6&EZ<G:^JTMW=!G.;:R('U3JVTYB6]6@U.\0U=S]EJ;! 9LY&L(RTL+
MM&17]PB@-U'B#G<R== TB_C,T51>&/ZR=P.A(V^ZU_.U[YG$K>U<OM^RF:0G
MP[)I-DTVI,SS!V.M.X)Q^)V[%FB]/C(D<IZ$F\I9X9_4LUH$WU=9+@\_7-/6
MI_';O2XISIO.U=[B"C<HS-UB(ZUTR@KK=#J+-B(EKW"$9:="RN2MH3B+:^-,
M2V<X2_GIP"N6G*]"9_];Q]/%\'__S/GU?W3^1T32S1YDA6DOAAX!'^4-4/FE
MCX!^A=6'OP%;/TJ%OKZ2?8+UYB4#%N%/F9V7DC+Y.5\EY'IHL01,++VX!52N
M?:7A=/._.>N;)BYMI1N_JL(X "="'(=X4)1%B( &ZM\#\U'ZYO>#O.JX'C')
M_4E[#X,YO[9]%B'V[ZE"(1@*(Q>^]AE3B *^M@76_9C94WMMH=SR'73YZ,:N
M1E/]4-W*Z^X3M7;;G]EKL)*7[>W4[)NGAOJ^$A9LKN8EX/CRB31+Q'J31F2\
MHSNRT(]6O;3_F+Q9IZ2WCEX[5_;-I<T[E[1\8;M"+>?XO7C&J=81>\N2'7BO
MARD0EIG@KG0'#_SPH6&[/6ZFJ-@"<T =@''#L0:>A8__Q+O8V*[ID_D6]X>&
MO;)F8JH3T?)A_\$;__K>7M*CFX;\Z+O[2/DBN743/HR3<W^]J:5>OY(1(>ZI
M4]T=G& (P7,.H9/A3*B@87/!S#CFJ-TO+51LC.6"!I6)EUE'FE@Z.0=:]A"J
M+:@)Z\79Y,1&FI YU?/1ZH#FQ-@NRMCH,&"K=_$!K@QSX_%8V95Z[R+)D361
M3+ZGY9W$NO^4']P_SF2T2 0+&:G9^_5N\1,K$3_U8<.#_0F2846Q:\'PA/+Y
MY/K$03E0R<+$M--/BC7_9W T8Z/YQ>!!-QN.30S\31;B0\7'^O'<)P\?G#/F
M-]M(4&()1<I\!=DXW"%J\<#]'(RVVD)JA-&?S9YEXD> <T3ACTB;S]MJ;A %
M7<@NR<!(">92SX0Z$FD_U&XJ.FW=5-TX*4%19O_6,=&H5(F[%EI:K%^+2 @\
MP$TU8(*-2>R5?J'.\"*DR(\];C8YN@0?Z2A=^K/\7D,XP&#\_MP'A"X4/8T&
M*L2@>F(#YOIH9M_>:@HI;16]2OT?L%QS49M>G<@3@B*&HBV9L@5;[>9C4I10
M=I'R!*B._"V<%QRR*!A"(H,@_O)AF/@YQ-1 Z90Q-KGQ;/-=-)*E\23>BQG?
M3OX4#E?^STP<4G37PYM@M7N' D=3=&)L&?0YG0IO-_,%7R$NJ075B'?4\.TY
MA3(%"FVPLJ&%-&8/S-4Q"<A4T<Z(B&"+[?19GT*&N!!S?%&!WHD[.2:EZ,FS
MWMWK$!<%4&^B)[4B=<"[,R-<+"?\%[PQ?2>7/; %J9@<?97B7;+$6;?@UG'&
MD2&8R8&2TO@'/A6!4'H12[U$N9\E3LYCG_=MV9L,C)H,#>?.Q$57,CD@K$(8
M$*O0G/V0HOM<79BDZX$7GC_-E*U(@]!Q]G*D!_]P.SR0Y.PJR&K"._,BV$<X
MV.'N=?:5>P !-(4)689<7S&=7U2H^TV^J63X<@1] T-VXQ*[S%,OV24L[;]E
MO1_B '49W6E=P3D'.YBRO2"4(O)M+1@'Y-X3YB#@'A+(XJ/"H?3593@H=KMZ
M.Q'37?/1*I&5P8 ^]E6S2Q]]"(C!C=%46$%704N.%0^'' D9S"==B[=Q7;G/
M%YF,:(E/R&PJ&2\U,SF?X;#!$7SEF0(^NAM1([VH!<X;UN8RQ6>RURS.>.]:
MCB;\R_R> 6PR\J$.Z/9VFZ]^'MX)3<6%';0GA.,P8PXL4V2)]\/%BYDDOPDB
MR^\DKPR6/]+.>8\V; PVY=9!_P ;8EV<9 VWC[WLG123V3^&DB]E$"!V;GR,
MZA,74EAU-H3"PL4:^K7*"YW>KT*?OLJ QZ;\OLKD-[M://Y;W68Q;H S@%\#
M(17^N,D<=4GP+0W@U*RGXZPS39.70?!ZWT+,*4(CB0%,HNB!#UV4&IT%<>I.
MUYR:XM=TCW^'XUEFBX%+E"6.+\)U;&2%M#5F36=O>FJS]I8$IV8:KO[+[M!'
MZ##'02*L),.1D33'=@:[RDG@/.5]T0RU\XB*8\F=:'"7S-&LGK6(MG2X8++,
M;M0 VV"+:(<L0'(W:6)/LZK^J=C9L\JQ0M.,C%94@-Z4A.ARA'Z%VX+LDEH@
M1*+H4U8MFHC-P3J$^/FZC5ER74R"@CK2@DK>0'!(';\"RK)L)PY#"XJJ'&-F
MJJ8K?\)DU"EU'1,8SYO-^%L2&B!3(773\XTT803=/>&#)O0S'8:2=6%\$K!"
M]AK98V6AP1JV.3GBGO;[U5_?XB)/1[Q4'Y*7&]:]5G^[&;T%ECVH)9=S-MM3
M!)D+Y>9#N7@OG;+UJ-B*VBDXCX.6FXT4Y]Q$/[3S]>1]TE245;O$^W! ;$L5
M$Z!6*6;:4&BPDZ(ZK'?CM^9OTS))P4H?,CLH]]P5(?R<,?Q#!64@N:N]&]N*
M+7EC^7%T; L;>X*!3^FE-S<P*6OZA0BWS\[4T4[I9=IF6(Q$(CK.37+;JVG(
M XZHK;F"H_Y-'DBX%8C3Z33>NL<6&W:Q.P6O!LE/'&R\^F.KM(R5]5XI=(,F
MR>+(MCTI1>]BCT9PFEN@5X[!M/;&[*\&%\GO6$N@(K[LM2K=3R4P@,/)\S5<
M*6SEI[E+'HUT.ZWV[A8T:?S<:$2XRY_EZ,ZEOJZQ=<+A@G>P?-KSKZ8Z&]6U
M(QWY4 Z1RPO77--XKZDODFR)A:(R)_52GGTI$O-(^9Z3?#<2QI91[TGV$5E]
M7QMOSJF\0M)531_14=[XK$TR09%"UX84][H4?J[5S@R<MID#Z^8IMS/,V< !
M;(].A9PKZAHTR#B,0>TW1"^Z1CG@.;>3FDQ72B"0S0\!BN_L6BE#* ^?]\"=
MR_\:SPY8NOW8S\9D1S,OL'?!'(E/\@?KPY9/@T?J3XY@&$>V'7RBT^X'LJ.[
M;6B9?:S1@@"4!ZWO4/Z9MX'.8'H:)])F,+WU\_Q7RH,TS,"Q58<NJ?92*LQ^
M S/NH0J'%1Q\X]LF-D_*$ U2$8@@8NO$\-^5?$]X_:^+[%NG6IY->%>9SHZR
M&^,(Q<KDVB%6\02L0RN& R(KL))-C"1C6GM VE!L6*D0:"4:_=+I4$@0<Z4O
MF@QYFD<4:;U@&!O)+O&Q(=_0H2P=I-K3*D_.K3(EQ>RY:U*G(NG1Z4\ZS=E)
MO>MFQ2Y6B<TT>[#4;6C]L_8/Y8_OK*OL[];TTG=8?5RK)=M"F#$V%']<]Q6Z
MYX*":8%D*5%K>]^JW0=<R/M0P@>Z'JMY5[N%NTI5GMX]9\&.;26>@;TG@E'D
M> +N45A:#OCD81)-?X8]X6_P>+>\ SI'N'M)-:"-,Q$5S08PWP+/Y]\? =88
M]P:ZW/#GIZ\XOM#PQ7)F:S<8OI=Y6F+E_"O)5Y+J,]N%.N&/\$[-NO#Q8M.X
M"N:6=#;^\ >'&T6ZSG7-R!K[/Y^*0;>_/G'8?R8OECQD(S<\[L T+E@ZN]K;
M9];4E;[V%1;L?Z9YW&57*0(VKQ,FP_34-[@,O/C&X "V6SU]/PFOEPAG^%/@
M^*GZZMD*25W=C  W:<>J"=^:/)^ANAAD8V5I$Z)+EC*MSK0:P\!O3PAT$;J&
M7<J.#ZS3O+]BMBC\.+8\]L8SZ -"<HU#V-)'ES,N"?WTZ:K_!+U @:@&"5O#
M(O/1X3=_!NXNH[F(F,A%IG?/0W\<"!#L<=*/W3)N&@VQN.$V<%4L3Q;P 6L6
MGQZKPURK2Y6C=879P0JM;!*+<XS=ELSDIVR_/O7A9[\LA2N[=$_E+ B4K^4&
M%PM->IF?\R.#AMB*AE[WU$N0L((4=&KPXG@NSO.YER=R\=I>1P4B6?.'V!JB
MWH%$1:=CV-JRMA?9KRB6=U>QHSE1AZ]WW_DNYT\<%OC)\ 6Y9-;\,9BU'R;_
M_CE<53#;\X S@SWB5_JBI/0/:5(I[*MI2M9_]<<B3:@P6%G%&1*'S"W<*_I)
MS52%:QU/3^V/OQA6L,TRC93E<2:^+_-15!CH\\1HA=L)6<.T-?1^E$<EPG;.
M.J].3?</";8=W0>2'0^M*]O..EX3^QDA,?G<RA!Z"_//L3(6Q&^,>D^4!O,0
MI'QO:']%38T'=V_4?-^>SDT<+]2:+E0.5IZ:4SMV8RL,+9C7S6S*0;(/J")I
M\86?_Y1%XOR#VM;/?Z*,0548)E+B3^;DLBP?V8O,;JL9-H![6CWSR12X]4]:
M:5.[9D?VC@WM304JJZ))4G#G'@$XD SC]EI[BQ?2%,1$O! *=XFO>4R*K/4*
M8G)Y^C6-*BO0JVP^D:C5WR/#O9S=LABC $@7L8N817Z8(Z/^GWU0/D!<TRSL
M$8"7^Q*);, .XKZ0*F'0'!L>GK;05"Q>+8!BOB#/HFS5ZR9KFR)@LKW[S^86
MC/@&\")^FU<H8)%8?^$3DC/?:-2QE^7=_&X]U\8?N9*^;V.C->"ZE-HD4D6\
MB0-7)B]YDY!+HD6\[\,^H.SIYG[N/J=:RR\0@^6)K?E31KK;:,@G<9:06R!A
M@H%CT[(BG7-_I&##]_F/!1P<MBSK&8-BWV?5E2C$_9U3G;M3D1=SVX3>@ X0
MQ@2>7,5"=%B]:G!G*\'E(=FD>3].IY.0H,PS,)]73.W]QE-2P9[:J,=CAA;7
M%?8*VI!B(MU]F?@M16Y#U<K1&B'GR,3[R_QATFY%[J1,H_WK$Z(9$[9?MJ]:
M9W"Q161&\=\BGS-[YE-P0Y@K! _2RU)0>UX)Q59@0_P0L9)@Y1(2*ZU$&I?O
M5,;Y+(+*K!5NI2*+^^);AW\\%9:6#[^[]9]#,]\N>(9LM(]R8F844@:? "M'
M['ME_)P^+5MD:.1(AAO$5_F5@MU::)<W\@70[_"+R^VB&!S?J!<:+LTJGEJ7
MT;F)@U:U\/DYT 3MXC%RFV*,]:F?943[L/Q-V@9Z5.#'#.TWG&NSOG%F]F2D
MY4?SY4GF#MDA=@,&=- P8 B9Y]RZ!:X221>K> @[B:Y6:(V^-U5LDG27YG^>
MI. ^K^2TW(:$[!"X5XL9JB-GFX*>CI=&(XT0O(C0:BCB=7VA,GF C?4Z4VI(
MM+J) 8KI&Y#YGJS;'5$ &.E!G7&H8\BY8KW.D^:86VUZ\M<;V(5*WV8-+$"(
M$;$[LF,77XX#^=JM'Y[E'(7&2%"O<BJ8D*F8*% KB(.XL=X%A_[MKCNJA?#W
ML($$;'+YBJU=(N5LA"V^[@F^IIG/%L>F>"#LNWX$[-Y,JX($TD4JU#S<=O=I
M\Q\!6IOOXFT'C.9D[6? =""A%%WW"W9T(K(\Q;F5] B6&>F8I%YWW.S^+BAW
M@#IJ(YAAA"=*99 >(0FF\U#J JU?!RI$ 5T5E/+LSIKECDZ[,LA^S=JWBJ4<
M:FBV[+DN$5S'9<V6$RDF&8<O4IB84%@B_GVR<F:.UPS2XWX9]_'8,;1BG[SW
MXF8Q;2U0RDY^GLDN;'4MD1"H1J#C0H UC8Y"*!SW_;C#Z$<9WEI8JM$+:WLI
M2P::LVSE1K/;BK&_'CGW%&O]*Y<\BFHPIHI;!Q-M.' Z0EU;Y^?KPZR(==ER
MNIK%2XJ++"8;EK7>.&^Z&JW5QLTEU\T(]2P1&%^]E6V,T(*Q&\V49[EY6DX6
MU%;7Z,G.64-]/"N2QQ;NY]&(SF[?WY6 &<651P#IE4?OC^K%*]V=&<UH7BJQ
MA(*R4B<&7:ZJ3S'YM1Z$I:3MYC7TS1'$X]B^QQ="N/2!"O YZI9'@-3"C;>N
MQX\[FV7I%RJO"RHXAV>#N^D]S^ZE)A=,<-TM(R1Z,LC-H_Y26)W:Z,99?9%]
M(LB#-.C A!?N;1XJOXH2=J^+B\]E-94$KKOE)Y=T=-;1DS!0R7_YJ*US#=5M
MMKK(R5939N/TA<@E+"V:5#-..*X,5#7KFG27S ./8)$GQ+]R&KD&G81]OT6K
MM3NQ$4=T/P_-Y"QS_NDA %_HO]X2*H4<!V44<O#J"BQ%+!%4.-#7-?AI*YV:
M6*FD:ZL1_BT5QMTTGAUSK61R3F;2B8(GNE$P3#D(_/ID:HGE:H,7_9VOF@>O
MK(ROK.PEVZ!3^YJ3O!4;/+C"LQ"%@5PS/P*P,7U@>:V(2.CO!%&0J12&BW.O
MO$YU?VE,U_D_7@I&AW/G5B;UJN:;*BMWP>!9R;KK_;1 84VH<G:8B'Q]R#/V
MN]@7[F"IDLR:28/[RPC;GQZXN3_&-MST'L#K.6\+=PUADU;0V27#>::)0!H<
MA,XCH-6$I*I/38W]@.W\9);<]Q,;VR3]IK*F\2!8"Q'O4-Z27Y[BG9<X#9J_
M;EXEB>S0R=FRM'GGELT\P.9*RY&UZJ/RURRA6&%@H=!M> +D11#2BN=IUG7I
MM$/VUG17./&@NNMB@LA0D<UOQDA?@S]8FB=ZQ6MU(81%N7S)-"?\8ELS7Y9+
MH+@7IZF)TVAVOZEN?Z%FHW0%NF)=:%JV,\#.S)RG9]=CR&NJJ<22$S[9ONOZ
M?U]>YO;__7+O_[<2B:_^Z<1SQY-"JA! D-67_[]&#_\_E1>+08\ 6D3 3,TC
M8.L/%%FN(O,(B!F0WOW["#C[(CC]^_]4Q'[[OU7&:E$!UR_G ^:X[PE)/O\O
M);-G]I5"<17VTV_9&0SMR9S\3P&5(5[TI]@E2E9<D2(L'2'R?J>F#,=DRY17
M:*V'N?%S7#^Q!R4M\7HN*S=T(X+Q9+6!OX.J.J]5*9J")"O!P"(R.ZIYC']H
MA ?%*[#=J+F9SHH>\C'E RG/0(32M-%@'S/;_;5?L_K*4U:FRL2[LNRS K.1
MVW6K/DP81/S4?B[J#%;QIGIR^56NAZ-CUQW!M>"8YVI'BD>T5N>V(*L TDPU
M7)^SO)L=[BA8.[(AB%IHO?I5,HSW/]5]H,\:EA*RUB/TGV+,>)M'T14DW@EG
M4I!1Y.8UU<6E]#*[+_%5S*N@UY<AZ^]/"K4F-7Y*"MO]LYW@R)V\K'@G(F%M
M:!^L@CR(.S?)/!LK*$SYMS4992BRX[HCOTBD>HLLE31$E<UZJ(\U_!.3[C#J
M*IY57:$.4*G'P+@L&A!+G]"-9!Z=.*3@;QG+6N+ZZ]::_*S)=]6#7XFH_-CA
MI7*URZ&B?5F',86%Z_I$=[Q7^0"PJM3H[N3<3AT;MFG(CL_G]\=3V&UP3>8N
M@G!AM6*N)$?[PB#@;'G*5FMP,&K^Q#RCR0H^$PU1(8AP-],M0;3$0T"<,(^<
MA;_0&TI+?GO]@=X"9IZN22?=J!U,5-*5MBH:9C3UE[/,8M<[WN4%F"[:"9M"
MJMV#N;#-PKC)*Q']Q(&!5^FH0ZJ74CELU4#'_%],0B_?DUZ<BJQF]B,A.RZ+
MEF.'_.>_?Y1E_DV!?CH:>C_O++DW;M3/@!69)[1+Q\ *I^'QCJ'QI:\Z-OD]
M)3!4.W[.%]LGPN-8VZAOJ63!:,5RI!2K2&PTJ4(1+=C-=KMP9F#*I;.NG<#*
M*I<8YZP=#[Y.GUM7%4)2",RV3H.. F#F=(;$8(7M^J&,QLAY!O&)=5VT1)RR
M+R;24#UQ%(2FS=AS8YED82X07[U[R$A0Z5VD0A\O1D$+7X/.AE(IU]NJ&TY:
MQ[%3UP:P8N?G0B,;)5RHRR.K9?_Q'3SO.+2^PET5X#"?.L.F[6C=U93U@:.5
MS?&E<M$D^G<45W$.,M$!!*.YD7(E)F&\?9"S.=?_WD[H25$T+@6^;I%.LV_<
M7&.3&5?A)_Y/Q&P*2 X8RRA!"A^L5*6MC;CU[ 89 T!?D7GQ8TU*V-ASQMR,
M6^4-3E1[O'0H_ZZ\1H/+'KQ;U4B;\R6EZR-&X)YF(.^6*=G6T0*Z*8HPHY]F
M#,.KZ-VD\Q %<($Z2[[F1/@*7.7BL*68-/^+/94OA934WZAZO+5%JV-B_<GO
MU!O\JB&5AL587G'VC?"*E?=-R?>B+SWW/Q99KC68TI28Y"IKFAJR()MO4RWY
MO3W1V#^&[736IEFG<Q"-)G2V 6:)!U=BHWDQZ7E$>83GNW<W?E(HYNC+CJ(K
M]PNP^6QFD"^W'QWLCRV,BU)64IBUQJ]+=).IA4#FBJQ,10)^E:I7&PCTVX<5
M",S E9X,QHBMX.HO.SEY?&GZ%$D^CY>I<GS8>2_=ZYY(.+=0%^>1/X=,3RLE
MRW2\T.\[R/H?\!C"65@G3I -H_4>.('-4KBSZ; +8U,(*^LLL\HK.^ ;+_C-
ML3;!!3UJJC8F1RJ)CT7L>M&2 J4**'T%-8')*2GPT2)H,*6-/@&QD,EFM%-,
MR0)T>@$2(1^X#\!/2%]]C0LZ'DV'0MU<I_4:?4?@!4N]I-J.P+#U(:K*JJ=&
M7DE/P5A\__A.7E;H)%UX'DNMT!V_^+F=06-6U]T-?P1P(#!NIO->(S'&>!06
M]QG-RCPVQTSQ>?A"C'M!TI$\:?BMFQ3_+*M#L*E)4[*!,VGBP,-#P]'#]5.T
MX<@1\>:[VN.JR)7K7);>"CZH:H,T=JY>P\D4NI-3:\,\Z8%I@K,,;9%758<P
M:GA#NTQ4W4=)&)>$7SK0L6VFX.F^I'B4$6:39;<\W=NM#,Y/&DGT*G3D6UGY
MO,HWO-9DSL8R^Z-)1[?OCH660K&^;\7D]<V^;H3&#QJ1^4Z*_MU)+@4>$4%*
M7[RKT*8HV\YU[Z>.;F[FO%L""A1C;9LZ1[^F&_PK6)"SQHD.TTWK[JW;IA?3
M"Q3ES%*Y49KZD9WI2GWZO9COCJC9"Z<IIO/I@1:4*+65861>,&A@3*ZO8M,X
M(YED\L;VAUMP5,KHBZKJY MK' <:Z"]]47*-8BNI%8*A^(6H[4S[B3;;=$.(
M%2R@.S'LI1.FIT#.V<5&,^8GR*7.U'0UK0$D% D(1?HLIOXSP]OVIW'$DRM4
MY$K@>K?.++[>D/:%?@?R0?=6MII!D?X++Q]S$MH.:;?N&9XVFJ.3!)ST2I^+
MB]#4C8 I[,.%D0D(VU0ST0X-#9V\8Z+-@O4!TEQR!>=X)&O1J=IXK59C4Y/]
M[!TM(29CF6NCICIE&P!N3)E>!$T&.-MZ#G_%>_)UM1*YNRT \U%L^HT2(+#P
M>0/2$CJ9%3(@U2\(CK=@"K$VT*R*6MWH9VJ-;[["^9<:J%ICGPBH$K=L.FT?
M&.5WC1,%;%)8]9)ED21*VP;@L0Y"Q7Z+CC']COY%Q?$27T0J(VM2D:5'VR,2
MP@J'PQ4@0E-E!ZMD?M+X*0RVW>04)\)&;\G4%D>4B1PRV55=Z@>5A7Q<]J9F
M,GNJ[ACXU"QC>A)W"S?MF_Z0M1'29(?H/EU6$#X Q&;PC[5>Z8[)'WT.@F5M
M$ZDSHFK&G($S1.RJ< _7!]CDR?-.!6M_76)*S0\=CLDQN=)[A_;59*CCD'PB
MYSK6VEVO*3]_NP/8K\W=OA;!-MO=N)^M(O&L>[, J^ORVJ^95P3+.D?DNT9_
MV;W4PIL.[M?]9FL.S@Y;&7X<7?5WDD?Z[BB\!BGHL.4/)R1<L^Q@&EOFEB9/
MU-_L'O_*>U*M?R2,=];+>YCY"# S/)3@SQEX!+R2,VM),(,M-GBML"B^_[6?
M53F1GC2EJT)Q^BVRU)SJ<R,[[=_9'FZZ3/"Q_&(^C.(U8YFAI8' =Y+W'(<!
MWH2>=/$=3'+4^3ZWX^.N8WOP+&2)8CXEOSFG5;_F%ZN3P1? *LOFFBI;#\:%
MY.2PK4Z;J9DZ-T2H( 4FL-EZ+@4$.CGETL^'FEYZH ,8*%,M8"'1[]0JF)BB
M[.,TTG0L0*<N\CJ:#JKGJ)8%HX8C^>@LAATGF8[- OZ^S8QZJ=I#(L@L;:1K
M+>;\<RP>T7U.[\D+<$-5XUSE$,U1_^!0<"+K$Q#)!Y'WA <>2S7=,#A''0U3
MPON?B)_S!C%"DMV;KN.?M!0D58!O6!UB2Z)0Q-(UY:*I/=IK:2OB'W1<Q"72
MSB[NO&>H7.Y<WZ&87<\0Q6IS1NI^D G3U(,Q55L#5YMW\<<NWU>!*U-LXVFF
MB2W9$S#@]"/ ^II4^KM'G.I:)BDDPK:>@-=U+J:._/Z35,#?YGD/HCU)I^<^
M2]_W7 .P['1O2),X)F2(XXR')+N*$U<.UB.3WE97#+QT9_ZBN?[VO?6Y5!#W
MWJE+V;N9WFC>N'75W+>9,IM<1<HW#F_2\"-2? -J[D]+O1YX3_1YP800;I=W
M/+GXH[-1R7K,[E8OES]H 6$]NHO85!,Q5;K>K0::>M[VLREW_DHS;[M=>6,C
MG<DOM0@A1;?OJF:@];WA3:#6;6B-1&;WNSM5O%S/@3%1[)--M)QQ1D.!2<>_
M1P#NCAI"GC0?Z1FBGFX@Y\5K][.'+VW?.AX;;"[*6S\P%WYCI'*?X4K.Q9"I
M/^/&:6(%6[(-)Z_=LND[^N0[]-?=0^I3I=2'[J"TFX"P5MHKCYYW).C0@_VU
MZNHJ\UD?R @5T=_*J-7[I63B<;%Z%TS>N!+P)\?([1E(3]G+E*ZS-"42^"^>
M?BU]?0Q':-X+85P%]5N<EIA-7L079&%S<'M? M=-"5+FN8"':T9>VS"/,'(B
ME,6$_AYMQ/C6[21;U%M1G?:IM66BX&*A7>D$FBT-;1-N/E'O5 9,?2+,Z-EW
MN:5TN3E^LH.P?H=1-=7Z?_E!E?Y-#]=,?^!6=.L.-X!PAQ<0L)Z?ITW4^CV_
M^YE4'@OM7GB"M&TZI_]E&(KKFA7RBL8G:J+_R;,_CP#E45%_,6&4H&TCO&#B
MW'CIR(=ZTC,()S03E1U1K.RNO).@6/@Y[5V ^+F$=+L_Y6\)XDN/NDO$CACJ
M3,51*M>EJFM]MC3L.3*]63[Q98J\ 9.[%V-RK#"//)@:M='VC.$;O>OJQB-
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MOF+7D-UWOD7M*NY( ]O(M\*E_8PI0&97K#V:J--T20]Q=M$;+\S[]@<WV9I
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M2]F)57-!3+_YMPLTJ[5Z5V&!)*X"32EV0D",2,V%%87J(.DF-8R0:SN8BM?
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MK,X!V\A\6T)I:7PH9HY-1K^YTKCBRACPY..':ZDM&,AX4*@J>$X$W9!S471
MZ7+W"?"KMZA"Z%LK(O*QD =7.E[.$85<R6[X>$.KHR6Y IOL,Q8_1-T..;E-
MHSIP)X#HQH]_'76U/R!W0<[U7$M!B.]_<:J41K$:'9#@USQ)]PS4+(I#S,79
M_X,MX5Q)!26UI,.X)2HK:2&[9AEO,];6$_A\**)A-B+$Z%E;2=#$FE5NBL-+
M^PNRKA^]? 0FY@]S2WZ9$OS809X$*8&H7@!$8V8'.26I%#F<H40G,=7Q+Y"R
MOOTHI6XK<+W/5J- Z-(UDA9GZN6'4<0^<QU;PYUH;&ZJFV-$VOXU&2][.P6(
MBDF,__#FA&KN.^YG!YVAHQHKWN#L]V\,S@/FP0R'_,M61F;-/Y59N5N%3]&F
M__[\U7W*/L\ K;1Y;_+OABX7U9D0;>2]"QMBQ$7W&ADL<K51[XA?8E_UXHNL
MPNO7'D2>,'$I?,^_DU<GT%>MJUM OT=#NY%TN5.#%#51,VF2RJJE&/_8"!WD
MCSL_2BKX2L?+01OL+ =%1F0IGJI/*:M]P5L_,;KI&L]+9J M%W:"AYZ!&JDJ
MM!LTYZ=W4JYS8QB8-DD=50)+IPC,<!X]T&$>F=\%HC+Q^DN^Y)J5!2WP:P9E
M/\[507VJ\JEZ@BTJSPI(AV5XY:DL4>0 :W6R#5"-+'4GU:;?<14$AE?=GOG6
M(,F08=UNG/5M^ $JZ$?8!6UI]AH,46G-I)?+)A_?5Q=,ROF"2F=JMJ,4[)L?
M[+V_]M6P(8!AJ8X_T_?A[*.[U0J/EB5DUD[\L4<V2A"$IQ/;U_L5&(6L11HR
MGZHL=.6-],,[9H1A/"?'43M_SL@.K#-^%Q9%O[U2KC%C)0@<#GQN^ZFB&:+V
ME_:,Y%L&-EGX]?0\OA7ZL&4L]'//PE[VF8+RA(&G'8G9PY'O[QVPR 0MP6^G
M34C2!?0+%D';M4*F<7=E_.-E=F'K BRO'B[?ZV;H8G5L>9(U9'$9!VJJ*VQQ
ME=[IXU 0&N)]^,Z #VV"E$8_1S!);%&A3]9Y] 2MM+L95W/#!P7*J?PB2 X
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MHB86R^4[.VE#Y=4I92&^\LDG/;R^_C%C,EG5M)9LP2/R]T@&[B@9N#:>"70
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M<_B8:TF89X5G_B,'7&&5>Z6G-N:P.:6JK__AR8-?[5D$P-YE:H)+$,HU=B(
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M"4V4A+H$,/R=8\]FFE ;%E,/!)!.8'3 2/W$?8J0LR*!3K ;!BL@V<%5NI9
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M*>%>%=7^JM!7V6PMW'%RN$ZY^VGB<K;[XKT#;=7?>GUYF%9"-P$\0A3*&AF
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M^1C,C(+OO:/N-8.NW]S(6D?/W.\=\6_(QPW=S>\H#NN91ZZ%P\V>#0ON4QA
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MVV*QL7HTB<.5XYZ\A;MZ$M_B2L3MS,/PNSH.;F'"L"D<C_)M'#(_&@7AE,4
M"3!*O5VI'5>:=6.<_ ^N&Z31J-0:E?IA.LBJ2=>;QD#J<3M(_#B<9S=$35[>
MQ*\TU0M1F$YRQ*(A#0X7,P\YW,T?$6YD'XS#2CR?\2A_TG#[+=Z6ZVP:F\7]
M9-K(.\=&[2W_%G,_<H<>K^!C/*3-BBJ-:DT?;K3P7;T6=2<S3SL)0T#:5?LD
M[V9>X=_L2?[C>"?SJ,]<.\I_EFYE#\"U\Q^%&]D'XUFXXDFXLWBHJ[9#W\J\
M )LT9FR6NWMX([MYT^DP<[Z P1.7^4'5#J;T9+UA'*SMK-@VVQ'#?OAYPIGS
MX><ICYF%3U;XOQ/W]I>#T\"'@X\K-S#? \L6OWXYB $>WB*!?&_9$Q9&//[E
MR\UYY?C@[8>?8S?V^(=3($;!E VMFPD RXPG,>RZ=1$[5:MBU=O-5J-U#'_!
MUUL_OQ6O_/Q63&(8./,//SONK17%<X__<C""SU8B]T_^SJK79O'[@^+N'MPM
M6?+_S,<<-YIY;/[.#WQN/N)^>X>'S\,/]*?K.-RG/T=!$/M!S"T78/C\$N&E
MUFRTZX=M@*'#9HM@_)W'@/,?<+_R97#PX3*9#GEH!2,K MCDD35AD37DW+="
M'H<!LV/WEGMSBSG_2J*8.U8<P)V1Q^W8BB=<O 574," 7S//C2T^&L%M>#;P
MK<\LM"=6_;",T%NWWL"[\#D8Y!+G6?_IY[?&O$'8@%^PW$NDFJYM^6R*^\#=
M=UT?X'Y^"@@5,J_G._S;;WPND>Q;W.<C0+]_(GK6ZK5Z'*1835MQ#NOX9TW_
M7^OXY. #_%>B%LTA_>J'E9,X"VRXYL?G;F0S[QKN!LXY7(M^>"(GM8,/YW]L
M/($.?-VA&7AL_.,?K1]\&#$OXAM]5Y+4=Q<<A+;NMYDKV-D9BWD]9PH@R,@I
MP%_UFIP"4E(Y09Q9L]%LG9PT#C[@I4JM#8QU&W.IUVMR+O!7H[5B+D>-QDFM
M37-I5>JU%7-9A5OP3^VD?53+P:T+'D6 ),RWZO"?((F8[^3 ^_+(3=@\F'"[
MWFRW&T<Y(P.?L.ZX.YX@EC' /396J#B#"<-0@,2P182"B*:GP73&_/E__><Q
M"*/O(RL(0?YGX5R^=,N\A';2 NQG K/'(.K%E@-;6[7N->L&;DG>K.' !%WP
MW!&W0(JD[\P(C2*8.(\ LN'V'4S"X3$/IR MPOILFZ8[1K)!-,>= IT9N7 /
M>/ D<. *".5E-7.<,U(T6D'97+_EN(X%LP8J=\M!#0J2\<2:N%$<P%; Z%/V
ME5MP7CR*W2FM_ ;NJJ\(NB;I810!<-#Q L'[QD/;!?H7V""+P>[><G-MUB@,
MIJ""P:"P")!I70]>4< +T_8=?!I(8P!G@>]QM5.X"7B8>''J.K/ A3,9\O@.
M*33M!0]O\<#EE^10A HAH'W"/#$&; =>9W<L='!5>;L(WV$SN&8S$%UQ.]3@
M,)KCD@Q+'\"3@^^1&N!G;]-V"# ,AC0,?)B!N 4, NE6U>J-X'.<=D+NT/(X
M.!,\)35(]@SO7,^SDHBG"XHD7"\OVQWE[1(,3XOG3MF24+BT&^75[\+IP":!
M& ;H$P.4.-7[X0>0OL,\>J'QXS;P #2 E<XSB"P %8[',Y_0P#8-HA@XL0W;
MK"8+ B[L>I2$B!%W;CS)@2X)&<$,=[YJ=:+,9J,XP(!*!"'@5L@(#17"(!RX
M\2(QB<K6W81GR,Y?(_UNNHLT)DV=^<O3*F<O97<$1!_ 0HE7! 62!!H[) F;
M>L\%7$4A!P45N)OX(??PZ*Q9,H3#Q)V"F>)3N$UN/M5T?0>$("05$TEJU#8!
MX$4N3"M"M!ER,5RH\(@VZ<ZWA@D0*F0*=&9,;0:I#\S#<Y,43AR&_FYF9^X'
M;,UZZS"7&",)"-WH:V44<O@+ 411Y#7P$2UQEH\>L[]6!O8D\'"+Z:D*,B$\
M[6G@<$\].7>YY] I?*D.@ :%P,03A!H.1%.<$($H$%[U&\A1&,!@:V?' 7.#
M.5<,4$Q!$H:ES7J;2LRT<R2/@O+,(T/ 1D/2NXA,1"!,6&18>H=:Z"\'1"?0
M_D/7)B'*&JA@5I3,5?T6.:#9I8.]S7Y%?#0*DI!^D<7IG91<Z/AR!3GU("<Q
M6(TN+P+@P66@7:%%D^:YIJ#3WF]9H7?QY0_JDOR('%T J;$@<1DH7QBCX"5E
MN#K\3PV0WEM\"\37])UZ@V2M[!UCXS+?5S_E5JW<N8;>N<8^[%SC!W:NL9V=
MJ^N=J^_#SM5_8.?JV]DYPM%_)A'J)M= L'@8SZ^!VL8=W^D"<9^AZ/-QCG:A
MSC<WDD\B[TB B.DG/G/4Q9]HW^6N\3%^6?QTX)M2M!%3 7$9Q0=T'&C5:X/U
M'7Q0#Z]8XL]O<S^G]UO/ZC[ (6SS<0YI47<>3%J*8]ZI8VYLYYA_#)O/D]!W
M07#A\-2Y^PW_BE[>2:]>Y:O"Z>*P7P5FHV!_P88!:$>@[[Y  HX+?+=RA:\$
MI8M3?@VX+)X<!*/XCH7\C-]R+WAAYZP>7KG(5X+0Q5&_,JPF=^ D\)S>=!8&
MPM/P N6Q-<M\59A='/>>8O>N6F2?B*[M]LJWA.+U6K-^N-LKKV-H9_UP*RN7
M).NC]/QU;,#XB)S<6O?XS,,Q#SOCD!.*_]V-)Z?3H?'D1>P,DF'D.BX+YU>C
MJR2,@':(H,'A7M"]%<N7JLEC;,"V*>*68,24=_K"(WW-@$'<8)PU!M\%?O1Q
M;MXQ^*!Y>2_ 8/,5IEQP>9$O0-8ICGHWCGI;W#[KO5=B:^"/;W@XO4Y">P*B
MW6DPG;JQD/Y.8>'C (E;+^;Z"<=T([&9&S.OX\A0J[V @A]<LN%9REWU5L!B
M5P,:'A>8D.$N;NJ5SU\V-)&4L7+5!33-!AC&B(L\]5@478T&<6!_U?#2H2AH
MYI_Q60 "&<A@ PKTVPN@6;DT"1;K%U? QG=@XTK&?HI-NPR >?_.O(1?\Y N
MO0@8V6R1KQI6'.YV:3U 7V&/(A[)/[3M#IY0:B FRH$\N-.PD28=K5K1P0=\
M)G=-KPH4%B(N)=GHP)(<UTLP7V*@(WR[WVPO<;AS'@93$35$.1!7HRX+?=<?
M1PJE/L[S!S DXJZ,^R5LO:*HWYV&*$5MMK@SJ>"\<G.V#YJ[&]):@.8K!\U=
MBAG.%;8*T'RMH+E##'U7P_\SYOBM&.YJN[_RVI963LG:.[[R6KM2KVUAY9F$
M]=W;@PR=H%VX)YU8V+G'HQ/9]/H=W[DZ)O??G_G7*EAUY=%W;B?W*TMAS94_
MHL.SWMCME1-7K3>>QBE41#T]<]33K@IAB^ 2A;$V4W[BP3ADLPDFN@M+K*B4
MUKO844B R;];.?N##W+Z[WH7Q1%_YXB_#"0YZ/EV,.4W[%LGB2=!Z&;"!<[@
M5A2[]JEX::>IQ(:P\66P$C8V)D3Y>Y;2GMQM>UT@6=":_8@C*H[H,8YH2_$_
M]>*('C'P<HN))K#*4UD\59R*_/%E<+;#YV).&8Y"_@(.>;;O)*TXC.<G7NLQ
MHW<QV+_#@$F_2,PH#N-),6/]8?SC'__8O\. 2>_I8:PG4\5A/"F9RK=M"G5;
M2Y$7@<UTXI-*:X@X%HCN@/J:9C!C'4P_VH_0P35K-!,;OKO,5V5ER(\8*\!E
ME\!EAZ*X?I2Z?.(^%GN%;>PX4]=WHQ@K+M_R%P<P&RVTH# %R.P<R.P0E:EI
MD-G5**#%.)![[UQMRTZ#/O/'PF4-/SX#5$V3Z4ZC# KC>M(''_!G9MK[*H[G
M'PC[MI<'8DY[7P]DV=-;X,H^RQ??/= "U_;[0&5TEL?\2S9-ZT3>W 4WLI-/
M=.Z.8LY]?&:GSUF'81F+D8F-:Y=3G/_Z\Q^ ;NZ_) C(6="K@H%&[40IC;63
M^HG*?]:5AP;,XXOYSWT^D[4&.F&(Q!2W8R^ 8>6Z)&2L6=F3Z(4G]]<+X9WZ
MR1:@HEDK8.%)82'C/H)3;3YZU@>&X"L#45V7:2O.]UEPO?XC-J"Z48[M\7"]
MI3E J]'>""HZ\527KGL1P+"\H">A]ZT?H/>M2J/]-*;C @9>DRVXKND _+4A
M]R]@X'$2].]-!^B=YN-G-]::&@::C<9W84#E<[FW\'70H.P7 0EI#E?>NIX$
M()H_ !#-2J.Q58"H?U\X* !BIP"B_NB2PHIZ:067V#8,[)#-*+_"4!'*M$NA
M3#M4]>='P:6(2WFU(-.LIURF7C_:];B4Y@]8<^B=^M'C[UQ-[UQM]R-ZFC]0
MGX3>V0;,97;N_E7KR5P:Q!-9=!EO %Y'%YXM4'4C6>DS"[_R^&HT@LG[X_T2
MF^Y3_UZ88-?LUDIZ]VA2W-JM?@J!;G= /U>H+T"_ /T7K\O4\JI^8[&>>(ZU
M%0,??D89'29FKL\=56MQ+Z!S[<),Q25O;=MV=FZKN-\]#U;U2$!\=)V>+Y'S
M)9WOVB6^DF/&_AF!3_3P)1WMTK+V]#CS;04%_CX3_NZJ?>#'P:3 _P(<"G'N
MU0!&P42>GXELO[!5@?7/K<1MZ6!7Q*45F+P#XN .A:[].)@4XF !#@8XW(2<
M14DXIYT3F_B2P&+E\@KP*.2&9](6=@DP"N;Q++;$K98N+$3&75'^=N28"R+^
M0@^V$-[VZG@+R_WS<-MMMA$LL/79L77G'+/%01>.E@(HG@C[M]4Y)#_KJY"V
MG\5DLD/ADS\.&(6V78!)P2B>47IX$>!1*(4O$1P*&>.9+7I;K=%<R B[8I'?
MD6,N>/R+/MZ"1^_2<2:^*\[R.@FY/HDI@2C_($> /]7KZH[ZC>]_*"T.-IBP
ME:-%>"^ZWWA?!F?_O.;A/[/C.NXM'+"YDLMDRD,6!^'BI]TH:#7J1VE/ROPO
M+[V/%\^X'TQ=/V_835>4&>)M=O9K%YY$SM(V;K@6&,S]]B[$?%-,/9VX,VL4
M!M,^'T6_')R?,SO^9TW_7[UV>&#%@;QY">#5JC4;[?IA&Q#JL-DZ>/MAW6CX
M52&Y-^HM^/]&\[A9KSUDQ*7Y'3W._.I KNK-9N.DW3A^C!'%2SC#XU:]_> 1
MHZ4Q6X\XRV:C5FL>Y:\;;YZTCVKW.Y?F47-AM";Z?FHP8+/=;AS==[3%4U:C
M-7!Z]QYM<:4/&^UDU6BMDY/#^^[;\2)V/&RT^HK1FO76X;U7>MQXR&@&+:@=
M-9J-P^;QT7'[GXL(W7P0>=CP(XW%,]O*1QZ%D*B/',.[S4=!>ASQN%9KU6LX
M[4<=L77<6 *Y!XT(_QZU%TG)\HAO:<@H2$*;1^+GA#.'I"K@IQ]^5O]843SW
M0%0\^&"!0$2723!*_\K^O?@+?D]"-<@P".$3[WP0^]Z+ORO#((Z#Z;OZ[)L5
M!9[K6$./V5_5W3B8O6LMW)IP=SR)W]5KLV_O[< +PG?_.:+_>S^$V^,P2'RG
MDKV!<EJ%>>[8?V>#=,C#]U,6CEV_XO%1_(XE<: NA#0V75EZ"?;-7-;",L45
MM5+/]7E%S;3::!]\^*__K!_6WHO=W?BU]R,0,BLC-G6]^;N_WH!,'5F7_,[J
M!U/F_[5,%\H1R*6C@^R@WYO-PL/9QY>W:VE><G\%XGYGEA9-4#P4N7_R=_76
M+!8_[\20P\!#Z2R:,5_-(?MTWDWYO87/9?>$WLK\^^6R=],]LP8WG9ONX.>W
MXL[:_RP=&&H$>1>+#<_;\$'W]$N_=]/K#JS.Y9G5_<?IKYW+3UWK].KSY]Y@
MT+NZW-HI;+"MFV_D=W9NX\W)V>^:WF_Y[]\9D'E_' =^V3JKGE:M1JW=.KG_
M!CW)7JPD; 5*K$")\ZO^9PN9.C!"4I1=FW34C/:'Q=* :1^W0?+R&5IK'.Z^
M.POL!(T=-_,9/["D"0(X?;[#Y^!#HU8Y)^Z>?NH[B/;\^+8Q2!G?^U<2Q>YH
MOB\(_@8+15E7/O_I04A=;&_^]LI_UV"8D(@;('XW#D_:>1C6YV-9,!2-D=)R
MN0'*6:,@G++XEP/W6_QNY'[C#JS-BSAN^\E1J_5^!3K^UW\>UT_:[_O=3[W!
M3;]S XQ12"F?NY<WUO67_N!+!_ZXN;* H]+=>N/-\"?KJF]>&,.%<^OFUZYE
M\%W-<SNG-WB[?M)L[3<SV5O.?M7?883?DSV\!W:W:T>(DLO8W?']A'E]/@O"
M'T3J.$P43A]^!Z<[EY=?.A=6OWM]U5^!RDW$XWK[C;,I_L+0C5K]O?Q/@<W/
M HGG06C%$VZ-W,AFGC7G++2X[W!GK70GH;-= ZG^I)8'G=?D:>J*L(_[@J<#
M[U2F\,H$!ZXX;%[!B56X?[ )TK1KS9/C>H8EGB9A"+,ZIU7^ 6,]WLQP4F?<
M%CY#],%E\:B\T4:"I-QN'.9M9#KE<[@2;28Q-YK+Z'P?";I M]UDGKNT\2]5
MH(;_'8'2FJNR8OE>BLEY"-N]CRP-8O3EH$<,]E%Y[XN!POU"?\5M8PU(E@C)
M('^()0\]]S]6'!2'5M#L@F;GT^S623W?S#B8<,_#0"WFSY^*:@]^[5Y<H'O@
MNG/Y1T&X7P -0%W!"D86M82W0O[OQ,7R^$#,W<B*$,0 J C&X"8"V0[;2![-
MQKWE/<<H2C?" $SKW/6X!;B&*M8FY*!1;[0P?B@E!UV*J,1QQ#";Z%&U6KW2
MJK5.:D^L/*&2.QU;S$,"-&5C7JO^:S8^L*+0_N4 FS3\$V[7ZO*B&/7.=>+)
M.UCW[)L.+\ ?%"FQ9WZMPWOYM0X?TZ^U@4NK5:\=U>J-9>!2YG8_OH0[FP#8
MZ81/859#ZV;"0S;C2>S:D741.]7]<WAMV]W4_<;LF/8<Z7"ZUQ8# CSC-D9V
M.Y;K6VX<6?:$A;"6/7%-[1<KO QBJS/#,'8V]/@NR"/;!SY2_$7T6A;ZT'A=
M/WH?"<!T_3BPNO[8<Z-) 7M;. CR8N()?%\(.,+_;]<.E^DT-EX,049+_:*G
M0>+'X?PT<.YK$*Y$W'['G3$+9V%P:XMQT"+<BT+&O5VTNFX?6_Z6A&[DN+9"
M%]?<<"L(X7]CYKM_TN\"3[:A.'\7/9JUPQ9@1WT9/3J.$_(HDO^Y@ 77-Y%E
M?G/#.8L7-K,3NXX[+5L?$]=S4%\Z6L*(#69Z!!\Y.5XYTU/X\RJ\">[\3>99
M7ICB#?>LSJU[NSBQ[Y(8("]-#()?,[/K((J9]_^YL\THRS]A@,S[7)T"QDI1
MVAP\\3&)X$Q@V3 :B$0Z;VX#M:C5 G4F1RWZL>D>?#BLMX]KM<;W?$V;N<#:
MM=IQN[7ZE 5M_1'Z+,DR#KS;I/GI"<7_>W+4L(Z.*@#)E5J]?;@+N[!]!B5!
M"GG3+ 3NY,Z89_%OW$ZPMS)<'KDVCPK.]"R<"2A!LWERF'7?"UIWS<,H\'WN
M;:9@/XB>#MPQ ,4YBX$D%K2"['$3EX^L<]=G@#&P-U>$)N'KW(R-)*QZL]%\
M+ GK0< LA#,ICJV3QHJS7'&6)W"6]372R3UDT >=Y"IQ=1,9"U:Q7@#<6,9Z
MR!(*\6QSR(33YK-)X/-WUIM-SA<TNM9AQC2-@-D).7L"#>2XW5X\M9\V@LIV
M\[!=ST017@0V\ZYQX9MZ:QXT\]9)H])N'^8$S3T_T&U?&D9AJFQI4"M;W<J4
MN9[%?.=M$(((9$?N%!UPOG# P77+D*"E;]V2>VH)(>UAPO-CA2P\>8S$]BV@
MH*2$;NS"4"%9H7G(';2IQ8$UY,:ULC5+PBA!#PG<@M?(^"82+N#4, JI8^^<
MFSI&GX)E<\^;,0=EE%\.@##@;YB2K7[G[&[.Y\0&+[L784_?"W=IO5;[BYDD
MC;G46=]ECBMTZ0)..UQ^3MQPL@[:=KMZU/C+^UL>QBZ0./E=D4&^D$\N9V U
M5/)XSEQ^B.K\J'/V21F?&WLBX(+9$\OV6!3=&U3EYKR-G0T/IU8]/%EQ-AOM
M_2.[P1NX*6N0Y=[KJ[>J1P7L?1_V0D;:T6 ^A>^]^0$[4 %Y"^MK'%?KJQ98
M@%X*>I<RO(&H'O]F3Y@_A@N^=3=QX4K*W1\9).%Z+@=[*&.+@]GS'=^SV@U4
M_GNKV5QP0DL);EYO#(G+;:#;+!14/$5V>#6B^H*DV6!,6(<FP?PS/@LB-V;A
MG KDZ8JWZKZ5/F"))\H"W$(^@Q]8>1#C&N_@C[GUIE$#:3$$<HB/1_)Q/[!F
M++1NF9=PC%\7-QZL/*T'T4VIYJ8@M^LD,Y=9%_C4:AX=9BT<DET+;OU$R'3Z
M^?/' MZ?0$0H +[5:A\>GN0QD*Z4#S9TACT"W"]'/L$4E-WVDD4.^_=2&(6L
M6FUAN1!^?WO#>C@JY)9M@5V[=GS4.'X"N>5*2A<"T"Z#:Q;^CH+%-0_IDB*Y
M5_E22(6DD$6H^U_/28P552Q8_0,I7_OX\+B];5:_*?Q==G:)X=\;Q@KVN@K(
M&L?M^A.QUPUA;4_8[%*J"1GO=R(F:L_R7/\7YE2,T(DC"-Q[*_"].2:SV!CN
M)%PW=VX\(;=-:)3U0F/1HF8?:,V^NA-.N.?/7-X=K]PJI]S8=,J]LY8_G-F^
MR\#_3N+-LSGP]OST$ F%K17.(N26&UE,9O2B62P8PG($XN4>)"5R%P?Y7 ?9
M\QT@A#&G_9?1"G :01)C/Q1RZ@CM0=O8Y5FY493P4"=SD;]1/&5+OAHA(T>,
MMJFWB_S-(C6"[0415S]D30\[N"6<'\[I*J.";1*:JE:'WC4J1Y4M%";*&1H/
M\#5A3F8%4JHY#YD NKR0FGJK=M1LY.0^&9UI!(NX2D?.$W)$0#VV$*&+HN>*
MY7#;G3(O^N6@=WF>+98 NUYQ@K@B'SGXT#ANE6LGK?)13:=1JZE_6&]:?ACW
MLCW.0G0Q351A=*S$3LY_^5O5;2<P6IOQ/&-C7AF&G'VML!'0\7?,NV/S*%=T
M7JH57Y&R/-9Z7YP358;'.T8\@L2J1EH;7LK4R[7A98S"VYS9/TK-[]=.1@!Q
M[0D'/)]BK5MWM(B:Q!WNN.=5OOK!'8S-6004W9'TI(STP>$CUQ>9R?W$XU:K
MUE9DPN [P"P>!NY[D6ZP]9/[ \80?^DZ+?1KDS#$>JMU7&_FA/C^'0[X-SS?
M@3S>'IWN)@E2E\%R6MEZB4!7XRR$@L?"YI&HTB+X+N&LKWBQ4+E4*2[Q1!E0
M=7/\]P-5#@9P'$3!$09*BH&B?!FQB5_-2(H&'5!&!R0(>!M+_A2$87N$X;O8
M*'9A<R+2KA_7CYO+1.3WP$M\=*A@"9IPHS*>!?%X?KBY#&)>.44:(*H] 4T(
MOEEL")*]=>=ZGL1_S^6W*.#/3>JP9;(@2@;"@VYHZ*41".L@=,)UU$?DZ \T
M!!6PL$XLO)MPM!4L\H8W]9] =8OHY!V+>9X^?A,NAEP^ &,^ !2<)%3P.0M!
MHR1%L=ZPJ%)Q9+V!\="R$26@\D:3 &OC*"4UGK!X<>YW+%J&7GI9KN&G,F4!
MO&F(-0XYAQU,AO^"%>#S]"B\A+.0XZ!-7)A7:)(LBJV3FN6 %K4GL+G3[&TC
MSM0Z.FG7<DP"HC1V7QFYT(6Q69WI/[#1Z4,XE'49Y'/EO8"(ET2M$(L!@:=N
M' /*<P\0.0Q\]!1Z<RQZ&,ZM'L(_&FZ TYVQF(FB? O$+!W#9'*FXMOGXT16
M4AI4;JPWN.]'[ZU&LU'5JK%+%;QF6,%KVZ1-3%A3+![]5-"CIZ%'A_56\R@G
M.]J ,P0S29Z>A![=1QLH2->.D"XRPGDL!)&(V3:0KI A_4%D1@N<GWL5Y':_
MDG,CP/1&"Z05M,Z.K7$8W,435=JU"G(8%P8]5SE?T6?0J+U?]7VZ77^O'EO]
M (I3\J$57U=/*D-BO3&L-)2 :$J%.T? 7GI27Z-=/6SO5FS-<]7J7C"[7N2C
MQ?8CI^HGU7:].)*<(^D\_6$T6M763AZ&#F5_UK/)BA^;F1D/6_7ZJ@+7X2D<
M[CCXL5IIG(8AP+#E,!1UEL<N'ZM(\;T!JEFKMIK/GPFQBZT0CAJUVO%1,Z<F
M85>*%9](JI!5&[;7.,[JYHLQ16CB3HO>HS7RKU"H00N?40P-%MH>Z6I@D8I\
MC5!"!5H1A [<XB)N\4MU4+4^=3K7]_"NH4V"+!% ;]#,#MIZ$HG8'MA.T:0N
MIY&.B-&9>7-< 'T<I^[#QL"=D-^Z$=$O-6^<:2*2'BD0AH5.)%L28DE?UUD5
MM-=\PW[*%;^MS7$5-.#680X9[WY+6TV)3GI;;%JR:^K"7N+-O:UMTB^@W-*!
M3RH@BV..F(00!L"&* :38F/"+!V?1M%I$5Y2 ,A'(TXF$U]6Y7$)#T%:\IE'
MH!,&GH7Q: ;HIW&-PF>D0+M5:QE58@8L'#(8MG+US>-S<CN\J;<)HT^KUE'C
M$$O*_*2"W#*AKD,/ -] L)$;3C-$A&)D*5C&H1FSQ'%C%2&W&1H=U1%7ZZVC
MC-.U9X_"#@X6A)UT2\\]EAOEM@N(5)0\6L.3HM3_!5"S03QUILC12IYCHF<N
M)PN60SY\VTL<$<\E7I->KI%'SB\,!0W"D.OBY\A.PU"$@L^0_01)A+'] NCS
MOEJ5![@I%VEB#_#\YE?GKC^(IW$7)W"JIU6@P5ZBP7H81B&'P!7]_@+B4D!4
M:&. -I%A[0E!/D3ARG,8B'GSR(UDY7Y4"&]Y9<A0;$+!BOL1D^%2-H=;Y+O6
M7S>11?.KQ=+*862Z=4(0\FY%P(2<@A3E3-P6;B( ^6J]=E:I X)7"_O[4T,:
MYD4 ( C8,/AZCGB31,*_)AG]:A*;):AN)"GJNUT[R)=NQ*[7J\<_;E-Y>1;3
MPWN$_1TUVO#O\5$>"^YH-!E(]7(35Z;6EY\^Z?BX5FT>%X"08SKO"7T*F1^6
MAM?43(?.6.J(4453(IY4C+(OIU!AO/,Q@/]L_X"/JD>O+A,\3U)8>CD#8-85
MBE7;,6D71LO'5A"EZYS.3#G*=60BR3!"P@ 1> ;B,$?11(84D49F_3L!X9C2
MZ=8)/SD2C.7"?]>9+C%^,O"\X&[G_/)[&%C4P\VN'^4G^8B;QX5>L.5,FDP*
MS7>29M8%[63[)K_)299;&>/RP"B]1P/W%X9>*_/G5+3;:GZY@=<:)-NC]DF.
MN\/LT?YPP]1*E^2CTH 7B=ZOR\[Z[/#P6FG!4?VX>=AN--J'3VVT+FC#'AJ?
MK=TS/EO/#B\OE78\*(<U[]*CU03YL8H@NU /Y/X[M3&$+ES(_#1^Z#_E'^(_
MYA<//J !Y.?TC?^H5*QSEWO..ZLGA('*#8#_>\H[>F==G___P\"95R?Q]#WF
M(\$EY"Y_:9S5FO!/X_BF7G_7:KZK'[^W!@BE5NU;K59O'S=/#M];5S.B3.^L
M?WR^N,;*YX&-@1.5"DR-9C8,81=+AM7?M/(O>@'$P=*?R.O^= [YL5T_!*'W
MA+7:O#UL'8^&S#FILR,^&AYF_03O+(0V:Q'QLDX"2P"$11!A&63 (L^ )0#
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MNS>XZ9T.Z)B[_[@&>.B>Z4G=]#YW;SH?+[K%P>_UP3?EP3>KUF_=/_(9M*%
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M+2F&>\RS3N$>)JL5RGD!R$]I5GHL0.Y^L\E++@ YV(X7JNB5\8QP_&B0LE^
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M?=[Y<G$S* ,Q_[UWU@5*W^GWNYU^YY.!V\@ SKH7O<O__M*]/-T>0A= \&1
MH/JOUUM87^NFV\="")^OSGKGO5.*IDM/_^:*DC3[O4^_W@P,ZO^'95;C^C+
M/$[L9'?:[9X5$++W$*(Z&=;;5>OTZO*F?W4Q4,T*3[MG*/5M.>*R..PG.VS5
M_J%^6+7^!TZVV_^]>_9_MGV^A2S_9.?;T0?<J5J=+V>]&VH]V[NYZ79S>I-V
M_W'=[=]LBX@7Y_YDY_Y1G_M').-GQ*2[-[_V3K=.O8M3?K)3/M6G?%H%_MP#
M9+X&>:YS>GKUY?*F8_3M.>]V!1='$M\[W9XH7^CF3W;Z9_KTSZI N;N?R4XS
ML,[[5Y]1=-?3D=55L/7XY5FG?P:/7/47N<&V(*+]D K,!43<"R*Z&B*Z0 ^^
M]$]_[0RZI+L)VYR>3FJCLS[^06I>;S#X(HOQ=,[/>Q<]46-9CM$OH&/_H>-<
M0\<YR 2_=BX_P;%?6OWN)Z /?> 6LH1[:@(X!6&P=_X'];+7/*6 A+V'A$\:
M$CZA=-B_ONH#NEN?KG[O]E$EZ&Y91BS.^NG.^E=]UK]6K<^]RZXUZ)QW;_XP
MW'C;/NV'U"S?U=/^D1D_\<GW],GWJL9I(\$'(1"(>JH=7/6[O4^7UM] *!B<
M]40W!73JW8!6T?V]>WD#C&)PW5ULLV!M:?<+D'DFD/F;!IF_5?'(>V?HW.UW
M$%JLZZN+WND?WR46!13L(YOX39_\;R 2_/$11'[I[BFXPPLX9.'-3]WYV_+G
MMQ_2/;<XS?N@K.J45#\RB]H/;D"2QY;=V[;S%B?]9">MNA?4CY_GI!_2LZ4X
MZ?N<M"J073]!B^ZOO8^]FZU9WHI3?8)3'8!:U;G!H(F##^G?VSK2AU2J*(YT
M?9>AR[/N/Q[_S,XK^>+O9CD%&Z51I =8)![<,_' V'OS[&R.+:?N7ZYD78X9
M!EJ=?3D5!>V6/_^(1Y^SH'\E4>R.YA)"7=_AF!'1:%7;/U*5)?OMY7]+/=^*
M)VYD97-Y M\Z#\*IU:A5SJTW6 42_1&-VOO,8W2M_OZGLI7X'H\B.%\?9VT%
MV#OGSHVX%?)_)V[(HW<;;>127LYFV2:48G+4;+'&D(V&M:-ABS?8L,7:M6&C
M-FP-6PYKMY\[Q:19;1QO1"\_T+8>OM^ P)T<5H\:]R+"N9"V.D4L' _?U,H6
M_N^G3<CUP0=@M3SDO@WWXD!!S>F$3^&AH9[2#< 'F_$$9AU9%[%3E:!47GRC
M+&]8!@QBFV+FS_4M>3F)%J_<<74!"T3(BT$2RJMZ-C1GG*[ZZO+\RC"$U8M"
MQCT7-H<F0*.Z,8%]VD8J4BF?+H^ _ 5W'$ZG#+ 43^!#T8S;E"J'ZYG!;\!N
MR@FU@I&>ST@WG8('$@^^, I""[ T#D(\9FL&>QTXL,,3%N,H-L?VS3CD9QZ.
M82UO6&0Y',:!RT/N!7> HW ;$!*(Y31*5XSO+'].5'Y-78]BO;JK]-TD\+RY
M%=SYYGKGY73_Q);=35Q[8MVQB#[#;!LH/;7W8#91A=!R?6/6&8B_/_O]@:S&
M)9I\#WIS;!\VFC5^/#QIM5N'A\ZP56^>'![5FG;=/K)!3]P7>O/X6_K2R!<(
M0( BX5Q/*<+:HTOD!BB+O&.2G<B%#[+0XM\0W2/LY9I%OT7L4E]37['\ /XW
MA6N>]6;&PI^L6^8E_'V>E6'GL:;E'!VU6]P>CAR[Q>QC-N+UP^,:.SIQCIR6
M;1=8\_Q8<[^)YV),YVRPDLDBS'>F'#F9;YV!(!FY,8([%?2-8%X1LM% <(9+
M%CGLWZK,KR4:EEAOY&?$726&@A3JX"?@M6@^!5E>"PR?/W\L+\Z',QL9LN3!
MR)7B._AC;KUIU'Y:1,+]8DU#YZA6:]7:K#5B+92+G9/:89N=C(Z/[/;QZ+!
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M"7E)\"N\J((52"30(0SD3J*14@:$KX?(0(%?D1RBQ^"JURT<X@CF,'0]-P;
M-R45F!)RR+%22V<>\Z/W)7P$7[?%S,WIXN8Z\#TOF%'/!MB&)5D(G\$X$A[#
M=&^YQ?U;-PQ\>CZ'/XLIY7^O!#)0[/,PFK@S,44;K?< F^))\6Y S!T^)<&4
MME-MA7Y*[@!"?<@P@ OU6;P/6VM+)QS<&R52G#/>+ZEE1<EHY-HNJ$ASM700
ML"9E^M?"@+!;YBEIQHJ *L85#$M!M0@$,SK\,HDTJW%)2#1WP NU\ #"DW:%
MJ$M(I):B@ES/6[QF!XGG+#V8=Q&FFW-5',SB5824Q2DQD 9M=P;K6'Q:T*/%
MJS'P=KXT<L3YU\5K0^ZY '1+4Y.B[N)$0'9VW)PY@^@%4V0Y6X1>TF1I?(KY
MF\)2EU<$N!BYH/\L7D]%[L7-<:=:4@N$B.ASI.*W7%(Y'<&T*K0"P4;L)$9$
M!19V"$)FM@:6,#0J2,:3DA^ ) UT;PT)3W "- T!>T'FZP25T3JXI?FEQ!2T
M3!^A <5\R=\BJ8&4@#!X/$>L_8UGF@E43#%7[S2]U=+OF,J0]*PO1M%I$;JM
MW[I2=))0^US3V#Z_=8&]4]>E,*"0MDCKW&('%E;L<Y<8!)#9J8OTUH>-&R<L
M!'3@J!P-DUA:1;CUU0_N?!H]\<7?J&U$Y5)&H3+USRGR(!A*:1]"*4)MRF9X
M8D39A.HEN4898^AH3V!,/$5F3Q![3)YOJ&!"*4/:C,I8"8/_) '=:#P)(JA[
MTFP!4;4HL0XN#5Z)&X3P2;R20+M<$J][7G 'C^1&V&YJ"-NR$=2N\T-V7&\,
M1T>CUJAY='+<8,W&<;O=JI\<-YO[%Y"P50-CQC+Z')]/CWF?[+)W*)'?(O4'
M.1AE]0B^XXXPS"C6L_& )<';(-G9]"2?$4TDVXSFS()\P'@H*EB*\1$WP;'Q
M7]#2(\16#\4\$G13H5)^ S4&R<*^Q3!)^ GT9PZ:>>KRD^8L10B <G+"*D%<
M2$U!\IGX=!4F(+DVO0##2NG2H$?JXR&:AWV]B"$'89-K,1=XLN7">\3OJGHZ
M79"1\3J\E?/"'2>2BE0(J*.:403G""29*)O8%T%O,Q(U,AUF_1L(/I!4M!L#
M@13ZPQ#V,7J?(2T:<GXD=6H=*M\O>6HM>!M#;9(JM<,$9A]1G&DVF&*=4#3G
M6=0"-45HFJ1.(?1.V5= _)@XNFL#ZT88YAA1BX@O 5>(-#2$YWX%N7H2! XB
M6I38-C#R%4[V D)?/81F# =N1&9TE!_YC),9S?1Y"5V9 $KIR1YGJ!0$Z&,"
MV16@%Y-*RM;IYTJ]5I<^!"#V@9*FLP]&FG,QYY8)%@?@;</JR (3Q2!-\DA8
M=\0G#8=7, [9-!+\0N9MF3PT8PI0(QIFC@(I"KEP5U$2G0,H?6DC&.(F8(;#
M$< S/$-"M"4,+ZAI@4PCC%(DJKG^R&/*GRULCT/@&&ZD7.KPA(L&%'C:3B*%
MZ(! ;!SX;C1%Q#L]O6BT"+E@U2F#@D%(X=430C,<'R=H7!'?@0V57GLY"V!Y
MB+I(1!"Q_SYQ/:Z%38GOPNB 0C&Y*,G_=L?F9:$7S^!UC(67]@=XEI$C3WW.
M 84=A+I4:'51?8=-DBHZVK^YV HE'@JE&$<47E22%26UR@I[!;4H6.C"Q VV
M.$H\,I)[?#%%<I&E(5 RU(Z(<45N+'63(8B)(N50@B+]/9MY\+((#1"!.>=G
MG8Q),?=A(AF4_!D*+0TT-I-\2%1%E&1)/ F$-X9"#$2ZR1+#QF^6*40&IDW8
M27F:%F /&6T%=H)T*LWZTRD/R027SD^J?\NR0*K6_5TH;FBD#M$L;UI526L+
MT,X4X6]MSDHEYA29$TPJM5TA4@=ANMY(R@LXGP3MJ8$*E#&$AM5GAPHP&MKH
M+S:$%<#!1*A^XF\MJN@UFKX5);:H&9,E7VD)RH*'XA /03'EHQ%&." L&:*/
M$M@*FE30I)6*)V&03RG,('IK]=$,X.9^&'C(SZT98!=)#*XO_%\+(&]Z)PE[
MDR$0&8R'\4"&X!2CY]O*RAURCU++\Z1NM&N[M\+M2["?0C4Z(3TV%U;GM"2#
MQ 40!!AAPV8QX\_<,54$F&0&7P[^./@@8C!RW\W8F'6@AX\F>T]" 3V@KAU\
M:,A(C>^N>0\C>/(/=3.3?F&K?P$4C9SW_C@0%,A1YF-%8M)4=\FCA21PRY&&
M96P"DK'JB$9W.DW\ ,B7:[OQO*)H%Y:^""C40BD*J5S!*)XFG@N;L2?M[X*3
M$PE+K28H!-"W,L*6$I(");AAL0D^BX4S+BL\: &IT$,*#/F>'I('9%K;3J%R
ME-$AEC4$4QT@9=SC_CB>H+ /'Y<A\@H3C6!B5*[)WR,<,'27O#/D%)(Z CV'
M#YA6@V!(3IF\^:,V(NR)P@VSVII8SL9!24<2A?NCMUVXQB<LG(((L<(Z1"=6
M(%6!5'+B GR=@,Q$,D9"D>=_D3"JYY01<C/:K_NGT-W' >J,TFZ%F#0"39!'
MA""^'V"X"+TIH[-4S-W"**OX _&\/&EZ,95!(\9*5"A0H$ !4Y<<,3M#1M-(
MT, OZQGEF6"(5$>43('Q!62)D8A"QJ P ^"DBDJS*P H<B.2D?"_J8F-<IP8
MFG<**OY\(%PX=.X;!3#D''@ A1 ZUE4X0Q@^"Y.QGM$9>7<$E3>D'I>RU'P9
M04]>FWB">4XN4'YEZ55:"D;:FH,O#:I2X-)7@UQ9*N-DDO:DH1G:,\7 1B:Y
MV9#[?.12SD 4 #+'*F5SQ52R^5;<TF&\-$>I%/%OPLP+>EEV.JG?QN9H!;[W
M>NE&$JZ4) N>6!"4G28H0D2D6*#42Y(70#@&N(JUL]0GTZ(2(3$,/IAS'?N'
MNIU.BK"#F;9%I%D390N3-]"2S,(T!AQ]L!03LNPP,J3B%(=--6\T8FXHX^.9
MI^TMTEU$(84DKR*F"HG YR)4'E:N1-L@'#-?"LAEDV(9NV.:P(6KUV=C#!97
MLZ(T(;%?6>\,2"]A,HL7$T@*&E'(S=]5'1?#88'/V7$VD(G%RA:IV=$,\Y.Q
M/@&5>H_(>RG&<_T12M%<<,WOOTHH3$*XL(X8.5RD"R*N*,70C*V2(862ZYNI
M!6S*QMS!A'7M+"W+L@>$5V)2EL?NA&@A?OXK"=UH%B8.X:+"JZGKN]&$UD)%
M0HF&R$6YJ:-Z#',-F5<61& XQYP$)MRW"TE@Q@87;+U V?N62L&\'>V^1+-D
MAN*G$46JMK8$9 ,]4F\EPJB$Q+2(1)KXB0$'K@[*,BI9&QRF -1"_MQ!-!'$
M568"@HC%[42F/(* 9?@9R',0V(1,*<H@N'\9"!.I2(];;](4_,=/,%<NP3P9
MANDD;NA44!2=HW$*R3]*=<;'N@FP0HY<*IV.YE9YZ=)SJ9%B<K521KVY%#*1
MTV"69B@42Y'_* *95L]=:J=1GE<C#7;JF-5(! %:U*'3I('%.:PA/TR&#AE+
M+>A)P?CR)SX)/ ?MM%@.ZVP@<V"#6,02&SX.T/*,1Q&VKE3A:5$.>ZV$]=H#
M=)HO.T"GB,9YM?1"&631SFW84[#PS!14NT 40!$*J6ROLIZ.Y)IYY3B*W0E7
MJBMJ[!D9GB"0A+8K"A^XJ9Y-G\?[,$P13%, ^+T!7(22H-??C%Q)BP'IW!D0
M*/UH).RL!(.2J4K3*LIT3LCNF*<B<2C#Q9LC<-^'GQ9P^NKA5%H845VAZBM8
MWA!K9F7Z83FB:8G%L#JBCD^)5;%2 L'46@BPJHES6OI05+$1*<63="2R3&).
M"MP&N(VY+":U\$%=.RO#'$"'I   /Y)U :C52OKY O@+X%\W<:*J"E2-4@\*
M&TPRS= "/1=Y.TO-[4 &=[%&$ZC?E!*DH3X/D W'4!KG0NTD1^PV$'&4 .E8
MCD)77)YY5 5H-'H3_61:$=& (!"*G/L%J#\-J%NF[KE/$"_"9%7DK8K D'Z0
M!8^2\H6@B5GD\Y. 0OF)+D6:$QJ@]2E((A$F["3D9G$".R$^00F)5"NL;(TX
M.ISFFG\(CY-,O!?YQEC8*A*EHL;H4J;R@$9POIP8D\E"91V:N#QC@6!##&EV
M$EOD!'&4M7RRBV$ AQ_XE<75B%IGYJ2*&+&"F13A\X\=/E\PJ@*-[LFA4N!,
MS<DZ$6JE$P6]0SX7X0.(&L3- JK(&%-MY6SQLV$F%Q]?'BY_?_&[9MQ#WO<)
M7\P9%)Z4 OY73)RG)>F6B/(RW"\3YYQB2@JV8::>)V+QJ90>%4 @"4KF11H0
MGA'+Z)FA)^N+1ZHJTQJP%]7V:)98P1MU*_JNS+I<3'4Q/FQ&V17Z>Q'%L+N8
M*J,Z!4;$&9&.*'X:?:95&:VYB#J]I.C(FGVB+C@;B_(@8R\8 GK+^@BRQTRD
MBGVX9%]8B%R; +J6 9-4<4I0V;Q@;GWE<ZJR)LJEIQ1$*V SN(/9 5XY6S9!
MY1W[L'#*H0',=+F3YM=0FY8AQ[E+?*9B_1+I%U-S1%0%(PG6P[*$\$FC(U(H
M:W-F[2.J;$M^-%1!'@I6^MIS+PO@+X!_[[(N"Z M@':M\K/&WJ0GE:8(W6F%
M(@V9S-2S(UVIC%60A2+B4D\7Q1&6*ZB 5#:;S",7P%MD+(GB5N5,V.B,S0.C
MLKF2G32/F*(E3B#=-/%12/,YH@+ZYD<9#"JJ+!=X\5UB'G(*UZ7:D/@GA8IH
M:-13BA(LWXA@2!FV.NHY6Y7-P417^6BDDUGSU'B9"B=[AU%Y5N/C(IE/N"G%
MVZ0WJ.^D3$9?6:SKJ">1K>J?DWI3($>!'!OGR?$(?2!N-$D1 W-#RR9?\"DQ
M,P[=82(\AFPFU&D$1]F_1Q3.Q+:_HG)HMM.8<AD:F+#8-2)K3%Z0FO3D5+ES
MPVA6P'L![_D39^L2/E*QODC\*(!Q^Q/768A1FJ%EU.9(?<SD';?)OA+'S/Z*
M0O:O;,K,OF8 C&$ $!UG\O&EI1%'^,3^9-8 2/9,M&^CS^'>U8_>1]8= WUA
MC*U5R1H[%7X' YR7,B/-0(X"L O -B8^Y**5'M-)AMAS;Z$JN^I1*NI\AD8O
M+F3VU(" K/U&MUC=P_<,)8FP+)NUYF3OJIAQ8>E#?)$C@I3L)=C=3WOC](2H
M3<*:2,#7GD'5>MD95#F'6B15O1J2=<>5_4NQ1M?P/:;N2*P@)K1^(W]:Y)E@
M1SX68CQQVAEFL>HZPZX(\!JF"PSA@3O1FU@'^,>3 .BF_(KJJY20C2 "VA2-
MYA8&3I,W,3409.0(PB:*?=:9,$D<N0[5]Y!IX&1C,PT<(\,(S:CWJ$_=92J3
MX(Z\K&D/4CE$S_>#6Z')=63$7:;T\O<GH,=W8Y"=1U6K1\JH,C&2O6:N(TNS
M415Z)!=KG>@^XZ+-M=(C39^0?)O,,#/@#<!WF!?K.%AIWA2E31:]PS [CZ[%
MW)[X %WC^?*2"C&_("TK20LY'E7IK,5>Z895?EW/=+/-BJ@%> N8HHPVHGF4
MM,/3-4%2TM@ *NVGFAP[KB<,-U@DR&,KZI<!10-]P=;Y=0MX(=O-%]IN@08;
MQG@#1W"$Q].UN9%TEKJ")BP2M3IE,\3; &5R'9$=R1@!@4EFM]TAU\\6,%C
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M;E>[E^USH,A+)FZ*V:(;L#"V$,G#PLVP/JI#(2[_*X"M*.&^)J%(-TE%>L!
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MO<LEI,<8Z83)*U@!2%)_K'"7:E%+;$VVY@AN>9879X>G)GQL)'()-5,@CI;
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M'1$D5/KQROX!)DD5W@D5PK.05J/"BE:U)UL-6*YOY#F2\,L<((4LEFWFR7G
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M,DH_K#HNI=#T/E_Y?VA$&4\ZA<=LNU%^[^R)=^DM8D!N;3LXDJV=:7C2?9Y
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M+:,IL2()Y:#M-Y)[TD,1<%%'BA[4'*=H#G20)#$%\RGEII@?L?</<B[&HZ#
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MP4#<0;F!!R+><)YPV1XB #0$0($XJVYGB]EX/ 1S7I+<&Y3>/5:\WK@5Z)'
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M^X#B-&V;,84/E$)FYH"'*]2*(].$D,1PSFWKQX0*\!=Y:H%KX.)JOQ'05X3
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M]R,X(Z1>[(TV7!II?MY,S)MQ&FVP?I2^@?F4W,E[>ZP>XS\@B\&\D&C(">#
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M70RPN[@13T2PN&&TWI4"P5G:=:6P2F;J0Y\]Q01[0.'H;A'R)0"XQ91FG\;
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M$/:E-/@0,,[?F?5JRP%@.P)@3)IES?OK2X<^\*7%B#V0/DF7\]=>7V6L;FM
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M=T\OC39N=M/U3>4/ _^N/P1B;GU3.I29P%(  .6Z!.*+ $W:Z3H4R^A%@SE
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M!B=M;S QECB,#\1'5*[=D].2O?6TM'Z7\%=J:.O4*;HLH9H29,YOFZI0SB9
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M>A3^JM]DDI?W>UO&7-GA4XRVXZ:KOMM2_P>]A7^\"MW0O1LC,)]>;D<$JP3
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MAX!R.N.E/XRE<>W*(.784J+'0YEG3OC$+(G!/G<1]E".1PWR&%C:-@<]<G+
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M98CU3($Q""4,0C(<1!;KP,$!=T>BZ9)]O_^^>$4LO$U3]J?6HC /7W'C"@6
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M]JW,NX\ F\915A0V8-61ZWZ]WPXC6](Z((T3YC%I(2BRB,'B;.=M\/R8]5P
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M=Q4[X:GKDU5)M". CYB@8T3M)=0;UFTR_?J"%WM_/9ZW[F5Z[L/0@*5]RQD
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M+?^",,9VG3S5%HC3#;3[V[2CMI&SE<EZ_[8JTG!_S\E98*)UGH8;?0&7#KN
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MR?4M$GZA1+GVT7*?MWH&AE. +^$=1AO7A) Z>8GKF]8>=[/FF/ F7]@Y1;V
MY]8PN-/%]H;:'8I]F['E<W&@82^;#"2N+\/:7S<AXY2](*D#LI%;?QX\M\/O
M>L+@HT_80_)Y3#P0-:%1N<!UW/@D[_I\+2V.F11,.D15\,NHAE.[L/E J'/4
M\V)KX<=<;(/DJWAGJ2GS(QC&X5O'):C_YL0L51DX$%_ :$H(1/X.,]7@#E%L
MO9!"">>/6[SNG(AO<B?]WW*%!CPP,V?2<M<E^WQF%NT+VS23AF..(R 6U9'K
M6#:\3!0Z&+RBY@FL7A5GX,02[HKNBK^&;]]9Y.C1-NM3THGSE32Y7A>T5DG/
MG4.+;,:S3S.DC1EIO@EDA)P)66+7MH%3$L& Q=(0706\=:1-!<,O05@Y.Y*X
M5V"5P%CI#<A-L>12K20.VQ'7O4OZ+,'O[_::E]4'@QG'-TNE2R\)(I 7\AI-
MUH.0B17+:+363S,:1.."!ZK]A  <^54(]G>Y9,KB@)#<DI800I><"U$WK9RU
M/GWSJ?"SNC@=Q_0*_"ZP$*FPTKM7HR$9G2FLJ-^R+=+"4MN3 8HIK=$]%AG'
MW2T[ _G=%QL(P!UV2-+C.\Y7R 27PDIKW@_;T-F3KL'/EQ2=_7O+U#/A;[7F
M]$0D20E*Q&.<9W.% 2.9;APQ;8-C<7)=BM!&7+K4^53'0)GLI9D^*>.59.AT
MDACRP,K@N)>NR&%JS5\@\V<Z9N5Y4%W&R8W49A9YJSDOO(%K_?Q-UZ-M$U.Y
MDN0*4L+9MS\72A5&L ,0B[0V(R[II;-DX 'PXGH99GK*EIH?\[=W4)??5W/8
MX8]*XV.@7[7>UFO9SV#3 <FVS?,9/MO]-5[E6O@FGROOE3.<0)T<)/Q 0JV5
MM)C((89F+BVX?[]092H<FC,0B@$;40G%BP4SGRPWGJ765\+/8EZ[2I4Q1BQ#
MM[UBB)B%Q*M)Q,,1BQ".7;"&K:TPX(X)D=:.);6> ;4Y$3T!PI$P-R0N"[<P
MXXQUN1AE94"ML"@*P2GC5QAGT?DM;@=#KC+M-UJS6[O1I6H[F7K45(;X"?%Y
M>">UOV#*LRE_L^7WRF.38Q&(616;?W?]R*T*#)HAMF9Y;&F/T'G:V,R1DV7'
MF;JAI)[BNOJC7)U?9^]]:Q&Z"<OUH6F1\40$D[)\;Y5/'>?(6)..HQGBV!5G
M$(7&FV>OK$P%QMS+QK]$,N'-O7OOP+F%H (;GR/IAIPJL<(A S:%'-&L.7K)
M\^*N>(^&!.Q:5NO6(O]?"T'-I2&W#"R![FV4$E_0\;5EF^AWX;<LEMDR9T<*
M^823[@2",GU(0<5)1?#+-H>AK<(9_@,FE;)!IA HJ([&IEA458;9Q\X8OU\[
M(I*N2[OM._)W00%TS7;[X6^=[<:C?WS&/VTFL;LA\I>!&@&ZXL<62L9N OB6
M%&,PXVCF5E=P+Z/;@5J8Y4KS^TJKX=FDX!3OQ*EC,4/(+]\M4V-H+[ 5T-)]
MZP-"G'951?,>5_%<3L!:6G'1U*M9\R\0F*GUF'!<L9=6&I)LZ@N"0T?Z%.BL
MU*["$X2=::HWK*Y8]($R-N1J1!^4NI9:+"PS)S\B?H'+8E)[;%EUNHQ7C\#[
M]; 7DD)1HPTA9GWM7E:#553L8=J>1942@SD*=+E$Z.*O^+:@9SPZ=G50@<8B
MPP4*OL1+)&;FN6MF?X\Z@X1@K_%$E+%!GQ&^$#025F:B!^&IB)KB<>&] AY(
M;4?2,SWX%G_?8\4=HSF+D3DR\*K)I[!=]T/@W5HW+W@D$](PDSR$YVYT;/F:
M+Y$F&I]3BLD;^J;T+CF6 0-)FEO+-16XI%RSV[Y2KV5>B*]M5I:U92=PW"=<
M)00($1N458%Y3GGC(JW8>%.;O2L.]24V4B'FHK0NL<K.&R#.#3Q]7:+O\DV>
MQ%W!VZ1Q5L!8,#DBLLD^/3+$_1D6_ZJ,>KOL>=!UJ#H=J[9[@Z)1R[:C.H/:
MXDY)2)B)Z4Z]J_:=CYA82,>W^_!]U[EGV)@B+M?L3I.>5N!\,Y@2V"Q'<CV+
MQ\MSS*!177;IM!3 SL\1B:9KGW=%D4Y9 P*!$-9=#C+81]<E5JKP^)1DK+/L
MW35 ;39K?O62%37^J\@]R9G:B(EED7!#GPC($XV$(B)U6]^ACO1GS[(=_<BR
M/4[_(\%/7(L74<AI,NV!9(&]G>;7>7MT<C+:E,T=?#M./=2C0T3>92#(SKJ[
M3@_FUK8*%+#O[=$DG=.&5PYB2C/0DTC+,ZE),NQ"L38I!LU+I366Y\;FYQ0Q
MB#&S:'A7G$;*<N$1*0;T6))MWU0P=Z:,8"K<"23MA#")5$#RM.XC9OH1#AJP
MEGWLVD0!M8^\+B'\0>ID^R1N:[]]+5IG(2S,4G!1N$S^;UF]UR.,K7>]P4QA
M7E"G%"\NDQI0 8MN_WE/TN.7)C4S^TSJ.)JW%X5,78I)6&E-P7Z_''8-(6 #
MI20JEBP?3W=*-EO\]JN@32)@!7K)7;()&T++ATU<W*LMP&/.\5_M\1GXQV<X
M(?6Z2,[$6T_!#G%4K<+>P8O2"U(<$-@5+'X8?[/=E$OKNL>.DX)+JI8[$'Z.
M!TC]V'Q[EZ'9@"8T?S7E[)?6LC$]3U3P+/MW4Z\X7;YYYCB@U<_BZIM4+-PH
MWPHZY_M6ES0SS$JSE$AY,/U/E5P(-:_(VOZ+Y79-E.=@J2LF_H%-J4].!C5P
M^^#%]HF3@SWG*4'823.6SX5DY6)$'/%"\V%UBAF+$\F=89ST7AP:T5F4.'8M
M4(99IVUZDC8][KLYVCUA1F+FB@U:O0@OC90(GVP#KPOR<ELSBE/.:HX8%L@*
M4A-!TC)Z&?GDUIN,UZ7+ P677PC2"QX[,(9\\ZE?2F2+XK*I8$OE&!"6^ULV
MK]JBDC[<N1>P4[O!T,&O69(IUPZB0$>YH<W?XMF6FSJ*O$Z9I=%;^'IQ<M-!
M?6RU&PGPJ)G%4)<I9-^%.I&?S](SM 86^".GK0A4ZQ!Y24\1)RZ*DD'@0F<=
M%214JYVCHN4B_=F?):_R>$WZV]@7^+O3+_(YKPPVZ,6S%V<]2D=2?2GZ0$TB
MR"L:9M.>DX24<T>;OQ3\G)?E^[Z2B- N[(DVR5_"G6PW/#KXSU![]"6##"$:
MZ692@FQ*232D J5;UH;Y@X<?\,>4_&.'H'Q3[:BCG2^$=0TH$OY)].OS\"T+
MA85G)0N##$^.#WM.TM$(M^ '=NFGG0P&?[!G!A_(-3W"%1@C\LCL6%_8A#(F
M1*%6-X;7.;UD8%$A6MX-DY4]@70&P!E#6?&EP;+S72C-R832# ZH4I&@E<$+
MV;2\('W_/(&#\,+[V7'?^;0FSIB.([5BG%9BN?]4C[075.5:%9?( ;+-DLQF
MDS7'PD_"9ZSS#520+Q.+A7",O"O'QO@X>M)5Q7Q^K)50!TL<C]NKX #.X7!B
MW]CG,J6DEG&J>(H)=LB,B[=_7B91$E$BLBKX?Q+UF*H_1AT_VG?*S7]N0WZ$
M?55($C:"?;(#QR:MKUV]#['.#,)3:0:5R!E?&)V0 F^<4/.>:- EY6K"<Y&4
M LQQXB:WP\R9HXCL@"&HP09CM06T+&^Q[G,4"O=5NJ3)@O,%R $4M&[5TZ:5
MVY'F;7"#5J4]KT!>!XR8BWO4QYAJO($0:7@6>C$B)TQ=,/52,D_HP>B-G4N)
M:F%AN))XR4;,SJD&4!EI*U6$3;#<A/M7^?M$OM?4E@K#5L,E+F=R$B3?IPH,
M@??=7JVN7K\!3X-"[^L9O5J< F*5HDH%JFGATQ HH)0\+'\2#N(HT?T:KVI:
M4TPTQT&+V&+F/MGS.)5>.&VA_?#I('PG4PP_O5(( 8WNF;RD%SRS\#DPLX[\
M4QW@LG,?Q-*HW&L3Z/VI(K&+EB6_/,&I&<,O_K]^_[2(9V75[_]5_!J:M?'
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MF^;1?,[L4G!)[KD@OXNDYE;%/%V2$'(]"'YU<76K HRYZ"!EUR7I3I6Y*7^
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MK^TM=,O1^G@->HZ6BJL$;O)F@0IV2XVV]ZD=[)UMG*[[WRBR1HQ$W,CE'=B
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MF+;2,GJ?FA(^3L,FL:7OJ[I^^-U4U[_\J'K8[,Z9FHS :8:]%8G\L -_1,"
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M%[@J"1P[+*S>SE!M?;"+UM.T*'NLS($ %,"9Q4DBSM62EX</$',*@A'ZTZS
MZRUA3\)1VZ%B$?\E94G3=!T5,.^4[@C!RZ[*7I!^@']=EU+YD7_7-?)7L\NG
MQ+8KH8]5+"X:G1:*S[PBQPJITV\*]:WV*^GI"XR8G";?#1_(E+:6V8B\_A $
M3*M6PUD9M[25,IG>B@DS#"N'(],@!O8:KIAXJ1]P1['>Z-;NU:<U4IR,\2/K
MR""^FB(3 \PWN3((,!98(NV3GA/7@Z*BMHR/AN%;HBM)(FSWVN[*B&KZ,W":
M,+C%\0J.65R>V_U,Y"'PJ5HIN29M6.Y##I2@S#2BL.^*&3MNFX"71]*)C'55
ME&G:L>@I96.8W;6GU4-%>.'N3<H]@C0.M-QORS6LN6=5FH;/2\RI1#F=MV^?
M/:?@^&59)*701O^:(97=U2R:8SR%5#M"YVC_T&M$6G3",!:% VDXEA?U6M@4
MJM5<EWO0$8HBW%[\!!9WA4-MB;6K>4:%8CKR*&T2D^HI3"7*%)<+LH$UX2O\
MQL<>^CN::Q'V3[/$%GCL5$4=F+YR)S6X8=_J9I5:$V8*Z;KTX,JW"+'J"EXP
MTNNX;'9J$)?<$DDS(_H $,0&9B[4W8A\TV_MH/,RX+O/\.%$PND%O,Z.R6ZV
M\=QZB^ E>I6--TZW_?LW:5LNT"YCIL#8Y>U^"A45HZ.FTX$*FEZWZS5)<I6H
M%F%-JGMF$H'ZZL'W+#'QT#K'X727 ]$Z!:P%G"862R.'7YH$RL9#9Z_>IL]*
MQKJ+!/WN9JP\Q$A),! ;Z\ '?2?"L8I)4ZM'#OM!X",#(H:H,SBI8R>]QCZV
M&&Q960MXH!>>E0M,*A(S\GE:H/J/W;=7W*8@YHU[NRSQ?5ER$W1@PQODD%*7
MP7=*5->D($=;B<9,FS/](E\3 T]6D@9117BWYHC96?=D=[N)H"FC"J^L7JKW
M34GQFM'ZAK#-$0.)X'_60AM&HBLF]F6;\EWAU _VOLN\D+:=W<6TJ;V4I.'&
MS&.-?$V>N8;X&"XQ,@(<2L[3Z&R#D8_VW.ZVGQ[/0LN-OXQ\:#LT'\3$!R;N
M8TE)\$VKB/P+%]3/<9)CUYI>Z3=PM"(N0(=?X(55I1<.5GU6 ^$G1[@7\FF&
M8=>JXE0#EAPG$2?NQ:WRG$,;.]M\%?]>Y>O=CC]&*RAJ,5 _U-';LR&_"7^U
M9@@'@_\8)"9%-!/XS:42BB$:@D"ZME(0,2,B?&J"RKP0%1 :EUT$(1.4R%_>
M?70=@3\K?5XK&:(5\M)N$>-DNT>^""VX/#525]V@8660"H'19;8NM?5N>EPA
M,:S@]$"&O(4#\S[\GUW)?2]&I^S)1\2\%MBX''!OVUQ80Q7-UDQ3*B:DN+K'
M(I&3>Z;$XU>F/KO?RL B6R!?P]V*:%L53W2W]M(R#'P9SNU^-GX/W6+T* O3
MR(Z[:?';.BO$.''K0QN4( R4^?IVP7MN#\58U&*51!O=5U T8A%J/OJ;0@HG
MP>GAKQF9.HQ<M3Z;8)&(/K 1O6N\(OWV1' D/0]Y8+.":'RLQ2$:$D8@/WMY
M;H-RR@DJ5%:!WI:*4P.!P/G^Y?-&"L7_DJ))N,]%,)F,=-]'^,HB9SP5MW=@
MW0+K#M%UR=(: HYI(BH,6B;P!2S]D> JP]R4QU2++5(%K*PYPFLH68;= ;6X
M&?Q\]@0P*@G2N":9&$;D&D4=IJIL='A9N!UCHD@Q.TZ3CA?$D"LJ(E&- 'NJ
MS;TVRY"I"&6]FAA209P059_8\ES)D[^>&E2V65"X_ZC*<A,8]88B?+I"Z3E&
MO/UC<#E@;'%=16FNL)7?4Z>/JB@@Z(A3[=&@W28I:_64T@+BVUSS%71ZLU0Z
M5PU%E=<3[5DPQ S,15*N##'OLK&&4>@S2]:PMJB= UF 1,&R];"8$..<._7V
ML?ZFS:/+8*S/$+3C=QV[/I9E"5+L%^83>-)>O#[7\IH,I8_/LAY80A)3$$/\
M4%%S-IA<B;1CY@))R]%ST.2Q$)#A^6S)ECFP(WS3_HS0S%,7%:QN3"TL4,AD
M^7V%^</O,LQ_?'#]5_?8I&TKN)3.3?1<!.ZW?"AZF7MD46([';G*?KVP@J.R
M%[A-V(A@9)TM1V9'%)'%0VLIC1%W8%H0C[T/QG41!T8M!U&D?8UXX9\B)Q08
ML*2"$RP &IU.3CS*\,A3<=7=>E9\312.''DV]G @"@5WD-$(Z0>$RQM%,IP=
M)I6I \0$YTB!3]2KCI25ZE)0"R_"& 450T]*N=A>>)U5*^IGH8. 9REJ<E4.
M]-0T;=W--F&OI74" \A]@I!?S^&80H3&!UB32^J#F&%]#AE("94Q92E<6%\9
MQN^V6L:.$5?9\YB.3')P4>>^%DH4]WM*VAS8"Z!WE=#1*6PU$.&S\K1TSX[W
M0CQ.:P1W)UET5>!;<2=R23/"*%Y56(QG69[ 6=8I< ?QZ'J^@ - .KX,W!.O
M<XW)]"L,"O*UT_]OG@&F6]U,.?\DIF!,EF5@K5S,?21WI)T <TY31B\+]ED2
MZ'BVWV>;,+%>SIB=.9(<]& S++.KE>S]1;6"R5QQ<T2VC&>TDRVMA9TO>6B=
M,4XVP0*8I$I\SR 1<I8IG:'B;3KAZ8)+I;PJ1%\B(XHEDQ+B_9H6?ZSGJ?)]
M:PUJDI=E0O50?*^H6 '[AJ!NX)'!NRTT7" 8LJP]U=$0</95%2UFL,-1OZVF
M<CIE[+(BJ.BAN2,M\LK1U,_CH*_-ZDQ9:PWATN6-11.+3 %,U:1>5BON=6!?
M#MQ_P8C@,IN =9TP1P8'#O2$PF+BZ)3AG]:I>FMB2^>K& .F>3J?5%$AFB3+
MU-C:=*VV"+')#4RSN\W-?G22C9&NG&!!LM H44(X<VKH9]>!*)>PCM4+"S2F
M40_L<?4^1+D?PA)0[W]>UCP,)$MGS;IY>A6Q7G0-?F8A/[-E-%$AHVO GO3!
M3T5](66#)WR+T9Z($=)?23 \WN-/A^U/6W1^5,49W#/J&?B/*3M&5LZSE 8"
MT^AC:*P#9-@O(3KF\T8-?6YNL<1?$]E!D[()HN0TX0UFTP(0N\(N+E!UF_04
MX^P;0)R],U0V-@HIK&!0H)!3;GG*%*^$]B+*ER37B=],)>A;5;7R]>O;P.YG
MF.@(!69L$MDVX$9N)]&RO(DJ\!)J)Z!ID#]KLLC0EADK3OTMPK?A[(L><:8C
M7@0I.U;5%9ZM<IK#2\78G9%J:<$-4'C3(JHJ%E<U#HTD1(AV]CH-E&H"@;C*
M'$<+3/J,NI:#VEDAL5!/@=AHTISDP/1KR)')B7\V""SGE0HTM,F[$,B%J:8+
MX2#[=*N:D_W+#"'+68Q#9=]K7>%-V-+_X^S\5 =F6918+SFZHF0 'R=<0N8/
M$KJ/R; 9J8?!.=X)L3MT[7H07'B9(:-P:$X@Y3V!]R-]VHVL495JNJ5S=\HT
MD% -+2M["-)10OQXK+M[5<JU"4R'<?:RV6M&";+^Z. _F7>.#@5<;'0I&@GY
MHR'%>]U7XX.2&"T+TC[+KI% L(: KC\<!>Q0Z6P1_P6Q7FU]UNC.\=6E4..8
M &OK8RI,HXBJN&4\\EQW<W8H612GG!"KDF%_(J9S?$84HP@233C%P%EK=L--
MGN8]GL?4P-5KR8F'(B<^2Q'*@O 25B.''?R&#C3"CVCCE<"\1-W4">6XG@46
ME7\2P\QWQL<UB7R'G9A.8!DWF,&,\DNX[Q>HXX>-_"16Y,J+.<P <CI@2*8R
MV,(*R7&DI/^Y9Q.?34(T8N>GWV)W(<GT49S%O%D3F!--8RF-E3W'EU:^E>,Z
MCN30X*E0+H1T94' Z=QJX(7_%!RE,C&U]!(VD0];*0RK:R6T3__"PY =W&OT
M+/'\0>H;,( Z<OHDO.<YZXU8479#F6*([["[M5K0_1T..8;R]/42)(DK?QP$
MLJ!M$"0>-!X)$E=1]97#O/T]NMJ!B?;8O94&4/3F)5E[ ][=MINI)W_]3:B$
M8()Q'LA-H5V'A]DZL$IFN/9\;6!+ZA<QW&V)>XFTI/5+;NCD-G&RU<?%BQ8!
M/6((#JIK]ZC3O6EC-G#BX?U<9>*_SM?TPR!\[G::8[$DPYYB7!&6\A7_]#9:
M@[>>L) 1O!LNNDOCK#R4P<K)=G81@C%ZXX@9QFXA*NN)H#HVQWZ(<(MPJZ9'
ML&4L0[V(:GHNH35%MP+<"Z.S9(R3/KDE%?3,D$LG2SMYBIRM;+<*['+ZK6D:
MFV\!'"4^B8E@AF\6Q1G6#$A/$Z^E+*\PM\V/PEXE/U*#'[*VR#R,4#F,H>"I
MP()FI6V3E7:;R THTO 6/MB/<,"*8P4WB914CKI/!\';M)""1,DGBGEX]L#K
M4@=#'QKM_6<+\\OQ5T%J!WFT6+"BGQ=4FQA)]4P$_*#]%8$Z?H9R!Q<OQT?Y
M:@%O&SNWUB1I@D -MD 0(I,/;N)B[3AC*:8&Z56"6&\5PT$R2E:H,?V_?U$M
MK\!J>>W )?MPVF'$H#[;KM?+;SZ+&2F6 J,B,TJ#Q?0O[)^"HRTA:CF35>5Y
M(2OH\IA1N[H[JN^K3#+Z;LHDVW2FO5-&/8C+*=1&)XI$*)XJUBE- B>BQIU*
MX:2P58K%H%,&PEZ2#EI["1,(1V)2VB,QZ*DP\G&E/BN\CW*,/P@OL!T#-BPB
M0U(#M^@%W ,[G?8AT$]SE]2=&F013(>AK6J+-=A6$9]]>?KBG$>;9#F'^.;4
M*2MNWJ\R2A=X?I8@(<HZ0GK*7E!G.<Q^-,U@%!E8K:H4%/3EY=L7G"<U)$0(
M6RB794$H^M5B&;UWZ4^\-(\ST5AUQA@Y==(-'3:"W&7FPZ $O_3]&I3#K02D
M:$SM*T3?LJ2SA]K93F$6\@YZM)Z]J"GD!WIYY5IF.YMD5QC/<2'!!3ST7#I2
MN%<7"8FDWBP%*WZ0:.?\$5AJAN!R&9'F%@^*OO^W"(W4QJ??P$'L';'L@ID*
MODU$R5F4I$LL:Q=:ZTH# FK2/6RTYA:Z8B^GP_X()X])&JS&: 4S@UC H):O
M:%YJ9*?\L-4L77'MP5(?/X-OK3'OA"8ZL-@(; 3F8P?F:ZCN.+T@V:.H-RR,
M&=:?<!DR&'5%?HZDG$UM+($YG7VCJJEW3CZ\6572\XUFCGFAI;F:;1YK\@JR
M[!LP^PS;;>!D"V37;/)&N^A9 :F Z9ODVNQO<'K4%>,W36N 2\K:)I#7TR)"
M1NW$0:NQUH5N4@Y[S7P+=1 SF2$$A1.*:/6[Q#?N]1U\8M="N\M@V.@RV J<
M?JA;<!L&8^D*&>]98F1<*PFT683*.[#M6^P%:M$1*J)T6M,9RZJALU%--^L7
MM\L"BY:6>$( IGG.50S"$I;:E"K%SX[&5]-5]U$8*U*Y:\H);E^G!@O0,XQ+
M" OU:V_R#&X--),^!7(K,,32Y@66AEMRKQL!/$V+![;2^_1R@_!7\KQ,#SOX
M2X70^UHLK_.T>/$F(8#M'G#:G0VO79\%3#]0-@*[-D@_1W6CD6\Y7HEWZ/?^
M$C^;VW^'<[I*A:]<UJU]G0B361GN,FZ?E=O0J!W-3IIR8XAMAU[ OFJ#Q$K;
M][ZK"''_1X2X%?Z12JWQ2@Y(+L"S 6:OZA[=[F=D[)L19'>RVXJ4K1G<9,GZ
M&%(6.N@+#W=F/[B17D=^H+YB8AI83?" X.##@:U1CP$#B3$0)\[M>*6 <$[N
MJ81.7L:6D,3E-*$+&E".9;;#H)D<M\9QHM4)F!U\"F+#Q,$DX1]ED0:*\Z.L
MM MK]XXQG$M7O!33<Q2IK[@KW#N.C%B(A<8T1NL)N[!T=" 8&O]<PX2RH63$
M-"V?FQ.TFIQ_\V:0"6RH34YP_=3WGK9U3!I30@)@8ML#E5SF4P[G%!_9-.P-
MPDL!/? ]:/AZ++C?H*RKH6+TV2(E:]\4;M<Z ZRY0,"1IT:F?;XN70U0K@ZM
M*LL18B$())ZF;#H(O('@O2#")=S.@L%$@%;.E26^>:4@%N<V/2(4HE(<IF2)
M]:NRD*,/U%'GJS])2[GW9A0)#Q>+6 >G8LI09OO)_@WK ;V0T=[/98%?P&.<
M?C'\&9DE%VE0,]*/%A(OEEI0#A+4LUN577>1>-![8(62UO; ,3EI%MH)BH34
M&U)<K_(F8">7#M^S^'T,*V4/@,=GM\Y]AB2?U('LMERW YG1IP4R]S_*Q\T4
M^#'+4R%Z#1I;^9L_$S>=^V_MN>^H:EGPL)&@EY+Q=C\E!)U.R)"O8FH'%L?>
MY+X"]RC5C8V[N34#3;H]1X4)/ HUI$SH(VBJ.MPI?MG?X\I2-W\1?F)\L!O<
M,'PVRM=_$)>8FL(W\.SO0\9Z8W @IP[W;$?K<.?BZ>DNU^./2"YCF69H "\I
M'J&?RSDJI5!HZ=\E4FEN/GFK-&5.2K#$8$3_$NX,=]M/= T7;SU%+]P9[5KW
MQX0R3I-?C_!LDD=]^O)96,<89^V<#(ZQV%9.I[N<%-[9WPV\:,I]0\9AV/:U
M=VZY$'./*5A?4;!S_O2BWN5ED2+7HG:H4:K?>1'\UBB##1=9FN6!R?1BA=-\
MP4LQ/"4*%G@!.R\N3G=[GK"1[5A(J21;LLJ-0]9@%_1JP0AD1[I $_:L;] W
M7)/24%%463QS+WS[U39<+-!2<P-RTIZ2'5,A]WQN6B>[J(MV=455_RLEY%2(
MAO.\3L[2*2G#:@[4!KCTV]I2JI_C)>DX%KQ:!^$;IUS>G@XM^B?A<S0VEN-2
M/M!S/5./!-]<8>>JBHI53GXC@ZZ\7R2SU$ #D@P<)11-D^JV%['8"[Z;#>G/
M[V8C9TB]D'[OLTAISA=S3*3%IS@F1()7\UU'Q:K#2G &BE[)+&('JK7+C9>,
M*!A;0D>F5:R?5('VFSAS;PC9#)KINTJ>C'\D3^[_PW(:-%]<VVG>_[C3O$TG
M$VQ$X\.X99LJ#58+>T2T^O-;H=(@W '7PYPY:+O[UUEZ\Q?'(6K[.VA$GI\U
M/!$NK;*S$SR5%*SU:-"#,7)4/;%L'SE?0SE?)1<K&BV3==@^.31G#0_TZVYX
M27X)#(&U62 N+>)L(>(J)&(L5&<,2),!IE82!&;N.3_G1>OI!6EP0SUE.*'&
M$\+I/-L-SR1K[&9Y NH=L-@QU@;AI]S8.P@7^(G(KI>4"M\A 1=\TO]S]G*X
MM]N38>X4X2\ANJAEU?&RZ!^G+R_"_[I:_AR@:-\_7KZ6[XQW8<3G_1>[MSDB
M!*ZZNTM <57?GK+L((2.M_'/M"@"1*&19@L>$]C2CVA4%V[5<>[NG)-#M A'
M_D>[AK+S3'Q1]X.=8T/IWIWGNT)R;0ZFOGLRR;L*<Y)01(2:IHNZAOETMWMZ
M=G[;W3Q%- QX$T1J1,M$:C&R$!N<'S!IFK_H*%^@WMP'PMDM^@(1).?SWRM$
M7.92 -9*%+4LU+PF1GM]6$J#X'_WPD7X7SG8J+W!'IBE_^W]8HB_P%]=F%_M
M[0V_KQ/[X,>)O1U)'J_:84IVO+:-;?XFGJN=SMEWJCANV?/BUU=GM>8[OHV4
M%<JY,45!HRR <0G"M"H"'I(^! II24*;NBHP0X<B"IB4H$9H1>6[C+B6B:4V
MV7&2PJ#P/*,DDBDEF,L[101$Q-OR B?033^PF?VR,+!E*;K4\'D1V.KD;OY[
MA%UBI+F)!\49F:.>T.D0AL!(NRE\+$"G3EK;F=3ZRG8WL#80,=Z);&"+$5A&
MB*M#1TFS/@@OX%TL9C2-C*!$;J]B119%GGF'5A?G-0)L.?"J4G3L-%-*+02!
M']EQ/9\ZR^<$X>23#Q_&K;=WQ8JRR)4JV\ .7,T^'4X"CU(]A 32UFVFV^J^
MB!)S3 =.(*$]_%RWB]'8[F=E,1Z-,SS@"JW0Q(+[NU>IR^0F936"P,A%)%%A
MQ-=HQIJX$JT/,L^T+$VW'!:X !.O-"G=#!!9+-4R1+4M(C:'H_?D"N4UFRM]
MAVX5S[\+][HEI10? _JMBETXSY;SEHD$:4/.'Y%L<<W326?IOM6MC,DPO*@R
MS(D4'Z,,;Q%Q"4Q=7:N<INN#V_L)-?T5\(![@_&75-_::8-Q!S5QL$WU+W=+
M!-XZQP.AG9NG-<8-0 ^.N#S81L3EG2>,%#P_-E_W7D']S ?UIFQTA($4WT,R
MO>T#L^M@"9SSQ%.::)TGTJ1JTR";T',:0KDE[<=A1561)#XDY*Q!B0[_41F@
MP>N"_NT!#SJ<&$MB(O2#9HZ, \.I.3FK/-JCUR7V^*R)V:;KE.MUW!Z)HZAI
M6\XH&&7AT)JJRV;+<+(&?"$%;B3P[0->/FA"(B.'Q%,[5J1TV&/T.H3T95:7
M<W Y,64GS?:F^UPA(%W/]WTE% Z_WX3"'4_@A_+K[_5<._R,6L+GM\*TANGG
M0UK&.N@VUIN@$MCCEDV93U![H4SOTT,4;#[Y..-G_CKG!?_"K*YWY/=*RF&6
M+;3@+6>&]QY<F+CE7ZR1IR(4=>,YN-DS$1" /9WW<YAYJWK<R #C*]PI?AD-
M]W=Y86.XH%@9)K9.N/N0N5XMTHTI()P7KG5Z.3'\,X6(U[#?FWKKM,D.5<BX
MQ0CK/;:3FU(WPB2'E1YES1@$?@#%I5Y[%>VC!TM(''X))DCH^+B,\Z.]4/";
M=*H8:(IVBEOJ:\Z<,]K_Q<MS_Q?2[1A0MZ,4*["-D"3%3",@9E20K!IK1$C,
M%M4KJ3J=OXQ+2O-$85XB"1&V9"#0-%TRAP EX]UWCZ\$1I!D#&%$OC/J6TR)
M-(&#P4%PJA@>4C#2MX!"$T1S[+P.AJ VRD4PN[88J%M33LXOKZEVF<:[V<&C
MKU%3O3\+<F:@*<1,KK-/KS/PMH01!L$%3_27E2XQ8A/ E>?A3K#&JHF'+GO1
MN%O;<-@OHF@+90;1:#S[YQF5;.GOE@AZ.,*<WG)68RWT^W*ACKY?%^K>4!1W
MVO&?G3(Y[E)S^CJZ)%V;7M)WQ'D78ZHM)C+$Z[16'"5L*-?"$AT+GK%][J^V
MC>#-^(Z,\W,\$O [+\N;IDF_I.ZS[<Z];I)7-*K#P5-$MT6QVWU,)9Q$8L>+
MR[.M,OV=Q.!61)GI4YGB :+NCS[' P\M;$P*4QU26G41H2#1+T_VGM#/"]3Q
MDY^SY)<G?XS3Z7%Z?'0R/IX.QY/AT>3HX&A\& _W3PZ/AO'!R#.O;,MO=W@;
M5LU]\CR=+INF#0Z&,/R?987_P7\D>C^YROY@= R7N4;A1)1GDDO!:?.$OT)?
MNX]LVO%H=/BS<8B6R:81G1P.CD:?-*3[>_M/_OJ<I*<V]/%X=3/P*!&W:49$
M1)295B8;+476+P +MYK8U#[O5;)2#)UR9PC_E]X<_!>7W"?OWD]9J..#X^'Q
M_N%XF,+_[QT>QZ-D;S1-QOO#_;W1Z.C'0OV&%JKD1F6)AL@OAZ>C7:M"\LM'
MH*->8IA?>$6R5OMC+<GD:'HPW)N.]PZB>!Q'R<GA=!R=#-/Q\>'^830]_K$D
MMVM)BC'SK"0)&Z/(L:%'D:8O,QJO[\#KY<3P#;,OE78Z\FJ>K)W6X1R5B4T?
M9!I>+JKH:I6&Y]%-GA(O$'M!C[:(#X^2(UBOQP=3= (.#J+1:'@\C9))=#*.
MXJ/)CT6\E8MXY_RXCRRD%24$L!<8%;#MD;VKY&2U-:H^4[HEUO=6>*L]GO..
MCFZ,4FL[S?*\AIUN-F;_1WT(EL#^ %<Y??WBG28:S"Q]]>5^N)\>3X^.DN/C
M\3@=IB='\=[TY&0<3PX/XJ/]_1_+?5N7^ZZX"[6S1!MM]&8T.YZ=WO4-=<_P
M*<-1P"GCDG0OXJI<S'C)6QB.Z@^Q3HG20A![+!T(#MS2HS @,4QL^#>#PHU4
M.*%C@ZF>MQ!\Z-7YVQ%J \?OD0-^GL7IXSG=<3R"@V O'H^C<7HTFNR/IWM'
M\>CP9)3&Q^GXQV[9RMVB&Z6Q<FT%Q!"*FQ$9]!5ZZ\B=TI!JCL)WIZ=]=7$:
MYX99NK!EZD=;K,/IP<G!WEZ41'O#\=%^$D40+>Z?3(\/1T>3./WACF_G8B73
M;N5./&?$0W^[=O1.J_'^3>?70QN]%0T)@RPG)K@^$L,&"$\GFJ%P1!RU>&#T
M^,0(Z<@H.>>,TR""%,2?4QN&=01I-D12N/TZ*Z,X1766) UW8(YW;82B5R&6
M-8J0[*M"@1Y#]CM)(5K_OBI*QS\J2E\E[7T;K*6-6 S: 7_-< %'_E( !*[O
MQBV!#5)5S0]X#EIKNTDZ8;O+-4_^^@HLHW2>$%]G2K"3:K5PE97I,5F^"/7!
M*W8+E.!?(T*1,C>T^";CUVUJ6/TE+VL4P4#8Q9R0'4:R"_D;ILS+F-5<6"%:
MY0E6P T3%PIW"E<DXU9:,BS>L#C8A7L,PG_0B-HN=KA39Q_"FS1]3W4<V)V[
MU'.#FA)*V2;:X#8M3D<7PN27,"XBJG39<ZSJ&$WW3O'+\. GW'*+72++S)#Z
M6CJ.KM-9%N=&G8O,NMQDN!?.KWYZ?Q5>G@7+&WIQ,$I4;5E1W9''?-@?CIQ$
M:6IYWPV@"*>$L:<0Z2#(!@N52V;S8@$,O%0X'!%\A=J'>'+G?-/*S :V[FCK
M$9[&^?N(*I:+65E#!+54 =/3EQ=NO,18A<[P*]Q!53"A2[W,JFR%;:G)KA>6
M&9@.Y]*$..XC:3FBWC-J*Y'7Z9ND#+OEA\@-_4AER>^,GMTB1ZICE_/K+YY[
MT@ONG"AD>3!O#9F\MMNP5)1%/Q*Y#?W ('R;J@Z3I!09#J),HW+@J^8'-:4Y
M8K_X'W@YV.IMLCWX<GJ6N$XGZVZ]%I]$2O8UH9D?QQ\-/4*'AF]\<'2,QZ8Y
M0P^'BP_? $"I/<6--EA:=8$?(=K L,5TV9EK:>:]F_84K?:7@/8?&/G*4^!Y
M!:TR  49OC]\E^!7!15%#9/4%G0^'O+A'XU0C\C7F-F4#V$EST=>=X)\!/:\
MU-J*L^!NE/49OONQF&X0OO1_BR;+J;J0SB-FUY9ED2+;>#+/BJR61!Z. ^Z
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M==7> 3PP!!RXAR6&#M?P"NZ\CP=#@(MOM8]OR&\A SZ,,5@/#1E\W_>$PN@
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MV<;^ 5+!)X-#4(N1HHAG(#.OMN3?RY2HHC(;QCLTTYS'P"E8$"\,QP6NB+!
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M]U!2HXA)5"R\QR*SI^(_!/VTBK\(Y,MCA7%=!-B120G=A!OMO:0NMBW6%*]
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M>&S2*[<D90XWU\^F16D&NT>\YZD=>P";O^"NK [B<:B1VX+B/:)1 <,9-_[
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M'%UT ?K"4HM4N1O7BBE?R9?A\-3*#3/52<MT")Z_>I$HEY40T^&H7KPJ:=,
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MXN-<PXF&B!$1=#9YG%"UIB*3P^%==PJQCE[0JBBF6&V3J)3]_!!8FA@GR[9
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MM97?3%K"AR\1>X.MXB^65:[.8\]QC4+'=9=60'=/+#ZQL;?Z).N!)2HG1S)
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MF55,MB)Y/\S :&M3>-M6V<]ZNP/Z<XGY1>I9*'#R'%NZ[O>S%(<L4#;W&N/
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M3;' =]3&Z;.06ZE06O9!VF4#NI<[B_-Y72BG'$%9TQ:._Z3$[-A[PST[H&O
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MBD]\1BLKFJ'DPJX'*![B:,#;+EN?I2$0&(&;<OH9Y1$DE\#-'<&+>Y-/$;5
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M6F_NOIO"/SD9'Q]FQ].#T6%^D!Z>3/+)\2@].AT=G9B]O?$CFI+VXRE\SLR
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M)B+;@:",Y\0UC&UZQ0:H,>?,ZU"0*(AE)3;)>B7OAHPNQ@<7^60&>;G&9TD
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ML1=&15Z6NLK.&19!1CL:V*I'A\4_+UPA5Y8)#0PG= ),P"-Z9$RYUHHJ883
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M/,LVLOD3;//I7![.<U#BKJAF)44T,%V"DF19)+KFAC2:6X 3B(A@7:DD@EN
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M,^Z.CSN#T70<#9+^"+3$N-\;##O19#@Z'B33R0O;[ G;:$NH3N#@E(&S+/D
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M:ZZ$D\1'4K0R:3(3R(H.4J8?=:=+('9>0(U'PH-M^6\;R E1O90-KLURS_H
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M11($2.N[3L?>B=?P^&L*_[YSU[;Y+<?.<36^1 U-FFG,$@)ZS/3(3>O!6 "
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M&.>L&]>[793*)4=2FJ58'<]P+P& G Z\0S=Y/-X5,'90=:@M)_3HYA?T58:
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MZPZ45<3YPY+C# MY&S6UOZ-GM-.G=$%*I$4<W68)X=I F9.6;;/K,6;F_"
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M@?*UU(R%R <0,TD4M[Z%;H&AWXCZJ&_KCVD_H1,-B16:\K<Y#H3:=7@V^,'
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MQR)691L0GMLBMUC[\;7W(G9NPV1L0DG4,_(=XT8F- %EG83!ZQ4&NLDATK6
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MED$J^97U&+DR/B\ZZY_7-'!4=ZG?ZI6IQB4$3Y5POV\I\DR,$]#ASPOB=Z+
MH'Y;C\=PN_!D%V^U<M,Z6"=DF]TUSO>KA\T(Y)J?BL7..<)Z/M@Z("/6E,;D
MIT*\=A!)*V>%#35@E5V[;RE4]D[(^CA8@\"S+$DWM8E"\;AB<[&,*V1Q:EHR
MDK_(V7MZA=Q37(2K*RGL5^PIWCM["PO@G7[.<H^>;Y+:SOPZZ*)SYUOO)HI;
MBD3,#C+C;=-N>!B7,H;,"LRDT)>?;65/!Y1'#325*:?<+@K7P*JWF-Y1PC1/
M<>,38WY)C#DOS+VQRB?Y5<QE+._GQ9Z#)F=#4=?RV= 6#;"]3HOD@B-C[,&I
MWJ@&/N*DT3;4&2*3B;%7%DXPK[%,2F>]27F$I3.?AS,&ER&<+OGIDC_B^INN
M\_Z+[]D6=/,;;GRSDXK;]&AS*,%NA"5:IM2-;J\.5M=0" U=TM3-E/SV--$=
MY^522PD>-,W^M2M,B-PQPFL3%E6O;9(=SQ#7Z?*V_UD5=TC[]#XIV"2V)G^)
M;E]LM+W52TGH$77<13G&=N?D _V1[)UP.I-S%S._!U9P8-ST,"?BUS@(DS@>
M319J,5H.)Z/QM#\?]T>].!XL^E$_&<8GS,67D&%S3_BI&C%R+4*'1@_'_F&4
MQ2CQ\;D74<EM+A;84.W&B;Y3*)U BU"9V!3J7\#.N3%K!36O#>#II$6\4A*F
M$&0E<NEHK%S8:35HW]LLGZS$^O!3F;J">2/5:Y=($V+'R6Y]K<1X3V"D#@^C
MIX1I>R8^XE+FB99.M/18M$3(>MI!(4Q.$*K:K(*3A?YZ2?")+.D&5;$6T'B0
M*6U=:(TVK)F4T\O[Z6S84_YE6_[E_'7G7SZ]KP*,I, &[,DG++@-+<X+K]F>
M^#">JLG0EU>1#L;)<M+OJWF\'(Z46D318#!=+-5R-D%O0WQR-;P 67*/J\%-
MP4<_EY[.R<5P4H..E73)Q: AAQ*):*6(:;)R0/H)Q_PS0CJMF,I/7H83/7YU
M03X#"N=K[,B=9PX54N"729&+QPJW!TFZ8J7<@.\L5*:6Z?949?MZJ0G]#*I3
M3[[A#/ABJ5($;+Y)K<%EO:A5EO1BHW^M%3[*K6NJIO4S,HVN=3)@2:$N"=6)
MOE5X62^HZT-OMB3)GA'0G)N0%1AH,(VS1%^^3M42*S*E,ZV@-W7TR&X9RKF3
M&LUIMX6ZVJT$6 ]AW7>KJ\COAEKODA[LVX!:(D@C.!Y.'NV7RDY1\=">[4I9
M)JKL*F*\JH !W!@?S&0>HX.+LI-ICE5D=Q-)]0/M^2J-,7N/^V9$9>T(O=)?
M_3=$*J/6&]$J,""*E7[QW*:C>3@3[37JJ=U<?@;3L*O@I_KL&YX-?+1H#86Z
MNM-@J ]"B<X7*W'XO+82ICVE9HA;F=^&.S(O3 59QZLG2+0ECBWC*U>$@7/O
M6GV\:\DLA4TG2%Z^9Z(#G/G ?UH?.'<(MZ7QZD))79//OZFHKC)#4G/1>T=P
MP#'0KTZ)J3 @#14GE!0X2ZJ0YK%U(7E$4OFG8MA3\J&Q66#+*$1P!-%5H01B
MCQB2-B^0/OP]K;'RTHHDAJU<^T4G@ABV TVOW)HT$F2&I!_"L:V0<U.7!*\V
M=%>V%'_NROMJ/K4UQ+4AK84U--G&"0;5"6)Q/]6"UNKHI&C&*99Q>'U4ZA(8
M-OM;BTY,?0SNN*V'Z03/4=SRRICI^\:JID]OW]05K$KSF*2)>7H%H6)+VXUV
M//N7\;8#;^IBL-*X03<[$&RQEIHP3$#POM0=:I<I[#$3$T%]:[;U "=I;]Y?
MC$9)-)G.!Z.D'T710,5JN9C-AM/Q9#1_=B?IMS=P*I1^<&&*6Y=2:2?5]4,8
MGD>PS;J;/I-IUPS30'#&2F./'F2HO6RYK$,FI+?]!'<"PU?AL-\)![W!$%1\
M%:"[>- CD71!G>&4WJ5_0[4+A%X$<L:-@DY9;'^\[O[410GQ*_YOHE"JETY;
M;7RT/R0$'E2BV%))I+Q=147,[NH$.-(JWY )8V51-P15@FT9L!02*GUE><7-
MD:CRB:HAJ:<=,DWQZV1J)<V]N1EML:,L C(J;JGM'^@..TX@WC)@#3Y=*,KX
M!8MLAU00F%T 89R'2V! P&4)'8%?TA8PO,>.3]S,$&$/;A1;&Y])XRW5ZD8W
MR8)=*5/IZ%5&2[#'\N+S9A7%&HW=-CI%EHU%!KAB,Q7\[E4!^K:S;Y(;FQ:D
M@Q" >+FCS[!HAADA3JN/<@ROB^^+#)ZK(EK#.G]#*&G1P^R8\-6@4 +DKU64
M18Y0_1Q,+ERM&/CB"JLP;C#L4)@6K$;CZX;ME^";BXW9,!D-H]%R/NP-1_WE
M9+Z83Y2:3D8#%2WGH^DK%!M[F&?W$&_>4?%[ IT./^@.:+7YB_3Z:NZODP4.
M+_S$&+ZX^^I9 =]&)CQ\RN^ '[D]!_W^ 0Q<ZK6;:S:0&3W]_1;,H6GWLJMQ
MU']%EU'XJ8I;_3MW/0P_4@J7VX7R@MX(W#<TM'KXCN+_=JH1\4YB;%CAA38Y
MYGE0=LTJRMPY3;H_FCEI*/<.:-+ [4#4^<+'*!0>"/Q%\+9Q$ O\WGKFWYX%
M]H?]?G\RZ@VBV:BW'"SB_DR!RIR,1K-^,GQ^J)-CXB?O7AX+M#U@V77QN[JB
MQ+)L:WI@Z5E=QKJ:ZW=%$CU\6X#NH/)=N;H++Q%B!.ZA2^@O+=XAM^4W[%YD
M&N$<UHSFE-C6DM@VZ+WNQ+;'NZI\+LB540Y-X0__X^+B,HNO\^+BXM]EE_&G
M8-H-'RPMC]=Y,YG-0/B,YSV5S$;S>7_>&P[B93*<J,4L6DYZ)Q'D$,GERQ-!
M=5+] D7\*.2'VR6<[6=R+;@Z;V#:X>E>R^4!X=A/;]^$Q6XE[A/;G,_IL7T7
M5K],(EHW!1,T,8U&7 :E8%O2PXENRT)J,>*FD I+@,A=4I9UVR[MD.;[NU"K
M_)8<&]AR2@]<[A;_$E"4?+/53H!;ZIVT%2QG+VP6R+3HFQ8SF?X3]P!V9=(+
M$Q !+6XJZ72UVV+,(-&M9/BO]B!@P_ H3$1"]^*6)F 8KF^:KP:><;< W24[
M'6/"#Z'P!+'EVS>T4AD% 3]QGW**^&^QD;@)8+H31Z>.,]KA@UE\:1Z1$:#=
MITU_[X8M29VHSV VZO3FH\ZTUZN1J[?'S<?QR@(VE]R9$6U'OT^?C3[74B)6
M*0'WR_6AB*A)D? ;QT7;;11?&YS9M*A>\]>VV]5>;IS>SYD;@8:<H#M!MP^/
M95/ 4:0;X,3>(="VHW>;V.R.+KWD_%/<<[E,5RE\N=0\B&Y?1+ &A5+A'>B6
MI8?)RX$U\0T(E+XWIU)<PJR$U?LV[&O]]K@ !8/9,NKU^]/A+!E-XT&T6,S4
M/%*#?J34;#[^B];0X^66/OL%2M9]>I6GAK4J654UA0T=T-%9_==V3W&U..MU
M0OQ_YZC4AR#?TJ2NY?#S+8K.X^DTOUW^^C;\\"[\\>UO;]^]?_/^\I?PPS]_
M>_M[HW(&VV+R/>VV7^VPF1F>WE_NVXNVO\NQFTV"?6G..#4S&-P[UE/L>]T*
M?4S]\H]\&ZWV /X\[>@_&EG[;%,P#N[P[/*G3^7Y XAPF1U$@*!E;M4%<ATR
M_6^+:/.85'FZ%T]!%A]=U?#9B!,I,OS144B?]9HD+^%N>-;P T1F@\7?Y.M"
MTAWT1J#,#V?P?\;C\R<0E^(FU)"FXQ](,_H9S2)UCS/@25G#8=OQE;SB*P[B
M<#[Y->1YR%S:>=DWY>6G WO\ WM4!B-*_G3RPV.R$6#7Q2+]%:PHKO5&Z.>G
MX12NT"&CO)T6M3WSPT..';U@7W4#OFC4;+?^JD$;=D4[EQ_YG >=P;37Z<W[
MSRR:OVB;3W3V8NCLL&_]Y=_[X^X\=#TOX?$0YF/NQP_WE[P^E=1\.J'Q.S;I
M2. (PO<FS%&&@UY_>C$_&QR1!'E\]>+@^_\UNL03<XFOF]JWXR7]3G_8[XPG
MPV_$&I[AR$[T?Z+_5OJ?=7LOC?)?@.A\*J'XG_DB#7]6>7&ESH9') -/VNWC
MG?%T..Q,1N/C456/1M*<J.SQJ&S</2(K_05P].<UABXW*BWR+/P99K Y&QT1
MYS]I?R]9^YM.>YWA;/;2-,"CD4@GZG_)U#_NCEX:Y;\ 2?DT,K Y&/V35Y;X
MUF#,?) "Q>.1DZ]==_TVP=67)#M.%'%\%/$H7/!A8O#)3(8D#7_-B_!L?+(6
M3OK2"_1,G:R%$_4?$_5_.X_9*[$6*A-^= GX*46(\'=8E[4*SR9') 9?N^KW
MJ-=RV.GWOY4=_Y*DS8G('H_(_K^CI*_OR%KY%;CT-?SQ71%EGS%'>'I$[/JD
MM[UDO6TX[_0F@Y>FNAV-&#D1_TLF_F\EN)[LJ&C*+\#8^$VEJ_!-?JVR\&QV
M1++KI 4^WAGWI[W.8#H_2EWP1&7/265 0T= #B_#W?.\AL9OV%EF'?X4%3=I
M>1V>S8^(5Y]4K9>L:@U'G<%D^M+UK1/QGXC_9&<<KYUQN8JR\%<"-SSK]XY(
M>+UV%?!1#8U99SC]5A6)+TE(G(CLY;'L5QO3>+.*=HD*?X.9I:4"=GU,N"<G
M=>LEJUO?5$"<;(T3\1\3\9]LC6]D:_Q'NEJ%_WN77JW4'8BO8P)=.2F"CW?,
MT\YX^JW\5B])2IQH[.7Q[&<P-IZ]/+P9K!=8MW3M:.J]3FU'G>[>9C81MB7=
M;<*SF32G>! (]4EO.^EM>Z"V>M-19S)_<8!#1R.13O3_DNE_VAU^J]R11SNM
M'P@^T[5:OJ0_Y%<T /M2?2/\1974P"H+L1>V-%<"*^8'*\\>WHQE$D?C/OR?
MV7(>C8:J%_5&D]YRF2@U'*EEWW9K?*8&=Z-N_T']XAZA0^#^]G7C[OQY)K17
MM?O"W7K,)HL&!/O)1SJZPWJZ%?/-DF$^[HIR%V74W"X*/V%KKAW<\_[PIW^[
M#)?I2G$[*3,;W;UO<1=6 ,M_3/-W.^QY\#'\)5VGNBNG:=4B;:3T6_*X-(@Z
M)UV[\D7\TC;IUE[]^:.\U;$*.;7'NU+4+X[Z7U7&Z825C_ 89O@\"W^-BO@Z
M['/7-Y !Y0X[#:Y!/FR!P61E6FZI0=Q9>AX..H-1OS.8CD+J]X'#GZ7IN9G/
M8-:9]:?\8UK"#B/SW&UR;KJENQ;BUVP;P1Q[Y,77$?P=W^N&=KT=.!OLFH?M
MO+C=8(R]U$K=.I%:;\&_J+N>HCY=0!9T"&9*&WL8V,RMI)DTO%_;.&ZY>/\+
M<FKZT)NHP!Z8]U%L&KZ5E6&7#/[K,B_458Z]XTJPS(ITFZJ2FP""P"E0<-4'
MAP^.P[]'UWEY#>L//VV[G?#OJOCO57H7A1_3[2Z*KSOR,'Q+K=3F&B3?7\V\
M_O_Y=!!.AW" @\&DU^MZ8O!1F&:3:G<XBSG4+C\&YCUX^<S[,6?YN]H U1)
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M4Z#6* OD(JDMW^YT;3SU=OK=X#*.R8*[6@$A>0N>Z 73EN@W$H.L4;ASTQM
M0QJFYYXF10+,]/[GH-N;C69TIV$[0*/&PB]_4W"V>*!_IFO8"!"%_Y,28G$#
M:O@9#PD8W1MD>BZ79/@Q!TEY]_TZ+] \6^011TUMJ![H*H@2L*R1]HV#J9!M
MVM V.=9ZN*%M$N5?@>4$%"3\@W["*XV$!;03JV2'LA:O''.,FU2QK6.8!?R$
M%.?J[69L0N'T7 4HB8$%RQS(Q$!VBB9=V3A=[29H8#E[7Z,L'+5,,XZJ(K6$
M[SMLNDR[/U(9(2I[@][%.\ZX<<=<J.TM:A$.E^=59[51->M#-HXWK<! LG!8
M>360[:N_RM^\8R/L2V<@X$,P_B[;E1B$9_D$$BN+MFB/,\=,4C8A@S2[R5<W
MR/ZN\CQAB^(&6$M)P"0@EZ]2C #E)*3T?X%&H;;?*EWC-485AZ>HHD05Y[TX
M&0_B7G\1J]$XGLZ'\_YT.1A&O8D:C<;/#JUQ5%'%-R\OJOA>&!@Y&=_^"6)"
MZLG? "F!WOTLL<7'S+;+M]INAYDVLLSC3&;[.@>T?\C\#;S/*'-G\(?_<7%Q
MF<5@REU<_+OP.OPIF'7#=VD6992"]3Y;(D=$227/?(N0:6UG'\*MXGE_U%>3
M^:(_&(WBV6P,+&LVG0]FT\%B/!^=N)4;AGYYW I#J*"N)I%)/.2 @XN?P>D$
M+51\<&[_"TU[]3RT]VYA8'?);N:WG^=S&G(FAM*?F2"*V97 [LJ1QN.?EE9^
M45<18?\%E\4BU5[ZCVB,*O*^'=EN/")=O"//#[J:T'Z$_R7OT3JZ"Q9H/*+1
MQM;L351@? .M@W3-JM.*MFUCMPD,PK3TG.AL:I"SKS3IQ8L=/(1(B&AXWG#P
MD,+Y&W$D(>2M5]N2Y13V5*O\EN:GXX62Y+Q"_Z[8I3D9MQA7O.)CQ&GDNVV<
MLSN-+&?Z"'PN55@;DR[!;-]B4!0M]RA!!P%ZKR@8VV$W/QBP<"II J8N_$(F
MZV<TE;6GFJ( D;7&Y2L2C4$_G;ORCEXK5BY0Z '^%$?E=;B$)9;X_:5A6<:,
M[H8_J24[$0.RWMVM3^%H\I*V K,V*.:QP53PR"O96>S ,D.0=YBJ%S!5.F#*
M@0O9L5)[(&D\.7N8G3-R)T"_9Y&L!-N2?)NP"5L&%TZS:R4IY[M,AW/T%'G7
M,K-;,.6(=VN'[H@XVC'5H),]*SEH6ZKM=L7SQ@7#* D%/\01Y"P+=A8V/59N
MLL@RXNR5EZ,@/XR5_81$"C02?.^>24SSR3FG/0.E+<74$(RWX.5 @DUD(TSD
M!&,CI5*D9"]WZ*.B! ];$8$^+D(/!\(A*N6G0A45&1$Z,@KX- 44^'HJAV=)
M_=*&:,VYZ]V@W8G*.+-8N0=#4DCTFMF)Q([,(KKA>^&=]>\D*DX3SN/RWNGH
M9:\[P) IG3^^HR1"B0)0K(SC$ASFP@%DT=5UF3V(!?)- C9&+P4.46Q6R"\U
M,G@#!^MP+A?<0>"C =KC11I+DHG[7^* I;!C 6QF&[X#BXB"=;6K+%%9KY0,
M<] P&HMN874#!,),S7/F"G\LO6EH1NV$!B6PSOYI[TR^C.P'H^[X*[(5GN_&
M?8PXQY.(3U\N!KP+G#"?#J-BA%"BEQC^5&X::;_7?=MU\@2(TB[< .P;-["D
MX[L4%$!;&/](/F=C\GSKHI,'&.O]V:*GAF,UG0^C412/%O/%(IX.>\/!,(Y[
MB3H9ZR^[8*&A)+VV!O$IOAQO8M;L0SR5<7U=P&7T?0=<OMVE\UV]\SVNWCG+
M_@_+I>0J_8*PK=G5\0J,.)K%_7%_.(C'R:BWB&:C:#E8]!;#?CR>S,?+D\!X
MV=[=&BF"70\&Q^I+"MR^#V/N@T[!0D5[E5*> :8V1642_5=@LS'*NS5LH4D
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M],H.D__-1Y/0[O-TO:'&=SE;OTE:4I\JJ9G3!C37V*-H=9SQ9C 2$/"YS:[
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M_9M.0D25Z]/07820JE>4RT&7UTTIQDN(MR11<,NU:X\1FM=N"1WM$DH?DU6
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M7N-MJJ%6/*C]ALT+8*Q<6;B/<Z=^;5M[[%/-66WLF/U'MJR>SPJVS#V@ICQ
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MV#$S'?9<#<'$&Z )#+: =@S4[3C7P>5(S6JW;D:Q^RO0)W4.;:[<=="S&C7
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M'Q^M& _Z8BPZ_7@XFO9/XG@LNKW!2/0F4S$82CG=1RL<U__BY44K+I7"2J
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MHO$ZWZH,S""H:ZF'>:S!P,4&J]G* '*3P<U#URID:6T*LWA<N-T+LYY3O9H
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MU ]P4G%BUJ*T1!-H^5=ZH7N((7L)35X?S<7PTYGN>N%8FLSA1B^4: 6V*Q!
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MV+C@9/(:. E:/HF/-%T"KIC$$GVW75$G*9R5Z[[S6K5$P2NU,YD36K)]?[H
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M)B-_73?R66,S;@!<<5YPAI&_MR;V\)L3%:3O;!SK-QL5+##^N3ZWL#GM04<
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MT\83+Y8+:,*PXL+<ORHVM+40$@H;B] *X&@K< Z\1<0FJ<$3^K-3?%?UN[+
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MC^8ZNX7/5KB[,0#)@-9V-,-41 YT"U88=8Y#C-3VC@%Y%%=V3F'7=WQQDKH
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M,>]RJ8P-47Q*PE]DC# "9UC8'!Y\/+W\Y>PP_%DY2M"B<4>*"R62;N73M_G
M2  M:)AR4(%:X5^DF"EQ<*D[%]\M4UO+P4$;M<P0EKEN><<Z3V4",AB/Z72P
M2T]0R0K%85;A&+_J;2X:1]7E?%&0^HN#TV8U^R#U7FY^31DQUG)SN)>;E3TY
M^^7,O,99-IN)2997DU_K!:/Z=7AQ]MME^&."/9Q1 6(Q,E+LK\M4AN2 #387
M4^,=$%,,ED]5YDTE\CO?\=/;[8Z?!Y?U;V&]_DN2[(/1^&1(4JQ_TAE@+6_'
MYB!'KU"PW[DEQ,TNV][7/.7] M\VEA%K@S\S_K)Z74AQ(F2G6ZI,\4'(/TC
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MD^H!K*W.#T*U:?K?C5N 4(">O<IV-JM*+7;H3XACD^\1YF:@G.XV[!_=TPS
M3A*=+F,BM*G+YC*7#>V9::Y:RH3?FU6F#O6!IH]'PY*L,B@;KI)3MNE^SF>7
M'>^JZ6[;_N26$SC9@"^9#_N60SOPZL["HO-AGMB105]^3UM$;1YY%F<6"@R
M6IJBFE5%2ZB'K28IX[&IE4C*>X_W2JLB+;'3/G77-R8OK8D+[V QC#M8-/L
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MQP.ZJP/Z%%EJ@,>AJF-O?4/O-0+DI39XJ:RKUOGQ4@]8I^,3?)MCI>KOJV@
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M^8BOK-GID/WR-&4F/[(V1>)YGG;L:>/3N83P/ FW =U,2NO 2-TV14P$*_7
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M-?_@N;;Z*2JC?B"AY'A! +27P@61'HGE=Q>;K;YQ-8.@Y\^(G[FM%'B./9.
MSQ19@O]UAH(G+.T@[MKX<@?,N'_6#;!>8RA3E?FZ4!=0,"Y9,*JE59H:W>]-
M=8("_*T[]9;D/47YLXM-(AX@'EP@'N!!B8*!@G'T06F,C6+V7W,'I4@A.L0%
MQ 7$A6VX8!JZUAXNU!ZB0VQ ;$!L.!0;GE1SUAM49RC,.&\.'.J+SFUZ\J6
M$HM^[>JE"NWQ1N<$%#UCO:<-;S4"(0)A_4 X'A7GG!X(A(ACB&/%K6XP!&O0
M[6\GG^ %V[4?_(V)Y\P:V?%7EL,ZG5H!U-2^(5.F'DBZ2I^#RI@P$=P3][W)
M8X8N39IYZXE#\F#>]7*KGD4-K+\YV&E'*JH<8(:I# R]6-?#"GCNUF$06BYP
M<-DAUFU%KZ:-9&6LR+IR1"I.FV?=24(O@ , 00M!2R#0XL']\6A8GBNXH LC
M?L!QJ&'4.D=7)*(5HA6B5:UH91AC76U%Q1*B'AK1"M$*T:JW:*6;0VH8MJ);
M76HJ"*(6HA:B5JW58ZHR,(SRHO.Z4:OY6O+Q4![H8\0PQ##$L// L$K!9$-3
M]-&61IQU@U@;"37Z0%:'^J7!6-]95? L',3M@Y>+N-VP[JD.!KIQ/&S7HC,.
M5-D8'#'<M]]@>T+S M_[<=#3;!\(7%5(2^[8\@B)0Y^YO1L>/%JBY4<^R6)!
MPB/AD?!(>"0\$AX)CX1'PB/AD? "//)9SR[KHO3BORQW;?F/$B^\T'"L6><+
MZ;JAJ#A^.L-437,PN+12A\X9&?L)H_AW+?ZLZ[BNJ,/R>27G6#30.0>CW*/<
MBR'WIF$4BX7.-?V^<PY&N;]@N:\JD\; ,,JG"?8ZR1RE400A$&8A74NC(*<P
M2Y+1QKIZ0I+,621H=\[7B :(!B*D.NNJKE,-X.)3G3MG[5-3F$7)24;T0O1J
M3Y<Q5'7<UX3?SOFQHZ!K+;9M_0S'_$'7$RL@0(3EBKB!!83L#O%:0;-ND$I0
M'M@_P*31;>_"*$ F$[+I_\@T-44]: @GX-<K@*_7&?0J.?FTI.>M=L'1-!3
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M3617K5]V54TVCDG31MEMKQ$1F!U=FVEI.C4N9&]6=^^WJ(7BJ?YO$O(1\I%
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M&>3+K.R\"KU5%YZKI>4_V.XU/-MS?;!JB25OW:FW)%)H_:3?B5FD/H]403U
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MGJF?JZ!"2,-*3_,<JDV.ZA#')X<*1U=-?/%O<N_#X@-!/1+;Y4SCX<4<Y&Y
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M8K 3E1QEX(^26\#*6IJNZUQ3*125)*%5K;'N1;3F,^DK$Q>9?8F6\U5*"._
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MSA>')')'S0$QP@YU82#@ 6IOR(8(L$!Y_$YH1!"M0P]?9J'U%[@+$6T[/!Z
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MCGH\"\I*8FIF4:$P=$EAQ@S3UJUYLNPT'@$=50/VK"A=*$:%&"F2"HI8A_
M23!6Y;&JUR )ZMNJ(R3!#D%P": K)2[5VY31%1>I5+8+">DE[/"KW89 I)&(
M4-93U67S 6TGH,NR0"Q-WJO+PN.O6!#5[[1@M?0EKBZ;JNZ 7[^XNOM]_=F+
M5U$N(* B*$_75O"_!PPZG4E_,Y>K-_"N2U"K7K"O48G*I2]F'I<=( 8KTH*P
MK!<40;"<YY,)J?Z'@FUA/K+$OU2%[*1(;B+FF+Y0$C[E\4@?9N#S*GYTO$!4
MX@&(!FSAXH_72U2$K'J"K+HF[T56?/%5L$P>60%3A_MR!7;HUG%T<;2Y4>)
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M1!VD3/TFA3'2QH8A<^1E:80JU8&F[?;X=6?Y3A38UV(O0^.6;^V+K0V&X\E
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M]K1:WJ'N>4=!C&N)BLB'.ZW:B=3ZOT2\ERH70Z=7=<_RH;+%*_RTL )R@1Q
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M\%D#0F @C_-IRUPY'BLS>XL*IL"?$\&?#N%&Z=Q^;0]NU,%HF"_:(>!&P(V
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M6U2M<%%_><=(+OZQ3:YOK&.*,O)1)A5V:B>1Y"3;?C)OF$0^+,@2;K^7[A:
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M^9(?WO^'3 ,L%F<"('LK%Q<?;Z&[(+ESJ9R*D\/^7^=S>##H-(D0^ 8/_$8
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MIV3?'4KK T/C$J:%.ML93$>G'!C<05C_8AYA66BQ.PF)4ZC<U&)U.0.3C/0
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M0:BB>/9?5Q"41RYX3L4YOIZ5IFM&[@#P=KH@L] F7^:_SN<$U(%'DEC8W\R
M9 G]#HE*U+F2#K1ZF[>;CG^#6MYNB$L2'ZCUEZGZW+YF'QOI;,G 4F_92(^*
M'M>CT!YN$\9[*RA'4(Z@G%.DG H"I$M/<2<'1XV\=!^5ESH#JH,5CO"Q\<D_
M!_O2Z_-AE<7A LIJ&)H+WM@L6@LZ/H*.#XOD%G0LZ'AGKZEM_L-Z#T5V^\R
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M2P$"% ,4    " !E,'Q8@?%4 8@-  "*NP  %0              @ %K%
M8VUM8BTR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ 93!\6.9O^!AE(@
M5?X! !4              ( !)B(  &-M;6(M,C R,S$R,S%?9&5F+GAM;%!+
M 0(4 Q0    ( &4P?%C1E!I@!YL  (R]!P 5              "  ;Y$  !C
M;6UB+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !E,'Q85<'&1U@_   1
M%00 %0              @ 'XWP  8VUM8BTR,#(S,3(S,5]P<F4N>&UL4$L!
M A0#%     @ 93!\6(K4>=JAO@( RB$#  X              ( !@Q\! &-M
M;6)?:6UG,#$N:G!G4$L! A0#%     @ 93!\6"M)@BWW"0  K H   X
M         ( !4-X# &-M;6)?:6UG,#(N:G!G4$L! A0#%     @ 93!\6 )\
M>UDW"   WB$  !               ( !<^@# &5X:&EB:71?,3(M,2YH=&U0
M2P$"% ,4    " !E,'Q8PW3_.5@(   G)   $               @ '8\ ,
M97AH:6)I=%\Q,BTR+FAT;5!+ 0(4 Q0    ( &4P?%@WW&F1I 0  +83   0
M              "  5[Y P!E>&AI8FET7S$S+3$N:'1M4$L! A0#%     @
M93!\6->=J#2Z!   ,Q0  !               ( !,/X# &5X:&EB:71?,3,M
M,BYH=&U02P$"% ,4    " !E,'Q8FZW)Y:(#  ! #0  $
M@ $8 P0 97AH:6)I=%\Q-2TQ+FAT;5!+ 0(4 Q0    ( &4P?%BP\-\/R4P
M !K6 0 /              "  >@&! !E>&AI8FET7S(M,2YH=&U02P$"% ,4
M    " !E,'Q8?Q0L<GH9  #:F0  $               @ '>4P0 97AH:6)I
M=%\Y-RTQ+FAT;5!+ 0(4 Q0    ( &4P?%@DK,04878  ,22   .
M      "  89M! !I;6%G93 P,#$Y+FIP9U!+ 0(4 Q0    ( &4P?%@WO9K4
MKI4  (6@   .              "  1/D! !I;6%G93 P,#(P+FIP9U!+ 0(4
M Q0    ( &4P?%BT%_2FIFL  )!T   .              "  >UY!0!I;6%G
M93 P,#(Q+FIP9U!+ 0(4 Q0    ( &4P?%@<A86X@G\  (""   .
M      "  ;_E!0!I;6%G93 P,#(R+FIP9U!+ 0(4 Q0    ( &4P?%CSRD9#
M>NT  %[X   .              "  6UE!@!I;6%G93 P,#(S+FIP9U!+ 0(4
M Q0    ( &4P?%C7(E,F06,  #1I   .              "  1-3!P!I;6%G
M93 P,#(T+FIP9U!+ 0(4 Q0    ( &4P?%A@/(O6O',  &][   .
M      "  8"V!P!I;6%G93 P,#(U+FIP9U!+ 0(4 Q0    ( &4P?%BR@5-0
MV#X  "U'   .              "  6@J" !I;6%G93 P,#(V+FIP9U!+ 0(4
M Q0    ( &4P?%A\OG, 8WT  +"$   .              "  6QI" !I;6%G
M93 P,#(W+FIP9U!+ 0(4 Q0    ( &4P?%@O8:Y7M#L  !5(   .
M      "  ?OF" !I;6%G93 P,#(X+FIP9U!+ 0(4 Q0    ( &4P?%B7;Y#T
M]4H  *I+   .              "  =LB"0!I;6%G93 P,#(Y+FIP9U!+ 0(4
M Q0    ( &4P?%AUX+\4/&L  &9M   .              "  ?QM"0!I;6%G
M93 P,#,P+FIP9U!+ 0(4 Q0    ( &4P?%B-*^T$=I(  #63   .
M      "  639"0!I;6%G93 P,#,Q+FIP9U!+ 0(4 Q0    ( &4P?%@,U$L>
M>"P  &$T   .              "  09L"@!I;6%G93 P,#,R+FIP9U!+ 0(4
M Q0    ( &4P?%C[N&7'1)H  %JW   .              "  :J8"@!I;6%G
M93 P,#,S+FIP9U!+ 0(4 Q0    ( &4P?%AI 5<SORX( %3N"  +
M      "  1HS"P!I;6%G93$S+FIP9U!+ 0(4 Q0    ( &4P?%AP>%AO\6H"
M .BP @ *              "  0)B$P!I;6%G93,N:G!G4$L! A0#%     @
M93!\6,F];[.A#P0 :P$F  T              ( !&\T5 'IK,C0S,3$X-2YH
8=&U02P4&     "  ( "D!P  Y]P9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>zk2431185_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmmb="http://www.anchiano.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cmmb-20231231.xsd" xlink:type="simple"/>
    <context id="C_20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cmmb:CapitalAdditionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20200510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2020-05-10</instant>
        </period>
    </context>
    <context id="C_20200501to20200510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-10</endDate>
        </period>
    </context>
    <context id="C_20211001to20211024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-24</endDate>
        </period>
    </context>
    <context id="C_20211024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-10-24</instant>
        </period>
    </context>
    <context id="C_20231212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2023-12-12</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtCurrencyAxis_currencyUSD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyUSD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtCurrencyAxis_currencyILS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyILS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyXXX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtCurrencyAxis_currencyXXX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_20220401to20220425_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20231101to20231117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="C_20231001to20231031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_20231001to20231031_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RothCapitalPartnersLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:MarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RothCapitalPartnersLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:MarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_20230101to20231231" id="FFact_0000000000489">0001534248</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus contextRef="C_20230101to20231231" id="FFact_0000000000490">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="C_20230101to20231231" id="FFact_0000000000491">false</dei:AmendmentFlag>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_20200501to20200510"
      id="Fxbrl_20230131233234992">2023-05-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_20211001to20211024"
      id="Fxbrl_20230131233722905">2024-10-31</us-gaap:LeaseExpirationDate1>
    <dei:DocumentType
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230213103251859">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325124822695">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325124850731">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325125020590">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325125039815">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325125103526">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325125127518">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325125149159">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325125212477">001-40490</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230213104107012">Chemomab Therapeutics Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325171717506">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325130645061">Kiryat               Atidim, Building 7</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325130702398">,               Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240327173314698">6158002</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325125444047">6158002</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325125500854">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325125533965">Sigal Fattal</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130613231">Kiryat Atidim Building 7</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130913214">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130944047">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130506462">855</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20230101to20231231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="Fxbrl_20240325130536510">492-5563</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="Fxbrl_20230213103433506">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="Fxbrl_20230213103437662">CMMB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="Fxbrl_20230213103445669">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20230213103508728">Ordinary shares, no par-value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20230213103458685">NA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20230213103452851">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20240325131407326"
      unitRef="Share">284094700</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325131448134">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325131518183">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325131547950">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325131614371">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325131641177">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325172008738">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325172437467">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240327182011473">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325173248259">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325172525187">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325132317597">false</dei:EntityShellCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240327183652256">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:AuditorFirmId
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325200052033">1057</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325173623987">Somekh Chaikin</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325173629952">Tel Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000038"
      unitRef="usd">9292000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000039"
      unitRef="usd">13519000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000040"
      unitRef="usd">10492000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000041"
      unitRef="usd">26374000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230213102216110_Fact_0000000000040"
      unitRef="usd">76000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230213102216110_Fact_0000000000041"
      unitRef="usd">77000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000042"
      unitRef="usd">1037000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000043"
      unitRef="usd">1766000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000044"
      unitRef="usd">20897000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000045"
      unitRef="usd">41736000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000048"
      unitRef="usd">559000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230131220311598"
      unitRef="usd">733000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230207200450049_Fact_0000000000050"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207200450049_Fact_0000000000051"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000052"
      unitRef="usd">303000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000053"
      unitRef="usd">367000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000054"
      unitRef="usd">392000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000055"
      unitRef="usd">227000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000056"
      unitRef="usd">1254000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000057"
      unitRef="usd">1327000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000058"
      unitRef="usd">22151000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000059"
      unitRef="usd">43063000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000060"
      unitRef="usd">516000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000061"
      unitRef="usd">1688000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000062"
      unitRef="usd">3423000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000063"
      unitRef="usd">3378000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000064"
      unitRef="usd">823000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000065"
      unitRef="usd">1560000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000066"
      unitRef="usd">76000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000067"
      unitRef="usd">123000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000068"
      unitRef="usd">4838000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000069"
      unitRef="usd">6749000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000070"
      unitRef="usd">316000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000071"
      unitRef="usd">91000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000072"
      unitRef="usd">316000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000073"
      unitRef="usd">91000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20231231"
      id="Fxbrl_20240325094639969"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20221231"
      id="Fxbrl_20240325094654148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000074"
      unitRef="usd">5154000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000075"
      unitRef="usd">6840000</us-gaap:Liabilities>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20211231"
      decimals="0"
      id="Fxbrl_20240325124641641"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20221231"
      decimals="0"
      id="Fxbrl_20230201163052384"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20231231"
      decimals="0"
      id="Fxbrl_20230131220607422"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20240325124631855"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230131221123913"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20230131221114549"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesOutstanding
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20240325094937707"
      unitRef="Share">284094700</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20230213101830930"
      unitRef="Share">284094700</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20240325094948068"
      unitRef="Share">232636700</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20240325094832822"
      unitRef="Share">232636700</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_s_20230131221353660"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20230131221353661"
      unitRef="Share">228090300</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230131221528825"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230131221535249"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230207202558860"
      unitRef="Share">11640460</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230207202444619"
      unitRef="usd">0</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207202534021"
      unitRef="usd">1218000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000086"
      unitRef="usd">105675000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000087"
      unitRef="usd">101260000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000088"
      unitRef="usd">-88678000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000089"
      unitRef="usd">-63819000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000090"
      unitRef="usd">16997000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000091"
      unitRef="usd">36223000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000092"
      unitRef="usd">22151000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000093"
      unitRef="usd">43063000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000094"
      unitRef="usd">18381000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000095"
      unitRef="usd">16977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325095930537"
      unitRef="usd">6334000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000096"
      unitRef="usd">7078000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000097"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325095935768"
      unitRef="usd">6033000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000098"
      unitRef="usd">25459000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000099"
      unitRef="usd">28533000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325095940813"
      unitRef="usd">12367000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230131223230473"
      unitRef="usd">1238000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131223237304"
      unitRef="usd">353000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325095946273"
      unitRef="usd">-111000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230207212310873_Fact_0000000000102"
      unitRef="usd">-24221000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207212310873_Fact_0000000000103"
      unitRef="usd">-28180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325095953001"
      unitRef="usd">-12478000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230131223639023"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000101"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325100001097"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000102"
      unitRef="usd">-24221000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000103"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325100006496"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20230131213305203"
      unitRef="USD_Per_Share">0.103</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000104"
      unitRef="USD_Per_Share">0.103</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230131213312166"
      unitRef="USD_Per_Share">0.121</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000105"
      unitRef="USD_Per_Share">0.121</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_s_20240325100011534"
      unitRef="USD_Per_Share">0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20240325100011535"
      unitRef="USD_Per_Share">0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20230214141238310"
      unitRef="Share">234998859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000106"
      unitRef="Share">234998859</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230131213329528"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000107"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_s_20240325100018414"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20240325100018415"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207232832534"
      unitRef="Share">9274838</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004148281"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004108785"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004208753"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000128"
      unitRef="usd">34497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000129"
      unitRef="usd">-23695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000130"
      unitRef="usd">10802000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004236209"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004232608"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232932528"
      unitRef="usd">2019000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004229458"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207232938175"
      unitRef="usd">2019000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:EffectOfReverseCapitalizationTransactionShares
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207232946871"
      unitRef="Share">152299702</cmmb:EffectOfReverseCapitalizationTransactionShares>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004310594"
      unitRef="usd">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransactionShares
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004631164"
      unitRef="Share">0</cmmb:EffectOfReverseCapitalizationTransactionShares>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004302609"
      unitRef="usd">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232952864"
      unitRef="usd">2476000</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004258843"
      unitRef="usd">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207232958504"
      unitRef="usd">2476000</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233006128"
      unitRef="Share">66381520</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004339738"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004626295"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004335122"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233012248"
      unitRef="usd">58637000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004332317"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233018475"
      unitRef="usd">58637000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233039147"
      unitRef="Share">134240</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004521301"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004621028"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004724885"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233033563"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004807831"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233028090"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004352160"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004349447"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208004345432"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233044479"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233049858"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207234506438"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004359870"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004449318"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004357072"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233106443"
      unitRef="usd">97639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207234203847"
      unitRef="usd">-36173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207233116634"
      unitRef="usd">61466000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207234515566"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004830175"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004835440"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004846448"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233129314"
      unitRef="usd">97639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233133644"
      unitRef="usd">-36173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207233141194"
      unitRef="usd">61466000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004855201"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004852649"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233154315"
      unitRef="usd">3211000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004943313"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233147476"
      unitRef="usd">3211000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233201211"
      unitRef="Share">2576400</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004904248"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004910523"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004901083"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233210018"
      unitRef="usd">267000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004950211"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233216009"
      unitRef="usd">267000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233237975"
      unitRef="Share">1970000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004927217"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230208004915442"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208004923369"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233227671"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004959684"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233221400"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004938057"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230207233301376"
      unitRef="Share">-11640460</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230207233406606"
      unitRef="usd">-1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208004934609"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004932393"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233411324"
      unitRef="usd">-1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208005011611"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230208005008418"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208005005802"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233416622"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233422744"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233430996"
      unitRef="Share">232636700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208005022333"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20230207233657770"
      unitRef="Share">-11640460</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20230207233728393"
      unitRef="usd">-1218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233439472"
      unitRef="usd">101260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233445148"
      unitRef="usd">-63819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207233450251"
      unitRef="usd">36223000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240325100756924_xbrl_20230207234515566"
      unitRef="Share">232636700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230208004830175"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20240325100756924_xbrl_20230208004835440"
      unitRef="Share">-11640460</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230208004846448"
      unitRef="usd">-1218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230207233129314"
      unitRef="usd">101260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230207233133644"
      unitRef="usd">-63819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240325100756924_xbrl_20230207233141194"
      unitRef="usd">36223000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230208004855201"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230208004852649"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230207233154315"
      unitRef="usd">1491000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230208004943313"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325100645650_xbrl_20230207233147476"
      unitRef="usd">1491000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240325100655099_xbrl_20230207233201211"
      unitRef="Share">51458000</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230208004904248"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20240325100655099_xbrl_20230208004910523"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230208004901083"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230207233210018"
      unitRef="usd">2924000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230208004950211"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325100655099_xbrl_20230207233216009"
      unitRef="usd">2924000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230208004938057"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20240325100724019_xbrl_20230207233301376"
      unitRef="Share">11640460</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230207233406606"
      unitRef="usd">1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230208004934609"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230208004932393"
      unitRef="usd">-638000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325100724019_xbrl_20230207233411324"
      unitRef="usd">580000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230208005011611"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230208005008418"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230208005005802"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230207233416622"
      unitRef="usd">-24221000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325100739987_xbrl_20230207233422744"
      unitRef="usd">-24221000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20240325100745487_xbrl_20230207233430996"
      unitRef="Share">284094700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230208005022333"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="INF"
      id="Fxbrl_20240325100745487_xbrl_20230207233657770"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockCommonMember"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230207233728393"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230207233439472"
      unitRef="usd">105675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230207233445148"
      unitRef="usd">-88678000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325100745487_xbrl_20230207233450251"
      unitRef="usd">16997000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000149"
      unitRef="usd">-24221000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000150"
      unitRef="usd">-27646000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104742349"
      unitRef="usd">-12478000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000151"
      unitRef="usd">67000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000152"
      unitRef="usd">58000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104746496"
      unitRef="usd">34000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000153"
      unitRef="usd">1491000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000154"
      unitRef="usd">3211000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104750812"
      unitRef="usd">2019000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000155"
      unitRef="usd">-903000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000156"
      unitRef="usd">64000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104755091"
      unitRef="usd">2058000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000157"
      unitRef="usd">-1172000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000158"
      unitRef="usd">352000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104759425"
      unitRef="usd">1175000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000159"
      unitRef="usd">45000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201002431792"
      unitRef="usd">2823000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104804410"
      unitRef="usd">-1279000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000161"
      unitRef="usd">-737000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000162"
      unitRef="usd">907000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104808746"
      unitRef="usd">215000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000163"
      unitRef="usd">13000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201002424683"
      unitRef="usd">-11000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104815058"
      unitRef="usd">-2000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000165"
      unitRef="usd">-23611000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000166"
      unitRef="usd">-20370000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104819434"
      unitRef="usd">-12374000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000167"
      unitRef="usd">-15882000</cmmb:PaymentsForInvestmentInDeposits>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000168"
      unitRef="usd">-19601000</cmmb:PaymentsForInvestmentInDeposits>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104823921"
      unitRef="usd">45951000</cmmb:PaymentsForInvestmentInDeposits>
    <cmmb:LongTermLeaseDeposit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000169"
      unitRef="usd">0</cmmb:LongTermLeaseDeposit>
    <cmmb:LongTermLeaseDeposit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131235620864"
      unitRef="usd">0</cmmb:LongTermLeaseDeposit>
    <cmmb:LongTermLeaseDeposit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104828616"
      unitRef="usd">4000</cmmb:LongTermLeaseDeposit>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000171"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131235631064"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104835346"
      unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000173"
      unitRef="usd">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000174"
      unitRef="usd">68000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104839642"
      unitRef="usd">239000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000175"
      unitRef="usd">15879000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000176"
      unitRef="usd">19533000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104844087"
      unitRef="usd">-45186000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cmmb:CashAcquiredInMerger
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000177"
      unitRef="usd">0</cmmb:CashAcquiredInMerger>
    <cmmb:CashAcquiredInMerger
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131235649216"
      unitRef="usd">0</cmmb:CashAcquiredInMerger>
    <cmmb:CashAcquiredInMerger
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104926796"
      unitRef="usd">2427000</cmmb:CashAcquiredInMerger>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000179"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131235658097"
      unitRef="usd">143000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104931102"
      unitRef="usd">10000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230201000241409"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000182"
      unitRef="usd">1218000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104937430"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325104521419"
      unitRef="usd">580000</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325104453631_xbrl_20230201000241409"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104453631_Fact_0000000000182"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000183"
      unitRef="usd">2924000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000184"
      unitRef="usd">267000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104942102"
      unitRef="usd">58637000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230201002754453"
      unitRef="usd">3504000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000186"
      unitRef="usd">-808000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325104946388"
      unitRef="usd">61074000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230201002721687"
      unitRef="usd">-4228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000188"
      unitRef="usd">-1645000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325105003435"
      unitRef="usd">3514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000189"
      unitRef="usd">13596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000190"
      unitRef="usd">15241000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="Fxbrl_20240325105007045"
      unitRef="usd">11727000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000191"
      unitRef="usd">9368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000192"
      unitRef="usd">13596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20240325105011131"
      unitRef="usd">15241000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230214142748754"
      unitRef="usd">187000</cmmb:IncomeTaxesReceived>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214143241770"
      unitRef="usd">351000</cmmb:IncomeTaxesReceived>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325105045604"
      unitRef="usd">0</cmmb:IncomeTaxesReceived>
    <cmmb:InterestReceived
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230207233819452"
      unitRef="usd">1463000</cmmb:InterestReceived>
    <cmmb:InterestReceived
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233829491"
      unitRef="usd">972000</cmmb:InterestReceived>
    <cmmb:InterestReceived
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325105050333"
      unitRef="usd">74000</cmmb:InterestReceived>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000193"
      unitRef="usd">392000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000194"
      unitRef="usd">17000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325105059739"
      unitRef="usd">345000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000195"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131235456185"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325105106698"
      unitRef="usd">49000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:NatureOfOperations contextRef="C_20230101to20231231" id="FFact_0000000000208">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 1 - General&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company&#x2019;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics Inc.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company currently has no products approved for sale. The Company&#x2019;s operations are funded primarily by its Shareholders. The Company has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it obtains marketing approval for its products. Continuation of the Company&#x2019;s development programs depend on its future ability to raise sources of financing. The Company believes that its cash and cash equivalents and bank deposits as of December 31, 2023 will be sufficient to fund its operations through March 31, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 14, 2020, the Company (formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and Plan of Merger (the "Merger" and &#x201c;Merger Agreement&#x201d;) with Chemomab Ltd., an Israeli limited company, and CMB Acquisition Ltd., an Israeli limited company and a wholly owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;). On March 16, 2021, (the &#x201c;Effective Time&#x201d;), the Company consummated the Merger pursuant to the Merger Agreement Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. surviving the Merger as the Company's wholly owned subsidiary. In connection with the Merger, on March 16, 2021, the Company changed its name from &#x201c;Anchiano Therapeutics Ltd.&#x201d; To &#x201c;Chemomab Therapeutics Ltd." and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;At the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd. option was assumed by the Company, based on the same exchange ratio.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For accounting purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab Share Incentive Plan (the &#x201c;2015 Plan&#x201d;), with such options representing the right to purchase a number of ADSs equal to approximately 12.86 multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in $ thousands):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Asset held for sale&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid and other assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net acquired assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,476&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:NatureOfOperations>
    <cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger
      contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember"
      decimals="INF"
      id="Fxbrl_20230131220949272"
      unitRef="Share">12.86</cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325095248894">
          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Asset held for sale&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid and other assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net acquired assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,476&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000202"
      unitRef="usd">2427000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000203"
      unitRef="usd">1000000</cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000204"
      unitRef="usd">236000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000205"
      unitRef="usd">1187000</cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <cmmb:EstimatedFairValueOfNetAssetsAcquired
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000206"
      unitRef="usd">2476000</cmmb:EstimatedFairValueOfNetAssetsAcquired>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000234">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 2 - Summary of Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;

            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Basis of Preparation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Use of estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Foreign currency&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;dollar&#x201d; or &#x201c;$&#x201d;), thus; the dollar is the functional currency of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Restricted cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Annual rates at depreciation are as follows:&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;

              &lt;div&gt;
                &lt;div style="margin-left:36pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;

          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;H.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s property and equipment are reviewed for impairment in accordance with ASC 360, &#x201c;Property and Equipment&#x201d;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;I.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;J.&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;K.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#x2019;s own credit risk.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#x2019;s non&lt;span style="font-weight:bold"&gt;- &lt;/span&gt;financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;L.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value for the Company&#x2019;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;M.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Government-sponsored research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab records grants received from the office of the Israel Innovation Authority (the &#x201c;IIA&#x201d;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;N.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Severance pay&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $86, $142 thousand, and $116 thousand for the year ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;O.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Concentrations of credit risk:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#x2019;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;P.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2023 5% in 2022 and 5.2% in 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Q.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Principles of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;R.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Earnings per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101130571">
            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Basis of Preparation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101147320">
          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Use of estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101207112">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Foreign currency&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;dollar&#x201d; or &#x201c;$&#x201d;), thus; the dollar is the functional currency of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101223928">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash equivalents are short-term liquid bank deposits that are readily convertible to cash with original maturities of three months or less at the date acquired.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101245836">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Restricted cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office lease payments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <cmmb:ShortTermBankDepositsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325102921313">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term investments. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </cmmb:ShortTermBankDepositsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101332820">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Annual rates at depreciation are as follows:&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;

              &lt;div&gt;
                &lt;div style="margin-left:36pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;

          &lt;/div&gt;
        </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101112603">
              &lt;div&gt;
                &lt;div style="margin-left:36pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            </cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="2"
      id="FFact_0000000000214"
      unitRef="Pure">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="2"
      id="FFact_0000000000215"
      unitRef="Pure">0.10</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="2"
      id="FFact_0000000000216"
      unitRef="Pure">0.07</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <cmmb:AnnualRatesOfDepreciation
      contextRef="C_20230101to20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      id="FFact_0000000000217">over the shorter of the lease term or the estimated useful life of the improvement</cmmb:AnnualRatesOfDepreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101350742">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;H.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s property and equipment are reviewed for impairment in accordance with ASC 360, &#x201c;Property and Equipment&#x201d;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101409349">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;I.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages. &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101429788">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;J.&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101455682">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;K.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#x2019;s own credit risk.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#x2019;s non&lt;span style="font-weight:bold"&gt;- &lt;/span&gt;financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101553859">
          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;L.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value for the Company&#x2019;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101618954">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;M.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Government-sponsored research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab records grants received from the office of the Israel Innovation Authority (the &#x201c;IIA&#x201d;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock>
    <cmmb:SeverancePayPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101636106">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;N.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Severance pay&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $86, $142 thousand, and $116 thousand for the year ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </cmmb:SeverancePayPolicyTextBlock>
    <cmmb:PercentageOfMonthlyDepositsRate
      contextRef="C_20230101to20231231"
      decimals="4"
      id="Fxbrl_20230215220314714"
      unitRef="Pure">0.0833</cmmb:PercentageOfMonthlyDepositsRate>
    <us-gaap:SeveranceCosts1
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230215220321806"
      unitRef="usd">86000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230215220329094"
      unitRef="usd">142000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325101644612"
      unitRef="usd">116000</us-gaap:SeveranceCosts1>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101706426">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;O.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Concentrations of credit risk:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#x2019;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101730315">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;P.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 9% in 2023 5% in 2022 and 5.2% in 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101745826">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Q.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Principles of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325101803004">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;R.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:20pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Earnings per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000244">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 3 - Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,663&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In NIS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In other currencies&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;
          &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*Less than 1 thousand&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325103135178">
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In USD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,663&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In NIS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In other currencies&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;*-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231_srtCurrencyAxis_currencyUSD"
      decimals="-3"
      id="FFact_0000000000235"
      unitRef="usd">6718000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_srtCurrencyAxis_currencyUSD"
      decimals="-3"
      id="FFact_0000000000236"
      unitRef="usd">10663000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231_srtCurrencyAxis_currencyILS"
      decimals="-3"
      id="FFact_0000000000237"
      unitRef="usd">2574000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_srtCurrencyAxis_currencyILS"
      decimals="-3"
      id="FFact_0000000000238"
      unitRef="usd">2756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231_srtCurrencyAxis_currencyXXX"
      decimals="-3"
      id="Fxbrl_20240325103200378"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_srtCurrencyAxis_currencyXXX"
      decimals="-3"
      id="FFact_0000000000240"
      unitRef="usd">100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000241"
      unitRef="usd">9292000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000242"
      unitRef="usd">13519000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000252">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 4 - Other Receivables and Prepaid Expenses&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Government institutions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,766&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;

  </cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325103414977">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Government institutions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,766&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock>
    <cmmb:ReceivablesFromGovernmentInstitutions
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000245"
      unitRef="usd">289000</cmmb:ReceivablesFromGovernmentInstitutions>
    <cmmb:ReceivablesFromGovernmentInstitutions
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000246"
      unitRef="usd">459000</cmmb:ReceivablesFromGovernmentInstitutions>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000247"
      unitRef="usd">748000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000248"
      unitRef="usd">1307000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000249"
      unitRef="usd">1037000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000250"
      unitRef="usd">1766000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000270">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 5 - Property and Equipment, Net&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Website development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less - accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325104029249">
          &lt;div&gt;
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cost:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Computers&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Furniture and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Laboratory equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Website development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less - accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000253"
      unitRef="usd">68000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000254"
      unitRef="usd">70000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="-3"
      id="FFact_0000000000255"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="-3"
      id="FFact_0000000000256"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="-3"
      id="FFact_0000000000257"
      unitRef="usd">400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="-3"
      id="FFact_0000000000258"
      unitRef="usd">399000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"
      decimals="-3"
      id="FFact_0000000000259"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"
      decimals="-3"
      id="FFact_0000000000260"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000261"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000262"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230201032006902"
      unitRef="usd">529000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000264"
      unitRef="usd">532000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000265"
      unitRef="usd">226000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000266"
      unitRef="usd">165000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230201033845372"
      unitRef="usd">303000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000268"
      unitRef="usd">367000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000294">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 6 - Leases&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter &#x2013; &#x201c;The Agreement&#x201d; .(According to the Agreement, Chemomab Leased a space in Atidim Park, Tel-Aviv for a period of three years, through &lt;span style="-sec-ix-hidden:Fxbrl_20230131233234992"&gt;May 2023&lt;/span&gt;. Chemomab was granted an option to extend the lease term by additional three years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab returned the previous office and lab space to the property owner and leased a larger space in Atidim Park Tel-Aviv, for a term of 3 years, through &lt;span style="-sec-ix-hidden:Fxbrl_20230131233722905"&gt;October 2024&lt;/span&gt;. In addition, Chemomab was granted an option to extend the lease term by additional three years. The annual lease and management fees are approximately $111 thousand. Pursuant to the Amendment, the bank guarantee issued in 2020 was canceled and a substitute bank guarantee of approximately $77 thousand was issued to the property owner during 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The above operating leases are included in &#x201c;Operating lease right-of-use assets&#x201d; on the Company&#x2019;s Consolidated Balance sheets as of December 31, 2023, 2022 and 2021 represent the Company&#x2019;s right to use the underlying asset for the lease term. The Company&#x2019;s obligations to pay lease payments are included in the current liabilities as &#x201c;Operating lease liabilities&#x201d; and in the non-current liabilities as &#x201c;Non-current operating lease liabilities&#x201d; on the Company&#x2019;s Consolidated Balance sheets as of December 31, 2023, 2022 and 2021. Based on the present value of the lease payments for the remaining lease term of the Company&#x2019;s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $392 thousand on December 12, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the years ended December 31, 2023, 2022 and 2021, the Company recognized an increase in right of use assets of $392, $17 thousand and $345 thousand, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023 the Company concluded it reasonably certain in the lease agreement for additional three years and accordingly performed a reassessment of the right of use asset which resulted in a new right of use asset in the amount of $392 thousand as of December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, 2022, and 2021 operating right-of-use asset was $392 thousand, $227 thousand and $345 thousand, respectively. The operating lease liabilities were $392 thousand, $214 thousand and $343 thousand, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As most of the Chemomab&#x2019;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#x2019;s incremental borrowing rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was 9% in 2023 5% in 2022 and 5.2% in 2021.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Maturities of lease liabilities under noncancellable leases as of December 31, 2023, are as follows: (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:36pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:88%;padding-bottom:4px;vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less imputed interest:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_20200510" id="Fxbrl_20230131233210356">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20200501to20200510"
      id="Fxbrl_20230131233301410">three years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_20211024" id="Fxbrl_20230131233734834">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20211001to20211024"
      id="Fxbrl_20230201000916081">three years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <cmmb:AnnualRentAndManagementFees
      contextRef="C_20211001to20211024"
      decimals="-3"
      id="Fxbrl_20230131234005244"
      unitRef="usd">111000</cmmb:AnnualRentAndManagementFees>
    <cmmb:BankGuaranteesToPropertyOwner
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325135011021"
      unitRef="usd">77000</cmmb:BankGuaranteesToPropertyOwner>
    <cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities
      contextRef="C_20231212"
      decimals="-3"
      id="Fxbrl_20230131234456429"
      unitRef="usd">392000</cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230131234508150"
      unitRef="usd">392000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131234513790"
      unitRef="usd">17000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325105850271"
      unitRef="usd">345000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325112042565">three years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <cmmb:ReassessmentOfRightOfUseAsset
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325112804525"
      unitRef="usd">392000</cmmb:ReassessmentOfRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230214143811730"
      unitRef="usd">392000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230214143818906"
      unitRef="usd">227000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20240325105759783"
      unitRef="usd">345000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230214143827206"
      unitRef="usd">392000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230214143833566"
      unitRef="usd">214000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20240325105743080"
      unitRef="usd">343000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20230131234937485"
      unitRef="Pure">0.09</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20230131234957047"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20210101to20211231"
      decimals="3"
      id="Fxbrl_20240325105827270"
      unitRef="Pure">0.052</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325105733072">
            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="width:88%;padding-bottom:4px;vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less imputed interest:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="width:1%;padding-bottom:2pt;vertical-align:baseline;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325112906183"
      unitRef="usd">115000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325112921124"
      unitRef="usd">121000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325112940611"
      unitRef="usd">121000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325113005077"
      unitRef="usd">107000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000290"
      unitRef="usd">464000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000291"
      unitRef="usd">72000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000292"
      unitRef="usd">392000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000311">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 7 - Commitments and Contingent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exclusive License Agreement (hereinafter- &#x201c;the License Agreement&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (&#x201c;Fund"), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(i)&lt;/span&gt;&lt;/span&gt;&lt;span style="padding-left:24pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Royalties in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to certain additional terms set forth therein.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to pay the Fund the following non-refundable, non-creditable amounts:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$100 thousand upon submission of a New Drug Application (&#x201c;NDA&#x201d;), Biological License Application (&#x201c;BLA&#x201d;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#x201c;FDA&#x201d;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:35.45pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:35.45pt;vertical-align:top"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-indent:36pt;line-height:1.25;text-align:justify"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023 no payments were made to the Fund.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In addition to the payments described above, upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (&#x201c;IIA&#x201d;) for the support of certain research and development activities conducted in Israel.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In return for the IIA&#x2019;s participation, Chemomab is committed to pay royalties at rate of 3% of sales of the developed product (linked to U.S. dollar), up to 100% of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology or development out of Israel.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab did not receive any grants from the IIA in the years ended December 31, 2023, 2022 and-2021.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Since Chemomab &#x2019;s incorporation through December 31, 2023 Chemomab received $1,227 thousand from the IIA, which were recognized as a reduction of research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, Chemomab has no commitment for royalties payable.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In June 2015, Chemomab entered into a license agreement with subcontractor (&#x201c;the Subcontractor&#x201d;), under which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediates and active pharmaceutical ingredients. According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with Chemomab's specifications and timeline. From time to time, Chemomab and the Subcontractor have been signing additional agreements for additional manufacturing and final process lock of the product for clinical use Under the agreement, Chemomab is also obligated to pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During 2023, 2022 and 2021, Chemomab recorded expenses related to the above agreements in the amounts of $4,832, $5,222 thousand and $2,590 thousand, respectively. The expenses were recorded under research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, the bank imposed restriction on a bank deposit in the amount of $76 thousand for the purpose of secure lease payments under an office lease agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;D.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During 2022, the Israeli tax authority ("ITA&#x201d;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 2022. The ITA raised several claims, mainly in respect with the recoverability of VAT related to the Merger Agreement expenses and the classification of the Company as a holding company. In July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued an assessment. In November 2022, the Company filed an appeal to the ITA&#x2019;s assessment. The Company has recorded a provision in 2022 that is inherently subjective due to the inherent uncertainty of these matters and the judicial process, therefore, the outcome may differ from the estimated liability recorded by the Company during 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="color:#000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In October 2023 the ITA rejected the company&#x2019;s appeal on the assessment. The Company is expected to submit an appeal in April 2024 to the Israeli district court. Based on the consultancy of its tax advisors, The Company estimates that the amount of provision recorded in 2022 remains adequate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"
      id="Fxbrl_20230215222406006">$100 thousand upon submission of a New Drug Application (&#x201c;NDA&#x201d;), Biological License Application (&#x201c;BLA&#x201d;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#x201c;FDA&#x201d;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember"
      id="Fxbrl_20230215222519809">$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:OtherCommitmentsDescription
      contextRef="C_20230101to20231231"
      id="Fxbrl_20230215222713212">upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.</us-gaap:OtherCommitmentsDescription>
    <cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct
      contextRef="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"
      decimals="2"
      id="Fxbrl_20230201002925810"
      unitRef="Pure">0.03</cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct>
    <cmmb:MaximumPercentageOfPaymentsOfRoyalties
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20230201002935951"
      unitRef="Pure">1</cmmb:MaximumPercentageOfPaymentsOfRoyalties>
    <cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230201002951961"
      unitRef="usd">1227000</cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized>
    <us-gaap:RoyaltyExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230213125722009"
      unitRef="usd">4832000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213125731080"
      unitRef="usd">5222000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325141025378"
      unitRef="usd">2590000</us-gaap:RoyaltyExpense>
    <us-gaap:RestrictedInvestments
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230213125744104"
      unitRef="usd">76000</us-gaap:RestrictedInvestments>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000385">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Note 8 - Share Capital&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:34.9pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Right attached to shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:34.9pt;margin-left:36pt;line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;1.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Voting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Dividends&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Since its inception, the Company has not declared any dividends.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Financing rounds&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:54pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately $45.5 million of its American Depositary Shares )ADSs( in a private placement transaction, (or "The Private Placement"). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately $4.5 million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:54pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp;amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $75 million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued 699,806 ADSs at an average price of $22.75 per ADS under the ATM Agreement, resulting in gross proceeds of $15,917 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:54pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000 of its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float. During the year ended December 31, 2022, the Company issued 130,505 ADSs at an average price of $2.11 per ADS under the ATM Agreement, resulting in gross proceeds of $275 thousand. During the year ended December 31, 2023, the Company issued 772,900 ADSs at an average price of $1.83 per ADS under the ATM Agreement, resulting in net proceeds of $1,371 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:54pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;
                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On September 19, 2022, the Company entered&#160; into a share purchase agreement (the &#x201c;Repurchase Arrangement&#x201d;) with Dr. Adi Mor, co-founder of Chemomab Ltd., then Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#x201c;Co-Founders&#x201d;), whereby the Company agreed, subject to the requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#x201c;Companies Law&#x201d;), which the Company received on November 14, 2022, to repurchase up to 582,023 of the Company's ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the company repurchased the entire amount of 582,023 ADSs (the "Treasury Shares") from the Co-Founders at an average price of $2.0848 and for total consideration of approximately $1,218 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 17, 2023, the company sold the Treasury Shares for an aggregate consideration of approximately $580 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:54pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In October 2023, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $2,863,664 of its ADSs in connection with the reactivation of the ATM Facility and pursuant to Rule 415(a)(6) under the Securities Act of 1933 Form F-3, which, subject to certain exceptions, limits the number of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:54pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In October 2023, the Company entered into an At the Market Offering Agreement (the "Roth ATM Agreement") with Roth Capital Partners, LLC, (&#x201c;Roth&#x201d;). According to the Roth ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $2,863,664 through Roth or the Roth ATM Agreement. From October 30, 2023 through December 31, 2023, the Company issued 1,800,000 ADSs at an average price of $0.96 per ADS under the Roth ATM Agreement, resulting in net proceeds of $1,553 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Share-based compensation plan:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company maintains (i) the 2011 Share Option Plan (the &#x201c;2011 Plan&#x201d;), (ii) the 2017 Equity-Based Incentive Plan (the &#x201c;2017 Plan&#x201d;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#x201c;2015 Plan&#x201d;),&#x2009;which was assumed by the Company from Chemomab upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, a total of 28,443,060 of our Ordinary Shares (equal to 1,422,153 ADSs) were reserved for issuance under the 2015 Plan, of which 3,445,520 Ordinary Shares (equal to 172,276 ADSs) had been issued pursuant to previous option exercise, and 6,826,440 Ordinary Shares (equal to 341,322 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 6,394,160 Ordinary Shares (equal to 319,708 ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $0.30 per Ordinary Share (or $5.98 per ADS). During the year ended December 31, 2023, options to purchase 16,634,300 Ordinary Shares (equal to 831,715 ADSs) were canceled.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2023, a total of 23,061,380 of our Ordinary Shares (equal to 1,153,069 of our ADSs) were reserved for issuance under the 2017 Plan, of which 23,046,660 Ordinary Shares (equal to 1,152,333 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 3,689,480 Ordinary Shares (equal to 184,474 ADSs) had vested and became exercisable as of that date, with a weighted average exercise price of $0.20 per Ordinary Share (or $3.91 per ADS). During the year ended December 31, 2023, options to purchase 3,739,320 Ordinary Shares (equal to 186,966 ADSs) were canceled.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The expenses that were recognized in the consolidated statements of operations for services received from employees and service providers are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

          &lt;div&gt;
            &lt;div&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total share-based compensation expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The number and weighted average exercise price of options are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="line-height:1.25;margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at January 1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,003,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;10,455,580&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Acquired in Merger&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;609,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,970,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(134,220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,240,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,712,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,398,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;17,784,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9.79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at December 31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,003,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25;margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at January 1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,003,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,970,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(20,373,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,240,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,055,180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,398,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at December 31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair value measurement:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="line-height:1.25;margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;padding-left:27pt;padding-bottom:2px;width:84%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023 grants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average share price (in U.S. dollar)&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercise price (in U.S. dollar)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.06-0.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life of options (in years)&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.53-9.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;97.79%-112.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.71%-4.43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left"&gt;&#160;&lt;/p&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The weighted average share price is based on the Company&#x2019;s Ordinary Share valuation as at the grant date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(c)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#x2019;s expected term.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:72pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(d)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20230213133908909"
      unitRef="usd">45500000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:NumberOfWarrantsPurchaseUpAdss
      contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230213133843633"
      unitRef="Share">2619270</cmmb:NumberOfWarrantsPurchaseUpAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230213133849363"
      unitRef="Share">261929</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20230213133830904"
      unitRef="USD_Per_Share">17.35</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210301to20210322_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20230213133820824"
      unitRef="usd">4500000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-6"
      id="Fxbrl_20230213133808746"
      unitRef="usd">75000000</cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133801744"
      unitRef="Share">699806</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="2"
      id="Fxbrl_20230213133754484"
      unitRef="USD_Per_Share">22.75</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20230213133747440"
      unitRef="usd">15917000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20220401to20220425_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133711976"
      unitRef="Share">18125000</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133726969"
      unitRef="Share">130505</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133719951"
      unitRef="USD_Per_Share">2.11</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20230213133734136"
      unitRef="usd">275000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20240325123733602"
      unitRef="Share">772900</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="2"
      id="Fxbrl_20240325123743170"
      unitRef="USD_Per_Share">1.83</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20240325164632464"
      unitRef="usd">1371000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:RepurchaseOfAmericanDepositaryReceiptsShares
      contextRef="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="INF"
      id="Fxbrl_20230213133614438"
      unitRef="Share">582023</cmmb:RepurchaseOfAmericanDepositaryReceiptsShares>
    <cmmb:RepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="0"
      id="Fxbrl_20230213133621142"
      unitRef="usd">2500000</cmmb:RepurchaseOfAmericanDepositaryReceipts>
    <cmmb:RepurchaseOfAmericanDepositaryReceiptsShares
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="INF"
      id="Fxbrl_20230213133633159"
      unitRef="Share">582023</cmmb:RepurchaseOfAmericanDepositaryReceiptsShares>
    <cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="4"
      id="Fxbrl_20230213133700406"
      unitRef="USD_Per_Share">2.0848</cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="-3"
      id="Fxbrl_20230213133643190"
      unitRef="usd">1218000</cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_20231101to20231117"
      decimals="-3"
      id="Fxbrl_20240325170937255"
      unitRef="usd">580000</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20231001to20231031"
      decimals="INF"
      id="Fxbrl_20240325171010296"
      unitRef="Share">2863664</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20231001to20231031_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"
      decimals="INF"
      id="Fxbrl_20240325171044931"
      unitRef="Share">2863664</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"
      decimals="INF"
      id="Fxbrl_20240325171233284"
      unitRef="Share">1800000</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"
      decimals="2"
      id="Fxbrl_20240325171244020"
      unitRef="USD_Per_Share">0.96</cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRothCapitalPartnersLlcMember_usgaapSubsidiarySaleOfStockAxis_cmmbMarketOfferingAgreementMember"
      decimals="-3"
      id="Fxbrl_20240325171253164"
      unitRef="usd">1553000</cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:NumberOfStockReservedForIssuance
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224906305"
      unitRef="Share">28443060</cmmb:NumberOfStockReservedForIssuance>
    <cmmb:NumberOfStockAdssResveredForIssuance
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223247056"
      unitRef="Share">1422153</cmmb:NumberOfStockAdssResveredForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225529762"
      unitRef="Share">3445520</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223254041"
      unitRef="Share">172276</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:NumberOfOptionsIssuableOutstanding
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225556251"
      unitRef="Share">6826440</cmmb:NumberOfOptionsIssuableOutstanding>
    <cmmb:NumberOfAdssOptionsIssuableOutstanding
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223300376"
      unitRef="Share">341322</cmmb:NumberOfAdssOptionsIssuableOutstanding>
    <cmmb:NumberOfOptionsVestedAndExercisable
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225618055"
      unitRef="Share">6394160</cmmb:NumberOfOptionsVestedAndExercisable>
    <cmmb:NumberOfAdssVestedAndExercisable
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223309640"
      unitRef="Share">319708</cmmb:NumberOfAdssVestedAndExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224602275"
      unitRef="USD_Per_Share">0.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223316544"
      unitRef="USD_Per_Share">5.98</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224845387"
      unitRef="Share">16634300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223324626"
      unitRef="Share">831715</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod>
    <cmmb:NumberOfStockReservedForIssuance
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225827725"
      unitRef="Share">23061380</cmmb:NumberOfStockReservedForIssuance>
    <cmmb:NumberOfStockAdssResveredForIssuance
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225729518"
      unitRef="Share">1153069</cmmb:NumberOfStockAdssResveredForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225858382"
      unitRef="Share">23046660</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225738550"
      unitRef="Share">1152333</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:NumberOfOptionsVestedAndExercisable
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225916606"
      unitRef="Share">3689480</cmmb:NumberOfOptionsVestedAndExercisable>
    <cmmb:NumberOfAdssVestedAndExercisable
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225743877"
      unitRef="Share">184474</cmmb:NumberOfAdssVestedAndExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225929980"
      unitRef="USD_Per_Share">0.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20230101to20231231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225750293"
      unitRef="USD_Per_Share">3.91</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325123602369">
          &lt;div&gt;
            &lt;div&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total share-based compensation expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000338"
      unitRef="usd">407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000339"
      unitRef="usd">448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fxbrl_20240325160020593_Fact_0000000000339"
      unitRef="usd">137000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000340"
      unitRef="usd">1084000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000341"
      unitRef="usd">2763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fxbrl_20240325160020594_Fact_0000000000341"
      unitRef="usd">1882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_0000000000342"
      unitRef="usd">1491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000343"
      unitRef="usd">3211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325160020595_Fact_0000000000343"
      unitRef="usd">2019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325123629767">
          &lt;div&gt;
            &lt;div style="line-height:1.25;margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at January 1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,003,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;10,455,580&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Acquired in Merger&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;609,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,970,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(134,220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,240,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,712,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,398,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;17,784,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9.79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at December 31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,003,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25;margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;of options&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;average&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;remaining contractual life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at January 1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,003,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercised&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,970,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(20,373,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,240,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;padding-bottom:2px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,055,180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,398,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;width:28%;padding-bottom:4px;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding at December 31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;35,191,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000345"
      unitRef="USD_Per_Share">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000346"
      unitRef="Share">27003260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20210101to20211231" id="FFact_0000000000347">P8Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20201231"
      decimals="INF"
      id="FFact_0000000000348"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20201231"
      decimals="INF"
      id="FFact_0000000000349"
      unitRef="Share">10455580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20200101to20201231" id="FFact_0000000000350">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="0"
      id="Fxbrl_20230214225414206"
      unitRef="USD_Per_Share">0</cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000351"
      unitRef="Share">0</cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230201024457584"
      unitRef="Share">609535</cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000352"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000353"
      unitRef="Share">1970000</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230201024523067"
      unitRef="USD_Per_Share">0.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230201024530820"
      unitRef="Share">134220</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000356"
      unitRef="USD_Per_Share">0.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000357"
      unitRef="Share">1240120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000358"
      unitRef="USD_Per_Share">1.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000359"
      unitRef="Share">1712275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000360"
      unitRef="USD_Per_Share">0.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000361"
      unitRef="Share">11398400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="C_20220101to20221231" id="FFact_0000000000362">P7Y9M18D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000363"
      unitRef="USD_Per_Share">0.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000364"
      unitRef="Share">17784640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="C_20210101to20211231" id="FFact_0000000000365">P9Y9M14D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000366"
      unitRef="USD_Per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000367"
      unitRef="Share">35191540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20220101to20221231" id="FFact_0000000000368">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000369"
      unitRef="USD_Per_Share">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000370"
      unitRef="Share">27003260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20210101to20211231" id="FFact_0000000000371">P8Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20240325121853866_Fact_0000000000345"
      unitRef="USD_Per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20240325121853866_Fact_0000000000346"
      unitRef="Share">35191540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231"
      id="Fxbrl_20240325121853866_Fact_0000000000347">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20240325121853866_Fact_0000000000348"
      unitRef="USD_Per_Share">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20240325121853866_Fact_0000000000349"
      unitRef="Share">27003260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20210101to20211231"
      id="Fxbrl_20240325121853866_Fact_0000000000350">P8Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240325122846802"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240325122903364"
      unitRef="Share">1970000</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240325122952018"
      unitRef="USD_Per_Share">0.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240325123000932"
      unitRef="Share">20373620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240325123010115"
      unitRef="USD_Per_Share">0.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240325123027691"
      unitRef="Share">1240120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240325121853884_Fact_0000000000360"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240325121853884_Fact_0000000000361"
      unitRef="Share">15055180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325121853884_Fact_0000000000362">P5Y10M9D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240325121853884_Fact_0000000000363"
      unitRef="USD_Per_Share">0.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20240325121853884_Fact_0000000000364"
      unitRef="Share">11398400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
      contextRef="C_20220101to20221231"
      id="Fxbrl_20240325121853884_Fact_0000000000365">P7Y9M18D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20240325121853889_Fact_0000000000366"
      unitRef="USD_Per_Share">0.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20240325121853889_Fact_0000000000367"
      unitRef="Share">29873100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325121853889_Fact_0000000000368">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20240325121853889_Fact_0000000000369"
      unitRef="USD_Per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20240325121853889_Fact_0000000000370"
      unitRef="Share">35191540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231"
      id="Fxbrl_20240325121853889_Fact_0000000000371">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325123652785">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="line-height:1.25;margin-left:72pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:top;padding-left:27pt;padding-bottom:2px;width:84%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                      &lt;div style="line-height:1.25"&gt;
                        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023 grants&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average share price (in U.S. dollar)&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercise price (in U.S. dollar)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.06-0.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life of options (in years)&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.53-9.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;97.79%-112.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.71%-4.43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:84%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:13%;vertical-align:bottom"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_20231231"
      decimals="INF"
      id="FFact_0000000000373"
      unitRef="USD_Per_Share">0.07</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20231231_srtRangeAxis_srtMinimumMember"
      decimals="INF"
      id="FFact_0000000000375"
      unitRef="USD_Per_Share">0.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20231231_srtRangeAxis_srtMaximumMember"
      decimals="INF"
      id="FFact_0000000000376"
      unitRef="USD_Per_Share">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember"
      id="FFact_0000000000377">P4Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember"
      id="FFact_0000000000378">P9Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20230101to20231231"
      decimals="4"
      id="FFact_0000000000379"
      unitRef="Pure">0.9779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20230101to20231231"
      decimals="4"
      id="FFact_0000000000380"
      unitRef="Pure">1.1294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20230101to20231231"
      decimals="4"
      id="FFact_0000000000381"
      unitRef="Pure">0.0371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20230101to20231231"
      decimals="4"
      id="FFact_0000000000382"
      unitRef="Pure">0.0443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="FFact_0000000000383"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000399">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 9 - Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Consultants and subcontractors&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease and maintenance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;461&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;18,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325111225857">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Consultants and subcontractors&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease and maintenance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;461&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;18,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325111304537"
      unitRef="usd">14014000</cmmb:ConsultantsAndSubcontractorsExpense>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000386"
      unitRef="usd">13052000</cmmb:ConsultantsAndSubcontractorsExpense>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000387"
      unitRef="usd">3894000</cmmb:ConsultantsAndSubcontractorsExpense>
    <us-gaap:OfficersCompensation
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325111310016"
      unitRef="usd">3362000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000388"
      unitRef="usd">2867000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000389"
      unitRef="usd">1789000</us-gaap:OfficersCompensation>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325111315367"
      unitRef="usd">137000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000390"
      unitRef="usd">245000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000391"
      unitRef="usd">114000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325111320717"
      unitRef="usd">407000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000392"
      unitRef="usd">448000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000393"
      unitRef="usd">137000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325111247489"
      unitRef="usd">461000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000394"
      unitRef="usd">365000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325111250767"
      unitRef="usd">400000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325111258130"
      unitRef="usd">18381000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000396"
      unitRef="usd">16977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000397"
      unitRef="usd">6334000</us-gaap:ResearchAndDevelopmentExpense>
    <cmmb:GeneralAndAdministrativeDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000417">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 10 - General and Administrative&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,545&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;943&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional services&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fees to Directors&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Insurance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Rent and maintenance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,078&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,556&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </cmmb:GeneralAndAdministrativeDisclosureTextBlock>
    <cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325110555714">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,545&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;943&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional services&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Fees to Directors&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Insurance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Rent and maintenance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,078&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,556&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325110603691"
      unitRef="usd">2545000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000400"
      unitRef="usd">3435000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000401"
      unitRef="usd">943000</us-gaap:SalariesAndWages>
    <us-gaap:ProfessionalFees
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325110618011"
      unitRef="usd">2139000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000402"
      unitRef="usd">2596000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000403"
      unitRef="usd">1695000</us-gaap:ProfessionalFees>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325110622931"
      unitRef="usd">1084000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000404"
      unitRef="usd">2763000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000405"
      unitRef="usd">1882000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325110632753"
      unitRef="usd">258000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000406"
      unitRef="usd">231000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201004651041"
      unitRef="usd">244000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325110648131"
      unitRef="usd">648000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000408"
      unitRef="usd">1084000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000409"
      unitRef="usd">1024000</us-gaap:GeneralInsuranceExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325110658345"
      unitRef="usd">81000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000410"
      unitRef="usd">24000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000411"
      unitRef="usd">29000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325110704195"
      unitRef="usd">323000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000412"
      unitRef="usd">1423000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000413"
      unitRef="usd">216000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325110711541"
      unitRef="usd">7078000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000414"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000415"
      unitRef="usd">6033000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000458">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Note 11 - Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Tax rates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Ordinary taxable income in Israel is subject to a corporate tax rate of 23%.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company&#x2019;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Chemomab Inc. is subject to a federal flat tax rate of 21% and state tax as applicable.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:36pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Tax assessments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2023, the Company&#x2019;s tax reports through December 31, 2018 are considered closed to audit inspections by the Israeli Tax Authority (&#x201c;ITA&#x201d;) due to statute of limitation rules effective in Israel.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company has not yet been assessed by the ITA since inception.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"&gt;

              &lt;tr style="vertical-align:top"&gt;
                &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right;vertical-align:top;width:36pt"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Losses for tax purposes carried forward to future years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2023, the Company and its subsidiaries had approximately $165 million (approximately $159 million and $143 million as of December 31, 2022 and 2021 respectively) of net operating loss carryforwards which are available to reduce future taxable income with no limitation on the period of use.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left"&gt;&#160;&lt;/p&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. Chemomab Therapeutics Inc received $351 thousand in December 2022 on account of 2016 and 2017 and received the remainder $183 thousand in 2023. Accordingly, a tax benefit in the total amount of $534 thousand was recorded in the Company&#x2019;s statement of operations during 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px"&gt;

              &lt;tr style="vertical-align:top"&gt;
                &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right;vertical-align:top;width:36pt"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman,Times,serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;Deferred taxes&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In respect of:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25;margin-left:72pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net operating loss carry-forward&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;38,258&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36,550&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33,396&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,163&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,147&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Research and development costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,041&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,449&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;43,471&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="width:64%;padding-bottom:2px;vertical-align:baseline"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less - Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(43,471&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;
          &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div&gt;&#160;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company has established a valuation allowance to offset deferred tax assets on December 31, 2023, 2022 and 2021 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2023 was an increase of approximately $2.3 million.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px"&gt;

              &lt;tr style="vertical-align:top"&gt;
                &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right;vertical-align:top;width:36pt"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Roll forward of valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:72pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,425&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Tax assets acquired through merger&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;24,535&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,316&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(3,295&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5,571&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;43,471&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left"&gt;&#160;&lt;/p&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px"&gt;

            &lt;tr style="vertical-align:top"&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:right;vertical-align:top;width:36pt"&gt;
                &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
              &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Reconciliation of theoretical income tax expense to actual income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;A reconciliation of the Company&#x2019;s theoretical income tax expense to actual income tax expense is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25;margin-left:72pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;202&lt;/span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(24,221&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(28,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(12,478&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Theoretical tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(5,571&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(2,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Change in temporary differences for which deferred taxes were not recognized&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,177&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,696&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,332&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Tax rate differential&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(101&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Non-deductible expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;744&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,392&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,879&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,064&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Actual income tax expense (Benefit)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(534&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;border:0px"&gt;

              &lt;tr style="vertical-align:top"&gt;
                &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="text-align:right;vertical-align:top;width:36pt"&gt;
                  &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span style="font-weight:bold"&gt;G&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
                &lt;td style="text-align:left;vertical-align:top;width:auto"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Accounting for uncertainty in income taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:72pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;For the year ended December 31, 2023, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company&#x2019;s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryIL"
      decimals="2"
      id="FFact_0000000000418"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"
      decimals="2"
      id="FFact_0000000000419"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20231231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20230213140532094"
      unitRef="usd">165000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20221231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20230213140537759"
      unitRef="usd">159000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20211231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20240325142108415"
      unitRef="usd">143000000</us-gaap:TaxCreditCarryforwardAmount>
    <cmmb:ReceivedAmountOfChemomabTherapeuticsInc
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213140710654"
      unitRef="usd">351000</cmmb:ReceivedAmountOfChemomabTherapeuticsInc>
    <cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230213140716671"
      unitRef="usd">183000</cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213140722797"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325113702579">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net operating loss carry-forward&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;38,258&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36,550&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;33,396&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,163&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,147&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Research and development costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,041&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,449&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;43,471&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="width:64%;padding-bottom:2px;vertical-align:baseline"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Less - Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(43,471&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325113127688"
      unitRef="usd">38258000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000422"
      unitRef="usd">36550000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000423"
      unitRef="usd">33396000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325113134551"
      unitRef="usd">1163000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000424"
      unitRef="usd">1774000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000425"
      unitRef="usd">1147000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325113142383"
      unitRef="usd">4041000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000426"
      unitRef="usd">2858000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000427"
      unitRef="usd">1449000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325113151187"
      unitRef="usd">9000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000428"
      unitRef="usd">13000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000429"
      unitRef="usd">38000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325113158306"
      unitRef="usd">43471000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000430"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000431"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325113204191"
      unitRef="usd">43471000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000432"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000433"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240325113212847"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201010225989_Fact_0000000000426"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230201010225989_Fact_0000000000427"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_20230101to20231231"
      decimals="-5"
      id="Fxbrl_20230201010356964"
      unitRef="usd">2300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325113717888">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,425&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Tax assets acquired through merger&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;24,535&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,316&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Currency translation Income&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(3,295&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;5,571&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;43,471&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000438"
      unitRef="usd">6200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000439"
      unitRef="usd">2425000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:TaxAssetsAcquiredThroughMergerValuationAllowance
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201010515039"
      unitRef="usd">24535000</cmmb:TaxAssetsAcquiredThroughMergerValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000440"
      unitRef="usd">2870000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000441"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201010936607"
      unitRef="usd">-1316000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000444"
      unitRef="usd">6481000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20240325112211572_Fact_0000000000441"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325112219753_xbrl_20230201010936607"
      unitRef="usd">-3295000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325112200162_Fact_0000000000444"
      unitRef="usd">5571000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_0000000000445"
      unitRef="usd">43471000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325113734351">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;202&lt;/span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(24,221&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(28,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(12,478&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Theoretical tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(5,571&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(2,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Change in temporary differences for which deferred taxes were not recognized&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,177&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,696&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(1,332&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Tax rate differential&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(101&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Non-deductible expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;744&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,392&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;6,879&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;4,064&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Actual income tax expense (Benefit)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(534&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:2.5px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325113300491"
      unitRef="usd">-24221000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000447"
      unitRef="usd">-28180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000448"
      unitRef="usd">-12478000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20230101to20231231"
      decimals="2"
      id="Fxbrl_20240325113309002"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20220101to20221231"
      decimals="2"
      id="FFact_0000000000449"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20210101to20211231"
      decimals="2"
      id="FFact_0000000000450"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325113316316"
      unitRef="usd">-5571000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000451"
      unitRef="usd">-6481000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000452"
      unitRef="usd">-2870000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325113329731"
      unitRef="usd">-1177000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113429979_Fact_0000000000453"
      unitRef="usd">-1696000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113429979_Fact_0000000000454"
      unitRef="usd">-1332000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325113338019"
      unitRef="usd">10000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113425908_Fact_0000000000453"
      unitRef="usd">20000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113425908_Fact_0000000000454"
      unitRef="usd">-101000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325113354492"
      unitRef="usd">346000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113423827_Fact_0000000000453"
      unitRef="usd">744000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113423827_Fact_0000000000454"
      unitRef="usd">239000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325113401417"
      unitRef="usd">6392000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113421604_Fact_0000000000453"
      unitRef="usd">6879000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325114521690"
      unitRef="usd">4064000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325115329121"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20240325115408857"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20240325115419350"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000477">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Note 12 - Related Parties Balances and Transactions&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balances with Related Parties:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following Related Party payables are included in the consolidated Balance Sheets:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25;margin-left:36pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employee and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;891&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On September 19, 2022, the Company entered into a share purchase agreement with the Company's Co- Founders, see Note 8B(4).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;B.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Transactions with Related Parties:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:36pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following transactions with related parties are included in the consolidated Statements of Operations:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25;margin-left:36pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,466&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional Services&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,393&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325105624656">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employee and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;891&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000459"
      unitRef="usd">490000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000460"
      unitRef="usd">891000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000461"
      unitRef="usd">74000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000462"
      unitRef="usd">58000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000463"
      unitRef="usd">564000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000464"
      unitRef="usd">949000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325105648481">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;USD&#160;thousands&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Salaries and related expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,466&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Professional Services&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;244&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,393&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325105700969"
      unitRef="usd">2795000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000466"
      unitRef="usd">2409000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000467"
      unitRef="usd">1255000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325105708763"
      unitRef="usd">1304000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000468"
      unitRef="usd">2466000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000469"
      unitRef="usd">1775000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325105715263"
      unitRef="usd">258000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000470"
      unitRef="usd">231000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000471"
      unitRef="usd">244000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325105723270"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000472"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000473"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <us-gaap:CostOfRevenue
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325105729174"
      unitRef="usd">4393000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000474"
      unitRef="usd">5142000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000475"
      unitRef="usd">3310000</us-gaap:CostOfRevenue>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_20230101to20231231" id="FFact_0000000000488">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold;font-size:10pt"&gt;Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:36pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In USD thousands, except share and per share data&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                  &lt;td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;24,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                  &lt;td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                  &lt;td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                  &lt;td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;234,998,859&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;strong&gt;227,589,288&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;strong&gt;207,468,650&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                  &lt;td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                  &lt;td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Net&#160;loss&#160;per&#160;share&#160;attributable&#160;to&#160;ordinary&#160;shareholders,&#160;basic&#160;and&#160;diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.103&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.121&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.060&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0.55pt;margin-left:35.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:36pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding options to purchase ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;35,191,540&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;27,003,260&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325110054121">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In USD thousands, except share and per share data&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                  &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                  &lt;td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;24,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;27,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                  &lt;td style="width:64%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                  &lt;td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                  &lt;td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;234,998,859&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;strong&gt;227,589,288&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;strong&gt;207,468,650&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                  &lt;td style="width:64%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                  &lt;td style="width:64%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Net&#160;loss&#160;per&#160;share&#160;attributable&#160;to&#160;ordinary&#160;shareholders,&#160;basic&#160;and&#160;diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.103&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.121&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.060&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20240325110200438"
      unitRef="usd">-24221000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000478"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000479"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_s_20240325110207874"
      unitRef="Share">234998859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240325110207874"
      unitRef="Share">234998859</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_s_20230215224008037"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230215224008037"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213429326"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000481"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_s_20240325110215226"
      unitRef="USD_Per_Share">0.103</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20230101to20231231"
      decimals="INF"
      id="Fxbrl_20240325110215226"
      unitRef="USD_Per_Share">0.103</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230131213444247"
      unitRef="USD_Per_Share">0.121</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000482"
      unitRef="USD_Per_Share">0.121</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213458553"
      unitRef="USD_Per_Share">0.06</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000483"
      unitRef="USD_Per_Share">0.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_20230101to20231231"
      id="Fxbrl_20240325110121565">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;text-align:center"&gt;
                    &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Number of shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding options to purchase ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;29,873,100&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;35,191,540&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;27,003,260&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20231231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="Fxbrl_20240325110228946"
      unitRef="Share">29873100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="FFact_0000000000485"
      unitRef="Share">35191540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="FFact_0000000000486"
      unitRef="Share">27003260</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#FFact_0000000000106"
          xlink:label="FFact_0000000000106"
          xlink:type="locator"/>
        <link:footnote id="FN20240325165534634" xlink:label="FN20240325165534634" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000106"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230214141238310"
          xlink:label="Fxbrl_20230214141238310"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230214141238310"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000107"
          xlink:label="FFact_0000000000107"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000107"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230131213329528"
          xlink:label="Fxbrl_20230131213329528"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230131213329528"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20240325100018415"
          xlink:label="Fxbrl_20240325100018415"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20240325100018415"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_s_20240325100018414"
          xlink:label="Fxbrl_s_20240325100018414"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_s_20240325100018414"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20240325103200378"
          xlink:label="Fxbrl_20240325103200378"
          xlink:type="locator"/>
        <link:footnote id="FN20240325103209570" xlink:label="FN20240325103209570" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Less than 1 thousand</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20240325103200378"
          xlink:to="FN20240325103209570"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000373"
          xlink:label="FFact_0000000000373"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025135527" xlink:label="FN20230201025135527" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The weighted average share price is based on the Company&#x2019;s ordinary share valuation as at the grant date. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000373"
          xlink:to="FN20230201025135527"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000377"
          xlink:label="FFact_0000000000377"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025203207" xlink:label="FN20230201025203207" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#x2019; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000377"
          xlink:to="FN20230201025203207"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000378"
          xlink:label="FFact_0000000000378"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000378"
          xlink:to="FN20230201025203207"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000379"
          xlink:label="FFact_0000000000379"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025249960" xlink:label="FN20230201025249960" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#x2019;s expected term.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000379"
          xlink:to="FN20230201025249960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000380"
          xlink:label="FFact_0000000000380"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000380"
          xlink:to="FN20230201025249960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000381"
          xlink:label="FFact_0000000000381"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025314607" xlink:label="FN20230201025314607" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000381"
          xlink:to="FN20230201025314607"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000382"
          xlink:label="FFact_0000000000382"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000382"
          xlink:to="FN20230201025314607"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207232638785_Fact_0000000000130"
          xlink:label="Fxbrl_20230207232638785_Fact_0000000000130"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207232638785_Fact_0000000000130"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207232638785_Fact_0000000000129"
          xlink:label="Fxbrl_20230207232638785_Fact_0000000000129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207232638785_Fact_0000000000129"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207232638785_Fact_0000000000128"
          xlink:label="Fxbrl_20230207232638785_Fact_0000000000128"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207232638785_Fact_0000000000128"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230207232832534"
          xlink:label="Fxbrl_20230207232832534"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230207232832534"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230208004108785"
          xlink:label="Fxbrl_20230208004108785"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230208004108785"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230208004148281"
          xlink:label="Fxbrl_20230208004148281"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230208004148281"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230208004208753"
          xlink:label="Fxbrl_20230208004208753"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230208004208753"
          xlink:to="FN20240325165534634"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
